assays_assay_id,assays_tid,assays_assay_test_type,assays_bao_format,assays_cell_id,assays_assay_cell_type,assays_description,assays_assay_category,assays_src_assay_id,assays_relationship_type,assays_curated_by,assays_assay_type,assays_assay_tax_id,assays_chembl_id,assays_variant_id,assays_tissue_id,assays_assay_tissue,assays_assay_subcellular_fraction,assays_confidence_score,assays_src_id
1,12052,,BAO_0000019,,,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 30 uM,,,H,Autocuration,B,,CHEMBL615117,,,,,8,1
2,22226,,BAO_0000219,,,Compound was evaluated for its ability to mobilize calcium in 1321NI cells,,,U,Autocuration,F,,CHEMBL615118,,,,,0,1
3,22226,,BAO_0000019,,,,,,U,Autocuration,B,,CHEMBL615119,,,,,0,1
4,104729,,BAO_0000249,,,Binding affinity against A2 adenosine receptor in bovine striatal membranes using [3H]CGS-21680,,,H,Autocuration,B,9913.0,CHEMBL615120,,,,,4,1
5,80001,,BAO_0000219,163.0,143B,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),,,N,Intermediate,F,9606.0,CHEMBL615121,,,,,1,1
6,80001,,BAO_0000219,163.0,143B,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),,,N,Intermediate,F,9606.0,CHEMBL615122,,,,,1,1
7,80001,,BAO_0000219,163.0,143B,Cytotoxic Activity was evaluated against 143B (TK-) tumor cells,,,N,Intermediate,F,10090.0,CHEMBL615123,,,,,1,1
8,80001,,BAO_0000219,163.0,143B,In vitro cell cytotoxicity was determined against 143B cell line,,,N,Expert,F,9606.0,CHEMBL615124,,,,,1,1
9,80001,,BAO_0000219,163.0,143B,Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound,,,N,Intermediate,F,9606.0,CHEMBL615125,,,,,1,1
10,80001,,BAO_0000219,163.0,143B,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,,,N,Intermediate,F,9606.0,CHEMBL615126,,,,,1,1
11,80001,,BAO_0000219,163.0,143B,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,,,N,Intermediate,F,9606.0,CHEMBL615127,,,,,1,1
12,80001,,BAO_0000219,163.0,143B,In vitro cell cytotoxicity was determined against 143B-LTK cell line,,,N,Expert,F,9606.0,CHEMBL615128,,,,,1,1
13,50185,,BAO_0000218,,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,,N,Intermediate,F,1280.0,CHEMBL857900,,,,,1,1
14,50185,,BAO_0000218,,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,,N,Intermediate,F,1280.0,CHEMBL615129,,,,,1,1
15,50185,,BAO_0000218,,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,,N,Intermediate,F,1280.0,CHEMBL615130,,,,,1,1
16,50185,,BAO_0000218,,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,,N,Intermediate,F,1280.0,CHEMBL615131,,,,,1,1
17,100122,,BAO_0000357,,,Inhibition of cytochrome P450 progesterone 15-alpha hydroxylase,,,D,Expert,A,10116.0,CHEMBL884521,,,,,9,1
18,12054,,BAO_0000357,,,Concentration that cause 50% activation of human reticulocyte 15-lipoxygenase (15-HLO),,,H,Autocuration,B,,CHEMBL615132,,,,,8,1
19,12054,,BAO_0000019,,,Inhibition of partially purified 15-lipoxygenase from human leukocytes,,,H,Autocuration,B,,CHEMBL615133,,,,,8,1
20,12054,,BAO_0000357,,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),,,H,Autocuration,B,,CHEMBL615134,,,,,8,1
21,12054,,BAO_0000357,,,Compound was evaluated for the percent increase in activation concentration of human reticulocyte 15-lipoxygenase (15-HLO),,,H,Autocuration,B,,CHEMBL615135,,,,,8,1
22,12054,,BAO_0000357,,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),,,H,Autocuration,B,,CHEMBL615136,,,,,8,1
23,12054,,BAO_0000357,,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,,,H,Autocuration,B,,CHEMBL615137,,,,,8,1
24,12054,,BAO_0000357,,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,,,H,Autocuration,B,,CHEMBL615138,,,,,8,1
25,22226,,BAO_0000219,,,"Inhibitory concentration against 15-lipoxygenase, by inhibiting 15-HETE production by human umbilical vein endothelial cells (HUVEC) stimulated by calcium ionophore A 23187 at concentration of 10e-5 M.",,,U,Autocuration,B,,CHEMBL836324,,,,,0,1
26,12054,,BAO_0000357,,,In vitro inhibitory activity of compound on rabbit reticulocyte 15-lipoxygenase,,,H,Autocuration,B,9986.0,CHEMBL615139,,,,,8,1
27,12054,,BAO_0000357,,,Inhibition of rabbit reticulocyte 15-lipoxygenase by compound (30 uM),,,H,Autocuration,B,9986.0,CHEMBL615140,,,,,8,1
28,12426,,BAO_0000219,,,Inhibitory activity against 15-lipoxygenase in rat polymorphonuclear leukocytes,,,H,Autocuration,B,,CHEMBL615141,,,,,8,1
29,12054,,BAO_0000357,,,Inhibitory activity against 15-lipoxygenase was determined obtained from soya bean,,,H,Autocuration,B,3847.0,CHEMBL615142,,,,,8,1
30,12054,,BAO_0000357,,,Inhibitory activity against soybean 15-lipoxygenase was evaluated,,,H,Autocuration,B,3847.0,CHEMBL615143,,,,,8,1
31,12054,,BAO_0000357,,,Inhibitory activity against soybean 15-lipoxygenase was evaluated at 100 uM,,,H,Autocuration,B,3847.0,CHEMBL615144,,,,,8,1
32,12054,,BAO_0000357,,,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 10 uM,,,H,Autocuration,B,3847.0,CHEMBL872867,,,,,8,1
33,12054,,BAO_0000357,,,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 100 uM,,,H,Autocuration,B,3847.0,CHEMBL615145,,,,,8,1
34,12054,,BAO_0000357,,,Compound was tested in vitro for inhibition of 15-lipoxygenase soybean,,,H,Autocuration,B,3847.0,CHEMBL615146,,,,,8,1
35,12054,,BAO_0000357,,,Compound at 100 uM was tested in vitro for inhibition of 15-lipoxygenase soybean,,,H,Autocuration,B,3847.0,CHEMBL615147,,,,,8,1
36,22226,,BAO_0000019,,,Inhibition of cytochrome P450 progesterone 16-alpha hydroxylase,,,U,Autocuration,A,10116.0,CHEMBL615148,,,,,0,1
37,22226,,BAO_0000019,,,Binding affinity against bacterial 16S rRNA using mass spectrometry based assay,,,U,Autocuration,B,562.0,CHEMBL615149,,,,,0,1
38,22226,,BAO_0000019,,,Dissociation constant with dimeric 16S rRNA RNA construct B,,,U,Autocuration,B,,CHEMBL615150,,,,,0,1
39,22222,,BAO_0000225,,,Dissociation constant towards 16S rRNA construct A,,,M,Intermediate,B,,CHEMBL615151,,,,,3,1
40,22222,,BAO_0000225,,,Dissociation constant towards 16S rRNA construct B,,,M,Intermediate,B,,CHEMBL615152,,,,,3,1
41,100263,,BAO_0000225,,,Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli,,,M,Expert,B,562.0,CHEMBL615153,,,,,3,1
42,100263,,BAO_0000225,,,Binding affinity for the 16S ribosomal RNA A-site of Escherichia coli,,,M,Expert,B,562.0,CHEMBL615154,,,,,3,1
43,13053,,BAO_0000019,,,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,,H,Autocuration,B,,CHEMBL615155,,,,,8,1
44,13053,,BAO_0000019,,,Inhibitory constant against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,,H,Autocuration,B,,CHEMBL615156,,,,,8,1
45,20001,,BAO_0000019,,,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,,,H,Autocuration,B,9606.0,CHEMBL615157,,,,,8,1
46,20001,,BAO_0000019,,,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,,,H,Autocuration,B,9606.0,CHEMBL615158,,,,,8,1
47,12971,,BAO_0000019,,,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",,,D,Expert,B,10116.0,CHEMBL615159,,,,,9,1
48,12971,,BAO_0000019,,,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",,,D,Expert,B,10116.0,CHEMBL615172,,,,,9,1
49,12971,,BAO_0000019,,,"Percent inhibition of 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",,,D,Expert,B,10116.0,CHEMBL615173,,,,,9,1
50,12971,,BAO_0000019,,,"Percent inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",,,D,Expert,B,10116.0,CHEMBL615174,,,,,9,1
51,13053,,BAO_0000019,,,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,,H,Autocuration,B,,CHEMBL884518,,,,,8,1
52,11512,,BAO_0000357,,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1),,,H,Autocuration,B,,CHEMBL615175,,,,,8,1
53,11512,,BAO_0000357,,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 1 uM concentration,,,H,Autocuration,B,,CHEMBL615176,,,,,8,1
54,11512,,BAO_0000357,,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 10 uM concentration,,,H,Autocuration,B,,CHEMBL615177,,,,,8,1
55,104740,,BAO_0000249,,,Selectivity ratio of binding affinity towards mu to delta receptors of rat brain membranes,,,D,Autocuration,B,10116.0,CHEMBL615178,,,,Membranes,5,1
56,80002,,BAO_0000219,506.0,1A9,Cytotoxicity against ovarian cancer cell line (1A-9) of humans was determined,,,N,Intermediate,F,9606.0,CHEMBL615179,,,,,1,1
57,104835,,BAO_0000219,,Oocytes,Functional antagonism by electrical assays in Xenopus oocytes expressing 1A/2A NMDA receptor subtype,,,D,Autocuration,F,10116.0,CHEMBL615180,,,,,7,1
58,104821,,BAO_0000219,,Oocytes,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2B NMDA receptor,,,D,Autocuration,F,10116.0,CHEMBL615181,,,,,7,1
59,104848,,BAO_0000219,,Oocytes,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2C NMDA receptor,,,D,Autocuration,F,10116.0,CHEMBL615182,,,,,7,1
60,80002,,BAO_0000219,506.0,1A9,In vitro effective concentration required to reduce the number of human ovarian cancer (1A9) after 3-day incubation,,,N,Expert,F,9606.0,CHEMBL615183,,,,,1,1
61,80002,,BAO_0000219,506.0,1A9,In vitro effective concentration required to reduce the number of human ovarian cancer cells (1A9) after 3-day incubation,,,N,Intermediate,F,9606.0,CHEMBL615184,,,,,1,1
62,80002,,BAO_0000219,506.0,1A9,Cytotoxic activity against human ovarian cancer (1A9) cell line,,,N,Intermediate,F,9606.0,CHEMBL615185,,,,,1,1
63,80002,,BAO_0000219,506.0,1A9,Cytotoxic activity against human ovarian cancer (1A9) cell line; ND=Not determined,,,N,Intermediate,F,9606.0,CHEMBL615186,,,,,1,1
64,80002,,BAO_0000219,506.0,1A9,Effective dose of compound against replication of 1A9 cell line was evaluated,,,N,Intermediate,F,9606.0,CHEMBL615187,,,,,1,1
65,80002,,BAO_0000219,506.0,1A9,In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line,,,N,Expert,F,9606.0,CHEMBL885343,,,,,1,1
66,80002,,BAO_0000219,506.0,1A9,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line),,,N,Intermediate,F,9606.0,CHEMBL615188,,,,,1,1
67,80002,,BAO_0000219,506.0,1A9,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line); NA is not active,,,N,Intermediate,F,9606.0,CHEMBL615189,,,,,1,1
68,80002,,BAO_0000219,506.0,1A9,In vitro percent inhibition evaluated against human ovarian cancer (1A9 cell line) at >20 ug/mL,,,N,Intermediate,F,9606.0,CHEMBL615190,,,,,1,1
69,80002,,BAO_0000219,506.0,1A9,Inhibitory activity against Taxol resistant 1A9 cell lines,,,N,Intermediate,F,9606.0,CHEMBL615191,,,,,1,1
70,80002,,BAO_0000219,506.0,1A9,Cytotoxicity against human ovarian cancer (1A9) cell lines.,,,N,Expert,F,9606.0,CHEMBL615192,,,,,1,1
71,80002,,BAO_0000219,506.0,1A9,Percentage inhibition of human ovarian cancer (1A9) cell lines.,,,N,Expert,F,9606.0,CHEMBL827083,,,,,1,1
72,80002,,BAO_0000219,506.0,1A9,Effective dose required for inhibitory activity against 1A9 human tumor cell line.,,,N,Expert,F,9606.0,CHEMBL615193,,,,,1,1
73,80002,,BAO_0000219,506.0,1A9,Percent inhibition against 1A9 human tumor cell line at 0.10 ug/mL,,,N,Intermediate,F,9606.0,CHEMBL615194,,,,,1,1
74,80002,,BAO_0000219,506.0,1A9,Percent inhibition against 1A9 human tumor cell line at <0.00008 ug/mL,,,N,Intermediate,F,9606.0,CHEMBL615195,,,,,1,1
75,80002,,BAO_0000219,506.0,1A9,Percent inhibition against 1A9 human tumor cell line at >10 ug/mL,,,N,Intermediate,F,9606.0,CHEMBL615196,,,,,1,1
76,81072,,BAO_0000219,503.0,Jurkat,Inhibitory concentration against Jurkat cells,,,N,Intermediate,F,9606.0,CHEMBL615197,,,,,1,1
77,22226,,BAO_0000019,,,In vitro anticancer activity against 2 NCI SCLC cell lines; inactive,,,U,Intermediate,F,,CHEMBL615198,,,,,0,1
78,100121,,BAO_0000357,,,Inhibition of cytochrome P450 progesterone 2-alpha-hydroxylase,,,D,Expert,A,10116.0,CHEMBL615199,,,,,9,1
79,11231,,BAO_0000357,,,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",,,H,Expert,B,,CHEMBL615200,,,,,8,1
80,11231,,BAO_0000357,,,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",,,H,Expert,B,,CHEMBL615201,,,,,8,1
81,11231,,BAO_0000357,,,"In vitro inhibition of human 2,3-oxidosqualene cyclase at 100 nM.",,,H,Expert,B,,CHEMBL615202,,,,,8,1
82,11231,,BAO_0000251,,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Candida albicans microsomes",,,H,Autocuration,B,5476.0,CHEMBL615203,,,,Microsomes,8,1
83,11231,,BAO_0000251,,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Candida albicans microsomes",,,H,Autocuration,B,5476.0,CHEMBL615204,,,,Microsomes,8,1
84,11231,,BAO_0000251,,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Saccharomyces cerevisiae microsomes",,,H,Autocuration,B,4932.0,CHEMBL615205,,,,Microsomes,8,1
85,11231,,BAO_0000251,,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Saccharomyces cerevisiae microsomes",,,H,Autocuration,B,4932.0,CHEMBL615206,,,,Microsomes,8,1
86,12083,,BAO_0000251,,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in pig liver microsomes",,,H,Autocuration,B,9823.0,CHEMBL615207,,2107.0,Liver,Microsomes,8,1
87,11231,,BAO_0000019,,,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase",,,H,Autocuration,B,10116.0,CHEMBL827084,,,,,8,1
88,11231,,BAO_0000019,,,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase (OSC)",,,H,Autocuration,B,10116.0,CHEMBL615208,,,,,8,1
89,11231,,BAO_0000019,,,"Evaluated for its activity to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase, activity expressed as Ki",,,H,Autocuration,B,10116.0,CHEMBL615209,,,,,8,1
90,12083,,BAO_0000251,,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in rat liver microsomes",,,D,Autocuration,B,10116.0,CHEMBL615210,,2107.0,Liver,Microsomes,9,1
91,12083,,BAO_0000251,,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",,,D,Autocuration,B,10116.0,CHEMBL615211,,2107.0,Liver,Microsomes,9,1
92,12083,,BAO_0000251,,,"Compound was evaluated for inhibitory activity against 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",,,D,Autocuration,B,10116.0,CHEMBL615212,,2107.0,Liver,Microsomes,9,1
93,11377,,BAO_0000357,,,Molar concentration needed to give 50% prevention of 2-5A (Adenosine dependent endoribonuclease),,,H,Expert,B,,CHEMBL615213,,,,,8,1
94,11377,,BAO_0000357,,,Molar concentration required to displace 50% of the radiolabeled probe from 2-5A (Adenosine dependent endoribonuclease) in endonuclease-nitrocellulose complex,,,H,Expert,B,,CHEMBL615273,,,,,8,1
95,81020,,BAO_0000219,726.0,HepG2,In vitro cytotoxic concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,,,N,Expert,F,9606.0,CHEMBL615274,,,,,1,1
96,81020,,BAO_0000219,726.0,HepG2,50% Effective concentration of compound required for inhibiting intracellular viral replicative intermediate DNA in HBV-transfected 2.2.15 cell line.,,,N,Intermediate,F,9606.0,CHEMBL615275,,,,,1,1
97,81020,,BAO_0000219,726.0,HepG2,Antiviral activity against Hepatitis B virus in 2.2.15 cell line,,,N,Intermediate,F,9606.0,CHEMBL615276,,,,,1,1
98,81020,,BAO_0000219,726.0,HepG2,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells,,,N,Intermediate,F,9606.0,CHEMBL615277,,,,,1,1
99,81020,,BAO_0000219,726.0,HepG2,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells; Not determined,,,N,Intermediate,F,9606.0,CHEMBL615326,,,,,1,1
100,50606,,BAO_0000218,,,In vitro effective concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,,,N,Expert,F,10407.0,CHEMBL883130,,,,,1,1
101,81020,,BAO_0000219,726.0,HepG2,Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.,,,N,Intermediate,F,9606.0,CHEMBL884519,,,,,1,1
102,81020,,BAO_0000219,726.0,HepG2,Concentration required to inhibit 50% of 2.2.15 cell line,,,N,Intermediate,F,9606.0,CHEMBL615327,,,,,1,1
103,81020,,BAO_0000219,726.0,HepG2,Anti viral activity against 2.2.15 cells (concentration required to reduce the log phase cell growth by 50%).,,,N,Intermediate,A,9606.0,CHEMBL615328,,,,,1,1
104,50587,,BAO_0000218,,2.2.15,Cytotoxic activity of compound against uninfected 2.2.15 cells.,,,N,Intermediate,F,9606.0,CHEMBL615329,,,,,1,1
105,50587,,BAO_0000218,,2.2.15,Anti hepatitis-B virus activity was evaluated in 2.2.15 cells.,,,N,Intermediate,F,9606.0,CHEMBL615330,,,,,1,1
106,50606,,BAO_0000218,,2.2.15,"Inhibition of the replication of HBV in 2.2.15 cells, by DNA hybridization assay",,,N,Expert,F,10407.0,CHEMBL615331,,,,,1,1
107,50587,,BAO_0000218,,2.2.15,In vitro anti-HBV activity in 2.2.15 cells,,,N,Intermediate,F,9606.0,CHEMBL615332,,,,,1,1
108,50587,,BAO_0000218,,2.2.15,In vitro anti-HBV activity in 2.2.15 cells; Not determined,,,N,Intermediate,F,9606.0,CHEMBL615333,,,,,1,1
109,50587,,BAO_0000218,,2.2.15,The compound was tested in vitro for the anti-HBV activity against 2.2.15 cells,,,N,Intermediate,F,9606.0,CHEMBL615334,,,,,1,1
110,50587,,BAO_0000218,,2.2.15,The compound was tested in vitro for the anti-HBV activity in 2.2.15 cells,,,N,Intermediate,F,9606.0,CHEMBL615335,,,,,1,1
111,50587,,BAO_0000218,,2.2.15,Cytotoxicity in 2.2.15 cells,,,N,Intermediate,F,9606.0,CHEMBL615336,,,,,1,1
112,50587,,BAO_0000218,,2.2.15,Cytotoxicity in 2.2.15 cells; Not determined,,,N,Intermediate,F,9606.0,CHEMBL615337,,,,,1,1
113,50587,,BAO_0000218,,2.2.15,Inhibitory activity of compound against hepatitis B virus (HBV) in growing cultures of 2.2.15 cells,,,N,Intermediate,F,9606.0,CHEMBL615338,,,,,1,1
114,50587,,BAO_0000218,,2.2.15,The growth inhibition activity for the compound was evaluated in 2.2.15 cells.,,,N,Intermediate,F,9606.0,CHEMBL615339,,,,,1,1
115,50587,,BAO_0000218,,2.2.15,Selectivity index was determined from the ratio of IC50 to the EC50 values evaluated in 2.2.15 cells.,,,N,Intermediate,F,9606.0,CHEMBL615340,,,,,1,1
116,81020,,BAO_0000219,726.0,HepG2,Antiviral activity against HBV was determined in 2.215 cell line,,,N,Intermediate,F,9606.0,CHEMBL615341,,,,,1,1
117,22226,,BAO_0000251,,,Inhibition of 20-HETE synthesis in human renal microsomes,,,U,Autocuration,B,9606.0,CHEMBL615342,,,,Microsomes,0,1
118,22226,,BAO_0000019,,,Inhibitory activity against 20-HETE production from arachidonic acid using human renal microsome 20-HETE synthase.,,,U,Autocuration,B,,CHEMBL615343,,,,,0,1
119,80612,,BAO_0000219,388.0,2008,Inhibitory concentration against 2008 (ovarian) cells,,,N,Intermediate,F,9606.0,CHEMBL615344,,,,,1,1
120,80612,,BAO_0000219,388.0,2008,50% Growth inhibitory concentration( GI 50 ) by using 2008 human ovarian carcinoma cell lines.,,,N,Intermediate,F,9606.0,CHEMBL615345,,,,,1,1
121,80612,,BAO_0000219,388.0,2008,Compound was tested for 50% growth inhibitory concentration by using human ovarian carcinoma cell lines (2008),,,N,Intermediate,F,9606.0,CHEMBL615346,,,,,1,1
122,80612,,BAO_0000219,388.0,2008,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells,,,N,Intermediate,F,9606.0,CHEMBL615347,,,,,1,1
123,80612,,BAO_0000219,388.0,2008,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells; not detected,,,N,Intermediate,F,9606.0,CHEMBL615348,,,,,1,1
124,80613,,BAO_0000219,561.0,2008/R,In vitro inhibition of 2008/R ovarian cancer cell line,,,N,Intermediate,F,9606.0,CHEMBL827085,,,,,1,1
125,80613,,BAO_0000219,561.0,2008/R,In vitro inhibition of 2008/R ovarian cancer cell line; NA= Not achievable,,,N,Intermediate,F,9606.0,CHEMBL615349,,,,,1,1
126,80614,,BAO_0000219,389.0,2008/S,In vitro inhibition of 2008/S ovarian cancer cell line,,,N,Intermediate,F,9606.0,CHEMBL615350,,,,,1,1
127,80614,,BAO_0000219,389.0,2008/S,In vitro inhibition of 2008/S ovarian cancer cell line; NA= Not achievable,,,N,Intermediate,F,9606.0,CHEMBL615351,,,,,1,1
128,100256,,BAO_0000220,,,Tested in vitro for inhibition of chymotrypsin like activity of purified human 20S proteasome,,,S,Expert,B,9606.0,CHEMBL615352,,,,,2,1
129,100256,,BAO_0000220,,,Compound was evaluated for inhibitory activity against 20S proteasome from human liver and brain,,,S,Intermediate,B,9606.0,CHEMBL615353,,,,,2,1
130,100256,,BAO_0000220,,,Inhibition of chymotrypsin-like activity of 20S proteasome,,,S,Expert,B,,CHEMBL615354,,,,,2,1
131,100256,,BAO_0000220,,,Inhibition of chymotrypsin-like activity of 20S proteasome; value ranges from 10-20 uM,,,S,Expert,B,,CHEMBL615355,,,,,2,1
132,100256,,BAO_0000220,,,Inhibitory activity against 20S proteosome,,,S,Intermediate,B,,CHEMBL615356,,,,,2,1
133,22226,,BAO_0000019,,,Compound was tested for inhibitory activity against tryptase,,,U,Autocuration,B,9606.0,CHEMBL615357,,,,,0,1
134,81020,,BAO_0000219,726.0,HepG2,Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line,,,N,Intermediate,F,9606.0,CHEMBL615358,,,,,1,1
135,81020,,BAO_0000219,726.0,HepG2,Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line,,,N,Intermediate,F,9606.0,CHEMBL827086,,,,,1,1
136,22226,,BAO_0000019,,,Compound was tested for the inhibition of Alpha-glucosidase,,,U,Autocuration,B,,CHEMBL615359,,,,,0,1
137,235,,BAO_0000357,,,Inhibitory concentration against human neutrophil elastase (HNE),,,H,Autocuration,B,,CHEMBL615360,,,,,8,1
138,22226,,BAO_0000218,,,Change in heart rate was expressed in percent at at a dose 0.002 mg/kg iv in anesthetized rat,,,U,Autocuration,F,10116.0,CHEMBL615361,,948.0,Heart,,0,1
139,19640,,BAO_0000019,,,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,,,H,Autocuration,F,,CHEMBL615362,,,,,8,1
140,19640,,BAO_0000019,,,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,,,H,Expert,F,,CHEMBL615363,,,,,8,1
141,19640,,BAO_0000357,,,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,,,H,Autocuration,B,,CHEMBL615364,,,,,8,1
142,19640,,BAO_0000019,,,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,,,H,Expert,F,,CHEMBL615365,,,,,8,1
143,80360,,BAO_0000219,524.0,P338,In Vitro evaluation for the growth inhibition of Subline (P388/AMSA) Leukemia cell lines,,,N,Intermediate,F,10090.0,CHEMBL615366,,,,,1,1
144,80360,,BAO_0000219,524.0,P338,In Vitro evaluation for the growth inhibition of Subline (P388/CP) Leukemia cell lines,,,N,Intermediate,F,10090.0,CHEMBL615367,,,,,1,1
145,80384,,BAO_0000219,554.0,PBL,Compound was evaluated for the inhibition of cell replication human peripheral blood lymphocytes (PBL's).,,,N,Intermediate,F,9606.0,CHEMBL615368,,,,,1,1
146,22226,,BAO_0000019,,,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells,,,U,Autocuration,F,9940.0,CHEMBL615369,,,,,0,1
147,22226,,BAO_0000019,,,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells.,,,U,Autocuration,F,9940.0,CHEMBL615370,,,,,0,1
148,191,,BAO_0000357,,,Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RT (Y181C),,,H,Autocuration,B,,CHEMBL615673,,,,,8,1
149,22226,,BAO_0000019,,,Compound was evaluated for its inhibitory effect on thymidine [3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-5,,,U,Autocuration,F,9606.0,CHEMBL615674,,,,,0,1
150,22226,,BAO_0000019,,,Compound was evaluated for its inhibitory effect on thymidine [3H]-dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-6,,,U,Autocuration,F,9606.0,CHEMBL615675,,,,,0,1
151,22226,,BAO_0000219,635.0,CCRF-CEM,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in at conc. 10e-7,,,U,Autocuration,F,9606.0,CHEMBL615676,,,,,0,1
152,22226,,BAO_0000219,635.0,CCRF-CEM,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM cells in culture at conc. 10e-4,,,U,Autocuration,F,9606.0,CHEMBL615677,,,,,0,1
153,22226,,BAO_0000219,635.0,CCRF-CEM,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-5,,,U,Autocuration,F,9606.0,CHEMBL615678,,,,,0,1
154,22226,,BAO_0000219,635.0,CCRF-CEM,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-6,,,U,Autocuration,F,9606.0,CHEMBL615679,,,,,0,1
155,22226,,BAO_0000019,,,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM/MTX cells in at conc. 10e-7.,,,U,Autocuration,F,9606.0,CHEMBL615680,,,,,0,1
156,22226,,BAO_0000019,,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-4,,,U,Autocuration,F,9606.0,CHEMBL615681,,,,,0,1
157,104290,,BAO_0000249,,,In vitro binding affinity towards (alpha-4)2(beta-2)3 neuronal nicotinic acetylcholine receptor in P2 membrane fractions of rat forebrain,,,H,Autocuration,B,,CHEMBL857972,,,,,6,1
158,50264,,BAO_0000218,,,Minimum inhibitory concentration of compound against Streptococcus pyogenus septicemia in the mouse,,,N,Intermediate,F,1314.0,CHEMBL857899,,,,,1,1
159,50527,,BAO_0000218,,,Antiviral activity against 07/1 strain of thymidine kinase negative (TK-) Varicella-Zoster Virus (VZV),,,N,Intermediate,F,10335.0,CHEMBL615371,,,,,1,1
160,50527,,BAO_0000218,468.0,HEL,Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells.,,,N,Expert,F,10335.0,CHEMBL615372,,,,,1,1
161,50527,,BAO_0000218,,,Antiviral activity against 07/1 strain of VZV; ND: No data,,,N,Intermediate,F,10335.0,CHEMBL615373,,,,,1,1
162,50527,,BAO_0000218,,,Antiviral activity against 07/1 strain of VZV; ND=No data,,,N,Intermediate,F,10335.0,CHEMBL615374,,,,,1,1
163,50145,,BAO_0000218,,,"Antibacterial activity was determined against gram negative organism, Enterobacter cloacae (MA2646)",,,N,Intermediate,F,561.0,CHEMBL615375,,,,,1,1
164,22226,,BAO_0000019,,,Ratio of Ki at A2 to Ki at A1 receptors,,,U,Autocuration,B,,CHEMBL615376,,,,,0,1
165,11143,,BAO_0000249,,,"In vitro inhibition of 1,3-beta-glucan synthase in Candida albicans membrane assay.",,,H,Expert,B,5476.0,CHEMBL615377,,,,,8,1
166,18077,,BAO_0000357,,,"Inhibition of 1,3-beta-glucan synthase",,,H,Expert,B,284593.0,CHEMBL615378,,,,,8,1
167,80609,,BAO_0000219,832.0,1-87 tumor cell line,Inhibition of growth of 1-87 human tumor cell line,,,N,Intermediate,F,9606.0,CHEMBL615379,,,,,1,1
168,12166,,BAO_0000219,,,Inhibition of 1-lipoxygenase (LOX)in RBL cells,,,D,Expert,B,10116.0,CHEMBL615380,,,,,9,1
169,100171,,BAO_0000357,,,Inhibitory activity against soybean 1-lipoxygenase (SLO),,,D,Autocuration,B,3847.0,CHEMBL615381,,,,,9,1
170,100171,,BAO_0000357,,,Inhibitory activity against soybean 1-lipoxygenase (SLO); no effect,,,D,Autocuration,B,3847.0,CHEMBL615382,,,,,9,1
171,100171,,BAO_0000357,,,% inhibition against soybean 1-lipoxygenase (SLO),,,D,Autocuration,B,3847.0,CHEMBL615383,,,,,9,1
172,100171,,BAO_0000357,,,percent inhibition against soybean 1-lipoxygenase (SLO);NI is no inhibition,,,D,Autocuration,B,3847.0,CHEMBL615384,,,,,9,1
173,100171,,BAO_0000357,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 10:90,,,D,Autocuration,B,3847.0,CHEMBL615385,,,,,9,1
174,100171,,BAO_0000357,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 1:99,,,D,Autocuration,B,3847.0,CHEMBL615386,,,,,9,1
175,100171,,BAO_0000357,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 25:75,,,D,Autocuration,B,3847.0,CHEMBL615387,,,,,9,1
176,100171,,BAO_0000357,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 35:65,,,D,Autocuration,B,3847.0,CHEMBL615388,,,,,9,1
177,100171,,BAO_0000357,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 50:50,,,D,Autocuration,B,3847.0,CHEMBL615214,,,,,9,1
178,100171,,BAO_0000357,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 76:24,,,D,Autocuration,B,3847.0,CHEMBL827087,,,,,9,1
179,100171,,BAO_0000357,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 87:13,,,D,Autocuration,B,3847.0,CHEMBL615215,,,,,9,1
180,100171,,BAO_0000357,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 89:11,,,D,Autocuration,B,3847.0,CHEMBL615216,,,,,9,1
181,100171,,BAO_0000357,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 95:5,,,D,Autocuration,B,3847.0,CHEMBL615217,,,,,9,1
182,100171,,BAO_0000357,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 97:3,,,D,Autocuration,B,3847.0,CHEMBL615218,,,,,9,1
183,100171,,BAO_0000357,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 99:1,,,D,Autocuration,B,3847.0,CHEMBL615219,,,,,9,1
184,22226,,BAO_0000019,,,Evaluated for inhibitory activity on 10-formyltetrahydrofolate synthetase(L cell) at folate substrate concentration of 100 uM,,,U,Autocuration,B,10090.0,CHEMBL615220,,,,,0,1
185,80049,,BAO_0000219,294.0,C3H 10T1/2,Cells were harvested and were assayed for luciferase and -galactosidase activities (Transcriptional activity),,,N,Intermediate,F,10090.0,CHEMBL615221,,,,,1,1
186,22226,,BAO_0000019,,,In vitro anticancer activity against 11 NCI NSCLC cell lines; inactive,,,U,Intermediate,F,,CHEMBL615222,,,,,0,1
187,11489,,BAO_0000357,,,In vitro inhibitory activity against human 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),,,H,Autocuration,B,,CHEMBL615223,,,,,8,1
188,11862,,BAO_0000357,,,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),,,H,Autocuration,B,,CHEMBL615224,,,,,8,1
189,11862,,BAO_0000357,,,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA).,,,H,Autocuration,B,,CHEMBL615225,,,,,8,1
190,11489,,BAO_0000357,,,Ability to convert [3H]cortisol to the tritium labeled cortisone in the presence of human 11 beta hydroxysteroid dehydrogenase type 2,,,H,Autocuration,B,,CHEMBL615226,,,,,8,1
191,11862,,BAO_0000357,,,Inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 2 at a concentration of 0.2 mM; NI means no inhibition,,,H,Autocuration,B,,CHEMBL615227,,,,,8,1
192,12347,,BAO_0000019,,,Evaluated for inhibition of bovine adrenal cortical mitochondrial 11 beta-hydroxylase,,,D,Expert,F,9913.0,CHEMBL615228,,,,,9,1
193,100120,,BAO_0000357,,,Effect on adrenal 11-beta-hydroxylase activity at 10e-4 M; No significant effect,,,D,Expert,B,10116.0,CHEMBL615229,,,,,9,1
194,100120,,BAO_0000357,,,Inhibition of 11 beta-hydroxylase from rat adrenal gland,,,D,Expert,B,10116.0,CHEMBL615230,,2369.0,Adrenal gland,,9,1
195,100120,,BAO_0000357,,,Inhibition of rat adrenal 11-beta-hydroxylase,,,D,Expert,B,10116.0,CHEMBL615231,,,,,9,1
196,100120,,BAO_0000357,,,Inhibition of rat adrenal 11-beta-hydroxylase,,,D,Expert,B,10116.0,CHEMBL884520,,,,,9,1
197,100120,,BAO_0000357,,,Inhibition of rat adrenal 11-beta-hydroxylase at 10e-5 M,,,D,Expert,B,10116.0,CHEMBL615232,,,,,9,1
198,10328,,BAO_0000019,,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 1 of wistar rat liver cytosol at 10 uM was determined using [3H]cortisone,,,H,Autocuration,B,,CHEMBL615233,,,,,8,1
199,11490,,BAO_0000357,,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,,,H,Autocuration,B,,CHEMBL827088,,,,,8,1
200,11490,,BAO_0000357,,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,,,H,Autocuration,B,,CHEMBL615234,,,,,8,1
201,11134,,BAO_0000019,,,Compound was tested for the percent of inhibition against 12-LO at 10 uM,,,H,Autocuration,F,,CHEMBL615235,,,,,8,1
202,12052,,BAO_0000019,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,,H,Autocuration,B,,CHEMBL615236,,,,,8,1
203,11134,,BAO_0000019,,,Compound was tested in vitro for inhibition of 12-LO human platelet,,,H,Autocuration,B,,CHEMBL615237,,,,,8,1
204,11134,,BAO_0000019,,,Inhibitory concentration against human platelet 12-lipoxygenase,,,H,Autocuration,F,,CHEMBL615238,,,,,8,1
205,11134,,BAO_0000019,,,Compound at 100 uM was tested in vitro for inhibition of 12-LO human platelet,,,H,Autocuration,B,,CHEMBL615239,,,,,8,1
206,11134,,BAO_0000019,,,Inhibitory concentration against human platelet 12-lipoxygenase,,,D,Autocuration,F,9606.0,CHEMBL615240,,,,,9,1
207,11835,,BAO_0000019,,,Tested for inhibition of 12-LO (12-lipoxygenase) as an inhibitor of 12(S)-HETE biosynthesis in mouse epidermal homogenates,,,H,Expert,B,,CHEMBL615241,,,,,8,1
208,11601,,BAO_0000357,,,Inhibitory activity against conversion of [1-14C]arachidonic acid to 12-HPETE and its reduction product 12-HETE by porcine leukocyte type 12-lipoxygenase,,,H,Expert,B,,CHEMBL615242,,,,,8,1
209,11134,,BAO_0000019,,,Inhibitory activity against human platelet 12-lipoxygenase (12-HLO),,,H,Autocuration,B,,CHEMBL615243,,,,,8,1
210,11134,,BAO_0000019,,,Inhibitory activity against human platelet 12-lipoxygenase,,,H,Autocuration,B,,CHEMBL615244,,,,,8,1
211,11134,,BAO_0000019,,,Inhibitory activity against human platelet 12-lipoxygenase was evaluated,,,H,Autocuration,B,,CHEMBL615245,,,,,8,1
212,11134,,BAO_0000019,,,% inhibition against human platelet 12-lipoxygenase (12-HLO),,,H,Autocuration,B,,CHEMBL615246,,,,,8,1
213,11134,,BAO_0000019,,,Inhibitory activity against human platelet 12-lipoxygenase was evaluated at 100 uM,,,H,Autocuration,B,,CHEMBL615247,,,,,8,1
214,11134,,BAO_0000019,,,percent inhibition against human platelet 12-lipoxygenase (12-HLO); NI is no inhibition,,,H,Autocuration,B,,CHEMBL615248,,,,,8,1
215,11601,,BAO_0000357,,,Inhibitory activity towards porcine 12-lipoxygenase,,,H,Autocuration,B,,CHEMBL615249,,,,,8,1
216,11601,,BAO_0000357,,,Tested for inhibition against porcine 12-LO,,,H,Autocuration,B,,CHEMBL615250,,,,,8,1
217,12052,,BAO_0000019,,,Inhibition of 12-lipoxygenase was evaluated in rat platelets stimulated by thrombin up to a concentration of 10 uM; NE means No effect,,,H,Autocuration,B,,CHEMBL615251,,,,,8,1
218,12052,,BAO_0000019,,,Inhibitory activity against 12-lipoxygenase in rat platelet rich plasma,,,H,Autocuration,B,,CHEMBL615252,,,,,8,1
219,12052,,BAO_0000019,,,In vitro inhibition of rat platelet 12-lipoxygenase,,,H,Expert,B,,CHEMBL828340,,,,,8,1
220,12052,,BAO_0000019,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,,H,Autocuration,B,,CHEMBL615253,,,,,8,1
221,12052,,BAO_0000019,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 100 uM,,,H,Autocuration,B,,CHEMBL615254,,,,,8,1
222,12052,,BAO_0000019,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 30 uM,,,H,Autocuration,B,,CHEMBL615255,,,,,8,1
223,12052,,BAO_0000019,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,,H,Autocuration,B,,CHEMBL615256,,,,,8,1
224,12052,,BAO_0000019,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase,,,H,Autocuration,B,,CHEMBL615257,,,,,8,1
225,12052,,BAO_0000019,,,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 100 uM,,,H,Autocuration,B,,CHEMBL615258,,,,,8,1
226,80007,,BAO_0000219,621.0,41M,Cytotoxic activity in a panel of Human ovarian tumor 41M cell line after 96h of drug exposure,,,N,Intermediate,F,9606.0,CHEMBL615259,,,,,1,1
227,80007,,BAO_0000219,621.0,41M,In vitro antitumor activity against 41M cell line.,,,N,Expert,F,9606.0,CHEMBL615260,,,,,1,1
228,80007,,BAO_0000219,621.0,41M,cytotoxicity against 41M cells incubated for 24 hr in MTT assay.,,,N,Intermediate,F,9606.0,CHEMBL615261,,,,,1,1
229,80007,,BAO_0000219,621.0,41M,Cytotoxic activity in a panel of Human ovarian tumor 41M/CDDP cell line after 96h of drug exposure,,,N,Intermediate,F,9606.0,CHEMBL615262,,,,,1,1
230,80007,,BAO_0000219,621.0,41M,In vitro antitumor activity against 41McisR cell line.,,,N,Expert,F,9606.0,CHEMBL615263,,,,,1,1
231,80007,,BAO_0000219,621.0,41M,Resistant factor was determined between IC50 of cisplatin-resistant human tumor cell lines to that of 41McisR cell line,,,N,Expert,F,9606.0,CHEMBL838393,,,,,1,1
232,80007,,BAO_0000219,621.0,41M,cytotoxicity against 41McisR cells incubated for 24 hr in MTT assay,,,N,Intermediate,F,9606.0,CHEMBL615264,,,,,1,1
233,84,,BAO_0000357,,,Inhibition of 5'-inosine monophosphate dehydrogenase type I (IMPDH I),,,D,Expert,B,9606.0,CHEMBL615265,,,,,9,1
234,68,,BAO_0000357,,,Inhibition of 5'-inosine monophosphate dehydrogenase type II (IMPDH II),,,D,Expert,B,9606.0,CHEMBL615266,,,,,9,1
235,68,,BAO_0000357,,,Inhibitory activity against inosine 5'-inosine monophosphate dehydrogenase type II (IMPDH II),,,H,Expert,B,,CHEMBL615267,,,,,8,1
236,10201,,BAO_0000357,,,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase,,,H,Expert,B,,CHEMBL615268,,,,,8,1
237,10201,,BAO_0000357,,,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase; nd = Not determined,,,H,Expert,B,,CHEMBL615269,,,,,8,1
238,10201,,BAO_0000357,,,Initial dissociation constant towards human 5'-methylthioadenosine phosphorylase,,,H,Expert,B,,CHEMBL615270,,,,,8,1
239,12220,,BAO_0000357,,,"Evaluated for inhibitory activity on 5,10-Methenyl Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",,,H,Autocuration,B,,CHEMBL615271,,,,,8,1
240,11303,,BAO_0000357,,,"Inhibitory activity against 5,10-methylenetetrahydrofolate dehydrogenase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",,,H,Autocuration,B,562.0,CHEMBL615272,,,,,8,1
241,11303,,BAO_0000357,,,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",,,H,Autocuration,B,562.0,CHEMBL615103,,,,,8,1
242,11303,,BAO_0000357,,,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM;NT=Not tested",,,H,Autocuration,B,562.0,CHEMBL615104,,,,,8,1
243,12220,,BAO_0000357,,,"Evaluated for inhibitory activity on 5,10-Methylene Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",,,H,Autocuration,B,,CHEMBL615105,,,,,8,1
244,12220,,BAO_0000357,,,"Evaluated for inhibitory activity on 5,10-methylenetetrahydrofolate dehydrogenase(L cell) at folate substrate concentration of 100 uM",,,H,Autocuration,B,,CHEMBL872866,,,,,8,1
245,11303,,BAO_0000357,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,,H,Autocuration,B,9823.0,CHEMBL615106,,,,,8,1
246,11303,,BAO_0000019,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (A,porcine liver) enzyme.",,,H,Autocuration,B,9823.0,CHEMBL615107,,,,,8,1
247,11303,,BAO_0000357,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-4 M inhibitory concentration",,,H,Autocuration,B,9823.0,CHEMBL615108,,,,,8,1
248,11303,,BAO_0000357,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-5 M inhibitory concentration",,,H,Autocuration,B,9823.0,CHEMBL615109,,,,,8,1
249,11303,,BAO_0000357,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,,H,Autocuration,B,9823.0,CHEMBL615110,,,,,8,1
250,11303,,BAO_0000019,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",,,H,Autocuration,B,9823.0,CHEMBL840105,,,,,8,1
251,11303,,BAO_0000019,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-5 M inhibitory concentration",,,H,Autocuration,B,9823.0,CHEMBL615111,,,,,8,1
252,11303,,BAO_0000019,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-6 M inhibitory concentration",,,H,Autocuration,B,9823.0,CHEMBL615112,,,,,8,1
253,11303,,BAO_0000019,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-7 M inhibitory concentration",,,H,Autocuration,B,9823.0,CHEMBL615113,,,,,8,1
254,11303,,BAO_0000019,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme.",,,H,Autocuration,B,9823.0,CHEMBL615114,,,,,8,1
255,11303,,BAO_0000357,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,,H,Autocuration,B,9823.0,CHEMBL615115,,,,,8,1
256,11303,,BAO_0000019,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",,,H,Autocuration,B,9823.0,CHEMBL615116,,,,,8,1
257,11303,,BAO_0000357,,,"Compound was tested for in vitro inhibition of 5,10-Methylene Tetrahydrofolate Cyclohydrolase, competitive against (+)-L-5,10-methenyltetrahydrofolate",,,H,Autocuration,B,,CHEMBL615698,,,,,8,1
258,22226,,BAO_0000019,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme at 10E-4 M inhibitory concentration",,,U,Autocuration,B,9823.0,CHEMBL615699,,,,,0,1
259,22226,,BAO_0000019,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme.",,,U,Autocuration,B,9823.0,CHEMBL615700,,,,,0,1
260,100249,,BAO_0000357,,,Inhibition of 5-Desaturase involved in ergosterol biosynthesis,,,H,Expert,B,4932.0,CHEMBL615701,,,,,8,1
261,22226,,BAO_0000019,,,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,,,U,Autocuration,B,10116.0,CHEMBL615702,,,,,0,1
262,22226,,BAO_0000019,,,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,,,U,Autocuration,B,10116.0,CHEMBL615703,,,,,0,1
263,22226,,BAO_0000019,,,"Irreversible inhibition of Walker 256 FUDR phosphorylase; expressed as Vo/Vi, velocity without inhibitor to that of velocity with inhibitor",,,U,Autocuration,B,10116.0,CHEMBL615704,,,,,0,1
264,104698,,BAO_0000019,,,"Tested for 5-HT 3 receptor antagonist potency by ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",,,H,Autocuration,F,,CHEMBL615705,,,,,6,1
265,104698,,BAO_0000019,,,"Compound was tested for its 5-HT 3 receptor antagonist potency by their ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",,,H,Autocuration,F,,CHEMBL615706,,,,,6,1
266,20033,,BAO_0000221,,,Relative ability to increase cholinergically mediated contractions in isolated ileum of guinea pig,,,D,Intermediate,F,10141.0,CHEMBL615707,,2116.0,Ileum,,9,1
267,10623,,BAO_0000019,,,Stimulatory activity of intragastric pressure was tested in the rat,,,H,Expert,F,,CHEMBL615708,,,,,8,1
268,121,,BAO_0000357,,,% Decrease of 5-HT carrier-receptor -bound radioactivity using paroxetine as a radioligand.,,,H,Autocuration,B,,CHEMBL615709,,,,,8,1
269,22226,,BAO_0000218,,,Dose to reduce neuronal firing against 5-HT cells in rats (iv),,,U,Autocuration,F,10116.0,CHEMBL615710,,,,,0,1
270,12688,,BAO_0000019,,,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,,,H,Autocuration,F,,CHEMBL615711,,,,,8,1
271,121,,BAO_0000357,,,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine,,,D,Expert,B,9606.0,CHEMBL615712,,,,,9,1
272,121,,BAO_0000357,,,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine; No data,,,D,Expert,B,9606.0,CHEMBL836325,,,,,9,1
273,12198,,BAO_0000019,,,Inhibition of high affinity 5-HT uptake at concentration of 1 uM,,,H,Autocuration,F,,CHEMBL615713,,,,,8,1
274,12198,,BAO_0000357,,,Inhibition constant of high-affinity 5-HT uptake,,,H,Autocuration,B,,CHEMBL615714,,,,,8,1
275,12198,,BAO_0000019,,,Michaelis-Menten constant was reported for high affinity transport of 5-HT,,,H,Autocuration,F,,CHEMBL615715,,,,,8,1
276,12198,,BAO_0000019,,,Maximum rate was determined for high affinity transport of 5-HT,,,H,Autocuration,F,,CHEMBL615716,,,,,8,1
277,104714,,BAO_0000019,,,Compound was tested for agonistic activity against 5-HT uptake,,,H,Autocuration,F,,CHEMBL615717,,,,,4,1
278,10577,,BAO_0000019,,,Inhibition affinity against 5-HT-1B receptor in rat frontal cortex using radio binding assay,,,H,Expert,B,,CHEMBL881818,,,,,8,1
279,105,,BAO_0000357,,,Inhibition affinity against 5-HT-1D receptor in bovine caudate nucleus using radio binding assay,,,H,Expert,B,9913.0,CHEMBL884540,,,,,8,1
280,104744,,BAO_0000224,,,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,,,D,Autocuration,B,10116.0,CHEMBL615718,,,,,5,1
281,104744,,BAO_0000224,,,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1 using [3H]5-HT as radioligand,,,H,Autocuration,B,,CHEMBL615719,,,,,4,1
282,104744,,BAO_0000249,,,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M,,,H,Autocuration,B,,CHEMBL615720,,,,Membranes,4,1
283,104744,,BAO_0000249,,,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M.,,,H,Autocuration,B,,CHEMBL615721,,,,Membranes,4,1
284,104744,,BAO_0000019,,,Displacement of binding of [3H]-5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,,H,Autocuration,B,,CHEMBL615722,,,,,4,1
285,51,,BAO_0000019,,,Dose required to reduce neuronal firing of 5-HT1A cells by 50%,,,H,Autocuration,F,,CHEMBL615723,,,,,8,1
286,51,,BAO_0000221,,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,H,Autocuration,B,,CHEMBL615724,,10000000.0,Hippocampus,,8,1
287,51,,BAO_0000221,,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,,H,Autocuration,B,,CHEMBL615725,,10000000.0,Hippocampus,,8,1
288,51,,BAO_0000221,,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,H,Autocuration,B,,CHEMBL615726,,10000000.0,Hippocampus,,8,1
289,10576,In vivo,BAO_0000218,,,Antagonistic activity at postsynaptic 5-HT1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (.26-3.52),,,H,Autocuration,F,,CHEMBL615727,,,,,8,1
290,105570,,BAO_0000019,,,Effect on forskolin stimulated adenylate cyclase activity at 5-HT1D receptor of guinea pig substantia nigra.,,,D,Intermediate,F,10141.0,CHEMBL615728,,,,,9,1
291,279,,BAO_0000219,449.0,CHO,Binding affinity towards 5-HT1F (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,,H,Autocuration,B,,CHEMBL857971,,,,,8,1
292,107,,BAO_0000357,,,Compound was tested for the displacement of [125I]DOI from clone human 5-hydroxytryptamine 2A receptor,,,H,Autocuration,B,,CHEMBL615729,,,,,8,1
293,12687,,BAO_0000019,,,Efficacy against 5-hydroxytryptamine 2A receptor,,,D,Expert,F,10116.0,CHEMBL615730,,,,,9,1
294,12687,,BAO_0000019,,,Intrinsic activity towards 5-HT2A receptor of rat tail artery,,,H,Expert,F,,CHEMBL615731,,,,,8,1
295,12687,,BAO_0000019,,,Relative potency towards 5-HT2A receptor of rat tail artery,,,H,Expert,F,,CHEMBL615732,,,,,8,1
296,12687,,BAO_0000019,,,Blocking 5-HT2A receptor-mediated contractions of rat tail artery,,,H,Expert,F,,CHEMBL615733,,,,,8,1
297,12687,,BAO_0000019,,,Partial agonism at 5-HT2A receptor was evaluated in presence of ketanserin (3-10 nM) in isolated rat tail artery,,,H,Expert,F,,CHEMBL615734,,,,,8,1
298,12687,,BAO_0000019,,,Compound was tested for the intrinsic activity against 5-HT2A receptors of rat tail artery.,,,H,Autocuration,F,,CHEMBL615735,,,,,8,1
299,12687,,BAO_0000019,,,Effectiveness in blocking 5-HT2A receptor-mediated contractions of rat tail artery,,,H,Expert,F,,CHEMBL615736,,,,,8,1
300,20033,,BAO_0000221,,,Evaluated for the agonistic activity against 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,,,D,Intermediate,F,10141.0,CHEMBL615737,,2116.0,Ileum,,9,1
301,20033,,BAO_0000221,,,Agonistic activity against Serotonin 5-HT4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI),,,D,Intermediate,F,10141.0,CHEMBL615738,,2116.0,Ileum,,9,1
302,20033,,BAO_0000221,,,Evaluated for the agonistic activity against Serotonin 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,,,D,Intermediate,F,10141.0,CHEMBL615739,,2116.0,Ileum,,9,1
303,10623,,BAO_0000357,,,The binding affinity was measured on 5-hydroxytryptamine 4 receptor using [3H]- GR-113808 as radioligand.,,,H,Autocuration,B,,CHEMBL615278,,,,,8,1
304,10623,,BAO_0000019,,,Antagonist activity against 5-HT4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,,,D,Expert,F,10116.0,CHEMBL615279,,,,,9,1
305,168,,BAO_0000357,,,Binding affinity against 5-hydroxytryptamine 4 receptor,,,H,Expert,B,,CHEMBL615280,,,,,8,1
306,22226,,BAO_0000019,,,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of chick intestine,,,U,Autocuration,B,9031.0,CHEMBL615281,,,,,0,1
307,22226,,BAO_0000019,,,Inhibitory effect (10e-6 M) on the 25-OH-D3-1-hydroxylase activity,,,U,Autocuration,F,9606.0,CHEMBL615282,,,,,0,1
308,22226,,BAO_0000019,,,25-OH-D3-1-hydroxylase activity (10e-6 M) was measured as %control,,,U,Autocuration,F,9606.0,CHEMBL615283,,,,,0,1
309,80156,,BAO_0000219,649.0,HL-60,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of human HL-60 cells,,,N,Autocuration,B,9606.0,CHEMBL615284,,,,,1,1
310,22226,,BAO_0000019,,,Inhibitory effect (10e-6 M) on the 25-hydroxyvitamin D3-1-hydroxylase activity,,,U,Autocuration,B,9606.0,CHEMBL615285,,,,,0,1
311,22226,,BAO_0000019,,,25-hydroxyvitamin D3-1-hydroxylase activity (10e-6 M) was measured as %control,,,U,Autocuration,B,9606.0,CHEMBL615286,,,,,0,1
312,104703,,BAO_0000219,,Oocytes,Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-1-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes,,,D,Autocuration,B,9606.0,CHEMBL615287,,,,,7,1
313,100256,,BAO_0000220,,,Chymotryptic inhibitory activity against 26S proteasome,,,S,Intermediate,F,,CHEMBL615288,,,,,2,1
314,100256,,BAO_0000220,,,Inhibitory activity against 26S proteasome degradation of IkB,,,S,Intermediate,B,,CHEMBL615289,,,,,2,1
315,81034,,BAO_0000219,478.0,A2780,In vitro inhibition of 2780/DOX ovarian cancer cell line,,,N,Intermediate,F,9606.0,CHEMBL615290,,,,,1,1
316,81034,,BAO_0000219,478.0,A2780,In vitro inhibition of 2780/S ovarian cancer cell line,,,N,Intermediate,F,9606.0,CHEMBL884522,,,,,1,1
317,22226,,BAO_0000019,,,Relative activity on the cellular accumulation of vincristine in multidrug-resistant (MDR) human ovarian cancer 2780AD cells,,,U,Autocuration,F,9606.0,CHEMBL615291,,,,,0,1
318,22222,,BAO_0000225,,,Association constant for binding to AATT 28-mer AATT hairpin,,,M,Intermediate,B,,CHEMBL615292,,,,,3,1
319,22222,,BAO_0000225,,,Kinetically Defined Association Constant for 28-mer AATT hairpin.,,,M,Intermediate,B,,CHEMBL615293,,,,,3,1
320,22222,,BAO_0000225,,,Reaction Rate Parameter for 28-mer AATT hairpin,,,M,Intermediate,B,,CHEMBL615294,,,,,3,1
321,22222,,BAO_0000225,,,Reaction Rate Parameter for 28-mer AATT hairpin,,,M,Intermediate,B,,CHEMBL615295,,,,,3,1
322,22226,,BAO_0000019,,,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 1),,,U,Autocuration,F,9606.0,CHEMBL825021,,,,,0,1
323,22226,,BAO_0000019,,,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 2),,,U,Autocuration,F,9606.0,CHEMBL615296,,,,,0,1
324,22226,,BAO_0000019,,,Inhibitory concentration by single cycle replication assay using envelope deficient HIV-1,,,U,Autocuration,F,9606.0,CHEMBL615297,,,,,0,1
325,22226,,BAO_0000019,,,Cytotoxicity against cell line 2SC/20 determined by MTT test,,,U,Autocuration,F,10029.0,CHEMBL615298,,,,,0,1
326,22226,,BAO_0000019,,,Cytotoxicity against cell line 2SC/20 of hamster determined by MTT test,,,U,Autocuration,F,10029.0,CHEMBL615299,,,,,0,1
327,22226,,BAO_0000019,,,Inhibitory concentration against the growth of 2SC/20 cell line after 72 hr of drug exposure by MTT test,,,U,Autocuration,F,10029.0,CHEMBL615300,,,,,0,1
328,241,,BAO_0000357,,,Binding affinity on 3 beta-hydroxysteroid dehydrogenase,,,H,Autocuration,B,,CHEMBL615301,,,,,8,1
329,241,,BAO_0000357,,,Binding affinity for 3-beta-hydroxysteroid dehydrogenase,,,D,Expert,B,9606.0,CHEMBL615302,,,,,9,1
330,22226,,BAO_0000019,,,Selectivity ratio of ID50 in liver and heart,,,U,Autocuration,B,10116.0,CHEMBL615303,,,,,0,1
331,12132,,BAO_0000019,,,"Selectivity, ratio of relative ID50 in liver and heart",,,H,Autocuration,B,,CHEMBL615304,,,,,8,1
332,12132,,BAO_0000019,,,Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to T3,,,H,Autocuration,B,,CHEMBL615305,,,,,8,1
333,12132,,BAO_0000218,,,"Binding affinity to the receptor was determined in nuclei of heart In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,,H,Autocuration,B,,CHEMBL615306,,,,,8,1
334,12132,,BAO_0000218,,,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,,H,Autocuration,B,,CHEMBL615307,,,,,8,1
335,12132,In vivo,BAO_0000218,,,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,,H,Autocuration,B,,CHEMBL615308,,,,,8,1
336,12132,In vivo,BAO_0000218,,,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,,H,Autocuration,F,,CHEMBL615309,,,,,8,1
337,22226,,BAO_0000019,,,"Binding affinity to the thyroid hormone receptor was determined in vitro in isolated nuclei of rat liver relative to 3,5,3' triiodothyronine",,,U,Autocuration,B,,CHEMBL615310,,,,,0,1
338,12132,,BAO_0000019,,,Binding affinity to the receptor was determined in vitro in isolated nuclei of rat liver relative to T3,,,H,Autocuration,B,,CHEMBL615311,,,,,8,1
339,22226,,BAO_0000019,,,"Binding affinity to thyroid hormone receptor beta, relative to 3,5,3' triiodothyronine receptor, in isolated nuclei of heart",,,U,Autocuration,B,9606.0,CHEMBL615312,,,,,0,1
340,12132,,BAO_0000019,,,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,,,H,Autocuration,B,,CHEMBL615313,,,,,8,1
341,12132,,BAO_0000019,,,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,,,H,Autocuration,F,,CHEMBL615314,,,,,8,1
342,12132,,BAO_0000019,,,"Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to 3,5,3' triiodothyronine receptor",,,H,Autocuration,B,,CHEMBL615315,,,,,8,1
343,22226,,BAO_0000218,,,"In vivo binding affinity for 3,5,3'' triiodothyronine receptor of heart nuclei 1 hr after intravenous administration",,,U,Autocuration,B,10116.0,CHEMBL615316,,,,,0,1
344,12132,In vivo,BAO_0000218,,,Binding affinity to the receptor was determined in nuclei of heart in vivo 1 hour after intravenous administration relative to T3,,,H,Autocuration,B,,CHEMBL615317,,,,,8,1
345,12132,,BAO_0000218,,,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,,H,Autocuration,B,,CHEMBL615318,,,,,8,1
346,22226,,BAO_0000218,,,"In vivo binding affinity for 3,5,3' triiodothyronine receptor of liver nuclei 1 hour after intravenous administration",,,U,Autocuration,B,10116.0,CHEMBL615319,,,,,0,1
347,12132,,BAO_0000019,,,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",,,H,Autocuration,B,,CHEMBL615320,,,,,8,1
348,12132,,BAO_0000019,,,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",,,H,Autocuration,F,,CHEMBL615321,,,,,8,1
349,22226,,BAO_0000019,,,"Inhibition of [125I]L-T3 binding to rat hepatic 3,5,3''-triiodo-L-thyronine receptor",,,U,Autocuration,B,10116.0,CHEMBL615322,,,,,0,1
350,19690,,BAO_0000357,,,Inhibition constant for binding to Co2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,,,H,Autocuration,B,562.0,CHEMBL615323,,,,,8,1
351,19690,,BAO_0000357,,,Inhibition constant for binding to Zn2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,,,H,Autocuration,B,562.0,CHEMBL615407,,,,,8,1
352,19690,,BAO_0000357,,,Kinetics expressed as Michaelis-Menten constant against Co2+ form of 3-dehydroquinate synthase purified from Escherichia coli,,,H,Autocuration,B,562.0,CHEMBL857267,,,,,8,1
353,19690,,BAO_0000357,,,Kinetics expressed as Michaelis-Menten constant against Zn2+ form of 3-dehydroquinate synthase purified from Escherichia coli,,,H,Autocuration,B,562.0,CHEMBL615408,,,,,8,1
354,19690,,BAO_0000357,,,Type of inhibition of 3-dehydroquinate synthase was determined; R - Slowly reversible,,,H,Autocuration,B,,CHEMBL615409,,,,,8,1
355,19690,,BAO_0000357,,,Compound was evaluated for its inhibitory constant against 3-dehydroquinate synthase,,,H,Autocuration,B,,CHEMBL615410,,,,,8,1
356,19690,,BAO_0000357,,,Inhibition constant against 3-dehydroquinate synthase,,,H,Autocuration,B,,CHEMBL615411,,,,,8,1
357,19690,,BAO_0000357,,,Association rate constant against 3-dehydroquinate synthase,,,H,Autocuration,B,,CHEMBL615412,,,,,8,1
358,19690,,BAO_0000357,,,Rate constant against 3-dehydroquinate synthase,,,H,Autocuration,B,,CHEMBL615413,,,,,8,1
359,22226,,BAO_0000019,,,Inhibitory activity against fuc-TVII,,,U,Autocuration,B,,CHEMBL615414,,,,,0,1
360,12236,,BAO_0000251,,,Ability of compound (2.5 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,,D,Autocuration,B,10116.0,CHEMBL615415,,2107.0,Liver,Microsomes,9,1
361,12236,,BAO_0000251,,,Ability of compound (2500 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,,D,Autocuration,B,10116.0,CHEMBL615416,,2107.0,Liver,Microsomes,9,1
362,12236,,BAO_0000251,,,Ability of compound (250 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,,D,Autocuration,B,10116.0,CHEMBL615417,,2107.0,Liver,Microsomes,9,1
363,12236,,BAO_0000251,,,Ability of compound (25 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,,D,Autocuration,B,10116.0,CHEMBL615418,,2107.0,Liver,Microsomes,9,1
364,12236,,BAO_0000251,,,Ability of compound at 0 uM to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,,D,Autocuration,B,10116.0,CHEMBL615419,,2107.0,Liver,Microsomes,9,1
365,12236,,BAO_0000251,,,Ability of compound to inhibit the activity of 3-hydroxy-3-methylglutarylcoenzyme A(HMGR) reductase in rat liver microsomes,,,D,Autocuration,B,10116.0,CHEMBL615420,,2107.0,Liver,Microsomes,9,1
366,12236,,BAO_0000251,,,Percentage inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A reductase in rat liver microsomes at 250 uM,,,D,Autocuration,B,10116.0,CHEMBL615421,,2107.0,Liver,Microsomes,9,1
367,12236,,BAO_0000251,,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 0 uM,,,D,Autocuration,B,10116.0,CHEMBL615422,,2107.0,Liver,Microsomes,9,1
368,12236,,BAO_0000251,,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2.5 uM,,,D,Autocuration,B,10116.0,CHEMBL615423,,2107.0,Liver,Microsomes,9,1
369,12236,,BAO_0000251,,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2500 uM,,,D,Autocuration,B,10116.0,CHEMBL872868,,2107.0,Liver,Microsomes,9,1
370,12236,,BAO_0000251,,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 25 uM,,,D,Autocuration,B,10116.0,CHEMBL615424,,2107.0,Liver,Microsomes,9,1
371,104832,,BAO_0000224,,,Inhibitory activity against 3-phosphoglycerate kinase.,,,H,Autocuration,B,,CHEMBL825022,,,,,4,1
372,104832,,BAO_0000224,,,Binding affinity was evaluated towards 3-phosphoglycerate kinase at 37 degrees Celsius in 0.1 m NaCl pH 7.1,,,H,Autocuration,B,,CHEMBL615425,,,,,4,1
373,104832,,BAO_0000224,,,"Michaelis-Menten constant with 1,3-bisphosphoglyceric acid (1,3-BPG) against 3-phosphoglycerate kinase",,,H,Autocuration,B,,CHEMBL615426,,,,,4,1
374,10612,,BAO_0000357,,,Inhibition of human 3-phosphoinositide-dependent protein kinase 1 at 10 uM,,,D,Expert,B,9606.0,CHEMBL615427,,,,,9,1
375,80616,,BAO_0000219,844.0,3677 melanoma cell line,Cytotoxicity on 3677 melanoma cells,,,N,Intermediate,F,9606.0,CHEMBL615428,,,,,1,1
376,80616,,BAO_0000219,844.0,3677 melanoma cell line,Cytotoxicity on 3677 melanoma cells in combination with L-49-sFv-bL,,,N,Intermediate,F,9606.0,CHEMBL615429,,,,,1,1
377,80617,,BAO_0000219,700.0,MC-38,Antitumor activity against Mouse colon 38 at 500 ug/disk in disk diffusion assay,,,N,Intermediate,F,10090.0,CHEMBL615430,,,,,1,1
378,22226,,BAO_0000019,,,Compound was evaluated for inhibition of tumor cell growth using sulforhodamine-B assay in 38 human cell lines,,,U,Intermediate,F,9606.0,CHEMBL615431,,,,,0,1
379,22226,,BAO_0000218,798.0,B16,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; NT= Not tested,,,U,Autocuration,F,,CHEMBL615432,,,,,0,1
380,22226,,BAO_0000218,798.0,B16,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; reproducible significant activity.,,,U,Autocuration,F,,CHEMBL615433,,,,,0,1
381,12464,,BAO_0000019,,,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease,,,D,Expert,F,12131.0,CHEMBL615434,,,,,9,1
382,50085,,BAO_0000218,,,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease; NI means No inhibition to 50 uM,,,N,Intermediate,F,169066.0,CHEMBL615435,,,,,1,1
383,50679,,BAO_0000218,,,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as KI,,,N,Intermediate,F,169066.0,CHEMBL615436,,,,,1,1
384,50679,,BAO_0000218,,,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as kinact,,,N,Intermediate,F,169066.0,CHEMBL615437,,,,,1,1
385,12464,,BAO_0000019,,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,,D,Expert,F,12131.0,CHEMBL615438,,,,,9,1
386,12464,,BAO_0000019,,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,,D,Expert,F,12131.0,CHEMBL615439,,,,,9,1
387,12464,,BAO_0000019,,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,,D,Expert,F,12131.0,CHEMBL615440,,,,,9,1
388,12464,,BAO_0000019,,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay; inactive,,,D,Expert,F,12131.0,CHEMBL615441,,,,,9,1
389,50665,,BAO_0000218,,,Compound was tested for the inhibitory activity of compound towards human rhinovirus 3C protease,,,N,Intermediate,F,12059.0,CHEMBL615641,,,,,1,1
390,50665,,BAO_0000218,,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-16 3C protease,,,N,Intermediate,F,12059.0,CHEMBL872065,,,,,1,1
391,50665,,BAO_0000218,,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-2 3C protease,,,N,Intermediate,F,12059.0,CHEMBL825023,,,,,1,1
392,50665,,BAO_0000218,,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-89 3C protease,,,N,Intermediate,F,12059.0,CHEMBL615642,,,,,1,1
393,12464,,BAO_0000357,,,Inhibition of human rhinovirus 3C protease,,,H,Expert,B,147712.0,CHEMBL615643,,,,,8,1
394,22226,,BAO_0000019,,,Compound was tested for inhibition of a proteinase 3CL pro of human coronavirus; Inhibited,,,U,Autocuration,B,9606.0,CHEMBL615644,,,,,0,1
395,80619,,BAO_0000218,833.0,3EM 37,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 100 mg/kg (Dose range 200-12.5),,,N,Intermediate,F,10090.0,CHEMBL615645,,,,,1,1
396,80619,,BAO_0000218,833.0,3EM 37,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 128 mg/kg (Dose range 256-16),,,N,Intermediate,F,10090.0,CHEMBL615646,,,,,1,1
397,80619,,BAO_0000218,833.0,3EM 37,Compound tested for toxicity against 3EM 37 Mouse Ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (10/10),,,N,Intermediate,F,10090.0,CHEMBL615647,,,,,1,1
398,80619,,BAO_0000218,833.0,3EM 37,Compound tested for toxicity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (6/6),,,N,Intermediate,F,10090.0,CHEMBL615648,,,,,1,1
399,80619,,BAO_0000218,833.0,3EM 37,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as animal weight difference of the treated and the control (T-C) at OD of 100 mg/kg,,,N,Intermediate,F,10090.0,CHEMBL615649,,,,,1,1
400,80619,,BAO_0000218,833.0,3EM 37,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as percentage of cured animals at OD of 100 mg/kg,,,N,Intermediate,F,10090.0,CHEMBL615650,,,,,1,1
401,80620,,BAO_0000218,847.0,3LL cell line,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing 15 mg/kg b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,,,N,Intermediate,F,10090.0,CHEMBL615651,,,,,1,1
402,80620,,BAO_0000218,847.0,3LL cell line,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,,,N,Intermediate,F,10090.0,CHEMBL615652,,,,,1,1
403,80620,,BAO_0000218,847.0,3LL cell line,In vivo anti-tumor and anti-metastatic activity following p.o. administration b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor; Not tested.,,,N,Expert,F,10090.0,CHEMBL615653,,,,,1,1
404,80620,,BAO_0000219,847.0,3LL cell line,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 1 uM dose,,,N,Intermediate,F,10090.0,CHEMBL615654,,,,,1,1
405,80620,,BAO_0000219,847.0,3LL cell line,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 10 uM dose,,,N,Intermediate,F,10090.0,CHEMBL615655,,,,,1,1
406,80620,,BAO_0000219,847.0,3LL cell line,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 250 uM dose,,,N,Intermediate,F,10090.0,CHEMBL825024,,,,,1,1
407,80620,,BAO_0000219,847.0,3LL cell line,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 50 uM dose,,,N,Intermediate,F,10090.0,CHEMBL615656,,,,,1,1
408,80620,,BAO_0000219,847.0,3LL cell line,accumulation of compound in 3LL cells was measured with DFMO by ICP-AES at 50 uM dose,,,N,Intermediate,F,10090.0,CHEMBL615657,,,,,1,1
409,80620,,BAO_0000219,847.0,3LL cell line,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 1 uM dose,,,N,Intermediate,F,10090.0,CHEMBL615658,,,,,1,1
410,80620,,BAO_0000219,847.0,3LL cell line,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 10 uM dose,,,N,Intermediate,F,10090.0,CHEMBL615659,,,,,1,1
411,80620,,BAO_0000219,847.0,3LL cell line,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 250 uM dose,,,N,Intermediate,F,10090.0,CHEMBL615660,,,,,1,1
412,80620,,BAO_0000219,847.0,3LL cell line,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,,,N,Intermediate,F,10090.0,CHEMBL615661,,,,,1,1
413,80620,,BAO_0000219,847.0,3LL cell line,accumulation of compound in 3LL cells was measured without DFMO by ICP-AES at 50 uM dose,,,N,Intermediate,F,10090.0,CHEMBL615662,,,,,1,1
414,80620,,BAO_0000219,847.0,3LL cell line,Effect on the growth of 3LL cells by DFMO pretreatment at 48 hr incubation,,,N,Intermediate,F,10090.0,CHEMBL615663,,,,,1,1
415,80620,,BAO_0000219,847.0,3LL cell line,Effect on the growth of 3LL cells was evaluated using an MTT assay at 48 hour incubation,,,N,Intermediate,F,10090.0,CHEMBL615664,,,,,1,1
416,80620,,BAO_0000219,847.0,3LL cell line,Effect on the growth of 3LL cells was evaluated using an MTT assay at 72 hour incubation,,,N,Intermediate,F,10090.0,CHEMBL615665,,,,,1,1
417,80620,,BAO_0000219,847.0,3LL cell line,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,,,N,Intermediate,F,10090.0,CHEMBL615666,,,,,1,1
418,80620,,BAO_0000219,847.0,3LL cell line,putrescine levels in 3LL cells after the treatment of 1 uM of Compound,,,N,Intermediate,F,10090.0,CHEMBL615667,,,,,1,1
419,80620,,BAO_0000219,847.0,3LL cell line,putrescine levels in 3LL cells after the treatment of 10 uM of Compound,,,N,Intermediate,F,10090.0,CHEMBL615668,,,,,1,1
420,80620,,BAO_0000219,847.0,3LL cell line,putrescine levels in 3LL cells after the treatment of 250 uM of Compound,,,N,Intermediate,F,10090.0,CHEMBL615669,,,,,1,1
421,80620,,BAO_0000219,847.0,3LL cell line,putrescine levels in 3LL cells after the treatment of 50 uM of Compound,,,N,Intermediate,F,10090.0,CHEMBL615670,,,,,1,1
422,80620,,BAO_0000219,847.0,3LL cell line,spermidine levels in 3LL cells after the treatment of 1 uM of Compound,,,N,Intermediate,F,10090.0,CHEMBL836739,,,,,1,1
423,80620,,BAO_0000219,847.0,3LL cell line,spermidine levels in 3LL cells after the treatment of 10 uM of Compound,,,N,Intermediate,F,10090.0,CHEMBL615671,,,,,1,1
424,80620,,BAO_0000219,847.0,3LL cell line,spermidine levels in 3LL cells after the treatment of 250 uM of Compound,,,N,Intermediate,F,10090.0,CHEMBL615672,,,,,1,1
425,80620,,BAO_0000219,847.0,3LL cell line,spermidine levels in 3LL cells after the treatment of 50 uM of Compound,,,N,Intermediate,F,10090.0,CHEMBL615791,,,,,1,1
426,80620,,BAO_0000219,847.0,3LL cell line,spermine levels in 3LL cells after the treatment of 1 uM of Compound,,,N,Intermediate,F,10090.0,CHEMBL615792,,,,,1,1
427,80620,,BAO_0000219,847.0,3LL cell line,spermine levels in 3LL cells after the treatment of 10 uM of Compound,,,N,Intermediate,F,10090.0,CHEMBL615793,,,,,1,1
428,80620,,BAO_0000219,847.0,3LL cell line,spermine levels in 3LL cells after the treatment of 250 uM of Compound,,,N,Intermediate,F,10090.0,CHEMBL615794,,,,,1,1
429,80620,,BAO_0000219,847.0,3LL cell line,spermine levels in 3LL cells after the treatment of 50 uM of Compound,,,N,Intermediate,F,10090.0,CHEMBL615795,,,,,1,1
430,80621,,BAO_0000219,971.0,3LLD122,Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%,,,N,Intermediate,F,9606.0,CHEMBL615590,,,,,1,1
431,22226,,BAO_0000218,,,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible minimal activity,,,U,Autocuration,F,,CHEMBL615591,,,,,0,1
432,22226,,BAO_0000218,,,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible significant activity.,,,U,Autocuration,F,,CHEMBL615592,,,,,0,1
433,22226,,BAO_0000218,,,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; NT= Not tested,,,U,Autocuration,F,,CHEMBL615593,,,,,0,1
434,22226,,BAO_0000218,,,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; reproducible significant activity.,,,U,Autocuration,F,,CHEMBL615594,,,,,0,1
435,80951,,BAO_0000219,723.0,NIH3T3,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,,,N,Intermediate,F,10090.0,CHEMBL615595,,,,,1,1
436,80951,,BAO_0000219,723.0,NIH3T3,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,,,N,Intermediate,F,10090.0,CHEMBL615596,,,,,1,1
437,11169,,BAO_0000219,723.0,NIH3T3,Inhibition of 6 nM bombesin induced [3H]thymidine incorporation measured in swiss 3T3 cells using a mitogenicity assay,,,H,Expert,F,,CHEMBL615597,,,,,8,1
438,80951,,BAO_0000219,723.0,NIH3T3,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; na=Not active,,,N,Intermediate,F,10090.0,CHEMBL615598,,,,,1,1
439,80951,,BAO_0000219,723.0,NIH3T3,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; nt=Not tested,,,N,Intermediate,F,10090.0,CHEMBL615599,,,,,1,1
440,80951,,BAO_0000219,723.0,NIH3T3,Effective dose against murine 3T3 fibroblasts cells,,,N,Expert,F,10090.0,CHEMBL615600,,,,,1,1
441,80951,,BAO_0000219,723.0,NIH3T3,Dose required against murine 3T3 fibroblasts cells; 1-10 uM,,,N,Expert,F,10090.0,CHEMBL615601,,,,,1,1
442,80951,,BAO_0000219,723.0,NIH3T3,Cytotoxic effect on 3T3 cells,,,N,Expert,F,10090.0,CHEMBL615602,,,,,1,1
443,80951,,BAO_0000219,723.0,NIH3T3,Cytotoxic effect on 3T3 cells,,,N,Expert,F,10090.0,CHEMBL615603,,,,,1,1
444,80951,,BAO_0000219,723.0,NIH3T3,Compound was tested for the concentration necessary to inhibit swiss 3T3 Mouse Fibroblast cell growth rate by 50%.,,,N,Intermediate,F,10090.0,CHEMBL615604,,,,,1,1
445,80951,,BAO_0000219,723.0,NIH3T3,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,,,N,Intermediate,F,10090.0,CHEMBL615605,,,,,1,1
446,80951,,BAO_0000219,723.0,NIH3T3,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration; nd=No data,,,N,Intermediate,F,10090.0,CHEMBL615606,,,,,1,1
447,80951,,BAO_0000219,723.0,NIH3T3,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration,,,N,Expert,F,10090.0,CHEMBL884526,,,,,1,1
448,80951,,BAO_0000219,723.0,NIH3T3,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.d.=no data,,,N,Expert,F,10090.0,CHEMBL615607,,,,,1,1
449,80951,,BAO_0000219,723.0,NIH3T3,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.t.=not tested,,,N,Intermediate,F,10090.0,CHEMBL615608,,,,,1,1
450,80951,,BAO_0000219,723.0,NIH3T3,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration,,,N,Expert,F,10090.0,CHEMBL615609,,,,,1,1
451,80951,,BAO_0000219,723.0,NIH3T3,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.d.=no data,,,N,Expert,F,10090.0,CHEMBL615682,,,,,1,1
452,80951,,BAO_0000219,723.0,NIH3T3,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.t.=not tested,,,N,Intermediate,F,10090.0,CHEMBL615683,,,,,1,1
453,80951,,BAO_0000218,723.0,NIH3T3,In vivo inhibition of H-ras-transformed 3T3 fibroblasts in nude mouse tumor models,,,N,Expert,F,10090.0,CHEMBL615684,,,,,1,1
454,104860,,BAO_0000219,,,Inhibition of PDGF-dependent autophosphorylation of PDGF-R in mouse BALB/c3T3 cells,,,D,Autocuration,F,10090.0,CHEMBL615685,,,,,7,1
455,80951,,BAO_0000219,723.0,NIH3T3,Inhibition of Swiss 3T3 Mouse fibroblast proliferation,,,N,Expert,F,10090.0,CHEMBL615686,,,,,1,1
456,80951,,BAO_0000219,723.0,NIH3T3,Inhibitory activity against 3T3 cell line,,,N,Intermediate,F,10090.0,CHEMBL615687,,,,,1,1
457,80951,,BAO_0000219,723.0,NIH3T3,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured,,,N,Intermediate,F,10090.0,CHEMBL884523,,,,,1,1
458,11169,,BAO_0000019,,,Ability of peptide to inhibit binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane.,,,H,Expert,F,,CHEMBL615688,,,,,8,1
459,80951,,BAO_0000219,723.0,NIH3T3,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured; nt=Not tested,,,N,Intermediate,F,10090.0,CHEMBL615689,,,,,1,1
460,80951,,BAO_0000219,723.0,NIH3T3,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells was measured,,,N,Intermediate,F,10090.0,CHEMBL615690,,,,,1,1
461,11169,,BAO_0000019,,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells,,,H,Expert,F,,CHEMBL615691,,,,,8,1
462,11169,,BAO_0000019,,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells; nt=Not tested,,,H,Expert,F,,CHEMBL615692,,,,,8,1
463,80951,,BAO_0000219,723.0,NIH3T3,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,,,N,Intermediate,F,10090.0,CHEMBL615693,,,,,1,1
464,80951,,BAO_0000219,723.0,NIH3T3,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line was determined using NR coloration; n.d.=no data,,,N,Expert,F,10090.0,CHEMBL615324,,,,,1,1
465,9,,BAO_0000219,723.0,NIH3T3,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,,,D,Expert,F,9606.0,CHEMBL615325,,,,,9,1
466,9,,BAO_0000219,723.0,NIH3T3,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells (Not tested),,,D,Expert,F,9606.0,CHEMBL615490,,,,,9,1
467,188,,BAO_0000219,723.0,NIH3T3,Inhibition of ligand induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells,,,D,Expert,F,9606.0,CHEMBL615491,,,,,9,1
468,188,,BAO_0000219,723.0,NIH3T3,Inhibition of ligand-induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells (Not tested),,,D,Expert,F,9606.0,CHEMBL615492,,,,,9,1
469,80951,,BAO_0000219,723.0,NIH3T3,Inhibitory concentration of compound rwas calculated on 3T3 cells by [3H]Thd incorporation,,,N,Intermediate,F,10090.0,CHEMBL615493,,,,,1,1
470,80951,,BAO_0000219,723.0,NIH3T3,Inhibitory concentration of compound was calculated on 3T3 cells by [14C]Leu incorporation,,,N,Intermediate,F,10090.0,CHEMBL615494,,,,,1,1
471,80951,,BAO_0000219,723.0,NIH3T3,Inhibitory concentration of compound was calculated on 3T3 cells by using clonal assay,,,N,Intermediate,F,10090.0,CHEMBL615495,,,,,1,1
472,80951,,BAO_0000219,723.0,NIH3T3,Inhibitory concentration was calculated on 3T3 cells by using growth assay,,,N,Intermediate,F,10090.0,CHEMBL615496,,,,,1,1
473,80951,,BAO_0000219,723.0,NIH3T3,In vitro cytotoxicity was evaluated in mouse embryo BALB/c 3T3 cells,,,N,Intermediate,F,10090.0,CHEMBL615497,,,,,1,1
474,80951,,BAO_0000219,723.0,NIH3T3,Inhibition of Swiss 3T3 mouse fibroblast proliferation,,,N,Expert,F,10090.0,CHEMBL615498,,,,,1,1
475,80951,,BAO_0000219,723.0,NIH3T3,The compound was tested for cytotoxicity against 3T3 fibroblast murine cell line.,,,N,Intermediate,A,10090.0,CHEMBL615499,,,,,1,1
476,80951,,BAO_0000219,723.0,NIH3T3,Effective concentration required to inhibit the growth of murine 3T3 fibroblasts,,,N,Expert,F,10090.0,CHEMBL835522,,,,,1,1
477,80951,,BAO_0000219,723.0,NIH3T3,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014); Not tested,,,N,Intermediate,F,10090.0,CHEMBL615500,,,,,1,1
478,80951,,BAO_0000219,723.0,NIH3T3,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,,N,Intermediate,F,10090.0,CHEMBL615501,,,,,1,1
479,80951,,BAO_0000219,723.0,NIH3T3,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,,N,Intermediate,F,10090.0,CHEMBL615502,,,,,1,1
480,80951,,BAO_0000219,723.0,NIH3T3,cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,,N,Intermediate,F,10090.0,CHEMBL615503,,,,,1,1
481,80951,,BAO_0000219,723.0,NIH3T3,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,,N,Intermediate,F,10090.0,CHEMBL615504,,,,,1,1
482,80951,,BAO_0000219,723.0,NIH3T3,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,,N,Intermediate,F,10090.0,CHEMBL615505,,,,,1,1
483,80951,,BAO_0000219,723.0,NIH3T3,Inhibition of swiss 3T3 mouse fibroblast proliferation,,,N,Expert,F,10090.0,CHEMBL615506,,,,,1,1
484,80951,,BAO_0000219,723.0,NIH3T3,Compound was tested for sublethal concentrations in 3T3 mouse fibroblast lysis.,,,N,Intermediate,F,10090.0,CHEMBL615507,,,,,1,1
485,80006,,BAO_0000218,620.0,3T3-L1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,,N,Intermediate,F,,CHEMBL615508,,,,,1,1
486,80006,,BAO_0000219,620.0,3T3-L1,Concentration required to stimulate glucose uptake in 3T3-L1 adipocytes after 48 hr incubation,,,N,Intermediate,F,10090.0,CHEMBL615509,,,,,1,1
487,80006,,BAO_0000219,620.0,3T3-L1,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 0.3 uM,,,N,Intermediate,F,10090.0,CHEMBL615510,,,,,1,1
488,80006,,BAO_0000219,620.0,3T3-L1,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 3 uM,,,N,Intermediate,F,10090.0,CHEMBL615511,,,,,1,1
489,80006,,BAO_0000219,620.0,3T3-L1,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 30 uM,,,N,Intermediate,F,10090.0,CHEMBL615512,,,,,1,1
490,80006,,BAO_0000218,620.0,3T3-L1,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 24 hr",,,N,Intermediate,F,10090.0,CHEMBL615513,,,,,1,1
491,80006,,BAO_0000218,620.0,3T3-L1,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 3 hr",,,N,Intermediate,F,10090.0,CHEMBL615514,,,,,1,1
492,80006,,BAO_0000219,620.0,3T3-L1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes,,,N,Intermediate,F,,CHEMBL615515,,,,,1,1
493,80006,,BAO_0000219,620.0,3T3-L1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,,,N,Intermediate,F,,CHEMBL615516,,,,,1,1
494,80006,,BAO_0000219,620.0,3T3-L1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,,N,Intermediate,F,,CHEMBL615517,,,,,1,1
495,80006,,BAO_0000219,620.0,3T3-L1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,,,N,Intermediate,F,,CHEMBL615518,,,,,1,1
496,80006,,BAO_0000219,620.0,3T3-L1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,,N,Intermediate,F,,CHEMBL615519,,,,,1,1
497,80006,,BAO_0000218,620.0,3T3-L1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.3 uM dose.,,,N,Intermediate,F,,CHEMBL615520,,,,,1,1
498,80006,,BAO_0000218,620.0,3T3-L1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.5 uM dose.,,,N,Intermediate,F,,CHEMBL615521,,,,,1,1
499,80006,,BAO_0000218,620.0,3T3-L1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,,,N,Intermediate,F,,CHEMBL615522,,,,,1,1
500,80006,,BAO_0000218,620.0,3T3-L1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,,N,Intermediate,F,,CHEMBL615523,,,,,1,1
501,80006,,BAO_0000218,620.0,3T3-L1,In vitro measurements 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,,,N,Expert,F,,CHEMBL615524,,,,,1,1
502,80006,,BAO_0000218,620.0,3T3-L1,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,,N,Expert,F,,CHEMBL615525,,,,,1,1
503,80006,,BAO_0000218,620.0,3T3-L1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,,,N,Intermediate,F,,CHEMBL615526,,,,,1,1
504,80006,,BAO_0000218,620.0,3T3-L1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,,N,Intermediate,F,,CHEMBL615527,,,,,1,1
505,80006,,BAO_0000218,620.0,3T3-L1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 300 uM dose.,,,N,Intermediate,F,,CHEMBL615528,,,,,1,1
506,80006,,BAO_0000218,620.0,3T3-L1,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,,N,Expert,F,,CHEMBL615529,,,,,1,1
507,80006,,BAO_0000218,620.0,3T3-L1,In vitro by measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,,N,Expert,F,,CHEMBL615530,,,,,1,1
508,80006,,BAO_0000218,620.0,3T3-L1,In vitro measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,,,N,Expert,F,,CHEMBL615531,,,,,1,1
509,80006,,BAO_0000219,620.0,3T3-L1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,,,N,Intermediate,F,,CHEMBL615532,,,,,1,1
510,80006,,BAO_0000219,620.0,3T3-L1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,,N,Intermediate,F,,CHEMBL615533,,,,,1,1
511,80006,,BAO_0000219,620.0,3T3-L1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,,,N,Intermediate,F,,CHEMBL615534,,,,,1,1
512,80006,,BAO_0000218,620.0,3T3-L1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,,,N,Intermediate,F,,CHEMBL615535,,,,,1,1
513,80006,,BAO_0000218,620.0,3T3-L1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,,N,Intermediate,F,,CHEMBL615536,,,,,1,1
514,80006,,BAO_0000218,620.0,3T3-L1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,,N,Intermediate,F,,CHEMBL615537,,,,,1,1
515,80006,,BAO_0000218,620.0,3T3-L1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,,N,Intermediate,F,,CHEMBL615538,,,,,1,1
516,80006,,BAO_0000218,620.0,3T3-L1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,,,N,Intermediate,F,,CHEMBL836166,,,,,1,1
517,11214,,BAO_0000219,620.0,3T3-L1,Inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells,,,H,Expert,F,,CHEMBL615539,,,,,8,1
518,80006,,BAO_0000219,620.0,3T3-L1,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; ND = No data,,,N,Intermediate,F,10090.0,CHEMBL615540,,,,,1,1
519,11214,,BAO_0000219,620.0,3T3-L1,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; Na = Not active,,,H,Expert,F,,CHEMBL615541,,,,,8,1
520,80006,,BAO_0000219,620.0,3T3-L1,Insulin-sensitizing activity; triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 1 uM expressed as percent activity of pioglitazone,,,N,Expert,F,10090.0,CHEMBL615542,,,,,1,1
521,80006,,BAO_0000219,620.0,3T3-L1,Compound was tested for insulin-sensitizing activity by measuring triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 10 uM expressed as percent activity of pioglitazone,,,N,Intermediate,F,10090.0,CHEMBL615543,,,,,1,1
522,80006,,BAO_0000219,620.0,3T3-L1,Stimulation of adipogenesis in 3T3-L1 cells is expressed as concentration equivalent to the [ 1-14C] uptake counts after treatment with 0.2 ug/mL troglitazone,,,N,Expert,F,10090.0,CHEMBL615544,,,,,1,1
523,80006,,BAO_0000219,620.0,3T3-L1,Effective concentration for enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,,,N,Expert,F,10090.0,CHEMBL615545,,,,,1,1
524,80006,,BAO_0000219,620.0,3T3-L1,Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,,,N,Expert,F,10090.0,CHEMBL615546,,,,,1,1
525,80006,,BAO_0000219,620.0,3T3-L1,Percentage of rosiglitazone response for insulin-sensitizing activity at 1 uM concentration in 3T3-L1 cells,,,N,Expert,F,10090.0,CHEMBL615547,,,,,1,1
526,80006,,BAO_0000219,620.0,3T3-L1,In vitro glucose transport activity in 3T3-LI adipocytes at 10 uM concentration.,,,N,Expert,F,10090.0,CHEMBL615548,,,,,1,1
527,80006,,BAO_0000219,620.0,3T3-L1,In vitro glucose transport activity in 3T3-LI adipocytes at 3 uM concentration.,,,N,Expert,F,10090.0,CHEMBL615549,,,,,1,1
528,80006,,BAO_0000219,620.0,3T3-L1,In vitro glucose transport activity in 3T3-LI adipocytes at 30 uM concentration.,,,N,Expert,F,10090.0,CHEMBL615550,,,,,1,1
529,80622,,BAO_0000219,1118.0,3Y1 cell line,Inhibitory activity against rat fibroblast (3Y1) cell line,,,N,Intermediate,F,10116.0,CHEMBL615551,,,,,1,1
530,80622,,BAO_0000219,1118.0,3Y1 cell line,Mean concentration causing inhibition of cell growth in 3Y1 cells.,,,N,Expert,F,10116.0,CHEMBL615552,,,,,1,1
531,80622,,BAO_0000219,1118.0,3Y1 cell line,Cytotoxicity in 3Y1 cells.,,,N,Expert,F,10116.0,CHEMBL615553,,,,,1,1
532,80622,,BAO_0000219,1118.0,3Y1 cell line,Cytostatic effect in 3Y1 cells.,,,N,Expert,F,10116.0,CHEMBL615554,,,,,1,1
533,80622,,BAO_0000219,1118.0,3Y1 cell line,"Mean averaged concentration for total growth inhibition, which signifies cytostatic effect",,,N,Intermediate,F,10116.0,CHEMBL615555,,,,,1,1
534,80622,,BAO_0000219,1118.0,3Y1 cell line,Concentration to inhibit growth of normal rat fibroblast cells (3Y1-B cells) after 72 h exposure,,,N,Expert,F,10116.0,CHEMBL615556,,,,,1,1
535,22226,,BAO_0000019,,,In vitro inhibitory activity against human adrenal 3-beta hydroxy-delta 5-teroid isomerase,,,U,Autocuration,B,,CHEMBL615557,,,,,0,1
536,22226,,BAO_0000019,,,Inhibition of recombinant human adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,,,U,Autocuration,B,,CHEMBL615558,,,,,0,1
537,22226,,BAO_0000019,,,Inhibition of recombinant rat adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,,,U,Autocuration,B,,CHEMBL872066,,,,,0,1
538,11607,,BAO_0000019,,,In vitro inhibition against of 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) from pig liver by the enol borate method,,,D,Expert,B,9823.0,CHEMBL615559,,,,,9,1
539,11607,,BAO_0000019,,,In vitro inhibitory concentration required against 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) taken from pig liver,,,H,Autocuration,B,,CHEMBL615560,,,,,8,1
540,11607,,BAO_0000019,,,Inhibition of pig liver 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) enzyme,,,H,Autocuration,B,,CHEMBL615561,,,,,8,1
541,11607,,BAO_0000019,,,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver,,,H,Expert,B,,CHEMBL857062,,,,,8,1
542,11607,,BAO_0000019,,,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver; (observed value),,,H,Expert,B,,CHEMBL615562,,,,,8,1
543,11607,,BAO_0000019,,,In vitro inhibitory activity against HPPD(4-hydroxyphenylpyruvate Dioxygenase) from pig liver using enol borate assay method,,,H,Autocuration,B,,CHEMBL615563,,,,,8,1
544,11607,,BAO_0000357,,,Compound was evaluated for complete competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD),,,H,Autocuration,B,,CHEMBL615564,,,,,8,1
545,11607,,BAO_0000019,,,In vitro inhibition of 4-hydroxyphenylpyruvate dioxygenase obtained from purified pig liver by enol-borate method,,,H,Autocuration,B,,CHEMBL615565,,,,,8,1
546,11607,,BAO_0000019,,,Inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated,,,H,Autocuration,B,,CHEMBL615566,,,,,8,1
547,11607,,BAO_0000019,,,Inhibition of 4-hydroxyphenylpyruvate dioxygenase of purified pig liver by enol-borate method,,,D,Expert,B,9823.0,CHEMBL615567,,,,,9,1
548,11607,,BAO_0000019,,,The inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated.,,,H,Autocuration,B,,CHEMBL615568,,,,,8,1
549,11607,,BAO_0000357,,,Compound was evaluated for competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) (complete inhibition was observed at a concentration of 0.5-1.0 mM),,,H,Autocuration,B,,CHEMBL615569,,,,,8,1
550,11607,,BAO_0000019,,,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver,,,H,Autocuration,B,,CHEMBL615570,,,,,8,1
551,11607,,BAO_0000019,,,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver; (observed value),,,H,Autocuration,B,,CHEMBL615571,,,,,8,1
552,104733,,BAO_0000224,,,Binding affinity against melatonin (MT1) receptor (pC1),,,H,Autocuration,B,,CHEMBL615572,,,,,4,1
553,22226,,BAO_0000019,,,Compound was tested for inhibitory activity against 5-hydroxytryptamine 1 receptor,,,U,Autocuration,B,,CHEMBL615573,,,,,0,1
554,22226,,BAO_0000019,,,Inhibition of [3H]- 5-HT binding to 5-hydroxytryptamine 1 receptor at 10e-5 M,,,U,Autocuration,B,,CHEMBL615574,,,,,0,1
555,22226,,BAO_0000019,,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1 receptor of central nervous system,,,U,Autocuration,B,,CHEMBL615575,,,,,0,1
556,10619,,BAO_0000357,,,Inhibitory activity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand at 10e-5 M concentration,,,H,Autocuration,B,,CHEMBL615576,,,,,8,1
557,10619,,BAO_0000357,,,Binding affinity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,,,H,Autocuration,B,,CHEMBL615577,,,,,8,1
558,51,,BAO_0000221,,,Binding affinity at 5-hydroxytryptamine 1A receptor in bovine hippocampal preparation using [3H]8-OH-DPAT,,,H,Autocuration,B,,CHEMBL615578,,10000000.0,Hippocampus,,8,1
559,51,,BAO_0000357,,,Binding affinity against 5-hydroxytryptamine 1A receptor was measured using [3H]8-OH-DPAT as radioligand,,,H,Expert,B,,CHEMBL615579,,,,,8,1
560,51,,BAO_0000357,,,Binding affinity for 5-hydroxytryptamine 1A receptor,,,H,Expert,B,,CHEMBL615580,,,,,8,1
561,51,,BAO_0000019,,,Affinity towards 5-hydroxytryptamine 1A receptor in membranes from bovine hippocampus using [3H]OH-DPAT,,,H,Expert,B,,CHEMBL615581,,,,,8,1
562,51,,BAO_0000221,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,,H,Autocuration,B,,CHEMBL615582,,10000000.0,Hippocampus,,8,1
563,51,,BAO_0000221,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,,H,Autocuration,B,,CHEMBL615583,,10000000.0,Hippocampus,,8,1
564,51,,BAO_0000221,,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,,,H,Autocuration,B,,CHEMBL615584,,10000000.0,Hippocampus,,8,1
565,51,,BAO_0000221,,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,H,Autocuration,B,,CHEMBL833691,,10000000.0,Hippocampus,,8,1
566,51,,BAO_0000221,,,In vitro inhibition of azido-[125I]-IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,,,H,Autocuration,B,,CHEMBL615585,,10000000.0,Hippocampus,,8,1
567,51,,BAO_0000221,,,In vitro inhibition of [125I]IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,,,H,Autocuration,B,,CHEMBL615586,,10000000.0,Hippocampus,,8,1
568,51,,BAO_0000221,,,In vitro inhibition of [125I]IPAPP (2.5 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,H,Autocuration,B,,CHEMBL884524,,10000000.0,Hippocampus,,8,1
569,51,,BAO_0000221,,,Inhibitory concentration against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,,H,Autocuration,B,,CHEMBL615587,,10000000.0,Hippocampus,,8,1
570,51,,BAO_0000221,,,"Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",,,H,Autocuration,B,,CHEMBL615588,,10000000.0,Hippocampus,,8,1
571,10576,,BAO_0000249,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampal membranes,,,D,Expert,B,10116.0,CHEMBL615589,,,,Membranes,9,1
572,51,,BAO_0000221,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of bovine hippocampus.,,,H,Expert,B,9913.0,CHEMBL615442,,10000000.0,Hippocampus,,8,1
573,51,,BAO_0000221,,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (0.5 nM) ligand in hippocampus + frontal bovine was determined,,,H,Autocuration,B,,CHEMBL615443,,10000000.0,Hippocampus,,8,1
574,51,,BAO_0000221,,,Compound was evaluated for its ability to displace [3H]DPAT from 5-HT1A receptor in homogenates of bovine hippocampus,,,H,Autocuration,B,,CHEMBL615444,,10000000.0,Hippocampus,,8,1
575,51,,BAO_0000221,,,Ability to displace [3H]-DPAT from 5-hydroxytryptamine 1A receptor in homogenates of bovine hippocampus.,,,H,Expert,B,,CHEMBL615445,,10000000.0,Hippocampus,,8,1
576,51,,BAO_0000221,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in bovine hippocampus,,,H,Autocuration,B,,CHEMBL615446,,10000000.0,Hippocampus,,8,1
577,51,,BAO_0000219,449.0,CHO,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in CHO cells,,,H,Autocuration,B,,CHEMBL615447,,,,,8,1
578,51,,BAO_0000221,,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,,H,Expert,B,,CHEMBL615448,,10000000.0,Hippocampus,,8,1
579,51,,BAO_0000221,,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,,H,Expert,B,,CHEMBL615449,,10000000.0,Hippocampus,,8,1
580,51,,BAO_0000219,449.0,CHO,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,,H,Autocuration,B,,CHEMBL615450,,,,,8,1
581,51,,BAO_0000221,,,"Binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",,,H,Expert,B,,CHEMBL615451,,10000000.0,Hippocampus,,8,1
582,51,,BAO_0000357,,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,,,H,Autocuration,B,,CHEMBL615452,,,,,8,1
583,51,,BAO_0000221,,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,,,H,Autocuration,B,,CHEMBL615453,,10000000.0,Hippocampus,,8,1
584,51,,BAO_0000221,,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,H,Autocuration,B,,CHEMBL615454,,10000000.0,Hippocampus,,8,1
585,51,,BAO_0000221,,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,,H,Autocuration,B,,CHEMBL615455,,10000000.0,Hippocampus,,8,1
586,51,,BAO_0000221,,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,H,Autocuration,B,,CHEMBL615456,,10000000.0,Hippocampus,,8,1
587,51,,BAO_0000221,,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,,H,Autocuration,B,,CHEMBL615457,,10000000.0,Hippocampus,,8,1
588,51,,BAO_0000218,,,In vivo binding affinity towards [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus.,,,H,Expert,B,,CHEMBL615458,,10000000.0,Hippocampus,,8,1
589,51,,BAO_0000221,,,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,H,Expert,B,,CHEMBL615459,,10000000.0,Hippocampus,,8,1
590,51,,BAO_0000219,449.0,CHO,"Tested in vitro for the inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor, expressed in cloned CHO cells.",,,D,Expert,B,9606.0,CHEMBL615460,,,,,9,1
591,51,,BAO_0000019,,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig,,,H,Autocuration,F,10141.0,CHEMBL615461,,,,,8,1
592,51,,BAO_0000019,,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig; NT means not tested,,,H,Autocuration,F,10141.0,CHEMBL615462,,,,,8,1
593,51,,BAO_0000221,,,Effect on forskolin stimulated adenylate cyclase activity at 5-hydroxytryptamine 1A receptor of guinea pig hippocampus.,,,H,Autocuration,F,10141.0,CHEMBL615463,,10000000.0,Hippocampus,,8,1
594,51,,BAO_0000221,,,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,,,H,Autocuration,B,10141.0,CHEMBL615464,,2116.0,Ileum,,8,1
595,51,,BAO_0000221,,,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,,,H,Autocuration,B,10141.0,CHEMBL615465,,2116.0,Ileum,,8,1
596,51,,BAO_0000221,,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,,,H,Autocuration,B,10141.0,CHEMBL615466,,2116.0,Ileum,,8,1
597,51,,BAO_0000221,,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,,,H,Autocuration,B,10141.0,CHEMBL615467,,2116.0,Ileum,,8,1
598,51,,BAO_0000221,,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,,,H,Autocuration,B,10141.0,CHEMBL615468,,2116.0,Ileum,,8,1
599,51,,BAO_0000221,,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor; Inactive at dose level of 1.0 uM,,,H,Autocuration,B,10141.0,CHEMBL615469,,2116.0,Ileum,,8,1
600,51,,BAO_0000357,,,Binding affinity against 5-hydroxytryptamine 1A receptor,,,H,Autocuration,B,10141.0,CHEMBL615470,,,,,8,1
601,51,,BAO_0000357,,,Compound is evaluated for in vitro receptor binding affinity against 5-hydroxytryptamine 1A receptor,,,H,Autocuration,B,10141.0,CHEMBL615471,,,,,8,1
602,51,,BAO_0000357,,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor,,,H,Autocuration,B,10141.0,CHEMBL615472,,,,,8,1
603,106,,BAO_0000221,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,,,H,Autocuration,B,10141.0,CHEMBL883242,,10000000.0,Hippocampus,,8,1
604,106,,BAO_0000221,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,,,H,Autocuration,F,10141.0,CHEMBL615473,,10000000.0,Hippocampus,,8,1
605,11863,,BAO_0000218,449.0,CHO,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),,,H,Autocuration,B,10029.0,CHEMBL615474,,,,,8,1
606,51,,BAO_0000357,,,Fraction involved in salt bridge interactions with Asp3:11 part of the 5-hydroxytryptamine 1A receptor,,,H,Autocuration,B,,CHEMBL615475,,,,,8,1
607,51,,BAO_0000219,308.0,HeLa,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-HT 1A receptor in HeLa cells; value ranges from 85-370,,,H,Autocuration,F,,CHEMBL615476,,,,,8,1
608,51,,BAO_0000219,308.0,HeLa,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1A receptor in HeLa cells; value ranges from 95-320,,,H,Autocuration,F,,CHEMBL615477,,,,,8,1
609,51,,BAO_0000019,,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,,,H,Autocuration,F,,CHEMBL615478,,,,,8,1
610,51,,BAO_0000219,449.0,CHO,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,,,H,Autocuration,F,,CHEMBL615160,,,,,8,1
611,51,,BAO_0000219,449.0,CHO,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,,,H,Expert,F,,CHEMBL615161,,,,,8,1
612,51,,BAO_0000219,449.0,CHO,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=Not determined,,,H,Autocuration,F,,CHEMBL615162,,,,,8,1
613,51,,BAO_0000219,449.0,CHO,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=not determined,,,H,Autocuration,F,,CHEMBL615163,,,,,8,1
614,51,,BAO_0000219,449.0,CHO,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,,H,Expert,B,,CHEMBL615164,,,,,8,1
615,51,,BAO_0000219,449.0,CHO,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,,H,Expert,B,,CHEMBL615165,,,,,8,1
616,51,,BAO_0000219,449.0,CHO,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells; nd=not determined,,,H,Autocuration,B,,CHEMBL615166,,,,,8,1
617,51,,BAO_0000219,,,In vitro potency at human 5-hydroxytryptamine 1A receptor in inhibiting forskolin-stimulated accumulation of intracellular cAMP,,,H,Autocuration,F,,CHEMBL615167,,,,,8,1
618,51,,BAO_0000219,308.0,HeLa,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,,,D,Expert,B,9606.0,CHEMBL615168,,,,,9,1
619,51,,BAO_0000219,308.0,HeLa,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells; Inverse,,,D,Expert,B,9606.0,CHEMBL615169,,,,,9,1
620,51,,BAO_0000219,449.0,CHO,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor,,,D,Expert,B,9606.0,CHEMBL615170,,,,,9,1
621,51,,BAO_0000219,449.0,CHO,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor; Not determined,,,D,Expert,B,9606.0,CHEMBL615171,,,,,9,1
622,51,,BAO_0000019,,,Eudisimic ratio(ER) is the antilog of the defference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,,,H,Autocuration,F,,CHEMBL615694,,,,,8,1
623,51,,BAO_0000019,,,Eudisimic ratio(ER) is the antilog of the difference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,,,H,Autocuration,F,,CHEMBL615695,,,,,8,1
624,51,,BAO_0000019,,,"Percent of maximum effect on binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,,H,Autocuration,F,,CHEMBL615696,,,,,8,1
625,51,,BAO_0000219,449.0,CHO,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,,H,Autocuration,F,,CHEMBL615697,,,,,8,1
626,51,,BAO_0000219,449.0,CHO,Agonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),,,D,Expert,F,9606.0,CHEMBL859410,,,,,9,1
627,51,,BAO_0000219,449.0,CHO,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),,,H,Autocuration,F,,CHEMBL615841,,,,,8,1
628,51,,BAO_0000219,449.0,CHO,Agonistic efficacy in adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),,,D,Expert,F,9606.0,CHEMBL615842,,,,,9,1
629,51,,BAO_0000219,449.0,CHO,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,,H,Autocuration,F,,CHEMBL835003,,,,,8,1
630,51,,BAO_0000219,449.0,CHO,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 1),,,H,Autocuration,F,,CHEMBL615843,,,,,8,1
631,51,,BAO_0000219,449.0,CHO,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),,,D,Expert,F,9606.0,CHEMBL615979,,,,,9,1
632,51,,BAO_0000219,449.0,CHO,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),,,H,Autocuration,F,,CHEMBL615980,,,,,8,1
633,51,,BAO_0000219,449.0,CHO,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),,,D,Expert,F,9606.0,CHEMBL615981,,,,,9,1
634,51,,BAO_0000019,,,Percent efficacy against cloned human 5-hydroxytryptamine 1A receptor normalized to the maximal 5-HT response,,,D,Expert,F,9606.0,CHEMBL615982,,,,,9,1
635,51,,BAO_0000019,,,"Agonist activity at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,,D,Expert,F,9606.0,CHEMBL615983,,,,,9,1
636,51,,BAO_0000019,,,"Agonist activity at the 5-hydroxytryptamine 1A receptor in vitro using a [35S]GTP-gamma-S, No data",,,D,Expert,F,9606.0,CHEMBL615984,,,,,9,1
637,51,,BAO_0000019,,,"Agonist activity at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S,",,,D,Expert,F,9606.0,CHEMBL615985,,,,,9,1
638,51,,BAO_0000219,449.0,CHO,Agonistic effect against 5-HT1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,,H,Autocuration,F,,CHEMBL615986,,,,,8,1
639,51,,BAO_0000219,449.0,CHO,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,,H,Autocuration,F,,CHEMBL615987,,,,,8,1
640,51,,BAO_0000219,449.0,CHO,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,,,H,Autocuration,F,,CHEMBL615988,,,,,8,1
641,51,,BAO_0000219,449.0,CHO,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,,H,Expert,F,,CHEMBL615989,,,,,8,1
642,51,,BAO_0000219,449.0,CHO,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,,,H,Autocuration,F,,CHEMBL615990,,,,,8,1
643,51,,BAO_0000219,449.0,CHO,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=not determined,,,H,Autocuration,F,,CHEMBL615991,,,,,8,1
644,51,,BAO_0000219,449.0,CHO,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,,H,Autocuration,F,,CHEMBL615992,,,,,8,1
645,51,,BAO_0000219,449.0,CHO,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=Not determined,,,H,Autocuration,F,,CHEMBL615993,,,,,8,1
646,51,,BAO_0000219,449.0,CHO,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,,H,Expert,F,,CHEMBL615994,,,,,8,1
647,51,,BAO_0000219,449.0,CHO,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=not determined,,,H,Autocuration,F,,CHEMBL615995,,,,,8,1
648,51,,BAO_0000219,449.0,CHO,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,,H,Autocuration,F,,CHEMBL615996,,,,,8,1
649,51,,BAO_0000219,449.0,CHO,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35]GTPgammaS as radioligand in CHO cells relative to 5-HT; nd=Not determined,,,H,Autocuration,F,,CHEMBL615997,,,,,8,1
650,51,,BAO_0000019,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,,H,Autocuration,F,,CHEMBL615998,,,,,8,1
651,51,,BAO_0000019,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,,H,Autocuration,F,,CHEMBL615999,,,,,8,1
652,51,,BAO_0000019,,,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,,,H,Autocuration,F,,CHEMBL616000,,,,,8,1
653,51,,BAO_0000219,722.0,HEK293,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,,H,Autocuration,F,,CHEMBL616001,,,,,8,1
654,51,,BAO_0000019,,,"Evaluated for stimulation at 1 uM concentration expressed as percent of the maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine",,,D,Expert,F,9606.0,CHEMBL616002,,,,,9,1
655,51,,BAO_0000019,,,"Stimulation of percent maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine at 1 uM; nd = not determined",,,H,Expert,F,,CHEMBL616003,,,,,8,1
656,51,,BAO_0000019,,,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor,,,D,Expert,F,9606.0,CHEMBL616004,,,,,9,1
657,51,,BAO_0000019,,,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor; No data,,,D,Expert,F,9606.0,CHEMBL616005,,,,,9,1
658,51,,BAO_0000019,,,"Maximal response as a result of 5-HT1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,,H,Autocuration,F,,CHEMBL616006,,,,,8,1
659,51,,BAO_0000019,,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding",,,H,Expert,F,,CHEMBL616007,,,,,8,1
660,51,,BAO_0000019,,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,,H,Autocuration,F,,CHEMBL616008,,,,,8,1
661,51,,BAO_0000019,,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,,H,Autocuration,F,,CHEMBL616009,,,,,8,1
662,51,,BAO_0000019,,,"Maximal stimulation of expressed human 5-hydroxytryptamine 1A receptor assayed by [35S]GTP-gamma-S, binding",,,H,Expert,F,,CHEMBL616010,,,,,8,1
663,51,,BAO_0000019,,,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND means not determined",,,D,Expert,F,9606.0,CHEMBL616011,,,,,9,1
664,51,,BAO_0000019,,,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND=Not determined",,,D,Expert,F,9606.0,CHEMBL615740,,,,,9,1
665,51,,BAO_0000019,,,"Maximal stimulation was expressed as percentage of the maximal 5-HT response in the [35S]GTP-gamma-S, binding assay on 5-hydroxytryptamine 1A receptor",,,H,Autocuration,F,,CHEMBL615741,,,,,8,1
666,51,,BAO_0000019,,,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",,,H,Expert,F,,CHEMBL615742,,,,,8,1
667,51,,BAO_0000019,,,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Emin (%): not determined",,,H,Autocuration,F,,CHEMBL615743,,,,,8,1
668,51,,BAO_0000219,449.0,CHO,Antagonist activity was measured against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay,,,H,Autocuration,F,,CHEMBL615744,,,,,8,1
669,51,,BAO_0000219,449.0,CHO,Antagonist activity against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay.,,,H,Expert,F,,CHEMBL615745,,,,,8,1
670,51,,BAO_0000357,,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,,H,Autocuration,B,,CHEMBL615746,,,,,8,1
671,51,,BAO_0000357,,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,,H,Autocuration,B,,CHEMBL615747,,,,,8,1
672,51,,BAO_0000019,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,,H,Autocuration,F,,CHEMBL615748,,,,,8,1
673,51,,BAO_0000019,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay; NA indicates not available",,,H,Autocuration,F,,CHEMBL615749,,,,,8,1
674,51,,BAO_0000019,,,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,,,H,Autocuration,F,,CHEMBL615750,,,,,8,1
675,51,,BAO_0000019,,,Forskolin stimulated cAMP assessment of agonist activity for 5-hydroxytryptamine 1A receptor,,,D,Expert,F,9606.0,CHEMBL616259,,,,,9,1
676,51,,BAO_0000019,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,,H,Autocuration,F,,CHEMBL616260,,,,,8,1
677,51,,BAO_0000019,,,Antagonism of 5-hydroxytryptamine 1A receptor determined in vitro,,,D,Expert,F,9606.0,CHEMBL616261,,,,,9,1
678,51,,BAO_0000019,,,"Antagonism of 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,,D,Expert,F,9606.0,CHEMBL616262,,,,,9,1
679,51,,BAO_0000019,,,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",,,D,Expert,F,9606.0,CHEMBL616263,,,,,9,1
680,51,,BAO_0000019,,,Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro; No data,,,D,Expert,F,9606.0,CHEMBL616264,,,,,9,1
681,51,,BAO_0000019,,,Antagonism at the 5-hydroxytryptamine 1A receptor in vitro,,,D,Expert,F,9606.0,CHEMBL616265,,,,,9,1
682,51,,BAO_0000019,,,"Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,,D,Expert,F,9606.0,CHEMBL616266,,,,,9,1
683,51,,BAO_0000019,,,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",,,D,Expert,F,9606.0,CHEMBL616267,,,,,9,1
684,51,,BAO_0000019,,,Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro; No data,,,D,Expert,F,9606.0,CHEMBL616268,,,,,9,1
685,51,,BAO_0000357,,,Inhibition of human 5-hydroxytryptamine 1A receptor,,,D,Expert,B,9606.0,CHEMBL616269,,,,,9,1
686,51,,BAO_0000219,449.0,CHO,Binding affinity against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,,H,Autocuration,B,,CHEMBL884528,,,,,8,1
687,105,,BAO_0000219,722.0,HEK293,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor alpha expressed in HEK 293 cells,,,D,Expert,B,,CHEMBL616270,,,,,9,1
688,51,,BAO_0000219,449.0,CHO,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1A receptor stably expressed in CHO cells,,,H,Autocuration,B,,CHEMBL616271,,,,,8,1
689,51,,BAO_0000219,449.0,CHO,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,,H,Autocuration,F,,CHEMBL616272,,,,,8,1
690,51,,BAO_0000357,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in human CYP3A4 assay,,,H,Expert,B,,CHEMBL616273,,,,,8,1
691,51,,BAO_0000357,,,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,,,D,Expert,B,9606.0,CHEMBL616274,,,,,9,1
692,51,,BAO_0000219,449.0,CHO,Inhibition concentration against 5-HT 1A receptor using cAMP as radioligand in CHO cells,,,H,Autocuration,B,,CHEMBL616275,,,,,8,1
693,51,,BAO_0000219,449.0,CHO,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,,H,Autocuration,B,,CHEMBL616276,,,,,8,1
694,22226,In vivo,BAO_0000218,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,,,U,Autocuration,F,10116.0,CHEMBL616277,,,,,0,1
695,22226,In vivo,BAO_0000218,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration; Inactive,,,U,Autocuration,F,10116.0,CHEMBL616278,,,,,0,1
696,22226,In vivo,BAO_0000218,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration,,,U,Autocuration,F,10116.0,CHEMBL616279,,,,,0,1
697,22226,In vivo,BAO_0000218,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,,,U,Autocuration,F,10116.0,CHEMBL616280,,,,,0,1
698,22226,In vivo,BAO_0000218,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Partial response at the highest dose tested,,,U,Autocuration,F,10116.0,CHEMBL616281,,,,,0,1
699,22226,In vivo,BAO_0000218,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,,,U,Autocuration,F,10116.0,CHEMBL616282,,,,,0,1
700,22226,In vivo,BAO_0000218,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration,,,U,Autocuration,F,10116.0,CHEMBL616283,,,,,0,1
701,22226,In vivo,BAO_0000218,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration; Inactive,,,U,Autocuration,F,10116.0,CHEMBL616284,,,,,0,1
702,22226,In vivo,BAO_0000218,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration,,,U,Autocuration,F,10116.0,CHEMBL616285,,,,,0,1
703,22226,In vivo,BAO_0000218,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; Inactive,,,U,Autocuration,F,10116.0,CHEMBL616286,,,,,0,1
704,22226,In vivo,BAO_0000218,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; partial response at the highest dose tested,,,U,Autocuration,F,10116.0,CHEMBL616287,,,,,0,1
705,22226,In vivo,BAO_0000218,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration,,,U,Autocuration,F,10116.0,CHEMBL616288,,,,,0,1
706,22226,In vivo,BAO_0000218,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Inactive,,,U,Autocuration,F,10116.0,CHEMBL616289,,,,,0,1
707,22226,In vivo,BAO_0000218,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Partial response at the highest dose tested,,,U,Autocuration,F,10116.0,CHEMBL615610,,,,,0,1
708,22226,In vivo,BAO_0000218,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration,,,U,Autocuration,F,10116.0,CHEMBL615611,,,,,0,1
709,22226,In vivo,BAO_0000218,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Inactive,,,U,Autocuration,F,10116.0,CHEMBL615612,,,,,0,1
710,22226,In vivo,BAO_0000218,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Partial response at the highest dose tested,,,U,Autocuration,F,10116.0,CHEMBL615613,,,,,0,1
711,22226,In vivo,BAO_0000218,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; partial response at the highest dose tested,,,U,Autocuration,F,10116.0,CHEMBL615614,,,,,0,1
712,22226,In vivo,BAO_0000218,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,,,U,Autocuration,F,10116.0,CHEMBL615615,,,,,0,1
713,105093,,BAO_0000019,,,Affinity in displacing [125I](R)-DOI from rat cortical homogenate 5-HT2 receptor.,,,H,Autocuration,B,,CHEMBL615616,,,,,4,1
714,11923,,BAO_0000249,,,Binding affinity towards 5-HT 7 receptor in rat hypothalamus membranes using [3H]5-CT as radioligand,,,H,Autocuration,B,,CHEMBL615617,,1898.0,Hypothalamus,,8,1
715,10577,,BAO_0000019,,,Inhibitory activity against 5-HT1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data,,,H,Autocuration,B,,CHEMBL615618,,,,,8,1
716,10577,,BAO_0000019,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data.,,,H,Autocuration,B,,CHEMBL615619,,,,,8,1
717,10577,,BAO_0000019,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,,,H,Expert,B,,CHEMBL615620,,,,,8,1
718,55,,BAO_0000357,,,"Inhibitory activity against human whole blood, LTB4 5-lipoxygenase was evaluated",,,H,Autocuration,B,,CHEMBL615621,,,,,8,1
719,55,,BAO_0000357,,,"Inhibitory activity against intact human PMNL, LTB4 5-lipoxygenase was evaluated",,,H,Autocuration,B,,CHEMBL615622,,,,,8,1
720,12166,,BAO_0000019,,,Compound was evaluated for the inhibition of 5-LO (lipoxygenase),,,H,Autocuration,F,,CHEMBL615623,,,,,8,1
721,12166,,BAO_0000019,,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,,H,Autocuration,F,,CHEMBL615624,,,,,8,1
722,12166,,BAO_0000019,,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,,H,Autocuration,F,,CHEMBL615625,,,,,8,1
723,12166,,BAO_0000019,,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,,H,Autocuration,F,,CHEMBL767045,,,,,8,1
724,55,,BAO_0000019,,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN,,,H,Autocuration,F,10141.0,CHEMBL615626,,,,,8,1
725,55,,BAO_0000019,,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN; not active at the highest concentration (3 ug/mL) tested; No activity,,,H,Autocuration,F,10141.0,CHEMBL615627,,,,,8,1
726,55,,BAO_0000019,,,The compound was tested for inhibitory activity against 5-Lipoxygenase in guinea pig polymorphonuclear leukocytes,,,H,Autocuration,B,10141.0,CHEMBL615628,,,,,8,1
727,55,,BAO_0000357,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,,,H,Autocuration,B,10141.0,CHEMBL615629,,,,,8,1
728,55,,BAO_0000357,,,Inhibitory concentration against 5-lipoxygenase from human whole blood,,,D,Expert,B,9606.0,CHEMBL615630,,,,,9,1
729,55,,BAO_0000219,,,The compound was tested for inhibitory activity against 5-Lipoxygenase in human polymorphonuclear leukocytes[PMNS],,,H,Autocuration,B,,CHEMBL615631,,,,,8,1
730,17087,,BAO_0000218,,,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,,,H,Autocuration,F,,CHEMBL615632,,,,,8,1
731,17087,,BAO_0000357,,,Inhibitory concentration against 5-lipoxygenase from mouse macrophage,,,H,Autocuration,B,,CHEMBL615633,,,,,8,1
732,17087,,BAO_0000218,,,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,,,H,Autocuration,F,,CHEMBL615634,,,,,8,1
733,55,,BAO_0000019,,,Inhibition of arachidonate 5-lipoxygenase purified from porcine leukocytes.,,,H,Expert,B,9823.0,CHEMBL615635,,,,,8,1
734,12166,,BAO_0000357,,,In vitro inhibition of rat 5-Lipoxygenase,,,H,Expert,B,,CHEMBL615636,,,,,8,1
735,12166,,BAO_0000357,,,Inhibitory activity against 5-Lipoxygenase,,,D,Expert,B,10116.0,CHEMBL615637,,,,,9,1
736,12166,,BAO_0000219,702.0,RBL-1,Inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells,,,H,Expert,B,,CHEMBL615638,,,,,8,1
737,12166,,BAO_0000219,702.0,RBL-1,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,,H,Autocuration,B,,CHEMBL615639,,,,,8,1
738,12166,,BAO_0000219,702.0,RBL-1,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat RBL-1,,,H,Autocuration,B,,CHEMBL615640,,,,,8,1
739,12166,,BAO_0000019,,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat blood,,,H,Autocuration,B,,CHEMBL615796,,,,,8,1
740,12166,,BAO_0000219,,,The compound was tested for inhibitory activity against 5-Lipoxygenase receptor in rat polymorphonuclear leukocytes[PMNS],,,H,Autocuration,B,,CHEMBL615845,,,,,8,1
741,12166,,BAO_0000357,,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,,,H,Autocuration,B,,CHEMBL615846,,,,,8,1
742,12166,,BAO_0000219,702.0,RBL-1,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,,,H,Autocuration,B,,CHEMBL615847,,,,,8,1
743,12166,,BAO_0000357,,,The compound was tested for inhibition of isolated 5-Lipoxygenase,,,H,Autocuration,B,,CHEMBL615848,,,,,8,1
744,22226,,BAO_0000019,,,Ratio of IC50 against 5-LO and COX,,,U,Autocuration,B,10116.0,CHEMBL615849,,,,,0,1
745,12166,,BAO_0000357,,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,,,H,Autocuration,B,,CHEMBL615850,,,,,8,1
746,12166,,BAO_0000357,,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM; range is 20-35%,,,H,Autocuration,B,,CHEMBL615851,,,,,8,1
747,12166,,BAO_0000219,,,The compound was tested for inhibition against 5-Lipoxygenase in rat polymorphonuclear leukocytes at 10 uM concentration,,,H,Autocuration,B,,CHEMBL615852,,,,,8,1
748,12166,,BAO_0000019,,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) ex vivo,,,H,Autocuration,F,,CHEMBL615853,,,,,8,1
749,120,,BAO_0000357,,,Compound was tested for the inhibition of type 2 5-alpha-reductase of human prostates,,,H,Autocuration,B,,CHEMBL884527,,2367.0,Prostate gland,,8,1
750,22226,,BAO_0000019,,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-4 M inhibitory concentration,,,U,Autocuration,B,8932.0,CHEMBL872871,,,,,0,1
751,22226,,BAO_0000019,,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-5 M inhibitory concentration,,,U,Autocuration,B,8932.0,CHEMBL615854,,,,,0,1
752,22226,,BAO_0000019,,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme.,,,U,Autocuration,B,8932.0,CHEMBL767046,,,,,0,1
753,10732,,BAO_0000357,,,Compound was evaluated for the inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide transformylase obtained from human at 100 uM,,,H,Autocuration,B,,CHEMBL615855,,,,,8,1
754,12198,,BAO_0000019,,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT); NT = Not Tested,,,D,Expert,F,10116.0,CHEMBL615856,,,,,9,1
755,12198,,BAO_0000019,,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),,,D,Expert,F,10116.0,CHEMBL615857,,,,,9,1
756,12198,,BAO_0000019,,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),,,D,Expert,F,10116.0,CHEMBL615858,,,,,9,1
757,10576,,BAO_0000221,,,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,,,H,Expert,B,,CHEMBL615859,,10000000.0,Hippocampus,,8,1
758,51,,BAO_0000357,,,Binding affinity towards human 5-hydroxytryptamine 1 receptor,,,H,Autocuration,B,,CHEMBL615860,,,,,8,1
759,22226,,BAO_0000019,,,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,,U,Autocuration,B,9986.0,CHEMBL615861,,,,,0,1
760,22226,,BAO_0000019,,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,,U,Autocuration,B,9986.0,CHEMBL615862,,,,,0,1
761,22226,,BAO_0000019,,,Binding affinity against 5-hydroxytryptamine 1D receptor using rabbit saphenous vein assay.,,,U,Autocuration,B,9986.0,CHEMBL615863,,,,,0,1
762,22226,,BAO_0000019,,,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,,,U,Autocuration,B,9986.0,CHEMBL615864,,,,,0,1
763,104744,,BAO_0000221,,,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,,H,Autocuration,B,,CHEMBL615865,,10000000.0,Hippocampus,,4,1
764,104744,,BAO_0000221,,,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,,H,Autocuration,B,,CHEMBL615866,,10000000.0,Hippocampus,,4,1
765,104744,,BAO_0000221,,,Ability to bind at serotonin 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,,H,Autocuration,B,,CHEMBL615867,,10000000.0,Hippocampus,,4,1
766,104744,,BAO_0000249,,,Ability to inhibit binding of titreated serotonin to the 5-hydroxytryptamine 1 receptor in rat brain frontal cortex membranes,,,H,Autocuration,B,,CHEMBL615868,,,,Membranes,4,1
767,104744,,BAO_0000249,,,Binding affinity towards 5-hydroxytryptamine 1 receptor in brain cortical membranes of rat,,,D,Autocuration,B,10116.0,CHEMBL615869,,,,,5,1
768,104744,,BAO_0000019,,,Binding affinity towards 5-hydroxytryptamine 1 receptor in rat frontal cortex homogenates using [3H]5-HT as a radioligand,,,D,Autocuration,B,10116.0,CHEMBL615870,,,,,5,1
769,104744,,BAO_0000019,,,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as a radioligand from rat frontal cortex homogenates,,,D,Autocuration,B,10116.0,CHEMBL615871,,,,,5,1
770,104744,,BAO_0000224,,,Binding affinity towards 5-hydroxytryptamine 1 receptor was measured using radioligand ([3H]5-HT) binding assay,,,H,Autocuration,B,,CHEMBL615872,,,,,4,1
771,104744,,BAO_0000221,,,Binding affinity towards hippocampus 5-hydroxytryptamine 1 receptor was measured using radioligand [3H]5-HT,,,H,Autocuration,B,,CHEMBL833492,,10000000.0,Hippocampus,,4,1
772,104744,,BAO_0000221,,,Compound was evaluated for the inhibition of [3H]5-HT (concentration of 12 nM) specific binding to rat hippocampus,,,H,Autocuration,B,,CHEMBL615873,,10000000.0,Hippocampus,,4,1
773,104744,,BAO_0000224,,,Inhibitory activity against 5-hydroxytryptamine 1 receptor by 3H ligand binding experiments.,,,H,Autocuration,B,,CHEMBL615479,,,,,4,1
774,104744,,BAO_0000019,,,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat,,,H,Autocuration,B,,CHEMBL615480,,,,,4,1
775,104744,,BAO_0000249,,,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat cortical membrane homogenates using radioligand ([3H]5-HT) binding assay.,,,D,Autocuration,B,10116.0,CHEMBL615481,,,,,5,1
776,104744,,BAO_0000019,,,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,,H,Autocuration,B,,CHEMBL872869,,,,,4,1
777,104744,,BAO_0000019,,,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,,H,Autocuration,B,,CHEMBL615482,,,,,4,1
778,104744,,BAO_0000221,,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,,H,Autocuration,B,,CHEMBL615483,,955.0,Brain,,4,1
779,104744,,BAO_0000221,,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,,H,Autocuration,B,,CHEMBL615484,,955.0,Brain,,4,1
780,104744,,BAO_0000019,,,Percent inhibition of 5-hydroxytryptamine 1 receptor from rat cortex membrane using [3H]- serotonin as radioligand at 33 uM,,,H,Autocuration,B,,CHEMBL615485,,,,,4,1
781,104744,,BAO_0000224,,,Inhibition of [3H]5-HT radioligand binding against 5-hydroxytryptamine 1 receptor,,,D,Autocuration,B,10116.0,CHEMBL615486,,,,,5,1
782,104744,,BAO_0000224,,,Ancillary Binding affinity towards rat 5-hydroxytryptamine 1 receptor,,,H,Autocuration,B,,CHEMBL615487,,,,,4,1
783,104744,,BAO_0000224,,,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,,H,Autocuration,B,,CHEMBL615488,,,,,4,1
784,104744,,BAO_0000224,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,,H,Autocuration,B,,CHEMBL615489,,,,,4,1
785,104744,,BAO_0000224,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,,H,Autocuration,B,,CHEMBL615389,,,,,4,1
786,104744,,BAO_0000019,,,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,,,H,Autocuration,B,,CHEMBL615390,,,,,4,1
787,104744,,BAO_0000019,,,Binding affinity towards central 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,,,H,Autocuration,B,,CHEMBL615391,,,,,4,1
788,104744,,BAO_0000224,,,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined,,,H,Autocuration,B,,CHEMBL615392,,,,,4,1
789,22226,,BAO_0000019,,,Affinity for 5-hydroxytryptamine 1 receptor,,,U,Autocuration,B,10116.0,CHEMBL615393,,,,,0,1
790,104744,,BAO_0000221,,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex,,,H,Autocuration,B,,CHEMBL615394,,955.0,Brain,,4,1
791,104744,,BAO_0000221,,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,,H,Autocuration,B,,CHEMBL615395,,955.0,Brain,,4,1
792,104744,,BAO_0000224,,,Compound was evaluated for 5-hydroxytryptamine 1 receptor binding,,,H,Autocuration,B,,CHEMBL615396,,,,,4,1
793,104744,,BAO_0000221,,,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 1 receptor in rat brain using [3H]HT radioligand assay,,,H,Autocuration,B,,CHEMBL615397,,955.0,Brain,,4,1
794,104744,,BAO_0000019,,,Displacement of binding of [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,,H,Autocuration,B,,CHEMBL615398,,,,,4,1
795,22226,,BAO_0000019,,,Displacement of [3H]spiperone from 5-hydroxytryptamine 1 receptor of rat cortex,,,U,Autocuration,B,10116.0,CHEMBL615399,,,,,0,1
796,104744,,BAO_0000019,,,Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.,,,H,Autocuration,B,,CHEMBL615400,,,,,4,1
797,104744,,BAO_0000019,,,Binding affinity for 5-hydroxytryptamine 1 receptor of rat prefrontal cortex,,,D,Autocuration,B,10116.0,CHEMBL615401,,,,,5,1
798,22226,,BAO_0000019,,,Displacement of [3H]5-HT from 5-hydroxytryptamine 1 receptor of rat cortical membrane homogenates,,,U,Autocuration,B,10116.0,CHEMBL615402,,,,,0,1
799,104744,,BAO_0000019,,,The ability to inhibit [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cortex,,,H,Autocuration,B,,CHEMBL615403,,,,,4,1
800,104744,,BAO_0000221,,,The binding affinity was measured on serotonin 5-hydroxytryptamine 1 receptor in rat brain tissue,,,H,Autocuration,B,,CHEMBL615404,,955.0,Brain,,4,1
801,104744,,BAO_0000019,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1 receptor by displacing [3H]5-HT radioligand in rat cerebral cortex,,,H,Autocuration,B,,CHEMBL615781,,,,,4,1
802,104744,,BAO_0000220,,,Tested for 5-hydroxytryptamine 1 receptor binding ability by displacement of [3H]5-HT from rat brain synaptosomes,,,H,Autocuration,B,,CHEMBL615782,,955.0,Brain,,4,1
803,104744,,BAO_0000221,,,Inhibition constant (1 uM) was measured on 5-hydroxytryptamine 1 receptor/uptake using [3H]- serotonin as radioligand in rat brain cortex.,,,H,Autocuration,B,,CHEMBL615783,,955.0,Brain,,4,1
804,22226,,BAO_0000019,,,Compound was tested for binding affinity against 5-HT1 receptor,,,U,Autocuration,B,,CHEMBL873481,,,,,0,1
805,22226,,BAO_0000019,,,Inhibitory concentration against 5-hydroxytryptamine 1 receptor,,,U,Autocuration,B,,CHEMBL615784,,,,,0,1
806,10576,,BAO_0000357,,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,,,H,Expert,B,,CHEMBL615785,,,,,8,1
807,10576,,BAO_0000249,,,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",,,H,Autocuration,F,,CHEMBL615786,,,,,8,1
808,10576,In vivo,BAO_0000218,,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,,,H,Autocuration,F,,CHEMBL615787,,,,,8,1
809,10576,In vivo,BAO_0000218,,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,,,H,Autocuration,F,,CHEMBL615788,,,,,8,1
810,10576,,BAO_0000019,,,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor,,,H,Autocuration,F,,CHEMBL767044,,,,,8,1
811,10576,In vivo,BAO_0000218,,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,,,H,Autocuration,F,,CHEMBL615789,,,,,8,1
812,10576,In vivo,BAO_0000218,,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,,,H,Autocuration,F,,CHEMBL615790,,,,,8,1
813,10576,,BAO_0000019,,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats,,,H,Autocuration,F,,CHEMBL615813,,,,,8,1
814,10576,,BAO_0000219,,,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 10 uM concentration,,,H,Autocuration,F,,CHEMBL615814,,,,,8,1
815,51,,BAO_0000219,,,Percent inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation in GH4ZD10 cells expressing 5-HT1A receptor at 50 uM relative to 5-HT,,,H,Expert,F,,CHEMBL615815,,,,,8,1
816,10576,,BAO_0000219,,,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 50 uM concentration; No effect,,,H,Autocuration,F,,CHEMBL615816,,,,,8,1
817,10576,,BAO_0000249,,,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes expressed as Hill values,,,H,Expert,B,,CHEMBL615817,,,,,8,1
818,10576,,BAO_0000221,,,Ability to bind at 5-hydroxytryptamine 1A receptor of rat hippocampus by displacing [3H]8-OH-DPAT,,,H,Autocuration,B,,CHEMBL615818,,10000000.0,Hippocampus,,8,1
819,10576,,BAO_0000221,,,Ability to bind at serotonin 5-hydroxytryptamine 1A receptors of rat hippocampus by displacing [3H]8-OH-DPAT,,,H,Autocuration,B,,CHEMBL615819,,10000000.0,Hippocampus,,8,1
820,10576,,BAO_0000249,,,Binding affinity against 5-hydroxytryptamine 1A receptor (5-HT1A) by displacement of [3H]8-OH-DPAT from rat hippocampus membranes,,,H,Expert,B,,CHEMBL615820,,,,Membranes,8,1
821,10576,,BAO_0000221,,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]8-OH-DPAT,,,D,Expert,B,10116.0,CHEMBL615821,,10000000.0,Hippocampus,,9,1
822,10576,,BAO_0000221,,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,,,D,Expert,B,10116.0,CHEMBL615822,,10000000.0,Hippocampus,,9,1
823,10576,,BAO_0000221,,,Binding affinity against 5-hydroxytryptamine 1A receptor using in rat hippocampal tissue using [3H]8-OH-DPAT as radioligand,,,H,Expert,B,,CHEMBL615823,,10000000.0,Hippocampus,,8,1
824,10576,,BAO_0000221,,,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor; IA-Inactive,,,D,Expert,B,10116.0,CHEMBL615824,,10000000.0,Hippocampus,,9,1
825,10576,,BAO_0000221,,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,,,D,Expert,B,10116.0,CHEMBL615825,,10000000.0,Hippocampus,,9,1
826,10576,,BAO_0000357,,,Binding affinity towards rat 5-hydroxytryptamine 1A receptor was evaluated using [3H]8-OH-DPAT as radioligand,,,H,Expert,B,,CHEMBL615826,,,,,8,1
827,10576,,BAO_0000249,,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using [3H]8-OH-DPAT as radioligand,,,H,Expert,B,,CHEMBL615827,,,,,8,1
828,10576,,BAO_0000249,,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus membrane using [3H]8-OH-DPAT as radioligand,,,H,Expert,B,,CHEMBL615828,,10000000.0,Hippocampus,,8,1
829,10576,,BAO_0000221,,,Binding affinity by measuring displacement of [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,,H,Expert,B,,CHEMBL615829,,10000000.0,Hippocampus,,8,1
830,10576,,BAO_0000221,,,Binding affinity to 5-hydroxytryptamine 1A receptor of rat hippocampus with [3H]8-OH-DPAT as radioligand,,,H,Autocuration,B,,CHEMBL615830,,10000000.0,Hippocampus,,8,1
831,10576,,BAO_0000221,,,Binding affinity towards serotonin 5-HT1A receptor was determined in rat hippocampus using [3H]8-OH-DPAT as ligand,,,H,Expert,B,,CHEMBL615831,,10000000.0,Hippocampus,,8,1
832,10576,,BAO_0000357,,,Binding affinity was measured against serotonin 5-hydroxytryptamine 1A receptor,,,H,Autocuration,B,,CHEMBL615832,,,,,8,1
833,10576,,BAO_0000019,,,Binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH- DPAT as radioligand,,,H,Autocuration,B,,CHEMBL615833,,,,,8,1
834,10576,,BAO_0000221,,,Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]-8-OH- DPAT as radioligand,,,H,Autocuration,B,,CHEMBL615834,,10000000.0,Hippocampus,,8,1
835,10576,,BAO_0000249,,,Binding affinity against 5-hydroxytryptamine 1A (5-HT1A) receptor in rat hippocampus membranes,,,H,Intermediate,B,,CHEMBL615835,,,,,8,1
836,10576,,BAO_0000249,,,Binding affinity was measured at the serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampal membrane.,,,H,Autocuration,B,,CHEMBL615836,,10000000.0,Hippocampus,,8,1
837,10576,,BAO_0000019,,,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand.,,,D,Expert,B,10116.0,CHEMBL615837,,,,,9,1
838,10576,,BAO_0000019,,,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand; ND-Not determined,,,D,Expert,B,10116.0,CHEMBL615838,,,,,9,1
839,10576,,BAO_0000249,,,"Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding (NSB)",,,H,Expert,B,,CHEMBL615839,,,,,8,1
840,10576,,BAO_0000019,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH-DPAT as radioligand,,,H,Autocuration,B,,CHEMBL884525,,,,,8,1
841,10576,,BAO_0000249,,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonin 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,,,H,Autocuration,B,,CHEMBL615840,,,,,8,1
842,10576,,BAO_0000221,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,,H,Expert,B,,CHEMBL615405,,10000000.0,Hippocampus,,8,1
843,10576,,BAO_0000019,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,,H,Expert,B,,CHEMBL615406,,,,,8,1
844,10576,,BAO_0000221,,,Affinity for 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,,,H,Expert,B,,CHEMBL615900,,10000000.0,Hippocampus,,8,1
845,10576,,BAO_0000221,,,Inhibition of [3H]8-OH-DPAT binding at serotonin 5-hydroxytryptamine 1A receptor from rat hippocampus tissue.,,,H,Expert,B,,CHEMBL615901,,10000000.0,Hippocampus,,8,1
846,10576,,BAO_0000357,,,In vitro inhibition of [3H]8-OH-DPAT binding to rat 5-HT 1a receptors.,,,H,Expert,B,,CHEMBL615902,,,,,8,1
847,10576,,BAO_0000221,,,Compound was measured for affinity at 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,,,H,Autocuration,B,,CHEMBL615903,,10000000.0,Hippocampus,,8,1
848,10576,,BAO_0000357,,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor<br>at 1 uM,,,H,Autocuration,B,,CHEMBL615904,,,,,8,1
849,10576,,BAO_0000357,,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,,,H,Expert,B,,CHEMBL615905,,,,,8,1
850,10576,,BAO_0000019,,,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,,,H,Autocuration,B,,CHEMBL615906,,,,,8,1
851,10576,,BAO_0000019,,,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,,,H,Autocuration,F,,CHEMBL615907,,,,,8,1
852,10576,,BAO_0000019,,,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,,H,Expert,B,,CHEMBL615908,,,,,8,1
853,10576,,BAO_0000221,,,In vitro affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT in rat hippocampus,,,H,Autocuration,B,,CHEMBL615909,,10000000.0,Hippocampus,,8,1
854,10576,,BAO_0000019,,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]-8-OH-DPAT as the radioligand",,,H,Autocuration,B,,CHEMBL615910,,,,,8,1
855,10576,,BAO_0000019,,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand.",,,H,Autocuration,B,,CHEMBL615911,,,,,8,1
856,10576,,BAO_0000019,,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand",,,H,Autocuration,B,,CHEMBL615912,,,,,8,1
857,10576,,BAO_0000019,,,In vitro binding affinity for serotonin 5-hydroxytryptamine 1A receptor fof rat cerebral cortex using [3H]8-OH-DPAT as radioligand,,,H,Expert,B,,CHEMBL615913,,,,,8,1
858,10576,,BAO_0000357,,,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,,H,Expert,B,,CHEMBL615914,,,,,8,1
859,10576,,BAO_0000221,,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,,,H,Autocuration,B,,CHEMBL615915,,10000000.0,Hippocampus,,8,1
860,10576,,BAO_0000357,,,In vitro binding affinity towards the 5-hydroxytryptamine 1A receptor was evaluated,,,H,Autocuration,B,,CHEMBL615916,,,,,8,1
861,10576,,BAO_0000357,,,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 1A receptor by displacement of [3H]- tetralin,,,H,Expert,B,,CHEMBL615917,,,,,8,1
862,10576,,BAO_0000357,,,In vitro inhibitory activity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,,H,Expert,B,,CHEMBL615918,,,,,8,1
863,10576,,BAO_0000249,,,In vitro inhibitory concentration against radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane.,,,H,Expert,B,,CHEMBL615919,,10000000.0,Hippocampus,,8,1
864,10576,,BAO_0000221,,,In vitro radioligand binding assay on 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,,,D,Expert,B,10116.0,CHEMBL615920,,10000000.0,Hippocampus,,9,1
865,10576,,BAO_0000357,,,Inhibition concentration against 5-hydroxytryptamine 1A receptor,,,H,Autocuration,B,,CHEMBL615921,,,,,8,1
866,10576,,BAO_0000357,,,Inhibitory concentration against 5-hydroxytryptamine 1A receptor (Inactive at >1000 nM concentration),,,H,Expert,B,,CHEMBL615922,,,,,8,1
867,10576,,BAO_0000249,,,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",,,D,Expert,F,10116.0,CHEMBL881290,,,,,9,1
868,10576,,BAO_0000221,,,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Residual radioligand binding higher than 50%",,,H,Autocuration,B,,CHEMBL615923,,10000000.0,Hippocampus,,8,1
869,10576,,BAO_0000221,,,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,,,H,Autocuration,F,,CHEMBL615924,,10000000.0,Hippocampus,,8,1
870,10576,,BAO_0000221,,,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,,,H,Autocuration,F,,CHEMBL615925,,10000000.0,Hippocampus,,8,1
871,10576,,BAO_0000357,,,Inhibition of radiolabeled [3H]-8-OH-DPAT ligand binding to 5-hydroxytryptamine 1A receptor,,,D,Expert,B,10116.0,CHEMBL615926,,,,,9,1
872,10576,,BAO_0000019,,,Displacement of [3H]8-OH-DPAT from rat cortex 5-hydroxytryptamine 1A receptor,,,D,Expert,B,10116.0,CHEMBL615927,,,,,9,1
873,10576,,BAO_0000221,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,,H,Autocuration,B,,CHEMBL615928,,10000000.0,Hippocampus,,8,1
874,10576,,BAO_0000357,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor subtype,,,D,Expert,B,10116.0,CHEMBL615929,,,,,9,1
875,10576,,BAO_0000221,,,Inhibitory activity against [3H]DPAT binding to 5-HT1A receptor in rat hippocampus,,,H,Autocuration,B,,CHEMBL615930,,10000000.0,Hippocampus,,8,1
876,51,,BAO_0000219,449.0,CHO,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,,H,Autocuration,B,,CHEMBL615931,,,,,8,1
877,51,,BAO_0000219,449.0,CHO,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,,H,Autocuration,F,,CHEMBL615932,,,,,8,1
878,51,,BAO_0000219,449.0,CHO,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,,H,Autocuration,F,,CHEMBL615933,,,,,8,1
879,51,,BAO_0000357,,,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,,,H,Autocuration,B,,CHEMBL615934,,,,,8,1
880,51,,BAO_0000357,,,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT; Not tested,,,H,Autocuration,B,,CHEMBL615935,,,,,8,1
881,51,,BAO_0000019,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,,H,Autocuration,F,,CHEMBL615936,,,,,8,1
882,51,,BAO_0000219,449.0,CHO,Ability to displace [3H]-8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor at a concentration of 1 uM,,,H,Autocuration,B,,CHEMBL615937,,,,,8,1
883,51,,BAO_0000357,,,Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor,,,H,Autocuration,B,,CHEMBL615938,,,,,8,1
884,51,,BAO_0000357,,,In vitro binding affinity against human 5-hydroxytryptamine 1A receptor at a concentration of 100 (nM),,,H,Autocuration,B,,CHEMBL615797,,,,,8,1
885,51,,BAO_0000357,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,H,Autocuration,B,,CHEMBL615798,,,,,8,1
886,51,,BAO_0000357,,,Inhibition of [3H]8-OH-DPAT binding to human 5-hydroxytryptamine 1A receptor at 1000 nM compound concentration,,,H,Autocuration,B,,CHEMBL872870,,,,,8,1
887,51,,BAO_0000357,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand at 100 nM concentration,,,H,Autocuration,B,,CHEMBL615799,,,,,8,1
888,51,,BAO_0000357,,,Percent binding affinity against 5-hydroxytryptamine 1A receptor,,,H,Autocuration,B,,CHEMBL615800,,,,,8,1
889,51,,BAO_0000219,722.0,HEK293,Intrinsic activity for human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,,H,Autocuration,F,,CHEMBL615801,,,,,8,1
890,51,,BAO_0000019,,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the absence of endothelium,,,H,Autocuration,B,,CHEMBL615802,,,,,8,1
891,51,,BAO_0000357,,,Dissociation constant against human 5-hydroxytryptamine 1A receptor receptor,,,H,Autocuration,B,,CHEMBL615803,,,,,8,1
892,51,,BAO_0000019,,,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",,,H,Expert,F,,CHEMBL835002,,,,,8,1
893,51,,BAO_0000019,,,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Ki (nM): not determined",,,H,Autocuration,F,,CHEMBL615804,,,,,8,1
894,51,,BAO_0000219,308.0,HeLa,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor,,,H,Expert,B,,CHEMBL615805,,,,,8,1
895,51,,BAO_0000219,449.0,CHO,Ability to displace [3H]8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor,,,H,Autocuration,B,,CHEMBL615806,,,,,8,1
896,51,,BAO_0000357,,,Affinity towards human 5-hydroxytryptamine 1A serotonin receptor,,,D,Expert,B,9606.0,CHEMBL615807,,,,,9,1
897,51,,BAO_0000357,,,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT-as radioligand,,,H,Autocuration,B,,CHEMBL615808,,,,,8,1
898,51,,BAO_0000357,,,Binding affinity against 5-hydroxytryptamine 1A receptor,,,D,Expert,B,9606.0,CHEMBL615809,,,,,9,1
899,51,,BAO_0000219,308.0,HeLa,Binding affinity against 5-hydroxytryptamine 1A receptor in HeLa cells was determined using [3H]5-HT,,,H,Autocuration,B,,CHEMBL615810,,,,,8,1
900,51,,BAO_0000357,,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,H,Autocuration,B,,CHEMBL615811,,,,,8,1
901,51,,BAO_0000219,449.0,CHO,Binding affinity against [3H]- -8-OH-DPAT -labeled 5-hydroxytryptamine 1A sites in cloned CHO cells,,,H,Autocuration,B,,CHEMBL615812,,,,,8,1
902,51,,BAO_0000219,449.0,CHO,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,,H,Autocuration,B,,CHEMBL615751,,,,,8,1
903,51,,BAO_0000357,,,Binding affinity against human 5-hydroxytryptamine 1A receptor,,,H,Autocuration,B,,CHEMBL615752,,,,,8,1
904,51,,BAO_0000219,449.0,CHO,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand,,,H,Expert,B,,CHEMBL615753,,,,,8,1
905,51,,BAO_0000219,449.0,CHO,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand; nd=not determined,,,H,Autocuration,B,,CHEMBL615754,,,,,8,1
906,51,,BAO_0000357,,,Binding affinity of compound to human 5-hydroxytryptamine 1A receptor,,,H,Autocuration,B,,CHEMBL615755,,,,,8,1
907,51,,BAO_0000219,449.0,CHO,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,,D,Expert,B,9606.0,CHEMBL615756,,,,,9,1
908,51,,BAO_0000019,,,Binding affinity for 5-hydroxytryptamine 1A receptor in HeLa transfected cell type using [3H]8-OH-DPAT as radioligand,,,H,Autocuration,B,,CHEMBL615757,,,,,8,1
909,51,,BAO_0000357,,,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,,,H,Autocuration,B,,CHEMBL615758,,,,,8,1
910,51,,BAO_0000357,,,In vitro affinity at human cloned 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,,,H,Expert,B,,CHEMBL615759,,,,,8,1
911,51,,BAO_0000357,,,Binding affinity towards human 5-hydroxytryptamine 1A receptor,,,H,Autocuration,B,,CHEMBL615760,,,,,8,1
912,51,,BAO_0000219,308.0,HeLa,Binding affinity towards human 5-hydroxytryptamine 1A receptor by the displacement of [3H]5-HT radioligand from the cloned receptor expressed in HeLa cells,,,H,Expert,B,,CHEMBL615761,,,,,8,1
913,51,,BAO_0000357,,,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]-5-HT as radioligand,,,H,Autocuration,B,,CHEMBL872104,,,,,8,1
914,51,,BAO_0000357,,,Binding affinity towards recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,,H,Autocuration,B,,CHEMBL615762,,,,,8,1
915,51,,BAO_0000357,,,Binding affinity towards recombinant human Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,,H,Autocuration,B,,CHEMBL615763,,,,,8,1
916,51,,BAO_0000357,,,Binding affinity for recombinant human 5-hydroxytryptamine 1A receptor using [3H]5-HT as radioligand.,,,H,Autocuration,B,,CHEMBL615764,,,,,8,1
917,51,,BAO_0000219,1167.0,Cell line,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines (He La),,,H,Autocuration,B,,CHEMBL615765,,,,,8,1
918,51,,BAO_0000019,,,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines(He La),,,H,Autocuration,B,,CHEMBL615766,,,,,8,1
919,51,,BAO_0000357,,,Binding affinity towards 5-HT1A receptor using [3H]8-OH-DPAT as radioligand,,,H,Autocuration,B,,CHEMBL615767,,,,,8,1
920,51,,BAO_0000357,,,Binding affinity was determined towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,H,Expert,B,,CHEMBL615768,,,,,8,1
921,51,,BAO_0000357,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,H,Autocuration,B,,CHEMBL615769,,,,,8,1
922,51,,BAO_0000357,,,Binding affinity was evaluated at 5-hydroxytryptamine 1A receptor labeled with [3H]-8-OH-DPAT,,,H,Expert,B,,CHEMBL615770,,,,,8,1
923,51,,BAO_0000357,,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,H,Autocuration,B,,CHEMBL615771,,,,,8,1
924,51,,BAO_0000357,,,Binding affinity to human 5-hydroxytryptamine 1A receptor was measured using [3H]-8-hydroxy-2-(di-n-propylamine) tetraline [3H]8-OH-DPAT) as radioligand,,,H,Expert,B,,CHEMBL615772,,,,,8,1
925,51,,BAO_0000357,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,,,H,Autocuration,B,,CHEMBL615773,,,,,8,1
926,51,,BAO_0000357,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,,,H,Expert,B,,CHEMBL615774,,,,,8,1
927,51,,BAO_0000357,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,H,Autocuration,B,,CHEMBL615775,,,,,8,1
928,51,,BAO_0000357,,,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,,,H,Autocuration,B,,CHEMBL615776,,,,,8,1
929,51,,BAO_0000357,,,Binding affinity towards human cloned 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,H,Expert,B,,CHEMBL615777,,,,,8,1
930,51,,BAO_0000219,,,Binding affinity was measured on 5-hydroxytryptamine 1A receptor in AK cells transfected with human 5-HT1A gene labeled with [3H]-8-OH-DPAT,,,H,Autocuration,B,,CHEMBL615778,,,,,8,1
931,51,,BAO_0000357,,,Binding affinity was measured on cloned Human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,,D,Expert,B,9606.0,CHEMBL615779,,,,,9,1
932,51,,BAO_0000357,,,Binding affinity was measured on cloned human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,,H,Autocuration,B,,CHEMBL615780,,,,,8,1
933,51,,BAO_0000357,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1A receptor,,,H,Autocuration,B,,CHEMBL616298,,,,,8,1
934,51,,BAO_0000357,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1A receptor,,,H,Autocuration,B,,CHEMBL616299,,,,,8,1
935,51,,BAO_0000219,485.0,CHO-K1,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells.,,,H,Autocuration,B,,CHEMBL616300,,,,,8,1
936,51,,BAO_0000219,485.0,CHO-K1,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1A receptor in CHO-K1 cells,,,H,Expert,F,,CHEMBL616301,,,,,8,1
937,51,,BAO_0000019,,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor,,,H,Autocuration,B,,CHEMBL616302,,,,,8,1
938,51,,BAO_0000019,,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 1),,,H,Autocuration,B,,CHEMBL616117,,,,,8,1
939,51,,BAO_0000019,,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 2),,,H,Autocuration,B,,CHEMBL616118,,,,,8,1
940,51,,BAO_0000019,,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor by Panlabs assay,,,H,Autocuration,B,,CHEMBL616119,,,,,8,1
941,51,,BAO_0000219,308.0,HeLa,Displacement of specific [3H]- 5-HT binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,,,D,Expert,B,9606.0,CHEMBL616120,,,,,9,1
942,51,,BAO_0000357,,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,,,H,Autocuration,B,,CHEMBL616121,,,,,8,1
943,51,,BAO_0000357,,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor receptor,,,H,Autocuration,B,,CHEMBL616122,,,,,8,1
944,51,,BAO_0000357,,,In vitro binding affinity tested on human 5-hydroxytryptamine 1A receptor,,,H,Autocuration,B,,CHEMBL616123,,,,,8,1
945,51,,BAO_0000357,,,In vitro binding affinity to human 5-hydroxytryptamine 1A receptor,,,D,Expert,B,9606.0,CHEMBL616124,,,,,9,1
946,51,,BAO_0000357,,,In vitro binding affinity at 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,,,H,Expert,B,,CHEMBL616125,,,,,8,1
947,51,,BAO_0000357,,,In vitro binding affinity towards Human 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT,,,H,Expert,B,10116.0,CHEMBL616126,,,,,8,1
948,51,,BAO_0000219,449.0,CHO,In vitro binding affinity towards cloned human 5-hydroxytryptamine 1A receptor expressed in Chinese hamster ovary (CHO) cells using [3H]8-OH-DPAT as radioligand,,,H,Autocuration,B,,CHEMBL616127,,,,,8,1
949,51,,BAO_0000019,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor,,,H,Expert,B,,CHEMBL616128,,,,,8,1
950,51,,BAO_0000357,,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,,,H,Autocuration,B,,CHEMBL616129,,,,,8,1
951,51,,BAO_0000357,,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor,,,H,Expert,B,,CHEMBL616130,,,,,8,1
952,51,,BAO_0000357,,,Inhibition of [3H]- OH-DPAT binding against 5-hydroxytryptamine 1A receptor from human recombinant,,,H,Autocuration,B,,CHEMBL616131,,,,,8,1
953,51,,BAO_0000219,308.0,HeLa,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor serotonergic receptor in human HeLa cells,,,H,Autocuration,B,,CHEMBL616132,,,,,8,1
954,51,,BAO_0000219,308.0,HeLa,Receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor in HeLa cells,,,D,Expert,B,9606.0,CHEMBL616133,,,,,9,1
955,51,,BAO_0000357,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,H,Autocuration,B,,CHEMBL616134,,,,,8,1
956,51,,BAO_0000357,,,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT,,,H,Autocuration,B,,CHEMBL616135,,,,,8,1
957,51,,BAO_0000357,,,Affinity for 5-hydroxytryptamine 1A receptor subtype,,,D,Expert,B,9606.0,CHEMBL616136,,,,,9,1
958,51,,BAO_0000019,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes,,,H,Autocuration,B,,CHEMBL616137,,,,,8,1
959,51,,BAO_0000019,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes.,,,H,Autocuration,B,,CHEMBL872105,,,,,8,1
960,51,,BAO_0000357,,,The compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor receptor,,,H,Autocuration,B,,CHEMBL616138,,,,,8,1
961,51,,BAO_0000357,,,Binding affinity for cloned human 5-hydroxytryptamine 1A receptor,,,D,Expert,B,9606.0,CHEMBL616139,,,,,9,1
962,51,,BAO_0000019,,,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor; Not active",,,H,Autocuration,F,,CHEMBL616140,,,,,8,1
963,51,,BAO_0000019,,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor; ND means not determined,,,H,Expert,B,,CHEMBL616141,,,,,8,1
964,51,,BAO_0000357,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,H,Autocuration,B,,CHEMBL616142,,,,,8,1
965,51,,BAO_0000357,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; ND means Not determined,,,H,Autocuration,B,,CHEMBL616143,,,,,8,1
966,51,,BAO_0000219,308.0,HeLa,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,,H,Autocuration,B,,CHEMBL616144,,,,,8,1
967,51,,BAO_0000219,308.0,HeLa,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT=not tested,,,H,Autocuration,B,,CHEMBL616145,,,,,8,1
968,51,,BAO_0000219,308.0,HeLa,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,,H,Autocuration,B,,CHEMBL616012,,,,,8,1
969,51,,BAO_0000219,308.0,HeLa,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,,H,Autocuration,B,,CHEMBL616013,,,,,8,1
970,51,,BAO_0000019,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,,H,Autocuration,F,,CHEMBL616014,,,,,8,1
971,51,,BAO_0000019,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,,H,Autocuration,F,,CHEMBL616015,,,,,8,1
972,51,,BAO_0000019,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,,H,Autocuration,F,,CHEMBL616016,,,,,8,1
973,51,In vivo,BAO_0000218,,,Antagonist induction of hypothermia by 8-OH-DPAT in 5-hydroxytryptamine 1A receptor after subcutaneous administration; NT is not tested,,,H,Autocuration,F,,CHEMBL616017,,,,,8,1
974,51,,BAO_0000019,,,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]-8-OH-DPAT binding in Chinese hamster ovary cell line; NT is not tested,,,H,Autocuration,B,,CHEMBL616018,,,,,8,1
975,51,,BAO_0000019,,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor receptor; Not tested,,,H,Autocuration,F,,CHEMBL616019,,,,,8,1
976,51,,BAO_0000019,,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor; Not tested,,,H,Autocuration,F,,CHEMBL616020,,,,,8,1
977,51,,BAO_0000357,,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,,,H,Autocuration,B,,CHEMBL858018,,,,,8,1
978,51,,BAO_0000219,722.0,HEK293,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,,H,Autocuration,F,,CHEMBL616021,,,,,8,1
979,51,,BAO_0000019,,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at 1 uM.",,,H,Expert,F,,CHEMBL616022,,,,,8,1
980,51,,BAO_0000019,,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means Not determined",,,H,Autocuration,F,,CHEMBL616023,,,,,8,1
981,51,,BAO_0000019,,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means not determined",,,H,Autocuration,F,,CHEMBL616024,,,,,8,1
982,51,,BAO_0000019,,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; Not determined",,,H,Autocuration,F,,CHEMBL616025,,,,,8,1
983,51,,BAO_0000219,449.0,CHO,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,,H,Autocuration,F,,CHEMBL616026,,,,,8,1
984,51,,BAO_0000019,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT",,,H,Autocuration,F,,CHEMBL616027,,,,,8,1
985,51,,BAO_0000019,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared to 5-HT",,,D,Expert,F,9606.0,CHEMBL616028,,,,,9,1
986,51,,BAO_0000019,,,Percent efficacy against human 5-hydroxytryptamine 1A receptor relative to maximal 5-HT response,,,D,Expert,F,9606.0,CHEMBL616029,,,,,9,1
987,51,,BAO_0000219,449.0,CHO,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by incubating human 5-hydroxytryptamine 1A receptor transfected CHO cells with [3H]8-OH-DPAT,,,H,Expert,B,,CHEMBL616030,,,,,8,1
988,51,,BAO_0000019,,,In vitro inhibition of [3H]8-OH-DPAT binding to human cloned 5-hydroxytryptamine 1A receptor on CHO cell membranes.,,,H,Expert,B,,CHEMBL616031,,,,,8,1
989,51,,BAO_0000019,,,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,,,D,Expert,F,9606.0,CHEMBL616032,,,,,9,1
990,51,,BAO_0000019,,,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,,,D,Expert,F,9606.0,CHEMBL616033,,,,,9,1
991,51,,BAO_0000019,,,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,,H,Autocuration,F,,CHEMBL616034,,,,,8,1
992,51,,BAO_0000019,,,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,,H,Autocuration,F,,CHEMBL616035,,,,,8,1
993,51,,BAO_0000019,,,Maximum binding affinity was evaluated as ([35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,,,H,Autocuration,F,,CHEMBL616036,,,,,8,1
994,51,,BAO_0000019,,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,,H,Autocuration,F,,CHEMBL616037,,,,,8,1
995,51,,BAO_0000019,,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,,H,Autocuration,F,,CHEMBL616038,,,,,8,1
996,51,,BAO_0000019,,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,,H,Autocuration,F,,CHEMBL616039,,,,,8,1
997,51,,BAO_0000019,,,Agonist efficacy was evaluated as [35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,,,H,Autocuration,F,,CHEMBL616040,,,,,8,1
998,51,,BAO_0000219,308.0,HeLa,Concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,,,D,Expert,F,9606.0,CHEMBL616041,,,,,9,1
999,51,,BAO_0000219,308.0,HeLa,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,,,D,Expert,F,9606.0,CHEMBL616042,,,,,9,1
1000,51,,BAO_0000219,308.0,HeLa,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,,,D,Expert,F,9606.0,CHEMBL616043,,,,,9,1
1001,51,,BAO_0000019,,,"Potency (pD2) for the stimulation of [35S]GTP-gamma-S, binding on 5-hydroxytryptamine 1A receptor",,,H,Autocuration,F,,CHEMBL616044,,,,,8,1
1002,51,,BAO_0000019,,,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,,H,Autocuration,F,,CHEMBL616045,,,,,8,1
1003,51,,BAO_0000219,722.0,HEK293,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,,H,Autocuration,F,,CHEMBL616046,,,,,8,1
1004,51,,BAO_0000219,449.0,CHO,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),,,H,Autocuration,F,,CHEMBL616047,,,,,8,1
1005,51,,BAO_0000219,449.0,CHO,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,,H,Autocuration,F,,CHEMBL616048,,,,,8,1
1006,51,,BAO_0000219,449.0,CHO,Potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 1),,,D,Expert,F,9606.0,CHEMBL616049,,,,,9,1
1007,51,,BAO_0000219,449.0,CHO,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),,,H,Autocuration,F,,CHEMBL616050,,,,,8,1
1008,51,,BAO_0000219,,,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor,,,H,Expert,F,,CHEMBL616051,,,,,8,1
1009,51,,BAO_0000219,,,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor; Not tested,,,H,Autocuration,F,,CHEMBL616212,,,,,8,1
1010,51,,BAO_0000019,,,"ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,,H,Autocuration,F,,CHEMBL616213,,,,,8,1
1011,51,In vitro,BAO_0000219,,,Ability to bind to 5-hydroxytryptamine 1A receptor from cloned human expressed in Ha7 cells,,,H,Expert,B,,CHEMBL616214,,,,,8,1
1012,51,In vitro,BAO_0000219,,,Ability to bind to 5-hydroxytryptamine 1A receptor subtype from cloned human expressed in Ha7 cells,,,H,Expert,B,,CHEMBL616215,,,,,8,1
1013,51,,BAO_0000357,,,Binding activity radioligand.,,,H,Autocuration,B,,CHEMBL616216,,,,,8,1
1014,51,,BAO_0000019,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,,H,Autocuration,B,,CHEMBL616217,,,,,8,1
1015,51,,BAO_0000357,,,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,,,H,Autocuration,B,,CHEMBL616218,,,,,8,1
1016,51,,BAO_0000357,,,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,,,H,Autocuration,B,,CHEMBL616219,,,,,8,1
1017,51,,BAO_0000357,,,binding affinity towards human recombinant 5-hydroxytryptamine 1A receptor,,,H,Autocuration,B,,CHEMBL616220,,,,,8,1
1018,51,,BAO_0000357,,,Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from human 5-hydroxytryptamine 1A receptor,,,D,Expert,B,9606.0,CHEMBL833493,,,,,9,1
1019,51,,BAO_0000357,,,Ability to displace the radioligand [3H]-8-OH-DPAT from human 5-hydroxytryptamine 1A receptor,,,H,Autocuration,B,,CHEMBL616221,,,,,8,1
1020,51,,BAO_0000219,449.0,CHO,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,,,D,Expert,B,9606.0,CHEMBL616222,,,,,9,1
1021,51,,BAO_0000019,,,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor,,,H,Autocuration,F,,CHEMBL616223,,,,,8,1
1022,51,,BAO_0000019,,,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor; Not determined,,,H,Autocuration,F,,CHEMBL616224,,,,,8,1
1023,51,,BAO_0000019,,,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding in Chinese hamster ovary cell line,,,H,Expert,B,,CHEMBL616225,,,,,8,1
1024,51,,BAO_0000219,722.0,HEK293,Binding affinity to human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]-8-OH- DPAT as radioligand,,,D,Expert,B,9606.0,CHEMBL616226,,,,,9,1
1025,51,,BAO_0000219,722.0,HEK293,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells,,,H,Autocuration,B,,CHEMBL616227,,,,,8,1
1026,51,,BAO_0000219,722.0,HEK293,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells using [3H]8-OH-DPAT as radioligand,,,H,Autocuration,B,,CHEMBL616228,,,,,8,1
1027,51,,BAO_0000219,722.0,HEK293,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,,,H,Autocuration,B,,CHEMBL616229,,,,,8,1
1028,51,,BAO_0000219,722.0,HEK293,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand; ND means no data,,,H,Autocuration,B,,CHEMBL616230,,,,,8,1
1029,51,,BAO_0000219,722.0,HEK293,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;ND means no data.,,,H,Autocuration,B,,CHEMBL616231,,,,,8,1
1030,51,,BAO_0000357,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,,,H,Autocuration,B,,CHEMBL616232,,,,,8,1
1031,51,,BAO_0000219,722.0,HEK293,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,,,H,Autocuration,B,,CHEMBL616233,,,,,8,1
1032,51,,BAO_0000219,722.0,HEK293,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT as the radioligand,,,H,Autocuration,B,,CHEMBL857973,,,,,8,1
1033,51,,BAO_0000219,,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT binding from human 5-hydroxytryptamine 1A receptor in mammalian cells,,,H,Autocuration,B,,CHEMBL616234,,,,,8,1
1034,51,,BAO_0000357,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1A receptor,,,H,Autocuration,B,,CHEMBL616235,,,,,8,1
1035,51,,BAO_0000219,308.0,HeLa,Binding affinity at human cloned 5-hydroxytryptamine 1A receptor expressed in HeLa cells by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,,,H,Expert,B,,CHEMBL616236,,,,,8,1
1036,51,,BAO_0000019,,,Binding affinity at native 5-hydroxytryptamine 1A receptor in rat by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,,,H,Expert,B,,CHEMBL616237,,,,,8,1
1037,51,,BAO_0000219,722.0,HEK293,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor in human cloned receptors in HEK 293 cells using [3H]8-OH-DPAT,,,H,Autocuration,B,,CHEMBL616238,,,,,8,1
1038,51,,BAO_0000219,722.0,HEK293,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1A receptor in HEK 293 using [3H]5-CT as a radioligand,,,H,Autocuration,B,,CHEMBL616239,,,,,8,1
1039,51,,BAO_0000219,,,In vitro binding affinity at human recombinant 5-hydroxytryptamine 1A receptor in mammalian cells using 3[H]8-OH-DPAT as the radioligand,,,H,Autocuration,B,,CHEMBL616240,,,,,8,1
1040,51,,BAO_0000219,308.0,HeLa,The binding affinity was evaluated on cloned human 5-hydroxytryptamine 1A receptor expressed in HeLa cells by using DPAT as radioligand.,,,D,Expert,B,9606.0,CHEMBL616241,,,,,9,1
1041,51,,BAO_0000219,722.0,HEK293,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT.,,,H,Autocuration,B,,CHEMBL616242,,,,,8,1
1042,51,,BAO_0000219,722.0,HEK293,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1A receptor in HEK293 cells, using [3H]8-OH-DPAT as radioligand",,,H,Autocuration,B,,CHEMBL616243,,,,,8,1
1043,51,,BAO_0000357,,,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,,,D,Expert,B,,CHEMBL616244,,,,,9,1
1044,51,,BAO_0000357,,,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor,,,D,Autocuration,B,9606.0,CHEMBL616245,,,,,9,1
1045,106,,BAO_0000357,,,Binding affinity towards 5-HT1B receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,,,H,Autocuration,B,,CHEMBL616246,,,,,8,1
1046,105,,BAO_0000357,,,Binding affinity against 5-HT1D receptor,,,H,Autocuration,B,,CHEMBL616247,,,,,8,1
1047,105,,BAO_0000357,,,Binding affinity against 5-hydroxytryptamine 1A receptor,,,H,Autocuration,B,,CHEMBL616248,,,,,8,1
1048,107,,BAO_0000357,,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,,H,Autocuration,B,,CHEMBL616249,,,,,8,1
1049,10576,,BAO_0000357,,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,,,H,Autocuration,B,9606.0,CHEMBL616250,,,,,8,1
1050,51,,BAO_0000357,,,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,,,H,Autocuration,B,,CHEMBL616251,,,,,8,1
1051,11863,In vivo,BAO_0000218,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 15 min after administration of the compound,,,H,Autocuration,F,,CHEMBL616252,,,,,8,1
1052,11863,In vivo,BAO_0000218,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 30 min after administration of the compound,,,H,Autocuration,F,,CHEMBL616253,,,,,8,1
1053,11863,In vivo,BAO_0000218,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 60 min after administration of the compound,,,H,Autocuration,F,,CHEMBL616254,,,,,8,1
1054,11863,,BAO_0000218,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 15 min,,,D,Expert,F,10090.0,CHEMBL616255,,,,,9,1
1055,11863,,BAO_0000218,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 30 min,,,D,Expert,F,10090.0,CHEMBL832872,,,,,9,1
1056,11863,,BAO_0000218,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 60 min,,,D,Expert,F,10090.0,CHEMBL616256,,,,,9,1
1057,11863,,BAO_0000218,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 15 min,,,D,Expert,F,10090.0,CHEMBL616257,,,,,9,1
1058,11863,,BAO_0000218,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 30 min,,,D,Expert,F,10090.0,CHEMBL616258,,,,,9,1
1059,11863,,BAO_0000218,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 60 min,,,D,Expert,F,10090.0,CHEMBL616384,,,,,9,1
1060,11863,,BAO_0000221,,,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,,,H,Autocuration,B,,CHEMBL616385,,10000000.0,Hippocampus,,8,1
1061,11863,,BAO_0000357,,,Inhibitory activity against serotonin 5-hydroxytryptamine 1A receptor from mice.,,,H,Expert,B,,CHEMBL616386,,,,,8,1
1062,11863,,BAO_0000221,,,Inhibitory activity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,,,D,Expert,B,10090.0,CHEMBL616387,,10000000.0,Hippocampus,,9,1
1063,11863,,BAO_0000221,,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,,,H,Autocuration,B,,CHEMBL616388,,10000000.0,Hippocampus,,8,1
1064,11863,,BAO_0000221,,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,,,D,Expert,B,10090.0,CHEMBL616389,,10000000.0,Hippocampus,,9,1
1065,11863,,BAO_0000221,,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,,,H,Autocuration,B,,CHEMBL616390,,10000000.0,Hippocampus,,8,1
1066,11863,,BAO_0000357,,,Compound was tested for binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as a radioligand,,,H,Autocuration,B,,CHEMBL616391,,,,,8,1
1067,11863,,BAO_0000221,,,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,,,D,Expert,B,10090.0,CHEMBL616392,,10000000.0,Hippocampus,,9,1
1068,51,,BAO_0000357,,,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor,,,H,Autocuration,B,9823.0,CHEMBL616393,,,,,8,1
1069,51,,BAO_0000357,,,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor; ND denotes not determined,,,H,Autocuration,B,9823.0,CHEMBL616394,,,,,8,1
1070,51,,BAO_0000019,,,Binding affinity of compound measured for 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT-labeled porcine brain homogenates,,,H,Autocuration,B,9823.0,CHEMBL616395,,,,,8,1
1071,51,,BAO_0000357,,,Compound was evaluated for the binding affinity at 5- HT1A receptor,,,H,Autocuration,B,9823.0,CHEMBL616396,,,,,8,1
1072,51,,BAO_0000019,,,Compound was tested in vitro for its ability to compete with [3H]8-OH-DPAT at 5-hydroxytryptamine 1A receptor in porcine brain homogenate,,,H,Autocuration,B,9823.0,CHEMBL872907,,,,,8,1
1073,51,,BAO_0000019,,,In vitro for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in porcine brain homogenate,,,H,Autocuration,B,9823.0,CHEMBL616397,,,,,8,1
1074,51,,BAO_0000019,,,Compound was tested for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in pig cortex,,,H,Autocuration,B,9823.0,CHEMBL616398,,,,,8,1
1075,51,,BAO_0000357,,,Displacement of [3H]- 8-OH-DPAT from porcine 5-hydroxytryptamine 1A receptor,,,H,Expert,B,9823.0,CHEMBL616399,,,,,8,1
1076,51,,BAO_0000357,,,Binding activity radioligand.,,,H,Autocuration,B,9823.0,CHEMBL857065,,,,,8,1
1077,51,,BAO_0000019,,,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,,,H,Expert,B,9823.0,CHEMBL616400,,,,,8,1
1078,51,,BAO_0000019,,,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,,,H,Autocuration,B,9823.0,CHEMBL616401,,,,,8,1
1079,10624,,BAO_0000019,,,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor from pig cortex,,,H,Expert,B,,CHEMBL616402,,,,,8,1
1080,51,,BAO_0000019,,,Displacement of [3H]8-OH-DPAT from pig cortex 5-hydroxytryptamine 1A receptor,,,H,Expert,B,9823.0,CHEMBL616403,,,,,8,1
1081,51,,BAO_0000221,,,Binding affinity for 5-hydroxytryptamine 1A receptor in piglet hippocampus using [3H]8-OH-DPAT,,,H,Autocuration,B,9823.0,CHEMBL616404,,10000000.0,Hippocampus,,8,1
1082,51,,BAO_0000249,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in pig frontal cortex membranes using [8H]-OH-DPAT,,,H,Autocuration,B,9823.0,CHEMBL616405,,,,,8,1
1083,51,,BAO_0000019,,,Binding affinity was evaluated by 5-hydroxytryptamine 1A receptor agonism in the pig cortex by displacing 8-OH-DPAT,,,H,Autocuration,B,9823.0,CHEMBL616406,,,,,8,1
1084,51,,BAO_0000019,,,Agonistic activity against 5-hydroxytryptamine 1A receptor in pig cortex using [3H]8-OH-DPAT,,,H,Expert,F,9823.0,CHEMBL616407,,,,,8,1
1085,51,,BAO_0000019,,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the presence of endothelium,,,H,Autocuration,B,9986.0,CHEMBL616408,,,,,8,1
1086,10576,,BAO_0000249,,,Inhibition activity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using radio binding assays,,,D,Expert,B,10116.0,CHEMBL616409,,,,,9,1
1087,10576,,BAO_0000221,,,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Less active",,,D,Expert,B,10116.0,CHEMBL616410,,10000000.0,Hippocampus,,9,1
1088,10576,,BAO_0000357,,,Tested for the effect on binding at 5-hydroxytryptamine 1A receptor; No activity,,,H,Autocuration,B,,CHEMBL616411,,,,,8,1
1089,10576,,BAO_0000249,,,"Antagonist activity to stimulate binding of [35S]GTP-gamma-S, to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",,,D,Expert,F,10116.0,CHEMBL616412,,,,Membranes,9,1
1090,10576,,BAO_0000249,,,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",,,D,Expert,F,10116.0,CHEMBL616413,,10000000.0,Hippocampus,Membranes,9,1
1091,10576,,BAO_0000221,,,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,,H,Autocuration,B,,CHEMBL616414,,10000000.0,Hippocampus,,8,1
1092,10576,,BAO_0000221,,,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding,,,D,Expert,B,10116.0,CHEMBL616415,,10000000.0,Hippocampus,,9,1
1093,10576,,BAO_0000019,,,Binding affinity measured at the 5-hydroxytryptamine 1A receptor by the inhibition of [3H]8-OH-DPAT binding to rat cortex using unlabeled buspirone for nonspecific binding.,,,H,Autocuration,B,,CHEMBL616416,,,,,8,1
1094,10576,,BAO_0000357,,,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand.,,,H,Expert,B,,CHEMBL616417,,,,,8,1
1095,10576,,BAO_0000357,,,Binding affinity of [3H]- -8-OH-DPAT labelled towards Rat Hippocampal 5-hydroxytryptamine 1A receptor using radioligand binding assay,,,H,Autocuration,B,,CHEMBL616418,,,,,8,1
1096,10576,In vitro,BAO_0000219,,,Binding affinity of [3H]-8-OH-DPAT towards 5-hydroxytryptamine 1A receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,,H,Autocuration,B,,CHEMBL616419,,,,,8,1
1097,10576,,BAO_0000357,,,Binding affinity of compound against 5-hydroxytryptamine 1A receptor binding site using radioligand [3H]8-OH-DPAT,,,H,Autocuration,B,,CHEMBL616420,,,,,8,1
1098,10576,,BAO_0000249,,,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,,,H,Autocuration,B,,CHEMBL616421,,,,Membranes,8,1
1099,10576,,BAO_0000249,,,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,,,H,Autocuration,B,,CHEMBL616422,,,,Membranes,8,1
1100,10576,,BAO_0000249,,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor in rat striatal membranes by [3H]OH-DPAT displacement.,,,H,Expert,B,,CHEMBL616423,,,,Membranes,8,1
1101,10576,,BAO_0000357,,,Binding affinity for 5-hydroxytryptamine 1A receptor with [3H]5-HT,,,D,Expert,B,10116.0,CHEMBL616424,,,,,9,1
1102,10576,,BAO_0000357,,,Binding affinity to the rat 5-hydroxytryptamine 1A receptor,,,H,Expert,B,,CHEMBL616425,,,,,8,1
1103,10576,,BAO_0000357,,,Binding affinity was tested on 5-hydroxytryptamine 1A receptor using radioligand [3H]5-HT binding assay.,,,H,Expert,B,,CHEMBL616426,,,,,8,1
1104,10576,,BAO_0000221,,,Binding affinity against 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as the radioligand.,,,H,Autocuration,B,,CHEMBL616427,,10000000.0,Hippocampus,,8,1
1105,10576,,BAO_0000221,,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus tissue.,,,H,Autocuration,B,,CHEMBL616428,,10000000.0,Hippocampus,,8,1
1106,10576,,BAO_0000221,,,Binding affinity by measuring displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,,H,Autocuration,B,,CHEMBL616290,,10000000.0,Hippocampus,,8,1
1107,10576,,BAO_0000357,,,Displacement of [3H]8-OH-DPAT from rat striata 5-hydroxytryptamine 1A receptor,,,D,Expert,B,10116.0,CHEMBL616052,,,,,9,1
1108,10576,,BAO_0000357,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1A receptor,,,H,Autocuration,B,,CHEMBL616053,,,,,8,1
1109,10576,,BAO_0000249,,,Binding affinity towards 5-HT 1A receptor in rat cerebral cortex membranes using [3H]8-OH-DPAT as radioligand,,,H,Autocuration,B,,CHEMBL616054,,,,,8,1
1110,10576,,BAO_0000357,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,,,H,Autocuration,B,,CHEMBL616055,,,,,8,1
1111,10576,,BAO_0000357,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in competitive binding assay,,,H,Autocuration,B,,CHEMBL616056,,,,,8,1
1112,10576,,BAO_0000019,,,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,,,H,Expert,B,,CHEMBL616057,,,,,8,1
1113,10576,,BAO_0000221,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,,,D,Expert,B,10116.0,CHEMBL616058,,955.0,Brain,,9,1
1114,10576,,BAO_0000221,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,,,H,Autocuration,B,,CHEMBL616059,,955.0,Brain,,8,1
1115,10576,,BAO_0000249,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hypocampus membrane using [3H]8-OH-DPAT as radioligand,,,H,Autocuration,B,,CHEMBL616060,,,,,8,1
1116,10576,,BAO_0000221,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in the rat brain (hippocampus) using [3H]8-OH-DPAT,,,D,Expert,B,10116.0,CHEMBL616061,,10000000.0,Hippocampus,,9,1
1117,10576,,BAO_0000221,,,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]-8-hydroxy-2-(di-n-propylamine) tetralin (8-OH-DPAT) as a radioligand,,,H,Expert,B,,CHEMBL616062,,10000000.0,Hippocampus,,8,1
1118,10576,,BAO_0000249,,,Binding affinity towards 5-hydroxytryptamine 1A receptor sites in cortical membranes using [3H]8-OH-DPAT as radioligand,,,H,Autocuration,B,,CHEMBL616063,,,,,8,1
1119,10576,,BAO_0000249,,,"Binding affinity towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",,,H,Autocuration,B,,CHEMBL616064,,2435.0,Striatum,,8,1
1120,10576,,BAO_0000249,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cortex membranes,,,D,Expert,B,10116.0,CHEMBL616065,,,,Membranes,9,1
1121,10576,,BAO_0000249,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cerebral cortex membranes,,,D,Expert,B,10116.0,CHEMBL616066,,,,Membranes,9,1
1122,10576,,BAO_0000221,,,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,H,Autocuration,B,,CHEMBL616067,,10000000.0,Hippocampus,,8,1
1123,10576,,BAO_0000221,,,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; Not tested,,,H,Autocuration,B,,CHEMBL616068,,10000000.0,Hippocampus,,8,1
1124,10576,,BAO_0000221,,,Binding affinity against rat hippocampal 5-hydroxytryptamine 1A (5-HT1A) receptor determined using [3H]8-OH-DPAT as radioligand,,,H,Intermediate,B,,CHEMBL616069,,10000000.0,Hippocampus,,8,1
1125,10576,,BAO_0000249,,,Binding was determined on 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,,H,Expert,B,,CHEMBL616070,,,,,8,1
1126,10576,,BAO_0000221,,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand,,,H,Autocuration,B,,CHEMBL616071,,10000000.0,Hippocampus,,8,1
1127,10576,,BAO_0000221,,,Binding affinity against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.,,,H,Expert,B,,CHEMBL616072,,10000000.0,Hippocampus,,8,1
1128,10576,,BAO_0000221,,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.; ND = Not determined,,,H,Autocuration,B,,CHEMBL616073,,10000000.0,Hippocampus,,8,1
1129,10576,,BAO_0000221,,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand; ND = Not determined,,,H,Autocuration,B,,CHEMBL616074,,10000000.0,Hippocampus,,8,1
1130,10576,,BAO_0000019,,,Binding affinity was evaluated by determining in vitro displacement of [3H]8-OH-DPAT from the central 5-hydroxytryptamine 1A receptor recognition site in rat frontal cortex homogenate.,,,H,Expert,B,,CHEMBL616075,,,,,8,1
1131,10576,,BAO_0000357,,,Binding affinity was evaluated by using [3H]8-OH-DPAT radioligand by using competitive binding assay on 5-hydroxytryptamine 1A receptor,,,H,Autocuration,B,,CHEMBL616076,,,,,8,1
1132,10576,,BAO_0000019,,,Binding affinity for 5-HT1A measured by displacing [3H]8-OH-DPAT from rat cortical membranes; Not determined,,,D,Expert,B,10116.0,CHEMBL616077,,,,,9,1
1133,10576,,BAO_0000019,,,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes,,,D,Expert,B,10116.0,CHEMBL616078,,,,,9,1
1134,10576,,BAO_0000019,,,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes;ND-Not determined,,,D,Expert,B,10116.0,CHEMBL616079,,,,,9,1
1135,10576,,BAO_0000219,485.0,CHO-K1,Binding affinity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,,,D,Expert,B,10116.0,CHEMBL616080,,,,,9,1
1136,10576,,BAO_0000357,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,,,H,Autocuration,B,,CHEMBL616081,,,,,8,1
1137,10576,,BAO_0000221,,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain,,,D,Expert,B,10116.0,CHEMBL616082,,10000000.0,Hippocampus,,9,1
1138,10576,,BAO_0000221,,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in membrane homogenates of hippocampal tissue of rat brain,,,H,Autocuration,B,,CHEMBL616083,,10000000.0,Hippocampus,,8,1
1139,10576,,BAO_0000019,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,,H,Autocuration,B,,CHEMBL616084,,,,,8,1
1140,10576,,BAO_0000019,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates,,,H,Expert,B,,CHEMBL616085,,,,,8,1
1141,10576,,BAO_0000019,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT,,,H,Autocuration,B,,CHEMBL616086,,,,,8,1
1142,10576,,BAO_0000221,,,"Binding affinity towards 5-hydroxytryptamine 1A receptor using 0.1 nM [3H]-8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tet-ralin), from rat hippocampal homogenate",,,H,Autocuration,B,,CHEMBL616087,,10000000.0,Hippocampus,,8,1
1143,10576,,BAO_0000357,,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor using [3H]WB-4101,,,H,Expert,B,,CHEMBL616088,,,,,8,1
1144,10576,,BAO_0000019,,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor was determined in male Sprague-Dawley rat brain.,,,H,Autocuration,B,,CHEMBL616089,,,,,8,1
1145,10576,,BAO_0000357,,,Binding affinity was measured against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT by lysergic acid amides,,,D,Expert,B,10116.0,CHEMBL616090,,,,,9,1
1146,10576,,BAO_0000357,,,Binding affinity was measured on cloned rat 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,,H,Autocuration,B,,CHEMBL616091,,,,,8,1
1147,10576,,BAO_0000249,,,"Binding affinity of the compound towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",,,H,Autocuration,B,,CHEMBL616092,,2435.0,Striatum,Membranes,8,1
1148,10576,,BAO_0000357,,,Binding constant against 5-hydroxytryptamine 1A receptor (in vitro),,,H,Autocuration,B,,CHEMBL616093,,,,,8,1
1149,10576,In vivo,BAO_0000218,,,Binding constant against 5-hydroxytryptamine 1A receptor (in vivo),,,H,Autocuration,B,,CHEMBL616094,,,,,8,1
1150,10576,,BAO_0000221,,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex,,,H,Autocuration,B,,CHEMBL616095,,955.0,Brain,,8,1
1151,10576,,BAO_0000357,,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,,D,Expert,B,10116.0,CHEMBL616096,,,,,9,1
1152,10576,,BAO_0000249,,,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes,,,H,Expert,B,,CHEMBL616097,,,,,8,1
1153,10576,,BAO_0000249,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus membranes,,,D,Expert,B,10116.0,CHEMBL616098,,,,Membranes,9,1
1154,10576,,BAO_0000221,,,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,,,H,Autocuration,B,,CHEMBL616099,,10000000.0,Hippocampus,,8,1
1155,10576,,BAO_0000221,,,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 1A receptor receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,,,H,Autocuration,B,,CHEMBL616100,,10000000.0,Hippocampus,,8,1
1156,10576,,BAO_0000357,,,Ability to displace [3H]-8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,,,H,Expert,B,,CHEMBL616101,,,,,8,1
1157,10576,,BAO_0000249,,,Binding affinity at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes by [3H]8-OH-DPAT displacement.,,,H,Expert,B,,CHEMBL616102,,,,,8,1
1158,10576,,BAO_0000357,,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,,,H,Autocuration,B,,CHEMBL616103,,,,,8,1
1159,10576,,BAO_0000019,,,Compound was evaluated for its binding affinity against 5-hydroxytryptamine 1A receptor from rat cerebral cortex,,,H,Expert,B,,CHEMBL616104,,,,,8,1
1160,10576,,BAO_0000019,,,"Binding affinity to 5-hydroxytryptamine 1A receptor (5-HT 1A receptor, serotonin receptor) from rat cortex using [3H]8-OH-DPAT as radioligand",,,H,Expert,B,,CHEMBL616105,,,,,8,1
1161,10576,,BAO_0000019,,,Displacement of [3H]prazosin from rat cortex membrane 5-hydroxytryptamine 1A receptor,,,D,Expert,B,10116.0,CHEMBL616106,,,,,9,1
1162,10576,,BAO_0000019,,,Compound was evaluated for its binding affinity with 5-hydroxytryptamine 1A receptor using membranes prepared from rat cerebral cortex,,,H,Autocuration,B,,CHEMBL616107,,,,,8,1
1163,10576,,BAO_0000357,,,Binding affinity towards rat 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand.,,,H,Expert,B,,CHEMBL616108,,,,,8,1
1164,10576,,BAO_0000221,,,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,,H,Expert,B,,CHEMBL616109,,10000000.0,Hippocampus,,8,1
1165,10576,,BAO_0000357,,,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site.,,,H,Autocuration,B,,CHEMBL616110,,,,,8,1
1166,10576,,BAO_0000219,449.0,CHO,Binding affinity against rat 5-hydroxytryptamine 1A receptor in CHO cells.,,,H,Expert,B,,CHEMBL616111,,,,,8,1
1167,10576,,BAO_0000019,,,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat brain using [3H]-8-OH-DPAT as radioligand,,,H,Expert,B,,CHEMBL616112,,,,,8,1
1168,10576,,BAO_0000221,,,Compound was tested for the Binding affinity against rat hippocampal 5-hydroxytryptamine 1A receptor by Radio ligand [3H]8-OH-DPAT binding assay.,,,H,Autocuration,B,,CHEMBL616113,,10000000.0,Hippocampus,,8,1
1169,10576,,BAO_0000019,,,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,,,H,Autocuration,B,,CHEMBL616114,,,,,8,1
1170,10576,,BAO_0000019,,,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,,,H,Autocuration,B,,CHEMBL616115,,,,,8,1
1171,10576,,BAO_0000357,,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1A receptor,,,H,Autocuration,B,,CHEMBL616116,,,,,8,1
1172,10576,,BAO_0000221,,,Binding affinity for 5-hydroxytryptamine 1A receptor in rat brain tissue using [3H]8-OH-DPAT as radioligand,,,H,Expert,B,,CHEMBL615844,,955.0,Brain,,8,1
1173,10576,,BAO_0000221,,,In vitro displacement of [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,,H,Expert,B,,CHEMBL615939,,10000000.0,Hippocampus,,8,1
1174,10576,,BAO_0000019,,,In vitro ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor sites of rat brain cortex.,,,H,Expert,B,,CHEMBL615940,,,,,8,1
1175,10576,,BAO_0000221,,,In vitro affinity at 5-hydroxytryptamine 1A receptor of rat hippocampus by [3H]8-OH-DPAT displacement.,,,H,Expert,B,,CHEMBL615941,,10000000.0,Hippocampus,,8,1
1176,10576,,BAO_0000221,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-HT1A receptor of rat hippocampus and the value ranges from 9 - 12,,,H,Autocuration,B,,CHEMBL615942,,10000000.0,Hippocampus,,8,1
1177,10576,,BAO_0000221,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,,,H,Autocuration,B,,CHEMBL615943,,10000000.0,Hippocampus,,8,1
1178,10576,,BAO_0000221,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 12 to 17,,,H,Autocuration,B,,CHEMBL615944,,10000000.0,Hippocampus,,8,1
1179,10576,,BAO_0000221,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 391-841,,,H,Autocuration,B,,CHEMBL615945,,10000000.0,Hippocampus,,8,1
1180,10576,,BAO_0000221,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 17.,,,H,Autocuration,B,,CHEMBL615946,,10000000.0,Hippocampus,,8,1
1181,10576,,BAO_0000221,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 20.,,,H,Autocuration,B,,CHEMBL615947,,10000000.0,Hippocampus,,8,1
1182,10576,,BAO_0000221,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 245 to 736,,,H,Autocuration,B,,CHEMBL615948,,10000000.0,Hippocampus,,8,1
1183,10576,,BAO_0000221,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 25 - 84,,,H,Autocuration,B,,CHEMBL615949,,10000000.0,Hippocampus,,8,1
1184,10576,,BAO_0000221,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 48 to 59,,,H,Autocuration,B,,CHEMBL615950,,10000000.0,Hippocampus,,8,1
1185,10576,,BAO_0000221,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 3 -5,,,H,Autocuration,B,,CHEMBL615951,,10000000.0,Hippocampus,,8,1
1186,10576,,BAO_0000221,,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 15 - 31,,,H,Autocuration,B,,CHEMBL615952,,10000000.0,Hippocampus,,8,1
1187,10576,,BAO_0000221,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 27 - 42,,,H,Autocuration,B,,CHEMBL615953,,10000000.0,Hippocampus,,8,1
1188,10576,,BAO_0000221,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 6 - 13,,,H,Autocuration,B,,CHEMBL615954,,10000000.0,Hippocampus,,8,1
1189,10576,,BAO_0000221,,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,,,D,Expert,B,10116.0,CHEMBL615955,,10000000.0,Hippocampus,,9,1
1190,10576,,BAO_0000221,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.; ND is No Data.,,,H,Autocuration,B,,CHEMBL615956,,10000000.0,Hippocampus,,8,1
1191,10576,,BAO_0000221,,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus. and the value ranges from 16 - 27,,,H,Autocuration,B,,CHEMBL615957,,10000000.0,Hippocampus,,8,1
1192,10576,,BAO_0000019,,,Displacement of [3H]2-(di-N-propylamino)-8-hydroxytetralin from central 5-hydroxytryptamine 1A receptor recognition sites in rat frontal cortex homogenates.,,,H,Expert,B,,CHEMBL615958,,,,,8,1
1193,10576,,BAO_0000019,,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate,,,H,Expert,B,,CHEMBL615959,,,,,8,1
1194,10576,,BAO_0000019,,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 1),,,H,Autocuration,B,,CHEMBL615960,,,,,8,1
1195,10576,,BAO_0000019,,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 2),,,H,Autocuration,B,,CHEMBL615961,,,,,8,1
1196,10576,,BAO_0000221,,,Evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,,,H,Expert,B,,CHEMBL615962,,955.0,Brain,,8,1
1197,10576,,BAO_0000019,,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand.,,,H,Expert,B,,CHEMBL615963,,,,,8,1
1198,10576,,BAO_0000019,,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand; ND is no data.,,,H,Autocuration,B,,CHEMBL615964,,,,,8,1
1199,10576,,BAO_0000019,,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand;ND means no data,,,H,Autocuration,B,,CHEMBL615965,,,,,8,1
1200,10576,,BAO_0000219,449.0,CHO,In vitro displacement of radioactively labeled ligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor site in CHO cells,,,H,Expert,B,,CHEMBL615966,,,,,8,1
1201,10576,,BAO_0000249,,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat cortical membranes,,,H,Expert,B,,CHEMBL615967,,,,,8,1
1202,10576,,BAO_0000019,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor of rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,,,H,Expert,B,,CHEMBL615968,,,,,8,1
1203,10576,,BAO_0000218,449.0,CHO,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),,,H,Autocuration,B,,CHEMBL615969,,,,,8,1
1204,10576,,BAO_0000218,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (agonist) as radioligand (sc),,,H,Autocuration,B,,CHEMBL615970,,,,,8,1
1205,10576,,BAO_0000357,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT,,,D,Expert,B,10116.0,CHEMBL615971,,,,,9,1
1206,10576,,BAO_0000249,,,In vitro binding affinity at 5-HT1A receptors assayed by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,,H,Expert,B,,CHEMBL615972,,,,Membranes,8,1
1207,10576,,BAO_0000249,,,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes + cortex,,,H,Autocuration,B,,CHEMBL615973,,,,,8,1
1208,10576,,BAO_0000249,,,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes+cortex,,,H,Autocuration,B,,CHEMBL615974,,,,,8,1
1209,51,,BAO_0000219,449.0,CHO,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,,D,Expert,B,9606.0,CHEMBL615975,,,,,9,1
1210,10576,,BAO_0000249,,,In vitro binding affinity for 5-hydroxytryptamine 1A receptor in rat hippocampal membranes by [125I]-labeled agonist displacement.,,,H,Expert,B,,CHEMBL615976,,,,,8,1
1211,10576,,BAO_0000221,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus,,,D,Expert,B,10116.0,CHEMBL872106,,10000000.0,Hippocampus,,9,1
1212,10576,,BAO_0000357,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,,H,Autocuration,B,,CHEMBL615977,,,,,8,1
1213,10576,,BAO_0000357,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=100-230,,,H,Autocuration,B,,CHEMBL615978,,,,,8,1
1214,10576,,BAO_0000357,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=12-14,,,H,Autocuration,B,,CHEMBL616166,,,,,8,1
1215,10576,,BAO_0000357,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=16-20,,,H,Autocuration,B,,CHEMBL616167,,,,,8,1
1216,10576,,BAO_0000357,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=160-430,,,H,Autocuration,B,,CHEMBL616168,,,,,8,1
1217,10576,,BAO_0000357,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=174-224,,,H,Autocuration,B,,CHEMBL616169,,,,,8,1
1218,10576,,BAO_0000357,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=184-503,,,H,Autocuration,B,,CHEMBL616170,,,,,8,1
1219,10576,,BAO_0000357,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=19-23,,,H,Autocuration,B,,CHEMBL616171,,,,,8,1
1220,10576,,BAO_0000357,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=2.2-3.2,,,H,Autocuration,B,,CHEMBL616172,,,,,8,1
1221,10576,,BAO_0000357,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=2.7-3.6,,,H,Autocuration,B,,CHEMBL616173,,,,,8,1
1222,10576,,BAO_0000357,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=20-23,,,H,Autocuration,B,,CHEMBL616174,,,,,8,1
1223,10576,,BAO_0000357,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=21-28,,,H,Autocuration,B,,CHEMBL616175,,,,,8,1
1224,10576,,BAO_0000357,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=240-760,,,H,Autocuration,B,,CHEMBL616176,,,,,8,1
1225,10576,,BAO_0000357,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=39-87,,,H,Autocuration,B,,CHEMBL616177,,,,,8,1
1226,10576,,BAO_0000357,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=4.6-5.2,,,H,Autocuration,B,,CHEMBL616178,,,,,8,1
1227,10576,,BAO_0000019,,,Inhibitory activity tested in vitro at 5-hydroxytryptamine 1A receptor binding site in rat,,,H,Autocuration,B,,CHEMBL616179,,,,,8,1
1228,10576,,BAO_0000357,,,Inhibitory concentration against 5-hydroxytryptamine 1A receptor,,,H,Autocuration,B,,CHEMBL616180,,,,,8,1
1229,10576,,BAO_0000357,,,Inhibitory concentration against binding of 5-hydroxytryptamine 1A receptor from striata of male Wistar rats by displacement of [3H]8-OH-DPAT,,,H,Autocuration,B,,CHEMBL616181,,,,,8,1
1230,10576,,BAO_0000019,,,Inhibitory concentration against radioligand [3H]hydroxy-2-(di-n-propylamino)-tetralin binding to 5-hydroxytryptamine 1A receptor in rat,,,H,Autocuration,B,,CHEMBL616182,,,,,8,1
1231,10576,,BAO_0000221,,,Inhibitory concentration against radioligand [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,,H,Autocuration,B,,CHEMBL616183,,10000000.0,Hippocampus,,8,1
1232,10576,,BAO_0000019,,,Inhibition of the 5-hydroxytryptamine 1A receptor in rat dorsal raphe,,,H,Expert,B,,CHEMBL615874,,,,,8,1
1233,10576,,BAO_0000219,485.0,CHO-K1,Inhibitory concentration against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,,,D,Expert,B,10116.0,CHEMBL615875,,,,,9,1
1234,10576,,BAO_0000019,,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand,,,H,Autocuration,B,,CHEMBL615876,,,,,8,1
1235,10576,,BAO_0000019,,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand; NT means not tested,,,H,Autocuration,B,,CHEMBL615877,,,,,8,1
1236,10576,,BAO_0000357,,,The compound was evaluated for the ability to displace [3H]- 8-OH -DPAT from 5-hydroxytryptamine 1A receptor ( striata of male wistar rats),,,H,Autocuration,B,,CHEMBL615878,,,,,8,1
1237,10576,,BAO_0000357,,,Binding affinity towards 5-hydroxytryptamine 1A receptor binding site using [3H]8-OH-DPAT. ,,,H,Expert,B,,CHEMBL615879,,,,,8,1
1238,10576,,BAO_0000357,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using receptor binding assay,,,H,Expert,B,,CHEMBL615880,,,,,8,1
1239,10576,,BAO_0000019,,,"The compound was tested in vitro for inhibitory activity against 5-HT1A receptor in rats, using [3H]8-OH-DPAT as radioligand",,,H,Autocuration,B,,CHEMBL615881,,,,,8,1
1240,10576,,BAO_0000019,,,"Inhibitory activity against 5-hydroxytryptamine 1A receptor in rats, using [3H]8-OH-DPAT as radioligand",,,D,Expert,B,10116.0,CHEMBL615882,,,,,9,1
1241,10576,In vivo,BAO_0000218,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat,,,H,Autocuration,F,,CHEMBL615883,,,,,8,1
1242,10576,In vivo,BAO_0000218,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.10-6.20),,,H,Autocuration,F,,CHEMBL615884,,,,,8,1
1243,10576,In vivo,BAO_0000218,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.60),,,H,Autocuration,F,,CHEMBL615885,,,,,8,1
1244,10576,In vivo,BAO_0000218,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.80),,,H,Autocuration,F,,CHEMBL615886,,,,,8,1
1245,10576,In vivo,BAO_0000218,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.37-4.27),,,H,Autocuration,F,,CHEMBL615887,,,,,8,1
1246,10576,In vivo,BAO_0000218,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-2.70),,,H,Autocuration,F,,CHEMBL615888,,,,,8,1
1247,10576,In vivo,BAO_0000218,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-4),,,H,Autocuration,F,,CHEMBL615889,,,,,8,1
1248,10576,In vivo,BAO_0000218,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.45-4.51),,,H,Autocuration,F,,CHEMBL615890,,,,,8,1
1249,10576,In vivo,BAO_0000218,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.50-5.30),,,H,Autocuration,F,,CHEMBL615891,,,,,8,1
1250,10576,In vivo,BAO_0000218,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.60-1.60),,,H,Autocuration,F,,CHEMBL615892,,,,,8,1
1251,10576,In vivo,BAO_0000218,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.72-2.87),,,H,Autocuration,F,,CHEMBL615893,,,,,8,1
1252,10576,In vivo,BAO_0000218,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.80-5.80),,,H,Autocuration,F,,CHEMBL615894,,,,,8,1
1253,10576,In vivo,BAO_0000218,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (1.50-16.5),,,H,Autocuration,F,,CHEMBL615895,,,,,8,1
1254,10576,In vivo,BAO_0000218,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (2.20-30.5),,,H,Autocuration,F,,CHEMBL615896,,,,,8,1
1255,10576,In vivo,BAO_0000218,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges is not computable,,,H,Autocuration,F,,CHEMBL615897,,,,,8,1
1256,10576,,BAO_0000249,,,"Percent increase of R(+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",,,D,Expert,F,10116.0,CHEMBL615898,,,,Membranes,9,1
1257,10576,,BAO_0000019,,,% inhibition towards 5-HT1A receptor from rat hippocampal membranes,,,H,Autocuration,B,,CHEMBL615899,,,,,8,1
1258,10576,,BAO_0000019,,,% inhibition towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,,,H,Autocuration,B,,CHEMBL616291,,,,,8,1
1259,10576,,BAO_0000357,,,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor.,,,H,Autocuration,B,,CHEMBL616292,,,,,8,1
1260,10576,,BAO_0000249,,,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",,,H,Autocuration,F,,CHEMBL616293,,,,,8,1
1261,10576,,BAO_0000221,,,Measurement of binding affinity by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,,H,Expert,B,,CHEMBL616294,,10000000.0,Hippocampus,,8,1
1262,10576,,BAO_0000249,,,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane,,,H,Autocuration,B,,CHEMBL616295,,10000000.0,Hippocampus,,8,1
1263,10576,,BAO_0000221,,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex at 10 uM,,,H,Autocuration,B,,CHEMBL616296,,955.0,Brain,,8,1
1264,10576,,BAO_0000019,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,,,H,Autocuration,F,,CHEMBL616297,,,,,8,1
1265,10576,,BAO_0000019,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0+ 1 uM 5-HT.,,,H,Autocuration,F,,CHEMBL616605,,,,,8,1
1266,10576,,BAO_0000019,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.01 uM+ 1 uM 5-HT.,,,H,Autocuration,F,,CHEMBL616606,,,,,8,1
1267,10576,,BAO_0000019,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,,,H,Autocuration,F,,CHEMBL616607,,,,,8,1
1268,10576,,BAO_0000019,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,,,H,Expert,F,,CHEMBL616608,,,,,8,1
1269,10576,,BAO_0000019,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM+ 1 uM 5-HT.,,,H,Autocuration,F,,CHEMBL616609,,,,,8,1
1270,10576,,BAO_0000019,,,Effect against 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at 0.1 uM dose,,,D,Expert,F,10116.0,CHEMBL616610,,,,,9,1
1271,10576,,BAO_0000019,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,,,H,Autocuration,F,,CHEMBL616611,,,,,8,1
1272,10576,,BAO_0000019,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 1 uM 5-HT.,,,H,Expert,F,,CHEMBL616612,,,,,8,1
1273,10576,,BAO_0000019,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 0.1 uM 5-HT.,,,H,Autocuration,F,,CHEMBL616613,,,,,8,1
1274,10576,,BAO_0000019,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM,,,H,Expert,F,,CHEMBL616614,,,,,8,1
1275,10576,,BAO_0000019,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM+ 10 uM 5-HT.,,,H,Autocuration,F,,CHEMBL616615,,,,,8,1
1276,10576,,BAO_0000019,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,,,H,Expert,F,,CHEMBL616616,,,,,8,1
1277,10576,,BAO_0000019,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 0.1 uM 5-HT.,,,H,Autocuration,F,,CHEMBL616617,,,,,8,1
1278,10576,,BAO_0000019,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,,,H,Autocuration,F,,CHEMBL616618,,,,,8,1
1279,10576,,BAO_0000019,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 1 uM 5-HT.,,,H,Autocuration,F,,CHEMBL616619,,,,,8,1
1280,10576,,BAO_0000019,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 3 uM 5-HT.,,,H,Expert,F,,CHEMBL616620,,,,,8,1
1281,10576,,BAO_0000019,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,,,H,Expert,F,,CHEMBL616621,,,,,8,1
1282,10576,,BAO_0000019,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 30 uM,,,H,Autocuration,F,,CHEMBL616622,,,,,8,1
1283,10576,,BAO_0000019,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM,,,H,Expert,F,,CHEMBL616146,,,,,8,1
1284,10576,,BAO_0000019,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM+ 50 uM 5-HT.,,,H,Autocuration,F,,CHEMBL832873,,,,,8,1
1285,10576,,BAO_0000019,,,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM,,,H,Autocuration,F,,CHEMBL616147,,,,,8,1
1286,10576,,BAO_0000019,,,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,,,H,Autocuration,F,,CHEMBL872872,,,,,8,1
1287,10576,,BAO_0000019,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,,,H,Autocuration,F,,CHEMBL616148,,,,,8,1
1288,10576,,BAO_0000221,,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue,,,H,Autocuration,B,,CHEMBL616149,,10000000.0,Hippocampus,,8,1
1289,10576,,BAO_0000221,,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue at 1 uM,,,H,Expert,B,,CHEMBL616150,,10000000.0,Hippocampus,,8,1
1290,10576,,BAO_0000249,,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membranes at 10e-7 M,,,D,Expert,B,10116.0,CHEMBL616151,,,,Membranes,9,1
1291,10576,,BAO_0000221,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue at 1 uM,,,H,Expert,B,,CHEMBL872873,,10000000.0,Hippocampus,,8,1
1292,10576,,BAO_0000221,,,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 0.1 uM concentration,,,H,Autocuration,B,,CHEMBL616670,,10000000.0,Hippocampus,,8,1
1293,10576,,BAO_0000221,,,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 1 uM concentration,,,H,Autocuration,B,,CHEMBL616671,,10000000.0,Hippocampus,,8,1
1294,10576,,BAO_0000249,,,"Percent inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",,,D,Expert,F,10116.0,CHEMBL884861,,,,,9,1
1295,10576,,BAO_0000357,,,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor,,,H,Autocuration,B,,CHEMBL616672,,,,,8,1
1296,10576,,BAO_0000019,,,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,,,H,Autocuration,B,,CHEMBL616673,,,,,8,1
1297,10576,,BAO_0000019,,,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,,,H,Expert,F,,CHEMBL616674,,,,,8,1
1298,10576,,BAO_0000357,,,Binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,,,H,Autocuration,B,,CHEMBL616675,,,,,8,1
1299,10576,,BAO_0000221,,,In vitro binding affinity for 5-hydroxytryptamine 1A receptor was determined by measuring specific inhibition of [125I]-binding to rat hippocampal membrane preparations,,,H,Autocuration,B,,CHEMBL616676,,10000000.0,Hippocampus,,8,1
1300,10576,,BAO_0000221,,,Inhibition of binding of [125I]-8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,,H,Autocuration,B,,CHEMBL616677,,10000000.0,Hippocampus,,8,1
1301,10576,,BAO_0000221,,,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,,H,Autocuration,B,,CHEMBL616678,,10000000.0,Hippocampus,,8,1
1302,10576,,BAO_0000357,,,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,,D,Expert,B,10116.0,CHEMBL616679,,,,,9,1
1303,10576,,BAO_0000221,,,Ability to bind to central serotonin 5-hydroxytryptamine 1A receptor in vitro in hippocampus of the rat brain using [3H]8-OH-DPAT radioligand,,,H,Expert,B,,CHEMBL616680,,10000000.0,Hippocampus,,8,1
1304,10576,,BAO_0000221,,,Ability to displace [3H]- -OH-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,,,H,Autocuration,B,,CHEMBL616681,,10000000.0,Hippocampus,,8,1
1305,10576,,BAO_0000221,,,Ability to displace [3H]- -(OH)-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,,,H,Autocuration,B,,CHEMBL616682,,10000000.0,Hippocampus,,8,1
1306,10576,,BAO_0000221,,,Ability to displace [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,,H,Autocuration,B,,CHEMBL616683,,10000000.0,Hippocampus,,8,1
1307,10576,,BAO_0000221,,,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor,,,H,Autocuration,B,,CHEMBL616684,,10000000.0,Hippocampus,,8,1
1308,10576,,BAO_0000221,,,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor; Not tested,,,H,Autocuration,B,,CHEMBL616685,,10000000.0,Hippocampus,,8,1
1309,10576,,BAO_0000221,,,Affinity at [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in rat brain homogenate was determined,,,H,Autocuration,B,,CHEMBL616686,,955.0,Brain,,8,1
1310,10576,,BAO_0000357,,,Affinity for 5-hydroxytryptamine 1A receptor site,,,H,Autocuration,B,,CHEMBL616687,,,,,8,1
1311,10576,,BAO_0000357,,,Affinity for 5-hydroxytryptamine 1A receptor site,,,H,Autocuration,B,,CHEMBL616688,,,,,8,1
1312,10576,,BAO_0000221,,,Affinity in displacing [3H]8-OH-DPAT from rat hippocampal 5-HT1A receptor.,,,H,Autocuration,B,,CHEMBL616689,,10000000.0,Hippocampus,,8,1
1313,10576,,BAO_0000357,,,Affinity on 5-hydroxytryptamine 1A receptor labeled by [3H]8-OH-DPAT,,,H,Autocuration,B,,CHEMBL616690,,,,,8,1
1314,10576,,BAO_0000357,,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand,,,H,Expert,B,,CHEMBL616691,,,,,8,1
1315,10576,,BAO_0000221,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus mambranes,,,D,Expert,B,10116.0,CHEMBL616692,,10000000.0,Hippocampus,,9,1
1316,10576,,BAO_0000249,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane,,,H,Expert,B,,CHEMBL616693,,,,,8,1
1317,10576,,BAO_0000019,,,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",,,D,Expert,B,10116.0,CHEMBL616694,,,,,9,1
1318,10576,,BAO_0000221,,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal tissue,,,H,Autocuration,B,,CHEMBL616695,,10000000.0,Hippocampus,,8,1
1319,10576,,BAO_0000357,,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat was determined using [3H]8-OH-DPAT in binding assay,,,H,Autocuration,B,,CHEMBL616696,,,,,8,1
1320,10576,,BAO_0000357,,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]DOB as radioligand,,,H,Autocuration,B,,CHEMBL616697,,,,,8,1
1321,10576,,BAO_0000357,,,Binding affinity against rat 5-hydroxytryptamine 1A receptor,,,H,Autocuration,B,,CHEMBL616698,,,,,8,1
1322,10576,,BAO_0000019,,,Binding affinity against rat brain 5-hydroxytryptamine 1A receptor,,,D,Expert,B,10116.0,CHEMBL616949,,,,,9,1
1323,10576,,BAO_0000221,,,Binding affinity against the 5-hydroxytryptamine 1A receptor labelled with [3H]8-OH-DPAT in rat hippocampal homogenates,,,H,Autocuration,B,,CHEMBL616950,,10000000.0,Hippocampus,,8,1
1324,10576,,BAO_0000357,,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,,,H,Autocuration,B,,CHEMBL832875,,,,,8,1
1325,10576,,BAO_0000221,,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,,H,Expert,B,,CHEMBL616951,,955.0,Brain,,8,1
1326,10576,,BAO_0000221,,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,,H,Expert,B,,CHEMBL616952,,955.0,Brain,,8,1
1327,10576,,BAO_0000357,,,Binding affinity at rat 5-hydroxytryptamine 1A receptor by [3H]WB-4101 displacement.,,,H,Expert,B,,CHEMBL616953,,,,,8,1
1328,10576,,BAO_0000357,,,Binding affinity for 5-hydroxytryptamine 1A receptor by use of [3H]8-OH-DPAT in male rat,,,H,Autocuration,B,,CHEMBL616954,,,,,8,1
1329,106,,BAO_0000357,,,GTPgammaS radioligand binding assay,,,H,Autocuration,B,,CHEMBL616955,,,,,8,1
1330,106,,BAO_0000357,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,,,H,Autocuration,B,,CHEMBL616956,,,,,8,1
1331,106,,BAO_0000019,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Partial agonist,,,H,Autocuration,F,,CHEMBL616957,,,,,8,1
1332,106,,BAO_0000019,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Slient antagonist,,,H,Autocuration,F,,CHEMBL616958,,,,,8,1
1333,106,,BAO_0000357,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,,,H,Autocuration,B,,CHEMBL616959,,,,,8,1
1334,106,,BAO_0000357,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,,,H,Autocuration,B,,CHEMBL616960,,,,,8,1
1335,106,,BAO_0000019,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; silent antagonist,,,H,Autocuration,F,,CHEMBL616961,,,,,8,1
1336,106,,BAO_0000219,308.0,HeLa,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor,,,H,Expert,B,,CHEMBL616962,,,,,8,1
1337,106,,BAO_0000219,308.0,HeLa,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor receptor,,,H,Autocuration,B,,CHEMBL616963,,,,,8,1
1338,106,,BAO_0000357,,,Affinity towards human 5-hydroxytryptamine 1B serotonin receptor,,,D,Expert,B,9606.0,CHEMBL616524,,,,,9,1
1339,106,,BAO_0000219,449.0,CHO,Binding affinity against 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,,,H,Autocuration,B,,CHEMBL616525,,,,,8,1
1340,106,,BAO_0000019,,,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]5-CT as radioligand,,,H,Autocuration,B,,CHEMBL872908,,,,,8,1
1341,106,,BAO_0000019,,,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]GR-125743 as radioligand,,,H,Autocuration,B,,CHEMBL616526,,,,,8,1
1342,106,,BAO_0000357,,,Binding affinity to cloned human 5-hydroxytryptamine 1B receptor,,,D,Expert,B,9606.0,CHEMBL616527,,,,,9,1
1343,106,,BAO_0000219,,,Binding affinity towards human 5-hydroxytryptamine 1B receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,,,H,Expert,B,,CHEMBL616528,,,,,8,1
1344,106,,BAO_0000357,,,Binding affinity for recombinant human 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,,H,Autocuration,B,,CHEMBL616529,,,,,8,1
1345,106,,BAO_0000357,,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1B receptor using [3H]5-CT as radioligand,,,H,Autocuration,B,,CHEMBL616530,,,,,8,1
1346,106,,BAO_0000357,,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,,,H,Expert,B,,CHEMBL616531,,,,,8,1
1347,106,,BAO_0000357,,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,,,H,Autocuration,B,,CHEMBL616532,,,,,8,1
1348,106,,BAO_0000357,,,Binding affinity towards 5-hydroxytryptamine 1B receptor,,,H,Autocuration,B,,CHEMBL616533,,,,,8,1
1349,106,,BAO_0000357,,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,,,H,Expert,B,,CHEMBL616534,,,,,8,1
1350,106,,BAO_0000357,,,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand,,,H,Expert,B,,CHEMBL616535,,,,,8,1
1351,106,,BAO_0000357,,,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT radioligand,,,H,Autocuration,B,,CHEMBL616536,,,,,8,1
1352,106,,BAO_0000357,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1B receptor,,,H,Autocuration,B,,CHEMBL616537,,,,,8,1
1353,106,,BAO_0000219,485.0,CHO-K1,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1B receptor in CHO-K1 cells,,,H,Expert,F,,CHEMBL616538,,,,,8,1
1354,106,,BAO_0000019,,,Agonist activity to the human recombinant 5-hydroxytryptamine 1B receptor,,,H,Expert,F,,CHEMBL616539,,,,,8,1
1355,106,,BAO_0000019,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor,,,H,Expert,B,,CHEMBL616540,,,,,8,1
1356,106,,BAO_0000357,,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,,,H,Autocuration,B,,CHEMBL616429,,,,,8,1
1357,106,,BAO_0000357,,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor,,,H,Expert,B,,CHEMBL616430,,,,,8,1
1358,106,,BAO_0000219,,,Receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor in Cos-7 cells,,,D,Expert,B,9606.0,CHEMBL616431,,,,,9,1
1359,106,,BAO_0000357,,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,,,D,Expert,B,9606.0,CHEMBL616432,,,,,9,1
1360,106,,BAO_0000357,,,Affinity for 5-hydroxytryptamine 1B receptor subtype,,,D,Expert,B,9606.0,CHEMBL616433,,,,,9,1
1361,106,,BAO_0000357,,,Binding affinity for human 5-hydroxytryptamine 1B receptor,,,D,Expert,B,9606.0,CHEMBL616434,,,,,9,1
1362,106,,BAO_0000219,449.0,CHO,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand; Not determined,,,H,Autocuration,B,,CHEMBL616435,,,,,8,1
1363,106,,BAO_0000019,,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor; ND means not determined,,,H,Expert,B,,CHEMBL616436,,,,,8,1
1364,106,,BAO_0000219,308.0,HeLa,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,,,H,Autocuration,B,,CHEMBL616437,,,,,8,1
1365,106,,BAO_0000219,308.0,HeLa,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT=not tested,,,H,Autocuration,B,,CHEMBL616438,,,,,8,1
1366,106,,BAO_0000219,308.0,HeLa,Ability to displace [3H]-5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,,,H,Autocuration,B,,CHEMBL616439,,,,,8,1
1367,106,,BAO_0000357,,,Binding activity against human 5-hydroxytryptamine 1B receptor; NT means not tested,,,D,Expert,B,9606.0,CHEMBL616440,,,,,9,1
1368,106,,BAO_0000219,485.0,CHO-K1,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor; not tested,,,H,Autocuration,B,,CHEMBL616441,,,,,8,1
1369,106,,BAO_0000357,,,Selectivity ratio against cloned human 5-HT1B receptor to that of h5-HT1D receptor,,,H,Expert,B,,CHEMBL616442,,,,,8,1
1370,106,,BAO_0000357,,,Selectivity ratio against cloned human 5-hydroxytryptamine 1B receptor to that of human 5-hydroxytryptamine 1D receptor,,,H,Autocuration,B,,CHEMBL616443,,,,,8,1
1371,106,,BAO_0000219,485.0,CHO-K1,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor,,,H,Expert,B,,CHEMBL616444,,,,,8,1
1372,106,,BAO_0000357,,,Binding activity against human 5-hydroxytryptamine 1B receptor,,,D,Expert,B,9606.0,CHEMBL616445,,,,,9,1
1373,106,,BAO_0000357,,,Binding activity against human 5-hydroxytryptamine 1B receptor,,,D,Expert,B,9606.0,CHEMBL616446,,,,,9,1
1374,106,,BAO_0000219,449.0,CHO,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,,,D,Expert,B,9606.0,CHEMBL616447,,,,,9,1
1375,106,,BAO_0000357,,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor was determined,,,H,Autocuration,B,,CHEMBL616448,,,,,8,1
1376,106,,BAO_0000219,449.0,CHO,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand,,,H,Autocuration,B,,CHEMBL616449,,,,,8,1
1377,106,,BAO_0000219,449.0,CHO,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells,,,H,Autocuration,B,,CHEMBL616450,,,,,8,1
1378,106,,BAO_0000219,449.0,CHO,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells using [3H]5-CT as radioligand,,,H,Autocuration,B,,CHEMBL857974,,,,,8,1
1379,106,,BAO_0000219,449.0,CHO,Binding affinity towards 5-hydroxytryptamine 1B (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,,H,Autocuration,B,,CHEMBL616451,,,,,8,1
1380,106,,BAO_0000219,449.0,CHO,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,,H,Autocuration,B,,CHEMBL616452,,,,,8,1
1381,106,,BAO_0000219,449.0,CHO,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand;ND means no data.,,,H,Autocuration,B,,CHEMBL616453,,,,,8,1
1382,106,,BAO_0000219,449.0,CHO,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as the radioligand,,,H,Autocuration,B,,CHEMBL616454,,,,,8,1
1383,106,,BAO_0000357,,,Binding affinity for human 5-hydroxytryptamine 1B receptor,,,D,Expert,B,9606.0,CHEMBL616455,,,,,9,1
1384,106,,BAO_0000219,449.0,CHO,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,,,H,Autocuration,B,,CHEMBL616456,,,,,8,1
1385,106,,BAO_0000357,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1B receptor in CHO using [3H]5-HT as a radioligand,,,H,Autocuration,B,,CHEMBL616457,,,,,8,1
1386,106,,BAO_0000219,449.0,CHO,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,,,H,Autocuration,B,,CHEMBL616458,,,,,8,1
1387,106,,BAO_0000219,449.0,CHO,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1B receptor in CHO cells, using [3H]5-HT as radioligand",,,H,Autocuration,B,,CHEMBL616459,,,,,8,1
1388,106,,BAO_0000019,,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 1 uM,,,H,Expert,F,,CHEMBL616460,,,,,8,1
1389,106,,BAO_0000019,,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 10 uM,,,H,Expert,F,,CHEMBL616461,,,,,8,1
1390,106,,BAO_0000219,449.0,CHO,"Effect of compound on [35S]GTP-gamma-S, radioligand binding CHO cells expressing human 5-hydroxytryptamine 1B receptor",,,H,Autocuration,F,,CHEMBL616462,,,,,8,1
1391,106,,BAO_0000219,449.0,CHO,"Effect of compound on [35S]GTP-gamma-S, radioligand binding in CHO cells expressing human 5-hydroxytryptamine 1B receptor",,,H,Autocuration,F,,CHEMBL616463,,,,,8,1
1392,105,,BAO_0000019,,,"Compound was tested for maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-HT.",,,H,Autocuration,F,,CHEMBL616464,,,,,8,1
1393,105,,BAO_0000219,449.0,CHO,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells.,,,H,Autocuration,B,,CHEMBL616465,,,,,8,1
1394,17105,,BAO_0000357,,,The compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,,,H,Autocuration,B,,CHEMBL832874,,,,,8,1
1395,106,,BAO_0000019,,,5-hydroxytryptamine 1B receptor agonist potency determined in rabbit saphenous vein contraction model,,,H,Autocuration,F,9986.0,CHEMBL616184,,,,,8,1
1396,106,,BAO_0000019,,,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein (RbSV).,,,H,Autocuration,B,9986.0,CHEMBL616185,,,,,8,1
1397,106,,BAO_0000019,,,"Binding affinity against vascular 5-hydroxytryptamine 1B receptor, measured using ring preparations of rabbit saphenous vein (RbSV)",,,H,Intermediate,B,9986.0,CHEMBL616186,,,,,8,1
1398,106,,BAO_0000019,,,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein(RbSV).,,,H,Autocuration,B,9986.0,CHEMBL616187,,,,,8,1
1399,10577,,BAO_0000357,,,Binding affinity towards 5-hydroxytryptamine 1B receptor was measured using [3H]5-HT as radioligand,,,H,Expert,B,,CHEMBL616188,,,,,8,1
1400,10577,,BAO_0000357,,,Binding affinity for 5-hydroxytryptamine 1B receptor,,,D,Intermediate,B,,CHEMBL873475,,,,,9,1
1401,10577,,BAO_0000019,,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Less active,,,D,Expert,B,10116.0,CHEMBL616189,,2435.0,Striatum,,9,1
1402,10577,,BAO_0000357,,,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,,,H,Expert,B,,CHEMBL616190,,,,,8,1
1403,10576,,BAO_0000357,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=48-77,,,H,Autocuration,B,,CHEMBL616191,,,,,8,1
1404,10576,,BAO_0000357,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=63-95,,,H,Autocuration,B,,CHEMBL616192,,,,,8,1
1405,10576,,BAO_0000357,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=710-980,,,H,Autocuration,B,,CHEMBL616193,,,,,8,1
1406,10576,,BAO_0000357,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=78-140,,,H,Autocuration,B,,CHEMBL616194,,,,,8,1
1407,10576,,BAO_0000357,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=85-130,,,H,Autocuration,B,,CHEMBL616195,,,,,8,1
1408,10576,,BAO_0000357,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=89-280,,,H,Autocuration,B,,CHEMBL616196,,,,,8,1
1409,10576,,BAO_0000249,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampus membrane.,,,H,Autocuration,B,,CHEMBL616197,,10000000.0,Hippocampus,,8,1
1410,10576,,BAO_0000019,,,Binding affinity at 5-hydroxytryptamine 1A (5-HT1A) receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand,,,H,Intermediate,B,,CHEMBL616198,,,,,8,1
1411,10576,,BAO_0000221,,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,,,H,Autocuration,B,,CHEMBL616199,,10000000.0,Hippocampus,,8,1
1412,10576,,BAO_0000221,,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampal homogenate by [125I](R)-(+)-trans-8-OH-PIPAT displacement.,,,H,Expert,B,,CHEMBL616200,,10000000.0,Hippocampus,,8,1
1413,10576,,BAO_0000221,,,In vitro binding affinity to rat hippocampal 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,,H,Expert,B,,CHEMBL616201,,10000000.0,Hippocampus,,8,1
1414,10576,,BAO_0000221,,,In vitro binding affinity towards 5-hydroxytryptamine 1A r receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,,,H,Expert,B,,CHEMBL616202,,10000000.0,Hippocampus,,8,1
1415,10576,,BAO_0000221,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,,,H,Expert,B,,CHEMBL616203,,10000000.0,Hippocampus,,8,1
1416,10576,,BAO_0000221,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; ND=not determined,,,H,Expert,B,,CHEMBL616204,,10000000.0,Hippocampus,,8,1
1417,10576,,BAO_0000221,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; Not determined,,,H,Expert,B,,CHEMBL616205,,10000000.0,Hippocampus,,8,1
1418,10576,,BAO_0000221,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; not determined,,,H,Expert,B,,CHEMBL616206,,10000000.0,Hippocampus,,8,1
1419,10576,,BAO_0000249,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,,,H,Expert,B,,CHEMBL616207,,,,,8,1
1420,10576,,BAO_0000249,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes,,,H,Autocuration,B,,CHEMBL616208,,,,,8,1
1421,10576,,BAO_0000249,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes; Inactive,,,H,Autocuration,B,,CHEMBL616209,,,,,8,1
1422,10576,,BAO_0000357,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using radioligand [3H]-8-OH-DPAT,,,H,Expert,B,,CHEMBL616210,,,,,8,1
1423,10576,,BAO_0000221,,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue.,,,H,Expert,B,,CHEMBL616211,,10000000.0,Hippocampus,,8,1
1424,10576,,BAO_0000221,,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue; NT=Not tested,,,H,Autocuration,B,,CHEMBL616504,,10000000.0,Hippocampus,,8,1
1425,10576,,BAO_0000221,,,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,,,D,Expert,B,10116.0,CHEMBL616505,,10000000.0,Hippocampus,,9,1
1426,10576,,BAO_0000019,,,Inhibition constant of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,,,H,Autocuration,F,,CHEMBL616506,,,,,8,1
1427,10576,,BAO_0000221,,,Inhibition of binding of [125I]8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,,H,Autocuration,B,,CHEMBL872107,,10000000.0,Hippocampus,,8,1
1428,10576,,BAO_0000221,,,Displacement of [3H]5-HT from rat hippocampal 5-hydroxytryptamine 1A receptor with 10e-6 M ketanserin,,,D,Expert,B,10116.0,CHEMBL616507,,10000000.0,Hippocampus,,9,1
1429,10576,,BAO_0000249,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor in rat cortical membranes using [3H]8-OH-DPAT as a radioligand,,,H,Autocuration,B,,CHEMBL616303,,,,,8,1
1430,10576,,BAO_0000221,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue,,,H,Autocuration,B,,CHEMBL616304,,10000000.0,Hippocampus,,8,1
1431,10576,,BAO_0000221,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,,,H,Expert,B,,CHEMBL616305,,10000000.0,Hippocampus,,8,1
1432,10576,,BAO_0000221,,,Antagonist activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor,,,H,Intermediate,F,,CHEMBL616306,,10000000.0,Hippocampus,,8,1
1433,10576,,BAO_0000357,,,Inhibitory affinity constant against 5-hydroxytryptamine 1A receptor,,,H,Autocuration,B,,CHEMBL616307,,,,,8,1
1434,10576,,BAO_0000221,,,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat brain hippocampus,,,D,Expert,B,10116.0,CHEMBL881829,,10000000.0,Hippocampus,,9,1
1435,10576,,BAO_0000357,,,Affinity against the 5-hydroxytryptamine receptor 1A using [3H]WB-4101.,,,H,Expert,B,,CHEMBL616308,,,,,8,1
1436,10576,,BAO_0000019,,,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain,,,H,Autocuration,B,,CHEMBL616309,,,,,8,1
1437,10576,,BAO_0000019,,,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain tissue,,,H,Expert,B,,CHEMBL616310,,,,,8,1
1438,10576,,BAO_0000219,449.0,CHO,Tested for affinity against 5-hydroxytryptamine 1A receptors using [3H]8-OH-DPAT in homogenized rat cloned CHO cells,,,H,Autocuration,B,,CHEMBL616311,,,,,8,1
1439,10576,,BAO_0000357,,,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand,,,H,Expert,B,,CHEMBL616312,,,,,8,1
1440,10576,,BAO_0000357,,,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand; ND is Not Determined,,,H,Autocuration,B,,CHEMBL616313,,,,,8,1
1441,10576,,BAO_0000221,,,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,,,D,Expert,B,10116.0,CHEMBL616314,,10000000.0,Hippocampus,,9,1
1442,10576,,BAO_0000221,,,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus,,,H,Autocuration,B,,CHEMBL616315,,10000000.0,Hippocampus,,8,1
1443,10576,,BAO_0000221,,,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; NA means Not Active,,,H,Autocuration,B,,CHEMBL616567,,10000000.0,Hippocampus,,8,1
1444,10576,,BAO_0000221,,,Tested for binding affinity by measuring displacement of [3H]-8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; ND means Not Determined,,,H,Autocuration,B,,CHEMBL616568,,10000000.0,Hippocampus,,8,1
1445,10576,,BAO_0000019,,,Binding affinity to displace [3H]2-(di-N-propylamino)-8-hydroxy-tetralin from 5-hydroxytryptamine 1A (5-HT1A) receptor in rat frontal cortex homogenates,,,H,Intermediate,B,,CHEMBL616569,,,,,8,1
1446,10576,,BAO_0000357,,,Binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand assay.,,,H,Expert,B,,CHEMBL616570,,,,,8,1
1447,10576,,BAO_0000357,,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,,,H,Autocuration,B,,CHEMBL616571,,,,,8,1
1448,10576,,BAO_0000221,,,Tested for the inhibitory activity against 5-hydroxytryptamine 1A receptor in rat hippocampal,,,H,Autocuration,B,,CHEMBL616572,,10000000.0,Hippocampus,,8,1
1449,10576,,BAO_0000249,,,Tested in vitro for binding affinity by measuring its ability to inhibit [3H]8-OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes.,,,H,Expert,B,,CHEMBL616573,,,,,8,1
1450,10576,,BAO_0000357,,,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT,,,D,Expert,B,10116.0,CHEMBL616574,,,,,9,1
1451,10576,,BAO_0000221,,,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation,,,H,Expert,B,,CHEMBL616575,,10000000.0,Hippocampus,,8,1
1452,10576,,BAO_0000221,,,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation; ND=not determined,,,H,Autocuration,B,,CHEMBL872108,,10000000.0,Hippocampus,,8,1
1453,10576,,BAO_0000357,,,The binding affinity was measured on 5-hydroxytryptamine 1A receptor using [3H]- 8-OH-DPAT as radioligand.,,,H,Autocuration,B,,CHEMBL616576,,,,,8,1
1454,10576,,BAO_0000249,,,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 1 mM of MnCl2,,,H,Autocuration,B,,CHEMBL616577,,,,,8,1
1455,10576,,BAO_0000249,,,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 3*10e-5 M GTP gamma S,,,H,Autocuration,B,,CHEMBL616578,,,,,8,1
1456,10576,,BAO_0000357,,,Binding affinity at 5-hydroxytryptamine 1A receptor from striata of wistar rats by [3H]- 8-OH -DPAT displacement.,,,H,Expert,B,,CHEMBL616579,,,,,8,1
1457,10576,,BAO_0000019,,,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat brain synaptosomal preparations,,,D,Expert,B,10116.0,CHEMBL616580,,,,,9,1
1458,10576,,BAO_0000019,,,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,,,H,Autocuration,B,,CHEMBL616581,,,,,8,1
1459,10576,,BAO_0000221,,,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,,,H,Autocuration,B,,CHEMBL616582,,10000000.0,Hippocampus,,8,1
1460,10576,,BAO_0000221,,,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,,,H,Expert,B,,CHEMBL616583,,10000000.0,Hippocampus,,8,1
1461,10576,,BAO_0000221,,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]8-OH-DPAT,,,D,Expert,B,10116.0,CHEMBL616584,,10000000.0,Hippocampus,,9,1
1462,10576,,BAO_0000357,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,,,H,Expert,B,,CHEMBL616585,,,,,8,1
1463,10576,,BAO_0000221,,,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 from rat hippocampus,,,D,Expert,B,10116.0,CHEMBL616586,,10000000.0,Hippocampus,,9,1
1464,10576,,BAO_0000221,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 radioligand in rat hippocampus,,,H,Autocuration,B,,CHEMBL616587,,10000000.0,Hippocampus,,8,1
1465,10576,,BAO_0000221,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]-8-OH-DPAT as radioligand,,,H,Autocuration,B,,CHEMBL616588,,10000000.0,Hippocampus,,8,1
1466,10576,,BAO_0000221,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand.,,,H,Autocuration,B,,CHEMBL616589,,10000000.0,Hippocampus,,8,1
1467,10576,,BAO_0000221,,,Binding affinity for 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand,,,H,Expert,B,,CHEMBL616590,,10000000.0,Hippocampus,,8,1
1468,10576,,BAO_0000219,449.0,CHO,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1A receptor expressed in CHO cells, by using [3H]8-OH-DPAT as radioligand.",,,H,Expert,B,,CHEMBL616591,,,,,8,1
1469,10576,,BAO_0000357,,,Displacement of the radioligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,,H,Expert,B,,CHEMBL616592,,,,,8,1
1470,10576,,BAO_0000357,,,The inhibition activity of 5-HT1A at 1 uM,,,H,Autocuration,B,,CHEMBL616593,,,,,8,1
1471,10576,,BAO_0000219,485.0,CHO-K1,"Binding affinity against 5-hydroxytryptamine 1A receptor from CHO-K1 cells, using [3H]8-OH-DPAT as the radioligand.",,,H,Expert,B,,CHEMBL616594,,,,,8,1
1472,10576,,BAO_0000249,,,Binding affinities against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membrane,,,H,Expert,B,,CHEMBL616595,,,,,8,1
1473,10576,,BAO_0000357,,,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-HT 1A receptor site.,,,H,Autocuration,B,,CHEMBL616596,,,,,8,1
1474,10576,,BAO_0000221,,,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,,H,Autocuration,B,,CHEMBL616597,,10000000.0,Hippocampus,,8,1
1475,10576,,BAO_0000221,,,Ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,,H,Expert,B,,CHEMBL616598,,10000000.0,Hippocampus,,8,1
1476,10576,,BAO_0000249,,,Antagonist activity to stimulate binding of [35S]-GTP-gamma S binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes,,,D,Expert,F,10116.0,CHEMBL616599,,,,Membranes,9,1
1477,10576,,BAO_0000249,,,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",,,D,Expert,F,10116.0,CHEMBL616600,,10000000.0,Hippocampus,Membranes,9,1
1478,10576,,BAO_0000019,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not -determined.,,,H,Autocuration,B,,CHEMBL616601,,,,,8,1
1479,10576,,BAO_0000019,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not defined.,,,H,Autocuration,B,,CHEMBL616602,,,,,8,1
1480,10576,,BAO_0000019,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not determined.,,,H,Autocuration,B,,CHEMBL616603,,,,,8,1
1481,10576,,BAO_0000019,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND means not determined.,,,H,Autocuration,B,,CHEMBL616604,,,,,8,1
1482,10576,,BAO_0000249,,,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; No data,,,H,Autocuration,B,,CHEMBL616316,,,,,8,1
1483,10576,,BAO_0000249,,,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; Not determined,,,H,Autocuration,B,,CHEMBL616317,,,,,8,1
1484,10576,,BAO_0000019,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates; ND means No data,,,D,Expert,B,10116.0,CHEMBL616318,,,,,9,1
1485,10576,,BAO_0000221,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes,,,H,Autocuration,B,,CHEMBL616319,,10000000.0,Hippocampus,,8,1
1486,10576,,BAO_0000221,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes; Not tested,,,H,Autocuration,B,,CHEMBL616320,,10000000.0,Hippocampus,,8,1
1487,10576,,BAO_0000221,,,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding; Not tested,,,D,Expert,B,10116.0,CHEMBL616321,,10000000.0,Hippocampus,,9,1
1488,10576,,BAO_0000019,,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,,,H,Autocuration,F,,CHEMBL616322,,,,,8,1
1489,10576,,BAO_0000019,,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; not tested,,,H,Autocuration,F,,CHEMBL616323,,,,,8,1
1490,10576,,BAO_0000357,,,Ratio of binding affinity to 5-HT 1A and D2 receptor,,,H,Autocuration,B,,CHEMBL616324,,,,,8,1
1491,10576,,BAO_0000221,,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,,,H,Autocuration,B,,CHEMBL616325,,10000000.0,Hippocampus,,8,1
1492,10576,,BAO_0000221,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,,,H,Autocuration,B,,CHEMBL616326,,10000000.0,Hippocampus,,8,1
1493,10576,,BAO_0000221,,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.,,,H,Autocuration,B,,CHEMBL616327,,10000000.0,Hippocampus,,8,1
1494,10576,,BAO_0000357,,,Percentage inhibition against 5-hydroxytryptamine 1A receptor,,,H,Autocuration,B,,CHEMBL616328,,,,,8,1
1495,10576,,BAO_0000249,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),,,H,Autocuration,B,,CHEMBL858110,,,,,8,1
1496,10576,,BAO_0000249,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),,,H,Autocuration,F,,CHEMBL616329,,,,,8,1
1497,10576,,BAO_0000249,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),,,H,Autocuration,B,,CHEMBL616330,,,,,8,1
1498,10576,,BAO_0000249,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),,,H,Autocuration,F,,CHEMBL616331,,,,,8,1
1499,10576,,BAO_0000249,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,,,H,Autocuration,F,,CHEMBL616332,,,,,8,1
1500,10576,,BAO_0000249,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,,H,Autocuration,B,,CHEMBL857063,,955.0,Brain,,8,1
1501,10576,,BAO_0000019,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [3H]8-OH-DPAT as a radioligand,,,H,Autocuration,B,,CHEMBL616333,,,,,8,1
1502,10576,,BAO_0000019,,,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT as radioligand.,,,H,Expert,F,,CHEMBL616334,,,,,8,1
1503,10576,,BAO_0000221,,,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,,,H,Autocuration,B,,CHEMBL616335,,10000000.0,Hippocampus,,8,1
1504,10576,,BAO_0000019,,,Affinity pKi for 5-hydroxytryptamine 1A receptor was measured in rat cortex homogenates.,,,H,Autocuration,B,,CHEMBL616336,,,,,8,1
1505,10576,,BAO_0000249,,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cerebral cortical membrane using [3H]-8-OH-DPAT as radioligand.,,,H,Expert,B,,CHEMBL616337,,,,,8,1
1506,10576,,BAO_0000019,,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cortex homogenates.,,,H,Autocuration,B,,CHEMBL616338,,,,,8,1
1507,10576,,BAO_0000221,,,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]- 8-hydri\oxy-2-(di-n-propylamino)tetraline) binding assay,,,H,Autocuration,B,,CHEMBL616339,,10000000.0,Hippocampus,,8,1
1508,10576,,BAO_0000221,,,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]8-hydroxy-2-(di-n-propylamino)-tetraline) binding assay,,,H,Autocuration,B,,CHEMBL616340,,10000000.0,Hippocampus,,8,1
1509,10576,,BAO_0000357,,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined,,,H,Autocuration,B,,CHEMBL616341,,,,,8,1
1510,10576,,BAO_0000357,,,Binding affinity against rat 5-hydroxytryptamine 1A receptor,,,D,Expert,B,10116.0,CHEMBL616342,,,,,9,1
1511,10576,,BAO_0000019,,,Inhibition of [3H]2-(di-N-propylamino)-8-hydroxytetralin binding to 5-HT1A receptor of rat frontal cortex homogenates,,,D,Expert,B,10116.0,CHEMBL616343,,,,,9,1
1512,10576,,BAO_0000019,,,Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement,,,H,Expert,B,,CHEMBL616344,,,,,8,1
1513,10576,,BAO_0000357,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,,H,Expert,B,,CHEMBL616345,,,,,8,1
1514,10576,,BAO_0000019,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]8-OH-DPAT as a radioligand,,,H,Expert,B,,CHEMBL616346,,,,,8,1
1515,10576,,BAO_0000221,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,,,H,Autocuration,B,,CHEMBL616347,,10000000.0,Hippocampus,,8,1
1516,10576,,BAO_0000019,,,In vitro by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor on rat cortical membrane,,,H,Expert,B,,CHEMBL616348,,,,,8,1
1517,10576,,BAO_0000357,,,Binding affinity at 5-hydroxytryptamine 1A receptor,,,H,Expert,B,,CHEMBL616349,,,,,8,1
1518,10576,,BAO_0000249,,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat frontal cortex membranes,,,D,Expert,B,10116.0,CHEMBL616152,,,,Membranes,9,1
1519,10576,,BAO_0000249,,,Compound was tested for inhibition constant against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,,,H,Autocuration,B,,CHEMBL616153,,,,,8,1
1520,10576,,BAO_0000019,,,"Binding affinity for rat cortex 5-hydroxytryptamine 1A receptor, by displacement of 0.2 nM [3H]8-OH-DPAT radioligand",,,H,Expert,B,,CHEMBL616154,,,,,8,1
1521,10576,,BAO_0000019,,,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,,H,Autocuration,B,,CHEMBL616155,,,,,8,1
1522,10576,,BAO_0000221,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT,,,D,Expert,B,10116.0,CHEMBL616156,,10000000.0,Hippocampus,,9,1
1523,10576,,BAO_0000221,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus with [3H]8-OH-DPAT,,,D,Expert,B,10116.0,CHEMBL616157,,10000000.0,Hippocampus,,9,1
1524,10576,,BAO_0000221,,,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]-SB 207710 as radioligand,,,H,Autocuration,B,,CHEMBL616158,,10000000.0,Hippocampus,,8,1
1525,10576,,BAO_0000357,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,,H,Autocuration,B,,CHEMBL616159,,,,,8,1
1526,10576,,BAO_0000357,,,pKi value against rat 5-hydroxytryptamine 1A receptor.,,,H,Expert,B,,CHEMBL616160,,,,,8,1
1527,10576,,BAO_0000019,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is define as non-determined.,,,H,Autocuration,B,,CHEMBL616161,,,,,8,1
1528,10576,,BAO_0000019,,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,,,H,Autocuration,F,,CHEMBL616162,,,,,8,1
1529,12687,,BAO_0000357,,,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,,,D,Expert,B,10116.0,CHEMBL616163,,,,,9,1
1530,10626,,BAO_0000249,,,Inhibition of specific [3H]OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,,H,Expert,B,,CHEMBL616164,,,,Membranes,8,1
1531,10576,,BAO_0000221,,,Concentration of compound required to inhibit cortical 5-hydroxytryptamine 1A receptor binding sites in rat brain was evaluated,,,H,Autocuration,B,,CHEMBL616165,,955.0,Brain,,8,1
1532,51,,BAO_0000019,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor isolated from rat hippocampus membranes membrane using [3H]5-HT as radioligand in the presence of 10e-6 M ketanserin as 5-HT2 blocker,,,H,Autocuration,B,10116.0,CHEMBL616355,,,,,8,1
1533,10576,,BAO_0000019,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,,,H,Autocuration,F,,CHEMBL616356,,,,,8,1
1534,10576,,BAO_0000221,,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,,H,Autocuration,B,,CHEMBL616357,,955.0,Brain,,8,1
1535,10576,,BAO_0000019,,,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",,,H,Autocuration,B,,CHEMBL616358,,,,,8,1
1536,51,,BAO_0000357,,,Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor,,,H,Autocuration,B,,CHEMBL616359,,,,,8,1
1537,51,,BAO_0000357,,,Percent decrease in 5-hydroxytryptamine 1A receptor binding using 8-OH-DPAT,,,H,Expert,B,,CHEMBL616360,,,,,8,1
1538,51,,BAO_0000357,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,,,H,Expert,B,,CHEMBL616361,,,,,8,1
1539,51,,BAO_0000357,,,Tested for binding affinity for 5-hydroxytryptamine 1A receptor,,,H,Autocuration,B,,CHEMBL616362,,,,,8,1
1540,51,,BAO_0000249,,,The compound was evaluated for its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in cellular brain membranes,,,H,Autocuration,B,,CHEMBL616363,,,,Brain membranes,8,1
1541,51,,BAO_0000357,,,Inhibition of binding towards 5-hydroxytryptamine 1A receptor at 100 nM concentration,,,H,Autocuration,B,,CHEMBL616364,,,,,8,1
1542,51,,BAO_0000357,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1A receptor,,,H,Autocuration,B,,CHEMBL616365,,,,,8,1
1543,51,,BAO_0000357,,,Binding affinity for 5-hydroxytryptamine 1A receptor determined using [3H]8-OH-DPAT as radioligand,,,H,Expert,B,,CHEMBL616366,,,,,8,1
1544,51,,BAO_0000357,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,,,H,Expert,B,,CHEMBL872906,,,,,8,1
1545,51,,BAO_0000357,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1A receptor; inactive at 10 uM,,,H,Autocuration,B,,CHEMBL616367,,,,,8,1
1546,51,,BAO_0000357,,,Binding affinity against 5-hydroxytryptamine 1A receptor,,,H,Autocuration,B,,CHEMBL616368,,,,,8,1
1547,51,,BAO_0000357,,,Binding affinity to 5-hydroxytryptamine 1A receptor was determined,,,H,Autocuration,B,,CHEMBL616369,,,,,8,1
1548,51,,BAO_0000357,,,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H]-(+)-8-OH-DPAT.,,,D,Expert,B,9606.0,CHEMBL616370,,,,,9,1
1549,51,,BAO_0000357,,,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H](+)-8-OH-DPAT; inactive,,,D,Expert,B,9606.0,CHEMBL616371,,,,,9,1
1550,51,,BAO_0000219,449.0,CHO,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,,H,Autocuration,B,,CHEMBL616372,,,,,8,1
1551,51,,BAO_0000219,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor expressed in CHO cell membranes,,,H,Expert,B,,CHEMBL616373,,,,,8,1
1552,51,In vivo,BAO_0000218,,,Compound was measured in vivo for its binding affinity at 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,H,Autocuration,B,,CHEMBL616374,,,,,8,1
1553,51,,BAO_0000221,,,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,H,Autocuration,B,,CHEMBL616375,,10000000.0,Hippocampus,,8,1
1554,51,,BAO_0000357,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1A receptor was determined,,,H,Autocuration,B,,CHEMBL616376,,,,,8,1
1555,51,,BAO_0000357,,,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT.,,,H,Expert,B,,CHEMBL857064,,,,,8,1
1556,51,,BAO_0000357,,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,,,H,Autocuration,B,,CHEMBL616377,,,,,8,1
1557,51,,BAO_0000357,,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,,,H,Autocuration,B,,CHEMBL616378,,,,,8,1
1558,51,,BAO_0000357,,,Evaluated for the binding affinity to 5-hydroxytryptamine 1A receptor,,,H,Autocuration,B,,CHEMBL616379,,,,,8,1
1559,11863,,BAO_0000357,,,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,,H,Autocuration,B,,CHEMBL616380,,,,,8,1
1560,11863,,BAO_0000357,,,Binding affinity against 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT radioligand,,,H,Autocuration,B,,CHEMBL616381,,,,,8,1
1561,11863,,BAO_0000357,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1A receptor,,,H,Autocuration,B,,CHEMBL616382,,,,,8,1
1562,11863,,BAO_0000357,,,Compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor by using [3H]DPAT as radioligand,,,H,Autocuration,B,,CHEMBL616383,,,,,8,1
1563,11863,,BAO_0000219,449.0,CHO,In vitro binding affinity against 5-hydroxytryptamine 1A receptor in CHO cells,,,D,Expert,B,10090.0,CHEMBL616350,,,,,9,1
1564,11863,,BAO_0000357,,,Inhibition of 5-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,,H,Autocuration,B,,CHEMBL616351,,,,,8,1
1565,11863,,BAO_0000357,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand at 10e-5 M concentration,,,H,Autocuration,B,,CHEMBL616352,,,,,8,1
1566,11863,,BAO_0000357,,,Binding affinity against 5-hydroxytryptamine 1A receptor,,,H,Autocuration,B,,CHEMBL616353,,,,,8,1
1567,11863,,BAO_0000357,,,Binding affinity against serotonergic 5-HT1a receptor,,,H,Autocuration,B,,CHEMBL616354,,,,,8,1
1568,11863,,BAO_0000357,,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by using [3H]8-OH-DPAT as radioligand,,,H,Autocuration,B,,CHEMBL616508,,,,,8,1
1569,11863,,BAO_0000357,,,Binding affinity for 5-hydroxytryptamine 1A receptor,,,D,Expert,B,10090.0,CHEMBL616559,,,,,9,1
1570,11863,,BAO_0000357,,,Binding affinity at 5-hydroxytryptamine 1A receptor,,,H,Autocuration,B,,CHEMBL616560,,,,,8,1
1571,11863,,BAO_0000357,,,"Binding affinity towards 5-hydroxytryptamine 1A receptor receptor, using [3H]5-HT as radioligand.",,,H,Autocuration,B,,CHEMBL616561,,,,,8,1
1572,11863,,BAO_0000219,449.0,CHO,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,,H,Autocuration,B,,CHEMBL616562,,,,,8,1
1573,11863,,BAO_0000219,449.0,CHO,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,,H,Autocuration,B,,CHEMBL616563,,,,,8,1
1574,11863,,BAO_0000357,,,Compound was tested for binding affinity using [3H]8-OH-DPAT against 5-hydroxytryptamine 1A receptor,,,H,Autocuration,B,,CHEMBL616564,,,,,8,1
1575,11863,,BAO_0000357,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by using [3H]-8-OH-DPAT as radioligand,,,H,Autocuration,B,,CHEMBL616565,,,,,8,1
1576,11863,,BAO_0000218,,,In vivo binding affinity was evaluated against 5-hydroxytryptamine 1A receptor,,,H,Autocuration,B,,CHEMBL616566,,,,,8,1
1577,11863,,BAO_0000357,,,The binding affinity towards 5-hydroxytryptamine 1A receptor; No affinity,,,H,Autocuration,B,,CHEMBL616989,,,,,8,1
1578,11863,,BAO_0000357,,,Ability to displace [125I]iodosulpiride from 5-hydroxytryptamine 1A receptor,,,H,Autocuration,B,,CHEMBL857975,,,,,8,1
1579,11863,,BAO_0000357,,,Binding affinity against 5-hydroxytryptamine 1A receptor,,,D,Expert,B,10090.0,CHEMBL616990,,,,,9,1
1580,11863,,BAO_0000357,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor using radioligand binding assay,,,H,Autocuration,B,,CHEMBL616991,,,,,8,1
1581,11863,,BAO_0000357,,,Tested against 5-hydroxytryptamine 1A receptor,,,H,Autocuration,B,,CHEMBL616992,,,,,8,1
1582,11863,,BAO_0000357,,,The compound's binding affinity against 5-hydroxytryptamine 1A receptor,,,H,Autocuration,B,,CHEMBL616993,,,,,8,1
1583,106,,BAO_0000019,,,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein,,,H,Expert,B,9986.0,CHEMBL616994,,,,,8,1
1584,106,,BAO_0000019,,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein(RbSV); NS=non surmountable,,,H,Autocuration,B,9986.0,CHEMBL616995,,,,,8,1
1585,105571,,BAO_0000219,722.0,HEK293,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1B receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,,,D,Intermediate,B,9593.0,CHEMBL616996,,,,,9,1
1586,106,In vivo,BAO_0000218,,,5-HT1B agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,,,H,Autocuration,F,10141.0,CHEMBL616997,,,,,8,1
1587,106,In vivo,BAO_0000218,,,5-hydroxytryptamine 1B receptor agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,,,H,Autocuration,F,10141.0,CHEMBL616998,,,,,8,1
1588,106,,BAO_0000019,,,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery,,,H,Autocuration,F,10141.0,CHEMBL616999,,,,,8,1
1589,106,,BAO_0000019,,,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery; n.d. indicates Not determined,,,H,Autocuration,F,10141.0,CHEMBL617000,,,,,8,1
1590,106,,BAO_0000019,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig,,,H,Autocuration,F,10141.0,CHEMBL617001,,,,,8,1
1591,106,,BAO_0000019,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig; ND means not done,,,H,Autocuration,F,10141.0,CHEMBL858111,,,,,8,1
1592,106,,BAO_0000019,,,Intrinsic activity for Antagonism of 5-hydroxytryptamine 1B receptor-mediated stimulation of [35S]GTP gamma S binding,,,H,Autocuration,F,,CHEMBL617002,,,,,8,1
1593,106,,BAO_0000019,,,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine (5-CT),,,H,Autocuration,F,,CHEMBL617003,,,,,8,1
1594,106,,BAO_0000019,,,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine(5-CT),,,H,Autocuration,F,,CHEMBL617004,,,,,8,1
1595,106,,BAO_0000019,,,Agonist activity at 5-hydroxytryptamine 1B receptor by measuring the inhibition of forskolin-stimulated cAMP formation,,,D,Expert,F,9606.0,CHEMBL617005,,,,,9,1
1596,106,,BAO_0000219,485.0,CHO-K1,Inhibition of forskolin-stimulated c-AMP formation by human 5-hydroxytryptamine 1B receptor expressed in CHO-K1 cells,,,D,Expert,F,9606.0,CHEMBL616623,,,,,9,1
1597,106,,BAO_0000219,449.0,CHO,Effective concentration determined by measuring inhibition of forskolin-stimulated c-AMP formation at 5-hydroxytryptamine 1B receptor stably transfected in CHO cell lines,,,H,Autocuration,F,,CHEMBL616624,,,,,8,1
1598,106,,BAO_0000357,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,,,H,Autocuration,B,,CHEMBL883243,,,,,8,1
1599,106,,BAO_0000019,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; full agonist,,,H,Autocuration,F,,CHEMBL616625,,,,,8,1
1600,106,,BAO_0000219,449.0,CHO,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1B receptor",,,H,Expert,F,,CHEMBL616626,,,,,8,1
1601,106,,BAO_0000219,449.0,CHO,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line,,,H,Autocuration,F,,CHEMBL616627,,,,,8,1
1602,106,,BAO_0000219,449.0,CHO,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Antagonist,,,H,Autocuration,F,,CHEMBL616628,,,,,8,1
1603,106,,BAO_0000219,449.0,CHO,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Full Agonist,,,H,Autocuration,F,,CHEMBL616629,,,,,8,1
1604,106,,BAO_0000219,449.0,CHO,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Partial Agonist,,,H,Autocuration,F,,CHEMBL616630,,,,,8,1
1605,106,,BAO_0000019,,,"Efficacy was evaluated relative to human 5-HT1B receptor using [35S]GTP-gamma-S, as radioligand",,,H,Expert,F,,CHEMBL616631,,,,,8,1
1606,106,,BAO_0000019,,,"Efficacy of compound was evaluated relative to human 5-hydroxytryptamine 1B receptor using [35S]GTP-gamma-S, as radioligand",,,H,Autocuration,F,,CHEMBL616632,,,,,8,1
1607,106,,BAO_0000357,,,Percentage Maximal inhibition obtained with 1 uM 5-HT against 5-hydroxytryptamine 1B receptor,,,D,Expert,B,9606.0,CHEMBL616633,,,,,9,1
1608,106,,BAO_0000219,449.0,CHO,Ability to displace [3H]5-HT from recombinant human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells determined in vitro,,,H,Expert,B,,CHEMBL616634,,,,,8,1
1609,106,,BAO_0000357,,,Affinity of compound towards 5-hydroxytryptamine 1B receptor was evaluated using radioligand binding technique,,,H,Autocuration,B,,CHEMBL616635,,,,,8,1
1610,106,,BAO_0000357,,,Binding affinity against 5-hydroxytryptamine 1B receptor,,,D,Expert,B,9606.0,CHEMBL885358,,,,,9,1
1611,106,,BAO_0000219,449.0,CHO,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1B receptor expressed in CHO cells,,,D,Expert,B,9606.0,CHEMBL616636,,,,,9,1
1612,106,,BAO_0000219,449.0,CHO,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells by [3H]5-HT binding displacement.,,,H,Expert,B,,CHEMBL616637,,,,,8,1
1613,106,,BAO_0000357,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1B receptor,,,H,Autocuration,B,,CHEMBL616638,,,,,8,1
1614,106,,BAO_0000219,449.0,CHO,Displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,,,H,Expert,B,,CHEMBL616639,,,,,8,1
1615,106,,BAO_0000219,449.0,CHO,Binding affinity at cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells by [3H]5-HT displacement.,,,H,Expert,B,,CHEMBL616640,,,,,8,1
1616,106,,BAO_0000219,449.0,CHO,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,,,H,Expert,B,,CHEMBL616641,,,,,8,1
1617,106,,BAO_0000219,449.0,CHO,Displacement of [3H]5-HT binding from cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells.,,,H,Expert,B,,CHEMBL616642,,,,,8,1
1618,106,,BAO_0000219,449.0,CHO,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1B receptor expressed in CHO cells,,,H,Expert,B,,CHEMBL616643,,,,,8,1
1619,106,,BAO_0000357,,,In vitro binding affinity against human 5-hydroxytryptamine 1B receptor at a concentration of 100 (nM),,,H,Autocuration,B,,CHEMBL616644,,,,,8,1
1620,106,,BAO_0000357,,,Intrinsic activity for each compound is calculated as a percentage of the 5-hydroxytryptamine 1B receptor response,,,H,Autocuration,B,,CHEMBL616645,,,,,8,1
1621,105,,BAO_0000019,,,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,,H,Autocuration,F,9986.0,CHEMBL616646,,,,,8,1
1622,105,,BAO_0000019,,,Tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,,H,Expert,F,9986.0,CHEMBL616647,,,,,8,1
1623,105,,BAO_0000357,,,Affinity at 5-hydroxytryptamine 1D receptor (For sumatriptan = Ki (nM)-12+/-1.9),,,H,Autocuration,B,,CHEMBL616509,,,,,8,1
1624,105,,BAO_0000357,,,Affinity at 5-hydroxytryptamine 1D receptor from calf caudate using [3H]5-HT as radioligand (For sumatriptan = Ki(nM)-12+/-1.9),,,H,Autocuration,B,,CHEMBL616510,,,,,8,1
1625,105,,BAO_0000357,,,Binding affinity against calf caudate 5-hydroxytryptamine 1D receptor,,,H,Autocuration,B,,CHEMBL616511,,,,,8,1
1626,105,,BAO_0000357,,,Inhibitory activity against 5-hydroxytryptamine 1D receptor subtype,,,H,Expert,B,9913.0,CHEMBL616512,,,,,8,1
1627,105,,BAO_0000357,,,Inhibitory concentration required against 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT,,,H,Autocuration,B,9913.0,CHEMBL616513,,,,,8,1
1628,105,,BAO_0000019,,,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,,,H,Autocuration,B,9913.0,CHEMBL616514,,2435.0,Striatum,,8,1
1629,105,,BAO_0000357,,,Ability to bind to 5-hydroxytryptamine 1D receptor of calf substantia nigra,,,H,Expert,B,9913.0,CHEMBL616515,,,,,8,1
1630,105,,BAO_0000019,,,Binding affinity against 5-hydroxytryptamine 1D receptor in calf caudate homogenates.,,,H,Autocuration,B,9913.0,CHEMBL616516,,,,,8,1
1631,105,,BAO_0000357,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,,,H,Autocuration,B,9913.0,CHEMBL616517,,,,,8,1
1632,105,,BAO_0000357,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,,,H,Autocuration,B,9913.0,CHEMBL616518,,,,,8,1
1633,105,,BAO_0000357,,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,,,H,Autocuration,B,9913.0,CHEMBL616519,,,,,8,1
1634,105,,BAO_0000357,,,Inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,,,H,Autocuration,B,9913.0,CHEMBL616520,,,,,8,1
1635,105,,BAO_0000357,,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand,,,H,Autocuration,B,9913.0,CHEMBL616521,,,,,8,1
1636,105,,BAO_0000357,,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand; NT means not tested,,,H,Autocuration,B,9913.0,CHEMBL616522,,,,,8,1
1637,105,,BAO_0000357,,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,,,H,Autocuration,B,9913.0,CHEMBL884531,,,,,8,1
1638,105,,BAO_0000357,,,Binding affinity towards 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand,,,H,Autocuration,B,9913.0,CHEMBL616523,,,,,8,1
1639,105,,BAO_0000019,,,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,,,H,Autocuration,B,9913.0,CHEMBL616731,,2435.0,Striatum,,8,1
1640,105,,BAO_0000019,,,Binding affinity was determined against 5-hydroxytryptamine 1D receptor in bovine caudate homogenate,,,H,Autocuration,B,9913.0,CHEMBL616732,,,,,8,1
1641,105,,BAO_0000357,,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT,,,H,Autocuration,B,9913.0,CHEMBL616733,,,,,8,1
1642,105,,BAO_0000357,,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,,,H,Autocuration,B,9913.0,CHEMBL616734,,,,,8,1
1643,105,,BAO_0000249,,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP,,,H,Autocuration,B,9913.0,CHEMBL616735,,,,,8,1
1644,105,,BAO_0000249,,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP; Not determined,,,H,Autocuration,B,9913.0,CHEMBL616736,,,,,8,1
1645,105,,BAO_0000019,,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,,H,Expert,F,9913.0,CHEMBL616737,,,,,8,1
1646,105,,BAO_0000019,,,Affinity pKi for 5-hydroxytryptamine 1D receptor was measured in calf caudate homogenate,,,H,Autocuration,B,9913.0,CHEMBL616738,,,,,8,1
1647,105,,BAO_0000019,,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,,H,Expert,F,9913.0,CHEMBL616739,,,,,8,1
1648,105,,BAO_0000019,,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,,H,Expert,F,9913.0,CHEMBL616740,,,,,8,1
1649,105,,BAO_0000019,,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,,H,Expert,F,9913.0,CHEMBL616741,,,,,8,1
1650,105,,BAO_0000219,722.0,HEK293,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1D receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,,,H,Autocuration,B,9593.0,CHEMBL616742,,,,,8,1
1651,105570,,BAO_0000019,,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra,,,D,Intermediate,B,10141.0,CHEMBL616743,,,,,9,1
1652,105570,,BAO_0000019,,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra; NT means not tested,,,D,Intermediate,B,10141.0,CHEMBL616744,,,,,9,1
1653,105570,,BAO_0000019,,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptor by the agonist GR-46611,,,D,Intermediate,F,10141.0,CHEMBL616745,,,,,9,1
1654,105570,,BAO_0000019,,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,,D,Intermediate,F,10141.0,CHEMBL616746,,,,,9,1
1655,105570,,BAO_0000019,,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611; range is 2-9,,,D,Intermediate,F,10141.0,CHEMBL616747,,,,,9,1
1656,105570,,BAO_0000019,,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-0.4,,,D,Intermediate,F,10141.0,CHEMBL616748,,,,,9,1
1657,105570,,BAO_0000019,,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-1.2,,,D,Intermediate,F,10141.0,CHEMBL616648,,,,,9,1
1658,105570,,BAO_0000357,,,Binding affinity against 5-hydroxytryptamine 1D receptor,,,D,Intermediate,B,10141.0,CHEMBL616649,,,,,9,1
1659,105570,,BAO_0000357,,,Binding affinity towards guinea pig 5-hydroxytryptamine 1D receptor was determined,,,D,Intermediate,B,10141.0,CHEMBL616650,,,,,9,1
1660,105570,,BAO_0000218,,,Compound at 3 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,,D,Intermediate,F,10141.0,CHEMBL616651,,,,,9,1
1661,105570,,BAO_0000218,,,Compound at 45 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,,D,Intermediate,F,10141.0,CHEMBL616652,,,,,9,1
1662,105570,,BAO_0000218,,,Compound at 50 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,,D,Intermediate,F,10141.0,CHEMBL616653,,,,,9,1
1663,105570,,BAO_0000218,,,Compound at oral dose of 45 mg/kg was tested for percent inhibition against 5-hydroxytryptamine 1D receptor causes hypothermia in guinea pig,,,D,Intermediate,F,10141.0,CHEMBL616654,,,,,9,1
1664,105570,,BAO_0000019,,,Binding affinity of 5-hydroxytryptamine 1D receptor using [3H]-8-HT in guinea pig cortex,,,D,Intermediate,B,10141.0,CHEMBL616655,,,,,9,1
1665,105570,,BAO_0000357,,,Binding affinity against guinea pig 5-hydroxytryptamine 1D receptor,,,D,Intermediate,B,10141.0,CHEMBL616656,,,,,9,1
1666,105,,BAO_0000019,,,Binding affinity was determined against 5-hydroxytryptamine 4 receptor using [125I]SB 207710 as radioligand from piglet hippocampal membranes,,,H,Autocuration,B,10141.0,CHEMBL616657,,,,,8,1
1667,105570,,BAO_0000357,,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor in guinea-pig striatum in presence of BMY-7378 and mesulergine,,,D,Intermediate,B,10141.0,CHEMBL616658,,2435.0,Striatum,,9,1
1668,105570,,BAO_0000357,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of guinea pig substantia nigra,,,D,Intermediate,B,10141.0,CHEMBL616659,,,,,9,1
1669,51,,BAO_0000357,,,Binding affinity against 5-hydroxytryptamine 1D receptor,,,H,Autocuration,B,,CHEMBL616660,,,,,8,1
1670,106,,BAO_0000357,,,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta,,,H,Autocuration,B,,CHEMBL616661,,,,,8,1
1671,105,,BAO_0000019,,,Maximum stimulation of [35S]GTP gamma-S binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor,,,H,Expert,F,,CHEMBL616662,,,,,8,1
1672,105,,BAO_0000019,,,Ability to inhibit forskolin-stimulated adenylate cyclase in a cell line expressing human 5-hydroxytryptamine 1D receptor,,,H,Autocuration,F,,CHEMBL616663,,,,,8,1
1673,105,,BAO_0000019,,,Ability to inhibit forskolin-stimulated adenylate cyclase activity in Chinese hamster ovary (CHO) stable cell lines expressing human 5-hydroxytryptamine 1D receptor,,,H,Autocuration,F,,CHEMBL616664,,,,,8,1
1674,105,,BAO_0000219,449.0,CHO,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing 5-hydroxytryptamine 1D receptor",,,D,Expert,F,9606.0,CHEMBL881820,,,,,9,1
1675,105,,BAO_0000219,449.0,CHO,"Compound was evaluated for the stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor.",,,H,Autocuration,F,,CHEMBL616665,,,,,8,1
1676,105,,BAO_0000219,449.0,CHO,Agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,,,H,Expert,B,,CHEMBL616666,,,,,8,1
1677,105,,BAO_0000219,449.0,CHO,Compound was tested for measuring agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor,,,H,Autocuration,B,,CHEMBL616667,,,,,8,1
1678,105,,BAO_0000219,449.0,CHO,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",,,H,Expert,F,,CHEMBL616668,,,,,8,1
1679,105,,BAO_0000219,449.0,CHO,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",,,D,Expert,F,9606.0,CHEMBL616669,,,,,9,1
1680,105,,BAO_0000219,449.0,CHO,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the human 5-hydroxytryptamine 1D receptor.",,,H,Expert,F,,CHEMBL617040,,,,,8,1
1681,105,,BAO_0000219,449.0,CHO,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor",,,H,Autocuration,F,,CHEMBL617041,,,,,8,1
1682,105,,BAO_0000219,449.0,CHO,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor.",,,H,Expert,F,,CHEMBL617042,,,,,8,1
1683,105,,BAO_0000219,449.0,CHO,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor",,,H,Expert,F,,CHEMBL617043,,,,,8,1
1684,105,,BAO_0000019,,,Compound was evaluated for its agonistic activity on 5-hydroxytryptamine 1D receptor,,,H,Autocuration,F,,CHEMBL617044,,,,,8,1
1685,105,,BAO_0000219,449.0,CHO,Measurement of agonist-induced [35S]-GTP gamma-S binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,,,H,Expert,F,,CHEMBL617045,,,,,8,1
1686,105,,BAO_0000219,449.0,CHO,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",,,D,Expert,F,9606.0,CHEMBL617046,,,,,9,1
1687,105,,BAO_0000219,449.0,CHO,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",,,D,Expert,F,9606.0,CHEMBL617047,,,,,9,1
1688,105,,BAO_0000019,,,"Efficacy was evaluated relative to human 5-hydroxytryptamine 1D receptor using [35S]GTP-gamma-S, as radioligand",,,H,Expert,F,,CHEMBL617048,,,,,8,1
1689,105,,BAO_0000019,,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor.",,,H,Autocuration,F,,CHEMBL616897,,,,,8,1
1690,105,,BAO_0000019,,,"Maximum stimulation of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1D receptor relative to 5-HT",,,D,Expert,F,9606.0,CHEMBL616898,,,,,9,1
1691,105,,BAO_0000219,449.0,CHO,Percent efficacy relative to 5-HT treatment of CHO cells expressing 5-HT 1d receptor,,,D,Expert,F,9606.0,CHEMBL858201,,,,,9,1
1692,105,,BAO_0000019,,,Intrinsic activity for 5-hydroxytryptamine 1D receptor,,,H,Autocuration,F,,CHEMBL616899,,,,,8,1
1693,105,In vitro,BAO_0000219,,,Ability to displace [3H]- -5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in chinese hamster cells (CHO cells),,,H,Autocuration,B,,CHEMBL616900,,,,,8,1
1694,105,,BAO_0000219,449.0,CHO,Ability to displace [3H]-5-HT from recombinant human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells determined in vitro,,,H,Expert,B,,CHEMBL616901,,,,,8,1
1695,105,,BAO_0000357,,,Affinity of compound towards 5-hydroxytryptamine 1D receptor was evaluated using radioligand binding technique,,,H,Autocuration,B,,CHEMBL616902,,,,,8,1
1696,105,,BAO_0000219,449.0,CHO,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,,D,Expert,B,9606.0,CHEMBL616903,,,,,9,1
1697,105,,BAO_0000219,449.0,CHO,Binding affinity by displacement to human cloned 5-hydroxytryptamine 1D receptor in CHO cells by [3H]5-HT displacement.,,,H,Expert,B,,CHEMBL616904,,,,,8,1
1698,105,,BAO_0000357,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1D receptor,,,H,Autocuration,B,,CHEMBL616905,,,,,8,1
1699,105,,BAO_0000219,449.0,CHO,Binding affinity at human cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells by [3H]5-HT displacement.,,,H,Expert,B,,CHEMBL616906,,,,,8,1
1700,105,,BAO_0000219,449.0,CHO,Displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,,H,Expert,B,,CHEMBL616907,,,,,8,1
1701,105,,BAO_0000219,449.0,CHO,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,,H,Expert,B,,CHEMBL616908,,,,,8,1
1702,105,,BAO_0000219,449.0,CHO,Displacement of [3H]5-HT binding from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,,D,Expert,B,9606.0,CHEMBL616909,,,,,9,1
1703,105,,BAO_0000219,449.0,CHO,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,,D,Expert,B,9606.0,CHEMBL616910,,,,,9,1
1704,105,,BAO_0000219,449.0,CHO,Displacement of [3H]5-HT binding to the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,,H,Expert,B,,CHEMBL616911,,,,,8,1
1705,105,,BAO_0000219,449.0,CHO,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,,H,Expert,B,,CHEMBL616912,,,,,8,1
1706,105,,BAO_0000357,,,In vitro binding affinity against human 5-hydroxytryptamine 1D receptor at a concentration of 100 (nM),,,H,Autocuration,B,,CHEMBL616913,,,,,8,1
1707,105,,BAO_0000219,449.0,CHO,Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 1D receptor expressed in CHO cells at 1 uM,,,D,Expert,B,9606.0,CHEMBL616914,,,,,9,1
1708,105,,BAO_0000219,449.0,CHO,Binding affinity against 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,,,H,Autocuration,B,,CHEMBL616915,,,,,8,1
1709,105,,BAO_0000019,,,Binding affinity for 5-hydroxytryptamine 1D receptor in Cos-7 transfected cell type using [3H]5-CT as radioligand,,,H,Autocuration,B,,CHEMBL616916,,,,,8,1
1710,105,,BAO_0000357,,,Binding affinity to cloned human 5-hydroxytryptamine 1D receptor,,,D,Expert,B,9606.0,CHEMBL616917,,,,,9,1
1711,105,,BAO_0000357,,,"Binding affinity towards 5-HT1D receptor, using [3H]5-HT as radioligand.",,,H,Autocuration,B,,CHEMBL616918,,,,,8,1
1712,105,,BAO_0000219,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,,,H,Expert,B,,CHEMBL616919,,,,,8,1
1713,105,,BAO_0000357,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor was determined using [3H]5-HT as radioligand,,,H,Autocuration,B,,CHEMBL616920,,,,,8,1
1714,105,,BAO_0000357,,,Binding affinity for recombinant human 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand.,,,H,Autocuration,B,,CHEMBL872914,,,,,8,1
1715,105,,BAO_0000357,,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1D receptor using [3H]-5-CT as radioligand,,,H,Autocuration,B,,CHEMBL616921,,,,,8,1
1716,105,,BAO_0000357,,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1D receptor,,,H,Expert,B,,CHEMBL616922,,,,,8,1
1717,105,,BAO_0000357,,,Binding affinity towards 5-hydroxytryptamine 1D receptor,,,H,Autocuration,B,,CHEMBL616923,,,,,8,1
1718,105,,BAO_0000357,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,,,H,Expert,B,,CHEMBL616924,,,,,8,1
1719,105,,BAO_0000357,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand,,,H,Expert,B,,CHEMBL875909,,,,,8,1
1720,105,,BAO_0000357,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; Not determined,,,H,Autocuration,B,,CHEMBL616925,,,,,8,1
1721,105,,BAO_0000357,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; not determined,,,H,Autocuration,B,,CHEMBL616926,,,,,8,1
1722,105,,BAO_0000357,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1D receptor,,,H,Autocuration,B,,CHEMBL616927,,,,,8,1
1723,105,,BAO_0000219,485.0,CHO-K1,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1D receptor in CHO-K1 cells,,,H,Expert,F,,CHEMBL616928,,,,,8,1
1724,105,In vitro,BAO_0000219,,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in Chinese hamster ovary cells (CHO cells),,,D,Expert,B,9606.0,CHEMBL616929,,,,,9,1
1725,105,,BAO_0000357,,,In vitro binding affinity to human 5-hydroxytryptamine 1D receptor,,,D,Expert,B,9606.0,CHEMBL616930,,,,,9,1
1726,105,,BAO_0000019,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,,,H,Expert,B,,CHEMBL616931,,,,,8,1
1727,105,,BAO_0000357,,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,,,H,Autocuration,B,,CHEMBL616932,,,,,8,1
1728,105,,BAO_0000357,,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor,,,H,Expert,B,,CHEMBL616933,,,,,8,1
1729,105,,BAO_0000219,,,Receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor in Cos-7 cells,,,D,Expert,B,9606.0,CHEMBL616934,,,,,9,1
1730,105,,BAO_0000357,,,Binding affinity for human 5-hydroxytryptamine 1D receptor,,,D,Expert,B,9606.0,CHEMBL616935,,,,,9,1
1731,105,,BAO_0000357,,,The binding affinity towards the 5-hydroxytryptamine 1D receptor; No affinity,,,H,Autocuration,B,,CHEMBL616936,,,,,8,1
1732,105,,BAO_0000357,,,Affinity for 5-hydroxytryptamine 1D receptor subtype,,,D,Expert,B,9606.0,CHEMBL616937,,,,,9,1
1733,105,,BAO_0000357,,,Binding affinity for human 5-hydroxytryptamine 1D receptor,,,D,Expert,B,9606.0,CHEMBL616938,,,,,9,1
1734,105,,BAO_0000019,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,,,H,Autocuration,B,,CHEMBL616939,,,,,8,1
1735,105,,BAO_0000019,,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor; ND means not determined,,,H,Expert,B,,CHEMBL616940,,,,,8,1
1736,105,,BAO_0000357,,,Binding activity against human 5-hydroxytryptamine 1D receptor; NT means not tested,,,D,Expert,B,9606.0,CHEMBL616941,,,,,9,1
1737,105,,BAO_0000219,485.0,CHO-K1,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; Not tested,,,H,Autocuration,B,,CHEMBL616942,,,,,8,1
1738,105,,BAO_0000219,485.0,CHO-K1,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; not tested,,,H,Autocuration,B,,CHEMBL616943,,,,,8,1
1739,104802,,BAO_0000219,449.0,CHO,Selectivity towards 5-HT1D and to that of 5-HT1B in CHO cells,,,H,Autocuration,B,,CHEMBL616944,,,,,4,1
1740,105,,BAO_0000019,,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by the 5-HT",,,H,Autocuration,F,,CHEMBL616945,,,,,8,1
1741,105,,BAO_0000357,,,Binding activity radioligand.,,,H,Autocuration,B,,CHEMBL616946,,,,,8,1
1742,105,,BAO_0000019,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,,H,Autocuration,B,,CHEMBL616947,,,,,8,1
1743,105,,BAO_0000219,485.0,CHO-K1,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor,,,H,Expert,B,,CHEMBL616948,,,,,8,1
1744,105,,BAO_0000357,,,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,,,H,Autocuration,B,,CHEMBL616851,,,,,8,1
1745,105,,BAO_0000357,,,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,,,H,Autocuration,B,,CHEMBL616852,,,,,8,1
1746,105,,BAO_0000357,,,Measured as -log Ka on 5-hydroxytryptamine 1D receptor,,,H,Autocuration,B,,CHEMBL616853,,,,,8,1
1747,105,,BAO_0000357,,,Binding activity against human 5-hydroxytryptamine 1D receptor,,,D,Expert,B,9606.0,CHEMBL616854,,,,,9,1
1748,105,,BAO_0000219,449.0,CHO,Binding affinity to human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,,,D,Expert,B,9606.0,CHEMBL616855,,,,,9,1
1749,105,,BAO_0000219,449.0,CHO,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]-5-HT as radioligand.,,,H,Autocuration,B,,CHEMBL616856,,,,,8,1
1750,105,,BAO_0000219,449.0,CHO,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,,H,Autocuration,B,,CHEMBL616857,,,,,8,1
1751,105,,BAO_0000357,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,,,H,Autocuration,B,,CHEMBL616858,,,,,8,1
1752,105,,BAO_0000219,449.0,CHO,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand.,,,H,Autocuration,B,,CHEMBL616859,,,,,8,1
1753,105,,BAO_0000219,449.0,CHO,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]-5-HT as radioligand.;ND means no data.,,,H,Autocuration,B,,CHEMBL616860,,,,,8,1
1754,105,,BAO_0000219,722.0,HEK293,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,,,H,Autocuration,B,,CHEMBL616861,,,,,8,1
1755,105,,BAO_0000219,722.0,HEK293,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,,,H,Autocuration,B,,CHEMBL616541,,,,,8,1
1756,105,,BAO_0000219,722.0,HEK293,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand; Not determined,,,H,Autocuration,B,,CHEMBL616542,,,,,8,1
1757,105,,BAO_0000219,449.0,CHO,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as the radioligand,,,H,Autocuration,B,,CHEMBL616543,,,,,8,1
1758,105,,BAO_0000357,,,Binding affinity for human 5-hydroxytryptamine 1D receptor,,,D,Expert,B,9606.0,CHEMBL616544,,,,,9,1
1759,105,,BAO_0000219,449.0,CHO,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT,,,H,Autocuration,B,,CHEMBL616545,,,,,8,1
1760,105,,BAO_0000357,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1D receptor in CHO using [3H]5-HT as a radioligand,,,H,Autocuration,B,,CHEMBL616546,,,,,8,1
1761,105,,BAO_0000219,449.0,CHO,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT.,,,H,Autocuration,B,,CHEMBL616547,,,,,8,1
1762,105,,BAO_0000219,449.0,CHO,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells, using [3H]5-HT as radioligand",,,H,Autocuration,B,,CHEMBL616548,,,,,8,1
1763,105,,BAO_0000019,,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 1 uM,,,H,Expert,F,,CHEMBL616549,,,,,8,1
1764,105,,BAO_0000019,,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 10 uM,,,H,Expert,F,,CHEMBL616550,,,,,8,1
1765,108,,BAO_0000357,,,Binding affinity against 5-HT2C receptor,,,H,Autocuration,B,,CHEMBL857066,,,,,8,1
1766,108,,BAO_0000357,,,Binding affinity against 5-hydroxytryptamine 1D receptor,,,H,Autocuration,B,,CHEMBL616551,,,,,8,1
1767,10577,,BAO_0000357,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,,,H,Autocuration,B,,CHEMBL616552,,,,,8,1
1768,10577,,BAO_0000019,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,,,H,Autocuration,F,,CHEMBL832876,,,,,8,1
1769,10577,,BAO_0000019,,,"Binding affinity for 5-hydroxytryptamine 1B receptor in rat cortex, striatum and globus pallidus",,,H,Expert,B,,CHEMBL616553,,,,,8,1
1770,10577,,BAO_0000357,,,Binding affinity towards 5-HT1B was determined,,,H,Autocuration,B,,CHEMBL616554,,,,,8,1
1771,10577,,BAO_0000019,,,Affinity towards 5-hydroxytryptamine 1B receptor in membranes from rat frontal cortex using [3H]5-HT,,,H,Expert,B,,CHEMBL616555,,,,,8,1
1772,10577,,BAO_0000019,,,"Binding affinity to 5-HT1B receptors using rat cortex+striatum + globus pallidus,[3H]-5-OH-tryptamine, and serotonin for NSB",,,H,Expert,B,,CHEMBL616556,,,,,8,1
1773,10577,,BAO_0000019,,,"Compound was evaluated for binding affinity on 5-HT1B receptors using rat cortex+striatum+ globus pallidus,[ 3H]-5-OH-tryptamine, and serotonin for NSB.",,,H,Autocuration,B,,CHEMBL616557,,,,,8,1
1774,10577,,BAO_0000019,,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,,H,Expert,B,,CHEMBL616558,,,,,8,1
1775,10577,,BAO_0000019,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT,,,D,Expert,B,10116.0,CHEMBL616749,,,,,9,1
1776,10577,,BAO_0000357,,,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,,,H,Autocuration,B,,CHEMBL616750,,,,,8,1
1777,10577,,BAO_0000357,,,"Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol, binds to 5-hydroxytryptamine 1B receptor at 1 uM",,,H,Autocuration,B,,CHEMBL616751,,,,,8,1
1778,10577,,BAO_0000249,,,In vitro inhibitory concentration against radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,,,H,Autocuration,B,,CHEMBL616752,,,,,8,1
1779,10577,,BAO_0000019,,,Inhibition of [3H]-5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Residual radioligand binding higher than 50%,,,H,Autocuration,B,,CHEMBL616753,,2435.0,Striatum,,8,1
1780,10577,,BAO_0000357,,,Inhibition of radiolabeled [3H]-5-HT ligand binding to 5-hydroxytryptamine 1B receptor,,,D,Expert,B,10116.0,CHEMBL616754,,,,,9,1
1781,10577,,BAO_0000019,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT as the radioligand.,,,H,Autocuration,B,,CHEMBL616755,,,,,8,1
1782,10577,,BAO_0000019,,,Inhibitory activity against [3H]5-HT binding to 5-HT1B receptor in rat striatum,,,H,Autocuration,B,,CHEMBL616756,,2435.0,Striatum,,8,1
1783,10577,,BAO_0000019,,,Inhibitory concentration required against 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT,,,H,Autocuration,B,,CHEMBL616757,,2435.0,Striatum,,8,1
1784,10577,,BAO_0000357,,,compound was measured for affinity against 5-hydroxytryptamine 1B receptor labelled with [3H]5-HT radioligand in striatum tissue,,,H,Autocuration,B,,CHEMBL616758,,2435.0,Striatum,,8,1
1785,10577,,BAO_0000249,,,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,,,H,Autocuration,B,,CHEMBL616759,,,,,8,1
1786,10577,,BAO_0000357,,,In vitro binding affinity towards the 5-hydroxytryptamine 1B receptor at 10 e-6 M,,,H,Autocuration,B,,CHEMBL616760,,,,,8,1
1787,10577,,BAO_0000019,,,Ability to displace [3H]5-HT bound to 5-hydroxytryptamine 1B receptor in rat striatum,,,H,Autocuration,B,,CHEMBL616761,,2435.0,Striatum,,8,1
1788,10577,,BAO_0000019,,,Binding affinity against 5-HT1B serotonin receptor in rat striatum,,,H,Autocuration,B,,CHEMBL616762,,2435.0,Striatum,,8,1
1789,10577,,BAO_0000019,,,Binding affinity against 5-hydroxytryptamine 1B receptor in membranes of Rat cerebral cortex,,,H,Autocuration,B,,CHEMBL616763,,,,,8,1
1790,10577,,BAO_0000357,,,Binding affinity at rat 5-hydroxytryptamine 1B receptor by [3H]5-HT displacement.,,,H,Expert,B,,CHEMBL872909,,,,,8,1
1791,10577,,BAO_0000357,,,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,,,H,Autocuration,B,,CHEMBL616764,,,,,8,1
1792,10577,,BAO_0000357,,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor,,,D,Expert,B,10116.0,CHEMBL616765,,,,,9,1
1793,10577,,BAO_0000357,,,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum,,,H,Autocuration,B,,CHEMBL616766,,2435.0,Striatum,,8,1
1794,10577,,BAO_0000357,,,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum.,,,H,Autocuration,B,,CHEMBL616767,,2435.0,Striatum,,8,1
1795,10577,,BAO_0000357,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,,,H,Autocuration,B,,CHEMBL616768,,,,,8,1
1796,10577,,BAO_0000357,,,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,,,H,Autocuration,B,,CHEMBL616769,,,,,8,1
1797,10577,,BAO_0000019,,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat was determined using 50 uL of [125I]ICYP in binding assay,,,H,Autocuration,B,,CHEMBL616770,,,,,8,1
1798,10577,,BAO_0000019,,,Binding affinity was determined against 5-hydroxytryptamine 1B receptor was determined in male Sprague-Dawley rat brain.,,,H,Autocuration,B,,CHEMBL616771,,,,,8,1
1799,10577,,BAO_0000019,,,Binding affinity was measured on 5-hydroxytryptamine 1B receptor in rat striatum labeled with [3H]5-HT,,,H,Autocuration,B,,CHEMBL616772,,2435.0,Striatum,,8,1
1800,10577,,BAO_0000019,,,Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.,,,H,Expert,B,,CHEMBL616773,,,,,8,1
1801,10577,,BAO_0000019,,,Compound was evaluated for the binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand; ND is no data.,,,H,Autocuration,B,,CHEMBL616774,,,,,8,1
1802,10577,,BAO_0000357,,,Evaluated for binding affinity towards 5-hydroxytryptamine 1B receptor,,,H,Autocuration,B,,CHEMBL616775,,,,,8,1
1803,10577,,BAO_0000249,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor in rat cortical membranes using [3H]5-HT as a radioligand,,,H,Autocuration,B,,CHEMBL616776,,,,,8,1
1804,10577,,BAO_0000357,,,The binding affinity was measured on 5-hydroxytryptamine 1B receptor using [3H]- serotonin as radioligand.,,,H,Autocuration,B,,CHEMBL616777,,,,,8,1
1805,10577,,BAO_0000357,,,The binding affinity towards the receptor rat 5-hydroxytryptamine 1B receptor; No affinity,,,H,Autocuration,B,,CHEMBL616778,,,,,8,1
1806,10577,,BAO_0000249,,,Binding affinity against 5-hydroxytryptamine 1B receptor in rat striatal membranes using [3H]5-HT as radioligand,,,D,Expert,B,10116.0,CHEMBL616779,,,,,9,1
1807,10577,,BAO_0000357,,,Binding affinity towards 5-hydroxytryptamine 1B receptor,,,D,Expert,B,10116.0,CHEMBL616780,,,,,9,1
1808,10577,,BAO_0000019,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1B receptor by displacing [3H]serotonin radioligand in rat cerebral cortex,,,H,Autocuration,B,,CHEMBL616781,,,,,8,1
1809,10577,,BAO_0000357,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand,,,H,Autocuration,B,,CHEMBL616782,,,,,8,1
1810,10577,,BAO_0000357,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand.,,,H,Autocuration,B,,CHEMBL616783,,,,,8,1
1811,10577,,BAO_0000019,,,Binding affinity for 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT as radioligand,,,H,Expert,B,,CHEMBL616784,,2435.0,Striatum,,8,1
1812,10577,,BAO_0000357,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand; Nonactive at 10 uM,,,H,Autocuration,B,,CHEMBL616785,,,,,8,1
1813,10577,,BAO_0000249,,,Binding affinity against 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,,H,Autocuration,B,,CHEMBL857067,,955.0,Brain,,8,1
1814,10577,,BAO_0000019,,,Binding affinity against 5-HT1B receptor in rat frontal cortex using [3H]-5-HT in presence of 0.1 uM [3H]-8-OH-DPAT as a radioligand,,,H,Autocuration,B,,CHEMBL616786,,,,,8,1
1815,10577,,BAO_0000249,,,Binding affinity towards 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,,H,Autocuration,B,,CHEMBL616787,,955.0,Brain,,8,1
1816,10577,,BAO_0000357,,,Binding affinity towards 5-hydroxytryptamine 2C receptor of porcine choroid plexus using [3H]mesulergine,,,H,Autocuration,B,,CHEMBL616788,,,,,8,1
1817,10577,,BAO_0000357,,,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-hydroxytryptamine 1B receptor,,,H,Autocuration,B,,CHEMBL616789,,,,,8,1
1818,10577,,BAO_0000019,,,Displacement of [3H]5-HT from 5-HT1B receptor of rat frontal cortex homogenate,,,D,Expert,B,10116.0,CHEMBL616790,,,,,9,1
1819,10577,,BAO_0000357,,,Binding affinity at 5-hydroxytryptamine 1B receptor,,,H,Expert,B,,CHEMBL616791,,,,,8,1
1820,10577,,BAO_0000019,,,In vitro binding affinity at 5-hydroxytryptamine 1B receptor in rat striatal muscles using [125I](-)-iodocyanopindolol as the radioligand,,,H,Autocuration,B,,CHEMBL616792,,,,,8,1
1821,10577,,BAO_0000249,,,In vitro binding affinity towards 5-hydroxytryptamine 1B receptor in rat striatal membrane with [125I]- iodocyanopindolol,,,D,Expert,B,10116.0,CHEMBL616793,,,,,9,1
1822,10577,,BAO_0000357,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,,,H,Autocuration,B,,CHEMBL616794,,,,,8,1
1823,10577,,BAO_0000357,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,,H,Autocuration,B,,CHEMBL616795,,,,,8,1
1824,104686,,BAO_0000019,,,Binding affinity towards 5-HT2 receptor by the displacement of [3H]-ketanserin] in rat cerebral cortex,,,H,Autocuration,B,,CHEMBL616796,,,,,4,1
1825,106,,BAO_0000357,,,Compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,,,H,Autocuration,B,,CHEMBL616797,,,,,8,1
1826,106,,BAO_0000249,,,The compound was evaluated for its ability to displace [3H]5-HT from 5-hydroxytryptamine 1B receptor in cellular brain membranes,,,H,Autocuration,B,,CHEMBL616798,,,,Brain membranes,8,1
1827,106,,BAO_0000357,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1B receptor at a concentration of 100 nM using [125I]CYP as radioligand,,,H,Autocuration,B,,CHEMBL616799,,,,,8,1
1828,106,,BAO_0000357,,,Inhibition of binding towards 5-hydroxytryptamine 1B receptor at 100 nM concentration,,,H,Autocuration,B,,CHEMBL616800,,,,,8,1
1829,106,,BAO_0000357,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1B receptor,,,H,Autocuration,B,,CHEMBL616801,,,,,8,1
1830,106,,BAO_0000357,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1B receptor; inactive at 10 uM,,,H,Autocuration,B,,CHEMBL616802,,,,,8,1
1831,106,,BAO_0000357,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1B receptor was determined,,,H,Autocuration,B,,CHEMBL616803,,,,,8,1
1832,106,,BAO_0000357,,,Binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]5-HT.,,,H,Expert,B,,CHEMBL857068,,,,,8,1
1833,106,,BAO_0000357,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]ketanserin.,,,H,Autocuration,B,,CHEMBL616804,,,,,8,1
1834,106,,BAO_0000357,,,Binding affinity for 5-hydroxytryptamine 1B receptor was determined,,,H,Autocuration,B,,CHEMBL616805,,,,,8,1
1835,106,,BAO_0000357,,,Evaluated for the binding affinity to 5-hydroxytryptamine 1B receptor,,,H,Autocuration,B,,CHEMBL616806,,,,,8,1
1836,106,,BAO_0000357,,,Binding affinity against 5-hydroxytryptamine 1B receptor,,,H,Autocuration,B,,CHEMBL616807,,,,,8,1
1837,106,,BAO_0000357,,,Binding affinity for 5-hydroxytryptamine 1B receptor was determined by using [3H]5-HT as radioligand,,,H,Autocuration,B,,CHEMBL616808,,,,,8,1
1838,106,,BAO_0000357,,,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,,H,Autocuration,B,,CHEMBL616809,,,,,8,1
1839,106,,BAO_0000357,,,Inhibitory constant against 5-hydroxytryptamine 1B receptor using with [125I]- cyanopindolol radioligand,,,H,Autocuration,B,,CHEMBL616810,,,,,8,1
1840,104802,,BAO_0000224,,,Binding affinity against 5-hydroxytryptamine 1B receptor - 5-hydroxytryptamine 1D receptor using [3H]5-HT as the radioligand.,,,H,Autocuration,B,,CHEMBL616811,,,,,4,1
1841,108,,BAO_0000357,,,Inhibitory concentration required against 5-hydroxytryptamine 1C receptor in bovine choroid plexus using [3H]mesulergine,,,H,Autocuration,B,9913.0,CHEMBL616812,,,,,8,1
1842,108,,BAO_0000357,,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,,,H,Autocuration,B,9823.0,CHEMBL616813,,,,,8,1
1843,108,,BAO_0000357,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1C receptor in pig choroid plexus using [3H]mesulergine as radioligand,,,H,Autocuration,B,9823.0,CHEMBL616814,,,,,8,1
1844,108,,BAO_0000357,,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,,,H,Autocuration,B,9823.0,CHEMBL616815,,,,,8,1
1845,108,,BAO_0000357,,,inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,,,H,Autocuration,B,9823.0,CHEMBL616816,,,,,8,1
1846,108,,BAO_0000357,,,Binding affinity of compound towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine (1.2 nM) ligand in choroid Plexus pig was determined,,,H,Autocuration,B,9823.0,CHEMBL616817,,,,,8,1
1847,108,,BAO_0000357,,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1C receptor,,,H,Autocuration,B,9823.0,CHEMBL616818,,,,,8,1
1848,108,,BAO_0000357,,,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 2C receptor binding site by using [3H]-MES as a radioligand.,,,H,Expert,B,9823.0,CHEMBL616819,,,,,8,1
1849,108,,BAO_0000357,,,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 1C receptor of pig choroid Plexus,,,H,Expert,B,9823.0,CHEMBL616820,,,,,8,1
1850,108,,BAO_0000019,,,Displacement of [3H]mesulergine from pig cortex 5-hydroxytryptamine 1C receptor,,,H,Expert,B,9823.0,CHEMBL616821,,,,,8,1
1851,108,,BAO_0000357,,,Binding affinity for 5-hydroxytryptamine 1C receptor in piglet choroid plexus using [3H]5-HT,,,H,Autocuration,B,9823.0,CHEMBL616822,,,,,8,1
1852,108,,BAO_0000019,,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,,,H,Autocuration,B,9986.0,CHEMBL616823,,,,,8,1
1853,12689,,BAO_0000357,,,Tested for the effect on binding at 5-hydroxytryptamine 1C receptor; No activity,,,D,Autocuration,B,10116.0,CHEMBL616824,,,,,9,1
1854,12689,,BAO_0000357,,,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,,,D,Autocuration,B,10116.0,CHEMBL616825,,,,,9,1
1855,12689,,BAO_0000357,,,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,,,D,Autocuration,B,10116.0,CHEMBL616826,,,,,9,1
1856,12689,,BAO_0000019,,,Binding affinity against 5-hydroxytryptamine 1C receptor in rat using [3H]mesulergine as radioligand,,,D,Expert,B,10116.0,CHEMBL616827,,,,,9,1
1857,12689,,BAO_0000357,,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [125 I]-SCH23982 as radioligand in competitive binding assay,,,D,Autocuration,B,10116.0,CHEMBL616828,,,,,9,1
1858,12689,,BAO_0000357,,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,,,D,Autocuration,B,10116.0,CHEMBL616829,,,,,9,1
1859,12689,,BAO_0000019,,,Binding affinity was determined against 5-hydroxytryptamine 1C receptor was determined in male Sprague-Dawley rat brain.,,,D,Autocuration,B,10116.0,CHEMBL616830,,,,,9,1
1860,12689,,BAO_0000357,,,Binding affinity against 5-hydroxytryptamine 1C receptor,,,D,Expert,B,10116.0,CHEMBL616831,,,,,9,1
1861,12689,,BAO_0000019,,,"Compound was tested for binding affinity towards 5-HT1C (5-HT1C) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,,D,Autocuration,B,10116.0,CHEMBL616832,,,,,9,1
1862,12689,,BAO_0000019,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,,D,Autocuration,B,10116.0,CHEMBL616833,,,,,9,1
1863,12689,,BAO_0000019,,,"Binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,,D,Expert,B,10116.0,CHEMBL616834,,,,,9,1
1864,12689,,BAO_0000019,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,,D,Autocuration,B,10116.0,CHEMBL829595,,,,,9,1
1865,12689,,BAO_0000357,,,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 1C receptor binding site by using [3H]- MES as a radioligand.,,,D,Autocuration,B,10116.0,CHEMBL616835,,,,,9,1
1866,12689,,BAO_0000249,,,Inhibitory activity against 5-hydroxytryptamine 1C receptor in rat cortical membranes using [3H]mesulergine as a radioligand,,,D,Autocuration,B,10116.0,CHEMBL872910,,,,,9,1
1867,12689,,BAO_0000357,,,Tested for binding affinity against 5-hydroxytryptamine 1C receptor from rat frontal cortical regions using [3H]mesulergine as radioligand,,,H,Expert,B,,CHEMBL616836,,,,,8,1
1868,12689,,BAO_0000357,,,The binding affinity was measured on 5-hydroxytryptamine 1C receptor using [3H]- serotonin as radioligand.,,,D,Autocuration,B,10116.0,CHEMBL616837,,,,,9,1
1869,12689,,BAO_0000019,,,Binding affinity of 5-hydroxytryptamine 1C receptor using [3H]- ketanserin in rat frontal cortex,,,D,Autocuration,B,10116.0,CHEMBL616466,,,,,9,1
1870,12689,,BAO_0000219,722.0,HEK293,Binding affinity towards rat 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand expressed in 293 cells,,,D,Autocuration,B,10116.0,CHEMBL616467,,,,,9,1
1871,108,,BAO_0000357,,,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,,,H,Autocuration,B,,CHEMBL616468,,,,,8,1
1872,108,,BAO_0000357,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,,,H,Autocuration,B,,CHEMBL616469,,,,,8,1
1873,108,,BAO_0000357,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,,,H,Autocuration,B,,CHEMBL616470,,,,,8,1
1874,12689,,BAO_0000357,,,Binding affinity against 5-hydroxytryptamine 1C receptor,,,H,Autocuration,B,,CHEMBL616471,,,,,8,1
1875,12689,,BAO_0000357,,,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,,,H,Autocuration,B,,CHEMBL616472,,,,,8,1
1876,12689,,BAO_0000357,,,Binding affinity against 5-hydroxytryptamine 1C receptor,,,H,Autocuration,B,,CHEMBL616473,,,,,8,1
1877,12689,,BAO_0000357,,,Binding affinity against serotonergic 5-HT1c receptor,,,H,Autocuration,B,,CHEMBL616474,,,,,8,1
1878,12689,,BAO_0000357,,,Binding affinity for 5-hydroxytryptamine 1C receptor was determined by using [3H]- mesulergine as radioligand,,,H,Autocuration,B,,CHEMBL616475,,,,,8,1
1879,12689,,BAO_0000357,,,Binding affinity for 5-hydroxytryptamine 1C receptor was determined,,,H,Autocuration,B,,CHEMBL616476,,,,,8,1
1880,105,,BAO_0000019,,,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,,H,Autocuration,B,9986.0,CHEMBL616477,,,,,8,1
1881,104686,,BAO_0000224,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [125I]DOI as radioligand.,,,H,Autocuration,B,,CHEMBL616478,,,,,4,1
1882,104686,,BAO_0000224,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ket as radioligand.,,,H,Autocuration,B,,CHEMBL616479,,,,,4,1
1883,104686,,BAO_0000019,,,Binding affinity towards serotonin 5-HT2 receptor was determined in rat cortex using [3H]spiperone as ligand,,,H,Autocuration,B,,CHEMBL616480,,,,,4,1
1884,104686,,BAO_0000019,,,Binding affinity towards 5-hydroxytryptamine 2 receptor as antagonism of serotonin-induced contractions in rat jugular vein,,,D,Autocuration,B,10116.0,CHEMBL616481,,,,,5,1
1885,104686,,BAO_0000249,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain cortical membranes,,,D,Autocuration,B,10116.0,CHEMBL616482,,,,,5,1
1886,104686,,BAO_0000221,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain using [3H]spiroperidol,,,D,Autocuration,B,10116.0,CHEMBL884713,,955.0,Brain,,5,1
1887,104686,,BAO_0000224,,,Binding affinity towards 5-hydroxytryptamine 2 receptor measured using radioligand ([3H]spiperone) binding assay,,,H,Autocuration,B,,CHEMBL616483,,,,,4,1
1888,104686,,BAO_0000224,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- spiroperidol,,,H,Autocuration,B,,CHEMBL616484,,,,,4,1
1889,104686,,BAO_0000019,,,Binding affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenates by [3H]-spiperone displacement.,,,H,Autocuration,B,,CHEMBL616485,,,,,4,1
1890,104686,,BAO_0000224,,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,,H,Autocuration,B,,CHEMBL616486,,,,,4,1
1891,104686,,BAO_0000224,,,Binding affinity towards 5-hydroxytryptamine 2 receptor was measured using radioligand ([3H]spiperone) binding assay,,,H,Autocuration,B,,CHEMBL616487,,,,,4,1
1892,104686,,BAO_0000224,,,Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,,,H,Autocuration,B,,CHEMBL616488,,,,,4,1
1893,104686,,BAO_0000019,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,,H,Autocuration,B,,CHEMBL616489,,,,,4,1
1894,104686,,BAO_0000019,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,,H,Autocuration,B,,CHEMBL616490,,,,,4,1
1895,104686,,BAO_0000019,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]-Ketanserin as radioligand; not determined,,,H,Autocuration,B,,CHEMBL616491,,,,,4,1
1896,104686,,BAO_0000019,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand; ND-Not determined,,,H,Autocuration,B,,CHEMBL616492,,,,,4,1
1897,104686,,BAO_0000019,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,,H,Autocuration,B,,CHEMBL616493,,,,,4,1
1898,104686,,BAO_0000019,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [125I]DOI as radioligand,,,H,Autocuration,B,,CHEMBL616494,,,,,4,1
1899,104686,,BAO_0000019,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [3H]ketanserin as radioligand,,,H,Autocuration,B,,CHEMBL616495,,,,,4,1
1900,104686,,BAO_0000019,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat pre frontal cortex,,,H,Autocuration,B,,CHEMBL616496,,,,,4,1
1901,104686,,BAO_0000019,,,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,,H,Autocuration,B,,CHEMBL616497,,,,,4,1
1902,104686,,BAO_0000019,,,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,,H,Autocuration,B,,CHEMBL616498,,,,,4,1
1903,104686,,BAO_0000019,,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 2 receptor of rat anterior cortex using [3H]ketanserin as the radioligand,,,H,Autocuration,B,,CHEMBL616499,,,,,4,1
1904,104686,,BAO_0000019,,,Compound was measured for affinity at 5-hydroxytryptamine 2 receptor in rat cortical by [3H]spiroperidol displacement.,,,H,Autocuration,B,,CHEMBL616500,,,,,4,1
1905,104686,,BAO_0000221,,,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,,,D,Autocuration,B,10116.0,CHEMBL616501,,955.0,Brain,,5,1
1906,104686,,BAO_0000221,,,Compound was tested for its inhibitory effect on the binding profile in 5-hydroxytryptamine 2 receptor using [3H]spiroperidol in rat brain.,,,H,Autocuration,B,,CHEMBL616502,,955.0,Brain,,4,1
1907,104686,,BAO_0000249,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor from rat cortical membranes.,,,H,Autocuration,B,,CHEMBL884529,,,,Membranes,4,1
1908,104686,,BAO_0000249,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,,,H,Autocuration,B,,CHEMBL616503,,,,Membranes,4,1
1909,104686,,BAO_0000224,,,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor,,,H,Autocuration,B,,CHEMBL616964,,,,,4,1
1910,104686,,BAO_0000249,,,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor from rat cortical membranes.,,,H,Autocuration,B,,CHEMBL616965,,,,Membranes,4,1
1911,104686,,BAO_0000224,,,Inhibition of [3H]ketanserin binding to rat 5-hydroxytryptamine 2 receptors.,,,H,Autocuration,B,,CHEMBL616966,,,,,4,1
1912,104686,,BAO_0000224,,,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor; NT=Not tested,,,H,Autocuration,B,,CHEMBL616967,,,,,4,1
1913,104686,,BAO_0000224,,,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor,,,D,Autocuration,B,10116.0,CHEMBL616968,,,,,5,1
1914,104686,,BAO_0000224,,,Compound was tested for the inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor; NT=Not tested,,,H,Autocuration,B,,CHEMBL616969,,,,,4,1
1915,104686,,BAO_0000019,,,Inhibition of [3H]ketanserin binding at 5-hydroxytryptamine 2 receptor from rat frontal cortex.,,,H,Autocuration,B,,CHEMBL884530,,,,,4,1
1916,104686,,BAO_0000224,,,Concentration necessary to achieve half maximal inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor,,,H,Autocuration,B,,CHEMBL616970,,,,,4,1
1917,104686,,BAO_0000224,,,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,,,H,Autocuration,B,,CHEMBL616971,,,,,4,1
1918,104686,,BAO_0000224,,,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",,,H,Autocuration,B,,CHEMBL616972,,,,,4,1
1919,104686,,BAO_0000224,,,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]-spiperone,,,H,Autocuration,B,,CHEMBL616973,,,,,4,1
1920,104686,,BAO_0000224,,,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]spiperone; IA=Inactive,,,H,Autocuration,B,,CHEMBL616974,,,,,4,1
1921,104686,,BAO_0000019,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.,,,H,Autocuration,B,,CHEMBL616975,,,,,4,1
1922,104686,,BAO_0000019,,,Inhibition of binding of radioligand [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cerebral cortex,,,H,Autocuration,B,,CHEMBL616976,,,,,4,1
1923,104686,,BAO_0000224,,,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand.,,,H,Autocuration,B,,CHEMBL616977,,,,,4,1
1924,104686,,BAO_0000224,,,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,,,H,Autocuration,B,,CHEMBL616978,,,,,4,1
1925,104686,,BAO_0000224,,,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 2 receptor by displacement of [3H]- ketanserin,,,H,Autocuration,B,,CHEMBL616979,,,,,4,1
1926,104686,,BAO_0000224,,,In vitro inhibitory activity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor,,,H,Autocuration,B,,CHEMBL616980,,,,,4,1
1927,104686,,BAO_0000249,,,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes,,,H,Autocuration,B,,CHEMBL616981,,,,Membranes,4,1
1928,104686,,BAO_0000249,,,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes; Not tested,,,H,Autocuration,B,,CHEMBL616982,,,,Membranes,4,1
1929,104686,,BAO_0000224,,,Inhibitory activity against 5-hydroxytryptamine 2 receptor by 3H ligand binding experiments.,,,H,Autocuration,B,,CHEMBL616983,,,,,4,1
1930,104686,,BAO_0000019,,,Inhibitory activity against [3H]spiroperidol binding to 5-HT2 receptor in rat cortex,,,H,Autocuration,B,,CHEMBL616984,,,,,4,1
1931,104686,,BAO_0000224,,,Inhibitory activity against 5-hydroxytryptamine 2 receptor,,,D,Autocuration,B,10116.0,CHEMBL616985,,,,,5,1
1932,104686,,BAO_0000224,,,Inhibitory concentration against 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,,,H,Autocuration,B,,CHEMBL616986,,,,,4,1
1933,104686,,BAO_0000224,,,Inhibitory concentration against binding of 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,,,H,Autocuration,B,,CHEMBL616987,,,,,4,1
1934,104686,,BAO_0000019,,,Inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat,,,H,Autocuration,B,,CHEMBL616988,,,,,4,1
1935,104686,,BAO_0000019,,,Inhibitory concentration against radioligand [3H]spiperone binding to 5-hydroxytryptamine 2 receptor in rat cortex,,,H,Autocuration,B,,CHEMBL617243,,,,,4,1
1936,104686,,BAO_0000019,,,Inhibitory concentration required against 5-hydroxytryptamine 2 receptor in rat cortex using [3H]spiperone,,,H,Autocuration,B,,CHEMBL617244,,,,,4,1
1937,104686,,BAO_0000219,485.0,CHO-K1,Inhibitory concentration against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,,,D,Autocuration,B,10116.0,CHEMBL617245,,,,,5,1
1938,104686,,BAO_0000249,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,,,H,Autocuration,B,,CHEMBL617246,,,,Membranes,4,1
1939,104686,,BAO_0000224,,,The compound was evaluated for the ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor ( striata of male wistar rats),,,H,Autocuration,B,,CHEMBL617546,,,,,4,1
1940,104686,,BAO_0000249,,,The concentration required to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat brain membranes (in vitro),,,H,Autocuration,B,,CHEMBL617547,,,,Brain membranes,4,1
1941,104686,In vitro,BAO_0000219,,,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,,H,Autocuration,B,,CHEMBL617548,,,,,4,1
1942,104686,,BAO_0000224,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,,,H,Autocuration,B,,CHEMBL617549,,,,,4,1
1943,104686,,BAO_0000224,,,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,,,H,Autocuration,B,,CHEMBL617550,,,,,4,1
1944,104686,,BAO_0000224,,,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,,,H,Autocuration,B,,CHEMBL617551,,,,,4,1
1945,104686,,BAO_0000249,,,Percent inhibition of binding of 1.0 nM [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e -5 M,,,H,Autocuration,B,,CHEMBL617552,,,,Membranes,4,1
1946,104686,,BAO_0000249,,,Percent inhibition of binding of 1.0 nM [3H]-ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e-5 M.,,,H,Autocuration,B,,CHEMBL617553,,,,Membranes,4,1
1947,104686,,BAO_0000019,,,Tested for antagonistic activity against 5-hydroxytryptamine 2 receptor from rat thoracic aorta,,,H,Autocuration,F,,CHEMBL617554,,1515.0,Thoracic aorta,,4,1
1948,104686,,BAO_0000019,,,Binding affinity for membrane-bound 5-hydroxytryptamine 2 receptor,,,H,Autocuration,B,,CHEMBL617555,,,,,4,1
1949,104686,,BAO_0000224,,,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,,,H,Autocuration,B,,CHEMBL617556,,,,,4,1
1950,10624,,BAO_0000357,,,Inhibitory constant against human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,,,H,Autocuration,B,,CHEMBL617557,,,,,8,1
1951,10624,,BAO_0000357,,,Inhibitory constant against human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,,,H,Autocuration,B,,CHEMBL617558,,,,,8,1
1952,17106,,BAO_0000357,,,Binding affinity against 5-hydroxytryptamine 1D receptor was measured using [3H]5-HT as radioligand,,,H,Expert,B,,CHEMBL617559,,,,,8,1
1953,17106,,BAO_0000357,,,Binding affinity for 5-hydroxytryptamine 1D receptor,,,D,Expert,B,,CHEMBL617560,,,,,9,1
1954,17106,,BAO_0000249,,,Compound was tested for its ability to displace [125I]GTI binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,,H,Autocuration,B,,CHEMBL617561,,,,,8,1
1955,17106,,BAO_0000249,,,Compound was tested for its ability to displace [3H]-5-HT binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,,H,Autocuration,B,,CHEMBL617562,,,,,8,1
1956,17106,,BAO_0000357,,,Binding affinity against 5-hydroxytryptamine 1D receptor using [3H]5-HT in pig striatum + frontalCortex,,,H,Autocuration,B,,CHEMBL617563,,2435.0,Striatum,,8,1
1957,17106,,BAO_0000019,,,Relative agonist efficacy against 1 uM 5-hydroxytryptamine 1D receptor,,,H,Autocuration,F,,CHEMBL617564,,,,,8,1
1958,17106,,BAO_0000019,,,Binding activity against 5-hydroxytryptamine 1D receptor from pig caudate membrane using [3H]5-HT as radioligand,,,H,Expert,B,,CHEMBL617565,,,,,8,1
1959,17106,,BAO_0000357,,,Binding activity radioligand.,,,H,Autocuration,B,,CHEMBL856076,,,,,8,1
1960,17106,,BAO_0000019,,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,,H,Autocuration,B,,CHEMBL617566,,,,,8,1
1961,17106,,BAO_0000019,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,,H,Expert,B,,CHEMBL875911,,,,,8,1
1962,17106,,BAO_0000019,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,,,H,Autocuration,B,,CHEMBL617567,,,,,8,1
1963,17106,,BAO_0000249,,,Compound was tested for the displacement of [3H]-5-HT to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,,H,Autocuration,B,,CHEMBL617568,,,,,8,1
1964,17106,,BAO_0000019,,,Displacement of [3H]5-HT binding to 5-hydroxytryptamine 1D receptor from pig caudate membrane,,,H,Expert,B,,CHEMBL617569,,,,,8,1
1965,17106,,BAO_0000249,,,Displacement of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1D receptor in pig caudate membrane,,,H,Expert,B,,CHEMBL617570,,,,,8,1
1966,17106,,BAO_0000357,,,Binding affinity for 5-hydroxytryptamine 1D receptor in piglet caudate using [3H]5-HT,,,H,Autocuration,B,,CHEMBL617571,,,,,8,1
1967,105,,BAO_0000357,,,In Vitro Binding affinity againist 5-hydroxytryptamine 1D receptor by displacing [125I]GTI from pig caudate,,,H,Autocuration,B,9823.0,CHEMBL617572,,,,,8,1
1968,105,,BAO_0000357,,,The compound was tested for intrinsic activity against 5-HT1D receptor,,,H,Expert,B,9986.0,CHEMBL617573,,,,,8,1
1969,105,,BAO_0000019,,,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,,H,Autocuration,B,9986.0,CHEMBL617574,,,,,8,1
1970,105,,BAO_0000357,,,The compound was tested for binding affinity against 5-HT1D receptor,,,H,Expert,B,9986.0,CHEMBL617575,,,,,8,1
1971,10578,,BAO_0000357,,,Tested for the effect on binding at 5-hydroxytryptamine 1D receptor; No activity,,,H,Autocuration,B,,CHEMBL617576,,,,,8,1
1972,10578,,BAO_0000019,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of rat substantia nigra,,,H,Autocuration,F,,CHEMBL617577,,,,,8,1
1973,10578,,BAO_0000019,,,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor,,,H,Autocuration,F,,CHEMBL617578,,,,,8,1
1974,10578,,BAO_0000357,,,Binding affinity was measured against serotonin 5-hydroxytryptamine 1D receptor,,,H,Autocuration,B,,CHEMBL617579,,,,,8,1
1975,10578,,BAO_0000019,,,Binding affinity towards 5-hydroxytryptamine 1D receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,,H,Expert,B,,CHEMBL617580,,,,,8,1
1976,10578,,BAO_0000249,,,Inhibitory activity against 5-hydroxytryptamine 1D receptor in rat cortical membranes using [3H]5-HT as a radioligand,,,H,Autocuration,B,,CHEMBL617581,,,,,8,1
1977,10578,,BAO_0000357,,,The binding affinity was measured on 5-hydroxytryptamine 1D receptor using [3H]- serotonin as radioligand.,,,H,Autocuration,B,,CHEMBL617582,,,,,8,1
1978,10578,,BAO_0000019,,,Binding affinity to 5-hydroxytryptamine 1D receptor in the rat forebrain by [3H]- SB-204269 displacement.,,,H,Expert,B,,CHEMBL617583,,,,,8,1
1979,105,,BAO_0000357,,,Inhibition of binding towards 5-hydroxytryptamine 1D receptor at 100 nM concentration,,,H,Autocuration,B,,CHEMBL617584,,,,,8,1
1980,105,,BAO_0000357,,,Compound was tested for binding affinity against 5-hydroxytryptamine 1D receptor,,,H,Autocuration,B,,CHEMBL617585,,,,,8,1
1981,105,,BAO_0000357,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1D receptor at a concentration of 10 uM using [3H]5-HT as radioligand,,,H,Autocuration,B,,CHEMBL875912,,,,,8,1
1982,105,,BAO_0000357,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1D receptor,,,H,Autocuration,B,,CHEMBL617586,,,,,8,1
1983,105,,BAO_0000357,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1D receptor; inactive at 10 uM,,,H,Autocuration,B,,CHEMBL617587,,,,,8,1
1984,105,,BAO_0000357,,,Binding affinity for 5-hydroxytryptamine 1D receptor was determined,,,H,Autocuration,B,,CHEMBL617588,,,,,8,1
1985,105,,BAO_0000357,,,Evaluated for the binding affinity against 5-hydroxytryptamine 1D receptor,,,H,Autocuration,B,,CHEMBL857980,,,,,8,1
1986,105,,BAO_0000357,,,Tested against 5-hydroxytryptamine 1D receptor,,,H,Autocuration,B,,CHEMBL617589,,,,,8,1
1987,105,,BAO_0000357,,,Binding affinity for 5-hydroxytryptamine 1D receptor was determined by using [3H]5-HT as radioligand,,,H,Autocuration,B,,CHEMBL617590,,,,,8,1
1988,105,,BAO_0000219,722.0,HEK293,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,,,H,Autocuration,B,,CHEMBL617591,,,,,8,1
1989,105,,BAO_0000357,,,Binding affinity against 5-Hydroxytryptamine 1D receptor,,,D,Expert,B,9606.0,CHEMBL617592,,,,,9,1
1990,105,,BAO_0000357,,,,,,H,Autocuration,B,,CHEMBL617593,,,,,8,1
1991,106,,BAO_0000219,485.0,CHO-K1,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,,H,Autocuration,B,,CHEMBL617594,,,,,8,1
1992,105,,BAO_0000219,485.0,CHO-K1,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,,H,Autocuration,B,,CHEMBL617595,,,,,8,1
1993,105,,BAO_0000219,722.0,HEK293,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line.,,,H,Autocuration,B,,CHEMBL617596,,,,,8,1
1994,105,,BAO_0000219,722.0,HEK293,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,,,H,Autocuration,B,,CHEMBL617597,,,,,8,1
1995,105,,BAO_0000019,,,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,,,H,Autocuration,B,,CHEMBL617598,,,,,8,1
1996,105,,BAO_0000357,,,Binding affinity of compound against 5-HT1Dalpha Binding affinity of compound against 5-HT1D alpha receptors in human,,,H,Autocuration,B,,CHEMBL872916,,,,,8,1
1997,105,,BAO_0000357,,,In vitro affinity human cloned 5-hydroxytryptamine 1D receptor alpha by [3H]5-HT displacement.,,,H,Expert,B,,CHEMBL617599,,,,,8,1
1998,105,,BAO_0000357,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor alpha was determined,,,H,Autocuration,B,,CHEMBL617091,,,,,8,1
1999,105,,BAO_0000219,485.0,CHO-K1,"Binding affinity against 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells, using [3H]-5-HT as the radioligand.",,,H,Expert,B,,CHEMBL617092,,,,,8,1
2000,105,,BAO_0000219,485.0,CHO-K1,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,,H,Autocuration,B,,CHEMBL617093,,,,,8,1
2001,105,,BAO_0000019,,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor alpha measured as the reduction of forskolin-stimulated cAMP.,,,H,Autocuration,F,,CHEMBL617094,,,,,8,1
2002,105,,BAO_0000019,,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,,H,Autocuration,F,,CHEMBL617095,,,,,8,1
2003,105,,BAO_0000019,,,Compound was tested for its agonist activity against human 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,,H,Autocuration,F,,CHEMBL617096,,,,,8,1
2004,105,,BAO_0000019,,,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,,H,Autocuration,F,,CHEMBL617097,,,,,8,1
2005,105,,BAO_0000019,,,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,,H,Autocuration,F,,CHEMBL617098,,,,,8,1
2006,105,,BAO_0000357,,,In vitro binding affinity towards 5-HT1D alpha receptor by using [3H]5-HT as radioligand,,,H,Autocuration,B,,CHEMBL617301,,,,,8,1
2007,105,,BAO_0000357,,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]5-HT as radioligand,,,H,Autocuration,B,,CHEMBL617302,,,,,8,1
2008,105,,BAO_0000357,,,Selectivity towards 5-hydroxytryptamine 1D receptor beta to that of 5-hydroxytryptamine 1D receptor alpha,,,H,Autocuration,B,,CHEMBL617303,,,,,8,1
2009,105,,BAO_0000357,,,Binding affinity to recombinant human 5-hydroxytryptamine 1D receptor alpha,,,H,Expert,B,,CHEMBL617304,,,,,8,1
2010,105,,BAO_0000219,449.0,CHO,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor alpha expressed in CHO cells, by using [3H]5-HT as radioligand",,,H,Expert,B,,CHEMBL617305,,,,,8,1
2011,105,,BAO_0000219,,,Binding affinity was measured on 5-hydroxytryptamine 1D receptor alpha in COS cells transfected with human 5-HT1D alpha gene labeled with [3H]5-HT,,,D,Autocuration,B,9606.0,CHEMBL617306,,,,,9,1
2012,17106,,BAO_0000357,,,Binding affinity (in vitro) against 5-hydroxytryptamine 1D receptor alpha using radio-ligand binding assay,,,H,Autocuration,B,,CHEMBL617307,,,,,8,1
2013,105,,BAO_0000019,,,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,,,H,Autocuration,B,9986.0,CHEMBL617308,,,,,8,1
2014,105,,BAO_0000357,,,Binding affinities against 5-hydroxytryptamine 1D receptor alpha,,,H,Autocuration,B,,CHEMBL617309,,,,,8,1
2015,105,,BAO_0000357,,,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,,,H,Autocuration,B,,CHEMBL617310,,,,,8,1
2016,105,,BAO_0000357,,,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,,,H,Autocuration,B,,CHEMBL617311,,,,,8,1
2017,105,,BAO_0000357,,,Binding affinity towards 5-hydroxytryptamine 1D receptor alpha using [3H]8-OH-DPAT as radioligand,,,H,Autocuration,B,,CHEMBL617312,,,,,8,1
2018,105,,BAO_0000357,,,Affinity against 5-hydroxytryptamine 1D receptor alpha,,,H,Autocuration,B,,CHEMBL617313,,,,,8,1
2019,105,,BAO_0000357,,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha,,,H,Expert,B,,CHEMBL617314,,,,,8,1
2020,106,,BAO_0000019,,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,,H,Autocuration,F,,CHEMBL617315,,,,,8,1
2021,106,,BAO_0000219,722.0,HEK293,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line.,,,H,Autocuration,B,,CHEMBL617316,,,,,8,1
2022,106,,BAO_0000219,722.0,HEK293,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,,,H,Autocuration,B,,CHEMBL617317,,,,,8,1
2023,106,,BAO_0000219,449.0,CHO,"The compound was tested in vitro for binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",,,H,Autocuration,B,,CHEMBL617318,,,,,8,1
2024,106,,BAO_0000019,,,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,,,H,Autocuration,B,,CHEMBL617319,,,,,8,1
2025,106,,BAO_0000357,,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,,D,Expert,B,,CHEMBL617320,,,,,9,1
2026,106,,BAO_0000357,,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,,D,Expert,B,,CHEMBL617321,,,,,9,1
2027,106,,BAO_0000357,,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,,D,Expert,B,,CHEMBL617322,,,,,9,1
2028,106,,BAO_0000357,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined using [3H]8-OH-DPAT as radioligand,,,H,Autocuration,B,,CHEMBL616862,,,,,8,1
2029,106,,BAO_0000357,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor was determined using [3H]8-OH-DPAT as radioligand,,,H,Autocuration,B,,CHEMBL616863,,,,,8,1
2030,106,,BAO_0000219,449.0,CHO,Binding affinity was measured on 5-hydroxytryptamine 1D receptor beta in CHO cells transfected with human 5-HT1D beta gene labeled with [3H]5-HT,,,H,Autocuration,B,,CHEMBL616864,,,,,8,1
2031,106,,BAO_0000219,485.0,CHO-K1,Compound was tested for binding affinity against cloned human 5-HT1D beta receptor expressed in CHO-K1 cells.,,,H,Autocuration,B,,CHEMBL616865,,,,,8,1
2032,106,,BAO_0000219,485.0,CHO-K1,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells.,,,H,Autocuration,B,,CHEMBL616866,,,,,8,1
2033,106,,BAO_0000019,,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,,H,Autocuration,F,,CHEMBL616867,,,,,8,1
2034,106,,BAO_0000219,485.0,CHO-K1,"Binding affinity against 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells, using [3H]5-HT as the radioligand.",,,H,Expert,B,,CHEMBL616868,,,,,8,1
2035,105,,BAO_0000357,,,Binding affinity for cloned human 5-hydroxytryptamine 1D receptor beta,,,H,Expert,B,,CHEMBL616869,,,,,8,1
2036,106,,BAO_0000219,449.0,CHO,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",,,H,Expert,B,,CHEMBL616870,,,,,8,1
2037,105,,BAO_0000219,485.0,CHO-K1,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.24-0.55,,,H,Autocuration,F,,CHEMBL616871,,,,,8,1
2038,105,,BAO_0000219,485.0,CHO-K1,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.6-2.0,,,H,Autocuration,F,,CHEMBL616872,,,,,8,1
2039,105,,BAO_0000219,485.0,CHO-K1,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 2.8-6.5,,,H,Autocuration,F,,CHEMBL616873,,,,,8,1
2040,105,,BAO_0000219,485.0,CHO-K1,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 30-70,,,H,Autocuration,F,,CHEMBL616838,,,,,8,1
2041,105,,BAO_0000357,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined,,,H,Autocuration,B,,CHEMBL616839,,,,,8,1
2042,106,,BAO_0000019,,,Binding affinity against 5-hydroxytryptamine 3 receptor using rabbit saphenous vein assay.,,,H,Autocuration,B,9986.0,CHEMBL616840,,,,,8,1
2043,105,,BAO_0000357,,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]-5-HT as radioligand,,,H,Autocuration,B,,CHEMBL616841,,,,,8,1
2044,105,,BAO_0000357,,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor beta by using [3H]5-HT as radioligand,,,H,Autocuration,B,,CHEMBL616842,,,,,8,1
2045,105,,BAO_0000357,,,Binding affinity against 5-hydroxytryptamine 1D receptor beta,,,H,Expert,B,,CHEMBL857976,,,,,8,1
2046,10618,,BAO_0000219,449.0,CHO,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1E receptor stably expressed in CHO cells,,,H,Autocuration,B,,CHEMBL616843,,,,,8,1
2047,10618,,BAO_0000357,,,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype,,,D,Expert,B,9606.0,CHEMBL616844,,,,,9,1
2048,10618,,BAO_0000357,,,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype; NA denotes data not available,,,H,Autocuration,B,,CHEMBL616845,,,,,8,1
2049,10618,,BAO_0000357,,,Binding affinity to cloned human 5-hydroxytryptamine 1E receptor,,,D,Expert,B,9606.0,CHEMBL616846,,,,,9,1
2050,10618,,BAO_0000357,,,Binding affinity towards human 5-hydroxytryptamine 1E receptor was determined using [3H]5-HT as radioligand,,,H,Autocuration,B,,CHEMBL616847,,,,,8,1
2051,10618,,BAO_0000019,,,Binding affinity was determined against 5-hydroxytryptamine 1E receptor in human cortical homogenate,,,H,Autocuration,B,,CHEMBL616848,,,,,8,1
2052,10618,,BAO_0000357,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1E receptor,,,H,Autocuration,B,,CHEMBL616849,,,,,8,1
2053,10618,,BAO_0000357,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1E receptor,,,H,Autocuration,B,,CHEMBL872911,,,,,8,1
2054,10618,,BAO_0000019,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1E receptor,,,H,Autocuration,B,,CHEMBL616850,,,,,8,1
2055,10618,,BAO_0000219,449.0,CHO,Binding affinity against human 5-hydroxytryptamine 1E receptor expressed in CHO cells,,,D,Expert,B,9606.0,CHEMBL616699,,,,,9,1
2056,10618,,BAO_0000357,,,Binding affinity towards cloned human 5-hydroxytryptamine 1E receptor was determined,,,H,Autocuration,B,,CHEMBL616700,,,,,8,1
2057,10618,,BAO_0000219,449.0,CHO,Binding affinity towards 5-hydroxytryptamine 1E receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,,H,Autocuration,B,,CHEMBL616701,,,,,8,1
2058,10618,,BAO_0000219,449.0,CHO,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand.,,,H,Autocuration,B,,CHEMBL616702,,,,,8,1
2059,10618,,BAO_0000219,449.0,CHO,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand;ND means no data.,,,H,Autocuration,B,,CHEMBL616703,,,,,8,1
2060,10618,,BAO_0000357,,,Binding affinity was determined against 5-hydroxytryptamine 1D receptor,,,H,Autocuration,B,,CHEMBL616704,,,,,8,1
2061,10618,,BAO_0000219,449.0,CHO,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as the radioligand,,,H,Autocuration,B,,CHEMBL616705,,,,,8,1
2062,10618,,BAO_0000357,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1E receptor,,,H,Autocuration,B,,CHEMBL616706,,,,,8,1
2063,10618,,BAO_0000219,449.0,CHO,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]-5-HT,,,H,Autocuration,B,,CHEMBL616707,,,,,8,1
2064,10618,,BAO_0000357,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1E receptor in CHO using [3H]5-HT as a radioligand,,,H,Autocuration,B,,CHEMBL616708,,,,,8,1
2065,10618,,BAO_0000357,,,Tested for binding affinity towards cloned human 5-hydroxytryptamine 1E receptor using [3H]5-HT as radioligand,,,H,Autocuration,B,,CHEMBL616709,,,,,8,1
2066,10618,,BAO_0000219,449.0,CHO,The binding affinity (pKi) measured against 5-hydroxytryptamine 1E receptor (cloned human receptors in CHO cells) using [3H]5-HT1E as radioligand,,,H,Autocuration,B,,CHEMBL616710,,,,,8,1
2067,10618,,BAO_0000219,449.0,CHO,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT.,,,H,Autocuration,B,,CHEMBL616711,,,,,8,1
2068,10618,,BAO_0000219,449.0,CHO,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells, using [3H]5-HT as radioligand",,,H,Autocuration,B,,CHEMBL616712,,,,,8,1
2069,10618,,BAO_0000357,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1E receptor was determined,,,H,Autocuration,B,,CHEMBL616713,,,,,8,1
2070,10618,,BAO_0000357,,,Binding affinity for 5-hydroxytryptamine 1E receptor was determined,,,H,Autocuration,B,,CHEMBL616714,,,,,8,1
2071,10618,,BAO_0000357,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1E receptor,,,H,Autocuration,B,,CHEMBL616715,,,,,8,1
2072,10618,,BAO_0000357,,,Binding affinity towards 5-hydroxytryptamine 1E receptor,,,H,Autocuration,B,,CHEMBL616716,,,,,8,1
2073,279,,BAO_0000019,,,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-HT1F receptor",,,H,Autocuration,F,,CHEMBL616717,,,,,8,1
2074,279,,BAO_0000019,,,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-hydroxytryptamine 1F receptor",,,H,Expert,F,,CHEMBL616718,,,,,8,1
2075,279,,BAO_0000019,,,In vitro effective concentration for inhibition of skolin-stimulated adenylate cyclase in cell line expressing human 5-hydroxytryptamine 1F receptor,,,H,Autocuration,F,,CHEMBL875905,,,,,8,1
2076,279,,BAO_0000019,,,In vitro agonist potency against human 5-hydroxytryptamine 1F receptor,,,H,Autocuration,F,,CHEMBL616719,,,,,8,1
2077,279,,BAO_0000019,,,"Maximum stimulation of of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine 1F receptor",,,H,Expert,F,,CHEMBL616720,,,,,8,1
2078,279,,BAO_0000357,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1F receptor,,,H,Autocuration,B,,CHEMBL616721,,,,,8,1
2079,279,,BAO_0000219,449.0,CHO,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1F receptor stably expressed in CHO cells,,,H,Autocuration,B,,CHEMBL616722,,,,,8,1
2080,279,,BAO_0000357,,,In vitro binding affinity against human 5-hydroxytryptamine 1F receptor at a concentration of 100 (nM),,,H,Autocuration,B,,CHEMBL616723,,,,,8,1
2081,279,,BAO_0000219,449.0,CHO,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT radioligand,,,H,Autocuration,B,,CHEMBL616724,,,,,8,1
2082,279,,BAO_0000357,,,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT radioligand,,,H,Autocuration,B,,CHEMBL616725,,,,,8,1
2083,279,,BAO_0000357,,,Binding affinity towards human 5-hydroxytryptamine 1F receptor,,,H,Autocuration,B,,CHEMBL616726,,,,,8,1
2084,279,,BAO_0000357,,,Binding affinity towards human 5-hydroxytryptamine 1F receptor was determined,,,H,Autocuration,B,,CHEMBL616727,,,,,8,1
2085,279,,BAO_0000357,,,Binding affinity towards human 5-hydroxytryptamine 1F receptor using [3H]-5-HT radioligand,,,H,Autocuration,B,,CHEMBL616728,,,,,8,1
2086,279,,BAO_0000357,,,In vitro binding affinity for human 5-hydroxytryptamine 1F receptor,,,H,Autocuration,B,,CHEMBL616729,,,,,8,1
2087,279,,BAO_0000019,,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1F receptor,,,H,Expert,B,,CHEMBL616730,,,,,8,1
2088,279,,BAO_0000357,,,Binding affinity towards human recombinant 5-hydroxytryptamine 1F receptor,,,H,Autocuration,B,,CHEMBL617125,,,,,8,1
2089,279,,BAO_0000357,,,Binding affinity towards cloned human 5-hydroxytryptamine 1F receptor was determined,,,H,Autocuration,B,,CHEMBL857977,,,,,8,1
2090,279,,BAO_0000219,449.0,CHO,Binding affinity towards 5-hydroxytryptamine 1F receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,,H,Autocuration,B,,CHEMBL617126,,,,,8,1
2091,279,,BAO_0000219,449.0,CHO,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1F receptor in CHO cells using [3H]-5-HT as the radioligand,,,H,Autocuration,B,,CHEMBL617127,,,,,8,1
2092,279,,BAO_0000357,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1F receptor,,,H,Autocuration,B,,CHEMBL617128,,,,,8,1
2093,279,,BAO_0000219,449.0,CHO,Compound was tested for its binding affinity against 5-hydroxytryptamine 1F receptor in human cloned receptors in CHO cells using [3H]5-HT,,,H,Autocuration,B,,CHEMBL617129,,,,,8,1
2094,279,,BAO_0000357,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT as a radioligand,,,H,Autocuration,B,,CHEMBL617130,,,,,8,1
2095,279,,BAO_0000219,449.0,CHO,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT.,,,H,Autocuration,B,,CHEMBL617131,,,,,8,1
2096,279,,BAO_0000219,449.0,CHO,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",,,H,Autocuration,B,,CHEMBL617132,,,,,8,1
2097,279,,BAO_0000219,449.0,CHO,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",,,H,Autocuration,B,,CHEMBL617133,,,,,8,1
2098,279,,BAO_0000357,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1F receptor was determined,,,H,Autocuration,B,,CHEMBL617134,,,,,8,1
2099,279,,BAO_0000357,,,Binding affinity for 5-hydroxytryptamine 1F receptor was determined,,,H,Autocuration,B,,CHEMBL617135,,,,,8,1
2100,279,,BAO_0000357,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1F receptor,,,H,Autocuration,B,,CHEMBL617136,,,,,8,1
2101,104686,,BAO_0000019,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]-ketanserin as radioligand",,,H,Autocuration,B,,CHEMBL617137,,,,,4,1
2102,104686,,BAO_0000019,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",,,H,Autocuration,B,,CHEMBL617138,,,,,4,1
2103,104686,,BAO_0000019,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,,H,Autocuration,B,,CHEMBL617139,,,,,4,1
2104,12687,,BAO_0000019,,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,,,H,Autocuration,B,,CHEMBL617140,,,,,8,1
2105,104686,In vivo,BAO_0000218,,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-HT2 receptor 1 hr after oral administration",,,H,Autocuration,F,,CHEMBL617141,,,,,4,1
2106,104686,,BAO_0000019,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,,H,Autocuration,F,,CHEMBL858112,,,,,4,1
2107,17005,,BAO_0000019,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in calf frontal cortex,,,H,Intermediate,B,,CHEMBL617142,,,,,8,1
2108,22226,,BAO_0000019,,,"Binding affinity to 5-hydroxytryptamine 2 receptor using calf frontal cortex, [3H]- ketanserin, and spiperone for NSB",,,U,Autocuration,B,9913.0,CHEMBL617143,,,,,0,1
2109,22226,,BAO_0000019,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex at 10e-7 M,,,U,Autocuration,B,9913.0,CHEMBL617144,,,,,0,1
2110,22226,,BAO_0000019,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex,,,U,Autocuration,B,9913.0,CHEMBL617145,,,,,0,1
2111,22226,,BAO_0000019,,,Binding affinity of compound towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin (0.8 nM) ligand in frontal cortex bovine was determined,,,U,Autocuration,B,,CHEMBL617146,,,,,0,1
2112,104784,,BAO_0000019,,,Binding affinity for serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin in guinea pig frontal cortex,,,H,Autocuration,B,10141.0,CHEMBL617147,,,,,4,1
2113,104784,,BAO_0000019,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of guinea pig frontal cortex membranes,,,H,Autocuration,B,10141.0,CHEMBL617148,,,,,4,1
2114,104784,,BAO_0000019,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin from guinea pig frontal cortex,,,H,Autocuration,B,10141.0,CHEMBL617149,,,,,4,1
2115,104784,,BAO_0000224,,,Binding affinity towards cloned human 5-hydroxytryptamine 2 receptor was determined,,,H,Autocuration,B,,CHEMBL617150,,,,,4,1
2116,104784,,BAO_0000224,,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,,H,Autocuration,B,,CHEMBL617151,,,,,4,1
2117,104784,,BAO_0000224,,,In vitro binding affinity of compound against neuronal 5-hydroxytryptamine 2 receptor,,,H,Autocuration,B,,CHEMBL617201,,,,,4,1
2118,10209,,BAO_0000357,,,Binding affinity towards 5-HT7 receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,,,H,Autocuration,B,,CHEMBL617202,,,,,8,1
2119,104826,In vivo,BAO_0000218,,,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,,,H,Autocuration,B,,CHEMBL617203,,,,,4,1
2120,104826,,BAO_0000019,,,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,,,H,Autocuration,B,,CHEMBL617204,,,,,4,1
2121,104826,,BAO_0000224,,,Inhibitory activity against serotonin 5-hydroxytryptamine 2 receptor from mice.,,,H,Autocuration,B,,CHEMBL617205,,,,,4,1
2122,104826,,BAO_0000019,,,Inhibitory activity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in mouse cerebral cortex,,,D,Autocuration,B,10090.0,CHEMBL617206,,,,,5,1
2123,104826,In vivo,BAO_0000218,,,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,,,H,Autocuration,B,,CHEMBL617207,,,,,4,1
2124,104826,,BAO_0000019,,,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]-ketanserin in mouse cerebral cortex,,,D,Autocuration,B,10090.0,CHEMBL617208,,,,,5,1
2125,104826,,BAO_0000224,,,The compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2 receptor,,,H,Autocuration,B,,CHEMBL617209,,,,,4,1
2126,104826,,BAO_0000224,,,In vitro binding affinity for serotonin 5-hydroxytryptamine (5-HT) 2 receptors,,,H,Autocuration,B,,CHEMBL617210,,,,,4,1
2127,104826,,BAO_0000224,,,The compound was tested in vitro for its binding affinity towards serotonin 5-hydroxytryptamine 2 receptor; nd = no data,,,H,Autocuration,B,,CHEMBL617211,,,,,4,1
2128,104826,,BAO_0000019,,,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,,,D,Autocuration,B,10090.0,CHEMBL617212,,,,,5,1
2129,104784,,BAO_0000224,,,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin,,,H,Autocuration,B,9823.0,CHEMBL617213,,,,,4,1
2130,104784,,BAO_0000224,,,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin with 10 uM prazosin,,,H,Autocuration,B,9823.0,CHEMBL617214,,,,,4,1
2131,22226,,BAO_0000221,,,Compound was tested in vitro for its ability to compete with [3H]-ketanserin at 5-hydroxytryptamine 2 receptor in porcine brain homogenate,,,U,Autocuration,B,,CHEMBL617215,,,,,0,1
2132,22226,,BAO_0000221,,,In vitro for its ability to displace [3H]- ketanserin from 5-hydroxytryptamine 2 receptor in porcine brain homogenate,,,U,Autocuration,B,,CHEMBL617216,,,,,0,1
2133,17005,,BAO_0000357,,,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2 receptor,,,H,Autocuration,B,9823.0,CHEMBL617217,,,,,8,1
2134,104686,,BAO_0000019,,,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,,,H,Autocuration,B,,CHEMBL617218,,,,,4,1
2135,104686,,BAO_0000019,,,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,,,H,Autocuration,B,,CHEMBL872913,,,,,4,1
2136,104826,,BAO_0000019,,,Binding affinity against 5-hydroxytryptamine 2 receptor from rat cortical synaptosomal membrane using radioligand [3H]ketanserin.,,,H,Autocuration,B,,CHEMBL617219,,,,,4,1
2137,104686,,BAO_0000224,,,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,,,H,Autocuration,B,,CHEMBL873482,,,,,4,1
2138,104686,,BAO_0000019,,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; ND means no data,,,D,Autocuration,B,10116.0,CHEMBL617220,,,,,5,1
2139,104686,,BAO_0000019,,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein.,,,H,Autocuration,B,,CHEMBL617221,,,,,4,1
2140,104686,,BAO_0000019,,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; no appreciable 5-HT2 receptor affinity,,,H,Autocuration,B,,CHEMBL617222,,,,,4,1
2141,104686,,BAO_0000019,,,Antagonistic activity against (5-hydroxytryptamine 2 receptor) serotonin-induced contractions in the rat jugular vein,,,H,Autocuration,F,,CHEMBL875906,,,,,4,1
2142,104686,,BAO_0000019,,,Binding affinity to the 5-hydroxytryptamine 2 receptor assayed by antagonism of serotonin-induced contractions in the rat jugular vein,,,H,Autocuration,B,,CHEMBL617223,,,,,4,1
2143,104686,,BAO_0000224,,,Binding affinity against serotonin 5-hydroxytryptamine 2 receptor,,,H,Autocuration,B,,CHEMBL617224,,,,,4,1
2144,104686,,BAO_0000224,,,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,,,D,Autocuration,B,10116.0,CHEMBL617225,,,,,5,1
2145,104686,,BAO_0000224,,,Tested for the effect on binding at 5-hydroxytryptamine 2 receptor; No activity,,,H,Autocuration,B,,CHEMBL617226,,,,,4,1
2146,104686,,BAO_0000224,,,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.4 nM dose of [3H]- spiperone as a radioligand.,,,H,Autocuration,B,,CHEMBL617227,,,,,4,1
2147,104686,,BAO_0000224,,,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.6 nM dose of [3H]- spiperone as a radioligand.,,,H,Autocuration,B,,CHEMBL617228,,,,,4,1
2148,104686,,BAO_0000224,,,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,,,H,Autocuration,B,,CHEMBL617229,,,,,4,1
2149,104686,,BAO_0000224,,,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,,,H,Autocuration,B,,CHEMBL617230,,,,,4,1
2150,104686,,BAO_0000224,,,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",,,H,Autocuration,B,,CHEMBL617231,,,,,4,1
2151,104686,,BAO_0000224,,,Compound was tested for the inhibition of quipazine binding at 5-HT2 receptor,,,H,Autocuration,B,,CHEMBL617232,,,,,4,1
2152,104686,,BAO_0000224,,,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor,,,H,Autocuration,B,,CHEMBL617233,,,,,4,1
2153,104686,,BAO_0000224,,,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor; NT=Not tested,,,H,Autocuration,B,,CHEMBL617234,,,,,4,1
2154,104686,,BAO_0000019,,,Compound was tested for the inhibition of quipazine induced head twitches in rats,,,H,Autocuration,F,,CHEMBL617235,,,,,4,1
2155,104686,,BAO_0000019,,,Compound was tested for the inhibition of quipazine induced head twitches in rats; NT=Not tested,,,H,Autocuration,F,,CHEMBL617236,,,,,4,1
2156,104686,,BAO_0000221,,,Ability to bind at 5-hydroxytryptamine 2 receptor of rat hippocampus by displacing [3H]spiperone,,,H,Autocuration,B,,CHEMBL617237,,10000000.0,Hippocampus,,4,1
2157,104686,,BAO_0000221,,,Ability to bind at serotonin 5-hydroxytryptamine 2 receptors of rat hippocampus by displacing [3H]spiperone,,,H,Autocuration,B,,CHEMBL617238,,10000000.0,Hippocampus,,4,1
2158,104686,,BAO_0000221,,,Displacement of [3H]spiroperidol from 5-hydroxytryptamine 2 receptor in rat brain,,,D,Autocuration,B,10116.0,CHEMBL617239,,955.0,Brain,,5,1
2159,104686,,BAO_0000019,,,Ability to inhibit binding of [3H]KET to 5-hydroxytryptamine 2 receptor in rat cortex,,,H,Autocuration,B,,CHEMBL617240,,,,,4,1
2160,104686,,BAO_0000249,,,Ability to inhibit binding of titreated spiperone to 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,,,H,Autocuration,B,,CHEMBL617241,,,,Membranes,4,1
2161,104686,,BAO_0000249,,,Ability to inhibit binding of titreated spiperone to the 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,,,H,Autocuration,B,,CHEMBL875907,,,,Membranes,4,1
2162,104686,,BAO_0000019,,,Affinity for 5-hydroxytryptamine 2 receptor binding sites by its ability to displace [3H]spiperone from rat frontal cortex.,,,H,Autocuration,B,,CHEMBL617242,,,,,4,1
2163,104686,,BAO_0000019,,,Antagonistic activity against 5-hydroxytryptamine 2 receptor on rat frontal cortex membrane.,,,H,Autocuration,F,,CHEMBL617152,,,,,4,1
2164,104686,,BAO_0000221,,,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,,,D,Autocuration,B,10116.0,CHEMBL617153,,955.0,Brain,,5,1
2165,104686,,BAO_0000249,,,Binding affinity at 5-hydroxytryptamine 2 receptor by the inhibition of binding to [3H]ketanserin in rat cortical membranes,,,D,Autocuration,B,10116.0,CHEMBL617154,,,,Membranes,5,1
2166,104686,,BAO_0000221,,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat brain using [3H]ketanserin as radioligand,,,H,Autocuration,B,,CHEMBL617155,,955.0,Brain,,4,1
2167,104686,,BAO_0000019,,,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,,,H,Autocuration,F,,CHEMBL617156,,,,,4,1
2168,104686,,BAO_0000019,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-HT2 receptor in rat thoracic aortic strips,,,H,Autocuration,F,,CHEMBL617157,,,,,4,1
2169,104686,,BAO_0000019,,,In vitro antagonistic activity tested against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,,H,Autocuration,F,,CHEMBL617158,,,,,4,1
2170,104686,,BAO_0000019,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,,,H,Autocuration,F,,CHEMBL617159,,,,,4,1
2171,104686,,BAO_0000019,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,,,H,Autocuration,F,,CHEMBL617160,,,,,4,1
2172,104686,,BAO_0000019,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,,H,Autocuration,F,,CHEMBL858113,,,,,4,1
2173,104686,,BAO_0000220,,,Tested for 5-hydroxytryptamine 2 receptor binding ability by displacement of [3H]spiperone from rat brain frontal cortex synaptosomes,,,H,Autocuration,B,,CHEMBL617247,,955.0,Brain,,4,1
2174,104686,,BAO_0000019,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,,,H,Autocuration,B,,CHEMBL617248,,,,,4,1
2175,104686,,BAO_0000249,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,,H,Autocuration,B,,CHEMBL617249,,955.0,Brain,,4,1
2176,104686,,BAO_0000019,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex,,,H,Autocuration,B,,CHEMBL617250,,,,,4,1
2177,104686,,BAO_0000019,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,,,H,Autocuration,B,,CHEMBL617251,,,,,4,1
2178,104686,,BAO_0000019,,,isplacement of [3H]DOB from rat cortex homogenate 5-hydroxytryptamine 2 receptor,,,D,Autocuration,B,10116.0,CHEMBL617252,,,,,5,1
2179,104686,,BAO_0000019,,,Binding affinity of 5-hydroxytryptamine 2 receptor using [3H]- ketanserin in rat frontal cortex,,,H,Autocuration,B,,CHEMBL617006,,,,,4,1
2180,104686,,BAO_0000019,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat frontal cortex,,,H,Autocuration,B,,CHEMBL617007,,,,,4,1
2181,104686,,BAO_0000019,,,"5-hydroxytryptamine 2 receptor antagonistic activity at concentrations of<br>3,10 and 30 uM on the rat tail artery.",,,H,Autocuration,F,,CHEMBL617008,,,,,4,1
2182,104686,,BAO_0000019,,,Binding affinity for 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- ketanserin,,,H,Autocuration,B,,CHEMBL617009,,,,,4,1
2183,104686,,BAO_0000224,,,Binding affinity against 5-hydroxytryptamine 2 receptor in serotonin-induced contraction of the rat aorta,,,D,Autocuration,B,10116.0,CHEMBL617010,,,,,5,1
2184,104686,,BAO_0000019,,,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,,,D,Autocuration,B,10116.0,CHEMBL857978,,,,,5,1
2185,104686,,BAO_0000019,,,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,,,D,Autocuration,B,10116.0,CHEMBL617011,,,,,5,1
2186,104686,,BAO_0000019,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat frontal cortex homogenate,,,D,Autocuration,B,10116.0,CHEMBL617012,,,,,5,1
2187,104686,,BAO_0000224,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand.,,,H,Autocuration,B,,CHEMBL617013,,,,,4,1
2188,104686,,BAO_0000249,,,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in rat cerebral cortex membrane,,,H,Autocuration,B,,CHEMBL617014,,,,,4,1
2189,104686,,BAO_0000019,,,Compound was evaluated for its ability to displace [3H]ketanserin binding from cloned rat cerebral cortex membranes 5-hydroxytryptamine 2 receptor,,,H,Autocuration,B,,CHEMBL617015,,,,,4,1
2190,104686,,BAO_0000019,,,In vitro binding affinity to 5-hydroxytryptamine 2 receptor of rat cerebral cortex membranes using [3H]ketanserin as the radioligand,,,H,Autocuration,B,,CHEMBL617016,,,,,4,1
2191,104686,,BAO_0000224,,,pKi value for 5-hydroxytryptamine 2 receptor binding site,,,H,Autocuration,B,,CHEMBL617017,,,,,4,1
2192,104686,,BAO_0000221,,,Inhibitory constant (1 uM) was measured on 5-hydroxytryptamine 2 receptor/uptake using [3H]- ketanserin as radioligand in rat brain cortex.,,,H,Autocuration,B,,CHEMBL617018,,955.0,Brain,,4,1
2193,104686,,BAO_0000019,,,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,,,H,Autocuration,F,,CHEMBL617019,,,,,4,1
2194,105075,,BAO_0000019,,,Binding affinity at 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,,H,Autocuration,B,,CHEMBL617020,,,,,4,1
2195,105075,,BAO_0000019,,,Binding affinity at 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,,H,Autocuration,B,,CHEMBL617021,,,,,4,1
2196,105075,,BAO_0000019,,,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,,H,Autocuration,B,,CHEMBL617022,,,,,4,1
2197,105075,,BAO_0000019,,,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,,H,Autocuration,B,,CHEMBL617023,,,,,4,1
2198,105075,,BAO_0000019,,,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,,H,Autocuration,B,,CHEMBL617024,,,,,4,1
2199,105075,,BAO_0000019,,,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,,H,Autocuration,B,,CHEMBL617025,,,,,4,1
2200,105075,,BAO_0000224,,,Hill coefficient of compound was determined,,,H,Autocuration,B,,CHEMBL617026,,,,,4,1
2201,22226,,BAO_0000019,,,Ancillary Binding affinity towards rat 5-hydroxytryptamine 2 receptor,,,U,Autocuration,B,,CHEMBL617027,,,,,0,1
2202,104686,,BAO_0000019,,,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-ketanserin) from 5-hydroxytryptamine 2 receptor of rat cerebral cortex membrane,,,D,Autocuration,B,10116.0,CHEMBL617028,,,,,5,1
2203,12687,,BAO_0000019,,,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand,,,H,Expert,B,,CHEMBL617029,,,,,8,1
2204,12687,,BAO_0000019,,,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand; IA-Inactive,,,H,Expert,B,,CHEMBL875908,,,,,8,1
2205,12687,,BAO_0000357,,,Affinity at 5-hydroxytryptamine 2 receptor (For ketanserin = Ki(nM)= 0.7+/-0.09),,,H,Autocuration,B,,CHEMBL617030,,,,,8,1
2206,12687,,BAO_0000019,,,Affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex using [3H]ketanserin as radioligand (For ketanserin = Ki(nM)=0.7+/-0.09),,,H,Autocuration,B,,CHEMBL617031,,,,,8,1
2207,12687,,BAO_0000019,,,Binding affinity for 5-hydroxytryptamine 2 receptor of rat cortical membrane using [3H]DOB radioligand,,,H,Autocuration,B,,CHEMBL617032,,,,,8,1
2208,104686,,BAO_0000224,,,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 2 receptor using radioligand [3H]ketanserin,,,D,Autocuration,B,10116.0,CHEMBL617033,,,,,5,1
2209,104686,,BAO_0000224,,,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand",,,H,Autocuration,B,,CHEMBL617034,,,,,4,1
2210,104686,,BAO_0000224,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand,,,H,Autocuration,B,,CHEMBL617035,,,,,4,1
2211,104686,,BAO_0000019,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,,H,Autocuration,B,,CHEMBL617036,,,,,4,1
2212,104784,,BAO_0000224,,,Inhibitory concentration against 5-hydroxytryptamine 2 receptor,,,H,Autocuration,B,,CHEMBL617037,,,,,4,1
2213,22226,,BAO_0000219,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2 receptor from mammalian clones expressed in CHO cell membranes using [3H]-ketanserin as radioligand,,,U,Autocuration,B,,CHEMBL617038,,,,,0,1
2214,104784,,BAO_0000219,,,"Binding affinity towards 5-hydroxytryptamine 2 receptor expressed in CHO cell membranes using [3H]ketanserin (60 Ci/mmol, 1 nM)",,,H,Autocuration,B,,CHEMBL617039,,,,,4,1
2215,104784,,BAO_0000224,,,Compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor,,,H,Autocuration,B,,CHEMBL617161,,,,,4,1
2216,104784,,BAO_0000224,,,Compound was tested for inhibitory activity against 5-hydroxytryptamine 2 receptor,,,H,Autocuration,B,,CHEMBL617162,,,,,4,1
2217,104784,,BAO_0000224,,,Compound was tested for its affinity towards 5-hydroxytryptamine 2 receptor,,,H,Autocuration,B,,CHEMBL617163,,,,,4,1
2218,104784,,BAO_0000224,,,Tested for binding affinity for 5-hydroxytryptamine 2 receptor,,,H,Autocuration,B,,CHEMBL617164,,,,,4,1
2219,104784,,BAO_0000249,,,The compound was evaluated for its ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor in cellular brain membranes,,,H,Autocuration,B,,CHEMBL617165,,,,Brain membranes,4,1
2220,104784,,BAO_0000224,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 2 receptor at a concentration of 10 uM using [3H]ketanserin as radioligand,,,H,Autocuration,B,,CHEMBL617166,,,,,4,1
2221,104784,,BAO_0000224,,,Binding affinity towards 5-HT2 receptor,,,H,Autocuration,B,,CHEMBL617167,,,,,4,1
2222,104784,,BAO_0000224,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,,H,Autocuration,B,,CHEMBL872912,,,,,4,1
2223,104784,,BAO_0000224,,,Compound was evaluated for 5-hydroxytryptamine 2 receptor binding,,,H,Autocuration,B,,CHEMBL617168,,,,,4,1
2224,104686,,BAO_0000224,,,In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.,,,H,Autocuration,B,,CHEMBL617169,,,,,4,1
2225,104784,,BAO_0000224,,,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,,,H,Autocuration,B,,CHEMBL617170,,,,,4,1
2226,104784,,BAO_0000224,,,The compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor using ketanserin as radioligand,,,H,Autocuration,B,,CHEMBL617171,,,,,4,1
2227,104784,,BAO_0000224,,,Binding affinity for 5-hydroxytryptamine 2 receptor was determined,,,H,Autocuration,B,,CHEMBL617172,,,,,4,1
2228,104784,,BAO_0000224,,,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,,,H,Autocuration,B,,CHEMBL617173,,,,,4,1
2229,22226,,BAO_0000019,,,In Vitro binding affinity for 5-hydroxytryptamine 2 receptor,,,U,Autocuration,B,,CHEMBL617174,,,,,0,1
2230,104784,,BAO_0000224,,,5-hydroxytryptamine 2 receptor binding affinity,,,H,Autocuration,B,,CHEMBL617175,,,,,4,1
2231,17005,,BAO_0000357,,,Binding affinity against 5-hydroxytryptamine 2 receptor was determined using [ [3H]spiperone radioligand,,,H,Autocuration,B,,CHEMBL617176,,,,,8,1
2232,17005,,BAO_0000357,,,Compound was tested for the binding affinity against 5-hydroxytryptamine 2 receptor by using [3H]ketanserin as radioligand,,,H,Autocuration,B,,CHEMBL617177,,,,,8,1
2233,104784,,BAO_0000224,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,,,H,Autocuration,B,,CHEMBL617178,,,,,4,1
2234,104784,,BAO_0000224,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of central nervous system,,,H,Autocuration,B,,CHEMBL617179,,,,,4,1
2235,104784,,BAO_0000224,,,Ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,,,H,Autocuration,B,,CHEMBL617180,,,,,4,1
2236,17005,,BAO_0000357,,,Inhibitory activity against 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand at 10e-5 M concentration,,,H,Autocuration,B,,CHEMBL617181,,,,,8,1
2237,17005,,BAO_0000357,,,Binding affinity against 5-hydroxytryptamine 2 receptor,,,H,Autocuration,B,,CHEMBL617182,,,,,8,1
2238,17005,,BAO_0000357,,,Binding affinity against 5-hydroxytryptamine 2 receptor,,,H,Autocuration,B,,CHEMBL617183,,,,,8,1
2239,17005,,BAO_0000357,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,,,H,Autocuration,B,,CHEMBL617184,,,,,8,1
2240,17005,,BAO_0000357,,,Binding affinity against serotonergic 5-HT2 receptor,,,H,Autocuration,B,,CHEMBL617185,,,,,8,1
2241,17005,,BAO_0000357,,,Binding affinity for 5-hydroxytryptamine 2 receptor was determined by using [3H]ketanserin as radioligand,,,H,Autocuration,B,,CHEMBL617186,,,,,8,1
2242,17005,,BAO_0000357,,,Compound was evaluated for the binding affinity at 5- HT2 receptor,,,H,Autocuration,B,,CHEMBL617187,,,,,8,1
2243,17005,,BAO_0000357,,,Compound was tested for binding affinity using [3H]ketanserin against 5-hydroxytryptamine 2 receptor,,,H,Autocuration,B,,CHEMBL617188,,,,,8,1
2244,17005,,BAO_0000218,,,In vivo binding affinity was evaluated against 5-hydroxytryptamine 2 receptor,,,H,Autocuration,B,,CHEMBL617189,,,,,8,1
2245,104784,,BAO_0000224,,,Inhibitory activity against cloned human 5-HT2 receptor,,,D,Autocuration,B,9606.0,CHEMBL617190,,,,,5,1
2246,104784,,BAO_0000219,449.0,CHO,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells",,,D,Autocuration,B,9606.0,CHEMBL617191,,,,,5,1
2247,104784,,BAO_0000219,449.0,CHO,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells.",,,D,Autocuration,B,9606.0,CHEMBL617192,,,,,5,1
2248,104784,,BAO_0000219,449.0,CHO,"Tested in vitro for the inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; Inactive",,,D,Autocuration,B,9606.0,CHEMBL617193,,,,,5,1
2249,104784,,BAO_0000219,449.0,CHO,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; not tested",,,D,Autocuration,B,9606.0,CHEMBL617194,,,,,5,1
2250,104784,,BAO_0000224,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,,,H,Autocuration,B,,CHEMBL617195,,,,,4,1
2251,104784,,BAO_0000224,,,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,,,H,Autocuration,B,,CHEMBL881830,,,,,4,1
2252,17005,,BAO_0000357,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,,,H,Autocuration,B,,CHEMBL617196,,,,,8,1
2253,104686,,BAO_0000224,,,Binding affinity towards 5-hydroxytryptamine 2- receptor using [3H]ketanserin as radioligand in competitive binding assay,,,H,Autocuration,B,,CHEMBL617197,,,,,4,1
2254,17005,,BAO_0000357,,,Binding affinity against 5-hydroxytryptamine 2A receptor was measured using [3H]ketanserin as radioligand,,,H,Expert,B,,CHEMBL617198,,,,,8,1
2255,17005,,BAO_0000357,,,Binding affinity towards 5-hydroxytryptamine 2A receptor,,,H,Expert,B,,CHEMBL873476,,,,,8,1
2256,17005,,BAO_0000019,,,Affinity towards 5-hydroxytryptamine 2A receptor in membranes from bovine frontal cortex using [3H]ketanserin,,,H,Expert,B,,CHEMBL617199,,,,,8,1
2257,107,,BAO_0000357,,,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,,,H,Autocuration,B,10141.0,CHEMBL617200,,,,,8,1
2258,51,,BAO_0000357,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,,H,Autocuration,B,,CHEMBL617484,,,,,8,1
2259,107,,BAO_0000357,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,,H,Autocuration,B,,CHEMBL617485,,,,,8,1
2260,51,,BAO_0000357,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,,H,Autocuration,B,,CHEMBL617486,,,,,8,1
2261,107,,BAO_0000357,,,Binding affinity analysed on 5-HT 2A human clone using [3H]ketanserin as radioligand,,,H,Autocuration,B,,CHEMBL858022,,,,,8,1
2262,107,,BAO_0000219,449.0,CHO,Effective concentration against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,,,H,Autocuration,B,,CHEMBL617049,,,,,8,1
2263,107,,BAO_0000219,449.0,CHO,Functional activity against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader,,,D,Expert,F,9606.0,CHEMBL617050,,,,,9,1
2264,107,,BAO_0000219,,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,,,H,Autocuration,F,,CHEMBL617051,,,,,8,1
2265,107,,BAO_0000219,,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line; no data,,,H,Autocuration,F,,CHEMBL617052,,,,,8,1
2266,107,,BAO_0000219,,,Functional antagonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,,,H,Autocuration,F,,CHEMBL617053,,,,,8,1
2267,107,,BAO_0000219,449.0,CHO,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand, expressed as Emax",,,H,Autocuration,B,,CHEMBL617054,,,,,8,1
2268,107,,BAO_0000219,449.0,CHO,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells, expressed as Emax",,,H,Autocuration,B,,CHEMBL617055,,,,,8,1
2269,107,,BAO_0000357,,,Affinity of compound towards human 5-hydroxytryptamine 2A receptor was evaluated using radioligand binding technique,,,H,Autocuration,B,,CHEMBL882924,,,,,8,1
2270,107,,BAO_0000357,,,Inhibition of human 5-hydroxytryptamine 2A receptor,,,D,Expert,B,9606.0,CHEMBL617056,,,,,9,1
2271,107,,BAO_0000219,449.0,CHO,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,,H,Autocuration,B,,CHEMBL617057,,,,,8,1
2272,107,,BAO_0000219,,,Inhibitory concentration against human 5-HT2A receptor in BEK cells,,,H,Expert,B,,CHEMBL617058,,,,,8,1
2273,107,,BAO_0000357,,,In vitro binding affinity against human 5-hydroxytryptamine 2A receptor at a concentration of 100 (nM),,,H,Autocuration,B,,CHEMBL617059,,,,,8,1
2274,107,,BAO_0000219,449.0,CHO,Ability to displace [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor was determined,,,H,Autocuration,B,,CHEMBL617060,,,,,8,1
2275,107,,BAO_0000219,449.0,CHO,Displacement of [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor.,,,H,Expert,B,,CHEMBL617061,,,,,8,1
2276,107,,BAO_0000219,307.0,L929,Ability to displace [125I]R91150 from human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells,,,H,Expert,B,,CHEMBL617062,,,,,8,1
2277,107,,BAO_0000219,449.0,CHO,Ability to displace [3H]ketanserin binding to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,,H,Expert,B,,CHEMBL617063,,,,,8,1
2278,107,,BAO_0000019,,,Agonist activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand,,,H,Autocuration,F,,CHEMBL617064,,,,,8,1
2279,107,,BAO_0000019,,,Agonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,,H,Autocuration,F,,CHEMBL617065,,,,,8,1
2280,107,,BAO_0000219,449.0,CHO,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,,,H,Autocuration,B,,CHEMBL617066,,,,,8,1
2281,107,,BAO_0000219,449.0,CHO,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand; Nd means not done,,,H,Autocuration,B,,CHEMBL617067,,,,,8,1
2282,107,,BAO_0000019,,,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]-Ketanserin radioligand,,,H,Autocuration,F,,CHEMBL617068,,,,,8,1
2283,107,,BAO_0000019,,,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand; Not tested,,,H,Autocuration,F,,CHEMBL617069,,,,,8,1
2284,107,,BAO_0000019,,,Antagonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,,H,Autocuration,F,,CHEMBL617070,,,,,8,1
2285,107,,BAO_0000357,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [125 I]DOI as radioligand,,,H,Autocuration,B,,CHEMBL617071,,,,,8,1
2286,107,,BAO_0000357,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,,H,Autocuration,B,,CHEMBL872915,,,,,8,1
2287,107,,BAO_0000357,,,Binding activity against cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand.,,,H,Autocuration,B,,CHEMBL617072,,,,,8,1
2288,107,,BAO_0000357,,,Binding affinity against 5-hydroxytryptamine 2A receptor in humans,,,H,Autocuration,B,,CHEMBL617073,,,,,8,1
2289,107,,BAO_0000357,,,Binding affinity against the cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand,,,H,Autocuration,B,,CHEMBL617074,,,,,8,1
2290,107,,BAO_0000219,449.0,CHO,Binding affinity for displacement of [3H]ketanserin to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,,H,Expert,B,,CHEMBL617075,,,,,8,1
2291,107,,BAO_0000357,,,Binding affinity of compound to human 5-hydroxytryptamine 2A receptor,,,H,Autocuration,B,,CHEMBL617076,,,,,8,1
2292,107,,BAO_0000019,,,Affinity for human 5-hydroxytryptamine 2A receptor expressed in mammalian cell line,,,D,Expert,B,9606.0,CHEMBL617077,,,,,9,1
2293,107,,BAO_0000357,,,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand.,,,H,Expert,B,,CHEMBL617078,,,,,8,1
2294,107,,BAO_0000357,,,Binding affinity to cloned human 5-hydroxytryptamine 2A receptor,,,D,Expert,B,9606.0,CHEMBL617079,,,,,9,1
2295,107,,BAO_0000357,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,,,H,Autocuration,B,,CHEMBL617080,,,,,8,1
2296,107,,BAO_0000219,449.0,CHO,Binding affinity towards human 5-hydroxytryptamine 2A receptor by the displacement of [3H]ketanserin radioligand from the cloned receptor expressed in CHO cells,,,H,Expert,B,,CHEMBL617081,,,,,8,1
2297,107,,BAO_0000219,,,Binding affinity towards human 5-HT2A receptor in BEK cells,,,H,Expert,B,,CHEMBL617082,,,,,8,1
2298,107,,BAO_0000357,,,Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor,,,H,Autocuration,B,,CHEMBL617083,,,,,8,1
2299,107,,BAO_0000357,,,Binding affinity for recombinant human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,,,H,Autocuration,B,,CHEMBL617084,,,,,8,1
2300,107,,BAO_0000357,,,Binding affinity for human 5-hydroxytryptamine 2A receptor,,,D,Expert,B,9606.0,CHEMBL617085,,,,,9,1
2301,107,,BAO_0000357,,,Binding affinity towards human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,,H,Autocuration,B,,CHEMBL617086,,,,,8,1
2302,107,,BAO_0000219,,,Binding affinity was measured on 5-hydroxytryptamine 2A receptor in GF6 cells transfected with human 5-HT2A gene labeled with [3H]ketanserin,,,H,Autocuration,B,,CHEMBL617087,,,,,8,1
2303,107,,BAO_0000357,,,Compound was tested for the displacement of [125I]-DOI from clone human 5-hydroxytryptamine 2A receptor,,,H,Autocuration,B,,CHEMBL617088,,,,,8,1
2304,107,,BAO_0000357,,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2A receptor,,,H,Autocuration,B,,CHEMBL617089,,,,,8,1
2305,107,,BAO_0000019,,,"Tested on genetically transfected COS7 cell membranes selectively expressing human 5-hydroxytryptamine 2A receptor, using [3H]ketanserin as radioligand",,,H,Expert,B,,CHEMBL617090,,,,,8,1
2306,107,,BAO_0000357,,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in human using [3H]ketanserin as radioligand,,,H,Autocuration,B,,CHEMBL617513,,,,,8,1
2307,107,,BAO_0000219,722.0,HEK293,In vitro binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells was determined using [3H]ketanserin as radioligand,,,H,Autocuration,B,,CHEMBL617514,,,,,8,1
2308,107,,BAO_0000019,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2A receptor,,,H,Autocuration,B,,CHEMBL617515,,,,,8,1
2309,107,,BAO_0000357,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,,H,Autocuration,B,,CHEMBL617516,,,,,8,1
2310,107,,BAO_0000357,,,Inhibitory constant determined against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,,D,Expert,B,9606.0,CHEMBL617517,,,,,9,1
2311,107,,BAO_0000219,449.0,CHO,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in CHO cells,,,D,Expert,B,9606.0,CHEMBL617518,,,,,9,1
2312,107,,BAO_0000357,,,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor,,,H,Autocuration,B,,CHEMBL617519,,,,,8,1
2313,107,,BAO_0000357,,,Displacement of [3H]DOB from human 5-hydroxytryptamine 2A receptor,,,D,Expert,B,9606.0,CHEMBL617520,,,,,9,1
2314,107,,BAO_0000357,,,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]DOB as labeled ligand; binding data not obtained,,,H,Autocuration,B,,CHEMBL617521,,,,,8,1
2315,107,,BAO_0000357,,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor,,,D,Expert,B,9606.0,CHEMBL617522,,,,,9,1
2316,107,,BAO_0000357,,,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand,,,H,Autocuration,B,,CHEMBL617523,,,,,8,1
2317,107,,BAO_0000357,,,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,,H,Autocuration,B,,CHEMBL617524,,,,,8,1
2318,104686,,BAO_0000019,,,Ability to displace 0.75 nM [3H]ketanserin in 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenate,,,H,Autocuration,B,,CHEMBL617525,,,,,4,1
2319,104686,,BAO_0000019,,,Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat,,,D,Autocuration,B,10116.0,CHEMBL617526,,,,,5,1
2320,104686,,BAO_0000224,,,Affinity on 5-hydroxytryptamine 2 receptor labeled by [125I]DOI,,,H,Autocuration,B,,CHEMBL617527,,,,,4,1
2321,104686,,BAO_0000019,,,Affinity towards [3H]- DOB -labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,,,H,Autocuration,B,,CHEMBL617528,,,,,4,1
2322,104686,,BAO_0000019,,,Affinity towards [3H]- ketanserin-labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,,,H,Autocuration,B,,CHEMBL617529,,,,,4,1
2323,104686,,BAO_0000224,,,Inhibition of 5-hydroxytryptamine 2 induced vasoconstriction of rat caudal artery.,,,H,Autocuration,B,,CHEMBL617530,,,,,4,1
2324,104686,,BAO_0000019,,,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,,,H,Autocuration,B,,CHEMBL617531,,,,,4,1
2325,104686,,BAO_0000019,,,Binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortex using [125]-(R)-DOI as radioligand,,,H,Autocuration,B,,CHEMBL617532,,,,,4,1
2326,104686,,BAO_0000019,,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat using [3H]ketanserin as radioligand,,,H,Autocuration,B,,CHEMBL617533,,,,,4,1
2327,104686,,BAO_0000019,,,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,,,H,Autocuration,B,,CHEMBL617534,,,,,4,1
2328,104686,,BAO_0000224,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,,,H,Autocuration,B,,CHEMBL617535,,,,,4,1
2329,104686,,BAO_0000224,,,Binding affinity at rat 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,,,H,Autocuration,B,,CHEMBL617536,,,,,4,1
2330,104686,,BAO_0000224,,,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,,,H,Autocuration,B,,CHEMBL617537,,,,,4,1
2331,104686,,BAO_0000224,,,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,,,H,Autocuration,B,,CHEMBL617538,,,,,4,1
2332,104686,In vitro,BAO_0000219,,,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,,H,Autocuration,B,,CHEMBL617539,,,,,4,1
2333,104686,,BAO_0000224,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,,D,Autocuration,B,10116.0,CHEMBL617540,,,,,5,1
2334,104686,,BAO_0000224,,,Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin,,,D,Autocuration,B,10116.0,CHEMBL617541,,,,,5,1
2335,104686,,BAO_0000224,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 2 receptor,,,H,Autocuration,B,,CHEMBL617542,,,,,4,1
2336,104686,,BAO_0000224,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]DOB as,,,H,Autocuration,B,,CHEMBL617543,,,,,4,1
2337,104686,,BAO_0000219,485.0,CHO-K1,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,,,D,Autocuration,B,10116.0,CHEMBL617544,,,,,5,1
2338,104686,,BAO_0000219,485.0,CHO-K1,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,,,D,Autocuration,B,10116.0,CHEMBL617545,,,,,5,1
2339,104686,,BAO_0000019,,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand,,,D,Autocuration,B,10116.0,CHEMBL617413,,,,,5,1
2340,104686,,BAO_0000019,,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand.,,,H,Autocuration,B,,CHEMBL617414,,,,,4,1
2341,104686,,BAO_0000019,,,Binding affinity to 5-hydroxytryptamine 2 receptor of rat cortical membranes using [3H]- DOB; ND means no data.,,,D,Autocuration,B,10116.0,CHEMBL617415,,,,,5,1
2342,104686,,BAO_0000224,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,,,H,Autocuration,B,,CHEMBL617416,,,,,4,1
2343,104686,,BAO_0000224,,,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,,,H,Autocuration,B,,CHEMBL617417,,,,,4,1
2344,104686,,BAO_0000019,,,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand in rat frontal cortex",,,H,Autocuration,B,,CHEMBL617418,,,,,4,1
2345,104686,,BAO_0000019,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand in rat frontal cortex,,,H,Autocuration,B,,CHEMBL617419,,,,,4,1
2346,104686,,BAO_0000224,,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,,H,Autocuration,B,,CHEMBL617420,,,,,4,1
2347,104686,,BAO_0000224,,,Affinity for 5-hydroxytryptamine 2 receptor,,,D,Autocuration,B,10116.0,CHEMBL617421,,,,,5,1
2348,104686,,BAO_0000224,,,Binding affinity towards serotonin 5-hydroxytryptamine 2 receptor of rat determined using 0.5 nM of [3H]ketanserin in binding assay,,,H,Autocuration,B,,CHEMBL617422,,,,,4,1
2349,104686,,BAO_0000019,,,Binding affinity was determined against 5-hydroxytryptamine 2 receptor from male Sprague-Dawley rat brain.,,,H,Autocuration,B,,CHEMBL617423,,,,,4,1
2350,104686,,BAO_0000019,,,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor from rat tissue homogenate,,,H,Autocuration,B,,CHEMBL617424,,,,,4,1
2351,104686,,BAO_0000019,,,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor rat tissue homogenate,,,H,Autocuration,B,,CHEMBL617425,,,,,4,1
2352,104686,,BAO_0000224,,,Binding constant against 5-hydroxytryptamine 2 receptor (in vitro),,,H,Autocuration,B,,CHEMBL617426,,,,,4,1
2353,104686,In vivo,BAO_0000218,,,Binding constant against 5-hydroxytryptamine 2 receptor (in vivo),,,H,Autocuration,B,,CHEMBL617427,,,,,4,1
2354,104686,,BAO_0000221,,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat brain,,,H,Autocuration,B,,CHEMBL617428,,955.0,Brain,,4,1
2355,104686,,BAO_0000224,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2 receptor from rat,,,H,Autocuration,B,,CHEMBL617429,,,,,4,1
2356,104686,,BAO_0000019,,,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,,,H,Autocuration,B,,CHEMBL617430,,,,,4,1
2357,104686,,BAO_0000019,,,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,,,H,Autocuration,B,,CHEMBL617431,,,,,4,1
2358,104686,,BAO_0000019,,,Compound was evaluated for its ability to displace 0.25 nM [125I](R)-DOI from binding sites in rat frontal cortex.,,,H,Autocuration,B,,CHEMBL617432,,1870.0,Frontal cortex,,4,1
2359,104686,,BAO_0000224,,,Ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,,,H,Autocuration,B,,CHEMBL617433,,,,,4,1
2360,104686,,BAO_0000224,,,Compound was evaluated for its ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,,,H,Autocuration,B,,CHEMBL617434,,,,,4,1
2361,104686,,BAO_0000224,,,Binding affinity against 5-Hydroxy tryptamine 2 (5-hydroxytryptamine 2)receptor,,,D,Autocuration,B,10116.0,CHEMBL617435,,,,,5,1
2362,104686,,BAO_0000019,,,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 2 receptor in rat cortex using [3H]ketanserin radioligand assay,,,H,Autocuration,B,,CHEMBL617436,,,,,4,1
2363,104686,,BAO_0000019,,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat striatum using [3H]-RP62203,,,D,Autocuration,B,10116.0,CHEMBL617437,,2435.0,Striatum,,5,1
2364,104686,,BAO_0000019,,,"Binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",,,H,Autocuration,B,,CHEMBL617438,,,,,4,1
2365,104686,,BAO_0000019,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,,H,Autocuration,B,,CHEMBL617439,,,,,4,1
2366,104686,,BAO_0000224,,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 2 receptor,,,H,Autocuration,B,,CHEMBL617440,,,,,4,1
2367,104686,,BAO_0000224,,,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,,,H,Autocuration,B,,CHEMBL617441,,,,,4,1
2368,104686,,BAO_0000019,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortical membrane homogenates,,,D,Autocuration,B,10116.0,CHEMBL872918,,,,,5,1
2369,104686,,BAO_0000019,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortex,,,D,Autocuration,B,10116.0,CHEMBL617442,,,,,5,1
2370,104686,,BAO_0000019,,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,,,H,Autocuration,B,,CHEMBL617443,,,,,4,1
2371,104686,,BAO_0000019,,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand,,,H,Autocuration,B,,CHEMBL617444,,,,,4,1
2372,104686,,BAO_0000019,,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,,,H,Autocuration,B,,CHEMBL617445,,,,,4,1
2373,104686,,BAO_0000019,,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.,,,H,Autocuration,B,,CHEMBL617446,,,,,4,1
2374,104686,,BAO_0000249,,,Binding affinity to 5-hydroxytryptamine 2 receptor in rat frontal cortical membranes by [3H]- KET displacement.,,,H,Autocuration,B,,CHEMBL617447,,,,,4,1
2375,104686,,BAO_0000019,,,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.;ND is not determined,,,H,Autocuration,B,,CHEMBL617448,,,,,4,1
2376,104686,,BAO_0000019,,,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand;ND means no data,,,H,Autocuration,B,,CHEMBL617449,,,,,4,1
2377,104686,,BAO_0000019,,,In vitro binding affinity at 5-hydroxytryptamine 2 receptor in rat cortical tissue by [3H]spiperone displacement; No data.,,,H,Autocuration,B,,CHEMBL617450,,,,,4,1
2378,104686,,BAO_0000019,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 165 to 263,,,H,Autocuration,B,,CHEMBL617451,,,,,4,1
2379,104686,,BAO_0000019,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 2.4 to 5.3,,,H,Autocuration,B,,CHEMBL617452,,,,,4,1
2380,104686,,BAO_0000019,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue.,,,H,Autocuration,B,,CHEMBL617453,,,,,4,1
2381,104686,,BAO_0000019,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 140 to 980,,,H,Autocuration,B,,CHEMBL617660,,,,,4,1
2382,104686,,BAO_0000019,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 76 to 299,,,H,Autocuration,B,,CHEMBL617661,,,,,4,1
2383,104686,,BAO_0000019,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue; value may range from 12 to 66,,,H,Autocuration,B,,CHEMBL617662,,,,,4,1
2384,104686,,BAO_0000019,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 136 to 220,,,H,Autocuration,B,,CHEMBL872919,,,,,4,1
2385,104686,,BAO_0000019,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 197 to 341,,,H,Autocuration,B,,CHEMBL617663,,,,,4,1
2386,104686,,BAO_0000019,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 23 to 187,,,H,Autocuration,B,,CHEMBL617664,,,,,4,1
2387,104686,,BAO_0000019,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 29 to 132,,,H,Autocuration,B,,CHEMBL617665,,,,,4,1
2388,104686,,BAO_0000019,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 6 to 75,,,H,Autocuration,B,,CHEMBL617666,,,,,4,1
2389,104686,,BAO_0000019,,,In vitro binding affinity on 5-hydroxytryptamine 2 receptor is inhibition of binding of [125I]- I-LSD to P11 cells,,,H,Autocuration,B,,CHEMBL617667,,,,,4,1
2390,104686,,BAO_0000249,,,In vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat striatal membranes by [3H]ketanserin displacement.,,,H,Autocuration,B,,CHEMBL617668,,,,,4,1
2391,104686,,BAO_0000249,,,Inhibitory activity against 5-hydroxytryptamine 2 receptor in rat cortical membranes using [3H]ketanserin as a radioligand,,,H,Autocuration,B,,CHEMBL617669,,,,,4,1
2392,104686,,BAO_0000224,,,Inhibitory activity against rat cortical 5-hydroxytryptamine 2 receptor,,,H,Autocuration,B,,CHEMBL617670,,,,,4,1
2393,104686,,BAO_0000224,,,Inhibitory constant against 5-hydroxytryptamine 2 receptor,,,D,Autocuration,B,10116.0,CHEMBL617671,,,,,5,1
2394,104686,,BAO_0000224,,,Percentage specific displacement of radioligand [3H]-ketanserin from 5-hydroxytryptamine 2 receptor,,,H,Autocuration,B,,CHEMBL617672,,,,,4,1
2395,104686,,BAO_0000019,,,Potency to displace [3H]- Spiperone from 5-hydroxytryptamine 2 receptor in rat striatum,,,H,Autocuration,B,,CHEMBL617673,,,,,4,1
2396,104686,,BAO_0000224,,,Tested for binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortical regions using [3H]ketanserin as radioligand,,,H,Autocuration,B,,CHEMBL617674,,,,,4,1
2397,104686,,BAO_0000019,,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex,,,H,Autocuration,B,,CHEMBL617675,,,,,4,1
2398,104686,,BAO_0000019,,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; NA means Not Active,,,H,Autocuration,B,,CHEMBL617676,,,,,4,1
2399,104686,,BAO_0000019,,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; not determined,,,H,Autocuration,B,,CHEMBL617677,,,,,4,1
2400,104686,,BAO_0000019,,,Displacement of [3H]ketanserin from rat prefrontal cortex 5-hydroxytryptamine 2 receptor,,,D,Autocuration,B,,CHEMBL617678,,,,,5,1
2401,104686,,BAO_0000224,,,Binding affinity to 5-hydroxytryptamine 2 receptor using [3H]ketanserin radioligand assay.,,,H,Autocuration,B,,CHEMBL617679,,,,,4,1
2402,104686,,BAO_0000224,,,Tested for its binding affinity to Tested for its binding affinity to 5-hydroxytryptamine 2 receptor using [3H]-ketanserin radioligand assay using [3H]-ketanserin radioligand assay,,,H,Autocuration,B,,CHEMBL617680,,,,,4,1
2403,104686,,BAO_0000019,,,The ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat whole brain,,,H,Autocuration,B,,CHEMBL617681,,,,,4,1
2404,104686,,BAO_0000221,,,The binding affinity was measured on 5-hydroxytryptamine 2 receptor in rat brain tissue,,,H,Autocuration,B,,CHEMBL617682,,955.0,Brain,,4,1
2405,104686,,BAO_0000224,,,The binding affinity was measured on 5-hydroxytryptamine 2 receptor using [3H]- spiperone as radioligand.,,,H,Autocuration,B,,CHEMBL617683,,,,,4,1
2406,104686,,BAO_0000224,,,Binding affinity at 5-hydroxytryptamine 2 receptor from striata wistar rats by [3H]ketanserin displacement.,,,H,Autocuration,B,,CHEMBL617684,,,,,4,1
2407,104686,,BAO_0000224,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,,,D,Autocuration,B,10116.0,CHEMBL617685,,,,,5,1
2408,104686,,BAO_0000019,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [3H]ketanserin radioligand in rat cerebral cortex,,,H,Autocuration,B,,CHEMBL617686,,,,,4,1
2409,104686,,BAO_0000224,,,The compound was tested in vitro for binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [125]I-LSD radioligand,,,H,Autocuration,B,,CHEMBL617687,,,,,4,1
2410,104686,,BAO_0000224,,,Percentage specific displacement of radioligand [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,,H,Autocuration,B,,CHEMBL617688,,,,,4,1
2411,104686,,BAO_0000019,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,,H,Autocuration,F,,CHEMBL617689,,,,,4,1
2412,104686,,BAO_0000019,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,,H,Autocuration,F,,CHEMBL617690,,,,,4,1
2413,104686,In vivo,BAO_0000218,,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",,,H,Autocuration,F,,CHEMBL617691,,,,,4,1
2414,104686,In vivo,BAO_0000218,,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",,,H,Autocuration,F,,CHEMBL617692,,,,,4,1
2415,104686,In vivo,BAO_0000218,,,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",,,H,Autocuration,F,,CHEMBL617693,,,,,4,1
2416,104686,In vivo,BAO_0000218,,,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",,,H,Autocuration,F,,CHEMBL617694,,,,,4,1
2417,12687,,BAO_0000221,,,Affinity for 5-hydroxytryptamine 2A receptor in rat brain cortex by ability to displace [3H]ketanserin,,,H,Expert,B,,CHEMBL857985,,955.0,Brain,,8,1
2418,12687,,BAO_0000019,,,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,,D,Expert,B,10116.0,CHEMBL617695,,,,,9,1
2419,12687,,BAO_0000019,,,Affinity pKi for 5-hydroxytryptamine 2A receptor was measured in rat cortex homogenates,,,H,Autocuration,B,,CHEMBL617696,,,,,8,1
2420,12687,,BAO_0000357,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor was determined,,,H,Autocuration,B,,CHEMBL617697,,,,,8,1
2421,12687,,BAO_0000019,,,Displacement of [3H]ketanserin from 5-HT2A receptor of rat frontal cortex,,,D,Expert,B,10116.0,CHEMBL617257,,,,,9,1
2422,12687,,BAO_0000357,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,,,D,Expert,B,10116.0,CHEMBL617258,,,,,9,1
2423,12687,,BAO_0000019,,,Binding affinity was evaluated in vitro by displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor on rat cortical membrane,,,H,Expert,B,,CHEMBL617259,,,,,8,1
2424,12687,,BAO_0000357,,,In vitro affinity against serotonin ( 5-hydroxytryptamine 2A receptor ) receptor,,,H,Autocuration,B,,CHEMBL617260,,,,,8,1
2425,12687,,BAO_0000357,,,In vitro affinity against serotonin 5-hydroxytryptamine 2A receptor,,,D,Expert,B,10116.0,CHEMBL617261,,,,,9,1
2426,12687,,BAO_0000019,,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]-ketanserin as radioligand,,,H,Autocuration,B,,CHEMBL617262,,,,,8,1
2427,12687,,BAO_0000019,,,Half-maximal inhibition of [3H]- Ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,,,H,Expert,B,,CHEMBL617263,,,,,8,1
2428,12687,,BAO_0000019,,,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat tissue homogenate,,,H,Autocuration,B,,CHEMBL617264,,,,,8,1
2429,12687,,BAO_0000019,,,Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor,,,D,Expert,B,10116.0,CHEMBL617265,,,,,9,1
2430,12687,,BAO_0000249,,,Inhibition constant for in vitro inhibition of [3H]ketanserin binding to rat frontal cortex membranes 5-hydroxytryptamine 2A receptor,,,H,Autocuration,B,,CHEMBL617266,,,,Membranes,8,1
2431,12687,,BAO_0000019,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor rat frontal cortex membrane,,,H,Autocuration,B,,CHEMBL617267,,,,,8,1
2432,12687,,BAO_0000019,,,Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex,,,H,Expert,B,,CHEMBL617268,,,,,8,1
2433,12687,,BAO_0000219,449.0,CHO,Inhibitory constant on human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,,,H,Autocuration,B,,CHEMBL617269,,,,,8,1
2434,12687,,BAO_0000357,,,Kinetic inhibition constant evaluated by measuring serotonergic activity,,,H,Expert,B,,CHEMBL617323,,,,,8,1
2435,12687,,BAO_0000357,,,Serotonergic activity of the compound.,,,H,Autocuration,B,,CHEMBL617324,,,,,8,1
2436,12687,,BAO_0000249,,,Tested in vitro for its ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat frontal cortex membranes,,,H,Autocuration,B,,CHEMBL617325,,,,,8,1
2437,12687,,BAO_0000019,,,The binding affinity was evaluated on 5-hydroxytryptamine 2A receptor expressed in rat cortex by using [3H]ketanserin as radioligand.,,,D,Expert,B,10116.0,CHEMBL617326,,,,,9,1
2438,12687,,BAO_0000249,,,In vitro ability to displace [3H]ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane.,,,H,Expert,B,,CHEMBL617327,,,,,8,1
2439,12687,,BAO_0000019,,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,,D,Expert,F,10116.0,CHEMBL617328,,,,,9,1
2440,12687,,BAO_0000019,,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,,D,Expert,F,10116.0,CHEMBL617329,,,,,9,1
2441,12687,,BAO_0000019,,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,,D,Expert,F,10116.0,CHEMBL617330,,,,,9,1
2442,12687,,BAO_0000357,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,,H,Autocuration,B,,CHEMBL617331,,,,,8,1
2443,12687,,BAO_0000357,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand.,,,H,Autocuration,B,,CHEMBL617332,,,,,8,1
2444,107,,BAO_0000357,,,Binding affinity towards 5-hydroxytryptamine 2A receptor,,,H,Expert,B,,CHEMBL617333,,,,,8,1
2445,107,,BAO_0000357,,,Binding affinity against serotonin 5-hydroxytryptamine 2A receptor was determined using human [125I]-eotaxin,,,H,Autocuration,B,,CHEMBL617334,,,,,8,1
2446,107,,BAO_0000357,,,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.000001 mol/L,,,H,Autocuration,B,,CHEMBL617335,,,,,8,1
2447,107,,BAO_0000357,,,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.00001 mol/L,,,H,Autocuration,B,,CHEMBL617336,,,,,8,1
2448,107,,BAO_0000357,,,Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration,,,H,Autocuration,B,,CHEMBL617337,,,,,8,1
2449,107,,BAO_0000357,,,Percent inhibition against 5-hydroxytryptamine 2A receptor using [3H]ketanserin at 1 uM,,,D,Expert,B,9606.0,CHEMBL617338,,,,,9,1
2450,107,,BAO_0000357,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2A receptor,,,H,Autocuration,B,,CHEMBL617339,,,,,8,1
2451,107,,BAO_0000357,,,Binding affinity towards 5-hydroxytryptamine 2A receptor,,,H,Expert,B,,CHEMBL617340,,,,,8,1
2452,107,,BAO_0000357,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor; inactive at 10 uM,,,H,Autocuration,B,,CHEMBL617341,,,,,8,1
2453,107,,BAO_0000357,,,Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptor,,,H,Expert,B,,CHEMBL617342,,,,,8,1
2454,107,,BAO_0000357,,,Affinity for 5-hydroxytryptamine 2A receptor,,,H,Expert,B,,CHEMBL617343,,,,,8,1
2455,107,,BAO_0000219,723.0,NIH3T3,Binding affinity was performed using [3H]ketanserin as the radioligand and stably transfected NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor (GF-62 cells).,,,H,Expert,B,,CHEMBL617344,,,,,8,1
2456,107,,BAO_0000357,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,,,H,Expert,B,,CHEMBL617345,,,,,8,1
2457,107,,BAO_0000357,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand.,,,H,Expert,B,,CHEMBL617346,,,,,8,1
2458,107,,BAO_0000357,,,Compound was evaluated for its binding against 5-hydroxytryptamine 2A receptor,,,H,Autocuration,B,,CHEMBL617347,,,,,8,1
2459,107,,BAO_0000357,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2A receptor was determined,,,H,Autocuration,B,,CHEMBL617348,,,,,8,1
2460,107,,BAO_0000357,,,Binding affinity relative to indolopiperidine (compound 1)for 5-hydroxytryptamine 2A receptor was determined,,,H,Autocuration,B,,CHEMBL617349,,,,,8,1
2461,107,,BAO_0000019,,,Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptor,,,H,Autocuration,F,,CHEMBL617350,,,,,8,1
2462,107,,BAO_0000357,,,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,,,H,Expert,B,,CHEMBL872339,,,,,8,1
2463,107,,BAO_0000357,,,Binding affinity for 5-hydroxytryptamine 2A receptor was determined,,,H,Autocuration,B,,CHEMBL617351,,,,,8,1
2464,107,,BAO_0000357,,,Binding affinity towards serotonin 5-hydroxytryptamine 2A receptor,,,H,Expert,B,,CHEMBL617352,,,,,8,1
2465,107,,BAO_0000357,,,Evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor,,,H,Autocuration,B,,CHEMBL617353,,,,,8,1
2466,107,,BAO_0000357,,,Ability to displace [3H]-ketanserin from 5-hydroxytryptamine 2A receptor,,,H,Autocuration,B,,CHEMBL617354,,,,,8,1
2467,107,,BAO_0000357,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 2A receptor,,,H,Autocuration,B,,CHEMBL617355,,,,,8,1
2468,107,,BAO_0000219,449.0,CHO,In vitro binding affinity against 5-hydroxytryptamine 2A receptor in CHO cells,,,H,Expert,B,10090.0,CHEMBL617356,,,,,8,1
2469,107,,BAO_0000357,,,Inhibition of ketanserin binding to 5-hydroxytryptamine 2A receptor,,,H,Autocuration,B,,CHEMBL617357,,,,,8,1
2470,107,,BAO_0000357,,,Binding affinity at 5-hydroxytryptamine 2A receptor,,,H,Autocuration,B,,CHEMBL617358,,,,,8,1
2471,107,,BAO_0000357,,,Binding affinity towards Serotonin 5-hydroxytryptamine 2A receptor,,,H,Expert,B,,CHEMBL617359,,,,,8,1
2472,107,,BAO_0000357,,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor was determined,,,H,Autocuration,B,,CHEMBL617360,,,,,8,1
2473,107,,BAO_0000357,,,The binding affinity towards 5-hydroxytryptamine 2A receptor; No affinity,,,H,Autocuration,B,,CHEMBL875913,,,,,8,1
2474,107,,BAO_0000357,,,Affinity against 5-hydroxytryptamine 2A receptor,,,H,Autocuration,B,,CHEMBL617361,,,,,8,1
2475,107,,BAO_0000357,,,Binding affinity against 5-Hydroxytryptamine 2A receptor,,,D,Expert,B,9606.0,CHEMBL617362,,,,,9,1
2476,107,,BAO_0000357,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using radioligand binding assay,,,H,Autocuration,B,,CHEMBL617363,,,,,8,1
2477,107,,BAO_0000357,,,Tested against 5-hydroxytryptamine 2A receptor,,,H,Autocuration,B,,CHEMBL617364,,,,,8,1
2478,105075,,BAO_0000224,,,Binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,,,H,Autocuration,B,,CHEMBL617365,,,,,4,1
2479,105075,,BAO_0000224,,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H] ketanserin,,,H,Autocuration,B,,CHEMBL617366,,,,,4,1
2480,105075,,BAO_0000224,,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor agonist [125I]- - (+/-)DOI,,,H,Autocuration,B,,CHEMBL617367,,,,,4,1
2481,105075,,BAO_0000224,,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,,,H,Autocuration,B,,CHEMBL617368,,,,,4,1
2482,107,,BAO_0000357,,,Selectivity ratio towards 5-hydroxytryptamine 2A receptor to Dopamine receptor D2 (5-HT2A/D2 ),,,H,Autocuration,B,,CHEMBL617369,,,,,8,1
2483,227,,BAO_0000219,722.0,HEK293,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND means no data,,,D,Expert,B,9606.0,CHEMBL617370,,,,,9,1
2484,227,,BAO_0000219,449.0,CHO,Functional activity against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader,,,D,Expert,F,9606.0,CHEMBL617371,,,,,9,1
2485,227,,BAO_0000357,,,In vitro binding affinity against human 5-HT2B receptor at a concentration of 100 (nM),,,H,Autocuration,B,,CHEMBL617372,,,,,8,1
2486,227,,BAO_0000357,,,Affinity towards human 5-hydroxytryptamine 2B serotonin receptor,,,D,Expert,B,9606.0,CHEMBL617373,,,,,9,1
2487,227,,BAO_0000019,,,Agonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT radioligand,,,H,Autocuration,F,,CHEMBL617374,,,,,8,1
2488,227,,BAO_0000019,,,Agonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]-5-HT as radioligand,,,H,Autocuration,F,,CHEMBL617375,,,,,8,1
2489,227,,BAO_0000019,,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand,,,H,Autocuration,F,,CHEMBL617376,,,,,8,1
2490,227,,BAO_0000019,,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand; Not tested,,,H,Autocuration,F,,CHEMBL617377,,,,,8,1
2491,227,,BAO_0000019,,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine radioligand,,,H,Autocuration,F,,CHEMBL617378,,,,,8,1
2492,227,,BAO_0000019,,,Antagonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,,,H,Autocuration,F,,CHEMBL617379,,,,,8,1
2493,227,,BAO_0000357,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine as radioligand,,,H,Autocuration,B,,CHEMBL617380,,,,,8,1
2494,227,,BAO_0000357,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT 2B as radioligand,,,H,Autocuration,B,,CHEMBL617381,,,,,8,1
2495,227,,BAO_0000357,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,,,H,Autocuration,B,,CHEMBL617382,,,,,8,1
2496,107,,BAO_0000357,,,The compound evaluated for its affinity against 5-hydroxytryptamine 2A receptor,,,H,Autocuration,B,,CHEMBL617383,,,,,8,1
2497,107,,BAO_0000357,,,Affinity against 5-hydroxytryptamine 2A receptor (D) labeled with [125I]DOI.,,,H,Expert,B,,CHEMBL617384,,,,,8,1
2498,107,,BAO_0000357,,,Affinity against 5-hydroxytryptamine 2A receptor (K) labeled with [3H]ketanserin.,,,H,Expert,B,,CHEMBL617385,,,,,8,1
2499,107,,BAO_0000019,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes,,,H,Autocuration,B,,CHEMBL617386,,,,,8,1
2500,107,,BAO_0000019,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes.,,,H,Autocuration,B,,CHEMBL617387,,,,,8,1
2501,107,,BAO_0000219,723.0,NIH3T3,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,,H,Autocuration,B,,CHEMBL617388,,,,,8,1
2502,107,,BAO_0000219,449.0,CHO,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,,H,Autocuration,F,,CHEMBL617389,,,,,8,1
2503,107,,BAO_0000219,449.0,CHO,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,,D,Expert,F,9606.0,CHEMBL617390,,,,,9,1
2504,104817,,BAO_0000224,,,Selectivity ratio of binding affinity of 5-hydroxytryptamine 2A receptor to that of 5-hydroxytryptamine 2C receptor.,,,H,Autocuration,B,,CHEMBL617391,,,,,4,1
2505,107,,BAO_0000357,,,Binding activity radioligand.,,,H,Autocuration,B,,CHEMBL617392,,,,,8,1
2506,107,,BAO_0000019,,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,,H,Autocuration,B,,CHEMBL617393,,,,,8,1
2507,107,,BAO_0000219,307.0,L929,Binding affinity for human cloned 5-HT2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,,H,Autocuration,B,,CHEMBL617394,,,,,8,1
2508,107,,BAO_0000219,307.0,L929,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,,H,Expert,B,,CHEMBL617395,,,,,8,1
2509,107,,BAO_0000219,307.0,L929,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,,,H,Expert,B,,CHEMBL617396,,,,,8,1
2510,107,,BAO_0000219,307.0,L929,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand; Not tested,,,H,Autocuration,B,,CHEMBL617397,,,,,8,1
2511,107,,BAO_0000357,,,Binding affinity against 5-HT2A receptor,,,H,Autocuration,B,,CHEMBL617398,,,,,8,1
2512,107,,BAO_0000357,,,Binding affinity against 5-hydroxytryptamine 2A receptor,,,H,Autocuration,B,,CHEMBL617399,,,,,8,1
2513,107,,BAO_0000219,722.0,HEK293,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,,,H,Autocuration,B,,CHEMBL617400,,,,,8,1
2514,107,,BAO_0000219,722.0,HEK293,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,,,H,Autocuration,B,,CHEMBL617401,,,,,8,1
2515,107,,BAO_0000219,722.0,HEK293,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells,,,D,Expert,B,9606.0,CHEMBL617402,,,,,9,1
2516,107,,BAO_0000219,722.0,HEK293,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,,D,Expert,B,9606.0,CHEMBL617403,,,,,9,1
2517,107,,BAO_0000357,,,Binding affinity against human 5-hydroxytryptamine 2A receptor using displacement of [3H]5-HT,,,H,Expert,B,,CHEMBL617404,,,,,8,1
2518,107,,BAO_0000219,722.0,HEK293,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,,D,Expert,B,9606.0,CHEMBL857981,,,,,9,1
2519,107,,BAO_0000219,722.0,HEK293,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,,D,Expert,B,9606.0,CHEMBL617405,,,,,9,1
2520,107,,BAO_0000219,722.0,HEK293,Binding affinity to human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]- ketanserin as radioligand,,,D,Expert,B,9606.0,CHEMBL617253,,,,,9,1
2521,107,,BAO_0000357,,,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor.,,,H,Expert,B,,CHEMBL617254,,,,,8,1
2522,107,,BAO_0000219,722.0,HEK293,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,,,H,Autocuration,B,,CHEMBL617255,,,,,8,1
2523,107,,BAO_0000219,722.0,HEK293,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,,,H,Autocuration,B,,CHEMBL617256,,,,,8,1
2524,107,,BAO_0000219,722.0,HEK293,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]ketanserin as radioligand,,,H,Autocuration,B,,CHEMBL616874,,,,,8,1
2525,107,,BAO_0000219,722.0,HEK293,Binding affinity towards 5-hydroxytryptamine 2A receptor (human cloned receptor) in HEK 293 cells using [3H]ketanserin as radioligand.,,,D,Expert,B,9606.0,CHEMBL616875,,,,,9,1
2526,107,,BAO_0000219,722.0,HEK293,Binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells using [3H]ketanserin as radioligand,,,H,Expert,B,,CHEMBL616876,,,,,8,1
2527,107,,BAO_0000219,722.0,HEK293,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2A in HEK293 cells, using [3H]ketanserin as radioligand.",,,H,Expert,B,,CHEMBL616877,,,,,8,1
2528,107,,BAO_0000219,722.0,HEK293,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells; compound is insoluble,,,D,Expert,B,9606.0,CHEMBL616878,,,,,9,1
2529,107,,BAO_0000219,722.0,HEK293,Binding affinity towards human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by displacement of [3H]ketanserin,,,H,Expert,B,,CHEMBL616879,,,,,8,1
2530,107,,BAO_0000219,722.0,HEK293,In vitro binding affinity at human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by [3H]ketanserin displacement.,,,H,Expert,B,,CHEMBL616880,,,,,8,1
2531,107,,BAO_0000219,722.0,HEK293,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,,D,Expert,B,9606.0,CHEMBL616881,,,,,9,1
2532,107,,BAO_0000219,723.0,NIH3T3,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand,,,H,Autocuration,B,,CHEMBL616882,,,,,8,1
2533,107,,BAO_0000219,723.0,NIH3T3,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,,H,Autocuration,B,,CHEMBL616883,,,,,8,1
2534,107,,BAO_0000219,723.0,NIH3T3,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,,H,Autocuration,B,,CHEMBL616884,,,,,8,1
2535,107,,BAO_0000219,722.0,HEK293,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]ketanserin as the radioligand,,,H,Autocuration,B,,CHEMBL616885,,,,,8,1
2536,107,,BAO_0000219,485.0,CHO-K1,Compound was evaluated for displacement of [3H]ketanserin from human cloned 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells,,,H,Autocuration,B,,CHEMBL616886,,,,,8,1
2537,107,,BAO_0000219,485.0,CHO-K1,Displacement of [3H]-ketanserin from human cloned 5-hydroxytryptamine 2A receptor expressed in CHO-K1 cells.,,,H,Expert,B,,CHEMBL616887,,,,,8,1
2538,107,,BAO_0000357,,,Binding affinity for human 5-hydroxytryptamine 2A receptor,,,D,Expert,B,9606.0,CHEMBL616888,,,,,9,1
2539,107,,BAO_0000219,722.0,HEK293,Compound was tested for its binding affinity against 5-hydroxytryptamine 2A receptor in human cloned receptors in HEK 293 cells using [3H]ketanserin,,,H,Autocuration,B,,CHEMBL616889,,,,,8,1
2540,107,,BAO_0000219,722.0,HEK293,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2A receptor in HEK 293 using [3H]ketanserin as a radioligand,,,H,Autocuration,B,,CHEMBL616890,,,,,8,1
2541,107,,BAO_0000219,449.0,CHO,Inhibitory constant for human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,,,D,Expert,B,9606.0,CHEMBL616891,,,,,9,1
2542,107,,BAO_0000219,722.0,HEK293,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2A receptor in HEK293 cells using [3H]-ketanserin.,,,H,Autocuration,B,,CHEMBL616892,,,,,8,1
2543,107,,BAO_0000219,722.0,HEK293,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2A receptor in HEK293 cells, using [3H]ketanserin as radioligand",,,H,Autocuration,B,,CHEMBL616893,,,,,8,1
2544,10620,,BAO_0000219,723.0,NIH3T3,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2A receptor in 3T3 cells,,,H,Autocuration,F,,CHEMBL616894,,,,,8,1
2545,107,,BAO_0000219,723.0,NIH3T3,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells,,,H,Expert,B,,CHEMBL616895,,,,,8,1
2546,10620,,BAO_0000019,,,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2A receptor,,,H,Autocuration,F,,CHEMBL616896,,,,,8,1
2547,10621,,BAO_0000357,,,Ability to displace [3H]-Ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor,,,H,Autocuration,B,,CHEMBL617099,,,,,8,1
2548,10621,,BAO_0000357,,,Ability to displace [3H]ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor; ND denotes not determined,,,H,Autocuration,B,,CHEMBL617100,,,,,8,1
2549,107,,BAO_0000357,,,Binding affinity against rabbit aorta 5-HT2A receptor,,,H,Autocuration,B,9986.0,CHEMBL884532,,,,,8,1
2550,107,,BAO_0000357,,,Binding affinity for 5-hydroxytryptamine 2A receptor of rabbit aorta ring preparations,,,H,Expert,B,9986.0,CHEMBL617101,,,,,8,1
2551,107,,BAO_0000357,,,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 2A receptor in the rabbit saphenous aorta,,,H,Expert,B,9986.0,CHEMBL617102,,,,,8,1
2552,107,,BAO_0000019,,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,,,H,Autocuration,B,9986.0,CHEMBL617103,,,,,8,1
2553,107,,BAO_0000357,,,The compound was tested for binding affinity against 5-HT2A receptor,,,H,Expert,B,9986.0,CHEMBL617104,,,,,8,1
2554,10576,,BAO_0000219,485.0,CHO-K1,Compound was evaluated for displacement of [3H]ketanserin from cloned rat 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells.,,,H,Autocuration,B,,CHEMBL857979,,,,,8,1
2555,12687,,BAO_0000019,,,Binding affinity analysed towards 5-HT 2A in rat jugular vein,,,H,Autocuration,B,,CHEMBL857502,,,,,8,1
2556,12687,,BAO_0000019,,,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,,,H,Autocuration,B,,CHEMBL617105,,,,,8,1
2557,12687,,BAO_0000019,,,Binding affinity analysed on 5-HT 2A in rat stomach fundus.,,,H,Autocuration,B,,CHEMBL858021,,945.0,Stomach,,8,1
2558,12687,,BAO_0000019,,,Binding affinity for 5-HT 2A in rat stomach fundus,,,D,Expert,B,10116.0,CHEMBL875910,,945.0,Stomach,,9,1
2559,12687,,BAO_0000019,,,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,,,H,Autocuration,B,,CHEMBL617106,,,,,8,1
2560,12687,,BAO_0000219,723.0,NIH3T3,Ability to stimulate phosphoinositide hydrolysis in NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor,,,H,Expert,B,,CHEMBL617107,,,,,8,1
2561,12687,,BAO_0000019,,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2A receptor,,,H,Autocuration,F,,CHEMBL617108,,,,,8,1
2562,12687,,BAO_0000019,,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast expressing 5-hydroxytryptamine 2A receptor,,,H,Autocuration,F,,CHEMBL617109,,,,,8,1
2563,12687,,BAO_0000357,,,Evaluated for the effective concentration at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,,,H,Autocuration,B,,CHEMBL617110,,,,,8,1
2564,12687,,BAO_0000357,,,Functional potency at the rat 5-hydroxytryptamine 2A receptor as effective concentration EC50 for stimulating Phosphoinositide accumulation,,,H,Autocuration,B,,CHEMBL617111,,,,,8,1
2565,12687,,BAO_0000019,,,In vitro relative agonist activity against 5-hydroxytryptamine 2A using PI assay in rat vascular smooth muscle cells,,,D,Expert,F,10116.0,CHEMBL617112,,,,,9,1
2566,12687,,BAO_0000357,,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,,H,Autocuration,B,,CHEMBL617113,,,,,8,1
2567,12687,,BAO_0000357,,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,,H,Autocuration,B,,CHEMBL617114,,,,,8,1
2568,12687,,BAO_0000357,,,Tested for its ability to activate phospholipase c by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,,H,Autocuration,B,,CHEMBL617115,,,,,8,1
2569,12687,,BAO_0000219,,,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,,H,Autocuration,F,,CHEMBL617116,,,,,8,1
2570,12687,,BAO_0000019,,,Efficacy at 5-hydroxytryptamine 2A receptor,,,H,Autocuration,F,,CHEMBL617117,,,,,8,1
2571,12687,,BAO_0000357,,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),,,H,Autocuration,B,,CHEMBL617118,,,,,8,1
2572,12687,,BAO_0000357,,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),,,D,Expert,B,10116.0,CHEMBL617119,,,,,9,1
2573,12687,,BAO_0000357,,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor determined by using PI assay (Emax),,,D,Expert,B,10116.0,CHEMBL617120,,,,,9,1
2574,12687,,BAO_0000219,,,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,,D,Expert,F,10116.0,CHEMBL617121,,,,,9,1
2575,12687,,BAO_0000219,,,The receptor (5-hydroxytryptamine 2A) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,,H,Autocuration,F,,CHEMBL617122,,,,,8,1
2576,12687,,BAO_0000019,,,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor,,,H,Autocuration,B,,CHEMBL617123,,,,,8,1
2577,12687,,BAO_0000019,,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes,,,H,Expert,B,,CHEMBL617124,,,,,8,1
2578,12687,,BAO_0000249,,,Binding affinity to serotonin 5-hydroxytryptamine 2A receptors using a radioligand [3H]ketanserin binding assay in rat cortical membranes,,,H,Expert,B,,CHEMBL617600,,,,,8,1
2579,12687,,BAO_0000357,,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was evaluated using [3H]- ketanserin as radioligand,,,H,Expert,B,,CHEMBL617601,,,,,8,1
2580,12687,,BAO_0000019,,,In vitro affinity towards 5-hydroxytryptamine 2A receptor using [3H]spiroperidol as radioligand in cortex,,,H,Expert,B,,CHEMBL882923,,,,,8,1
2581,12687,,BAO_0000357,,,Compound was tested for it's binding affinity towards 5-hydroxytryptamine 2A receptor,,,H,Autocuration,B,,CHEMBL617602,,,,,8,1
2582,12687,,BAO_0000019,,,Compound was tested for its ability to displace [3H]DOB from 5-hydroxytryptamine 2A receptor in rat cortex homogenates,,,H,Autocuration,B,,CHEMBL617603,,,,,8,1
2583,12687,,BAO_0000357,,,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor,,,H,Autocuration,B,,CHEMBL617604,,,,,8,1
2584,12687,,BAO_0000019,,,Binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]ketanserin as radioligand,,,H,Expert,B,,CHEMBL617605,,,,,8,1
2585,12687,,BAO_0000019,,,In vitro binding affinity for serotonin 5-hydroxytryptamine 2A receptor of rat cerebral cortex using [3H]ketanserin as radioligand,,,H,Expert,B,,CHEMBL617606,,,,,8,1
2586,12687,,BAO_0000019,,,Inhibition of [3H]ketanserin binding to rat frontal cortex membrane 5-hydroxytryptamine 2A receptor,,,D,Expert,B,10116.0,CHEMBL617607,,,,,9,1
2587,12687,,BAO_0000249,,,In vitro inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cortical membrane,,,H,Autocuration,B,,CHEMBL617455,,,,,8,1
2588,12687,,BAO_0000019,,,In vitro inhibition of [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,,,D,Expert,B,10116.0,CHEMBL617456,,,,,9,1
2589,12687,,BAO_0000357,,,Inhibitory concentration against 5-hydroxytryptamine 2A receptor (Inactive at >1000 nM concentration),,,H,Expert,B,,CHEMBL617457,,,,,8,1
2590,12687,,BAO_0000357,,,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2A receptor,,,D,Expert,B,10116.0,CHEMBL617458,,,,,9,1
2591,12687,,BAO_0000019,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor from rat brain,,,D,Expert,B,10116.0,CHEMBL617459,,,,,9,1
2592,12687,,BAO_0000357,,,Binding affinity towards 5-hydroxytryptamine 2A receptor binding site using [3H]ketanserin. ,,,H,Expert,B,,CHEMBL617460,,,,,8,1
2593,12687,,BAO_0000357,,,"Binding affinity for 5-hydroxytryptamine 2A receptor, activity is expressed as IC50 values.",,,H,Expert,B,,CHEMBL617461,,,,,8,1
2594,12687,,BAO_0000019,,,Displacement of [3H]ketanserin from rat cortical membrane 5-hydroxytryptamine 2A receptor at 10e-7 M,,,D,Expert,B,10116.0,CHEMBL617462,,,,,9,1
2595,12687,,BAO_0000357,,,Intrinsic activity was determined at 5-hydroxytryptamine 2A receptor which is percentage response given compared with the response produced by 10 uM serotonin.,,,H,Autocuration,B,,CHEMBL617463,,,,,8,1
2596,12687,,BAO_0000019,,,"Compound was tested for binding affinity at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate using [125I]-2,5-Dimethoxy -4-iodoamphetamine (DOI).",,,H,Autocuration,B,,CHEMBL617464,,,,,8,1
2597,12687,,BAO_0000019,,,"Compound was tested for binding affinity using [3H]MDL-100,907 at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate.",,,H,Autocuration,B,,CHEMBL617465,,,,,8,1
2598,12687,,BAO_0000019,,,Ability to bind to central serotonin 5-hydroxytryptamine 2A receptor in vitro in cortex of the rat brain using [3H]ketanserin radioligand,,,H,Expert,B,,CHEMBL617466,,,,,8,1
2599,12687,,BAO_0000019,,,Ability to displace [3H]- ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,,,H,Autocuration,B,,CHEMBL617467,,,,,8,1
2600,12687,,BAO_0000019,,,Displacement of [3H]ketanserin (0.5 nM) from rat cerebral cortex 5-hydroxytryptamine 2A receptors,,,H,Expert,B,,CHEMBL617468,,,,,8,1
2601,12687,,BAO_0000019,,,Ability to displace [3H]ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,,,H,Autocuration,B,,CHEMBL617469,,,,,8,1
2602,12687,,BAO_0000019,,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,,,H,Autocuration,B,,CHEMBL617470,,,,,8,1
2603,12687,,BAO_0000019,,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor; Not tested,,,H,Autocuration,B,,CHEMBL617471,,,,,8,1
2604,12687,,BAO_0000219,723.0,NIH3T3,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor in NIH3T3 cell line membranes,,,H,Expert,B,,CHEMBL617472,,,,,8,1
2605,12687,,BAO_0000357,,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor.,,,H,Expert,B,,CHEMBL617473,,,,,8,1
2606,12687,,BAO_0000019,,,Affinity 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,,D,Expert,B,10116.0,CHEMBL617474,,,,,9,1
2607,12687,,BAO_0000019,,,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,,D,Expert,B,10116.0,CHEMBL617475,,,,,9,1
2608,12687,,BAO_0000221,,,Affinity at [3H]ketanserin-labeled 5-hydroxytryptamine 2A receptor in rat brain homogenate was determined,,,H,Autocuration,B,,CHEMBL617476,,955.0,Brain,,8,1
2609,12687,,BAO_0000357,,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2A receptor,,,H,Expert,B,,CHEMBL617477,,,,,8,1
2610,12687,,BAO_0000219,723.0,NIH3T3,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2A receptor,,,H,Expert,B,,CHEMBL617478,,,,,8,1
2611,12687,,BAO_0000221,,,"Antagonistic activity measured for 5-hydroxytryptamine 2A receptor using [3H]-MDL- 100,907 as radioligand in rat cortical homogenates.",,,H,Autocuration,F,,CHEMBL617479,,,,,8,1
2612,12687,,BAO_0000357,,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was determined using [125I]- DOI as radioligand,,,H,Autocuration,B,,CHEMBL617480,,,,,8,1
2613,12687,,BAO_0000357,,,Binding affinity against 5-hydroxytryptamine 2A receptor,,,H,Expert,B,,CHEMBL617481,,,,,8,1
2614,12687,,BAO_0000019,,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat prefrontal cerebral cortex mambranes,,,H,Expert,B,,CHEMBL617482,,,,,8,1
2615,12687,,BAO_0000019,,,Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand,,,H,Autocuration,B,,CHEMBL617483,,,,,8,1
2616,12687,,BAO_0000357,,,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,,H,Autocuration,B,,CHEMBL621528,,,,,8,1
2617,12687,,BAO_0000219,723.0,NIH3T3,Binding affinity against 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells using [3H]ketanserin,,,D,Expert,B,10116.0,CHEMBL621529,,,,,9,1
2618,12687,,BAO_0000357,,,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,,H,Expert,B,,CHEMBL621530,,,,,8,1
2619,12687,,BAO_0000357,,,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,,H,Expert,B,,CHEMBL621531,,,,,8,1
2620,12687,,BAO_0000019,,,Binding affinity against rat brain 5-hydroxytryptamine 2A receptor,,,D,Expert,B,10116.0,CHEMBL621532,,,,,9,1
2621,12687,,BAO_0000357,,,Binding affinity at cloned rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,,H,Expert,B,,CHEMBL621533,,,,,8,1
2622,12687,,BAO_0000219,449.0,CHO,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,,H,Expert,B,,CHEMBL621534,,,,,8,1
2623,12687,,BAO_0000019,,,Binding affinity measured at the 5-hydroxytryptamine 2A receptor by the inhibition of [3H]ketanserin binding to rat cortex using unlabeled mianserin for nonspecific binding.,,,H,Autocuration,B,,CHEMBL621535,,,,,8,1
2624,12687,,BAO_0000357,,,Binding affinity of [3H]- ketanserin labelled towards Rat cortical 5-hydroxytryptamine 2A receptor using radioligand binding assay,,,H,Autocuration,B,,CHEMBL621536,,,,,8,1
2625,12687,,BAO_0000357,,,Binding affinity of compound was tested for 5-hydroxytryptamine 2A receptor,,,H,Autocuration,B,,CHEMBL621537,,,,,8,1
2626,12687,,BAO_0000357,,,Binding affinity for 5-hydroxytryptamine 2A receptor,,,D,Expert,B,10116.0,CHEMBL621538,,,,,9,1
2627,12687,,BAO_0000019,,,Binding affinity against 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as the radioligand.,,,H,Autocuration,B,,CHEMBL621539,,,,,8,1
2628,12687,,BAO_0000019,,,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex,,,H,Autocuration,B,,CHEMBL621540,,,,,8,1
2629,12687,,BAO_0000019,,,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex.,,,H,Autocuration,B,,CHEMBL621541,,,,,8,1
2630,12687,,BAO_0000019,,,Binding affinity towards 5-HT 2A receptor in rat cerebral frontal cortex membranes using [3H]ketanserin as radioligand,,,H,Autocuration,B,,CHEMBL621542,,,,,8,1
2631,12687,,BAO_0000357,,,Binding affinity at 5-hydroxytryptamine 2A receptor of rat.,,,H,Expert,B,,CHEMBL621543,,,,,8,1
2632,12687,,BAO_0000357,,,Binding affinity towards 5-hydroxytryptamine 2A receptor sites by using [3H]ketanserin as radioligand,,,H,Expert,B,,CHEMBL621544,,,,,8,1
2633,12687,,BAO_0000357,,,Binding affinity for 5-hydroxytryptamine 2A serotonin receptor,,,D,Expert,B,10116.0,CHEMBL621545,,,,,9,1
2634,12687,,BAO_0000357,,,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,,H,Autocuration,B,,CHEMBL621546,,,,,8,1
2635,12687,,BAO_0000357,,,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand; Not tested,,,H,Autocuration,B,,CHEMBL621547,,,,,8,1
2636,12687,,BAO_0000219,723.0,NIH3T3,Displacement of [3H]ketanserin from NIH3T3 cells stably expressing rat 5-hydroxytryptamine 2A receptor,,,H,Expert,B,,CHEMBL618692,,,,,8,1
2637,12687,,BAO_0000357,,,Binding affinity towards 5-hydroxytryptamine 2A receptor,,,H,Autocuration,B,,CHEMBL618693,,,,,8,1
2638,12687,,BAO_0000357,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,,H,Autocuration,B,,CHEMBL872922,,,,,8,1
2639,12687,,BAO_0000357,,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor from fundus tissue was determined using [3H]mesulergine as radioligand,,,H,Autocuration,B,,CHEMBL618694,,,,,8,1
2640,12687,,BAO_0000357,,,Binding affinity for rat 5-hydroxytryptamine 2A receptor using [3H]DOB,,,D,Expert,B,10116.0,CHEMBL618695,,,,,9,1
2641,12687,,BAO_0000357,,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor was determined using [3H]DOB as radioligand; ND=No data,,,H,Autocuration,B,,CHEMBL618696,,,,,8,1
2642,12687,,BAO_0000357,,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor by [3H]ketanserin displacement.,,,H,Expert,B,,CHEMBL618697,,,,,8,1
2643,12687,,BAO_0000357,,,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]DOB as radioligand,,,H,Autocuration,B,,CHEMBL618892,,,,,8,1
2644,12687,,BAO_0000357,,,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]ketanserin as radioligand,,,H,Autocuration,B,,CHEMBL618893,,,,,8,1
2645,12687,,BAO_0000357,,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor,,,H,Autocuration,B,,CHEMBL618894,,,,,8,1
2646,12687,,BAO_0000219,723.0,NIH3T3,Binding affinity towards rat 5-hydroxytryptamine 2A receptor expressed in NIH3T3 cells using [3H]ketanserin as radioligand,,,H,Expert,B,,CHEMBL618895,,,,,8,1
2647,12687,,BAO_0000357,,,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,,,D,Expert,B,10116.0,CHEMBL618896,,,,,9,1
2648,12687,,BAO_0000019,,,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2A receptor in homogenate of caudate putamen tissue from rat brain,,,H,Autocuration,B,,CHEMBL618897,,5383.0,Caudate-putamen,,8,1
2649,12687,,BAO_0000357,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand,,,H,Autocuration,B,,CHEMBL618898,,,,,8,1
2650,12687,,BAO_0000357,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand; Not determined,,,H,Autocuration,B,,CHEMBL618899,,,,,8,1
2651,12687,,BAO_0000357,,,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2A receptor in cloned rat cell culture,,,H,Autocuration,B,,CHEMBL618900,,,,,8,1
2652,12687,,BAO_0000019,,,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2A receptor in cloned rat prefrontal cortex homogenate,,,H,Autocuration,B,,CHEMBL618901,,,,,8,1
2653,12687,,BAO_0000357,,,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2A receptor,,,H,Autocuration,B,,CHEMBL618902,,,,,8,1
2654,12687,,BAO_0000221,,,Displacement of [3H]8-OH-DPAT from rat hippocampus membrane 5-hydroxytryptamine 2A receptor,,,D,Expert,B,10116.0,CHEMBL618903,,10000000.0,Hippocampus,,9,1
2655,12687,,BAO_0000357,,,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2A receptor,,,H,Autocuration,B,,CHEMBL618904,,,,,8,1
2656,12687,,BAO_0000357,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand.,,,H,Autocuration,B,,CHEMBL618905,,,,,8,1
2657,12687,,BAO_0000357,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]-ketanserin radioligand.,,,H,Autocuration,B,,CHEMBL618906,,,,,8,1
2658,12687,,BAO_0000219,723.0,NIH3T3,Binding affinity against rat 5-hydroxytryptamine 2A receptor in NIH3T3 cells.,,,H,Expert,B,,CHEMBL618907,,,,,8,1
2659,12687,,BAO_0000019,,,Compound was tested for the Binding affinity against rat frontal cortex 5-hydroxytryptamine 2A receptor by Radio ligand [3H]ketanserin binding assay.,,,H,Autocuration,B,,CHEMBL618908,,,,,8,1
2660,12687,,BAO_0000357,,,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,,,H,Autocuration,B,,CHEMBL617909,,,,,8,1
2661,12687,,BAO_0000019,,,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,,,H,Expert,B,,CHEMBL617910,,,,,8,1
2662,12687,,BAO_0000221,,,In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain.,,,H,Autocuration,B,,CHEMBL617911,,955.0,Brain,,8,1
2663,12687,,BAO_0000249,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,,H,Autocuration,B,,CHEMBL872923,,,,,8,1
2664,12687,,BAO_0000249,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,,H,Autocuration,B,,CHEMBL617912,,,,,8,1
2665,12687,,BAO_0000019,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat cortex,,,D,Expert,B,10116.0,CHEMBL617913,,,,,9,1
2666,12687,,BAO_0000249,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,,H,Expert,B,,CHEMBL617914,,,,,8,1
2667,12687,,BAO_0000249,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,,H,Autocuration,B,,CHEMBL617915,,,,,8,1
2668,12687,,BAO_0000249,,,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane,,,H,Autocuration,B,,CHEMBL617916,,,,,8,1
2669,12687,,BAO_0000019,,,Displacement of [3H]- Ketanserin from rat cortex 5-hydroxytryptamine 2A receptor,,,D,Expert,B,10116.0,CHEMBL617917,,,,,9,1
2670,12687,,BAO_0000019,,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand,,,H,Expert,B,,CHEMBL617918,,,,,8,1
2671,12687,,BAO_0000019,,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand; Not active at 10-5 M,,,H,Autocuration,B,,CHEMBL617919,,,,,8,1
2672,12687,,BAO_0000019,,,In vitro inhibitory constant against [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,,,D,Expert,B,10116.0,CHEMBL617920,,,,,9,1
2673,12687,,BAO_0000019,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor of rat brain cortex,,,D,Expert,B,10116.0,CHEMBL617921,,,,,9,1
2674,105102,,BAO_0000224,,,"Relative binding affinity for D2 receptor and 5-hydroxytryptamine 2A receptor, ratio of Ki",,,D,Expert,B,10116.0,CHEMBL617922,,,,,5,1
2675,12687,,BAO_0000357,,,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,,H,Autocuration,B,,CHEMBL617923,,,,,8,1
2676,12687,,BAO_0000357,,,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,,H,Autocuration,B,,CHEMBL617924,,,,,8,1
2677,12687,,BAO_0000357,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2A receptor using [125 I]-DOI as radioligand,,,H,Autocuration,B,,CHEMBL617925,,,,,8,1
2678,12687,,BAO_0000357,,,In vitro binding to 5-hydroxytryptamine 2A receptor using [125 I]-DOI,,,D,Expert,B,10116.0,CHEMBL617926,,,,,9,1
2679,12687,,BAO_0000357,,,The binding affinity at 5-hydroxytryptamine 2A receptor was determined using [3H]ketanserin,,,H,Autocuration,B,,CHEMBL617927,,,,,8,1
2680,12687,,BAO_0000357,,,The compound was tested for binding affinity against 5-hydroxytryptamine 2A receptor,,,H,Autocuration,B,,CHEMBL617928,,,,,8,1
2681,12687,,BAO_0000019,,,Binding affinity for 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,,D,Expert,B,10116.0,CHEMBL617929,,,,,9,1
2682,12687,,BAO_0000019,,,Binding affinity to 5-hydroxytryptamine 2A receptor from rat cortex assayed using [3H]ketanserin as radioligand.,,,H,Expert,B,,CHEMBL617930,,,,,8,1
2683,12687,,BAO_0000019,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as radioligand.; Nonactive at 10 uM,,,H,Autocuration,B,,CHEMBL617931,,,,,8,1
2684,12687,,BAO_0000019,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]-ketanserin as radioligand; Nonactive at 10 uM,,,H,Autocuration,B,,CHEMBL617932,,,,,8,1
2685,12687,,BAO_0000219,449.0,CHO,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells; ND is No Data,,,H,Autocuration,B,,CHEMBL617933,,,,,8,1
2686,12687,,BAO_0000019,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,,,H,Autocuration,B,,CHEMBL617934,,,,,8,1
2687,12687,,BAO_0000019,,,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,,,H,Autocuration,B,,CHEMBL617935,,,,,8,1
2688,12687,,BAO_0000357,,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor; Not determined,,,H,Autocuration,B,,CHEMBL617936,,,,,8,1
2689,12687,,BAO_0000019,,,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor; NT=not tested,,,H,Autocuration,B,,CHEMBL617937,,,,,8,1
2690,12687,,BAO_0000019,,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes; Not tested,,,H,Autocuration,B,,CHEMBL617938,,,,,8,1
2691,12687,,BAO_0000218,,,Compound was evaluated for effective dose measured in nmol/kg following a dose of 0.04 mg/kg and 0.093 uM/kg (95%CI); range 32-63,,,H,Autocuration,B,,CHEMBL617939,,,,,8,1
2692,12687,,BAO_0000218,,,Compound was evaluated for the percentage of rats disrupted following a dose of 0.04 mg/kg and 0.097 uM/kg,,,H,Autocuration,B,,CHEMBL617940,,,,,8,1
2693,12687,,BAO_0000218,,,Compound was evaluated for the percentage of rats disrupted following a dose of 0.08 mg/kg and 0.194 uM/kg,,,H,Autocuration,B,,CHEMBL617941,,,,,8,1
2694,12687,,BAO_0000357,,,Ratio of pKi of 5-HT2A to that of 5-HT2C receptor,,,H,Expert,B,,CHEMBL617942,,,,,8,1
2695,12687,,BAO_0000357,,,Ratio of pKi of 5-HT2A to that of D2 receptor,,,H,Expert,B,,CHEMBL617943,,,,,8,1
2696,105093,,BAO_0000224,,,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,,,H,Expert,B,,CHEMBL617944,,,,,4,1
2697,105093,,BAO_0000224,,,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,,,H,Expert,B,,CHEMBL617945,,,,,4,1
2698,105075,,BAO_0000224,,,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor,,,H,Expert,B,,CHEMBL617946,,,,,4,1
2699,12687,,BAO_0000357,,,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor; ND is no data,,,H,Autocuration,B,,CHEMBL617947,,,,,8,1
2700,12687,,BAO_0000357,,,Percent maximal 5-HT stimulation at cloned rat 5-hydroxytryptamine 2A receptor (phosphoinositide hydrolysis study) at a conc of 100 uM,,,H,Expert,B,,CHEMBL617948,,,,,8,1
2701,12687,,BAO_0000019,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat,,,H,Autocuration,F,,CHEMBL858116,,,,,8,1
2702,12687,,BAO_0000019,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat; ND means not done,,,H,Autocuration,F,,CHEMBL617949,,,,,8,1
2703,12687,,BAO_0000019,,,Effectiveness of compound in blocking 5-hydroxytryptamine 2A receptor-mediated contractions of rat tail artery,,,H,Autocuration,F,,CHEMBL617950,,,,,8,1
2704,12687,,BAO_0000019,,,Negative log concentration of antagonist on 5-hydroxytryptamine 2A receptor in rat thoracic aorta,,,H,Expert,F,,CHEMBL617951,,1515.0,Thoracic aorta,,8,1
2705,12687,,BAO_0000019,,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta,,,H,Expert,F,,CHEMBL617952,,1515.0,Thoracic aorta,,8,1
2706,12687,,BAO_0000019,,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta; ND is not determined.,,,H,Autocuration,F,,CHEMBL617953,,1515.0,Thoracic aorta,,8,1
2707,12687,,BAO_0000357,,,Binding activity radioligand.,,,H,Autocuration,B,,CHEMBL617954,,,,,8,1
2708,12687,,BAO_0000019,,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,,H,Expert,B,,CHEMBL617955,,,,,8,1
2709,12687,,BAO_0000019,,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,,,H,Autocuration,B,,CHEMBL857071,,,,,8,1
2710,12687,,BAO_0000019,,,Displacement of [3H]DOB binding to 5-hydroxytryptamine 2A receptor from rat cortex homogenate,,,H,Expert,B,,CHEMBL617270,,,,,8,1
2711,12687,,BAO_0000219,339.0,N1E-115,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930,,,H,Autocuration,B,,CHEMBL617271,,,,,8,1
2712,12687,,BAO_0000219,339.0,N1E-115,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930; Not determined,,,H,Autocuration,B,,CHEMBL617272,,,,,8,1
2713,12687,,BAO_0000019,,,Binding affinity was evaluated by 5-hydroxytryptamine 2A receptor agonism in the rat cortex by displacing ketanserin,,,H,Autocuration,B,,CHEMBL617273,,,,,8,1
2714,12687,,BAO_0000019,,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]-ketanserin,,,D,Expert,F,10116.0,CHEMBL617274,,,,,9,1
2715,108,,BAO_0000357,,,Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor,,,H,Autocuration,B,,CHEMBL617275,,,,,8,1
2716,108,,BAO_0000357,,,Binding affinity towards 5-hydroxytryptamine 2C receptor,,,H,Autocuration,B,,CHEMBL617276,,,,,8,1
2717,108,,BAO_0000357,,,Binding affinity towards human 5-hydroxytryptamine 2C receptor,,,H,Autocuration,B,,CHEMBL617277,,,,,8,1
2718,108,,BAO_0000019,,,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,,,H,Expert,B,,CHEMBL617278,,,,,8,1
2719,108,,BAO_0000019,,,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor; Not determined,,,H,Expert,B,,CHEMBL617279,,,,,8,1
2720,108,,BAO_0000019,,,Binding affinity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,,,H,Expert,B,,CHEMBL617280,,,,,8,1
2721,108,,BAO_0000357,,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,,,H,Autocuration,B,,CHEMBL617281,,,,,8,1
2722,108,,BAO_0000357,,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,,,H,Autocuration,B,,CHEMBL617282,,,,,8,1
2723,108,,BAO_0000019,,,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]mesulergine,,,H,Expert,B,,CHEMBL617283,,,,,8,1
2724,108,,BAO_0000019,,,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]-mesulergine; ND is No Data.,,,H,Expert,B,,CHEMBL617284,,,,,8,1
2725,108,,BAO_0000219,722.0,HEK293,In vitro binding affinity towards human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells was determined using [3H]mesulergine as radioligand,,,H,Autocuration,B,,CHEMBL617285,,,,,8,1
2726,108,,BAO_0000019,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2C receptor,,,H,Autocuration,B,,CHEMBL617286,,,,,8,1
2727,108,,BAO_0000357,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2C receptor using with [125I]- DOI radioligand,,,D,Expert,B,9606.0,CHEMBL617287,,,,,9,1
2728,108,,BAO_0000357,,,Binding affinity towards human 5-hydroxytryptamine 2C receptor.,,,H,Expert,B,,CHEMBL617288,,,,,8,1
2729,108,,BAO_0000357,,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]DOB as radioligand,,,H,Autocuration,B,,CHEMBL617289,,,,,8,1
2730,108,,BAO_0000357,,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,,H,Autocuration,B,,CHEMBL872917,,,,,8,1
2731,108,,BAO_0000357,,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,,,H,Autocuration,B,,CHEMBL617290,,,,,8,1
2732,108,,BAO_0000219,449.0,CHO,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,,H,Autocuration,B,,CHEMBL617291,,,,,8,1
2733,108,,BAO_0000219,449.0,CHO,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells; ND is no data,,,H,Autocuration,B,,CHEMBL617292,,,,,8,1
2734,108,,BAO_0000219,723.0,NIH3T3,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,,H,Autocuration,B,,CHEMBL617293,,,,,8,1
2735,108,,BAO_0000219,449.0,CHO,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,,D,Expert,F,9606.0,CHEMBL617294,,,,,9,1
2736,108,,BAO_0000019,,,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,,,H,Expert,B,,CHEMBL617295,,,,,8,1
2737,108,,BAO_0000357,,,Binding activity radioligand.,,,H,Autocuration,B,,CHEMBL617296,,,,,8,1
2738,108,,BAO_0000019,,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,,H,Autocuration,B,,CHEMBL617297,,,,,8,1
2739,108,,BAO_0000219,449.0,CHO,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand,,,H,Expert,B,,CHEMBL617298,,,,,8,1
2740,108,,BAO_0000219,449.0,CHO,Binding affinity at human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells by [3H]mesulergine displacement.,,,H,Expert,B,,CHEMBL617299,,,,,8,1
2741,108,,BAO_0000219,449.0,CHO,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand; NT means not tested,,,H,Autocuration,B,,CHEMBL617300,,,,,8,1
2742,108,,BAO_0000357,,,Binding affinity against 5-HT2C receptor,,,H,Autocuration,B,,CHEMBL617454,,,,,8,1
2743,108,,BAO_0000219,722.0,HEK293,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,,,H,Autocuration,B,,CHEMBL617505,,,,,8,1
2744,108,,BAO_0000219,722.0,HEK293,Displacement of [3H]mesulergine from 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells,,,D,Expert,B,9606.0,CHEMBL617506,,,,,9,1
2745,108,,BAO_0000219,722.0,HEK293,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,,,D,Expert,B,9606.0,CHEMBL617507,,,,,9,1
2746,108,,BAO_0000357,,,Binding affinity against human 5-hydroxytryptamine 2C receptor using displacement of [3H]DOB,,,H,Expert,B,,CHEMBL617508,,,,,8,1
2747,108,,BAO_0000219,722.0,HEK293,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,,,D,Expert,B,9606.0,CHEMBL857982,,,,,9,1
2748,108,,BAO_0000219,722.0,HEK293,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand,,,D,Expert,B,9606.0,CHEMBL617509,,,,,9,1
2749,108,,BAO_0000219,722.0,HEK293,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand; Nd means not determined,,,D,Expert,B,9606.0,CHEMBL617510,,,,,9,1
2750,108,,BAO_0000357,,,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor was determined,,,H,Autocuration,B,,CHEMBL617511,,,,,8,1
2751,108,,BAO_0000219,722.0,HEK293,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptors in HEK 293 cells using [3H]mesulergine as radioligand,,,H,Autocuration,B,,CHEMBL617512,,,,,8,1
2752,108,,BAO_0000219,722.0,HEK293,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]mesulergine as radioligand,,,H,Autocuration,B,,CHEMBL617749,,,,,8,1
2753,108,,BAO_0000219,722.0,HEK293,Binding affinity towards 5-HT2C (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,,H,Autocuration,B,,CHEMBL617750,,,,,8,1
2754,108,,BAO_0000219,722.0,HEK293,Binding affinity towards 5-hydroxytryptamine 2C receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,,H,Autocuration,B,,CHEMBL617751,,,,,8,1
2755,108,,BAO_0000219,722.0,HEK293,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells using [3H]mesulergine as radioligand,,,H,Expert,B,,CHEMBL617752,,,,,8,1
2756,108,,BAO_0000219,722.0,HEK293,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand",,,H,Autocuration,B,,CHEMBL617753,,,,,8,1
2757,108,,BAO_0000219,722.0,HEK293,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.",,,H,Expert,B,,CHEMBL617754,,,,,8,1
2758,108,,BAO_0000219,722.0,HEK293,Displacement of [3H]mesulergine from human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells; compound insoluble,,,D,Expert,B,9606.0,CHEMBL617755,,,,,9,1
2759,108,,BAO_0000219,722.0,HEK293,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand; no data",,,H,Autocuration,B,,CHEMBL617756,,,,,8,1
2760,108,,BAO_0000219,722.0,HEK293,Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergine,,,H,Expert,B,,CHEMBL617757,,,,,8,1
2761,108,,BAO_0000219,722.0,HEK293,In vitro binding affinity at human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by [3H]mesulergine displacement.,,,H,Expert,B,,CHEMBL617758,,,,,8,1
2762,108,,BAO_0000219,723.0,NIH3T3,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand,,,H,Autocuration,B,,CHEMBL617759,,,,,8,1
2763,108,,BAO_0000219,722.0,HEK293,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine as the radioligand,,,H,Autocuration,B,,CHEMBL617760,,,,,8,1
2764,108,,BAO_0000219,485.0,CHO-K1,Displacement of [3H]mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO-K1 cells,,,H,Expert,B,,CHEMBL617761,,,,,8,1
2765,108,,BAO_0000357,,,Binding affinity against 5-hydroxytryptamine 2C receptor,,,D,Expert,B,9606.0,CHEMBL617762,,,,,9,1
2766,108,,BAO_0000357,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 2C receptor,,,H,Autocuration,B,,CHEMBL617763,,,,,8,1
2767,108,,BAO_0000219,722.0,HEK293,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine,,,H,Autocuration,B,,CHEMBL857983,,,,,8,1
2768,108,,BAO_0000219,722.0,HEK293,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2C receptor in HEK 293 using [3H]mesulergine as a radioligand,,,H,Autocuration,B,,CHEMBL617764,,,,,8,1
2769,108,,BAO_0000219,308.0,HeLa,Inhibitory constant on human 5-hydroxytryptamine 2C receptor transfected in to HeLa cells,,,H,Autocuration,B,,CHEMBL617765,,,,,8,1
2770,108,,BAO_0000019,,,Selectivity as the ratio of Ki value towards 5-hydroxytryptamine 2C receptor to that of pA2 value towards 5-hydroxytryptamine 2B receptor,,,H,Autocuration,F,,CHEMBL617766,,,,,8,1
2771,108,,BAO_0000221,,,The binding affinity (pKi) measured against 5-hydroxytryptamine 3 receptor of rat hippocampus and entorhinal cortex using [3H]granisetron as radioligand,,,H,Autocuration,F,,CHEMBL617767,,10000000.0,Hippocampus,,8,1
2772,108,,BAO_0000219,722.0,HEK293,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2C receptor in HEK293 cells using [3H]mesulergine.,,,H,Autocuration,B,,CHEMBL617768,,,,,8,1
2773,108,,BAO_0000219,722.0,HEK293,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]5-mesulergine as radioligand",,,H,Autocuration,B,,CHEMBL617769,,,,,8,1
2774,11864,,BAO_0000357,,,Binding affinity analysed on 5-HT 2C in human clone using [3H]mesulergine as radioligand,,,H,Autocuration,B,,CHEMBL858023,,,,,8,1
2775,11864,,BAO_0000019,,,Binding affinity analysed on 5-HT 2C in rat stomach fundus,,,H,Autocuration,B,,CHEMBL617770,,945.0,Stomach,,8,1
2776,11864,,BAO_0000019,,,Binding affinity analysed towards 5-HT 2C in rat stomach fundus,,,H,Autocuration,B,,CHEMBL617771,,945.0,Stomach,,8,1
2777,11864,,BAO_0000219,625.0,A9,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2C receptor in A9 cells,,,H,Autocuration,F,,CHEMBL617772,,,,,8,1
2778,11864,,BAO_0000219,723.0,NIH3T3,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,,,H,Autocuration,B,,CHEMBL617773,,,,,8,1
2779,11864,,BAO_0000219,723.0,NIH3T3,Binding affinity to 5-hydroxytryptamine 2C receptor measured using radioligand [3H]Mesulergine in stably transfected NIH3T3 cells,,,H,Autocuration,B,,CHEMBL617850,,,,,8,1
2780,11864,,BAO_0000219,723.0,NIH3T3,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,,,H,Autocuration,B,,CHEMBL617851,,,,,8,1
2781,11864,,BAO_0000019,,,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2C receptor,,,H,Autocuration,F,,CHEMBL617852,,,,,8,1
2782,12689,,BAO_0000019,,,Binding affinity analysed on 5-HT 2C in rat stomach fundus.,,,H,Autocuration,B,10090.0,CHEMBL858024,,945.0,Stomach,,8,1
2783,12689,,BAO_0000019,,,Binding affinity towards 5-HT 2C receptor in rat stomach fundus,,,D,Expert,B,10116.0,CHEMBL617853,,945.0,Stomach,,9,1
2784,108,,BAO_0000357,,,Binding affinity against 5-Hydroxytryptamine 2C Receptor was measured using [3H]N-methyl-mesulergine as radioligand,,,H,Expert,B,,CHEMBL617854,,,,,8,1
2785,108,,BAO_0000357,,,Binding affinity for 5-hydroxytryptamine 2C receptor,,,H,Expert,B,9823.0,CHEMBL873477,,,,,8,1
2786,108,,BAO_0000357,,,Binding affinity towards 5-hydroxytryptamine 2C receptor,,,H,Expert,B,,CHEMBL617855,,,,,8,1
2787,108,,BAO_0000019,,,Affinity towards 5-hydroxytryptamine 2C receptor in membranes from pig choroid plexus using [3H]N-methyl-mesulergine,,,H,Expert,B,,CHEMBL617856,,,,,8,1
2788,108,,BAO_0000019,,,Compound was tested for its ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor in pig cortex,,,H,Autocuration,B,,CHEMBL617857,,,,,8,1
2789,108,,BAO_0000249,,,In vitro inhibitory concentration against radioligand [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in pig cortical membrane,,,H,Autocuration,B,,CHEMBL617858,,,,,8,1
2790,108,,BAO_0000357,,,Binding affinity towards pig 5-hydroxytryptamine 2C receptor,,,H,Autocuration,B,,CHEMBL617859,,,,,8,1
2791,108,,BAO_0000357,,,The compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,,,H,Autocuration,B,,CHEMBL617860,,,,,8,1
2792,108,,BAO_0000357,,,Binding activity radioligand.,,,H,Autocuration,B,,CHEMBL617861,,,,,8,1
2793,108,,BAO_0000019,,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,,H,Expert,B,,CHEMBL617862,,,,,8,1
2794,108,,BAO_0000019,,,Binding activity against 5-hydroxytryptamine 3 receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,,,H,Autocuration,B,,CHEMBL617863,,,,,8,1
2795,108,,BAO_0000249,,,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT,,,H,Autocuration,B,,CHEMBL617864,,,,,8,1
2796,108,,BAO_0000249,,,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT; Not determined,,,H,Autocuration,B,,CHEMBL617649,,,,,8,1
2797,108,,BAO_0000019,,,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,,,H,Expert,F,9823.0,CHEMBL617650,,,,,8,1
2798,108,,BAO_0000019,,,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,,,H,Expert,F,9823.0,CHEMBL617651,,,,,8,1
2799,108,,BAO_0000357,,,In vitro binding affinity at 5-hydroxytryptamine 2C receptor in pig choroid plexus using 3[H]mesulergine as the radioligand,,,H,Autocuration,B,9823.0,CHEMBL617652,,,,,8,1
2800,108,,BAO_0000019,,,In Vitro Binding affinity againist 5-hydroxytryptamine 2C receptor by displacing [3H]mesulergine from pig cortex,,,H,Autocuration,B,9823.0,CHEMBL857072,,,,,8,1
2801,108,,BAO_0000357,,,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2C receptor,,,H,Autocuration,B,9823.0,CHEMBL617653,,,,,8,1
2802,12687,,BAO_0000019,,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,,H,Autocuration,B,,CHEMBL617654,,,,,8,1
2803,12689,,BAO_0000019,,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2C receptor,,,H,Autocuration,F,,CHEMBL617655,,,,,8,1
2804,12689,,BAO_0000357,,,Binding affinity towards 5-HT2C receptor from rat using [3H]mesulergine as radioligand,,,H,Expert,B,,CHEMBL617656,,,,,8,1
2805,12689,,BAO_0000357,,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand,,,H,Autocuration,B,,CHEMBL617657,,,,,8,1
2806,12689,,BAO_0000357,,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand; Not tested,,,H,Autocuration,B,,CHEMBL617658,,,,,8,1
2807,12689,,BAO_0000357,,,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2C receptor,,,D,Expert,B,10116.0,CHEMBL617659,,,,,9,1
2808,12689,,BAO_0000357,,,Inhibition of radiolabeled [3H]mesulergine ligand binding to 5-hydroxytryptamine 2C receptor,,,D,Expert,B,10116.0,CHEMBL617838,,,,,9,1
2809,12689,,BAO_0000249,,,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in rat brain membranes,,,D,Expert,B,10116.0,CHEMBL617839,,,,Brain membranes,9,1
2810,12689,,BAO_0000357,,,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine; Not tested,,,H,Autocuration,B,,CHEMBL617840,,,,,8,1
2811,12689,,BAO_0000019,,,Ability to displace [3H]mesulergine bound to 5-hydroxytryptamine 2C receptor in rat cortex,,,H,Autocuration,B,,CHEMBL617841,,,,,8,1
2812,12689,,BAO_0000019,,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-HT2C receptor,,,H,Autocuration,B,,CHEMBL875915,,,,,8,1
2813,12689,In vitro,BAO_0000219,,,Displacement of [3H]mesulergine (0.5 nM) from rat 5-hydroxytryptamine 2C receptor expressed in SR-3T3 cells,,,H,Expert,B,,CHEMBL617842,,,,,8,1
2814,12689,,BAO_0000219,723.0,NIH3T3,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor in NIH3T3 cell line membranes,,,H,Expert,B,,CHEMBL617843,,,,,8,1
2815,12689,,BAO_0000357,,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor.,,,H,Expert,B,,CHEMBL617844,,,,,8,1
2816,12689,,BAO_0000357,,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2C receptor,,,H,Expert,B,,CHEMBL617845,,,,,8,1
2817,12689,,BAO_0000219,723.0,NIH3T3,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2C receptor,,,H,Expert,B,,CHEMBL617846,,,,,8,1
2818,12689,,BAO_0000357,,,Binding affinity towards rat 5-hydroxytryptamine 2C receptor was determined using [125I]- DOI as radioligand,,,H,Autocuration,B,,CHEMBL617847,,,,,8,1
2819,12689,,BAO_0000357,,,Binding affinity against 5-hydroxytryptamine 2C receptor,,,H,Expert,B,,CHEMBL617848,,,,,8,1
2820,12689,,BAO_0000357,,,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,,H,Autocuration,B,,CHEMBL617849,,,,,8,1
2821,12689,,BAO_0000357,,,Binding affinity against rat 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,,H,Expert,B,,CHEMBL621507,,,,,8,1
2822,12689,,BAO_0000357,,,Binding affinity at cloned rat 5-hydroxytryptamine 2C receptor using [3H]DOI as radioligand,,,H,Expert,B,,CHEMBL621508,,,,,8,1
2823,12689,,BAO_0000019,,,Binding affinity against 5-hydroxytryptamine 2C receptor from rat cortex using [3H]mesulergine as the radioligand.,,,H,Autocuration,B,,CHEMBL621509,,,,,8,1
2824,12689,,BAO_0000019,,,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex,,,H,Autocuration,B,,CHEMBL621510,,,,,8,1
2825,12689,,BAO_0000019,,,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex.,,,H,Autocuration,B,,CHEMBL621511,,,,,8,1
2826,12689,,BAO_0000219,625.0,A9,Displacement of [3H]mesulergine from A9 cells stably expressing rat 5-hydroxytryptamine 2C receptor,,,H,Expert,B,,CHEMBL621512,,,,,8,1
2827,12689,,BAO_0000357,,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,,H,Autocuration,B,,CHEMBL621513,,,,,8,1
2828,12689,,BAO_0000357,,,Binding affinity towards cloned rat 5-hydroxytryptamine 2C receptor from fundus tissue by [3H]mesulergine displacement.,,,H,Expert,B,,CHEMBL621514,,,,,8,1
2829,12689,In vitro,BAO_0000219,,,Binding affinity towards rat 5-hydroxytryptamine 2C receptor expressed in A-9 cells using [3H]mesulergine as radioligand,,,H,Expert,B,,CHEMBL621515,,,,,8,1
2830,12689,,BAO_0000219,,,Binding affinity was measured on 5-hydroxytryptamine 2C receptor in J1 cells transfected with rat 5-HT2C gene labeled with [3H]mesulergine,,,H,Autocuration,B,,CHEMBL621516,,,,,8,1
2831,12689,,BAO_0000019,,,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2C receptor in homogenate of caudate putamen tissue from rat brain,,,H,Autocuration,B,,CHEMBL621517,,5383.0,Caudate-putamen,,8,1
2832,12689,,BAO_0000357,,,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2C receptor in cloned rat cell culture,,,H,Autocuration,B,,CHEMBL621518,,,,,8,1
2833,12689,,BAO_0000019,,,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2C receptor in cloned rat prefrontal cortex homogenate; ND denotes no data,,,H,Autocuration,B,,CHEMBL621519,,,,,8,1
2834,12689,,BAO_0000357,,,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2C receptor,,,H,Autocuration,B,,CHEMBL621520,,,,,8,1
2835,12689,,BAO_0000357,,,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2C receptor,,,H,Autocuration,B,,CHEMBL621521,,,,,8,1
2836,12689,,BAO_0000357,,,Compound was evaluated for its binding affinity towards rat r5-hydroxytryptamine 2C receptor,,,H,Autocuration,B,,CHEMBL621522,,,,,8,1
2837,12689,,BAO_0000219,,,Binding affinity against rat 5-hydroxytryptamine 2C receptor in A-9 cells.,,,H,Expert,B,,CHEMBL621523,,,,,8,1
2838,12689,,BAO_0000357,,,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2C receptor,,,H,Autocuration,B,,CHEMBL621524,,,,,8,1
2839,12689,,BAO_0000357,,,In vitro binding to 5-hydroxytryptamine 2C receptor using [125 I]-DOI,,,D,Expert,B,10116.0,CHEMBL621525,,,,,9,1
2840,12689,,BAO_0000357,,,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine,,,H,Autocuration,B,,CHEMBL872921,,,,,8,1
2841,12689,,BAO_0000357,,,The compound evaluated for its affinity against 5-hydroxytryptamine 2C receptor,,,H,Autocuration,B,,CHEMBL621526,,,,,8,1
2842,12689,,BAO_0000219,,,Affinity against 5-hydroxytryptamine 2C receptor in J1 cells transfected with the rat 5-HT2C gene labeled with [3H]mesulergine.,,,H,Expert,B,,CHEMBL621527,,,,,8,1
2843,12689,,BAO_0000019,,,Binding affinity against 5-hydroxytryptamine 2C receptor in rat choroid plexus using [3H]N-methyl-mesulergine,,,D,Expert,B,10116.0,CHEMBL617865,,,,,9,1
2844,12689,,BAO_0000357,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor,,,H,Autocuration,B,,CHEMBL617866,,,,,8,1
2845,12689,,BAO_0000019,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor from rat cortex using [3H]-citalopram as radioligand; Nonactive at 10 uM,,,H,Autocuration,B,,CHEMBL617867,,,,,8,1
2846,12689,,BAO_0000357,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand; Nonactive at 10 uM,,,H,Autocuration,B,,CHEMBL617487,,,,,8,1
2847,12689,,BAO_0000357,,,Binding affinity for 5-hydroxytryptamine 2C receptor,,,H,Expert,B,,CHEMBL617488,,,,,8,1
2848,12689,,BAO_0000357,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2C receptor using [125 I]-DOI as radioligand; Not determined,,,H,Autocuration,B,,CHEMBL617489,,,,,8,1
2849,12689,,BAO_0000019,,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT denotes not tested,,,H,Autocuration,B,,CHEMBL617490,,,,,8,1
2850,12689,,BAO_0000019,,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT=not tested,,,H,Autocuration,B,,CHEMBL617491,,,,,8,1
2851,12689,,BAO_0000019,,,Affinity pKi for 5-hydroxytryptamine 2C receptor was measured in rat cortex homogenates.,,,H,Autocuration,B,,CHEMBL617492,,,,,8,1
2852,12689,,BAO_0000019,,,Binding affinity against 5-hydroxytryptamine 2C receptor in rat cortex homogenates.,,,H,Autocuration,B,,CHEMBL617493,,,,,8,1
2853,12689,,BAO_0000357,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2C receptor was determined,,,H,Autocuration,B,,CHEMBL617494,,,,,8,1
2854,12689,,BAO_0000019,,,Displacement of [3H]mesulergine from rat 5-HT2C receptor expressed in HEK293,,,D,Expert,B,10116.0,CHEMBL617495,,,,,9,1
2855,12689,,BAO_0000357,,,Binding affinity was determined against cloned human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,,,H,Autocuration,B,,CHEMBL617496,,,,,8,1
2856,12689,,BAO_0000219,485.0,CHO-K1,Compound was evaluated for displacement of [3H]mesulergine from cloned rat 5-hydroxytryptamine 2C receptor in transfected CHO-K1 cells.,,,H,Autocuration,B,,CHEMBL617497,,,,,8,1
2857,12689,,BAO_0000357,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,,H,Autocuration,B,,CHEMBL617498,,,,,8,1
2858,12689,,BAO_0000357,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand.,,,H,Autocuration,B,,CHEMBL617499,,,,,8,1
2859,12689,,BAO_0000019,,,Compound tested for relative response using 0.1 uM 5-HT as agonist against 5-hydroxytryptamine 2C receptor,,,H,Autocuration,F,,CHEMBL617500,,,,,8,1
2860,108,,BAO_0000357,,,Compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,,,H,Autocuration,B,,CHEMBL617501,,,,,8,1
2861,108,,BAO_0000357,,,Binding affinity towards 5-hydroxytryptamine 2C receptor,,,H,Expert,B,,CHEMBL617502,,,,,8,1
2862,227,,BAO_0000357,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand; Not Tested,,,H,Autocuration,B,,CHEMBL617503,,,,,8,1
2863,227,,BAO_0000357,,,Binding activity against cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand.,,,H,Autocuration,B,,CHEMBL617504,,,,,8,1
2864,227,,BAO_0000357,,,Binding affinity against the cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand,,,H,Autocuration,B,,CHEMBL617406,,,,,8,1
2865,227,,BAO_0000019,,,Affinity for human 5-hydroxytryptamine 2B receptor expressed in mammalian cell line,,,D,Expert,B,9606.0,CHEMBL617407,,,,,9,1
2866,227,,BAO_0000357,,,Binding affinity towards human 5-hydroxytryptamine 2B receptor using [3H]5-HT as radioligand,,,H,Autocuration,B,,CHEMBL617408,,,,,8,1
2867,227,,BAO_0000357,,,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,,,H,Autocuration,B,,CHEMBL617409,,,,,8,1
2868,227,,BAO_0000357,,,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,,,H,Autocuration,B,,CHEMBL617410,,,,,8,1
2869,227,,BAO_0000357,,,Compound was tested for the displacement of [3H]5-HT from cloned human 5-hydroxytryptamine 2B receptor,,,H,Autocuration,B,,CHEMBL617411,,,,,8,1
2870,227,,BAO_0000019,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2B receptor,,,H,Autocuration,B,,CHEMBL617412,,,,,8,1
2871,227,,BAO_0000357,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2B receptor using with [125I]- DOI radioligand,,,D,Expert,B,9606.0,CHEMBL617774,,,,,9,1
2872,227,,BAO_0000219,722.0,HEK293,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,,,D,Expert,B,9606.0,CHEMBL617775,,,,,9,1
2873,227,,BAO_0000219,722.0,HEK293,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,,,D,Expert,B,9606.0,CHEMBL617776,,,,,9,1
2874,227,,BAO_0000219,449.0,CHO,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,,D,Expert,F,9606.0,CHEMBL617777,,,,,9,1
2875,227,,BAO_0000219,449.0,CHO,Rleative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,,D,Expert,F,9606.0,CHEMBL617778,,,,,9,1
2876,227,,BAO_0000219,722.0,HEK293,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,,H,Autocuration,B,,CHEMBL617779,,,,,8,1
2877,227,,BAO_0000219,722.0,HEK293,Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells using [3H]5-HT as radioligand.,,,H,Expert,B,,CHEMBL617780,,,,,8,1
2878,227,,BAO_0000219,722.0,HEK293,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand; no data",,,H,Autocuration,B,,CHEMBL617781,,,,,8,1
2879,227,,BAO_0000219,722.0,HEK293,Displacement of [3H]5-HT from 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells,,,D,Expert,B,9606.0,CHEMBL617782,,,,,9,1
2880,227,,BAO_0000219,722.0,HEK293,Binding affinity to human cloned 5-HT2B receptor in HEK 293 cells using [3H]- -5-HT as radioligand,,,D,Expert,B,9606.0,CHEMBL617783,,,,,9,1
2881,227,,BAO_0000357,,,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor was determined,,,H,Autocuration,B,,CHEMBL617784,,,,,8,1
2882,227,,BAO_0000219,722.0,HEK293,Binding affinity towards 5-hydroxytryptamine 2B receptor (human cloned receptor) in HEK 293 cells using [3H]5-HT as radioligand.,,,H,Autocuration,B,,CHEMBL617785,,,,,8,1
2883,227,,BAO_0000219,722.0,HEK293,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells using [3H]5-HT as radioligand,,,H,Expert,B,,CHEMBL857984,,,,,8,1
2884,227,,BAO_0000219,722.0,HEK293,Binding affinity towards human cloned 5-HT2B receptor of HEK293 cells by displacement of [3H]5-HT,,,H,Expert,B,,CHEMBL617786,,,,,8,1
2885,227,,BAO_0000219,722.0,HEK293,In vitro binding affinity at human cloned 5-hydroxytryptamine 2B receptor of HEK293 cells by [3H]5-HT displacement.,,,H,Expert,B,,CHEMBL617787,,,,,8,1
2886,227,,BAO_0000219,722.0,HEK293,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells,,,D,Expert,B,9606.0,CHEMBL617788,,,,,9,1
2887,227,,BAO_0000219,722.0,HEK293,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; compound is insoluble,,,D,Expert,B,9606.0,CHEMBL617789,,,,,9,1
2888,227,,BAO_0000219,722.0,HEK293,Compound was evaluated for binding affinity against human cloned 5-HT2B receptor in HEK 293 cells using [3H]5-HT as the radioligand,,,H,Autocuration,B,,CHEMBL617790,,,,,8,1
2889,227,,BAO_0000219,485.0,CHO-K1,Displacement of [3H]-5-5HT from human cloned 5-hydroxytryptamine 2B receptor expressed in CHO-K1 cells,,,H,Expert,B,,CHEMBL617791,,,,,8,1
2890,227,,BAO_0000357,,,Binding affinity against 5-hydroxytryptamine 2B receptor,,,H,Expert,B,,CHEMBL617608,,,,,8,1
2891,227,,BAO_0000219,722.0,HEK293,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 2B receptor in HEK 293 cells using [3H]5-HT,,,H,Autocuration,B,,CHEMBL617609,,,,,8,1
2892,227,,BAO_0000219,722.0,HEK293,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2B receptor in HEK 293 using [3H]ketanserin as a radioligand,,,H,Autocuration,B,,CHEMBL617610,,,,,8,1
2893,227,,BAO_0000219,722.0,HEK293,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2B receptors in HEK293 cells using [3H]5-HT.,,,H,Autocuration,B,,CHEMBL617611,,,,,8,1
2894,227,,BAO_0000219,722.0,HEK293,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,,H,Autocuration,B,,CHEMBL617612,,,,,8,1
2895,227,,BAO_0000219,722.0,HEK293,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,,H,Autocuration,B,,CHEMBL617613,,,,,8,1
2896,227,,BAO_0000019,,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 2B receptor in the endothelium intact rabbit jugular vein.,,,H,Autocuration,B,9986.0,CHEMBL617614,,,,,8,1
2897,12688,,BAO_0000019,,,Binding affinity analysed for 5-HT 2B receptor in rat stomach fundus,,,H,Expert,B,,CHEMBL617615,,945.0,Stomach,,8,1
2898,12688,,BAO_0000357,,,Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus,,,H,Expert,B,,CHEMBL858114,,945.0,Stomach,,8,1
2899,12688,,BAO_0000357,,,Affinity against serotonergic receptor in the isolated rat stomach fundus,,,H,Autocuration,B,,CHEMBL617616,,945.0,Stomach,,8,1
2900,12688,,BAO_0000019,,,Antagonistic activity against 5-hydroxytryptamine 2B receptor obtained from rat stomach fundus preparation,,,D,Expert,F,10116.0,CHEMBL617617,,945.0,Stomach,,9,1
2901,12688,,BAO_0000019,,,Antagonistic against 5-hydroxytryptamine 2B receptor,,,D,Expert,F,10116.0,CHEMBL875914,,,,,9,1
2902,12688,,BAO_0000019,,,Antagonistic affinity measured as pA2 value on 5-hydroxytryptamine 2B receptor of the rat stomach fundus,,,H,Autocuration,F,,CHEMBL617618,,945.0,Stomach,,8,1
2903,12688,,BAO_0000357,,,Inhibition of 5-HT binding to 5-HT2B receptor of Rat stomach fundus,,,D,Expert,B,10116.0,CHEMBL617619,,945.0,Stomach,,9,1
2904,12688,,BAO_0000019,,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor,,,H,Autocuration,F,,CHEMBL617620,,,,,8,1
2905,12688,,BAO_0000019,,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor; No data,,,H,Autocuration,F,,CHEMBL617621,,,,,8,1
2906,12688,,BAO_0000019,,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B) receptor,,,H,Autocuration,F,,CHEMBL617622,,,,,8,1
2907,12688,,BAO_0000357,,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,,D,Expert,B,10116.0,CHEMBL617623,,945.0,Stomach,,9,1
2908,12688,,BAO_0000357,,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,,D,Expert,B,10116.0,CHEMBL617624,,945.0,Stomach,,9,1
2909,12688,,BAO_0000357,,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,,D,Expert,B,10116.0,CHEMBL617625,,945.0,Stomach,,9,1
2910,12688,,BAO_0000357,,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,,D,Expert,B,10116.0,CHEMBL617626,,945.0,Stomach,,9,1
2911,12688,,BAO_0000019,,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,,,H,Autocuration,F,,CHEMBL617627,,945.0,Stomach,,8,1
2912,12688,,BAO_0000019,,,Negative log concentration of antagonist was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,,,H,Expert,F,,CHEMBL617628,,945.0,Stomach,,8,1
2913,12688,,BAO_0000019,,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is No Data.,,,H,Autocuration,F,,CHEMBL617629,,945.0,Stomach,,8,1
2914,12688,,BAO_0000019,,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is not determined.,,,H,Autocuration,F,,CHEMBL858115,,945.0,Stomach,,8,1
2915,12688,,BAO_0000019,,,Antagonistic activity on 5-hydroxytryptamine 2B receptor of Rat stomach fundus;ND is not determined,,,D,Expert,F,10116.0,CHEMBL617630,,945.0,Stomach,,9,1
2916,12688,,BAO_0000019,,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat thoracic aorta; ND is not determined,,,H,Autocuration,F,,CHEMBL617631,,1515.0,Thoracic aorta,,8,1
2917,12688,,BAO_0000357,,,The binding affinity of compound to 5-HT receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,,,H,Autocuration,B,,CHEMBL617632,,,,,8,1
2918,12688,,BAO_0000357,,,The binding affinity to 5-hydroxytryptamine 2B receptor of rat fundus,,,H,Expert,B,,CHEMBL617633,,,,,8,1
2919,12688,,BAO_0000357,,,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,,,H,Autocuration,B,,CHEMBL617634,,,,,8,1
2920,12688,,BAO_0000357,,,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus; Unable to determine valid PA2 value due to slope of Schild plot,,,H,Autocuration,B,,CHEMBL617635,,,,,8,1
2922,12688,,BAO_0000019,,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,,,D,Autocuration,F,10116.0,CHEMBL617637,,945.0,Stomach,,9,1
2923,227,,BAO_0000357,,,Binding affinity against 5-hydroxytryptamine 1A receptor,,,H,Autocuration,B,,CHEMBL617638,,,,,8,1
2924,227,,BAO_0000357,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2B receptor was determined,,,H,Autocuration,B,,CHEMBL617639,,,,,8,1
2925,227,,BAO_0000357,,,Binding affinity for 5-hydroxytryptamine 2B receptor was determined,,,H,Autocuration,B,,CHEMBL617640,,,,,8,1
2926,227,,BAO_0000357,,,Evaluated for the binding affinity to 5-HT 2B receptor,,,H,Autocuration,B,,CHEMBL617641,,,,,8,1
2927,227,,BAO_0000357,,,Ability to displace [3H]5-HT from 5-hydroxytryptamine 2B receptor,,,H,Autocuration,B,,CHEMBL617642,,,,,8,1
2928,227,,BAO_0000357,,,Binding affinities against 5-hydroxytryptamine 2B receptor,,,H,Autocuration,B,,CHEMBL617643,,,,,8,1
2929,227,,BAO_0000357,,,Binding affinities towards 5-hydroxytryptamine 2B receptor,,,H,Autocuration,B,,CHEMBL617644,,,,,8,1
2930,227,,BAO_0000357,,,Binding affinity towards 5-hydroxytryptamine 2B receptor using [125I]DOI as radioligand,,,H,Autocuration,B,,CHEMBL617645,,,,,8,1
2931,108,,BAO_0000357,,,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,,,H,Expert,B,,CHEMBL617646,,,,,8,1
2932,108,,BAO_0000357,,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,,,H,Autocuration,B,9913.0,CHEMBL617647,,,,,8,1
2933,108,,BAO_0000357,,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10E-6 M,,,H,Autocuration,B,9913.0,CHEMBL617648,,,,,8,1
2934,108,,BAO_0000357,,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10e-6 M,,,H,Autocuration,B,9913.0,CHEMBL617875,,,,,8,1
2935,108,,BAO_0000357,,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at concentration of 10e-6 M,,,H,Autocuration,B,9913.0,CHEMBL617876,,,,,8,1
2936,108,,BAO_0000357,,,Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus,,,H,Expert,B,9913.0,CHEMBL617877,,,,,8,1
2937,108,,BAO_0000357,,,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,,,H,Expert,B,9913.0,CHEMBL617878,,,,,8,1
2938,108,,BAO_0000357,,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,,,H,Autocuration,B,9913.0,CHEMBL617879,,,,,8,1
2939,108,,BAO_0000019,,,Binding affinity against guinea pig cortex 5-HT2C receptor in the presence of [3H]mesulergine,,,H,Autocuration,B,10141.0,CHEMBL617880,,,,,8,1
2940,20033,,BAO_0000357,,,Binding affinity towards 5-HT4 receptor by the displacement of [3H]GR-113808 in guinea-pig striatum,,,D,Intermediate,B,10141.0,CHEMBL617881,,2435.0,Striatum,,9,1
2941,51,,BAO_0000357,,,Binding affinity against 5-HT1A receptor,,,H,Autocuration,B,,CHEMBL857073,,,,,8,1
2942,108,,BAO_0000219,449.0,CHO,Agonistic activity for 5-HT2c (5-HT2C) by measuring [3H]inositol monophosphate fromation in CHO cells in which the human 5-HT2C receptor subtype was stably expressed,,,H,Expert,F,,CHEMBL617882,,,,,8,1
2943,108,,BAO_0000219,449.0,CHO,Functional activity against human 5-hydroxytryptamine 2C receptor expressed in CHO cells using fluorometric imaging plate reader,,,D,Expert,F,9606.0,CHEMBL617883,,,,,9,1
2944,108,,BAO_0000219,,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2c receptor cell line,,,H,Autocuration,F,,CHEMBL617884,,,,,8,1
2945,108,,BAO_0000219,449.0,CHO,Agonistic binding efficacy against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand,,,H,Autocuration,B,,CHEMBL617885,,,,,8,1
2946,108,,BAO_0000219,449.0,CHO,"Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand, expressed as Emax",,,H,Autocuration,B,,CHEMBL617886,,,,,8,1
2947,108,,BAO_0000357,,,Inhibition of human 5-hydroxytryptamine 2C receptor,,,D,Expert,B,9606.0,CHEMBL617887,,,,,9,1
2948,108,,BAO_0000357,,,In vitro binding affinity against human 5-hydroxytryptamine 2C receptor at a concentration of 100 (nM),,,H,Autocuration,B,,CHEMBL617888,,,,,8,1
2949,108,,BAO_0000019,,,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,,,H,Autocuration,B,,CHEMBL617889,,,,,8,1
2950,108,,BAO_0000357,,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor,,,H,Autocuration,B,,CHEMBL617890,,,,,8,1
2951,108,,BAO_0000357,,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,,,H,Autocuration,B,,CHEMBL617891,,,,,8,1
2952,108,,BAO_0000357,,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,,,H,Autocuration,B,,CHEMBL617892,,,,,8,1
2953,108,,BAO_0000219,449.0,CHO,Displacement of [H]-mesulergine from CHO cells expressing human 5-hydroxytryptamine 2C receptor.,,,H,Expert,B,,CHEMBL617893,,,,,8,1
2954,108,,BAO_0000219,449.0,CHO,Ability to displace [3H]- mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells,,,H,Expert,B,,CHEMBL617894,,,,,8,1
2955,108,,BAO_0000219,449.0,CHO,Ability to displace [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,,H,Expert,B,,CHEMBL617895,,,,,8,1
2956,108,,BAO_0000219,449.0,CHO,Ability to displace [3H]mesulergine (0.5 nM) from CHO cells of human 5-hydroxytryptamine 2C receptor,,,H,Autocuration,B,,CHEMBL617896,,,,,8,1
2957,108,,BAO_0000357,,,Affinity towards human 5-hydroxytryptamine 2C serotonin receptor,,,D,Expert,B,9606.0,CHEMBL617897,,,,,9,1
2958,108,,BAO_0000019,,,Agonist activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand,,,H,Autocuration,F,,CHEMBL617898,,,,,8,1
2959,108,,BAO_0000019,,,Agonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,,H,Autocuration,F,,CHEMBL617899,,,,,8,1
2960,108,,BAO_0000219,449.0,CHO,Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI ,,,H,Expert,B,10116.0,CHEMBL617900,,,,,8,1
2961,108,,BAO_0000019,,,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand,,,H,Autocuration,F,,CHEMBL617901,,,,,8,1
2962,108,,BAO_0000019,,,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand; Not tested,,,H,Autocuration,F,,CHEMBL617902,,,,,8,1
2963,108,,BAO_0000019,,,Antagonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,,H,Autocuration,F,,CHEMBL617903,,,,,8,1
2964,108,,BAO_0000357,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [125 I]DOI as radioligand,,,H,Autocuration,B,,CHEMBL617904,,,,,8,1
2965,108,,BAO_0000357,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand,,,H,Autocuration,B,,CHEMBL617905,,,,,8,1
2966,108,,BAO_0000357,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand;not tested,,,H,Autocuration,B,,CHEMBL617906,,,,,8,1
2967,108,,BAO_0000357,,,Binding activity against cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand.,,,H,Autocuration,B,,CHEMBL617907,,,,,8,1
2968,108,,BAO_0000357,,,Binding affinity against the cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand,,,H,Autocuration,B,,CHEMBL617908,,,,,8,1
2969,108,,BAO_0000219,449.0,CHO,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,,H,Expert,B,,CHEMBL620617,,,,,8,1
2970,108,,BAO_0000019,,,Affinity for human 5-hydroxytryptamine 2C receptor expressed in mammalian cell line,,,D,Expert,B,9606.0,CHEMBL620618,,,,,9,1
2971,108,,BAO_0000357,,,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand.,,,H,Expert,B,,CHEMBL620619,,,,,8,1
2972,108,,BAO_0000357,,,Binding affinity to cloned human 5-hydroxytryptamine 2C receptor,,,D,Expert,B,9606.0,CHEMBL620620,,,,,9,1
2973,108,,BAO_0000357,,,Binding affinity towards human 5-HT2C receptor was determined using [125I]- DOI as radioligand,,,H,Autocuration,B,,CHEMBL620621,,,,,8,1
2974,104698,,BAO_0000249,,,Binding affinity for 5-HT3 receptor by displacement of [3H]-LY 278584 in rat cerebral cortex membranes,,,D,Autocuration,B,10116.0,CHEMBL872920,,,,Membranes,7,1
2975,104698,,BAO_0000223,,,Binding affinity towards rat 5-hydroxytryptamine 3 receptor was evaluated,,,H,Autocuration,B,,CHEMBL620622,,,,,6,1
2976,104698,,BAO_0000019,,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 in rat posterior cortex,,,D,Autocuration,B,10116.0,CHEMBL620623,,,,,7,1
2977,104698,,BAO_0000019,,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex,,,H,Autocuration,B,,CHEMBL620624,,,,,6,1
2978,104698,,BAO_0000019,,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex; Not tested,,,H,Autocuration,B,,CHEMBL620625,,,,,6,1
2979,104698,,BAO_0000219,,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor in NG-108 cells labeled with [3H]GR-65630,,,H,Autocuration,B,,CHEMBL620626,,,,,6,1
2980,104698,,BAO_0000019,,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex,,,H,Autocuration,B,,CHEMBL621307,,,,,6,1
2981,104698,,BAO_0000019,,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex.,,,H,Autocuration,B,,CHEMBL621308,,,,,6,1
2982,104698,,BAO_0000223,,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-5-HT,,,H,Autocuration,B,,CHEMBL621309,,,,,6,1
2983,104698,,BAO_0000223,,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]GR-65630,,,H,Autocuration,B,,CHEMBL621310,,,,,6,1
2984,104698,,BAO_0000223,,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-ketanserin,,,H,Autocuration,B,,CHEMBL621311,,,,,6,1
2985,104698,,BAO_0000249,,,"Compound was evaluated for its in vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",,,H,Autocuration,B,,CHEMBL621502,,,,,6,1
2986,104698,,BAO_0000249,,,"In vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",,,H,Autocuration,B,,CHEMBL621503,,,,,6,1
2987,104698,,BAO_0000249,,,Displacement of the 5-hydroxytryptamine 3 receptor ligand [3H]GR-65630 from rat brain cortical membranes.,,,H,Autocuration,B,,CHEMBL621504,,,,Membranes,6,1
2988,104698,,BAO_0000223,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor,,,H,Autocuration,B,,CHEMBL621505,,,,,6,1
2989,104698,,BAO_0000019,,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,,,H,Autocuration,B,,CHEMBL621506,,,,,6,1
2990,104698,,BAO_0000223,,,Ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15.,,,H,Autocuration,B,,CHEMBL619781,,,,,6,1
2991,104698,,BAO_0000223,,,Compound was evaluated for its ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15. ,,,H,Autocuration,B,,CHEMBL619782,,,,,6,1
2992,104698,,BAO_0000019,,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex,,,H,Autocuration,B,,CHEMBL619783,,,,,6,1
2993,104698,,BAO_0000019,,,Displacement of [3H]ketanserin from rat cortex 5-HT3 receptor,,,D,Autocuration,B,10116.0,CHEMBL619784,,,,,7,1
2994,104698,,BAO_0000249,,,Ability to displace [3H]granisetron specifically bound to 5-hydroxytryptamine 3 receptor in rat cortical membrane,,,H,Autocuration,B,,CHEMBL619785,,,,,6,1
2995,104698,,BAO_0000223,,,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,,,H,Autocuration,B,,CHEMBL619786,,,,,6,1
2996,104698,,BAO_0000019,,,Displacement of binding of [3H]-BRL 43694 to 5-hydroxytryptamine 3 receptor in rat cerebral cortex,,,H,Autocuration,B,,CHEMBL619787,,,,,6,1
2997,104698,,BAO_0000019,,,In vitro affinity for 5-hydroxytryptamine 3 (5-HT3) receptor by displacement of [3H]BRL-43694 from rat entorhinal cortex,,,H,Autocuration,B,,CHEMBL872925,,,,,6,1
2998,104698,,BAO_0000019,,,In vitro binding affinity at serotonin 5-hydroxytryptamine 3 receptor in rat cortex by [3H]granisetron displacement.,,,H,Autocuration,B,,CHEMBL619788,,,,,6,1
2999,104698,,BAO_0000249,,,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,,,H,Autocuration,B,,CHEMBL619789,,,,,6,1
3000,104698,,BAO_0000249,,,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]-1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,,,H,Autocuration,B,,CHEMBL619790,,,,,6,1
3001,104698,,BAO_0000019,,,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,,,H,Autocuration,B,,CHEMBL619791,,,,,6,1
3002,104698,,BAO_0000019,,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,,,H,Autocuration,B,,CHEMBL619792,,,,,6,1
3003,104698,,BAO_0000249,,,Displacement of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortical membranes,,,H,Autocuration,B,,CHEMBL619793,,,,Membranes,6,1
3004,104698,,BAO_0000223,,,Inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor,,,D,Autocuration,B,10116.0,CHEMBL619794,,,,,7,1
3005,104698,,BAO_0000221,,,The ability to inhibit [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortices,,,H,Autocuration,B,,CHEMBL619795,,955.0,Brain,,6,1
3006,104698,,BAO_0000019,,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat posterior cortex by [3H]-BRL 43694 displacement.,,,H,Autocuration,B,,CHEMBL619796,,,,,6,1
3007,104698,,BAO_0000223,,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584,,,H,Autocuration,B,,CHEMBL620448,,,,,6,1
3008,104698,,BAO_0000223,,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,,,H,Autocuration,B,,CHEMBL620449,,,,,6,1
3009,104698,,BAO_0000223,,,The binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand.,,,H,Autocuration,B,,CHEMBL620450,,,,,6,1
3010,104698,,BAO_0000223,,,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630,,,H,Autocuration,B,,CHEMBL620451,,,,,6,1
3011,104698,,BAO_0000223,,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630.,,,H,Autocuration,B,,CHEMBL620631,,,,,6,1
3012,104698,,BAO_0000019,,,Binding affinity for 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand,,,H,Autocuration,B,,CHEMBL620632,,,,,6,1
3013,104698,,BAO_0000019,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand; NA means Not active,,,H,Autocuration,B,,CHEMBL620633,,,,,6,1
3014,104698,,BAO_0000223,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 3 receptor; Nonactive at 10 uM,,,H,Autocuration,B,,CHEMBL620634,,,,,6,1
3015,104698,,BAO_0000019,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,,,H,Autocuration,B,,CHEMBL620635,,,,,6,1
3016,104698,In vivo,BAO_0000218,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 0.5 hours in urethane-anesthetized rats,,,H,Autocuration,F,,CHEMBL620636,,,,,6,1
3017,104698,In vivo,BAO_0000218,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 1 hour in urethane-anesthetized rats,,,H,Autocuration,F,,CHEMBL620637,,,,,6,1
3018,104698,In vivo,BAO_0000218,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 3 hours in urethane-anesthetized rats,,,H,Autocuration,F,,CHEMBL620638,,,,,6,1
3019,104698,In vivo,BAO_0000218,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 6 hours in urethane-anesthetized rats,,,H,Autocuration,F,,CHEMBL620639,,,,,6,1
3020,104698,In vivo,BAO_0000218,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 0.5 hours in urethane-anesthetized rats,,,H,Autocuration,F,,CHEMBL620640,,,,,6,1
3021,104698,In vivo,BAO_0000218,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 1 hour in urethane-anesthetized rats,,,H,Autocuration,F,,CHEMBL620641,,,,,6,1
3022,104698,In vivo,BAO_0000218,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 16 hours in urethane-anesthetized rats,,,H,Autocuration,F,,CHEMBL620642,,,,,6,1
3023,104698,In vivo,BAO_0000218,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 3 hours in urethane-anesthetized rats,,,H,Autocuration,F,,CHEMBL620643,,,,,6,1
3024,104698,In vivo,BAO_0000218,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 6 hours in urethane-anesthetized rats,,,H,Autocuration,F,,CHEMBL620644,,,,,6,1
3025,104698,In vivo,BAO_0000218,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 0.5 hours in urethane-anesthetized rats,,,H,Autocuration,F,,CHEMBL620645,,,,,6,1
3026,104698,In vivo,BAO_0000218,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 1 hour in urethane-anesthetized rats,,,H,Autocuration,F,,CHEMBL620646,,,,,6,1
3027,104698,In vivo,BAO_0000218,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 3 hours in urethane-anesthetized rats,,,H,Autocuration,F,,CHEMBL620647,,,,,6,1
3028,104698,In vivo,BAO_0000218,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 6 hours in urethane-anesthetized rats,,,H,Autocuration,F,,CHEMBL620648,,,,,6,1
3029,104698,In vivo,BAO_0000218,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 0.5 hours in urethane-anesthetized rats,,,H,Autocuration,F,,CHEMBL620649,,,,,6,1
3030,104698,In vivo,BAO_0000218,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 3 hours in urethane-anesthetized rats,,,H,Autocuration,F,,CHEMBL620650,,,,,6,1
3031,104698,In vivo,BAO_0000218,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 1 hour in urethane-anesthetized rats,,,H,Autocuration,F,,CHEMBL620651,,,,,6,1
3032,104698,In vivo,BAO_0000218,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 3 hours in urethane-anesthetized rats,,,H,Autocuration,F,,CHEMBL872875,,,,,6,1
3033,104698,In vivo,BAO_0000218,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 1 hour in urethane-anesthetized rats,,,H,Autocuration,F,,CHEMBL620652,,,,,6,1
3034,104698,,BAO_0000019,,,5-hydroxytryptamine 3 receptor antagonist activity was confirmed by its ability to antagonize 5-HT evoked tachycardia of rabbit isolated heart,,,H,Autocuration,F,,CHEMBL620653,,,,,6,1
3035,104698,,BAO_0000019,,,Binding activity against 5-hydroxytryptamine 2A receptor from rat cortex homogenates using [3H]DOB as radioligand.,,,H,Autocuration,B,,CHEMBL857076,,,,,6,1
3036,104698,,BAO_0000019,,,Inhibition of [3H]-Q-ICS 205-930 binding to rat cortex homogenate 5-hydroxytryptamine 3 receptor,,,D,Autocuration,B,10116.0,CHEMBL620654,,,,,7,1
3037,104698,,BAO_0000223,,,Binding activity radioligand.,,,H,Autocuration,B,,CHEMBL620655,,,,,6,1
3038,104698,,BAO_0000249,,,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor in rat brain membranes,,,H,Autocuration,B,,CHEMBL620656,,,,Brain membranes,6,1
3039,104698,,BAO_0000249,,,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes.,,,H,Autocuration,B,,CHEMBL620657,,,,Brain membranes,6,1
3040,108,,BAO_0000357,,,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.000001 mol/L,,,H,Autocuration,B,,CHEMBL620658,,,,,8,1
3041,108,,BAO_0000357,,,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.00001 mol/L,,,H,Autocuration,B,,CHEMBL620659,,,,,8,1
3042,108,,BAO_0000357,,,Inhibition of binding towards 5-hydroxytryptamine 2C receptor at 100 nM concentration,,,H,Autocuration,B,,CHEMBL620660,,,,,8,1
3043,108,,BAO_0000357,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2C receptor,,,H,Autocuration,B,,CHEMBL620661,,,,,8,1
3044,108,,BAO_0000357,,,Binding affinity of compound towards 5-hydroxytryptamine 2C receptor,,,H,Autocuration,B,,CHEMBL620662,,,,,8,1
3045,108,,BAO_0000357,,,Affinity for 5-hydroxytryptamine 2C receptor,,,H,Expert,B,,CHEMBL620663,,,,,8,1
3046,108,,BAO_0000357,,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,,H,Autocuration,B,,CHEMBL620664,,,,,8,1
3047,108,,BAO_0000357,,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand.,,,H,Expert,B,,CHEMBL620665,,,,,8,1
3048,108,,BAO_0000357,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2C receptor was determined,,,H,Autocuration,B,,CHEMBL620666,,,,,8,1
3049,108,,BAO_0000357,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]-Ketanserin,,,H,Autocuration,B,,CHEMBL620667,,,,,8,1
3050,108,,BAO_0000357,,,Binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]N-methyl-mesulergine,,,H,Expert,B,,CHEMBL620668,,,,,8,1
3051,108,,BAO_0000357,,,Binding affinity for 5-hydroxytryptamine 2C receptor was determined,,,H,Autocuration,B,,CHEMBL620669,,,,,8,1
3052,108,,BAO_0000357,,,Binding affinity towards serotonin 5-hydroxytryptamine 2C receptor,,,H,Expert,B,,CHEMBL620670,,,,,8,1
3053,108,,BAO_0000357,,,Evaluated for the binding affinity to 5-hydroxytryptamine 2C receptor,,,H,Autocuration,B,,CHEMBL620671,,,,,8,1
3054,108,,BAO_0000357,,,Tested agains t5-hydroxytryptamine 2C receptor in experiment 1,,,H,Autocuration,B,,CHEMBL620672,,,,,8,1
3055,108,,BAO_0000357,,,Tested against 5-hydroxytryptamine 2C receptor in experiment 2,,,H,Autocuration,B,,CHEMBL620673,,,,,8,1
3056,108,,BAO_0000357,,,Ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor,,,H,Autocuration,B,,CHEMBL620674,,,,,8,1
3057,108,,BAO_0000357,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 2C receptor,,,H,Autocuration,B,,CHEMBL620675,,,,,8,1
3058,108,,BAO_0000357,,,The binding affinity towards 5-hydroxytryptamine 2C receptor; No affinity,,,H,Autocuration,B,,CHEMBL620676,,,,,8,1
3059,108,,BAO_0000357,,,Affinity against 5-hydroxytryptamine 2C receptor,,,H,Autocuration,B,,CHEMBL621382,,,,,8,1
3060,108,,BAO_0000357,,,Binding affinity against 5-hydroxytryptamine 2C receptor,,,D,Expert,B,9606.0,CHEMBL621383,,,,,9,1
3061,108,,BAO_0000357,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2C receptor using radioligand binding assay,,,H,Autocuration,B,,CHEMBL621384,,,,,8,1
3062,144,,BAO_0000357,,,Inhibitory concentration required against 5-HT3 receptor in bovine area postrema using [3H]GR-65630,,,H,Autocuration,B,9913.0,CHEMBL621385,,,,,8,1
3063,144,,BAO_0000357,,,Binding affinity towards 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand,,,H,Autocuration,B,9913.0,CHEMBL617989,,,,,8,1
3064,104714,,BAO_0000019,,,Antagonistic potency against serotonin 5-hydroxytryptamine 3 receptor in GPI assay,,,H,Expert,F,10141.0,CHEMBL617990,,,,,4,1
3065,104714,,BAO_0000221,,,Binding affinity to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,,,H,Autocuration,B,10141.0,CHEMBL875085,,2116.0,Ileum,,4,1
3066,104714,,BAO_0000019,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig,,,H,Autocuration,F,10141.0,CHEMBL617991,,,,,4,1
3067,104714,,BAO_0000019,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig; ND means not done,,,H,Autocuration,F,10141.0,CHEMBL617992,,,,,4,1
3068,104714,,BAO_0000221,,,Potency to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,,,H,Autocuration,B,10141.0,CHEMBL617993,,2116.0,Ileum,,4,1
3069,104714,,BAO_0000221,,,In vitro binding affinity was measured for 5-hydroxytryptamine 3 receptor in the guinea pig ileum.,,,H,Autocuration,B,10141.0,CHEMBL617994,,2116.0,Ileum,,4,1
3070,104714,,BAO_0000019,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea colon at a concentration 0.01 uM,,,H,Autocuration,F,10141.0,CHEMBL617995,,,,,4,1
3071,104714,,BAO_0000019,,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.1 uM,,,H,Autocuration,F,10141.0,CHEMBL617996,,,,,4,1
3072,104714,,BAO_0000019,,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM,,,H,Autocuration,F,10141.0,CHEMBL617997,,,,,4,1
3073,104714,,BAO_0000019,,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM in the presence of 30 uM MDL 72222,,,H,Autocuration,F,10141.0,CHEMBL617998,,,,,4,1
3074,104714,,BAO_0000019,,,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 0.01 uM,,,H,Autocuration,F,10141.0,CHEMBL617999,,,,,4,1
3075,104714,,BAO_0000019,,,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 1 uM,,,H,Autocuration,F,10141.0,CHEMBL618000,,,,,4,1
3076,104714,,BAO_0000221,,,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum",,,H,Autocuration,F,10141.0,CHEMBL617815,,2116.0,Ileum,,4,1
3077,104714,,BAO_0000221,,,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum.",,,H,Autocuration,F,10141.0,CHEMBL617816,,2116.0,Ileum,,4,1
3078,104714,,BAO_0000221,,,Tested for the antagonistic activity against 5-hydroxytryptamine 3 receptor from guinea pig ileum,,,H,Autocuration,F,10141.0,CHEMBL617817,,2116.0,Ileum,,4,1
3079,104714,,BAO_0000221,,,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum,,,H,Autocuration,B,10141.0,CHEMBL617818,,2116.0,Ileum,,4,1
3080,104714,,BAO_0000221,,,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum; Not tested,,,H,Autocuration,B,10141.0,CHEMBL617819,,2116.0,Ileum,,4,1
3081,104714,,BAO_0000223,,,Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15,,,H,Autocuration,B,10141.0,CHEMBL617820,,,,,4,1
3082,104714,,BAO_0000221,,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,,,H,Autocuration,B,10141.0,CHEMBL617821,,2116.0,Ileum,,4,1
3083,104714,,BAO_0000221,,,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),,,H,Autocuration,F,10141.0,CHEMBL617822,,2116.0,Ileum,,4,1
3084,104714,,BAO_0000221,,,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor of isolated guinea pig ileum (GPI),,,H,Autocuration,F,10141.0,CHEMBL617823,,2116.0,Ileum,,4,1
3085,104714,,BAO_0000221,,,Tested for antagonistic activity on 5-hydroxytryptamine 3 receptor mediated effects of 5-HT in guinea pig isolated ileum,,,H,Autocuration,F,10141.0,CHEMBL617824,,2116.0,Ileum,,4,1
3086,104714,,BAO_0000221,,,Agonistic activity against 5-hydroxytryptamine 3 receptor in guinea pig ileum assay,,,H,Autocuration,F,10141.0,CHEMBL617825,,2116.0,Ileum,,4,1
3087,104714,,BAO_0000221,,,5-hydroxytryptamine 3 receptor agonism in the guinea pig ileum by functional 5-HT3 receptor assay,,,H,Autocuration,F,10141.0,CHEMBL617826,,2116.0,Ileum,,4,1
3088,104714,,BAO_0000221,,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,,,H,Autocuration,B,10141.0,CHEMBL617827,,2116.0,Ileum,,4,1
3089,104714,,BAO_0000221,,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),,,H,Autocuration,F,10141.0,CHEMBL617828,,2116.0,Ileum,,4,1
3090,104714,,BAO_0000221,,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,,,H,Autocuration,B,10141.0,CHEMBL617829,,2116.0,Ileum,,4,1
3091,104714,,BAO_0000221,,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum; Not determined,,,H,Autocuration,B,10141.0,CHEMBL617830,,2116.0,Ileum,,4,1
3092,104714,,BAO_0000221,,,Binding affinity towards 5-hydroxytryptamine 3 receptor of guinea pig ileum; not determined,,,H,Autocuration,B,10141.0,CHEMBL617831,,2116.0,Ileum,,4,1
3093,104714,,BAO_0000221,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor in guinea pig ileum.,,,H,Autocuration,B,10141.0,CHEMBL617832,,2116.0,Ileum,,4,1
3094,22226,,BAO_0000019,,,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,,,U,Autocuration,B,10141.0,CHEMBL617833,,,,,0,1
3095,51,,BAO_0000357,,,Binding affinity towards 5-HT1A receptor by the displacement of [3H]-8-OH-DPAT] in human recombinant receptors in mammalian cell,,,H,Autocuration,B,,CHEMBL617834,,,,,8,1
3096,104714,,BAO_0000223,,,Affinity towards human 5-hydroxytryptamine 3 serotonin receptor,,,D,Expert,B,9606.0,CHEMBL617835,,,,,5,1
3097,104714,,BAO_0000223,,,Binding affinity towards 5-HT3 receptor,,,H,Autocuration,B,,CHEMBL617836,,,,,4,1
3098,104714,,BAO_0000223,,,Binding activity radioligand.,,,H,Autocuration,B,,CHEMBL617837,,,,,4,1
3099,104714,,BAO_0000019,,,Binding activity against 5-hydroxytryptamine 1A receptor from human brain cortex using [3H]8-OH-DPAT-HT as radioligand.,,,H,Autocuration,B,,CHEMBL620392,,,,,4,1
3100,104714,,BAO_0000223,,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,,,H,Autocuration,B,,CHEMBL620393,,,,,4,1
3101,104714,,BAO_0000223,,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,,,H,Autocuration,B,,CHEMBL620394,,,,,4,1
3102,104714,,BAO_0000223,,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor; NT means Not tested,,,H,Autocuration,B,,CHEMBL620395,,,,,4,1
3103,22226,,BAO_0000019,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 3 receptor,,,U,Autocuration,B,,CHEMBL620396,,,,,0,1
3104,105030,,BAO_0000219,433.0,NG108-15,Displacement of [3H]-BRC 36694 from 5-hydroxytryptamine 3 receptor in NG108-15 cells,,,H,Expert,B,,CHEMBL620582,,,,,4,1
3105,105030,In vivo,BAO_0000218,,,"Percent inhibition of [3H]5 binding to 5-hydroxytryptamine 3 receptor was evaluated by injection of compound (75 microCi/kg, 1.32 ug/kg) into the tail vein of mice (in vivo)",,,H,Autocuration,B,,CHEMBL620583,,,,,4,1
3106,105030,,BAO_0000019,,,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),,,H,Autocuration,B,,CHEMBL620584,,,,,4,1
3107,105030,,BAO_0000224,,,Compound was evaluated for the binding affinity at 5- HT3 receptor subtype,,,H,Autocuration,B,,CHEMBL620585,,,,,4,1
3108,105030,,BAO_0000224,,,Compound was evaluated for the binding affinity at 5- HT3 receptor,,,H,Autocuration,B,,CHEMBL620586,,,,,4,1
3109,105030,,BAO_0000019,,,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),,,H,Autocuration,B,,CHEMBL620587,,,,,4,1
3110,105030,,BAO_0000019,,,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,,,H,Autocuration,B,,CHEMBL620588,,,,,4,1
3111,105030,,BAO_0000218,,,5-hydroxytryptamine 3 receptor agonism in mouse,,,H,Autocuration,F,,CHEMBL620589,,,,,4,1
3112,105030,,BAO_0000219,,,Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells,,,H,Autocuration,B,,CHEMBL620590,,,,,4,1
3113,105030,,BAO_0000019,,,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,,,H,Autocuration,B,,CHEMBL617956,,,,,4,1
3114,105030,,BAO_0000019,,,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,,,H,Autocuration,B,,CHEMBL617957,,,,,4,1
3115,105030,,BAO_0000224,,,Binding affinity was evaluated by 5-hydroxytryptamine 3 receptor agonism in the mouse NIE-115 by displacing tropisetron,,,H,Autocuration,B,,CHEMBL617958,,,,,4,1
3116,105030,,BAO_0000219,,,Compound was evaluated for binding to 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,,,H,Autocuration,B,,CHEMBL617959,,,,,4,1
3117,105030,,BAO_0000219,,,Compound was evaluated for binding to Serotonin 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,,,H,Autocuration,B,,CHEMBL617960,,,,,4,1
3118,105030,,BAO_0000224,,,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,,,H,Autocuration,B,,CHEMBL617961,,,,,4,1
3119,105030,In vitro,BAO_0000219,,,Ability to displace the radioligand [3H]GR-65630 from 5-hydroxytryptamine 3 receptor expressed in NIE-115 cells,,,H,Autocuration,B,,CHEMBL617962,,,,,4,1
3120,105030,,BAO_0000219,339.0,N1E-115,In vitro binding affinity at 5-hydroxytryptamine 3 receptor in N1E-115 cells using 3[H]GR-65630 as the radioligand,,,H,Autocuration,B,,CHEMBL617963,,,,,4,1
3121,11765,,BAO_0000019,,,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,,,H,Autocuration,B,,CHEMBL617964,,,,,8,1
3122,11765,,BAO_0000219,,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in NG cells 108-15,,,H,Autocuration,B,,CHEMBL617965,,,,,8,1
3123,10630,,BAO_0000357,,,Compound was tested for the Binding affinity against N1e-115 neuroblastoma 5-hydroxytryptamine 3 receptor by Radio ligand [3H]GR-65630 binding assay.,,,D,Autocuration,B,10090.0,CHEMBL617966,,,,,9,1
3124,17106,,BAO_0000019,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,,H,Autocuration,B,,CHEMBL857074,,,,,8,1
3125,144,,BAO_0000357,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor,,,H,Autocuration,B,9823.0,CHEMBL617967,,,,,8,1
3126,144,,BAO_0000357,,,Binding activity radioligand.,,,H,Autocuration,B,9823.0,CHEMBL617968,,,,,8,1
3127,104714,,BAO_0000223,,,Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vagus,,,H,Autocuration,B,9986.0,CHEMBL617969,,,,,4,1
3128,104714,,BAO_0000223,,,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,,,H,Autocuration,B,9986.0,CHEMBL617970,,,,,4,1
3129,104714,,BAO_0000223,,,Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heart,,,H,Autocuration,B,9986.0,CHEMBL617971,,,,,4,1
3130,104714,,BAO_0000019,,,Potency to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,,,H,Autocuration,B,9986.0,CHEMBL617972,,,,,4,1
3131,104714,,BAO_0000019,,,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,,H,Autocuration,F,9986.0,CHEMBL617973,,,,,4,1
3132,104714,,BAO_0000019,,,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,,H,Autocuration,F,9986.0,CHEMBL617974,,,,,4,1
3133,104714,,BAO_0000221,,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),,,H,Autocuration,F,9986.0,CHEMBL617975,,2116.0,Ileum,,4,1
3134,104714,,BAO_0000019,,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,,H,Autocuration,F,9986.0,CHEMBL617976,,,,,4,1
3135,104714,,BAO_0000019,,,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,,H,Autocuration,F,9986.0,CHEMBL617977,,,,,4,1
3136,104714,,BAO_0000019,,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,,H,Autocuration,F,9986.0,CHEMBL617978,,,,,4,1
3137,104714,,BAO_0000019,,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,,H,Autocuration,F,9986.0,CHEMBL617979,,,,,4,1
3138,104714,,BAO_0000219,449.0,CHO,Binding affinity against 5-hydroxytryptamine 3 receptor in CHO cells using [3H]5-HT as radioligand,,,H,Autocuration,B,9986.0,CHEMBL617980,,,,,4,1
3139,104698,,BAO_0000019,,,In vitro displacement of [3H]-LY 278584 from rat cerebral cortex 5-hydroxytryptamine 3 receptor,,,D,Autocuration,B,10116.0,CHEMBL617981,,,,,7,1
3140,12020,,BAO_0000019,,,Affinity at 5-hydroxytryptamine 3 receptor from rat frontal cortex using [3H]granisetron as radioligand (For granisetron = Ki(nM)=0.3+/-0.01),,,H,Autocuration,B,,CHEMBL617982,,,,,8,1
3141,12020,,BAO_0000357,,,Affinity at 5-hydroxytryptamine 3 receptor (For granisetron = Ki (nM)=0.3+/-0.01),,,H,Autocuration,B,,CHEMBL617983,,,,,8,1
3142,104698,,BAO_0000019,,,In vitro displacement of [3H]ICS-205-930 from 5-hydroxytryptamine 3 receptor in cultured NG-108-15 rat glioma cells,,,D,Autocuration,B,10116.0,CHEMBL617984,,,,,7,1
3143,104698,,BAO_0000019,,,"Binding affinity for 5-hydroxytryptamine 3 receptor in rat cerebral cortex, determined by displacement of [3H]GR-65630",,,H,Autocuration,B,,CHEMBL617985,,,,,6,1
3144,104698,In vivo,BAO_0000218,,,"5-Hydroxy tryptamine 3 receptor showing agonist activity (in vivo) in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",,,H,Autocuration,F,,CHEMBL617986,,948.0,Heart,,6,1
3145,104698,,BAO_0000019,,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",,,H,Autocuration,F,,CHEMBL617987,,948.0,Heart,,6,1
3146,104698,,BAO_0000019,,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",,,H,Autocuration,F,,CHEMBL617988,,948.0,Heart,,6,1
3147,104698,,BAO_0000019,,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as change in heart rate",,,H,Autocuration,F,,CHEMBL617792,,948.0,Heart,,6,1
3148,104698,,BAO_0000019,,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptorr in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",,,H,Autocuration,F,,CHEMBL617793,,948.0,Heart,,6,1
3149,104698,,BAO_0000019,,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100(ug/kg), evaluated as percent inhibition of bradycardia",,,H,Autocuration,F,,CHEMBL617794,,,,,6,1
3150,104698,,BAO_0000019,,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",,,H,Autocuration,F,,CHEMBL617795,,,,,6,1
3151,104698,,BAO_0000019,,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",,,H,Autocuration,F,,CHEMBL617796,,,,,6,1
3152,104698,,BAO_0000019,,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60(ug/kg), evaluated as percent inhibition of bradycardia",,,H,Autocuration,F,,CHEMBL617797,,,,,6,1
3153,104698,In vivo,BAO_0000218,,,Antagonism of 5-HT-induced Von Bezold-Jarisch reflex in rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor antagonism),,,D,Autocuration,F,10116.0,CHEMBL617798,,,,,7,1
3154,104698,In vivo,BAO_0000218,,,Ability to antagonise the 5-HT- induced Von Bezold-Jarisch reflex in the rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor),,,H,Autocuration,F,,CHEMBL617799,,,,,6,1
3155,104698,In vivo,BAO_0000218,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,,,D,Autocuration,F,10116.0,CHEMBL617800,,,,,7,1
3156,104698,,BAO_0000019,,,Inhibition of 5-HT-induced bradycardia by 5-hydroxytryptamine 3+,,,D,Autocuration,F,10116.0,CHEMBL617801,,,,,7,1
3157,104698,In vivo,BAO_0000218,,,In vivo inhibitory concentration after 5 minutes against 5-hydroxytryptamine 3 receptor induced bradycardia [bezold-jarisch (B-J) reflex test] in rat by intravenous administration,,,D,Autocuration,F,10116.0,CHEMBL617802,,,,,7,1
3158,104698,,BAO_0000019,,,Inhibition of 5-HT (1 ug/mL) induced depolarization in rat vagus nerve (5-hydroxytryptamine 3 receptor antagonism),,,D,Autocuration,F,10116.0,CHEMBL617803,,,,,7,1
3159,104698,,BAO_0000019,,,Binding affinity towards 5-HT3 receptor in rat was evaluated,,,H,Autocuration,B,,CHEMBL617804,,,,,6,1
3160,104698,,BAO_0000019,,,Inhibition of [3H]GR-65630 binding to rat cortical membrane 5-hydroxytryptamine 3 receptor,,,D,Autocuration,B,10116.0,CHEMBL617805,,,,,7,1
3161,104698,,BAO_0000223,,,Binding affinity was evaluated in vitro by displacement of [3H]zacopride radioligand from 5-hydroxytryptamine 3 receptor,,,H,Autocuration,B,,CHEMBL617806,,,,,6,1
3162,104698,,BAO_0000019,,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex.,,,H,Autocuration,B,,CHEMBL617807,,,,,6,1
3163,104698,,BAO_0000019,,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement of [3H]granisetron from rat cerebral cortex,,,H,Autocuration,B,,CHEMBL617808,,,,,6,1
3164,104698,,BAO_0000249,,,Binding affinity against 5-hydroxytryptamine 3 receptor in rat cortical membrane using [3H]GR-65630 as radioligand,,,H,Autocuration,B,,CHEMBL617809,,,,,6,1
3165,104698,,BAO_0000019,,,Compound was tested for its ability to displace [3H]-Q-ICS 205-930 from 5-hydroxytryptamine 3 receptor in rat cortex homogenates,,,H,Autocuration,B,,CHEMBL617810,,,,,6,1
3166,104698,,BAO_0000249,,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to 5-hydroxytryptamine 3 receptor in rat brain cortical membrane,,,H,Autocuration,B,,CHEMBL617811,,955.0,Brain,,6,1
3167,104698,,BAO_0000221,,,Concentration required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine-3 receptor (5-HT 3 receptor)in rat brain cortical membrane,,,H,Autocuration,B,,CHEMBL617812,,955.0,Brain,,6,1
3168,104698,,BAO_0000249,,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine 3 receptor in rat cortical membrane,,,H,Autocuration,B,,CHEMBL617813,,,,,6,1
3169,104698,,BAO_0000249,,,In vitro inhibitory concentration against radioligand [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in rat cortical membrane,,,H,Autocuration,B,,CHEMBL617814,,,,,6,1
3170,104698,,BAO_0000019,,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate.,,,H,Autocuration,B,,CHEMBL617698,,,,,6,1
3171,104698,,BAO_0000019,,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; Not active at 10000 nm,,,D,Autocuration,B,10116.0,CHEMBL617699,,,,,7,1
3172,104698,,BAO_0000019,,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; not active at 10000 nM,,,D,Autocuration,B,10116.0,CHEMBL617700,,,,,7,1
3173,104698,,BAO_0000223,,,Inhibition of radiolabeled [3H]-Zacopride ligand binding to 5-hydroxytryptamine 3 receptor,,,D,Autocuration,B,10116.0,CHEMBL617701,,,,,7,1
3174,104698,,BAO_0000019,,,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,,,H,Autocuration,B,,CHEMBL617702,,,,,6,1
3175,104698,,BAO_0000249,,,"Tested for inhibition of binding of [3H]GR-65630 to rat cortical membranes, expressed as IC50",,,H,Autocuration,B,,CHEMBL617703,,,,Membranes,6,1
3176,104698,,BAO_0000019,,,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 3 receptor,,,D,Autocuration,B,10116.0,CHEMBL617704,,,,,7,1
3177,104698,,BAO_0000223,,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,,,H,Autocuration,B,,CHEMBL617705,,,,,6,1
3178,104698,,BAO_0000223,,,Inhibition of [3H]BRL-43694 binding to rat 5-hydroxytryptamine 3 receptor,,,D,Autocuration,B,10116.0,CHEMBL617706,,,,,7,1
3179,104698,,BAO_0000219,433.0,NG108-15,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells (using [3H]zacopride as radioligand),,,H,Autocuration,B,,CHEMBL617707,,,,,6,1
3180,104698,,BAO_0000219,433.0,NG108-15,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells using [3H]zacopride as radioligand,,,H,Autocuration,B,,CHEMBL617708,,,,,6,1
3181,104698,,BAO_0000019,,,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor from rat cortical homogenate using [3H]zacopride as radioligand,,,H,Autocuration,B,,CHEMBL617709,,,,,6,1
3182,104698,,BAO_0000019,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA= Not active,,,H,Autocuration,B,,CHEMBL617710,,,,,6,1
3183,104698,,BAO_0000019,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA=Not active,,,H,Autocuration,B,,CHEMBL882925,,,,,6,1
3184,104698,,BAO_0000019,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; not active,,,H,Autocuration,B,,CHEMBL617711,,,,,6,1
3185,104698,,BAO_0000019,,,Antagonist potency to 5-hydroxytryptamine 3 receptor was assayed by antagonism of the 5-HT-evoked reflex bradycardia [Bezold-Jarisch(BJ) reflex] in rats,,,H,Autocuration,F,,CHEMBL617712,,,,,6,1
3186,104698,,BAO_0000019,,,Antagonistic activity against 5-hydroxytryptamine 3 receptor as inhibition of 5-HT-induced bradycardia (von Bezold-jarisch reflex) in anesthetized rat,,,D,Autocuration,F,10116.0,CHEMBL617713,,,,,7,1
3187,104698,,BAO_0000019,,,"Compound was tested as a 5-hydroxytryptamine 3 receptor antagonist in the rat by assessment of the inhibition of the Bezold-Jarisch effect, when administered intravenously",,,H,Autocuration,F,,CHEMBL617714,,,,,6,1
3188,104698,,BAO_0000218,,,In vivo 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) antagonistic activity expressed as ability to inhibit Bezold-Jarich reflex evoked by 5-HT in rats,,,H,Autocuration,F,,CHEMBL617715,,,,,6,1
3189,104698,In vivo,BAO_0000218,,,Inhibition dose for 50 percent antagonism for 5-hydroxytryptamine 3 receptor in vivo in rats,,,H,Autocuration,F,,CHEMBL617716,,,,,6,1
3190,104698,,BAO_0000218,,,Inhibition of 5-HT evoked reflex bradycardia in rat.,,,H,Autocuration,F,,CHEMBL617717,,,,,6,1
3191,104698,In vivo,BAO_0000218,,,5-HT3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,,H,Autocuration,F,,CHEMBL617718,,,,,6,1
3192,104698,In vivo,BAO_0000218,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1 ug/kg dose in urethane-anesthetized rats,,,H,Autocuration,F,,CHEMBL617719,,,,,6,1
3193,104698,In vivo,BAO_0000218,,,5-hydroxytryptamine 3 receptor antagonistic activity measured by inhibition of 5-HT-induced bradycardia (iv administration 10 ug/kg dose in urethane-anesthetized rats),,,H,Autocuration,F,,CHEMBL617720,,,,,6,1
3194,104698,In vivo,BAO_0000218,,,5-hydroxytryptamine 3 receptor antagonistic activity as inhibition of 5-HT-induced bradycardia after iv administration of 100 ug/kg dose in urethane-anesthetized rats,,,D,Autocuration,F,10116.0,CHEMBL617721,,,,,7,1
3195,104698,In vivo,BAO_0000218,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,,H,Autocuration,F,,CHEMBL617722,,,,,6,1
3196,104698,In vivo,BAO_0000218,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kgetized rats,,,H,Autocuration,F,,CHEMBL617723,,,,,6,1
3197,104698,In vivo,BAO_0000218,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 3 ug/kg dose in urethane-anesthetized rats,,,H,Autocuration,F,,CHEMBL617724,,,,,6,1
3198,104698,In vivo,BAO_0000218,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 10 ug/kg dose in urethane-anesthetized rats,,,H,Autocuration,F,,CHEMBL617725,,,,,6,1
3199,104698,In vivo,BAO_0000218,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 100 ug/kg dose in urethane-anesthetized rats,,,H,Autocuration,F,,CHEMBL617726,,,,,6,1
3200,104698,In vivo,BAO_0000218,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 1000 ug/kg dose in urethane-anesthetized rats,,,H,Autocuration,F,,CHEMBL617727,,,,,6,1
3201,104698,In vivo,BAO_0000218,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 30 ug/kg dose in urethane-anesthetized rats,,,H,Autocuration,F,,CHEMBL617728,,,,,6,1
3202,104698,In vivo,BAO_0000218,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 300 ug/kg dose in urethane-anesthetized rats,,,H,Autocuration,F,,CHEMBL617729,,,,,6,1
3203,104698,In vivo,BAO_0000218,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 3ug/kg dose in urethane-anesthetized rats,,,H,Autocuration,F,,CHEMBL617730,,,,,6,1
3204,104698,In vivo,BAO_0000218,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,,H,Autocuration,F,,CHEMBL617731,,,,,6,1
3205,104698,In vivo,BAO_0000218,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 0.3 ug/kg dose in urethane-anesthetized rats,,,H,Autocuration,F,,CHEMBL617732,,,,,6,1
3206,104698,In vivo,BAO_0000218,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 1 ug/kg dose in urethane-anesthetized rats,,,H,Autocuration,F,,CHEMBL617733,,,,,6,1
3207,104698,In vivo,BAO_0000218,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 30 ug/kg dose in urethane-anesthetized rats,,,H,Autocuration,F,,CHEMBL617734,,,,,6,1
3208,104698,In vivo,BAO_0000218,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 0.05 hour,,,H,Autocuration,F,,CHEMBL872874,,,,,6,1
3209,104698,In vivo,BAO_0000218,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 1 hour,,,H,Autocuration,F,,CHEMBL617735,,,,,6,1
3210,104698,In vivo,BAO_0000218,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 16 hour,,,H,Autocuration,F,,CHEMBL617736,,,,,6,1
3211,104698,In vivo,BAO_0000218,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 3 hour,,,H,Autocuration,F,,CHEMBL617737,,,,,6,1
3212,104698,In vivo,BAO_0000218,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 6 hour,,,H,Autocuration,F,,CHEMBL617738,,,,,6,1
3213,104698,In vivo,BAO_0000218,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,,,H,Autocuration,F,,CHEMBL617739,,,,,6,1
3214,104698,In vivo,BAO_0000218,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 100 ug/kg dose in urethane-anesthetized rats,,,H,Autocuration,F,,CHEMBL617740,,,,,6,1
3215,104698,In vivo,BAO_0000218,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,,,H,Autocuration,F,,CHEMBL617741,,,,,6,1
3216,104698,In vivo,BAO_0000218,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,,,H,Autocuration,F,,CHEMBL617742,,,,,6,1
3217,104698,In vivo,BAO_0000218,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 3 ug/kg dose in urethane-anesthetized rats,,,H,Autocuration,F,,CHEMBL617743,,,,,6,1
3218,104698,In vivo,BAO_0000218,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 30 ug/kg dose in urethane-anesthetized rats,,,H,Autocuration,F,,CHEMBL617744,,,,,6,1
3219,104698,In vivo,BAO_0000218,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 300 ug/kg dose in urethane-anesthetized rats,,,H,Autocuration,F,,CHEMBL617745,,,,,6,1
3220,104698,,BAO_0000218,,,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.)",,,H,Autocuration,F,,CHEMBL617746,,,,,6,1
3221,104698,,BAO_0000218,,,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.); Not tested",,,H,Autocuration,F,,CHEMBL617747,,,,,6,1
3222,104698,In vivo,BAO_0000218,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 10 ug/Kg,,,H,Autocuration,F,,CHEMBL617748,,,,,6,1
3223,104698,In vivo,BAO_0000218,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 100 ug/Kg,,,H,Autocuration,F,,CHEMBL618909,,,,,6,1
3224,104698,In vivo,BAO_0000218,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 2 ug/Kg,,,H,Autocuration,F,,CHEMBL618910,,,,,6,1
3225,104698,In vivo,BAO_0000218,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 20 ug/Kg,,,H,Autocuration,F,,CHEMBL618911,,,,,6,1
3226,104698,In vivo,BAO_0000218,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 5 ug/Kg,,,H,Autocuration,F,,CHEMBL618912,,,,,6,1
3227,104698,In vivo,BAO_0000218,,,Tested for inhibition of Bezold-Jarisch (B-J) reflex mediated by 5-hydroxytryptamine 3 receptor in rats after intravenous administration (2.0 ug/kg),,,H,Autocuration,F,,CHEMBL618913,,,,,6,1
3228,104698,,BAO_0000019,,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,,,H,Autocuration,F,,CHEMBL618914,,,,,6,1
3229,104698,,BAO_0000019,,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,,,H,Autocuration,F,,CHEMBL618915,,,,,6,1
3230,104698,,BAO_0000223,,,Intrinsic efficacy for rat 5-hydroxytryptamine 3 receptor,,,D,Autocuration,B,10116.0,CHEMBL618916,,,,,7,1
3231,104698,,BAO_0000019,,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; PA means partial agonist,,,H,Autocuration,F,,CHEMBL618917,,,,,6,1
3232,104698,,BAO_0000221,,,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) of rat cortex and hippocampus tissue,,,D,Intermediate,B,,CHEMBL618918,,10000000.0,Hippocampus,,7,1
3233,104698,,BAO_0000019,,,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor of rat cortical membrane,,,D,Autocuration,B,10116.0,CHEMBL618919,,,,,7,1
3234,104698,,BAO_0000019,,,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 5-hydroxytryptamine 3 receptor,,,D,Autocuration,B,10116.0,CHEMBL618920,,,,,7,1
3235,104698,,BAO_0000223,,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 3 receptor,,,H,Autocuration,B,,CHEMBL618921,,,,,6,1
3236,104698,,BAO_0000019,,,Affinity was evaluated by inhibition of [3H]GR-65630 binding to NG108-15 cell transfected with cloned rat 5-hydroxytryptamine 3 receptor,,,H,Autocuration,B,,CHEMBL618922,,,,,6,1
3237,104698,,BAO_0000019,,,Binding affinity against radioligand [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in neuroblastoma-glioma (NG108-15) cells.,,,H,Autocuration,B,,CHEMBL618923,,,,,6,1
3238,104698,,BAO_0000019,,,Binding affinity for 5-hydroxytryptamine 3 receptor was determined by measuring displacement of [3H]GR-65630 from rat brain cortices,,,H,Autocuration,B,,CHEMBL618924,,,,,6,1
3239,104698,,BAO_0000019,,,Binding affinity to 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-BRL 43694 as radioligand,,,H,Autocuration,B,,CHEMBL618925,,,,,6,1
3240,104698,,BAO_0000019,,,Binding affinity towards 5-HT3 receptor in rat was evaluated,,,H,Autocuration,B,,CHEMBL618926,,,,,6,1
3241,20033,,BAO_0000221,,,5-hydroxytryptamine 4 receptor agonist activity as increased response to electrical stimulation in guinea pig ileum,,,D,Intermediate,F,10141.0,CHEMBL618927,,2116.0,Ileum,,9,1
3242,20033,,BAO_0000221,,,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum; Not tested,,,D,Intermediate,F,10141.0,CHEMBL618928,,2116.0,Ileum,,9,1
3243,20033,,BAO_0000221,,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum",,,D,Intermediate,F,10141.0,CHEMBL618929,,2116.0,Ileum,,9,1
3244,20033,,BAO_0000221,,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Inactive up to 10E-5 M",,,D,Intermediate,F,10141.0,CHEMBL618930,,2116.0,Ileum,,9,1
3245,20033,,BAO_0000221,,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",,,D,Intermediate,F,10141.0,CHEMBL618931,,2116.0,Ileum,,9,1
3246,20033,,BAO_0000221,,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",,,D,Intermediate,F,10141.0,CHEMBL619594,,2116.0,Ileum,,9,1
3247,20033,,BAO_0000221,,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not capable of evaluation",,,D,Intermediate,F,10141.0,CHEMBL619595,,2116.0,Ileum,,9,1
3248,20033,,BAO_0000221,,,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum.,,,D,Intermediate,F,10141.0,CHEMBL619596,,2116.0,Ileum,,9,1
3249,20033,,BAO_0000221,,,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum. Activity expressed as percent of the maximum 5-HT response given in brackets.,,,D,Intermediate,F,10141.0,CHEMBL619755,,2116.0,Ileum,,9,1
3250,20033,,BAO_0000221,,,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum,,,D,Intermediate,F,10141.0,CHEMBL619756,,2116.0,Ileum,,9,1
3251,20033,,BAO_0000221,,,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not evaluable,,,D,Intermediate,F,10141.0,CHEMBL619757,,2116.0,Ileum,,9,1
3252,20033,,BAO_0000221,,,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not tested,,,D,Intermediate,F,10141.0,CHEMBL619758,,2116.0,Ileum,,9,1
3253,20033,,BAO_0000221,,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum",,,D,Intermediate,F,10141.0,CHEMBL619759,,2116.0,Ileum,,9,1
3254,20033,,BAO_0000221,,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10-5 M",,,D,Intermediate,F,10141.0,CHEMBL619760,,2116.0,Ileum,,9,1
3255,20033,,BAO_0000221,,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10E-5 M",,,D,Intermediate,F,10141.0,CHEMBL619761,,2116.0,Ileum,,9,1
3256,20033,,BAO_0000221,,,5-hydroxytryptamine 4 receptor antagonist activity as inhibition of 5-HT-induced contractions in guinea pig ileum; Not capable of evaluation.,,,D,Intermediate,F,10141.0,CHEMBL619762,,2116.0,Ileum,,9,1
3257,20033,,BAO_0000221,,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",,,D,Intermediate,F,10141.0,CHEMBL619763,,2116.0,Ileum,,9,1
3258,20033,,BAO_0000221,,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",,,D,Intermediate,F,10141.0,CHEMBL617868,,2116.0,Ileum,,9,1
3259,20033,,BAO_0000357,,,Displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor in guinea pig striatum,,,D,Intermediate,B,10141.0,CHEMBL617869,,,,,9,1
3260,20033,,BAO_0000249,,,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,,,D,Intermediate,B,10141.0,CHEMBL882926,,2435.0,Striatum,,9,1
3261,20033,,BAO_0000249,,,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,,,D,Intermediate,B,10141.0,CHEMBL617870,,2435.0,Striatum,,9,1
3262,20033,,BAO_0000357,,,Inhibitory activity against 5-hydroxytryptamine 4 receptor of guinea pig striatum using [3H]GR-113808 as radioligand,,,D,Intermediate,B,10141.0,CHEMBL617871,,2435.0,Striatum,,9,1
3263,20033,,BAO_0000357,,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea pig striatum,,,D,Intermediate,B,10141.0,CHEMBL617872,,2435.0,Striatum,,9,1
3264,20033,,BAO_0000357,,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea-pig striatum,,,D,Intermediate,B,10141.0,CHEMBL617873,,2435.0,Striatum,,9,1
3265,20033,,BAO_0000357,,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to serotonin 5-hydroxytryptamine 4 receptor in guinea-pig striatum,,,D,Intermediate,B,10141.0,CHEMBL617874,,2435.0,Striatum,,9,1
3266,20033,,BAO_0000221,,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum.,,,D,Intermediate,F,10141.0,CHEMBL619067,,2116.0,Ileum,,9,1
3267,20033,,BAO_0000221,,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum. 95% confidence limits are in brackets.,,,D,Intermediate,F,10141.0,CHEMBL619068,,2116.0,Ileum,,9,1
3268,20033,,BAO_0000221,,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,,,D,Intermediate,F,10141.0,CHEMBL619069,,2116.0,Ileum,,9,1
3269,20033,,BAO_0000357,,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-6 M in guinea pig,,,D,Intermediate,B,10141.0,CHEMBL619070,,,,,9,1
3270,20033,,BAO_0000357,,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-8 M in guinea pig,,,D,Intermediate,B,10141.0,CHEMBL619071,,,,,9,1
3271,20033,,BAO_0000019,,,Agonistic activity against 5-hydroxytryptamine 4 receptor,,,D,Intermediate,F,10141.0,CHEMBL619072,,,,,9,1
3272,20033,,BAO_0000019,,,Agonistic activity against 5-hydroxytryptamine 4 receptor; not tested,,,D,Intermediate,F,10141.0,CHEMBL619073,,,,,9,1
3273,20033,,BAO_0000019,,,Compound was evaluated for the relative potency with respect to serotonin against 5-hydroxytryptamine 4 receptor,,,D,Intermediate,F,10141.0,CHEMBL619074,,,,,9,1
3274,20033,,BAO_0000357,,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor,,,D,Intermediate,B,10141.0,CHEMBL619075,,,,,9,1
3275,20033,,BAO_0000357,,,Inhibition of [3H]GR-113808 binding to guinea pig striatum 5-hydroxytryptamine 4 receptor,,,D,Intermediate,B,10141.0,CHEMBL619076,,2435.0,Striatum,,9,1
3276,20033,,BAO_0000357,,,Binding affinity against 5-hydroxytryptamine 4 receptor in guinea pig striatum using [3H]GR-113808 as radioligand,,,D,Intermediate,B,10141.0,CHEMBL619077,,2435.0,Striatum,,9,1
3277,20033,,BAO_0000249,,,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,,,D,Intermediate,B,10141.0,CHEMBL619078,,2435.0,Striatum,,9,1
3278,20033,,BAO_0000249,,,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,,,D,Intermediate,B,10141.0,CHEMBL619079,,2435.0,Striatum,,9,1
3279,20033,,BAO_0000221,,,Tested for affinity against 5-hydroxytryptamine 4 receptor in the myenteric plexus of the guinea pig ileum.,,,D,Intermediate,B,10141.0,CHEMBL619080,,2116.0,Ileum,,9,1
3280,20033,,BAO_0000357,,,Displacement of [3H]-GR113808 from 5-HT4 receptor of guinea pig striatum,,,D,Expert,B,10141.0,CHEMBL619081,,,,,9,1
3281,20033,,BAO_0000357,,,The compound was tested for their binding affinity towards 5-HT4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,,,D,Intermediate,B,10141.0,CHEMBL619082,,,,,9,1
3282,20033,,BAO_0000357,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand.,,,D,Intermediate,B,10141.0,CHEMBL619083,,,,,9,1
3283,20033,,BAO_0000357,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,,,D,Intermediate,B,10141.0,CHEMBL619084,,,,,9,1
3284,20033,,BAO_0000221,,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,,,D,Intermediate,F,10141.0,CHEMBL859397,,2116.0,Ileum,,9,1
3285,20033,,BAO_0000221,,,5-hydroxytryptamine 4 receptor agonist activity in the guinea pig ileum assay,,,D,Intermediate,F,10141.0,CHEMBL619085,,2116.0,Ileum,,9,1
3286,20033,,BAO_0000221,,,5-hydroxytryptamine 4 receptor agonistic activity was measured by twitch response enhancing activity in electrically stimulated guinea pig ileum preparation,,,D,Intermediate,F,10141.0,CHEMBL619086,,2116.0,Ileum,,9,1
3287,20033,,BAO_0000221,,,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI).,,,D,Intermediate,F,10141.0,CHEMBL619087,,2116.0,Ileum,,9,1
3288,20033,,BAO_0000221,,,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,,,D,Intermediate,F,10141.0,CHEMBL619088,,2116.0,Ileum,,9,1
3289,20033,,BAO_0000357,,,Ability to antagonize 5-HT-evoked contractions mediated through 5-hydroxytryptamine 4 receptor activation in the guinea pig distal colon LMMP,,,D,Intermediate,B,10141.0,CHEMBL619089,,,,,9,1
3290,168,,BAO_0000357,,,Binding affinity was determined against 5-hydroxytryptamine 3 receptor,,,H,Autocuration,B,10141.0,CHEMBL619090,,,,,8,1
3291,20033,,BAO_0000019,,,Antagonistic activity against 5-hydroxytryptamine 4 receptor,,,D,Intermediate,F,10141.0,CHEMBL619091,,,,,9,1
3292,20033,,BAO_0000357,,,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-hydroxytryptamine 4 receptor,,,D,Intermediate,B,10141.0,CHEMBL619092,,,,,9,1
3293,20033,,BAO_0000019,,,Binding affinity for 5-hydroxytryptamine 4 receptor by displacement of [3H]GR-113808 from guinea pig brain striatum.,,,D,Intermediate,B,10141.0,CHEMBL619093,,,,,9,1
3294,168,,BAO_0000219,722.0,HEK293,Binding affinity was determined against 5-hydroxytryptamine 2C receptor using cloned rat receptors expressed in 293 cells radiolabeled with [3H]mesulergine,,,H,Autocuration,B,10141.0,CHEMBL619094,,,,,8,1
3295,20033,,BAO_0000019,,,In vitro by displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor on guinea pig striatal membrane,,,D,Intermediate,B,10141.0,CHEMBL619095,,,,,9,1
3296,20033,,BAO_0000357,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 4 receptor using radioligand binding assay using [3H]GR as radioligand,,,D,Intermediate,B,10141.0,CHEMBL857988,,,,,9,1
3297,20033,,BAO_0000357,,,Compound was evaluated for its ability to displace [3H]GR-113808 binding from 5-hydroxytryptamine 4 receptor in guinea pig striatum.,,,D,Intermediate,B,10141.0,CHEMBL619096,,,,,9,1
3298,20033,,BAO_0000357,,,In vitro binding affinity at 5-hydroxytryptamine 4 receptor in guinea pig striatum using 3[H]GR-113808 as the radioligand,,,D,Intermediate,B,10141.0,CHEMBL619097,,2435.0,Striatum,,9,1
3299,20033,,BAO_0000221,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 4 receptor in guinea pig hippocampus using [125I]SB-207710.,,,D,Intermediate,B,10141.0,CHEMBL619098,,10000000.0,Hippocampus,,9,1
3300,20033,,BAO_0000357,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand,,,D,Intermediate,B,10141.0,CHEMBL619751,,,,,9,1
3301,20033,,BAO_0000357,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand.,,,D,Intermediate,B,10141.0,CHEMBL619752,,,,,9,1
3302,20033,,BAO_0000221,,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,,,D,Intermediate,F,10141.0,CHEMBL875096,,2116.0,Ileum,,9,1
3303,108,,BAO_0000357,,,Binding affinity towards 5-HT2C receptor by the displacement of [3H]mesulergine] in human recombinant receptors in mammalian cell,,,H,Autocuration,B,,CHEMBL619004,,,,,8,1
3304,168,,BAO_0000357,,,Binding affinity towards human 5-hydroxytryptamine 4 receptor using [3H]5-HT as radioligand,,,H,Autocuration,B,,CHEMBL619005,,,,,8,1
3305,168,,BAO_0000019,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 4 receptor,,,H,Autocuration,B,,CHEMBL619006,,,,,8,1
3306,168,,BAO_0000219,308.0,HeLa,Compound was evaluated for the binding affinity against human cloned 5-hydroxytryptamine 4 receptor in HeLa cells using [3H]-LSD as the radioligand,,,H,Autocuration,B,,CHEMBL619007,,,,,8,1
3307,168,,BAO_0000357,,,Compound was tested for its binding affinity against 5-hydroxytryptamine 4 receptor,,,H,Autocuration,B,,CHEMBL619008,,,,,8,1
3308,168,,BAO_0000357,,,Compound was tested for its binding affinity for 5-hydroxytryptamine 4 receptor,,,H,Autocuration,B,,CHEMBL619009,,,,,8,1
3309,168,,BAO_0000219,308.0,HeLa,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 4 receptor in HeLa cells, using [3H]LSD as radioligand",,,H,Autocuration,B,,CHEMBL619010,,,,,8,1
3310,10622,,BAO_0000357,,,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons,,,H,Autocuration,B,,CHEMBL619011,,,,,8,1
3311,10622,,BAO_0000357,,,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons; IA means inactive,,,H,Autocuration,B,,CHEMBL619012,,,,,8,1
3312,10622,,BAO_0000219,,,Ability to displace [3H]GR-113808 from mouse 5-hydroxytryptamine 4 receptor in COS7 cells,,,H,Autocuration,B,,CHEMBL619013,,,,,8,1
3313,10622,,BAO_0000357,,,Tested for ability to stimulate 5-hydroxytryptamine 4 receptors in mouse Coliculi neurons,,,H,Autocuration,B,,CHEMBL619014,,,,,8,1
3314,11249,,BAO_0000019,,,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model,,,H,Autocuration,F,,CHEMBL857503,,2081.0,Cardiac atrium,,8,1
3315,11249,,BAO_0000019,,,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model; compound found inactive at 1 uM,,,H,Autocuration,F,,CHEMBL619015,,2081.0,Cardiac atrium,,8,1
3316,11249,,BAO_0000357,,,The compound was tested for binding affinity against 5-hydroxytryptamine 4 receptor,,,H,Autocuration,B,,CHEMBL619016,,,,,8,1
3317,11249,,BAO_0000221,,,Compound was tested for binding affinity against piglet hippocampus 5-hydroxytryptamine 4 receptor,,,H,Autocuration,B,,CHEMBL619017,,10000000.0,Hippocampus,,8,1
3318,168,,BAO_0000221,,,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]SB 207710 as radioligand,,,H,Autocuration,B,9823.0,CHEMBL619018,,10000000.0,Hippocampus,,8,1
3319,168,,BAO_0000019,,,Binding affinity against 5-hydroxytryptamine 2A receptor using rabbit saphenous vein assay.,,,H,Autocuration,B,9986.0,CHEMBL619019,,,,,8,1
3320,10623,,BAO_0000357,,,Displacement of [3H]GR-113808 from rat striatum 5-hydroxytryptamine 4 receptor,,,D,Expert,B,10116.0,CHEMBL619020,,,,,9,1
3321,10623,,BAO_0000019,,,Tested for its agonist potency against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,,,H,Autocuration,F,,CHEMBL619021,,,,,8,1
3322,10623,,BAO_0000357,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in relaxation of rat oesophagus,,,H,Autocuration,B,,CHEMBL619022,,,,,8,1
3323,10623,,BAO_0000357,,,Tested for the effect on binding at 5-hydroxytryptamine 4 receptor; No activity,,,H,Autocuration,B,,CHEMBL619023,,,,,8,1
3324,10623,,BAO_0000019,,,lntrinsic activity relative to 5-HT receptor,,,H,Autocuration,F,,CHEMBL619024,,,,,8,1
3325,10623,,BAO_0000019,,,Compound was evaluated for the agonistic activity towards 5-hydroxytryptamine 4 receptor using the rat tunica muscularis mucosae (TMM) esophagus strip assay,,,H,Autocuration,F,,CHEMBL619025,,,,,8,1
3326,10623,,BAO_0000019,,,In vitro relaxation of carbachol pre-contracted rat oesophageal TMM.,,,H,Expert,F,,CHEMBL619026,,,,,8,1
3327,10623,,BAO_0000019,,,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay,,,H,Autocuration,F,,CHEMBL619027,,,,,8,1
3328,10623,,BAO_0000019,,,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay; IN = Inactive,,,H,Autocuration,F,,CHEMBL619028,,,,,8,1
3329,10623,,BAO_0000019,,,Efficient 5-hydroxytryptamine 4 agonist in the rat tunica muscularis mucosae,,,H,Autocuration,F,,CHEMBL619029,,,,,8,1
3330,10623,,BAO_0000019,,,Tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay of racemate mixture,,,H,Autocuration,F,,CHEMBL619030,,,,,8,1
3331,10623,,BAO_0000357,,,Relaxation of carbachol induced contractions of rat tunica muscularis mucosae,,,H,Expert,B,,CHEMBL619031,,,,,8,1
3332,10623,,BAO_0000019,,,5-hydroxytryptamine 4 receptor agonist activity was determined by the relaxation of the carbachol-contracted rat esophageal tunica muscularis mucosae,,,H,Autocuration,F,,CHEMBL619032,,,,,8,1
3333,10623,,BAO_0000357,,,Inhibition of radiolabeled [3H]GR-113808 ligand binding to 5-hydroxytryptamine 4 receptor,,,D,Expert,B,10116.0,CHEMBL619033,,,,,9,1
3334,10623,,BAO_0000357,,,Tested for its efficacy against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,,,H,Autocuration,B,,CHEMBL619034,,,,,8,1
3335,10623,,BAO_0000357,,,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae.,,,H,Autocuration,B,,CHEMBL619035,,,,,8,1
3336,10623,,BAO_0000357,,,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae; No activity up to 104M concentration,,,H,Autocuration,B,,CHEMBL619036,,,,,8,1
3337,10623,,BAO_0000019,,,Binding affinity (Ki+/-SEM) against 5-hydroxytryptamine 4 receptor from cheng Prusoff equation by using [3H]GR-113808 in rat striatum,,,D,Expert,B,10116.0,CHEMBL619037,,,,,9,1
3338,10623,,BAO_0000249,,,Binding affinity towards 5-HT 4 receptor in rat striatum membranes using [3H]GR-113808 as radioligand,,,H,Autocuration,B,,CHEMBL619038,,2435.0,Striatum,,8,1
3339,10623,,BAO_0000249,,,Binding affinity towards 5-HT4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand; Not tested,,,H,Autocuration,B,,CHEMBL619039,,,,,8,1
3340,10623,,BAO_0000249,,,Binding affinity towards 5-hydroxytryptamine 4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand,,,H,Expert,B,,CHEMBL619040,,,,,8,1
3341,10623,,BAO_0000019,,,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,,,D,Expert,B,10116.0,CHEMBL619041,,2435.0,Striatum,,9,1
3342,10623,,BAO_0000019,,,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,,,H,Autocuration,B,,CHEMBL619042,,2435.0,Striatum,,8,1
3343,10623,,BAO_0000249,,,Binding affinity to 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum membrane,,,H,Expert,B,,CHEMBL619043,,2435.0,Striatum,,8,1
3344,10623,,BAO_0000019,,,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatum by [3H]GR-113808 displacement.,,,H,Expert,B,,CHEMBL619044,,2435.0,Striatum,,8,1
3345,10623,,BAO_0000249,,,In vitro affinity at serotonergic 5-hydroxytryptamine 4 receptor by radioligand binding assay using [3H]GR-113808 in rat striatum membranes.,,,H,Expert,B,,CHEMBL619045,,2435.0,Striatum,,8,1
3346,10623,,BAO_0000249,,,In vitro binding affinity to 5-hydroxytryptamine 4 receptor in rat striatum membrane,,,H,Expert,B,,CHEMBL619046,,2435.0,Striatum,,8,1
3347,10623,,BAO_0000249,,,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatal membranes by [3H]GR-113808 displacement.,,,H,Expert,B,,CHEMBL619047,,,,,8,1
3348,10623,,BAO_0000221,,,Tested for potency against 5-hydroxytryptamine 4 receptor agonist in rat brain,,,H,Autocuration,F,,CHEMBL619048,,955.0,Brain,,8,1
3349,10623,,BAO_0000019,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat,,,H,Autocuration,F,,CHEMBL859398,,,,,8,1
3350,10623,,BAO_0000019,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat; ND means not done,,,H,Autocuration,F,,CHEMBL619049,,,,,8,1
3351,10623,,BAO_0000019,,,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae,,,H,Autocuration,F,,CHEMBL857886,,,,,8,1
3352,10623,,BAO_0000019,,,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae; Not tested,,,H,Autocuration,F,,CHEMBL619050,,,,,8,1
3353,10623,,BAO_0000019,,,Antagonist activity against 5-hydroxytryptamine 4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,,,H,Autocuration,F,,CHEMBL620591,,,,,8,1
3354,10623,,BAO_0000357,,,Binding affinity against rat 5-hydroxytryptamine 4 receptor,,,D,Expert,B,10116.0,CHEMBL620592,,,,,9,1
3355,10623,,BAO_0000249,,,pKi against 5-hydroxytryptamine 4 receptor in rat striatum membrane,,,H,Expert,B,,CHEMBL620593,,2435.0,Striatum,,8,1
3356,10623,,BAO_0000019,,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.,,,D,Expert,F,10116.0,CHEMBL620594,,,,,9,1
3357,10623,,BAO_0000019,,,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-6 M.,,,H,Expert,F,,CHEMBL875079,,,,,8,1
3358,10623,,BAO_0000019,,,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,,,H,Expert,F,,CHEMBL620595,,,,,8,1
3359,10623,,BAO_0000019,,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-8 M.,,,D,Expert,F,10116.0,CHEMBL620596,,,,,9,1
3360,10623,,BAO_0000019,,,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-7 M.,,,H,Autocuration,F,,CHEMBL620597,,,,,8,1
3361,10623,,BAO_0000019,,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-8 M.,,,H,Expert,F,,CHEMBL620598,,,,,8,1
3362,10623,,BAO_0000218,,,Antagonistic activity evaluated by ability to block serotonin induced relaxation via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 0.1 mg/kg (p.o.),,,H,Expert,F,,CHEMBL620599,,,,,8,1
3363,10623,,BAO_0000019,,,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,,,H,Autocuration,F,,CHEMBL620600,,,,,8,1
3364,168,,BAO_0000019,,,Estimate from relaxation of carbachol-contracted rat esophageal muscularis mucosae,,,H,Autocuration,F,10116.0,CHEMBL620601,,,,,8,1
3365,168,,BAO_0000019,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 4 receptor on guinea colon at a concentration 0.1 uM,,,H,Autocuration,F,,CHEMBL620602,,,,,8,1
3366,168,,BAO_0000357,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor,,,H,Autocuration,B,,CHEMBL620603,,,,,8,1
3367,168,,BAO_0000357,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor.,,,H,Autocuration,B,,CHEMBL620604,,,,,8,1
3368,168,,BAO_0000357,,,Compound was tested for 5-hydroxytryptamine 4 binding affinity,,,H,Autocuration,B,,CHEMBL620605,,,,,8,1
3369,168,,BAO_0000357,,,Compound was tested for its affinity towards 5-hydroxytryptamine 4 receptor,,,H,Autocuration,B,,CHEMBL620606,,,,,8,1
3370,168,,BAO_0000019,,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,,H,Autocuration,F,,CHEMBL620607,,,,,8,1
3371,168,,BAO_0000357,,,In vitro binding affinity towards 5-HT4 receptor was determined,,,H,Autocuration,B,,CHEMBL620608,,,,,8,1
3372,168,,BAO_0000019,,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,,H,Autocuration,F,,CHEMBL620609,,,,,8,1
3373,168,,BAO_0000019,,,Tested for agonist activity against 5-hydroxytryptamine 4 receptor,,,H,Autocuration,F,,CHEMBL620610,,,,,8,1
3374,168,,BAO_0000357,,,Tested for selectivity for 5-hydroxytryptamine 4 receptor,,,H,Autocuration,B,,CHEMBL620611,,,,,8,1
3375,168,,BAO_0000357,,,Tested for 5-hydroxytryptamine 4 binding affinity against cisapride,,,H,Autocuration,B,,CHEMBL620612,,,,,8,1
3376,168,,BAO_0000357,,,Tested for 5-hydroxytryptamine 4 binding affinity against renzapride,,,H,Autocuration,B,,CHEMBL620613,,,,,8,1
3377,168,,BAO_0000357,,,Tested for 5-hydroxytryptamine 4 binding affinity against zacopride,,,H,Autocuration,B,,CHEMBL620614,,,,,8,1
3378,168,,BAO_0000357,,,Binding affinity against 5-Hydroxytryptamine 4 receptor,,,H,Expert,B,,CHEMBL620615,,,,,8,1
3379,104698,,BAO_0000249,,,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 recognition sites in rat brain membranes,,,H,Autocuration,B,,CHEMBL857075,,,,Brain membranes,6,1
3380,104698,,BAO_0000249,,,Compound was evaluated for the displacement of [3H]Q-ICS-205-930 from 5-HT3 recognition sites in rat brain membranes,,,H,Autocuration,B,,CHEMBL620616,,,,Brain membranes,6,1
3381,104698,,BAO_0000249,,,Displacement of [3H]Q-ICS-205-930 from 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes,,,H,Autocuration,B,,CHEMBL619411,,,,Brain membranes,6,1
3382,104698,,BAO_0000019,,,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor from rat cortex homogenate,,,H,Autocuration,B,,CHEMBL619412,,,,,6,1
3383,104698,,BAO_0000019,,,Displacement of [3H]-Q-ICS 205-930 from rat cortex homogenate 5-hydroxytryptamine 3 receptor,,,D,Autocuration,B,10116.0,CHEMBL619413,,,,,7,1
3384,104698,,BAO_0000221,,,Binding affinity of 5-hydroxytryptamine 3 receptor using [3H]granisetron in rat hippocampus and entorhinal cortex,,,H,Autocuration,B,,CHEMBL619414,,10000000.0,Hippocampus,,6,1
3385,104698,,BAO_0000019,,,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,,,H,Autocuration,B,,CHEMBL619415,,,,,6,1
3386,104698,,BAO_0000019,,,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex,,,H,Autocuration,B,,CHEMBL619416,,,,,6,1
3387,104698,,BAO_0000019,,,Rat 5-hydroxytryptamine 3 receptor (5-HT3) antagonist,,,H,Autocuration,F,,CHEMBL619417,,,,,6,1
3388,104698,,BAO_0000223,,,Binding affinity against rat 5-hydroxytryptamine 3 receptor,,,D,Autocuration,B,10116.0,CHEMBL619418,,,,,7,1
3389,104698,,BAO_0000223,,,Binding affinity against 5-Hydroxytryptamine 3 receptor,,,D,Autocuration,B,10116.0,CHEMBL619419,,,,,7,1
3390,104698,,BAO_0000019,,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of racemic [3H]zacopride from rat cortex,,,H,Autocuration,B,,CHEMBL619420,,,,,6,1
3391,104698,,BAO_0000249,,,Binding affinity to 5-hydroxytryptamine 3 receptor was determined in rat cerebro cortical membranes using [3H]quipazine.,,,H,Autocuration,B,,CHEMBL619421,,,,,6,1
3392,104698,,BAO_0000019,,,Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortex,,,D,Autocuration,B,10116.0,CHEMBL619422,,,,,7,1
3393,104698,,BAO_0000019,,,In vitro by displacement of [3H]LY-278584 from 5-hydroxytryptamine 3 receptor on rat entorhinal cortex,,,H,Autocuration,B,,CHEMBL619423,,,,,6,1
3394,104698,,BAO_0000019,,,Tested for its binding affinity by measuring its ability to displace [3H]granisetron from 5-hydroxytryptamine 3 receptor in rat cortex,,,H,Autocuration,B,,CHEMBL875080,,,,,6,1
3395,104698,,BAO_0000019,,,The binding affinity (pKi) measured against 5-hydroxytryptamine 1A receptor of rat cortex using [3H]8-OH-DPAT as radioligand,,,H,Autocuration,B,,CHEMBL619424,,,,,6,1
3396,104698,,BAO_0000249,,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat cortical membrane by [3H]graniestron displacement.,,,H,Autocuration,B,,CHEMBL619425,,,,,6,1
3397,104698,,BAO_0000223,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand,,,H,Autocuration,B,,CHEMBL619426,,,,,6,1
3398,104698,,BAO_0000223,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand.,,,H,Autocuration,B,,CHEMBL619427,,,,,6,1
3399,104698,,BAO_0000223,,,pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor,,,D,Autocuration,B,10116.0,CHEMBL619645,,,,,7,1
3400,10576,,BAO_0000249,,,"Compound was evaluated for binding affinity on 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding",,,D,Expert,B,,CHEMBL619646,,,,,9,1
3401,12020,,BAO_0000221,,,Compound was tested for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat brain using [3H]zacopride as the radioligand.,,,H,Autocuration,F,,CHEMBL619647,,955.0,Brain,,8,1
3402,12020,,BAO_0000019,,,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor,,,H,Autocuration,F,,CHEMBL619648,,,,,8,1
3403,12020,,BAO_0000019,,,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat CNS.,,,H,Autocuration,F,,CHEMBL619165,,,,,8,1
3404,12020,In vivo,BAO_0000218,,,Compound was evaluated in vivo for the antagonistic activity towards 5-hydroxytryptamine 3 receptor,,,H,Autocuration,F,,CHEMBL620719,,,,,8,1
3405,12020,,BAO_0000019,,,Compound was tested for its binding affinity towards 5-HT-3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,,,H,Autocuration,B,,CHEMBL872924,,,,,8,1
3406,12020,,BAO_0000357,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor,,,H,Autocuration,B,,CHEMBL620720,,,,,8,1
3407,12020,,BAO_0000019,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,,,H,Autocuration,B,,CHEMBL620721,,,,,8,1
3408,12020,,BAO_0000019,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using [125I]DAIZAC as the radioligand.,,,H,Autocuration,B,,CHEMBL620722,,,,,8,1
3409,104698,,BAO_0000019,,,"Concentration that inhibits the binding of radioligand, [3H]-ICS 205930, to 5-hydroxytryptamine 3 receptor from rat cortex",,,H,Autocuration,B,,CHEMBL620723,,,,,6,1
3410,12020,,BAO_0000019,,,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,,,H,Autocuration,B,,CHEMBL620724,,,,,8,1
3411,104698,,BAO_0000249,,,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor in rat brain cortical membranes using radioligand [3H]quipazine,,,H,Autocuration,B,,CHEMBL620725,,,,,6,1
3412,12020,,BAO_0000019,,,Antagonist activity (100 ug/kg) for the Bezold Jarisch reflex evoked by 30 (ug/Kg) of 5-hydroxytryptamine 3 receptor in ethylurethane anesthetized rats i.v.,,,D,Autocuration,F,10116.0,CHEMBL620726,,,,,9,1
3413,144,,BAO_0000357,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,,,H,Expert,B,,CHEMBL620727,,,,,8,1
3414,104714,,BAO_0000223,,,Compound was evaluated for 5-hydroxytryptamine 3 receptor binding,,,H,Autocuration,B,,CHEMBL620728,,,,,4,1
3415,22226,,BAO_0000019,,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,,,U,Autocuration,B,,CHEMBL620729,,,,,0,1
3416,104714,,BAO_0000019,,,Tested for 5-hydroxytryptamine 3 receptor antagonist activity by inhibiting the 5-HT evoked Bezold-Jarisch reflex,,,H,Autocuration,F,,CHEMBL858288,,,,,4,1
3417,104714,,BAO_0000223,,,Compound was tested for binding affinity towards 5-hydroxytryptamine 3 receptor,,,H,Autocuration,B,,CHEMBL620730,,,,,4,1
3418,104714,,BAO_0000223,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,,,H,Autocuration,B,,CHEMBL620731,,,,,4,1
3419,104714,,BAO_0000019,,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 0.3 uM,,,H,Autocuration,F,10141.0,CHEMBL620732,,,,,4,1
3420,104714,,BAO_0000019,,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,,,H,Autocuration,F,10141.0,CHEMBL618042,,,,,4,1
3421,104714,,BAO_0000019,,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 30 uM,,,H,Autocuration,F,10141.0,CHEMBL618043,,,,,4,1
3422,104714,,BAO_0000223,,,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,,,H,Autocuration,B,,CHEMBL618044,,,,,4,1
3423,104714,,BAO_0000019,,,Evaluated for the 5-hydroxytryptamine 3 receptor antagonistic activity in Bezold-Jarisch model expressed as inhibition of the reflex bradycardia induced by an intravenous injection,,,H,Autocuration,F,,CHEMBL618045,,,,,4,1
3424,104714,,BAO_0000223,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 3 receptor at a concentration of 10 uM using [3H]BRL-43694 as radioligand,,,H,Autocuration,B,,CHEMBL618046,,,,,4,1
3425,104714,,BAO_0000019,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); A: agonist,,,H,Autocuration,F,,CHEMBL618047,,,,,4,1
3426,104714,,BAO_0000019,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: agonist,,,H,Autocuration,F,,CHEMBL875084,,,,,4,1
3427,104714,,BAO_0000019,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: antagonist,,,H,Autocuration,F,,CHEMBL618048,,,,,4,1
3428,104714,,BAO_0000223,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); NA means data not available,,,H,Autocuration,B,,CHEMBL618049,,,,,4,1
3429,104714,,BAO_0000019,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); PA: Partial agonist,,,H,Autocuration,F,,CHEMBL619764,,,,,4,1
3430,104714,,BAO_0000019,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; A: agonist,,,H,Autocuration,F,,CHEMBL619765,,,,,4,1
3431,104714,,BAO_0000019,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; ANT: Antagonist,,,H,Autocuration,F,,CHEMBL619766,,,,,4,1
3432,104714,,BAO_0000223,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA: not active,,,H,Autocuration,B,,CHEMBL619767,,,,,4,1
3433,104714,,BAO_0000223,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA means data not available,,,H,Autocuration,B,,CHEMBL619768,,,,,4,1
3434,104714,,BAO_0000019,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; PA: Partial agonist,,,H,Autocuration,F,,CHEMBL619769,,,,,4,1
3435,104714,,BAO_0000223,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; na means data not available,,,H,Autocuration,B,,CHEMBL619770,,,,,4,1
3436,104714,,BAO_0000223,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,,,H,Autocuration,B,,CHEMBL619771,,,,,4,1
3437,104714,,BAO_0000219,,,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor using [3H]-BRL-43694 (1 nM) ligand in NG cells 108-15 was determined,,,H,Autocuration,B,,CHEMBL619772,,,,,4,1
3438,104714,,BAO_0000223,,,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor; NA: not active,,,H,Autocuration,B,,CHEMBL619773,,,,,4,1
3439,104714,,BAO_0000219,433.0,NG108-15,Binding affinity for 5-HT3 receptor of NG108-15 cells using [3H]GR-65630,,,H,Autocuration,B,,CHEMBL619774,,,,,4,1
3440,104714,,BAO_0000019,,,Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand.,,,H,Autocuration,B,,CHEMBL875083,,,,,4,1
3441,104714,,BAO_0000219,433.0,NG108-15,Binding affinity to 5-HT3 serotonin receptor in NG108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand,,,H,Autocuration,B,,CHEMBL620718,,,,,4,1
3442,104714,,BAO_0000223,,,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,,,H,Autocuration,B,,CHEMBL618127,,,,,4,1
3443,104714,,BAO_0000223,,,Compound was tested for selectivity against 5-hydroxytryptamine 3 receptor binding affinity,,,H,Autocuration,B,,CHEMBL618128,,,,,4,1
3444,104714,In vitro,BAO_0000219,,,Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells,,,H,Autocuration,B,,CHEMBL618129,,,,,4,1
3445,104714,,BAO_0000223,,,In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined,,,H,Autocuration,B,,CHEMBL618130,,,,,4,1
3446,104714,,BAO_0000019,,,Tested for 5-hydroxytryptamine 3 receptor antagonist activity,,,H,Autocuration,F,,CHEMBL618131,,,,,4,1
3447,104714,,BAO_0000019,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 1 uM,,,H,Autocuration,F,10141.0,CHEMBL618132,,,,,4,1
3448,104714,,BAO_0000019,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM,,,H,Autocuration,F,10141.0,CHEMBL618133,,,,,4,1
3449,104714,,BAO_0000019,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM in the presence of 30 uM MDL 72222,,,H,Autocuration,F,10141.0,CHEMBL618134,,,,,4,1
3450,104714,,BAO_0000019,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,,,H,Autocuration,F,10141.0,CHEMBL618135,,,,,4,1
3451,104714,,BAO_0000223,,,Binding affinity for the 5-hydroxytryptamine 3 receptor was evaluated in vitro by examining its ability to displace [3H]-BRL 43694.,,,H,Autocuration,B,,CHEMBL618136,,,,,4,1
3452,104714,,BAO_0000223,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,,,H,Autocuration,B,,CHEMBL618137,,,,,4,1
3453,104714,,BAO_0000223,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor using radioligand binding assay,,,H,Autocuration,B,,CHEMBL618138,,,,,4,1
3454,104714,,BAO_0000223,,,Tested against 5-hydroxytryptamine 3 receptor in experiment 1,,,H,Autocuration,B,,CHEMBL618139,,,,,4,1
3455,104714,,BAO_0000223,,,Tested against 5-hydroxytryptamine 3 receptor in experiment 2,,,H,Autocuration,B,,CHEMBL618140,,,,,4,1
3456,104714,,BAO_0000223,,,Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligand,,,H,Autocuration,B,,CHEMBL618141,,,,,4,1
3457,108,,BAO_0000357,,,Binding affinity for 5-hydroxytryptamine 2C receptor,,,H,Expert,B,,CHEMBL873478,,,,,8,1
3458,104698,,BAO_0000223,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,,,H,Autocuration,B,,CHEMBL618142,,,,,6,1
3459,144,,BAO_0000357,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 3 receptor,,,H,Autocuration,B,,CHEMBL618143,,,,,8,1
3460,144,,BAO_0000357,,,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,,,H,Autocuration,B,,CHEMBL618144,,,,,8,1
3461,144,,BAO_0000357,,,Inhibition of GR-65630 binding to 5-hydroxytryptamine 3 receptor,,,H,Autocuration,B,,CHEMBL618145,,,,,8,1
3462,104714,,BAO_0000223,,,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,,,H,Autocuration,B,,CHEMBL618146,,,,,4,1
3463,104714,,BAO_0000223,,,Inhibition of [3H]-BRL 43 694 binding to 5-hydroxytryptamine 3 receptor of central nervous system,,,H,Autocuration,B,,CHEMBL618147,,,,,4,1
3464,104714,,BAO_0000223,,,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,,,H,Autocuration,B,,CHEMBL618148,,,,,4,1
3465,144,,BAO_0000019,,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,,,H,Autocuration,B,,CHEMBL618149,,,,,8,1
3466,144,,BAO_0000357,,,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,,,H,Autocuration,B,,CHEMBL872927,,,,,8,1
3467,144,,BAO_0000357,,,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,,,H,Autocuration,B,,CHEMBL618150,,,,,8,1
3468,144,,BAO_0000357,,,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,,,H,Autocuration,B,,CHEMBL618151,,,,,8,1
3469,144,,BAO_0000357,,,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,,,H,Autocuration,B,,CHEMBL875094,,,,,8,1
3470,144,,BAO_0000019,,,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,,,H,Autocuration,B,,CHEMBL618152,,,,,8,1
3471,144,,BAO_0000357,,,In vitro binding affinity towards 5-hydroxytryptamine 3 receptor was determined,,,H,Autocuration,B,,CHEMBL618153,,,,,8,1
3472,144,,BAO_0000357,,,Inhibitory constant against 5-hydroxytryptamine 3 receptor using [3H]GR-65630 radioligand,,,H,Autocuration,B,,CHEMBL618888,,,,,8,1
3473,144,,BAO_0000019,,,Tested for 5-hydroxytryptamine 3 receptor agonist activity,,,H,Autocuration,F,,CHEMBL618889,,,,,8,1
3474,144,,BAO_0000357,,,The binding affinity towards 5-hydroxytryptamine 3 receptor; No affinity,,,H,Autocuration,B,,CHEMBL618890,,,,,8,1
3475,144,,BAO_0000019,,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes,,,H,Autocuration,B,,CHEMBL618891,,,,,8,1
3476,144,,BAO_0000019,,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes,,,H,Autocuration,B,,CHEMBL619054,,,,,8,1
3477,104714,,BAO_0000223,,,Binding affinity against the 5-hydroxytryptamine 3 receptor,,,H,Autocuration,B,,CHEMBL619055,,,,,4,1
3478,144,,BAO_0000357,,,Binding affinity against human 5-hydroxytryptamine 3A receptor,,,H,Autocuration,B,,CHEMBL619056,,,,,8,1
3479,144,,BAO_0000019,,,Percent efficacy against 5-hydroxytryptamine 3A receptor,,,H,Autocuration,F,,CHEMBL619057,,,,,8,1
3480,144,,BAO_0000357,,,Binding affinity against human 5-hydroxytryptamine 3A receptor,,,H,Autocuration,B,,CHEMBL619058,,,,,8,1
3481,12020,,BAO_0000219,,Oocytes,Response at rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes,,,D,Expert,F,10116.0,CHEMBL619059,,,,,9,1
3482,12020,,BAO_0000219,,Oocytes,Ability to block serotonin (30 uM)-evoked responses at rat 5HT3-alpha receptor expressed in xenopus oocytes,,,D,Expert,F,10116.0,CHEMBL619060,,,,,9,1
3483,12020,,BAO_0000219,,Oocytes,Effect on rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes at concentration up to 100 uM,,,D,Expert,F,10116.0,CHEMBL875095,,,,,9,1
3484,20033,,BAO_0000221,,,5-hydroxytryptamine 4 receptor agonist activity as percent maximum 5-HT effect in response to electrical stimulation in male guinea pig ileum,,,D,Intermediate,F,10141.0,CHEMBL619061,,2116.0,Ileum,,9,1
3485,20033,,BAO_0000221,,,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum,,,D,Intermediate,F,10141.0,CHEMBL619062,,2116.0,Ileum,,9,1
3486,20033,,BAO_0000019,,,5-hydroxytryptamine 4 receptor agonist activity is expressed as percent of the maximum 5-HT response,,,D,Intermediate,F,10141.0,CHEMBL619063,,,,,9,1
3487,20033,,BAO_0000221,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in electrically stimulated longitudinal muscle preparation of guinea pig ileum,,,D,Intermediate,B,10141.0,CHEMBL619064,,2116.0,Ileum,,9,1
3488,20033,,BAO_0000357,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in guinea pig distal colon preparation,,,D,Intermediate,B,10141.0,CHEMBL619065,,,,,9,1
3489,20033,,BAO_0000221,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in isolated guinea pig ileum longitudinal muscle preparation,,,D,Intermediate,B,10141.0,CHEMBL619066,,2116.0,Ileum,,9,1
3490,10209,,BAO_0000221,,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,,,H,Autocuration,B,,CHEMBL619775,,2116.0,Ileum,,8,1
3491,10209,,BAO_0000357,,,Affinity against 5-hydroxytryptamine 7 receptor,,,H,Autocuration,B,,CHEMBL619776,,,,,8,1
3492,104841,,BAO_0000224,,,Ability to displace [3H]5-HT binding from 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,,,H,Autocuration,B,10141.0,CHEMBL619777,,,,,4,1
3493,104841,,BAO_0000224,,,Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,,,H,Autocuration,B,10141.0,CHEMBL619778,,,,,4,1
3494,104841,,BAO_0000221,,,Evaluated for inhibition of 5-hydroxytryptamine receptor on guinea pig ileum at 10 uM; No effect,,,H,Autocuration,B,10141.0,CHEMBL619779,,2116.0,Ileum,,4,1
3495,104841,,BAO_0000224,,,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand, activity is expressed as Kd.",,,H,Autocuration,B,10141.0,CHEMBL619780,,,,,4,1
3496,104841,,BAO_0000224,,,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor using 1 uM LSD as masking ligand, activity is expressed as Kd.",,,H,Autocuration,B,10141.0,CHEMBL619166,,,,,4,1
3497,104841,,BAO_0000019,,,5-HT level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,,,H,Autocuration,F,10141.0,CHEMBL619167,,,,,4,1
3498,104841,,BAO_0000019,,,5-hydroxytryptamine level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,,,H,Autocuration,F,10141.0,CHEMBL619168,,,,,4,1
3499,168,,BAO_0000219,,,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor in the presence of 10 nM compound in isolated human atrial myocytes,,,D,Expert,B,9606.0,CHEMBL619169,,2081.0,Cardiac atrium,,9,1
3500,168,,BAO_0000219,,,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes,,,D,Expert,B,9606.0,CHEMBL619170,,2081.0,Cardiac atrium,,9,1
3501,104841,,BAO_0000019,,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine",,,D,Autocuration,F,9606.0,CHEMBL619171,,,,,5,1
3502,168,,BAO_0000219,,,",Antagonism of stimulation of 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes",,,D,Expert,F,9606.0,CHEMBL619172,,2081.0,Cardiac atrium,,9,1
3503,22226,,BAO_0000019,,,Ability (10 ug/kg) to inhibit binding of [125I]iododexetimide to 5-hydroxytryptamine receptor in mice,,,U,Autocuration,B,10090.0,CHEMBL619173,,,,,0,1
3504,22226,,BAO_0000019,,,Percent inhibition of radioligand [3H]-LSD binding to 5-HT receptor at 10 uM concentration,,,U,Autocuration,B,10090.0,CHEMBL619174,,,,,0,1
3505,104705,,BAO_0000019,,,5-hydroxytryptamine receptor binding affinity was determined in rats,,,H,Autocuration,B,,CHEMBL619175,,,,,4,1
3506,104705,,BAO_0000224,,,Binding affinity at rat 5-hydroxytryptamine receptor.,,,H,Autocuration,B,,CHEMBL619176,,,,,4,1
3507,104705,,BAO_0000019,,,Affinity against 5-hydroxytryptamine receptors in rat fundus model,,,H,Autocuration,B,,CHEMBL619177,,,,,4,1
3508,104705,,BAO_0000224,,,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation,,,H,Autocuration,B,,CHEMBL619178,,,,,4,1
3509,104705,,BAO_0000224,,,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation; Not determined,,,H,Autocuration,B,,CHEMBL619179,,,,,4,1
3510,104705,,BAO_0000019,,,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation,,,H,Autocuration,F,,CHEMBL619180,,945.0,Stomach,,4,1
3511,104705,,BAO_0000019,,,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation (resulted in discoloration in the oxygenated muscle bath to give varying results).,,,H,Autocuration,F,,CHEMBL619181,,945.0,Stomach,,4,1
3512,104705,,BAO_0000019,,,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,,,H,Autocuration,F,,CHEMBL619182,,,,,4,1
3513,104705,,BAO_0000224,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2,,,H,Autocuration,B,,CHEMBL619183,,,,,4,1
3514,104705,,BAO_0000224,,,"Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2; Valid pA2, can not be determined because of slope of Schild plot.",,,H,Autocuration,B,,CHEMBL619184,,,,,4,1
3515,10576,,BAO_0000221,,,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,,,H,Autocuration,B,,CHEMBL619185,,10000000.0,Hippocampus,,8,1
3516,12198,,BAO_0000357,,,Binding affinity for rat 5-hydroxytryptamine transporter.,,,H,Expert,B,,CHEMBL619186,,,,,8,1
3517,104705,,BAO_0000019,,,Evaluated for inhibition of specific [3H]5-HT receptor binding in rat cortex.,,,H,Autocuration,B,,CHEMBL619187,,,,,4,1
3518,104705,,BAO_0000019,,,Binding affinity at serotonin 5-HT1-type site receptor in rat cortex by displacing [3H]5-HT,,,D,Autocuration,B,10116.0,CHEMBL619188,,,,,5,1
3519,104705,,BAO_0000224,,,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,,,D,Autocuration,B,10116.0,CHEMBL619189,,,,,5,1
3520,12198,,BAO_0000019,,,Inhibitory activity against [3H]- 5-hydroxytryptamine reuptake in whole rat brain minus cerebellum,,,D,Expert,F,10116.0,CHEMBL619190,,955.0,Brain,,9,1
3521,12198,,BAO_0000221,,,Inhibition of [3H]5-HT reuptake in whole rat brain (minus cerebellum) homogenate.,,,D,Expert,F,10116.0,CHEMBL619191,,2037.0,Cerebellum,,9,1
3522,104705,,BAO_0000019,,,Displacement of [3H]-citalopram from rat forebrain membrane 5-hydroxytryptamine receptor at 10e-7 M,,,D,Autocuration,B,10116.0,CHEMBL619192,,,,,5,1
3523,104705,,BAO_0000224,,,Percent binding affinity against 5-hydroxytryptamine receptor,,,D,Autocuration,B,10116.0,CHEMBL619193,,,,,5,1
3524,22226,,BAO_0000019,,,Ability to displace 0.4 nM [3H]paroxetine binding to 5-hydroxytryptamine receptor in rat frontal cortex,,,U,Autocuration,B,,CHEMBL619194,,,,,0,1
3525,104705,,BAO_0000224,,,The binding affinity was measured on 5-hydroxytryptamine receptor uptake receptor using [3H]- paroxetine as radioligand.,,,D,Autocuration,B,10116.0,CHEMBL619195,,,,,5,1
3526,104705,,BAO_0000224,,,Affinity against 5-hydroxytryptamine receptor was determined,,,D,Autocuration,B,10116.0,CHEMBL619196,,,,,5,1
3527,104705,,BAO_0000019,,,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,,,D,Autocuration,B,10116.0,CHEMBL619197,,945.0,Stomach,,5,1
3528,121,In vitro,BAO_0000219,,,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,,,D,Expert,B,9606.0,CHEMBL619198,,,,,9,1
3529,121,In vitro,BAO_0000219,,,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,,,D,Expert,B,9606.0,CHEMBL875081,,,,,9,1
3530,18065,,BAO_0000357,,,Ability to compete with radioactive ligands specific to the Serotonergic 5-HT receptor at 10 uM; NA means compound failed to compete,,,H,Autocuration,B,,CHEMBL884712,,,,,8,1
3531,121,,BAO_0000357,,,Inhibition of 5-hydroxytryptamine reuptake,,,H,Expert,B,,CHEMBL884710,,,,,8,1
3532,18065,,BAO_0000019,,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding",,,H,Autocuration,F,,CHEMBL619199,,,,,8,1
3533,18065,,BAO_0000019,,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 1)",,,H,Autocuration,F,,CHEMBL619200,,,,,8,1
3534,18065,,BAO_0000019,,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 2)",,,H,Autocuration,F,,CHEMBL619201,,,,,8,1
3535,18065,,BAO_0000019,,,Tested for 5-hydroxytryptamine receptor uptake,,,H,Autocuration,F,,CHEMBL619202,,,,,8,1
3536,51,,BAO_0000219,449.0,CHO,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,,,D,Expert,B,9606.0,CHEMBL619203,,,,,9,1
3537,51,,BAO_0000019,,,Antagonistic affinity tested against isolated human cloned alpha-1d adrenoceptor subtype,,,D,Expert,F,9606.0,CHEMBL619204,,,,,9,1
3538,10576,,BAO_0000249,,,In vitro binding affinity towards 5-hydroxytryptamine receptor 1A receptor by using [3H]8-OH-DPAT in rat hippocampal membranes.,,,H,Autocuration,B,9606.0,CHEMBL619205,,,,,8,1
3539,10576,,BAO_0000357,,,Tested in vitro for % inhibition against 5-hydroxytryptamine receptor 1A,,,H,Autocuration,B,,CHEMBL619206,,,,,8,1
3540,10576,,BAO_0000249,,,In vitro binding affinity at 5-hydroxytryptamine receptor 1A receptor in rat hippocampal membranes by [3H]8-OH-DPAT displacement.,,,H,Expert,B,,CHEMBL619207,,,,,8,1
3541,10825,,BAO_0000019,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 0.10 umol/kg,,,H,Autocuration,F,,CHEMBL619208,,2435.0,Striatum,,8,1
3542,10825,,BAO_0000019,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 10 umol/kg,,,H,Autocuration,F,,CHEMBL619209,,2435.0,Striatum,,8,1
3543,10825,,BAO_0000019,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 0.32 umol/kg,,,H,Autocuration,F,,CHEMBL619210,,2435.0,Striatum,,8,1
3544,10825,,BAO_0000019,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 3.2 umol/kg,,,H,Autocuration,F,,CHEMBL619211,,2435.0,Striatum,,8,1
3545,10825,,BAO_0000019,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 32 umol/kg,,,H,Autocuration,F,,CHEMBL619212,,2435.0,Striatum,,8,1
3546,10825,,BAO_0000019,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 0.032 umol/kg,,,H,Autocuration,F,,CHEMBL620681,,2435.0,Striatum,,8,1
3547,10825,,BAO_0000019,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 1.0 umol/kg,,,H,Autocuration,F,,CHEMBL620682,,2435.0,Striatum,,8,1
3548,10825,,BAO_0000019,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 10 umol/kg,,,H,Autocuration,F,,CHEMBL620683,,2435.0,Striatum,,8,1
3549,10825,,BAO_0000019,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 100 umol/kg,,,H,Autocuration,F,,CHEMBL620684,,2435.0,Striatum,,8,1
3550,10825,,BAO_0000019,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 3.2 umol/kg,,,H,Autocuration,F,,CHEMBL620685,,2435.0,Striatum,,8,1
3551,10825,,BAO_0000019,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 32 umol/kg,,,H,Autocuration,F,,CHEMBL620686,,2435.0,Striatum,,8,1
3552,10825,,BAO_0000019,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.032 umol/kg,,,H,Autocuration,F,,CHEMBL620687,,349.0,Limbic system,,8,1
3553,10825,,BAO_0000019,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,,,H,Autocuration,F,,CHEMBL620688,,349.0,Limbic system,,8,1
3554,10825,,BAO_0000019,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.32 umol/kg,,,H,Autocuration,F,,CHEMBL620689,,349.0,Limbic system,,8,1
3555,10825,,BAO_0000019,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 1.0 umol/kg,,,H,Autocuration,F,,CHEMBL620690,,349.0,Limbic system,,8,1
3556,10825,,BAO_0000019,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 10 umol/kg,,,H,Autocuration,F,,CHEMBL620691,,349.0,Limbic system,,8,1
3557,10825,,BAO_0000019,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 100 umol/kg,,,H,Autocuration,F,,CHEMBL620692,,349.0,Limbic system,,8,1
3558,10825,,BAO_0000019,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 3.2 umol/kg,,,H,Autocuration,F,,CHEMBL620693,,349.0,Limbic system,,8,1
3559,168,,BAO_0000357,,,Binding affinity against 5-hydroxytryptamine 4 receptor,,,H,Expert,B,,CHEMBL620694,,,,,8,1
3560,168,,BAO_0000019,,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,,H,Autocuration,F,,CHEMBL857986,,,,,8,1
3561,168,,BAO_0000357,,,Inhibitory activity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand at 10e-5 M concentration,,,H,Autocuration,B,,CHEMBL620695,,,,,8,1
3562,168,,BAO_0000357,,,Binding affinity towards Serotonin 5-hydroxytryptamine 4 receptor,,,H,Expert,B,,CHEMBL620696,,,,,8,1
3563,168,,BAO_0000357,,,Inhibitory constant against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 radioligand,,,H,Autocuration,B,,CHEMBL620697,,,,,8,1
3564,168,,BAO_0000357,,,Binding affinity towards 5-hydroxytryptamine 4 receptor,,,H,Autocuration,B,,CHEMBL620698,,,,,8,1
3565,168,,BAO_0000357,,,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,,,H,Autocuration,B,,CHEMBL620699,,,,,8,1
3566,168,,BAO_0000357,,,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,,,H,Autocuration,B,,CHEMBL620700,,,,,8,1
3567,168,,BAO_0000219,643.0,COS-7,Binding affinity was determined against cloned 5-hydroxytryptamine 4A receptor isoform expressed in COS-7 cells,,,H,Autocuration,B,,CHEMBL620701,,,,,8,1
3568,168,,BAO_0000219,643.0,COS-7,Binding affinity was determined against cloned 5-hydroxytryptamine 4B receptor isoform expressed in COS-7 cells,,,H,Autocuration,B,,CHEMBL875082,,,,,8,1
3569,168,,BAO_0000219,643.0,COS-7,Binding affinity was determined against cloned 5-hydroxytryptamine 4C receptor isoform expressed in COS-7 cells,,,H,Autocuration,B,,CHEMBL620702,,,,,8,1
3570,168,,BAO_0000219,643.0,COS-7,Binding affinity was determined against cloned 5-hydroxytryptamine 4D receptor isoform expressed in COS-7 cells,,,H,Autocuration,B,,CHEMBL620703,,,,,8,1
3571,168,,BAO_0000219,673.0,C6,Binding affinity of compound towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,,,H,Autocuration,B,,CHEMBL620704,,,,,8,1
3572,168,,BAO_0000219,673.0,C6,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,,,H,Expert,B,,CHEMBL620705,,,,,8,1
3573,168,,BAO_0000219,673.0,C6,Binding affinity was determined against cloned 5-hydroxytryptamine 4E receptor isoform expressed in C6 glial cells incubated with 0.2 nM [3H]GR-113808,,,H,Expert,B,,CHEMBL620706,,,,,8,1
3574,168,,BAO_0000219,673.0,C6,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand; Not determined,,,H,Expert,B,,CHEMBL620707,,,,,8,1
3575,10624,,BAO_0000357,,,Binding affinity towards 5-hydroxytryptamine 5 receptor,,,H,Expert,B,,CHEMBL620708,,,,,8,1
3576,105,,BAO_0000357,,,Inhibitory constant against human 5-hydroxytryptamine 5A receptor using [3H]LSD radioligand,,,H,Autocuration,B,,CHEMBL620709,,,,,8,1
3577,10624,,BAO_0000357,,,Binding affinity against 5-hydroxytryptamine 5A receptor,,,D,Expert,B,9606.0,CHEMBL620710,,,,,9,1
3578,10624,,BAO_0000219,449.0,CHO,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 5A receptor stably expressed in CHO cells,,,H,Autocuration,B,,CHEMBL620711,,,,,8,1
3579,10624,,BAO_0000357,,,Affinity towards human 5-hydroxytryptamine 5A serotonin receptor,,,D,Expert,B,9606.0,CHEMBL620712,,,,,9,1
3580,10624,,BAO_0000357,,,Binding affinity towards human 5-hydroxytryptamine 5A receptor,,,D,Expert,B,9606.0,CHEMBL620713,,,,,9,1
3581,10624,,BAO_0000357,,,Binding affinity towards human 5-hydroxytryptamine 5A receptor was evaluated using [3H]-5-CT as radioligand,,,D,Expert,B,9606.0,CHEMBL620714,,,,,9,1
3582,10624,,BAO_0000357,,,Binding affinity to cloned human 5-hydroxytryptamine 5A receptor,,,D,Expert,B,9606.0,CHEMBL620715,,,,,9,1
3583,10624,,BAO_0000357,,,Binding affinity towards 5-HT5A receptor,,,H,Autocuration,B,,CHEMBL620716,,,,,8,1
3584,10624,,BAO_0000357,,,Binding affinity towards human 5-hydroxytryptamine 5A receptor using LSD as radioligand,,,H,Expert,B,,CHEMBL620717,,,,,8,1
3585,10624,,BAO_0000357,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 5A receptor,,,H,Autocuration,B,,CHEMBL618072,,,,,8,1
3586,10624,,BAO_0000357,,,Binding affinity towards cloned human 5-HT5A receptor was determined,,,H,Autocuration,B,,CHEMBL857987,,,,,8,1
3587,10624,,BAO_0000219,722.0,HEK293,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,,H,Autocuration,B,,CHEMBL618073,,,,,8,1
3588,10624,,BAO_0000219,722.0,HEK293,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,,,H,Autocuration,B,,CHEMBL618074,,,,,8,1
3589,10624,,BAO_0000219,722.0,HEK293,Compound was tested for its binding affinity in 5-hydroxytryptamine 5A receptor (using human cloned receptors in HEK 293 and [3H]5-CTas a radioligand ),,,H,Autocuration,B,,CHEMBL618075,,,,,8,1
3590,10625,,BAO_0000357,,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor,,,D,Expert,B,10090.0,CHEMBL618076,,,,,9,1
3591,10625,,BAO_0000357,,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [125I]-2-iodo LSD as radioligand,,,D,Expert,B,10090.0,CHEMBL618077,,,,,9,1
3592,10625,,BAO_0000357,,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]- LSD as radioligand,,,D,Expert,B,10090.0,CHEMBL618078,,,,,9,1
3593,10625,,BAO_0000357,,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]LSD as radioligand,,,D,Expert,B,10090.0,CHEMBL881821,,,,,9,1
3594,10625,,BAO_0000357,,,Binding affinity towards murine 5-hydroxytryptamine 5A receptor,,,D,Expert,B,10090.0,CHEMBL618079,,,,,9,1
3595,10625,,BAO_0000357,,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor using LSD as radioligand,,,H,Expert,B,,CHEMBL618080,,,,,8,1
3596,10576,,BAO_0000219,722.0,HEK293,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,,,H,Autocuration,B,,CHEMBL618081,,,,,8,1
3597,10626,,BAO_0000219,722.0,HEK293,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,,,H,Autocuration,B,,CHEMBL618082,,,,,8,1
3598,10624,,BAO_0000357,,,Binding affinity towards 5-HT5a receptor,,,H,Expert,B,,CHEMBL618083,,,,,8,1
3599,10624,,BAO_0000357,,,Binding affinity towards 5-hydroxytryptamine 5A receptor,,,D,Expert,B,9606.0,CHEMBL618084,,,,,9,1
3600,10624,,BAO_0000357,,,Binding affinity for rodent 5-hydroxytryptamine 5A receptor,,,H,Expert,B,,CHEMBL618085,,,,,8,1
3601,10624,,BAO_0000357,,,Binding affinity towards 5-hydroxytryptamine 5A receptor using lysergic acid diethylamide (LSD) as radioligand,,,H,Expert,B,,CHEMBL618086,,,,,8,1
3602,10624,,BAO_0000357,,,Binding affinities against 5-hydroxytryptamine 5A receptor,,,H,Autocuration,B,,CHEMBL875092,,,,,8,1
3603,10624,,BAO_0000357,,,Binding affinities towards 5-hydroxytryptamine 5A receptor,,,H,Autocuration,B,,CHEMBL618087,,,,,8,1
3604,10624,,BAO_0000357,,,The binding affinity towards 5-hydroxytryptamine 5A receptor; No affinity,,,H,Autocuration,B,,CHEMBL872926,,,,,8,1
3605,104714,,BAO_0000019,,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.01 uM,,,H,Autocuration,F,10141.0,CHEMBL618088,,,,,4,1
3606,104714,,BAO_0000223,,,Binding affinity towards 5-HT3 receptor by the displacement of [3H]GR-65630] in human recombinant receptors in mammalian cell,,,H,Autocuration,B,,CHEMBL618089,,,,,4,1
3607,10627,,BAO_0000357,,,Inhibition of human 5-hydroxytryptamine 6 receptor,,,D,Expert,B,9606.0,CHEMBL618090,,,,,9,1
3608,10627,,BAO_0000357,,,Binding affinity towards 5-hydroxytryptamine 6 receptor using [3H]- LSD as radioligand,,,D,Expert,B,9606.0,CHEMBL618091,,,,,9,1
3609,10627,,BAO_0000357,,,Inhibition against human 5-hydroxytryptamine 6 receptor,,,H,Autocuration,B,,CHEMBL618092,,,,,8,1
3610,10627,,BAO_0000357,,,Affinity towards human 5-hydroxytryptamine 6 serotonin receptor,,,D,Expert,B,9606.0,CHEMBL618093,,,,,9,1
3611,10627,,BAO_0000219,308.0,HeLa,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells.,,,H,Expert,B,,CHEMBL618094,,,,,8,1
3612,10627,,BAO_0000357,,,Binding affinity towards [3H]LSD-labeled human 5-hydroxytryptamine 6 receptor,,,D,Expert,B,9606.0,CHEMBL618095,,,,,9,1
3613,10627,,BAO_0000357,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,,D,Expert,B,9606.0,CHEMBL875093,,,,,9,1
3614,10627,,BAO_0000357,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [125I]-2-iodo LSD as radioligand,,,D,Expert,B,9606.0,CHEMBL618096,,,,,9,1
3615,10627,,BAO_0000357,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [3H]-LSD as radioligand,,,D,Expert,B,9606.0,CHEMBL618118,,,,,9,1
3616,10627,,BAO_0000357,,,Binding affinity against 5-hydroxytryptamine 6 receptor,,,D,Expert,B,9606.0,CHEMBL618119,,,,,9,1
3617,10627,,BAO_0000357,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,,H,Expert,B,,CHEMBL618120,,,,,8,1
3618,10627,,BAO_0000357,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,,H,Autocuration,B,,CHEMBL618121,,,,,8,1
3619,10627,,BAO_0000219,722.0,HEK293,"Binding affinity for human 5-hydroxytryptamine 6 receptor expressed in HEK 293 human embryonic kidney cells, [3H]-lysergic acid diethylamide as radioligand",,,H,Expert,B,,CHEMBL618122,,,,,8,1
3620,10627,,BAO_0000357,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor using [3H]LSD as radioligand,,,H,Autocuration,B,,CHEMBL618123,,,,,8,1
3621,10627,,BAO_0000219,722.0,HEK293,Binding affinity against human 5-hydroxytryptamine 6 receptor stably transfected to HEK 293 human embryonic kidney cells using [3H]-lysergic acid diethylamide as radioligand,,,H,Expert,B,,CHEMBL618124,,,,,8,1
3622,10627,,BAO_0000357,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 6 receptor,,,H,Autocuration,B,,CHEMBL618125,,,,,8,1
3623,10627,,BAO_0000219,722.0,HEK293,Displacement of [3H]LSD from human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,,,D,Expert,B,9606.0,CHEMBL618126,,,,,9,1
3624,10627,,BAO_0000019,,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD,,,H,Expert,B,,CHEMBL618236,,,,,8,1
3625,10627,,BAO_0000019,,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD; ND is No Data.,,,H,Expert,B,,CHEMBL618237,,,,,8,1
3626,10627,,BAO_0000219,643.0,COS-7,Ability to displace [3H]LSD from human 5-hydroxytryptamine 6 receptor transiently expressed in COS-7 cells,,,H,Expert,B,,CHEMBL618238,,,,,8,1
3627,10627,,BAO_0000357,,,In vitro binding affinity to human 5-hydroxytryptamine 6 receptor,,,D,Expert,B,9606.0,CHEMBL618239,,,,,9,1
3628,10627,,BAO_0000019,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 6 receptor,,,H,Autocuration,B,,CHEMBL618240,,,,,8,1
3629,10627,,BAO_0000357,,,Inhibitory constant against human 5-hydroxytryptamine 6 receptor using [3H]LSD radioligand,,,H,Autocuration,B,,CHEMBL618241,,,,,8,1
3630,10627,,BAO_0000219,722.0,HEK293,Antagonism assessed in a functional cAMP binding assay using 5-CT to stimulate human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,,,H,Autocuration,B,,CHEMBL859399,,,,,8,1
3631,10627,,BAO_0000019,,,The compound was tested for antagonist activity by inhibition of human 5-HT6 stimulated adenylate cyclase,,,H,Autocuration,F,,CHEMBL618242,,,,,8,1
3632,10627,,BAO_0000357,,,Ability to displace the radioligand [3H]LSD from human 5-hydroxytryptamine 6 receptor,,,H,Autocuration,B,,CHEMBL857991,,,,,8,1
3633,10627,,BAO_0000357,,,Binding affinity against human 5-hydroxytryptamine 6 receptor,,,H,Expert,B,,CHEMBL619951,,,,,8,1
3634,10627,,BAO_0000219,308.0,HeLa,Binding affinity to human cloned 5-HT6 receptor in HeLa cells using [3H]- LSD as radioligand,,,D,Expert,B,9606.0,CHEMBL619952,,,,,9,1
3635,10627,,BAO_0000219,308.0,HeLa,Binding affinity to human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]- LSD as radioligand,,,D,Expert,B,9606.0,CHEMBL619953,,,,,9,1
3636,10627,,BAO_0000219,308.0,HeLa,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells,,,H,Autocuration,B,,CHEMBL619954,,,,,8,1
3637,10627,,BAO_0000219,308.0,HeLa,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,,,H,Autocuration,B,,CHEMBL619955,,,,,8,1
3638,10627,,BAO_0000219,308.0,HeLa,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,,,H,Autocuration,B,,CHEMBL619956,,,,,8,1
3639,10627,,BAO_0000219,449.0,CHO,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,,H,Autocuration,B,,CHEMBL619957,,,,,8,1
3640,10627,,BAO_0000219,722.0,HEK293,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,,H,Autocuration,B,,CHEMBL619958,,,,,8,1
3641,10627,,BAO_0000219,722.0,HEK293,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand; ND means no data.,,,H,Autocuration,B,,CHEMBL620627,,,,,8,1
3642,10627,,BAO_0000219,722.0,HEK293,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,,,H,Autocuration,B,,CHEMBL620628,,,,,8,1
3643,10627,,BAO_0000219,308.0,HeLa,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HeLa cells using [3H]LSD as radioligand;ND means no data.,,,H,Autocuration,B,,CHEMBL620629,,,,,8,1
3644,10627,,BAO_0000357,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,,H,Autocuration,B,,CHEMBL620630,,,,,8,1
3645,10627,,BAO_0000219,308.0,HeLa,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 6 receptor expressed in HeLa cells using [3H]LSD as radioligand,,,H,Autocuration,B,,CHEMBL620782,,,,,8,1
3646,10627,,BAO_0000357,,,Compound was evaluated for its ability to displace [3H]LSD binding from human recombinant 5-hydroxytryptamine 6 receptor,,,H,Autocuration,B,,CHEMBL620783,,,,,8,1
3647,10627,,BAO_0000357,,,Binding affinity against human 5-hydroxytryptamine 6 receptor,,,H,Expert,B,,CHEMBL620784,,,,,8,1
3648,10627,,BAO_0000219,308.0,HeLa,Binding affinity against human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]LSD,,,H,Expert,B,,CHEMBL620785,,,,,8,1
3649,10627,,BAO_0000357,,,Compound was tested for its binding affinity in 5-hydroxytryptamine 6 receptor (using human cloned receptors in HeLa and [3H]LSD as a radioligand ),,,H,Autocuration,B,,CHEMBL857992,,,,,8,1
3650,10627,,BAO_0000219,,,In vitro binding affinity at human recombinant 5-hydroxytryptamine 6 receptor in mammalian cells using 3[H]LSD as the radioligand,,,H,Autocuration,B,,CHEMBL620786,,,,,8,1
3651,10627,,BAO_0000219,308.0,HeLa,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]5-LSD.,,,H,Autocuration,B,,CHEMBL620787,,,,,8,1
3652,10627,,BAO_0000219,308.0,HeLa,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=3",,,H,Autocuration,B,,CHEMBL620788,,,,,8,1
3653,10627,,BAO_0000219,308.0,HeLa,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=9",,,H,Autocuration,B,,CHEMBL620789,,,,,8,1
3654,10627,,BAO_0000219,308.0,HeLa,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]LSD as radioligand; n=3",,,H,Autocuration,B,,CHEMBL620790,,,,,8,1
3655,10628,,BAO_0000219,449.0,CHO,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 6 receptor stably expressed in CHO cells,,,H,Autocuration,B,,CHEMBL620791,,,,,8,1
3656,10628,,BAO_0000019,,,Binding affinity against 5-hydroxytryptamine 6 receptor from CHO cell membranes using [3H]5-HT as the radioligand.,,,H,Autocuration,B,,CHEMBL620792,,,,,8,1
3657,10628,,BAO_0000357,,,The compound was tested for binding affinity against 5-hydroxytryptamine 6 receptor,,,H,Autocuration,B,,CHEMBL620793,,,,,8,1
3658,10628,,BAO_0000357,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor was determined,,,H,Autocuration,B,,CHEMBL620794,,,,,8,1
3659,10627,,BAO_0000219,308.0,HeLa,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells,,,D,Autocuration,B,9606.0,CHEMBL620795,,,,,9,1
3660,10627,,BAO_0000357,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,,H,Expert,B,,CHEMBL620796,,,,,8,1
3661,10627,,BAO_0000357,,,Percentage of displacement at 5-hydroxytryptamine 6 receptor at 10e-8 M,,,H,Autocuration,B,,CHEMBL620797,,,,,8,1
3662,10627,,BAO_0000019,,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,,,D,Expert,F,9606.0,CHEMBL620798,,,,,9,1
3663,10627,,BAO_0000357,,,Inhibition of binding towards 5-hydroxytryptamine 6 receptor at 100 nM concentration,,,H,Autocuration,B,,CHEMBL620799,,,,,8,1
3664,10627,,BAO_0000357,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,,H,Expert,B,,CHEMBL620800,,,,,8,1
3665,10627,,BAO_0000357,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor; inactive at 10 uM,,,H,Autocuration,B,,CHEMBL620801,,,,,8,1
3666,10627,,BAO_0000357,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 6 receptor,,,H,Autocuration,B,,CHEMBL875100,,,,,8,1
3667,10627,,BAO_0000357,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 6 receptor was determined,,,H,Autocuration,B,,CHEMBL620802,,,,,8,1
3668,10627,,BAO_0000019,,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor,,,H,Expert,F,,CHEMBL620803,,,,,8,1
3669,10627,,BAO_0000019,,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,,,H,Expert,F,,CHEMBL620804,,,,,8,1
3670,10627,,BAO_0000357,,,Binding affinity for 5-hydroxytryptamine 6 receptor was determined,,,H,Autocuration,B,,CHEMBL620805,,,,,8,1
3671,10627,,BAO_0000357,,,Evaluated for the binding affinity towards 5-hydroxytryptamine 6 receptor,,,H,Autocuration,B,,CHEMBL620806,,,,,8,1
3672,10627,,BAO_0000357,,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-6 M,,,H,Autocuration,B,,CHEMBL620807,,,,,8,1
3673,10627,,BAO_0000357,,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-8 M,,,H,Autocuration,B,,CHEMBL620808,,,,,8,1
3674,10627,,BAO_0000357,,,Binding affinities against 5-hydroxytryptamine 6 receptor,,,H,Autocuration,B,,CHEMBL620809,,,,,8,1
3675,10627,,BAO_0000357,,,Binding affinities towards 5-hydroxytryptamine 6 receptor,,,H,Autocuration,B,,CHEMBL620810,,,,,8,1
3676,10627,,BAO_0000357,,,Binding affinity towards 5-hydroxytryptamine 6 receptor,,,D,Expert,B,9606.0,CHEMBL620811,,,,,9,1
3677,10627,,BAO_0000357,,,The binding affinity towards 5-hydroxytryptamine 6 receptor; No affinity,,,H,Autocuration,B,,CHEMBL620812,,,,,8,1
3678,10627,,BAO_0000357,,,Affinity against 5-hydroxytryptamine 6 receptor,,,H,Autocuration,B,,CHEMBL620813,,,,,8,1
3679,10627,,BAO_0000357,,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-CT],,,H,Autocuration,B,,CHEMBL620814,,,,,8,1
3680,10209,,BAO_0000357,,,Inhibition of human 5-hydroxytryptamine 7 receptor,,,D,Expert,B,9606.0,CHEMBL620815,,,,,9,1
3681,10209,,BAO_0000219,722.0,HEK293,Compound was tested for its binding affinity towards human 5-hydroxytryptamine 7 receptor from HEK293 cells using radioligand [3H]LSD,,,H,Autocuration,B,,CHEMBL620816,,,,,8,1
3682,10209,,BAO_0000357,,,Compound at 1 uM was tested for the inhibition of radioligand [3H]LSD binding to recombinant human 5-hydroxytryptamine 7 receptor,,,H,Autocuration,B,,CHEMBL620817,,,,,8,1
3683,10209,,BAO_0000357,,,In vitro binding affinity against human 5-hydroxytryptamine 7 receptor at a concentration of 100 (nM),,,H,Autocuration,B,,CHEMBL620818,,,,,8,1
3684,10209,,BAO_0000219,722.0,HEK293,Inhibition (at 1 uM) of radioligand [3H]LSD binding to human 5-hydroxytryptamine 7 receptor on HEK293 cells,,,H,Expert,B,,CHEMBL620819,,,,,8,1
3685,10209,,BAO_0000357,,,Affinity towards human 5-hydroxytryptamine 7 serotonin receptor,,,D,Expert,B,9606.0,CHEMBL620820,,,,,9,1
3686,10209,,BAO_0000219,449.0,CHO,Binding affinity for 5-hydroxytryptamine 7 receptor human cloned receptors in CHO cells using [3H]5-HT,,,H,Autocuration,B,,CHEMBL620821,,,,,8,1
3687,10209,,BAO_0000357,,,Binding affinity towards human 5-hydroxytryptamine 7 receptor,,,D,Expert,B,9606.0,CHEMBL620822,,,,,9,1
3688,10209,,BAO_0000357,,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 7 receptor,,,D,Expert,B,9606.0,CHEMBL620823,,,,,9,1
3689,10209,,BAO_0000357,,,Binding affinity against 5-hydroxytryptamine 7 receptor,,,D,Expert,B,9606.0,CHEMBL620824,,,,,9,1
3690,10209,,BAO_0000219,449.0,CHO,Binding affinity towards human 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-HT radioligand from the cloned receptor expressed in CHO cells,,,H,Expert,B,,CHEMBL620825,,,,,8,1
3691,10209,,BAO_0000357,,,Binding affinity towards recombinant human 5-hydroxytryptamine 7 receptor was determined using [3H]LSD as radioligand,,,H,Autocuration,B,,CHEMBL872930,,,,,8,1
3692,10209,,BAO_0000357,,,Binding affinity towards 5-hydroxytryptamine 7 receptor,,,H,Autocuration,B,,CHEMBL620826,,,,,8,1
3693,10209,,BAO_0000357,,,Binding affinity towards human 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,,,H,Autocuration,B,,CHEMBL620827,,,,,8,1
3694,10209,,BAO_0000357,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 7 receptor,,,H,Autocuration,B,,CHEMBL620828,,,,,8,1
3695,10209,,BAO_0000357,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 7 receptor,,,H,Autocuration,B,,CHEMBL620829,,,,,8,1
3696,10209,,BAO_0000219,722.0,HEK293,Binding affinity towards human 5-hydroxytryptamine 7 receptor on HEK293 cells using radioligand [3H]LSD,,,H,Expert,B,,CHEMBL620830,,,,,8,1
3697,10209,,BAO_0000019,,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD,,,H,Expert,B,,CHEMBL620831,,,,,8,1
3698,10209,,BAO_0000019,,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD; ND is No Data.,,,H,Expert,B,,CHEMBL620832,,,,,8,1
3699,10209,,BAO_0000357,,,In vitro binding affinity to human 5-hydroxytryptamine 7 receptor,,,D,Expert,B,9606.0,CHEMBL621548,,,,,9,1
3700,10209,,BAO_0000019,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor,,,H,Autocuration,B,,CHEMBL621549,,,,,8,1
3701,10209,,BAO_0000357,,,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]LSD radioligand,,,H,Autocuration,B,,CHEMBL621550,,,,,8,1
3702,10209,,BAO_0000219,449.0,CHO,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]-LSD as radioligand; Not determined,,,H,Autocuration,B,,CHEMBL621551,,,,,8,1
3703,10209,,BAO_0000019,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor; ND means not determined,,,H,Autocuration,B,,CHEMBL621552,,,,,8,1
3704,10209,,BAO_0000357,,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor,,,H,Autocuration,B,,CHEMBL857077,,,,,8,1
3705,10209,,BAO_0000357,,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor; Not tested,,,H,Autocuration,B,,CHEMBL618158,,,,,8,1
3706,10209,,BAO_0000219,643.0,COS-7,Ability to displace the radioligand [3H]5-carboxyamidotryptamine ([3H]5-CT) from human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,,,D,Expert,B,9606.0,CHEMBL618159,,,,,9,1
3707,10209,,BAO_0000219,643.0,COS-7,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-5-CT) from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,,,H,Autocuration,B,,CHEMBL875101,,,,,8,1
3708,10209,,BAO_0000219,722.0,HEK293,Binding affinity to human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]-5-CT as radioligand,,,D,Expert,B,9606.0,CHEMBL618160,,,,,9,1
3709,10209,,BAO_0000357,,,Binding affinity at human cloned 5-hydroxytryptamine 7 receptor.,,,H,Expert,B,,CHEMBL618161,,,,,8,1
3710,10209,,BAO_0000219,722.0,HEK293,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor was determined in HEK293 cells using [3H]5-CT as radioligand,,,H,Expert,B,,CHEMBL618162,,,,,8,1
3711,10209,,BAO_0000357,,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor was determined using [3H]5-CT as radioligand,,,H,Expert,B,,CHEMBL618163,,,,,8,1
3712,10209,,BAO_0000357,,,Binding affinity against 5-hydroxytryptamine 7 human receptors,,,H,Autocuration,B,,CHEMBL618164,,,,,8,1
3713,10209,,BAO_0000219,,,Binding affinity to human recombinant 5-hydroxytryptamine 7 receptor in mammalian cells using [3H]5-CT as radioligand,,,H,Expert,B,,CHEMBL618165,,,,,8,1
3714,10209,,BAO_0000219,722.0,HEK293,Binding affinity toward 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]-5-CT as radioligand.,,,H,Autocuration,B,,CHEMBL618166,,,,,8,1
3715,10209,,BAO_0000219,722.0,HEK293,Binding affinity towards 5-hydroxytryptamine 7 receptor (a) (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,,H,Autocuration,B,,CHEMBL857989,,,,,8,1
3716,10209,,BAO_0000219,722.0,HEK293,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,,H,Autocuration,B,,CHEMBL619888,,,,,8,1
3717,10209,,BAO_0000219,722.0,HEK293,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,,H,Autocuration,B,,CHEMBL619889,,,,,8,1
3718,10209,,BAO_0000219,722.0,HEK293,Binding affinity towards 5-hydroxytryptamine 7 receptor 7(a) (human cloned receptor in HEK 293 cells using [3H]5-CT as radioligand.,,,H,Autocuration,B,,CHEMBL619890,,,,,8,1
3719,10209,,BAO_0000219,449.0,CHO,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]LSD as radioligand,,,H,Autocuration,B,,CHEMBL619891,,,,,8,1
3720,10209,,BAO_0000219,722.0,HEK293,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand (n=3),,,H,Autocuration,B,,CHEMBL619892,,,,,8,1
3721,10209,,BAO_0000219,722.0,HEK293,Displacement of [3H]-5-CT from human 5-hydroxytryptamine 7 receptor expressed in HEK-293 cells,,,D,Expert,B,,CHEMBL619893,,,,,9,1
3722,10209,,BAO_0000219,722.0,HEK293,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand(n=6),,,H,Autocuration,B,,CHEMBL619894,,,,,8,1
3723,10209,,BAO_0000219,722.0,HEK293,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells,,,D,Intermediate,B,,CHEMBL619895,,,,,9,1
3724,10209,,BAO_0000357,,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor using [3H]5-CT as radioligand,,,D,Intermediate,B,,CHEMBL619896,,,,,9,1
3725,10209,,BAO_0000219,643.0,COS-7,Compound was evaluated for its ability to displace [3H]5-CT binding from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells.,,,H,Autocuration,B,,CHEMBL619897,,,,,8,1
3726,10209,,BAO_0000219,722.0,HEK293,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT,,,H,Autocuration,B,,CHEMBL619898,,,,,8,1
3727,10209,,BAO_0000219,722.0,HEK293,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor in HEK 293 using [3H]5-CT as a radioligand,,,H,Expert,B,,CHEMBL619899,,,,,8,1
3728,10209,,BAO_0000219,722.0,HEK293,Compound was tested for its binding affinity in 5-hydroxytryptamine 7 receptor (using human cloned receptors in HEK 293 and [3H]5-CT as a radioligand ),,,H,Autocuration,B,,CHEMBL619900,,,,,8,1
3729,10209,,BAO_0000219,722.0,HEK293,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT,,,D,Expert,B,9606.0,CHEMBL619901,,,,,9,1
3730,10209,,BAO_0000219,722.0,HEK293,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT. ,,,H,Autocuration,B,,CHEMBL620580,,,,,8,1
3731,10209,,BAO_0000219,722.0,HEK293,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT.,,,H,Autocuration,B,,CHEMBL620581,,,,,8,1
3732,10209,,BAO_0000219,722.0,HEK293,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 7 receptor in HEK293 cells, using [3H]5-CT as radioligand",,,H,Autocuration,B,,CHEMBL620733,,,,,8,1
3733,10209,,BAO_0000357,,,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]-LSD radioligand; Not determined,,,D,Autocuration,B,9606.0,CHEMBL620734,,,,,9,1
3734,10022,,BAO_0000357,,,Binding affinity towards mouse 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,,,D,Expert,B,10090.0,CHEMBL620735,,,,,9,1
3735,10209,,BAO_0000019,,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 7 receptor in the endothelium denuded rabbit jugular vein.,,,H,Autocuration,B,9986.0,CHEMBL620736,,,,,8,1
3736,11923,,BAO_0000219,449.0,CHO,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 7 receptor stably expressed in CHO cells,,,H,Autocuration,B,,CHEMBL620737,,,,,8,1
3737,11923,,BAO_0000219,449.0,CHO,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 10000 nM,,,H,Autocuration,B,,CHEMBL620738,,,,,8,1
3738,11923,,BAO_0000219,449.0,CHO,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 100 nM,,,H,Autocuration,B,,CHEMBL620739,,,,,8,1
3739,11923,,BAO_0000219,449.0,CHO,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 1 nM,,,H,Autocuration,B,,CHEMBL620740,,,,,8,1
3740,11923,,BAO_0000219,449.0,CHO,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 10000 nM 5-HT.,,,H,Autocuration,B,,CHEMBL620741,,,,,8,1
3741,11923,,BAO_0000219,449.0,CHO,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 100 nM 5-HT.,,,H,Autocuration,B,,CHEMBL620742,,,,,8,1
3742,11923,,BAO_0000219,449.0,CHO,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 1 nM 5-HT,,,H,Autocuration,B,,CHEMBL620743,,,,,8,1
3743,11923,,BAO_0000219,449.0,CHO,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 10000 nM,,,H,Autocuration,B,,CHEMBL620744,,,,,8,1
3744,11923,,BAO_0000219,449.0,CHO,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 100 nM,,,H,Autocuration,B,,CHEMBL620745,,,,,8,1
3745,11923,,BAO_0000219,449.0,CHO,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM,,,H,Autocuration,B,,CHEMBL620746,,,,,8,1
3746,11923,,BAO_0000219,449.0,CHO,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 10000 nM 5-HT.,,,H,Autocuration,B,,CHEMBL620747,,,,,8,1
3747,11923,,BAO_0000219,449.0,CHO,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 100 nM 5-HT.,,,H,Autocuration,B,,CHEMBL620748,,,,,8,1
3748,11923,,BAO_0000219,449.0,CHO,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT.,,,H,Autocuration,B,,CHEMBL620749,,,,,8,1
3749,11923,,BAO_0000357,,,Binding affinity towards rat 5-hydroxytryptamine 7 receptor,,,H,Expert,B,,CHEMBL620750,,,,,8,1
3750,11923,,BAO_0000357,,,Binding affinity towards rat 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,,,D,Expert,B,10116.0,CHEMBL620751,,,,,9,1
3751,11923,,BAO_0000357,,,Binding affinity to the rat 5-hydroxytryptamine 7 receptor,,,H,Expert,B,,CHEMBL620752,,,,,8,1
3752,11923,,BAO_0000019,,,Binding affinity against 5-hydroxytryptamine 7 receptor using from CHO cell membranes [3H]5-HT as the radioligand.,,,H,Autocuration,B,,CHEMBL872929,,,,,8,1
3753,11923,,BAO_0000357,,,Binding affinity against Rat 5-hydroxytryptamine 7 receptor using [3H]5-HT,,,D,Expert,B,10116.0,CHEMBL620753,,,,,9,1
3754,11923,,BAO_0000357,,,Displacement of [3H]5-HT from over-expressed rat 5-hydroxytryptamine 7 receptor,,,D,Expert,B,10116.0,CHEMBL620754,,,,,9,1
3755,11923,,BAO_0000219,449.0,CHO,Displacement of [3H]5-HT from rat 5-hydroxytryptamine 7 receptor expressed in CHO cells,,,D,Expert,B,10116.0,CHEMBL620755,,,,,9,1
3756,11923,,BAO_0000357,,,In vitro binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,,,H,Autocuration,B,,CHEMBL620756,,,,,8,1
3757,11923,,BAO_0000357,,,The compound was tested for binding affinity against 5-hydroxytryptamine 7 receptor,,,H,Autocuration,B,,CHEMBL620757,,,,,8,1
3758,11923,,BAO_0000219,449.0,CHO,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; Not tested",,,H,Autocuration,B,,CHEMBL620758,,,,,8,1
3759,11923,,BAO_0000219,449.0,CHO,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; not tested",,,H,Autocuration,B,,CHEMBL620759,,,,,8,1
3760,11923,,BAO_0000219,449.0,CHO,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM; not tested,,,H,Autocuration,B,,CHEMBL620760,,,,,8,1
3761,11923,,BAO_0000219,449.0,CHO,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT; Not tested,,,H,Autocuration,B,,CHEMBL620761,,,,,8,1
3762,11923,,BAO_0000221,,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,,,H,Autocuration,F,,CHEMBL620762,,2116.0,Ileum,,8,1
3763,11923,,BAO_0000221,,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,,,H,Autocuration,F,,CHEMBL620763,,2116.0,Ileum,,8,1
3764,11923,,BAO_0000221,,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine receptor desensitization,,,H,Autocuration,F,,CHEMBL620764,,2116.0,Ileum,,8,1
3765,11923,,BAO_0000249,,,Inhibition of [3H]-5-CT binding to 5-hydroxytryptamine 7 receptor of rat cortical membranes,,,D,Expert,B,10116.0,CHEMBL857990,,,,Membranes,9,1
3766,11923,,BAO_0000357,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor was determined,,,H,Autocuration,B,,CHEMBL620765,,,,,8,1
3767,11923,,BAO_0000357,,,Binding affinity at rat 5-hydroxytryptamine 7 receptor.,,,H,Expert,B,,CHEMBL620766,,,,,8,1
3768,11923,,BAO_0000019,,,Binding affinity towards 5-hydroxytryptamine receptor 7 on rat hypothalamus membranes using [3H]5-CT as radioligand.,,,H,Expert,B,,CHEMBL620767,,1898.0,Hypothalamus,,8,1
3769,11923,,BAO_0000357,,,Binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor was determined using [3H]5-HT as radioligand,,,H,Autocuration,B,,CHEMBL620768,,,,,8,1
3770,11923,,BAO_0000249,,,Binding affinity against 5-hydroxytryptamine 7 receptor using [3H]-5-CT in rat hypothalamus membranes,,,H,Expert,B,,CHEMBL619051,,1898.0,Hypothalamus,,8,1
3771,11923,,BAO_0000357,,,Binding affinity towards 5-hydroxytryptamine 7 receptor,,,H,Expert,B,,CHEMBL619052,,,,,8,1
3772,11923,,BAO_0000219,722.0,HEK293,Agonistic activity against rat 5-HT7 adenyl cyclase expressed by HEK293 cells,,,D,Expert,F,10116.0,CHEMBL619053,,,,,9,1
3773,11923,,BAO_0000219,722.0,HEK293,Agonistic activity against rat 5-HT7 adenyl cyclase expressed in HEK293 cells; Active,,,D,Expert,F,10116.0,CHEMBL619703,,,,,9,1
3774,11923,,BAO_0000219,722.0,HEK293,Agonistic activity against rat 5-HT7-adenyl cyclase expressed by HEK293 cells; Active,,,D,Autocuration,F,10116.0,CHEMBL619704,,,,,9,1
3775,10209,,BAO_0000357,,,Binding affinity towards 5-hydroxytryptamine 7 receptor,,,H,Expert,B,,CHEMBL619851,,,,,8,1
3776,10209,,BAO_0000357,,,Percentage of displacement at 5-hydroxytryptamine 7 receptor at 10e-8 M,,,H,Autocuration,B,,CHEMBL619852,,,,,8,1
3777,10209,,BAO_0000357,,,Inhibition of binding towards 5-hydroxytryptamine 7 receptor at 100 nM concentration,,,H,Autocuration,B,,CHEMBL619853,,,,,8,1
3778,10209,,BAO_0000357,,,Binding affinity towards human 5-hydroxytryptamine 7 receptor,,,D,Expert,B,9606.0,CHEMBL619854,,,,,9,1
3779,10209,,BAO_0000357,,,Binding affinity of compound towards rodent 5-hydroxytryptamine 7 receptor,,,H,Expert,B,,CHEMBL619855,,,,,8,1
3780,10209,,BAO_0000357,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor; inactive at 10 uM,,,H,Autocuration,B,,CHEMBL619856,,,,,8,1
3781,10209,,BAO_0000357,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,,,H,Autocuration,B,,CHEMBL619857,,,,,8,1
3782,10209,,BAO_0000019,,,Antagonistic activity towards 5-hydroxytryptamine 7 receptor was evaluated by cAMP assay,,,H,Expert,F,,CHEMBL619858,,,,,8,1
3783,10209,,BAO_0000357,,,Binding affinity for 5-hydroxytryptamine 7 receptor was determined,,,H,Autocuration,B,,CHEMBL619859,,,,,8,1
3784,10209,,BAO_0000357,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,,,H,Autocuration,B,,CHEMBL619860,,,,,8,1
3785,10209,,BAO_0000357,,,Evaluated for the binding affinity to 5-hydroxytryptamine 7 receptor,,,H,Autocuration,B,,CHEMBL619861,,,,,8,1
3786,10209,,BAO_0000357,,,Non-selective inhibitory activity was determined against 5-hydroxytryptamine 7 receptor,,,H,Expert,B,,CHEMBL619862,,,,,8,1
3787,10209,,BAO_0000357,,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-6 M,,,H,Autocuration,B,,CHEMBL619863,,,,,8,1
3788,10209,,BAO_0000357,,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-8 M,,,H,Autocuration,B,,CHEMBL619864,,,,,8,1
3789,10209,,BAO_0000357,,,Binding affinities against 5-hydroxytryptamine 7 receptor,,,H,Autocuration,B,,CHEMBL872928,,,,,8,1
3790,10209,,BAO_0000357,,,Binding affinities towards 5-hydroxytryptamine 7 receptor,,,H,Autocuration,B,,CHEMBL619865,,,,,8,1
3791,10209,,BAO_0000357,,,Binding affinity towards rodent 5-hydroxytryptamine 7 receptor,,,H,Expert,B,,CHEMBL619866,,,,,8,1
3792,10209,,BAO_0000357,,,The binding affinity towards 5-hydroxytryptamine 7 receptor; No affinity,,,H,Autocuration,B,,CHEMBL619867,,,,,8,1
3793,10209,,BAO_0000221,,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,,,H,Autocuration,B,,CHEMBL619868,,2116.0,Ileum,,8,1
3794,55,,BAO_0000019,,,Compound was evaluated for the potency to inhibit oxidation of arachidonic acid by human recombinant 5-Lipoxygenase using a spectrophotometric assay,,,H,Autocuration,F,,CHEMBL619869,,,,,8,1
3795,55,,BAO_0000019,,,Inhibition of oxidation of arachidonic acid by human 5-Lipoxygenase using spectrophotometric assay,,,D,Expert,F,9606.0,CHEMBL619870,,,,,9,1
3796,55,,BAO_0000357,,,In vitro inhibition of human recombinant 5-lipoxygenase enzyme,,,H,Autocuration,B,,CHEMBL619871,,,,,8,1
3797,55,,BAO_0000357,,,In vitro inhibition of human recombinant lipoxygenase enzyme,,,H,Autocuration,B,,CHEMBL619872,,,,,8,1
3798,55,,BAO_0000357,,,In vitro inhibition of human recombinant lipoxygenase enzyme; No inhibition,,,H,Autocuration,B,,CHEMBL619873,,,,,8,1
3799,55,,BAO_0000357,,,Inhibition of 5-lipoxygenase in human whole blood.,,,H,Expert,B,,CHEMBL619874,,178.0,Blood,,8,1
3800,55,,BAO_0000357,,,Inhibition of 5-lipoxygenase in human whole blood.,,,H,Expert,B,,CHEMBL619875,,178.0,Blood,,8,1
3801,55,,BAO_0000357,,,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of 5-HETE,,,H,Autocuration,B,,CHEMBL619876,,,,,8,1
3802,55,,BAO_0000357,,,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of leukotriene B4 (LTB4),,,H,Autocuration,B,,CHEMBL619877,,,,,8,1
3803,55,,BAO_0000219,,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human polymorphonuclear leukocytes.,,,H,Expert,F,,CHEMBL619878,,,,,8,1
3804,55,,BAO_0000019,,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human whole blood,,,H,Autocuration,F,,CHEMBL619879,,178.0,Blood,,8,1
3805,55,,BAO_0000357,,,In vitro inhibition of 5-lipoxygenase from human polymorphs,,,H,Autocuration,B,,CHEMBL619880,,,,,8,1
3806,55,,BAO_0000357,,,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-LPO (5-lipoxygenase),,,H,Autocuration,B,,CHEMBL619881,,,,,8,1
3807,55,,BAO_0000357,,,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-lipoxygenase,,,H,Expert,B,,CHEMBL619882,,,,,8,1
3808,55,,BAO_0000357,,,In vitro inhibitory activity against 5-lipoxygenase in a human whole blood assay,,,H,Autocuration,B,,CHEMBL619883,,,,,8,1
3809,55,,BAO_0000357,,,Inhibition of 5-Lipoxygenase (5-LO) of human whole blood (HWB),,,D,Expert,B,9606.0,CHEMBL619884,,178.0,Blood,,9,1
3810,55,,BAO_0000357,,,In vitro potency against human 5-Lipoxygenase,,,H,Autocuration,B,,CHEMBL619885,,,,,8,1
3811,55,,BAO_0000019,,,Inhibitory activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay,,,D,Expert,F,9606.0,CHEMBL619886,,,,,9,1
3812,55,,BAO_0000019,,,Inhibition activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay; No data,,,H,Autocuration,F,,CHEMBL619887,,178.0,Blood,,8,1
3813,55,,BAO_0000019,,,Inhibition of 5-lipoxygenase activity of compound evaluated as determined by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,,,H,Autocuration,F,,CHEMBL875097,,,,,8,1
3814,55,,BAO_0000219,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE,,,H,Autocuration,B,,CHEMBL618001,,,,,8,1
3815,55,,BAO_0000219,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE; NA means Not active,,,H,Autocuration,B,,CHEMBL618002,,,,,8,1
3816,55,,BAO_0000219,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4,,,H,Autocuration,B,,CHEMBL618003,,,,,8,1
3817,55,,BAO_0000219,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4; NA means Not active,,,H,Autocuration,B,,CHEMBL618004,,,,,8,1
3818,55,,BAO_0000219,,,Inhibition of human 5-lipoxygenase in human cells,,,H,Autocuration,B,,CHEMBL618005,,,,,8,1
3819,55,,BAO_0000357,,,Inhibition of human neutrophil 5-lipoxygenase,,,H,Expert,B,,CHEMBL618006,,,,,8,1
3820,55,,BAO_0000019,,,Inhibitory activity against 5-lipoxygenase expressed from human polymorphonuclear cells,,,H,Autocuration,B,,CHEMBL875086,,,,,8,1
3821,55,,BAO_0000357,,,Inhibition of 5-lipoxygenase from human whole blood,,,H,Expert,B,,CHEMBL618007,,178.0,Blood,,8,1
3822,55,,BAO_0000357,,,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,,,H,Autocuration,B,,CHEMBL618008,,,,,8,1
3823,55,,BAO_0000219,,,Inhibitory concentration required against 5-lipoxygenase activity in intact cells of human neutrophils,,,H,Autocuration,B,,CHEMBL618009,,,,,8,1
3824,55,,BAO_0000357,,,In vitro inhibition of polymorphonuclear leukocyte derived human 5-lipoxygenase,,,H,Expert,B,,CHEMBL618010,,,,,8,1
3825,55,,BAO_0000357,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,,H,Autocuration,B,,CHEMBL618011,,,,,8,1
3826,55,,BAO_0000357,,,Potency to inhibit oxidation of arachidonic acid by recombinant human 5-lipoxygenase,,,H,Expert,B,,CHEMBL618012,,,,,8,1
3827,55,,BAO_0000357,,,Tested against 5-lipoxygenase,,,H,Autocuration,B,,CHEMBL882927,,,,,8,1
3828,55,,BAO_0000357,,,Tested for activity against 5-Lipoxygenase (5-LO),,,H,Autocuration,B,,CHEMBL618013,,,,,8,1
3829,55,,BAO_0000357,,,Tested for activity against 5-lipoxygenase,,,H,Autocuration,B,,CHEMBL618014,,,,,8,1
3830,55,,BAO_0000357,,,Tested for inhibition of 5-HPETE production by human 5-LO,,,H,Autocuration,B,,CHEMBL618015,,,,,8,1
3831,55,,BAO_0000019,,,The 5-lipoxygenase activity by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,,,H,Autocuration,F,,CHEMBL618016,,,,,8,1
3832,55,,BAO_0000357,,,Inhibition of Human 5-lipoxygenase,,,H,Expert,B,,CHEMBL618017,,,,,8,1
3833,55,,BAO_0000019,,,The compound was evaluated for its inhibitory activity against 5-lipoxygenase using granulocytes-type cells,,,H,Autocuration,B,,CHEMBL618018,,,,,8,1
3834,55,,BAO_0000219,,,The compound was tested for inhibitory activity against 5-lipoxygenase in human polymorphonuclear leukocytes[PMNS],,,H,Autocuration,B,,CHEMBL875087,,,,,8,1
3835,55,,BAO_0000219,,,The compound was tested for inhibitory activity against LT synthesis in human polymorphonuclear leukocytes[PMNS],,,H,Autocuration,B,,CHEMBL618019,,,,,8,1
3836,55,,BAO_0000019,,,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50.,,,H,Autocuration,B,,CHEMBL618020,,,,,8,1
3837,55,,BAO_0000019,,,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50; Not tested,,,H,Autocuration,B,,CHEMBL618021,,,,,8,1
3838,55,,BAO_0000357,,,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in human whole blood (HWBL),,,H,Autocuration,B,,CHEMBL618022,,178.0,Blood,,8,1
3839,55,,BAO_0000357,,,The compound was tested in vitro for inhibition against 5-lipoxygenase in intact human neutrophils,,,H,Autocuration,B,,CHEMBL618023,,,,,8,1
3840,55,,BAO_0000357,,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,,H,Autocuration,B,,CHEMBL618024,,,,,8,1
3841,55,,BAO_0000019,,,In vitro inhibitory activity against 5-lipoxygenase in human polymorphonuclear (PMN) cells,,,H,Expert,B,,CHEMBL873950,,,,,8,1
3842,55,,BAO_0000357,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,,H,Autocuration,B,,CHEMBL618025,,,,,8,1
3843,55,,BAO_0000219,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM,,,H,Autocuration,B,,CHEMBL618026,,,,,8,1
3844,55,,BAO_0000219,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM; NA means Inactive,,,H,Autocuration,B,,CHEMBL618027,,,,,8,1
3845,55,,BAO_0000219,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM,,,H,Autocuration,B,,CHEMBL618028,,,,,8,1
3846,55,,BAO_0000219,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM; NA means Inactive,,,H,Autocuration,B,,CHEMBL618029,,,,,8,1
3847,55,,BAO_0000357,,,Inhibitory activity against 5-lipoxygenase at 10 uM concentration,,,H,Expert,B,,CHEMBL618030,,,,,8,1
3848,55,,BAO_0000357,,,Inhibitory activity against 5-lipoxygenase at 1 uM concentration,,,H,Expert,B,,CHEMBL618031,,,,,8,1
3849,55,,BAO_0000357,,,Inhibitory activity against lipoxygenase (LO) at 10 uM concentration,,,H,Autocuration,B,,CHEMBL618032,,,,,8,1
3850,55,,BAO_0000357,,,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,,,H,Autocuration,B,,CHEMBL618033,,,,,8,1
3851,55,,BAO_0000357,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 1 uM,,,H,Autocuration,B,,CHEMBL618034,,,,,8,1
3852,55,,BAO_0000357,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,,H,Autocuration,B,,CHEMBL875088,,,,,8,1
3853,55,,BAO_0000019,,,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; IA= Inactive,,,H,Autocuration,B,,CHEMBL618035,,,,,8,1
3854,55,,BAO_0000019,,,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; value ranges from 70-90,,,H,Autocuration,B,,CHEMBL618036,,,,,8,1
3855,55,,BAO_0000357,,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 0.1 uM,,,H,Expert,B,,CHEMBL618037,,,,,8,1
3856,55,,BAO_0000357,,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,,,H,Expert,B,,CHEMBL618038,,,,,8,1
3857,55,,BAO_0000019,,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,,,H,Autocuration,F,,CHEMBL618761,,,,,8,1
3858,55,,BAO_0000357,,,Inhibition of lipoxygenase at the concentration of 0.1 uM,,,H,Expert,B,,CHEMBL618762,,,,,8,1
3859,55,,BAO_0000357,,,Inhibition of lipoxygenase at the concentration of 1 uM,,,H,Expert,B,,CHEMBL618763,,,,,8,1
3860,55,,BAO_0000357,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell,,,H,Autocuration,B,,CHEMBL618764,,,,,8,1
3861,55,,BAO_0000357,,,Inhibition of 5-Lipoxygenase (5-LOX),,,D,Expert,B,9606.0,CHEMBL618765,,,,,9,1
3862,17087,,BAO_0000357,,,Inhibition of 5-lipoxygenase in mouse macrophages.,,,H,Expert,B,,CHEMBL618766,,,,,8,1
3863,17087,,BAO_0000357,,,Inhibition of 5-lipoxygenase in mouse macrophages.,,,H,Expert,B,,CHEMBL618767,,,,,8,1
3864,17087,,BAO_0000357,,,Inhibitory activity against lipoxygenase-2 in mice,,,H,Autocuration,B,,CHEMBL619380,,,,,8,1
3865,17087,,BAO_0000357,,,Inhibitory activity against murine lipoxygenase-2.,,,H,Expert,B,,CHEMBL619381,,,,,8,1
3866,17087,,BAO_0000357,,,Inhibition of 5-lipoxygenase from mouse macrophage,,,D,Expert,B,10090.0,CHEMBL619382,,,,,9,1
3867,17087,,BAO_0000357,,,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse macrophages,,,H,Autocuration,B,,CHEMBL619383,,,,,8,1
3868,55,,BAO_0000019,,,The compound was tested for the inhibition of Arachidonate 5-lipoxygenase purified from porcine leukocytes.,,,H,Autocuration,B,9823.0,CHEMBL619384,,,,,8,1
3869,55,,BAO_0000019,,,Inhibition of 5-lipoxygenase reaction catalyzed by purified enzyme from porcine leukocytes,,,H,Autocuration,B,9823.0,CHEMBL619385,,,,,8,1
3870,55,,BAO_0000019,,,Inhibitory concentration against 5-lipoxygenase from isolated rabbit granulocytes,,,H,Autocuration,B,9986.0,CHEMBL882928,,,,,8,1
3871,12166,,BAO_0000019,,,5-lipoxygenase Inhibitory activity against rat polymorphonuclear leucocytes using 5-HETE,,,D,Expert,B,10116.0,CHEMBL619386,,,,,9,1
3872,12166,,BAO_0000019,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE. ",,,H,Autocuration,B,,CHEMBL619387,,,,,8,1
3873,12166,,BAO_0000019,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",,,H,Autocuration,B,,CHEMBL619388,,,,,8,1
3874,12166,,BAO_0000019,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4.",,,H,Autocuration,B,,CHEMBL619389,,,,,8,1
3875,12166,,BAO_0000019,,,Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay (inhibition of 5-HETE formation),,,H,Expert,B,,CHEMBL619390,,,,,8,1
3876,12166,,BAO_0000019,,,"Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay, by ability to inhibit formation of LTB4 AT 10 uM",,,H,Expert,B,,CHEMBL619391,,,,,8,1
3877,12166,,BAO_0000019,,,Inhibition of 5-lipoxygenase pathway was evaluated in rat polymorphonuclear assay by compound (50 uM) ability to inhibit formation of 5-HETE,,,H,Autocuration,B,,CHEMBL619392,,,,,8,1
3878,12166,,BAO_0000019,,,The effective dose for inhibition of 5-lipoxygenase in rat blood leukocyte (ex vivo),,,H,Autocuration,B,,CHEMBL619393,,,,,8,1
3879,12166,,BAO_0000019,,,The effective dose for inhibition of 5-lipoxygenase in rat passive Arthus model after oral administration,,,H,Autocuration,B,,CHEMBL619394,,,,,8,1
3880,12166,,BAO_0000219,702.0,RBL-1,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",,,H,Autocuration,B,,CHEMBL619395,,,,,8,1
3881,12166,,BAO_0000219,702.0,RBL-1,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",,,H,Autocuration,B,,CHEMBL619396,,,,,8,1
3882,12166,,BAO_0000357,,,Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),,,H,Autocuration,B,,CHEMBL619397,,,,,8,1
3883,12166,,BAO_0000357,,,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),",,,H,Autocuration,B,,CHEMBL619398,,,,,8,1
3884,12166,,BAO_0000357,,,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO), (at a concentration of 0.2 nM ),",,,H,Autocuration,B,,CHEMBL619399,,,,,8,1
3885,12166,,BAO_0000357,,,5-LO inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,,,H,Autocuration,B,,CHEMBL619400,,,,,8,1
3886,12166,,BAO_0000019,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",,,H,Autocuration,B,,CHEMBL619401,,,,,8,1
3887,12166,,BAO_0000019,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4. ",,,H,Autocuration,B,,CHEMBL619402,,,,,8,1
3888,12166,,BAO_0000219,663.0,RBL-2H3,Inhibition of 5-lipoxygenase mediated conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cells,,,D,Expert,B,10116.0,CHEMBL619403,,,,,9,1
3889,12166,,BAO_0000357,,,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,,,H,Autocuration,B,,CHEMBL619404,,,,,8,1
3890,12166,,BAO_0000357,,,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography.,,,H,Autocuration,B,,CHEMBL619405,,,,,8,1
3891,12166,,BAO_0000219,702.0,RBL-1,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line,,,H,Expert,B,,CHEMBL619406,,,,,8,1
3892,12166,,BAO_0000219,702.0,RBL-1,Inhibition of 5-Lipoxygenase of rat basophilic leukemia cells,,,D,Expert,B,10116.0,CHEMBL619407,,,,,9,1
3893,12166,,BAO_0000357,,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase),,,H,Autocuration,B,,CHEMBL619408,,,,,8,1
3894,12166,,BAO_0000219,702.0,RBL-1,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) in intact RBL-1 cell line assay,,,H,Autocuration,B,,CHEMBL619409,,,,,8,1
3895,12166,,BAO_0000219,702.0,RBL-1,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-lipoxygenase,,,H,Expert,B,,CHEMBL619410,,,,,8,1
3896,12166,,BAO_0000219,702.0,RBL-1,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,,,H,Autocuration,B,,CHEMBL619753,,,,,8,1
3897,12166,,BAO_0000219,702.0,RBL-1,Compound was evaluated in an intact RBL-1 cell line for inhibition of 5-lipoxygenase,,,H,Autocuration,B,,CHEMBL619754,,,,,8,1
3898,12166,,BAO_0000357,,,Evaluated in vitro for its inhibitory activity against 5-lipoxygenase,,,H,Expert,B,,CHEMBL619903,,,,,8,1
3899,12166,,BAO_0000357,,,"Evaluated in vitro for its inhibitory activity against 5-lipoxygenase; N=Inactive, <50% inhibition at 10 uM concentration",,,H,Expert,B,,CHEMBL619904,,,,,8,1
3900,12166,,BAO_0000357,,,Inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase in vitro,,,H,Expert,B,,CHEMBL619905,,,,,8,1
3901,12166,,BAO_0000019,,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells,,,H,Autocuration,B,,CHEMBL619906,,,,,8,1
3902,12166,,BAO_0000019,,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 32 uM; Not active,,,H,Autocuration,B,,CHEMBL619907,,,,,8,1
3903,12166,,BAO_0000019,,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 50 uM; Not active,,,H,Autocuration,B,,CHEMBL619908,,,,,8,1
3904,12166,,BAO_0000019,,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells; No data,,,H,Autocuration,B,,CHEMBL619909,,,,,8,1
3905,12166,,BAO_0000219,702.0,RBL-1,Inhibition of 5-lipoxygenase by measuring 5-HETE levels in RBL-1 cell-free supernatant,,,H,Expert,F,,CHEMBL619910,,,,,8,1
3906,12166,,BAO_0000219,702.0,RBL-1,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells,,,H,Expert,B,,CHEMBL882929,,,,,8,1
3907,12166,,BAO_0000219,702.0,RBL-1,Ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells.,,,H,Expert,B,,CHEMBL619911,,,,,8,1
3908,12166,,BAO_0000019,,,Compound was tested for its ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells; No data,,,H,Autocuration,B,,CHEMBL619912,,,,,8,1
3909,12166,,BAO_0000357,,,Inhibition of rat basophilic leukemia cell 5-lipoxygenase,,,D,Expert,B,10116.0,CHEMBL619913,,,,,9,1
3910,12166,,BAO_0000219,702.0,RBL-1,In vitro inhibitory activity against RBL-1 5-LO,,,H,Expert,B,,CHEMBL619914,,,,,8,1
3911,12166,,BAO_0000219,702.0,RBL-1,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (insoluble above 45 uM),,,H,Autocuration,B,,CHEMBL619915,,,,,8,1
3912,12166,,BAO_0000219,702.0,RBL-1,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (time dependent),,,H,Autocuration,B,,CHEMBL619916,,,,,8,1
3913,12166,,BAO_0000218,,,Compound was tested for its inhibition activity against 5-LO of the whole cell in vitro in rat.,,,H,Autocuration,B,,CHEMBL619917,,,,,8,1
3914,12166,,BAO_0000357,,,Compound was tested for its inhibition activity against the 5-LO in isolated enzyme,,,H,Autocuration,B,,CHEMBL619918,,,,,8,1
3915,12166,,BAO_0000218,,,Compound was tested for its inhibitory activity against 5-lipoxygenase in rat.,,,H,Autocuration,B,,CHEMBL619919,,,,,8,1
3916,12166,,BAO_0000219,702.0,RBL-1,Compound was tested for the inhibition of 5-lipoxygenase (5-LPO) in rat basophilic leukemia (RBL) cells.,,,H,Autocuration,B,,CHEMBL883710,,,,,8,1
3917,12166,,BAO_0000019,,,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in rat whole blood.,,,H,Autocuration,B,,CHEMBL619920,,178.0,Blood,,8,1
3918,12166,,BAO_0000357,,,Concentration required for 50 % inhibition of arachidonic acid oxidation by rat 5-lipoxygenase,,,H,Expert,B,,CHEMBL619921,,,,,8,1
3919,12166,,BAO_0000019,,,Concentration that produces 50% inhibition of A-23187-stimulated radiolabeled 5-HETE and TXB2 synthesis by PMN 5-lipoxygenase.,,,H,Autocuration,F,,CHEMBL619922,,,,,8,1
3920,12166,,BAO_0000219,,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in rat polymorphonuclear leukocytes,,,H,Autocuration,F,,CHEMBL619923,,,,,8,1
3921,12166,,BAO_0000219,702.0,RBL-1,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined,,,H,Expert,B,,CHEMBL619924,,,,,8,1
3922,12166,,BAO_0000357,,,In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assay,,,H,Expert,B,,CHEMBL619925,,,,,8,1
3923,12166,,BAO_0000219,702.0,RBL-1,In vitro inhibition of 5-lipoxygenase from RBL-1 cells,,,H,Expert,B,,CHEMBL619926,,,,,8,1
3924,12166,,BAO_0000219,702.0,RBL-1,In vitro inhibition of 5-lipoxygenase in RBL-1 cells,,,H,Autocuration,B,,CHEMBL619927,,,,,8,1
3925,12166,,BAO_0000219,702.0,RBL-1,In vitro inhibition of 5-lipoxygenase pathway in rat basophilic leukemia (RBL-1) cells,,,H,Expert,B,,CHEMBL619928,,,,,8,1
3926,12166,,BAO_0000219,702.0,RBL-1,In vitro inhibition of RBL-1 5-lipoxygenase,,,H,Autocuration,B,,CHEMBL619929,,,,,8,1
3927,12166,,BAO_0000219,702.0,RBL-1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.18-0.31,,,H,Autocuration,B,,CHEMBL875089,,,,,8,1
3928,12166,,BAO_0000219,702.0,RBL-1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.3-1.6,,,H,Autocuration,B,,CHEMBL619930,,,,,8,1
3929,12166,,BAO_0000219,702.0,RBL-1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.4-2.2,,,H,Autocuration,B,,CHEMBL619931,,,,,8,1
3930,12166,,BAO_0000219,702.0,RBL-1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.72-1.07,,,H,Autocuration,B,,CHEMBL619932,,,,,8,1
3931,12166,,BAO_0000219,702.0,RBL-1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.9-4.0,,,H,Autocuration,B,,CHEMBL619933,,,,,8,1
3932,12166,,BAO_0000219,702.0,RBL-1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.5,,,H,Autocuration,B,,CHEMBL619934,,,,,8,1
3933,12166,,BAO_0000219,702.0,RBL-1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.7,,,H,Autocuration,B,,CHEMBL619935,,,,,8,1
3934,12166,,BAO_0000219,702.0,RBL-1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-2.4,,,H,Autocuration,B,,CHEMBL619936,,,,,8,1
3935,12166,,BAO_0000219,702.0,RBL-1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.07-5.54,,,H,Autocuration,B,,CHEMBL619937,,,,,8,1
3936,12166,,BAO_0000219,702.0,RBL-1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.1-1.6,,,H,Autocuration,B,,CHEMBL619938,,,,,8,1
3937,12166,,BAO_0000219,702.0,RBL-1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.3-2.8,,,H,Autocuration,B,,CHEMBL619939,,,,,8,1
3938,12166,,BAO_0000219,702.0,RBL-1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.4-3.2,,,H,Autocuration,B,,CHEMBL619940,,,,,8,1
3939,12166,,BAO_0000219,702.0,RBL-1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.7-2.6,,,H,Autocuration,B,,CHEMBL875090,,,,,8,1
3940,12166,,BAO_0000219,702.0,RBL-1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-2.8,,,H,Autocuration,B,,CHEMBL619941,,,,,8,1
3941,12166,,BAO_0000219,702.0,RBL-1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-5.7,,,H,Autocuration,B,,CHEMBL619942,,,,,8,1
3942,12166,,BAO_0000219,702.0,RBL-1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.9-2.4,,,H,Autocuration,B,,CHEMBL883711,,,,,8,1
3943,12166,,BAO_0000219,702.0,RBL-1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.3-.8,,,H,Autocuration,B,,CHEMBL619943,,,,,8,1
3944,12166,,BAO_0000219,702.0,RBL-1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.46-2.63,,,H,Autocuration,B,,CHEMBL619944,,,,,8,1
3945,12166,,BAO_0000219,702.0,RBL-1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.3-3.5,,,H,Autocuration,B,,CHEMBL619945,,,,,8,1
3946,12166,,BAO_0000219,702.0,RBL-1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.8-7.1,,,H,Autocuration,B,,CHEMBL619946,,,,,8,1
3947,12166,,BAO_0000219,702.0,RBL-1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.0-6.4,,,H,Autocuration,B,,CHEMBL619947,,,,,8,1
3948,12166,,BAO_0000219,702.0,RBL-1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.9-11.6,,,H,Autocuration,B,,CHEMBL619948,,,,,8,1
3949,12166,,BAO_0000219,702.0,RBL-1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 7.5-11.8,,,H,Autocuration,B,,CHEMBL619949,,,,,8,1
3950,12166,,BAO_0000019,,,In vitro inhibitory activity against 5-lipoxygenase from rat basophilic leukemia cells.,,,H,Expert,B,,CHEMBL619950,,,,,8,1
3951,12166,,BAO_0000019,,,In vitro inhibitory activity against 5-Lipoxygenase in rat by Peritoneal 5-lipoxygenase assay,,,H,Autocuration,B,,CHEMBL618050,,,,,8,1
3952,12166,,BAO_0000219,663.0,RBL-2H3,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells.,,,H,Expert,F,,CHEMBL875091,,,,,8,1
3953,12166,,BAO_0000219,663.0,RBL-2H3,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells; Not tested,,,H,Expert,F,,CHEMBL618051,,,,,8,1
3954,12166,,BAO_0000219,702.0,RBL-1,Inhibition of 5-lipoxygenase from rat basophilic leukemia(RBL-1) cells,,,D,Expert,B,10116.0,CHEMBL618052,,,,,9,1
3955,12166,,BAO_0000019,,,In vitro inhibitory activity against 5-lipoxygenase in an RBL-2H3 cell lysate,,,H,Autocuration,B,,CHEMBL618053,,,,,8,1
3956,12166,,BAO_0000019,,,In vitro inhibition of 5-lipoxygenase in rat (peritoneal assay),,,H,Expert,B,,CHEMBL618054,,,,,8,1
3957,12166,,BAO_0000219,702.0,RBL-1,In vitro inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,,,D,Expert,B,10116.0,CHEMBL618055,,,,,9,1
3958,12166,,BAO_0000219,702.0,RBL-1,inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cell line.,,,H,Expert,B,,CHEMBL618056,,,,,8,1
3959,12166,,BAO_0000357,,,In vitro inhibitory activity against 5-lipoxygenase was determined,,,H,Autocuration,B,,CHEMBL618057,,,,,8,1
3960,12166,,BAO_0000219,702.0,RBL-1,In vitro inhibitory concentration against 5-lipoxygenase in RBL-1 cells,,,H,Autocuration,B,,CHEMBL618058,,,,,8,1
3961,12166,,BAO_0000219,702.0,RBL-1,Inhibition of 5-lipoxygenase in intact RBL-1 cell line,,,H,Expert,B,,CHEMBL618059,,,,,8,1
3962,12166,,BAO_0000019,,,Inhibitory activity against 5-lipoxygenase catalysis (5-LO) in sonicated rat basophilic leukemia cell lysate,,,D,Expert,F,10116.0,CHEMBL618060,,,,,9,1
3963,12166,,BAO_0000219,702.0,RBL-1,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemia cells,,,H,Autocuration,B,,CHEMBL618061,,,,,8,1
3964,12166,,BAO_0000019,,,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemic cells,,,H,Autocuration,B,,CHEMBL618062,,,,,8,1
3965,12166,,BAO_0000219,702.0,RBL-1,Inhibition of 5-lipoxygenase catalysis in rat basophilic leukemia (RBL) cells by measuring 5-HETE product formation,,,H,Expert,B,,CHEMBL618063,,,,,8,1
3966,12166,,BAO_0000357,,,Inhibition of 5-lipoxygenase from rat peritoneal neutrophils after oral administration,,,H,Autocuration,B,,CHEMBL618064,,,,,8,1
3967,12166,,BAO_0000219,702.0,RBL-1,Inhibition of 5-lipoxygenase of rat basophilic leukemia (RBL) cell cytosolic enzymes,,,D,Expert,B,10116.0,CHEMBL618065,,,,,9,1
3968,12166,,BAO_0000219,702.0,RBL-1,Inhibition 5-lipoxygenase mediated LTB4 formation in rat basophilic leukemia (RBL-1) cells,,,D,Expert,B,10116.0,CHEMBL618066,,,,,9,1
3969,12166,,BAO_0000219,702.0,RBL-1,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,,H,Autocuration,B,,CHEMBL618067,,,,,8,1
3970,12166,,BAO_0000219,702.0,RBL-1,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),,,H,Autocuration,B,,CHEMBL618068,,,,,8,1
3971,12166,,BAO_0000219,702.0,RBL-1,Inhibition of 5-lipoxygenase in rat RBL-1 cells,,,D,Expert,B,10116.0,CHEMBL618069,,,,,9,1
3972,12166,,BAO_0000219,702.0,RBL-1,Inhibition of 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,,H,Expert,B,,CHEMBL618070,,,,,8,1
3973,10825,,BAO_0000019,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 32 umol/kg,,,H,Autocuration,F,,CHEMBL618071,,349.0,Limbic system,,8,1
3974,10825,,BAO_0000019,,,Compound was tested for its effects on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,,,H,Autocuration,F,,CHEMBL619247,,349.0,Limbic system,,8,1
3975,10825,,BAO_0000019,,,Approximate dose levels for a half maximal reduction of 5-HTP levels,,,H,Autocuration,F,,CHEMBL619248,,,,,8,1
3976,10576,,BAO_0000221,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,,,H,Autocuration,B,,CHEMBL619249,,10000000.0,Hippocampus,,8,1
3977,10576,,BAO_0000221,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,,,H,Autocuration,B,,CHEMBL619250,,10000000.0,Hippocampus,,8,1
3978,10577,,BAO_0000019,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,,,H,Autocuration,B,,CHEMBL619251,,,,,8,1
3979,55,,BAO_0000019,,,Inhibitory concentration against human platelet 5-lipoxygenase in dog whole blood,,,H,Autocuration,F,9615.0,CHEMBL619252,,178.0,Blood,,8,1
3980,55,,BAO_0000019,,,Inhibitory concentration against human platelet 5-lipoxygenase in human whole blood,,,H,Autocuration,F,,CHEMBL619253,,178.0,Blood,,8,1
3981,12166,,BAO_0000219,,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat polymorphonuclear leukocytes[PMNS],,,H,Autocuration,B,,CHEMBL619254,,,,,8,1
3982,17140,,BAO_0000219,,,Inhibition of 5-lipoxygenase in bovine polymorphonuclear leukocytes,,,H,Expert,B,,CHEMBL619255,,,,,8,1
3983,17140,,BAO_0000219,,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL).,,,H,Expert,B,,CHEMBL619256,,,,,8,1
3984,17140,,BAO_0000219,,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL),,,H,Autocuration,B,,CHEMBL875418,,,,,8,1
3985,17140,,BAO_0000219,,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,,,H,Expert,B,,CHEMBL619257,,,,,8,1
3986,17140,,BAO_0000219,,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,,,H,Autocuration,B,,CHEMBL619258,,,,,8,1
3987,17140,,BAO_0000357,,,Inhibition of 5-lipoxygenase in bovine PMNL cell assay.,,,H,Expert,B,,CHEMBL619259,,,,,8,1
3988,17140,,BAO_0000357,,,Tested for inhibition of 5-lipoxygenase as inhibition of 5-HETE and LTB4 biosynthesis in bovine PMNL,,,H,Expert,B,,CHEMBL619260,,,,,8,1
3989,55,In vivo,BAO_0000218,,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",,,H,Autocuration,F,9615.0,CHEMBL619261,,178.0,Blood,,8,1
3990,55,In vivo,BAO_0000218,,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",,,H,Autocuration,F,9615.0,CHEMBL619263,,178.0,Blood,,8,1
3991,55,In vivo,BAO_0000218,,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",,,H,Autocuration,F,9615.0,CHEMBL619264,,178.0,Blood,,8,1
3992,55,In vivo,BAO_0000218,,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",,,H,Autocuration,F,9615.0,CHEMBL619265,,178.0,Blood,,8,1
3993,55,In vivo,BAO_0000218,,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",,,H,Autocuration,F,9615.0,CHEMBL619266,,178.0,Blood,,8,1
3994,55,In vivo,BAO_0000218,,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",,,H,Autocuration,F,9615.0,CHEMBL619902,,178.0,Blood,,8,1
3995,55,In vivo,BAO_0000218,,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",,,H,Autocuration,F,9615.0,CHEMBL620058,,178.0,Blood,,8,1
3996,55,In vivo,BAO_0000218,,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",,,H,Autocuration,F,9615.0,CHEMBL620059,,178.0,Blood,,8,1
3997,55,In vivo,BAO_0000218,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",,,H,Autocuration,F,9615.0,CHEMBL620060,,178.0,Blood,,8,1
3998,55,In vivo,BAO_0000218,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",,,H,Autocuration,F,9615.0,CHEMBL620061,,178.0,Blood,,8,1
3999,55,In vivo,BAO_0000218,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 0.3 mg/kg",,,H,Autocuration,F,9615.0,CHEMBL620062,,178.0,Blood,,8,1
4000,55,In vivo,BAO_0000218,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",,,H,Autocuration,F,9615.0,CHEMBL620063,,178.0,Blood,,8,1
4001,55,In vivo,BAO_0000218,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 3.0 mg/kg",,,H,Autocuration,F,9615.0,CHEMBL620064,,178.0,Blood,,8,1
4002,55,In vivo,BAO_0000218,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",,,H,Autocuration,F,9615.0,CHEMBL620065,,178.0,Blood,,8,1
4003,55,In vivo,BAO_0000218,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 0.3 mg/kg",,,H,Autocuration,F,9615.0,CHEMBL620066,,178.0,Blood,,8,1
4004,55,In vivo,BAO_0000218,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 1.0 mg/kg",,,H,Autocuration,F,9615.0,CHEMBL620067,,178.0,Blood,,8,1
4005,55,In vivo,BAO_0000218,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 3.0 mg/kg",,,H,Autocuration,F,9615.0,CHEMBL620068,,178.0,Blood,,8,1
4006,55,In vivo,BAO_0000218,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",,,H,Autocuration,F,9615.0,CHEMBL620069,,178.0,Blood,,8,1
4007,55,In vivo,BAO_0000218,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 0.3 mg/kg",,,H,Autocuration,F,9615.0,CHEMBL620070,,178.0,Blood,,8,1
4008,55,In vivo,BAO_0000218,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 1.0 mg/kg",,,H,Autocuration,F,9615.0,CHEMBL620071,,178.0,Blood,,8,1
4009,55,In vivo,BAO_0000218,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 3.0 mg/kg",,,H,Autocuration,F,9615.0,CHEMBL620072,,178.0,Blood,,8,1
4010,55,In vivo,BAO_0000218,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",,,H,Autocuration,F,9615.0,CHEMBL620036,,178.0,Blood,,8,1
4011,55,In vivo,BAO_0000218,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 0.3 mg/kg",,,H,Autocuration,F,9615.0,CHEMBL857702,,178.0,Blood,,8,1
4012,55,In vivo,BAO_0000218,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 1.0 mg/kg",,,H,Autocuration,F,9615.0,CHEMBL620037,,178.0,Blood,,8,1
4013,55,In vivo,BAO_0000218,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 3.0 mg/kg",,,H,Autocuration,F,9615.0,CHEMBL620038,,178.0,Blood,,8,1
4014,55,In vivo,BAO_0000218,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",,,H,Autocuration,F,9615.0,CHEMBL620039,,178.0,Blood,,8,1
4015,55,In vivo,BAO_0000218,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 0.3 mg/kg",,,H,Autocuration,F,9615.0,CHEMBL620040,,178.0,Blood,,8,1
4016,55,In vivo,BAO_0000218,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 1.0 mg/kg",,,H,Autocuration,F,9615.0,CHEMBL620041,,178.0,Blood,,8,1
4017,55,In vivo,BAO_0000218,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 3.0 mg/kg",,,H,Autocuration,F,9615.0,CHEMBL620042,,178.0,Blood,,8,1
4018,55,In vivo,BAO_0000218,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",,,H,Autocuration,F,9615.0,CHEMBL620043,,178.0,Blood,,8,1
4019,55,In vivo,BAO_0000218,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 0.3 mg/kg",,,H,Autocuration,F,9615.0,CHEMBL620044,,178.0,Blood,,8,1
4020,55,In vivo,BAO_0000218,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 1.0 mg/kg",,,H,Autocuration,F,9615.0,CHEMBL620045,,178.0,Blood,,8,1
4021,55,In vivo,BAO_0000218,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 3.0 mg/kg",,,H,Autocuration,F,9615.0,CHEMBL620046,,178.0,Blood,,8,1
4022,55,In vivo,BAO_0000218,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",,,H,Autocuration,F,9615.0,CHEMBL620047,,178.0,Blood,,8,1
4023,55,In vivo,BAO_0000218,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 0.3 mg/kg",,,H,Autocuration,F,9615.0,CHEMBL620048,,178.0,Blood,,8,1
4024,55,In vivo,BAO_0000218,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 1.0 mg/kg",,,H,Autocuration,F,9615.0,CHEMBL857703,,178.0,Blood,,8,1
4025,55,In vivo,BAO_0000218,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 3.0 mg/kg",,,H,Autocuration,F,9615.0,CHEMBL620049,,178.0,Blood,,8,1
4026,55,In vivo,BAO_0000218,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",,,H,Autocuration,F,9615.0,CHEMBL620050,,178.0,Blood,,8,1
4027,55,In vivo,BAO_0000218,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",,,H,Autocuration,F,9615.0,CHEMBL620051,,178.0,Blood,,8,1
4028,55,In vivo,BAO_0000218,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",,,H,Autocuration,F,9615.0,CHEMBL619213,,178.0,Blood,,8,1
4029,55,In vivo,BAO_0000218,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",,,H,Autocuration,F,9615.0,CHEMBL619214,,178.0,Blood,,8,1
4030,55,In vivo,BAO_0000218,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",,,H,Autocuration,F,9615.0,CHEMBL619804,,178.0,Blood,,8,1
4031,55,In vivo,BAO_0000218,,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",,,H,Autocuration,F,9615.0,CHEMBL619805,,178.0,Blood,,8,1
4032,55,In vivo,BAO_0000218,,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",,,H,Autocuration,F,9615.0,CHEMBL619806,,178.0,Blood,,8,1
4033,55,In vivo,BAO_0000218,,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",,,H,Autocuration,F,9615.0,CHEMBL619807,,178.0,Blood,,8,1
4034,55,In vivo,BAO_0000218,,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",,,H,Autocuration,F,9615.0,CHEMBL619808,,178.0,Blood,,8,1
4035,55,,BAO_0000218,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r,,,H,Autocuration,B,9615.0,CHEMBL619809,,,,,8,1
4036,55,,BAO_0000218,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r to canine,,,H,Autocuration,B,9615.0,CHEMBL619810,,,,,8,1
4037,55,,BAO_0000218,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr,,,H,Autocuration,B,9615.0,CHEMBL619811,,,,,8,1
4038,55,,BAO_0000218,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr to canine,,,H,Autocuration,B,9615.0,CHEMBL620769,,,,,8,1
4039,55,,BAO_0000218,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr,,,H,Autocuration,B,9615.0,CHEMBL620770,,,,,8,1
4040,55,,BAO_0000218,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr to canine,,,H,Autocuration,B,9615.0,CHEMBL620771,,,,,8,1
4041,55,,BAO_0000218,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr,,,H,Autocuration,B,9615.0,CHEMBL620772,,,,,8,1
4042,55,,BAO_0000218,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr to canine,,,H,Autocuration,B,9615.0,CHEMBL620773,,,,,8,1
4043,55,,BAO_0000357,,,Ability to inhibit 5-lipoxygenase in guinea pig,,,H,Autocuration,B,10141.0,CHEMBL620774,,,,,8,1
4044,55,,BAO_0000357,,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-lipoxygenase in vitro (guinea pig PMN),,,H,Expert,B,10141.0,CHEMBL620775,,,,,8,1
4045,55,,BAO_0000357,,,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in guinea pig.,,,H,Autocuration,B,10141.0,CHEMBL620776,,,,,8,1
4046,55,,BAO_0000218,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 12 h, following intravenous administration at the dose of 1.0 mg/kg",,,H,Autocuration,B,10141.0,CHEMBL620777,,178.0,Blood,,8,1
4047,55,,BAO_0000357,,,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on 5-hydroxyeicosapentaenoic acid (5-HETE) production,,,H,Autocuration,B,10141.0,CHEMBL620778,,,,,8,1
4048,55,,BAO_0000357,,,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on LTB4 production,,,H,Autocuration,B,10141.0,CHEMBL620779,,,,,8,1
4049,55,,BAO_0000019,,,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]-AA to 5-HETE in guinea pig peritoneal polymorphonuclear leukocytes,,,H,Expert,B,10141.0,CHEMBL621500,,,,,8,1
4050,55,,BAO_0000019,,,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,,,H,Expert,B,10141.0,CHEMBL621501,,,,,8,1
4051,55,,BAO_0000019,,,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,,,H,Autocuration,B,10141.0,CHEMBL618098,,,,,8,1
4052,55,,BAO_0000019,,,Inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,,,H,Autocuration,B,10141.0,CHEMBL618099,,,,,8,1
4053,55,,BAO_0000357,,,Inhibitory activity against 5-lipoxygenase,,,H,Autocuration,B,10141.0,CHEMBL618100,,,,,8,1
4054,55,,BAO_0000357,,,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte,,,H,Autocuration,B,10141.0,CHEMBL618101,,,,,8,1
4055,55,,BAO_0000357,,,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant,,,H,Autocuration,B,10141.0,CHEMBL618102,,,,,8,1
4056,55,,BAO_0000357,,,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase,,,H,Autocuration,B,10141.0,CHEMBL618103,,,,,8,1
4057,55,,BAO_0000357,,,Inhibitory activity uM,,,H,Autocuration,B,10141.0,CHEMBL618104,,,,,8,1
4058,55,,BAO_0000219,,,Inhibitory activity against 5-lipoxygenase in guinea pig leukocytes was determined,,,H,Autocuration,B,10141.0,CHEMBL883712,,,,,8,1
4059,55,,BAO_0000357,,,Inhibitory activity against 5-lipoxygenase at 10 uM,,,H,Autocuration,B,10141.0,CHEMBL618105,,,,,8,1
4060,55,,BAO_0000357,,,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,,,H,Autocuration,B,10141.0,CHEMBL618106,,,,,8,1
4061,55,,BAO_0000357,,,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte at 30 uM,,,H,Autocuration,B,10141.0,CHEMBL618107,,,,,8,1
4062,55,,BAO_0000357,,,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,,,H,Autocuration,B,10141.0,CHEMBL618108,,,,,8,1
4063,55,,BAO_0000357,,,Inhibitory activity uM,,,H,Autocuration,B,10141.0,CHEMBL618109,,,,,8,1
4064,55,,BAO_0000357,,,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase at 10 uM,,,H,Autocuration,B,10141.0,CHEMBL618110,,,,,8,1
4065,55,,BAO_0000357,,,Inhibitory activity uM,,,H,Expert,B,10141.0,CHEMBL618111,,,,,8,1
4066,55,,BAO_0000019,,,Inhibitory activity uM,,,H,Autocuration,F,10141.0,CHEMBL618112,,,,,8,1
4067,55,,BAO_0000019,,,Percent inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,,,H,Autocuration,B,10141.0,CHEMBL618113,,,,,8,1
4068,55,,BAO_0000357,,,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,,,H,Autocuration,B,10141.0,CHEMBL618114,,,,,8,1
4069,55,,BAO_0000221,,,Evaluated for inhibition of the formation and release of 5-lipoxygenase in isolated guinea pig ileum,,,H,Expert,F,10141.0,CHEMBL620871,,2116.0,Ileum,,8,1
4070,55,,BAO_0000357,,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,,H,Autocuration,B,,CHEMBL620872,,,,,8,1
4071,55,,BAO_0000357,,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,,H,Autocuration,B,,CHEMBL620873,,,,,8,1
4072,55,,BAO_0000357,,,Compound was evaluated for in vitro inhibition of recombinant human 5-lipoxygenase (5-LO),,,H,Autocuration,B,,CHEMBL620874,,,,,8,1
4073,55,,BAO_0000357,,,In vitro inhibition of human 5-Lipoxygenase.,,,H,Expert,B,,CHEMBL620875,,,,,8,1
4074,22226,,BAO_0000251,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,,,U,Autocuration,B,10116.0,CHEMBL620876,,2107.0,Liver,Microsomes,0,1
4075,22226,,BAO_0000251,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,,,U,Autocuration,B,10116.0,CHEMBL620877,,2107.0,Liver,Microsomes,0,1
4076,22226,,BAO_0000251,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,,,U,Autocuration,B,10116.0,CHEMBL857854,,2107.0,Liver,Microsomes,0,1
4077,22226,,BAO_0000251,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM exposed 100 uM,,,U,Autocuration,B,10116.0,CHEMBL620878,,2107.0,Liver,Microsomes,0,1
4078,22226,,BAO_0000251,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,,,U,Autocuration,B,10116.0,CHEMBL620879,,2107.0,Liver,Microsomes,0,1
4079,22226,,BAO_0000251,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,,,U,Autocuration,B,10116.0,CHEMBL620880,,2107.0,Liver,Microsomes,0,1
4080,22226,,BAO_0000251,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,,,U,Autocuration,B,10116.0,CHEMBL620881,,2107.0,Liver,Microsomes,0,1
4081,22226,,BAO_0000251,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,,,U,Autocuration,B,10116.0,CHEMBL620882,,2107.0,Liver,Microsomes,0,1
4082,22226,,BAO_0000251,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,,,U,Autocuration,B,10116.0,CHEMBL620883,,2107.0,Liver,Microsomes,0,1
4083,22226,,BAO_0000251,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,,,U,Autocuration,B,10116.0,CHEMBL620884,,2107.0,Liver,Microsomes,0,1
4084,22226,,BAO_0000251,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,,,U,Autocuration,B,10116.0,CHEMBL620885,,2107.0,Liver,Microsomes,0,1
4085,22226,,BAO_0000251,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 27.5 uM,,,U,Autocuration,B,10116.0,CHEMBL620886,,2107.0,Liver,Microsomes,0,1
4086,22226,,BAO_0000251,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,,,U,Autocuration,B,10116.0,CHEMBL620887,,2107.0,Liver,Microsomes,0,1
4087,22226,,BAO_0000251,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,,,U,Autocuration,B,10116.0,CHEMBL618039,,2107.0,Liver,Microsomes,0,1
4088,22226,,BAO_0000251,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,,,U,Autocuration,B,10116.0,CHEMBL618040,,2107.0,Liver,Microsomes,0,1
4089,22226,,BAO_0000251,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to exposed to 3-methylcholanthrene at concentration of 200 uM,,,U,Autocuration,B,10116.0,CHEMBL618041,,2107.0,Liver,Microsomes,0,1
4090,22226,,BAO_0000251,,,"Compound was evaluated for inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",,,U,Autocuration,B,10116.0,CHEMBL618216,,2107.0,Liver,Microsomes,0,1
4091,22226,,BAO_0000251,,,"Compound was evaluated for inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",,,U,Autocuration,B,10116.0,CHEMBL618217,,2107.0,Liver,Microsomes,0,1
4092,22226,,BAO_0000251,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 100 uM,,,U,Autocuration,B,10116.0,CHEMBL618218,,2107.0,Liver,Microsomes,0,1
4093,22226,,BAO_0000251,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 200 uM,,,U,Autocuration,B,10116.0,CHEMBL618219,,2107.0,Liver,Microsomes,0,1
4094,22226,,BAO_0000251,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 50 uM,,,U,Autocuration,B,10116.0,CHEMBL618220,,2107.0,Liver,Microsomes,0,1
4095,22226,,BAO_0000251,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 5 uM,,,U,Autocuration,B,10116.0,CHEMBL618221,,2107.0,Liver,Microsomes,0,1
4096,22226,,BAO_0000251,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 50 uM,,,U,Autocuration,B,10116.0,CHEMBL618222,,2107.0,Liver,Microsomes,0,1
4097,22226,,BAO_0000251,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,,,U,Autocuration,B,10116.0,CHEMBL618223,,2107.0,Liver,Microsomes,0,1
4098,22226,,BAO_0000251,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,,,U,Autocuration,B,10116.0,CHEMBL618224,,2107.0,Liver,Microsomes,0,1
4099,22226,,BAO_0000251,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 1 uM,,,U,Autocuration,B,10116.0,CHEMBL618225,,2107.0,Liver,Microsomes,0,1
4100,22226,,BAO_0000251,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 20 uM,,,U,Autocuration,B,10116.0,CHEMBL618226,,2107.0,Liver,Microsomes,0,1
4101,22226,,BAO_0000251,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,,,U,Autocuration,B,10116.0,CHEMBL618227,,2107.0,Liver,Microsomes,0,1
4102,22226,,BAO_0000251,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,,,U,Autocuration,B,10116.0,CHEMBL618228,,2107.0,Liver,Microsomes,0,1
4103,22226,,BAO_0000251,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,,,U,Autocuration,B,10116.0,CHEMBL618229,,2107.0,Liver,Microsomes,0,1
4104,22226,,BAO_0000251,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,,,U,Autocuration,B,10116.0,CHEMBL618230,,2107.0,Liver,Microsomes,0,1
4105,22226,,BAO_0000251,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,,,U,Autocuration,B,10116.0,CHEMBL618231,,2107.0,Liver,Microsomes,0,1
4106,22226,,BAO_0000251,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,,,U,Autocuration,B,10116.0,CHEMBL618232,,2107.0,Liver,Microsomes,0,1
4107,22226,,BAO_0000251,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,,,U,Autocuration,B,10116.0,CHEMBL618233,,2107.0,Liver,Microsomes,0,1
4108,22226,,BAO_0000251,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,,,U,Autocuration,B,10116.0,CHEMBL618234,,2107.0,Liver,Microsomes,0,1
4109,22226,,BAO_0000251,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,,,U,Autocuration,B,10116.0,CHEMBL618235,,2107.0,Liver,Microsomes,0,1
4110,22226,,BAO_0000251,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,,,U,Autocuration,B,10116.0,CHEMBL618115,,2107.0,Liver,Microsomes,0,1
4111,22226,,BAO_0000251,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,,,U,Autocuration,B,10116.0,CHEMBL618116,,2107.0,Liver,Microsomes,0,1
4112,22226,,BAO_0000251,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,,,U,Autocuration,B,10116.0,CHEMBL618117,,2107.0,Liver,Microsomes,0,1
4113,22226,,BAO_0000251,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,,,U,Autocuration,B,10116.0,CHEMBL619968,,2107.0,Liver,Microsomes,0,1
4114,22226,,BAO_0000251,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,,,U,Autocuration,B,10116.0,CHEMBL619969,,2107.0,Liver,Microsomes,0,1
4115,22226,,BAO_0000251,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,,,U,Autocuration,B,10116.0,CHEMBL619970,,2107.0,Liver,Microsomes,0,1
4116,22226,,BAO_0000251,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1000 uM,,,U,Autocuration,B,10116.0,CHEMBL619971,,2107.0,Liver,Microsomes,0,1
4117,22226,,BAO_0000251,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1500 uM,,,U,Autocuration,B,10116.0,CHEMBL619972,,2107.0,Liver,Microsomes,0,1
4118,22226,,BAO_0000251,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 27.5 uM,,,U,Autocuration,B,10116.0,CHEMBL619973,,2107.0,Liver,Microsomes,0,1
4119,22226,,BAO_0000251,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 500 uM,,,U,Autocuration,B,10116.0,CHEMBL619974,,2107.0,Liver,Microsomes,0,1
4120,22226,,BAO_0000251,,,Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,,,U,Autocuration,B,10116.0,CHEMBL619975,,2107.0,Liver,Microsomes,0,1
4121,22226,,BAO_0000251,,,Vmax determined by 7-ethoxycoumarin deethylation in the presence by liver microsomes from rats exposed to 3-methylcholanthrene at concentration of 10 uM,,,U,Autocuration,B,10116.0,CHEMBL619976,,,,Microsomes,0,1
4122,22226,,BAO_0000251,,,"Compound was evaluated for alpha -rate constant, in liver microsomes from 3-methylcholanthrene-exposed rats",,,U,Autocuration,B,10116.0,CHEMBL619977,,2107.0,Liver,Microsomes,0,1
4123,22226,,BAO_0000251,,,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats",,,U,Autocuration,B,10116.0,CHEMBL619978,,2107.0,Liver,Microsomes,0,1
4124,22226,,BAO_0000251,,,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats; competitive inhibition",,,U,Autocuration,B,10116.0,CHEMBL619979,,2107.0,Liver,Microsomes,0,1
4125,22226,,BAO_0000251,,,"Compound was evaluated for alpha inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",,,U,Autocuration,B,10116.0,CHEMBL619980,,2107.0,Liver,Microsomes,0,1
4126,22226,,BAO_0000251,,,"Compound was evaluated for alpha inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",,,U,Autocuration,B,10116.0,CHEMBL619981,,2107.0,Liver,Microsomes,0,1
4127,80433,,BAO_0000219,741.0,RPMI-8226,In vitro inhibition of 7226/S myeloma cancer cell line,,,N,Intermediate,F,9606.0,CHEMBL619982,,,,,1,1
4128,80698,,BAO_0000219,993.0,BEL-7404 tumor cell line,In vitro antitumor activity of compound against 7404 cell line (human liver carcinoma cells),,,N,Intermediate,F,9606.0,CHEMBL619983,,,,,1,1
4129,80640,,BAO_0000219,391.0,786-0,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,,,N,Intermediate,F,9606.0,CHEMBL620031,,,,,1,1
4130,80640,,BAO_0000219,391.0,786-0,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,,,N,Intermediate,F,9606.0,CHEMBL620032,,,,,1,1
4131,81264,,BAO_0000219,505.0,V79,Net accumulation of the [99mTc]Isonitrile complex was measured in 77A cell lines in the presence of Verapamil.,,,N,Expert,F,10029.0,CHEMBL620033,,,,,1,1
4132,81264,,BAO_0000219,505.0,V79,Verapamil index represents the ratio of net uptake in the presense of verapamil over control in 77A cell lines.,,,N,Expert,F,10029.0,CHEMBL620034,,,,,1,1
4133,80635,,BAO_0000219,1119.0,7800C1 cell line,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 10 ug/mL dose,,,N,Intermediate,F,10116.0,CHEMBL620035,,,,,1,1
4134,80635,,BAO_0000219,1119.0,7800C1 cell line,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 2 ug/mL dose,,,N,Intermediate,F,10116.0,CHEMBL618318,,,,,1,1
4135,80635,,BAO_0000219,1119.0,7800C1 cell line,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 20 ug/mL dose,,,N,Intermediate,F,10116.0,CHEMBL618319,,,,,1,1
4136,80635,,BAO_0000219,1119.0,7800C1 cell line,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 5 ug/mL dose,,,N,Intermediate,F,10116.0,CHEMBL618320,,,,,1,1
4137,80635,,BAO_0000219,1119.0,7800C1 cell line,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 50 ug/mL dose,,,N,Intermediate,F,10116.0,CHEMBL618321,,,,,1,1
4138,80635,,BAO_0000219,1119.0,7800C1 cell line,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 75 ug/mL dose,,,N,Intermediate,F,10116.0,CHEMBL883118,,,,,1,1
4139,80640,,BAO_0000219,391.0,786-0,In vitro antitumor activity against renal 786-0 tumor cell lines,,,N,Intermediate,F,9606.0,CHEMBL883795,,,,,1,1
4140,80640,,BAO_0000219,391.0,786-0,Cytotoxic activity against 786-0 Renal cancer cell line,,,N,Intermediate,F,9606.0,CHEMBL618322,,,,,1,1
4141,80640,,BAO_0000219,391.0,786-0,Growth inhibitory activity was determined against 786-0 cancer cell line of Renal cancer,,,N,Intermediate,F,9606.0,CHEMBL618323,,,,,1,1
4142,80640,,BAO_0000219,391.0,786-0,Growth inhibitory activity was determined against 786-0 cancer cell line of renal cancer,,,N,Intermediate,F,9606.0,CHEMBL618324,,,,,1,1
4143,80640,,BAO_0000219,391.0,786-0,In vitro antitumor activity against human renal 786-0 cell line,,,N,Intermediate,F,9606.0,CHEMBL618325,,,,,1,1
4144,80640,,BAO_0000219,391.0,786-0,Inhibition of Renal cancer in 786-0 cancer cell lines,,,N,Intermediate,F,9606.0,CHEMBL875416,,,,,1,1
4145,80640,,BAO_0000219,391.0,786-0,Inhibition of the growth of renal cancer(786-0) cell line. value in parentheses is percent inhibition at 0.01 uM,,,N,Intermediate,F,9606.0,CHEMBL618326,,,,,1,1
4146,80640,,BAO_0000219,391.0,786-0,The compound was tested for its cytotoxic activity against the following renal cancer cell lines 786-0,,,N,Intermediate,F,9606.0,CHEMBL618327,,,,,1,1
4147,80640,,BAO_0000219,391.0,786-0,inhibition of the growth of renal cancer(786-0) cell line,,,N,Intermediate,F,9606.0,CHEMBL619215,,,,,1,1
4148,80640,,BAO_0000219,391.0,786-0,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),,,N,Intermediate,F,9606.0,CHEMBL619216,,,,,1,1
4149,80640,,BAO_0000219,391.0,786-0,Compound was tested for the growth inhibition of 786-0 renal tumor cell line,,,N,Intermediate,F,9606.0,CHEMBL619217,,,,,1,1
4150,80640,,BAO_0000219,391.0,786-0,The IC50 value was measured on 786-0 cell line in ovarian tumor,,,N,Intermediate,F,9606.0,CHEMBL619218,,,,,1,1
4151,80640,,BAO_0000219,391.0,786-0,The IC50 value was measured on 786-0 cell line in ovarian tumor t,,,N,Intermediate,F,9606.0,CHEMBL619219,,,,,1,1
4152,80640,,BAO_0000219,391.0,786-0,The IC50 value was measured on 786-0 cell line in renal tumor type.,,,N,Intermediate,F,9606.0,CHEMBL619220,,,,,1,1
4153,80640,,BAO_0000219,391.0,786-0,Inhibition of the growth of renal cancer(786-0) cell line at 0.01 uM,,,N,Intermediate,F,9606.0,CHEMBL619221,,,,,1,1
4154,80640,,BAO_0000219,391.0,786-0,Tested for cytotoxic activity against renal cancer 786-0 cell line,,,N,Intermediate,F,9606.0,CHEMBL619222,,,,,1,1
4155,80640,,BAO_0000219,391.0,786-0,Compound was tested for growth inhibitory activity against 786-0 cell line,,,N,Intermediate,F,9606.0,CHEMBL857454,,,,,1,1
4156,12166,,BAO_0000219,702.0,RBL-1,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; Inactive(N)= <50% inhibition at 10 uM,,,H,Autocuration,B,,CHEMBL619223,,,,,8,1
4157,12166,,BAO_0000219,702.0,RBL-1,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; N=Inactive,,,H,Autocuration,B,,CHEMBL619224,,,,,8,1
4158,12166,,BAO_0000019,,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,,,H,Autocuration,B,,CHEMBL619225,,,,,8,1
4159,12166,,BAO_0000219,702.0,RBL-1,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,,H,Expert,B,,CHEMBL619226,,,,,8,1
4160,12166,,BAO_0000219,702.0,RBL-1,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),,,H,Expert,B,,CHEMBL619227,,,,,8,1
4161,12166,,BAO_0000357,,,Inhibitory activity against rat basophilic leukemia 5-lipoxygenase,,,H,Autocuration,B,,CHEMBL619228,,,,,8,1
4162,12166,,BAO_0000219,,,Inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes,,,H,Autocuration,B,,CHEMBL619229,,,,,8,1
4163,12166,,BAO_0000219,702.0,RBL-1,Inhibitory activity against 5-lipoxygenase of RBL-1 cell line,,,H,Autocuration,B,,CHEMBL619230,,,,,8,1
4164,12166,,BAO_0000357,,,Inhibitory activity against RBL broken cell-supematant 5-lipoxygenase was evaluated,,,H,Autocuration,B,,CHEMBL619231,,,,,8,1
4165,12166,,BAO_0000357,,,"Inhibitory activity against intact rat PMNL, LTB4 5-lipoxygenase was evaluated",,,H,Autocuration,B,,CHEMBL619232,,,,,8,1
4166,12166,,BAO_0000357,,,Inhibitory activity against rat 5-lipoxygenase by using continuous oxygen consumption assay.,,,H,Expert,B,,CHEMBL619233,,,,,8,1
4167,12166,,BAO_0000357,,,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase,,,H,Autocuration,B,,CHEMBL619234,,,,,8,1
4168,12166,,BAO_0000357,,,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase (5-LO),,,H,Autocuration,B,,CHEMBL619235,,,,,8,1
4169,12166,,BAO_0000019,,,"Inhibitory activity against 5-lipoxygenase in rat neutrophils as inhibition of A 23,187-induced LTB4 production",,,D,Expert,B,10116.0,CHEMBL619236,,,,,9,1
4170,12166,,BAO_0000219,702.0,RBL-1,Inhibitory concentration against 5-lipoxygenase in rat RBL-1 cells,,,H,Autocuration,B,,CHEMBL619237,,,,,8,1
4171,12166,,BAO_0000357,,,Inhibitory concentration to inhibit 5-lipoxygenase in the rat,,,H,Autocuration,B,,CHEMBL619238,,,,,8,1
4172,12166,,BAO_0000357,,,In vitro inhibition of rat polymorphonuclear leukocyte 5-lipoxygenase,,,H,Expert,B,,CHEMBL619239,,,,,8,1
4173,12166,,BAO_0000357,,,Tested for inhibition of 5-HPETE production by rat 5-LO; value ranges from 16-36 nM,,,H,Autocuration,B,,CHEMBL619240,,,,,8,1
4174,12166,,BAO_0000019,,,Tested for inhibition of 5-LO by measuring the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,,,H,Autocuration,B,,CHEMBL875417,,,,,8,1
4175,12166,,BAO_0000219,702.0,RBL-1,Tested for inhibition of 5-Lipoxygenase (ARBL) in calcium-stimulated rat basophilic leukemia cells(RBL-1),,,H,Autocuration,B,,CHEMBL619241,,,,,8,1
4176,12166,,BAO_0000019,,,Inhibition of 5-lipoxygenase measured by the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,,,H,Expert,F,,CHEMBL619242,,,,,8,1
4177,12166,,BAO_0000219,702.0,RBL-1,Tested for inhibitory activity against 5-lipoxygenase in microsome of RBL-1 cells,,,H,Autocuration,B,,CHEMBL883796,,,,,8,1
4178,12166,,BAO_0000357,,,Tested for its inhibitory activity against 5-lipoxygenase,,,H,Autocuration,B,,CHEMBL619243,,,,,8,1
4179,12166,,BAO_0000357,,,Tested for its inhibitory activity against 5-lipoxygenase; Not determined,,,H,Autocuration,B,,CHEMBL619244,,,,,8,1
4180,12166,,BAO_0000019,,,"Iin vitro inhibition of 5-lipoxygenase activity in rat basophil leukemia type 1(RBL1) cell homogenates, (reduction of [14C]-5-HETE formation)",,,H,Expert,B,,CHEMBL619245,,,,,8,1
4181,12166,,BAO_0000019,,,In vitro test for inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,,,H,Expert,B,,CHEMBL619246,,,,,8,1
4182,12166,,BAO_0000219,702.0,RBL-1,In vitro inhibition of 5-lipoxygenase activity in RBL-1 cells.,,,H,Expert,B,,CHEMBL619984,,,,,8,1
4183,12166,,BAO_0000219,702.0,RBL-1,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells; No significant inhibitory activity up to 30 uM,,,H,Autocuration,B,,CHEMBL619985,,,,,8,1
4184,12166,,BAO_0000219,702.0,RBL-1,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,,,H,Autocuration,B,,CHEMBL619986,,,,,8,1
4185,12166,,BAO_0000219,702.0,RBL-1,In vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,,,H,Expert,B,,CHEMBL619987,,,,,8,1
4186,12166,,BAO_0000218,,,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse,,,H,Autocuration,B,,CHEMBL619988,,,,,8,1
4187,12166,,BAO_0000219,702.0,RBL-1,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1,,,H,Autocuration,B,,CHEMBL619989,,,,,8,1
4188,12166,,BAO_0000219,702.0,RBL-1,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,,,H,Autocuration,B,,CHEMBL619990,,,,,8,1
4189,12166,,BAO_0000219,,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS],,,H,Autocuration,B,,CHEMBL619991,,,,,8,1
4190,12166,,BAO_0000219,,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vitro),,,H,Autocuration,B,,CHEMBL619992,,,,,8,1
4191,12166,In vivo,BAO_0000218,,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vivo),,,H,Autocuration,B,,CHEMBL619993,,,,,8,1
4192,12166,,BAO_0000219,663.0,RBL-2H3,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in RBL-2H3 cells,,,H,Autocuration,F,,CHEMBL619994,,,,,8,1
4193,12166,,BAO_0000219,663.0,RBL-2H3,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in rat RBL-2H3 cells,,,H,Autocuration,F,,CHEMBL619995,,,,,8,1
4194,12166,,BAO_0000019,,,The compound was tested for inhibitory activity against 5-lipoxygenase using rat polymorphonuclear leukocytes[PMNS],,,H,Autocuration,B,,CHEMBL619996,,,,,8,1
4195,12166,,BAO_0000019,,,The compound was tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase,,,H,Autocuration,B,,CHEMBL619997,,,,,8,1
4196,12166,,BAO_0000019,,,Tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase.,,,H,Expert,B,,CHEMBL619998,,,,,8,1
4197,12166,,BAO_0000019,,,In vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells,,,H,Expert,B,,CHEMBL619999,,,,,8,1
4198,12166,,BAO_0000019,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells,,,H,Autocuration,B,,CHEMBL620000,,,,,8,1
4199,12166,,BAO_0000219,702.0,RBL-1,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in homogenized rat basophilic leukemia (RBL-1) cells,,,H,Autocuration,B,,CHEMBL620001,,,,,8,1
4200,12166,,BAO_0000357,,,Inhibition of 5-lipoxygenase (5-lo) in intact rat polymorphonuclear leukocyte RPMNL,,,D,Expert,B,10116.0,CHEMBL620002,,,,,9,1
4201,12166,,BAO_0000219,702.0,RBL-1,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells,,,H,Autocuration,B,,CHEMBL620003,,,,,8,1
4202,12166,,BAO_0000219,702.0,RBL-1,Inhibition of 5-lipoxygenase on rat basophil leukemia cell line lysate (RBL-1 2H3 subline) by measuring 5-HETE production,,,H,Expert,F,,CHEMBL620004,,,,,8,1
4203,12166,,BAO_0000357,,,Compound was evaluated for the inhibition of 5-lipoxygenase,,,H,Autocuration,B,,CHEMBL874063,,,,,8,1
4204,12166,,BAO_0000219,702.0,RBL-1,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line at a concentration of 25 uM,,,H,Autocuration,B,,CHEMBL620005,,,,,8,1
4205,12166,,BAO_0000219,702.0,RBL-1,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay,,,H,Autocuration,B,,CHEMBL620006,,,,,8,1
4206,12166,,BAO_0000219,702.0,RBL-1,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay; Less than 5% inhibition at 10 uM reported as not active,,,H,Autocuration,B,,CHEMBL620007,,,,,8,1
4207,12166,,BAO_0000219,702.0,RBL-1,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 10 uM,,,H,Autocuration,B,,CHEMBL620008,,,,,8,1
4208,12166,,BAO_0000219,702.0,RBL-1,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM,,,D,Expert,B,10116.0,CHEMBL620009,,,,,9,1
4209,12166,,BAO_0000219,702.0,RBL-1,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,,,H,Autocuration,B,,CHEMBL620010,,,,,8,1
4210,12166,,BAO_0000219,702.0,RBL-1,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 30 uM,,,H,Autocuration,B,,CHEMBL620011,,,,,8,1
4211,12166,,BAO_0000219,702.0,RBL-1,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 300 uM,,,H,Autocuration,B,,CHEMBL620677,,,,,8,1
4212,12166,,BAO_0000219,702.0,RBL-1,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 33 uM,,,H,Autocuration,B,,CHEMBL620678,,,,,8,1
4213,12166,,BAO_0000219,702.0,RBL-1,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 40 uM,,,H,Autocuration,B,,CHEMBL620679,,,,,8,1
4214,12166,,BAO_0000219,702.0,RBL-1,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 75 uM,,,H,Autocuration,B,,CHEMBL620680,,,,,8,1
4215,12166,,BAO_0000357,,,Inhibitory activity against 5-lipoxygenase at 10 uM,,,D,Expert,B,10116.0,CHEMBL620838,,,,,9,1
4216,12166,,BAO_0000357,,,In vitro inhibition of 5-lipoxygenase; NS means no significant inhibition,,,H,Autocuration,B,,CHEMBL620839,,,,,8,1
4217,12166,,BAO_0000357,,,In vitro inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase at 10 uM,,,H,Expert,B,,CHEMBL620840,,,,,8,1
4218,12166,,BAO_0000219,702.0,RBL-1,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells at 20 uM,,,H,Expert,B,,CHEMBL620841,,,,,8,1
4219,12166,,BAO_0000219,702.0,RBL-1,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 100 uM,,,H,Autocuration,B,,CHEMBL620842,,,,,8,1
4220,12166,,BAO_0000219,702.0,RBL-1,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 10e-4 M,,,H,Autocuration,B,,CHEMBL620843,,,,,8,1
4221,12166,,BAO_0000219,702.0,RBL-1,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determinedb at 100 uM,,,H,Autocuration,B,,CHEMBL620844,,,,,8,1
4222,12166,,BAO_0000219,702.0,RBL-1,In vitro inhibition of RBL-1 5-lipoxygenase at 20 uM,,,H,Autocuration,B,,CHEMBL620845,,,,,8,1
4223,12166,,BAO_0000019,,,In vitro inhibitory activity against 5-Lipoxygenase from rat basophilic leukemia cells at 30 uM concentration,,,H,Autocuration,B,,CHEMBL620846,,,,,8,1
4224,12166,,BAO_0000357,,,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,,,H,Autocuration,B,,CHEMBL873951,,,,,8,1
4225,12166,,BAO_0000357,,,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,,,H,Autocuration,B,,CHEMBL620847,,,,,8,1
4226,12166,,BAO_0000219,702.0,RBL-1,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,,,H,Autocuration,B,,CHEMBL620848,,,,,8,1
4227,12166,,BAO_0000219,702.0,RBL-1,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,,,H,Autocuration,B,,CHEMBL620849,,,,,8,1
4228,12166,,BAO_0000219,702.0,RBL-1,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at 40 uM concentration,,,H,Autocuration,B,,CHEMBL620850,,,,,8,1
4229,12166,,BAO_0000219,702.0,RBL-1,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM,,,H,Autocuration,B,,CHEMBL620851,,,,,8,1
4230,12166,,BAO_0000219,702.0,RBL-1,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM.,,,H,Autocuration,B,,CHEMBL620852,,,,,8,1
4231,12166,,BAO_0000219,702.0,RBL-1,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,,H,Autocuration,B,,CHEMBL875098,,,,,8,1
4232,12166,,BAO_0000219,702.0,RBL-1,Inhibition of 5-lipoxygenase of rat basophilic leukemia cells at 30 uM,,,D,Expert,B,10116.0,CHEMBL620853,,,,,9,1
4233,12166,,BAO_0000019,,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells at 30 uM concentration; NT=Not tested,,,H,Autocuration,B,,CHEMBL620854,,,,,8,1
4234,12166,,BAO_0000219,702.0,RBL-1,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,,,H,Autocuration,B,,CHEMBL620855,,,,,8,1
4235,12166,,BAO_0000219,702.0,RBL-1,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,,,H,Expert,B,,CHEMBL839884,,,,,8,1
4236,12166,,BAO_0000219,702.0,RBL-1,Inhibitory activity at 10 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,,H,Autocuration,B,,CHEMBL620856,,,,,8,1
4237,12166,,BAO_0000219,702.0,RBL-1,Inhibitory activity at 1 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,,H,Autocuration,B,,CHEMBL620857,,,,,8,1
4238,12166,,BAO_0000019,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,,,H,Autocuration,B,,CHEMBL620858,,,,,8,1
4239,12166,,BAO_0000019,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,,,H,Autocuration,B,,CHEMBL620859,,,,,8,1
4240,12166,,BAO_0000019,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,,,H,Autocuration,B,,CHEMBL620860,,,,,8,1
4241,12166,,BAO_0000019,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 3 uM,,,H,Autocuration,B,,CHEMBL620861,,,,,8,1
4242,12166,,BAO_0000357,,,Percent inhibition of rat neutrophil 5-lipoxygenase (5-LO),,,H,Expert,B,,CHEMBL620862,,,,,8,1
4243,12166,,BAO_0000357,,,Percent inhibition of rat neutrophil 5- Lipoxygenase (5-LO) at 100 uM,,,H,Autocuration,B,,CHEMBL620863,,,,,8,1
4244,12166,,BAO_0000019,,,Tested in vitro for the inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,,,H,Autocuration,B,,CHEMBL620864,,,,,8,1
4245,12166,,BAO_0000219,702.0,RBL-1,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 100 uM,,,H,Autocuration,B,,CHEMBL620865,,,,,8,1
4246,12166,,BAO_0000219,702.0,RBL-1,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 30 uM,,,H,Autocuration,B,,CHEMBL620866,,,,,8,1
4247,12166,,BAO_0000219,663.0,RBL-2H3,The compound was tested for inhibition of 5-lipoxygenase in rat RBL-2H3 cells,,,H,Autocuration,B,,CHEMBL620867,,,,,8,1
4248,12166,,BAO_0000219,663.0,RBL-2H3,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,,,H,Autocuration,B,,CHEMBL620868,,,,,8,1
4249,12166,,BAO_0000219,663.0,RBL-2H3,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,,,H,Autocuration,F,,CHEMBL620869,,,,,8,1
4250,12166,,BAO_0000019,,,The compound was tested for inhibition of LTB4 synthesis on isolated 5-lipoxygenase,,,H,Autocuration,F,,CHEMBL873952,,,,,8,1
4251,12166,,BAO_0000357,,,The compound was tested for inhibition of isolated 5-lipoxygenase,,,H,Autocuration,B,,CHEMBL875099,,,,,8,1
4252,12166,,BAO_0000219,663.0,RBL-2H3,The compound was tested for inhibition of isolated 5-lipoxygenase translocation into rat RBL-2H3 cells,,,H,Autocuration,F,,CHEMBL620870,,,,,8,1
4253,12166,,BAO_0000019,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 30 uM,,,H,Autocuration,B,,CHEMBL618261,,,,,8,1
4254,12166,,BAO_0000019,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 32 uM,,,H,Autocuration,B,,CHEMBL618262,,,,,8,1
4255,12166,,BAO_0000019,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells measured at a concentration of 30 uM,,,H,Autocuration,B,,CHEMBL619428,,,,,8,1
4256,12166,,BAO_0000019,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,,,H,Autocuration,B,,CHEMBL619429,,,,,8,1
4257,12166,,BAO_0000019,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,,,H,Autocuration,B,,CHEMBL619430,,,,,8,1
4258,12166,,BAO_0000219,702.0,RBL-1,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 1.0 uM,,,H,Autocuration,B,,CHEMBL620017,,,,,8,1
4259,12166,,BAO_0000219,702.0,RBL-1,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 10 uM,,,H,Autocuration,B,,CHEMBL620018,,,,,8,1
4260,12166,,BAO_0000219,702.0,RBL-1,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.1 uM,,,H,Autocuration,F,,CHEMBL620019,,,,,8,1
4261,12166,,BAO_0000219,702.0,RBL-1,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.195 uM,,,H,Autocuration,F,,CHEMBL620020,,,,,8,1
4262,12166,,BAO_0000219,702.0,RBL-1,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.2 at uM,,,H,Autocuration,F,,CHEMBL620021,,,,,8,1
4263,12166,,BAO_0000219,702.0,RBL-1,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.25 uM,,,H,Autocuration,F,,CHEMBL620022,,,,,8,1
4264,12166,,BAO_0000219,702.0,RBL-1,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39,,,H,Autocuration,F,,CHEMBL620023,,,,,8,1
4265,12166,,BAO_0000219,702.0,RBL-1,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39 uM,,,H,Autocuration,F,,CHEMBL620024,,,,,8,1
4266,12166,,BAO_0000219,702.0,RBL-1,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.195 uM,,,H,Autocuration,F,,CHEMBL620025,,,,,8,1
4267,12166,,BAO_0000219,702.0,RBL-1,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.2 uM,,,H,Autocuration,F,,CHEMBL620026,,,,,8,1
4268,12166,,BAO_0000219,702.0,RBL-1,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.39 uM,,,H,Autocuration,F,,CHEMBL620027,,,,,8,1
4269,12166,,BAO_0000019,,,Inhibition of 5-lipoxygenase on rat basophil leukemia cell (RBL-2H3) lysate as 5-HETE production at 32 uM,,,D,Expert,F,10116.0,CHEMBL620028,,,,,9,1
4270,12166,,BAO_0000357,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase,,,H,Autocuration,B,,CHEMBL620029,,,,,8,1
4271,12166,,BAO_0000357,,,Compound was tested for the percent of inhibition against 5-LO at 10 uM,,,H,Autocuration,B,,CHEMBL620030,,,,,8,1
4272,12166,,BAO_0000219,702.0,RBL-1,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 1 uM concentration,,,H,Autocuration,B,,CHEMBL875415,,,,,8,1
4273,12166,,BAO_0000219,702.0,RBL-1,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,,,H,Autocuration,B,,CHEMBL618256,,,,,8,1
4274,12166,,BAO_0000219,702.0,RBL-1,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line,,,H,Autocuration,B,,CHEMBL618257,,,,,8,1
4275,12166,,BAO_0000219,702.0,RBL-1,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 10 uM,,,H,Autocuration,B,,CHEMBL618258,,,,,8,1
4276,12166,,BAO_0000219,702.0,RBL-1,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 16 uM,,,H,Autocuration,B,,CHEMBL618259,,,,,8,1
4277,12166,,BAO_0000019,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,,,H,Autocuration,B,,CHEMBL618260,,,,,8,1
4278,12166,,BAO_0000219,702.0,RBL-1,Percent inhibition against RBL-1 5-LO in vitro at 10 uM,,,H,Autocuration,B,,CHEMBL618215,,,,,8,1
4279,12166,,BAO_0000219,702.0,RBL-1,Percent inhibition against RBL-1 5-LO in vitro at 100 uM,,,H,Autocuration,B,,CHEMBL618390,,,,,8,1
4280,12166,,BAO_0000219,702.0,RBL-1,Percent inhibition against RBL-1 5-LO in vitro at 30 uM,,,H,Autocuration,B,,CHEMBL618391,,,,,8,1
4281,12166,,BAO_0000219,702.0,RBL-1,Percent inhibition against RBL-1 5-LO in vitro at 300 uM,,,H,Autocuration,B,,CHEMBL618392,,,,,8,1
4282,12166,,BAO_0000219,702.0,RBL-1,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 20 uM,,,H,Autocuration,B,,CHEMBL618393,,,,,8,1
4283,12166,,BAO_0000219,,,The compound was tested for inhibition against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] at 10 uM concentration,,,H,Autocuration,B,,CHEMBL618394,,,,,8,1
4284,12166,,BAO_0000219,702.0,RBL-1,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),,,H,Expert,B,9606.0,CHEMBL618395,,,,,8,1
4285,12166,,BAO_0000219,702.0,RBL-1,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),,,D,Expert,B,10116.0,CHEMBL618396,,,,,9,1
4286,12166,,BAO_0000219,702.0,RBL-1,Logarithmic value of inhibitory concentration against 5-lipoxygenase in rat basophilic leukemia cells (RBL-1),,,D,Expert,B,10116.0,CHEMBL858253,,,,,9,1
4287,12166,,BAO_0000019,,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,,,D,Autocuration,B,10116.0,CHEMBL618397,,,,,9,1
4288,12054,,BAO_0000357,,,Compound was tested for the percent of inhibition against soybean 15-LO (at 100 uM),,,H,Autocuration,B,3847.0,CHEMBL618398,,,,,8,1
4289,22226,,BAO_0000019,,,"Inhibitory activity against 5-lipoxygenase, by using soybean lipoxygenase spectrophotometric assay",,,U,Autocuration,B,,CHEMBL618399,,,,,0,1
4290,55,,BAO_0000357,,,In vitro inhibition of 5-Lipoxygenase; Inactive.,,,H,Expert,B,,CHEMBL618400,,,,,8,1
4291,55,,BAO_0000357,,,Inhibitory concentration against 5-lipoxygenase was determined; No inhibition,,,H,Autocuration,B,,CHEMBL618401,,,,,8,1
4292,55,,BAO_0000357,,,Inhibitory concentration against 5-lipoxygenase; No inhibition,,,H,Autocuration,B,,CHEMBL618402,,,,,8,1
4293,55,,BAO_0000219,702.0,RBL-1,Evaluated for inhibitory activity against RBL-1 cell 5-lipoxygenase in guinea pig,,,H,Autocuration,B,,CHEMBL876400,,,,,8,1
4294,55,,BAO_0000357,,,Inhibitory activity against 5-lipoxygenase.,,,H,Expert,B,,CHEMBL618403,,,,,8,1
4295,55,,BAO_0000357,,,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive,,,H,Autocuration,B,,CHEMBL618404,,,,,8,1
4296,55,,BAO_0000357,,,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive at concentrations less than 32 uM,,,H,Autocuration,B,,CHEMBL618405,,,,,8,1
4297,55,,BAO_0000357,,,Inhibitory Activity against 5-Lipoxygenase was determined; NA=No significant inhibitory activity up to 300 uM,,,H,Autocuration,B,,CHEMBL618406,,,,,8,1
4298,55,,BAO_0000019,,,Inhibitory concentration against arachidonic acid 5-lipoxygenation,,,H,Expert,F,,CHEMBL618407,,,,,8,1
4299,55,,BAO_0000357,,,Tested for the inhibitory activity against 5-lipoxygenase,,,H,Autocuration,B,,CHEMBL618408,,,,,8,1
4300,55,,BAO_0000357,,,Compound was tested for its inhibitory activity against 5-lipoxygenase,,,H,Autocuration,B,,CHEMBL618409,,,,,8,1
4301,55,,BAO_0000357,,,Compound was tested for inhibition of 5-lipoxygenase at 50 uM; NI means no inhibition was observed,,,H,Autocuration,B,,CHEMBL618410,,,,,8,1
4302,55,,BAO_0000357,,,Inhibitory Activity against 5-Lipoxygenase at 30 uM was determined; Weakly active,,,H,Autocuration,B,,CHEMBL618411,,,,,8,1
4303,55,,BAO_0000357,,,Inhibitory Activity against 5-Lipoxygenase at concentration 32 uM was determined,,,H,Autocuration,B,,CHEMBL618412,,,,,8,1
4304,12166,,BAO_0000219,702.0,RBL-1,Concentration required to inhibit RBL-1 supernatant 5-lipoxygenase,,,H,Autocuration,B,,CHEMBL618413,,,,,8,1
4305,12166,,BAO_0000357,,,,,,H,Autocuration,B,,CHEMBL618414,,,,,8,1
4306,10102,,BAO_0000357,,,Compound was tested for its binding activity towards 5-lipoxygenase activating protein (FLAP),,,H,Autocuration,B,,CHEMBL618415,,,,,8,1
4307,10102,,BAO_0000019,,,Inhibition of 5-lipoxygenase activating protein using human leukocyte membrane preparations,,,H,Autocuration,B,,CHEMBL618416,,,,,8,1
4308,10102,,BAO_0000357,,,Measuring the affinity of leukotriene synthesis inhibitor for 5-Lipoxygenase activating protein (FLAP) by using [125I]L-691831 as radioligand.,,,H,Autocuration,B,,CHEMBL876401,,,,,8,1
4309,10102,,BAO_0000357,,,Measuring the affinity of leukotriene synthesis inhibitor for 5-lipoxygenase activating protein by using [125I]L-691831 as radioligand.,,,H,Expert,B,,CHEMBL618417,,,,,8,1
4310,10102,,BAO_0000357,,,Tested for inhibition of leukotriene biosynthesis by binding to 5-lipoxygenase activating protein,,,H,Autocuration,B,,CHEMBL618418,,,,,8,1
4311,10102,,BAO_0000357,,,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein",,,H,Autocuration,B,,CHEMBL618419,,,,,8,1
4312,10102,,BAO_0000357,,,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein (FLAP)",,,H,Autocuration,B,,CHEMBL618420,,,,,8,1
4313,10102,,BAO_0000357,,,Binding affinity of compound for 5-lipoxygenase activating protein protein by FLAP binding assay,,,H,Autocuration,B,,CHEMBL618421,,,,,8,1
4314,11238,,BAO_0000019,,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane,,,H,Autocuration,B,,CHEMBL618422,,,,,8,1
4315,11238,,BAO_0000019,,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (R metabolically resistant),,,H,Autocuration,B,,CHEMBL618423,,,,,8,1
4316,11238,,BAO_0000019,,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (S substrate),,,H,Autocuration,B,,CHEMBL618424,,,,,8,1
4317,100284,,BAO_0000220,,,Inhibition of protein biosynthesis at the level of the peptidyl transferase center of the 50 s ribosomal subunit,,,S,Intermediate,B,,CHEMBL618425,,,,,2,1
4318,22226,,BAO_0000019,,,The dark toxicity against 543 human galactophore carcinoma cells,,,U,Autocuration,F,9606.0,CHEMBL618426,,,,,0,1
4319,80623,,BAO_0000219,390.0,Panel (56 tumour cell lines),Tested in vitro for cytotoxicity against 56 human tumor cell lines,,,N,Expert,F,9606.0,CHEMBL618427,,,,,1,1
4320,80008,,BAO_0000219,345.0,5637,Cytotoxic activity against human 5637 cell line at 20 uM expressed as percent growth value,,,N,Expert,F,9606.0,CHEMBL618428,,,,,1,1
4321,80008,,BAO_0000219,345.0,5637,Antitumor activity was evaluated against human bladder carcinoma cell line 5637.,,,N,Intermediate,F,9606.0,CHEMBL618429,,,,,1,1
4322,80008,,BAO_0000219,345.0,5637,"Compound was tested for antiproliferative activity against 5637, human bladder carcinoma cell line",,,N,Intermediate,F,9606.0,CHEMBL618430,,,,,1,1
4323,80008,,BAO_0000219,345.0,5637,Growth inhibition against human 5637 cell lines,,,N,Expert,F,9606.0,CHEMBL618431,,,,,1,1
4324,80008,,BAO_0000219,345.0,5637,Antitumor activity against human bladder carcinoma 5637 cells.,,,N,Expert,F,9606.0,CHEMBL883799,,,,,1,1
4325,80008,,BAO_0000219,345.0,5637,Antitumor activity against human bladder carcinoma 5637 cells,,,N,Intermediate,F,9606.0,CHEMBL618432,,,,,1,1
4326,80008,,BAO_0000219,345.0,5637,Antitumor activity against human bladder carcinoma 5637 cells,,,N,Intermediate,F,9606.0,CHEMBL618433,,,,,1,1
4327,10443,,BAO_0000357,,,In vitro inhibition of bovine trypsin(Trp).,,,D,Expert,B,9913.0,CHEMBL618434,,,,,9,1
4328,240,,BAO_0000219,407.0,CV-1,Transcriptional activation in CV-1 cells expressing retinoic acid gamma receptor,,,H,Expert,B,9527.0,CHEMBL618435,,,,,8,1
4329,10577,,BAO_0000357,,,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-HT1B receptor,,,H,Autocuration,B,,CHEMBL876402,,,,,8,1
4330,104698,,BAO_0000019,,,In vitro antagonism of the 5-HT-3 receptor determined by inhibition of 5-HT-induced depolarization of the isolated rat vagus nerve.,,,H,Autocuration,F,,CHEMBL618436,,,,,6,1
4331,22226,In vivo,BAO_0000218,,,Concentration required to inhibit pressor response to serotonin after 15 min i.v. administration of compound mediated via activation of vascular 5-HT2 receptors in rat,,,U,Autocuration,F,,CHEMBL618437,,,,,0,1
4332,20033,,BAO_0000357,,,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-HT4 receptor,,,D,Intermediate,B,10141.0,CHEMBL618438,,,,,9,1
4333,17045,,BAO_0000251,,,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,,,H,Expert,A,10116.0,CHEMBL883800,,,,Microsomes,8,1
4334,17045,,BAO_0000251,,,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,,,H,Expert,A,10116.0,CHEMBL618439,,,,Microsomes,8,1
4335,22226,,BAO_0000019,,,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,,,U,Intermediate,F,,CHEMBL618440,,,,,0,1
4336,22226,,BAO_0000019,,,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,,,U,Intermediate,F,,CHEMBL618441,,,,,0,1
4337,11938,,BAO_0000019,,,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli,,,H,Expert,B,5691.0,CHEMBL618442,,,,,8,1
4338,11938,,BAO_0000019,,,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli; NI denotes no inhibition,,,H,Autocuration,B,5691.0,CHEMBL618443,,,,,8,1
4339,11938,,BAO_0000019,,,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver,,,H,Expert,B,9940.0,CHEMBL619158,,,,,8,1
4340,11938,,BAO_0000019,,,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver; NI denotes no inhibition,,,H,Autocuration,B,9940.0,CHEMBL620974,,,,,8,1
4341,11938,,BAO_0000357,,,log Kd which is the binding affinity against 6-phosphogluconate dehydrogenase,,,H,Autocuration,B,,CHEMBL620975,,,,,8,1
4342,22226,,BAO_0000019,,,Average inhibitory concentration against 60 human cell lines was reported,,,U,Intermediate,F,9606.0,CHEMBL620976,,,,,0,1
4343,22226,,BAO_0000019,,,Inhibition of proliferation in NCI panel of 60 human tumor cell lines,,,U,Expert,F,9606.0,CHEMBL620977,,,,,0,1
4344,80315,,BAO_0000219,542.0,Panel NCI-60 (60 carcinoma cell lines),Cancer specificity was measured from the +/- value under average log LC50 60-cell line,,,N,Intermediate,F,9606.0,CHEMBL620978,,,,,1,1
4345,80315,,BAO_0000219,542.0,Panel NCI-60 (60 carcinoma cell lines),Cancer specificity was measured from the +/- value under average log LC50 60-cell line. ,,,N,Intermediate,F,9606.0,CHEMBL620979,,,,,1,1
4346,80315,,BAO_0000219,542.0,Panel NCI-60 (60 carcinoma cell lines),In vitro mean growth inhibitory activity against 60-cell panel,,,N,Expert,F,,CHEMBL620980,,,,,1,1
4347,80315,,BAO_0000219,542.0,Panel NCI-60 (60 carcinoma cell lines),In vitro mean growth lethal concentration against 60-cell panel,,,N,Expert,F,,CHEMBL620981,,,,,1,1
4348,80315,,BAO_0000219,542.0,Panel NCI-60 (60 carcinoma cell lines),In vitro mean growth lethal concentration in colon subpanel against 60-cell panel,,,N,Expert,F,,CHEMBL620982,,,,,1,1
4349,80315,,BAO_0000219,542.0,Panel NCI-60 (60 carcinoma cell lines),In vitro mean growth lethal concentration in renal subpanel against 60-cell panel,,,N,Expert,F,,CHEMBL620983,,,,,1,1
4350,104775,,BAO_0000019,,,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,,,H,Autocuration,F,,CHEMBL620984,,,,,4,1
4351,104775,,BAO_0000019,,,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,,,H,Autocuration,F,,CHEMBL620985,,,,,4,1
4352,275,,BAO_0000357,,,Transcriptional activation in CV-1 expressing retinoid X receptor RXR alpha,,,H,Expert,B,,CHEMBL620986,,,,,8,1
4353,50425,,BAO_0000218,,,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase,,,N,Expert,F,5833.0,CHEMBL620987,,,,,1,1
4354,50425,,BAO_0000218,,,In vitro inhibition of Plasmodium falciparum 68 neutral proteinase activity by reinvasion of red blood cells,,,N,Expert,F,5833.0,CHEMBL620988,,,,,1,1
4355,50425,,BAO_0000218,,,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase.,,,N,Expert,F,5833.0,CHEMBL620989,,,,,1,1
4356,50425,,BAO_0000218,,,Substrate affinity for Plasmodium falciparum 68 neutral proteinase.,,,N,Expert,F,5833.0,CHEMBL620990,,,,,1,1
4357,50425,,BAO_0000218,,,Reaction velocity for Plasmodium falciparum 68 neutral proteinase.,,,N,Intermediate,F,5833.0,CHEMBL620991,,,,,1,1
4358,80628,,BAO_0000218,850.0,6C3HED,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,,,N,Intermediate,F,10090.0,CHEMBL620992,,,,,1,1
4359,80628,,BAO_0000218,850.0,6C3HED,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,,,N,Intermediate,F,10090.0,CHEMBL620993,,,,,1,1
4360,80628,,BAO_0000218,850.0,6C3HED,Percent inhibition against 6C3HED lymphosarcoma at dose 200 mg/kg in C3H mice,,,N,Intermediate,F,10090.0,CHEMBL620994,,,,,1,1
4361,80628,,BAO_0000218,850.0,6C3HED,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,,,N,Intermediate,F,10090.0,CHEMBL620995,,,,,1,1
4362,80628,,BAO_0000218,850.0,6C3HED,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,,,N,Intermediate,F,10090.0,CHEMBL620996,,,,,1,1
4363,80628,,BAO_0000218,850.0,6C3HED,Percent inhibition against 6C3HED lymphosarcoma at dose 6 mg/kg in C3H mice,,,N,Intermediate,F,10090.0,CHEMBL875581,,,,,1,1
4364,22224,In vivo,BAO_0000218,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 100 mg/kg,,,U,Autocuration,F,10090.0,CHEMBL620997,,,,,0,1
4365,22224,In vivo,BAO_0000218,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 150 mg/kg,,,U,Autocuration,F,10090.0,CHEMBL620998,,,,,0,1
4366,22224,In vivo,BAO_0000218,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 1600 mg/kg (intraperitoneal dosing for 8 days),,,U,Autocuration,F,10090.0,CHEMBL620999,,,,,0,1
4367,22224,In vivo,BAO_0000218,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 200 mg/kg,,,U,Autocuration,F,10090.0,CHEMBL621000,,,,,0,1
4368,22224,In vivo,BAO_0000218,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 225 mg/kg,,,U,Autocuration,F,10090.0,CHEMBL621001,,,,,0,1
4369,22224,In vivo,BAO_0000218,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 270 mg/kg,,,U,Autocuration,F,10090.0,CHEMBL621002,,,,,0,1
4370,22224,In vivo,BAO_0000218,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 275 mg/kg,,,U,Autocuration,F,10090.0,CHEMBL621003,,,,,0,1
4371,22224,In vivo,BAO_0000218,,,"Antitumor activity in vivo against the 6C3HED lymphosarcoma, dosed for 10 days at 300 mg/kg",,,U,Autocuration,F,10090.0,CHEMBL621004,,,,,0,1
4372,22224,In vivo,BAO_0000218,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (intraperitoneal dosing for 8 days),,,U,Autocuration,F,10090.0,CHEMBL621005,,,,,0,1
4373,22224,In vivo,BAO_0000218,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (ip dosing daily for 8 days),,,U,Autocuration,F,10090.0,CHEMBL621006,,,,,0,1
4374,22224,In vivo,BAO_0000218,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 600 mg/kg,,,U,Autocuration,F,10090.0,CHEMBL621007,,,,,0,1
4375,22224,,BAO_0000218,,,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,,,U,Autocuration,F,10090.0,CHEMBL621008,,,,,0,1
4376,22224,,BAO_0000218,,,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,,,U,Autocuration,F,10090.0,CHEMBL621009,,,,,0,1
4377,22224,,BAO_0000218,,,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,,,U,Autocuration,F,10090.0,CHEMBL857705,,,,,0,1
4378,22224,,BAO_0000218,,,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,,,U,Autocuration,F,10090.0,CHEMBL619828,,,,,0,1
4379,22224,,BAO_0000218,,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 100 mg/kg dosage administered for 8 days intraperitoneally,,,U,Autocuration,F,10090.0,CHEMBL619829,,,,,0,1
4380,22224,,BAO_0000218,,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 10 days intraperitoneally,,,U,Autocuration,F,10090.0,CHEMBL619830,,,,,0,1
4381,22224,,BAO_0000218,,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 8 days intraperitoneally,,,U,Autocuration,F,10090.0,CHEMBL619831,,,,,0,1
4382,22224,,BAO_0000218,,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 50 mg/kg dosage administered for 8 days intraperitoneally,,,U,Autocuration,F,10090.0,CHEMBL619832,,,,,0,1
4383,22224,,BAO_0000218,,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 100 mg/kg dosage administered for 8 days intraperitoneally; 0/10,,,U,Autocuration,A,10090.0,CHEMBL619833,,,,,0,1
4384,22224,,BAO_0000218,,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 8 days perorally; 1/10,,,U,Autocuration,A,10090.0,CHEMBL619834,,,,,0,1
4385,22224,,BAO_0000218,,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 10 days intraperitoneally; 1/10,,,U,Autocuration,A,10090.0,CHEMBL619835,,,,,0,1
4386,22224,,BAO_0000218,,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 50 mg/kg dosage administered for 8 days perorally; 3/10,,,U,Autocuration,A,10090.0,CHEMBL619836,,,,,0,1
4387,80628,,BAO_0000218,850.0,6C3HED,"Compound was evaluated for the antitumor activity against 6C3HED lymphosarcoma for ip administration and daily x 8 schedule; Number of toxic deaths over total number of mice per group (T/C), 0/10 at dose of 35 mg/kg",,,N,Intermediate,F,10090.0,CHEMBL619837,,,,,1,1
4388,22224,In vivo,BAO_0000218,,,In vivo antitumor activity against 6C3HED tumor type after intraperitoneal administration of 400 mg/kg,,,U,Autocuration,F,,CHEMBL619838,,,,,0,1
4389,50594,,BAO_0000218,,,In vivo antitumor activity against 6C3HED tumor type was expressed as toxic deaths/total treated mice at 400 mg/kg dose; 2/10,,,N,Intermediate,A,10090.0,CHEMBL619839,,,,,1,1
4390,80628,In vivo,BAO_0000218,850.0,6C3HED,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line,,,N,Intermediate,F,10090.0,CHEMBL619840,,,,,1,1
4391,80628,In vivo,BAO_0000218,850.0,6C3HED,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line; 95-100% inhibition,,,N,Intermediate,F,10090.0,CHEMBL619841,,,,,1,1
4392,80628,,BAO_0000218,850.0,6C3HED,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 150 mg/kg given orally(daily x 8),,,N,Expert,F,10090.0,CHEMBL857704,,,,,1,1
4393,80628,,BAO_0000218,850.0,6C3HED,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 200 mg/kg given orally(daily x 8),,,N,Intermediate,F,10090.0,CHEMBL619842,,,,,1,1
4394,80628,,BAO_0000218,850.0,6C3HED,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 300 mg/kg given orally (daily x 8),,,N,Expert,F,10090.0,CHEMBL619843,,,,,1,1
4395,22226,,BAO_0000019,,,"Inhibition of Staphylococcus aureus 7,8-dihydroneopterin aldolase",,,U,Autocuration,B,1280.0,CHEMBL619844,,,,,0,1
4396,22226,,BAO_0000251,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at a concentration of 5 uM,,,U,Autocuration,B,10116.0,CHEMBL857855,,2107.0,Liver,Microsomes,0,1
4397,22226,,BAO_0000251,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,,,U,Autocuration,B,10116.0,CHEMBL619845,,2107.0,Liver,Microsomes,0,1
4398,22226,,BAO_0000251,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 1 uM,,,U,Autocuration,B,10116.0,CHEMBL619846,,2107.0,Liver,Microsomes,0,1
4399,22226,,BAO_0000251,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 20 uM,,,U,Autocuration,B,10116.0,CHEMBL619847,,2107.0,Liver,Microsomes,0,1
4400,22226,,BAO_0000251,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 25 uM,,,U,Autocuration,B,10116.0,CHEMBL619848,,2107.0,Liver,Microsomes,0,1
4401,22226,,BAO_0000251,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 50 uM,,,U,Autocuration,B,10116.0,CHEMBL620893,,2107.0,Liver,Microsomes,0,1
4402,22226,,BAO_0000251,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 5 uM,,,U,Autocuration,B,10116.0,CHEMBL620894,,2107.0,Liver,Microsomes,0,1
4403,22226,,BAO_0000251,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 10 uM,,,U,Autocuration,B,10116.0,CHEMBL620895,,2107.0,Liver,Microsomes,0,1
4404,22226,,BAO_0000251,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,,,U,Autocuration,B,10116.0,CHEMBL620896,,2107.0,Liver,Microsomes,0,1
4405,22226,,BAO_0000251,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,,,U,Autocuration,B,10116.0,CHEMBL620897,,2107.0,Liver,Microsomes,0,1
4406,22226,,BAO_0000251,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,,,U,Autocuration,B,10116.0,CHEMBL620898,,2107.0,Liver,Microsomes,0,1
4407,22226,,BAO_0000251,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,,,U,Autocuration,B,10116.0,CHEMBL620899,,2107.0,Liver,Microsomes,0,1
4408,22224,In vivo,BAO_0000218,,,The apparent total plasma clearance in monkey,,,U,Autocuration,A,9527.0,CHEMBL620900,,1969.0,Plasma,,0,1
4409,22224,In vivo,BAO_0000218,,,Compound was evaluated for Hepatic clearance in monkey,,,U,Autocuration,A,9527.0,CHEMBL620901,,,,,0,1
4410,22224,In vivo,BAO_0000218,,,Lower clearance in monkey (i.v.) at 0.5 mpk,,,U,Autocuration,A,9527.0,CHEMBL620902,,,,,0,1
4411,22224,In vivo,BAO_0000218,,,Plasma clearance in rhesus monkey,,,U,Autocuration,A,9527.0,CHEMBL620903,,,,,0,1
4412,22224,In vivo,BAO_0000218,,,Plasma clearance for the compound was measured in monkey after an iv dose of 1 mg/kg,,,U,Autocuration,A,9527.0,CHEMBL620904,,,,,0,1
4413,22224,In vivo,BAO_0000218,,,Plasma clearance of compound was determined in monkey,,,U,Autocuration,A,9527.0,CHEMBL620905,,,,,0,1
4414,22224,In vivo,BAO_0000218,,,Plasma clearance was calculated in rhesus monkey,,,U,Autocuration,A,9527.0,CHEMBL620906,,,,,0,1
4415,22224,In vivo,BAO_0000218,,,Plasma clearance in rhesus monkey,,,U,Autocuration,A,9527.0,CHEMBL875420,,,,,0,1
4416,22224,In vivo,BAO_0000218,,,Plasma clearance in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,,U,Autocuration,A,9527.0,CHEMBL620907,,,,,0,1
4417,22224,In vivo,BAO_0000218,,,Plasma clearance was evaluated in rhesus,,,U,Autocuration,A,9527.0,CHEMBL620908,,,,,0,1
4418,22224,In vivo,BAO_0000218,,,Plasma clearance value was determined in monkey after a 3 mg/kg of iv dose,,,U,Autocuration,A,9527.0,CHEMBL620909,,,,,0,1
4419,22224,In vivo,BAO_0000218,,,Plasma clearance was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,,,U,Autocuration,A,9527.0,CHEMBL620910,,,,,0,1
4420,22224,In vivo,BAO_0000218,,,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),,,U,Autocuration,A,9527.0,CHEMBL620911,,,,,0,1
4421,22224,In vivo,BAO_0000218,,,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),,,U,Autocuration,A,9527.0,CHEMBL620912,,,,,0,1
4422,22224,In vivo,BAO_0000218,,,Cmax 24 hr after 2 mg/kg oral administration in monkeys,,,U,Autocuration,A,9527.0,CHEMBL620913,,,,,0,1
4423,22224,In vivo,BAO_0000218,,,Cmax in monkey after administration of 1 mg/kg iv,,,U,Autocuration,A,9527.0,CHEMBL620914,,,,,0,1
4424,22224,In vivo,BAO_0000218,,,Cmax was determine after peroral administration at 10 mpk in Rhesus,,,U,Autocuration,A,9527.0,CHEMBL620915,,,,,0,1
4425,22224,In vivo,BAO_0000218,,,Cmax in cynomolgus monkey by iv administration,,,U,Autocuration,A,9527.0,CHEMBL620916,,,,,0,1
4426,22224,In vivo,BAO_0000218,,,Cmax in cynomolgus monkey by po administration,,,U,Autocuration,A,9527.0,CHEMBL620917,,,,,0,1
4427,22224,In vivo,BAO_0000218,,,Cmax value evaluated in monkey,,,U,Autocuration,A,9527.0,CHEMBL620918,,,,,0,1
4428,22224,In vivo,BAO_0000218,,,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,,U,Autocuration,A,9527.0,CHEMBL620919,,,,,0,1
4429,22224,In vivo,BAO_0000218,,,Maximal concentration (Cmax) in rhesus monkey plasma at a dose of 5 mg/kg,,,U,Autocuration,A,9527.0,CHEMBL620920,,1969.0,Plasma,,0,1
4430,22224,In vivo,BAO_0000218,,,Maximal concentration (Cmax) in squirrel monkey plasma at a dose of 5 mg/kg,,,U,Autocuration,A,9527.0,CHEMBL620921,,1969.0,Plasma,,0,1
4431,22224,In vivo,BAO_0000218,,,Maximal plasma concentration in squirrel monkeys,,,U,Autocuration,A,9527.0,CHEMBL620922,,1969.0,Plasma,,0,1
4432,22224,In vivo,BAO_0000218,,,Maximum concentration was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,,U,Autocuration,A,9527.0,CHEMBL620923,,,,,0,1
4433,22224,In vivo,BAO_0000218,,,Maximum plasma concentration (Cmax) in rhesus monkey(in vivo) at a dose of 5 mg/kg,,,U,Autocuration,A,9527.0,CHEMBL620924,,1969.0,Plasma,,0,1
4434,22224,In vivo,BAO_0000218,,,Pharmacokinetic parameter Cmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),,,U,Autocuration,A,9527.0,CHEMBL620925,,,,,0,1
4435,22224,In vivo,BAO_0000218,,,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means Not applicable,,,U,Autocuration,A,9527.0,CHEMBL620926,,,,,0,1
4436,22224,In vivo,BAO_0000218,,,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means not applicable,,,U,Autocuration,A,9527.0,CHEMBL620927,,,,,0,1
4437,22224,In vivo,BAO_0000218,,,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys;NA means not applicable,,,U,Autocuration,A,9527.0,CHEMBL620928,,,,,0,1
4438,22224,In vivo,BAO_0000218,,,The peak concentration (Cmax) value after oral administration in cynomolgus monkeys,,,U,Autocuration,A,9527.0,CHEMBL620929,,,,,0,1
4439,22224,In vivo,BAO_0000218,,,The peak plasma concentration after 5 hr administration (2.5 mg/kg) in monkey was determined,,,U,Autocuration,A,9527.0,CHEMBL620930,,1969.0,Plasma,,0,1
4440,22224,,BAO_0000218,,,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 0.4 hours,,,U,Autocuration,A,9527.0,CHEMBL620931,,,,,0,1
4441,22224,,BAO_0000218,,,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 1.0 hours,,,U,Autocuration,A,9527.0,CHEMBL620932,,,,,0,1
4442,22224,In vivo,BAO_0000218,,,Absolute bioavailability was evaluated in monkey,,,U,Autocuration,A,9443.0,CHEMBL620933,,,,,0,1
4443,22224,In vivo,BAO_0000218,,,Bioavailability after oral administration (2.5 mg/kg) in monkey was determined,,,U,Autocuration,A,9443.0,CHEMBL620934,,,,,0,1
4444,22224,In vivo,BAO_0000218,,,Bioavailability of compound at 3 mg/kg in monkey after i.v. administration,,,U,Autocuration,A,9443.0,CHEMBL620935,,,,,0,1
4445,22224,In vivo,BAO_0000218,,,Bioavailability of compound was determined in rhesus monkey,,,U,Autocuration,A,9544.0,CHEMBL620936,,,,,0,1
4446,22224,In vivo,BAO_0000218,,,Bioavailability determined after oral administration in marmoset,,,U,Autocuration,A,38020.0,CHEMBL620937,,,,,0,1
4447,22224,In vivo,BAO_0000218,,,Oral bioavailability in cynomolgus monkey,,,U,Autocuration,A,9541.0,CHEMBL620938,,,,,0,1
4448,22224,In vivo,BAO_0000218,,,Bioavailability in monkey (p.o.) at 2.0 mpk,,,U,Autocuration,A,9443.0,CHEMBL620939,,,,,0,1
4449,22224,In vivo,BAO_0000218,,,Bioavailability was evaluated after oral administration in monkey,,,U,Autocuration,A,9443.0,CHEMBL620940,,,,,0,1
4450,22224,In vivo,BAO_0000218,,,Bioavailability was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,,U,Autocuration,A,9541.0,CHEMBL620941,,,,,0,1
4451,22224,In vivo,BAO_0000218,,,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),,,U,Autocuration,A,9544.0,CHEMBL620942,,,,,0,1
4452,22224,In vivo,BAO_0000218,,,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),,,U,Autocuration,A,9544.0,CHEMBL620943,,,,,0,1
4453,22224,In vivo,BAO_0000218,,,Bioavailability of the compound was determined in monkey,,,U,Autocuration,A,9443.0,CHEMBL620944,,,,,0,1
4454,22224,In vivo,BAO_0000218,,,Bioavailability in squirrel monkey (dose 5 mg/kg),,,U,Autocuration,A,9521.0,CHEMBL620945,,,,,0,1
4455,22224,In vivo,BAO_0000218,,,Bioavailability was determined in monkey after (po) administration of a dose of 50 (uM/kg),,,U,Autocuration,A,9443.0,CHEMBL620946,,,,,0,1
4456,22224,In vivo,BAO_0000218,,,Oral bioavailability in monkey,,,U,Autocuration,A,9443.0,CHEMBL620947,,,,,0,1
4457,22224,In vivo,BAO_0000218,,,Compound was tested for bioavailability in squirrel monkey,,,U,Autocuration,A,9521.0,CHEMBL620948,,,,,0,1
4458,22224,In vivo,BAO_0000218,,,Oral bioavailability in Rhesus monkey,,,U,Autocuration,A,9544.0,CHEMBL620949,,,,,0,1
4459,22224,In vivo,BAO_0000218,,,Oral bioavailability in Rhesus monkey (dose of 0.75 mg/kg i.v. and 1.5 mg/kg p.o.),,,U,Autocuration,A,9544.0,CHEMBL620950,,,,,0,1
4460,22224,In vivo,BAO_0000218,,,Oral bioavailability in cynomolgus monkeys for the compound was determined; Acceptable,,,U,Autocuration,A,9541.0,CHEMBL620951,,,,,0,1
4461,22224,In vivo,BAO_0000218,,,Oral bioavailability in cynomolgus monkeys was determined; Acceptable,,,U,Autocuration,A,9541.0,CHEMBL620952,,,,,0,1
4462,22224,In vivo,BAO_0000218,,,Oral bioavailability in monkey (dose 5 mg/kg),,,U,Autocuration,A,9443.0,CHEMBL875421,,,,,0,1
4463,22224,In vivo,BAO_0000218,,,Oral bioavailability of compound at 5 mg/kg in monkey,,,U,Autocuration,A,9443.0,CHEMBL620953,,,,,0,1
4464,50588,In vivo,BAO_0000218,,,Pharmacokinetic profile in terms of half life was determined at a dose of 0.5 mg/kg administered intravenously in dog,,,N,Intermediate,A,9615.0,CHEMBL873491,,,,,1,1
4465,50588,In vivo,BAO_0000218,,,Pharmacokinetic profile in terms of half life was determined at a dose of 5 mg/kg administered intravenously in dog,,,N,Intermediate,A,9615.0,CHEMBL620954,,,,,1,1
4466,50588,,BAO_0000218,,,Plasma half life determined,,,N,Intermediate,A,9615.0,CHEMBL620955,,1969.0,Plasma,,1,1
4467,50588,,BAO_0000218,,,Plasma half life in dog,,,N,Intermediate,A,9615.0,CHEMBL618097,,1969.0,Plasma,,1,1
4468,50588,,BAO_0000218,,,Plasma half-life in Beagle dogs,,,N,Intermediate,A,9615.0,CHEMBL618268,,1969.0,Plasma,,1,1
4469,50588,In vivo,BAO_0000218,,,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),,,N,Intermediate,A,9615.0,CHEMBL618269,,1969.0,Plasma,,1,1
4470,50588,In vivo,BAO_0000218,,,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg respectively in Beagle dog (male),,,N,Intermediate,A,9615.0,CHEMBL618270,,1969.0,Plasma,,1,1
4471,50588,In vivo,BAO_0000218,,,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in dog,,,N,Intermediate,A,9615.0,CHEMBL618271,,,,,1,1
4472,50588,In vivo,BAO_0000218,,,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in dog,,,N,Intermediate,A,9615.0,CHEMBL873493,,,,,1,1
4473,50588,,BAO_0000218,,,Tested for the half life period in dog,,,N,Intermediate,A,9615.0,CHEMBL621031,,,,,1,1
4474,50588,In vivo,BAO_0000218,,,Tested for the half life period in dog at dosage of 10 mpk,,,N,Intermediate,A,9615.0,CHEMBL621032,,,,,1,1
4475,50588,,BAO_0000218,,,The compound was tested for half life in dog,,,N,Intermediate,A,9615.0,CHEMBL621033,,,,,1,1
4476,50588,,BAO_0000218,,,"The compound was tested for time taken to decrease, half of its initial concentration in dog plasma.",,,N,Intermediate,A,9615.0,CHEMBL621034,,1969.0,Plasma,,1,1
4477,50588,,BAO_0000218,,,The half life was determined,,,N,Intermediate,A,9615.0,CHEMBL621035,,,,,1,1
4478,50588,,BAO_0000218,,,The plasma half-life in dogs,,,N,Intermediate,A,9615.0,CHEMBL621036,,1969.0,Plasma,,1,1
4479,50588,,BAO_0000218,,,suboptimal plasma half-life caused a10% prolongation of QTc interval in dogs at a plasma level of 2.5 M,,,N,Intermediate,A,9615.0,CHEMBL621037,,1969.0,Plasma,,1,1
4480,50588,,BAO_0000218,,,Half life in dog,,,N,Intermediate,A,9615.0,CHEMBL619812,,,,,1,1
4481,50588,In vivo,BAO_0000218,,,Pharmacokinetic property (t1/2beta) was measured in dog at the dose of 0.032 mg/kg i.v.,,,N,Intermediate,A,9615.0,CHEMBL619813,,,,,1,1
4482,50588,In vivo,BAO_0000218,,,tmax upon peroral administration of 10.0 mg/Kg dose in dog,,,N,Intermediate,A,9615.0,CHEMBL873335,,,,,1,1
4483,50588,In vivo,BAO_0000218,,,Volume of distribution in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,,N,Intermediate,A,9615.0,CHEMBL619814,,,,,1,1
4484,50506,In vivo,BAO_0000218,,,Cmax in ferrets after 30 mg/kg oral dose,,,N,Expert,A,9669.0,CHEMBL619815,,,,,1,1
4485,50506,In vivo,BAO_0000218,,,Emesis in ferrets at 30 mg/kg oral dose,,,N,Expert,F,9669.0,CHEMBL619816,,,,,1,1
4486,22224,In vivo,BAO_0000218,,,Bioavailability in cynomolgus monkey,,,U,Autocuration,A,9541.0,CHEMBL619817,,,,,0,1
4487,100710,In vivo,BAO_0000218,,,Volume of distribution in cynomolgus,,,N,Intermediate,A,9541.0,CHEMBL619818,,,,,1,1
4488,22224,,BAO_0000218,,,AUC tested in guinea pig when 3 mg/kg dose was given perorally,,,U,Autocuration,A,10141.0,CHEMBL619819,,1969.0,Plasma,,0,1
4489,22224,,BAO_0000218,,,Tested for concentration as Area Under Curve against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,,,U,Autocuration,A,10141.0,CHEMBL619820,,,,,0,1
4490,22224,,BAO_0000218,,,"Tested for the pharmacokinetic parameter in guinea pig, administered orally at 5 mg/kg",,,U,Autocuration,A,10141.0,CHEMBL875419,,,,,0,1
4491,22224,In vivo,BAO_0000218,,,AUC in guinea pig after 3mg/kg oral dose,,,U,Autocuration,A,10141.0,CHEMBL619821,,1969.0,Plasma,,0,1
4492,22224,In vivo,BAO_0000218,,,Bioavailability in guinea pig was tested,,,U,Autocuration,A,10141.0,CHEMBL619822,,,,,0,1
4493,22224,In vivo,BAO_0000218,,,Tested for oral bioavailability in guinea pig at 5 mg/kg,,,U,Autocuration,A,10141.0,CHEMBL619823,,,,,0,1
4494,22224,In vivo,BAO_0000218,,,Tested for the oral bioavailability of the compound,,,U,Autocuration,A,10141.0,CHEMBL619824,,,,,0,1
4495,22224,In vivo,BAO_0000218,,,Compound at a dose 5 mg/kg was administered orally to guinea pig and the pharmacokinetic parameter (Cmax) was reported,,,U,Autocuration,A,10141.0,CHEMBL619825,,,,,0,1
4496,22224,In vivo,BAO_0000218,,,Maximum plsma drug concentration in guinea pig when 3 mg/kg dose was given perorally,,,U,Autocuration,A,10141.0,CHEMBL619826,,,,,0,1
4497,22224,In vivo,BAO_0000218,,,Tested for maximum concentration against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,,,U,Autocuration,A,10141.0,CHEMBL619827,,2048.0,Lung,,0,1
4498,22224,In vivo,BAO_0000218,,,Cmax in guinea pig after 3mg/kg oral dose,,,U,Autocuration,A,10141.0,CHEMBL618167,,,,,0,1
4499,22224,,BAO_0000019,,,Distribution in blood expressed as [18F]- organ uptake in % of injected activity/gram,,,U,Autocuration,A,10141.0,CHEMBL618168,,178.0,Blood,,0,1
4500,22224,,BAO_0000019,,,Distribution in brain expressed as [18F]- organ uptake in % of injected activity/gram,,,U,Autocuration,A,10141.0,CHEMBL618169,,955.0,Brain,,0,1
4501,22224,,BAO_0000019,,,Distribution in heart expressed as [18F]- organ uptake in % of injected activity/gram,,,U,Autocuration,A,10141.0,CHEMBL618170,,,,,0,1
4502,22224,,BAO_0000019,,,Distribution in intestine expressed as [18F]- organ uptake in % of injected activity/gram,,,U,Autocuration,A,10141.0,CHEMBL618171,,160.0,Intestine,,0,1
4503,22224,,BAO_0000019,,,Distribution in kidney expressed as [18F]- organ uptake in % of injected activity/gram,,,U,Autocuration,A,10141.0,CHEMBL618172,,2113.0,Kidney,,0,1
4504,22224,,BAO_0000019,,,Distribution in liver expressed as [18F]- organ uptake in % of injected activity/gram,,,U,Autocuration,A,10141.0,CHEMBL618173,,2107.0,Liver,,0,1
4505,22224,,BAO_0000019,,,Distribution in lung expressed as [18F]- organ uptake in % of injected activity/gram,,,U,Autocuration,A,10141.0,CHEMBL618174,,,,,0,1
4506,22224,,BAO_0000019,,,Distribution in spleen expressed as [18F]- organ uptake in % of injected activity/gram,,,U,Autocuration,A,10141.0,CHEMBL875408,,2106.0,Spleen,,0,1
4507,22224,In vivo,BAO_0000218,,,Elimination T1/2 in Guinea pig (PO dose),,,U,Autocuration,A,10141.0,CHEMBL839827,,,,,0,1
4508,22224,,BAO_0000019,,,Partition coefficient was measured as -log (counts per min ),,,U,Autocuration,A,10141.0,CHEMBL618175,,,,,0,1
4509,22224,In vivo,BAO_0000218,,,Biological half life when administered at 0.1 umol/kg intravenously to guinea pig in GR-64349 antagonism,,,U,Autocuration,A,10141.0,CHEMBL618176,,,,,0,1
4510,22224,In vivo,BAO_0000218,,,Biological half life when administered at 5 umol/kg intravenously to guinea pig in GR-64349 antagonism,,,U,Autocuration,A,10141.0,CHEMBL618177,,,,,0,1
4511,22224,In vivo,BAO_0000218,,,Elimination T1/2 in Guinea pig (PO dose),,,U,Autocuration,A,10141.0,CHEMBL618178,,,,,0,1
4512,22224,In vivo,BAO_0000218,,,"Tested for the half life period of the compound, intravenously",,,U,Autocuration,A,10141.0,CHEMBL618179,,,,,0,1
4513,22224,,BAO_0000019,,,Half-life was measured,,,U,Autocuration,A,10141.0,CHEMBL873489,,,,,0,1
4514,22224,,BAO_0000019,,,The time required for onset of inotropy after addition of a single dose of delta F75,,,U,Autocuration,A,10141.0,CHEMBL618180,,,,,0,1
4515,22224,In vivo,BAO_0000218,,,Bioavailability of compound at 10 mg/kg in guinea pig after i.v. administration,,,U,Autocuration,A,10141.0,CHEMBL618181,,,,,0,1
4516,22224,In vivo,BAO_0000218,,,Bioavailability of compound at 3 mg/kg in guinea pig after i.v. administration,,,U,Autocuration,A,10141.0,CHEMBL618182,,,,,0,1
4517,22224,In vivo,BAO_0000218,,,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,,,U,Autocuration,A,10029.0,CHEMBL618183,,,,,0,1
4518,50594,In vivo,BAO_0000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,,N,Intermediate,A,10090.0,CHEMBL618184,,,,,1,1
4519,50594,In vivo,BAO_0000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,,N,Intermediate,A,10090.0,CHEMBL618185,,,,,1,1
4520,50594,In vivo,BAO_0000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,,N,Intermediate,A,10090.0,CHEMBL618186,,,,,1,1
4521,50594,In vivo,BAO_0000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,,N,Intermediate,A,10090.0,CHEMBL618187,,,,,1,1
4522,50594,In vivo,BAO_0000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hr,,,N,Intermediate,A,10090.0,CHEMBL618188,,,,,1,1
4523,50594,In vivo,BAO_0000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,,N,Intermediate,A,10090.0,CHEMBL875409,,,,,1,1
4524,50594,In vivo,BAO_0000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,,N,Intermediate,A,10090.0,CHEMBL618189,,,,,1,1
4525,50594,In vivo,BAO_0000218,,,Biodistribution of the injected compound in blood of female BALB/C mice for 0.5 hours,,,N,Intermediate,A,10090.0,CHEMBL618190,,178.0,Blood,,1,1
4526,50594,In vivo,BAO_0000218,,,Biodistribution of the injected compound in blood of female BALB/C mice for 2.5 hours,,,N,Intermediate,A,10090.0,CHEMBL618191,,178.0,Blood,,1,1
4527,50594,In vivo,BAO_0000218,,,Biodistribution of the injected compound in blood of female BALB/C mice for 5 hours,,,N,Intermediate,A,10090.0,CHEMBL618192,,178.0,Blood,,1,1
4528,50594,In vivo,BAO_0000218,,,Biodistribution of the injected compound in bone of female BALB/C mice for 0.5 hours,,,N,Intermediate,A,10090.0,CHEMBL618193,,10000001.0,Bone,,1,1
4529,50594,In vivo,BAO_0000218,,,Biodistribution of the injected compound in bone of female BALB/C mice for 2.5 hours,,,N,Intermediate,A,10090.0,CHEMBL618194,,10000001.0,Bone,,1,1
4530,50594,In vivo,BAO_0000218,,,Biodistribution of the injected compound in bone of female BALB/C mice for 5 hours,,,N,Intermediate,A,10090.0,CHEMBL618195,,10000001.0,Bone,,1,1
4531,50594,In vivo,BAO_0000218,,,Biodistribution of the injected compound in brain of female BALB/C mice for 0.5 hours,,,N,Intermediate,A,10090.0,CHEMBL618196,,955.0,Brain,,1,1
4532,50594,In vivo,BAO_0000218,,,Biodistribution of the injected compound in brain of female BALB/C mice for 2.5 hours,,,N,Intermediate,A,10090.0,CHEMBL618197,,955.0,Brain,,1,1
4533,50594,In vivo,BAO_0000218,,,Biodistribution of the injected compound in brain of female BALB/C mice for 5 hours,,,N,Intermediate,A,10090.0,CHEMBL618198,,955.0,Brain,,1,1
4534,50594,In vivo,BAO_0000218,,,Biodistribution of the injected compound in heart of female BALB/C mice for 0.5 hours,,,N,Intermediate,A,10090.0,CHEMBL618199,,948.0,Heart,,1,1
4535,50594,In vivo,BAO_0000218,,,Biodistribution of the injected compound in heart of female BALB/C mice for 2.5 hours,,,N,Intermediate,A,10090.0,CHEMBL618200,,948.0,Heart,,1,1
4536,50594,In vivo,BAO_0000218,,,Biodistribution of the injected compound in heart of female BALB/C mice for 5 hours,,,N,Intermediate,A,10090.0,CHEMBL618201,,948.0,Heart,,1,1
4537,50594,In vivo,BAO_0000218,,,Biodistribution of the injected compound in intestines of female BALB/C mice for 0.5 hours,,,N,Intermediate,A,10090.0,CHEMBL618202,,160.0,Intestine,,1,1
4538,50594,In vivo,BAO_0000218,,,Biodistribution of the injected compound in intestines of female BALB/C mice for 2.5 hours,,,N,Intermediate,A,10090.0,CHEMBL618203,,160.0,Intestine,,1,1
4539,50594,In vivo,BAO_0000218,,,Biodistribution of the injected compound in intestines of female BALB/C mice for 5 hours,,,N,Intermediate,A,10090.0,CHEMBL618204,,160.0,Intestine,,1,1
4540,50594,In vivo,BAO_0000218,,,Biodistribution of the injected compound in kidneys of female BALB/C mice for 0.5 hours,,,N,Intermediate,A,10090.0,CHEMBL618205,,2113.0,Kidney,,1,1
4541,50594,In vivo,BAO_0000218,,,Biodistribution of the injected compound in kidneys of female BALB/C mice for 2.5 hours,,,N,Intermediate,A,10090.0,CHEMBL618206,,2113.0,Kidney,,1,1
4542,50594,In vivo,BAO_0000218,,,Biodistribution of the injected compound in kidneys of female BALB/C mice for 5 hours,,,N,Intermediate,A,10090.0,CHEMBL618207,,2113.0,Kidney,,1,1
4543,50594,In vivo,BAO_0000218,,,Biodistribution of the injected compound in liver of female BALB/C mice for 0.5 hours,,,N,Intermediate,A,10090.0,CHEMBL618208,,2107.0,Liver,,1,1
4544,50594,In vivo,BAO_0000218,,,Biodistribution of the injected compound in liver of female BALB/C mice for 2.5 hours,,,N,Intermediate,A,10090.0,CHEMBL618932,,2107.0,Liver,,1,1
4545,50594,In vivo,BAO_0000218,,,Biodistribution of the injected compound in liver of female BALB/C mice for 5 hours,,,N,Intermediate,A,10090.0,CHEMBL618933,,2107.0,Liver,,1,1
4546,50594,In vivo,BAO_0000218,,,Biodistribution of the injected compound in lung of female BALB/C mice for 0.5 hours,,,N,Intermediate,A,10090.0,CHEMBL618934,,2048.0,Lung,,1,1
4547,50594,In vivo,BAO_0000218,,,Biodistribution of the injected compound in lung of female BALB/C mice for 2.5 hours,,,N,Intermediate,A,10090.0,CHEMBL618935,,2048.0,Lung,,1,1
4548,50594,In vivo,BAO_0000218,,,Biodistribution of the injected compound in lung of female BALB/C mice for 5 hours,,,N,Intermediate,A,10090.0,CHEMBL618936,,2048.0,Lung,,1,1
4549,50594,In vivo,BAO_0000218,,,Biodistribution of the injected compound in muscle of female BALB/C mice for 0.5 hours,,,N,Intermediate,A,10090.0,CHEMBL618937,,2385.0,Muscle tissue,,1,1
4550,50594,In vivo,BAO_0000218,,,Biodistribution of the injected compound in muscle of female BALB/C mice for 2.5 hours,,,N,Intermediate,A,10090.0,CHEMBL618938,,2385.0,Muscle tissue,,1,1
4551,50594,In vivo,BAO_0000218,,,Biodistribution of the injected compound in muscle of female BALB/C mice for 5 hours,,,N,Intermediate,A,10090.0,CHEMBL619104,,2385.0,Muscle tissue,,1,1
4552,50594,In vivo,BAO_0000218,,,Biodistribution of the injected compound in spleen of female BALB/C mice for 0.5 hours,,,N,Intermediate,A,10090.0,CHEMBL619105,,2106.0,Spleen,,1,1
4553,50594,In vivo,BAO_0000218,,,Biodistribution of the injected compound in spleen of female BALB/C mice for 2.5 hours,,,N,Intermediate,A,10090.0,CHEMBL619106,,2106.0,Spleen,,1,1
4554,50594,In vivo,BAO_0000218,,,Biodistribution of the injected compound in spleen of female BALB/C mice for 5 hours,,,N,Intermediate,A,10090.0,CHEMBL619107,,2106.0,Spleen,,1,1
4555,50594,In vivo,BAO_0000218,,,Biodistribution of the injected compound in stomach of female BALB/C mice for 0.5 hours,,,N,Intermediate,A,10090.0,CHEMBL875410,,945.0,Stomach,,1,1
4556,50594,In vivo,BAO_0000218,,,Biodistribution of the injected compound in stomach of female BALB/C mice for 2.5 hours,,,N,Intermediate,A,10090.0,CHEMBL619108,,945.0,Stomach,,1,1
4557,50594,In vivo,BAO_0000218,,,Biodistribution of the injected compound in stomach of female BALB/C mice for 5 hours,,,N,Intermediate,A,10090.0,CHEMBL619109,,945.0,Stomach,,1,1
4558,50594,In vivo,BAO_0000218,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,,,N,Intermediate,A,10090.0,CHEMBL619110,,,,,1,1
4559,50594,In vivo,BAO_0000218,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,,,N,Intermediate,F,10090.0,CHEMBL619111,,,,,1,1
4560,50594,In vivo,BAO_0000218,,,MRT value at a dose of 10 mg/kg intravenous administration in mice.,,,N,Intermediate,A,10090.0,CHEMBL619112,,,,,1,1
4561,50594,In vivo,BAO_0000218,,,MRT value at a dose of 10 mg/kg peroral administration in mice.,,,N,Intermediate,A,10090.0,CHEMBL619113,,,,,1,1
4562,50594,In vivo,BAO_0000218,,,Mean-residence time of compound after intravenous administration in mice at 24 uM/kg,,,N,Intermediate,A,10090.0,CHEMBL619114,,,,,1,1
4563,50594,In vivo,BAO_0000218,,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 18 uM/kg,,,N,Intermediate,F,10090.0,CHEMBL619115,,,,,1,1
4564,81034,,BAO_0000219,478.0,A2780,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C after 96 hr,,,N,Intermediate,F,9606.0,CHEMBL619116,,,,,1,1
4565,81034,,BAO_0000219,478.0,A2780,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C for 96 hr,,,N,Intermediate,F,9606.0,CHEMBL619117,,,,,1,1
4566,81034,,BAO_0000219,478.0,A2780,Compound was evaluated for cytotoxicity against A2780 cell lines.,,,N,Intermediate,F,9606.0,CHEMBL619118,,,,,1,1
4567,81034,,BAO_0000219,478.0,A2780,Potentiation of growth inhibition of A2780 by compound alone in experiment 1,,,N,Intermediate,F,9606.0,CHEMBL619119,,,,,1,1
4568,81034,,BAO_0000219,478.0,A2780,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,,,N,Intermediate,F,9606.0,CHEMBL619120,,,,,1,1
4569,81034,,BAO_0000219,478.0,A2780,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,,,N,Intermediate,F,9606.0,CHEMBL619121,,,,,1,1
4570,81034,,BAO_0000219,478.0,A2780,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,,,N,Intermediate,F,9606.0,CHEMBL619122,,,,,1,1
4571,81034,,BAO_0000219,478.0,A2780,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,,,N,Intermediate,F,9606.0,CHEMBL619123,,,,,1,1
4572,81034,,BAO_0000219,478.0,A2780,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,,,N,Intermediate,F,9606.0,CHEMBL619124,,,,,1,1
4573,81034,,BAO_0000219,478.0,A2780,Compound was evaluated for cytotoxicity against A2780 cell line,,,N,Intermediate,F,9606.0,CHEMBL619125,,,,,1,1
4574,81034,,BAO_0000219,478.0,A2780,In vitro inhibitory activity against human tumor cell line A2780,,,N,Intermediate,F,9606.0,CHEMBL875411,,,,,1,1
4575,81034,,BAO_0000219,478.0,A2780,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 1,,,N,Intermediate,F,9606.0,CHEMBL619126,,,,,1,1
4576,81034,,BAO_0000219,478.0,A2780,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,,,N,Intermediate,F,9606.0,CHEMBL619127,,,,,1,1
4577,81034,,BAO_0000219,478.0,A2780,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,,,N,Intermediate,F,9606.0,CHEMBL619128,,,,,1,1
4578,81034,,BAO_0000219,478.0,A2780,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,,,N,Intermediate,F,9606.0,CHEMBL619129,,,,,1,1
4579,81034,,BAO_0000219,478.0,A2780,The compound was tested for cytotoxic potency against A2780 human tumor cell lines,,,N,Intermediate,F,9606.0,CHEMBL619130,,,,,1,1
4580,81034,,BAO_0000219,478.0,A2780,The compound was tested for cytotoxic potency against A2780 human tumor cell lines.,,,N,Intermediate,F,9606.0,CHEMBL619131,,,,,1,1
4581,81034,,BAO_0000219,478.0,A2780,cytotoxicity against A2780 cells incubated for 24 hr in MTT assay.,,,N,Intermediate,F,9606.0,CHEMBL619132,,,,,1,1
4582,81034,,BAO_0000218,478.0,A2780,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,,,N,Expert,F,9606.0,CHEMBL619133,,,,,1,1
4583,81034,,BAO_0000219,478.0,A2780,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,,,N,Intermediate,F,9606.0,CHEMBL619134,,,,,1,1
4584,81034,,BAO_0000219,478.0,A2780,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,,,N,Intermediate,F,9606.0,CHEMBL619135,,,,,1,1
4585,81034,,BAO_0000219,478.0,A2780,Compound was evaluated for cytotoxicity against A2780 cis cell lines.,,,N,Intermediate,F,9606.0,CHEMBL619136,,,,,1,1
4586,81034,,BAO_0000219,478.0,A2780,Relative resistance factor in A2780 cisplatin-resistant line,,,N,Intermediate,F,9606.0,CHEMBL619137,,,,,1,1
4587,81034,,BAO_0000219,478.0,A2780,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells,,,N,Intermediate,F,9606.0,CHEMBL883713,,,,,1,1
4588,81034,,BAO_0000219,478.0,A2780,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells.,,,N,Intermediate,F,9606.0,CHEMBL875412,,,,,1,1
4589,81034,,BAO_0000218,478.0,A2780,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,,,N,Expert,F,9606.0,CHEMBL619138,,,,,1,1
4590,81034,,BAO_0000218,478.0,A2780,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,,,N,Expert,F,9606.0,CHEMBL619262,,,,,1,1
4591,81034,,BAO_0000219,478.0,A2780,Cytotoxicity against A2780 ovarian carcinoma cells was evaluated using standard sulforhodamine 96h assay test,,,N,Intermediate,F,9606.0,CHEMBL619139,,,,,1,1
4592,81034,,BAO_0000219,478.0,A2780,In vitro cytotoxicity was determined against A2780 human ovarian cell line using NCI screen,,,N,Intermediate,F,9606.0,CHEMBL619140,,,,,1,1
4593,81034,,BAO_0000219,478.0,A2780,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin,,,N,Intermediate,F,9606.0,CHEMBL619141,,,,,1,1
4594,81034,,BAO_0000219,478.0,A2780,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 1,,,N,Intermediate,F,9606.0,CHEMBL619142,,,,,1,1
4595,81034,,BAO_0000219,478.0,A2780,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 2,,,N,Intermediate,F,9606.0,CHEMBL619143,,,,,1,1
4596,81034,,BAO_0000219,478.0,A2780,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 3,,,N,Intermediate,F,9606.0,CHEMBL619144,,,,,1,1
4597,81034,,BAO_0000219,478.0,A2780,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 5,,,N,Intermediate,F,9606.0,CHEMBL619145,,,,,1,1
4598,81034,,BAO_0000219,478.0,A2780,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 8,,,N,Intermediate,F,9606.0,CHEMBL619146,,,,,1,1
4599,81034,,BAO_0000219,478.0,A2780,Cytotoxic activity in a panel of Human ovarian tumor A2780/CDDP cell line after 96h of drug exposure,,,N,Intermediate,F,9606.0,CHEMBL619147,,,,,1,1
4600,81034,,BAO_0000219,478.0,A2780,Antiproliferative effect of compound on A2780/DX cell line,,,N,Intermediate,F,9606.0,CHEMBL619148,,,,,1,1
4601,81034,,BAO_0000219,478.0,A2780,Antiproliferative effect of compound on A2780/DX cell line; n.d. indicates not determined,,,N,Intermediate,F,9606.0,CHEMBL619149,,,,,1,1
4602,81034,,BAO_0000219,478.0,A2780,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/DX(RI),,,N,Intermediate,F,9606.0,CHEMBL619150,,,,,1,1
4603,81034,,BAO_0000219,478.0,A2780,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/Dx(RI),,,N,Intermediate,F,9606.0,CHEMBL619151,,,,,1,1
4604,81034,,BAO_0000219,478.0,A2780,Cytotoxicity against ovarian carcinoma A2780/cis tumor cell lines,,,N,Intermediate,F,9606.0,CHEMBL883794,,,,,1,1
4605,81034,,BAO_0000219,478.0,A2780,Cytotoxicity against ovarian carcinoma A2780/cis90 tumor cell lines,,,N,Intermediate,F,9606.0,CHEMBL619152,,,,,1,1
4606,81034,,BAO_0000219,478.0,A2780,In vitro cytotoxicity against A2780ADR cell line,,,N,Intermediate,F,9606.0,CHEMBL619153,,,,,1,1
4607,81034,,BAO_0000219,478.0,A2780,In vitro cytotoxicity against A2780CIS cell line,,,N,Intermediate,F,9606.0,CHEMBL619154,,,,,1,1
4608,81034,,BAO_0000219,478.0,A2780,In vitro cytotoxic activity against human tumor cell line A2780CisR after incubation for 96 hours,,,N,Intermediate,F,9606.0,CHEMBL619155,,,,,1,1
4609,81034,,BAO_0000219,478.0,A2780,The compound was tested for cytotoxic potency against A2780R human tumor cell lines.,,,N,Intermediate,F,9606.0,CHEMBL619156,,,,,1,1
4610,81034,,BAO_0000219,478.0,A2780,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-resistant A2780/R human tumor cell lines",,,N,Intermediate,F,9606.0,CHEMBL619157,,,,,1,1
4611,81034,,BAO_0000219,478.0,A2780,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-resistant A2780/R human tumor cell lines",,,N,Intermediate,F,9606.0,CHEMBL619797,,,,,1,1
4612,22224,In vivo,BAO_0000218,,,Oral bioavailability of compound in rhesus macaques,,,U,Autocuration,A,9544.0,CHEMBL619798,,,,,0,1
4613,22224,In vivo,BAO_0000218,,,Oral bioavailability in monkey,,,U,Autocuration,A,9443.0,CHEMBL619799,,,,,0,1
4614,22224,In vivo,BAO_0000218,,,Oral bioavailability evaluated in monkey,,,U,Autocuration,A,9443.0,CHEMBL619800,,,,,0,1
4615,22224,In vivo,BAO_0000218,,,Oral bioavailability in monkey (dose 1 mg/kg p.o.),,,U,Autocuration,A,9443.0,CHEMBL619801,,,,,0,1
4616,22224,In vivo,BAO_0000218,,,Oral bioavailability in Rhesus monkey,,,U,Autocuration,A,9544.0,CHEMBL619802,,,,,0,1
4617,22224,In vivo,BAO_0000218,,,Oral bioavailability was calculated in rhesus monkey,,,U,Autocuration,A,9544.0,CHEMBL619803,,,,,0,1
4618,22224,In vivo,BAO_0000218,,,Oral bioavailability in cynomolgus monkey,,,U,Autocuration,A,9541.0,CHEMBL619965,,,,,0,1
4619,22224,In vivo,BAO_0000218,,,Oral bioavailability in monkey,,,U,Autocuration,A,9443.0,CHEMBL619966,,,,,0,1
4620,22224,In vivo,BAO_0000218,,,Oral bioavailability in monkey,,,U,Autocuration,A,9443.0,CHEMBL619967,,,,,0,1
4621,22224,In vivo,BAO_0000218,,,Oral bioavailability in monkey (dose 1 mg/kg),,,U,Autocuration,A,9443.0,CHEMBL620073,,,,,0,1
4622,22224,In vivo,BAO_0000218,,,Oral bioavailability in monkey (dose 5 mg/kg),,,U,Autocuration,A,9443.0,CHEMBL620074,,,,,0,1
4623,22224,In vivo,BAO_0000218,,,Oral bioavailability in monkey,,,U,Autocuration,A,9443.0,CHEMBL620075,,,,,0,1
4624,22224,In vivo,BAO_0000218,,,Oral bioavailability in monkey,,,U,Autocuration,A,9443.0,CHEMBL620076,,,,,0,1
4625,22224,In vivo,BAO_0000218,,,Oral bioavailability in rhesus monkey,,,U,Autocuration,A,9544.0,CHEMBL620077,,,,,0,1
4626,22224,In vivo,BAO_0000218,,,Oral bioavailability in rhesus monkey at a dose of 2 mg/kg by po administration,,,U,Autocuration,A,9544.0,CHEMBL620078,,,,,0,1
4627,22224,In vivo,BAO_0000218,,,Oral bioavailability in squirrel monkey at a dose of 10 mg/kg,,,U,Autocuration,A,9521.0,CHEMBL620079,,,,,0,1
4628,22224,In vivo,BAO_0000218,,,Oral bioavailability in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,,U,Autocuration,A,9443.0,CHEMBL620080,,,,,0,1
4629,22224,In vivo,BAO_0000218,,,Oral bioavailability in Rhesus monkey,,,U,Autocuration,A,9544.0,CHEMBL620081,,,,,0,1
4630,22224,In vivo,BAO_0000218,,,Oral bioavailability in Rhesus monkey (dose 10 mg/kg p.o.),,,U,Autocuration,A,9544.0,CHEMBL620082,,,,,0,1
4631,22224,In vivo,BAO_0000218,,,Oral bioavailability in monkey at 10 mg/kg of the compound,,,U,Autocuration,A,9443.0,CHEMBL620083,,,,,0,1
4632,22224,In vivo,BAO_0000218,,,Bioavailability in Rhesus monkey,,,U,Autocuration,A,9544.0,CHEMBL620084,,,,,0,1
4633,22224,,BAO_0000218,,,Glomerular Filtration Rate(GFR) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,U,Autocuration,A,9527.0,CHEMBL620085,,,,,0,1
4634,22224,,BAO_0000218,,,Glomerular Filtration Rate(GFR)of the compound compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,U,Autocuration,A,9527.0,CHEMBL874595,,,,,0,1
4635,22224,In vivo,BAO_0000218,,,Half life by ''Cr'' assay in rhesus monkey at a dose of 5 mg/kg,,,U,Autocuration,A,9527.0,CHEMBL873352,,,,,0,1
4636,22224,In vivo,BAO_0000218,,,Half life the of compound was determined by ''Cr'' assay in squirrel monkey at a dose of 5 mg/kg,,,U,Autocuration,A,9527.0,CHEMBL620086,,,,,0,1
4637,22224,In vivo,BAO_0000218,,,Mean residence time was determined after intravenous administration in cynomolgus monkeys,,,U,Autocuration,A,9527.0,CHEMBL620087,,,,,0,1
4638,22224,In vivo,BAO_0000218,,,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means Not applicable,,,U,Autocuration,A,9527.0,CHEMBL620088,,,,,0,1
4639,22224,In vivo,BAO_0000218,,,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means not applicable,,,U,Autocuration,A,9527.0,CHEMBL620089,,,,,0,1
4640,22224,In vivo,BAO_0000218,,,Pharmacokinetic parameter MRT was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,,U,Autocuration,A,9527.0,CHEMBL620090,,,,,0,1
4641,22224,In vivo,BAO_0000218,,,Pharmacokinetic parameter MRT was determined in monkey after (po) administration of a dose of 50 (uM/kg),,,U,Autocuration,A,9527.0,CHEMBL620091,,,,,0,1
4642,22224,,BAO_0000251,,,Metabolism of compound in monkey S9 microsomes ('+''indicates <20% largest observed peak),,,U,Autocuration,A,9527.0,CHEMBL620092,,,,Microsomes,0,1
4643,22224,,BAO_0000251,,,Metabolism of compound in monkey S9 microsomes ('++''indicates 20-50% largest observed peak),,,U,Autocuration,A,9527.0,CHEMBL620093,,,,Microsomes,0,1
4644,22224,,BAO_0000251,,,Metabolism of compound in monkey S9 microsomes ('+++'indicates 50-80% largest observed peak),,,U,Autocuration,A,9527.0,CHEMBL620094,,,,Microsomes,0,1
4645,22224,,BAO_0000251,,,Metabolism of compound in monkey S9 microsomes ('++++' indicates largest observed peak),,,U,Autocuration,A,9527.0,CHEMBL620095,,,,Microsomes,0,1
4646,22224,In vivo,BAO_0000218,,,Plasma clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,U,Autocuration,A,9527.0,CHEMBL620096,,,,,0,1
4647,22224,In vivo,BAO_0000218,,,Plasma clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,U,Autocuration,A,9527.0,CHEMBL620097,,,,,0,1
4648,22224,,BAO_0000019,,,Clearance from plasma(with matabolite-corrected plasma radioactivity-time integral) at 30 min after administration.,,,U,Autocuration,A,9527.0,CHEMBL620098,,,,,0,1
4649,22224,,BAO_0000218,,,Renal clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,U,Autocuration,A,9527.0,CHEMBL620099,,,,,0,1
4650,22224,,BAO_0000218,,,Renal clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,U,Autocuration,A,9527.0,CHEMBL620100,,,,,0,1
4651,22224,,BAO_0000019,,,Elimination Half-life of compound was determined in monkey,,,U,Autocuration,A,9527.0,CHEMBL620101,,,,,0,1
4652,22224,,BAO_0000019,,,Half life of compound was determined in rhesus monkey,,,U,Autocuration,A,9527.0,CHEMBL620102,,,,,0,1
4653,22224,,BAO_0000366,,,Half life in monkey plasma,,,U,Autocuration,A,9527.0,CHEMBL620103,,1969.0,Plasma,,0,1
4654,22224,,BAO_0000366,,,Half life in monkey plasma; Not detected,,,U,Autocuration,A,9527.0,CHEMBL620104,,1969.0,Plasma,,0,1
4655,22224,In vivo,BAO_0000218,,,Half life period was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,,U,Autocuration,A,9527.0,CHEMBL874596,,,,,0,1
4656,22224,In vivo,BAO_0000218,,,Half-life 24 hr after 2 mg/kg iv administration in monkeys,,,U,Autocuration,A,9527.0,CHEMBL873490,,,,,0,1
4657,22224,,BAO_0000019,,,Terminal half life of the compound.,,,U,Autocuration,A,9527.0,CHEMBL620105,,,,,0,1
4658,22224,In vivo,BAO_0000218,,,Maximum time was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,,U,Autocuration,A,9527.0,CHEMBL620780,,,,,0,1
4659,22224,In vivo,BAO_0000218,,,Pharmacokinetic parameter Tmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),,,U,Autocuration,A,9527.0,CHEMBL620781,,,,,0,1
4660,22224,,BAO_0000218,,,Unbound plasma was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,,,U,Autocuration,A,9527.0,CHEMBL620956,,,,,0,1
4661,22224,,BAO_0000218,,,Urinary recovery evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,U,Autocuration,A,9527.0,CHEMBL620957,,1088.0,Urine,,0,1
4662,22224,,BAO_0000218,,,Urinary recovery compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,U,Autocuration,A,9527.0,CHEMBL620958,,1088.0,Urine,,0,1
4663,22224,In vivo,BAO_0000218,,,Volume of distribution was determined in monkey after a 3 mg/kg of iv dose,,,U,Autocuration,A,9527.0,CHEMBL620959,,,,,0,1
4664,22224,In vivo,BAO_0000218,,,Volume distribution after oral administration (2.5 mg/kg) in monkey was determined,,,U,Autocuration,A,9527.0,CHEMBL620960,,,,,0,1
4665,22224,In vivo,BAO_0000218,,,Volume of distribution was evaluated in rhesus,,,U,Autocuration,A,9527.0,CHEMBL620961,,,,,0,1
4666,22224,In vivo,BAO_0000218,,,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,,,U,Autocuration,A,10029.0,CHEMBL620962,,,,,0,1
4667,22224,In vivo,BAO_0000218,,,Plasma clearance was measured in hamster at the dose of 3 mg/kg by intravenous administration,,,U,Autocuration,A,10029.0,CHEMBL620963,,,,,0,1
4668,22224,In vivo,BAO_0000218,,,Bioavailability in hamster was determined,,,U,Autocuration,A,10029.0,CHEMBL620964,,,,,0,1
4669,22224,In vivo,BAO_0000218,,,Bioavailability in hamster at a dose of 3 mg/kg by intravenous administration,,,U,Autocuration,A,10029.0,CHEMBL620965,,,,,0,1
4670,22224,In vivo,BAO_0000218,,,Bioavailability in hamster at a dose of 3 mg/kg by oral administration,,,U,Autocuration,A,10029.0,CHEMBL620966,,,,,0,1
4671,22224,,BAO_0000221,,,Half life of compound was determined in hamster blood,,,U,Autocuration,A,10029.0,CHEMBL620967,,178.0,Blood,,0,1
4672,22224,,BAO_0000019,,,Michaelis-Menten constant of the compound.,,,U,Autocuration,A,9823.0,CHEMBL620968,,,,,0,1
4673,22224,,BAO_0000019,,,Vmax value was measured at 0 uM concentration of silyl ether.,,,U,Autocuration,A,9823.0,CHEMBL874597,,,,,0,1
4674,22224,,BAO_0000019,,,Vmax value was measured at 10 uM concentration of silyl ether.,,,U,Autocuration,A,9823.0,CHEMBL620969,,,,,0,1
4675,22224,,BAO_0000019,,,Vmax value was measured at 5 uM concentration of silyl ether.,,,U,Autocuration,A,9823.0,CHEMBL620970,,,,,0,1
4676,235,,BAO_0000357,,,Inactivation of human leukocyte (neutrophil) elastase(HLE)(HNE) as rate constant,,,D,Expert,B,9606.0,CHEMBL620971,,,,,9,1
4677,22224,,BAO_0000218,,,Area under curve was evaluated against man at a dose of 10 mg/kg after po administration,,,U,Autocuration,A,9606.0,CHEMBL620972,,,,,0,1
4678,22224,,BAO_0000019,,,Compound was evaluated for area under the curve expressed as (h*ug/ml),,,U,Autocuration,A,9606.0,CHEMBL620973,,,,,0,1
4679,22224,,BAO_0000019,,,Active metabolite of ifosfamide determined in humans; A-Active,,,U,Autocuration,A,9606.0,CHEMBL618243,,,,,0,1
4680,22224,,BAO_0000019,,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis,,,U,Autocuration,A,9606.0,CHEMBL618244,,,,,0,1
4681,22224,,BAO_0000019,,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; -0.5 to 1,,,U,Autocuration,A,9606.0,CHEMBL618245,,,,,0,1
4682,22224,,BAO_0000019,,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; 1-2,,,U,Autocuration,A,9606.0,CHEMBL618246,,,,,0,1
4683,22224,,BAO_0000019,,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; trace,,,U,Autocuration,A,9606.0,CHEMBL618247,,,,,0,1
4684,22224,,BAO_0000218,,,Compound was evaluated for oral bioavailability in human,,,U,Autocuration,A,9606.0,CHEMBL618248,,,,,0,1
4685,22224,,BAO_0000019,,,Metabolite of ifosfamide determined in urine; NF-Not found,,,U,Autocuration,A,9606.0,CHEMBL618249,,1088.0,Urine,,0,1
4686,22224,,BAO_0000019,,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection (Group A and B),,,U,Autocuration,A,9606.0,CHEMBL618250,,,,,0,1
4687,22224,,BAO_0000019,,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics,,,U,Autocuration,A,9606.0,CHEMBL874598,,,,,0,1
4688,22224,,BAO_0000019,,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics and lactose,,,U,Autocuration,A,9606.0,CHEMBL618251,,,,,0,1
4689,22224,,BAO_0000019,,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics,,,U,Autocuration,A,9606.0,CHEMBL618252,,,,,0,1
4690,22224,,BAO_0000019,,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics and lactose,,,U,Autocuration,A,9606.0,CHEMBL618253,,,,,0,1
4691,22224,,BAO_0000019,,,Percent of compound in cirrhotic patients of sterile ascitic fluid (Group C),,,U,Autocuration,A,9606.0,CHEMBL618254,,,,,0,1
4692,22224,,BAO_0000019,,,Percent of compound in healthy individuals (Group D),,,U,Autocuration,A,9606.0,CHEMBL618255,,,,,0,1
4693,22224,,BAO_0000251,,,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,,,U,Autocuration,A,9606.0,CHEMBL618983,,2107.0,Liver,Microsomes,0,1
4694,22224,,BAO_0000019,,,Binding towards human plasma protein at 10 uM,,,U,Autocuration,A,9606.0,CHEMBL618984,,,,,0,1
4695,22224,,BAO_0000019,,,Binding towards human plasma protein at 100 uM,,,U,Autocuration,A,9606.0,CHEMBL618985,,,,,0,1
4696,22224,,BAO_0000019,,,Human plasma protein binding activity was determined,,,U,Autocuration,A,9606.0,CHEMBL618986,,,,,0,1
4697,22224,,BAO_0000019,,,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),,,U,Autocuration,A,9606.0,CHEMBL618987,,,,,0,1
4698,22224,,BAO_0000019,,,Percent binding of compound towards human plasma protein was determined,,,U,Autocuration,A,9606.0,CHEMBL618988,,,,,0,1
4699,22224,In vitro,BAO_0000251,,,Plasma clearance in human liver microsomes,,,U,Autocuration,A,9606.0,CHEMBL618989,,2107.0,Liver,Microsomes,0,1
4700,22224,In vitro,BAO_0000251,,,In vitro intrinsic clearance in human liver microsome,,,U,Autocuration,A,9606.0,CHEMBL618990,,2107.0,Liver,Microsomes,0,1
4701,22224,In vitro,BAO_0000251,,,In vitro intrinsic clearance in human liver microsome,,,U,Autocuration,A,9606.0,CHEMBL618991,,2107.0,Liver,Microsomes,0,1
4702,22224,In vitro,BAO_0000251,,,In vitro microsome metabolism clearance in human was determined,,,U,Autocuration,A,9606.0,CHEMBL876725,,,,Microsomes,0,1
4703,22224,In vitro,BAO_0000251,,,In vitro microsome metabolism clearance in human was determined; High,,,U,Autocuration,A,9606.0,CHEMBL618992,,,,Microsomes,0,1
4704,22224,In vitro,BAO_0000251,,,In vitro microsome metabolism clearance in human was determined; ND denotes no data,,,U,Autocuration,A,9606.0,CHEMBL618993,,,,Microsomes,0,1
4705,22224,In vitro,BAO_0000251,,,Pharmacokinetic property (clearance) in human liver microsome,,,U,Autocuration,A,9606.0,CHEMBL618994,,2107.0,Liver,Microsomes,0,1
4706,22224,In vitro,BAO_0000251,,,Plasma clearance in human liver microsomes,,,U,Autocuration,A,9606.0,CHEMBL618995,,2107.0,Liver,Microsomes,0,1
4707,22224,In vitro,BAO_0000251,,,In vitro clearance in human liver microsomes,,,U,Autocuration,A,9606.0,CHEMBL618996,,2107.0,Liver,Microsomes,0,1
4708,22224,In vitro,BAO_0000251,,,Intrinsic clearance in human liver microsomes was determined,,,U,Autocuration,A,9606.0,CHEMBL618997,,2107.0,Liver,Microsomes,0,1
4709,22224,In vitro,BAO_0000251,,,Intrinsic clearance in human liver microsomes was determined,,,U,Autocuration,A,9606.0,CHEMBL618998,,2107.0,Liver,Microsomes,0,1
4710,22224,In vivo,BAO_0000218,,,Cmax (Tissue distribution) of compound was determined at a dose of 5 mg/kg in human,,,U,Autocuration,A,9606.0,CHEMBL618999,,,,,0,1
4711,22224,In vivo,BAO_0000218,,,Maximum concentration was evaluated against man at a dose of 10 mg/kg after po administration,,,U,Autocuration,A,9606.0,CHEMBL620223,,,,,0,1
4712,22224,,BAO_0000218,,,Cmin (Clearance) of compound was determined at a dose of 5 mg/kg in human,,,U,Autocuration,A,9606.0,CHEMBL620224,,,,,0,1
4713,22224,,BAO_0000019,,,Stability in human plasma 2 hr after incubation expressed as percent concentration,,,U,Autocuration,A,9606.0,CHEMBL620225,,,,,0,1
4714,22224,,BAO_0000019,,,Stability in human plasma 4 hr after incubation expressed as percent concentration,,,U,Autocuration,A,9606.0,CHEMBL620226,,,,,0,1
4715,22224,,BAO_0000019,,,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 3 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,,U,Autocuration,A,9606.0,CHEMBL620227,,1088.0,Urine,,0,1
4716,22224,,BAO_0000019,,,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 7 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,,U,Autocuration,A,9606.0,CHEMBL876726,,1088.0,Urine,,0,1
4717,22224,,BAO_0000019,,,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 6 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,,U,Autocuration,A,9606.0,CHEMBL620228,,1088.0,Urine,,0,1
4718,22224,,BAO_0000019,,,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 8 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,,U,Autocuration,A,9606.0,CHEMBL620229,,1088.0,Urine,,0,1
4719,50594,In vivo,BAO_0000218,,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 23 uM/kg,,,N,Intermediate,F,10090.0,CHEMBL620230,,,,,1,1
4720,50594,In vivo,BAO_0000218,,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 25 uM/kg,,,N,Intermediate,F,10090.0,CHEMBL620231,,,,,1,1
4721,50594,In vivo,BAO_0000218,,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 26 uM/kg,,,N,Intermediate,F,10090.0,CHEMBL620232,,,,,1,1
4722,50594,In vivo,BAO_0000218,,,Mean-residence time was determined for compound intravenous administration in mice at 23 uM/kg,,,N,Intermediate,F,10090.0,CHEMBL620233,,,,,1,1
4723,50594,,BAO_0000218,,,Metabolism of compound in Mouse S9 microsomes ('++++'indicates largest observed peak),,,N,Intermediate,A,10090.0,CHEMBL620234,,,,,1,1
4724,50594,,BAO_0000218,,,Metabolism of compound in mouse S9 microsomes ('+''indicates <20% largest observed peak),,,N,Intermediate,A,10090.0,CHEMBL620235,,,,,1,1
4725,50594,,BAO_0000218,,,Metabolism of compound in mouse S9 microsomes ('++++' indicates largest observed peak),,,N,Intermediate,A,10090.0,CHEMBL620236,,,,,1,1
4726,50594,,BAO_0000218,,,In vitro metabolic potential in mouse liver microsomes,,,N,Intermediate,A,10090.0,CHEMBL620237,,2107.0,Liver,,1,1
4727,50594,,BAO_0000218,,,Ability of compound to bind to plasma protein was evaluated in HSA cells,,,N,Intermediate,A,10090.0,CHEMBL620238,,,,,1,1
4728,50594,,BAO_0000218,,,Compound was tested for radioactivity level in mice adrenal glands (Compound is radiolabeled),,,N,Intermediate,A,10090.0,CHEMBL620239,,2369.0,Adrenal gland,,1,1
4729,50594,,BAO_0000218,,,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.2-4.9% ID/g,,,N,Intermediate,A,10090.0,CHEMBL620240,,955.0,Brain,,1,1
4730,50594,,BAO_0000218,,,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.6-4.4% ID/g,,,N,Intermediate,A,10090.0,CHEMBL620241,,955.0,Brain,,1,1
4731,50594,,BAO_0000218,,,Compound was tested for radioactivity level in mice heart (Compound is radiolabeled),,,N,Intermediate,A,10090.0,CHEMBL876727,,,,,1,1
4732,50594,,BAO_0000218,,,Compound was tested for radioactivity level in mice kidney (Compound is radiolabeled),,,N,Intermediate,A,10090.0,CHEMBL620242,,2113.0,Kidney,,1,1
4733,50594,,BAO_0000218,,,Compound was tested for radioactivity level in mice lungs (Compound is radiolabeled),,,N,Intermediate,A,10090.0,CHEMBL620243,,,,,1,1
4734,50594,,BAO_0000218,,,Tested for urinary recovery in mice after subcutaneous administration of 20 mg/Kg,,,N,Intermediate,A,10090.0,CHEMBL620244,,,,,1,1
4735,50594,,BAO_0000218,,,Compound was evaluated for its potency in CDF1 mice and the serum cholesterol levels were determined,,,N,Intermediate,A,10090.0,CHEMBL620245,,1977.0,Serum,,1,1
4736,50594,,BAO_0000218,,,Compound was evaluated for its potency in CDF1 mice and the serum metabolite levels were determined,,,N,Intermediate,A,10090.0,CHEMBL620246,,1977.0,Serum,,1,1
4737,50594,,BAO_0000218,,,Compound was evaluated for its potency in CDF1 mice and the serum triglyceride levels were determined,,,N,Intermediate,A,10090.0,CHEMBL620247,,1977.0,Serum,,1,1
4738,50594,In vivo,BAO_0000218,,,Half life of compound was determined in plasma of mice at 24 mg/Kg,,,N,Intermediate,A,10090.0,CHEMBL620248,,1969.0,Plasma,,1,1
4739,50594,In vivo,BAO_0000218,,,Half life of compound was determined in plasma of mice at 40 mg/Kg,,,N,Intermediate,A,10090.0,CHEMBL873497,,1969.0,Plasma,,1,1
4740,50594,In vivo,BAO_0000218,,,Half life of compound was determined in plasma of mice at 5 mg/Kg,,,N,Intermediate,A,10090.0,CHEMBL620249,,1969.0,Plasma,,1,1
4741,50594,In vivo,BAO_0000218,,,Half life after intraperitoneal administration in mice at 18 uM/kg,,,N,Intermediate,F,10090.0,CHEMBL620250,,,,,1,1
4742,50594,In vivo,BAO_0000218,,,Half life after intraperitoneal administration in mice at 23 uM/kg,,,N,Intermediate,F,10090.0,CHEMBL620251,,,,,1,1
4743,50594,In vivo,BAO_0000218,,,Half life after intraperitoneal administration in mice at 25 uM/kg,,,N,Intermediate,F,10090.0,CHEMBL620252,,,,,1,1
4744,50594,In vivo,BAO_0000218,,,Half life after intraperitoneal administration in mice at 26 uM/kg,,,N,Intermediate,F,10090.0,CHEMBL620253,,,,,1,1
4745,50594,In vivo,BAO_0000218,,,Half life after intravenous administration in mice at 23 uM/kg,,,N,Intermediate,F,10090.0,CHEMBL620254,,,,,1,1
4746,50594,In vivo,BAO_0000218,,,Half life after intravenous administration in mice at 24 uM/kg,,,N,Intermediate,A,10090.0,CHEMBL620255,,,,,1,1
4747,50594,In vivo,BAO_0000218,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,,,N,Intermediate,A,10090.0,CHEMBL620256,,,,,1,1
4748,50594,In vivo,BAO_0000218,,,Maximum time required to reach Cp max was evaluated in mice after intravenous administration; T max Not determined,,,N,Intermediate,A,10090.0,CHEMBL876728,,,,,1,1
4749,50594,In vivo,BAO_0000218,,,Maximum time required to reach Cp max was evaluated in mice after oral administration,,,N,Intermediate,A,10090.0,CHEMBL620257,,,,,1,1
4750,50594,In vivo,BAO_0000218,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),,,N,Intermediate,A,10090.0,CHEMBL620258,,,,,1,1
4751,50594,In vivo,BAO_0000218,,,"Compound was evaluated for the pharmacokinetic parameter, Terminal half life period",,,N,Intermediate,A,10090.0,CHEMBL620259,,,,,1,1
4752,50594,In vivo,BAO_0000218,,,Evaluated for pharmacokinetic parameter half-life in mouse at the dose 20 mg/kg,,,N,Intermediate,A,10090.0,CHEMBL620260,,,,,1,1
4753,50594,In vivo,BAO_0000218,,,Half life of compound in mouse blood following i.v. administration of 10 mg/kg,,,N,Intermediate,A,10090.0,CHEMBL620261,,178.0,Blood,,1,1
4754,50594,In vivo,BAO_0000218,,,Half life at a dose of 10 mg/kg intravenous administration in mice.,,,N,Intermediate,A,10090.0,CHEMBL620262,,,,,1,1
4755,50594,In vivo,BAO_0000218,,,Half life at a dose of 10 mg/kg peroral administration in mice.,,,N,Intermediate,A,10090.0,CHEMBL620263,,,,,1,1
4756,50594,,BAO_0000218,,,Half life in ob/ob mice,,,N,Intermediate,A,10090.0,CHEMBL620264,,,,,1,1
4757,50594,In vivo,BAO_0000218,,,Half-life at a single subcutaneous administration of 40 mg/kg in mice,,,N,Intermediate,A,10090.0,CHEMBL620265,,,,,1,1
4758,50594,,BAO_0000218,,,Half-life was measured in mouse,,,N,Intermediate,A,10090.0,CHEMBL620266,,,,,1,1
4759,50594,In vivo,BAO_0000218,,,In vivo half life period was determined in murine septicemia at dose of 50 mg/kg,,,N,Intermediate,A,10090.0,CHEMBL620267,,,,,1,1
4760,50594,,BAO_0000218,,,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation,,,N,Intermediate,A,10090.0,CHEMBL619364,,,,,1,1
4761,50594,,BAO_0000218,,,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation; 10 % hydrolysis at 60 mins,,,N,Intermediate,A,10090.0,CHEMBL619365,,,,,1,1
4762,50594,,BAO_0000218,,,T2 in brain of mice at the oral dose of 50 mg/kg,,,N,Intermediate,A,10090.0,CHEMBL619366,,955.0,Brain,,1,1
4763,50594,,BAO_0000218,,,T2 in kidney of mice at the oral dose of 50 mg/kg,,,N,Intermediate,A,10090.0,CHEMBL619367,,2113.0,Kidney,,1,1
4764,50594,,BAO_0000218,,,T2 in liver of mice at the oral dose of 50 mg/kg,,,N,Intermediate,A,10090.0,CHEMBL619368,,2107.0,Liver,,1,1
4765,50594,,BAO_0000218,,,T2 in lungs of mice at the oral dose of 50 mg/kg,,,N,Intermediate,A,10090.0,CHEMBL619369,,2048.0,Lung,,1,1
4766,50594,,BAO_0000218,,,T2 in spleen of mice at the oral dose of 50 mg/kg,,,N,Intermediate,A,10090.0,CHEMBL876729,,2106.0,Spleen,,1,1
4767,50594,In vivo,BAO_0000218,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,,,N,Intermediate,A,10090.0,CHEMBL619370,,,,,1,1
4768,50594,In vivo,BAO_0000218,,,"Compound was evaluated for the pharmacokinetic parameter, maximum time constant",,,N,Intermediate,A,10090.0,CHEMBL619371,,,,,1,1
4769,50594,In vivo,BAO_0000218,,,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg,,,N,Intermediate,A,10090.0,CHEMBL619372,,,,,1,1
4770,50594,In vivo,BAO_0000218,,,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg was determined,,,N,Intermediate,A,10090.0,CHEMBL620012,,,,,1,1
4771,50594,In vivo,BAO_0000218,,,In vivo Tmax was determined in murine septicemia at dose of 100 mg/kg,,,N,Intermediate,A,10090.0,CHEMBL620013,,,,,1,1
4772,81034,,BAO_0000219,478.0,A2780,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",,,N,Intermediate,F,9606.0,CHEMBL620014,,,,,1,1
4773,81034,,BAO_0000219,478.0,A2780,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",,,N,Intermediate,F,9606.0,CHEMBL620015,,,,,1,1
4774,81034,,BAO_0000219,478.0,A2780,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-sensitive A2780/S human tumor cell lines",,,N,Intermediate,F,9606.0,CHEMBL621010,,,,,1,1
4775,81034,,BAO_0000219,478.0,A2780,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-sensitive A2780/S human tumor cell lines",,,N,Intermediate,F,9606.0,CHEMBL621011,,,,,1,1
4776,81034,,BAO_0000219,478.0,A2780,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",,,N,Intermediate,F,9606.0,CHEMBL621012,,,,,1,1
4777,81034,,BAO_0000219,478.0,A2780,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",,,N,Intermediate,F,9606.0,CHEMBL621013,,,,,1,1
4778,81034,,BAO_0000219,478.0,A2780,In vitro cytotoxicity against A2780TAX cell line,,,N,Intermediate,F,9606.0,CHEMBL621014,,,,,1,1
4779,80017,,BAO_0000219,481.0,A2780cisR,In vitro inhibitory activity against human tumor cell line A2780cis,,,N,Intermediate,F,9606.0,CHEMBL618154,,,,,1,1
4780,81034,,BAO_0000219,478.0,A2780,Growth inhibition against A2780 cisplatin resistant wild-type ovarian cell lines,,,N,Expert,F,9606.0,CHEMBL618155,,,,,1,1
4781,80017,,BAO_0000219,481.0,A2780cisR,Antitumor activity of compound for 96-h exposure in A2780cisR (acquired resistance to cisplatin) human ovarian cell line,,,N,Intermediate,F,9606.0,CHEMBL618156,,,,,1,1
4782,80017,,BAO_0000219,481.0,A2780cisR,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),,,N,Intermediate,F,9606.0,CHEMBL618157,,,,,1,1
4783,81034,,BAO_0000219,478.0,A2780,Concentration required to inhibit A2780cisR cell growth when compared with control after incubation for 96 h at 37 C,,,N,Intermediate,F,9606.0,CHEMBL618328,,,,,1,1
4784,81034,,BAO_0000219,478.0,A2780,Compound was evaluated against human Ovarian carcinoma cell line A2780cisR,,,N,Intermediate,F,9606.0,CHEMBL618329,,,,,1,1
4785,81034,,BAO_0000219,478.0,A2780,Cytotoxicity against human ovarian carcinoma A2780cisR cell line,,,N,Intermediate,F,9606.0,CHEMBL618330,,,,,1,1
4786,81034,,BAO_0000219,478.0,A2780,In vitro antitumor activity against A2780cisR cell line.,,,N,Expert,F,9606.0,CHEMBL618331,,,,,1,1
4787,81034,,BAO_0000219,478.0,A2780,Tested for the cytotoxicity in A2780cisR ovarian cell line (cisR denotes resistance to cisplatin),,,N,Intermediate,F,9606.0,CHEMBL618332,,,,,1,1
4788,81034,,BAO_0000219,478.0,A2780,Resistant factor determined between IC50 of resistant line to that of A2780cisR cell line,,,N,Expert,F,9606.0,CHEMBL618333,,,,,1,1
4789,80017,,BAO_0000219,481.0,A2780cisR,cytotoxicity against A2780cisR cells incubated for 24 hr in MTT assay,,,N,Intermediate,F,9606.0,CHEMBL618334,,,,,1,1
4790,81034,,BAO_0000219,478.0,A2780,Inhibition of A2780 / DDP-S human ovarian carcinoma cell proliferation,,,N,Expert,F,9606.0,CHEMBL618335,,,,,1,1
4791,11736,,BAO_0000019,,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes,,,D,Expert,B,10116.0,CHEMBL618336,,,,,9,1
4792,11736,,BAO_0000019,,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),,,H,Expert,F,,CHEMBL618337,,,,,8,1
4793,11736,,BAO_0000019,,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),,,D,Expert,F,10116.0,CHEMBL618338,,,,,9,1
4794,278,,BAO_0000219,722.0,HEK293,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells uisng [3H]ZM-241385 or [125I]-IABOPX,,,D,Expert,F,9606.0,CHEMBL618339,,,,,9,1
4795,278,,BAO_0000219,722.0,HEK293,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells using [3H]ZM-241385 (or) [125 I]IABOPX at 10e-5 M,,,D,Expert,F,9606.0,CHEMBL618340,,,,,9,1
4796,11831,,BAO_0000019,,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes,,,D,Expert,B,10090.0,CHEMBL618341,,,,,9,1
4797,11831,,BAO_0000019,,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),,,H,Expert,F,,CHEMBL618342,,,,,8,1
4798,11831,,BAO_0000019,,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),,,D,Expert,F,10090.0,CHEMBL618343,,,,,9,1
4799,280,,BAO_0000357,,,Ability to displace the binding of [3H]-MRE 3008-F20 to the ligand binding site of CHO:hA3 (human Adenosine receptor) at concentration of 10 uM,,,H,Expert,B,,CHEMBL621038,,,,,8,1
4800,22226,,BAO_0000219,574.0,T-cells,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01),,,U,Autocuration,F,9606.0,CHEMBL621039,,,,,0,1
4801,22226,,BAO_0000219,574.0,T-cells,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01); Not active,,,U,Autocuration,F,9606.0,CHEMBL621040,,,,,0,1
4802,80018,,BAO_0000219,455.0,A-375,Compound was evaluated for cytotoxic activity against human melanoma cell line A375,,,N,Intermediate,F,9606.0,CHEMBL621041,,,,,1,1
4803,80018,,BAO_0000219,455.0,A-375,In vitro antitumor activity against A375 (melanoma) human tumor cell lines.,,,N,Intermediate,F,9606.0,CHEMBL621042,,,,,1,1
4804,80018,,BAO_0000219,455.0,A-375,In vitro antitumor activity against A375cell line extracted form melanoma,,,N,Intermediate,F,9606.0,CHEMBL621043,,,,,1,1
4805,80018,,BAO_0000219,455.0,A-375,Inhibition of cell growth in (A375) melan cell line,,,N,Expert,F,9606.0,CHEMBL621044,,,,,1,1
4806,80018,,BAO_0000219,455.0,A-375,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines A375,,,N,Intermediate,F,9606.0,CHEMBL621045,,,,,1,1
4807,80018,,BAO_0000219,455.0,A-375,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines. A375,,,N,Intermediate,F,9606.0,CHEMBL621046,,,,,1,1
4808,80018,,BAO_0000219,455.0,A-375,Compound was tested in vitro for cytotoxicity against A375 cell lines from melanoma.,,,N,Intermediate,F,9606.0,CHEMBL621047,,,,,1,1
4809,80019,,BAO_0000219,797.0,A-427,Antiproliferative activity measured against A427 human lung carcinoma,,,N,Intermediate,F,9606.0,CHEMBL621048,,,,,1,1
4810,80019,,BAO_0000219,797.0,A-427,Antiproliferative activity measured against A427 human lung carcinoma,,,N,Intermediate,F,9606.0,CHEMBL883798,,,,,1,1
4811,80019,,BAO_0000219,797.0,A-427,Cytotoxicity against lung carcinoma A427 tumor cell lines,,,N,Intermediate,F,9606.0,CHEMBL621049,,,,,1,1
4812,80019,,BAO_0000219,797.0,A-427,Inhibition of large cell lung carcinoma (A427),,,N,Intermediate,F,9606.0,CHEMBL621050,,,,,1,1
4813,80019,,BAO_0000219,797.0,A-427,Inhibition of large cell lung carcinoma (A427) after 48-h treatment,,,N,Intermediate,F,9606.0,CHEMBL621051,,,,,1,1
4814,80019,,BAO_0000219,797.0,A-427,Inhibitory activity against A427 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,,,N,Intermediate,F,9606.0,CHEMBL621052,,,,,1,1
4815,80019,,BAO_0000219,797.0,A-427,Inhibitory concentration in human lung carcinoma A427 cell line,,,N,Intermediate,F,9606.0,CHEMBL621053,,,,,1,1
4816,80019,,BAO_0000219,797.0,A-427,Inhibitory concentration in human lung carcinoma A427/VCR cell line,,,N,Intermediate,F,9606.0,CHEMBL621054,,,,,1,1
4817,22224,In vivo,BAO_0000218,,,Terminal phase volume of distribution was measured in monkey after an iv dose of 1 mg/kg,,,U,Autocuration,A,9527.0,CHEMBL621055,,,,,0,1
4818,22224,In vivo,BAO_0000218,,,Tested for volume of distribution upon iv administration to african green monkey,,,U,Autocuration,A,9527.0,CHEMBL876398,,,,,0,1
4819,22224,In vivo,BAO_0000218,,,Volume of distribution in monkey,,,U,Autocuration,A,9527.0,CHEMBL621056,,,,,0,1
4820,22224,In vivo,BAO_0000218,,,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,,,U,Autocuration,A,9544.0,CHEMBL621057,,,,,0,1
4821,22224,In vivo,BAO_0000218,,,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,,,U,Autocuration,A,9544.0,CHEMBL621058,,,,,0,1
4822,22224,In vivo,BAO_0000218,,,Pharmacokinetic property(Vdss) in cynomolgus monkey,,,U,Autocuration,A,9527.0,CHEMBL621059,,,,,0,1
4823,22224,In vivo,BAO_0000218,,,The distribution volume after intravenous administration in cynomolgus monkeys,,,U,Autocuration,A,9527.0,CHEMBL621060,,,,,0,1
4824,22224,In vivo,BAO_0000218,,,The distribution volume after oral administration in cynomolgus monkeys; NA means Not applicable,,,U,Autocuration,A,9527.0,CHEMBL621061,,,,,0,1
4825,22224,In vivo,BAO_0000218,,,The distribution volume after oral administration in cynomolgus monkeys; NA means not applicable,,,U,Autocuration,A,9527.0,CHEMBL621062,,,,,0,1
4826,22224,In vivo,BAO_0000218,,,Volume displacement was calculated in rhesus monkey,,,U,Autocuration,A,9527.0,CHEMBL621063,,,,,0,1
4827,22224,In vivo,BAO_0000218,,,Volume of distribution in steady state was determined in rhesus monkey,,,U,Autocuration,A,9527.0,CHEMBL621064,,,,,0,1
4828,22224,In vivo,BAO_0000218,,,Volume of distribution of compound was determined in monkey,,,U,Autocuration,A,9527.0,CHEMBL621065,,,,,0,1
4829,22224,In vivo,BAO_0000218,,,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),,,U,Autocuration,A,9527.0,CHEMBL621066,,,,,0,1
4830,22224,In vivo,BAO_0000218,,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),,,U,Autocuration,A,9527.0,CHEMBL621067,,,,,0,1
4831,22224,In vivo,BAO_0000218,,,Volumes of distribution in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,,U,Autocuration,A,9527.0,CHEMBL621068,,,,,0,1
4832,22224,In vivo,BAO_0000218,,,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,,U,Autocuration,A,9527.0,CHEMBL876399,,,,,0,1
4833,22224,In vivo,BAO_0000218,,,Volume distribution in monkey after administration of 1 mg/kg iv,,,U,Autocuration,A,9527.0,CHEMBL621069,,,,,0,1
4834,22224,In vivo,BAO_0000218,,,Volume distribution was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,,U,Autocuration,A,9527.0,CHEMBL621070,,,,,0,1
4835,22224,In vivo,BAO_0000218,,,Volume of distribution was measured in monkey after an iv dose of 1 mg/kg,,,U,Autocuration,A,9527.0,CHEMBL621071,,,,,0,1
4836,22224,In vivo,BAO_0000218,,,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,U,Autocuration,A,9527.0,CHEMBL621072,,,,,0,1
4837,22224,In vivo,BAO_0000218,,,Oral systemic bioavailability upon iv administration to african green monkey,,,U,Autocuration,A,9527.0,CHEMBL618209,,,,,0,1
4838,22224,In vivo,BAO_0000218,,,Plasma clearance was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,,U,Autocuration,A,9527.0,CHEMBL618210,,,,,0,1
4839,22224,,BAO_0000019,,,Baboon plasma free fraction. ,,,U,Autocuration,A,9527.0,CHEMBL618211,,,,,0,1
4840,22224,,BAO_0000218,,,Area under the curve was calculated in rhesus monkey after iv administration,,,U,Autocuration,A,9527.0,CHEMBL618212,,,,,0,1
4841,22224,,BAO_0000019,,,Area under the curve was calculated in rhesus monkey after peroral administration,,,U,Autocuration,A,9527.0,CHEMBL618213,,,,,0,1
4842,22224,,BAO_0000019,,,Dose-normalized area under curve in monkey (p.o.) at 2.0 mpk,,,U,Autocuration,A,9527.0,CHEMBL618214,,,,,0,1
4843,22224,In vivo,BAO_0000218,,,Half life period in monkey after 5 mg/kg dose,,,U,Autocuration,A,9527.0,CHEMBL873492,,,,,0,1
4844,22224,In vivo,BAO_0000218,,,Half-life was determined in monkey after 3 mg/kg of i.v. dose,,,U,Autocuration,A,9527.0,CHEMBL618272,,,,,0,1
4845,22224,In vivo,BAO_0000218,,,Half-life was determined in monkey after 3 mg/kg of i.v. dose; Not determined,,,U,Autocuration,A,9527.0,CHEMBL618273,,,,,0,1
4846,22224,In vivo,BAO_0000218,,,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,,,U,Autocuration,A,9527.0,CHEMBL618274,,1969.0,Plasma,,0,1
4847,22224,In vivo,BAO_0000218,,,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for half life after administration into monkey at 3 mg/kg,,,U,Autocuration,A,9527.0,CHEMBL618275,,,,,0,1
4848,22224,In vivo,BAO_0000218,,,Compound was evaluated for half-life after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,,U,Autocuration,A,9527.0,CHEMBL618276,,,,,0,1
4849,22224,,BAO_0000019,,,Compound was evaluated for terminal half life in monkey,,,U,Autocuration,A,9527.0,CHEMBL618277,,,,,0,1
4850,22224,In vivo,BAO_0000218,,,Compound was evaluated for the half life period after iv administration in cynomolgus monkey,,,U,Autocuration,A,9527.0,CHEMBL618278,,,,,0,1
4851,22224,In vivo,BAO_0000218,,,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,,,U,Autocuration,A,9544.0,CHEMBL618279,,1969.0,Plasma,,0,1
4852,22224,,BAO_0000019,,,Half life of compound was determined in squirrel monkey,,,U,Autocuration,A,9527.0,CHEMBL618280,,,,,0,1
4853,22224,In vivo,BAO_0000218,,,Half life after iv administration in cynomolgus monkey,,,U,Autocuration,A,9541.0,CHEMBL618281,,,,,0,1
4854,22224,In vivo,BAO_0000218,,,Half life in monkey plasma after administration of 1 mg/kg iv,,,U,Autocuration,A,9527.0,CHEMBL618282,,1969.0,Plasma,,0,1
4855,22224,,BAO_0000019,,,Half life was calculated in rhesus monkey,,,U,Autocuration,A,9527.0,CHEMBL618283,,,,,0,1
4856,22224,,BAO_0000019,,,Half life in monkey,,,U,Autocuration,A,9527.0,CHEMBL618284,,,,,0,1
4857,22224,In vivo,BAO_0000218,,,Half life in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,,U,Autocuration,A,9527.0,CHEMBL618285,,,,,0,1
4858,22224,,BAO_0000019,,,Half life was evaluated in rhesus,,,U,Autocuration,A,9527.0,CHEMBL618286,,,,,0,1
4859,22224,In vivo,BAO_0000218,,,Half life period after oral administration (2.5 mg/kg) in monkey was determined,,,U,Autocuration,A,9527.0,CHEMBL618287,,,,,0,1
4860,22224,In vivo,BAO_0000218,,,Half life period was determine after peroral administration at 10 mpk in Rhesus,,,U,Autocuration,A,9527.0,CHEMBL618288,,,,,0,1
4861,22224,In vivo,BAO_0000218,,,Half life period was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,,U,Autocuration,A,9527.0,CHEMBL876393,,,,,0,1
4862,22224,In vivo,BAO_0000218,,,Half life period was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,,,U,Autocuration,A,9527.0,CHEMBL618289,,,,,0,1
4863,22224,In vivo,BAO_0000218,,,Half life period was determined in squirrel monkey after iv administration at a dose of 5 mg/kg,,,U,Autocuration,A,9527.0,CHEMBL618290,,,,,0,1
4864,22224,,BAO_0000019,,,Half-life was calculated in monkey,,,U,Autocuration,A,9527.0,CHEMBL618291,,,,,0,1
4865,22224,,BAO_0000019,,,Half-life in Squirrel monkey,,,U,Autocuration,A,9527.0,CHEMBL618292,,,,,0,1
4866,22224,,BAO_0000019,,,Half-life in rhesus monkey,,,U,Autocuration,A,9527.0,CHEMBL618293,,,,,0,1
4867,22224,In vivo,BAO_0000218,,,Half-life was measured in monkey after an iv dose of 1 mg/kg,,,U,Autocuration,A,9527.0,CHEMBL618294,,,,,0,1
4868,22224,In vivo,BAO_0000218,,,Half-life period after intravenous administration in cynomolgus monkeys,,,U,Autocuration,A,9527.0,CHEMBL618295,,,,,0,1
4869,22224,In vivo,BAO_0000218,,,Half-life period after oral administration in cynomolgus monkeys,,,U,Autocuration,A,9527.0,CHEMBL618296,,,,,0,1
4870,22224,In vivo,BAO_0000218,,,Half-life period after oral administration in cynomolgus monkeys; ND meansn Not determined,,,U,Autocuration,A,9527.0,CHEMBL618297,,,,,0,1
4871,22224,,BAO_0000019,,,Portion of holoxan excreted in the form of the metabolite from 1500 mL of urine on day 9 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,,U,Autocuration,A,9606.0,CHEMBL618298,,1088.0,Urine,,0,1
4872,22224,,BAO_0000019,,,Portion of holoxan excreted in the form of the metabolite from 1600 mL of urine on day 10 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,,U,Autocuration,A,9606.0,CHEMBL618299,,1088.0,Urine,,0,1
4873,22224,,BAO_0000019,,,Portion of holoxan excreted in the form of the metabolite from 1700 mL of urine on day 5 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,,U,Autocuration,A,9606.0,CHEMBL618300,,1088.0,Urine,,0,1
4874,22224,,BAO_0000019,,,Portion of holoxan excreted in the form of the metabolite from 2310 mL of urine on day 4 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,,U,Autocuration,A,9606.0,CHEMBL618301,,1088.0,Urine,,0,1
4875,22224,,BAO_0000019,,,Percent ratio of the enantiomeric form (+)R extracted from the urine of alveolar rhabdomyosarcoma patients was determined,,,U,Autocuration,A,9606.0,CHEMBL618302,,1088.0,Urine,,0,1
4876,22224,,BAO_0000019,,,Percent ratio of the enantiomeric form (+)R extracted from the urine of embryonal rhabdomyosarcoma patients was determined,,,U,Autocuration,A,9606.0,CHEMBL876394,,1088.0,Urine,,0,1
4877,22224,,BAO_0000019,,,Percent ratio of the enantiomeric form (-)S extracted from the urine of alveolar rhabdomyosarcoma patients was determined,,,U,Autocuration,A,9606.0,CHEMBL618303,,1088.0,Urine,,0,1
4878,22224,,BAO_0000019,,,Percent ratio of the enantiomeric form (-)S extracted from the urine of embryonal rhabdomyosarcoma patients was determined,,,U,Autocuration,A,9606.0,CHEMBL618304,,1088.0,Urine,,0,1
4879,22224,In vivo,BAO_0000218,,,Bioavailability was evaluated in man at a dose of 10 mg/kg after po administration; not determined,,,U,Autocuration,A,9606.0,CHEMBL618305,,,,,0,1
4880,22224,In vivo,BAO_0000218,,,Oral bioavailability in human,,,U,Autocuration,A,9606.0,CHEMBL618306,,,,,0,1
4881,22224,,BAO_0000019,,,Compound was tested for human plasma protein binding,,,U,Autocuration,A,9606.0,CHEMBL618307,,,,,0,1
4882,22224,,BAO_0000019,,,Compound was tested for human plasma protein binding; Not determined,,,U,Autocuration,A,9606.0,CHEMBL618308,,,,,0,1
4883,22224,,BAO_0000019,,,Protein binding activity of compound in human plasma; % Free,,,U,Autocuration,A,9606.0,CHEMBL618309,,,,,0,1
4884,22224,,BAO_0000019,,,Unbound fraction (plasma),,,U,Autocuration,A,9606.0,CHEMBL618310,,,,,0,1
4885,22224,,BAO_0000366,,,Half life for the hydrolysis of compound in human blood serum,,,U,Autocuration,A,9606.0,CHEMBL873353,,1969.0,Plasma,,0,1
4886,22224,,BAO_0000366,,,Half life period in human plasma using phosphate buffer (0.08 M),,,U,Autocuration,A,9606.0,CHEMBL618311,,1969.0,Plasma,,0,1
4887,22224,,BAO_0000366,,,Half life period in human plasma using phosphate buffer (0.1 M),,,U,Autocuration,A,9606.0,CHEMBL618312,,1969.0,Plasma,,0,1
4888,22224,,BAO_0000366,,,Half-life in human plasma was determined,,,U,Autocuration,A,9606.0,CHEMBL618313,,1969.0,Plasma,,0,1
4889,22224,,BAO_0000019,,,Concentration required for 50% toxicity in metastatic lung carcinoma (MV522) cells.,,,U,Autocuration,A,9606.0,CHEMBL618314,,,,,0,1
4890,22224,,BAO_0000019,,,Effect of compound on gelation time of human serum induced by dithiothreitol (DTT),,,U,Autocuration,A,9606.0,CHEMBL618315,,,,,0,1
4891,22224,,BAO_0000019,,,"Rate constant in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",,,U,Autocuration,A,9606.0,CHEMBL618316,,,,,0,1
4892,22224,,BAO_0000019,,,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",,,U,Autocuration,A,9606.0,CHEMBL618317,,,,,0,1
4893,22224,,BAO_0000019,,,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",,,U,Autocuration,A,9606.0,CHEMBL620138,,,,,0,1
4894,22224,,BAO_0000019,,,Partition coefficient (logP),,,U,Autocuration,A,9606.0,CHEMBL858280,,,,,0,1
4895,22224,,BAO_0000019,,,In vitro metabolic stability in human was measured as pmol/min/mg/protein,,,U,Autocuration,A,9606.0,CHEMBL620139,,,,,0,1
4896,22224,,BAO_0000251,,,In vitro metabolic stability determined after 30 min of incubation in human hepatic microsomes,,,U,Autocuration,A,9606.0,CHEMBL620140,,,,Microsomes,0,1
4897,22224,,BAO_0000019,,,Metabolism of compound in human liver slices (male) ('+''indicates <20% largest observed peak),,,U,Autocuration,A,9606.0,CHEMBL620141,,,,,0,1
4898,22224,,BAO_0000019,,,Metabolism of compound in human liver slices (male) ('++''indicates 20-50% largest observed peak),,,U,Autocuration,A,9606.0,CHEMBL620142,,,,,0,1
4899,22224,,BAO_0000019,,,Metabolism of compound in human liver slices (male) ('++++' indicates largest observed peak),,,U,Autocuration,A,9606.0,CHEMBL620143,,,,,0,1
4900,22224,,BAO_0000251,,,Metabolism of compound in human microsomes ('+''indicates <20% largest observed peak),,,U,Autocuration,A,9606.0,CHEMBL620144,,,,Microsomes,0,1
4901,22224,,BAO_0000251,,,Metabolism of compound in human microsomes ('++++' indicates largest observed peak),,,U,Autocuration,A,9606.0,CHEMBL620145,,,,Microsomes,0,1
4902,22224,,BAO_0000251,,,Metabolism of compound in human microsomes; Trace,,,U,Autocuration,A,9606.0,CHEMBL620146,,,,Microsomes,0,1
4903,22224,,BAO_0000251,,,Percent of compound remaining after 120 min of Metabolization upon incubation with human liver microsomes,,,U,Autocuration,A,9606.0,CHEMBL620147,,2107.0,Liver,Microsomes,0,1
4904,22224,,BAO_0000251,,,Percent metabolized in an in vitro human liver microsomal incubation assay after 60 min,,,U,Autocuration,A,9606.0,CHEMBL620148,,,,Microsomes,0,1
4905,22224,,BAO_0000251,,,In vitro metabolic potential in human liver microsomes,,,U,Autocuration,A,9606.0,CHEMBL620149,,2107.0,Liver,Microsomes,0,1
4906,22224,,BAO_0000019,,,Metabolism by recombinant human NAD(P)H:quinone oxidoreductase (NQO1) was evaluated,,,U,Autocuration,A,9606.0,CHEMBL876412,,,,,0,1
4907,22224,,BAO_0000019,,,Tested for human plasma protein binding of the compound; Not tested,,,U,Autocuration,A,9606.0,CHEMBL619352,,,,,0,1
4908,22224,,BAO_0000019,,,Compound was tested for percent protein binding (PB) in human,,,U,Autocuration,A,9606.0,CHEMBL619353,,,,,0,1
4909,22224,,BAO_0000019,,,Protein binding in human plasma,,,U,Autocuration,A,9606.0,CHEMBL619354,,1969.0,Plasma,,0,1
4910,22224,,BAO_0000019,,,Permeability coefficient (B to A) in Caco-2 cell,,,U,Autocuration,A,9606.0,CHEMBL619355,,,,,0,1
4911,22224,,BAO_0000019,,,Permeability directional ratio (PB-A/PA-B) in Caco-2 cell,,,U,Autocuration,A,9606.0,CHEMBL619356,,,,,0,1
4912,22224,,BAO_0000019,,,Apparent permeability coefficient (Papp) was determined in human Caco-2 cell monolayer (n = 3),,,U,Autocuration,A,9606.0,CHEMBL619357,,,,,0,1
4913,22224,,BAO_0000019,,,In vitro rate of absorption observed as Caco-2 permeability in humans,,,U,Autocuration,A,9606.0,CHEMBL619358,,,,,0,1
4914,22224,,BAO_0000219,495.0,Caco-2,Cellular permeability of compound was determined in Caco-2 cells; High,,,U,Autocuration,A,9606.0,CHEMBL619359,,,,,0,1
4915,22224,,BAO_0000219,495.0,Caco-2,Permeability in Caco-2 cells of compound,,,U,Autocuration,A,9606.0,CHEMBL619360,,,,,0,1
4916,22224,,BAO_0000019,,,Permeability coefficient (A to B) in Caco-2 cell,,,U,Autocuration,A,9606.0,CHEMBL619361,,,,,0,1
4917,22224,,BAO_0000019,,,Permeability coefficient (B to A) in Caco-2 cell,,,U,Autocuration,A,9606.0,CHEMBL619362,,,,,0,1
4918,22224,,BAO_0000019,,,Permeability coefficient (Papp) (Caco-2 cell monolayer),,,U,Autocuration,A,9606.0,CHEMBL619363,,,,,0,1
4919,22224,,BAO_0000019,,,Compound was measured for binding rate for human serum at a carbapenem concentration of 10 ug/mL,,,U,Autocuration,A,9606.0,CHEMBL618942,,,,,0,1
4920,22224,,BAO_0000019,,,Compound was tested for protein binding in human plasma,,,U,Autocuration,A,9606.0,CHEMBL618943,,,,,0,1
4921,22224,,BAO_0000019,,,Transcellular permeability of the [(PA-B+PB-A)/2)] compound was determined in Caco-2 cell,,,U,Autocuration,A,9606.0,CHEMBL618944,,,,,0,1
4922,22224,,BAO_0000019,,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 3,,,U,Autocuration,A,9606.0,CHEMBL618945,,1088.0,Urine,,0,1
4923,50594,In vivo,BAO_0000218,,,In vivo Tmax was determined in murine septicemia at dose of 50 mg/kg,,,N,Intermediate,A,10090.0,CHEMBL618946,,,,,1,1
4924,50594,In vivo,BAO_0000218,,,Maximum time was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),,,N,Intermediate,A,10090.0,CHEMBL876413,,,,,1,1
4925,50594,In vivo,BAO_0000218,,,Tested for Tmax value at the dose of 10 mg/kg when administered perorally in mouse,,,N,Intermediate,A,10090.0,CHEMBL618947,,,,,1,1
4926,50594,In vivo,BAO_0000218,,,Time taken to reach maximum concentration in plasma upon oral administration in mouse,,,N,Intermediate,A,10090.0,CHEMBL618948,,1969.0,Plasma,,1,1
4927,50594,In vivo,BAO_0000218,,,Time to reach maximum plasma concentration was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,,N,Intermediate,A,10090.0,CHEMBL618949,,1969.0,Plasma,,1,1
4928,50594,In vivo,BAO_0000218,,,Tmax after intraperitoneal administration in mice at 23 uM/kg,,,N,Intermediate,F,10090.0,CHEMBL618950,,,,,1,1
4929,50594,In vivo,BAO_0000218,,,Tmax after oral administration at 30 mg/kg in ICR mouse,,,N,Intermediate,A,10090.0,CHEMBL618951,,,,,1,1
4930,50594,In vivo,BAO_0000218,,,Tmax after peroral administration in mice at 2.4 uM/kg,,,N,Intermediate,A,10090.0,CHEMBL618952,,,,,1,1
4931,50594,In vivo,BAO_0000218,,,Tmax at a single subcutaneous administration of 40 mg/kg in mice,,,N,Intermediate,A,10090.0,CHEMBL618953,,,,,1,1
4932,50594,In vivo,BAO_0000218,,,Tmax in brain of mice at the oral dose of 50 mg/kg,,,N,Intermediate,A,10090.0,CHEMBL618954,,955.0,Brain,,1,1
4933,50594,In vivo,BAO_0000218,,,Tmax in kidney of mice at the oral dose of 50 mg/kg,,,N,Intermediate,A,10090.0,CHEMBL618955,,2113.0,Kidney,,1,1
4934,50594,In vivo,BAO_0000218,,,Tmax in liver of mice at the oral dose of 50 mg/kg,,,N,Intermediate,A,10090.0,CHEMBL618956,,2107.0,Liver,,1,1
4935,50594,In vivo,BAO_0000218,,,Tmax in lungs of mice at the oral dose of 50 mg/kg,,,N,Intermediate,A,10090.0,CHEMBL618957,,2048.0,Lung,,1,1
4936,50594,In vivo,BAO_0000218,,,Tmax in mice at 18 uM/kg i.p. administration,,,N,Intermediate,F,10090.0,CHEMBL618958,,,,,1,1
4937,50594,In vivo,BAO_0000218,,,Tmax in mice at 23 uM/kg i.v. administration,,,N,Intermediate,F,10090.0,CHEMBL618959,,,,,1,1
4938,50594,In vivo,BAO_0000218,,,Tmax in mice at 25 uM/kg i.p. administration,,,N,Intermediate,F,10090.0,CHEMBL618960,,,,,1,1
4939,50594,In vivo,BAO_0000218,,,Tmax in mice at 26 uM/kg i.p. administration,,,N,Intermediate,F,10090.0,CHEMBL876723,,,,,1,1
4940,50594,In vivo,BAO_0000218,,,Tmax in spleen of mice at the oral dose of 50 mg/kg,,,N,Intermediate,A,10090.0,CHEMBL618961,,2106.0,Spleen,,1,1
4941,50594,In vivo,BAO_0000218,,,Tmax value at a dose of 10 mg/kg intravenous administration in mice.,,,N,Intermediate,A,10090.0,CHEMBL618962,,,,,1,1
4942,50594,In vivo,BAO_0000218,,,Tmax value at a dose of 10 mg/kg peroral administration in mice.,,,N,Intermediate,A,10090.0,CHEMBL618963,,,,,1,1
4943,50594,,BAO_0000218,,,Tmax value in IRC mice,,,N,Intermediate,A,10090.0,CHEMBL618964,,,,,1,1
4944,50594,In vivo,BAO_0000218,,,Tmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,,,N,Intermediate,A,10090.0,CHEMBL618965,,,,,1,1
4945,50594,In vivo,BAO_0000218,,,Tmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,,,N,Intermediate,A,10090.0,CHEMBL618966,,,,,1,1
4946,50594,,BAO_0000218,,,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg ( 0-24 hr ),,,N,Intermediate,A,10090.0,CHEMBL618967,,1088.0,Urine,,1,1
4947,50594,,BAO_0000218,,,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg (0-24 hr),,,N,Intermediate,A,10090.0,CHEMBL618968,,1088.0,Urine,,1,1
4948,50594,,BAO_0000218,,,Urinary recovery by disk method using Streptococcus pyogenes (0-24 h),,,N,Intermediate,A,10090.0,CHEMBL618969,,1088.0,Urine,,1,1
4949,50594,,BAO_0000218,,,The first compartment constitutes the majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,,,N,Intermediate,A,10090.0,CHEMBL618970,,,,,1,1
4950,50594,,BAO_0000218,,,The second majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,,,N,Intermediate,A,10090.0,CHEMBL618971,,,,,1,1
4951,50594,In vivo,BAO_0000218,,,Terminal phase volume of distribution was measured in mouse after an iv dose of 1 mg/kg,,,N,Intermediate,A,10090.0,CHEMBL618972,,,,,1,1
4952,50594,In vivo,BAO_0000218,,,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 100 mg/kg,,,N,Intermediate,A,10090.0,CHEMBL618973,,,,,1,1
4953,50594,In vivo,BAO_0000218,,,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg,,,N,Intermediate,A,10090.0,CHEMBL618974,,,,,1,1
4954,50594,In vivo,BAO_0000218,,,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,,,N,Intermediate,A,10090.0,CHEMBL618975,,,,,1,1
4955,50594,In vivo,BAO_0000218,,,Vd in mice,,,N,Intermediate,A,10090.0,CHEMBL618976,,,,,1,1
4956,50594,In vivo,BAO_0000218,,,Volume of distribution in mouse,,,N,Intermediate,A,10090.0,CHEMBL618977,,,,,1,1
4957,50594,In vivo,BAO_0000218,,,Volume of distribution was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,,N,Intermediate,A,10090.0,CHEMBL876724,,,,,1,1
4958,50594,In vivo,BAO_0000218,,,Volume of distribution of compound in plasma was determined at 24 mg/Kg,,,N,Intermediate,A,10090.0,CHEMBL618978,,,,,1,1
4959,50594,In vivo,BAO_0000218,,,Volume of distribution of compound in plasma was determined at 40 mg/Kg,,,N,Intermediate,A,10090.0,CHEMBL618979,,,,,1,1
4960,50594,In vivo,BAO_0000218,,,Volume of distribution of compound in plasma was determined at 5 mg/Kg,,,N,Intermediate,A,10090.0,CHEMBL618980,,,,,1,1
4961,50594,In vivo,BAO_0000218,,,Pharmacokinetic property (vdss) was measured in mouse,,,N,Intermediate,A,10090.0,CHEMBL618981,,,,,1,1
4962,50594,In vivo,BAO_0000218,,,Value distribution upon iv administration in mouse,,,N,Intermediate,A,10090.0,CHEMBL618982,,,,,1,1
4963,50594,In vivo,BAO_0000218,,,Volume of distribution after intraperitoneal administration of 100 mg/kg in mice,,,N,Intermediate,A,10090.0,CHEMBL620150,,,,,1,1
4964,50594,In vivo,BAO_0000218,,,Volume of distribution was evaluated in mice after intravenous administration,,,N,Intermediate,A,10090.0,CHEMBL620151,,,,,1,1
4965,50594,In vivo,BAO_0000218,,,Volume of distribution was evaluated in mice after oral administration,,,N,Intermediate,A,10090.0,CHEMBL620152,,,,,1,1
4966,50594,In vivo,BAO_0000218,,,Steady state volume of distribution of compound in mouse blood following i.v. administration of 10 mg/kg,,,N,Intermediate,A,10090.0,CHEMBL620153,,,,,1,1
4967,50594,In vivo,BAO_0000218,,,Steady state volume of distribution was determined in mice,,,N,Intermediate,A,10090.0,CHEMBL876395,,,,,1,1
4968,50594,In vivo,BAO_0000218,,,Volume distribution (steady state) of compound was determined in mouse,,,N,Intermediate,A,10090.0,CHEMBL620154,,,,,1,1
4969,50594,In vivo,BAO_0000218,,,Volume of solubility in solution after intravenous administration in mice at 24 uM/kg,,,N,Intermediate,A,10090.0,CHEMBL620155,,,,,1,1
4970,50594,In vivo,BAO_0000218,,,Vss value at a dose of 10 mg/kg intravenous administration in mice.,,,N,Intermediate,A,10090.0,CHEMBL620156,,,,,1,1
4971,50594,In vivo,BAO_0000218,,,Volume of distribution was measured in mouse after an iv dose of 1 mg/kg,,,N,Intermediate,A,10090.0,CHEMBL620157,,,,,1,1
4972,50594,In vivo,BAO_0000218,,,Biodistribution of compound (oxidized form) in in kidney tissue,,,N,Intermediate,A,10090.0,CHEMBL620158,,2113.0,Kidney,,1,1
4973,50594,In vivo,BAO_0000218,,,Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip administration in DMSO solution,,,N,Intermediate,A,10090.0,CHEMBL620159,,178.0,Blood,,1,1
4974,50594,In vivo,BAO_0000218,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",,,N,Intermediate,A,10090.0,CHEMBL620160,,178.0,Blood,,1,1
4975,50594,In vivo,BAO_0000218,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,,N,Intermediate,A,10090.0,CHEMBL620161,,178.0,Blood,,1,1
4976,80019,,BAO_0000219,797.0,A-427,Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay,,,N,Intermediate,F,9606.0,CHEMBL620162,,,,,1,1
4977,80852,,BAO_0000219,500.0,A-431,Inhibition of A431 human squamous cell carcinoma cell proliferation,,,N,Expert,F,9606.0,CHEMBL620163,,,,,1,1
4978,80852,,BAO_0000219,500.0,A-431,Inhibition of cell growth of human epidermoid carcinoma xenograft (A431) model using cell based assay,,,N,Expert,F,9606.0,CHEMBL620833,,,,,1,1
4979,80852,,BAO_0000219,500.0,A-431,Inhibition of human epidermoid carcinoma xenograft (A431) tumor growth,,,N,Expert,F,9606.0,CHEMBL876396,,,,,1,1
4980,80852,,BAO_0000219,500.0,A-431,Concentration required to inhibit growth of human carcinoma epidermoid (A431) cell line,,,N,Expert,F,9606.0,CHEMBL620834,,,,,1,1
4981,80852,,BAO_0000219,500.0,A-431,Inhibition of A431 human carcinoma cell proliferation,,,N,Expert,F,9606.0,CHEMBL620835,,,,,1,1
4982,80852,,BAO_0000219,500.0,A-431,In vitro inhibition of A431 (human carcinoma) cell basal growth.,,,N,Expert,F,9606.0,CHEMBL620836,,,,,1,1
4983,80852,,BAO_0000219,500.0,A-431,Inhibitory concentration of compound against growth of human A431 cell line; Resistant,,,N,Intermediate,F,9606.0,CHEMBL620837,,,,,1,1
4984,80852,,BAO_0000219,500.0,A-431,In vitro cytotoxicity against epidermoid carcinoma cell line,,,N,Intermediate,F,9606.0,CHEMBL621017,,,,,1,1
4985,9,,BAO_0000218,500.0,A-431,"In vivo efficacy following oral administration in nude mouse tumor model, xenograft A431 cells expressing EGF-R",,,D,Expert,F,9606.0,CHEMBL621018,,,,,9,1
4986,80852,,BAO_0000219,500.0,A-431,Antiproliferative activity of compound was measured on human tumor cell line A431.,,,N,Intermediate,F,9606.0,CHEMBL621019,,,,,1,1
4987,80852,,BAO_0000219,500.0,A-431,Antiproliferative effect of compound on A431 cell line expressing mutant p53,,,N,Intermediate,F,9606.0,CHEMBL621020,,,,,1,1
4988,80852,,BAO_0000219,500.0,A-431,Compound was evaluated for cell growth inhibition against A 431 cell line by irradiation in the presence of examined compound,,,N,Intermediate,F,9606.0,CHEMBL621021,,,,,1,1
4989,9,,BAO_0000219,500.0,A-431,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,,,H,Expert,F,,CHEMBL621022,,,,,8,1
4990,80852,,BAO_0000219,500.0,A-431,Tested for antiproliferative activity against human A431 cells,,,N,Expert,F,9606.0,CHEMBL621023,,,,,1,1
4991,9,,BAO_0000219,500.0,A-431,Inhibition of epidermal growth factor receptor (EGF-R) autophosphorylation in A431 cells,,,D,Expert,F,9606.0,CHEMBL621024,,,,,9,1
4992,80852,,BAO_0000219,500.0,A-431,Concentration needed to inhibit 50% growth of the human A431 (epidermoid carcinoma) cell lines,,,N,Expert,F,9606.0,CHEMBL621025,,,,,1,1
4993,80852,,BAO_0000219,500.0,A-431,Inhibition of A431 cell proliferation,,,N,Expert,F,9606.0,CHEMBL621026,,,,,1,1
4994,80852,,BAO_0000219,500.0,A-431,Cytotoxic effect on A431 human epidermoid carcinoma cells,,,N,Expert,F,9606.0,CHEMBL621027,,,,,1,1
4995,80852,,BAO_0000219,500.0,A-431,Cytotoxic effect on A431 human epidermoid carcinoma cells (No response to 1 mM),,,N,Expert,F,9606.0,CHEMBL876397,,,,,1,1
4996,80852,,BAO_0000219,500.0,A-431,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line,,,N,Intermediate,F,9606.0,CHEMBL883797,,,,,1,1
4997,80852,,BAO_0000219,500.0,A-431,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line; NT=Not tested,,,N,Intermediate,F,9606.0,CHEMBL621028,,,,,1,1
4998,80852,,BAO_0000219,500.0,A-431,In vitro Growth Inhibitory activity against A431 Human vulva cancer cell line,,,N,Intermediate,F,9606.0,CHEMBL621029,,,,,1,1
4999,80852,,BAO_0000219,500.0,A-431,In vitro cytotoxicity of compound against human A431 (epidermoid) cancer cell line after 72 hr of drug exposure,,,N,Intermediate,F,9606.0,CHEMBL621030,,,,,1,1
5000,9,,BAO_0000219,500.0,A-431,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells expressing EGF-R,,,H,Expert,F,,CHEMBL621147,,,,,8,1
5001,80852,,BAO_0000218,500.0,A-431,In vivo antiproliferative activity against A431 cell line,,,N,Intermediate,F,9606.0,CHEMBL621148,,,,,1,1
5002,9,,BAO_0000219,500.0,A-431,Inhibition of EGF-dependent autophosphorylation of EGF-R in human A431 cells,,,D,Expert,F,9606.0,CHEMBL621149,,,,,9,1
5003,80852,,BAO_0000219,500.0,A-431,Inhibition of A431 human epidermoid carcinoma cell proliferation,,,N,Expert,F,9606.0,CHEMBL621150,,,,,1,1
5004,9,,BAO_0000219,500.0,A-431,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells,,,D,Expert,F,9606.0,CHEMBL621151,,,,,9,1
5005,80852,,BAO_0000219,500.0,A-431,Inhibitory effect on nonphospho-Src after EGF (100 uM) stimulation of A431 cells (control=178),,,N,Intermediate,F,9606.0,CHEMBL621152,,,,,1,1
5006,80852,,BAO_0000219,500.0,A-431,Inhibitory effect on phospho-Src (Tyr416) after EGF (100 uM) stimulation of A431 cells (38),,,N,Intermediate,F,9606.0,CHEMBL621153,,,,,1,1
5007,80852,,BAO_0000219,500.0,A-431,Inhibitory effect on phospho-Src/nonphospho after EGF (100 uM) stimulation of A431 cells (21),,,N,Intermediate,F,9606.0,CHEMBL884000,,,,,1,1
5008,9,,BAO_0000019,,,Inhibition of EGFR overexpressing A431 cell proliferation,,,D,Expert,F,9606.0,CHEMBL621154,,,,,9,1
5009,80852,,BAO_0000219,500.0,A-431,Inhibition of A431 cell proliferation,,,N,Expert,F,9606.0,CHEMBL621155,,,,,1,1
5010,9,,BAO_0000219,500.0,A-431,No inhibition of EGFR phosphorylation in A431 cells 8 hour after washing cells free of the inhibitor,,,D,Expert,F,9606.0,CHEMBL621156,,,,,9,1
5011,9,,BAO_0000219,500.0,A-431,"Partial inhibition of EGFR phosphorylation in A431 cells, 8 hour after washing cells free of the inhibitor",,,D,Expert,F,9606.0,CHEMBL621157,,,,,9,1
5012,9,,BAO_0000219,500.0,A-431,Irreversible inhibition of ATP binding site of EGFR (lack of phosphorylated EGFR) in A431 cells 8 hour after washing cells free of the inhibitor),,,H,Expert,F,,CHEMBL621158,,,,,8,1
5013,80852,,BAO_0000219,500.0,A-431,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,,,N,Intermediate,F,9606.0,CHEMBL621159,,,,,1,1
5014,80852,,BAO_0000219,500.0,A-431,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,,,N,Intermediate,F,9606.0,CHEMBL621160,,,,,1,1
5015,80852,,BAO_0000219,500.0,A-431,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration at 2 uM after 48 h; Did not affect the viability,,,N,Intermediate,F,9606.0,CHEMBL621161,,,,,1,1
5016,80852,,BAO_0000219,500.0,A-431,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration in the range of 1-10 uM after 48 h; Did not affect the viability,,,N,Intermediate,F,9606.0,CHEMBL621162,,,,,1,1
5017,80852,,BAO_0000219,500.0,A-431,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,,,N,Intermediate,F,9606.0,CHEMBL621163,,,,,1,1
5018,80852,,BAO_0000219,500.0,A-431,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 0.01 uM after 48 h; Cell death,,,N,Intermediate,F,9606.0,CHEMBL621164,,,,,1,1
5019,80852,,BAO_0000219,500.0,A-431,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 2 uM after 48 h; Cell death,,,N,Intermediate,F,9606.0,CHEMBL621165,,,,,1,1
5020,22224,,BAO_0000019,,,Half-life period in cynomolgus monkey,,,U,Autocuration,A,9527.0,CHEMBL619159,,,,,0,1
5021,22224,In vitro,BAO_0000366,,,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in monkey plasma",,,U,Autocuration,A,9527.0,CHEMBL619160,,1969.0,Plasma,,0,1
5022,22224,In vivo,BAO_0000218,,,Longer half-life in monkey (i.v.) at 0.5 mpk,,,U,Autocuration,A,9527.0,CHEMBL619161,,,,,0,1
5023,22224,,BAO_0000366,,,Plasma half life in monkey,,,U,Autocuration,A,9527.0,CHEMBL619162,,1969.0,Plasma,,0,1
5024,22224,,BAO_0000366,,,Plasma half-life in rhesus monkey,,,U,Autocuration,A,9527.0,CHEMBL619163,,1969.0,Plasma,,0,1
5025,22224,In vivo,BAO_0000218,,,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),,,U,Autocuration,A,9527.0,CHEMBL619164,,1969.0,Plasma,,0,1
5026,22224,In vivo,BAO_0000218,,,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),,,U,Autocuration,A,9527.0,CHEMBL619320,,1969.0,Plasma,,0,1
5027,22224,In vivo,BAO_0000218,,,Tested for half life upon iv administration to african green monkey,,,U,Autocuration,A,9527.0,CHEMBL619321,,,,,0,1
5028,22224,In vivo,BAO_0000218,,,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,,U,Autocuration,A,9527.0,CHEMBL873336,,,,,0,1
5029,22224,In vivo,BAO_0000218,,,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means Not applicable,,,U,Autocuration,A,9527.0,CHEMBL619322,,,,,0,1
5030,22224,In vivo,BAO_0000218,,,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means not applicable,,,U,Autocuration,A,9527.0,CHEMBL619323,,,,,0,1
5031,22224,In vivo,BAO_0000218,,,The time for peak concentration value after oral administration in cynomolgus monkeys,,,U,Autocuration,A,9527.0,CHEMBL619324,,,,,0,1
5032,22224,,BAO_0000019,,,Percentage of tracer or metabolite (CO2) in baboon plasma at 10 min after injection of the compound,,,U,Autocuration,A,9527.0,CHEMBL619325,,,,,0,1
5033,22224,,BAO_0000019,,,Percentage of tracer or metabolite (CO2) in baboon plasma at 1 min after injection of the compound,,,U,Autocuration,A,9527.0,CHEMBL876411,,,,,0,1
5034,22224,,BAO_0000019,,,Percentage of tracer or metabolite (CO2) in baboon plasma at 30 min after injection of the compound,,,U,Autocuration,A,9527.0,CHEMBL619326,,,,,0,1
5035,22224,,BAO_0000019,,,Percentage of tracer or metabolite (CO2) in baboon plasma at 5 min after injection of the compound,,,U,Autocuration,A,9527.0,CHEMBL619327,,,,,0,1
5036,22224,,BAO_0000019,,,Percentage of tracer or metabolite(EME) in baboon plasma at 10 min after injection of the compound,,,U,Autocuration,A,9527.0,CHEMBL619328,,,,,0,1
5037,22224,,BAO_0000019,,,Percentage of tracer or metabolite(EME) in baboon plasma at 1 min after injection of the compound,,,U,Autocuration,A,9527.0,CHEMBL619329,,,,,0,1
5038,22224,,BAO_0000019,,,Percentage of tracer or metabolite(EME) in baboon plasma at 30 min after injection of the compound,,,U,Autocuration,A,9527.0,CHEMBL619330,,,,,0,1
5039,22224,,BAO_0000019,,,Percentage of tracer or metabolite(EME) in baboon plasma at 5 min after injection of the compound,,,U,Autocuration,A,9527.0,CHEMBL619331,,,,,0,1
5040,22224,,BAO_0000019,,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 10 min after injection of the compound,,,U,Autocuration,A,9527.0,CHEMBL619332,,,,,0,1
5041,22224,,BAO_0000019,,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 1 min after injection of the compound,,,U,Autocuration,A,9527.0,CHEMBL619333,,,,,0,1
5042,22224,,BAO_0000019,,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 30 min after injection of the compound,,,U,Autocuration,A,9527.0,CHEMBL619334,,,,,0,1
5043,22224,,BAO_0000019,,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 5 min after injection of the compound,,,U,Autocuration,A,9527.0,CHEMBL619335,,,,,0,1
5044,22224,,BAO_0000019,,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 10 min after injection of the compound,,,U,Autocuration,A,9527.0,CHEMBL619336,,,,,0,1
5045,22224,,BAO_0000019,,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 1 min after injection of the compound,,,U,Autocuration,A,9527.0,CHEMBL619337,,,,,0,1
5046,22224,,BAO_0000019,,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 30 min after injection of the compound,,,U,Autocuration,A,9527.0,CHEMBL619338,,,,,0,1
5047,22224,,BAO_0000019,,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 5 min after injection of the compound,,,U,Autocuration,A,9527.0,CHEMBL619339,,,,,0,1
5048,50597,In vivo,BAO_0000218,,,Bioavailability in rat (cannulated) (dose 2 mg/kg),,,N,Intermediate,A,10116.0,CHEMBL619340,,,,,1,1
5049,50597,In vivo,BAO_0000218,,,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,,,N,Intermediate,A,10116.0,CHEMBL873496,,1969.0,Plasma,,1,1
5050,50597,,BAO_0000218,,,AUC value in rat after IV administration at a dose of 10 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL619341,,1969.0,Plasma,,1,1
5051,50597,,BAO_0000218,,,AUC value in rat after oral administration at a dose of 10 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL619342,,1969.0,Plasma,,1,1
5052,50597,In vivo,BAO_0000218,,,Cmax value in rat after oral administration at a dose of 10 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL619343,,,,,1,1
5053,50597,In vivo,BAO_0000218,,,Bioavailability in rat after oral administration at a dose of 10 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL619344,,,,,1,1
5054,50597,In vivo,BAO_0000218,,,Tmax value in rat after oral administration at a dose of 10 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL619345,,,,,1,1
5055,50597,,BAO_0000218,,,Vc value in rat after IV administration at a dose of 10 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL619346,,,,,1,1
5056,50597,In vivo,BAO_0000218,,,Half life period in rat after IV administration at a dose of 10 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL619347,,,,,1,1
5057,22224,,BAO_0000019,,,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,,,U,Autocuration,A,9557.0,CHEMBL619348,,,,,0,1
5058,22224,,BAO_0000019,,,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 0.5 min after injection in baboon; (Range = 0.08-0.11),,,U,Autocuration,A,9557.0,CHEMBL619349,,,,,0,1
5059,22224,,BAO_0000019,,,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 1.5 min after injection in baboon; (Range = 0.08-0.11),,,U,Autocuration,A,9557.0,CHEMBL619350,,,,,0,1
5060,22224,,BAO_0000019,,,The amount of unchanged tracer in baboon plasma was determined 1 min after injection of the carbon-11 labeled compound,,,U,Autocuration,A,9557.0,CHEMBL619351,,,,,0,1
5061,22224,,BAO_0000019,,,The amount of unchanged tracer in baboon plasma was determined 10 min after injection of the carbon-11 labeled compound,,,U,Autocuration,A,9557.0,CHEMBL875953,,,,,0,1
5062,22224,,BAO_0000019,,,The amount of unchanged tracer in baboon plasma was determined 30 min after injection of the carbon-11 labeled compound,,,U,Autocuration,A,9557.0,CHEMBL621716,,,,,0,1
5063,22224,,BAO_0000019,,,The amount of unchanged tracer in baboon plasma was determined 60 min after injection of the carbon-11 labeled compound,,,U,Autocuration,A,9557.0,CHEMBL621717,,,,,0,1
5064,22224,,BAO_0000019,,,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,,,U,Autocuration,A,9557.0,CHEMBL621718,,,,,0,1
5065,22224,,BAO_0000019,,,Area under curve after 1 mpk peroral administration to beagles,,,U,Autocuration,A,9615.0,CHEMBL621719,,,,,0,1
5066,22224,,BAO_0000019,,,Area under curve after 2 mpk peroral administration to beagles,,,U,Autocuration,A,9615.0,CHEMBL621720,,,,,0,1
5067,22224,In vivo,BAO_0000218,,,Cmax value after 1 mpk peroral administration to beagles,,,U,Autocuration,A,9615.0,CHEMBL621721,,,,,0,1
5068,22224,,BAO_0000019,,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 7,,,U,Autocuration,A,9606.0,CHEMBL621722,,1088.0,Urine,,0,1
5069,22224,,BAO_0000019,,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 6,,,U,Autocuration,A,9606.0,CHEMBL621723,,1088.0,Urine,,0,1
5070,22224,,BAO_0000019,,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 8,,,U,Autocuration,A,9606.0,CHEMBL621724,,1088.0,Urine,,0,1
5071,22224,,BAO_0000019,,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1500 mL of urine tested on day 9,,,U,Autocuration,A,9606.0,CHEMBL623443,,1088.0,Urine,,0,1
5072,22224,,BAO_0000019,,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1600 mL of urine tested on day 10,,,U,Autocuration,A,9606.0,CHEMBL623444,,1088.0,Urine,,0,1
5073,22224,,BAO_0000019,,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1700 mL of urine tested on day 5,,,U,Autocuration,A,9606.0,CHEMBL623445,,1088.0,Urine,,0,1
5074,22224,,BAO_0000019,,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 2310 mL of urine tested on day 4,,,U,Autocuration,A,9606.0,CHEMBL623446,,1088.0,Urine,,0,1
5075,22224,,BAO_0000251,,,Metabolic stability observed at 30 min after administration in human liver microsomes,,,U,Autocuration,A,9606.0,CHEMBL623447,,2107.0,Liver,Microsomes,0,1
5076,22224,,BAO_0000019,,,Percent recovery of 100 ug/mL compound after administration in cirrhotic patients,,,U,Autocuration,A,9606.0,CHEMBL623448,,,,,0,1
5077,22224,,BAO_0000019,,,Percent recovery of 10 ug/mL compound after administration in cirrhotic patients,,,U,Autocuration,A,9606.0,CHEMBL623449,,,,,0,1
5078,22224,,BAO_0000019,,,Percent recovery of 500 ug/mL compound after administration in cirrhotic patients,,,U,Autocuration,A,9606.0,CHEMBL623450,,,,,0,1
5079,22224,,BAO_0000251,,,"Compound remaining after incubation with 2 mg/mL of human liver microsomes at 37 degrees C for 30 min in a pH 7.4, 0.05 M phosphate buffer",,,U,Autocuration,A,9606.0,CHEMBL623451,,2107.0,Liver,Microsomes,0,1
5080,22224,,BAO_0000019,,,Metabolic stability (% remaining at 30 mins) in human S9.,,,U,Autocuration,A,9606.0,CHEMBL623452,,,,,0,1
5081,22224,,BAO_0000019,,,Metabolic stability determined as remaining percent after 30 min of incubation in human isolated liver S9 preparations; N/D= Not determined,,,U,Autocuration,A,9606.0,CHEMBL623453,,,,,0,1
5082,22224,,BAO_0000251,,,Percent parent compound remaining after 20 min incubation with human liver microsomes,,,U,Autocuration,A,9606.0,CHEMBL623454,,2107.0,Liver,Microsomes,0,1
5083,22224,,BAO_0000251,,,Percent parent compound remaining after 20 min incubation with human liver microsomes; ND=No data,,,U,Autocuration,A,9606.0,CHEMBL623455,,2107.0,Liver,Microsomes,0,1
5084,22224,,BAO_0000251,,,Percent parent compound remaining after 20 min incubation with human liver microsomes; No data,,,U,Autocuration,A,9606.0,CHEMBL624371,,2107.0,Liver,Microsomes,0,1
5085,22224,,BAO_0000218,,,First pass metabolism and metabolic bioavailability using human hepatic microsomes,,,U,Autocuration,A,9606.0,CHEMBL624372,,,,,0,1
5086,22224,,BAO_0000019,,,Percent compound remaining in human plasma after incubation for 60 min at 37 C.,,,U,Autocuration,A,9606.0,CHEMBL624373,,,,,0,1
5087,22224,,BAO_0000019,,,Percent remaining in human plasma after incubation for 60 min at 37 C.,,,U,Autocuration,A,9606.0,CHEMBL624374,,,,,0,1
5088,22224,,BAO_0000019,,,The percent remaining in human plasma after 30 min was determined,,,U,Autocuration,A,9606.0,CHEMBL624556,,,,,0,1
5089,22224,,BAO_0000366,,,Conversion rate of the prodrug in human plasma,,,U,Autocuration,A,9606.0,CHEMBL624557,,1969.0,Plasma,,0,1
5090,22224,,BAO_0000366,,,Conversion rate of the prodrug in human plasma; ND means no data,,,U,Autocuration,A,9606.0,CHEMBL624558,,1969.0,Plasma,,0,1
5091,22224,,BAO_0000221,,,Half life of compound was determined in human blood,,,U,Autocuration,A,9606.0,CHEMBL624559,,178.0,Blood,,0,1
5092,22224,,BAO_0000019,,,Half life of compound was determined in man with once daily dosing,,,U,Autocuration,A,9606.0,CHEMBL624560,,,,,0,1
5093,22224,In vitro,BAO_0000251,,,Half life in human microsomes,,,U,Autocuration,A,9606.0,CHEMBL624561,,,,Microsomes,0,1
5094,22224,,BAO_0000366,,,Half life in human plasma,,,U,Autocuration,A,9606.0,CHEMBL624562,,1969.0,Plasma,,0,1
5095,22224,,BAO_0000366,,,Half life in human plasma; Not detected,,,U,Autocuration,A,9606.0,CHEMBL624563,,1969.0,Plasma,,0,1
5096,22224,In vivo,BAO_0000218,,,Half life period was evaluated against man at a dose of 10 mg/kg after po administration,,,U,Autocuration,A,9606.0,CHEMBL624564,,,,,0,1
5097,22224,In vitro,BAO_0000251,,,Half-life for oxidative metabolic stability was determined using rat liver microsomes,,,U,Autocuration,A,9606.0,CHEMBL624565,,2107.0,Liver,Microsomes,0,1
5098,22224,,BAO_0000366,,,Half-life in human plasma,,,U,Autocuration,A,9606.0,CHEMBL875152,,1969.0,Plasma,,0,1
5099,22224,,BAO_0000366,,,Half-life of the parent prodrug in plasma,,,U,Autocuration,A,9606.0,CHEMBL624566,,1969.0,Plasma,,0,1
5100,22224,In vitro,BAO_0000366,,,In vitro half life in human plasma was determined,,,U,Autocuration,A,9606.0,CHEMBL873805,,1969.0,Plasma,,0,1
5101,22224,In vitro,BAO_0000251,,,The compound was tested In Vitro for half life in human liver microsomes.,,,U,Autocuration,A,9606.0,CHEMBL624567,,2107.0,Liver,Microsomes,0,1
5102,22224,In vivo,BAO_0000218,,,Maximum time was evaluated against man at a dose of 10 mg/kg after po administration,,,U,Autocuration,A,9606.0,CHEMBL624568,,,,,0,1
5103,22224,In vivo,BAO_0000218,,,Observed volume of distribution,,,U,Autocuration,A,9606.0,CHEMBL624569,,,,,0,1
5104,22224,In vivo,BAO_0000218,,,Oral bioavailability in human,,,U,Autocuration,A,9606.0,CHEMBL624570,,,,,0,1
5105,22224,,BAO_0000019,,,Tested for human plasma protein binding of the compound,,,U,Autocuration,A,9606.0,CHEMBL624571,,,,,0,1
5106,22224,,BAO_0000019,,,"First order rate constant, k was determined in human plasma",,,U,Autocuration,A,9606.0,CHEMBL624572,,,,,0,1
5107,22224,,BAO_0000019,,,Observed rate constant in 80% human plasma at 37 degree Centigrade,,,U,Autocuration,A,9606.0,CHEMBL624573,,,,,0,1
5108,22224,,BAO_0000019,,,Observed rate constant in 80% human plasma at 37 degree Centigrade,,,U,Autocuration,A,9606.0,CHEMBL875153,,,,,0,1
5109,22224,,BAO_0000251,,,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,,,U,Autocuration,A,9606.0,CHEMBL624574,,2107.0,Liver,Microsomes,0,1
5110,22224,,BAO_0000019,,,The compound was tested for the plasma binding in human,,,U,Autocuration,A,9606.0,CHEMBL624575,,,,,0,1
5111,22224,,BAO_0000019,,,Plasma protein binding (human),,,U,Autocuration,A,9606.0,CHEMBL624576,,,,,0,1
5112,22224,In vitro,BAO_0000251,,,Compound was evaluated for half-life in human liver microsomes,,,U,Autocuration,A,9606.0,CHEMBL624577,,2107.0,Liver,Microsomes,0,1
5113,22224,In vitro,BAO_0000221,,,Half life measured in vitro for its stability in human blood,,,U,Autocuration,A,9606.0,CHEMBL624578,,178.0,Blood,,0,1
5114,22224,,BAO_0000019,,,Half life in human serum,,,U,Autocuration,A,9606.0,CHEMBL622796,,1977.0,Serum,,0,1
5115,22224,,BAO_0000019,,,Half life in human serum; ND=not determined,,,U,Autocuration,A,9606.0,CHEMBL622797,,1977.0,Serum,,0,1
5116,22224,,BAO_0000019,,,Half life were determined in CEM-SS cell extract in decomposition step 1,,,U,Autocuration,A,9606.0,CHEMBL622798,,,,,0,1
5117,22224,,BAO_0000019,,,Half life were determined in CEM-SS cell extract in decomposition step 2,,,U,Autocuration,A,9606.0,CHEMBL622799,,,,,0,1
5118,22224,,BAO_0000366,,,Half life of the in human plasma,,,U,Autocuration,A,9606.0,CHEMBL622800,,1969.0,Plasma,,0,1
5119,22224,In vitro,BAO_0000220,,,Half life period in human hepatic S9 fraction was determined,,,U,Autocuration,A,9606.0,CHEMBL622801,,,,S9,0,1
5120,22224,In vitro,BAO_0000251,,,Half life period in human liver microsome was determined,,,U,Autocuration,A,9606.0,CHEMBL622802,,2107.0,Liver,Microsomes,0,1
5121,22224,,BAO_0000019,,,Half life period was determined; 6-7,,,U,Autocuration,A,9606.0,CHEMBL622803,,,,,0,1
5122,22224,,BAO_0000019,,,Half life period was evaluated in human,,,U,Autocuration,A,9606.0,CHEMBL875154,,,,,0,1
5123,22224,,BAO_0000366,,,Half life time in human plasma,,,U,Autocuration,A,9606.0,CHEMBL622804,,1969.0,Plasma,,0,1
5124,50594,In vivo,BAO_0000218,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,,N,Intermediate,A,10090.0,CHEMBL622805,,955.0,Brain,,1,1
5125,50594,In vivo,BAO_0000218,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,,N,Intermediate,A,10090.0,CHEMBL622611,,948.0,Heart,,1,1
5126,50594,In vivo,BAO_0000218,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,,N,Intermediate,A,10090.0,CHEMBL622612,,948.0,Heart,,1,1
5127,50594,In vivo,BAO_0000218,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after dosing, in DMSO sol.",,,N,Intermediate,A,10090.0,CHEMBL875160,,2113.0,Kidney,,1,1
5128,50594,In vivo,BAO_0000218,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",,,N,Intermediate,A,10090.0,CHEMBL622613,,2113.0,Kidney,,1,1
5129,50594,In vivo,BAO_0000218,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,,N,Intermediate,A,10090.0,CHEMBL622614,,2113.0,Kidney,,1,1
5130,50594,In vivo,BAO_0000218,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after dosing, in DMSO sol.",,,N,Intermediate,A,10090.0,CHEMBL622615,,2107.0,Liver,,1,1
5131,50594,In vivo,BAO_0000218,,,Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after ip administration in DMSO solution,,,N,Intermediate,A,10090.0,CHEMBL622616,,2107.0,Liver,,1,1
5132,50594,In vivo,BAO_0000218,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,,N,Intermediate,A,10090.0,CHEMBL622617,,2107.0,Liver,,1,1
5133,50594,In vivo,BAO_0000218,,,Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip administration in DMSO solution,,,N,Intermediate,A,10090.0,CHEMBL622618,,2106.0,Spleen,,1,1
5134,50594,In vivo,BAO_0000218,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",,,N,Intermediate,A,10090.0,CHEMBL622619,,2106.0,Spleen,,1,1
5135,50594,In vivo,BAO_0000218,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,,N,Intermediate,A,10090.0,CHEMBL622620,,2106.0,Spleen,,1,1
5136,50594,In vivo,BAO_0000218,,,"Biodistribution in mice, total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,,N,Intermediate,A,10090.0,CHEMBL622621,,955.0,Brain,,1,1
5137,50594,In vivo,BAO_0000218,,,Biodistribution of compound (oxidized form) in blood tissue,,,N,Intermediate,A,10090.0,CHEMBL622622,,178.0,Blood,,1,1
5138,50594,In vivo,BAO_0000218,,,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,,N,Intermediate,A,10090.0,CHEMBL622623,,178.0,Blood,,1,1
5139,50594,In vivo,BAO_0000218,,,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",,,N,Intermediate,A,10090.0,CHEMBL622624,,178.0,Blood,,1,1
5140,50594,In vivo,BAO_0000218,,,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,,N,Intermediate,A,10090.0,CHEMBL622625,,178.0,Blood,,1,1
5141,50594,In vivo,BAO_0000218,,,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,,N,Intermediate,A,10090.0,CHEMBL622626,,178.0,Blood,,1,1
5142,50594,In vivo,BAO_0000218,,,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",,,N,Intermediate,A,10090.0,CHEMBL622627,,178.0,Blood,,1,1
5143,50594,In vivo,BAO_0000218,,,Biodistribution of compound (oxidized form) in brain tissue of mice,,,N,Intermediate,A,10090.0,CHEMBL622628,,955.0,Brain,,1,1
5144,50594,In vivo,BAO_0000218,,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,,N,Intermediate,A,10090.0,CHEMBL622629,,955.0,Brain,,1,1
5145,50594,In vivo,BAO_0000218,,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO",,,N,Intermediate,A,10090.0,CHEMBL622630,,955.0,Brain,,1,1
5146,50594,In vivo,BAO_0000218,,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,,N,Intermediate,A,10090.0,CHEMBL622631,,955.0,Brain,,1,1
5147,50594,In vivo,BAO_0000218,,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",,,N,Intermediate,A,10090.0,CHEMBL622632,,955.0,Brain,,1,1
5148,50594,In vivo,BAO_0000218,,,"Biodistribution of compound (oxidized form) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO solution",,,N,Intermediate,A,10090.0,CHEMBL622633,,955.0,Brain,,1,1
5149,50594,In vivo,BAO_0000218,,,Biodistribution of compound (oxidized form) in heart tissue of mice,,,N,Intermediate,A,10090.0,CHEMBL622634,,948.0,Heart,,1,1
5150,50594,In vivo,BAO_0000218,,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,,N,Intermediate,A,10090.0,CHEMBL622635,,948.0,Heart,,1,1
5151,50594,In vivo,BAO_0000218,,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,,N,Intermediate,A,10090.0,CHEMBL875161,,948.0,Heart,,1,1
5152,50594,In vivo,BAO_0000218,,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO",,,N,Intermediate,A,10090.0,CHEMBL622636,,948.0,Heart,,1,1
5153,50594,In vivo,BAO_0000218,,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,,N,Intermediate,A,10090.0,CHEMBL623335,,948.0,Heart,,1,1
5154,50594,In vivo,BAO_0000218,,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",,,N,Intermediate,A,10090.0,CHEMBL623336,,948.0,Heart,,1,1
5155,50594,In vivo,BAO_0000218,,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,,N,Intermediate,A,10090.0,CHEMBL623337,,2113.0,Kidney,,1,1
5156,50594,In vivo,BAO_0000218,,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",,,N,Intermediate,A,10090.0,CHEMBL623338,,2113.0,Kidney,,1,1
5157,50594,In vivo,BAO_0000218,,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO",,,N,Intermediate,A,10090.0,CHEMBL623339,,2113.0,Kidney,,1,1
5158,50594,In vivo,BAO_0000218,,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,,N,Intermediate,A,10090.0,CHEMBL623524,,2113.0,Kidney,,1,1
5159,50594,In vivo,BAO_0000218,,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",,,N,Intermediate,A,10090.0,CHEMBL623525,,2113.0,Kidney,,1,1
5160,50594,In vivo,BAO_0000218,,,Biodistribution of compound (oxidized form) in liver tissue,,,N,Intermediate,A,10090.0,CHEMBL623526,,2107.0,Liver,,1,1
5161,50594,In vivo,BAO_0000218,,,"Biodistribution of compound (oxidized form) in liver tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,,N,Intermediate,A,10090.0,CHEMBL623527,,2107.0,Liver,,1,1
5162,50594,In vivo,BAO_0000218,,,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,,N,Intermediate,A,10090.0,CHEMBL623528,,2107.0,Liver,,1,1
5163,80852,,BAO_0000219,500.0,A-431,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration in the range of 1-10 uM of the compound after 48 h; Cell death,,,N,Intermediate,F,9606.0,CHEMBL624615,,,,,1,1
5164,80852,,BAO_0000219,500.0,A-431,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,,,N,Intermediate,F,9606.0,CHEMBL621672,,,,,1,1
5165,80852,,BAO_0000218,500.0,A-431,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 10-24 days)",,,N,Expert,F,,CHEMBL621673,,,,,1,1
5166,80852,,BAO_0000218,500.0,A-431,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 12-26 days)",,,N,Expert,F,,CHEMBL621674,,,,,1,1
5167,9,,BAO_0000219,500.0,A-431,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,,,D,Expert,F,9606.0,CHEMBL884002,,,,,9,1
5168,80852,,BAO_0000219,500.0,A-431,"Concentration required to inhibit the epidermoid A431 cell growth by 50%, P53 status of cell line used was wild-type. ",,,N,Intermediate,F,9606.0,CHEMBL621850,,,,,1,1
5169,80852,,BAO_0000219,500.0,A-431,Inhibitory activity against proliferation of human epidermoid carcinoma (A431) cells,,,N,Intermediate,F,9606.0,CHEMBL621851,,,,,1,1
5170,9,,BAO_0000219,500.0,A-431,Inhibition of EGF-dependent autophosphorylation of EGF-R in A431 cells,,,D,Expert,F,9606.0,CHEMBL621852,,,,,9,1
5171,9,,BAO_0000219,500.0,A-431,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,,,D,Expert,F,9606.0,CHEMBL621853,,,,,9,1
5172,80852,,BAO_0000218,500.0,A-431,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 10-24 days)",,,N,Expert,F,,CHEMBL621854,,,,,1,1
5173,80852,,BAO_0000218,500.0,A-431,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",,,N,Expert,F,,CHEMBL621855,,,,,1,1
5174,80852,,BAO_0000218,500.0,A-431,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",,,N,Expert,F,,CHEMBL623724,,,,,1,1
5175,80852,,BAO_0000218,500.0,A-431,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 24",,,N,Expert,F,,CHEMBL623725,,,,,1,1
5176,80852,,BAO_0000218,500.0,A-431,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 26",,,N,Expert,F,,CHEMBL623726,,,,,1,1
5177,9,,BAO_0000219,500.0,A-431,"Irreversible inhibition of EGF-R phosphorylation in A431 cells, 8 hr after washing cells free of compound",,,D,Expert,F,9606.0,CHEMBL623727,,,,,9,1
5178,9,,BAO_0000219,500.0,A-431,Irreversible inhibition of formation of phosphorylated EGFR in A431 cells 8 hr after washing cells free of compound,,,H,Expert,F,,CHEMBL623728,,,,,8,1
5179,80852,,BAO_0000218,500.0,A-431,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 10-24",,,N,Expert,F,,CHEMBL623729,,,,,1,1
5180,80852,,BAO_0000218,500.0,A-431,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",,,N,Expert,F,,CHEMBL623730,,,,,1,1
5181,80852,,BAO_0000218,500.0,A-431,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",,,N,Expert,F,,CHEMBL623731,,,,,1,1
5182,80852,,BAO_0000218,500.0,A-431,"Ratio of treated and control A431 cell tumor mass in mice at 5 mg/kg peroral dose, days 7-21 administration",,,N,Expert,F,10090.0,CHEMBL623732,,,,,1,1
5183,80852,,BAO_0000218,500.0,A-431,"Difference in days for treated (T) and control (C) A431 cell tumors to reach 750 mg in mice at 5 mg/kg peroral dose, days 7-21 administration",,,N,Expert,F,10090.0,CHEMBL623733,,,,,1,1
5184,80852,,BAO_0000218,500.0,A-431,"Net reduction in tumor burden between first and last treatments of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",,,N,Expert,F,10090.0,CHEMBL623734,,,,,1,1
5185,80852,,BAO_0000218,500.0,A-431,"Weight change of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",,,N,Expert,F,10090.0,CHEMBL623735,,,,,1,1
5186,80852,,BAO_0000219,500.0,A-431,In vitro antiproliferative effect against A431 human epidermoid carcinoma cells,,,N,Expert,F,9606.0,CHEMBL623736,,,,,1,1
5187,80852,,BAO_0000219,500.0,A-431,In vitro tumor cell growth inhibitory activity against Human leiomyosarcoma A431 cell lines,,,N,Intermediate,F,9606.0,CHEMBL623737,,,,,1,1
5188,80852,,BAO_0000219,500.0,A-431,Cytotoxicity against A437 cells is the dose giving 50% decrease in the formation of formazan dye,,,N,Intermediate,F,9606.0,CHEMBL623738,,,,,1,1
5189,80852,,BAO_0000219,500.0,A-431,Dose giving a 50% decrease in the living cell number (A437 cells),,,N,Intermediate,F,9606.0,CHEMBL875168,,,,,1,1
5190,80682,,BAO_0000219,646.0,A549,In vitro inhibitory concentration against proliferation of A459 cell line.,,,N,Expert,F,9606.0,CHEMBL623739,,,,,1,1
5191,80682,,BAO_0000219,646.0,A549,Inhibitory concentration of compound for cytotoxicity against A459 human lung cells was determined,,,N,Intermediate,F,9606.0,CHEMBL623740,,,,,1,1
5192,80682,,BAO_0000219,646.0,A549,Inhibition of growth of human NSCL non small cell lung carcinoma cell line (A459) after 72 hr of drug exposure,,,N,Intermediate,F,9606.0,CHEMBL624424,,,,,1,1
5193,80021,,BAO_0000219,624.0,A498,In vitro antitumor activity against renal A498 tumor cell lines,,,N,Intermediate,F,9606.0,CHEMBL624425,,,,,1,1
5194,80021,,BAO_0000219,624.0,A498,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors",,,N,Intermediate,F,9606.0,CHEMBL624426,,,,,1,1
5195,80021,,BAO_0000219,624.0,A498,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors in folate deficient medium",,,N,Intermediate,F,9606.0,CHEMBL624427,,,,,1,1
5196,80021,,BAO_0000219,624.0,A498,Cytotoxicity against A498 Tumor cell line in SRB Cell viability test,,,N,Intermediate,F,9606.0,CHEMBL624428,,,,,1,1
5197,80021,,BAO_0000219,624.0,A498,Cytotoxicity concentration against human kidney carcinoma A-498 cell line,,,N,Intermediate,F,9606.0,CHEMBL624429,,,,,1,1
5198,80021,,BAO_0000219,624.0,A498,Cytotoxicity concentration against human kidney carcinoma A-498 cell line; NT =Not tested,,,N,Intermediate,F,9606.0,CHEMBL624620,,,,,1,1
5199,80021,,BAO_0000219,624.0,A498,Cytotoxicity on kidney carcinoma (A-498) cell line,,,N,Intermediate,F,9606.0,CHEMBL624621,,,,,1,1
5200,80021,,BAO_0000219,624.0,A498,Compound was evaluated against Human cell line renal A498,,,N,Intermediate,F,9606.0,CHEMBL624622,,,,,1,1
5201,80021,,BAO_0000219,624.0,A498,Compound was tested for inhibition of A498 human renal cancer cell line,,,N,Intermediate,F,9606.0,CHEMBL624623,,,,,1,1
5202,80021,,BAO_0000219,624.0,A498,Growth inhibitory activity against A498 human cancer cell line,,,N,Intermediate,F,9606.0,CHEMBL874365,,,,,1,1
5203,80021,,BAO_0000219,624.0,A498,In vitro antitumor activity against human renal A498 cell line,,,N,Intermediate,F,9606.0,CHEMBL624624,,,,,1,1
5204,80021,,BAO_0000219,624.0,A498,In vitro cytotoxic activity against renal (A498) cell line,,,N,Intermediate,F,9606.0,CHEMBL624625,,,,,1,1
5205,80021,,BAO_0000219,624.0,A498,In vitro cytotoxic activity against human renal cancer (A498) cell line,,,N,Intermediate,F,9606.0,CHEMBL624626,,,,,1,1
5206,80021,,BAO_0000219,624.0,A498,Tested for cytostatic activity against renal A498 cell line,,,N,Intermediate,F,9606.0,CHEMBL624627,,,,,1,1
5207,80021,,BAO_0000219,624.0,A498,The compound was tested for the concentration to inhibit 50% of renal A498 cell lines.,,,N,Intermediate,F,9606.0,CHEMBL883157,,,,,1,1
5208,80021,,BAO_0000219,624.0,A498,In vitro cytotoxic activity against renal (A498) cell line at a concentration of 10e-5 M,,,N,Expert,F,9606.0,CHEMBL624628,,,,,1,1
5209,22224,In vivo,BAO_0000218,,,Cmax value after 2 mpk peroral administration to beagles,,,U,Autocuration,A,9615.0,CHEMBL624629,,,,,0,1
5210,22224,In vivo,BAO_0000218,,,Bioavailability,,,U,Autocuration,A,9615.0,CHEMBL623551,,,,,0,1
5211,22224,In vivo,BAO_0000218,,,Bioavailability after 1 mpk peroral administration to beagles,,,U,Autocuration,A,9615.0,CHEMBL623552,,,,,0,1
5212,22224,In vivo,BAO_0000218,,,Bioavailability after 2 mpk peroral administration to beagles,,,U,Autocuration,A,9615.0,CHEMBL623553,,,,,0,1
5213,22224,,BAO_0000019,,,Specificity constant of the BSA-catalyzed deprotonation of compound at pH 9,,,U,Autocuration,A,9913.0,CHEMBL623554,,,,,0,1
5214,22224,,BAO_0000019,,,Specificity constant of the bovine serum albumin catalyzed reaction expressed as (kcat/KM)/kuncat,,,U,Autocuration,A,9913.0,CHEMBL623555,,,,,0,1
5215,22224,,BAO_0000019,,,Michaelis-Menten kinetics of the bovine serum albumin catalyzed reaction of the compound,,,U,Autocuration,A,9913.0,CHEMBL623556,,,,,0,1
5216,22224,,BAO_0000019,,,Solubility against bovine alpha-chymotrypsin,,,U,Autocuration,A,9913.0,CHEMBL623557,,,,,0,1
5217,22224,,BAO_0000019,,,Rate constant of the bovine serum albumin catalyzed reaction of the compound,,,U,Autocuration,A,9913.0,CHEMBL623558,,,,,0,1
5218,22224,,BAO_0000019,,,Rate constant of the bovine serum albumin catalyzed reaction of the compound,,,U,Autocuration,A,9913.0,CHEMBL623559,,,,,0,1
5219,22224,,BAO_0000221,,,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards calf spleen (CS-PDE) at a concentration of 20 microg,,,U,Autocuration,A,9913.0,CHEMBL623560,,2106.0,Spleen,,0,1
5220,22224,,BAO_0000019,,,Half life in culture medium containing 10% of heat inactivated foetal calf serum,,,U,Autocuration,A,9913.0,CHEMBL623561,,,,,0,1
5221,22224,,BAO_0000019,,,Half life in culture medium containing 10% of heat inactivated foetal calf serum; ND=not determined,,,U,Autocuration,A,9913.0,CHEMBL623562,,,,,0,1
5222,22224,,BAO_0000019,,,Ability to get deaminated by adenosine deaminase (ADA); Expressed as t1/2,,,U,Autocuration,A,9913.0,CHEMBL623563,,,,,0,1
5223,22224,,BAO_0000221,,,Enzymatic stability was assessed with bovine spleen phosphodiesterase (BS PDE) exonuclase,,,U,Autocuration,A,9913.0,CHEMBL623564,,2106.0,Spleen,,0,1
5224,22224,,BAO_0000019,,,Half life in presence of 2 mg/mL BSA at pH 8.8,,,U,Autocuration,A,9913.0,CHEMBL873806,,,,,0,1
5225,22224,,BAO_0000019,,,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 1,,,U,Autocuration,A,9913.0,CHEMBL623565,,,,,0,1
5226,22224,,BAO_0000019,,,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2,,,U,Autocuration,A,9913.0,CHEMBL623566,,,,,0,1
5227,22224,,BAO_0000019,,,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2; Not determined,,,U,Autocuration,A,9913.0,CHEMBL623567,,,,,0,1
5228,22224,,BAO_0000019,,,Half-life in the culture medium (RPMI 1640+10% fetal calf serum FCS),,,U,Autocuration,A,9913.0,CHEMBL623568,,,,,0,1
5229,50588,,BAO_0000218,,,AUC (Area Under Plasma concentration-time curve) was after oral administration at 5 mg/kg,,,N,Intermediate,A,9615.0,CHEMBL623569,,1969.0,Plasma,,1,1
5230,50588,,BAO_0000218,,,AUC after administration at 100 mg/kg/day in dogs,,,N,Intermediate,A,9615.0,CHEMBL623570,,1969.0,Plasma,,1,1
5231,50588,,BAO_0000218,,,AUC in dog at 0-24 hr by peroral administration at 3 mpk,,,N,Intermediate,A,9615.0,CHEMBL624254,,1969.0,Plasma,,1,1
5232,50588,,BAO_0000218,,,AUC value after 15 mg/kg iv dose in Dogs,,,N,Intermediate,A,9615.0,CHEMBL624255,,1969.0,Plasma,,1,1
5233,50588,,BAO_0000218,,,AUC value after 30 mg/kg po dose in Dogs,,,N,Intermediate,A,9615.0,CHEMBL624256,,1969.0,Plasma,,1,1
5234,50588,,BAO_0000218,,,AUC value after administration of 4 mg/Kg oral dose in dog,,,N,Intermediate,A,9615.0,CHEMBL624257,,1969.0,Plasma,,1,1
5235,50588,,BAO_0000218,,,AUC0-infinity after single intravenous bolus of 1 mg/kg in dogs,,,N,Intermediate,A,9615.0,CHEMBL624258,,1969.0,Plasma,,1,1
5236,50588,,BAO_0000218,,,Area Under Curve for the compound was determined in dogs at 1 mg/kg oral dosing; 25-50 ug min/mL,,,N,Intermediate,A,9615.0,CHEMBL875277,,,,,1,1
5237,50588,,BAO_0000218,,,Area under curve (AUC) value in dogs after an intravenous dose of 0.2 mg/Kg in 0.025 M aqueous methanesulfonic acid solution with 5% mannitol at a concentration of 0.2,,,N,Intermediate,A,9615.0,CHEMBL622667,,,,,1,1
5238,50588,,BAO_0000218,,,Area under curve by intravenous administration at a dose of 1 uM/kg in dog was determined,,,N,Intermediate,A,9615.0,CHEMBL622668,,,,,1,1
5239,50588,,BAO_0000218,,,Area under curve by oral administration at a dose of 10 uM/kg in dog was determined,,,N,Intermediate,A,9615.0,CHEMBL622669,,,,,1,1
5240,50588,,BAO_0000218,,,Area under curve determined in dogs after intravenous administration of 3 mg/kg,,,N,Intermediate,A,9615.0,CHEMBL622670,,,,,1,1
5241,50588,,BAO_0000218,,,Area under curve determined in dogs after oral administration of 10 mg/kg,,,N,Intermediate,A,9615.0,CHEMBL622671,,,,,1,1
5242,50588,,BAO_0000218,,,Area under curve of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,,N,Intermediate,A,9615.0,CHEMBL622672,,,,,1,1
5243,50588,,BAO_0000218,,,Area under curve of compound determined in dog after iv administration at a dose of 10 mg/kg,,,N,Expert,A,9615.0,CHEMBL622673,,,,,1,1
5244,50588,,BAO_0000218,,,Area under curve of compound from zero time to infinity determined in dog after iv administration at a dose of 10 mg/kg,,,N,Expert,A,9615.0,CHEMBL622674,,,,,1,1
5245,50588,,BAO_0000218,,,Area under curve determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),,,N,Intermediate,A,9615.0,CHEMBL622675,,,,,1,1
5246,50588,,BAO_0000218,,,Area under curve determined in dog at a dose of 10 mg/kg by oral administration,,,N,Intermediate,A,9615.0,CHEMBL622676,,,,,1,1
5247,50588,,BAO_0000218,,,Area under curve determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),,,N,Intermediate,A,9615.0,CHEMBL622677,,,,,1,1
5248,50588,,BAO_0000218,,,Area under curve determined in dog at a dose of 5 mg/kg by oral administration,,,N,Intermediate,A,9615.0,CHEMBL622678,,,,,1,1
5249,50588,,BAO_0000218,,,Area under curve in dog after administration of 20 mg/kg dose through peroral route,,,N,Intermediate,A,9615.0,CHEMBL622679,,,,,1,1
5250,50588,,BAO_0000218,,,Area under curve in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,,N,Intermediate,A,9615.0,CHEMBL622680,,,,,1,1
5251,50588,,BAO_0000218,,,Area under curve was determine after peroral administration at 10 mpk in dog,,,N,Intermediate,A,9615.0,CHEMBL622681,,,,,1,1
5252,50588,,BAO_0000218,,,Area under curve was determine after peroral administration at 5 mpk in dog,,,N,Intermediate,A,9615.0,CHEMBL875278,,,,,1,1
5253,50588,,BAO_0000218,,,Area under curve was determined,,,N,Intermediate,A,9615.0,CHEMBL622682,,,,,1,1
5254,50588,,BAO_0000218,,,Area under curve in dogs,,,N,Intermediate,A,9615.0,CHEMBL622683,,,,,1,1
5255,50588,,BAO_0000218,,,Area under curve in dogs at 10 mg/kg dose fo oral administration,,,N,Intermediate,A,9615.0,CHEMBL622684,,,,,1,1
5256,50588,,BAO_0000218,,,Area under curve in dogs at 10 mg/kg dose fo oral administration (Evokes hyperglycerolemia),,,N,Intermediate,A,9615.0,CHEMBL622685,,,,,1,1
5257,50588,,BAO_0000218,,,Area under curve in dogs at 3 mg/kg dose fo intravenous administration,,,N,Intermediate,A,9615.0,CHEMBL622686,,,,,1,1
5258,50588,,BAO_0000218,,,Area under curve was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,,N,Intermediate,A,9615.0,CHEMBL618344,,,,,1,1
5259,50588,,BAO_0000218,,,Area under curve value in dog at a dose of 5 mg/kg,,,N,Intermediate,A,9615.0,CHEMBL875582,,,,,1,1
5260,50588,,BAO_0000218,,,Area under curve was determined after 0.1 mg/kg iv administration in dog,,,N,Intermediate,A,9615.0,CHEMBL618345,,,,,1,1
5261,50588,,BAO_0000218,,,Area under curve was determined after 0.3 mg/kg po administration in dog,,,N,Intermediate,A,9615.0,CHEMBL618346,,,,,1,1
5262,50588,,BAO_0000218,,,Area under curve was determined for compound after intravenous administration in dogs at 1.2 uM/kg,,,N,Intermediate,A,9615.0,CHEMBL618347,,,,,1,1
5263,50588,,BAO_0000218,,,Area under curve was determined for the compound by intravenous administration of 1.2 mg/kg in dog,,,N,Intermediate,A,9615.0,CHEMBL618348,,,,,1,1
5264,22224,,BAO_0000019,,,Tested for half life period at 37 degree Celsius in PBS buffer at 10.5 pH containing human serum esterase,,,U,Autocuration,A,9606.0,CHEMBL618349,,,,,0,1
5265,22224,,BAO_0000019,,,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,,,U,Autocuration,A,9606.0,CHEMBL618350,,,,,0,1
5266,22224,,BAO_0000019,,,Tested for half life period at 37 degree Celsius in PBS buffer at 8.0 pH containing human serum esterase,,,U,Autocuration,A,9606.0,CHEMBL618351,,,,,0,1
5267,22224,,BAO_0000019,,,Tested for half life period at 37 degree Celsius in PBS buffer at 8.8 pH containing human serum esterase,,,U,Autocuration,A,9606.0,CHEMBL618352,,,,,0,1
5268,22224,,BAO_0000221,,,Time taken to reduce 50% of the concentration of compound in blood plasma,,,U,Autocuration,A,9606.0,CHEMBL873494,,178.0,Blood,,0,1
5269,22224,,BAO_0000366,,,"Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",,,U,Autocuration,A,9606.0,CHEMBL618353,,1969.0,Plasma,,0,1
5270,22224,,BAO_0000366,,,Half life in human plasma,,,U,Autocuration,A,9606.0,CHEMBL618354,,1969.0,Plasma,,0,1
5271,22224,,BAO_0000366,,,Half life in human plasma was reported,,,U,Autocuration,A,9606.0,CHEMBL875583,,1969.0,Plasma,,0,1
5272,22224,,BAO_0000019,,,Half life in human serum,,,U,Autocuration,A,9606.0,CHEMBL618355,,1977.0,Serum,,0,1
5273,22224,,BAO_0000366,,,Half life upon exposure to human plasma,,,U,Autocuration,A,9606.0,CHEMBL618356,,1969.0,Plasma,,0,1
5274,22224,In vitro,BAO_0000251,,,t1/2 in human microsomes,,,U,Autocuration,A,9606.0,CHEMBL618357,,,,Microsomes,0,1
5275,22224,,BAO_0000366,,,Half life period in 80% human plasma at 37 degree Centigrade,,,U,Autocuration,A,9606.0,CHEMBL618358,,1969.0,Plasma,,0,1
5276,22224,,BAO_0000221,,,Half-life for rate of hydrolysis was determined in in human skin homogenate (pH 7.4),,,U,Autocuration,A,9606.0,CHEMBL618359,,14.0,Zone of skin,,0,1
5277,22224,In vitro,BAO_0000366,,,Half-life measured in in vitro Cathepsin B assay in human plasma,,,U,Autocuration,A,9606.0,CHEMBL618360,,1969.0,Plasma,,0,1
5278,22224,,BAO_0000019,,,Half-life at initial concentration of 5*10e-5 M in CEM cell extract,,,U,Autocuration,A,9606.0,CHEMBL618361,,,,,0,1
5279,22224,In vitro,BAO_0000251,,,Half-life determined by human liver microsome stability assay at a concentration of 5 uM,,,U,Autocuration,A,9606.0,CHEMBL618362,,2107.0,Liver,Microsomes,0,1
5280,22224,,BAO_0000366,,,"Half-life in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",,,U,Autocuration,A,9606.0,CHEMBL618363,,1969.0,Plasma,,0,1
5281,22224,,BAO_0000366,,,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",,,U,Autocuration,A,9606.0,CHEMBL618364,,1969.0,Plasma,,0,1
5282,22224,,BAO_0000366,,,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",,,U,Autocuration,A,9606.0,CHEMBL875584,,1969.0,Plasma,,0,1
5283,22224,,BAO_0000019,,,Half-life in the CEM cell extracts,,,U,Autocuration,A,9606.0,CHEMBL618365,,,,,0,1
5284,22224,,BAO_0000366,,,Half-life was calculated by Human plasma stability assay at 37 degree Centigrade,,,U,Autocuration,A,9606.0,CHEMBL873495,,1969.0,Plasma,,0,1
5285,22224,,BAO_0000366,,,Half-life was calculated by Human plasma stability assay at 37 degree centigrade; Not hydrolyzed,,,U,Autocuration,A,9606.0,CHEMBL618366,,1969.0,Plasma,,0,1
5286,22224,,BAO_0000019,,,Half-life was determined,,,U,Autocuration,A,9606.0,CHEMBL618367,,,,,0,1
5287,22224,,BAO_0000221,,,Half-life (human blood stability),,,U,Autocuration,A,9606.0,CHEMBL618368,,178.0,Blood,,0,1
5288,22224,,BAO_0000221,,,Half-life (human blood stability); no data,,,U,Autocuration,A,9606.0,CHEMBL618369,,178.0,Blood,,0,1
5289,22224,,BAO_0000366,,,Half-life in human plasma,,,U,Autocuration,A,9606.0,CHEMBL618370,,1969.0,Plasma,,0,1
5290,22224,,BAO_0000019,,,CYP3A4 metabolism half-life (t1/2),,,U,Autocuration,A,9606.0,CHEMBL618371,,,,,0,1
5291,22224,,BAO_0000221,,,Half-life was determined; 88% of parent remained after incubation for 120 min (human blood stability),,,U,Autocuration,A,9606.0,CHEMBL618372,,178.0,Blood,,0,1
5292,22224,In vitro,BAO_0000366,,,In vitro half life in human plasma,,,U,Autocuration,A,9606.0,CHEMBL618373,,1969.0,Plasma,,0,1
5293,22224,In vitro,BAO_0000366,,,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in human plasma",,,U,Autocuration,A,9606.0,CHEMBL618374,,1969.0,Plasma,,0,1
5294,22224,In vitro,BAO_0000366,,,In vitro hydrolysis in human plasma,,,U,Autocuration,A,9606.0,CHEMBL618375,,1969.0,Plasma,,0,1
5295,22224,In vitro,BAO_0000366,,,In vitro hydrolysis in human plasma; no data,,,U,Autocuration,A,9606.0,CHEMBL618376,,1969.0,Plasma,,0,1
5296,22224,In vitro,BAO_0000251,,,In vitro metabolic stability at 5 uM was determined by incubating with human liver microsomes at 37 degree C,,,U,Autocuration,A,9606.0,CHEMBL618377,,2107.0,Liver,Microsomes,0,1
5297,22224,,BAO_0000366,,,Plasma half life in human,,,U,Autocuration,A,9606.0,CHEMBL618378,,1969.0,Plasma,,0,1
5298,22224,,BAO_0000366,,,Stability after incubation with human plasma (at 37 degree C),,,U,Autocuration,A,9606.0,CHEMBL618379,,1969.0,Plasma,,0,1
5299,22224,,BAO_0000366,,,T1/2 was evaluated in human plasma,,,U,Autocuration,A,9606.0,CHEMBL618380,,1969.0,Plasma,,0,1
5300,22224,,BAO_0000366,,,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",,,U,Autocuration,A,9606.0,CHEMBL618381,,1969.0,Plasma,,0,1
5301,22224,,BAO_0000366,,,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I); Not determined",,,U,Autocuration,A,9606.0,CHEMBL618382,,1969.0,Plasma,,0,1
5302,22224,,BAO_0000019,,,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,,,U,Autocuration,A,9606.0,CHEMBL618383,,,,,0,1
5303,22224,In vitro,BAO_0000019,,,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase,,,U,Autocuration,A,9606.0,CHEMBL618384,,,,,0,1
5304,22224,In vitro,BAO_0000019,,,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase; ND=Not determined,,,U,Autocuration,A,9606.0,CHEMBL618385,,,,,0,1
5305,22224,,BAO_0000366,,,The release rate of the free drug from the substrate in human plasma by human plasma stability assay,,,U,Autocuration,A,9606.0,CHEMBL619099,,1969.0,Plasma,,0,1
5306,22224,,BAO_0000366,,,The release rate of the free drug from the substrate in human plasma by human plasma stability assay; Not hydrolyzed,,,U,Autocuration,A,9606.0,CHEMBL619100,,1969.0,Plasma,,0,1
5307,22224,,BAO_0000019,,,Time taken for 50% to be consumed by serum PON1 was determined,,,U,Autocuration,A,9606.0,CHEMBL619101,,,,,0,1
5308,22224,,BAO_0000019,,,Time taken for 50% to be consumed by serum PON1; NH is Not hydrolysed,,,U,Autocuration,A,9606.0,CHEMBL619102,,,,,0,1
5309,22224,,BAO_0000251,,,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,,,U,Autocuration,A,9606.0,CHEMBL619103,,2107.0,Liver,Microsomes,0,1
5310,22224,,BAO_0000218,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 1 hour,,,U,Autocuration,A,10095.0,CHEMBL619268,,,,,0,1
5311,22224,,BAO_0000218,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 3 hour,,,U,Autocuration,A,10095.0,CHEMBL619269,,,,,0,1
5312,22224,,BAO_0000218,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 1 hour,,,U,Autocuration,A,10095.0,CHEMBL619270,,,,,0,1
5313,22224,,BAO_0000218,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 3 hour,,,U,Autocuration,A,10095.0,CHEMBL619271,,,,,0,1
5314,22224,,BAO_0000218,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 1 hour,,,U,Autocuration,A,10095.0,CHEMBL875585,,,,,0,1
5315,22224,,BAO_0000218,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 24 hour,,,U,Autocuration,A,10095.0,CHEMBL619272,,,,,0,1
5316,80640,,BAO_0000219,391.0,786-0,Compound tested for growth inhibition of renal cancer cell line 786-0,,,N,Intermediate,F,9606.0,CHEMBL619273,,,,,1,1
5317,80640,,BAO_0000219,391.0,786-0,Compound was tested for 50% growth inhibition against human renal cancer 786-0 cell line,,,N,Intermediate,F,9606.0,CHEMBL619274,,,,,1,1
5318,80640,,BAO_0000219,391.0,786-0,Concentration which reduced cell growth to 50 % of level against 786-0 renal cancer line,,,N,Expert,F,9606.0,CHEMBL619275,,,,,1,1
5319,80640,,BAO_0000219,391.0,786-0,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-4 concentration",,,N,Intermediate,F,9606.0,CHEMBL619276,,,,,1,1
5320,80640,,BAO_0000219,391.0,786-0,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-6 concentration",,,N,Intermediate,F,9606.0,CHEMBL619277,,,,,1,1
5321,80640,,BAO_0000219,391.0,786-0,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-8 concentration",,,N,Intermediate,F,9606.0,CHEMBL619278,,,,,1,1
5322,80640,,BAO_0000219,391.0,786-0,Tested for cytotoxicity against 786-0 cell lines in renal cancer,,,N,Intermediate,F,9606.0,CHEMBL619279,,,,,1,1
5323,80640,,BAO_0000219,391.0,786-0,Tested in vitro for cytotoxicity in 786-0 cell line of Renal cancer,,,N,Intermediate,F,9606.0,CHEMBL858458,,,,,1,1
5324,80640,,BAO_0000219,391.0,786-0,Cytotoxic effect on renal cancer line 786-0,,,N,Expert,F,9606.0,CHEMBL619280,,,,,1,1
5325,80640,,BAO_0000219,391.0,786-0,In vitro antitumor activity against Renal cancer 786-0 cell lines by 6-day assay,,,N,Intermediate,F,9606.0,CHEMBL619281,,,,,1,1
5326,80640,,BAO_0000219,391.0,786-0,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),,,N,Intermediate,F,9606.0,CHEMBL619282,,,,,1,1
5327,80640,,BAO_0000219,391.0,786-0,"Cytotoxicity against NCI tumor panel, 786-0 renal cancer cell line",,,N,Intermediate,F,9606.0,CHEMBL619283,,,,,1,1
5328,80640,,BAO_0000219,391.0,786-0,Concentration of compound that cause 50% cytotoxicity of 786-0 renal cancer cell line,,,N,Intermediate,F,9606.0,CHEMBL619284,,,,,1,1
5329,80640,,BAO_0000219,391.0,786-0,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration that inhibits 50% net cell growth).,,,N,Intermediate,F,9606.0,CHEMBL619285,,,,,1,1
5330,80640,,BAO_0000219,391.0,786-0,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration leading to 50% net cell death),,,N,Intermediate,F,9606.0,CHEMBL619286,,,,,1,1
5331,80640,,BAO_0000219,391.0,786-0,Growth inhibition of the 786-O Renal cancer cell line for 2-day in vitro assay.,,,N,Intermediate,F,9606.0,CHEMBL619287,,,,,1,1
5332,80640,,BAO_0000219,391.0,786-0,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,,,N,Intermediate,F,9606.0,CHEMBL857455,,,,,1,1
5333,80640,,BAO_0000219,391.0,786-0,The compound was tested in vitro for cytotoxic activity against 786-O cell line (human perirenal carcinoma),,,N,Intermediate,F,9606.0,CHEMBL883801,,,,,1,1
5334,80641,,BAO_0000219,972.0,791T cell line,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression,,,N,Intermediate,F,9606.0,CHEMBL619288,,,,,1,1
5335,80641,,BAO_0000219,972.0,791T cell line,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression (49% inhibition achieved at 100 micro g/mL),,,N,Intermediate,F,9606.0,CHEMBL619289,,,,,1,1
5336,80641,,BAO_0000219,972.0,791T cell line,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression; <20% inhibition achieved,,,N,Intermediate,F,9606.0,CHEMBL619290,,,,,1,1
5337,80641,,BAO_0000219,972.0,791T cell line,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H1: MSR-33),,,N,Intermediate,F,9606.0,CHEMBL619291,,,,,1,1
5338,80641,,BAO_0000219,972.0,791T cell line,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H2: MSR-26),,,N,Intermediate,F,9606.0,CHEMBL619292,,,,,1,1
5339,80641,,BAO_0000219,972.0,791T cell line,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H3: MSR-28); <20% inhibition achieved,,,N,Intermediate,F,9606.0,CHEMBL619293,,,,,1,1
5340,80641,,BAO_0000219,972.0,791T cell line,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H1: MSR-33),,,N,Intermediate,F,9606.0,CHEMBL619294,,,,,1,1
5341,80641,,BAO_0000219,972.0,791T cell line,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26),,,N,Intermediate,F,9606.0,CHEMBL619295,,,,,1,1
5342,80641,,BAO_0000219,972.0,791T cell line,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26) (less than 20% inhibition achieved),,,N,Intermediate,F,9606.0,CHEMBL619296,,,,,1,1
5343,80641,,BAO_0000219,972.0,791T cell line,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H3: MSR-28); <20% inhibition achieved,,,N,Intermediate,F,9606.0,CHEMBL619297,,,,,1,1
5344,80640,,BAO_0000219,391.0,786-0,Growth inhibitory concentration against tumor cells in culture renal cancer 796-0 cell line,,,N,Intermediate,F,9606.0,CHEMBL619298,,,,,1,1
5345,22226,,BAO_0000019,,,In vitro anticancer activity against 8 NCI CNS cancer cell lines; inactive,,,U,Intermediate,F,,CHEMBL619299,,,,,0,1
5346,80433,,BAO_0000219,741.0,RPMI-8226,Inhibition of cell growth in drug resistant 8226 myeloma cell line,,,N,Expert,F,9606.0,CHEMBL619300,,,,,1,1
5347,80433,,BAO_0000219,741.0,RPMI-8226,Inhibition of cell growth in drug sensitive 8226 myeloma cell line,,,N,Expert,F,9606.0,CHEMBL619301,,,,,1,1
5348,80433,,BAO_0000219,741.0,RPMI-8226,In vitro inhibition of tumor cell growth in the human myeloma 8226 system.,,,N,Intermediate,F,9606.0,CHEMBL619302,,,,,1,1
5349,80433,,BAO_0000219,741.0,RPMI-8226,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,,,N,Intermediate,F,9606.0,CHEMBL619303,,,,,1,1
5350,80433,,BAO_0000219,741.0,RPMI-8226,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,,,N,Intermediate,F,9606.0,CHEMBL619304,,,,,1,1
5351,80433,,BAO_0000219,741.0,RPMI-8226,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),,,N,Intermediate,F,9606.0,CHEMBL857706,,,,,1,1
5352,80433,,BAO_0000219,741.0,RPMI-8226,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),,,N,Intermediate,F,9606.0,CHEMBL619305,,,,,1,1
5353,80433,,BAO_0000219,741.0,RPMI-8226,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),,,N,Intermediate,F,9606.0,CHEMBL619306,,,,,1,1
5354,80433,,BAO_0000219,741.0,RPMI-8226,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,,N,Intermediate,F,9606.0,CHEMBL619307,,,,,1,1
5355,80433,,BAO_0000219,741.0,RPMI-8226,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,,N,Intermediate,F,9606.0,CHEMBL619308,,,,,1,1
5356,80433,,BAO_0000219,741.0,RPMI-8226,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),,,N,Intermediate,F,9606.0,CHEMBL619309,,,,,1,1
5357,80433,,BAO_0000219,741.0,RPMI-8226,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),,,N,Intermediate,F,9606.0,CHEMBL619310,,,,,1,1
5358,80021,,BAO_0000219,624.0,A498,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),,,N,Intermediate,F,9606.0,CHEMBL619311,,,,,1,1
5359,80021,,BAO_0000219,624.0,A498,Compound was tested for the growth inhibition of A498 renal tumor cell line,,,N,Intermediate,F,9606.0,CHEMBL619312,,,,,1,1
5360,80021,,BAO_0000219,624.0,A498,In vitro cytotoxicity against human tumor A498 cell line (renal cancer),,,N,Intermediate,F,9606.0,CHEMBL619313,,,,,1,1
5361,80021,,BAO_0000219,624.0,A498,In vitro inhibitory concentration against renal cancer cell line A498,,,N,Intermediate,F,9606.0,CHEMBL619314,,,,,1,1
5362,80021,,BAO_0000219,624.0,A498,Cytotoxicity against A 498 tumor cell line,,,N,Intermediate,F,9606.0,CHEMBL619959,,,,,1,1
5363,80021,,BAO_0000219,624.0,A498,In vitro antitumor activity against A498 human cancer cell line,,,N,Intermediate,F,9606.0,CHEMBL619960,,,,,1,1
5364,80021,,BAO_0000219,624.0,A498,In vitro antitumor activity against A498 human cancer cell line (Data from NCI-screening),,,N,Intermediate,F,9606.0,CHEMBL619961,,,,,1,1
5365,80021,,BAO_0000219,624.0,A498,Inhibitory dose required against A498 human tumor cell lines,,,N,Intermediate,F,9606.0,CHEMBL619962,,,,,1,1
5366,80021,,BAO_0000219,624.0,A498,Anticancer activity against one renal cancer (A498 cell line),,,N,Intermediate,F,9606.0,CHEMBL875586,,,,,1,1
5367,80021,,BAO_0000219,624.0,A498,In vitro cytotoxicity against melanoma A498 cell line,,,N,Intermediate,F,9606.0,CHEMBL619963,,,,,1,1
5368,80021,,BAO_0000219,624.0,A498,Compound was tested for growth inhibitory activity against A498 cell line,,,N,Intermediate,F,9606.0,CHEMBL619964,,,,,1,1
5369,80021,,BAO_0000219,624.0,A498,Compound tested for growth inhibition of renal cancer cell line A498,,,N,Intermediate,F,9606.0,CHEMBL620108,,,,,1,1
5370,80021,,BAO_0000219,624.0,A498,Compound was tested for 50% growth inhibition against human renal cancer A498 cell line,,,N,Intermediate,F,9606.0,CHEMBL620109,,,,,1,1
5371,80021,,BAO_0000219,624.0,A498,Growth inhibition of the A498 Renal cancer cell line for 2-day in vitro assay.,,,N,Intermediate,F,9606.0,CHEMBL620110,,,,,1,1
5372,80021,,BAO_0000219,624.0,A498,In vitro antitumor activity against Renal cancer A498 cell lines by 6-day assay,,,N,Intermediate,F,9606.0,CHEMBL620111,,,,,1,1
5373,80021,,BAO_0000219,624.0,A498,Tested for cytotoxicity against A498 cell lines in renal cancer,,,N,Intermediate,F,9606.0,CHEMBL620112,,,,,1,1
5374,80021,,BAO_0000219,624.0,A498,Tested in vitro for cytotoxicity in A498 cell line of Renal cancer,,,N,Intermediate,F,9606.0,CHEMBL620113,,,,,1,1
5375,80021,,BAO_0000219,624.0,A498,Cytotoxic effect on renal cancer lines A498,,,N,Expert,F,9606.0,CHEMBL620114,,,,,1,1
5376,80021,,BAO_0000219,624.0,A498,Antitumor activity was evaluated for reduction of growth of renal cancer (A498) cells at a concentration of 100 uM,,,N,Intermediate,F,9606.0,CHEMBL620115,,,,,1,1
5377,80021,,BAO_0000219,624.0,A498,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),,,N,Intermediate,F,9606.0,CHEMBL620116,,,,,1,1
5378,80021,,BAO_0000219,624.0,A498,Concentration of compound that cause 50% cytotoxicity of A498 renal cancer cell line,,,N,Intermediate,F,9606.0,CHEMBL620117,,,,,1,1
5379,80021,,BAO_0000219,624.0,A498,Growth inhibitory activity against A498-2LM human solid tumor cell line using MTT assay,,,N,Intermediate,F,9606.0,CHEMBL620118,,,,,1,1
5380,80021,,BAO_0000219,624.0,A498,Cytotoxicity against human kidney carcinoma cell lines A4982LM,,,N,Intermediate,F,9606.0,CHEMBL620119,,,,,1,1
5381,80021,,BAO_0000219,624.0,A498,Evaluated for the inhibitory concentration required to cause growth inhibition of A498Rem- renal cell line using the MTT Cytotoxicity Assay,,,N,Intermediate,F,9606.0,CHEMBL620120,,,,,1,1
5382,80682,,BAO_0000219,646.0,A549,Antiproliferative activity in vitro against A549 (human non-small lung carcinoma) cell line.,,,N,Expert,F,9606.0,CHEMBL620121,,,,,1,1
5383,80682,,BAO_0000219,646.0,A549,Antitumor activity against A549 human lung carcinoma cell line,,,N,Intermediate,F,9606.0,CHEMBL620122,,,,,1,1
5384,80682,,BAO_0000219,646.0,A549,Antitumor activity against A549 human lung carcinoma cell line in experiment 1,,,N,Intermediate,F,9606.0,CHEMBL620123,,,,,1,1
5385,80682,,BAO_0000219,646.0,A549,Antitumor activity against A549 human lung carcinoma cell line in experiment 2,,,N,Intermediate,F,9606.0,CHEMBL620124,,,,,1,1
5386,80682,,BAO_0000219,646.0,A549,"Concentration required to inhibit tumor growth in A549, human lung carcinoma (NSCLC) cell line",,,N,Intermediate,F,9606.0,CHEMBL620125,,,,,1,1
5387,80682,,BAO_0000219,646.0,A549,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay,,,N,Expert,F,9606.0,CHEMBL620126,,,,,1,1
5388,80682,,BAO_0000219,646.0,A549,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,,N,Intermediate,F,9606.0,CHEMBL883027,,,,,1,1
5389,80682,,BAO_0000219,646.0,A549,In vitro cytotoxic activity against human lung A549 cell line,,,N,Expert,F,9606.0,CHEMBL620127,,,,,1,1
5390,80682,,BAO_0000219,646.0,A549,In vitro cytotoxic activity against human lung A549 cell line ( standard deviation in parenthesis),,,N,Intermediate,F,9606.0,CHEMBL620128,,,,,1,1
5391,80682,,BAO_0000219,646.0,A549,In vitro cytotoxic activity against human lung A549 cell line),,,N,Intermediate,F,9606.0,CHEMBL620129,,,,,1,1
5392,80682,,BAO_0000219,646.0,A549,In vitro cytotoxic activity against human lung A549 cell line;NT is not tested,,,N,Intermediate,F,9606.0,CHEMBL620130,,,,,1,1
5393,80682,,BAO_0000219,646.0,A549,In vitro cytotoxicity against human non small-cell-lung cell line A549.,,,N,Expert,F,9606.0,CHEMBL620131,,,,,1,1
5394,80682,,BAO_0000219,646.0,A549,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors",,,N,Intermediate,F,9606.0,CHEMBL620132,,,,,1,1
5395,80682,,BAO_0000219,646.0,A549,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors in folate deficient medium",,,N,Intermediate,F,9606.0,CHEMBL620133,,,,,1,1
5396,80682,,BAO_0000219,646.0,A549,Inhibition of A549 human lung carcinoma cell proliferation,,,N,Expert,F,9606.0,CHEMBL620134,,,,,1,1
5397,80682,,BAO_0000219,646.0,A549,Inhibitory activity against A549 lung adenocarcinoma cell line,,,N,Intermediate,F,9606.0,CHEMBL620135,,,,,1,1
5398,80682,,BAO_0000219,646.0,A549,Inhibitory concentration required to reduce A549 tumor cell growth by 50% in MTT assay,,,N,Intermediate,F,9606.0,CHEMBL620136,,,,,1,1
5399,80682,,BAO_0000219,646.0,A549,in vitro anticancer activity against cultured A549 human tumor(lung) cell line,,,N,Intermediate,F,9606.0,CHEMBL620137,,,,,1,1
5400,80682,,BAO_0000219,646.0,A549,in vitro inhibition of tumor cell growth in cultured A549 human tumor cell line,,,N,Intermediate,F,9606.0,CHEMBL620268,,,,,1,1
5401,80682,,BAO_0000219,646.0,A549,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,,N,Intermediate,F,9606.0,CHEMBL620269,,,,,1,1
5402,80682,,BAO_0000219,646.0,A549,Cytotoxicity was evaluated against A549 non-small cell lung carcinoma human cancer cell line,,,N,Intermediate,F,9606.0,CHEMBL620270,,,,,1,1
5403,80682,,BAO_0000219,646.0,A549,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,,,N,Intermediate,F,9606.0,CHEMBL620271,,,,,1,1
5404,80682,,BAO_0000219,646.0,A549,Inhibition of A549 cancer cell proliferation,,,N,Expert,F,9606.0,CHEMBL620272,,,,,1,1
5405,80682,,BAO_0000219,646.0,A549,Inhibition of A549 cancer cell proliferation (Not tested),,,N,Expert,F,9606.0,CHEMBL620273,,,,,1,1
5406,80682,,BAO_0000219,646.0,A549,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,,,N,Intermediate,F,9606.0,CHEMBL620274,,,,,1,1
5407,80682,,BAO_0000219,646.0,A549,In vitro inhibitory concentration required against human lung A549 carcinoma cells proliferation,,,N,Intermediate,F,9606.0,CHEMBL620275,,,,,1,1
5408,80682,,BAO_0000219,646.0,A549,Antiproliferative potency determined as inhibitory concentration against A549 cells,,,N,Intermediate,F,9606.0,CHEMBL620276,,,,,1,1
5409,80682,,BAO_0000219,646.0,A549,Percent assembly of bovine brain tubulin induced by compound at 10 uM versus that caused by 10 uM paclitaxel,,,N,Intermediate,F,9606.0,CHEMBL620277,,,,,1,1
5410,80682,,BAO_0000219,646.0,A549,Cytotoxicity against Renal cell lines A549 was determined,,,N,Intermediate,F,9606.0,CHEMBL620278,,,,,1,1
5411,50588,,BAO_0000218,,,Area under curve was determined in dog after a 3 mg/kg of oral dose,,,N,Intermediate,A,9615.0,CHEMBL620279,,,,,1,1
5412,50588,,BAO_0000218,,,Area under curve was determined in dog after oral administration at 1 mg/kg,,,N,Intermediate,A,9615.0,CHEMBL620280,,,,,1,1
5413,50588,,BAO_0000218,,,Area under curve was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,,,N,Intermediate,A,9615.0,CHEMBL620281,,,,,1,1
5414,50588,,BAO_0000218,,,Area under curve was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,,,N,Intermediate,A,9615.0,CHEMBL620282,,,,,1,1
5415,50588,,BAO_0000218,,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-2 mins),,,N,Intermediate,A,9615.0,CHEMBL621134,,,,,1,1
5416,50588,,BAO_0000218,,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-5 mins),,,N,Intermediate,A,9615.0,CHEMBL621135,,,,,1,1
5417,50588,,BAO_0000218,,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of (0-15 mins),,,N,Intermediate,A,9615.0,CHEMBL621136,,,,,1,1
5418,50588,,BAO_0000218,,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of( 0-120 mins),,,N,Intermediate,A,9615.0,CHEMBL621137,,,,,1,1
5419,50588,,BAO_0000218,,,Area under plasma concentration time curve in dog upon oral administration,,,N,Intermediate,A,9615.0,CHEMBL621138,,1969.0,Plasma,,1,1
5420,50588,,BAO_0000218,,,Area under plasma concentration time curve was measured in dogs after an oral dose of 10 uM/kg,,,N,Intermediate,A,9615.0,CHEMBL875587,,1969.0,Plasma,,1,1
5421,50588,,BAO_0000218,,,Area under the curve for compound was evaluated in dog at a dose of 10 mg/kg.,,,N,Intermediate,A,9615.0,CHEMBL621139,,,,,1,1
5422,50588,,BAO_0000218,,,Area under the curve for compound was evaluated in dog at a dose of 20 mg/kg.,,,N,Intermediate,A,9615.0,CHEMBL621140,,,,,1,1
5423,50588,,BAO_0000218,,,Area under the curve for the compound was obtained when tested in dog,,,N,Intermediate,A,9615.0,CHEMBL621141,,,,,1,1
5424,50588,,BAO_0000218,,,Area under the curve at a dose of 1 mg/kg,,,N,Intermediate,A,9615.0,CHEMBL621142,,,,,1,1
5425,50588,,BAO_0000218,,,Area under the curve at a dose of 1 mg/kg (oral),,,N,Intermediate,A,9615.0,CHEMBL621143,,,,,1,1
5426,50588,,BAO_0000218,,,Area under the curve at i.v. dose of 0.2 mg/kg,,,N,Intermediate,A,9615.0,CHEMBL621144,,,,,1,1
5427,50588,,BAO_0000218,,,Area under the curve was measured in dog after an iv dose of 1 mg/kg,,,N,Intermediate,A,9615.0,CHEMBL621145,,,,,1,1
5428,50588,,BAO_0000218,,,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in dog,,,N,Intermediate,A,9615.0,CHEMBL621146,,,,,1,1
5429,50588,,BAO_0000218,,,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 1 mpk perorally,,,N,Intermediate,A,9615.0,CHEMBL622567,,,,,1,1
5430,50588,,BAO_0000218,,,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 5 mpk perorally,,,N,Intermediate,A,9615.0,CHEMBL622568,,,,,1,1
5431,50588,,BAO_0000218,,,Compound was evaluated for area under the curve in dog blood.,,,N,Intermediate,A,9615.0,CHEMBL622569,,,,,1,1
5432,50588,,BAO_0000218,,,In vivo area under curve was calculated by peroral administration at 1 mg/kg in fasted dog,,,N,Intermediate,A,9615.0,CHEMBL622570,,,,,1,1
5433,50588,,BAO_0000218,,,AUC in dog after oral dose (1 mg/kg),,,N,Intermediate,A,9615.0,CHEMBL622571,,1969.0,Plasma,,1,1
5434,50588,,BAO_0000218,,,Pharmacokinetic (PK) property (AUC) was determined in dog at the single oral dose of 1 mg/kg,,,N,Intermediate,A,9615.0,CHEMBL622572,,,,,1,1
5435,50588,,BAO_0000218,,,"Pharmacokinetic data in dogs at dose of 1 mg/kg perorally, and the area under curve (AUC) was reported.",,,N,Intermediate,A,9615.0,CHEMBL622573,,,,,1,1
5436,50588,,BAO_0000218,,,Pharmacokinetic parameter AUC after intravenous administration to dogs,,,N,Intermediate,A,9615.0,CHEMBL622574,,,,,1,1
5437,50588,,BAO_0000218,,,Pharmacokinetic parameter AUC after oral administration to dogs,,,N,Intermediate,A,9615.0,CHEMBL622575,,,,,1,1
5438,50588,,BAO_0000218,,,Pharmacokinetic parameter AUC was determined in dog after oral administration of 17b,,,N,Intermediate,A,9615.0,CHEMBL622576,,,,,1,1
5439,50588,,BAO_0000218,,,Pharmacokinetic parameter AUC was determined in dog after oral administration of 2b,,,N,Intermediate,A,9615.0,CHEMBL622577,,,,,1,1
5440,50588,,BAO_0000218,,,Pharmacokinetic property (AUC) was measured in dog at the dose of 0.032 mg/kg p.o.,,,N,Intermediate,A,9615.0,CHEMBL622578,,,,,1,1
5441,50588,,BAO_0000218,,,Pharmacokinetic property in dogs after oral administration at 1 mg/kg,,,N,Intermediate,A,9615.0,CHEMBL622579,,,,,1,1
5442,50588,,BAO_0000218,,,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog",,,N,Intermediate,A,9615.0,CHEMBL622580,,,,,1,1
5443,50588,,BAO_0000218,,,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog at dosage of 10 mpk",,,N,Intermediate,A,9615.0,CHEMBL622581,,,,,1,1
5444,50588,,BAO_0000218,,,Oral AUCN in dog ( (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,,N,Intermediate,A,9615.0,CHEMBL622582,,,,,1,1
5445,50588,,BAO_0000218,,,Oral AUCN in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,,N,Intermediate,A,9615.0,CHEMBL622583,,,,,1,1
5446,50588,,BAO_0000218,,,Oral AUCN in dog (dosed at 0.5 mpk iv ),,,N,Intermediate,A,9615.0,CHEMBL622584,,,,,1,1
5447,50588,,BAO_0000218,,,Oral AUCN in dog (dosed at 0.5 mpk iv ),,,N,Intermediate,A,9615.0,CHEMBL622585,,,,,1,1
5448,50588,,BAO_0000218,,,Compound was evaluated for oral bioavailability in dog; 90-100,,,N,Intermediate,A,9615.0,CHEMBL622586,,,,,1,1
5449,50588,,BAO_0000218,,,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay,,,N,Intermediate,A,9615.0,CHEMBL623281,,,,,1,1
5450,50588,,BAO_0000218,,,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay; Not determined,,,N,Intermediate,A,9615.0,CHEMBL623282,,,,,1,1
5451,50588,,BAO_0000218,,,PAPP (membrane permeability) in dog kidney cell monolayer assay,,,N,Intermediate,A,9615.0,CHEMBL623283,,,,,1,1
5452,50588,,BAO_0000218,,,Oral bioavailability in dog,,,N,Intermediate,A,9615.0,CHEMBL623284,,,,,1,1
5453,50588,,BAO_0000218,,,Bioavailability administered orally at a dose of 10 mg/kg to dogs,,,N,Intermediate,A,9615.0,CHEMBL623285,,,,,1,1
5454,50588,,BAO_0000218,,,Plasma protein binding towards dog plasma at 10 uM,,,N,Intermediate,A,9615.0,CHEMBL623463,,1969.0,Plasma,,1,1
5455,50588,,BAO_0000218,,,Plasma protein binding towards dog plasma at 100 uM,,,N,Intermediate,A,9615.0,CHEMBL875952,,1969.0,Plasma,,1,1
5456,50588,In vivo,BAO_0000218,,,Bioavailability in dog (dose 4 mg/kg p.o.),,,N,Intermediate,A,9615.0,CHEMBL621705,,,,,1,1
5457,50588,In vivo,BAO_0000218,,,Bioavailability was determined after oral administration of compound 18 at a dose of 2 mg/kg to dog,,,N,Intermediate,A,9615.0,CHEMBL621706,,,,,1,1
5458,50588,In vivo,BAO_0000218,,,Bioavailability by oral administration at a dose of 10 uM/kg in dog was determined,,,N,Intermediate,A,9615.0,CHEMBL621707,,,,,1,1
5459,50588,In vivo,BAO_0000218,,,Bioavailability in dogs,,,N,Intermediate,A,9615.0,CHEMBL621708,,,,,1,1
5460,50588,In vivo,BAO_0000218,,,Bioavailability,,,N,Intermediate,A,9615.0,CHEMBL621709,,,,,1,1
5461,50588,In vivo,BAO_0000218,,,Oral bioavailability in dog (dose 10 mg/kg),,,N,Intermediate,A,9615.0,CHEMBL621710,,,,,1,1
5462,50588,In vivo,BAO_0000218,,,Bioavailability in dog after po administration at a dose of 10 mg/kg; nd is not determined,,,N,Intermediate,A,9615.0,CHEMBL621711,,,,,1,1
5463,50588,In vivo,BAO_0000218,,,Bioavailability in dog (dose 10.0 mg/kg p.o.),,,N,Intermediate,A,9615.0,CHEMBL621712,,,,,1,1
5464,50588,In vivo,BAO_0000218,,,Bioavailability was measured in dogs after an oral dose of 10 uM/kg,,,N,Intermediate,A,9615.0,CHEMBL621713,,,,,1,1
5465,50588,In vivo,BAO_0000218,,,Bioavailability was obtained by the comparison of AUC of intravenous dosing and AUC of oral dosing in dog,,,N,Intermediate,A,9615.0,CHEMBL621714,,,,,1,1
5466,22224,,BAO_0000218,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 3 hour,,,U,Autocuration,A,10095.0,CHEMBL621715,,,,,0,1
5467,22224,,BAO_0000218,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 1 hour,,,U,Autocuration,A,10095.0,CHEMBL623717,,2107.0,Liver,,0,1
5468,22224,,BAO_0000218,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 24 hour,,,U,Autocuration,A,10095.0,CHEMBL623718,,2107.0,Liver,,0,1
5469,22224,,BAO_0000218,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 3 hour,,,U,Autocuration,A,10095.0,CHEMBL623719,,2107.0,Liver,,0,1
5470,22224,,BAO_0000218,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 1 hour,,,U,Autocuration,A,10095.0,CHEMBL623720,,,,,0,1
5471,22224,,BAO_0000218,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 3 hour,,,U,Autocuration,A,10095.0,CHEMBL623721,,,,,0,1
5472,22224,,BAO_0000218,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 1 hour,,,U,Autocuration,A,10095.0,CHEMBL623722,,2385.0,Muscle tissue,,0,1
5473,22224,,BAO_0000218,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 24 hour,,,U,Autocuration,A,10095.0,CHEMBL623723,,2385.0,Muscle tissue,,0,1
5474,22224,,BAO_0000218,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 3 hour,,,U,Autocuration,A,10095.0,CHEMBL618543,,2385.0,Muscle tissue,,0,1
5475,22224,,BAO_0000218,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 1 hour,,,U,Autocuration,A,10095.0,CHEMBL618544,,2106.0,Spleen,,0,1
5476,22224,,BAO_0000218,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 3 hour,,,U,Autocuration,A,10095.0,CHEMBL875155,,2106.0,Spleen,,0,1
5477,22224,,BAO_0000218,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 1 hour,,,U,Autocuration,A,10095.0,CHEMBL618545,,,,,0,1
5478,22224,,BAO_0000218,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 24 hour,,,U,Autocuration,A,10095.0,CHEMBL618546,,,,,0,1
5479,22224,,BAO_0000218,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 3 hour,,,U,Autocuration,A,10095.0,CHEMBL623529,,,,,0,1
5480,22224,,BAO_0000218,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 24 hour,,,U,Autocuration,A,10095.0,CHEMBL623530,,,,,0,1
5481,22224,,BAO_0000218,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 3 hour,,,U,Autocuration,A,10095.0,CHEMBL621764,,,,,0,1
5482,22224,,BAO_0000019,,,Compound (i.v.) was evaluated for elimination rate constants in brainstem of rhesus monkeys (Radiolabeled compound),,,U,Autocuration,A,9527.0,CHEMBL621765,,,,,0,1
5483,22224,,BAO_0000019,,,Compound (i.v.) was evaluated for elimination rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),,,U,Autocuration,A,9527.0,CHEMBL621766,,2037.0,Cerebellum,,0,1
5484,22224,,BAO_0000019,,,Compound (i.v.) was evaluated for elimination rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),,,U,Autocuration,A,9527.0,CHEMBL621767,,1870.0,Frontal cortex,,0,1
5485,22224,,BAO_0000019,,,Compound (i.v.) was evaluated for elimination rate constants in jaw bone of rhesus monkeys; NA = not active (Radiolabeled compound),,,U,Autocuration,A,9527.0,CHEMBL621768,,,,,0,1
5486,22224,,BAO_0000019,,,Compound (i.v.) was evaluated for elimination rate constants in striatum of rhesus monkey (Radiolabeled compound),,,U,Autocuration,A,9527.0,CHEMBL621769,,2435.0,Striatum,,0,1
5487,22224,,BAO_0000019,,,Compound (i.v.) was evaluated for uptake rate constants in brainstem of rhesus monkeys (Radiolabeled compound),,,U,Autocuration,A,9527.0,CHEMBL621770,,,,,0,1
5488,22224,,BAO_0000019,,,Compound (i.v.) was evaluated for uptake rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),,,U,Autocuration,A,9527.0,CHEMBL621771,,2037.0,Cerebellum,,0,1
5489,22224,,BAO_0000019,,,Compound (i.v.) was evaluated for uptake rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),,,U,Autocuration,A,9527.0,CHEMBL621772,,1870.0,Frontal cortex,,0,1
5490,22224,,BAO_0000019,,,Compound (i.v.) was evaluated for uptake rate constants in jaw bone of rhesus monkey (Radiolabeled compound),,,U,Autocuration,A,9527.0,CHEMBL621773,,,,,0,1
5491,22224,,BAO_0000019,,,Compound (i.v.) was evaluated for uptake rate constants in striatum of rhesus monkeys (Radiolabeled compound),,,U,Autocuration,A,9527.0,CHEMBL621774,,2435.0,Striatum,,0,1
5492,22224,,BAO_0000218,,,Compound was evaluated for oral bioavailability in rats,,,U,Autocuration,A,9527.0,CHEMBL621775,,,,,0,1
5493,22224,In vivo,BAO_0000218,,,Maximum concentration of compound found in plasma at 5 mg/kg after oral administration,,,U,Autocuration,A,9527.0,CHEMBL621776,,1969.0,Plasma,,0,1
5494,22224,,BAO_0000019,,,Half life period was evaluated in monkey,,,U,Autocuration,A,9527.0,CHEMBL621777,,,,,0,1
5495,22224,In vivo,BAO_0000218,,,Half-life in rhesus monkeys by intravenous administration of dose,,,U,Autocuration,A,9527.0,CHEMBL875162,,,,,0,1
5496,50594,,BAO_0000218,,,AUC (0-6 hr) after oral administration at 30 mg/kg in ICR mouse,,,N,Intermediate,A,10090.0,CHEMBL621778,,1969.0,Plasma,,1,1
5497,50594,,BAO_0000218,,,AUC after intraperitoneal administration of 100 mg/kg in mice,,,N,Intermediate,A,10090.0,CHEMBL621779,,1969.0,Plasma,,1,1
5498,50594,,BAO_0000218,,,AUC value was determined after oral administration,,,N,Intermediate,A,10090.0,CHEMBL622479,,1969.0,Plasma,,1,1
5499,50594,,BAO_0000218,,,Area under curve (AUC) determined at a dose 10 mg/kg administered intraperitoneally to mice,,,N,Intermediate,A,10090.0,CHEMBL622480,,,,,1,1
5500,50594,,BAO_0000218,,,Area under curve (AUC) was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),,,N,Intermediate,A,10090.0,CHEMBL622481,,,,,1,1
5501,50594,,BAO_0000218,,,Area under curve by ioral administration in mouse,,,N,Intermediate,A,10090.0,CHEMBL622482,,,,,1,1
5502,50594,,BAO_0000218,,,Area under curve by iv administration in mouse,,,N,Intermediate,A,10090.0,CHEMBL622483,,,,,1,1
5503,50594,,BAO_0000218,,,Area under curve at 0-8 hr in IRC mice after peroral administration,,,N,Intermediate,A,10090.0,CHEMBL622484,,,,,1,1
5504,50594,,BAO_0000218,,,Area under curve when injected i.p. in mice at a dose of 50 mg/kg,,,N,Intermediate,A,10090.0,CHEMBL622641,,,,,1,1
5505,50594,,BAO_0000218,,,Area under curve when injected intraperitoneally in BALB/C mice at a dose of 20 mg/kg,,,N,Intermediate,A,10090.0,CHEMBL622642,,,,,1,1
5506,50594,,BAO_0000218,,,Area under curve when injected intravenously in BALB/C mice at a dose of 20 mg/kg,,,N,Intermediate,A,10090.0,CHEMBL622643,,,,,1,1
5507,50594,,BAO_0000218,,,Area under curve when injected intravenously in mice at a dose of 20 mg/kg,,,N,Intermediate,A,10090.0,CHEMBL622644,,,,,1,1
5508,80433,,BAO_0000219,741.0,RPMI-8226,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,,,N,Intermediate,F,9606.0,CHEMBL622645,,,,,1,1
5509,80433,,BAO_0000219,741.0,RPMI-8226,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,,,N,Intermediate,F,9606.0,CHEMBL622646,,,,,1,1
5510,80433,,BAO_0000219,741.0,RPMI-8226,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),,,N,Intermediate,F,9606.0,CHEMBL621238,,,,,1,1
5511,80433,,BAO_0000219,741.0,RPMI-8226,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),,,N,Intermediate,F,9606.0,CHEMBL621239,,,,,1,1
5512,80433,,BAO_0000219,741.0,RPMI-8226,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),,,N,Intermediate,F,9606.0,CHEMBL621240,,,,,1,1
5513,80433,,BAO_0000219,741.0,RPMI-8226,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,,N,Intermediate,F,9606.0,CHEMBL621241,,,,,1,1
5514,80433,,BAO_0000219,741.0,RPMI-8226,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),,,N,Intermediate,F,9606.0,CHEMBL621242,,,,,1,1
5515,80433,,BAO_0000219,741.0,RPMI-8226,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),,,N,Intermediate,F,9606.0,CHEMBL620350,,,,,1,1
5516,80433,,BAO_0000219,741.0,RPMI-8226,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,,,N,Intermediate,F,9606.0,CHEMBL620351,,,,,1,1
5517,80433,,BAO_0000219,741.0,RPMI-8226,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,,,N,Intermediate,F,9606.0,CHEMBL620352,,,,,1,1
5518,80433,,BAO_0000219,741.0,RPMI-8226,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),,,N,Intermediate,F,9606.0,CHEMBL620353,,,,,1,1
5519,80433,,BAO_0000219,741.0,RPMI-8226,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),,,N,Intermediate,F,9606.0,CHEMBL620354,,,,,1,1
5520,80433,,BAO_0000219,741.0,RPMI-8226,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),,,N,Intermediate,F,9606.0,CHEMBL620355,,,,,1,1
5521,80433,,BAO_0000219,741.0,RPMI-8226,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,,N,Intermediate,F,9606.0,CHEMBL620356,,,,,1,1
5522,80433,,BAO_0000219,741.0,RPMI-8226,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),,,N,Intermediate,F,9606.0,CHEMBL620357,,,,,1,1
5523,80433,,BAO_0000219,741.0,RPMI-8226,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),,,N,Intermediate,F,9606.0,CHEMBL620358,,,,,1,1
5524,80433,,BAO_0000219,741.0,RPMI-8226,In vitro inhibition of human 8226 myeloma tumor cell line growth.,,,N,Expert,F,9606.0,CHEMBL620359,,,,,1,1
5525,80433,,BAO_0000219,741.0,RPMI-8226,In vitro inhibition of tumor cell growth in the human myeloma 8226/ADR system.,,,N,Intermediate,F,9606.0,CHEMBL620360,,,,,1,1
5526,80433,,BAO_0000219,741.0,RPMI-8226,Cytotoxicity of compound against 8226/DOX1V cells,,,N,Intermediate,F,9606.0,CHEMBL620361,,,,,1,1
5527,80433,,BAO_0000219,741.0,RPMI-8226,Cytotoxicity of compound against 8226/S cells,,,N,Intermediate,F,9606.0,CHEMBL620362,,,,,1,1
5528,80433,,BAO_0000219,741.0,RPMI-8226,Inhibitory concentration against 8226 myeloma cancer cell line,,,N,Intermediate,F,9606.0,CHEMBL620363,,,,,1,1
5529,80433,,BAO_0000219,741.0,RPMI-8226,Inhibitory concentration against 8226/Dox40 (Dox-Re) cancer cell line,,,N,Intermediate,F,9606.0,CHEMBL620364,,,,,1,1
5530,80647,,BAO_0000219,854.0,833K,Inhibition of cell growth was studied in human teratocarcinoma (833K).,,,N,Intermediate,F,9606.0,CHEMBL620365,,,,,1,1
5531,80647,,BAO_0000219,854.0,833K,Inhibition of cell growth was studied in human teratocarcinoma (833K); ND ='not determined',,,N,Intermediate,F,9606.0,CHEMBL620366,,,,,1,1
5532,80647,,BAO_0000219,854.0,833K,Tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells,,,N,Expert,F,9606.0,CHEMBL620367,,,,,1,1
5533,80647,,BAO_0000219,854.0,833K,The compound was tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells; No data,,,N,Intermediate,F,9606.0,CHEMBL620368,,,,,1,1
5534,22226,,BAO_0000019,,,Inhibitory activity against caspase-1,,,U,Autocuration,B,,CHEMBL620369,,,,,0,1
5535,45,,BAO_0000357,,,Percent inhibition of DAla-DAla Ligase at 10e -3 M of the compound,,,H,Autocuration,B,1351.0,CHEMBL620370,,,,,8,1
5536,80648,,BAO_0000219,705.0,8701-BC,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM) for 72 hr using MTT assay,,,N,Intermediate,F,9606.0,CHEMBL620371,,,,,1,1
5537,80648,,BAO_0000219,705.0,8701-BC,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM,,,N,Intermediate,F,9606.0,CHEMBL620372,,,,,1,1
5538,22226,,BAO_0000019,,,In vitro anticancer activity against 9 NCI colon cancer cell lines; inactive,,,U,Intermediate,F,,CHEMBL876492,,,,,0,1
5539,22226,,BAO_0000019,,,In vitro anticancer activity against 9 NCI melanoma cell lines; inactive,,,U,Intermediate,F,,CHEMBL620373,,,,,0,1
5540,22226,,BAO_0000019,,,In vitro anticancer activity against 9 NCI renal cancer cell lines; inactive,,,U,Intermediate,F,,CHEMBL620374,,,,,0,1
5541,22226,,BAO_0000019,,,Inhibitory activity was determined against 9-cis-epoxycarotenoid dioxygenase (NCED) expressed in Escherichia coli in presence of 9''-cis-neo-xanthin,,,U,Autocuration,B,,CHEMBL620375,,,,,0,1
5542,22226,,BAO_0000019,,,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,,,U,Autocuration,F,1314.0,CHEMBL857902,,,,,0,1
5543,22226,,BAO_0000019,,,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,,,U,Autocuration,F,1314.0,CHEMBL620376,,,,,0,1
5544,11922,,BAO_0000357,,,Percent inhibition against Cdc25C phosphatase at 50 uM of compound,,,H,Autocuration,B,,CHEMBL620377,,,,,8,1
5545,81115,,BAO_0000219,324.0,KB ,Tested for in vitro cytotoxic potency of compound in 9KB assay,,,N,Intermediate,F,9606.0,CHEMBL620378,,,,,1,1
5546,81115,,BAO_0000219,324.0,KB ,Tested for in vitro cytotoxic potency of compound in 9KB assay,,,N,Intermediate,A,9606.0,CHEMBL620379,,,,,1,1
5547,22226,,BAO_0000219,,,In vitro cytotoxicity of compound was tested against 9KB cells.,,,U,Autocuration,F,9606.0,CHEMBL620380,,,,,0,1
5548,80653,,BAO_0000219,392.0,9L,Cytotoxic concentration against 9L cells was determined on day 3,,,N,Intermediate,F,10116.0,CHEMBL884006,,,,,1,1
5549,80653,,BAO_0000219,392.0,9L,Tested in vitro for anticancer activity against 9L cells,,,N,Expert,F,10116.0,CHEMBL620381,,,,,1,1
5550,80653,,BAO_0000219,392.0,9L,Tested in vitro for anticancer activity against 9L cells; Not determined,,,N,Expert,F,10116.0,CHEMBL620382,,,,,1,1
5551,80682,,BAO_0000219,646.0,A549,In vitro inhibitory activity against human A549 non-small cell lung tumor; Active,,,N,Intermediate,F,9606.0,CHEMBL620383,,,,,1,1
5552,80682,,BAO_0000219,646.0,A549,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; No inhibition,,,N,Intermediate,F,9606.0,CHEMBL876493,,,,,1,1
5553,80682,,BAO_0000219,646.0,A549,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Significant inhibition,,,N,Intermediate,F,9606.0,CHEMBL620384,,,,,1,1
5554,80682,,BAO_0000219,646.0,A549,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Slight inhibition,,,N,Intermediate,F,9606.0,CHEMBL620385,,,,,1,1
5555,80682,,BAO_0000219,646.0,A549,Cytotoxicity against human lung carcinoma A549 cell line,,,N,Expert,F,9606.0,CHEMBL620386,,,,,1,1
5556,25,,BAO_0000219,646.0,A549,Ability to induce human IL-6 assay in A549 lung carcinoma cell line.,,,D,Expert,F,9606.0,CHEMBL620387,,,,,9,1
5557,25,,BAO_0000219,646.0,A549,"Ability to induce human IL-6 assay in A549 lung carcinoma cell line; n.r.: not reported, EC50 values not reported in cases were %dex e 35%.",,,D,Expert,F,9606.0,CHEMBL621404,,,,,9,1
5558,80682,,BAO_0000219,646.0,A549,"In vitro growth inhibition of A549, lung carcinoma",,,N,Intermediate,F,9606.0,CHEMBL621405,,,,,1,1
5559,80682,,BAO_0000219,646.0,A549,"In vitro growth inhibition of A549, lung carcinoma.",,,N,Intermediate,F,9606.0,CHEMBL621406,,,,,1,1
5560,80682,,BAO_0000219,646.0,A549,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,,,N,Expert,F,9606.0,CHEMBL621407,,,,,1,1
5561,80682,,BAO_0000219,646.0,A549,Cytotoxic activity against human lung cancer A549 cell line was determined,,,N,Intermediate,F,9606.0,CHEMBL621408,,,,,1,1
5562,80682,,BAO_0000219,646.0,A549,Cytotoxicity against human solid tumor lung carcinoma A549 cell line,,,N,Expert,F,9606.0,CHEMBL885345,,,,,1,1
5563,80682,,BAO_0000219,646.0,A549,Cytotoxicity concentration against human lung carcinoma A-549 cell line,,,N,Intermediate,F,9606.0,CHEMBL621409,,,,,1,1
5564,80682,,BAO_0000219,646.0,A549,Cytotoxicity in A549 (human carcinoma) cell line.,,,N,Expert,F,9606.0,CHEMBL876034,,,,,1,1
5565,80682,,BAO_0000219,646.0,A549,Cytotoxicity on lung carcinoma (A-549) cell line,,,N,Intermediate,F,9606.0,CHEMBL621410,,,,,1,1
5566,80682,,BAO_0000219,646.0,A549,Effective dose against 50% reduction in Human lung carcinoma (A-549) cell number after 3-day incubation.,,,N,Expert,F,9606.0,CHEMBL621411,,,,,1,1
5567,80682,,BAO_0000219,646.0,A549,Effective dose of compound against replication of A549 cell line was evaluated,,,N,Intermediate,F,9606.0,CHEMBL621412,,,,,1,1
5568,80682,,BAO_0000219,646.0,A549,In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line,,,N,Expert,F,9606.0,CHEMBL621413,,,,,1,1
5569,80682,,BAO_0000219,646.0,A549,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line),,,N,Intermediate,F,9606.0,CHEMBL621414,,,,,1,1
5570,80682,,BAO_0000219,646.0,A549,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line); NA is not active,,,N,Intermediate,F,9606.0,CHEMBL621415,,,,,1,1
5571,80682,,BAO_0000219,646.0,A549,The compound was evaluated for antiproliferative activity against A549 cell line,,,N,Intermediate,F,9606.0,CHEMBL621416,,,,,1,1
5572,80682,,BAO_0000219,646.0,A549,The compound was tested for tumor cell growth inhibitory activity against human lung carcinoma (A549) cell line.,,,N,Intermediate,F,9606.0,CHEMBL621417,,,,,1,1
5573,80682,,BAO_0000219,646.0,A549,Concentration required for growth inhibition of human lung carcinoma cell line A549,,,N,Intermediate,F,9606.0,CHEMBL621418,,,,,1,1
5574,80682,,BAO_0000219,646.0,A549,Cytotoxic activity against A549/ATCC non-small cell-lung cancer cell line,,,N,Intermediate,F,9606.0,CHEMBL621419,,,,,1,1
5575,80682,,BAO_0000219,646.0,A549,Growth inhibition against A549 cell line was evaluated,,,N,Intermediate,F,9606.0,CHEMBL621420,,,,,1,1
5576,80682,,BAO_0000219,646.0,A549,Growth inhibitory activity against A549 human solid tumor cell line using MTT assay,,,N,Intermediate,F,9606.0,CHEMBL875823,,,,,1,1
5577,80682,,BAO_0000219,646.0,A549,Inhibition of anchorage independent growth of human tumor cell line A549 K-ras-transformed in soft agar,,,N,Expert,F,9606.0,CHEMBL621421,,,,,1,1
5578,80682,,BAO_0000219,646.0,A549,Inhibitor activity against A549 (Human lung carcinoma)cell line with varying concentration of the drug for 72 hrs,,,N,Intermediate,F,9606.0,CHEMBL621422,,,,,1,1
5579,80682,,BAO_0000219,646.0,A549,Chemosensitivity against DT-diaphorase rich A549 cell lines,,,N,Expert,F,9606.0,CHEMBL884014,,,,,1,1
5580,80682,,BAO_0000219,646.0,A549,Compound tested against A549 lung carcinoma in the sulforhodamine B assay.,,,N,Intermediate,F,9606.0,CHEMBL621423,,,,,1,1
5581,80682,,BAO_0000219,646.0,A549,In vitro cytotoxicity against human A549 (lung cancer) cell line.,,,N,Expert,F,9606.0,CHEMBL621424,,,,,1,1
5582,80682,,BAO_0000219,646.0,A549,In vitro antitumor activity against A549 (lung) human tumor cell lines.,,,N,Intermediate,F,9606.0,CHEMBL621425,,,,,1,1
5583,80682,,BAO_0000219,646.0,A549,In vitro cytotoxic activity against human lung carcinoma A549 cell line,,,N,Expert,F,9606.0,CHEMBL621426,,,,,1,1
5584,80682,,BAO_0000219,646.0,A549,Compound was tested against A549 lung cancer cell line in the sulforhodamine B assay.,,,N,Intermediate,F,9606.0,CHEMBL621427,,,,,1,1
5585,80682,,BAO_0000219,646.0,A549,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,,,N,Intermediate,F,9606.0,CHEMBL621428,,,,,1,1
5586,80682,,BAO_0000219,646.0,A549,Tested against A549 lung carcinoma in the sulforhodamine B assay.,,,N,Expert,F,9606.0,CHEMBL621429,,,,,1,1
5587,80682,,BAO_0000219,646.0,A549,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction),,,N,Intermediate,F,9606.0,CHEMBL621430,,,,,1,1
5588,80682,,BAO_0000219,646.0,A549,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction).,,,N,Intermediate,F,9606.0,CHEMBL621431,,,,,1,1
5589,80682,,BAO_0000219,646.0,A549,Compound was tested for inhibition of growth of human lung carcinoma cell line A549 up to a conc of 10 uM; NI means no inhibition,,,N,Intermediate,F,9606.0,CHEMBL621432,,,,,1,1
5590,80682,,BAO_0000219,646.0,A549,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line,,,N,Expert,F,9606.0,CHEMBL621433,,,,,1,1
5591,80682,,BAO_0000219,646.0,A549,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,,,N,Intermediate,F,9606.0,CHEMBL875824,,,,,1,1
5592,80682,,BAO_0000219,646.0,A549,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,,,N,Intermediate,F,9606.0,CHEMBL621434,,,,,1,1
5593,80682,,BAO_0000219,646.0,A549,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line; NA=Not assayed,,,N,Intermediate,F,9606.0,CHEMBL621435,,,,,1,1
5594,80682,,BAO_0000219,646.0,A549,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay.,,,N,Intermediate,F,9606.0,CHEMBL621436,,,,,1,1
5595,80682,,BAO_0000219,646.0,A549,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay; UA=Potency was so low that the IC50 was unachievable.,,,N,Intermediate,F,9606.0,CHEMBL621437,,,,,1,1
5596,80682,,BAO_0000219,646.0,A549,Compound was tested for the growth inhibition of A549 lung tumor cell line,,,N,Intermediate,F,9606.0,CHEMBL621438,,,,,1,1
5597,80682,,BAO_0000219,646.0,A549,Growth inhibition of human non-small-lung carcinoma (A549) cell line,,,N,Expert,F,9606.0,CHEMBL621439,,,,,1,1
5598,80682,,BAO_0000219,646.0,A549,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,,,N,Intermediate,F,9606.0,CHEMBL621440,,,,,1,1
5599,50588,In vivo,BAO_0000218,,,Oral bioavailability in dog (conscious),,,N,Intermediate,A,9615.0,CHEMBL621441,,,,,1,1
5600,50588,In vivo,BAO_0000218,,,Compound was evaluated for the oral bioavailability after oral administration in dog.,,,N,Intermediate,A,9615.0,CHEMBL621442,,,,,1,1
5601,50588,In vivo,BAO_0000218,,,Compound was tested for percent of oral bioavailability at 10 mg/ml dose in dogs,,,N,Intermediate,A,9615.0,CHEMBL621443,,,,,1,1
5602,50588,In vivo,BAO_0000218,,,Oral bioavailability in dog,,,N,Intermediate,A,9615.0,CHEMBL621444,,,,,1,1
5603,50588,In vivo,BAO_0000218,,,Oral bioavailability in dog,,,N,Intermediate,A,9615.0,CHEMBL625133,,,,,1,1
5604,50588,In vivo,BAO_0000218,,,Oral bioavailability in dog,,,N,Intermediate,A,9615.0,CHEMBL625134,,,,,1,1
5605,50588,In vivo,BAO_0000218,,,Oral bioavailability in dog (fasted),,,N,Intermediate,A,9615.0,CHEMBL625135,,,,,1,1
5606,50588,In vivo,BAO_0000218,,,Oral bioavailability after intravenous administration in dogs at 1.2 uM/kg,,,N,Intermediate,A,9615.0,CHEMBL625136,,,,,1,1
5607,50588,In vivo,BAO_0000218,,,Oral bioavailability in dog,,,N,Intermediate,A,9615.0,CHEMBL625137,,,,,1,1
5608,50588,In vivo,BAO_0000218,,,Oral bioavailability in dog,,,N,Intermediate,A,9615.0,CHEMBL625138,,,,,1,1
5609,50588,In vivo,BAO_0000218,,,Percent bioavailability in dog,,,N,Intermediate,A,9615.0,CHEMBL625139,,,,,1,1
5610,50588,In vivo,BAO_0000218,,,Percent oral bioavailability of intravenously administered compound (6 mg/kg) was tested in dog,,,N,Intermediate,A,9615.0,CHEMBL872264,,,,,1,1
5611,50588,In vivo,BAO_0000218,,,Oral bioavailability in dog,,,N,Intermediate,A,9615.0,CHEMBL625140,,,,,1,1
5612,50588,In vivo,BAO_0000218,,,The compound was evaluated for bioavailability in dogs; 34-44,,,N,Intermediate,A,9615.0,CHEMBL624436,,,,,1,1
5613,50588,In vivo,BAO_0000218,,,Bioavailability in dog (dose 4 mg/kg p.o.),,,N,Intermediate,A,9615.0,CHEMBL624437,,,,,1,1
5614,50588,In vivo,BAO_0000218,,,Oral bioavailability in dog,,,N,Intermediate,A,9615.0,CHEMBL872261,,,,,1,1
5615,50588,,BAO_0000218,,,8 hour trough Blood level in dog was measured after administration of compound,,,N,Intermediate,A,9615.0,CHEMBL624438,,,,,1,1
5616,50588,In vivo,BAO_0000218,,,The compound was tested for maximum concentration ( Cmax ) in dog plasma.,,,N,Intermediate,A,9615.0,CHEMBL624439,,1969.0,Plasma,,1,1
5617,50588,,BAO_0000218,,,C24 after oral administration at 5 mg/kg,,,N,Intermediate,A,9615.0,CHEMBL624440,,,,,1,1
5618,50588,,BAO_0000218,,,Clearance after oral and iv dosing in dogs,,,N,Intermediate,A,9615.0,CHEMBL624441,,,,,1,1
5619,50588,,BAO_0000218,,,Clearance of the drug was measured in the plasma of dog,,,N,Intermediate,A,9615.0,CHEMBL624442,,1969.0,Plasma,,1,1
5620,50588,,BAO_0000218,,,Compound was evaluated for Clearance in dogs at a dose of 1 mpk intravenously,,,N,Intermediate,A,9615.0,CHEMBL624443,,,,,1,1
5621,50588,In vivo,BAO_0000218,,,CL (clearance) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,,,N,Intermediate,A,9615.0,CHEMBL624444,,,,,1,1
5622,50588,In vivo,BAO_0000218,,,Clearance of compound was determined in dogs,,,N,Intermediate,A,9615.0,CHEMBL624445,,,,,1,1
5623,50588,In vivo,BAO_0000218,,,Clearance on i.v. administration of 2 mg/kg was measured in dog,,,N,Intermediate,A,9615.0,CHEMBL624446,,,,,1,1
5624,50588,In vivo,BAO_0000218,,,Clearance of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,,N,Intermediate,A,9615.0,CHEMBL624447,,,,,1,1
5625,50588,In vivo,BAO_0000218,,,Plasma clearance in dog was determined,,,N,Intermediate,A,9615.0,CHEMBL624448,,,,,1,1
5626,50588,In vivo,BAO_0000218,,,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,,N,Intermediate,A,9615.0,CHEMBL624449,,,,,1,1
5627,50588,In vivo,BAO_0000218,,,Plasma clearance in dog after administration of 0.25 mg/kg iv,,,N,Intermediate,A,9615.0,CHEMBL624450,,,,,1,1
5628,50588,In vivo,BAO_0000218,,,Plasma clearance in dog after administration of 1 mg/kg iv,,,N,Intermediate,A,9615.0,CHEMBL875942,,,,,1,1
5629,50588,In vivo,BAO_0000218,,,Plasma clearance in dogs,,,N,Intermediate,A,9615.0,CHEMBL624451,,,,,1,1
5630,50588,In vivo,BAO_0000218,,,Plasma clearance by iv administration in dog at a dose of 0.3 mg/kg,,,N,Intermediate,A,9615.0,CHEMBL624452,,,,,1,1
5631,50588,In vivo,BAO_0000218,,,Plasma clearance was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,,,N,Intermediate,A,9615.0,CHEMBL624453,,,,,1,1
5632,50588,In vivo,BAO_0000218,,,Plasma clearance after 15 mg/kg iv dose in Dogs,,,N,Intermediate,A,9615.0,CHEMBL624454,,,,,1,1
5633,50588,In vivo,BAO_0000218,,,Plasma clearance after 30 mg/kg po dose in Dogs,,,N,Intermediate,A,9615.0,CHEMBL624455,,,,,1,1
5634,50588,In vivo,BAO_0000218,,,Plasma administration to dogs,,,N,Intermediate,A,9615.0,CHEMBL624456,,,,,1,1
5635,50588,In vivo,BAO_0000218,,,Plasma clearance was determined,,,N,Intermediate,A,9615.0,CHEMBL624457,,,,,1,1
5636,50588,In vivo,BAO_0000218,,,Systemic clearance after intravenous administration (0.5 mg/kg) was determined in dog,,,N,Intermediate,A,9615.0,CHEMBL624458,,,,,1,1
5637,50588,In vivo,BAO_0000218,,,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in dog,,,N,Intermediate,A,9615.0,CHEMBL624459,,,,,1,1
5638,102164,In vitro,BAO_0000251,,,Intrinsic clearance in human liver microsomes,,,S,Intermediate,A,9606.0,CHEMBL624460,,2107.0,Liver,Microsomes,2,1
5639,102164,In vitro,BAO_0000251,,,Intrinsic clearance in human liver microsomes,,,S,Intermediate,A,9606.0,CHEMBL624461,,2107.0,Liver,Microsomes,2,1
5640,50588,In vivo,BAO_0000218,,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,,,N,Intermediate,A,9615.0,CHEMBL875943,,,,,1,1
5641,50588,In vivo,BAO_0000218,,,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,,,N,Intermediate,A,9615.0,CHEMBL624462,,,,,1,1
5642,50588,In vivo,BAO_0000218,,,Clearance in dog (dose 1 mg/kg i.v.),,,N,Intermediate,A,9615.0,CHEMBL624463,,,,,1,1
5643,50588,In vivo,BAO_0000218,,,Plasma clearance after oral administration (2.5 mg/kg) in dog was determined,,,N,Intermediate,A,9615.0,CHEMBL624464,,,,,1,1
5644,50588,In vivo,BAO_0000218,,,Plasma clearance in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,,N,Intermediate,A,9615.0,CHEMBL624465,,,,,1,1
5645,50588,In vivo,BAO_0000218,,,Plasma clearance after peroral administration at 10 mpk in dog,,,N,Intermediate,A,9615.0,CHEMBL624466,,,,,1,1
5646,50588,In vivo,BAO_0000218,,,Plasma clearance after peroral administration at 5 mpk in dog,,,N,Intermediate,A,9615.0,CHEMBL624467,,,,,1,1
5647,50588,In vivo,BAO_0000218,,,Plasma clearance after peroral administration at 5 mg/kg in dog,,,N,Intermediate,A,9615.0,CHEMBL624468,,,,,1,1
5648,50588,In vivo,BAO_0000218,,,Plasma clearance was measured in dog,,,N,Intermediate,A,9615.0,CHEMBL624469,,,,,1,1
5649,50588,In vivo,BAO_0000218,,,Plasma clearance was measured in dog,,,N,Intermediate,A,9615.0,CHEMBL624470,,,,,1,1
5650,50588,In vivo,BAO_0000218,,,Pharmacokinetic property (CLtot) was measured in dog at the dose of 0.032 mg/kg i.v.,,,N,Intermediate,A,9615.0,CHEMBL624471,,,,,1,1
5651,50588,In vivo,BAO_0000218,,,Total clearance was determined after 0.1 mg/kg iv administration in dog,,,N,Intermediate,A,9615.0,CHEMBL624472,,,,,1,1
5652,50588,In vivo,BAO_0000218,,,Clearance of compound after intravenous administration in dogs at 1.2 uM/kg,,,N,Intermediate,A,9615.0,CHEMBL622775,,,,,1,1
5653,50588,In vivo,BAO_0000218,,,Clearance after intravenous administration of 0.5 mg/kg in dog was determined,,,N,Intermediate,A,9615.0,CHEMBL622776,,,,,1,1
5654,50588,In vivo,BAO_0000218,,,Clearance after intravenous administration of 1.0 mg/kg in dog was determined,,,N,Intermediate,A,9615.0,CHEMBL622777,,,,,1,1
5655,50588,In vivo,BAO_0000218,,,Clearance after peroral administration of 0.2 mg/kg in dog was determined,,,N,Intermediate,A,9615.0,CHEMBL622778,,,,,1,1
5656,50588,In vivo,BAO_0000218,,,Clearance by intravenous administration of 1.2 mg/kg in dog,,,N,Intermediate,A,9615.0,CHEMBL622779,,,,,1,1
5657,50588,In vivo,BAO_0000218,,,Clearance by iv administration in dogs at a dose of 1 mg/kg,,,N,Intermediate,A,9615.0,CHEMBL622780,,,,,1,1
5658,50588,In vivo,BAO_0000218,,,Clearance value was evaluated in dog plasma,,,N,Intermediate,A,9615.0,CHEMBL622781,,1969.0,Plasma,,1,1
5659,50588,In vivo,BAO_0000218,,,Clearance was evaluated after i.v. administration in dog at a dose of 1 mg/kg,,,N,Intermediate,A,9615.0,CHEMBL622782,,,,,1,1
5660,50588,In vivo,BAO_0000218,,,Compound was tested for plasma clearance in dog,,,N,Intermediate,A,9615.0,CHEMBL622783,,1969.0,Plasma,,1,1
5661,50588,In vivo,BAO_0000218,,,Pharmacokinetic property (Plasma clearance) was measured in dog,,,N,Intermediate,A,9615.0,CHEMBL622784,,,,,1,1
5662,50594,,BAO_0000218,,,Area under curve when injected perorally in mice at a dose of 50 mg/kg,,,N,Intermediate,A,10090.0,CHEMBL622785,,,,,1,1
5663,50594,,BAO_0000218,,,Area under curve when injected perorally in BALB/C mice at a dose of 50 mg/kg,,,N,Intermediate,A,10090.0,CHEMBL622786,,,,,1,1
5664,50594,,BAO_0000218,,,Area under curve value in mouse at a dose of 10 mg/kg,,,N,Intermediate,A,10090.0,CHEMBL622787,,,,,1,1
5665,50594,,BAO_0000218,,,Area under curve was determined at a dose of 100 mg/kg (i.p.) in Mice,,,N,Intermediate,A,10090.0,CHEMBL875949,,,,,1,1
5666,50594,,BAO_0000218,,,Area under curve was determined at a dose of 200 mg/kg (i.p.) in Mice,,,N,Intermediate,A,10090.0,CHEMBL622788,,,,,1,1
5667,50594,,BAO_0000218,,,Area under curve was determined for compound after intraperitoneal administration in mice at 18 uM/kg,,,N,Intermediate,F,10090.0,CHEMBL622789,,,,,1,1
5668,50594,,BAO_0000218,,,Area under curve was determined for compound after intraperitoneal administration in mice at 23 uM/kg,,,N,Intermediate,F,10090.0,CHEMBL622790,,,,,1,1
5669,50594,,BAO_0000218,,,Area under curve was determined for compound after intraperitoneal administration in mice at 25 uM/kg,,,N,Intermediate,F,10090.0,CHEMBL622791,,,,,1,1
5670,50594,,BAO_0000218,,,Area under curve was determined for compound after intraperitoneal administration in mice at 26 uM/kg,,,N,Intermediate,F,10090.0,CHEMBL622792,,,,,1,1
5671,50594,,BAO_0000218,,,Area under curve was determined for compound after intravenous administration in mice at 24 uM/kg,,,N,Intermediate,A,10090.0,CHEMBL622793,,,,,1,1
5672,50594,,BAO_0000218,,,Area under curve was determined for the compound at 24 mg/Kg,,,N,Intermediate,A,10090.0,CHEMBL622794,,,,,1,1
5673,50594,,BAO_0000218,,,Area under curve was determined for the compound at 40 mg/Kg,,,N,Intermediate,A,10090.0,CHEMBL622795,,,,,1,1
5674,50594,,BAO_0000218,,,Area under curve was determined for the compound at 5 mg/Kg,,,N,Intermediate,A,10090.0,CHEMBL621803,,,,,1,1
5675,50594,,BAO_0000218,,,Area under the curve for the compound is obtained at dose 25 mg/kg,,,N,Intermediate,A,10090.0,CHEMBL621804,,,,,1,1
5676,50594,,BAO_0000218,,,Area under the curve for the compound was obtained when tested in mouse,,,N,Intermediate,A,10090.0,CHEMBL621805,,,,,1,1
5677,50594,,BAO_0000218,,,Area under the curve of compound in mouse blood following i.v. administration of 10 mg/kg,,,N,Intermediate,A,10090.0,CHEMBL621806,,,,,1,1
5678,50594,,BAO_0000218,,,Area under the curve of compound in mouse blood following p.o. administration of 30 mg/kg,,,N,Intermediate,A,10090.0,CHEMBL621807,,,,,1,1
5679,50594,,BAO_0000218,,,Area under the curve was measured in mouse after an iv dose of 1 mg/kg,,,N,Intermediate,A,10090.0,CHEMBL621808,,,,,1,1
5680,50594,,BAO_0000218,,,Area under the curve was determined for the compound at a single subcutaneous administration of 40 mg/kg in mice,,,N,Intermediate,A,10090.0,CHEMBL621809,,,,,1,1
5681,50594,,BAO_0000218,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),,,N,Intermediate,A,10090.0,CHEMBL621810,,,,,1,1
5682,50594,,BAO_0000218,,,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,,,N,Intermediate,A,10090.0,CHEMBL875164,,,,,1,1
5683,50594,,BAO_0000218,,,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,,,N,Intermediate,A,10090.0,CHEMBL621811,,,,,1,1
5684,50594,,BAO_0000218,,,"Compound was evaluated for the pharmacokinetic parameter, area under curve",,,N,Intermediate,A,10090.0,CHEMBL621812,,,,,1,1
5685,50594,,BAO_0000218,,,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr ),,,N,Intermediate,A,10090.0,CHEMBL621813,,,,,1,1
5686,50594,,BAO_0000218,,,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr),,,N,Intermediate,A,10090.0,CHEMBL621814,,,,,1,1
5687,50594,,BAO_0000218,,,In vivo area under curve (AUC) was determined in murine septicemia at dose of 100 mg/kg,,,N,Intermediate,A,10090.0,CHEMBL621815,,,,,1,1
5688,50594,,BAO_0000218,,,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg,,,N,Intermediate,A,10090.0,CHEMBL621816,,,,,1,1
5689,50594,,BAO_0000218,,,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,,,N,Intermediate,A,10090.0,CHEMBL621817,,,,,1,1
5690,50594,,BAO_0000218,,,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse,,,N,Intermediate,A,10090.0,CHEMBL621818,,,,,1,1
5691,50594,,BAO_0000218,,,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse;ND=Not determined,,,N,Intermediate,A,10090.0,CHEMBL621819,,,,,1,1
5692,50594,,BAO_0000218,,,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice,,,N,Intermediate,A,10090.0,CHEMBL621820,,,,,1,1
5693,50594,,BAO_0000218,,,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice;ND=Not determined,,,N,Intermediate,A,10090.0,CHEMBL621821,,,,,1,1
5694,50594,,BAO_0000218,,,Pharmacokinetic property (AUC) was determined after ip administration of 32 mg/kg in mice,,,N,Intermediate,A,10090.0,CHEMBL621822,,,,,1,1
5695,50594,,BAO_0000218,,,Pharmacokinetic property (AUC) was determined after po administration of 32 mg/kg in mice,,,N,Intermediate,A,10090.0,CHEMBL619474,,,,,1,1
5696,50594,,BAO_0000218,,,"Reduction in area under curve was determined in DIO mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",,,N,Intermediate,A,10090.0,CHEMBL619475,,,,,1,1
5697,50594,,BAO_0000218,,,"Reduction in area under curve was determined in ob/ob mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",,,N,Intermediate,A,10090.0,CHEMBL619476,,,,,1,1
5698,50594,,BAO_0000218,,,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered intravenously in mice",,,N,Intermediate,A,10090.0,CHEMBL619477,,,,,1,1
5699,50594,,BAO_0000218,,,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered perorally in mice",,,N,Intermediate,A,10090.0,CHEMBL619478,,,,,1,1
5700,50594,,BAO_0000218,,,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered intravenously in mice",,,N,Intermediate,A,10090.0,CHEMBL619479,,,,,1,1
5701,50594,,BAO_0000218,,,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered perorally in mice",,,N,Intermediate,A,10090.0,CHEMBL619480,,,,,1,1
5702,50594,,BAO_0000218,,,The area under curve in vivo in mouse blood level after oral administration at dose 50 mk/kg e-1,,,N,Intermediate,A,10090.0,CHEMBL619481,,,,,1,1
5703,50594,,BAO_0000218,,,The area under curve in vivo in mouse blood level after subcutaneous administration at dose 50 mk/kg e-1,,,N,Intermediate,A,10090.0,CHEMBL619482,,,,,1,1
5704,50594,,BAO_0000218,,,Area under the curve was evaluated in mice after intravenous administration,,,N,Intermediate,A,10090.0,CHEMBL619483,,,,,1,1
5705,50594,,BAO_0000218,,,Area under the curve was evaluated in mice after oral administration,,,N,Intermediate,A,10090.0,CHEMBL619484,,,,,1,1
5706,50594,,BAO_0000218,,,AUC total value at a dose of 10 mg/kg intravenous administration in mice.,,,N,Intermediate,A,10090.0,CHEMBL619485,,1969.0,Plasma,,1,1
5707,50594,,BAO_0000218,,,AUC total value at a dose of 10 mg/kg peroral administration in mice.,,,N,Intermediate,A,10090.0,CHEMBL619486,,1969.0,Plasma,,1,1
5708,50594,,BAO_0000218,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),,,N,Intermediate,A,10090.0,CHEMBL619487,,,,,1,1
5709,50594,,BAO_0000218,,,AUMC after intraperitoneal administration of 100 mg/kg in mice,,,N,Intermediate,A,10090.0,CHEMBL619488,,,,,1,1
5710,50594,In vivo,BAO_0000218,,,Biodistribution in blood was determined in mice after iv administration at 15 min Value expressed as percent injected dose per gram,,,N,Intermediate,A,10090.0,CHEMBL620106,,178.0,Blood,,1,1
5711,80653,,BAO_0000219,392.0,9L,The compound was tested in vitro for anticancer activity against 9L cells,,,N,Intermediate,F,,CHEMBL620107,,,,,1,1
5712,22226,,BAO_0000019,,,Anti proliferation activity determined; Weak effect,,,U,Autocuration,F,10116.0,CHEMBL620283,,,,,0,1
5713,22226,,BAO_0000219,,,Inhibition of cell growth by compound at a concentration of 100 uM in 9Ltk+ cells; Completely stopped the process,,,U,Autocuration,F,10116.0,CHEMBL875176,,,,,0,1
5714,22226,,BAO_0000219,,,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells,,,U,Autocuration,F,10116.0,CHEMBL620284,,,,,0,1
5715,22226,,BAO_0000219,,,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells; Completely stopped the process,,,U,Autocuration,F,10116.0,CHEMBL623515,,,,,0,1
5716,22226,,BAO_0000019,,,The cytotoxic activity was in vitro tested by 9PS assay method,,,U,Autocuration,F,10090.0,CHEMBL623516,,,,,0,1
5717,22226,,BAO_0000019,,,The cytotoxic activity was in vitro tested by 9PS assay method.,,,U,Autocuration,F,10090.0,CHEMBL623517,,,,,0,1
5718,22224,,BAO_0000019,,,Partition coefficient (logD6.5),,,U,Autocuration,A,,CHEMBL857878,,,,,0,1
5719,81034,,BAO_0000219,478.0,A2780,Inhibitory concentration in vitro for cytotoxic activity against A 2780 human ovarian carcinoma cells,,,N,Expert,F,9606.0,CHEMBL623518,,,,,1,1
5720,80018,,BAO_0000219,455.0,A-375,Effective concentration against A 375 cell line growth (DFMO concentration is 5.0 mM),,,N,Intermediate,F,9606.0,CHEMBL624195,,,,,1,1
5721,80852,,BAO_0000219,500.0,A-431,Inhibitory concentration required against A 431 human epidermoid carcinoma cell line,,,N,Expert,F,9606.0,CHEMBL624196,,,,,1,1
5722,9,,BAO_0000219,500.0,A-431,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,,,D,Expert,F,9606.0,CHEMBL624197,,,,,9,1
5723,80021,,BAO_0000219,624.0,A498,Compound was evaluated for in vitro cytotoxicity against A 498 cancer cell line,,,N,Intermediate,F,9606.0,CHEMBL624198,,,,,1,1
5724,80021,,BAO_0000219,624.0,A498,in vitro cytotoxicity against A 498 cancer cell line,,,N,Intermediate,F,9606.0,CHEMBL621287,,,,,1,1
5725,80021,,BAO_0000219,624.0,A498,In vitro cytotoxic activity against renal (A 498) cancer cell line.,,,N,Intermediate,F,9606.0,CHEMBL621288,,,,,1,1
5726,80021,,BAO_0000219,624.0,A498,Cytotoxic activity against A 498 renal cancer cell lines.,,,N,Intermediate,F,9606.0,CHEMBL876496,,,,,1,1
5727,80021,,BAO_0000219,624.0,A498,In vitro cytotoxicity was determined against A 498 human renal tumor cell line using NCI screen,,,N,Intermediate,F,9606.0,CHEMBL621289,,,,,1,1
5728,22226,,BAO_0000019,,,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,,,U,Autocuration,F,1280.0,CHEMBL621290,,,,,0,1
5729,22226,,BAO_0000019,,,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,,,U,Autocuration,F,1280.0,CHEMBL621291,,,,,0,1
5730,22226,,BAO_0000019,,,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,,,U,Autocuration,F,1280.0,CHEMBL621292,,,,,0,1
5731,22226,,BAO_0000019,,,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,,,U,Autocuration,F,1280.0,CHEMBL621293,,,,,0,1
5732,80682,,BAO_0000219,646.0,A549,Inhibitory concentration required against A 549 lung cancer cell line,,,N,Intermediate,F,9606.0,CHEMBL621294,,,,,1,1
5733,80682,,BAO_0000219,646.0,A549,Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time,,,N,Intermediate,F,9606.0,CHEMBL621295,,,,,1,1
5734,80682,,BAO_0000219,646.0,A549,Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time,,,N,Intermediate,F,9606.0,CHEMBL884007,,,,,1,1
5735,80682,,BAO_0000219,646.0,A549,In vitro cytotoxicity against lung cancer A 549 cell lines,,,N,Intermediate,F,9606.0,CHEMBL621296,,,,,1,1
5736,80682,,BAO_0000219,646.0,A549,Compound was tested for its cytotoxicity against A 549 cell line,,,N,Intermediate,F,9606.0,CHEMBL621297,,,,,1,1
5737,80682,,BAO_0000219,646.0,A549,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.",,,N,Expert,F,9606.0,CHEMBL839828,,,,,1,1
5738,80682,,BAO_0000219,646.0,A549,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.; No data",,,N,Intermediate,F,9606.0,CHEMBL620397,,,,,1,1
5739,80682,,BAO_0000219,646.0,A549,In vitro cytotoxic activity against A 549 (non-small cell lung) using SRB (sulforhodamine B) assay,,,N,Expert,F,9606.0,CHEMBL620398,,,,,1,1
5740,80682,,BAO_0000219,646.0,A549,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,,,N,Intermediate,F,9606.0,CHEMBL620399,,,,,1,1
5741,80682,,BAO_0000219,646.0,A549,In vitro inhibition of A549 (human lung cancer) cell growth.,,,N,Expert,F,9606.0,CHEMBL620400,,,,,1,1
5742,80682,,BAO_0000219,646.0,A549,Cytotoxic related antitumor activity against human cancer cell lines A 549; No data available,,,N,Intermediate,F,9606.0,CHEMBL620401,,,,,1,1
5743,80682,,BAO_0000219,646.0,A549,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,,,N,Expert,F,9606.0,CHEMBL620402,,,,,1,1
5744,80682,,BAO_0000219,646.0,A549,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay; not active (> 100 uM),,,N,Expert,F,9606.0,CHEMBL620403,,,,,1,1
5745,22226,,BAO_0000218,,,Tested against A II at (100 ng/kg iv) in Dawley rats (n=2). 24 h,,,U,Autocuration,F,,CHEMBL620404,,,,,0,1
5746,104694,In vivo,BAO_0000218,,,The duration of action for the % peak inhibition of A II pressor response for dose of 0.1 mg/kg intravenous administration in conscious dogs.,,,H,Autocuration,F,,CHEMBL620405,,,,,4,1
5747,104694,In vivo,BAO_0000218,,,The duration of action for the % peak inhibition of A II pressor response for dose of 1.0 mg/kg peroral administration in rhesus monkeys.,,,H,Autocuration,F,,CHEMBL620406,,,,,4,1
5748,104694,In vivo,BAO_0000218,,,The duration of action for the % peak inhibition of angiotensin II pressor response for dose of 0.1 mg/kg peroral administration in conscious rats.,,,H,Autocuration,F,,CHEMBL620407,,,,,4,1
5749,104694,In vivo,BAO_0000218,,,The compound was evaluated for the % peak inhibition of A II pressor response for dose of 0.3 mg/kg peroral administration in rhesus monkeys.,,,H,Autocuration,F,,CHEMBL620408,,,,,4,1
5750,104694,In vivo,BAO_0000218,,,The compound was evaluated for the percentage of inhibition of A II pressor response in rats for peroral administration.,,,H,Autocuration,F,,CHEMBL620409,,,,,4,1
5751,80021,,BAO_0000219,624.0,A498,Inhibition of A-498 human Renal cell proliferation,,,N,Expert,F,9606.0,CHEMBL620410,,,,,1,1
5752,22226,,BAO_0000019,,,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 0.1 uM",,,U,Autocuration,F,10116.0,CHEMBL620411,,,,,0,1
5753,22226,,BAO_0000019,,,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 1 uM",,,U,Autocuration,F,10116.0,CHEMBL620412,,,,,0,1
5754,22226,,BAO_0000019,,,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 10 uM",,,U,Autocuration,F,10116.0,CHEMBL876596,,,,,0,1
5755,80012,,BAO_0000219,622.0,A 172,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay,,,N,Expert,F,9606.0,CHEMBL620413,,,,,1,1
5756,80012,,BAO_0000219,622.0,A 172,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,,N,Intermediate,F,9606.0,CHEMBL620414,,,,,1,1
5757,80012,,BAO_0000219,622.0,A 172,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,,N,Intermediate,F,9606.0,CHEMBL620415,,,,,1,1
5758,80682,,BAO_0000219,646.0,A549,Concentration required to inhibit growth of human tumor A549 (NSCL) cell line.,,,N,Expert,F,9606.0,CHEMBL620416,,,,,1,1
5759,80682,,BAO_0000219,646.0,A549,Concentration which produces 50% inhibition of growth of human lung carcinoma cell line A549,,,N,Intermediate,F,9606.0,CHEMBL620417,,,,,1,1
5760,80682,,BAO_0000219,646.0,A549,Cytotoxic activity evaluated against A549 tumor cells,,,N,Expert,F,9606.0,CHEMBL620418,,,,,1,1
5761,80682,,BAO_0000219,646.0,A549,Cytotoxic potentiation of Topotecan (TP) by the compound in human lung carcinoma A549 cell line,,,N,Intermediate,F,9606.0,CHEMBL620419,,,,,1,1
5762,80682,,BAO_0000219,646.0,A549,Cytotoxicity against A549 cells when the drug is exposed for a time of 1 hr,,,N,Intermediate,F,9606.0,CHEMBL620420,,,,,1,1
5763,80682,,BAO_0000219,646.0,A549,Cytotoxicity against A549 cells when the drug is exposed for a time of 96 hrs,,,N,Intermediate,F,9606.0,CHEMBL620421,,,,,1,1
5764,80682,,BAO_0000219,646.0,A549,Cytotoxicity against A549 tumor cell line determined by WST-1 assay,,,N,Intermediate,F,9606.0,CHEMBL620422,,,,,1,1
5765,80682,,BAO_0000219,646.0,A549,Cytotoxicity of compound against A549 cell line,,,N,Intermediate,F,9606.0,CHEMBL620423,,,,,1,1
5766,80682,,BAO_0000219,646.0,A549,Cytotoxicity against human lung cell carcinoma A549 cell line,,,N,Expert,F,9606.0,CHEMBL620424,,,,,1,1
5767,80682,,BAO_0000219,646.0,A549,Cytotoxicity against human lung carcinoma A549 cell line using MTT assay,,,N,Intermediate,F,9606.0,CHEMBL620425,,,,,1,1
5768,80682,,BAO_0000219,646.0,A549,Cytotoxicity was evaluated in vitro against A549 (non-small cell lung carcinoma) human tumor cell lines,,,N,Intermediate,F,9606.0,CHEMBL620426,,,,,1,1
5769,80682,,BAO_0000219,646.0,A549,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum,,,N,Intermediate,F,9606.0,CHEMBL620427,,,,,1,1
5770,80682,,BAO_0000219,646.0,A549,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum; Not determined,,,N,Intermediate,F,9606.0,CHEMBL620428,,,,,1,1
5771,80682,,BAO_0000219,646.0,A549,In vitro antitumor activity against A549 human NSCLC lung carcinoma cells,,,N,Intermediate,F,9606.0,CHEMBL620429,,,,,1,1
5772,80682,,BAO_0000219,646.0,A549,In vitro concentration required to inhibit the TNF-alpha-induced RANTES production in A549 human lung epithelium cell line,,,N,Expert,F,9606.0,CHEMBL620430,,,,,1,1
5773,80682,,BAO_0000219,646.0,A549,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,,,N,Expert,F,9606.0,CHEMBL839887,,,,,1,1
5774,80682,,BAO_0000219,646.0,A549,In vitro cytotoxicity against parental and drug resistant lung human tumor cell line A549,,,N,Intermediate,F,9606.0,CHEMBL620431,,,,,1,1
5775,80682,,BAO_0000219,646.0,A549,In vitro cytotoxicity of compound against human A549 (non small cell lung) cancer cell line after 72 hr of drug exposure,,,N,Intermediate,F,9606.0,CHEMBL884010,,,,,1,1
5776,80682,,BAO_0000219,646.0,A549,In vitro cytotoxicity against A549 (human lung cancer),,,N,Intermediate,F,9606.0,CHEMBL620538,,,,,1,1
5777,80682,,BAO_0000219,646.0,A549,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,,,N,Expert,F,9606.0,CHEMBL620539,,,,,1,1
5778,80682,,BAO_0000218,646.0,A549,In vivo antiproliferative activity against A549 cell line,,,N,Intermediate,F,9606.0,CHEMBL623373,,,,,1,1
5779,80682,,BAO_0000219,646.0,A549,Inhibition of non-small-cell lung adenocarcinoma (A549),,,N,Intermediate,F,9606.0,CHEMBL623374,,,,,1,1
5780,80682,,BAO_0000219,646.0,A549,Inhibition of non-small-cell lung adenocarcinoma (A549) after 48-h treatment,,,N,Intermediate,F,9606.0,CHEMBL623375,,,,,1,1
5781,80682,,BAO_0000219,646.0,A549,Inhibition of the growth against human non-small-lung carcinoma (A549) cell line after 72 hr exposure,,,N,Intermediate,F,9606.0,CHEMBL623376,,,,,1,1
5782,80682,,BAO_0000219,646.0,A549,Inhibitory activity against A549 cell line using MTT assay(Wild type p53),,,N,Intermediate,F,9606.0,CHEMBL623377,,,,,1,1
5783,80682,,BAO_0000219,646.0,A549,Inhibitory activity against A549 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,,,N,Intermediate,F,9606.0,CHEMBL623378,,,,,1,1
5784,80682,,BAO_0000219,646.0,A549,Inhibitory activity of compound against human A549 lung carcinoma cell line.,,,N,Intermediate,F,9606.0,CHEMBL623379,,,,,1,1
5785,80682,,BAO_0000219,646.0,A549,Inhibitory activity against A549 lung cancer cell line,,,N,Intermediate,F,9606.0,CHEMBL623380,,,,,1,1
5786,80682,,BAO_0000219,646.0,A549,Inhibitory activity against Taxol-resistant A549 lung cancer cell line,,,N,Intermediate,F,9606.0,CHEMBL623381,,,,,1,1
5787,80682,,BAO_0000219,646.0,A549,Inhibitory activity against Taxol-resistant A549 lung cancer cell line; not determined,,,N,Intermediate,F,9606.0,CHEMBL623382,,,,,1,1
5788,80682,,BAO_0000219,646.0,A549,Inhibitory concentration against A549 (lung cancer) cell line,,,N,Intermediate,F,9606.0,CHEMBL623383,,,,,1,1
5789,80682,,BAO_0000219,646.0,A549,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,,,N,Expert,F,9606.0,CHEMBL623384,,,,,1,1
5790,80682,,BAO_0000219,646.0,A549,Tested in vitro for inhibitory effect on the growth of human A-549 cancer cell line,,,N,Intermediate,F,9606.0,CHEMBL623385,,,,,1,1
5791,80682,,BAO_0000219,646.0,A549,Activity against A549 cancer cell line.,,,N,Expert,F,9606.0,CHEMBL623386,,,,,1,1
5792,80682,,BAO_0000219,646.0,A549,The compound was evaluated for cytotoxicity against A549 cell line,,,N,Intermediate,F,9606.0,CHEMBL884105,,,,,1,1
5793,80682,,BAO_0000219,646.0,A549,The compound was examined for its ability to block tumor necrosis factor alpha (TNF alpha) induced IL-8 production in A549 human lung carcinoma cell line using an ELISA,,,N,Intermediate,F,9606.0,CHEMBL623387,,,,,1,1
5794,80682,,BAO_0000219,646.0,A549,The compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,,,N,Intermediate,F,9606.0,CHEMBL621568,,,,,1,1
5795,80682,,BAO_0000219,646.0,A549,Growth inhibitory activity was measured for human A549 tumor cell line.,,,N,Intermediate,F,9606.0,CHEMBL621569,,,,,1,1
5796,80682,,BAO_0000219,646.0,A549,Inhibitory activity against A549 lung cancer cell line,,,N,Intermediate,F,9606.0,CHEMBL621570,,,,,1,1
5797,80682,,BAO_0000219,646.0,A549,Inhibitory activity against A549 cell line; inactive,,,N,Intermediate,F,9606.0,CHEMBL621571,,,,,1,1
5798,80682,,BAO_0000219,646.0,A549,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,,,N,Expert,F,9606.0,CHEMBL621572,,,,,1,1
5799,80682,,BAO_0000219,646.0,A549,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,,,N,Expert,F,9606.0,CHEMBL621573,,,,,1,1
5800,80682,,BAO_0000219,646.0,A549,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,,,N,Intermediate,F,9606.0,CHEMBL621574,,,,,1,1
5801,80682,,BAO_0000219,646.0,A549,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-4 (M/L),,,N,Intermediate,F,9606.0,CHEMBL621575,,,,,1,1
5802,80682,,BAO_0000219,646.0,A549,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-5 (M/L),,,N,Intermediate,F,9606.0,CHEMBL621576,,,,,1,1
5803,80682,,BAO_0000219,646.0,A549,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-6 (M/L),,,N,Intermediate,F,9606.0,CHEMBL621577,,,,,1,1
5804,80682,,BAO_0000219,646.0,A549,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-7 (M/L),,,N,Intermediate,F,9606.0,CHEMBL621578,,,,,1,1
5805,80682,,BAO_0000219,646.0,A549,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-8 (M/L),,,N,Intermediate,F,9606.0,CHEMBL621579,,,,,1,1
5806,80682,,BAO_0000219,646.0,A549,In vitro percent inhibition evaluated against human lung cancer (A549 cell line) at >20 ug/mL,,,N,Intermediate,F,9606.0,CHEMBL621580,,,,,1,1
5807,50588,In vivo,BAO_0000218,,,Plasma clearance (in vivo) in mongrel dogs was determined,,,N,Intermediate,A,9615.0,CHEMBL621581,,,,,1,1
5808,50588,In vivo,BAO_0000218,,,Plasma clearance was measured in dog,,,N,Intermediate,A,9615.0,CHEMBL621582,,,,,1,1
5809,50588,In vivo,BAO_0000218,,,Plasma clearance in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,,,N,Intermediate,A,9615.0,CHEMBL621583,,,,,1,1
5810,50588,In vivo,BAO_0000218,,,Plasma clearance in vivo in dog by intravenous administration at a dose of 1 mg/kg,,,N,Intermediate,A,9615.0,CHEMBL621584,,,,,1,1
5811,50588,In vivo,BAO_0000218,,,Tested for plasma clearance in dog,,,N,Intermediate,A,9615.0,CHEMBL621585,,1969.0,Plasma,,1,1
5812,50588,In vivo,BAO_0000218,,,The compound was tested for clearance in dog plasma.,,,N,Intermediate,A,9615.0,CHEMBL621586,,,,,1,1
5813,50588,In vivo,BAO_0000218,,,"The pharmacokinetic parameter, clearance was reported in dog after intravenous administration",,,N,Intermediate,A,9615.0,CHEMBL875835,,,,,1,1
5814,50588,In vivo,BAO_0000218,,,Clearance value of compound was determined after intravenous administration of 1 mg/kg/h in dog,,,N,Intermediate,A,9615.0,CHEMBL621587,,,,,1,1
5815,50588,In vivo,BAO_0000218,,,Compound was tested for its ability of plasma clearance when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),,,N,Intermediate,A,9615.0,CHEMBL621588,,1969.0,Plasma,,1,1
5816,50588,In vitro,BAO_0000218,,,In vitro clearance in dog liver microsomes,,,N,Intermediate,A,9615.0,CHEMBL621589,,2107.0,Liver,Microsomes,1,1
5817,50588,In vivo,BAO_0000218,,,Pharmacokinetic profile in terms of clearance was determined at a dose of 0.5 mg/kg administered intravenously in dog,,,N,Intermediate,A,9615.0,CHEMBL621590,,,,,1,1
5818,50588,In vivo,BAO_0000218,,,Pharmacokinetic profile in terms of clearance was determined at a dose of 5 mg/kg administered intravenously in dog,,,N,Intermediate,A,9615.0,CHEMBL621591,,,,,1,1
5819,50588,In vivo,BAO_0000218,,,Plasma clearance in dog,,,N,Intermediate,A,9615.0,CHEMBL621592,,,,,1,1
5820,50588,In vivo,BAO_0000218,,,Clearance rate in dog,,,N,Intermediate,A,9615.0,CHEMBL621593,,,,,1,1
5821,50588,In vivo,BAO_0000218,,,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,,,N,Intermediate,A,9615.0,CHEMBL621594,,1969.0,Plasma,,1,1
5822,50588,In vivo,BAO_0000218,,,Clearance in dogs,,,N,Intermediate,A,9615.0,CHEMBL621595,,,,,1,1
5823,50588,In vivo,BAO_0000218,,,Plasma clearance in dogs,,,N,Intermediate,A,9615.0,CHEMBL621596,,,,,1,1
5824,50588,In vivo,BAO_0000218,,,Plasma clearance was determined,,,N,Intermediate,A,9615.0,CHEMBL621597,,,,,1,1
5825,50588,In vivo,BAO_0000218,,,Lower clearance in dog (i.v.) at 0.5 mpk,,,N,Intermediate,A,9615.0,CHEMBL621598,,,,,1,1
5826,50588,In vivo,BAO_0000218,,,Plasma clearance in Beagle dogs,,,N,Intermediate,A,9615.0,CHEMBL621599,,,,,1,1
5827,50588,In vivo,BAO_0000218,,,Plasma clearance (Clp) in dog,,,N,Intermediate,A,9615.0,CHEMBL875836,,,,,1,1
5828,50588,In vivo,BAO_0000218,,,Plasma clearance (pharmacokinetic parameter) in dog (in vivo) at a dose of 1 mg/kg,,,N,Intermediate,A,9615.0,CHEMBL621600,,,,,1,1
5829,50588,In vivo,BAO_0000218,,,Plasma clearance (pharmacokinetic parameter) in dog was determined,,,N,Intermediate,A,9615.0,CHEMBL621601,,,,,1,1
5830,50588,In vivo,BAO_0000218,,,Plasma clearance for the compound was measured in dog after an iv dose of 1 mg/kg,,,N,Intermediate,A,9615.0,CHEMBL618474,,,,,1,1
5831,50588,In vivo,BAO_0000218,,,Plasma clearance of compound was determined in dog,,,N,Intermediate,A,9615.0,CHEMBL618475,,,,,1,1
5832,50588,In vivo,BAO_0000218,,,Plasma clearance after intravenous administration of 1 mg/kg in dog,,,N,Intermediate,A,9615.0,CHEMBL624524,,,,,1,1
5833,50588,In vivo,BAO_0000218,,,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,,,N,Intermediate,A,9615.0,CHEMBL624525,,,,,1,1
5834,50588,In vivo,BAO_0000218,,,Plasma clearance in dog was determined,,,N,Intermediate,A,9615.0,CHEMBL624526,,,,,1,1
5835,50588,In vivo,BAO_0000218,,,Plasma clearance was calculated in dog,,,N,Intermediate,A,9615.0,CHEMBL624527,,,,,1,1
5836,50588,In vivo,BAO_0000218,,,Plasma clearance at the dose of 2 mg/kg in dog,,,N,Intermediate,A,9615.0,CHEMBL624528,,,,,1,1
5837,50588,In vivo,BAO_0000218,,,Plasma clearance in dog,,,N,Intermediate,A,9615.0,CHEMBL624529,,,,,1,1
5838,50588,In vivo,BAO_0000218,,,Plasma clearance in dog,,,N,Intermediate,A,9615.0,CHEMBL624530,,,,,1,1
5839,50588,In vivo,BAO_0000218,,,Plasma clearance in dog; Unable to calculate,,,N,Intermediate,A,9615.0,CHEMBL624531,,,,,1,1
5840,50588,In vivo,BAO_0000218,,,Plasma clearance in rhesus monkey,,,N,Intermediate,A,9615.0,CHEMBL624532,,,,,1,1
5841,50588,In vivo,BAO_0000218,,,Plasma clearance in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,,N,Intermediate,A,9615.0,CHEMBL624533,,,,,1,1
5842,50588,In vivo,BAO_0000218,,,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,,N,Intermediate,A,9615.0,CHEMBL624534,,,,,1,1
5843,50588,In vivo,BAO_0000218,,,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,,N,Intermediate,A,9615.0,CHEMBL624535,,,,,1,1
5844,50588,In vivo,BAO_0000218,,,Plasma clearance was evaluated in dog,,,N,Intermediate,A,9615.0,CHEMBL624536,,,,,1,1
5845,50588,In vivo,BAO_0000218,,,Plasma clearance was evaluated in dog; Not tested,,,N,Intermediate,A,9615.0,CHEMBL624537,,,,,1,1
5846,50588,In vivo,BAO_0000218,,,Plasma clearance was evaluated in rhesus,,,N,Intermediate,A,9615.0,CHEMBL624538,,,,,1,1
5847,50588,In vivo,BAO_0000218,,,Plasma clearance was evaluated in rhesus; Not tested,,,N,Intermediate,A,9615.0,CHEMBL624539,,,,,1,1
5848,50588,In vivo,BAO_0000218,,,Plasma clearance value was determined in dog after a 3 mg/kg of iv dose,,,N,Intermediate,A,9615.0,CHEMBL624540,,,,,1,1
5849,50588,In vivo,BAO_0000218,,,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,,N,Intermediate,A,9615.0,CHEMBL624541,,,,,1,1
5850,50588,In vivo,BAO_0000218,,,Plasma clearance was determined in Beagle dog at a dose of 1 mg/kg by iv administration,,,N,Intermediate,A,9615.0,CHEMBL624542,,,,,1,1
5851,50588,In vivo,BAO_0000218,,,Plasma clearance was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,,N,Intermediate,A,9615.0,CHEMBL624543,,,,,1,1
5852,50588,In vivo,BAO_0000218,,,Clearance value at a dose of 0.2 mg/kg i.v.,,,N,Intermediate,A,9615.0,CHEMBL624544,,,,,1,1
5853,50588,In vivo,BAO_0000218,,,Cmax (Maximum (Peak) plasma drug concentration) was after oral administration at 5 mg/kg,,,N,Intermediate,A,9615.0,CHEMBL624545,,1969.0,Plasma,,1,1
5854,50588,In vivo,BAO_0000218,,,Cmax after oral dose of compound at 3 mg/kg in dogs,,,N,Intermediate,A,9615.0,CHEMBL624546,,,,,1,1
5855,50588,In vivo,BAO_0000218,,,Cmax after single intravenous bolus of 1 mg/kg in dogs,,,N,Intermediate,A,9615.0,CHEMBL875957,,,,,1,1
5856,50588,In vivo,BAO_0000218,,,Cmax of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,,N,Intermediate,A,9615.0,CHEMBL624547,,,,,1,1
5857,50588,In vivo,BAO_0000218,,,Cmax in dog after administration of 0.25 mg/kg iv; ND = not determined,,,N,Intermediate,A,9615.0,CHEMBL624548,,,,,1,1
5858,50588,In vivo,BAO_0000218,,,Cmax in dog after administration of 1 mg/kg iv,,,N,Intermediate,A,9615.0,CHEMBL624549,,,,,1,1
5859,50588,In vivo,BAO_0000218,,,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in dog,,,N,Intermediate,A,9615.0,CHEMBL624550,,1969.0,Plasma,,1,1
5860,50588,In vivo,BAO_0000218,,,Cmax on p.o. administration of 10 mg/kg was measured in dog,,,N,Intermediate,A,9615.0,CHEMBL621613,,,,,1,1
5861,50588,In vivo,BAO_0000218,,,Cmax was determine after peroral administration at 10 mpk in dog,,,N,Intermediate,A,9615.0,CHEMBL621614,,,,,1,1
5862,50588,In vivo,BAO_0000218,,,Cmax was determine after peroral administration at 5 mpk in dog,,,N,Intermediate,A,9615.0,CHEMBL623431,,,,,1,1
5863,50588,In vivo,BAO_0000218,,,Cmax was determine after peroral administration at 5 mg/kg in dog,,,N,Intermediate,A,9615.0,CHEMBL623432,,,,,1,1
5864,50588,In vivo,BAO_0000218,,,Cmax after 0.3 mg/kg po administration in dog,,,N,Intermediate,A,9615.0,CHEMBL623433,,,,,1,1
5865,50588,In vivo,BAO_0000218,,,Cmax after peroral administration in dogs at 2.4 uM/kg,,,N,Intermediate,A,9615.0,CHEMBL623434,,,,,1,1
5866,50588,In vivo,BAO_0000218,,,Cmax in dog after oral administration at 1 mg/kg,,,N,Intermediate,A,9615.0,CHEMBL623435,,,,,1,1
5867,50588,In vivo,BAO_0000218,,,Cmax in dog after oral administration at 1 mg/kg; Below the level of quantitation,,,N,Intermediate,A,9615.0,CHEMBL623436,,,,,1,1
5868,50588,In vivo,BAO_0000218,,,Cmax upon oral administration in male Beagle dog at 10 mg/kg,,,N,Intermediate,A,9615.0,CHEMBL875958,,,,,1,1
5869,50588,In vivo,BAO_0000218,,,Cmax value after 15 mg/kg iv dose in Dogs,,,N,Intermediate,A,9615.0,CHEMBL623437,,,,,1,1
5870,50594,In vivo,BAO_0000218,,,Biodistribution in blood was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,,N,Intermediate,A,10090.0,CHEMBL623438,,178.0,Blood,,1,1
5871,50594,In vivo,BAO_0000218,,,Biodistribution in blood was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,,N,Intermediate,A,10090.0,CHEMBL623439,,178.0,Blood,,1,1
5872,50594,In vivo,BAO_0000218,,,Biodistribution in bone was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,,N,Intermediate,A,10090.0,CHEMBL623440,,10000001.0,Bone,,1,1
5873,50594,In vivo,BAO_0000218,,,Biodistribution in bone was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,,N,Intermediate,A,10090.0,CHEMBL623441,,10000001.0,Bone,,1,1
5874,50594,In vivo,BAO_0000218,,,Biodistribution in bone was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,,N,Intermediate,A,10090.0,CHEMBL623442,,10000001.0,Bone,,1,1
5875,50594,In vivo,BAO_0000218,,,Biodistribution in fat and fur was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,,N,Intermediate,A,10090.0,CHEMBL623469,,,,,1,1
5876,50594,In vivo,BAO_0000218,,,Biodistribution in fat and fur was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,,N,Intermediate,A,10090.0,CHEMBL623470,,,,,1,1
5877,50594,In vivo,BAO_0000218,,,Biodistribution in fat and fur was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,,N,Intermediate,A,10090.0,CHEMBL623471,,,,,1,1
5878,50594,In vivo,BAO_0000218,,,Biodistribution in heart was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,,N,Intermediate,A,10090.0,CHEMBL623472,,948.0,Heart,,1,1
5879,50594,In vivo,BAO_0000218,,,Biodistribution in heart was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,,N,Intermediate,A,10090.0,CHEMBL623473,,948.0,Heart,,1,1
5880,50594,In vivo,BAO_0000218,,,Biodistribution in heart was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,,N,Intermediate,A,10090.0,CHEMBL623474,,948.0,Heart,,1,1
5881,50594,In vivo,BAO_0000218,,,Biodistribution in kidney was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,,N,Intermediate,A,10090.0,CHEMBL623475,,2113.0,Kidney,,1,1
5882,50594,In vivo,BAO_0000218,,,Biodistribution in kidney was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,,N,Intermediate,A,10090.0,CHEMBL623476,,2113.0,Kidney,,1,1
5883,50594,In vivo,BAO_0000218,,,Biodistribution in kidney was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,,N,Intermediate,A,10090.0,CHEMBL623477,,2113.0,Kidney,,1,1
5884,50594,In vivo,BAO_0000218,,,Biodistribution in large intestine after iv administration at 1 hr; Value expressed as percent injected dose per gram,,,N,Intermediate,A,10090.0,CHEMBL621896,,160.0,Intestine,,1,1
5885,50594,In vivo,BAO_0000218,,,Biodistribution in large intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,,N,Intermediate,A,10090.0,CHEMBL621897,,160.0,Intestine,,1,1
5886,50594,In vivo,BAO_0000218,,,Biodistribution in large intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,,N,Intermediate,A,10090.0,CHEMBL621898,,160.0,Intestine,,1,1
5887,50594,In vivo,BAO_0000218,,,Biodistribution in liver was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,,N,Intermediate,A,10090.0,CHEMBL621899,,2107.0,Liver,,1,1
5888,50594,In vivo,BAO_0000218,,,Biodistribution in liver was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,,N,Intermediate,A,10090.0,CHEMBL621900,,2107.0,Liver,,1,1
5889,50594,In vivo,BAO_0000218,,,Biodistribution in liver was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,,N,Intermediate,A,10090.0,CHEMBL621901,,2107.0,Liver,,1,1
5890,50594,In vivo,BAO_0000218,,,Biodistribution in lung was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,,N,Intermediate,A,10090.0,CHEMBL621902,,2048.0,Lung,,1,1
5891,50594,In vivo,BAO_0000218,,,Biodistribution in lung was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,,N,Intermediate,A,10090.0,CHEMBL621903,,2048.0,Lung,,1,1
5892,50594,In vivo,BAO_0000218,,,Biodistribution in lung was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,,N,Intermediate,A,10090.0,CHEMBL622587,,2048.0,Lung,,1,1
5893,50594,In vivo,BAO_0000218,,,Biodistribution in muscle was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,,N,Intermediate,A,10090.0,CHEMBL620285,,2385.0,Muscle tissue,,1,1
5894,50594,In vivo,BAO_0000218,,,Biodistribution in muscle was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,,N,Intermediate,A,10090.0,CHEMBL875285,,2385.0,Muscle tissue,,1,1
5895,50594,In vivo,BAO_0000218,,,Biodistribution in muscle was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,,N,Intermediate,A,10090.0,CHEMBL620286,,2385.0,Muscle tissue,,1,1
5896,50594,In vivo,BAO_0000218,,,Biodistribution in pancreatic tissue was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,,N,Intermediate,A,10090.0,CHEMBL620287,,,,,1,1
5897,50594,In vivo,BAO_0000218,,,Biodistribution in pancreatic tissue was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,,N,Intermediate,A,10090.0,CHEMBL620288,,,,,1,1
5898,50594,In vivo,BAO_0000218,,,Biodistribution in pancreatic tissue was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,,N,Intermediate,A,10090.0,CHEMBL620289,,,,,1,1
5899,50594,In vivo,BAO_0000218,,,Biodistribution in small intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,,N,Intermediate,A,10090.0,CHEMBL620290,,160.0,Intestine,,1,1
5900,50594,In vivo,BAO_0000218,,,Biodistribution in small intestine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,,N,Intermediate,A,10090.0,CHEMBL620291,,160.0,Intestine,,1,1
5901,50594,In vivo,BAO_0000218,,,Biodistribution in small intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,,N,Intermediate,A,10090.0,CHEMBL620292,,160.0,Intestine,,1,1
5902,50594,In vivo,BAO_0000218,,,Biodistribution in spleen was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,,N,Intermediate,A,10090.0,CHEMBL620293,,2106.0,Spleen,,1,1
5903,50594,In vivo,BAO_0000218,,,Biodistribution in spleen was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,,N,Intermediate,A,10090.0,CHEMBL620294,,2106.0,Spleen,,1,1
5904,50594,In vivo,BAO_0000218,,,Biodistribution in spleen was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,,N,Intermediate,A,10090.0,CHEMBL618614,,2106.0,Spleen,,1,1
5905,50594,In vivo,BAO_0000218,,,Biodistribution in stomach was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,,N,Intermediate,A,10090.0,CHEMBL618615,,945.0,Stomach,,1,1
5906,50594,In vivo,BAO_0000218,,,Biodistribution in stomach was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,,N,Intermediate,A,10090.0,CHEMBL618616,,945.0,Stomach,,1,1
5907,80012,,BAO_0000219,622.0,A 172,Cytotoxicity against A-172 human tumor cell lines,,,N,Expert,F,9606.0,CHEMBL618617,,,,,1,1
5908,80012,,BAO_0000219,622.0,A 172,Compound was evaluated for the in vitro cytotoxicity against A-172 human glioblastoma cell line,,,N,Intermediate,F,9606.0,CHEMBL618618,,,,,1,1
5909,80014,,BAO_0000219,623.0,A204,Antiproliferative activity of compound was tested against rhabdomyosarcoma (A-204) human tumor cells,,,N,Intermediate,F,9606.0,CHEMBL618619,,,,,1,1
5910,81034,,BAO_0000219,478.0,A2780,Tested for antiproliferative activity against A-2780 tumoral cell line,,,N,Intermediate,F,9606.0,CHEMBL618620,,,,,1,1
5911,80018,,BAO_0000219,455.0,A-375,Inhibitory concentration against melanoma A-375 cell line for cytotoxicity was determined,,,N,Intermediate,F,9606.0,CHEMBL618621,,,,,1,1
5912,80018,,BAO_0000219,455.0,A-375,Tested in vitro against A-375 cell line human melanoma,,,N,Intermediate,F,9606.0,CHEMBL618622,,,,,1,1
5913,80019,,BAO_0000219,797.0,A-427,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay,,,N,Expert,F,9606.0,CHEMBL618623,,,,,1,1
5914,80019,,BAO_0000219,797.0,A-427,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,,N,Intermediate,F,9606.0,CHEMBL618624,,,,,1,1
5915,80019,,BAO_0000219,797.0,A-427,In vitro cytotoxicity against human non small-cell-lung cell line A-427.,,,N,Expert,F,9606.0,CHEMBL618625,,,,,1,1
5916,80019,,BAO_0000219,797.0,A-427,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,,N,Intermediate,F,9606.0,CHEMBL618626,,,,,1,1
5917,80019,,BAO_0000219,797.0,A-427,Antitumor activity on A-427 lung carcinoma cell lines,,,N,Intermediate,F,9606.0,CHEMBL618627,,,,,1,1
5918,80019,,BAO_0000219,797.0,A-427,Cytotoxic activity against human A-427 lung tumor cell line,,,N,Intermediate,F,9606.0,CHEMBL618628,,,,,1,1
5919,80019,,BAO_0000219,797.0,A-427,In vitro antitumor effects against human A-427 cell lines.,,,N,Expert,F,9606.0,CHEMBL618629,,,,,1,1
5920,80019,,BAO_0000219,797.0,A-427,In vitro inhibition of A-427 (human lung cancer) cell growth.,,,N,Expert,F,9606.0,CHEMBL618630,,,,,1,1
5921,80019,,BAO_0000219,797.0,A-427,Cytotoxic related antitumor activity against human cancer cell lines A-427; No data available,,,N,Intermediate,F,9606.0,CHEMBL618631,,,,,1,1
5922,80019,,BAO_0000219,797.0,A-427,Cytotoxic activity of compound against A-427 lung human tumor cell line,,,N,Intermediate,F,9606.0,CHEMBL618632,,,,,1,1
5923,80852,,BAO_0000219,500.0,A-431,Cytotoxicity measured for the growth inhibition of A-431 Human epidermoid carcinoma cell line,,,N,Expert,F,9606.0,CHEMBL618633,,,,,1,1
5924,80021,,BAO_0000219,624.0,A498,Cytotoxic activity was tested against human A-498 (Kidney carcinoma) cell line,,,N,Intermediate,F,9606.0,CHEMBL619315,,,,,1,1
5925,80021,,BAO_0000219,624.0,A498,Cytotoxicity against A-498 cell line in the purdue cell culture screen was determined,,,N,Expert,F,9606.0,CHEMBL619316,,,,,1,1
5926,80021,,BAO_0000219,624.0,A498,Cytotoxicity against human kidney carcinoma A-498cell lines,,,N,Intermediate,F,9606.0,CHEMBL619317,,,,,1,1
5927,80021,,BAO_0000219,624.0,A498,In vitro cytotoxic activity against A-498 (human kidney carcinoma) cell line,,,N,Intermediate,F,9606.0,CHEMBL619318,,,,,1,1
5928,80021,,BAO_0000219,624.0,A498,In vitro cytotoxicity against Renal A-498 human tumors following a 6 day exposure.,,,N,Intermediate,F,9606.0,CHEMBL619319,,,,,1,1
5929,80021,,BAO_0000219,624.0,A498,Antitumor cytotoxic activity against A-498 cell line was determined,,,N,Intermediate,F,9606.0,CHEMBL619739,,,,,1,1
5930,80021,,BAO_0000219,624.0,A498,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure.,,,N,Intermediate,F,9606.0,CHEMBL619740,,,,,1,1
5931,80021,,BAO_0000219,624.0,A498,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure; ND is no data,,,N,Intermediate,F,9606.0,CHEMBL883158,,,,,1,1
5932,80021,,BAO_0000219,624.0,A498,Antiproliferative activity of compound was tested against renal cancer (A-498) human tumor cells,,,N,Intermediate,F,9606.0,CHEMBL884012,,,,,1,1
5933,80021,,BAO_0000219,624.0,A498,In vitro inhibitory activity against A-498 ovarian cancer cell lines,,,N,Intermediate,F,9606.0,CHEMBL619741,,,,,1,1
5934,80021,,BAO_0000219,624.0,A498,"Cytotoxicity against NCI tumor panel, A-498 renal cancer cell line",,,N,Intermediate,F,9606.0,CHEMBL619742,,,,,1,1
5935,80682,,BAO_0000219,646.0,A549,Inhibition of growth lung non-small cell carcinoma A-549 cell line,,,N,Intermediate,F,9606.0,CHEMBL876610,,,,,1,1
5936,80682,,BAO_0000219,646.0,A549,Inhibition of growth of lung non-small cell carcinoma A-549 cell line,,,N,Intermediate,F,9606.0,CHEMBL619743,,,,,1,1
5937,80682,,BAO_0000219,646.0,A549,In vitro antiproliferative activity against human A-549 NSCL cell line,,,N,Intermediate,F,9606.0,CHEMBL619744,,,,,1,1
5938,80682,,BAO_0000219,646.0,A549,In vitro antiproliferative activity against human A-549 NSCL cell line; NS = Not significant,,,N,Intermediate,F,9606.0,CHEMBL619745,,,,,1,1
5939,80682,,BAO_0000219,646.0,A549,Growth inhibition of A-549 human lung adenocarcinoma at 0.01 uM compound concentration in standard MTT assay,,,N,Intermediate,F,9606.0,CHEMBL619746,,,,,1,1
5940,80682,,BAO_0000219,646.0,A549,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay,,,N,Intermediate,F,9606.0,CHEMBL619747,,,,,1,1
5941,80682,,BAO_0000219,646.0,A549,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay; ND means No data,,,N,Intermediate,F,9606.0,CHEMBL619748,,,,,1,1
5942,80682,,BAO_0000219,646.0,A549,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay,,,N,Intermediate,F,9606.0,CHEMBL619749,,,,,1,1
5943,80682,,BAO_0000219,646.0,A549,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay; ND means No data,,,N,Intermediate,F,9606.0,CHEMBL619750,,,,,1,1
5944,80682,,BAO_0000219,646.0,A549,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay,,,N,Intermediate,F,9606.0,CHEMBL624014,,,,,1,1
5945,80682,,BAO_0000219,646.0,A549,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay; ND means No data,,,N,Intermediate,F,9606.0,CHEMBL624015,,,,,1,1
5946,80682,,BAO_0000219,646.0,A549,In vitro effective concentration required to reduce the number of human lung carcinoma (A-549) after 3-day incubation,,,N,Expert,F,9606.0,CHEMBL885344,,,,,1,1
5947,80682,,BAO_0000219,646.0,A549,In vitro effective concentration required to reduce the number of human lung carcinoma cells (A-549) after 3-day incubation,,,N,Intermediate,F,9606.0,CHEMBL623224,,,,,1,1
5948,80682,,BAO_0000219,646.0,A549,Cytotoxic activity against A-549 cell line,,,N,Intermediate,F,9606.0,CHEMBL623225,,,,,1,1
5949,80682,,BAO_0000219,646.0,A549,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 0.01 to 0.03,,,N,Intermediate,F,9606.0,CHEMBL622698,,,,,1,1
5950,80682,,BAO_0000219,646.0,A549,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 10.4 to 118.1,,,N,Intermediate,F,9606.0,CHEMBL622699,,,,,1,1
5951,80682,,BAO_0000219,646.0,A549,"Cytotoxicity in vitro expressed as 50% reduction in cell number after a 3-day incubation, in human lung carcinoma A-549 cell line",,,N,Expert,F,9606.0,CHEMBL622700,,,,,1,1
5952,80682,,BAO_0000219,646.0,A549,Compound was tested for cytotoxic activity against human lung carcinoma (A-549),,,N,Intermediate,F,9606.0,CHEMBL622701,,,,,1,1
5953,80682,,BAO_0000219,646.0,A549,Compound was tested for its cytotoxic activity in MTT assay against A-549 cell line (human lung carcinoma),,,N,Intermediate,F,9606.0,CHEMBL622702,,,,,1,1
5954,80682,,BAO_0000219,646.0,A549,Cytotoxic activity against human lung carcinoma (A-549) cell line,,,N,Intermediate,F,9606.0,CHEMBL622703,,,,,1,1
5955,80682,,BAO_0000219,646.0,A549,Cytotoxic activity towards A-549 cells,,,N,Expert,F,9606.0,CHEMBL622704,,,,,1,1
5956,80682,,BAO_0000219,646.0,A549,"In vitro percent inhibition of A549, lung carcinoma.",,,N,Intermediate,F,9606.0,CHEMBL622705,,,,,1,1
5957,80682,,BAO_0000219,646.0,A549,"In vitro percent inhibition of A549, lung carcinoma",,,N,Intermediate,F,9606.0,CHEMBL622706,,,,,1,1
5958,80682,,BAO_0000219,646.0,A549,"In vitro percent inhibition of A549, lung carcinoma.",,,N,Intermediate,F,9606.0,CHEMBL622707,,,,,1,1
5959,80682,,BAO_0000219,646.0,A549,"In vitro percent inhibition of A549, lung carcinoma.; Range 18-23",,,N,Intermediate,F,9606.0,CHEMBL622708,,,,,1,1
5960,80682,,BAO_0000219,646.0,A549,Percentage inhibition against parental and drug resistant lung human tumor cell line A549 at 10 uM,,,N,Intermediate,F,9606.0,CHEMBL622709,,,,,1,1
5961,80682,,BAO_0000219,646.0,A549,Growth inhibition of the A549/ATCC non-small cell lung cancer cell line for 2-day in vitro assay.,,,N,Intermediate,F,9606.0,CHEMBL622710,,,,,1,1
5962,80682,,BAO_0000219,646.0,A549,In vitro antitumor activity against Non-small cell lung cancer A549/ATCC cell lines by 6-day assay,,,N,Intermediate,F,9606.0,CHEMBL622711,,,,,1,1
5963,80682,,BAO_0000218,646.0,A549,"Antitumor activity against A549 non small cell carcinoma at dose range of 1.56-6.25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,,N,Intermediate,F,9606.0,CHEMBL622712,,,,,1,1
5964,80682,,BAO_0000218,646.0,A549,"Antitumor activity against A549 non small cell carcinoma at dose range of 25-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,,N,Intermediate,F,9606.0,CHEMBL622713,,,,,1,1
5965,80682,,BAO_0000218,646.0,A549,"Antitumor activity against A549 non small cell carcinoma at dose range of 3.12-12.5 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,,N,Intermediate,F,9606.0,CHEMBL622714,,,,,1,1
5966,80682,,BAO_0000218,646.0,A549,"Antitumor activity against A549 non small cell carcinoma at dose range of 6.25-25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,,N,Intermediate,F,9606.0,CHEMBL622715,,,,,1,1
5967,80682,,BAO_0000218,646.0,A549,"Antitumor activity against A549 non small cell carcinoma at dose range of 70-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,,N,Intermediate,F,9606.0,CHEMBL622716,,,,,1,1
5968,80682,,BAO_0000219,646.0,A549,"Antitumor activity against A549 non small cell carcinoma on day 14, 21, 28; activity expressed as maximum tolerated dose; NT = Not tested",,,N,Intermediate,F,9606.0,CHEMBL622717,,,,,1,1
5969,80682,,BAO_0000218,646.0,A549,Optimal dose required to inhibit human non small cell lung A549 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q7dX3),,,N,Intermediate,F,9606.0,CHEMBL622718,,,,,1,1
5970,80682,,BAO_0000219,646.0,A549,Cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration,,,N,Expert,F,9606.0,CHEMBL622719,,,,,1,1
5971,80682,,BAO_0000219,646.0,A549,Compound was evaluated for cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,,,N,Intermediate,F,9606.0,CHEMBL622720,,,,,1,1
5972,80682,,BAO_0000219,646.0,A549,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration,,,N,Intermediate,F,9606.0,CHEMBL622721,,,,,1,1
5973,80682,,BAO_0000219,646.0,A549,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,,,N,Intermediate,F,9606.0,CHEMBL622722,,,,,1,1
5974,80682,,BAO_0000219,646.0,A549,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,,,N,Intermediate,F,9606.0,CHEMBL876030,,,,,1,1
5975,80682,,BAO_0000219,646.0,A549,"Concentration required for 50% inhibition of proliferation of lung cancer cell line, A549 with respect to paclitaxel was tested in vitro after 72 hr of incubation",,,N,Intermediate,F,9606.0,CHEMBL620206,,,,,1,1
5976,80682,,BAO_0000219,646.0,A549,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-4 mol/L,,,N,Expert,F,9606.0,CHEMBL620207,,,,,1,1
5977,80682,,BAO_0000219,646.0,A549,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-5 mol/L,,,N,Expert,F,9606.0,CHEMBL620208,,,,,1,1
5978,80682,,BAO_0000219,646.0,A549,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-6 mol/L,,,N,Expert,F,9606.0,CHEMBL620209,,,,,1,1
5979,80682,,BAO_0000219,646.0,A549,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-7 mol/L,,,N,Expert,F,9606.0,CHEMBL620210,,,,,1,1
5980,80682,,BAO_0000219,646.0,A549,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-8 mol/L,,,N,Expert,F,9606.0,CHEMBL621639,,,,,1,1
5981,80682,,BAO_0000219,646.0,A549,Tested for cytotoxicity against human lung adenocarcinoma A549 cell line,,,N,Intermediate,F,9606.0,CHEMBL621640,,,,,1,1
5982,80682,,BAO_0000219,646.0,A549,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,,,N,Expert,F,9606.0,CHEMBL621641,,,,,1,1
5983,80682,,BAO_0000219,646.0,A549,Cytotoxic effect on non-small-cell lung cancer cell line A549/ATCC,,,N,Expert,F,9606.0,CHEMBL621642,,,,,1,1
5984,80682,,BAO_0000219,646.0,A549,Cytotoxicity of compound in synergy in 94% BCNU (10 uM) against A549 cell line,,,N,Intermediate,F,9606.0,CHEMBL621643,,,,,1,1
5985,80682,,BAO_0000219,646.0,A549,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line,,,N,Intermediate,F,9606.0,CHEMBL621644,,,,,1,1
5986,80682,,BAO_0000219,646.0,A549,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line; No data,,,N,Intermediate,F,9606.0,CHEMBL621645,,,,,1,1
5987,80682,,BAO_0000219,646.0,A549,In vitro antiproliferative activity against A549 cell line,,,N,Intermediate,F,10090.0,CHEMBL621646,,,,,1,1
5988,80682,,BAO_0000219,646.0,A549,Synergism with indomethacin in A549 cells,,,N,Intermediate,F,,CHEMBL621647,,,,,1,1
5989,80682,,BAO_0000219,646.0,A549,Synergism with tolmetin in A549 cells,,,N,Intermediate,F,,CHEMBL621648,,,,,1,1
5990,80682,,BAO_0000219,646.0,A549,Synergism with sulindac in A549 cells,,,N,Intermediate,F,,CHEMBL621649,,,,,1,1
5991,80682,,BAO_0000219,646.0,A549,Antagonism of indomethacin in A549 cells,,,N,Intermediate,F,,CHEMBL621650,,,,,1,1
5992,80682,,BAO_0000219,646.0,A549,Antagonism of sulindac in A549 cells,,,N,Intermediate,F,,CHEMBL621651,,,,,1,1
5993,80682,,BAO_0000219,646.0,A549,Antagonism of tolmetin in A549 cells,,,N,Intermediate,F,,CHEMBL621652,,,,,1,1
5994,80682,,BAO_0000219,646.0,A549,Synergism with indomethacin in A549 cells,,,N,Intermediate,F,,CHEMBL621653,,,,,1,1
5995,80682,,BAO_0000219,646.0,A549,Synergism with sulindac in A549 cells,,,N,Intermediate,F,,CHEMBL621654,,,,,1,1
5996,80682,,BAO_0000219,646.0,A549,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tolmetin; Not available,,,N,Intermediate,F,,CHEMBL621655,,,,,1,1
5997,50588,In vivo,BAO_0000218,,,Cmax value after 30 mg/kg po dose in Dogs,,,N,Intermediate,A,9615.0,CHEMBL621656,,,,,1,1
5998,50588,In vivo,BAO_0000218,,,Cmax value determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),,,N,Intermediate,A,9615.0,CHEMBL621657,,,,,1,1
5999,50588,In vivo,BAO_0000218,,,Cmax value determined in dog at a dose of 10 mg/kg by oral administration,,,N,Intermediate,A,9615.0,CHEMBL621658,,,,,1,1
6000,50588,In vivo,BAO_0000218,,,Cmax value determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),,,N,Intermediate,A,9615.0,CHEMBL621659,,,,,1,1
6001,50588,In vivo,BAO_0000218,,,Cmax value determined in dog at a dose of 5 mg/kg by oral administration,,,N,Intermediate,A,9615.0,CHEMBL621660,,,,,1,1
6002,50588,In vivo,BAO_0000218,,,Cmax value after administration of 4 mg/Kg oral dose in dog,,,N,Intermediate,A,9615.0,CHEMBL621661,,,,,1,1
6003,50588,In vivo,BAO_0000218,,,Cmax value in dog,,,N,Intermediate,A,9615.0,CHEMBL621662,,,,,1,1
6004,50588,In vivo,BAO_0000218,,,Cmax value in dogs after oral administration at 1 mg/kg,,,N,Intermediate,A,9615.0,CHEMBL621663,,,,,1,1
6005,50588,In vivo,BAO_0000218,,,Bioavailability as Cmax in dogs at 5 mg/kg oral dose,,,N,Intermediate,A,9615.0,CHEMBL621664,,,,,1,1
6006,50588,In vivo,BAO_0000218,,,Compound was evaluated for maximum observed plasma concentration at dose 27.5 mg/kg DMP323 equiv in dogs,,,N,Intermediate,A,9615.0,CHEMBL621665,,1969.0,Plasma,,1,1
6007,50588,In vivo,BAO_0000218,,,Compound was evaluated for maximum observed plasma concentration at dose 7.7 mg/kg DMP323 equiv in dogs,,,N,Intermediate,A,9615.0,CHEMBL621666,,1969.0,Plasma,,1,1
6008,50588,In vivo,BAO_0000218,,,Concentration maxima after oral dosing in dogs,,,N,Intermediate,A,9615.0,CHEMBL621667,,,,,1,1
6009,50588,In vivo,BAO_0000218,,,Concentration maxima after oral dosing in dogs; not available,,,N,Intermediate,A,9615.0,CHEMBL876738,,,,,1,1
6010,50588,In vivo,BAO_0000218,,,Concentration maxima after oral dosing in dogs; not available,,,N,Intermediate,A,9615.0,CHEMBL621668,,,,,1,1
6011,50588,In vivo,BAO_0000218,,,In vivo maximal concentration was calculated at 0.4 mg/kg in dog; Not absorbed,,,N,Intermediate,A,9615.0,CHEMBL621669,,,,,1,1
6012,50588,In vivo,BAO_0000218,,,In vivo maximal concentration was calculated at 0.6 mg/kg in dog; Not absorbed,,,N,Intermediate,A,9615.0,CHEMBL621670,,,,,1,1
6013,50588,In vivo,BAO_0000218,,,In vivo maximal concentration was calculated at 1 mg/kg in dog,,,N,Intermediate,A,9615.0,CHEMBL621671,,,,,1,1
6014,50588,In vivo,BAO_0000218,,,In vivo maximal concentration was calculated at 1 mg/kg in dog; Not absorbed,,,N,Intermediate,A,9615.0,CHEMBL622360,,,,,1,1
6015,50588,In vivo,BAO_0000218,,,In vivo maximal concentration was calculated at 1 mg/kg in dog; Poor absorption,,,N,Intermediate,A,9615.0,CHEMBL622361,,,,,1,1
6016,50588,In vivo,BAO_0000218,,,Cmax in dog plasma after oral dose (1 mg/kg),,,N,Intermediate,A,9615.0,CHEMBL622362,,1969.0,Plasma,,1,1
6017,50588,In vivo,BAO_0000218,,,Maximal concentration (Cmax) in dog plasma at a dose of 5 mg/kg,,,N,Intermediate,A,9615.0,CHEMBL622363,,1969.0,Plasma,,1,1
6018,50588,In vivo,BAO_0000218,,,Maximal plasma concentration at a dose of 1 mg/kg,,,N,Intermediate,A,9615.0,CHEMBL622364,,1969.0,Plasma,,1,1
6019,50588,In vivo,BAO_0000218,,,Maximal plasma concentration at a dose of 1 mg/kg (oral),,,N,Intermediate,A,9615.0,CHEMBL622365,,1969.0,Plasma,,1,1
6020,50588,In vivo,BAO_0000218,,,Maximal plasma concentration required for pharmacokinetic data in dogs at dose of 1 mg/kg perorally,,,N,Intermediate,A,9615.0,CHEMBL622533,,1969.0,Plasma,,1,1
6021,50588,In vivo,BAO_0000218,,,Maximum concentration of compound in dog was evaluated.,,,N,Intermediate,A,9615.0,CHEMBL622534,,,,,1,1
6022,50588,In vivo,BAO_0000218,,,Maximum concentration by oral administration at a dose of 10 uM/kg in dog was determined,,,N,Intermediate,A,9615.0,CHEMBL622535,,,,,1,1
6023,50588,In vivo,BAO_0000218,,,Maximum concentration in dog after administration of 20 mg/kg dose through peroral route,,,N,Intermediate,A,9615.0,CHEMBL876739,,,,,1,1
6024,50588,In vivo,BAO_0000218,,,Maximum concentration in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,,N,Intermediate,A,9615.0,CHEMBL622536,,,,,1,1
6025,50588,In vivo,BAO_0000218,,,Maximum concentration obtained in dog plasma was determined,,,N,Intermediate,A,9615.0,CHEMBL622537,,1969.0,Plasma,,1,1
6026,50588,In vivo,BAO_0000218,,,Maximum concentration was determined,,,N,Intermediate,A,9615.0,CHEMBL622538,,,,,1,1
6027,50588,In vivo,BAO_0000218,,,Maximum concentration at the dose of 2 mg/kg in dog,,,N,Intermediate,A,9615.0,CHEMBL627867,,,,,1,1
6028,50588,In vivo,BAO_0000218,,,Maximum concentration was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,,N,Intermediate,A,9615.0,CHEMBL627868,,,,,1,1
6029,50588,In vivo,BAO_0000218,,,Maximum concentration was evaluated in dog plasma,,,N,Intermediate,A,9615.0,CHEMBL627869,,1969.0,Plasma,,1,1
6030,50588,In vivo,BAO_0000218,,,Maximum concentration was evaluated after 75 min after administration in dog,,,N,Intermediate,A,9615.0,CHEMBL627870,,,,,1,1
6031,50588,In vivo,BAO_0000218,,,Maximum plasma concentration determined in dog after oral administration of 17b,,,N,Intermediate,A,9615.0,CHEMBL627871,,1969.0,Plasma,,1,1
6032,50588,In vivo,BAO_0000218,,,Maximum plasma concentration determined in dog after oral administration of 2b,,,N,Intermediate,A,9615.0,CHEMBL627872,,1969.0,Plasma,,1,1
6033,50588,In vivo,BAO_0000218,,,Maximum plasma concentration in dog,,,N,Intermediate,A,9615.0,CHEMBL627873,,1969.0,Plasma,,1,1
6034,50588,In vivo,BAO_0000218,,,Maximum plasma concentration of compound in dog following p.o. administration of 0.5 mg/kg,,,N,Intermediate,A,9615.0,CHEMBL627874,,1969.0,Plasma,,1,1
6035,50588,In vivo,BAO_0000218,,,Maximum plasma concentration of compound in dog following p.o. administration of 0.9 mg/kg,,,N,Intermediate,A,9615.0,CHEMBL627875,,1969.0,Plasma,,1,1
6036,50588,In vivo,BAO_0000218,,,Maximum plasma concentration of compound in dog following p.o. administration of 0.95 mg/kg,,,N,Intermediate,A,9615.0,CHEMBL627876,,1969.0,Plasma,,1,1
6037,50588,In vivo,BAO_0000218,,,Maximum plasma concentration of compound in dog following p.o. administration of 1 mg/kg,,,N,Intermediate,A,9615.0,CHEMBL627877,,1969.0,Plasma,,1,1
6038,50588,In vivo,BAO_0000218,,,Maximum plasma concentration of compound was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,,N,Intermediate,A,9615.0,CHEMBL627878,,1969.0,Plasma,,1,1
6039,50588,In vivo,BAO_0000218,,,Maximum plasma concentration after oral administration to dogs at a dose of 10 mg/kg,,,N,Intermediate,A,9615.0,CHEMBL627879,,1969.0,Plasma,,1,1
6040,50588,In vivo,BAO_0000218,,,Maximum plasma concentration in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,,,N,Intermediate,A,9615.0,CHEMBL875355,,1969.0,Plasma,,1,1
6041,50588,In vivo,BAO_0000218,,,Maximum plasma concentration in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,,,N,Intermediate,A,9615.0,CHEMBL627880,,1969.0,Plasma,,1,1
6042,50588,In vivo,BAO_0000218,,,Maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,,,N,Intermediate,A,9615.0,CHEMBL627881,,1969.0,Plasma,,1,1
6043,50588,In vivo,BAO_0000218,,,Maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,,,N,Intermediate,A,9615.0,CHEMBL627882,,1969.0,Plasma,,1,1
6044,50588,In vivo,BAO_0000218,,,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,,,N,Intermediate,A,9615.0,CHEMBL627883,,1969.0,Plasma,,1,1
6045,50588,In vivo,BAO_0000218,,,Maximum plasma concentration was determined as in dogs at 1 mg/kg oral dosing Cmax; 0.05-0.2 ug/mL,,,N,Intermediate,A,9615.0,CHEMBL628526,,1969.0,Plasma,,1,1
6046,50588,In vivo,BAO_0000218,,,Maximum plasma concentration was determined in dogs at 1 mg/kg oral dosing; 0.05-0.2 ug/mL,,,N,Intermediate,A,9615.0,CHEMBL628527,,1969.0,Plasma,,1,1
6047,50588,In vivo,BAO_0000218,,,Maximum plasma concentration (Cmax) in dog (in vivo) at a dose of 1 mg/kg,,,N,Intermediate,A,9615.0,CHEMBL628528,,1969.0,Plasma,,1,1
6048,50588,In vivo,BAO_0000218,,,Maximum plasma concentration (Cmax) in dog at a dose of 0.5 mg/kg,,,N,Intermediate,A,9615.0,CHEMBL628529,,1969.0,Plasma,,1,1
6049,50588,In vivo,BAO_0000218,,,Maximum plasma concentration (Cmax) in dog at a dose of 0.7 mg/kg,,,N,Intermediate,A,9615.0,CHEMBL628530,,1969.0,Plasma,,1,1
6050,50588,In vivo,BAO_0000218,,,Maximum plasma concentration (Cmax) in dog at a dose of 1 mg/kg,,,N,Intermediate,A,9615.0,CHEMBL625243,,1969.0,Plasma,,1,1
6051,50588,In vivo,BAO_0000218,,,Maximum plasma drug concentration of compound determined in dog after iv administration at a dose of 10 mg/kg,,,N,Expert,A,9615.0,CHEMBL625244,,1969.0,Plasma,,1,1
6052,50588,In vivo,BAO_0000218,,,Maximum concentration by intravenous administration of 1.2 mg/kg in dog,,,N,Intermediate,A,9615.0,CHEMBL625245,,,,,1,1
6053,50588,In vivo,BAO_0000218,,,Pharmacokinetic (PK) property (Cmax) was determined in dog at the single dose of 1 mg/kg,,,N,Intermediate,A,9615.0,CHEMBL625246,,,,,1,1
6054,50594,In vivo,BAO_0000218,,,Biodistribution in stomach was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,,N,Intermediate,A,10090.0,CHEMBL625247,,945.0,Stomach,,1,1
6055,50594,In vivo,BAO_0000218,,,Biodistribution in urine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,,N,Intermediate,A,10090.0,CHEMBL625248,,1088.0,Urine,,1,1
6056,50594,In vivo,BAO_0000218,,,Biodistribution in urine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram; ND- No data,,,N,Intermediate,A,10090.0,CHEMBL625249,,1088.0,Urine,,1,1
6057,50594,In vivo,BAO_0000218,,,Biodistribution in urine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram; ND- No data,,,N,Intermediate,A,10090.0,CHEMBL625250,,1088.0,Urine,,1,1
6058,50594,,BAO_0000218,,,Compound (0.09% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 120 min; No increase,,,N,Intermediate,A,10090.0,CHEMBL625251,,,,,1,1
6059,50594,,BAO_0000218,,,Compound (0.31% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 30 min; Low increase,,,N,Intermediate,A,10090.0,CHEMBL875356,,,,,1,1
6060,50594,,BAO_0000218,,,Compound (i.v.) was tested for maximum activity in mice (Radiolabeled compound),,,N,Intermediate,A,10090.0,CHEMBL625252,,,,,1,1
6061,50594,,BAO_0000218,,,Compound was evaluated for elimination rate constants in vivo in whole blood of normal mice (Radiolabeled compound),,,N,Intermediate,A,10090.0,CHEMBL625253,,178.0,Blood,,1,1
6062,50594,,BAO_0000218,,,Compound was evaluated for rate of bone uptake after administration of radiolabeled in mice (Radiolabeled compound),,,N,Intermediate,A,10090.0,CHEMBL625254,,,,,1,1
6063,50594,,BAO_0000218,,,Compound was evaluated for rate of bone uptake in mice (Radiolabeled compound),,,N,Intermediate,A,10090.0,CHEMBL625255,,,,,1,1
6064,50594,,BAO_0000218,,,Compound was evaluated for rate of bone uptake in mice; NA - not active (Radiolabeled compound),,,N,Intermediate,A,10090.0,CHEMBL625256,,,,,1,1
6065,50594,,BAO_0000218,,,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice (Radiolabeled compound),,,N,Intermediate,A,10090.0,CHEMBL625257,,178.0,Blood,,1,1
6066,50594,,BAO_0000218,,,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice; NA = not active (Radiolabeled compound),,,N,Intermediate,A,10090.0,CHEMBL625258,,178.0,Blood,,1,1
6067,50594,,BAO_0000218,,,Compound was evaluated for washout rate in mice (Radiolabeled compound),,,N,Intermediate,A,10090.0,CHEMBL625259,,,,,1,1
6068,50594,,BAO_0000218,,,Compound was evaluated for washout rate in mice after radiolabeled ligand injected,,,N,Intermediate,A,10090.0,CHEMBL625260,,,,,1,1
6069,50594,,BAO_0000218,,,"Maximum activity (i.v.) after in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,,N,Intermediate,A,10090.0,CHEMBL625261,,,,,1,1
6070,50594,,BAO_0000218,,,"Maximum activity in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,,N,Intermediate,A,10090.0,CHEMBL625262,,,,,1,1
6071,50594,,BAO_0000218,,,"Residual activity in mice at 120 minutes, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,,N,Intermediate,A,10090.0,CHEMBL622639,,,,,1,1
6072,50594,,BAO_0000218,,,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice,,,N,Intermediate,A,10090.0,CHEMBL622640,,,,,1,1
6073,50594,,BAO_0000218,,,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice; Not detected.,,,N,Intermediate,A,10090.0,CHEMBL622812,,,,,1,1
6074,50594,,BAO_0000218,,,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice,,,N,Intermediate,A,10090.0,CHEMBL622813,,,,,1,1
6075,50594,,BAO_0000218,,,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice; Not determined,,,N,Intermediate,A,10090.0,CHEMBL622814,,,,,1,1
6076,50594,,BAO_0000218,,,Time at maximum activity in mice (Radiolabeled compound),,,N,Intermediate,A,10090.0,CHEMBL622815,,,,,1,1
6077,50594,,BAO_0000218,,,Percent oral bioavailability was determined after administration of compound at 5 mg/kg perorally in mice,,,N,Intermediate,A,10090.0,CHEMBL625342,,,,,1,1
6078,50594,,BAO_0000218,,,Percent oral bioavailability was determined after administration of compound at 50 mg/kg perorally in mice,,,N,Intermediate,A,10090.0,CHEMBL625343,,,,,1,1
6079,50594,,BAO_0000218,,,Binding towards mouse plasma protein at 10 uM,,,N,Intermediate,A,10090.0,CHEMBL877591,,,,,1,1
6080,50594,,BAO_0000218,,,Binding towards mouse plasma protein at 100 uM,,,N,Intermediate,A,10090.0,CHEMBL625344,,,,,1,1
6081,50594,In vivo,BAO_0000218,,,Bioavailability was evaluated in mice after intravenous administration,,,N,Intermediate,A,10090.0,CHEMBL625345,,,,,1,1
6082,50594,In vivo,BAO_0000218,,,Bioavailability was evaluated in mice after oral administration,,,N,Intermediate,A,10090.0,CHEMBL625346,,,,,1,1
6083,50594,In vivo,BAO_0000218,,,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse,,,N,Intermediate,A,10090.0,CHEMBL625347,,,,,1,1
6084,50594,In vivo,BAO_0000218,,,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse at dose 25 mg/kg,,,N,Intermediate,A,10090.0,CHEMBL625348,,,,,1,1
6085,50594,In vivo,BAO_0000218,,,Bioavailability at a dose of 10 mg/kg peroral administration in mice.,,,N,Intermediate,A,10090.0,CHEMBL625349,,,,,1,1
6086,50594,In vivo,BAO_0000218,,,Oral bioavailability in mouse,,,N,Intermediate,A,10090.0,CHEMBL625350,,,,,1,1
6087,50594,In vivo,BAO_0000218,,,Oral bioavailability after intravenous administration in mice at 24 uM/kg,,,N,Intermediate,A,10090.0,CHEMBL882952,,,,,1,1
6088,50594,In vivo,BAO_0000218,,,Biodistribution of [123I]- labeled compound in mice brain was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,,,N,Intermediate,A,10090.0,CHEMBL625351,,955.0,Brain,,1,1
6089,50594,In vivo,BAO_0000218,,,Biodistribution of [123I]- labeled compound in mice brain was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,,,N,Intermediate,A,10090.0,CHEMBL625352,,955.0,Brain,,1,1
6090,50594,In vivo,BAO_0000218,,,Biodistribution of [123I]- labeled compound in mice brain was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,,,N,Intermediate,A,10090.0,CHEMBL877592,,955.0,Brain,,1,1
6091,50594,In vivo,BAO_0000218,,,Biodistribution of [123I]- labeled compound in mice brain was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,,,N,Intermediate,A,10090.0,CHEMBL625353,,955.0,Brain,,1,1
6092,50594,In vivo,BAO_0000218,,,Biodistribution of [123I]- labeled compound in mice brain was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,,,N,Intermediate,A,10090.0,CHEMBL625354,,955.0,Brain,,1,1
6093,50594,In vivo,BAO_0000218,,,Biodistribution of [123I]- labeled compound in mice brain was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,,,N,Intermediate,A,10090.0,CHEMBL626019,,955.0,Brain,,1,1
6094,50594,In vivo,BAO_0000218,,,Biodistribution of [123I]- labeled compound in mice heart was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,,,N,Intermediate,A,10090.0,CHEMBL626020,,948.0,Heart,,1,1
6095,50594,In vivo,BAO_0000218,,,Biodistribution of [123I]- labeled compound in mice heart was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,,,N,Intermediate,A,10090.0,CHEMBL626021,,948.0,Heart,,1,1
6096,50594,In vivo,BAO_0000218,,,Biodistribution of [123I]- labeled compound in mice heart was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,,,N,Intermediate,A,10090.0,CHEMBL626022,,948.0,Heart,,1,1
6097,50594,In vivo,BAO_0000218,,,Biodistribution of [123I]- labeled compound in mice heart was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,,,N,Intermediate,A,10090.0,CHEMBL626192,,948.0,Heart,,1,1
6098,80682,,BAO_0000219,646.0,A549,Cytotoxic activity was tested against human prostate cell line A-549 (lung carcinoma),,,N,Intermediate,F,9606.0,CHEMBL626193,,,,,1,1
6099,80682,,BAO_0000219,646.0,A549,Cytotoxicity against A-549 cell line in the purdue cell culture screen was determined,,,N,Expert,F,9606.0,CHEMBL626194,,,,,1,1
6100,80682,,BAO_0000219,646.0,A549,Cytotoxicity against human lung carcinoma A-549 cell lines,,,N,Intermediate,F,9606.0,CHEMBL626195,,,,,1,1
6101,80682,,BAO_0000219,646.0,A549,In vitro cytotoxic activity against A-549 (human lung carcinoma) cell line,,,N,Intermediate,F,9606.0,CHEMBL626196,,,,,1,1
6102,80682,,BAO_0000219,646.0,A549,In vitro cytotoxicity against human lung carcinoma cell line A-549,,,N,Intermediate,F,9606.0,CHEMBL626197,,,,,1,1
6103,80682,,BAO_0000219,646.0,A549,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 3.6*10e-5 M,,,N,Intermediate,F,9606.0,CHEMBL626198,,,,,1,1
6104,80682,,BAO_0000219,646.0,A549,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.2*10e-5M,,,N,Intermediate,F,9606.0,CHEMBL626199,,,,,1,1
6105,80682,,BAO_0000219,646.0,A549,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.3*10e-5M,,,N,Intermediate,F,9606.0,CHEMBL626200,,,,,1,1
6106,80682,,BAO_0000219,646.0,A549,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 5.0*10e-5M,,,N,Intermediate,F,9606.0,CHEMBL626201,,,,,1,1
6107,80682,,BAO_0000219,646.0,A549,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 6.1*10e-5 M,,,N,Intermediate,F,9606.0,CHEMBL626202,,,,,1,1
6108,80682,,BAO_0000219,646.0,A549,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 7.4*10e-5 M,,,N,Intermediate,F,9606.0,CHEMBL626203,,,,,1,1
6109,80682,,BAO_0000219,646.0,A549,In vitro cytotoxicity against A-549 human lung cancer cells,,,N,Intermediate,F,9606.0,CHEMBL626204,,,,,1,1
6110,80682,,BAO_0000219,646.0,A549,In vitro cytotoxicity against human lung carcinoma (A-549) cell line,,,N,Intermediate,F,9606.0,CHEMBL624701,,,,,1,1
6111,80682,,BAO_0000219,646.0,A549,In vitro cytotoxicity in human tumor lung carcinoma A-549 cell lines,,,N,Intermediate,F,9606.0,CHEMBL624702,,,,,1,1
6112,80682,,BAO_0000219,646.0,A549,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,,,N,Expert,F,9606.0,CHEMBL624703,,,,,1,1
6113,80682,,BAO_0000219,646.0,A549,Tested in vitro for cytotoxicity against A-549 lung cancer cells,,,N,Intermediate,F,9606.0,CHEMBL624704,,,,,1,1
6114,80682,,BAO_0000219,646.0,A549,The compound was tested for cytotoxicity against A-549 cell in human lung carcinoma,,,N,Intermediate,F,9606.0,CHEMBL624705,,,,,1,1
6115,80682,,BAO_0000219,646.0,A549,Cytotoxicity against human lung carcinoma cells (A-549) using SRB assay.,,,N,Expert,F,9606.0,CHEMBL624706,,,,,1,1
6116,80682,,BAO_0000219,646.0,A549,Antitumor cytotoxic activity against A-549 cell line was determined,,,N,Intermediate,F,9606.0,CHEMBL624707,,,,,1,1
6117,80682,,BAO_0000219,646.0,A549,"Tested for the cytotoxicity against the Non-small cell lung cancer cell line A-549, growth inhibition by 50% is reported",,,N,Intermediate,F,9606.0,CHEMBL624708,,,,,1,1
6118,80682,,BAO_0000219,646.0,A549,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,,,N,Intermediate,F,9606.0,CHEMBL624709,,,,,1,1
6119,80682,,BAO_0000219,646.0,A549,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,,,N,Expert,F,9606.0,CHEMBL884107,,,,,1,1
6120,80682,,BAO_0000219,646.0,A549,Antitumoral activity was assayed against A-549 cell line,,,N,Intermediate,F,9606.0,CHEMBL624710,,,,,1,1
6121,80682,,BAO_0000219,646.0,A549,Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation,,,N,Intermediate,F,9606.0,CHEMBL624711,,,,,1,1
6122,80682,,BAO_0000219,646.0,A549,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,,,N,Intermediate,F,9606.0,CHEMBL624712,,,,,1,1
6123,80682,,BAO_0000219,646.0,A549,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,,,N,Expert,F,9606.0,CHEMBL624713,,,,,1,1
6124,80682,,BAO_0000219,646.0,A549,Compound was tested for inhibition of cell growth of A-549 cells,,,N,Intermediate,F,9606.0,CHEMBL624714,,,,,1,1
6125,80682,,BAO_0000219,646.0,A549,Compound was tested for its inhibitory effect on the growth of A-549 tumor cell line from lung.,,,N,Intermediate,F,9606.0,CHEMBL624715,,,,,1,1
6126,80682,,BAO_0000219,646.0,A549,Concentration required for 50% inhibition of growth in human lung carcinoma cell line was determined,,,N,Intermediate,F,9606.0,CHEMBL624716,,,,,1,1
6127,80682,,BAO_0000219,646.0,A549,In vitro cytotoxicity against A549-human lung carcinoma cells.,,,N,Expert,F,9606.0,CHEMBL619505,,,,,1,1
6128,80682,,BAO_0000219,646.0,A549,Cytotoxic activity against cultured cells of A-549 human lung carcinoma.,,,N,Expert,F,9606.0,CHEMBL619506,,,,,1,1
6129,80682,,BAO_0000219,646.0,A549,Cytotoxic activity against A-549 cell lines.,,,N,Intermediate,F,9606.0,CHEMBL619507,,,,,1,1
6130,80682,,BAO_0000219,646.0,A549,Cytotoxicity was measured against neoplastic cultured A-549 cells of human lung carcinoma.,,,N,Expert,F,9606.0,CHEMBL619508,,,,,1,1
6131,80682,,BAO_0000219,646.0,A549,Cytotoxicity against human A549 non small cell lung cell lines,,,N,Intermediate,F,9606.0,CHEMBL619509,,,,,1,1
6132,80682,,BAO_0000219,646.0,A549,Inhibition of cell growth in (A-549) lung cell line,,,N,Expert,F,9606.0,CHEMBL619510,,,,,1,1
6133,80682,,BAO_0000219,646.0,A549,Growth inhibitory effect of compound was measured on A-549 human lung adenocarcinoma cancer cell line,,,N,Intermediate,F,9606.0,CHEMBL619511,,,,,1,1
6134,80682,,BAO_0000219,646.0,A549,In vitro antitumor activity against A-549 tumor cells.,,,N,Intermediate,F,9606.0,CHEMBL619512,,,,,1,1
6135,80682,,BAO_0000219,646.0,A549,In vitro antitumor effects against human A-549 cell lines.,,,N,Expert,F,9606.0,CHEMBL619513,,,,,1,1
6136,80682,,BAO_0000219,646.0,A549,In vitro cytotoxic activity of compound against A-549 cell line,,,N,Intermediate,F,9606.0,CHEMBL619514,,,,,1,1
6137,80682,,BAO_0000219,646.0,A549,In vitro cytotoxicity against human lung carcinoma A-549 cell line,,,N,Intermediate,F,9606.0,CHEMBL619515,,,,,1,1
6138,80682,,BAO_0000219,646.0,A549,In vitro cytotoxicity against human non-small cell lung carcinoma A549,,,N,Intermediate,F,9606.0,CHEMBL619516,,,,,1,1
6139,80682,,BAO_0000219,646.0,A549,In vitro cytotoxicity against human A-549 cancer cell line was evaluated,,,N,Intermediate,F,9606.0,CHEMBL884005,,,,,1,1
6140,80682,,BAO_0000219,646.0,A549,In vitro cytotoxicity against the A-549 (human lung carcinoma) neoplastic cell line,,,N,Expert,F,9606.0,CHEMBL619517,,,,,1,1
6141,80682,,BAO_0000219,646.0,A549,Inhibitory concentration of compound against A-549 cell line,,,N,Intermediate,F,9606.0,CHEMBL619518,,,,,1,1
6142,80682,,BAO_0000219,646.0,A549,Tested for the cytostatic activity as inhibitory concentration against A-549 human pulmonary adenocarcinoma cells,,,N,Intermediate,F,9606.0,CHEMBL619519,,,,,1,1
6143,80682,,BAO_0000219,646.0,A549,cytotoxic activity against leukemia (A-549) cancer cell line,,,N,Intermediate,F,9606.0,CHEMBL876489,,,,,1,1
6144,80682,,BAO_0000219,646.0,A549,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,,,N,Expert,F,9606.0,CHEMBL619520,,,,,1,1
6145,80682,,BAO_0000219,646.0,A549,Percent inhibition for cytotoxic activity against lung carcinoma (A-549) cell line,,,N,Intermediate,F,9606.0,CHEMBL619521,,,,,1,1
6146,80682,,BAO_0000219,646.0,A549,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.1(ug/ml),,,N,Intermediate,F,9606.0,CHEMBL619522,,,,,1,1
6147,80682,,BAO_0000219,646.0,A549,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.4(ug/ml),,,N,Intermediate,F,9606.0,CHEMBL619523,,,,,1,1
6148,80682,,BAO_0000219,646.0,A549,Cytotoxic activity of compound against A-549 cell lines at concentration of 1.1 (ug/ml),,,N,Intermediate,F,9606.0,CHEMBL619524,,,,,1,1
6149,80682,,BAO_0000219,646.0,A549,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml),,,N,Intermediate,F,9606.0,CHEMBL619525,,,,,1,1
6150,80682,,BAO_0000219,646.0,A549,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tometin; Not available,,,N,Intermediate,F,,CHEMBL619526,,,,,1,1
6151,80682,,BAO_0000219,646.0,A549,Influence of PARP-1 cellular activity in human lung carcinoma A549 cells on %ADP Polymer formation at a concentration of 25 uM of the compound,,,N,Intermediate,F,9606.0,CHEMBL619527,,,,,1,1
6152,80682,,BAO_0000219,646.0,A549,Cytotoxicity against A549 cells; No cytotoxicity,,,N,Intermediate,F,9606.0,CHEMBL619528,,,,,1,1
6153,80682,,BAO_0000219,646.0,A549,Cytotoxicity against human lung carcinoma (A549) cell lines,,,N,Expert,F,9606.0,CHEMBL619529,,,,,1,1
6154,80682,,BAO_0000219,646.0,A549,Cytotoxicity against human lung carcinoma (A549) cell lines; Not active,,,N,Expert,F,9606.0,CHEMBL619530,,,,,1,1
6155,80682,,BAO_0000219,646.0,A549,In vitro anticancer activity against human lung (A549) cell line,,,N,Intermediate,F,9606.0,CHEMBL876490,,,,,1,1
6156,80682,,BAO_0000219,646.0,A549,Percent growth inhibition at 200 uM PARP inhibitor in A549 cells,,,N,Intermediate,F,9606.0,CHEMBL619531,,,,,1,1
6157,80682,,BAO_0000219,646.0,A549,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..006 uM compound concentration in A549 cells,,,N,Intermediate,F,9606.0,CHEMBL619532,,,,,1,1
6158,80682,,BAO_0000219,646.0,A549,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..03 uM compound concentration in A549 cells,,,N,Intermediate,F,9606.0,CHEMBL619533,,,,,1,1
6159,80682,,BAO_0000219,646.0,A549,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..15 uM compound concentration in A549 cells,,,N,Intermediate,F,9606.0,CHEMBL619534,,,,,1,1
6160,80682,,BAO_0000219,646.0,A549,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..4 uM compound concentration in A549 cells,,,N,Intermediate,F,9606.0,CHEMBL620164,,,,,1,1
6161,80682,,BAO_0000219,646.0,A549,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,,,N,Intermediate,F,9606.0,CHEMBL620165,,,,,1,1
6162,80682,,BAO_0000219,646.0,A549,Inhibition of A549 human lung tumor cell proliferation,,,N,Expert,F,9606.0,CHEMBL620166,,,,,1,1
6163,80682,,BAO_0000219,646.0,A549,"Concentration required to inhibit the lung A549 cell growth by 50%,P53 status of cell line used was wild-type. ",,,N,Intermediate,F,9606.0,CHEMBL620167,,,,,1,1
6164,80682,,BAO_0000219,646.0,A549,In vitro cytotoxicity against human tumor cell line A549,,,N,Expert,F,9606.0,CHEMBL620168,,,,,1,1
6165,80682,,BAO_0000219,646.0,A549,In vitro growth inhibitory activity against A549 human nonsmall cell lung carcinoma cells. ,,,N,Intermediate,F,9606.0,CHEMBL620338,,,,,1,1
6166,80682,,BAO_0000219,646.0,A549,Inhibitory concentration of compound against proliferation of lung carcinoma A549 cell line,,,N,Intermediate,F,9606.0,CHEMBL620339,,,,,1,1
6167,80682,,BAO_0000219,646.0,A549,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells,,,N,Intermediate,F,9606.0,CHEMBL620340,,,,,1,1
6168,80682,,BAO_0000219,646.0,A549,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells,,,N,Intermediate,F,9606.0,CHEMBL620341,,,,,1,1
6169,80682,,BAO_0000219,646.0,A549,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells: Not tested,,,N,Intermediate,F,9606.0,CHEMBL876491,,,,,1,1
6170,80682,,BAO_0000219,646.0,A549,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,,,N,Intermediate,F,9606.0,CHEMBL620342,,,,,1,1
6171,80682,,BAO_0000219,646.0,A549,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,,,N,Intermediate,F,9606.0,CHEMBL620343,,,,,1,1
6172,80682,,BAO_0000219,646.0,A549,% inhibition against A549 cells (lung cancer) at 4 ug/mL,,,N,Intermediate,F,9606.0,CHEMBL620344,,,,,1,1
6173,80682,,BAO_0000219,646.0,A549,In vitro anticancer activity against human lung (A549) cell line,,,N,Intermediate,F,9606.0,CHEMBL620345,,,,,1,1
6174,80682,,BAO_0000219,646.0,A549,Inhibition of proliferation of A549 cells at concentration of 0.1 uM was determined,,,N,Intermediate,F,9606.0,CHEMBL620346,,,,,1,1
6175,80682,,BAO_0000219,646.0,A549,Inhibition of proliferation of A549 cells at concentration of 100 uM was determined,,,N,Intermediate,F,9606.0,CHEMBL620347,,,,,1,1
6176,80682,,BAO_0000219,646.0,A549,Inhibition of proliferation of A549 cells at concentration of 10 uM was determined,,,N,Intermediate,F,9606.0,CHEMBL620348,,,,,1,1
6177,80682,,BAO_0000219,646.0,A549,Inhibition of proliferation of A549 cells at concentration of 1 uM was determined,,,N,Intermediate,F,9606.0,CHEMBL620349,,,,,1,1
6178,80682,,BAO_0000219,646.0,A549,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells at 20 uM,,,N,Intermediate,F,9606.0,CHEMBL618667,,,,,1,1
6179,80682,,BAO_0000219,646.0,A549,Percentage inhibition of human lung carcinoma (A549) cell lines,,,N,Expert,F,9606.0,CHEMBL618668,,,,,1,1
6180,80682,,BAO_0000219,646.0,A549,Influence of PARP-1 cellular activity on NAD+ levels at a concentration of 25 uM of the compound,,,N,Intermediate,F,9606.0,CHEMBL876031,,,,,1,1
6181,80682,,BAO_0000219,646.0,A549,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM); ND denotes not determined",,,N,Intermediate,F,9606.0,CHEMBL618759,,,,,1,1
6182,80682,,BAO_0000219,646.0,A549,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells; ND denotes not determined,,,N,Intermediate,F,9606.0,CHEMBL618760,,,,,1,1
6183,80682,,BAO_0000219,646.0,A549,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells; ND denotes not determined,,,N,Intermediate,F,9606.0,CHEMBL619000,,,,,1,1
6184,80682,,BAO_0000219,646.0,A549,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM)",,,N,Intermediate,F,9606.0,CHEMBL619001,,,,,1,1
6185,80682,,BAO_0000219,646.0,A549,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.006 uM",,,N,Intermediate,F,9606.0,CHEMBL619002,,,,,1,1
6186,80682,,BAO_0000219,646.0,A549,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.03 uM",,,N,Intermediate,F,9606.0,CHEMBL619003,,,,,1,1
6187,80682,,BAO_0000219,646.0,A549,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.15 uM",,,N,Intermediate,F,9606.0,CHEMBL619597,,,,,1,1
6188,80682,,BAO_0000219,646.0,A549,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.4 uM",,,N,Intermediate,F,9606.0,CHEMBL619598,,,,,1,1
6189,80682,,BAO_0000219,646.0,A549,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells,,,N,Intermediate,F,9606.0,CHEMBL619599,,,,,1,1
6190,80682,,BAO_0000219,646.0,A549,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells,,,N,Intermediate,F,9606.0,CHEMBL619600,,,,,1,1
6191,80682,,BAO_0000219,646.0,A549,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,,,N,Intermediate,F,9606.0,CHEMBL619601,,,,,1,1
6192,80682,,BAO_0000219,646.0,A549,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.006 uM compound concentration in A549 cells,,,N,Intermediate,F,9606.0,CHEMBL619602,,,,,1,1
6193,80682,,BAO_0000219,646.0,A549,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.03 uM compound concentration in A549 cells,,,N,Intermediate,F,9606.0,CHEMBL619603,,,,,1,1
6194,80682,,BAO_0000219,646.0,A549,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.15 uM compound concentration in A549 cells,,,N,Intermediate,F,9606.0,CHEMBL619604,,,,,1,1
6195,80682,,BAO_0000219,646.0,A549,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.4 uM compound concentration in A549 cells,,,N,Intermediate,F,9606.0,CHEMBL619605,,,,,1,1
6196,50588,In vivo,BAO_0000218,,,Pharmacokinetic activity (Cmax) (10 mg/kg) was determined in dog,,,N,Intermediate,A,9615.0,CHEMBL619606,,,,,1,1
6197,50588,In vivo,BAO_0000218,,,Pharmacokinetic activity (Cmax) in dog,,,N,Intermediate,A,9615.0,CHEMBL876032,,,,,1,1
6198,50588,In vivo,BAO_0000218,,,Pharmacokinetic parameter Cmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),,,N,Intermediate,A,9615.0,CHEMBL619607,,,,,1,1
6199,50588,In vivo,BAO_0000218,,,Pharmacokinetic property (Cmax) was measured in dog at the dose of 0.032 mg/kg,,,N,Intermediate,A,9615.0,CHEMBL619608,,,,,1,1
6200,50588,In vivo,BAO_0000218,,,Plasma clearance rate by iv administration in dog at a dose of 6 mg/kg,,,N,Intermediate,A,9615.0,CHEMBL619609,,,,,1,1
6201,50588,In vivo,BAO_0000218,,,Cmax in dog plasma after 30mg/kg oral dose,,,N,Intermediate,A,9615.0,CHEMBL619610,,1969.0,Plasma,,1,1
6202,50588,In vivo,BAO_0000218,,,Tested for the peak blood level in dog,,,N,Intermediate,A,9615.0,CHEMBL619611,,178.0,Blood,,1,1
6203,50588,In vivo,BAO_0000218,,,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog",,,N,Intermediate,A,9615.0,CHEMBL619612,,,,,1,1
6204,50588,In vivo,BAO_0000218,,,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog at dosage of 10 mpk",,,N,Intermediate,A,9615.0,CHEMBL619613,,,,,1,1
6205,50588,In vivo,BAO_0000218,,,The peak blood concentration after 5 hr administration (2.5 mg/kg) in dog was determined,,,N,Intermediate,A,9615.0,CHEMBL619614,,178.0,Blood,,1,1
6206,50588,,BAO_0000218,,,Concentration in the plasma after intravenous administration of 1 mg/kg in dog,,,N,Intermediate,A,9615.0,CHEMBL619615,,,,,1,1
6207,50588,,BAO_0000218,,,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Dog at maximum of 0.3 hours,,,N,Intermediate,A,9615.0,CHEMBL619616,,,,,1,1
6208,50588,,BAO_0000218,,,Final plasma concentration in dogs after oral administration at 1 mg/kg,,,N,Intermediate,A,9615.0,CHEMBL619617,,1969.0,Plasma,,1,1
6209,50588,,BAO_0000218,,,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 300 min,,,N,Intermediate,A,9615.0,CHEMBL619618,,,,,1,1
6210,50588,,BAO_0000218,,,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 30 min,,,N,Intermediate,A,9615.0,CHEMBL876033,,,,,1,1
6211,50588,,BAO_0000218,,,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 60 min,,,N,Intermediate,A,9615.0,CHEMBL619619,,,,,1,1
6212,50588,,BAO_0000218,,,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by dogs,,,N,Intermediate,A,9615.0,CHEMBL619620,,,,,1,1
6213,50588,,BAO_0000218,,,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs,,,N,Intermediate,A,9615.0,CHEMBL619621,,1088.0,Urine,,1,1
6214,50588,,BAO_0000218,,,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs; NA is <10% inhibition at 1 uM for binding data,,,N,Intermediate,A,9615.0,CHEMBL619622,,1088.0,Urine,,1,1
6215,50588,,BAO_0000218,,,Percent of radioactive dose in urine and feces excreted in 0-24 hr by dogs; NA is <10% inhibition at 1 uM for binding data,,,N,Intermediate,A,9615.0,CHEMBL618874,,1088.0,Urine,,1,1
6216,50588,In vivo,BAO_0000218,,,Absolute bioavailability was evaluated in dog,,,N,Intermediate,A,9615.0,CHEMBL618875,,,,,1,1
6217,50588,In vivo,BAO_0000218,,,Bioavailability after oral administration (2.5 mg/kg) in dog was determined,,,N,Intermediate,A,9615.0,CHEMBL618876,,,,,1,1
6218,50588,In vivo,BAO_0000218,,,Bioavailability after peroral administration (1 mg/kg) was determined in dog,,,N,Intermediate,A,9615.0,CHEMBL618877,,,,,1,1
6219,50588,In vivo,BAO_0000218,,,Bioavailability in dog,,,N,Intermediate,A,9615.0,CHEMBL618878,,,,,1,1
6220,50588,In vivo,BAO_0000218,,,Bioavailability in dog,,,N,Intermediate,A,9615.0,CHEMBL618879,,,,,1,1
6221,50588,In vivo,BAO_0000218,,,Bioavailability after intravenous administration in dogs,,,N,Intermediate,A,9615.0,CHEMBL618880,,,,,1,1
6222,50588,In vivo,BAO_0000218,,,Bioavailability after peroral administration in dogs,,,N,Intermediate,A,9615.0,CHEMBL618881,,,,,1,1
6223,50588,In vivo,BAO_0000218,,,Bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),,,N,Intermediate,A,9615.0,CHEMBL618882,,,,,1,1
6224,50588,In vivo,BAO_0000218,,,Bioavailability in dog (Beagle) (male) (dose 3 mg/kg i.v. and 10 mg/kg p.o.) measured from 1 to 24 hr,,,N,Intermediate,A,9615.0,CHEMBL624226,,,,,1,1
6225,50588,In vivo,BAO_0000218,,,Bioavailability in plasma of male Beagle dogs treated with 3 mg/kg (i.v.) and 10 mg/kg (p.o.) measured from 1 to 24 hr; ND indicates not determined,,,N,Intermediate,A,9615.0,CHEMBL624227,,1969.0,Plasma,,1,1
6226,50588,In vivo,BAO_0000218,,,Bioavailability,,,N,Intermediate,A,9615.0,CHEMBL624228,,,,,1,1
6227,50588,In vivo,BAO_0000218,,,Bioavailability,,,N,Intermediate,A,9615.0,CHEMBL624229,,,,,1,1
6228,50588,In vivo,BAO_0000218,,,Bioavailability by intravenous administration of 1.2 mg/kg in dog,,,N,Intermediate,A,9615.0,CHEMBL624230,,,,,1,1
6229,50588,In vivo,BAO_0000218,,,Bioavailability in dog,,,N,Intermediate,A,9615.0,CHEMBL624231,,,,,1,1
6230,50588,In vivo,BAO_0000218,,,Bioavailability in dog,,,N,Intermediate,A,9615.0,CHEMBL624232,,,,,1,1
6231,50588,In vivo,BAO_0000218,,,Bioavailability in dog,,,N,Intermediate,A,9615.0,CHEMBL625127,,,,,1,1
6232,50588,In vivo,BAO_0000218,,,Bioavailability in dog,,,N,Intermediate,A,9615.0,CHEMBL625128,,,,,1,1
6233,50588,In vivo,BAO_0000218,,,Bioavailability in dog,,,N,Intermediate,A,9615.0,CHEMBL621675,,,,,1,1
6234,50588,In vivo,BAO_0000218,,,Bioavailability in dog (p.o.) at 2.0 mpk,,,N,Intermediate,A,9615.0,CHEMBL621676,,,,,1,1
6235,50588,In vivo,BAO_0000218,,,Bioavailability in dog (dose 2 mg/kg p.o. and 0.5 mg/kg i.v.),,,N,Intermediate,A,9615.0,CHEMBL621677,,,,,1,1
6236,50588,In vivo,BAO_0000218,,,Bioavailability in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,,N,Intermediate,A,9615.0,CHEMBL621678,,,,,1,1
6237,50588,In vivo,BAO_0000218,,,Bioavailability in dog,,,N,Intermediate,A,9615.0,CHEMBL621679,,,,,1,1
6238,50588,In vivo,BAO_0000218,,,Bioavailability was evaluated after oral administration in dog,,,N,Intermediate,A,9615.0,CHEMBL621680,,,,,1,1
6239,50588,In vivo,BAO_0000218,,,Bioavailability was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,,N,Intermediate,A,9615.0,CHEMBL621681,,,,,1,1
6240,50588,In vivo,BAO_0000218,,,Bioavailability was evaluated in dog,,,N,Intermediate,A,9615.0,CHEMBL876740,,,,,1,1
6241,50588,In vivo,BAO_0000218,,,Bioavailability in dog,,,N,Intermediate,A,9615.0,CHEMBL621682,,,,,1,1
6242,50588,In vivo,BAO_0000218,,,Bioavailability in dog,,,N,Intermediate,A,9615.0,CHEMBL621683,,,,,1,1
6243,50588,In vivo,BAO_0000218,,,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),,,N,Intermediate,A,9615.0,CHEMBL621684,,,,,1,1
6244,50588,In vivo,BAO_0000218,,,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),,,N,Intermediate,A,9615.0,CHEMBL621685,,,,,1,1
6245,50588,In vivo,BAO_0000218,,,Bioavailability was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),,,N,Intermediate,A,9615.0,CHEMBL621686,,,,,1,1
6246,50588,In vivo,BAO_0000218,,,Bioavailability was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,,N,Intermediate,A,9615.0,CHEMBL621687,,,,,1,1
6247,50588,In vivo,BAO_0000218,,,Bioavailability was evaluated in dog after peroral administration at a dose of 1 mg/kg,,,N,Intermediate,A,9615.0,CHEMBL621688,,,,,1,1
6248,50588,In vivo,BAO_0000218,,,Bioavailability of compound in dog was determined after peroral administration,,,N,Intermediate,A,9615.0,CHEMBL621689,,,,,1,1
6249,50588,In vivo,BAO_0000218,,,Oral bioavailability in dog,,,N,Intermediate,A,9615.0,CHEMBL621690,,,,,1,1
6250,50588,In vivo,BAO_0000218,,,Compound was evaluated for oral bioavailability at different dose 27.5 mg/kg DMP323 equiv in dogs,,,N,Intermediate,A,9615.0,CHEMBL621691,,,,,1,1
6251,50588,In vivo,BAO_0000218,,,Compound was evaluated for oral bioavailability at different dose 7.7 mg/kg DMP323 equiv in dogs,,,N,Intermediate,A,9615.0,CHEMBL875941,,,,,1,1
6252,50588,In vivo,BAO_0000218,,,Compound was evaluated for oral bioavailability in dogs; 37-38 %,,,N,Intermediate,A,9615.0,CHEMBL621692,,,,,1,1
6253,50588,In vivo,BAO_0000218,,,Bioavailability in dog,,,N,Intermediate,A,9615.0,CHEMBL621693,,,,,1,1
6254,50588,In vivo,BAO_0000218,,,Oral bioavailability in dog (1 mg/kg p.o. and 0.2 mg/kg i.v.),,,N,Intermediate,A,9615.0,CHEMBL621694,,,,,1,1
6255,50594,In vivo,BAO_0000218,,,Biodistribution of [123I]- labeled compound in mice heart was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,,,N,Intermediate,A,10090.0,CHEMBL621695,,948.0,Heart,,1,1
6256,50594,In vivo,BAO_0000218,,,Biodistribution of [123I]- labeled compound in mice heart was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,,,N,Intermediate,A,10090.0,CHEMBL621696,,948.0,Heart,,1,1
6257,50594,In vivo,BAO_0000218,,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,,,N,Intermediate,A,10090.0,CHEMBL621697,,2113.0,Kidney,,1,1
6258,50594,In vivo,BAO_0000218,,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,,,N,Intermediate,A,10090.0,CHEMBL621698,,2113.0,Kidney,,1,1
6259,50594,In vivo,BAO_0000218,,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,,,N,Intermediate,A,10090.0,CHEMBL623420,,2113.0,Kidney,,1,1
6260,50594,In vivo,BAO_0000218,,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,,,N,Intermediate,A,10090.0,CHEMBL623421,,2113.0,Kidney,,1,1
6261,50594,In vivo,BAO_0000218,,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,,,N,Intermediate,A,10090.0,CHEMBL623422,,2113.0,Kidney,,1,1
6262,50594,In vivo,BAO_0000218,,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,,,N,Intermediate,A,10090.0,CHEMBL623423,,2113.0,Kidney,,1,1
6263,50594,In vivo,BAO_0000218,,,Biodistribution of [123I]- labeled compound in mice liver was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,,,N,Intermediate,A,10090.0,CHEMBL623424,,2107.0,Liver,,1,1
6264,50594,In vivo,BAO_0000218,,,Biodistribution of [123I]- labeled compound in mice liver was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,,,N,Intermediate,A,10090.0,CHEMBL623425,,2107.0,Liver,,1,1
6265,50594,In vivo,BAO_0000218,,,Biodistribution of [123I]- labeled compound in mice liver was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,,,N,Intermediate,A,10090.0,CHEMBL623426,,2107.0,Liver,,1,1
6266,50594,In vivo,BAO_0000218,,,Biodistribution of [123I]- labeled compound in mice liver was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,,,N,Intermediate,A,10090.0,CHEMBL623427,,2107.0,Liver,,1,1
6267,50594,In vivo,BAO_0000218,,,Biodistribution of [123I]- labeled compound in mice liver was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,,,N,Intermediate,A,10090.0,CHEMBL623428,,2107.0,Liver,,1,1
6268,50594,In vivo,BAO_0000218,,,Biodistribution of [123I]- labeled compound in mice liver was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,,,N,Intermediate,A,10090.0,CHEMBL875947,,2107.0,Liver,,1,1
6269,50594,In vivo,BAO_0000218,,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,,,N,Intermediate,A,10090.0,CHEMBL623429,,2048.0,Lung,,1,1
6270,50594,In vivo,BAO_0000218,,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,,,N,Intermediate,A,10090.0,CHEMBL623430,,2048.0,Lung,,1,1
6271,50594,In vivo,BAO_0000218,,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,,,N,Intermediate,A,10090.0,CHEMBL622588,,2048.0,Lung,,1,1
6272,50594,In vivo,BAO_0000218,,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,,,N,Intermediate,A,10090.0,CHEMBL622589,,2048.0,Lung,,1,1
6273,50594,In vivo,BAO_0000218,,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,,,N,Intermediate,A,10090.0,CHEMBL622751,,2048.0,Lung,,1,1
6274,50594,In vivo,BAO_0000218,,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,,,N,Intermediate,A,10090.0,CHEMBL622752,,2048.0,Lung,,1,1
6275,50594,,BAO_0000218,42.0,CCRF S-180,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 1 hour,,,N,Intermediate,A,10090.0,CHEMBL622753,,,,,1,1
6276,50594,,BAO_0000218,42.0,CCRF S-180,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 2 hours,,,N,Intermediate,A,10090.0,CHEMBL622647,,,,,1,1
6277,50594,,BAO_0000218,42.0,CCRF S-180,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 30 minutes,,,N,Intermediate,A,10090.0,CHEMBL875163,,,,,1,1
6278,50594,,BAO_0000218,42.0,CCRF S-180,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 4 hours,,,N,Intermediate,A,10090.0,CHEMBL622648,,,,,1,1
6279,50594,,BAO_0000218,42.0,CCRF S-180,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 8 hours,,,N,Intermediate,A,10090.0,CHEMBL622649,,,,,1,1
6280,50594,,BAO_0000218,42.0,CCRF S-180,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice brain bearing S180 tumor cell line for 1 hour,,,N,Intermediate,A,10090.0,CHEMBL622650,,955.0,Brain,,1,1
6281,50594,,BAO_0000218,42.0,CCRF S-180,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 2 hours,,,N,Intermediate,A,10090.0,CHEMBL622651,,955.0,Brain,,1,1
6282,50594,,BAO_0000218,42.0,CCRF S-180,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 30 minutes,,,N,Intermediate,A,10090.0,CHEMBL622652,,955.0,Brain,,1,1
6283,50594,,BAO_0000218,42.0,CCRF S-180,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 4 hours,,,N,Intermediate,A,10090.0,CHEMBL622653,,955.0,Brain,,1,1
6284,50594,,BAO_0000218,42.0,CCRF S-180,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 8 hours,,,N,Intermediate,A,10090.0,CHEMBL622654,,955.0,Brain,,1,1
6285,50594,,BAO_0000218,42.0,CCRF S-180,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 1 hour,,,N,Intermediate,A,10090.0,CHEMBL622655,,948.0,Heart,,1,1
6286,50594,,BAO_0000218,42.0,CCRF S-180,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 2 hours,,,N,Intermediate,A,10090.0,CHEMBL622656,,948.0,Heart,,1,1
6287,50594,,BAO_0000218,42.0,CCRF S-180,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 30 minutes,,,N,Intermediate,A,10090.0,CHEMBL622657,,948.0,Heart,,1,1
6288,50594,,BAO_0000218,42.0,CCRF S-180,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 4 hours,,,N,Intermediate,A,10090.0,CHEMBL622658,,948.0,Heart,,1,1
6289,50594,,BAO_0000218,42.0,CCRF S-180,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 8 hours,,,N,Intermediate,A,10090.0,CHEMBL622659,,948.0,Heart,,1,1
6290,50594,,BAO_0000218,42.0,CCRF S-180,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 1 hour,,,N,Intermediate,A,10090.0,CHEMBL624630,,2113.0,Kidney,,1,1
6291,50594,,BAO_0000218,42.0,CCRF S-180,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 2 hours,,,N,Intermediate,A,10090.0,CHEMBL624631,,2113.0,Kidney,,1,1
6292,50594,,BAO_0000218,42.0,CCRF S-180,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 30 minutes,,,N,Intermediate,A,10090.0,CHEMBL624632,,2113.0,Kidney,,1,1
6293,80682,,BAO_0000219,646.0,A549,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml) on,,,N,Intermediate,F,9606.0,CHEMBL624633,,,,,1,1
6294,80682,,BAO_0000219,646.0,A549,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml)on,,,N,Intermediate,F,9606.0,CHEMBL624634,,,,,1,1
6295,80682,,BAO_0000219,646.0,A549,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml),,,N,Intermediate,F,9606.0,CHEMBL624635,,,,,1,1
6296,80682,,BAO_0000219,646.0,A549,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml)),,,N,Intermediate,F,9606.0,CHEMBL624636,,,,,1,1
6297,80682,,BAO_0000219,646.0,A549,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,,,N,Expert,F,9606.0,CHEMBL857055,,,,,1,1
6298,80682,,BAO_0000219,646.0,A549,In vitro rate of inhibition of A-549 tumor cell growth at 10E-4 mol/L,,,N,Expert,F,9606.0,CHEMBL624637,,,,,1,1
6299,80682,,BAO_0000219,646.0,A549,In vitro rate of inhibition of A-549 tumor cell growth at 10E-5 mol/L,,,N,Expert,F,9606.0,CHEMBL624638,,,,,1,1
6300,80682,,BAO_0000219,646.0,A549,In vitro rate of inhibition of A-549 tumor cell growth at 10E-6 mol/L,,,N,Expert,F,9606.0,CHEMBL874366,,,,,1,1
6301,80682,,BAO_0000219,646.0,A549,In vitro rate of inhibition of A-549 tumor cell growth at 10E-7 mol/L,,,N,Expert,F,9606.0,CHEMBL624639,,,,,1,1
6302,80682,,BAO_0000219,646.0,A549,In vitro rate of inhibition of A-549 tumor cell growth at 10E-8 mol/L,,,N,Expert,F,9606.0,CHEMBL624640,,,,,1,1
6303,80682,,BAO_0000219,646.0,A549,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.0625 uM,,,N,Intermediate,F,9606.0,CHEMBL624641,,,,,1,1
6304,80682,,BAO_0000219,646.0,A549,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.125 uM,,,N,Intermediate,F,9606.0,CHEMBL624642,,,,,1,1
6305,80682,,BAO_0000219,646.0,A549,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.25 uM,,,N,Intermediate,F,9606.0,CHEMBL624643,,,,,1,1
6306,80682,,BAO_0000219,646.0,A549,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.5 uM,,,N,Intermediate,F,9606.0,CHEMBL624644,,,,,1,1
6307,80682,,BAO_0000219,646.0,A549,Rate of inhibition of A-549 tumor cell growth at a concentration of 1 uM,,,N,Intermediate,F,9606.0,CHEMBL624645,,,,,1,1
6308,80682,,BAO_0000219,646.0,A549,The compound was evaluated for its cytotoxic potency against A-549 cell line,,,N,Intermediate,F,9606.0,CHEMBL619445,,,,,1,1
6309,80682,,BAO_0000219,646.0,A549,Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines,,,N,Expert,F,9606.0,CHEMBL839886,,,,,1,1
6310,80682,,BAO_0000219,646.0,A549,Cytotoxic activity of compound against A-549 tumor cell line.,,,N,Intermediate,F,9606.0,CHEMBL619446,,,,,1,1
6311,80682,,BAO_0000219,646.0,A549,In vitro cytotoxicity against Lung A-549 human tumors following a 6 day exposure.,,,N,Intermediate,F,9606.0,CHEMBL619447,,,,,1,1
6312,80682,,BAO_0000219,646.0,A549,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure.,,,N,Intermediate,F,9606.0,CHEMBL619448,,,,,1,1
6313,80682,,BAO_0000219,646.0,A549,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure; ND is no data,,,N,Intermediate,F,9606.0,CHEMBL619449,,,,,1,1
6314,80682,,BAO_0000219,646.0,A549,Cytotoxic activity of compound against A-549 tumor cell line at conc. of 20 ug/mL,,,N,Intermediate,F,9606.0,CHEMBL619450,,,,,1,1
6315,80682,,BAO_0000219,646.0,A549,Compound was tested for cytotoxic activity against A-549 human lung carcinoma (ATCC:CCL-185),,,N,Intermediate,F,9606.0,CHEMBL619451,,,,,1,1
6316,80682,,BAO_0000219,646.0,A549,In vitro inhibitory concentration against cell culture of A-549 human lung carcinoma,,,N,Expert,F,9606.0,CHEMBL619452,,,,,1,1
6317,80682,,BAO_0000219,646.0,A549,Concentration for in vitro cytotoxicity against A-549 human lung tumor cells,,,N,Intermediate,F,9606.0,CHEMBL619453,,,,,1,1
6318,80682,,BAO_0000219,646.0,A549,Dose required for in vitro cytotoxic activity against A-549 lung carcinoma cells at concentration of 10 ug/ml; NA is no cytotoxicity,,,N,Intermediate,F,9606.0,CHEMBL874367,,,,,1,1
6319,80682,,BAO_0000219,646.0,A549,Cytotoxic concentration against A-549 tumor cells.,,,N,Intermediate,F,9606.0,CHEMBL619454,,,,,1,1
6320,80682,,BAO_0000219,646.0,A549,Cytotoxic concentration against A-549 tumor cells; Inactive at 10 ug/mL.,,,N,Intermediate,F,9606.0,CHEMBL619455,,,,,1,1
6321,80682,,BAO_0000219,646.0,A549,"Cytotoxicity against NCI tumor panel, A-549/ATCC non small-cell lung cancer cell line",,,N,Intermediate,F,9606.0,CHEMBL619456,,,,,1,1
6322,50191,,BAO_0000218,,,Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Acinetobacter baumannii 118A,,,N,Expert,F,470.0,CHEMBL619457,,,,,1,1
6323,50192,,BAO_0000218,,,Activity against Acinetobacter calcoaceticus (AC54),,,N,Intermediate,F,471.0,CHEMBL619458,,,,,1,1
6324,50274,,BAO_0000218,,,In vitro antifungal activity against Aspergillus flavus CM74,,,N,Expert,F,5059.0,CHEMBL619459,,,,,1,1
6325,50274,,BAO_0000218,,,In vitro antifungal activity against Aspergillus flavus CM74,,,N,Expert,F,5059.0,CHEMBL619460,,,,,1,1
6326,50416,,BAO_0000218,,,Inhibitory activity tested against Aspergillus fumigatus at 256 ug/mL concentration,,,N,Intermediate,F,746128.0,CHEMBL619461,,,,,1,1
6327,50416,,BAO_0000218,,,In vitro minimum fungicidal concentration required to inhibit Aspergillus fumigatus(MFC),,,N,Intermediate,F,746128.0,CHEMBL619462,,,,,1,1
6328,50416,,BAO_0000218,,,Antimicrobial activity against Aspergillus fumigatus (MIC),,,N,Intermediate,F,746128.0,CHEMBL620388,,,,,1,1
6329,50416,,BAO_0000218,,,Antimicrobial activity against Aspergillus fumigatus (MIC),,,N,Intermediate,F,746128.0,CHEMBL620389,,,,,1,1
6330,50416,,BAO_0000218,,,In vitro antimicrobial activity against Aspergillus fumigatus (MIC),,,N,Intermediate,F,746128.0,CHEMBL620390,,,,,1,1
6331,50416,,BAO_0000218,,,In vitro antifungal activity against Aspergillus fumigatus 48238E,,,N,Expert,F,746128.0,CHEMBL620391,,,,,1,1
6332,50416,,BAO_0000218,,,In vitro antifungal activity against Aspergillus fumigatus 48238E,,,N,Expert,F,746128.0,CHEMBL621073,,,,,1,1
6333,50296,,BAO_0000218,,,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces naeslundii 631,,,N,Intermediate,F,1655.0,CHEMBL621074,,,,,1,1
6334,50366,,BAO_0000218,,,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces viscosus M-100,,,N,Intermediate,F,1656.0,CHEMBL621075,,,,,1,1
6335,50535,,BAO_0000218,,,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),,,N,Intermediate,F,6277.0,CHEMBL619554,,,,,1,1
6336,50535,,BAO_0000218,,,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),,,N,Intermediate,F,6277.0,CHEMBL619555,,,,,1,1
6337,50169,,BAO_0000218,,,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527,,,N,Intermediate,F,714.0,CHEMBL619556,,,,,1,1
6338,50169,,BAO_0000218,,,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2,,,N,Intermediate,F,714.0,CHEMBL619557,,,,,1,1
6339,50169,,BAO_0000218,,,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2; ND is Not Determined,,,N,Intermediate,F,714.0,CHEMBL619558,,,,,1,1
6340,80682,,BAO_0000219,646.0,A549,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,,,N,Intermediate,F,9606.0,CHEMBL619559,,,,,1,1
6341,80682,,BAO_0000219,646.0,A549,Percent ADP-ribose polymer formation at 25 uM compound concentration in A549 cells,,,N,Intermediate,F,9606.0,CHEMBL619560,,,,,1,1
6342,80682,,BAO_0000219,646.0,A549,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,,,N,Intermediate,F,9606.0,CHEMBL619561,,,,,1,1
6343,80682,,BAO_0000219,646.0,A549,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,,,N,Intermediate,F,9606.0,CHEMBL619562,,,,,1,1
6344,80682,,BAO_0000219,646.0,A549,% inhibition against A549 cells (lung cancer) at 4 ug/mL,,,N,Intermediate,F,9606.0,CHEMBL619563,,,,,1,1
6345,80682,,BAO_0000219,646.0,A549,GI values against A549 cells (lung cancer),,,N,Intermediate,F,9606.0,CHEMBL857457,,,,,1,1
6346,80682,,BAO_0000219,646.0,A549,Effect on NAD+ depletion (% remaining versus vehicle control) 25 uM compound concentration in A549 cells,,,N,Intermediate,F,9606.0,CHEMBL619564,,,,,1,1
6347,80682,,BAO_0000219,646.0,A549,Inhibitory activity against A549 human adenocarcinoma,,,N,Intermediate,F,9606.0,CHEMBL619565,,,,,1,1
6348,80682,,BAO_0000218,646.0,A549,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 200 mg/kg,,,N,Intermediate,F,9606.0,CHEMBL619566,,,,,1,1
6349,80682,,BAO_0000218,646.0,A549,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 100 mg/kg,,,N,Intermediate,F,9606.0,CHEMBL619567,,,,,1,1
6350,80682,,BAO_0000219,646.0,A549,Inhibitory activity against A549 lung adenocarcinoma cell line,,,N,Intermediate,F,9606.0,CHEMBL619568,,,,,1,1
6351,80682,,BAO_0000219,646.0,A549,Inhibitory activity against A549 lung adenocarcinoma cell line; not determined,,,N,Intermediate,F,9606.0,CHEMBL619569,,,,,1,1
6352,80682,,BAO_0000219,646.0,A549,Cytotoxicity against human A549 lung cells,,,N,Intermediate,F,9606.0,CHEMBL619570,,,,,1,1
6353,80682,,BAO_0000218,646.0,A549,In vivo percent inhibitory activity of intraperitoneally administered compound (50 mg/kg/day) against mice infected with A549 tumor,,,N,Intermediate,F,9606.0,CHEMBL619571,,,,,1,1
6354,80682,,BAO_0000219,646.0,A549,Growth inhibition of A549 (human lung carcinoma) cell line.,,,N,Expert,F,9606.0,CHEMBL619572,,,,,1,1
6355,80682,,BAO_0000219,646.0,A549,Effective dose required for inhibitory activity against A549 human tumor cell line.,,,N,Expert,F,9606.0,CHEMBL619573,,,,,1,1
6356,80682,,BAO_0000219,646.0,A549,Effective dose required for inhibitory activity against A549 human tumor cell line; Not active,,,N,Intermediate,F,9606.0,CHEMBL619574,,,,,1,1
6357,80682,,BAO_0000219,646.0,A549,Cytotoxicity was evaluated against A549 tumor cell lines; Inactive,,,N,Intermediate,F,9606.0,CHEMBL619575,,,,,1,1
6358,80682,,BAO_0000219,646.0,A549,Cytotoxicity evaluated against A549 tumor cell lines; significant activity,,,N,Expert,F,9606.0,CHEMBL619576,,,,,1,1
6359,80682,,BAO_0000219,646.0,A549,Cytotoxicity was evaluated against A549 tumor cell lines; Slightly active,,,N,Intermediate,F,9606.0,CHEMBL619577,,,,,1,1
6360,80682,,BAO_0000219,646.0,A549,In vitro inhibitory activity against A549 tumor cell culture,,,N,Intermediate,F,9606.0,CHEMBL619578,,,,,1,1
6361,80682,,BAO_0000219,646.0,A549,In vitro inhibitory activity against A549 tumor cell culture; IA= Inactive,,,N,Intermediate,F,9606.0,CHEMBL884009,,,,,1,1
6362,80682,,BAO_0000219,646.0,A549,Activity against human lung cancer with mutated beta-tubulin (A549-T2415),,,N,Intermediate,F,9606.0,CHEMBL619579,,,,,1,1
6363,80682,,BAO_0000219,646.0,A549,Growth inhibitory activity was determined against A549/ATCC cancer cell line of non-small cell lung cancer,,,N,Intermediate,F,9606.0,CHEMBL619580,,,,,1,1
6364,80682,,BAO_0000219,646.0,A549,Inhibition of growth of A549/ATCC nonsmall cell lung cancer cell line,,,N,Intermediate,F,9606.0,CHEMBL619581,,,,,1,1
6365,80682,,BAO_0000219,646.0,A549,In vitro antitumor activity against NSCL A549/ATCC tumor cell lines,,,N,Intermediate,F,9606.0,CHEMBL619582,,,,,1,1
6366,80682,,BAO_0000219,646.0,A549,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells,,,N,Intermediate,F,9606.0,CHEMBL619583,,,,,1,1
6367,80682,,BAO_0000219,646.0,A549,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells; No data,,,N,Intermediate,F,9606.0,CHEMBL876502,,,,,1,1
6368,80682,,BAO_0000219,646.0,A549,In vitro cytotoxicity against human Non-small cell lung cancer A549/ATCC cell line.,,,N,Intermediate,F,9606.0,CHEMBL619584,,,,,1,1
6369,80682,,BAO_0000219,646.0,A549,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,,,N,Intermediate,F,9606.0,CHEMBL619585,,,,,1,1
6370,80682,,BAO_0000219,646.0,A549,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,,,N,Intermediate,F,9606.0,CHEMBL619586,,,,,1,1
6371,80682,,BAO_0000219,646.0,A549,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,,,N,Intermediate,F,9606.0,CHEMBL619587,,,,,1,1
6372,80682,,BAO_0000219,646.0,A549,Tested for in vitro cytotoxicity against non-small cell lung cancer cell line A549/ATCC,,,N,Intermediate,F,9606.0,CHEMBL619588,,,,,1,1
6373,80682,,BAO_0000219,646.0,A549,Tested in vitro for cytotoxicity in A549/ATCC cell lines,,,N,Intermediate,F,9606.0,CHEMBL619589,,,,,1,1
6374,80682,,BAO_0000219,646.0,A549,inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,,,N,Intermediate,F,9606.0,CHEMBL619590,,,,,1,1
6375,80682,,BAO_0000219,646.0,A549,Compound was evaluated for in vitro activity against A549/ATCC lung cancer cell lines (Human tumor cells ),,,N,Intermediate,F,9606.0,CHEMBL619591,,,,,1,1
6376,80682,,BAO_0000219,646.0,A549,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line at 0.01 uM,,,N,Intermediate,F,9606.0,CHEMBL619592,,,,,1,1
6377,80682,,BAO_0000219,646.0,A549,Compound was evaluated for cytotoxic activity against non-small lung cancer A549/ATCC cell lines.,,,N,Intermediate,F,9606.0,CHEMBL619593,,,,,1,1
6378,80682,,BAO_0000219,646.0,A549,Tested for cytotoxic activity against non-small cell lung cancer A549/ATCC cell line,,,N,Intermediate,F,9606.0,CHEMBL620217,,,,,1,1
6379,80682,,BAO_0000219,646.0,A549,Compound tested for growth inhibition of non-small cell lung cancer cell line A549/ATCC,,,N,Intermediate,F,9606.0,CHEMBL620218,,,,,1,1
6380,80682,,BAO_0000219,646.0,A549,Compound was tested for 50% growth inhibition against human non-small cell lung cancer A549/ATCC cell line,,,N,Intermediate,F,9606.0,CHEMBL620219,,,,,1,1
6381,80682,,BAO_0000219,646.0,A549,Antitumor activity against A549/ATCC cell line,,,N,Intermediate,F,9606.0,CHEMBL620220,,,,,1,1
6382,80682,,BAO_0000219,646.0,A549,Tested for cytotoxicity against A549/ATCC cell lines in non-small-cell lung cancer,,,N,Intermediate,F,9606.0,CHEMBL625141,,,,,1,1
6383,80682,,BAO_0000219,646.0,A549,In vitro cytotoxicity against A549/ATCC cell line.,,,N,Expert,F,9606.0,CHEMBL625142,,,,,1,1
6384,80682,,BAO_0000219,646.0,A549,Tested in vitro for cytotoxicity in A549/ATCC cell line of Non-Small Cell Lung Cancer,,,N,Intermediate,F,9606.0,CHEMBL625143,,,,,1,1
6385,80682,,BAO_0000219,646.0,A549,In vitro inhibition of Non-Small Cell Lung Cancer A549/ATCC cell lines,,,N,Intermediate,F,9606.0,CHEMBL625144,,,,,1,1
6386,80682,,BAO_0000219,646.0,A549,Concentration of compound that cause 50% cytotoxicity of A549/ATCC non small cell lung cancer cell line,,,N,Intermediate,F,9606.0,CHEMBL622474,,,,,1,1
6387,80682,,BAO_0000219,646.0,A549,Evaluated for the inhibitory concentration required to cause growth inhibition of A549Rem- cell line of lung using the MTT Cytotoxicity Assay,,,N,Intermediate,F,9606.0,CHEMBL884104,,,,,1,1
6388,22226,,BAO_0000219,,,Cytotoxicity was evaluated against A649 human mammary carcinoma cells,,,U,Autocuration,F,9606.0,CHEMBL622475,,,,,0,1
6389,22224,In vivo,BAO_0000218,,,Compound was tested for oral bioavailability in dogs,,,U,Intermediate,A,9615.0,CHEMBL622476,,,,,0,1
6390,50588,In vivo,BAO_0000218,,,Compound was tested for orally bioavailable in dogs with a half life of 0.7 hr,,,N,Intermediate,A,9615.0,CHEMBL875831,,,,,1,1
6391,50588,In vivo,BAO_0000218,,,Compound was tested for orally bioavailable in dogs with a half life of 1.2h,,,N,Intermediate,A,9615.0,CHEMBL622477,,,,,1,1
6392,50588,In vivo,BAO_0000218,,,Oral bioavailability in dog,,,N,Intermediate,A,9615.0,CHEMBL622478,,,,,1,1
6393,50588,In vivo,BAO_0000218,,,Compound was tested for the oral bioavailability in dog; No availability,,,N,Intermediate,A,9615.0,CHEMBL623172,,,,,1,1
6394,50588,In vivo,BAO_0000218,,,Oral bioavailability in dog (dose 5 mg/kg),,,N,Intermediate,A,9615.0,CHEMBL623173,,,,,1,1
6395,50588,In vivo,BAO_0000218,,,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,,,N,Intermediate,A,9615.0,CHEMBL623174,,,,,1,1
6396,50588,In vivo,BAO_0000218,,,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,,,N,Intermediate,A,9615.0,CHEMBL623175,,,,,1,1
6397,50588,In vivo,BAO_0000218,,,Oral bioavailability in Beagle dogs after Per oral administration at dose of 50(mg/kg),,,N,Intermediate,A,9615.0,CHEMBL623340,,,,,1,1
6398,50588,In vivo,BAO_0000218,,,Oral bioavailability in dog (dose 5 mg/kg),,,N,Intermediate,A,9615.0,CHEMBL623341,,,,,1,1
6399,50588,In vivo,BAO_0000218,,,Oral bioavailability in dog (p.o. dosing of 0.05 M citric acid/0.05 M hydrochloric acid solution),,,N,Intermediate,A,9615.0,CHEMBL623342,,,,,1,1
6400,50588,In vivo,BAO_0000218,,,Oral bioavailability of active FTIs in dogs,,,N,Intermediate,A,9615.0,CHEMBL623343,,,,,1,1
6401,50588,In vivo,BAO_0000218,,,Oral bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),,,N,Intermediate,A,9615.0,CHEMBL623344,,,,,1,1
6402,50588,In vivo,BAO_0000218,,,Oral bioavailability of compound determined in dog after iv administration at a dose of 10 mg/kg,,,N,Expert,A,9615.0,CHEMBL623345,,,,,1,1
6403,50588,In vivo,BAO_0000218,,,Oral bioavailability in dog,,,N,Intermediate,A,9615.0,CHEMBL875832,,,,,1,1
6404,50588,In vivo,BAO_0000218,,,Oral bioavailability in dog,,,N,Intermediate,A,9615.0,CHEMBL623346,,,,,1,1
6405,50588,In vivo,BAO_0000218,,,Oral bioavailability in dog,,,N,Intermediate,A,9615.0,CHEMBL623347,,,,,1,1
6406,50588,In vivo,BAO_0000218,,,Oral bioavailability of compound was determined in dog; Not tested,,,N,Intermediate,A,9615.0,CHEMBL623348,,,,,1,1
6407,50588,In vivo,BAO_0000218,,,Oral bioavailability in dog,,,N,Intermediate,A,9615.0,CHEMBL623349,,,,,1,1
6408,50588,In vivo,BAO_0000218,,,Oral bioavailability (10 mg/kg) was determined in dog,,,N,Intermediate,A,9615.0,CHEMBL623350,,,,,1,1
6409,50588,In vivo,BAO_0000218,,,Oral bioavailability,,,N,Intermediate,A,9615.0,CHEMBL623351,,,,,1,1
6410,50588,In vivo,BAO_0000218,,,Oral bioavailability in dog (dosed as neat powder in hard gelatin capsule),,,N,Intermediate,A,9615.0,CHEMBL623352,,,,,1,1
6411,50588,In vivo,BAO_0000218,,,Oral bioavailability administered in solution in rats,,,N,Intermediate,A,9615.0,CHEMBL623353,,,,,1,1
6412,50588,In vivo,BAO_0000218,,,Oral bioavailability after 30 mg/kg po dose in Dogs,,,N,Intermediate,A,9615.0,CHEMBL875833,,,,,1,1
6413,50588,In vivo,BAO_0000218,,,Oral bioavailability at a dose of 1 mg/kg in dogs,,,N,Intermediate,A,9615.0,CHEMBL623354,,,,,1,1
6414,50588,In vivo,BAO_0000218,,,Oral bioavailability in dog (dose 1 mg/kg p.o.),,,N,Intermediate,A,9615.0,CHEMBL623355,,,,,1,1
6415,50588,In vivo,BAO_0000218,,,Oral bioavailability in Dog; ND = not determined,,,N,Intermediate,A,9615.0,CHEMBL623356,,,,,1,1
6416,50588,In vivo,BAO_0000218,,,Oral bioavailability in dog,,,N,Intermediate,A,9615.0,CHEMBL623357,,,,,1,1
6417,50588,In vivo,BAO_0000218,,,Oral bioavailability in dog,,,N,Intermediate,A,9615.0,CHEMBL623358,,,,,1,1
6418,50588,In vivo,BAO_0000218,,,Oral bioavailability in dog,,,N,Intermediate,A,9615.0,CHEMBL623359,,,,,1,1
6419,50588,In vivo,BAO_0000218,,,Oral bioavailability in dog,,,N,Intermediate,A,9615.0,CHEMBL623360,,,,,1,1
6420,50588,In vivo,BAO_0000218,,,Oral bioavailability in dogs; No data,,,N,Intermediate,A,9615.0,CHEMBL623361,,,,,1,1
6421,50588,In vivo,BAO_0000218,,,Oral bioavailability measured in dogs,,,N,Intermediate,A,9615.0,CHEMBL623362,,,,,1,1
6422,50588,In vivo,BAO_0000218,,,Oral bioavailability in dog,,,N,Intermediate,A,9615.0,CHEMBL623363,,,,,1,1
6423,50588,In vivo,BAO_0000218,,,Oral bioavailability was calculated in dog,,,N,Intermediate,A,9615.0,CHEMBL623364,,,,,1,1
6424,50588,In vivo,BAO_0000218,,,Oral bioavailability after 0.3 mg/kg po administration in dog,,,N,Intermediate,A,9615.0,CHEMBL875834,,,,,1,1
6425,50588,In vivo,BAO_0000218,,,Oral bioavailability in dog (i.v. dosing),,,N,Intermediate,A,9615.0,CHEMBL623365,,,,,1,1
6426,50588,In vivo,BAO_0000218,,,Oral bioavailability in dog,,,N,Intermediate,A,9615.0,CHEMBL623366,,,,,1,1
6427,50588,In vivo,BAO_0000218,,,Oral bioavailability in Beagle dog at a dose of 2 mg/kg by po administration,,,N,Intermediate,A,9615.0,CHEMBL623367,,,,,1,1
6428,50588,In vivo,BAO_0000218,,,Oral bioavailability in Beagle dogs,,,N,Intermediate,A,9615.0,CHEMBL623368,,,,,1,1
6429,50588,In vivo,BAO_0000218,,,Oral bioavailability in dog,,,N,Intermediate,A,9615.0,CHEMBL623369,,,,,1,1
6430,50588,In vivo,BAO_0000218,,,Oral bioavailability in dog,,,N,Intermediate,A,9615.0,CHEMBL623370,,,,,1,1
6431,50588,In vivo,BAO_0000218,,,Oral bioavailability in dog,,,N,Intermediate,A,9615.0,CHEMBL623371,,,,,1,1
6432,50588,In vivo,BAO_0000218,,,Oral bioavailability in dog,,,N,Intermediate,A,9615.0,CHEMBL623372,,,,,1,1
6433,50588,In vivo,BAO_0000218,,,Oral bioavailability in dog,,,N,Intermediate,A,9615.0,CHEMBL621351,,,,,1,1
6434,50588,In vivo,BAO_0000218,,,Oral bioavailability in dog,,,N,Intermediate,A,9615.0,CHEMBL621352,,,,,1,1
6435,50588,In vivo,BAO_0000218,,,Oral bioavailability in dog,,,N,Intermediate,A,9615.0,CHEMBL621353,,,,,1,1
6436,50588,In vivo,BAO_0000218,,,Oral bioavailability in dog,,,N,Intermediate,A,9615.0,CHEMBL621354,,,,,1,1
6437,50588,In vivo,BAO_0000218,,,Oral bioavailability in dog,,,N,Intermediate,A,9615.0,CHEMBL621355,,,,,1,1
6438,50588,In vivo,BAO_0000218,,,Oral bioavailability in dog,,,N,Intermediate,A,9615.0,CHEMBL621356,,,,,1,1
6439,50588,In vivo,BAO_0000218,,,Oral bioavailability in dog,,,N,Intermediate,A,9615.0,CHEMBL621357,,,,,1,1
6440,50588,In vivo,BAO_0000218,,,Oral bioavailability in dog,,,N,Intermediate,A,9615.0,CHEMBL621358,,,,,1,1
6441,50588,In vivo,BAO_0000218,,,Oral bioavailability in dog (dosed as a mixture of five compounds at 0.5 mg/kg each via i.v. only),,,N,Intermediate,A,9615.0,CHEMBL621359,,,,,1,1
6442,50588,In vivo,BAO_0000218,,,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),,,N,Intermediate,A,9615.0,CHEMBL621360,,,,,1,1
6443,50588,In vivo,BAO_0000218,,,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),,,N,Intermediate,A,9615.0,CHEMBL621361,,,,,1,1
6444,50588,In vivo,BAO_0000218,,,Oral bioavailability in dog,,,N,Intermediate,A,9615.0,CHEMBL621362,,,,,1,1
6445,50588,In vivo,BAO_0000218,,,Oral bioavailability in dog,,,N,Intermediate,A,9615.0,CHEMBL621363,,,,,1,1
6446,50588,In vivo,BAO_0000218,,,Oral bioavailability in dog,,,N,Intermediate,A,9615.0,CHEMBL621364,,,,,1,1
6447,50588,In vivo,BAO_0000218,,,Oral bioavailability in dog (dose 0.2 mg/kg i.v.),,,N,Intermediate,A,9615.0,CHEMBL621166,,,,,1,1
6448,50588,In vivo,BAO_0000218,,,Oral bioavailability in dog (dose 1 mg/kg i.v.),,,N,Intermediate,A,9615.0,CHEMBL621167,,,,,1,1
6449,50588,In vivo,BAO_0000218,,,Oral bioavailability (F) in dogs,,,N,Intermediate,A,9615.0,CHEMBL621168,,,,,1,1
6450,50588,In vivo,BAO_0000218,,,Oral bioavailability in dog,,,N,Intermediate,A,9615.0,CHEMBL621169,,,,,1,1
6451,50588,In vivo,BAO_0000218,,,Bioavailability in dog,,,N,Intermediate,A,9615.0,CHEMBL875950,,,,,1,1
6452,50588,In vivo,BAO_0000218,,,Oral bioavailability in dog (dose 10 mg/kg),,,N,Intermediate,A,9615.0,CHEMBL621170,,,,,1,1
6453,50588,In vivo,BAO_0000218,,,Oral bioavailability after peroral administration at 5 mpk in Dog,,,N,Intermediate,A,9615.0,CHEMBL621171,,,,,1,1
6454,50588,In vivo,BAO_0000218,,,Oral bioavailability in dog (dose 5 mg/kg),,,N,Intermediate,A,9615.0,CHEMBL621172,,,,,1,1
6455,50588,In vivo,BAO_0000218,,,Oral bioavailability in dog (dose 10 mg/kg),,,N,Intermediate,A,9615.0,CHEMBL621173,,,,,1,1
6456,50594,,BAO_0000218,42.0,CCRF S-180,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 4 hours,,,N,Intermediate,A,10090.0,CHEMBL621174,,2113.0,Kidney,,1,1
6457,50594,,BAO_0000218,42.0,CCRF S-180,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 8 hours,,,N,Intermediate,A,10090.0,CHEMBL621175,,2113.0,Kidney,,1,1
6458,50594,,BAO_0000218,42.0,CCRF S-180,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 1 hour,,,N,Intermediate,A,10090.0,CHEMBL621176,,2107.0,Liver,,1,1
6459,50594,,BAO_0000218,42.0,CCRF S-180,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 2 hours,,,N,Intermediate,A,10090.0,CHEMBL621177,,2107.0,Liver,,1,1
6460,50594,,BAO_0000218,42.0,CCRF S-180,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 30 minutes,,,N,Intermediate,A,10090.0,CHEMBL621178,,2107.0,Liver,,1,1
6461,50594,,BAO_0000218,42.0,CCRF S-180,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 4 hours,,,N,Intermediate,A,10090.0,CHEMBL621179,,2107.0,Liver,,1,1
6462,50594,,BAO_0000218,42.0,CCRF S-180,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 8 hours,,,N,Intermediate,A,10090.0,CHEMBL621180,,2107.0,Liver,,1,1
6463,50594,,BAO_0000218,42.0,CCRF S-180,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 1 hour,,,N,Intermediate,A,10090.0,CHEMBL875951,,2048.0,Lung,,1,1
6464,50594,,BAO_0000218,42.0,CCRF S-180,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 2 hours,,,N,Intermediate,A,10090.0,CHEMBL621181,,2048.0,Lung,,1,1
6465,50594,,BAO_0000218,42.0,CCRF S-180,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 30 minutes,,,N,Intermediate,A,10090.0,CHEMBL621182,,2048.0,Lung,,1,1
6466,50594,,BAO_0000218,42.0,CCRF S-180,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 4 hours,,,N,Intermediate,A,10090.0,CHEMBL621183,,2048.0,Lung,,1,1
6467,50594,,BAO_0000218,42.0,CCRF S-180,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 8 hours,,,N,Intermediate,A,10090.0,CHEMBL621184,,2048.0,Lung,,1,1
6468,50594,,BAO_0000218,42.0,CCRF S-180,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 1 hour,,,N,Intermediate,A,10090.0,CHEMBL621185,,,,,1,1
6469,50594,,BAO_0000218,42.0,CCRF S-180,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice muscle bearing S180 tumor cell line for 2 hours,,,N,Intermediate,A,10090.0,CHEMBL621186,,,,,1,1
6470,50594,,BAO_0000218,42.0,CCRF S-180,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 30 minutes,,,N,Intermediate,A,10090.0,CHEMBL621187,,,,,1,1
6471,50594,,BAO_0000218,42.0,CCRF S-180,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 4 hours,,,N,Intermediate,A,10090.0,CHEMBL621188,,,,,1,1
6472,50594,,BAO_0000218,42.0,CCRF S-180,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 8 hours,,,N,Intermediate,A,10090.0,CHEMBL621189,,,,,1,1
6473,50594,,BAO_0000218,42.0,CCRF S-180,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice spleen bearing S180 tumor cell line for 1 hour,,,N,Intermediate,A,10090.0,CHEMBL621190,,2106.0,Spleen,,1,1
6474,50594,,BAO_0000218,42.0,CCRF S-180,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 2 hours,,,N,Intermediate,A,10090.0,CHEMBL618520,,2106.0,Spleen,,1,1
6475,50594,,BAO_0000218,42.0,CCRF S-180,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 30 minutes,,,N,Intermediate,A,10090.0,CHEMBL621739,,2106.0,Spleen,,1,1
6476,50594,,BAO_0000218,42.0,CCRF S-180,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 4 hours,,,N,Intermediate,A,10090.0,CHEMBL621740,,2106.0,Spleen,,1,1
6477,50594,,BAO_0000218,42.0,CCRF S-180,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 8 hours,,,N,Intermediate,A,10090.0,CHEMBL621741,,2106.0,Spleen,,1,1
6478,50594,,BAO_0000218,42.0,CCRF S-180,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 1 hour,,,N,Intermediate,A,10090.0,CHEMBL621742,,,,,1,1
6479,50594,,BAO_0000218,42.0,CCRF S-180,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 2 hours,,,N,Intermediate,A,10090.0,CHEMBL621743,,,,,1,1
6480,50594,,BAO_0000218,42.0,CCRF S-180,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 30 minutes,,,N,Intermediate,A,10090.0,CHEMBL621744,,,,,1,1
6481,50594,,BAO_0000218,42.0,CCRF S-180,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 4 hours,,,N,Intermediate,A,10090.0,CHEMBL621745,,,,,1,1
6482,50594,,BAO_0000218,42.0,CCRF S-180,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 8 hours,,,N,Intermediate,A,10090.0,CHEMBL621746,,,,,1,1
6483,50594,,BAO_0000218,42.0,CCRF S-180,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 1 hour,,,N,Intermediate,A,10090.0,CHEMBL621747,,,,,1,1
6484,50594,,BAO_0000218,42.0,CCRF S-180,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 2 hours,,,N,Intermediate,A,10090.0,CHEMBL621748,,,,,1,1
6485,50594,,BAO_0000218,42.0,CCRF S-180,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 30 minutes,,,N,Intermediate,A,10090.0,CHEMBL621749,,,,,1,1
6486,50594,,BAO_0000218,42.0,CCRF S-180,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 4 hours,,,N,Intermediate,A,10090.0,CHEMBL621750,,,,,1,1
6487,50594,,BAO_0000218,42.0,CCRF S-180,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 8 hours,,,N,Intermediate,A,10090.0,CHEMBL621751,,,,,1,1
6488,50594,,BAO_0000218,42.0,CCRF S-180,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 1 hour,,,N,Intermediate,A,10090.0,CHEMBL621752,,948.0,Heart,,1,1
6489,50594,,BAO_0000218,42.0,CCRF S-180,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 2 hours,,,N,Intermediate,A,10090.0,CHEMBL621753,,948.0,Heart,,1,1
6490,50594,,BAO_0000218,42.0,CCRF S-180,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 30 minutes,,,N,Intermediate,A,10090.0,CHEMBL875955,,948.0,Heart,,1,1
6491,50594,,BAO_0000218,42.0,CCRF S-180,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 4 hours,,,N,Intermediate,A,10090.0,CHEMBL621754,,948.0,Heart,,1,1
6492,50594,,BAO_0000218,42.0,CCRF S-180,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 8 hours,,,N,Intermediate,A,10090.0,CHEMBL621755,,948.0,Heart,,1,1
6493,50594,,BAO_0000218,42.0,CCRF S-180,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 1 hour,,,N,Intermediate,A,10090.0,CHEMBL621756,,2107.0,Liver,,1,1
6494,50594,,BAO_0000218,42.0,CCRF S-180,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 2 hours,,,N,Intermediate,A,10090.0,CHEMBL624199,,2107.0,Liver,,1,1
6495,50594,,BAO_0000218,42.0,CCRF S-180,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 30 minutes,,,N,Intermediate,A,10090.0,CHEMBL624200,,2107.0,Liver,,1,1
6496,50594,,BAO_0000218,42.0,CCRF S-180,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 4 hours,,,N,Intermediate,A,10090.0,CHEMBL624375,,2107.0,Liver,,1,1
6497,50594,,BAO_0000218,42.0,CCRF S-180,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 8 hours,,,N,Intermediate,A,10090.0,CHEMBL624376,,2107.0,Liver,,1,1
6498,50594,,BAO_0000218,42.0,CCRF S-180,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 1 hour,,,N,Intermediate,A,10090.0,CHEMBL624377,,2048.0,Lung,,1,1
6499,50594,,BAO_0000218,42.0,CCRF S-180,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/lung bearing S180 tumor cell line for 2 hours,,,N,Intermediate,A,10090.0,CHEMBL624378,,2048.0,Lung,,1,1
6500,50067,,BAO_0000218,,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,,N,Intermediate,F,107673.0,CHEMBL857901,,,,,1,1
6501,50067,,BAO_0000218,,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,,N,Intermediate,F,107673.0,CHEMBL875274,,,,,1,1
6502,50067,,BAO_0000218,,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,,N,Intermediate,F,107673.0,CHEMBL624379,,,,,1,1
6503,50067,,BAO_0000218,,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,,N,Intermediate,F,107673.0,CHEMBL624380,,,,,1,1
6504,50192,,BAO_0000218,,,Activity against Acinetobacter calcoaceticus (AC54),,,N,Intermediate,F,471.0,CHEMBL624381,,,,,1,1
6505,50714,,BAO_0000218,,,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates no prolonged biological activity,,,N,Intermediate,F,28377.0,CHEMBL624382,,,,,1,1
6506,50714,,BAO_0000218,,,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates prolonged biological activity,,,N,Intermediate,F,28377.0,CHEMBL624383,,,,,1,1
6507,50296,,BAO_0000218,,,Chlorohexidine coefficient for Actinomyces naeslundii 631,,,N,Intermediate,F,1655.0,CHEMBL624384,,,,,1,1
6508,50296,,BAO_0000218,,,Chlorohexidine coefficient for Actinomyces naeslundii B74,,,N,Intermediate,F,1655.0,CHEMBL624385,,,,,1,1
6509,50296,,BAO_0000218,,,Chlorohexidine coefficient for Actinomyces naeslundii N/3,,,N,Intermediate,F,1655.0,CHEMBL624386,,,,,1,1
6510,50296,,BAO_0000218,,,Chlorohexidine coefficient for Actinomyces naeslundii N/9,,,N,Intermediate,F,1655.0,CHEMBL624387,,,,,1,1
6511,50296,,BAO_0000218,,,Plaque bactericidal index against Actinomyces naeslundii 631,,,N,Intermediate,F,1655.0,CHEMBL624388,,,,,1,1
6512,50296,,BAO_0000218,,,Plaque bactericidal index against Actinomyces naeslundii N/9,,,N,Intermediate,F,1655.0,CHEMBL624389,,,,,1,1
6513,50296,,BAO_0000218,,,Plaque bactericidal index against Actinomyces naeslundii B74,,,N,Intermediate,F,1655.0,CHEMBL624390,,,,,1,1
6514,50296,,BAO_0000218,,,Plaque bactericidal index against Actinomyces naeslundii N/3,,,N,Intermediate,F,1655.0,CHEMBL875275,,,,,1,1
6515,50056,,BAO_0000218,,,Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay,,,N,Intermediate,F,85549.0,CHEMBL624391,,,,,1,1
6516,50056,,BAO_0000218,,,"Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay; highest level tested, showed <100% activity",,,N,Intermediate,F,85549.0,CHEMBL623636,,,,,1,1
6517,50532,,BAO_0000218,,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 0 uM,,,N,Intermediate,F,6253.0,CHEMBL623637,,,,,1,1
6518,50532,,BAO_0000218,,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 10 uM,,,N,Intermediate,F,6253.0,CHEMBL623638,,,,,1,1
6519,50532,,BAO_0000218,,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 200 uM,,,N,Intermediate,F,6253.0,CHEMBL623639,,,,,1,1
6520,50532,,BAO_0000218,,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 25 uM,,,N,Intermediate,F,6253.0,CHEMBL623640,,,,,1,1
6521,50532,,BAO_0000218,,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 3 uM,,,N,Intermediate,F,6253.0,CHEMBL623641,,,,,1,1
6522,50532,,BAO_0000218,,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 50 uM.,,,N,Intermediate,F,6253.0,CHEMBL623642,,,,,1,1
6523,50532,,BAO_0000218,,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 0 uM,,,N,Intermediate,F,6253.0,CHEMBL623643,,,,,1,1
6524,50532,,BAO_0000218,,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 10 uM,,,N,Intermediate,F,6253.0,CHEMBL623644,,,,,1,1
6525,50532,,BAO_0000218,,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 200 uM,,,N,Intermediate,F,6253.0,CHEMBL623645,,,,,1,1
6526,50532,,BAO_0000218,,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 25 uM,,,N,Intermediate,F,6253.0,CHEMBL623646,,,,,1,1
6527,50532,,BAO_0000218,,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 3 uM,,,N,Intermediate,F,6253.0,CHEMBL623647,,,,,1,1
6528,50532,,BAO_0000218,,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 50 uM,,,N,Intermediate,F,6253.0,CHEMBL623648,,,,,1,1
6529,50366,,BAO_0000218,,,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,,,N,Intermediate,F,1656.0,CHEMBL623649,,,,,1,1
6530,50366,,BAO_0000218,,,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,,,N,Intermediate,F,1656.0,CHEMBL623650,,,,,1,1
6531,50366,,BAO_0000218,,,Chlorohexidine coefficient for Actinomyces viscosus 8A06,,,N,Intermediate,F,1656.0,CHEMBL623651,,,,,1,1
6532,50366,,BAO_0000218,,,Chlorohexidine coefficient for Actinomyces viscosus M-100,,,N,Expert,F,1656.0,CHEMBL623652,,,,,1,1
6533,50366,,BAO_0000218,,,Chlorohexidine coefficient for Actinomyces viscosus M-626,,,N,Intermediate,F,1656.0,CHEMBL623653,,,,,1,1
6534,50366,,BAO_0000218,,,Chlorohexidine coefficient for Actinomyces viscosus T14V,,,N,Intermediate,F,1656.0,CHEMBL623654,,,,,1,1
6535,50366,,BAO_0000218,,,Plaque bactericidal index against Actinomyces viscosus 8A06,,,N,Intermediate,F,1656.0,CHEMBL623655,,,,,1,1
6536,50366,,BAO_0000218,,,Plaque bactericidal index against Actinomyces viscosus M-100,,,N,Intermediate,F,1656.0,CHEMBL623656,,,,,1,1
6537,50366,,BAO_0000218,,,Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient,,,N,Expert,F,1656.0,CHEMBL623657,,,,,1,1
6538,50366,,BAO_0000218,,,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; d=Not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",,,N,Intermediate,F,1656.0,CHEMBL623658,,,,,1,1
6539,50366,,BAO_0000218,,,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",,,N,Intermediate,F,1656.0,CHEMBL623659,,,,,1,1
6540,50366,,BAO_0000218,,,Plaque bactericidal index against Actinomyces viscosus 626,,,N,Intermediate,F,1656.0,CHEMBL623660,,,,,1,1
6541,50366,,BAO_0000218,,,Plaque bactericidal index against Actinomyces viscosus T14V,,,N,Intermediate,F,1656.0,CHEMBL623661,,,,,1,1
6542,50535,,BAO_0000218,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 1.56 mg/kg/day(5 days) dose,,,N,Intermediate,F,6277.0,CHEMBL875281,,,,,1,1
6543,50535,,BAO_0000218,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 100 mg/kg/day(5 days) dose,,,N,Intermediate,F,6277.0,CHEMBL623662,,,,,1,1
6544,50535,,BAO_0000218,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 12.5 mg/kg/day(5 days) dose,,,N,Intermediate,F,6277.0,CHEMBL623663,,,,,1,1
6545,50535,,BAO_0000218,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 200 mg/kg/day(5 days) dose,,,N,Intermediate,F,6277.0,CHEMBL623664,,,,,1,1
6546,50535,,BAO_0000218,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 25 mg/kg/day(5 days) dose,,,N,Intermediate,F,6277.0,CHEMBL623665,,,,,1,1
6547,80023,,BAO_0000219,165.0,A673,Evaluated for the inhibitory concentration required to cause growth inhibition of A673Mer+ sarcoma cell line using the MTT Cytotoxicity Assay,,,N,Intermediate,F,9606.0,CHEMBL621856,,,,,1,1
6548,80661,,BAO_0000219,645.0,A704,Evaluated for the inhibitory concentration required to cause growth inhibition of A704Rem- renal cell line using the MTT Cytotoxicity Assay,,,N,Intermediate,F,9606.0,CHEMBL620432,,,,,1,1
6549,22226,,BAO_0000219,,,Tested for inhibition of ET-1 induced phosphoinositide (PI) turnover in A7r5 smooth muscle cells,,,U,Autocuration,F,10116.0,CHEMBL620433,,,,,0,1
6550,80024,,BAO_0000219,625.0,A9,Inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,,,N,Intermediate,F,10090.0,CHEMBL620434,,,,,1,1
6551,80024,,BAO_0000219,625.0,A9,Percent inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,,,N,Intermediate,F,10090.0,CHEMBL620435,,,,,1,1
6552,80024,,BAO_0000219,625.0,A9,Cytotoxicity against Beta- tubulin mutant expressing A9-PTX10 cell line of humans was tested,,,N,Intermediate,F,9606.0,CHEMBL620436,,,,,1,1
6553,80024,,BAO_0000219,625.0,A9,Percentage inhibition at higher concentration (100 nM) against Beta- tubulin mutant expressing A9-PTX10 cell line,,,N,Intermediate,F,9606.0,CHEMBL876597,,,,,1,1
6554,81037,,BAO_0000219,874.0,Human ovarian carcinoma cell line,Inhibition of human ovarian carcinoma (A90) FGF-R overexpressing cell proliferation,,,N,Expert,F,9606.0,CHEMBL620437,,,,,1,1
6555,80024,,BAO_0000219,625.0,A9,"Tested for stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells, activity expressed as EC50 mM.",,,N,Expert,F,10090.0,CHEMBL620438,,,,,1,1
6556,80024,,BAO_0000219,625.0,A9,Stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells.,,,N,Expert,F,10090.0,CHEMBL620439,,,,,1,1
6557,80024,,BAO_0000219,625.0,A9,Increase in phosphoinositide (PI) metabolism in A9L-m1 cells at 100 uM.,,,N,Expert,F,10090.0,CHEMBL619657,,,,,1,1
6558,80024,,BAO_0000219,625.0,A9,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; - = Not determined,,,N,Intermediate,F,10090.0,CHEMBL619658,,,,,1,1
6559,80024,,BAO_0000219,625.0,A9,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; i = inactive,,,N,Intermediate,F,10090.0,CHEMBL619659,,,,,1,1
6560,10649,,BAO_0000019,,,"Increase in phosphoinositide (PI) metabolism in A9L-cholinergic receptor, muscarinic 3 expressing cells was measured at 100 uMolar",,,H,Expert,F,,CHEMBL619660,,,,,8,1
6561,80024,,BAO_0000219,625.0,A9,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; - = Not determined,,,N,Intermediate,F,10090.0,CHEMBL619661,,,,,1,1
6562,80024,,BAO_0000219,625.0,A9,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; i = inactive,,,N,Intermediate,F,10090.0,CHEMBL619662,,,,,1,1
6563,80663,,BAO_0000219,975.0,AA6,Ability to inhibit growth of AA-6 cells (a mutant cell line resistant to 8-azaadenine and lacks adenine phosphoryltransferase) was determined,,,N,Intermediate,F,10029.0,CHEMBL619663,,,,,1,1
6564,22226,,BAO_0000219,,,Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied after 5 hrs of Incubation.,,,U,Autocuration,F,9606.0,CHEMBL619664,,,,,0,1
6565,22226,,BAO_0000219,,,"Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied, after 5 hrs of Incubation.",,,U,Autocuration,F,9606.0,CHEMBL619665,,,,,0,1
6566,80662,,BAO_0000219,974.0,AA5,Anti -HIV activity was measured against AA5/HIV-1(IIIB),,,N,Intermediate,F,9606.0,CHEMBL883244,,,,,1,1
6567,80662,,BAO_0000219,974.0,AA5,Cytotoxicity was measured against AA5/HIV-1(IIIB),,,N,Intermediate,F,9606.0,CHEMBL884011,,,,,1,1
6568,80662,,BAO_0000219,974.0,AA5,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in AA5 EBV-infected B-cell,,,N,Intermediate,F,9606.0,CHEMBL619666,,,,,1,1
6569,80566,,BAO_0000219,379.0,U-937,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in U937 monocytic cell,,,N,Intermediate,F,9606.0,CHEMBL619667,,,,,1,1
6570,80578,,BAO_0000219,274.0,UV4,Hypersensitivity factor obtained from in vitro cytotoxicities against Chinese hamster ovary derived AA8 / UV4 cell lines,,,N,Intermediate,F,10029.0,CHEMBL619668,,,,,1,1
6571,80089,,BAO_0000219,185.0,CHO-AA8,"Inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",,,N,Expert,F,10029.0,CHEMBL619669,,,,,1,1
6572,80089,,BAO_0000219,185.0,CHO-AA8,Average intracellular compound concentration when the hypoxic SER=1.6,,,N,Intermediate,F,10029.0,CHEMBL876608,,,,,1,1
6573,80089,,BAO_0000219,185.0,CHO-AA8,Average intracellular compound concentration when the hypoxic SER=1.6.,,,N,Intermediate,F,10029.0,CHEMBL619670,,,,,1,1
6574,80089,,BAO_0000219,185.0,CHO-AA8,Average intracellular compound concentration where the hypoxia sensitizer enhancement ratio (SER)=1.6,,,N,Intermediate,F,10029.0,CHEMBL619671,,,,,1,1
6575,80089,,BAO_0000219,185.0,CHO-AA8,Average intracellular compound concentration where the sensitizer enhancement ratio (SER)=1.6 under hypoxia,,,N,Intermediate,F,10029.0,CHEMBL619672,,,,,1,1
6576,80089,,BAO_0000219,185.0,CHO-AA8,Compound concentration at which sensitizer enhancement ratio =1.6 under hypoxia.,,,N,Intermediate,F,10029.0,CHEMBL619673,,,,,1,1
6577,80089,,BAO_0000219,185.0,CHO-AA8,"Compound was tested for the concentration required to reduce cell survival under hypoxic conditions, using the cell line AA8 in the clonogenic assay.",,,N,Intermediate,F,10029.0,CHEMBL619674,,,,,1,1
6578,80089,,BAO_0000219,185.0,CHO-AA8,"Concentration needed to reduce cell survival to 10% of control values, using 1 hour exposure of plateau phase AA8 cells at 10e6 cells/ml",,,N,Intermediate,F,10029.0,CHEMBL619675,,,,,1,1
6579,80089,,BAO_0000219,185.0,CHO-AA8,Activity to reduce the surviving fraction to 10% (CT10) was used as an inverse measure of cytotoxic potency in aerobic conditions,,,N,Intermediate,F,10029.0,CHEMBL619676,,,,,1,1
6580,80089,,BAO_0000219,185.0,CHO-AA8,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,,,N,Intermediate,F,10029.0,CHEMBL619677,,,,,1,1
6581,80089,,BAO_0000219,185.0,CHO-AA8,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,,,N,Intermediate,A,10029.0,CHEMBL619678,,,,,1,1
6582,80089,,BAO_0000219,185.0,CHO-AA8,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition.,,,N,Intermediate,A,10029.0,CHEMBL619679,,,,,1,1
6583,80089,,BAO_0000219,185.0,CHO-AA8,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay,,,N,Expert,A,10029.0,CHEMBL619680,,,,,1,1
6584,80089,,BAO_0000219,185.0,CHO-AA8,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay. Inactive at the solubility limit,,,N,Intermediate,A,10029.0,CHEMBL621457,,,,,1,1
6585,80089,,BAO_0000219,185.0,CHO-AA8,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% controls in clonogenic assay,,,N,Expert,F,10029.0,CHEMBL876609,,,,,1,1
6586,80089,,BAO_0000219,185.0,CHO-AA8,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% of controls in clonogenic assay,,,N,Intermediate,F,10029.0,CHEMBL621458,,,,,1,1
6587,80089,,BAO_0000219,185.0,CHO-AA8,Aerobic cytotoxicity was assessed in a growth inhibition assay using log phase cultures of the chinese hamster ovary fibroblast line AA8,,,N,Expert,F,36483.0,CHEMBL621459,,,,,1,1
6588,80089,,BAO_0000219,185.0,CHO-AA8,Aerobic growth inhibition in Chinese hamster cell line AA8,,,N,Expert,F,10029.0,CHEMBL621460,,,,,1,1
6589,80089,,BAO_0000219,185.0,CHO-AA8,Cytotoxicity against AA8 cell and IC50 values were determined as drug concentration required to inhibit cell protein to 50%.,,,N,Expert,F,10029.0,CHEMBL621461,,,,,1,1
6590,80089,,BAO_0000219,185.0,CHO-AA8,Inhibition of growth under aerobic conditions in AA8 cells,,,N,Expert,F,10029.0,CHEMBL621462,,,,,1,1
6591,50588,In vivo,BAO_0000218,,,Oral bioavailability in dog (dose 10 mg/kg),,,N,Intermediate,A,9615.0,CHEMBL621463,,,,,1,1
6592,50588,In vivo,BAO_0000218,,,Oral bioavailability in dog at 10 mg/kg of the compound,,,N,Intermediate,A,9615.0,CHEMBL621464,,,,,1,1
6593,50588,In vivo,BAO_0000218,,,Oral bioavailability in dog (dose 5 uM/kg),,,N,Intermediate,A,9615.0,CHEMBL621465,,,,,1,1
6594,50588,In vivo,BAO_0000218,,,Oral bioavailability in dog (dose 5 uM/kg),,,N,Intermediate,A,9615.0,CHEMBL621466,,,,,1,1
6595,50588,In vivo,BAO_0000218,,,Oral bioavailability in dog (mongrel),,,N,Intermediate,A,9615.0,CHEMBL621467,,,,,1,1
6596,50588,In vivo,BAO_0000218,,,Oral bioavailability in dog (dose 10 mg/kg),,,N,Intermediate,A,9615.0,CHEMBL621468,,,,,1,1
6597,50588,In vivo,BAO_0000218,,,Oral bioavailability in dog (dose 10 mg/kg),,,N,Intermediate,F,9615.0,CHEMBL876734,,,,,1,1
6598,50588,In vivo,BAO_0000218,,,Bioavailability in dog,,,N,Intermediate,A,9615.0,CHEMBL618476,,,,,1,1
6599,50588,In vivo,BAO_0000218,,,Bioavailability in dog (dose 1 mg/kg i.v.),,,N,Intermediate,A,9615.0,CHEMBL618477,,,,,1,1
6600,50588,In vivo,BAO_0000218,,,Pharmacokinetic data for dose given to dogs intravenously (oral PK study in parentheses),,,N,Intermediate,A,9615.0,CHEMBL618478,,,,,1,1
6601,50588,In vivo,BAO_0000218,,,Pharmacokinetic property (F) was measured in dog at the dose of 0.032 mg/kg,,,N,Intermediate,A,9615.0,CHEMBL618479,,,,,1,1
6602,50588,In vivo,BAO_0000218,,,Bioavailability in dog,,,N,Intermediate,A,9615.0,CHEMBL618480,,,,,1,1
6603,50588,In vivo,BAO_0000218,,,Bioavailability in dog (dose 3-10 mg/kg),,,N,Intermediate,A,9615.0,CHEMBL618481,,,,,1,1
6604,50588,In vivo,BAO_0000218,,,The compound was tested for bioavailability of compound in plasma of dog; Complete,,,N,Intermediate,A,9615.0,CHEMBL618482,,1969.0,Plasma,,1,1
6605,50588,In vivo,BAO_0000218,,,Oral bioavailability in dog,,,N,Intermediate,A,9615.0,CHEMBL618483,,,,,1,1
6606,50588,In vivo,BAO_0000218,,,Oral bioavailability in dog,,,N,Intermediate,A,9615.0,CHEMBL618484,,,,,1,1
6607,50588,In vivo,BAO_0000218,,,Bioavailability in dog,,,N,Intermediate,A,9615.0,CHEMBL618485,,,,,1,1
6608,50588,In vivo,BAO_0000218,,,oral bioavailability was measured in dogs,,,N,Intermediate,A,9615.0,CHEMBL618486,,,,,1,1
6609,50588,,BAO_0000218,,,Compound was tested for plasma protein binding in dog; Not determined,,,N,Intermediate,A,9615.0,CHEMBL618487,,,,,1,1
6610,50588,,BAO_0000218,,,Compound was tested for plasma protein binding of dog,,,N,Intermediate,A,9615.0,CHEMBL618488,,,,,1,1
6611,50588,,BAO_0000218,,,Compound was tested for plasma protein binding of dog; Not determined,,,N,Intermediate,A,9615.0,CHEMBL876735,,,,,1,1
6612,50588,,BAO_0000218,,,Concentration in dogs after oral administration at dose of 1 mg/kg after 180 min.,,,N,Intermediate,A,9615.0,CHEMBL618489,,,,,1,1
6613,50588,In vivo,BAO_0000218,,,Apparent terminal elimination half-life in dog after administration of 20 mg/kg dose through peroral route,,,N,Intermediate,A,9615.0,CHEMBL618490,,,,,1,1
6614,50588,,BAO_0000218,,,Half life was determined,,,N,Intermediate,A,9615.0,CHEMBL618491,,,,,1,1
6615,50588,In vivo,BAO_0000218,,,Half life by ''Cr'' assay in dog at a dose of 5 mg/kg,,,N,Intermediate,A,9615.0,CHEMBL618492,,,,,1,1
6616,50588,,BAO_0000218,,,Half life was evaluated in dog,,,N,Intermediate,A,9615.0,CHEMBL873354,,,,,1,1
6617,50588,,BAO_0000218,,,Half life was determined,,,N,Intermediate,A,9615.0,CHEMBL618493,,,,,1,1
6618,50588,In vivo,BAO_0000218,,,Biodistribution of compound was measured in bile at 2 hr post-injection in canine deep vein thrombosis model (DVT),,,N,Intermediate,A,9615.0,CHEMBL618494,,,,,1,1
6619,50588,In vivo,BAO_0000218,,,Biodistribution of compound was measured in heart at 2 hr post-injection in canine deep vein thrombosis model (DVT),,,N,Intermediate,A,9615.0,CHEMBL618495,,948.0,Heart,,1,1
6620,50588,In vivo,BAO_0000218,,,Biodistribution of compound was measured in kidney at 2 hr post-injection in canine deep vein thrombosis model (DVT),,,N,Intermediate,A,9615.0,CHEMBL618496,,2113.0,Kidney,,1,1
6621,50588,In vivo,BAO_0000218,,,Biodistribution of compound was measured in liver at 2 hr post-injection in canine deep vein thrombosis model (DVT),,,N,Intermediate,A,9615.0,CHEMBL618497,,2107.0,Liver,,1,1
6622,50588,In vivo,BAO_0000218,,,Biodistribution of compound was measured in lung at 2 hr post-injection in canine deep vein thrombosis model (DVT),,,N,Intermediate,A,9615.0,CHEMBL618498,,2048.0,Lung,,1,1
6623,50588,In vivo,BAO_0000218,,,Biodistribution of compound was measured in spleen at 2 hr post-injection in canine deep vein thrombosis model (DVT),,,N,Intermediate,A,9615.0,CHEMBL618499,,2106.0,Spleen,,1,1
6624,50588,,BAO_0000218,,,LogP in dog,,,N,Intermediate,A,9615.0,CHEMBL876736,,,,,1,1
6625,50588,,BAO_0000218,,,Partition coefficient (logP),,,N,Intermediate,A,9615.0,CHEMBL618500,,,,,1,1
6626,50588,,BAO_0000218,,,Partition coefficient in dog,,,N,Intermediate,A,9615.0,CHEMBL857831,,,,,1,1
6627,50588,In vivo,BAO_0000218,,,Mean-residence time of compound after intravenous administration in dogs at 1.2 uM/kg,,,N,Intermediate,A,9615.0,CHEMBL618501,,,,,1,1
6628,50588,In vivo,BAO_0000218,,,Pharmacokinetic parameter MRT was determined in Beagle dogs after (po) administration of a dose of 28 (uM/kg),,,N,Intermediate,A,9615.0,CHEMBL618502,,,,,1,1
6629,50588,,BAO_0000218,,,In vitro metabolic stability determined after 30 min of incubation in dog hepatic microsomes,,,N,Intermediate,A,9615.0,CHEMBL618503,,,,,1,1
6630,50588,,BAO_0000218,,,Metabolism of compound in dog S9 microsomes ('++''indicates 20-50% largest observed peak),,,N,Intermediate,A,9615.0,CHEMBL618504,,,,,1,1
6631,50588,,BAO_0000218,,,Metabolism of compound in dog S9 microsomes ('++++' indicates largest observed peak),,,N,Intermediate,A,9615.0,CHEMBL618505,,,,,1,1
6632,50588,,BAO_0000218,,,Metabolism of compound in dog S9 microsomes; Trace,,,N,Intermediate,A,9615.0,CHEMBL618506,,,,,1,1
6633,50588,,BAO_0000218,,,In vitro metabolic potential in dog liver microsomes,,,N,Intermediate,A,9615.0,CHEMBL618507,,2107.0,Liver,,1,1
6634,50588,In vivo,BAO_0000218,,,Oral bioavailability of perorally administered compound (10 mg/kg) was tested in dogs,,,N,Intermediate,A,9615.0,CHEMBL876737,,,,,1,1
6635,50588,In vivo,BAO_0000218,,,Oral bioavailability in dog,,,N,Intermediate,A,9615.0,CHEMBL618508,,,,,1,1
6636,50588,In vivo,BAO_0000218,,,Oral bioavailability in dog,,,N,Intermediate,A,9615.0,CHEMBL618509,,,,,1,1
6637,50588,In vivo,BAO_0000218,,,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,,N,Intermediate,A,9615.0,CHEMBL618510,,,,,1,1
6638,50588,In vivo,BAO_0000218,,,The compound was tested for bioavailability in dogs,,,N,Intermediate,A,9615.0,CHEMBL618511,,,,,1,1
6639,50588,In vivo,BAO_0000218,,,The compound was tested for oral bioavailability in dogs,,,N,Intermediate,A,9615.0,CHEMBL618512,,,,,1,1
6640,50588,In vivo,BAO_0000218,,,Oral bioavailability in dog,,,N,Intermediate,A,9615.0,CHEMBL618513,,,,,1,1
6641,50588,,BAO_0000218,,,Compound was tested for percent protein binding (PB) in dog,,,N,Intermediate,A,9615.0,CHEMBL618514,,,,,1,1
6642,50588,,BAO_0000218,,,Apparent permeability coefficient (Papp) for apical to basolateral flux was determined in MadinDarby Canine Kidney cells,,,N,Intermediate,A,9615.0,CHEMBL620052,,,,,1,1
6643,50588,In vivo,BAO_0000218,,,Compound was evaluated for plasma clearance.,,,N,Intermediate,A,9615.0,CHEMBL620053,,1969.0,Plasma,,1,1
6644,50588,In vivo,BAO_0000218,,,The compound was tested for plasma clearance in dog,,,N,Intermediate,A,9615.0,CHEMBL620054,,1969.0,Plasma,,1,1
6645,50588,In vivo,BAO_0000218,,,The compound was tested for plasma clearance in dog at dose of 3-10 mgkg,,,N,Intermediate,A,9615.0,CHEMBL620055,,1969.0,Plasma,,1,1
6646,50588,,BAO_0000218,,,Plasma protein binding was determined after intravenous administration of 1 mg/kg in dog,,,N,Intermediate,A,9615.0,CHEMBL620056,,,,,1,1
6647,50588,,BAO_0000218,,,In vitro relative rate of metabolism was determined in dog liver microsomes,,,N,Intermediate,A,9615.0,CHEMBL620057,,2107.0,Liver,,1,1
6648,50588,In vivo,BAO_0000218,,,Relative bioavailability after oral dose of compound at 3 mg/kg in dogs,,,N,Intermediate,A,9615.0,CHEMBL618939,,,,,1,1
6649,50588,In vivo,BAO_0000218,,,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,,,N,Intermediate,A,9615.0,CHEMBL618940,,,,,1,1
6650,50588,In vivo,BAO_0000218,,,Half life after intravenous administration in dogs at 1.2 uM/kg,,,N,Intermediate,A,9615.0,CHEMBL618941,,,,,1,1
6651,50594,,BAO_0000218,42.0,CCRF S-180,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 30 minutes,,,N,Intermediate,A,10090.0,CHEMBL624473,,2048.0,Lung,,1,1
6652,50594,,BAO_0000218,42.0,CCRF S-180,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 4 hours,,,N,Intermediate,A,10090.0,CHEMBL624474,,2048.0,Lung,,1,1
6653,50594,,BAO_0000218,42.0,CCRF S-180,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 8 hours,,,N,Intermediate,A,10090.0,CHEMBL624475,,2048.0,Lung,,1,1
6654,50594,,BAO_0000218,42.0,CCRF S-180,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 1 hour,,,N,Intermediate,A,10090.0,CHEMBL624476,,,,,1,1
6655,50594,,BAO_0000218,42.0,CCRF S-180,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 2 hours,,,N,Intermediate,A,10090.0,CHEMBL623478,,,,,1,1
6656,50594,,BAO_0000218,42.0,CCRF S-180,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 30 minutes,,,N,Intermediate,A,10090.0,CHEMBL623479,,,,,1,1
6657,50594,,BAO_0000218,42.0,CCRF S-180,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 4 hours,,,N,Intermediate,A,10090.0,CHEMBL623480,,,,,1,1
6658,50594,,BAO_0000218,42.0,CCRF S-180,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 8 hours,,,N,Intermediate,A,10090.0,CHEMBL623481,,,,,1,1
6659,50594,,BAO_0000218,,,C2 in brain of mice at the oral dose of 50 mg/kg,,,N,Intermediate,A,10090.0,CHEMBL623482,,955.0,Brain,,1,1
6660,50594,,BAO_0000218,,,C2 in kidney of mice at the oral dose of 50 mg/kg,,,N,Intermediate,A,10090.0,CHEMBL623483,,2113.0,Kidney,,1,1
6661,50594,,BAO_0000218,,,C2 in liver of mice at the oral dose of 50 mg/kg,,,N,Intermediate,A,10090.0,CHEMBL623484,,2107.0,Liver,,1,1
6662,50594,,BAO_0000218,,,C2 in lungs of mice at the oral dose of 50 mg/kg,,,N,Intermediate,A,10090.0,CHEMBL623485,,2048.0,Lung,,1,1
6663,50594,,BAO_0000218,,,C2 in spleen of mice at the oral dose of 50 mg/kg,,,N,Intermediate,A,10090.0,CHEMBL623486,,2106.0,Spleen,,1,1
6664,50594,In vivo,BAO_0000218,,,Plasma clearance in mouse,,,N,Intermediate,A,10090.0,CHEMBL623487,,,,,1,1
6665,50594,In vivo,BAO_0000218,,,Clearance of compound after intravenous administration in mice at 24 uM/kg,,,N,Intermediate,A,10090.0,CHEMBL623488,,,,,1,1
6666,50594,In vivo,BAO_0000218,,,Clearance from mouse blood following i.v. administration of 10 mg/kg,,,N,Intermediate,A,10090.0,CHEMBL623489,,,,,1,1
6667,50594,In vivo,BAO_0000218,,,Clearance was evaluated in mice after intravenous administration,,,N,Intermediate,A,10090.0,CHEMBL875157,,,,,1,1
6668,50594,In vivo,BAO_0000218,,,Clearance was evaluated in mice after oral administration,,,N,Intermediate,A,10090.0,CHEMBL623490,,,,,1,1
6669,50594,In vivo,BAO_0000218,,,Pharmacokinetic property (Plasma clearance) was measured in mouse,,,N,Intermediate,A,10090.0,CHEMBL623491,,,,,1,1
6670,50594,In vivo,BAO_0000218,,,Plasma clearance of compound was determined at 40 mg/Kg,,,N,Intermediate,A,10090.0,CHEMBL623492,,,,,1,1
6671,50594,In vivo,BAO_0000218,,,Plasma clearance of at 24 mg/Kg,,,N,Intermediate,A,10090.0,CHEMBL623493,,,,,1,1
6672,50594,In vivo,BAO_0000218,,,Plasma clearance at 24 mg/Kg,,,N,Intermediate,A,10090.0,CHEMBL623494,,,,,1,1
6673,50594,In vivo,BAO_0000218,,,Plasma clearance at 5 mg/Kg,,,N,Intermediate,A,10090.0,CHEMBL623495,,,,,1,1
6674,50594,In vivo,BAO_0000218,,,Plasma clearance in mice,,,N,Intermediate,A,10090.0,CHEMBL623496,,,,,1,1
6675,50594,In vivo,BAO_0000218,,,Plasma clearance value upon iv administration in mouse,,,N,Intermediate,A,10090.0,CHEMBL623497,,,,,1,1
6676,50594,In vivo,BAO_0000218,,,Total plasma clearance in mice,,,N,Intermediate,A,10090.0,CHEMBL623498,,1969.0,Plasma,,1,1
6677,50594,In vivo,BAO_0000218,,,Clearance in mouse,,,N,Intermediate,A,10090.0,CHEMBL623499,,,,,1,1
6678,50594,In vivo,BAO_0000218,,,Clearance value was determined,,,N,Intermediate,A,10090.0,CHEMBL623500,,,,,1,1
6679,50594,In vivo,BAO_0000218,,,Plasma clearance at a dose of 10 mg/kg intravenous administration in mice.,,,N,Intermediate,A,10090.0,CHEMBL623501,,,,,1,1
6680,22229,,BAO_0000100,,,Calculated partition coefficient (clogP),,,U,Intermediate,P,,CHEMBL875158,,,,,0,1
6681,50594,In vivo,BAO_0000218,,,Plasma clearance for the compound was measured in mouse after an iv dose of 1 mg/kg,,,N,Intermediate,A,10090.0,CHEMBL623502,,,,,1,1
6682,50594,In vivo,BAO_0000218,,,Plasma clearance rate after intraperitoneal administration of 100 mg/kg in mice,,,N,Intermediate,A,10090.0,CHEMBL623503,,,,,1,1
6683,50594,In vivo,BAO_0000218,,,Plasma clearance was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,,N,Intermediate,A,10090.0,CHEMBL623504,,,,,1,1
6684,50594,In vivo,BAO_0000218,,,In vivo total clearance was determined in murine septicemia at dose of 100 mg/kg,,,N,Intermediate,A,10090.0,CHEMBL623505,,,,,1,1
6685,50594,In vivo,BAO_0000218,,,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg,,,N,Intermediate,A,10090.0,CHEMBL623506,,,,,1,1
6686,50594,In vivo,BAO_0000218,,,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,,,N,Intermediate,A,10090.0,CHEMBL623507,,,,,1,1
6687,50594,In vivo,BAO_0000218,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for Cmax,,,N,Intermediate,A,10090.0,CHEMBL623508,,,,,1,1
6688,50594,In vivo,BAO_0000218,,,Cmax after oral administration at 30 mg/kg in ICR mouse,,,N,Intermediate,A,10090.0,CHEMBL623509,,,,,1,1
6689,50594,In vivo,BAO_0000218,,,Cmax after peroral administration in mice at 2.4 uM/kg,,,N,Intermediate,A,10090.0,CHEMBL875159,,,,,1,1
6690,50594,In vivo,BAO_0000218,,,Cmax in brain of mice at the oral dose of 50 mg/kg,,,N,Intermediate,A,10090.0,CHEMBL623510,,955.0,Brain,,1,1
6691,50594,In vivo,BAO_0000218,,,Cmax in kidney of mice at the oral dose of 50 mg/kg,,,N,Intermediate,A,10090.0,CHEMBL623511,,2113.0,Kidney,,1,1
6692,50594,In vivo,BAO_0000218,,,Cmax in liver of mice at the oral dose of 50 mg/kg,,,N,Intermediate,A,10090.0,CHEMBL623512,,2107.0,Liver,,1,1
6693,50594,In vivo,BAO_0000218,,,Cmax in lungs of mice at the oral dose of 50 mg/kg,,,N,Intermediate,A,10090.0,CHEMBL623513,,2048.0,Lung,,1,1
6694,50594,In vivo,BAO_0000218,,,Cmax in mice at 18 uM/kg i.p. administration,,,N,Intermediate,F,10090.0,CHEMBL623514,,,,,1,1
6695,50594,In vivo,BAO_0000218,,,Cmax in mice at 23 uM/kg i.v. administration,,,N,Intermediate,F,10090.0,CHEMBL622609,,,,,1,1
6696,50594,In vivo,BAO_0000218,,,Cmax in mice at 24 uM/kg i.p. administration,,,N,Intermediate,F,10090.0,CHEMBL622610,,,,,1,1
6697,50594,In vivo,BAO_0000218,,,Cmax in mice at 25 uM/kg i.p. administration,,,N,Intermediate,F,10090.0,CHEMBL621823,,,,,1,1
6698,50594,In vivo,BAO_0000218,,,Cmax in mice at 26 uM/kg i.p. administration,,,N,Intermediate,F,10090.0,CHEMBL621824,,,,,1,1
6699,50594,In vivo,BAO_0000218,,,Cmax in spleen of mice at the oral dose of 50 mg/kg,,,N,Intermediate,A,10090.0,CHEMBL621825,,2106.0,Spleen,,1,1
6700,50594,In vivo,BAO_0000218,,,Cmax value at a dose of 10 mg/kg intravenous administration in mice.,,,N,Intermediate,A,10090.0,CHEMBL621826,,,,,1,1
6701,50594,In vivo,BAO_0000218,,,Cmax value at a dose of 10 mg/kg peroral administration in mice.,,,N,Intermediate,A,10090.0,CHEMBL621827,,,,,1,1
6702,50594,In vivo,BAO_0000218,,,Cmax value was determined,,,N,Intermediate,A,10090.0,CHEMBL621828,,,,,1,1
6703,50594,In vivo,BAO_0000218,,,Cmax value in IRC mice,,,N,Intermediate,A,10090.0,CHEMBL621829,,,,,1,1
6704,50594,In vivo,BAO_0000218,,,Cmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,,,N,Intermediate,A,10090.0,CHEMBL621830,,,,,1,1
6705,50594,In vivo,BAO_0000218,,,Cmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,,,N,Intermediate,A,10090.0,CHEMBL621831,,,,,1,1
6706,50594,In vivo,BAO_0000218,,,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,,,N,Intermediate,A,10090.0,CHEMBL621832,,1969.0,Plasma,,1,1
6707,50594,In vivo,BAO_0000218,,,"Compound was evaluated for the pharmacokinetic parameter, maximum plasma concentration",,,N,Intermediate,A,10090.0,CHEMBL624579,,1969.0,Plasma,,1,1
6708,50594,In vivo,BAO_0000218,,,Evaluated for pharmacokinetic parameter Cmax in mouse at the dose 20 mg/kg,,,N,Intermediate,A,10090.0,CHEMBL624580,,,,,1,1
6709,50535,,BAO_0000218,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 50 mg/kg/day(5 days) dose,,,N,Intermediate,F,6277.0,CHEMBL624581,,,,,1,1
6710,50535,,BAO_0000218,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 6.25 mg/kg/day(5 days) dose,,,N,Intermediate,F,6277.0,CHEMBL624582,,,,,1,1
6711,50535,,BAO_0000218,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 75 mg/kg/day(5 days) dose,,,N,Intermediate,F,6277.0,CHEMBL624583,,,,,1,1
6712,80018,,BAO_0000219,455.0,A-375,Inhibitory activity against human tumor cell line A0375 melanoma.,,,N,Intermediate,F,9606.0,CHEMBL624584,,,,,1,1
6713,12512,,BAO_0000249,,,Displacement of [3H]N6-PIA binding from A1 receptor in whole rat brain membranes,,,D,Expert,B,10116.0,CHEMBL624585,,,,Brain membranes,9,1
6714,114,,BAO_0000019,,,Forskolin-induced cAMP production at human A1 adenosine receptor,,,D,Expert,F,9606.0,CHEMBL875165,,,,,9,1
6715,114,,BAO_0000219,449.0,CHO,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1; change of less than 5% of allosteric enhancement.,,,H,Autocuration,F,,CHEMBL619490,,,,,8,1
6716,114,,BAO_0000219,449.0,CHO,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,,,H,Autocuration,F,,CHEMBL619491,,,,,8,1
6717,114,,BAO_0000219,449.0,CHO,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM,,,H,Expert,F,,CHEMBL619492,,,,,8,1
6718,114,,BAO_0000219,449.0,CHO,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration,,,H,Expert,F,,CHEMBL619493,,,,,8,1
6719,114,,BAO_0000219,449.0,CHO,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; An increase of cAmp content of cells,,,H,Autocuration,F,,CHEMBL619494,,,,,8,1
6720,114,,BAO_0000219,449.0,CHO,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement,,,H,Autocuration,F,,CHEMBL619495,,,,,8,1
6721,114,,BAO_0000219,449.0,CHO,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement.,,,H,Autocuration,F,,CHEMBL619496,,,,,8,1
6722,114,,BAO_0000219,449.0,CHO,Percent response to 10 uM PD-81723 on CHO cells expressing human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,,,D,Expert,F,9606.0,CHEMBL619497,,,,,9,1
6723,114,,BAO_0000219,449.0,CHO,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM,,,H,Autocuration,F,,CHEMBL619498,,,,,8,1
6724,114,,BAO_0000219,449.0,CHO,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; change of less than 5% of allosteric enhancement.,,,H,Autocuration,F,,CHEMBL619499,,,,,8,1
6725,114,,BAO_0000219,449.0,CHO,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration,,,H,Expert,F,,CHEMBL619500,,,,,8,1
6726,114,,BAO_0000219,449.0,CHO,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration; change of less than 5% of allosteric enhancement.,,,H,Autocuration,F,,CHEMBL619501,,,,,8,1
6727,114,,BAO_0000219,449.0,CHO,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; An increase of cAmp content of cells,,,H,Expert,F,,CHEMBL619502,,,,,8,1
6728,114,,BAO_0000219,449.0,CHO,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM,,,H,Autocuration,F,,CHEMBL619503,,,,,8,1
6729,114,,BAO_0000219,449.0,CHO,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,,,H,Autocuration,F,,CHEMBL619504,,,,,8,1
6730,114,,BAO_0000219,449.0,CHO,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; change of less than 5% of allosteric enhancement.,,,H,Autocuration,F,,CHEMBL621298,,,,,8,1
6731,114,,BAO_0000219,449.0,CHO,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration,,,H,Expert,F,,CHEMBL621299,,,,,8,1
6732,114,,BAO_0000219,449.0,CHO,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; An increase of cAmp content of cells,,,H,Autocuration,F,,CHEMBL621300,,,,,8,1
6733,114,,BAO_0000219,449.0,CHO,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; change of less than 5% of allosteric enhancement.,,,H,Autocuration,F,,CHEMBL621301,,,,,8,1
6734,114,,BAO_0000219,449.0,CHO,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,,,H,Expert,F,,CHEMBL621302,,,,,8,1
6735,80013,,BAO_0000219,164.0,A10,Ability to inhibit [125I]ET1 binding to vascular smooth muscle (vsm)- A10 cells,,,N,Intermediate,F,9986.0,CHEMBL621303,,,,,1,1
6736,22226,,BAO_0000219,164.0,A10,In vitro potassium channel opening activity in A10 (smooth muscle) cells,,,U,Autocuration,F,10116.0,CHEMBL621304,,,,,0,1
6737,22226,,BAO_0000219,164.0,A10,In vitro potassium channel opening activity in A10 (smooth muscle) cells; Inactive,,,U,Autocuration,F,10116.0,CHEMBL621305,,,,,0,1
6738,80013,,BAO_0000219,164.0,A10,Effect on membrane potential of mitochondria in A10 smooth muscle cells from rats,,,N,Intermediate,F,10116.0,CHEMBL621306,,,,,1,1
6739,80013,,BAO_0000219,164.0,A10,Effect on membrane potential of mitochondria of A10 smooth muscle cells in rats,,,N,Intermediate,F,10116.0,CHEMBL618444,,,,,1,1
6740,80013,,BAO_0000219,164.0,A10,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.001 uM,,,N,Intermediate,F,10116.0,CHEMBL618445,,,,,1,1
6741,80089,,BAO_0000219,185.0,CHO-AA8,Compound was tested for aerobic growth inhibition against AA8 cells after 4 hr of exposure,,,N,Intermediate,F,10029.0,CHEMBL618446,,,,,1,1
6742,80089,,BAO_0000219,185.0,CHO-AA8,Concentration required to reduce AA8 cell numbers to 50% of controls in a growth inhibition microassay,,,N,Intermediate,F,10029.0,CHEMBL618447,,,,,1,1
6743,80089,,BAO_0000219,185.0,CHO-AA8,Concentration of the drug to inhibit chinese hamster ovary derived cell (AA8) growth in culture,,,N,Intermediate,F,10029.0,CHEMBL618448,,,,,1,1
6744,80089,,BAO_0000219,185.0,CHO-AA8,Cytotoxicity in a growth inhibition assay against aerobic cultures of AA8 cells was determined,,,N,Intermediate,F,10029.0,CHEMBL618449,,,,,1,1
6745,80089,,BAO_0000219,185.0,CHO-AA8,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,,,N,Intermediate,F,10029.0,CHEMBL618637,,,,,1,1
6746,80089,,BAO_0000219,185.0,CHO-AA8,"Cytotoxicity in chinese hamster ovary tumor cell line-AA8, by growth inhibition assay.",,,N,Intermediate,F,10029.0,CHEMBL618638,,,,,1,1
6747,80089,,BAO_0000219,185.0,CHO-AA8,Growth inhibition activity was measured in repair proficient AA8 cells under aerobic conditions (4 hours drug exposure),,,N,Intermediate,F,10029.0,CHEMBL618639,,,,,1,1
6748,80089,,BAO_0000219,185.0,CHO-AA8,"Growth inhibition of aerobic AA8 cells, after 18 hours exposure",,,N,Expert,F,10029.0,CHEMBL618640,,,,,1,1
6749,80089,,BAO_0000219,185.0,CHO-AA8,In vitro cellular toxicity against chinese hamster AA8 cell line after 4 hr of compound exposure,,,N,Expert,F,10029.0,CHEMBL618641,,,,,1,1
6750,80089,,BAO_0000219,185.0,CHO-AA8,Inhibitory activity against AA8 cell growth in aerobic condition after 4 hr of exposure,,,N,Intermediate,F,10029.0,CHEMBL618642,,,,,1,1
6751,80089,,BAO_0000219,185.0,CHO-AA8,Inhibitory activity against aerobic growth of AA8 cells.,,,N,Intermediate,F,10029.0,CHEMBL618643,,,,,1,1
6752,80089,,BAO_0000219,185.0,CHO-AA8,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,,,N,Intermediate,A,10029.0,CHEMBL884013,,,,,1,1
6753,80089,,BAO_0000219,185.0,CHO-AA8,In vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,,,N,Expert,F,10029.0,CHEMBL622723,,,,,1,1
6754,80089,,BAO_0000219,185.0,CHO-AA8,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,,,N,Intermediate,F,10029.0,CHEMBL622724,,,,,1,1
6755,80089,,BAO_0000219,185.0,CHO-AA8,Tested for growth inhibition against AA8 tumor cell line(chinese hamster ovary).,,,N,Expert,F,10029.0,CHEMBL622725,,,,,1,1
6756,80089,,BAO_0000219,185.0,CHO-AA8,Cytotoxicity against AA8 cell line,,,N,Expert,F,10029.0,CHEMBL622726,,,,,1,1
6757,80089,,BAO_0000219,185.0,CHO-AA8,Hypersensitivity factor(HF) was determined as ratio of IC50(AA8) to IC50(UV4),,,N,Intermediate,F,10029.0,CHEMBL622727,,,,,1,1
6758,80089,,BAO_0000219,185.0,CHO-AA8,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),,,N,Intermediate,A,10029.0,CHEMBL622728,,,,,1,1
6759,80089,,BAO_0000219,185.0,CHO-AA8,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),,,N,Intermediate,F,10029.0,CHEMBL622729,,,,,1,1
6760,80089,,BAO_0000219,185.0,CHO-AA8,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),,,N,Intermediate,A,10029.0,CHEMBL622730,,,,,1,1
6761,80089,,BAO_0000219,185.0,CHO-AA8,Compound was evaluated for cytotoxicity against CHO AA8 cell lines for 4 hr at pH-7.4,,,N,Intermediate,F,10029.0,CHEMBL622731,,,,,1,1
6762,80089,,BAO_0000219,185.0,CHO-AA8,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,,,N,Intermediate,F,10029.0,CHEMBL622732,,,,,1,1
6763,80089,,BAO_0000219,185.0,CHO-AA8,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,,,N,Intermediate,F,10029.0,CHEMBL622733,,,,,1,1
6764,22224,,BAO_0000218,,,Maximum tolerated dose (MTD) in C3H/HeN mice (single ip dose),,,U,Autocuration,F,10029.0,CHEMBL622734,,,,,0,1
6765,80089,,BAO_0000219,185.0,CHO-AA8,Concentration required to increase radiation sensitivity by 1.3 when AA8 cells are exposed to drug for 30 min before and during irradiation under hypoxic condition.,,,N,Expert,F,10029.0,CHEMBL622735,,,,,1,1
6766,22224,,BAO_0000219,185.0,CHO-AA8,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under anoxic conditions,,,U,Autocuration,F,10029.0,CHEMBL618746,,,,,0,1
6767,22224,,BAO_0000219,185.0,CHO-AA8,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under anoxic conditions,,,U,Autocuration,F,10029.0,CHEMBL618747,,,,,0,1
6768,22224,,BAO_0000219,185.0,CHO-AA8,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under anoxic conditions,,,U,Autocuration,F,10029.0,CHEMBL620540,,,,,0,1
6769,22224,,BAO_0000219,185.0,CHO-AA8,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under aerobic conditions,,,U,Autocuration,F,10029.0,CHEMBL620541,,,,,0,1
6770,22224,,BAO_0000219,185.0,CHO-AA8,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under aerobic conditions,,,U,Autocuration,F,10029.0,CHEMBL620542,,,,,0,1
6771,22224,,BAO_0000219,185.0,CHO-AA8,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under aerobic conditions,,,U,Autocuration,F,10029.0,CHEMBL620543,,,,,0,1
6772,22224,,BAO_0000219,185.0,CHO-AA8,Ratio of oxygen dependence of cytotoxicities of AA8 cells in aerobic condition to anoxic condition,,,U,Autocuration,F,10029.0,CHEMBL618832,,,,,0,1
6773,80089,,BAO_0000219,185.0,CHO-AA8,Concentration required to reduce AA8 cell survival by 10%,,,N,Expert,F,10029.0,CHEMBL618833,,,,,1,1
6774,22224,,BAO_0000219,185.0,CHO-AA8,"Concentration required to reduce cell survival to 10% of controls under hypoxic conditions, using the AA8 (chinese hamster) aerobic cells",,,U,Autocuration,F,10029.0,CHEMBL618834,,,,,0,1
6775,22224,,BAO_0000219,185.0,CHO-AA8,Tested for the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,,,U,Autocuration,F,10029.0,CHEMBL618835,,,,,0,1
6776,22224,,BAO_0000219,185.0,CHO-AA8,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,,,U,Autocuration,F,10029.0,CHEMBL618836,,,,,0,1
6777,22224,,BAO_0000219,185.0,CHO-AA8,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 0.8-1.5,,,U,Autocuration,F,10029.0,CHEMBL618837,,,,,0,1
6778,22224,,BAO_0000219,185.0,CHO-AA8,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 1-2,,,U,Autocuration,F,10029.0,CHEMBL618838,,,,,0,1
6779,22224,,BAO_0000219,185.0,CHO-AA8,Ability to reduce cell density of AA8 cells to 50% after 4 hr of exposure to air,,,U,Autocuration,F,10029.0,CHEMBL618839,,,,,0,1
6780,22224,,BAO_0000219,185.0,CHO-AA8,Aerobic cytotoxic activity was evaluated by the growth inhibition of AA8 (chinese hamster) aerobic cells,,,U,Autocuration,F,10029.0,CHEMBL618840,,,,,0,1
6781,22224,,BAO_0000019,,,"Compound was evaluated for the inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",,,U,Autocuration,F,10029.0,CHEMBL618841,,,,,0,1
6782,22224,,BAO_0000219,185.0,CHO-AA8,Concentration for 50% inhibition of AA8 cells growth under aerobic conditions after 18 hours exposure,,,U,Autocuration,F,10029.0,CHEMBL618842,,,,,0,1
6783,22224,,BAO_0000219,185.0,CHO-AA8,Concentration required for 50% inhibition of growth of AA8 cells following 4 hr drug exposure,,,U,Autocuration,F,10029.0,CHEMBL618843,,,,,0,1
6784,50588,In vivo,BAO_0000218,,,Half life period after 15 mg/kg iv dose in Dogs,,,N,Intermediate,A,9615.0,CHEMBL618844,,,,,1,1
6785,50588,In vivo,BAO_0000218,,,Half life period after 30 mg/kg po dose in Dogs,,,N,Intermediate,A,9615.0,CHEMBL618845,,,,,1,1
6786,50588,In vivo,BAO_0000218,,,Half life was measured after oral 2b administration (tested in 6 dogs),,,N,Intermediate,A,9615.0,CHEMBL618846,,,,,1,1
6787,50588,In vivo,BAO_0000218,,,Half life was measured in dog after oral 17b administration,,,N,Intermediate,A,9615.0,CHEMBL618847,,,,,1,1
6788,50588,In vivo,BAO_0000218,,,Pharmacokinetic parameter T max determined in dog after oral administration of 17b,,,N,Intermediate,A,9615.0,CHEMBL618848,,,,,1,1
6789,50588,In vivo,BAO_0000218,,,Pharmacokinetic parameter T max determined in dog after oral administration of 2b,,,N,Intermediate,A,9615.0,CHEMBL618849,,,,,1,1
6790,50588,In vivo,BAO_0000218,,,Tmax value after 15 mg/kg iv dose in Dogs,,,N,Intermediate,A,9615.0,CHEMBL618850,,,,,1,1
6791,50588,In vivo,BAO_0000218,,,Tmax value after 30 mg/kg po dose in Dogs,,,N,Intermediate,A,9615.0,CHEMBL618851,,,,,1,1
6792,50588,In vivo,BAO_0000218,,,Compound was evaluated for its half life when administered intravenously in dog,,,N,Intermediate,A,9615.0,CHEMBL873815,,,,,1,1
6793,50588,In vivo,BAO_0000218,,,Compound was tested for plasma half life when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),,,N,Intermediate,A,9615.0,CHEMBL618852,,1969.0,Plasma,,1,1
6794,50588,,BAO_0000218,,,Elimination Half-life of compound was determined in dog,,,N,Intermediate,A,9615.0,CHEMBL618853,,,,,1,1
6795,50588,In vivo,BAO_0000218,,,Half life of compound in dog following oral administration,,,N,Intermediate,A,9615.0,CHEMBL618854,,,,,1,1
6796,50588,,BAO_0000218,,,Half life of compound was determined in dog,,,N,Intermediate,A,9615.0,CHEMBL618855,,,,,1,1
6797,50588,,BAO_0000218,,,Half life of compound was determined in dog blood,,,N,Intermediate,A,9615.0,CHEMBL618856,,178.0,Blood,,1,1
6798,50588,In vivo,BAO_0000218,,,Half life after oral and iv dosing in dogs,,,N,Intermediate,A,9615.0,CHEMBL875827,,,,,1,1
6799,50588,,BAO_0000218,,,Half life in dogs in hours,,,N,Intermediate,A,9615.0,CHEMBL618857,,,,,1,1
6800,50588,In vivo,BAO_0000218,,,Half life on i.v. administration of 2 mg/kg was measured in dog,,,N,Intermediate,A,9615.0,CHEMBL618858,,,,,1,1
6801,50588,In vivo,BAO_0000218,,,t1/2 in dog after oral dose (1 mg/kg),,,N,Intermediate,A,9615.0,CHEMBL618859,,,,,1,1
6802,50588,,BAO_0000218,,,Half life was evaluated in dog,,,N,Intermediate,A,9615.0,CHEMBL618860,,,,,1,1
6803,50588,In vivo,BAO_0000218,,,Half life period of compound was determined after intravenous administration at 2 mg/kg,,,N,Intermediate,A,9615.0,CHEMBL618861,,,,,1,1
6804,50588,In vivo,BAO_0000218,,,Half life period of compound was determined after peroral administration at 2 mg/kg,,,N,Intermediate,A,9615.0,CHEMBL622539,,,,,1,1
6805,50588,In vivo,BAO_0000218,,,Half life period (10 mg/kg) was determined in dog,,,N,Intermediate,A,9615.0,CHEMBL622540,,,,,1,1
6806,50588,In vivo,BAO_0000218,,,Half life period (10 mg/kg) was determined in dog,,,N,Intermediate,A,9615.0,CHEMBL873803,,,,,1,1
6807,50588,In vivo,BAO_0000218,,,Half life period by iv administration in dog at a dose of 0.3 mg/kg,,,N,Intermediate,A,9615.0,CHEMBL873804,,,,,1,1
6808,50588,In vivo,BAO_0000218,,,Half life period by po administration in dog at a dose of 0.3 mg/kg,,,N,Intermediate,A,9615.0,CHEMBL624311,,,,,1,1
6809,50588,,BAO_0000218,,,Half life period in dog,,,N,Intermediate,A,9615.0,CHEMBL624312,,,,,1,1
6810,50588,In vivo,BAO_0000218,,,Half life period in dogs after oral administration at 1 mg/kg,,,N,Intermediate,A,9615.0,CHEMBL624313,,,,,1,1
6811,50588,In vivo,BAO_0000218,,,Half life period was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,,N,Intermediate,A,9615.0,CHEMBL624314,,,,,1,1
6812,50588,,BAO_0000218,,,Half-life of compound was determined in dogs,,,N,Intermediate,A,9615.0,CHEMBL624315,,,,,1,1
6813,50588,,BAO_0000218,,,Half-life in dog plasma,,,N,Intermediate,A,9615.0,CHEMBL624316,,1969.0,Plasma,,1,1
6814,50588,,BAO_0000218,,,Half-life in mongrel dogs was determined,,,N,Intermediate,A,9615.0,CHEMBL624317,,,,,1,1
6815,50588,In vivo,BAO_0000218,,,Half-life in dog upon oral administration,,,N,Intermediate,A,9615.0,CHEMBL624318,,,,,1,1
6816,50588,In vivo,BAO_0000218,,,Half-life in dog upon oral administration; Unable to calculate,,,N,Intermediate,A,9615.0,CHEMBL624319,,,,,1,1
6817,50588,,BAO_0000218,,,Half-life was measured in dog,,,N,Intermediate,A,9615.0,CHEMBL624496,,,,,1,1
6818,50588,,BAO_0000218,,,Half-life was measured in dog,,,N,Intermediate,A,9615.0,CHEMBL624497,,,,,1,1
6819,50588,,BAO_0000218,,,Half-recovery time (T1/2) of the vascular resistance decrease at ED30 in anesthetized dogs,,,N,Intermediate,A,9615.0,CHEMBL624498,,,,,1,1
6820,50588,In vivo,BAO_0000218,,,Oral half life was determined,,,N,Intermediate,A,9615.0,CHEMBL624499,,,,,1,1
6821,50588,In vivo,BAO_0000218,,,Plasma elimination half-life (08 h) was determined in canine following intravenous (iv) administration (1 mg/kg).,,,N,Intermediate,A,9615.0,CHEMBL624500,,1969.0,Plasma,,1,1
6822,50588,,BAO_0000218,,,Plasma half life was evaluated,,,N,Intermediate,A,9615.0,CHEMBL624501,,1969.0,Plasma,,1,1
6823,50588,,BAO_0000218,,,Plasma half life was evaluated in Dog,,,N,Intermediate,A,9615.0,CHEMBL623666,,1969.0,Plasma,,1,1
6824,50588,,BAO_0000218,,,Plasma half life was evaluated in dog,,,N,Intermediate,A,9615.0,CHEMBL623667,,1969.0,Plasma,,1,1
6825,50588,In vivo,BAO_0000218,,,T1/2 (Half-life) was after oral administration at 5 mg/kg,,,N,Intermediate,A,9615.0,CHEMBL623668,,,,,1,1
6826,50588,,BAO_0000218,,,Tested for the half life value in dog,,,N,Intermediate,A,9615.0,CHEMBL623669,,,,,1,1
6827,50588,In vivo,BAO_0000218,,,Maximum time at the dose of 2 mg/kg in dog,,,N,Intermediate,A,9615.0,CHEMBL623670,,,,,1,1
6828,50588,In vivo,BAO_0000218,,,Maximum time was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,,N,Intermediate,A,9615.0,CHEMBL623671,,,,,1,1
6829,50588,In vivo,BAO_0000218,,,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,,,N,Intermediate,A,9615.0,CHEMBL875945,,178.0,Blood,,1,1
6830,50588,In vivo,BAO_0000218,,,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,,,N,Intermediate,A,9615.0,CHEMBL623672,,178.0,Blood,,1,1
6831,50588,In vivo,BAO_0000218,,,Pharmacokinetic (PK) property (Tmax) was determined in dog at the single dose of 1 mg/kg,,,N,Intermediate,A,9615.0,CHEMBL623673,,,,,1,1
6832,50588,In vivo,BAO_0000218,,,Pharmacokinetic parameter Tmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),,,N,Intermediate,A,9615.0,CHEMBL623674,,,,,1,1
6833,50588,In vivo,BAO_0000218,,,Pharmacokinetic property (Tmax) was measured in dog at the dose of 0.032 mg/kg p.o.,,,N,Intermediate,A,9615.0,CHEMBL623675,,,,,1,1
6834,50588,,BAO_0000218,,,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog",,,N,Intermediate,A,9615.0,CHEMBL872526,,,,,1,1
6835,50588,In vivo,BAO_0000218,,,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog at dosage of 10 mpk",,,N,Intermediate,A,9615.0,CHEMBL623676,,,,,1,1
6836,50588,In vivo,BAO_0000218,,,Time for maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,,,N,Intermediate,A,9615.0,CHEMBL623677,,1969.0,Plasma,,1,1
6837,50588,In vivo,BAO_0000218,,,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,,,N,Intermediate,A,9615.0,CHEMBL623678,,1969.0,Plasma,,1,1
6838,50588,,BAO_0000218,,,Time taken for maximum plasma concentration in dog,,,N,Intermediate,A,9615.0,CHEMBL623679,,1969.0,Plasma,,1,1
6839,50588,In vivo,BAO_0000218,,,Time to reach Cmax after oral administration to dogs,,,N,Intermediate,A,9615.0,CHEMBL623680,,,,,1,1
6840,50588,In vivo,BAO_0000218,,,Time to reach maximum plasma concentration was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,,N,Intermediate,A,9615.0,CHEMBL623681,,1969.0,Plasma,,1,1
6841,50588,In vivo,BAO_0000218,,,Tmax (time to reach maximum concentration) was after oral administration at 5 mg/kg,,,N,Intermediate,A,9615.0,CHEMBL623682,,,,,1,1
6842,50588,In vivo,BAO_0000218,,,Tmax after peroral administration (1 mg/kg) was determined in dog,,,N,Intermediate,A,9615.0,CHEMBL623683,,,,,1,1
6843,50588,In vivo,BAO_0000218,,,Tmax of compound determined in dog after iv administration at a dose of 10 mg/kg,,,N,Expert,A,9615.0,CHEMBL623684,,,,,1,1
6844,50588,In vivo,BAO_0000218,,,Tmax by oral administration at a dose of 10 uM/kg in dog was determined,,,N,Intermediate,A,9615.0,CHEMBL622745,,,,,1,1
6845,50588,In vivo,BAO_0000218,,,Tmax after peroral administration in dogs at 2.4 uM/kg,,,N,Intermediate,A,9615.0,CHEMBL622746,,,,,1,1
6846,50594,In vivo,BAO_0000218,,,In vivo Cmax in mice at dose of 100 mg/kg,,,N,Intermediate,A,10090.0,CHEMBL622747,,,,,1,1
6847,50594,In vivo,BAO_0000218,,,In vivo Cmax in mice at dose of 50 mg/kg,,,N,Intermediate,A,10090.0,CHEMBL622748,,,,,1,1
6848,50594,In vivo,BAO_0000218,,,Maximal concentration determined at a dose 10 mg/kg administered intraperitoneally to mice,,,N,Intermediate,A,10090.0,CHEMBL622749,,,,,1,1
6849,50594,In vivo,BAO_0000218,,,Maximum plasma concentration was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),,,N,Intermediate,A,10090.0,CHEMBL622750,,1969.0,Plasma,,1,1
6850,50594,In vivo,BAO_0000218,,,Maximum concentration in plasma was determined after intraperitoneal administration of 100 mg/kg in mice,,,N,Intermediate,A,10090.0,CHEMBL623411,,1969.0,Plasma,,1,1
6851,50594,In vivo,BAO_0000218,,,Maximum concentration obtained in mouse plasma was determined,,,N,Intermediate,A,10090.0,CHEMBL875946,,1969.0,Plasma,,1,1
6852,50594,In vivo,BAO_0000218,,,Maximum concentration obtained in mouse plasma was determined at dose 25 mg/kg,,,N,Intermediate,A,10090.0,CHEMBL623412,,1969.0,Plasma,,1,1
6853,50594,In vivo,BAO_0000218,,,Maximum plasma concentration of compound was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,,N,Intermediate,A,10090.0,CHEMBL623413,,1969.0,Plasma,,1,1
6854,50594,In vivo,BAO_0000218,,,Maximum plasma concentration when injected i.p. in mice at a dose of 50 mg/kg,,,N,Intermediate,A,10090.0,CHEMBL623414,,1969.0,Plasma,,1,1
6855,50594,In vivo,BAO_0000218,,,Maximum plasma concentration when injected intravenously in mice at a dose of 20 mg/kg,,,N,Intermediate,A,10090.0,CHEMBL623415,,1969.0,Plasma,,1,1
6856,50594,In vivo,BAO_0000218,,,Maximum plasma concentration when injected perorally in mice at a dose of 50 mg/kg,,,N,Intermediate,A,10090.0,CHEMBL623416,,1969.0,Plasma,,1,1
6857,50594,In vivo,BAO_0000218,,,Maximal plasma concentration in BALB/C mice after 20 mg/kg intraperitoneal dose,,,N,Intermediate,A,10090.0,CHEMBL623417,,1969.0,Plasma,,1,1
6858,50594,In vivo,BAO_0000218,,,Maximal plasma concentration in BALB/C mice after 20 mg/kg intravenous dose,,,N,Intermediate,A,10090.0,CHEMBL623418,,1969.0,Plasma,,1,1
6859,50594,In vivo,BAO_0000218,,,Maximal plasma concentration in BALB/C mice after 50 mg/kg oral dose,,,N,Intermediate,A,10090.0,CHEMBL623419,,1969.0,Plasma,,1,1
6860,50594,In vivo,BAO_0000218,,,Peak concentration at a single subcutaneous administration of 40 mg/kg in mice,,,N,Intermediate,A,10090.0,CHEMBL622816,,,,,1,1
6861,50594,In vivo,BAO_0000218,,,Pharmacokinetic property (C(max)) was determined after ip administration of 32 mg/kg in mice,,,N,Intermediate,A,10090.0,CHEMBL623313,,,,,1,1
6862,50594,In vivo,BAO_0000218,,,Pharmacokinetic property (C(max)) was determined after po administration of 32 mg/kg in mice,,,N,Intermediate,A,10090.0,CHEMBL623314,,,,,1,1
6863,50594,In vivo,BAO_0000218,,,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg intravenously in mice,,,N,Intermediate,A,10090.0,CHEMBL876788,,,,,1,1
6864,50594,In vivo,BAO_0000218,,,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg perorally in mice,,,N,Intermediate,A,10090.0,CHEMBL623315,,,,,1,1
6865,50594,In vivo,BAO_0000218,,,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg intravenously in mice,,,N,Intermediate,A,10090.0,CHEMBL623316,,,,,1,1
6866,50594,In vivo,BAO_0000218,,,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg perorally in mice,,,N,Intermediate,A,10090.0,CHEMBL623317,,,,,1,1
6868,50594,In vivo,BAO_0000218,,,Cmax in male mice after 2 mg/kg oral dose,,,N,Intermediate,A,10090.0,CHEMBL623319,,,,,1,1
6869,50594,In vivo,BAO_0000218,,,Plasma concentration of 5-FU in HT-3 (human cervical cancer) xenograft mice at 1.38 mg/kg oral dose co-administered with 135 mg/kg Capecitabine,,,N,Intermediate,A,10090.0,CHEMBL623320,,,,,1,1
6870,50594,In vivo,BAO_0000218,,,Tested for Cmax value at the dose of 10 mg/kg when administered perorally in mouse,,,N,Intermediate,A,10090.0,CHEMBL623321,,,,,1,1
6871,50594,,BAO_0000218,,,Concentration in plasma (systemic) following oral dose in mouse at 0.25 hr,,,N,Intermediate,A,10090.0,CHEMBL623322,,,,,1,1
6872,50594,,BAO_0000218,,,Concentration in plasma (systemic) following oral dose in mouse at 1 hr,,,N,Intermediate,A,10090.0,CHEMBL623323,,,,,1,1
6873,50594,,BAO_0000218,,,Concentration in plasma (systemic) following oral dose in mouse at 24 hr,,,N,Intermediate,A,10090.0,CHEMBL623324,,,,,1,1
6874,50594,,BAO_0000218,,,Concentration in plasma (systemic) following oral dose in mouse at 2 hr,,,N,Intermediate,A,10090.0,CHEMBL623325,,,,,1,1
6875,50594,,BAO_0000218,,,Concentration in plasma (systemic) following oral dose in mouse at 4 hr,,,N,Intermediate,A,10090.0,CHEMBL623326,,,,,1,1
6876,50594,,BAO_0000218,,,Concentration in plasma (systemic) following oral dose in mouse at 6 hr,,,N,Intermediate,A,10090.0,CHEMBL623327,,,,,1,1
6877,50594,,BAO_0000218,,,Maximum concentration in plasma upon oral administration in mouse,,,N,Intermediate,A,10090.0,CHEMBL623328,,1969.0,Plasma,,1,1
6878,50594,,BAO_0000218,,,Maximum plasma concentration was evaluated in mice after oral administration,,,N,Intermediate,A,10090.0,CHEMBL623329,,1969.0,Plasma,,1,1
6879,50594,In vivo,BAO_0000218,,,Maximum plasma concentration was evaluated in mice after intravenous administration; Cp max Not determined,,,N,Intermediate,A,10090.0,CHEMBL623330,,1969.0,Plasma,,1,1
6880,50594,,BAO_0000218,,,Dose at which the compound induced fecal excretion in mice,,,N,Intermediate,A,10090.0,CHEMBL876789,,,,,1,1
6893,80013,,BAO_0000219,164.0,A10,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.01 uM,,,N,Expert,F,10116.0,CHEMBL623333,,,,,1,1
6894,80013,,BAO_0000219,164.0,A10,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.1 uM,,,N,Expert,F,10116.0,CHEMBL623334,,,,,1,1
6895,80013,,BAO_0000219,164.0,A10,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 1.0 uM,,,N,Expert,F,10116.0,CHEMBL627536,,,,,1,1
6896,80013,,BAO_0000219,164.0,A10,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 10.0 uM,,,N,Expert,F,10116.0,CHEMBL627537,,,,,1,1
6897,80013,,BAO_0000219,164.0,A10,In vitro [14C]- creatine uptake (1 mM) was determined in rat A10 smooth muscle cells at a concentration of (1 mM),,,N,Intermediate,F,10116.0,CHEMBL627538,,,,,1,1
6898,80655,,BAO_0000219,393.0,A121,Cytotoxicity was evaluated against A121 ovarian carcinoma human cancer cell line,,,N,Intermediate,F,9606.0,CHEMBL884106,,,,,1,1
6899,80655,,BAO_0000219,393.0,A121,Anticancer activity against human ovarian carcinoma A121 cells,,,N,Intermediate,F,9606.0,CHEMBL625294,,,,,1,1
6900,80655,,BAO_0000219,393.0,A121,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 16.6 mM,,,N,Intermediate,F,9606.0,CHEMBL625295,,,,,1,1
6901,80655,,BAO_0000219,393.0,A121,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 83 mM,,,N,Intermediate,F,9606.0,CHEMBL625296,,,,,1,1
6902,80655,,BAO_0000219,393.0,A121,Growth inhibition of human ovarian carcinoma (A121) cell line,,,N,Expert,F,9606.0,CHEMBL625297,,,,,1,1
6903,80655,,BAO_0000219,393.0,A121,Concentration required to inhibit growth of human tumor A121 (ovarian) cell line.,,,N,Expert,F,9606.0,CHEMBL625298,,,,,1,1
6904,80655,,BAO_0000219,393.0,A121,Cytotoxicity against human A121 ovarian cells,,,N,Intermediate,F,9606.0,CHEMBL625960,,,,,1,1
6905,80655,,BAO_0000219,393.0,A121,Cytotoxicity was evaluated in vitro against A121 (ovarian carcinoma) human tumor cell lines,,,N,Intermediate,F,9606.0,CHEMBL625961,,,,,1,1
6906,80655,,BAO_0000219,393.0,A121,In vitro cytotoxicity against human ovarian carcinoma A21,,,N,Intermediate,F,9606.0,CHEMBL625962,,,,,1,1
6907,80655,,BAO_0000219,393.0,A121,Inhibition of the growth against human Ovarian Carcinoma (A121) cell line after 72 hr exposure,,,N,Intermediate,F,9606.0,CHEMBL624717,,,,,1,1
6908,80655,,BAO_0000219,393.0,A121,Inhibitory activity of compound against human A121 ovarian cell line.,,,N,Intermediate,F,9606.0,CHEMBL624718,,,,,1,1
6909,80655,,BAO_0000219,393.0,A121,Dose at which compound exhibits cytotoxicity in the A121 ovarian carcinoma cell line.,,,N,Intermediate,F,9606.0,CHEMBL624719,,,,,1,1
6910,80655,,BAO_0000219,393.0,A121,Inhibition of growth of human ovarian tumor cell line (A121) after 72 hr of drug exposure,,,N,Intermediate,F,9606.0,CHEMBL624720,,,,,1,1
6911,80012,,BAO_0000219,622.0,A 172,Compound was evaluated for in vitro antiproliferative activity against A172 human CNS cancer cell line,,,N,Intermediate,F,9606.0,CHEMBL624721,,,,,1,1
6912,80012,,BAO_0000219,622.0,A 172,In vitro cytotoxicity against A172 human tumor cell lines.,,,N,Expert,F,9606.0,CHEMBL624722,,,,,1,1
6913,80012,,BAO_0000219,622.0,A 172,Growth inhibition time for A172 Human Glioma cell growth at concentration 5 uM,,,N,Intermediate,F,9606.0,CHEMBL877597,,,,,1,1
6914,80012,,BAO_0000219,622.0,A 172,Compound was evaluated for cytotoxicity against human glioblastoma (A172) cell line,,,N,Intermediate,F,9606.0,CHEMBL624723,,,,,1,1
6915,80012,,BAO_0000219,622.0,A 172,Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay,,,N,Intermediate,F,9606.0,CHEMBL624724,,,,,1,1
6916,104729,,BAO_0000224,,,Association constant against A2 adenosine receptor,,,H,Autocuration,B,9615.0,CHEMBL624725,,,,,4,1
6917,80656,,BAO_0000219,1085.0,A2,In vitro effective dose that causes 50% inhibition of growth of A2 cell line - amelanotic melanoma,,,N,Intermediate,F,,CHEMBL624726,,,,,1,1
6918,104713,,BAO_0000224,,,Ratio of Ki for adenosine A2 and A1 receptor binding,,,D,Autocuration,B,10116.0,CHEMBL857535,,,,,5,1
6919,80014,,BAO_0000219,623.0,A204,In vitro cytotoxicity against A204 human rhabdomyosarcoma cancer cell line,,,N,Expert,F,9606.0,CHEMBL624727,,,,,1,1
6920,80014,,BAO_0000219,623.0,A204,In vitro antitumor activity against A204 rhabdomyosarcoma tumor cell line was determined,,,N,Expert,F,9606.0,CHEMBL624728,,,,,1,1
6921,80015,,BAO_0000219,404.0,A2058,The compound was tested in vitro for antiproliferative activity against A2058 tumor cell lines,,,N,Intermediate,F,9606.0,CHEMBL624729,,,,,1,1
6922,80657,,BAO_0000219,973.0,A253 cell line,Growth inhibition against Human squamous cell line(A 253),,,N,Intermediate,F,9606.0,CHEMBL624730,,,,,1,1
6923,80657,,BAO_0000219,973.0,A253 cell line,Growth inhibition of human squamous carcinoma cell lines following continuous (120 hours) exposure to MTX and compound A253 cell line,,,N,Intermediate,F,9606.0,CHEMBL624731,,,,,1,1
6924,80657,,BAO_0000219,973.0,A253 cell line,The compound was tested for Growth inhibition of the human squamous cell carcinoma A253 cells,,,N,Intermediate,F,9606.0,CHEMBL624732,,,,,1,1
6925,80657,,BAO_0000219,973.0,A253 cell line,Growth inhibition of A253 cell lines.,,,N,Intermediate,F,9606.0,CHEMBL883245,,,,,1,1
6926,80657,,BAO_0000219,973.0,A253 cell line,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h),,,N,Intermediate,F,9606.0,CHEMBL624733,,,,,1,1
6927,80657,,BAO_0000219,973.0,A253 cell line,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,,,N,Intermediate,F,9606.0,CHEMBL624734,,,,,1,1
6928,80657,,BAO_0000219,973.0,A253 cell line,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,,,N,Intermediate,F,9606.0,CHEMBL624735,,,,,1,1
6929,81034,,BAO_0000219,478.0,A2780,In vitro cytotoxicity causing 50% growth inhibition was determined against A270 (human ovarian cancer)cell line,,,N,Intermediate,F,9606.0,CHEMBL621780,,,,,1,1
6930,81034,,BAO_0000219,478.0,A2780,Antitumor activity of compound for 96-h exposure in A2780 human ovarian cell line,,,N,Intermediate,F,9606.0,CHEMBL877598,,,,,1,1
6931,81034,,BAO_0000219,478.0,A2780,Cytotoxic activity against A2780 human ovarian carcinoma cell line,,,N,Expert,F,9606.0,CHEMBL621781,,,,,1,1
6932,81034,,BAO_0000219,478.0,A2780,Cytotoxicity against human cancer cell lines A2780 (ovarian),,,N,Intermediate,F,9606.0,CHEMBL621782,,,,,1,1
6933,81034,,BAO_0000219,478.0,A2780,Growth and colony formation inhibition of A2780 ovarian cancer cell lines,,,N,Expert,F,9606.0,CHEMBL621783,,,,,1,1
6934,81034,,BAO_0000219,478.0,A2780,Inhibition of cell growth in human ovarian carcinoma cell line (A2780) using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay,,,N,Intermediate,F,9606.0,CHEMBL621784,,,,,1,1
6935,81034,,BAO_0000219,478.0,A2780,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),,,N,Intermediate,F,9606.0,CHEMBL621785,,,,,1,1
6936,81034,,BAO_0000219,478.0,A2780,Inhibition of A2780 / DDP-R human ovarian carcinoma cell proliferation,,,N,Expert,F,9606.0,CHEMBL621968,,,,,1,1
6937,81034,,BAO_0000219,478.0,A2780,Inhibition of A2780 / TAX-R human ovarian carcinoma cell proliferation,,,N,Expert,F,9606.0,CHEMBL621969,,,,,1,1
6938,81034,,BAO_0000219,478.0,A2780,Inhibition of A2780 / TAX-S human ovarian carcinoma cell proliferation,,,N,Expert,F,9606.0,CHEMBL621970,,,,,1,1
6939,81034,,BAO_0000219,478.0,A2780,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 2,,,N,Intermediate,F,9606.0,CHEMBL621971,,,,,1,1
6940,81034,,BAO_0000219,478.0,A2780,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 3,,,N,Intermediate,F,9606.0,CHEMBL621972,,,,,1,1
6941,81034,,BAO_0000219,478.0,A2780,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 5,,,N,Intermediate,F,9606.0,CHEMBL884108,,,,,1,1
6942,22224,,BAO_0000019,,,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,,,U,Autocuration,F,10029.0,CHEMBL623826,,,,,0,1
6943,22224,,BAO_0000219,185.0,CHO-AA8,Evaluated for cytotoxicity under aerobic conditions against AA8 cells using microassay,,,U,Autocuration,A,10029.0,CHEMBL623827,,,,,0,1
6944,22224,,BAO_0000219,185.0,CHO-AA8,Evaluated for growth inhibition of AA8 cells under aerobic conditions,,,U,Autocuration,F,10029.0,CHEMBL623828,,,,,0,1
6945,22224,,BAO_0000219,185.0,CHO-AA8,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions,,,U,Autocuration,F,10029.0,CHEMBL623829,,,,,0,1
6946,22224,,BAO_0000219,185.0,CHO-AA8,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions (air/N2),,,U,Autocuration,F,10029.0,CHEMBL623830,,,,,0,1
6947,22224,,BAO_0000019,,,Growth inhibition against CHO-derived cell line AA8,,,U,Autocuration,F,10029.0,CHEMBL623831,,,,,0,1
6948,22224,,BAO_0000219,185.0,CHO-AA8,Growth inhibition against CHO-derived cell line AA8 (Non toxic at solubility limit) [RB6145 used as positive control],,,U,Autocuration,F,10029.0,CHEMBL623832,,,,,0,1
6949,80089,,BAO_0000219,185.0,CHO-AA8,Growth inhibition in CHO subline AA8 cells exposed for 18 hr under aerobic(air) conditions,,,N,Expert,F,36483.0,CHEMBL623833,,,,,1,1
6950,80089,,BAO_0000219,185.0,CHO-AA8,Growth inhibitory activity against CHO subline AA8 cells exposed for 18 hr under aerobic conditions,,,N,Expert,F,10029.0,CHEMBL623834,,,,,1,1
6951,22224,,BAO_0000219,185.0,CHO-AA8,Tested for the concentration of the drug to reduce cell numbers to 50 percent of controls against AA8 cells in the microassay,,,U,Autocuration,F,10029.0,CHEMBL623835,,,,,0,1
6952,22224,,BAO_0000219,185.0,CHO-AA8,Growth inhibition of aerobic chinese hamster ovary fibroblast AA8 cell line using an exposure time of 18 hours,,,U,Autocuration,F,10029.0,CHEMBL623836,,,,,0,1
6953,22224,,BAO_0000219,185.0,CHO-AA8,IC50 (air/N2) ratio of the drug to reduce cell numbers to 50 percent of controls using AA8 cells in the microassay,,,U,Autocuration,F,10029.0,CHEMBL623837,,,,,0,1
6954,80089,,BAO_0000219,185.0,CHO-AA8,In vitro therapeutic index as ratio of CT10 and C1.3 calculated for AA8 cells.,,,N,Expert,F,10029.0,CHEMBL623838,,,,,1,1
6955,12675,,BAO_0000019,,,compound was evaluated for association constant (Ka) of isolated serum protein AAG,,,H,Autocuration,F,,CHEMBL623839,,,,,8,1
6956,12675,,BAO_0000019,,,Number of binding sites (n) of isolated serum protein AAG,,,H,Autocuration,F,,CHEMBL623840,,,,,8,1
6957,22222,,BAO_0000225,,,Association constant for binding to AATT duplex,,,M,Intermediate,B,,CHEMBL623841,,,,,3,1
6958,100090,,BAO_0000219,416.0,ABAE,Inhibition of ABAE human fibroblast cell proliferation,,,N,Expert,F,9606.0,CHEMBL623842,,,,,1,1
6959,80668,,BAO_0000218,1064.0,AC755,"Compound was evaluated for the antitumor activity against AC755 breast carcinoma for ip administration and daily x 10 schedule; Number of toxic deaths over total number of mice per group (T/C), 1/7 at dose of 25 mg/kg",,,N,Intermediate,F,10090.0,CHEMBL623843,,,,,1,1
6960,102444,,BAO_0000218,,,Percent change in total cholesterol(TC) versus (T0)- at which drug intervention begins at a dose of 25 mg/kg in the chronic cholesterol-fed rabbit model,,,D,Expert,F,9986.0,CHEMBL618669,,,,,9,1
6961,102444,In vivo,BAO_0000218,,,Oral bioactivity expressed as %inhibition after 4 hours of drug administration (dose 25 mg/kg) in rabbit bioassay,,,D,Expert,F,9986.0,CHEMBL618670,,,,,9,1
6962,69,,BAO_0000357,,,Inhibitory activity against angiotensin-converting enzyme (ACE).,,,H,Autocuration,B,,CHEMBL618671,,,,,8,1
6963,69,,BAO_0000357,,,oral activity against angiotensin -converting enzyme ( ACE) and neutral endopeptidase in mouse.,,,H,Autocuration,B,,CHEMBL618672,,,,,8,1
6964,80669,,BAO_0000219,978.0,ACH-2 cell line,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells,,,N,Intermediate,F,9606.0,CHEMBL618673,,,,,1,1
6965,80669,,BAO_0000219,978.0,ACH-2 cell line,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells in the presence of PMA(phorbol 12-myristate 13-acetate),,,N,Intermediate,F,9606.0,CHEMBL618674,,,,,1,1
6966,22224,,BAO_0000219,998.0,T cell line,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2,,,U,Autocuration,F,11676.0,CHEMBL618675,,,,,0,1
6967,22224,,BAO_0000219,998.0,T cell line,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2 in the presence of PMA(phorbol 12-myristate 13-acetate),,,U,Autocuration,F,11676.0,CHEMBL618676,,,,,0,1
6968,22224,,BAO_0000219,998.0,T cell line,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2i n the presence of PMA(phorbol 12-myristate 13-acetate),,,U,Autocuration,F,11676.0,CHEMBL618677,,,,,0,1
6969,80025,,BAO_0000219,626.0,ACHN,Inhibition of growth of renal cancer ACHN cell line,,,N,Intermediate,F,9606.0,CHEMBL618678,,,,,1,1
6970,80025,,BAO_0000219,626.0,ACHN,Inhibition of growth of ACHN renal cancer cell line,,,N,Intermediate,F,9606.0,CHEMBL618679,,,,,1,1
6971,80025,,BAO_0000219,626.0,ACHN,Inhibitory concentration required against ACHN renal cancer cell line,,,N,Intermediate,F,9606.0,CHEMBL618680,,,,,1,1
6972,80025,,BAO_0000219,626.0,ACHN,Concentration required to inhibit growth of human renal (ACHN) cell line,,,N,Expert,F,9606.0,CHEMBL618681,,,,,1,1
6973,80025,,BAO_0000219,626.0,ACHN,Concentration required to inhibit growth of human renal (ACHN) cell line; nt = not tested,,,N,Intermediate,F,9606.0,CHEMBL618682,,,,,1,1
6974,80025,,BAO_0000219,626.0,ACHN,Cytotoxic activity against ACHN Renal cancer cell line,,,N,Intermediate,F,9606.0,CHEMBL618683,,,,,1,1
6975,80025,,BAO_0000219,626.0,ACHN,Cytotoxicity evaluation against ACHN renal cancer cells,,,N,Intermediate,F,9606.0,CHEMBL618684,,,,,1,1
6976,80025,,BAO_0000219,626.0,ACHN,In vitro antitumor activity against human renal ACHN cell line,,,N,Intermediate,F,9606.0,CHEMBL618685,,,,,1,1
6977,80025,,BAO_0000219,626.0,ACHN,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,,,N,Intermediate,F,9606.0,CHEMBL876499,,,,,1,1
6978,80025,,BAO_0000219,626.0,ACHN,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,,,N,Intermediate,F,9606.0,CHEMBL618686,,,,,1,1
6979,80025,,BAO_0000219,626.0,ACHN,"Tested for the cytotoxicity against the Renal cancer cell line ACHN, growth inhibition by 50% is reported",,,N,Intermediate,F,9606.0,CHEMBL618687,,,,,1,1
6980,80025,,BAO_0000219,626.0,ACHN,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,,,N,Intermediate,F,9606.0,CHEMBL618688,,,,,1,1
6981,80025,,BAO_0000219,626.0,ACHN,Tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,,,N,Expert,F,9606.0,CHEMBL618689,,,,,1,1
6982,80025,,BAO_0000219,626.0,ACHN,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal); Not determined,,,N,Intermediate,F,9606.0,CHEMBL618690,,,,,1,1
6983,80025,,BAO_0000219,626.0,ACHN,Antitumor activity was evaluated against human renal adenocarcinoma cell line ACHN.,,,N,Intermediate,F,9606.0,CHEMBL618691,,,,,1,1
6984,80025,,BAO_0000219,626.0,ACHN,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),,,N,Intermediate,F,9606.0,CHEMBL619373,,,,,1,1
6985,80025,,BAO_0000219,626.0,ACHN,"Compound was tested for antiproliferative activity against ACHN, human renal adenocarcinoma",,,N,Intermediate,F,9606.0,CHEMBL884008,,,,,1,1
6986,80025,,BAO_0000219,626.0,ACHN,Compound was tested for its effect on the proliferation of ACHN human kidney adenocarcinoma,,,N,Intermediate,F,9606.0,CHEMBL619374,,,,,1,1
6987,80025,,BAO_0000219,626.0,ACHN,Compound was tested for the growth inhibition of ACHN renal tumor cell line,,,N,Intermediate,F,9606.0,CHEMBL619375,,,,,1,1
6988,80025,,BAO_0000219,626.0,ACHN,Compound was tested for the growth inhibition of ACHN renal tumor cell line; ND=Not determined,,,N,Intermediate,F,9606.0,CHEMBL619376,,,,,1,1
6989,80025,,BAO_0000219,626.0,ACHN,In vitro Growth Inhibitory activity against ACHN Human kidney cancer cell line,,,N,Intermediate,F,9606.0,CHEMBL619377,,,,,1,1
6990,80025,,BAO_0000219,626.0,ACHN,In vitro cytotoxicity against human renal adenocarcinoma (ACHN) tumor cell line,,,N,Intermediate,F,9606.0,CHEMBL619378,,,,,1,1
6991,50588,In vivo,BAO_0000218,,,Tmax value after administration of 4 mg/Kg oral dose in dog,,,N,Intermediate,A,9615.0,CHEMBL872527,,,,,1,1
6992,50588,,BAO_0000218,,,"Time to peak response on lowering of vascular resistance, in dogs when administered intravenously",,,N,Intermediate,A,9615.0,CHEMBL876500,,,,,1,1
6993,50588,,BAO_0000218,,,Unbound plasma was determined in Beagle dog at a dose of 1 mg/kg by iv administration,,,N,Intermediate,A,9615.0,CHEMBL619379,,,,,1,1
6994,50588,In vivo,BAO_0000218,,,Volume distribution after 15 mg/kg iv dose in Dogs,,,N,Intermediate,A,9615.0,CHEMBL619538,,,,,1,1
6995,50588,In vivo,BAO_0000218,,,Volume distribution after 30 mg/kg po dose in Dogs,,,N,Intermediate,A,9615.0,CHEMBL619539,,,,,1,1
6996,50588,In vivo,BAO_0000218,,,Volume of distribution was determined in dog after a 3 mg/kg of iv dose,,,N,Intermediate,A,9615.0,CHEMBL619540,,,,,1,1
6997,50588,In vivo,BAO_0000218,,,Volume of distribution was determined by iv administration in dogs at a dose of 1 mg/kg,,,N,Intermediate,A,9615.0,CHEMBL619541,,,,,1,1
6998,50588,In vivo,BAO_0000218,,,Volume of distribution was evaluated in dog,,,N,Intermediate,A,9615.0,CHEMBL619542,,,,,1,1
6999,50588,In vivo,BAO_0000218,,,Terminal phase volume of distribution was measured in dog after an iv dose of 1 mg/kg,,,N,Intermediate,A,9615.0,CHEMBL619543,,,,,1,1
7000,50588,,BAO_0000218,,,Apparent volume of the central plasma compartment (Vc) of compound determined in dog after iv administration at a dose of 10 mg/kg,,,N,Expert,A,9615.0,CHEMBL619544,,,,,1,1
7001,50588,In vivo,BAO_0000218,,,The compound was tested for volume of distribution in dog,,,N,Intermediate,A,9615.0,CHEMBL619545,,,,,1,1
7002,50588,In vivo,BAO_0000218,,,The compound was tested for volume of distribution in dog at dose of 3-10 mgkg,,,N,Intermediate,A,9615.0,CHEMBL619546,,,,,1,1
7003,50588,In vivo,BAO_0000218,,,Vd (1 mg/kg) was determined in dog (in vivo),,,N,Intermediate,A,9615.0,CHEMBL619547,,,,,1,1
7004,50588,In vivo,BAO_0000218,,,Vd in dog,,,N,Intermediate,A,9615.0,CHEMBL619548,,,,,1,1
7005,50588,In vivo,BAO_0000218,,,Volume distribution was determined,,,N,Intermediate,A,9615.0,CHEMBL619549,,,,,1,1
7006,50588,In vivo,BAO_0000218,,,Volume of distribution in dog,,,N,Intermediate,A,9615.0,CHEMBL619550,,,,,1,1
7007,50588,In vivo,BAO_0000218,,,Volume of distribution by as 4 fold increase by iv administration in dogs,,,N,Intermediate,A,9615.0,CHEMBL876501,,,,,1,1
7008,50588,In vivo,BAO_0000218,,,Volume of distribution was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,,,N,Intermediate,A,9615.0,CHEMBL619551,,,,,1,1
7009,50588,In vivo,BAO_0000218,,,Volume of distribution was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,,N,Intermediate,A,9615.0,CHEMBL619552,,,,,1,1
7010,50588,In vivo,BAO_0000218,,,Volume distribution at the dose of 2 mg/kg in dog,,,N,Intermediate,A,9615.0,CHEMBL619553,,,,,1,1
7011,50588,In vivo,BAO_0000218,,,Steady state volume of distribution was determined,,,N,Intermediate,A,9615.0,CHEMBL618722,,,,,1,1
7012,50588,In vivo,BAO_0000218,,,Bioavailability as Vdss in dogs at 1 mg/kg intravenous dose,,,N,Intermediate,A,9615.0,CHEMBL618723,,,,,1,1
7013,50588,In vivo,BAO_0000218,,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,,,N,Intermediate,A,9615.0,CHEMBL618724,,,,,1,1
7014,50588,In vivo,BAO_0000218,,,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,,,N,Intermediate,A,9615.0,CHEMBL618725,,,,,1,1
7015,50588,In vivo,BAO_0000218,,,Bioavailability in dog (dose 1 mg/kg i.v.),,,N,Intermediate,A,9615.0,CHEMBL618726,,,,,1,1
7016,50588,In vivo,BAO_0000218,,,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),,,N,Intermediate,A,9615.0,CHEMBL618727,,,,,1,1
7017,50588,In vivo,BAO_0000218,,,Pharmacokinetic property (vdss) was measured in dog,,,N,Intermediate,A,9615.0,CHEMBL624233,,,,,1,1
7018,50588,In vivo,BAO_0000218,,,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in dog,,,N,Intermediate,A,9615.0,CHEMBL624234,,,,,1,1
7019,50588,In vivo,BAO_0000218,,,Vdss was determined after iv 0.1 mg/kg administration in dog,,,N,Intermediate,A,9615.0,CHEMBL624235,,,,,1,1
7020,50588,In vivo,BAO_0000218,,,Volume displacement was calculated in dog,,,N,Intermediate,A,9615.0,CHEMBL624236,,,,,1,1
7021,50588,In vivo,BAO_0000218,,,Volume distribution (Vdss) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,,,N,Intermediate,A,9615.0,CHEMBL624237,,,,,1,1
7022,50588,In vivo,BAO_0000218,,,Volume distribution constant was determined,,,N,Intermediate,A,9615.0,CHEMBL624238,,,,,1,1
7023,50588,In vivo,BAO_0000218,,,Volume distribution at a dose of 1 uM/kg in dog was determined,,,N,Intermediate,A,9615.0,CHEMBL624239,,,,,1,1
7024,50588,In vivo,BAO_0000218,,,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,,,N,Intermediate,A,9615.0,CHEMBL875829,,,,,1,1
7025,50588,In vivo,BAO_0000218,,,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,,N,Intermediate,A,9615.0,CHEMBL624240,,,,,1,1
7026,50588,In vivo,BAO_0000218,,,Volume distribution (Vdss) was measured in dog,,,N,Intermediate,A,9615.0,CHEMBL624241,,,,,1,1
7027,50588,In vivo,BAO_0000218,,,Volume distribution (Vdss) was measured in dog,,,N,Intermediate,A,9615.0,CHEMBL624242,,,,,1,1
7028,50588,In vivo,BAO_0000218,,,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,,N,Intermediate,A,9615.0,CHEMBL624243,,,,,1,1
7029,50588,In vivo,BAO_0000218,,,Volume of distribution in steady state was determined in dog,,,N,Intermediate,A,9615.0,CHEMBL624244,,,,,1,1
7030,50588,In vivo,BAO_0000218,,,Volume of distribution of compound was determined in dog,,,N,Intermediate,A,9615.0,CHEMBL624245,,,,,1,1
7031,50588,In vivo,BAO_0000218,,,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,,,N,Intermediate,A,9615.0,CHEMBL624246,,,,,1,1
7032,50588,In vivo,BAO_0000218,,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),,,N,Intermediate,A,9615.0,CHEMBL624247,,,,,1,1
7033,50588,In vivo,BAO_0000218,,,Volume of distribution (Vdss) was measured in dog,,,N,Intermediate,A,9615.0,CHEMBL624248,,,,,1,1
7034,50588,In vivo,BAO_0000218,,,Volumes of distribution in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,,N,Intermediate,A,9615.0,CHEMBL624249,,,,,1,1
7035,50588,In vivo,BAO_0000218,,,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,,N,Intermediate,A,9615.0,CHEMBL624250,,,,,1,1
7036,50588,In vivo,BAO_0000218,,,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,,N,Intermediate,A,9615.0,CHEMBL624251,,,,,1,1
7037,50588,,BAO_0000218,,,Maximum rate of depolarization of the upstroke of the action potential,,,N,Intermediate,A,9615.0,CHEMBL624252,,,,,1,1
7038,50588,In vivo,BAO_0000218,,,Steady state volume distribution in dog,,,N,Intermediate,A,9615.0,CHEMBL624253,,,,,1,1
7039,50588,In vivo,BAO_0000218,,,Steady state volume of distribution at a dose of 0.2 mg/kg i.v.,,,N,Intermediate,A,9615.0,CHEMBL624950,,,,,1,1
7040,50588,In vivo,BAO_0000218,,,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in dog,,,N,Intermediate,A,9615.0,CHEMBL624951,,,,,1,1
7041,50588,In vivo,BAO_0000218,,,Volume distribution in dog after administration of 0.25 mg/kg iv; ND = not determined,,,N,Intermediate,A,9615.0,CHEMBL875830,,,,,1,1
7042,50588,In vivo,BAO_0000218,,,Volume distribution in dog after administration of 1 mg/kg iv,,,N,Intermediate,A,9615.0,CHEMBL624952,,,,,1,1
7043,50588,In vivo,BAO_0000218,,,Volume of solubility in solution after intravenous administration in dogs at 1.2 uM/kg,,,N,Intermediate,A,9615.0,CHEMBL624953,,,,,1,1
7044,50588,In vivo,BAO_0000218,,,Vss after intravenous administration (0.5 mg/kg) was determined in dog,,,N,Intermediate,A,9615.0,CHEMBL624954,,,,,1,1
7045,50588,In vivo,BAO_0000218,,,Vss on i.v. administration of 2 mg/kg was measured in dog,,,N,Intermediate,A,9615.0,CHEMBL624955,,,,,1,1
7046,50588,,BAO_0000218,,,Vss was determined,,,N,Intermediate,A,9615.0,CHEMBL624956,,,,,1,1
7047,50588,,BAO_0000218,,,Vss in dog,,,N,Intermediate,A,9615.0,CHEMBL625129,,,,,1,1
7048,50588,In vivo,BAO_0000218,,,Volume of distribution was measured in dog after an iv dose of 1 mg/kg,,,N,Intermediate,A,9615.0,CHEMBL625130,,,,,1,1
7049,50588,In vivo,BAO_0000218,,,Volume distribution in dogs,,,N,Intermediate,A,9615.0,CHEMBL625131,,,,,1,1
7050,50588,In vivo,BAO_0000218,,,Volume of distribution in dog,,,N,Intermediate,A,9615.0,CHEMBL625132,,,,,1,1
7051,50588,In vivo,BAO_0000218,,,Tested for the oral bioavailability in dog,,,N,Intermediate,A,9615.0,CHEMBL872263,,,,,1,1
7060,50594,In vivo,BAO_0000218,,,Bioavailability of compound in mouse blood following p.o. administration of 30 mg/kg,,,N,Intermediate,A,10090.0,CHEMBL624336,,,,,1,1
7061,50594,In vivo,BAO_0000218,,,Bioavailability after i.p. administration of 50 mg/kg of dose in mice,,,N,Intermediate,A,10090.0,CHEMBL624337,,,,,1,1
7062,50594,In vivo,BAO_0000218,,,Bioavailability after peroral administration of 50 mg/kg of dose in mice,,,N,Intermediate,A,10090.0,CHEMBL624338,,,,,1,1
7063,50594,In vivo,BAO_0000218,,,Bioavailability was measured in mouse,,,N,Intermediate,A,10090.0,CHEMBL624339,,,,,1,1
7064,50594,In vivo,BAO_0000218,,,Bioavailability in mouse,,,N,Intermediate,A,10090.0,CHEMBL624340,,,,,1,1
7065,50594,In vivo,BAO_0000218,,,Bioavailability was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,,N,Intermediate,A,10090.0,CHEMBL624341,,,,,1,1
7066,50594,In vivo,BAO_0000218,,,Bioavailability in mouse,,,N,Intermediate,A,10090.0,CHEMBL624342,,,,,1,1
7067,50594,In vivo,BAO_0000218,,,Compound was evaluated for its bioavailability in mice at a dose of 1 mg/kg,,,N,Intermediate,A,10090.0,CHEMBL624343,,,,,1,1
7068,50594,In vivo,BAO_0000218,,,Oral bioavailability in mouse,,,N,Intermediate,A,10090.0,CHEMBL624344,,,,,1,1
7069,50594,In vivo,BAO_0000218,,,Oral availability at 50 mg/kg po in male mice,,,N,Intermediate,A,10090.0,CHEMBL624345,,,,,1,1
7070,50594,In vivo,BAO_0000218,,,Oral bioavailability in mouse (dose 10 mg/kg),,,N,Intermediate,A,10090.0,CHEMBL624346,,,,,1,1
7071,50594,In vivo,BAO_0000218,,,Oral bioavailability of compound determined in mouse after iv administration at a dose of 10 mg/kg,,,N,Expert,A,10090.0,CHEMBL624347,,,,,1,1
7072,50594,In vivo,BAO_0000218,,,"Bioavailability in male mice, 2mg/kg oral and 1 mg/kg intravenous dose",,,N,Intermediate,A,10090.0,CHEMBL624348,,,,,1,1
7074,50594,In vivo,BAO_0000218,,,Oral bioavailability in mouse,,,N,Intermediate,A,10090.0,CHEMBL622754,,,,,1,1
7075,50594,In vivo,BAO_0000218,,,Oral bioavailability in vivo in mice;ND=Not determined,,,N,Intermediate,A,10090.0,CHEMBL622755,,,,,1,1
7076,50594,In vivo,BAO_0000218,,,Oral bioavailability in mouse at 10 mg/kg of the compound,,,N,Intermediate,A,10090.0,CHEMBL622756,,,,,1,1
7077,50594,In vivo,BAO_0000218,,,Bioavailability in mouse (BALB/C) (dose 50 mg/kg i.p.),,,N,Intermediate,A,10090.0,CHEMBL622757,,,,,1,1
7078,50594,In vivo,BAO_0000218,,,Bioavailability in mouse (BALB/C) (dose 20 mg/kg i.v.),,,N,Intermediate,A,10090.0,CHEMBL622758,,,,,1,1
7079,50594,In vivo,BAO_0000218,,,Tested for bioavailability of the compound,,,N,Intermediate,A,10090.0,CHEMBL622759,,,,,1,1
7080,50594,In vivo,BAO_0000218,,,Tested for half life at the dose of 10 mg/kg when administered intravenously,,,N,Intermediate,A,10090.0,CHEMBL622760,,,,,1,1
7081,50594,,BAO_0000218,,,The plasma half life of compound was determined on EDTA prepared by mouse plasma. ,,,N,Intermediate,A,10090.0,CHEMBL622761,,1969.0,Plasma,,1,1
7082,50594,,BAO_0000218,,,The plasma half life of compound was determined on heparin prepared by human plasma. ,,,N,Intermediate,A,10090.0,CHEMBL622762,,1969.0,Plasma,,1,1
7083,50594,,BAO_0000218,,,The plasma half life of compound was determined on heparin prepared by human plasma; Not degraded,,,N,Intermediate,A,10090.0,CHEMBL622763,,1969.0,Plasma,,1,1
7084,50594,,BAO_0000218,,,The plasma half life of compound was determined on heparin prepared by mouse plasma. ,,,N,Intermediate,A,10090.0,CHEMBL622764,,1969.0,Plasma,,1,1
7085,50594,,BAO_0000218,,,The plasma half life of compound was determined on heparin prepared by mouse plasma; Not degraded,,,N,Intermediate,A,10090.0,CHEMBL622765,,1969.0,Plasma,,1,1
7086,50594,,BAO_0000218,,,Inhibitory concentration of compound was determined after intravenous administration in mice after 6 hours of exposure at 40 mg/Kg,,,N,Intermediate,F,10090.0,CHEMBL622766,,,,,1,1
7087,50594,,BAO_0000218,,,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 24 mg/Kg,,,N,Intermediate,A,10090.0,CHEMBL622767,,,,,1,1
7088,50594,,BAO_0000218,,,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 5 mg/Kg,,,N,Intermediate,A,10090.0,CHEMBL622768,,,,,1,1
7089,50594,In vivo,BAO_0000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,,N,Intermediate,A,10090.0,CHEMBL875948,,178.0,Blood,,1,1
7090,50594,In vivo,BAO_0000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,,N,Intermediate,A,10090.0,CHEMBL622769,,178.0,Blood,,1,1
7091,50594,In vivo,BAO_0000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,,N,Intermediate,A,10090.0,CHEMBL622770,,178.0,Blood,,1,1
7092,50594,In vivo,BAO_0000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,,N,Intermediate,A,10090.0,CHEMBL622771,,178.0,Blood,,1,1
7093,50594,In vivo,BAO_0000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,,N,Intermediate,A,10090.0,CHEMBL622772,,178.0,Blood,,1,1
7094,50594,In vivo,BAO_0000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,,N,Intermediate,A,10090.0,CHEMBL622773,,178.0,Blood,,1,1
7095,50594,In vivo,BAO_0000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,,N,Intermediate,A,10090.0,CHEMBL622774,,178.0,Blood,,1,1
7096,50594,In vivo,BAO_0000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,,N,Intermediate,A,10090.0,CHEMBL621725,,10000001.0,Bone,,1,1
7097,50594,In vivo,BAO_0000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,,,N,Intermediate,A,10090.0,CHEMBL621726,,10000001.0,Bone,,1,1
7098,81034,,BAO_0000219,478.0,A2780,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 8,,,N,Intermediate,F,9606.0,CHEMBL621727,,,,,1,1
7099,81034,,BAO_0000219,478.0,A2780,In vitro cytotoxicity against human ovarian carcinoma cell line A2780 using sulforhodamine B (SRB) assay,,,N,Expert,F,9606.0,CHEMBL622413,,,,,1,1
7100,81034,,BAO_0000219,478.0,A2780,Compound was evaluated for cytotoxicity against A2780 cell line,,,N,Intermediate,F,9606.0,CHEMBL622414,,,,,1,1
7101,81034,,BAO_0000219,478.0,A2780,Inhibition of A2780 cell clonogenic assay,,,N,Expert,F,9606.0,CHEMBL622415,,,,,1,1
7102,81034,,BAO_0000219,478.0,A2780,Cytotoxic effect on ovarian cancer cell line (A2780),,,N,Expert,F,9606.0,CHEMBL884001,,,,,1,1
7103,81034,,BAO_0000219,478.0,A2780,Concentration required to inhibit A2780 cell growth when compared with control after incubation for 96 hr at 37 C,,,N,Intermediate,F,9606.0,CHEMBL622416,,,,,1,1
7104,81034,,BAO_0000219,478.0,A2780,"MDR-reversing activity was measured by vincristine accumulation in the multidrug resistant 2780AD, a subline of A2780 ovarian carcinoma cells at 10 mg/mL",,,N,Intermediate,F,9606.0,CHEMBL622417,,,,,1,1
7105,81034,,BAO_0000219,478.0,A2780,50% growth inhibition of A2780 (Human ovarian carcinoma) cell line compared with untreated control cells,,,N,Expert,F,9606.0,CHEMBL622590,,,,,1,1
7106,81034,,BAO_0000219,478.0,A2780,Antiproliferative activity against human A2780 cells,,,N,Expert,F,9606.0,CHEMBL622591,,,,,1,1
7107,81034,,BAO_0000219,478.0,A2780,Inhibition of human A2780 cell proliferation,,,N,Expert,F,9606.0,CHEMBL622592,,,,,1,1
7108,81034,,BAO_0000219,478.0,A2780,Antiproliferative effect against human A2780 cell line was determined in a whole cell 72 hr cytotoxicity assay,,,N,Expert,F,9606.0,CHEMBL622593,,,,,1,1
7109,81034,,BAO_0000219,478.0,A2780,Inhibition of human A2780 cell proliferation (No data),,,N,Expert,F,9606.0,CHEMBL622594,,,,,1,1
7110,81034,,BAO_0000219,478.0,A2780,Cell cytotoxicity was determined against human ovarian cancer (A2780) cell line,,,N,Intermediate,F,9606.0,CHEMBL622595,,,,,1,1
7111,81034,,BAO_0000219,478.0,A2780,Compound was evaluated against human Ovarian carcinoma cell line A2780,,,N,Intermediate,F,9606.0,CHEMBL622596,,,,,1,1
7112,81034,,BAO_0000219,478.0,A2780,Growth inhibition against A2780 wild-type ovarian cell lines,,,N,Expert,F,9606.0,CHEMBL622597,,,,,1,1
7113,81034,,BAO_0000219,478.0,A2780,Compound was evaluated for growth inhibition against A2780 wild-type ovarian cell lines; No data,,,N,Intermediate,F,9606.0,CHEMBL622598,,,,,1,1
7114,104766,,BAO_0000019,,,Inhibition of tubulin polymerization in human ovarian cancer cell lines,,,D,Autocuration,F,9606.0,CHEMBL622599,,,,,5,1
7115,81034,,BAO_0000219,478.0,A2780,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,,,N,Intermediate,F,9606.0,CHEMBL622600,,,,,1,1
7116,81034,,BAO_0000219,478.0,A2780,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,,,N,Intermediate,F,9606.0,CHEMBL622601,,,,,1,1
7117,81034,,BAO_0000219,478.0,A2780,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,,,N,Intermediate,F,9606.0,CHEMBL622602,,,,,1,1
7118,81034,,BAO_0000219,478.0,A2780,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,,,N,Intermediate,F,9606.0,CHEMBL622603,,,,,1,1
7119,81034,,BAO_0000219,478.0,A2780,Compound was tested for inhibitory activity against A2780 human ovarian carcinoma cell line; activity expressed in Mean IC50 values,,,N,Intermediate,F,9606.0,CHEMBL622604,,,,,1,1
7120,81034,,BAO_0000219,478.0,A2780,Compound was tested for inhibitory activity against A2780cisR human ovarian carcinoma cell line; activity expressed in Mean IC50 values,,,N,Intermediate,F,9606.0,CHEMBL622605,,,,,1,1
7121,81034,,BAO_0000219,478.0,A2780,In vitro inhibition of human ovarian cell line A2780,,,N,Expert,F,9606.0,CHEMBL622606,,,,,1,1
7122,81034,,BAO_0000219,478.0,A2780,"In vitro inhibition of human ovarian cell line, resistant to cisplatin (A2780cisR).",,,N,Expert,F,9606.0,CHEMBL619463,,,,,1,1
7123,81034,,BAO_0000219,478.0,A2780,Concentration of compound to inhibit the growth of human A2780 ovarian carcinoma cells(in vitro),,,N,Intermediate,F,9606.0,CHEMBL619464,,,,,1,1
7124,81034,,BAO_0000219,478.0,A2780,Concentration required to inhibit A2780-cell growth by 50%,,,N,Expert,F,9606.0,CHEMBL619465,,,,,1,1
7125,81034,,BAO_0000219,478.0,A2780,Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells.,,,N,Expert,F,9606.0,CHEMBL619466,,,,,1,1
7126,81034,,BAO_0000219,478.0,A2780,Cytotoxic effect on human ovarian (A2780) cancer cell line,,,N,Expert,F,9606.0,CHEMBL619467,,,,,1,1
7127,81034,,BAO_0000219,478.0,A2780,Cytotoxic activity in a panel of Human ovarian tumor A2780 cell line after 96h of drug exposure,,,N,Intermediate,F,9606.0,CHEMBL619468,,,,,1,1
7128,81034,,BAO_0000219,478.0,A2780,Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs,,,N,Expert,F,9606.0,CHEMBL619469,,,,,1,1
7129,81034,,BAO_0000219,478.0,A2780,Cytotoxicity measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,,,N,Expert,F,9606.0,CHEMBL619470,,,,,1,1
7130,81034,,BAO_0000219,478.0,A2780,Cytotoxicity activity of the compound was measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,,,N,Intermediate,F,9606.0,CHEMBL619471,,,,,1,1
7131,81034,,BAO_0000219,478.0,A2780,Cytotoxicity against human ovarian carcinoma A2780 cell line,,,N,Intermediate,F,9606.0,CHEMBL619472,,,,,1,1
7132,81034,,BAO_0000219,478.0,A2780,"Cytotoxicity against A2780-C25, oxaliplatin-resistant Ovarian carcinoma cell line",,,N,Intermediate,F,9606.0,CHEMBL619473,,,,,1,1
7133,81034,,BAO_0000219,478.0,A2780,"Cytotoxicity against A2780-CP3, cisplatin-resistant Ovarian carcinoma cell line",,,N,Intermediate,F,9606.0,CHEMBL874368,,,,,1,1
7134,81034,,BAO_0000219,478.0,A2780,"Cytotoxicity against A2780-DX5, Doxorubicin-resistant Ovarian carcinoma cell line",,,N,Intermediate,F,9606.0,CHEMBL884003,,,,,1,1
7135,81034,,BAO_0000219,478.0,A2780,"Cytotoxicity against A2780-WT, human ovarian carcinoma cell line",,,N,Intermediate,F,9606.0,CHEMBL622690,,,,,1,1
7136,81034,,BAO_0000219,478.0,A2780,Cytotoxicity against ovarian carcinoma A2780 tumor cell lines,,,N,Intermediate,F,9606.0,CHEMBL622691,,,,,1,1
7137,81034,,BAO_0000219,478.0,A2780,Dose of required to inhibit growth of cisplatin resistant human ovarian carcinoma (A2780 cisR) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,,,N,Intermediate,F,9606.0,CHEMBL622692,,,,,1,1
7138,81034,,BAO_0000219,478.0,A2780,Dose of required to inhibit growth of human ovarian carcinoma (A2780) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,,,N,Intermediate,F,9606.0,CHEMBL623406,,,,,1,1
7139,81034,,BAO_0000219,478.0,A2780,"Growth inhibition in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant) using the 96 hour exposure sulforhodamine B (SRB) growth delay assay",,,N,Intermediate,F,9606.0,CHEMBL884004,,,,,1,1
7140,81034,,BAO_0000219,478.0,A2780,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780,,,N,Intermediate,F,9606.0,CHEMBL623407,,,,,1,1
7141,81034,,BAO_0000219,478.0,A2780,In vitro Growth Inhibitory activity against A2780 Human ovarian cancer cell line,,,N,Intermediate,F,9606.0,CHEMBL623408,,,,,1,1
7142,81034,,BAO_0000219,478.0,A2780,In vitro antitumor activity against A2780 cell line.,,,N,Expert,F,9606.0,CHEMBL623409,,,,,1,1
7143,81034,,BAO_0000219,478.0,A2780,In vitro cytotoxic activity against human tumor cell line A2780 after incubation for 96 hours,,,N,Intermediate,F,9606.0,CHEMBL623410,,,,,1,1
7144,81034,,BAO_0000219,478.0,A2780,In vitro cytotoxicity against A2780 human ovarian cancer cell line,,,N,Expert,F,9606.0,CHEMBL623576,,,,,1,1
7145,80025,,BAO_0000219,626.0,ACHN,Inhibitory activity against kidney A-CHN tumor cell growth in culture,,,N,Intermediate,F,9606.0,CHEMBL623577,,,,,1,1
7146,80025,,BAO_0000219,626.0,ACHN,The IC50 value was measured on ACHN cell line in renal tumor type.,,,N,Intermediate,F,9606.0,CHEMBL623578,,,,,1,1
7147,80025,,BAO_0000219,626.0,ACHN,Concentration required for killing 50% of cells of renal ACHN cell lines was determined in vitro,,,N,Intermediate,F,9606.0,CHEMBL623579,,,,,1,1
7148,80025,,BAO_0000219,626.0,ACHN,In vitro lethal concentration against most sensitive ACHN cell line,,,N,Expert,F,9606.0,CHEMBL623580,,,,,1,1
7149,80025,,BAO_0000219,626.0,ACHN,Tested for cytotoxic activity against renal cancer ACHN cell line,,,N,Intermediate,F,9606.0,CHEMBL623581,,,,,1,1
7150,80025,,BAO_0000219,626.0,ACHN,Compound tested for growth inhibition of renal cancer cell line ACHN,,,N,Intermediate,F,9606.0,CHEMBL857456,,,,,1,1
7151,80025,,BAO_0000219,626.0,ACHN,Compound was tested for 50% growth inhibition against human renal cancer ACHN cell line,,,N,Intermediate,F,9606.0,CHEMBL623582,,,,,1,1
7152,80025,,BAO_0000219,626.0,ACHN,Growth inhibition of the ACHN Renal cancer cell line for 2-day in vitro assay.,,,N,Intermediate,F,9606.0,CHEMBL623583,,,,,1,1
7153,80025,,BAO_0000219,626.0,ACHN,In vitro anticancer activity against ACHN renal cancer cell line,,,N,Intermediate,F,9606.0,CHEMBL623584,,,,,1,1
7154,80025,,BAO_0000219,626.0,ACHN,In vitro antitumor activity against Renal cancer ACHN cell lines by 6-day assay,,,N,Intermediate,F,9606.0,CHEMBL623585,,,,,1,1
7155,80025,,BAO_0000219,626.0,ACHN,Percent selectivity was evaluated in renal ACHN cell lines,,,N,Intermediate,F,9606.0,CHEMBL623586,,,,,1,1
7156,80025,,BAO_0000219,626.0,ACHN,In vitro inhibitory activity against renal ACHN cancer cell line,,,N,Intermediate,F,9606.0,CHEMBL623587,,,,,1,1
7157,80025,,BAO_0000219,626.0,ACHN,Tested for cytotoxicity against ACHN cell lines in renal cancer,,,N,Intermediate,F,9606.0,CHEMBL875279,,,,,1,1
7158,80025,,BAO_0000219,626.0,ACHN,Tested for the in vitro cytotoxicity against ACHN renal cancer cell line,,,N,Intermediate,F,9606.0,CHEMBL623588,,,,,1,1
7159,80025,,BAO_0000219,626.0,ACHN,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,,,N,Intermediate,F,9606.0,CHEMBL623589,,,,,1,1
7160,80025,,BAO_0000219,626.0,ACHN,Tested in vitro for cytotoxicity in ACHN cell line of Renal cancer,,,N,Intermediate,F,9606.0,CHEMBL623590,,,,,1,1
7161,80025,,BAO_0000219,626.0,ACHN,Cytotoxic effect on renal cancer line ACHN,,,N,Expert,F,9606.0,CHEMBL623591,,,,,1,1
7162,80025,,BAO_0000219,626.0,ACHN,In vitro anti-cancer activity against ACHN(Renal) human tumor cell line,,,N,Intermediate,F,9606.0,CHEMBL623592,,,,,1,1
7163,80025,,BAO_0000219,626.0,ACHN,In vitro inhibition of Renal Cancer ACHN cell lines,,,N,Intermediate,F,9606.0,CHEMBL623593,,,,,1,1
7164,80025,,BAO_0000219,626.0,ACHN,Antitumor activity against human renal adenocarcinoma ACHN cells,,,N,Intermediate,F,9606.0,CHEMBL623594,,,,,1,1
7165,80025,,BAO_0000219,626.0,ACHN,Antitumor activity against human renal adenocarcinoma ACHN cells.,,,N,Expert,F,9606.0,CHEMBL621833,,,,,1,1
7166,80025,,BAO_0000219,626.0,ACHN,Inhibitory concentration required to decrease cell viability in cell growth culture against kidney cells ACHN,,,N,Intermediate,F,9606.0,CHEMBL621834,,,,,1,1
7167,80025,,BAO_0000219,626.0,ACHN,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),,,N,Intermediate,F,9606.0,CHEMBL621835,,,,,1,1
7168,80025,,BAO_0000219,626.0,ACHN,"Cytotoxicity against NCI tumor panel, ACHN renal cancer cell line",,,N,Intermediate,F,9606.0,CHEMBL621836,,,,,1,1
7169,80025,,BAO_0000219,626.0,ACHN,Concentration of compound that cause 50% cytotoxicity of ACHN renal cancer cell line,,,N,Intermediate,F,9606.0,CHEMBL621837,,,,,1,1
7170,80025,,BAO_0000219,626.0,ACHN,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration that inhibits 50% net cell growth).,,,N,Intermediate,F,9606.0,CHEMBL875280,,,,,1,1
7171,80025,,BAO_0000219,626.0,ACHN,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration leading to 50% net cell death).,,,N,Intermediate,F,9606.0,CHEMBL621838,,,,,1,1
7172,80025,,BAO_0000219,626.0,ACHN,Cytotoxicity was tested against renal cancer ACHN tumor cell lines.,,,N,Intermediate,F,9606.0,CHEMBL621839,,,,,1,1
7173,22224,,BAO_0000019,,,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,,,U,Autocuration,A,,CHEMBL621840,,,,,0,1
7174,10647,,BAO_0000019,,,Compound tested for relative response using 1 uM ACh as agonist against AChM1 receptor.,,,H,Autocuration,F,,CHEMBL621841,,,,,8,1
7175,50529,,BAO_0000218,468.0,HEL,Antiviral activity against AD169 strain of cytomegalovirus (CMV) in HEL (human erythroleukemia) cells.,,,N,Expert,F,10358.0,CHEMBL622979,,,,,1,1
7176,50529,,BAO_0000218,,,Antiviral activity against AD169 strain of cytomegalovirus (CMV); ND=No data,,,N,Intermediate,F,10358.0,CHEMBL876595,,,,,1,1
7177,12159,,BAO_0000357,,,Compound was evaluated for its inhibitory activity against calf intestinal Adenosine deaminase (ADA),,,H,Autocuration,B,,CHEMBL620221,,,,,8,1
7178,12159,,BAO_0000357,,,Evaluated for the inhibition of calf intestinal Adenosine deaminase (ADA),,,H,Autocuration,B,,CHEMBL620222,,,,,8,1
7179,80670,,BAO_0000219,979.0,ADDP cell line,Inhibitory activity against ovarian tumor cell line ADDP after 72 hr continuous exposure to compound,,,N,Intermediate,F,9913.0,CHEMBL620506,,,,,1,1
7180,80671,,BAO_0000219,980.0,ADJ/PC6,Tumor growth inhibition activity after subcutaneous transplanted tumor in ADJ-PC6 plasmacytoma cells,,,N,Intermediate,F,10090.0,CHEMBL620507,,,,,1,1
7181,80671,,BAO_0000219,980.0,ADJ/PC6,Tumor growth inhibition activity after subcutaneously transplanted tumor in ADJ-PC6 plasmacytoma cells,,,N,Intermediate,F,10090.0,CHEMBL620508,,,,,1,1
7182,80671,,BAO_0000219,980.0,ADJ/PC6,"Compound was tested for dose producing 90% reduction in tumor weight, in ADJ/PC6 mouse plasma cell tumor",,,N,Intermediate,F,10090.0,CHEMBL620509,,,,,1,1
7183,80671,,BAO_0000219,980.0,ADJ/PC6,Compound was tested for inhibition against ADJ/PC6 mouse plasma cell tumor at the dose of 320 mg/Kg,,,N,Intermediate,F,10090.0,CHEMBL620510,,,,,1,1
7184,80671,,BAO_0000219,980.0,ADJ/PC6,Compound was tested for dose required to kill 50 % of ADJ/PC6 mouse plasma cell tumor in a group,,,N,Intermediate,A,10090.0,CHEMBL620511,,,,,1,1
7185,80671,,BAO_0000219,980.0,ADJ/PC6,In vitro incorporation of the [3H]thymidine into the ADJ/PC6 Plasmacytoma cells,,,N,Intermediate,F,10090.0,CHEMBL620512,,,,,1,1
7186,22224,,BAO_0000019,,,Tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma,,,U,Autocuration,F,10090.0,CHEMBL620513,,,,,0,1
7187,22224,,BAO_0000019,,,The compound was tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma; Not determined,,,U,Autocuration,F,10090.0,CHEMBL620514,,,,,0,1
7188,22224,,BAO_0000019,,,Tested for cytotoxicity against ADJ/PC6 plasmacytoma,,,U,Autocuration,F,10090.0,CHEMBL620515,,,,,0,1
7189,22224,In vivo,BAO_0000218,,,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),,,U,Autocuration,A,1423.0,CHEMBL620516,,,,,0,1
7190,50588,,BAO_0000218,,,AUC value in dog after IV administration at a dose of 5 mg/kg,,,N,Intermediate,A,9615.0,CHEMBL620517,,1969.0,Plasma,,1,1
7191,50588,,BAO_0000218,,,AUC value in dog after oral administration at a dose of 5 mg/kg,,,N,Intermediate,A,9615.0,CHEMBL620518,,1969.0,Plasma,,1,1
7192,50588,In vivo,BAO_0000218,,,Cmax value in dog after oral administration at a dose of 5 mg/kg,,,N,Intermediate,A,9615.0,CHEMBL620519,,,,,1,1
7193,50588,In vivo,BAO_0000218,,,Bioavailability in dog after oral administration at a dose of 5 mg/kg,,,N,Intermediate,A,9615.0,CHEMBL621386,,,,,1,1
7194,50588,In vivo,BAO_0000218,,,Tmax value in dog after oral administration at a dose of 5 mg/kg,,,N,Intermediate,A,9615.0,CHEMBL621387,,,,,1,1
7195,50588,In vivo,BAO_0000218,,,Compound was evaluated for its clearance when administered intravenously in dog,,,N,Intermediate,A,9615.0,CHEMBL621388,,,,,1,1
7196,50588,In vivo,BAO_0000218,,,Plasma clearance in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,,N,Intermediate,A,9615.0,CHEMBL621389,,,,,1,1
7197,50588,In vivo,BAO_0000218,,,Plasma clearance was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),,,N,Intermediate,A,9615.0,CHEMBL621390,,,,,1,1
7198,22229,,BAO_0000100,,,Calculated partition coefficient (clogP),,,U,Intermediate,P,,CHEMBL621391,,,,,0,1
7199,50588,,BAO_0000218,,,Half life in dog,,,N,Intermediate,A,9615.0,CHEMBL621392,,,,,1,1
7200,50588,,BAO_0000218,,,Time taken for EC90 was determined when tested in dog,,,N,Intermediate,A,9615.0,CHEMBL621393,,,,,1,1
7201,50588,,BAO_0000218,,,Half life (iv) was determined,,,N,Intermediate,A,9615.0,CHEMBL621394,,,,,1,1
7202,50588,,BAO_0000218,,,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,,,N,Intermediate,A,9615.0,CHEMBL621395,,2107.0,Liver,,1,1
7203,50588,,BAO_0000218,,,Area under the curve was calculated in dog after iv administration,,,N,Intermediate,A,9615.0,CHEMBL621396,,,,,1,1
7204,50588,,BAO_0000218,,,Area under the curve was calculated in dog after peroral administration,,,N,Intermediate,A,9615.0,CHEMBL621397,,,,,1,1
7205,50588,,BAO_0000218,,,Dose-normalized area under curve in dog (p.o.) at 2.0 mpk,,,N,Intermediate,A,9615.0,CHEMBL621398,,,,,1,1
7206,50588,,BAO_0000218,,,pKa was evaluated in dog,,,N,Intermediate,A,9615.0,CHEMBL618818,,,,,1,1
7207,50588,,BAO_0000218,,,Compound was evaluated for pronounced GH response at 100 mg (n=6)(area under concentration curve was determined from 0-8 hr following morning and evening dosing with 25 mg of the compound,,,N,Intermediate,A,9615.0,CHEMBL618819,,,,,1,1
7208,50588,In vivo,BAO_0000218,,,Alpha-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,,N,Intermediate,A,9615.0,CHEMBL618820,,,,,1,1
7209,50588,In vivo,BAO_0000218,,,Beta-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,,N,Intermediate,A,9615.0,CHEMBL873810,,,,,1,1
7210,50588,In vivo,BAO_0000218,,,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,,,N,Intermediate,A,9615.0,CHEMBL876606,,,,,1,1
7211,50588,,BAO_0000218,,,Compound was evaluated for the half-life (t 1/2) in hours,,,N,Intermediate,A,9615.0,CHEMBL618821,,,,,1,1
7212,50588,In vivo,BAO_0000218,,,Half life to reach the blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,,,N,Intermediate,A,9615.0,CHEMBL618822,,178.0,Blood,,1,1
7213,50588,In vivo,BAO_0000218,,,Half life to reach the blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,,,N,Intermediate,A,9615.0,CHEMBL618823,,178.0,Blood,,1,1
7214,50588,In vivo,BAO_0000218,,,Half life after intravenous administration of 1 mg/kg in dog,,,N,Intermediate,A,9615.0,CHEMBL618824,,,,,1,1
7215,50588,,BAO_0000218,,,Half life was measured in dog,,,N,Intermediate,A,9615.0,CHEMBL618825,,,,,1,1
7216,50588,In vivo,BAO_0000218,,,Half life period in dog after 5 mg/kg dose,,,N,Intermediate,A,9615.0,CHEMBL618826,,,,,1,1
7217,50588,,BAO_0000218,,,Half life period was evaluated in dog; 4-4.8,,,N,Intermediate,A,9615.0,CHEMBL618827,,,,,1,1
7218,50588,In vivo,BAO_0000218,,,Half life was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,,N,Intermediate,A,9615.0,CHEMBL618828,,,,,1,1
7219,50588,In vivo,BAO_0000218,,,Half-life was determined in dog after a3 mg/kg of iv dose,,,N,Intermediate,A,9615.0,CHEMBL618829,,,,,1,1
7220,50588,,BAO_0000218,,,Half-life was determined,,,N,Intermediate,A,9615.0,CHEMBL618830,,,,,1,1
7221,50588,,BAO_0000218,,,Half life in dogs,,,N,Intermediate,A,9615.0,CHEMBL618831,,,,,1,1
7222,50588,In vivo,BAO_0000218,,,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 2 mg/kg tp dog,,,N,Intermediate,A,9615.0,CHEMBL619489,,1969.0,Plasma,,1,1
7223,50588,In vivo,BAO_0000218,,,Apparent half-life after single intravenous bolus of 1 mg/kg in dogs,,,N,Intermediate,A,9615.0,CHEMBL619649,,,,,1,1
7224,50588,In vivo,BAO_0000218,,,Compound was evaluated for the half life period after iv administration in Beagle dog.,,,N,Intermediate,A,9615.0,CHEMBL876607,,,,,1,1
7225,50588,In vivo,BAO_0000218,,,Compound was evaluated for the half life period after oral administration in conscious dog.,,,N,Intermediate,A,9615.0,CHEMBL619650,,,,,1,1
7226,50588,,BAO_0000218,,,Compound was tested for half life in dog,,,N,Intermediate,A,9615.0,CHEMBL619651,,,,,1,1
7227,50588,,BAO_0000218,,,Compound was tested for its half life in dog,,,N,Intermediate,A,9615.0,CHEMBL619652,,,,,1,1
7228,50588,In vivo,BAO_0000218,,,Half life of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,,N,Intermediate,A,9615.0,CHEMBL619653,,,,,1,1
7229,50588,,BAO_0000218,,,Half life of compound in dog was determined,,,N,Intermediate,A,9615.0,CHEMBL619654,,,,,1,1
7230,50588,In vivo,BAO_0000218,,,Half life (iv) was determined,,,N,Intermediate,A,9615.0,CHEMBL619655,,,,,1,1
7231,50588,,BAO_0000218,,,Half life following administration of 70 nM in canine whole blood (dose exceeding platelet binding capacity),,,N,Intermediate,A,9615.0,CHEMBL619656,,178.0,Blood,,1,1
7232,50588,In vivo,BAO_0000218,,,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,,,N,Intermediate,A,9615.0,CHEMBL873812,,1969.0,Plasma,,1,1
7233,50588,In vivo,BAO_0000218,,,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,,,N,Intermediate,F,9615.0,CHEMBL621365,,1969.0,Plasma,,1,1
7234,50588,,BAO_0000218,,,Half life in dog,,,N,Intermediate,A,9615.0,CHEMBL621366,,,,,1,1
7235,50588,,BAO_0000218,,,Half life in dog plasma,,,N,Intermediate,A,9615.0,CHEMBL621367,,1969.0,Plasma,,1,1
7236,50588,In vivo,BAO_0000218,,,Half life in dog plasma after administration of 0.25 mg/kg iv,,,N,Intermediate,A,9615.0,CHEMBL621368,,1969.0,Plasma,,1,1
7237,50588,In vivo,BAO_0000218,,,Half life in dog plasma after administration of 1 mg/kg iv,,,N,Intermediate,A,9615.0,CHEMBL621369,,1969.0,Plasma,,1,1
7238,50588,In vivo,BAO_0000218,,,Half life in dog plasma was determined at dose 10 mg/kg,,,N,Intermediate,A,9615.0,CHEMBL621370,,1969.0,Plasma,,1,1
7239,50588,,BAO_0000218,,,Half life in dog was determined,,,N,Intermediate,A,9615.0,CHEMBL621371,,,,,1,1
7240,50588,In vivo,BAO_0000218,,,Half life in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,,N,Intermediate,A,9615.0,CHEMBL621372,,,,,1,1
7241,50588,,BAO_0000218,,,Half life upon exposure to human plasma,,,N,Intermediate,A,9615.0,CHEMBL621373,,1969.0,Plasma,,1,1
7242,50588,,BAO_0000218,,,Half life was calculated in dog,,,N,Intermediate,A,9615.0,CHEMBL621374,,,,,1,1
7243,50588,,BAO_0000218,,,Half life was determined,,,N,Intermediate,A,9615.0,CHEMBL621375,,,,,1,1
7244,50588,,BAO_0000218,,,Half life was determined,,,N,Intermediate,A,9615.0,CHEMBL621376,,,,,1,1
7245,50588,In vivo,BAO_0000218,,,Half life by intravenous administration of 1.2 mg/kg in dog,,,N,Intermediate,A,9615.0,CHEMBL619624,,,,,1,1
7246,50588,,BAO_0000218,,,Half life in dog,,,N,Intermediate,A,9615.0,CHEMBL875840,,,,,1,1
7247,50588,,BAO_0000218,,,Half life in dog after intra venous administration of the compound,,,N,Intermediate,A,9615.0,CHEMBL619625,,,,,1,1
7248,50588,,BAO_0000218,,,Half life in dog after intra venous administration of the compound; ND means Not determined,,,N,Intermediate,A,9615.0,CHEMBL619626,,,,,1,1
7249,50588,In vivo,BAO_0000218,,,Half life in dog after po administration of the compound,,,N,Intermediate,A,9615.0,CHEMBL619627,,,,,1,1
7250,50588,In vivo,BAO_0000218,,,Half life in dog after po administration of the compound; ND means Not determined,,,N,Intermediate,A,9615.0,CHEMBL873817,,,,,1,1
7251,50588,In vivo,BAO_0000218,,,Half life in dog at the single oral dose of 1 mg/kg,,,N,Intermediate,A,9615.0,CHEMBL619628,,,,,1,1
7252,50588,,BAO_0000218,,,Half life in dogs,,,N,Intermediate,A,9615.0,CHEMBL619629,,,,,1,1
7253,50588,In vivo,BAO_0000218,,,Half life in dogs at 1 mg/kg oral dosing; 35-100 min,,,N,Intermediate,A,9615.0,CHEMBL619630,,,,,1,1
7254,50588,,BAO_0000218,,,Half life in rat,,,N,Intermediate,A,9615.0,CHEMBL619631,,,,,1,1
7255,50588,In vivo,BAO_0000218,,,Half life in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,,N,Intermediate,A,9615.0,CHEMBL619632,,,,,1,1
7256,50594,In vivo,BAO_0000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,,N,Intermediate,A,10090.0,CHEMBL619633,,10000001.0,Bone,,1,1
7257,50594,In vivo,BAO_0000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,,N,Intermediate,A,10090.0,CHEMBL875841,,10000001.0,Bone,,1,1
7258,50594,In vivo,BAO_0000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,,N,Intermediate,A,10090.0,CHEMBL619634,,10000001.0,Bone,,1,1
7259,50594,In vivo,BAO_0000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,,N,Intermediate,A,10090.0,CHEMBL619635,,10000001.0,Bone,,1,1
7260,50594,In vivo,BAO_0000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,,N,Intermediate,A,10090.0,CHEMBL619636,,10000001.0,Bone,,1,1
7261,50594,In vivo,BAO_0000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,,N,Intermediate,A,10090.0,CHEMBL619637,,10000004.0,Gut,,1,1
7262,50594,In vivo,BAO_0000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,,N,Intermediate,A,10090.0,CHEMBL619638,,10000004.0,Gut,,1,1
7263,50594,In vivo,BAO_0000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,,N,Intermediate,A,10090.0,CHEMBL619639,,10000004.0,Gut,,1,1
7264,50594,In vivo,BAO_0000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,,N,Intermediate,A,10090.0,CHEMBL619640,,10000004.0,Gut,,1,1
7265,50594,In vivo,BAO_0000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,,N,Intermediate,A,10090.0,CHEMBL619641,,10000004.0,Gut,,1,1
7266,50594,In vivo,BAO_0000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,,N,Intermediate,A,10090.0,CHEMBL619642,,10000004.0,Gut,,1,1
7267,50594,In vivo,BAO_0000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,,N,Intermediate,A,10090.0,CHEMBL619643,,10000004.0,Gut,,1,1
7268,50594,In vivo,BAO_0000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,,N,Intermediate,A,10090.0,CHEMBL619644,,948.0,Heart,,1,1
7269,50594,In vivo,BAO_0000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,,N,Intermediate,A,10090.0,CHEMBL621112,,948.0,Heart,,1,1
7270,50594,In vivo,BAO_0000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,,N,Intermediate,A,10090.0,CHEMBL621113,,948.0,Heart,,1,1
7271,50594,In vivo,BAO_0000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,,N,Intermediate,A,10090.0,CHEMBL621114,,948.0,Heart,,1,1
7272,50594,In vivo,BAO_0000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,,N,Intermediate,A,10090.0,CHEMBL621115,,948.0,Heart,,1,1
7273,50594,In vivo,BAO_0000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,,N,Intermediate,A,10090.0,CHEMBL621116,,948.0,Heart,,1,1
7274,50594,In vivo,BAO_0000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,,N,Intermediate,A,10090.0,CHEMBL621117,,948.0,Heart,,1,1
7275,50594,In vivo,BAO_0000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,,N,Intermediate,A,10090.0,CHEMBL621118,,2113.0,Kidney,,1,1
7276,50594,In vivo,BAO_0000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,,,N,Intermediate,A,10090.0,CHEMBL621119,,2113.0,Kidney,,1,1
7277,50594,In vivo,BAO_0000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,,N,Intermediate,A,10090.0,CHEMBL621120,,2113.0,Kidney,,1,1
7278,50594,In vivo,BAO_0000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,,N,Intermediate,A,10090.0,CHEMBL621757,,2113.0,Kidney,,1,1
7279,50594,In vivo,BAO_0000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,,N,Intermediate,A,10090.0,CHEMBL621758,,2113.0,Kidney,,1,1
7280,50594,In vivo,BAO_0000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,,N,Intermediate,A,10090.0,CHEMBL621759,,2113.0,Kidney,,1,1
7281,50594,In vivo,BAO_0000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,,N,Intermediate,A,10090.0,CHEMBL621760,,2113.0,Kidney,,1,1
7282,50594,In vivo,BAO_0000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,,N,Intermediate,A,10090.0,CHEMBL621761,,2107.0,Liver,,1,1
7283,50594,In vivo,BAO_0000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,,N,Intermediate,A,10090.0,CHEMBL621762,,2107.0,Liver,,1,1
7284,50594,In vivo,BAO_0000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,,N,Intermediate,A,10090.0,CHEMBL621763,,2107.0,Liver,,1,1
7285,50594,In vivo,BAO_0000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,,N,Intermediate,A,10090.0,CHEMBL624502,,2107.0,Liver,,1,1
7286,50594,In vivo,BAO_0000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,,N,Intermediate,A,10090.0,CHEMBL624503,,2107.0,Liver,,1,1
7287,50594,In vivo,BAO_0000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,,N,Intermediate,A,10090.0,CHEMBL624504,,2107.0,Liver,,1,1
7288,50594,In vivo,BAO_0000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,,N,Intermediate,A,10090.0,CHEMBL624505,,2107.0,Liver,,1,1
7289,50594,In vivo,BAO_0000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,,N,Intermediate,A,10090.0,CHEMBL624506,,2048.0,Lung,,1,1
7290,81034,,BAO_0000219,478.0,A2780,In vitro cytotoxicity against A2780 (human ovarian cancer),,,N,Intermediate,F,9606.0,CHEMBL624507,,,,,1,1
7291,81034,,BAO_0000219,478.0,A2780,In vitro cytotoxicity against the paclitaxel sensitive human breast carcinoma cell line A2780,,,N,Intermediate,F,9606.0,CHEMBL624508,,,,,1,1
7292,81034,,BAO_0000219,478.0,A2780,In vitro cytotoxicity against. ovarian carcinoma cell line A2780.,,,N,Intermediate,F,9606.0,CHEMBL624509,,,,,1,1
7293,81034,,BAO_0000219,478.0,A2780,In vitro cytotoxicity against. ovarian carcinoma cell line A2780cisR (cisplatin resistant counter part of A2780).,,,N,Intermediate,F,9606.0,CHEMBL624510,,,,,1,1
7294,81034,,BAO_0000219,478.0,A2780,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cell line,,,N,Expert,F,9606.0,CHEMBL875956,,,,,1,1
7295,81034,,BAO_0000219,478.0,A2780,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cisplatin resistant cell line,,,N,Expert,F,9606.0,CHEMBL839885,,,,,1,1
7296,81034,,BAO_0000219,478.0,A2780,In vitro cytotoxicity against A2780 ovarian cells using the sulforhodamine B(SRB) assay.,,,N,Expert,F,9606.0,CHEMBL624511,,,,,1,1
7297,81034,,BAO_0000219,478.0,A2780,In vitro cytotoxicity against A2780 cell line,,,N,Intermediate,F,9606.0,CHEMBL624512,,,,,1,1
7298,81034,,BAO_0000219,478.0,A2780,In vitro growth inhibitory activity against A2780 human ovarium carcinoma cell line was determined,,,N,Intermediate,F,9606.0,CHEMBL624513,,,,,1,1
7299,81034,,BAO_0000219,478.0,A2780,In vitro inhibitory activity against human ovarian cancer A2780 cell line,,,N,Intermediate,F,9606.0,CHEMBL624514,,,,,1,1
7300,81034,,BAO_0000218,478.0,A2780,In vivo cytotoxic concentration of compound against A2780 cell line after 72 hr exposure,,,N,Intermediate,F,9606.0,CHEMBL618547,,,,,1,1
7301,81034,,BAO_0000219,478.0,A2780,"Inhibition of cell growth in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant)using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay",,,N,Intermediate,F,9606.0,CHEMBL618548,,,,,1,1
7302,81034,,BAO_0000219,478.0,A2780,Inhibition of tubulin polymerization in analogy of ca.,,,N,Intermediate,F,9606.0,CHEMBL618549,,,,,1,1
7303,81034,,BAO_0000219,478.0,A2780,Inhibitory activity against ovarian tumor cell line A2780 after 72 hr continuous exposure to compound,,,N,Intermediate,F,9606.0,CHEMBL618550,,,,,1,1
7304,81034,,BAO_0000219,478.0,A2780,Cytotoxic effect in ovarian cancer cell line (A2780),,,N,Expert,F,9606.0,CHEMBL618551,,,,,1,1
7305,81034,,BAO_0000219,478.0,A2780,Tested for cytotoxicity against Ovarian carcinoma parental type A2780 cell line expressing MDR-1 (-) gene,,,N,Intermediate,F,9606.0,CHEMBL618552,,,,,1,1
7306,81034,,BAO_0000219,478.0,A2780,Tested for the cytotoxicity in A2780 ovarian cell line,,,N,Intermediate,F,9606.0,CHEMBL618553,,,,,1,1
7307,81034,,BAO_0000219,478.0,A2780,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),,,N,Intermediate,F,9606.0,CHEMBL618554,,,,,1,1
7308,81034,,BAO_0000219,478.0,A2780,The compound was tested for cytotoxic activity against A2780/Cs cell line(human ovarian carcinoma,,,N,Intermediate,F,9606.0,CHEMBL618555,,,,,1,1
7309,80017,,BAO_0000219,481.0,A2780cisR,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma,,,N,Intermediate,F,,CHEMBL618556,,,,,1,1
7310,80017,,BAO_0000219,481.0,A2780cisR,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),,,N,Intermediate,F,,CHEMBL618557,,,,,1,1
7311,80017,,BAO_0000219,481.0,A2780cisR,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ); ND means no data,,,N,Intermediate,F,,CHEMBL618558,,,,,1,1
7312,80017,,BAO_0000219,481.0,A2780cisR,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma),,,N,Intermediate,F,,CHEMBL618559,,,,,1,1
7313,81034,,BAO_0000218,478.0,A2780,In vivo log of cells killed after administration of compound in A2780 cell line,,,N,Intermediate,F,9606.0,CHEMBL618560,,,,,1,1
7314,81034,In vivo,BAO_0000218,478.0,A2780,Compound was tested in vivo for maximum tolerated dose after i.v. administration twice a day for 5 days in A2780 cell line,,,N,Intermediate,F,9606.0,CHEMBL618561,,,,,1,1
7315,81034,,BAO_0000219,478.0,A2780,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.;NA means not active,,,N,Intermediate,F,9606.0,CHEMBL618562,,,,,1,1
7316,81034,,BAO_0000219,478.0,A2780,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines (at 5 uM );NA means not active,,,N,Intermediate,F,9606.0,CHEMBL618563,,,,,1,1
7317,81034,,BAO_0000219,478.0,A2780,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines; ND means no data,,,N,Intermediate,F,9606.0,CHEMBL618564,,,,,1,1
7318,81034,,BAO_0000219,478.0,A2780,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines. (at 5 uM ); ND means no data,,,N,Intermediate,F,9606.0,CHEMBL618565,,,,,1,1
7319,81034,,BAO_0000218,478.0,A2780,Optimal dose required to inhibit human ovarian A2780 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q4dX2),,,N,Intermediate,F,9606.0,CHEMBL618566,,,,,1,1
7320,81034,,BAO_0000219,478.0,A2780,Resistance factor was determined as IC50 cisplatin-resistant/parent for human A2780 ovarian cell line,,,N,Intermediate,F,9606.0,CHEMBL618567,,,,,1,1
7321,81034,,BAO_0000219,478.0,A2780,Resistance index is IC50 ratio of A2780 cell line and A2780cisR cell line,,,N,Expert,F,9606.0,CHEMBL618568,,,,,1,1
7322,81034,,BAO_0000219,478.0,A2780,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,,,N,Expert,F,9606.0,CHEMBL618569,,,,,1,1
7323,81034,,BAO_0000219,478.0,A2780,Compound was tested for Tubulin polymerization inhibition by using human ovarian cancer cell lines.,,,N,Intermediate,F,9606.0,CHEMBL621857,,,,,1,1
7324,81034,,BAO_0000219,478.0,A2780,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.,,,N,Intermediate,F,9606.0,CHEMBL621858,,,,,1,1
7325,81034,,BAO_0000219,478.0,A2780,Percent of Tubulin polymerization inhibition by using human ovarian cancer cell lines at a concentration of 5 uM,,,N,Intermediate,F,9606.0,CHEMBL621859,,,,,1,1
7326,81034,,BAO_0000219,478.0,A2780,"Colchicine Binding Inhibition ( CBI ) by using human ovarian cancer cell lines at 5 uM, (values are mean of 9 over 4 concentrations +/- SD)",,,N,Intermediate,F,9606.0,CHEMBL621860,,,,,1,1
7327,81034,,BAO_0000219,478.0,A2780,Compound tested for colchicine Binding Inhibition by using human ovarian cancer cell line (at 5 uM ),,,N,Intermediate,F,9606.0,CHEMBL621861,,,,,1,1
7328,81034,,BAO_0000219,478.0,A2780,"Tested for colchicine binding inhibition, using human ovarian cancer cell lines (at 5 uM )",,,N,Expert,F,9606.0,CHEMBL621862,,,,,1,1
7329,81034,,BAO_0000219,478.0,A2780,Compound tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),,,N,Intermediate,F,9606.0,CHEMBL621863,,,,,1,1
7330,81034,,BAO_0000219,478.0,A2780,Compound was tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),,,N,Intermediate,F,9606.0,CHEMBL621864,,,,,1,1
7331,81034,,BAO_0000219,478.0,A2780,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell line (at 5 uM ),,,N,Intermediate,F,9606.0,CHEMBL621865,,,,,1,1
7332,81034,,BAO_0000219,478.0,A2780,In vitro antiproliferative activity against A2780 cell line,,,N,Intermediate,F,10090.0,CHEMBL621866,,,,,1,1
7333,81034,,BAO_0000219,478.0,A2780,Maximum tolerated dose in A2780 tumor in mice after intraperitoneal administration daily for 8 days,,,N,Expert,F,10090.0,CHEMBL621867,,,,,1,1
7334,81034,,BAO_0000219,478.0,A2780,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C after 96 hr,,,N,Intermediate,F,9606.0,CHEMBL621868,,,,,1,1
7335,81034,,BAO_0000219,478.0,A2780,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C for 96 hr,,,N,Intermediate,F,9606.0,CHEMBL875282,,,,,1,1
7336,50588,,BAO_0000218,,,Vc value in dog after IV administration at a dose of 5 mg/kg,,,N,Intermediate,A,9615.0,CHEMBL621869,,,,,1,1
7337,50588,In vivo,BAO_0000218,,,Half life period in dog after IV administration at a dose of 5 mg/kg,,,N,Intermediate,A,9615.0,CHEMBL621870,,,,,1,1
7338,22224,,BAO_0000019,,,Area under curve was determine after peroral administration at 10 mpk in Rhesus,,,U,Autocuration,A,9527.0,CHEMBL621871,,,,,0,1
7339,22224,,BAO_0000218,,,AUC (area under curve) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,U,Autocuration,A,9527.0,CHEMBL621243,,1969.0,Plasma,,0,1
7340,22224,,BAO_0000218,,,AUC (area under curve) compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,U,Autocuration,A,9527.0,CHEMBL621244,,1969.0,Plasma,,0,1
7341,22224,In vivo,BAO_0000218,,,Area under curve determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,,,U,Autocuration,A,9541.0,CHEMBL621245,,,,,0,1
7342,22224,In vivo,BAO_0000218,,,Area under curve determined after peroral administration at a dose of 10 mg/kg in cynomolgus monkey,,,U,Autocuration,A,9541.0,CHEMBL621246,,,,,0,1
7343,22224,In vivo,BAO_0000218,,,Area under curve determined after peroral administration at a dose of 3 mg/kg in cynomolgus monkey,,,U,Autocuration,A,9541.0,CHEMBL621247,,,,,0,1
7344,22224,In vivo,BAO_0000218,,,Oral Bioavailability in rat,,,U,Autocuration,A,10116.0,CHEMBL618386,,,,,0,1
7345,22224,,BAO_0000218,,,Area under curve was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,,U,Autocuration,A,9527.0,CHEMBL618387,,,,,0,1
7346,22224,,BAO_0000218,,,Area under curve value in monkey at a dose of 5 mg/kg,,,U,Autocuration,A,9527.0,CHEMBL618388,,,,,0,1
7347,22224,,BAO_0000218,,,Area under curve was determined in monkey after a 3 mg/kg of oral dose,,,U,Autocuration,A,9527.0,CHEMBL618389,,,,,0,1
7348,22224,,BAO_0000019,,,Area under curve was determined using trapezoidal rule after intravenous administration in cynomolgus monkeys,,,U,Autocuration,A,9527.0,CHEMBL618574,,,,,0,1
7349,22224,,BAO_0000019,,,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys,,,U,Autocuration,A,9527.0,CHEMBL618575,,,,,0,1
7350,22224,,BAO_0000019,,,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys; ND means Not determined,,,U,Autocuration,A,9527.0,CHEMBL618576,,,,,0,1
7351,22224,,BAO_0000218,,,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in monkey,,,U,Autocuration,A,9527.0,CHEMBL618577,,,,,0,1
7352,22224,,BAO_0000218,,,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in monkey,,,U,Autocuration,A,9527.0,CHEMBL876487,,,,,0,1
7353,22224,,BAO_0000218,,,Area under the curve was measured in monkey after an iv dose of 1 mg/kg,,,U,Autocuration,A,9527.0,CHEMBL618578,,,,,0,1
7354,22224,,BAO_0000218,,,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,,U,Autocuration,A,9527.0,CHEMBL618579,,,,,0,1
7355,22224,,BAO_0000019,,,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,,U,Autocuration,A,9527.0,CHEMBL618580,,,,,0,1
7356,22224,,BAO_0000218,,,Pharmacokinetic parameter Cmax was measured after administration into monkey at 3 mg/kg,,,U,Autocuration,A,9527.0,CHEMBL618581,,,,,0,1
7357,22224,,BAO_0000218,,,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in cynomolgus monkeys (0 to 24 hr) p.o.,,,U,Autocuration,A,9527.0,CHEMBL618582,,,,,0,1
7358,22224,,BAO_0000218,,,Area under curve value 24 hr after 2 mg/kg iv administration in monkeys,,,U,Autocuration,A,9527.0,CHEMBL618583,,,,,0,1
7359,22224,,BAO_0000218,,,Area under curve value 24 hr after 2 mg/kg oral administration in monkeys,,,U,Autocuration,A,9527.0,CHEMBL618584,,,,,0,1
7360,22224,In vivo,BAO_0000218,,,Oral AUCN in monkey (dosed at 0.5 mpk iv ),,,U,Autocuration,A,9527.0,CHEMBL618585,,,,,0,1
7361,22224,,BAO_0000218,,,Bioavailability was reported in cynomolgus monkeys (ratio of AUC in oral administration to that of intravenous administration),,,U,Autocuration,A,9527.0,CHEMBL618586,,,,,0,1
7362,22224,In vivo,BAO_0000218,,,Half life compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,U,Autocuration,A,9527.0,CHEMBL618587,,,,,0,1
7363,22224,In vivo,BAO_0000218,,,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,U,Autocuration,A,9527.0,CHEMBL618588,,,,,0,1
7364,22224,,BAO_0000019,,,Binding towards monkey plasma protein at 10 uM,,,U,Autocuration,A,9527.0,CHEMBL618589,,,,,0,1
7365,22224,,BAO_0000019,,,Binding towards monkey plasma protein at 100 uM,,,U,Autocuration,A,9527.0,CHEMBL618590,,,,,0,1
7366,22224,In vivo,BAO_0000218,,,Apparent bioavailability in squirrel monkey was determined,,,U,Autocuration,A,9527.0,CHEMBL872262,,,,,0,1
7367,22224,In vivo,BAO_0000218,,,Bioavailability was determined after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,,,U,Autocuration,A,9527.0,CHEMBL618591,,,,,0,1
7368,22224,In vivo,BAO_0000218,,,Bioavailability in monkey (dose 2 mg/kg),,,U,Autocuration,A,9443.0,CHEMBL618592,,,,,0,1
7369,22224,In vivo,BAO_0000218,,,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for bioavailability after administration into monkey at 3 mg/kg,,,U,Autocuration,A,9527.0,CHEMBL876488,,,,,0,1
7370,22224,In vivo,BAO_0000218,,,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,,U,Autocuration,A,9527.0,CHEMBL618593,,,,,0,1
7371,22224,In vivo,BAO_0000218,,,Bioavailability in monkey (i.d. dosing),,,U,Autocuration,A,9443.0,CHEMBL618594,,,,,0,1
7372,22224,In vivo,BAO_0000218,,,Oral bioavailability after 5 mg/kg in cynomolgus monkey was determined,,,U,Autocuration,A,9527.0,CHEMBL618595,,,,,0,1
7373,22224,,BAO_0000019,,,Clearance of the drug was measured in cynomolgus,,,U,Autocuration,A,9527.0,CHEMBL621469,,,,,0,1
7374,22224,In vivo,BAO_0000218,,,Clearance was estimated in two squirrel monkeys after iv administration at 5 mg/kg,,,U,Autocuration,A,9527.0,CHEMBL621470,,,,,0,1
7375,22224,In vivo,BAO_0000218,,,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,,U,Autocuration,A,9527.0,CHEMBL621471,,,,,0,1
7376,22224,In vivo,BAO_0000218,,,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,,,U,Autocuration,A,9544.0,CHEMBL621472,,1969.0,Plasma,,0,1
7377,22224,In vivo,BAO_0000218,,,Plasma clearance in rhesus monkey was determined,,,U,Autocuration,A,9527.0,CHEMBL621473,,,,,0,1
7378,22224,In vivo,BAO_0000218,,,Plasma clearance in monkey after administration of 1 mg/kg iv,,,U,Autocuration,A,9527.0,CHEMBL621474,,,,,0,1
7379,22224,In vivo,BAO_0000218,,,Plasma clearance in cynomolgus monkey,,,U,Autocuration,A,9527.0,CHEMBL621475,,,,,0,1
7380,22224,In vivo,BAO_0000218,,,Plasma clearance after oral administration (2.5 mg/kg) in monkey was determined,,,U,Autocuration,A,9527.0,CHEMBL621476,,,,,0,1
7381,22224,In vivo,BAO_0000218,,,Plasma clearance after peroral administration at 10 mpk in Rhesus,,,U,Autocuration,A,9527.0,CHEMBL624290,,,,,0,1
7382,22224,In vivo,BAO_0000218,,,The total clearance was determined after intravenous administration in cynomolgus monkeys,,,U,Autocuration,A,9527.0,CHEMBL624291,,,,,0,1
7383,22224,In vivo,BAO_0000218,,,The total clearance was determined after oral administration in cynomolgus monkeys; NA means Not applicable,,,U,Autocuration,A,9527.0,CHEMBL624292,,,,,0,1
7384,22224,In vivo,BAO_0000218,,,The total clearance was determined after oral administration in cynomolgus monkeys; NA means not applicable,,,U,Autocuration,A,9527.0,CHEMBL624293,,,,,0,1
7385,22224,In vivo,BAO_0000218,,,Tested for Clearance upon iv administration to african green monkey,,,U,Autocuration,A,9527.0,CHEMBL624294,,,,,0,1
7386,22224,In vivo,BAO_0000218,,,Clearance in monkey,,,U,Autocuration,A,9527.0,CHEMBL624295,,,,,0,1
7387,50588,In vivo,BAO_0000218,,,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,,N,Intermediate,A,9615.0,CHEMBL624296,,,,,1,1
7388,50588,In vivo,BAO_0000218,,,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,,N,Intermediate,A,9615.0,CHEMBL624297,,,,,1,1
7389,50588,In vivo,BAO_0000218,,,Half life was evaluated after intravenous administration to dogs,,,N,Intermediate,A,9615.0,CHEMBL624298,,,,,1,1
7390,50588,,BAO_0000218,,,Half life was evaluated in dog,,,N,Intermediate,A,9615.0,CHEMBL624299,,,,,1,1
7391,50588,,BAO_0000218,,,Half life was evaluated in dog,,,N,Intermediate,A,9615.0,CHEMBL624300,,,,,1,1
7392,50588,In vivo,BAO_0000218,,,Half life period (t1/2) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,,,N,Intermediate,A,9615.0,CHEMBL624301,,,,,1,1
7393,50588,In vivo,BAO_0000218,,,Half life period after intravenous administration (1 mg/kg) was determined in dog (in vivo),,,N,Intermediate,A,9615.0,CHEMBL624302,,,,,1,1
7394,50588,In vivo,BAO_0000218,,,Half life period after intravenous administration in dog,,,N,Intermediate,A,9615.0,CHEMBL876026,,,,,1,1
7395,50588,In vivo,BAO_0000218,,,Half life period after oral administration (2.5 mg/kg) in dog was determined,,,N,Intermediate,A,9615.0,CHEMBL624303,,,,,1,1
7396,50588,,BAO_0000218,,,Half life period at a dose of 1 uM/kg in dog was determined,,,N,Intermediate,A,9615.0,CHEMBL624304,,,,,1,1
7397,50588,In vivo,BAO_0000218,,,Half life period was determine after peroral administration at 10 mpk in dog,,,N,Intermediate,A,9615.0,CHEMBL624305,,,,,1,1
7398,50588,In vivo,BAO_0000218,,,Half life period was determine after peroral administration at 5 mpk in dog,,,N,Intermediate,A,9615.0,CHEMBL624306,,,,,1,1
7399,50588,,BAO_0000218,,,Half life period was determined,,,N,Intermediate,A,9615.0,CHEMBL624307,,,,,1,1
7400,50588,,BAO_0000218,,,Half life period was determined,,,N,Intermediate,A,9615.0,CHEMBL624308,,,,,1,1
7401,50588,In vivo,BAO_0000218,,,Half life period by iv administration in dog at a dose of 6 mg/kg,,,N,Intermediate,A,9615.0,CHEMBL624309,,,,,1,1
7402,50588,,BAO_0000218,,,Half life period was evaluated in dog,,,N,Intermediate,A,9615.0,CHEMBL624310,,,,,1,1
7403,50588,In vivo,BAO_0000218,,,Half life period was determined in Beagle dog at a dose of 1 mg/kg by iv administration,,,N,Intermediate,A,9615.0,CHEMBL625003,,,,,1,1
7404,50588,In vivo,BAO_0000218,,,Half life period was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),,,N,Intermediate,A,9615.0,CHEMBL625004,,,,,1,1
7405,50588,In vivo,BAO_0000218,,,Half life time after intravenous administration (0.5 mg/kg) was determined in dog,,,N,Intermediate,A,9615.0,CHEMBL625005,,,,,1,1
7406,50588,In vivo,BAO_0000218,,,Half-life period by oral administration at a dose of 10 uM/kg in dog was determined,,,N,Intermediate,A,9615.0,CHEMBL873813,,,,,1,1
7407,50588,In vivo,BAO_0000218,,,Half-life after oral dose of compound at 3 mg/kg in dogs,,,N,Intermediate,A,9615.0,CHEMBL625006,,,,,1,1
7408,50588,In vivo,BAO_0000218,,,Half-life of compound in dog following p.o. administration of 0.5 mg/kg,,,N,Intermediate,A,9615.0,CHEMBL625007,,,,,1,1
7409,50588,In vivo,BAO_0000218,,,Half-life of compound in dog following p.o. administration of 0.9 mg/kg,,,N,Intermediate,A,9615.0,CHEMBL876027,,,,,1,1
7410,50588,In vivo,BAO_0000218,,,Half-life of compound in dog following p.o. administration of 0.95 mg/kg,,,N,Intermediate,A,9615.0,CHEMBL625008,,,,,1,1
7411,50588,In vivo,BAO_0000218,,,Half-life of compound in dog following p.o. administration of 1 mg/kg,,,N,Intermediate,A,9615.0,CHEMBL625009,,,,,1,1
7412,50588,,BAO_0000218,,,Half-life of compound in plasma of dog was determined,,,N,Intermediate,A,9615.0,CHEMBL625010,,1969.0,Plasma,,1,1
7413,50588,,BAO_0000218,,,Half-life of compound was determined in dogs,,,N,Intermediate,A,9615.0,CHEMBL625011,,,,,1,1
7414,50588,In vivo,BAO_0000218,,,Half-life after administration of 4 mg/Kg oral dose in dog,,,N,Intermediate,A,9615.0,CHEMBL621553,,,,,1,1
7415,50588,In vivo,BAO_0000218,,,Half-life after intravenous administration of 1 mg/kg/h in dog,,,N,Intermediate,A,9615.0,CHEMBL621554,,,,,1,1
7416,50588,,BAO_0000218,,,Half-life in Dog,,,N,Intermediate,A,9615.0,CHEMBL621555,,,,,1,1
7417,50588,,BAO_0000218,,,Half-life in Dog,,,N,Intermediate,A,9615.0,CHEMBL621556,,,,,1,1
7418,50588,,BAO_0000218,,,Half-life in dog,,,N,Intermediate,A,9615.0,CHEMBL621557,,,,,1,1
7419,50588,In vivo,BAO_0000218,,,Half-life in dog after oral administration at 1 mg/kg,,,N,Intermediate,A,9615.0,CHEMBL621558,,,,,1,1
7420,50588,In vivo,BAO_0000218,,,Half-life in dog after oral administration at 1 mg/kg; nd is not determined,,,N,Intermediate,A,9615.0,CHEMBL621559,,,,,1,1
7421,50588,,BAO_0000218,,,Half-life in dogs,,,N,Intermediate,A,9615.0,CHEMBL621560,,,,,1,1
7422,50588,,BAO_0000218,,,Half-life in dogs; ND indicates not determined,,,N,Intermediate,A,9615.0,CHEMBL876028,,,,,1,1
7423,50588,,BAO_0000218,,,Half-life in plasma of dog,,,N,Intermediate,A,9615.0,CHEMBL621561,,1969.0,Plasma,,1,1
7424,50588,,BAO_0000218,,,Half-life in plasma of dog at dose of 3-10 mgkg,,,N,Intermediate,A,9615.0,CHEMBL621562,,1969.0,Plasma,,1,1
7425,50588,In vivo,BAO_0000218,,,Half-life was evaluated after i.v. administration in dog at a dose of 1 mg/kg,,,N,Intermediate,A,9615.0,CHEMBL621563,,,,,1,1
7426,50588,In vivo,BAO_0000218,,,Half-life was measured in dog after an iv dose of 1 mg/kg,,,N,Intermediate,A,9615.0,CHEMBL621564,,,,,1,1
7427,50588,In vivo,BAO_0000218,,,Half-life was measured in dogs after an oral dose of 10 uM/kg,,,N,Intermediate,A,9615.0,CHEMBL621565,,,,,1,1
7428,50588,In vivo,BAO_0000218,,,Half-life in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,,,N,Intermediate,A,9615.0,CHEMBL621566,,,,,1,1
7429,50588,In vivo,BAO_0000218,,,Half-life in vivo in dog by intravenous administration at a dose of 1 mg/kg,,,N,Intermediate,A,9615.0,CHEMBL621567,,,,,1,1
7430,50588,In vivo,BAO_0000218,,,Half-life of the compound after 0.3 mg/kg po administration in dog,,,N,Intermediate,A,9615.0,CHEMBL622978,,,,,1,1
7431,50588,In vivo,BAO_0000218,,,Half-life period after intravenous administration of 0.5 mg/kg in dog was determined,,,N,Intermediate,A,9615.0,CHEMBL873814,,,,,1,1
7432,50588,In vivo,BAO_0000218,,,Half-life period after intravenous administration of 1.0 mg/kg in dog was determined,,,N,Intermediate,A,9615.0,CHEMBL623219,,,,,1,1
7433,50588,In vivo,BAO_0000218,,,Half-life period after peroral administration of 0.2 mg/kg in dog was determined,,,N,Intermediate,A,9615.0,CHEMBL624477,,,,,1,1
7434,50588,,BAO_0000218,,,t1/2 in dog,,,N,Intermediate,A,9615.0,CHEMBL624478,,,,,1,1
7435,50588,,BAO_0000218,,,Half-life period measured in dogs,,,N,Intermediate,A,9615.0,CHEMBL624479,,,,,1,1
7436,50588,In vivo,BAO_0000218,,,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,,,N,Intermediate,A,9615.0,CHEMBL624480,,,,,1,1
7437,50588,In vivo,BAO_0000218,,,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,,N,Intermediate,A,9615.0,CHEMBL623595,,,,,1,1
7438,50588,In vivo,BAO_0000218,,,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,,N,Intermediate,A,9615.0,CHEMBL623596,,,,,1,1
7439,50588,In vitro,BAO_0000218,,,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in dog plasma",,,N,Intermediate,A,9615.0,CHEMBL623597,,1969.0,Plasma,,1,1
7440,50588,In vivo,BAO_0000218,,,In vivo half life period was calculated at 1 mg/kg in dog,,,N,Intermediate,A,9615.0,CHEMBL623598,,,,,1,1
7441,50588,In vivo,BAO_0000218,,,In vivo half life period was calculated at 1 mg/kg in dog; ND=Not determined,,,N,Intermediate,A,9615.0,CHEMBL623599,,,,,1,1
7442,50588,In vivo,BAO_0000218,,,Longer half-life in dog (i.v.) at 0.5 mpk,,,N,Intermediate,A,9615.0,CHEMBL623600,,,,,1,1
7443,50588,In vivo,BAO_0000218,,,Oral bioavailability in dog (dose 5 uM/kg),,,N,Intermediate,A,9615.0,CHEMBL623601,,,,,1,1
7444,50588,In vivo,BAO_0000218,,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,,,N,Intermediate,A,9615.0,CHEMBL623602,,,,,1,1
7445,50588,In vivo,BAO_0000218,,,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,,,N,Intermediate,A,9615.0,CHEMBL623603,,,,,1,1
7446,50588,In vivo,BAO_0000218,,,Bioavailability in dog (dose 1 mg/kg i.v.),,,N,Intermediate,A,9615.0,CHEMBL623604,,,,,1,1
7447,50594,In vivo,BAO_0000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,,,N,Intermediate,A,10090.0,CHEMBL623605,,2048.0,Lung,,1,1
7448,50594,In vivo,BAO_0000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,,N,Intermediate,A,10090.0,CHEMBL623606,,2048.0,Lung,,1,1
7449,50594,In vivo,BAO_0000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,,N,Intermediate,A,10090.0,CHEMBL623607,,2048.0,Lung,,1,1
7450,50594,In vivo,BAO_0000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,,N,Intermediate,A,10090.0,CHEMBL623608,,2048.0,Lung,,1,1
7451,50594,In vivo,BAO_0000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,,N,Intermediate,A,10090.0,CHEMBL623609,,2048.0,Lung,,1,1
7452,50594,In vivo,BAO_0000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,,N,Intermediate,A,10090.0,CHEMBL623610,,2048.0,Lung,,1,1
7453,50594,In vivo,BAO_0000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,,N,Intermediate,A,10090.0,CHEMBL623611,,2385.0,Muscle tissue,,1,1
7454,50594,In vivo,BAO_0000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,,,N,Intermediate,A,10090.0,CHEMBL623612,,2385.0,Muscle tissue,,1,1
7455,50594,In vivo,BAO_0000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,,N,Intermediate,A,10090.0,CHEMBL623613,,2385.0,Muscle tissue,,1,1
7456,50594,In vivo,BAO_0000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,,N,Intermediate,A,10090.0,CHEMBL623614,,2385.0,Muscle tissue,,1,1
7457,50594,In vivo,BAO_0000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,,N,Intermediate,A,10090.0,CHEMBL623615,,2385.0,Muscle tissue,,1,1
7458,50594,In vivo,BAO_0000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,,N,Intermediate,A,10090.0,CHEMBL623616,,2385.0,Muscle tissue,,1,1
7459,50594,In vivo,BAO_0000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,,N,Intermediate,A,10090.0,CHEMBL623617,,2385.0,Muscle tissue,,1,1
7460,50594,In vivo,BAO_0000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,,N,Intermediate,A,10090.0,CHEMBL875944,,14.0,Zone of skin,,1,1
7461,50594,In vivo,BAO_0000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,,N,Intermediate,A,10090.0,CHEMBL623618,,14.0,Zone of skin,,1,1
7462,50594,In vivo,BAO_0000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,,N,Intermediate,A,10090.0,CHEMBL623619,,14.0,Zone of skin,,1,1
7463,50594,In vivo,BAO_0000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,,N,Intermediate,A,10090.0,CHEMBL623620,,14.0,Zone of skin,,1,1
7464,50594,In vivo,BAO_0000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,,N,Intermediate,A,10090.0,CHEMBL623621,,14.0,Zone of skin,,1,1
7465,50594,In vivo,BAO_0000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,,N,Intermediate,A,10090.0,CHEMBL623622,,14.0,Zone of skin,,1,1
7466,50594,In vivo,BAO_0000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,,N,Intermediate,A,10090.0,CHEMBL623623,,14.0,Zone of skin,,1,1
7467,50594,In vivo,BAO_0000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,,N,Intermediate,A,10090.0,CHEMBL623624,,2106.0,Spleen,,1,1
7468,50594,In vivo,BAO_0000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,,N,Intermediate,A,10090.0,CHEMBL618521,,2106.0,Spleen,,1,1
7469,50594,In vivo,BAO_0000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,,N,Intermediate,A,10090.0,CHEMBL618522,,2106.0,Spleen,,1,1
7470,50594,In vivo,BAO_0000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,,N,Intermediate,A,10090.0,CHEMBL618523,,2106.0,Spleen,,1,1
7471,50594,In vivo,BAO_0000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,,N,Intermediate,A,10090.0,CHEMBL618524,,2106.0,Spleen,,1,1
7472,50594,In vivo,BAO_0000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,,N,Intermediate,A,10090.0,CHEMBL618525,,2106.0,Spleen,,1,1
7473,50594,In vivo,BAO_0000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,,N,Intermediate,A,10090.0,CHEMBL624586,,2106.0,Spleen,,1,1
7474,50594,In vivo,BAO_0000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,,N,Intermediate,A,10090.0,CHEMBL624587,,945.0,Stomach,,1,1
7475,50594,In vivo,BAO_0000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,,N,Intermediate,A,10090.0,CHEMBL624588,,945.0,Stomach,,1,1
7476,50594,In vivo,BAO_0000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,,N,Intermediate,A,10090.0,CHEMBL624589,,945.0,Stomach,,1,1
7477,50594,In vivo,BAO_0000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,,N,Intermediate,A,10090.0,CHEMBL624590,,945.0,Stomach,,1,1
7478,50594,In vivo,BAO_0000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,,N,Intermediate,A,10090.0,CHEMBL624591,,945.0,Stomach,,1,1
7479,50594,In vivo,BAO_0000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,,N,Intermediate,A,10090.0,CHEMBL624592,,945.0,Stomach,,1,1
7480,50594,In vivo,BAO_0000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,,N,Intermediate,A,10090.0,CHEMBL624593,,945.0,Stomach,,1,1
7481,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL624594,,,,,1,1
7482,50597,In vivo,BAO_0000218,,,Tested for the bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL624595,,,,,1,1
7483,50597,In vivo,BAO_0000218,,,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),,,N,Intermediate,A,10116.0,CHEMBL624596,,,,,1,1
7484,50597,In vivo,BAO_0000218,,,Bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL624597,,,,,1,1
7485,50597,In vivo,BAO_0000218,,,Bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL624598,,,,,1,1
7486,50597,In vivo,BAO_0000218,,,Bioavailability in rat (dose 3-10 mg/kg),,,N,Intermediate,A,10116.0,CHEMBL624599,,,,,1,1
7487,50597,In vivo,BAO_0000218,,,Bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL875166,,,,,1,1
7488,50597,In vivo,BAO_0000218,,,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,,,N,Intermediate,A,10116.0,CHEMBL624600,,1969.0,Plasma,,1,1
7489,50597,In vivo,BAO_0000218,,,Apparent terminal elimination half-life in rat plasma after administration of 50 mg/kg dose through subcutaneous route,,,N,Intermediate,A,10116.0,CHEMBL624601,,1969.0,Plasma,,1,1
7490,50597,In vivo,BAO_0000218,,,Half life after oral administration was determined in rats at 6 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL624602,,,,,1,1
7491,50597,,BAO_0000218,,,Half life was determined,,,N,Intermediate,A,10116.0,CHEMBL624603,,,,,1,1
7492,50597,In vivo,BAO_0000218,,,Half life the of compound was determined by ''Cr'' assay in rat at a dose of 10 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL624604,,,,,1,1
7493,50597,In vivo,BAO_0000218,,,Plasma half life in rat at oral dose 2.8 mg/mk body weight,,,N,Intermediate,A,10116.0,CHEMBL624605,,1969.0,Plasma,,1,1
7494,50597,,BAO_0000218,,,Half life in rats,,,N,Intermediate,A,10116.0,CHEMBL624606,,,,,1,1
7495,50597,In vivo,BAO_0000218,,,Half-lives were estimated from the elimination phase of the blood conc-time curve after oral administration,,,N,Intermediate,A,10116.0,CHEMBL624607,,178.0,Blood,,1,1
7496,50597,,BAO_0000218,,,Hill coefficient of the compound,,,N,Intermediate,A,10116.0,CHEMBL624608,,,,,1,1
7497,50597,,BAO_0000218,,,Compound was tested for percent hydrolysis in whole blood after a time interval of 0.5 min,,,N,Intermediate,A,10116.0,CHEMBL624609,,178.0,Blood,,1,1
7498,50597,,BAO_0000218,,,Compound was tested for percent hydrolysis in whole blood after a time interval of 180.0 min,,,N,Intermediate,A,10116.0,CHEMBL624610,,178.0,Blood,,1,1
7499,50597,,BAO_0000218,,,Compound was tested for percent hydrolysis in whole blood after a time interval of 2.0 min,,,N,Intermediate,A,10116.0,CHEMBL624611,,178.0,Blood,,1,1
7500,50597,,BAO_0000218,,,Compound was tested for percent hydrolysis in whole blood after a time interval of 5.0 min,,,N,Intermediate,A,10116.0,CHEMBL624612,,178.0,Blood,,1,1
7501,50597,,BAO_0000218,,,Compound was tested for percent hydrolysis in whole blood after a time interval of 60.0 min,,,N,Intermediate,A,10116.0,CHEMBL875167,,178.0,Blood,,1,1
7502,50597,,BAO_0000218,,,Compound was tested for percent hydrolysis in whole blood after a time interval of 7.0 min,,,N,Intermediate,A,10116.0,CHEMBL624613,,178.0,Blood,,1,1
7503,50597,,BAO_0000218,,,"Compound was tested for percent hydrolysis in whole blood, after a time interval of 15.0 min",,,N,Intermediate,A,10116.0,CHEMBL624614,,178.0,Blood,,1,1
7504,50597,,BAO_0000218,,,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,,,N,Intermediate,A,10116.0,CHEMBL624392,,,,,1,1
7505,50597,In vivo,BAO_0000218,,,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/organ,,,N,Intermediate,A,10116.0,CHEMBL624393,,955.0,Brain,,1,1
7506,50597,In vivo,BAO_0000218,,,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/organ,,,N,Intermediate,A,10116.0,CHEMBL624394,,955.0,Brain,,1,1
7507,50597,In vivo,BAO_0000218,,,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/organ,,,N,Intermediate,A,10116.0,CHEMBL624395,,955.0,Brain,,1,1
7508,50597,In vivo,BAO_0000218,,,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/organ,,,N,Intermediate,A,10116.0,CHEMBL624396,,955.0,Brain,,1,1
7509,50597,In vivo,BAO_0000218,,,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/organ,,,N,Intermediate,A,10116.0,CHEMBL624397,,955.0,Brain,,1,1
7510,50597,In vivo,BAO_0000218,,,Biodistribution of [123I]-label in rat thyroid was reported at 0.33 hr post injection. Value shown is %ID/organ,,,N,Intermediate,A,10116.0,CHEMBL624398,,2046.0,Thyroid gland,,1,1
7511,50597,In vivo,BAO_0000218,,,Biodistribution of [123I]-label in rat thyroid was reported at 1 hr post injection. Value shown is %ID/organ,,,N,Intermediate,A,10116.0,CHEMBL624399,,2046.0,Thyroid gland,,1,1
7512,50597,In vivo,BAO_0000218,,,Biodistribution of [123I]-label in rat thyroid was reported at 2 hr post injection. Value shown is %ID/organ,,,N,Intermediate,A,10116.0,CHEMBL624400,,2046.0,Thyroid gland,,1,1
7513,50597,In vivo,BAO_0000218,,,Biodistribution of [123I]-label in rat thyroid was reported at 24 hr post injection. Value shown is %ID/organ,,,N,Intermediate,A,10116.0,CHEMBL624401,,2046.0,Thyroid gland,,1,1
7514,50597,In vivo,BAO_0000218,,,Biodistribution of [123I]-label in rat thyroid was reported at 4 hr post injection. Value shown is %ID/organ,,,N,Intermediate,A,10116.0,CHEMBL624402,,2046.0,Thyroid gland,,1,1
7515,50597,In vivo,BAO_0000218,,,Biodistribution in normal rat blood in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,,N,Intermediate,A,10116.0,CHEMBL624403,,178.0,Blood,,1,1
7516,50597,In vivo,BAO_0000218,,,Biodistribution in normal rat blood in the presence of 0.01 M Gd/0.05 M lig,,,N,Intermediate,A,10116.0,CHEMBL624404,,178.0,Blood,,1,1
7517,50597,In vivo,BAO_0000218,,,Biodistribution in normal rat blood in the presence of NAC Gd 0.01 M lig at 2 hr,,,N,Intermediate,A,10116.0,CHEMBL624405,,178.0,Blood,,1,1
7518,50597,In vivo,BAO_0000218,,,Biodistribution in normal rat bone in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,,N,Intermediate,A,10116.0,CHEMBL624406,,10000001.0,Bone,,1,1
7519,50597,In vivo,BAO_0000218,,,Biodistribution in normal rat bone in the presence of 0.01 M Gd/0.05 M lig,,,N,Intermediate,A,10116.0,CHEMBL624407,,10000001.0,Bone,,1,1
7520,50597,In vivo,BAO_0000218,,,Biodistribution in normal rat bone in the presence of NAC Gd 0.01 M lig at 2 hr,,,N,Intermediate,A,10116.0,CHEMBL624408,,10000001.0,Bone,,1,1
7521,50597,In vivo,BAO_0000218,,,Biodistribution in normal rat heart in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,,N,Intermediate,A,10116.0,CHEMBL618644,,948.0,Heart,,1,1
7522,50597,In vivo,BAO_0000218,,,Biodistribution in normal rat heart in the presence of 0.01 M Gd/0.05 M lig,,,N,Intermediate,A,10116.0,CHEMBL618645,,948.0,Heart,,1,1
7523,50597,In vivo,BAO_0000218,,,Biodistribution in normal rat heart in the presence of NAC Gd 0.01 M lig at 2 hr,,,N,Intermediate,A,10116.0,CHEMBL618646,,948.0,Heart,,1,1
7524,50597,In vivo,BAO_0000218,,,Biodistribution in normal rat kidney in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,,N,Intermediate,A,10116.0,CHEMBL618647,,2113.0,Kidney,,1,1
7525,50597,In vivo,BAO_0000218,,,Biodistribution in normal rat kidney in the presence of 0.01 M Gd/0.05 M lig,,,N,Intermediate,A,10116.0,CHEMBL618648,,2113.0,Kidney,,1,1
7526,50597,In vivo,BAO_0000218,,,Biodistribution in normal rat kidney in the presence of NAC Gd 0.01 M lig at 2 hr,,,N,Intermediate,A,10116.0,CHEMBL618649,,2113.0,Kidney,,1,1
7527,50597,In vivo,BAO_0000218,,,Biodistribution in normal rat liver in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,,N,Intermediate,A,10116.0,CHEMBL618650,,2107.0,Liver,,1,1
7528,50597,In vivo,BAO_0000218,,,Biodistribution in normal rat liver in the presence of 0.01 M Gd/0.05 M lig,,,N,Intermediate,A,10116.0,CHEMBL618651,,2107.0,Liver,,1,1
7529,50597,In vivo,BAO_0000218,,,Biodistribution in normal rat liver in the presence of NAC Gd 0.01 M lig at 2 hr,,,N,Intermediate,A,10116.0,CHEMBL876497,,2107.0,Liver,,1,1
7530,50597,In vivo,BAO_0000218,,,Biodistribution in normal rat lung in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,,N,Intermediate,A,10116.0,CHEMBL618652,,2048.0,Lung,,1,1
7531,50597,In vivo,BAO_0000218,,,Biodistribution in normal rat lung in the presence of 0.01 M Gd/0.05 M lig,,,N,Intermediate,A,10116.0,CHEMBL618653,,2048.0,Lung,,1,1
7532,50597,In vivo,BAO_0000218,,,Biodistribution in normal rat lung in the presence of NAC Gd 0.01 M lig at 2 hr,,,N,Intermediate,A,10116.0,CHEMBL618654,,2048.0,Lung,,1,1
7533,50597,,BAO_0000218,,,Recovery rate from urine and bile was determined after iv administration at 20 mg/kg in rats; Not tested,,,N,Intermediate,A,10116.0,CHEMBL618655,,,,,1,1
7534,50597,,BAO_0000218,,,Compound was tested for solubility in water,,,N,Intermediate,A,10116.0,CHEMBL618656,,,,,1,1
7535,22229,,BAO_0000100,,,Solubility in phosphate buffered saline (1% DMSO) at pH 6.5 (24 hr equilibration),,,U,Intermediate,P,,CHEMBL618657,,,,,0,1
7536,50597,,BAO_0000218,,,Solubility was determined,,,N,Intermediate,A,10116.0,CHEMBL618658,,,,,1,1
7537,50597,,BAO_0000218,,,solubility in water (ug/mL) at 37 degree C.,,,N,Intermediate,A,10116.0,CHEMBL618659,,,,,1,1
7538,50597,,BAO_0000218,,,First pass metabolism and metabolic bioavailability using rat hepatic microsomes,,,N,Intermediate,A,10116.0,CHEMBL618660,,,,,1,1
7539,50597,,BAO_0000218,,,In vitro stability relative to (+)-AJ76 in rat hepatocyte assay,,,N,Intermediate,A,10116.0,CHEMBL618661,,,,,1,1
7540,50597,,BAO_0000218,,,Half life in rats,,,N,Intermediate,A,10116.0,CHEMBL873807,,,,,1,1
7541,50597,,BAO_0000218,,,Half life in Dawley rat,,,N,Intermediate,A,10116.0,CHEMBL618662,,,,,1,1
7542,50597,In vivo,BAO_0000218,,,Half life period after 3 mg/kg iv administration,,,N,Intermediate,A,10116.0,CHEMBL618663,,,,,1,1
7543,50597,In vivo,BAO_0000218,,,Half life period after 3 mg/kg iv administration in rat,,,N,Intermediate,A,10116.0,CHEMBL618664,,,,,1,1
7544,50597,In vivo,BAO_0000218,,,Half life period after 3 mg/kg iv administration in the rat,,,N,Intermediate,A,10116.0,CHEMBL618665,,,,,1,1
7545,50597,,BAO_0000218,,,Half life period in female Sprague-Dawley rats,,,N,Intermediate,A,10116.0,CHEMBL876498,,,,,1,1
7546,50597,,BAO_0000218,,,Half life period in rat,,,N,Intermediate,A,10116.0,CHEMBL618666,,,,,1,1
7547,50597,,BAO_0000218,,,Half-life in rats was determined,,,N,Intermediate,A,10116.0,CHEMBL620440,,,,,1,1
7548,50597,,BAO_0000218,,,Half-life in rats with metabolic oxidation,,,N,Intermediate,A,10116.0,CHEMBL620441,,,,,1,1
7549,50597,,BAO_0000218,,,Half-life in rats,,,N,Intermediate,A,10116.0,CHEMBL620442,,,,,1,1
7550,50597,In vivo,BAO_0000218,,,T 1/2 at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,,,N,Intermediate,A,10116.0,CHEMBL620443,,,,,1,1
7551,50597,In vivo,BAO_0000218,,,T 1/2 at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,,,N,Intermediate,A,10116.0,CHEMBL620444,,,,,1,1
7552,50597,In vivo,BAO_0000218,,,T max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,,,N,Intermediate,A,10116.0,CHEMBL620445,,,,,1,1
7553,50597,In vivo,BAO_0000218,,,T max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,,,N,Intermediate,A,10116.0,CHEMBL620446,,,,,1,1
7554,50597,,BAO_0000218,,,Biological half-life measured in plasma of rat,,,N,Intermediate,A,10116.0,CHEMBL620447,,1969.0,Plasma,,1,1
7555,50597,,BAO_0000218,,,Biological half-life measured in plasma of rat; 22-25,,,N,Intermediate,A,10116.0,CHEMBL621129,,1969.0,Plasma,,1,1
7556,50597,,BAO_0000218,,,Biological half-life measured in plasma of rat; 9-16,,,N,Intermediate,A,10116.0,CHEMBL621130,,1969.0,Plasma,,1,1
7557,50597,In vivo,BAO_0000218,,,Compound was evaluated for its half life when administered intravenously in rat,,,N,Intermediate,A,10116.0,CHEMBL873808,,,,,1,1
7558,50597,In vivo,BAO_0000218,,,Compound was evaluated for pharmacokinetic parameter percent bioavailability at 8 h,,,N,Intermediate,A,10116.0,CHEMBL876598,,,,,1,1
7559,50597,In vivo,BAO_0000218,,,Evaluated for pharmacokinetic parameter half-life in rat at the dose 50 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL621131,,,,,1,1
7560,50597,In vivo,BAO_0000218,,,Half life (T1/2) after oral administration in rat,,,N,Intermediate,A,10116.0,CHEMBL621132,,,,,1,1
7561,50597,In vivo,BAO_0000218,,,Half life of compound after iv administration of 20 mg/kg dose in rat,,,N,Intermediate,A,10116.0,CHEMBL621133,,,,,1,1
7562,50597,In vivo,BAO_0000218,,,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg,,,N,Expert,A,10116.0,CHEMBL621312,,,,,1,1
7563,50597,,BAO_0000218,,,Half life of compound was determined in rat,,,N,Intermediate,A,10116.0,CHEMBL621313,,,,,1,1
7564,50597,,BAO_0000218,,,Half life of compound was determined in rat blood,,,N,Intermediate,A,10116.0,CHEMBL621314,,178.0,Blood,,1,1
7565,50597,In vivo,BAO_0000218,,,Half life at 1 mg/kg was determined in rat,,,N,Intermediate,A,10116.0,CHEMBL621315,,,,,1,1
7566,50597,In vivo,BAO_0000218,,,Half life at 10 mg/kg was determined in rat,,,N,Intermediate,A,10116.0,CHEMBL621316,,,,,1,1
7567,50597,,BAO_0000218,,,Half life in rats,,,N,Intermediate,A,10116.0,CHEMBL621317,,,,,1,1
7568,50597,,BAO_0000218,,,Half life in rats in hours,,,N,Intermediate,A,10116.0,CHEMBL621318,,,,,1,1
7569,50597,In vivo,BAO_0000218,,,Half life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,,,N,Intermediate,A,10116.0,CHEMBL621319,,,,,1,1
7570,50597,In vivo,BAO_0000218,,,Half life was calculated at a single intravenous administration of 20 mg/kg in rat,,,N,Intermediate,A,10116.0,CHEMBL621377,,,,,1,1
7571,50597,,BAO_0000218,,,Half life was determined,,,N,Intermediate,A,10116.0,CHEMBL621378,,,,,1,1
7572,50597,In vivo,BAO_0000218,,,Half life after i.v. administration,,,N,Intermediate,A,10116.0,CHEMBL876599,,,,,1,1
7573,50597,In vivo,BAO_0000218,,,Half life in rat after intravenous administration at a concentration 0.5 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL621379,,,,,1,1
7574,50597,,BAO_0000218,,,Half life in rat plasma,,,N,Intermediate,A,10116.0,CHEMBL621380,,1969.0,Plasma,,1,1
7575,50597,,BAO_0000218,,,Half life in rat plasma; Not detected,,,N,Intermediate,A,10116.0,CHEMBL621381,,1969.0,Plasma,,1,1
7576,50597,,BAO_0000218,,,Half life in rats,,,N,Intermediate,A,10116.0,CHEMBL618515,,,,,1,1
7577,50597,In vivo,BAO_0000218,,,Half life period of compound was determined after peroral administration,,,N,Intermediate,A,10116.0,CHEMBL618516,,,,,1,1
7578,50597,In vivo,BAO_0000218,,,Half life period of compound was determined at a dose of 3 mg/kg by intravenous administration,,,N,Intermediate,A,10116.0,CHEMBL618517,,,,,1,1
7579,50597,,BAO_0000218,,,Half life period in rat,,,N,Intermediate,A,10116.0,CHEMBL618518,,,,,1,1
7580,50597,In vivo,BAO_0000218,,,Half life period was evaluated against Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,,,N,Intermediate,A,10116.0,CHEMBL618519,,,,,1,1
7581,50597,In vivo,BAO_0000218,,,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,,,N,Intermediate,A,10116.0,CHEMBL618698,,,,,1,1
7582,50597,In vivo,BAO_0000218,,,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration; Not available,,,N,Intermediate,A,10116.0,CHEMBL618862,,,,,1,1
7583,50597,In vivo,BAO_0000218,,,Half life period was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,,,N,Intermediate,A,10116.0,CHEMBL618863,,,,,1,1
7584,50597,In vivo,BAO_0000218,,,Half life period was determined for compound after intravenous administration in rats at 24 uM/kg,,,N,Intermediate,A,10116.0,CHEMBL618864,,,,,1,1
7585,50597,In vivo,BAO_0000218,,,Half life time in rat the dose of 2 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL618865,,,,,1,1
7586,50597,In vivo,BAO_0000218,,,Half-life 24 hr after 10 mg/kg iv administration in rats,,,N,Intermediate,A,10116.0,CHEMBL618866,,,,,1,1
7587,50597,In vivo,BAO_0000218,,,Half-life 24 hr after 2 mg/kg iv administration in rats,,,N,Intermediate,A,10116.0,CHEMBL618867,,,,,1,1
7588,50597,,BAO_0000218,,,Half-life consistent with the observed metabolic steady state in rats,,,N,Intermediate,A,10116.0,CHEMBL875828,,,,,1,1
7589,50597,In vivo,BAO_0000218,,,Half-life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,,,N,Intermediate,A,10116.0,CHEMBL618868,,,,,1,1
7590,50597,,BAO_0000218,,,Half-life for oxidative metabolic stability was determined using male human,,,N,Intermediate,A,10116.0,CHEMBL618869,,,,,1,1
7591,50597,In vivo,BAO_0000218,,,"Half-life in fischer rats at 5 mg/kg dose, administered intravenously",,,N,Intermediate,A,10116.0,CHEMBL618870,,,,,1,1
7592,50597,,BAO_0000218,,,Half-life in rat plasma,,,N,Intermediate,A,10116.0,CHEMBL618871,,1969.0,Plasma,,1,1
7593,50597,,BAO_0000218,,,Half-life in rat plasma was determined,,,N,Intermediate,A,10116.0,CHEMBL618872,,1969.0,Plasma,,1,1
7594,50597,,BAO_0000218,,,Half-life in rats was determined,,,N,Intermediate,A,10116.0,CHEMBL873816,,,,,1,1
7595,22224,,BAO_0000218,,,Area under curve of acid 2a was determined by HPLC at a dosage of 54.5 mg/kg administered intragastrically by gavage method in dog,,,U,Autocuration,A,,CHEMBL618873,,,,,0,1
7596,22224,,BAO_0000019,,,Area under curve after oral dose of 0.1 mg//kg,,,U,Autocuration,A,,CHEMBL621602,,,,,0,1
7597,22224,,BAO_0000218,,,Area under curve after oral dose of 0.3 mg/kg,,,U,Autocuration,A,,CHEMBL621603,,,,,0,1
7598,22224,,BAO_0000218,,,Area under curve after oral dose of 1 mg/kg,,,U,Autocuration,A,,CHEMBL621604,,,,,0,1
7599,22224,,BAO_0000218,,,Area under curve after oral dose of 10 mg/kg,,,U,Autocuration,A,,CHEMBL621605,,,,,0,1
7600,22224,,BAO_0000218,,,Area under curve after oral dose of 23.4 mg/kg,,,U,Autocuration,A,,CHEMBL621606,,,,,0,1
7601,22224,,BAO_0000218,,,Area under curve after oral dose of 3 mg/kg,,,U,Autocuration,A,,CHEMBL621607,,,,,0,1
7602,22224,,BAO_0000218,,,Area under curve after oral dose of 3.87 mg/kg,,,U,Autocuration,A,,CHEMBL621608,,,,,0,1
7603,22224,,BAO_0000019,,,Area under curve was determined,,,U,Autocuration,A,,CHEMBL621609,,,,,0,1
7604,22224,,BAO_0000218,,,Area under curve at a dose of 10 mg/kg,,,U,Autocuration,A,,CHEMBL621610,,,,,0,1
7605,50597,,BAO_0000218,,,Area under curve was determined; ND=No data,,,N,Intermediate,A,10116.0,CHEMBL621611,,,,,1,1
7606,50597,,BAO_0000218,,,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours,,,N,Intermediate,A,10116.0,CHEMBL621612,,,,,1,1
7607,50597,,BAO_0000218,,,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for infinite hours,,,N,Intermediate,A,10116.0,CHEMBL622308,,,,,1,1
7608,50597,,BAO_0000218,,,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours,,,N,Intermediate,A,10116.0,CHEMBL622309,,,,,1,1
7609,50597,,BAO_0000218,,,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for infinite hours,,,N,Intermediate,A,10116.0,CHEMBL622310,,,,,1,1
7610,50597,,BAO_0000218,,,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for 4 or 6 hours,,,N,Intermediate,A,10116.0,CHEMBL622311,,,,,1,1
7611,50597,,BAO_0000218,,,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for infinite hours; Not calculated,,,N,Intermediate,A,10116.0,CHEMBL622312,,,,,1,1
7612,50597,,BAO_0000218,,,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for 4 or 6 hours,,,N,Intermediate,A,10116.0,CHEMBL622931,,,,,1,1
7613,50597,,BAO_0000218,,,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for infinite hours; Not calculated,,,N,Intermediate,A,10116.0,CHEMBL622932,,,,,1,1
7614,50597,,BAO_0000218,,,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours,,,N,Intermediate,A,10116.0,CHEMBL622736,,1969.0,Plasma,,1,1
7615,50597,,BAO_0000218,,,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for infinite hours,,,N,Intermediate,A,10116.0,CHEMBL622737,,1969.0,Plasma,,1,1
7616,50597,,BAO_0000218,,,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours,,,N,Intermediate,A,10116.0,CHEMBL622738,,1969.0,Plasma,,1,1
7617,50597,,BAO_0000218,,,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for infinite hours,,,N,Intermediate,A,10116.0,CHEMBL622739,,1969.0,Plasma,,1,1
7618,50597,,BAO_0000218,,,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for 4 or 6 hours,,,N,Intermediate,A,10116.0,CHEMBL622740,,1969.0,Plasma,,1,1
7619,50597,,BAO_0000218,,,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for infinite hours,,,N,Intermediate,A,10116.0,CHEMBL622741,,1969.0,Plasma,,1,1
7620,50597,,BAO_0000218,,,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for 4 or 6 hours,,,N,Intermediate,A,10116.0,CHEMBL622742,,1969.0,Plasma,,1,1
7621,50597,,BAO_0000218,,,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for infinite hours,,,N,Intermediate,A,10116.0,CHEMBL622743,,1969.0,Plasma,,1,1
7622,50594,,BAO_0000218,,,AUC in mice,,,N,Intermediate,A,10090.0,CHEMBL622744,,1969.0,Plasma,,1,1
7623,22224,,BAO_0000019,,,Area under curve was measured from the graph obtained from concentration Vs time,,,U,Autocuration,A,,CHEMBL624134,,,,,0,1
7624,22224,,BAO_0000019,,,Area under curve value of compound per hour after oral administration,,,U,Autocuration,A,,CHEMBL624135,,,,,0,1
7625,50597,,BAO_0000218,,,Area under curve was determined after oral administration in rats,,,N,Intermediate,A,10116.0,CHEMBL624136,,,,,1,1
7626,50597,,BAO_0000218,,,Area under curve was determined after oral administration in rats; No data,,,N,Intermediate,A,10116.0,CHEMBL624137,,,,,1,1
7627,50597,,BAO_0000218,,,Area under curve was determined after oral administration in rats;No data,,,N,Intermediate,A,10116.0,CHEMBL624320,,,,,1,1
7628,50588,,BAO_0000218,,,Area under curve was determined by HPLC at a dosage of 2.27 mg/kg administered intravenously by bolus method in dog,,,N,Intermediate,A,9615.0,CHEMBL624321,,,,,1,1
7629,50597,,BAO_0000218,,,Area under curve was determined for the compound after iv dose of 4.74 mg/kg in rats,,,N,Intermediate,A,10116.0,CHEMBL624322,,,,,1,1
7630,50597,,BAO_0000218,,,Area under curve was determined for the compound after iv dose of 5.06 in rats,,,N,Intermediate,A,10116.0,CHEMBL624323,,,,,1,1
7631,50597,,BAO_0000218,,,Area under curve was determined for the compound after iv dose of 5.10 mg/kg in rats,,,N,Intermediate,A,10116.0,CHEMBL624324,,,,,1,1
7632,50597,,BAO_0000218,,,Area under curve was determined for the compound after po dose of 5.01 mg/kg in rats,,,N,Intermediate,A,10116.0,CHEMBL624325,,,,,1,1
7633,50597,,BAO_0000218,,,Area under curve was determined for the compound after po dose of 5.03 mg/kg in rats,,,N,Intermediate,A,10116.0,CHEMBL624326,,,,,1,1
7634,50597,,BAO_0000218,,,Area under curve was determined for the compound after po dose of 5.22 mg/kg in rats,,,N,Intermediate,A,10116.0,CHEMBL624327,,,,,1,1
7635,50597,,BAO_0000218,,,Area under curve was determined for the compound after po dose of 5.46 mg/kg in rats,,,N,Intermediate,A,10116.0,CHEMBL624328,,,,,1,1
7636,50588,,BAO_0000218,,,Area under curve was determined in Dogs after peroral administration,,,N,Intermediate,A,9615.0,CHEMBL627848,,,,,1,1
7637,50597,,BAO_0000218,,,Area under curve was determined in Rats after peroral administration,,,N,Intermediate,A,10116.0,CHEMBL627849,,,,,1,1
7638,50597,,BAO_0000218,,,Area under curve was determined in carotid blood of rat when administered intradermally,,,N,Intermediate,A,10116.0,CHEMBL627850,,,,,1,1
7639,50597,,BAO_0000218,,,Area under curve was determined in portal blood of rat when administered intradermally,,,N,Intermediate,A,10116.0,CHEMBL627851,,,,,1,1
7640,50594,,BAO_0000218,,,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg,,,N,Intermediate,A,10090.0,CHEMBL627852,,,,,1,1
7641,50594,,BAO_0000218,,,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg,,,N,Intermediate,A,10090.0,CHEMBL627853,,,,,1,1
7642,50594,,BAO_0000218,,,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (micronized sample),,,N,Intermediate,A,10090.0,CHEMBL627854,,,,,1,1
7643,50594,,BAO_0000218,,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg,,,N,Intermediate,A,10090.0,CHEMBL627855,,,,,1,1
7644,50594,,BAO_0000218,,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg (run time 7 hr),,,N,Intermediate,A,10090.0,CHEMBL627856,,,,,1,1
7645,50594,,BAO_0000218,,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg,,,N,Intermediate,A,10090.0,CHEMBL875339,,,,,1,1
7646,50594,,BAO_0000218,,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (Run time = 7 hr),,,N,Intermediate,A,10090.0,CHEMBL627857,,,,,1,1
7647,50597,In vivo,BAO_0000218,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 65 mins after i.v. administration,,,N,Intermediate,A,10116.0,CHEMBL627858,,2106.0,Spleen,,1,1
7648,50597,,BAO_0000218,,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in blood; Expressed as percent dose/organ,,,N,Intermediate,A,10116.0,CHEMBL627859,,178.0,Blood,,1,1
7649,50597,,BAO_0000218,,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in brain; Expressed as percent dose/organ,,,N,Intermediate,A,10116.0,CHEMBL627860,,955.0,Brain,,1,1
7650,50597,,BAO_0000218,,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in heart; Expressed as percent dose/organ,,,N,Intermediate,A,10116.0,CHEMBL627019,,948.0,Heart,,1,1
7651,50597,,BAO_0000218,,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in liver; Expressed as percent dose/organ,,,N,Intermediate,A,10116.0,CHEMBL627020,,2107.0,Liver,,1,1
7652,50597,,BAO_0000218,,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in lung; Expressed as percent dose/organ,,,N,Intermediate,A,10116.0,CHEMBL627021,,2048.0,Lung,,1,1
7653,50597,,BAO_0000218,,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in muscle; Expressed as percent dose/organ,,,N,Intermediate,A,10116.0,CHEMBL627022,,2385.0,Muscle tissue,,1,1
7654,50597,,BAO_0000218,,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in skin; Expressed as percent dose/organ,,,N,Intermediate,A,10116.0,CHEMBL627023,,,,,1,1
7655,50597,,BAO_0000218,,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in spleen; Expressed as percent dose/organ,,,N,Intermediate,A,10116.0,CHEMBL627024,,2106.0,Spleen,,1,1
7656,50597,,BAO_0000218,,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in thyroid; Expressed as percent dose/organ,,,N,Intermediate,A,10116.0,CHEMBL627025,,2046.0,Thyroid gland,,1,1
7657,50597,,BAO_0000218,,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in kidney; Expressed as percent dose/organ,,,N,Intermediate,A,10116.0,CHEMBL627026,,2113.0,Kidney,,1,1
7658,50597,,BAO_0000218,,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in blood; Expressed as percent dose/organ,,,N,Intermediate,A,10116.0,CHEMBL627027,,178.0,Blood,,1,1
7659,50597,,BAO_0000218,,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in brain; Expressed as percent dose/organ,,,N,Intermediate,A,10116.0,CHEMBL627028,,955.0,Brain,,1,1
7660,50597,,BAO_0000218,,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in heart; Expressed as percent dose/organ,,,N,Intermediate,A,10116.0,CHEMBL627029,,948.0,Heart,,1,1
7661,50597,,BAO_0000218,,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in kidney; Expressed as percent dose/organ,,,N,Intermediate,A,10116.0,CHEMBL627030,,2113.0,Kidney,,1,1
7662,50597,,BAO_0000218,,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in liver; Expressed as percent dose/organ,,,N,Intermediate,A,10116.0,CHEMBL627031,,2107.0,Liver,,1,1
7663,50597,,BAO_0000218,,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in lung; Expressed as percent dose/organ,,,N,Intermediate,A,10116.0,CHEMBL627032,,2048.0,Lung,,1,1
7664,50597,,BAO_0000218,,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in muscle; Expressed as percent dose/organ,,,N,Intermediate,A,10116.0,CHEMBL627033,,2385.0,Muscle tissue,,1,1
7665,50597,,BAO_0000218,,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in skin; Expressed as percent dose/organ,,,N,Intermediate,A,10116.0,CHEMBL627034,,,,,1,1
7666,50597,,BAO_0000218,,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in spleen; Expressed as percent dose/organ,,,N,Intermediate,A,10116.0,CHEMBL627035,,2106.0,Spleen,,1,1
7667,50597,,BAO_0000218,,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in thyroid; Expressed as percent dose/organ,,,N,Intermediate,A,10116.0,CHEMBL627036,,2046.0,Thyroid gland,,1,1
7668,50597,,BAO_0000218,,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in blood; Expressed as percent dose/organ,,,N,Intermediate,A,10116.0,CHEMBL875340,,178.0,Blood,,1,1
7669,50597,,BAO_0000218,,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in heart; Expressed as percent dose/organ,,,N,Intermediate,A,10116.0,CHEMBL627037,,948.0,Heart,,1,1
7670,50597,,BAO_0000218,,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in kidney; Expressed as percent dose/organ,,,N,Intermediate,A,10116.0,CHEMBL627038,,2113.0,Kidney,,1,1
7671,50597,,BAO_0000218,,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in liver; Expressed as percent dose/organ,,,N,Intermediate,A,10116.0,CHEMBL627039,,2107.0,Liver,,1,1
7672,50597,,BAO_0000218,,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in muscle; Expressed as percent dose/organ,,,N,Intermediate,A,10116.0,CHEMBL627040,,2385.0,Muscle tissue,,1,1
7673,50597,,BAO_0000218,,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in spleen; Expressed as percent dose/organ,,,N,Intermediate,A,10116.0,CHEMBL624663,,2106.0,Spleen,,1,1
7674,50597,,BAO_0000218,,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in thyroid; Expressed as percent dose/organ,,,N,Intermediate,A,10116.0,CHEMBL625963,,2046.0,Thyroid gland,,1,1
7675,50597,,BAO_0000218,,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in brain; Expressed as percent dose/organ,,,N,Intermediate,A,10116.0,CHEMBL876799,,955.0,Brain,,1,1
7676,50597,,BAO_0000218,,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in lung; Expressed as percent dose/organ,,,N,Intermediate,A,10116.0,CHEMBL626133,,2048.0,Lung,,1,1
7677,50597,,BAO_0000218,,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in skin; Expressed as percent dose/organ,,,N,Intermediate,A,10116.0,CHEMBL626134,,,,,1,1
7678,50597,,BAO_0000218,,,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL626135,,,,,1,1
7679,50597,,BAO_0000218,,,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL626136,,,,,1,1
7680,50597,,BAO_0000218,,,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg; Below detection limit,,,N,Intermediate,A,10116.0,CHEMBL626137,,,,,1,1
7681,50597,,BAO_0000218,,,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL626138,,,,,1,1
7682,50597,,BAO_0000218,,,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL626139,,,,,1,1
7683,50597,In vivo,BAO_0000218,,,C max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,,,N,Intermediate,A,10116.0,CHEMBL626140,,,,,1,1
7684,50597,In vivo,BAO_0000218,,,C max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,,,N,Intermediate,A,10116.0,CHEMBL626141,,,,,1,1
7685,50597,,BAO_0000218,,,C24h in rat p.o. at 20 mg/kg concentration,,,N,Intermediate,A,10116.0,CHEMBL626142,,,,,1,1
7686,50597,In vivo,BAO_0000218,,,Biodistribution in normal rat muscle in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,,N,Intermediate,A,10116.0,CHEMBL627930,,2385.0,Muscle tissue,,1,1
7687,50597,In vivo,BAO_0000218,,,Biodistribution in normal rat muscle in the presence of 0.01 M Gd/0.05 M lig,,,N,Intermediate,A,10116.0,CHEMBL627931,,2385.0,Muscle tissue,,1,1
7688,50597,In vivo,BAO_0000218,,,Biodistribution in normal rat muscle in the presence of NAC Gd 0.01 M lig at 2 hr,,,N,Intermediate,A,10116.0,CHEMBL627932,,2385.0,Muscle tissue,,1,1
7689,50597,In vivo,BAO_0000218,,,Biodistribution in normal rat spleen in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,,N,Intermediate,A,10116.0,CHEMBL627933,,2106.0,Spleen,,1,1
7690,50597,In vivo,BAO_0000218,,,Biodistribution in normal rat spleen in the presence of 0.01 M Gd/0.05 M lig,,,N,Intermediate,A,10116.0,CHEMBL627934,,2106.0,Spleen,,1,1
7691,50597,In vivo,BAO_0000218,,,Biodistribution in normal rat spleen in the presence of NAC Gd 0.01 M lig at 2 hr,,,N,Intermediate,A,10116.0,CHEMBL627935,,2106.0,Spleen,,1,1
7692,50597,In vivo,BAO_0000218,,,Biodistribution in rat blood in the presence of 0.001 M/0.008 M GdDTPA-AEP,,,N,Intermediate,A,10116.0,CHEMBL627936,,178.0,Blood,,1,1
7693,50597,In vivo,BAO_0000218,,,Biodistribution in rat blood in the presence of 0.01 M GdDTPA-BDP,,,N,Intermediate,A,10116.0,CHEMBL627937,,178.0,Blood,,1,1
7694,50597,In vivo,BAO_0000218,,,Biodistribution in rat blood in the presence of 0.01 M/0.01 M GdDTPA-AEP,,,N,Intermediate,A,10116.0,CHEMBL627938,,178.0,Blood,,1,1
7695,50597,In vivo,BAO_0000218,,,Biodistribution in rat blood in the presence of 0.05 M Gd/0.15 M lig,,,N,Intermediate,A,10116.0,CHEMBL627939,,178.0,Blood,,1,1
7696,50597,In vivo,BAO_0000218,,,Biodistribution in rat blood in the presence of 0.05 M GdDTPA-BDP,,,N,Intermediate,A,10116.0,CHEMBL627940,,178.0,Blood,,1,1
7697,50597,In vivo,BAO_0000218,,,Biodistribution in rat blood in the presence of 0.05 M/0.05 M GdDTPA-AEP,,,N,Intermediate,A,10116.0,CHEMBL627941,,178.0,Blood,,1,1
7698,50597,In vivo,BAO_0000218,,,Biodistribution in rat blood in the presence of 0.05 M/0.08 M GdDTPA-HPDP,,,N,Intermediate,A,10116.0,CHEMBL876800,,178.0,Blood,,1,1
7699,50597,In vivo,BAO_0000218,,,Biodistribution in rat blood in the presence of 0.10 M GdDTPA-BDP,,,N,Intermediate,A,10116.0,CHEMBL627942,,178.0,Blood,,1,1
7700,50597,In vivo,BAO_0000218,,,Biodistribution in rat blood in the presence of 0.10 M/0.11 M GdDTPA-AEP,,,N,Intermediate,A,10116.0,CHEMBL627943,,178.0,Blood,,1,1
7701,50597,In vivo,BAO_0000218,,,Biodistribution in rat blood in the presence of 50 Gd/kg at 15 min,,,N,Intermediate,A,10116.0,CHEMBL627944,,178.0,Blood,,1,1
7702,50597,In vivo,BAO_0000218,,,Biodistribution in rat blood in the presence of 50 Gd/kg at 2 hr,,,N,Intermediate,A,10116.0,CHEMBL627945,,178.0,Blood,,1,1
7703,50597,In vivo,BAO_0000218,,,Biodistribution in rat blood in the presence of 50 Gd/kg at 6 hr,,,N,Intermediate,A,10116.0,CHEMBL628584,,178.0,Blood,,1,1
7704,50597,In vivo,BAO_0000218,,,Biodistribution in rat blood in the presence of GdDTPA at 15 min,,,N,Intermediate,A,10116.0,CHEMBL628585,,178.0,Blood,,1,1
7705,50597,In vivo,BAO_0000218,,,Biodistribution in rat blood in the presence of GdDTPA at 1 hr,,,N,Intermediate,A,10116.0,CHEMBL628586,,178.0,Blood,,1,1
7706,50597,In vivo,BAO_0000218,,,Biodistribution in rat blood in the presence of GdDTPA at 30 min,,,N,Intermediate,A,10116.0,CHEMBL628587,,178.0,Blood,,1,1
7707,50597,In vivo,BAO_0000218,,,Biodistribution in rat blood in the presence of GdDTPA at 4 hr,,,N,Intermediate,A,10116.0,CHEMBL628588,,178.0,Blood,,1,1
7708,50597,In vivo,BAO_0000218,,,Biodistribution in rat blood in the presence of GdDTPA-BDP at 15 min,,,N,Intermediate,A,10116.0,CHEMBL628589,,178.0,Blood,,1,1
7709,50597,In vivo,BAO_0000218,,,Biodistribution in rat blood in the presence of GdDTPA-BDP at 30 min,,,N,Intermediate,A,10116.0,CHEMBL625304,,178.0,Blood,,1,1
7710,50597,In vivo,BAO_0000218,,,Biodistribution in rat blood in the presence of GdDTPA-BDP at 4 hr,,,N,Intermediate,A,10116.0,CHEMBL625305,,178.0,Blood,,1,1
7711,50597,In vivo,BAO_0000218,,,Biodistribution in rat blood in the presence of GdDTPA-BDPat 1 hr,,,N,Intermediate,A,10116.0,CHEMBL625306,,178.0,Blood,,1,1
7712,50597,In vivo,BAO_0000218,,,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 15 min,,,N,Intermediate,A,10116.0,CHEMBL625307,,178.0,Blood,,1,1
7713,50597,In vivo,BAO_0000218,,,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 30 min,,,N,Intermediate,A,10116.0,CHEMBL625308,,178.0,Blood,,1,1
7714,50597,In vivo,BAO_0000218,,,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 4 hr,,,N,Intermediate,A,10116.0,CHEMBL627740,,178.0,Blood,,1,1
7715,50597,In vivo,BAO_0000218,,,Biodistribution in rat blood in the presence of GdDTPA-HPDPat 1 hr,,,N,Intermediate,A,10116.0,CHEMBL627741,,178.0,Blood,,1,1
7716,50597,In vivo,BAO_0000218,,,Biodistribution in rat blood in the presence of NAC Gd/0.01 M GdDTPA-HPDP,,,N,Intermediate,A,10116.0,CHEMBL627742,,178.0,Blood,,1,1
7717,50597,In vivo,BAO_0000218,,,Biodistribution in rat blood in the presence of NCA Gd/0.01 M lip,,,N,Intermediate,A,10116.0,CHEMBL627743,,178.0,Blood,,1,1
7718,50597,In vivo,BAO_0000218,,,Biodistribution in rat blood in the presence of NCAGd/0.01 M lig,,,N,Intermediate,A,10116.0,CHEMBL627744,,178.0,Blood,,1,1
7719,50597,In vivo,BAO_0000218,,,Biodistribution in rat bone in the presence of 0.01 M GdDTPA-BDP,,,N,Intermediate,A,10116.0,CHEMBL627745,,10000001.0,Bone,,1,1
7720,50597,In vivo,BAO_0000218,,,Biodistribution in rat bone in the presence of 0.01 M/0.01 M GdDTPA-AEP,,,N,Intermediate,A,10116.0,CHEMBL627746,,10000001.0,Bone,,1,1
7721,50597,In vivo,BAO_0000218,,,Biodistribution in rat bone in the presence of 0.01 M/0.08 M GdDTPA-AEP,,,N,Intermediate,A,10116.0,CHEMBL627747,,10000001.0,Bone,,1,1
7722,50597,In vivo,BAO_0000218,,,Biodistribution in rat bone in the presence of 0.05 M Gd/0.15 M lig,,,N,Intermediate,A,10116.0,CHEMBL876810,,10000001.0,Bone,,1,1
7723,50597,In vivo,BAO_0000218,,,Biodistribution in rat bone in the presence of 0.05 M GdDTPA-BDP,,,N,Intermediate,A,10116.0,CHEMBL627748,,10000001.0,Bone,,1,1
7724,50597,In vivo,BAO_0000218,,,Biodistribution in rat bone in the presence of 0.05 M/0.05 M GdDTPA-AEP,,,N,Intermediate,A,10116.0,CHEMBL627749,,10000001.0,Bone,,1,1
7725,50597,In vivo,BAO_0000218,,,Biodistribution in rat bone in the presence of 0.05 M/0.08 M GdDTPA-HPDP,,,N,Intermediate,A,10116.0,CHEMBL627750,,10000001.0,Bone,,1,1
7726,50597,In vivo,BAO_0000218,,,Biodistribution in rat bone in the presence of 0.10 M GdDTPA-BDP,,,N,Intermediate,A,10116.0,CHEMBL618728,,10000001.0,Bone,,1,1
7727,50597,In vivo,BAO_0000218,,,Biodistribution in rat bone in the presence of 0.10 M/0.11 M GdDTPA-AEP,,,N,Intermediate,A,10116.0,CHEMBL618729,,10000001.0,Bone,,1,1
7728,50597,In vivo,BAO_0000218,,,Biodistribution in rat bone in the presence of GdDTPA at 15 min,,,N,Intermediate,A,10116.0,CHEMBL618730,,10000001.0,Bone,,1,1
7729,50597,In vivo,BAO_0000218,,,Biodistribution in rat bone in the presence of GdDTPA at 1 hr,,,N,Intermediate,A,10116.0,CHEMBL618731,,10000001.0,Bone,,1,1
7730,50597,In vivo,BAO_0000218,,,Biodistribution in rat bone in the presence of GdDTPA at 30 min,,,N,Intermediate,A,10116.0,CHEMBL618732,,10000001.0,Bone,,1,1
7731,50597,In vivo,BAO_0000218,,,Biodistribution in rat bone in the presence of GdDTPA at 4 hr,,,N,Intermediate,A,10116.0,CHEMBL618733,,10000001.0,Bone,,1,1
7732,50597,In vivo,BAO_0000218,,,Biodistribution in rat bone in the presence of GdDTPA-BDP at 15 min,,,N,Intermediate,A,10116.0,CHEMBL618734,,10000001.0,Bone,,1,1
7733,50597,In vivo,BAO_0000218,,,Biodistribution in rat bone in the presence of GdDTPA-BDP at 1 hr,,,N,Intermediate,A,10116.0,CHEMBL618735,,10000001.0,Bone,,1,1
7734,50597,In vivo,BAO_0000218,,,Biodistribution in rat bone in the presence of GdDTPA-BDP at 30 min,,,N,Intermediate,A,10116.0,CHEMBL876602,,10000001.0,Bone,,1,1
7735,50597,In vivo,BAO_0000218,,,Biodistribution in rat bone in the presence of GdDTPA-BDP at 4 hr,,,N,Intermediate,A,10116.0,CHEMBL618736,,10000001.0,Bone,,1,1
7736,50597,In vivo,BAO_0000218,,,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 15 min,,,N,Intermediate,A,10116.0,CHEMBL618737,,10000001.0,Bone,,1,1
7737,50597,In vivo,BAO_0000218,,,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 1 hr,,,N,Intermediate,A,10116.0,CHEMBL618738,,10000001.0,Bone,,1,1
7738,50597,In vivo,BAO_0000218,,,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 30 min,,,N,Intermediate,A,10116.0,CHEMBL618739,,10000001.0,Bone,,1,1
7739,50597,In vivo,BAO_0000218,,,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 4 hr,,,N,Intermediate,A,10116.0,CHEMBL618740,,10000001.0,Bone,,1,1
7740,50597,In vivo,BAO_0000218,,,Biodistribution in rat bone in the presence of NAC Gd/0.01 M GdDTPA-HPDP,,,N,Intermediate,A,10116.0,CHEMBL618741,,10000001.0,Bone,,1,1
7741,50597,In vivo,BAO_0000218,,,Biodistribution in rat bone in the presence of NCA Gd/0.01 M lip,,,N,Intermediate,A,10116.0,CHEMBL618742,,10000001.0,Bone,,1,1
7742,50597,In vivo,BAO_0000218,,,Biodistribution in rat bone in the presence of NCAGd/0.01 M lig,,,N,Intermediate,A,10116.0,CHEMBL618743,,10000001.0,Bone,,1,1
7743,50597,In vivo,BAO_0000218,,,Half-life from rat plasma at a single oral dose of 25 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL618744,,1969.0,Plasma,,1,1
7744,50597,,BAO_0000218,,,Half-life in male rat,,,N,Intermediate,A,10116.0,CHEMBL618745,,,,,1,1
7745,50597,In vivo,BAO_0000218,,,Half-life in rat after peroral administration at 10 mg/kg concentration,,,N,Intermediate,A,10116.0,CHEMBL620479,,,,,1,1
7746,50597,In vivo,BAO_0000218,,,Half-life in rat after peroral administration at 5 mg/kg concentration,,,N,Intermediate,A,10116.0,CHEMBL620480,,,,,1,1
7747,50597,In vivo,BAO_0000218,,,Half-life in rat at a dose of 3 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL620481,,,,,1,1
7748,50597,,BAO_0000218,,,Half-life was evaluated in rats,,,N,Intermediate,A,10116.0,CHEMBL620482,,,,,1,1
7749,50597,,BAO_0000218,,,Half-life was measured in rat,,,N,Intermediate,A,10116.0,CHEMBL876603,,,,,1,1
7750,50597,In vivo,BAO_0000218,,,Half-life period for the compound was determined in rats at 50 mg/kg dose,,,N,Intermediate,A,10116.0,CHEMBL620483,,,,,1,1
7751,50597,In vivo,BAO_0000218,,,Half-life period in rats after intravenous administration at 5 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL620484,,,,,1,1
7752,50597,In vivo,BAO_0000218,,,Half-life period in rat at 10 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL620485,,,,,1,1
7753,50597,In vivo,BAO_0000218,,,"Half-life period was determined in rats at 10 mg/kg, p.o. dose",,,N,Intermediate,A,10116.0,CHEMBL620486,,,,,1,1
7754,50597,In vivo,BAO_0000218,,,"Half-life period was determined in rats at 20 mg/kg, i.p. dose",,,N,Intermediate,A,10116.0,CHEMBL620487,,,,,1,1
7755,50597,In vivo,BAO_0000218,,,"Half-life period was determined in rats at 2 mg/kg, i.v. dose",,,N,Intermediate,A,10116.0,CHEMBL620488,,,,,1,1
7756,50597,In vivo,BAO_0000218,,,Half-life time in rat the dose of 2 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL620489,,,,,1,1
7757,50597,In vivo,BAO_0000218,,,Half-life was estimated from the elimination phase of the oral [C] vs time curves in 4 rats,,,N,Intermediate,A,10116.0,CHEMBL620490,,,,,1,1
7758,50597,In vivo,BAO_0000218,,,In vivo activity against Staphylococcus aureus when administered orally for 1 hr in rat at a dose of 15 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL620491,,,,,1,1
7759,50597,In vivo,BAO_0000218,,,"In vivo half life of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)",,,N,Intermediate,A,10116.0,CHEMBL876604,,1969.0,Plasma,,1,1
7760,50597,In vivo,BAO_0000218,,,Oral half life was determined,,,N,Intermediate,A,10116.0,CHEMBL620492,,,,,1,1
7761,50597,In vivo,BAO_0000218,,,"Pharmacokinetic Parameter, half life period measured in Female Wistar Rats at 100 mg/kg by po administration",,,N,Intermediate,A,10116.0,CHEMBL620493,,,,,1,1
7762,50597,In vivo,BAO_0000218,,,Pharmacokinetic property (t1/2) in rat,,,N,Intermediate,A,10116.0,CHEMBL620494,,,,,1,1
7763,50597,,BAO_0000218,,,Plasma elimination half-life was determined,,,N,Intermediate,A,10116.0,CHEMBL620495,,1969.0,Plasma,,1,1
7764,50597,In vivo,BAO_0000218,,,Plasma elimination half-life was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,,,N,Intermediate,A,10116.0,CHEMBL620496,,1969.0,Plasma,,1,1
7765,50597,In vivo,BAO_0000218,,,Plasma half life was observed after intravenous administration in rat,,,N,Intermediate,A,10116.0,CHEMBL620497,,1969.0,Plasma,,1,1
7766,50597,,BAO_0000218,,,Plasma half-life was determined,,,N,Intermediate,A,10116.0,CHEMBL620498,,1969.0,Plasma,,1,1
7767,50597,In vivo,BAO_0000218,,,Plasma half-life following oral administration in Fisher rats,,,N,Intermediate,A,10116.0,CHEMBL620499,,1969.0,Plasma,,1,1
7768,50597,,BAO_0000218,,,Plasma half-life in rat,,,N,Intermediate,A,10116.0,CHEMBL620500,,1969.0,Plasma,,1,1
7769,50597,In vivo,BAO_0000218,,,Plasmatic Half-life after intravenous administration to rat,,,N,Intermediate,A,10116.0,CHEMBL873809,,1969.0,Plasma,,1,1
7770,50597,In vivo,BAO_0000218,,,T1/2 (half life) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat,,,N,Intermediate,A,10116.0,CHEMBL620501,,,,,1,1
7771,50597,In vivo,BAO_0000218,,,Terminal half life after intravenous administration (1 mg/kg) in rat,,,N,Intermediate,A,10116.0,CHEMBL620502,,,,,1,1
7772,50597,In vivo,BAO_0000218,,,Terminal half life in Rat at a oral dose of 5 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL620503,,,,,1,1
7773,50597,In vivo,BAO_0000218,,,Terminal phase half-life was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration,,,N,Intermediate,A,10116.0,CHEMBL620504,,,,,1,1
7774,50597,In vivo,BAO_0000218,,,Tested for half life value after intravenous administration at dose of 0.2 mg/kg in rat,,,N,Intermediate,A,10116.0,CHEMBL876605,,,,,1,1
7775,50597,In vivo,BAO_0000218,,,Tested for half life value after oral administration at dosage of 4 mg/kg in rat,,,N,Intermediate,A,10116.0,CHEMBL620505,,,,,1,1
7776,50597,In vivo,BAO_0000218,,,plasma half life was observed after intravenous administration in rat,,,N,Intermediate,A,10116.0,CHEMBL873811,,1969.0,Plasma,,1,1
7777,50597,In vivo,BAO_0000218,,,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg,,,N,Expert,A,10116.0,CHEMBL624016,,,,,1,1
7778,50597,,BAO_0000218,,,Half life of compound determined in rat,,,N,Intermediate,A,10116.0,CHEMBL624017,,,,,1,1
7779,50597,,BAO_0000218,,,Mean residence time determined in rat,,,N,Intermediate,A,10116.0,CHEMBL624018,,,,,1,1
7780,50597,,BAO_0000218,,,Plasma half life determined in rat,,,N,Intermediate,A,10116.0,CHEMBL624019,,,,,1,1
7781,50597,In vivo,BAO_0000218,,,Compound was evaluated for Tmax in brain after intravenous administration in male rats,,,N,Intermediate,A,10116.0,CHEMBL624020,,955.0,Brain,,1,1
7782,50597,In vivo,BAO_0000218,,,Compound was evaluated for pharmacokinetic parameter maximum time period,,,N,Intermediate,A,10116.0,CHEMBL624201,,,,,1,1
7783,50597,In vivo,BAO_0000218,,,Evaluated for pharmacokinetic parameter tmax in rat at the dose 50 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL872528,,,,,1,1
7784,50597,In vivo,BAO_0000218,,,In vivo Tmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,,N,Intermediate,A,10116.0,CHEMBL624202,,,,,1,1
7785,50597,In vivo,BAO_0000218,,,In vivo Tmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,,N,Intermediate,A,10116.0,CHEMBL624203,,,,,1,1
7786,50597,In vivo,BAO_0000218,,,In vivo Tmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,,,N,Intermediate,A,10116.0,CHEMBL624350,,,,,1,1
7787,50597,In vivo,BAO_0000218,,,In vivo Tmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,,N,Intermediate,A,10116.0,CHEMBL621320,,,,,1,1
7788,50597,In vivo,BAO_0000218,,,In vivo maximum time required for clearance of compound after oral (po) administration at a dose of 10 mg/kg was measured in rats,,,N,Intermediate,A,10116.0,CHEMBL621321,,,,,1,1
7789,50597,,BAO_0000218,,,Maximum time (Tmax) required to reach Cmax in rats,,,N,Intermediate,A,10116.0,CHEMBL621322,,,,,1,1
7790,50597,In vivo,BAO_0000218,,,Maximum time constant was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,,,N,Intermediate,A,10116.0,CHEMBL621323,,,,,1,1
7791,50597,In vivo,BAO_0000218,,,Maximum time of clearance of compound in rats after peroral administration,,,N,Intermediate,A,10116.0,CHEMBL621324,,,,,1,1
7792,50597,,BAO_0000218,,,Maximum time at the dose of 2 mg/kg in rat,,,N,Intermediate,A,10116.0,CHEMBL621325,,,,,1,1
7793,50597,In vivo,BAO_0000218,,,Maximum time to achieve peak plasma concentration was determined in rat at 1 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL875837,,1969.0,Plasma,,1,1
7794,50597,In vivo,BAO_0000218,,,Maximum time to achieve peak plasma concentration was determined in rat at 10 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL621326,,1969.0,Plasma,,1,1
7795,50597,In vivo,BAO_0000218,,,Tmax in Guinea pig (PO dose),,,N,Intermediate,A,10116.0,CHEMBL621327,,,,,1,1
7796,50597,In vivo,BAO_0000218,,,"Pharmacokinetic Parameter, Tmax is the time at which maximum concentration (Cmax) is reached in Female Wistar Rats at 100 mg/kg by po administration",,,N,Intermediate,A,10116.0,CHEMBL621328,,,,,1,1
7797,50597,In vivo,BAO_0000218,,,Pharmacokinetic parameter (Tmax) in rat,,,N,Intermediate,A,10116.0,CHEMBL621329,,,,,1,1
7798,50597,In vivo,BAO_0000218,,,Pharmacokinetic parameter (Tmax) was estimated,,,N,Intermediate,A,10116.0,CHEMBL621330,,,,,1,1
7799,50597,In vivo,BAO_0000218,,,Pharmacokinetic property (Tmax) in rat,,,N,Intermediate,A,10116.0,CHEMBL621331,,,,,1,1
7800,50597,In vivo,BAO_0000218,,,Pharmacokinetic property (Tmax) was measured in rat at the dose of 0.32 mg/kg p.o.,,,N,Intermediate,A,10116.0,CHEMBL621332,,,,,1,1
7801,50597,In vivo,BAO_0000218,,,T max in Rat at a oral dose of 5 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL621333,,,,,1,1
7802,50597,In vivo,BAO_0000218,,,T max was determined at 10 mg/kg po dose in rats,,,N,Intermediate,A,10116.0,CHEMBL621334,,,,,1,1
7803,50594,,BAO_0000218,,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (run time 7 hr),,,N,Intermediate,A,10090.0,CHEMBL621335,,,,,1,1
7804,50588,,BAO_0000218,,,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in dogs,,,N,Intermediate,A,9615.0,CHEMBL621336,,,,,1,1
7805,50597,,BAO_0000218,,,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in rats,,,N,Intermediate,A,10116.0,CHEMBL621337,,,,,1,1
7806,50588,,BAO_0000218,,,Area under curve was measured after i.v. administration into Beagle dog.,,,N,Intermediate,A,9615.0,CHEMBL621338,,,,,1,1
7807,50588,,BAO_0000218,,,Area under curve was measured after iv administration into Beagle dog,,,N,Intermediate,A,9615.0,CHEMBL875838,,,,,1,1
7808,50588,,BAO_0000218,,,Area under curve was measured after po administration into Beagle dog,,,N,Intermediate,A,9615.0,CHEMBL621339,,,,,1,1
7809,50588,,BAO_0000218,,,Area under curve was measured after po administration into Beagle dog.,,,N,Intermediate,A,9615.0,CHEMBL621340,,,,,1,1
7810,22224,,BAO_0000218,,,Area under curve was measured at peroral dose of 3 mg/kg,,,U,Autocuration,A,,CHEMBL621341,,,,,0,1
7811,22224,,BAO_0000019,,,Area under curve was measured by using concentration Vs time,,,U,Autocuration,A,,CHEMBL621342,,,,,0,1
7812,22224,,BAO_0000019,,,Area under curve was measured by using concentration Vs time; not tested,,,U,Autocuration,A,,CHEMBL621343,,,,,0,1
7813,50594,,BAO_0000218,,,Area under curve(AUC) was measured in mice after oral administration (50 mg/kg),,,N,Intermediate,A,10090.0,CHEMBL621344,,,,,1,1
7814,50594,,BAO_0000218,,,Area under curve(AUC) was measured in mice after oral administration.,,,N,Intermediate,A,10090.0,CHEMBL621345,,,,,1,1
7815,22224,,BAO_0000019,,,Area under curve(AUC) value of the compound,,,U,Autocuration,A,,CHEMBL621346,,,,,0,1
7816,22224,,BAO_0000218,,,Area under curve(AUC) value of the compound in dogs at 0.5 mg/kg dose upon oral administration,,,U,Autocuration,A,,CHEMBL621347,,,,,0,1
7817,50588,,BAO_0000218,,,Area under curve(AUC) value of the compound in dogs at 1 mg/kg dose upon oral administration,,,N,Intermediate,A,9615.0,CHEMBL621348,,,,,1,1
7818,22224,,BAO_0000019,,,Area under curve(carotid artery) was determined by the availability in blood,,,U,Autocuration,A,,CHEMBL621349,,178.0,Blood,,0,1
7819,22224,,BAO_0000019,,,Area under curve(carotid artery) was determined by the availability in blood; ND means no data,,,U,Autocuration,A,,CHEMBL621350,,178.0,Blood,,0,1
7820,22224,,BAO_0000019,,,Area under curve(carotid artery) was determined by the availability in blood; No data,,,U,Autocuration,A,,CHEMBL875839,,178.0,Blood,,0,1
7821,22224,,BAO_0000019,,,Area under curve(portal vein) was determined by the availability in blood,,,U,Autocuration,A,,CHEMBL620211,,178.0,Blood,,0,1
7822,22224,,BAO_0000019,,,Area under curve(portal vein) was determined by the availability in blood; ND means no data,,,U,Autocuration,A,,CHEMBL620212,,178.0,Blood,,0,1
7823,22224,,BAO_0000019,,,Area under curve(portal vein) was determined by the availability in blood; No data,,,U,Autocuration,A,,CHEMBL620213,,178.0,Blood,,0,1
7824,50797,,BAO_0000218,,,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose",,,N,Intermediate,A,9544.0,CHEMBL620214,,1969.0,Plasma,,1,1
7825,50797,,BAO_0000218,,,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose",,,N,Intermediate,A,9544.0,CHEMBL620215,,1969.0,Plasma,,1,1
7826,50797,,BAO_0000218,,,Area under plasma concentration vs time curve observed in Rhesus monkeys after oral administration of single 30 mg/kg dose,,,N,Intermediate,A,9544.0,CHEMBL620216,,1969.0,Plasma,,1,1
7827,50588,,BAO_0000218,,,"Area under plasma concentration vs time curve observed in female mongrel dogs after, iv administration of single 15 mg/kg dose",,,N,Intermediate,A,9615.0,CHEMBL620888,,1969.0,Plasma,,1,1
7828,50588,,BAO_0000218,,,"Area under plasma concentration vs time curve observed in female mongrel dogs after, oral administration of single 15 mg/kg dose",,,N,Intermediate,A,9615.0,CHEMBL620889,,1969.0,Plasma,,1,1
7829,22224,,BAO_0000019,,,Area under plasma concentration vs time curve observed in rats for 0-3 h,,,U,Autocuration,A,,CHEMBL620890,,1969.0,Plasma,,0,1
7830,50597,,BAO_0000218,,,Area under plasma time curve determined in male rat,,,N,Intermediate,A,10116.0,CHEMBL620891,,1969.0,Plasma,,1,1
7831,22224,,BAO_0000019,,,Area under the MAP curve measured over 5 min.,,,U,Autocuration,A,,CHEMBL620892,,,,,0,1
7832,50594,,BAO_0000218,,,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through iv route in mice,,,N,Intermediate,A,10090.0,CHEMBL621079,,,,,1,1
7833,50594,,BAO_0000218,,,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through oral route in mice,,,N,Intermediate,A,10090.0,CHEMBL621080,,,,,1,1
7834,50588,,BAO_0000218,,,Area under the concentration vs time curve in dog at 10 mg/kg oral dose,,,N,Intermediate,A,9615.0,CHEMBL621081,,,,,1,1
7835,100712,,BAO_0000218,,,Area under the concentration vs time curve in hamster at 10 mg/kg oral dose,,,N,Intermediate,A,10026.0,CHEMBL621082,,,,,1,1
7836,50597,,BAO_0000218,,,Area under the concentration vs time curve in rat at 10 mg/kg oral dose,,,N,Intermediate,A,10116.0,CHEMBL621083,,,,,1,1
7837,50588,,BAO_0000218,,,Area under the concentration-time curve from time zero to infinity after intravenous administration of 2.5 mg/kg in dogs,,,N,Intermediate,A,9615.0,CHEMBL621084,,,,,1,1
7838,50588,,BAO_0000218,,,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fasted dogs,,,N,Intermediate,A,9615.0,CHEMBL621085,,,,,1,1
7839,50588,,BAO_0000218,,,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fed dogs,,,N,Intermediate,A,9615.0,CHEMBL621086,,,,,1,1
7840,50588,,BAO_0000218,,,Area under the concentration/ time determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),,,N,Intermediate,A,9615.0,CHEMBL621087,,,,,1,1
7841,50588,,BAO_0000218,,,Area under the concentration/ time in plasma after oral administration in dog (25 mg/kg),,,N,Intermediate,A,9615.0,CHEMBL622607,,,,,1,1
7842,50588,,BAO_0000218,,,Serum AUC in marmosets (IV dose),,,N,Intermediate,A,9615.0,CHEMBL622608,,,,,1,1
7843,22224,,BAO_0000019,,,Area under the curve after intravenous administration at a dose of 10 umol/kg,,,U,Autocuration,A,,CHEMBL624481,,,,,0,1
7844,22224,,BAO_0000019,,,Area under the curve after intravenous administration at a dose of 2 umol/kg,,,U,Autocuration,A,,CHEMBL624482,,,,,0,1
7845,22224,,BAO_0000019,,,Area under the curve after intravenous administration at a dose of 4 umol/kg,,,U,Autocuration,A,,CHEMBL624483,,,,,0,1
7846,22224,,BAO_0000019,,,Area under the curve after intravenous administration at a dose of 40 umol/kg,,,U,Autocuration,A,,CHEMBL624484,,,,,0,1
7847,22224,,BAO_0000019,,,Area under the curve after intravenous administration at a dose of 5 umol/kg,,,U,Autocuration,A,,CHEMBL624485,,,,,0,1
7848,50597,,BAO_0000218,,,Area under the curve for fumarate salt was evaluated in F344 Rats.,,,N,Intermediate,A,10116.0,CHEMBL624486,,,,,1,1
7849,22224,,BAO_0000019,,,Area under the curve for the compound was calculated.,,,U,Autocuration,A,,CHEMBL624487,,,,,0,1
7850,22224,,BAO_0000019,,,Area under the curve in concentration/ time,,,U,Autocuration,A,,CHEMBL624488,,,,,0,1
7851,50597,,BAO_0000218,,,Area under the curve administered intraintestinal in rats.,,,N,Intermediate,A,10116.0,CHEMBL624489,,,,,1,1
7852,50597,,BAO_0000218,,,Area under the curve administered intravenously in rats.,,,N,Intermediate,A,10116.0,CHEMBL625184,,,,,1,1
7853,22224,,BAO_0000019,,,Area under the curve during intravenous administration,,,U,Autocuration,A,,CHEMBL625185,,,,,0,1
7854,22224,,BAO_0000019,,,Area under the curve during intravenous administration; Not determined,,,U,Autocuration,A,,CHEMBL875954,,,,,0,1
7855,22224,,BAO_0000019,,,Area under the curve during systemic administration,,,U,Autocuration,A,,CHEMBL625186,,,,,0,1
7856,22224,,BAO_0000019,,,Area under the curve during systemic administration; Not determined,,,U,Autocuration,A,,CHEMBL625187,,,,,0,1
7857,22224,,BAO_0000019,,,Area under the curve was calculated for the compound.,,,U,Autocuration,A,,CHEMBL625188,,,,,0,1
7858,50588,,BAO_0000218,,,Area under the curve was determined after intravenous administration of 1.8 mg/kg in male Beagle dogs,,,N,Intermediate,A,9615.0,CHEMBL625189,,,,,1,1
7859,50588,,BAO_0000218,,,Area under the curve was determined after intravenous administration of 10 mg/kg in male Beagle dogs,,,N,Intermediate,A,9615.0,CHEMBL625190,,,,,1,1
7860,50597,,BAO_0000218,,,Area under the curve was determined after intravenous administration of 2.5 mg/kg in male Dawley rats,,,N,Intermediate,A,10116.0,CHEMBL621733,,,,,1,1
7861,50597,,BAO_0000218,,,Area under the curve was determined after intravenous administration of 2.6 mg/kg in male Dawley rats,,,N,Intermediate,A,10116.0,CHEMBL621734,,,,,1,1
7862,50597,,BAO_0000218,,,C6h was measured as concentration obtained after 6 hr of oral administration in air pouch exudate after oral administration to male F344 rats,,,N,Intermediate,A,10116.0,CHEMBL621735,,,,,1,1
7863,50597,,BAO_0000218,,,Clearance of the drug was measured in the plasma of rat; No data,,,N,Intermediate,A,10116.0,CHEMBL621736,,1969.0,Plasma,,1,1
7864,50597,,BAO_0000218,,,The pharmacokinetic parameter plasma clearance in vivo in rats,,,N,Intermediate,A,10116.0,CHEMBL621737,,1969.0,Plasma,,1,1
7865,50597,,BAO_0000218,,,Plasma clearance at the dose of 2 mg/kg in rat,,,N,Intermediate,A,10116.0,CHEMBL621738,,,,,1,1
7866,50597,In vivo,BAO_0000218,,,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,,,N,Intermediate,A,10116.0,CHEMBL622806,,,,,1,1
7867,50597,In vivo,BAO_0000218,,,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,,,N,Intermediate,A,10116.0,CHEMBL623519,,,,,1,1
7868,50597,In vivo,BAO_0000218,,,CL at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,,,N,Intermediate,A,10116.0,CHEMBL623520,,,,,1,1
7869,50597,In vivo,BAO_0000218,,,Clearance measured after intravenous bolus administration of 50 mg/kg of compound to rats,,,N,Intermediate,A,10116.0,CHEMBL623521,,,,,1,1
7870,50597,In vivo,BAO_0000218,,,Clearance in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL623522,,,,,1,1
7871,50597,In vivo,BAO_0000218,,,Clearance rate in rat,,,N,Intermediate,A,10116.0,CHEMBL623523,,,,,1,1
7872,50597,In vivo,BAO_0000218,,,Clearance rate in rat,,,N,Intermediate,A,10116.0,CHEMBL623690,,,,,1,1
7873,50597,In vivo,BAO_0000218,,,Clearance (Cl) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,,,N,Intermediate,A,10116.0,CHEMBL623691,,,,,1,1
7874,50597,In vivo,BAO_0000218,,,Clearance (Cl) of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,,,N,Intermediate,A,10116.0,CHEMBL623692,,,,,1,1
7875,50597,In vivo,BAO_0000218,,,Clearance (Cl) of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,,,N,Intermediate,A,10116.0,CHEMBL623693,,,,,1,1
7876,50597,In vivo,BAO_0000218,,,Clearance (Cl) of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat,,,N,Intermediate,A,10116.0,CHEMBL623694,,,,,1,1
7877,50597,In vivo,BAO_0000218,,,Clearance of compound after iv administration of 20 mg/kg dose in rat,,,N,Intermediate,A,10116.0,CHEMBL623695,,,,,1,1
7878,50597,In vivo,BAO_0000218,,,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female wistar rats,,,N,Intermediate,A,10116.0,CHEMBL623696,,,,,1,1
7879,50597,In vivo,BAO_0000218,,,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to male wistar rats,,,N,Intermediate,A,10116.0,CHEMBL623697,,,,,1,1
7880,22224,In vivo,BAO_0000218,,,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,,,U,Intermediate,A,9544.0,CHEMBL623698,,1969.0,Plasma,,0,1
7881,22224,In vivo,BAO_0000218,,,Compound was tested for its plasma clearance rate in Sprague Dawley rats,,,U,Intermediate,A,10116.0,CHEMBL623699,,1969.0,Plasma,,0,1
7882,50597,In vivo,BAO_0000218,,,Mean (%CV) PK parameters for CL(mL/min/kg).,,,N,Intermediate,A,10116.0,CHEMBL623700,,,,,1,1
7883,50597,In vivo,BAO_0000218,,,Pharmacokinetic studies were carried out to determine the clearance after administration at 20 mg/kg intravenously in rat,,,N,Intermediate,A,10116.0,CHEMBL623701,,,,,1,1
7884,50597,In vivo,BAO_0000218,,,Pharmacokinetic parameter plasma clearance was determined at when a dose of 1 mg/kg is administered,,,N,Intermediate,A,10116.0,CHEMBL623702,,1969.0,Plasma,,1,1
7885,50597,In vivo,BAO_0000218,,,Plasma Clearance measured at steady-state following iv infusion at 0.6 mg/kg/h in rats,,,N,Intermediate,A,10116.0,CHEMBL623703,,,,,1,1
7886,50597,In vivo,BAO_0000218,,,Plasma clearance in rat was determined,,,N,Intermediate,A,10116.0,CHEMBL623704,,,,,1,1
7887,50597,In vivo,BAO_0000218,,,Plasma clearance in rat after administration of 2 mg/kg iv,,,N,Intermediate,A,10116.0,CHEMBL623705,,,,,1,1
7888,50597,In vivo,BAO_0000218,,,Plasma clearance in rat after administration of 2 mg/kg iv,,,N,Intermediate,A,10116.0,CHEMBL623706,,,,,1,1
7889,50597,In vivo,BAO_0000218,,,Plasma clearance was determined,,,N,Intermediate,A,10116.0,CHEMBL623707,,,,,1,1
7890,50597,In vivo,BAO_0000218,,,Plasma clearance in rat,,,N,Intermediate,A,10116.0,CHEMBL623708,,,,,1,1
7891,50597,In vivo,BAO_0000218,,,Plasma clearance in rat after intravenous administration at a concentration 0.5 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL623709,,,,,1,1
7892,50597,In vivo,BAO_0000218,,,Plasma clearance in rat by iv administration,,,N,Intermediate,A,10116.0,CHEMBL623710,,,,,1,1
7893,50597,In vivo,BAO_0000218,,,Plasma clearance in rat by iv administration at a dose of 3 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL623711,,,,,1,1
7894,50597,In vivo,BAO_0000218,,,Plasma clearance in rat p.o.,,,N,Intermediate,A,10116.0,CHEMBL623712,,,,,1,1
7895,50597,In vivo,BAO_0000218,,,Plasma clearance in rats,,,N,Intermediate,A,10116.0,CHEMBL623713,,,,,1,1
7896,50597,In vivo,BAO_0000218,,,Plasma clearance was determined; ND denotes no data,,,N,Intermediate,A,10116.0,CHEMBL623714,,,,,1,1
7897,50597,In vivo,BAO_0000218,,,Plasma clearance was determined; ND denotes not determined,,,N,Intermediate,A,10116.0,CHEMBL623715,,,,,1,1
7898,50597,In vivo,BAO_0000218,,,Plasma clearance was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,,,N,Intermediate,A,10116.0,CHEMBL623716,,,,,1,1
7899,50597,In vivo,BAO_0000218,,,Plasma clearance was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,,,N,Intermediate,A,10116.0,CHEMBL622980,,,,,1,1
7900,50597,In vivo,BAO_0000218,,,Plasma administration to rats,,,N,Intermediate,A,10116.0,CHEMBL622981,,,,,1,1
7901,50597,In vivo,BAO_0000218,,,Plasma clearance of the compound in female Sprague-Dawley rats,,,N,Intermediate,A,10116.0,CHEMBL622982,,,,,1,1
7902,50597,In vivo,BAO_0000218,,,Plasma clearance was observed after intravenous administration in rat,,,N,Intermediate,A,10116.0,CHEMBL622983,,,,,1,1
7903,50597,In vivo,BAO_0000218,,,Systemic clearance after intravenous administration (5.0 mg/kg) was determined in rat,,,N,Intermediate,A,10116.0,CHEMBL622984,,,,,1,1
7904,50597,In vivo,BAO_0000218,,,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in rat,,,N,Intermediate,A,10116.0,CHEMBL622985,,,,,1,1
7905,50597,In vivo,BAO_0000218,,,plasma clearance was observed after intravenous administration in rat,,,N,Intermediate,A,10116.0,CHEMBL623631,,1969.0,Plasma,,1,1
7906,50597,In vivo,BAO_0000218,,,In vivo CL/F determined,,,N,Intermediate,A,10116.0,CHEMBL623632,,,,,1,1
7907,50597,In vivo,BAO_0000218,,,Pharmacokinetic parameter plasma clearance was determined at 2 mg/kg i.v. dose in rats,,,N,Intermediate,A,10116.0,CHEMBL623633,,1969.0,Plasma,,1,1
7908,50597,In vivo,BAO_0000218,,,Pharmacokinetic parameter plasma clearance was determined at 5 mg/kg i.v. dose in rats,,,N,Intermediate,A,10116.0,CHEMBL623634,,1969.0,Plasma,,1,1
7909,50597,In vivo,BAO_0000218,,,Compound was tested for the lower blood clearance in rat,,,N,Intermediate,A,10116.0,CHEMBL623635,,,,,1,1
7910,50597,In vivo,BAO_0000218,,,Evaluated for the low clearance in rat (in vivo),,,N,Intermediate,A,10116.0,CHEMBL621195,,,,,1,1
7911,50597,In vivo,BAO_0000218,,,Pharmacokinetic property (CLb)of the compound was determined in rat,,,N,Intermediate,A,10116.0,CHEMBL621196,,,,,1,1
7912,50597,In vivo,BAO_0000218,,,Rapid clearance after intravenous administration in rat was determined,,,N,Intermediate,A,10116.0,CHEMBL875287,,,,,1,1
7913,50597,In vivo,BAO_0000218,,,Clearance measured in rat,,,N,Intermediate,A,10116.0,CHEMBL621197,,,,,1,1
7914,50597,In vivo,BAO_0000218,,,Compound was evaluated for plasma clearance in rat,,,N,Intermediate,A,10116.0,CHEMBL621198,,1969.0,Plasma,,1,1
7915,50597,In vivo,BAO_0000218,,,Low plasma clearance was calculated in rat,,,N,Intermediate,A,10116.0,CHEMBL621199,,1969.0,Plasma,,1,1
7916,50597,In vivo,BAO_0000218,,,Pharmacokinetic property (Clp) in rat,,,N,Intermediate,A,10116.0,CHEMBL621200,,,,,1,1
7917,50597,In vivo,BAO_0000218,,,Plasma clearance in dog at a dose of 1 uM/kg in rat was determined,,,N,Intermediate,A,10116.0,CHEMBL621201,,,,,1,1
7918,50597,In vivo,BAO_0000218,,,Plasma clearance in rat at a dose of 10 uM/kg in rat was determined,,,N,Intermediate,A,10116.0,CHEMBL621202,,,,,1,1
7919,50597,In vivo,BAO_0000218,,,Plasma clearance after IV dosing at 0.5 mg/kg in rat,,,N,Intermediate,A,10116.0,CHEMBL621203,,,,,1,1
7920,50597,In vivo,BAO_0000218,,,Plasma clearance after IV dosing at 1 mg/kg in rat,,,N,Intermediate,A,10116.0,CHEMBL621204,,,,,1,1
7921,50597,In vivo,BAO_0000218,,,Biodistribution in rat heart in the presence of 0.01 M Gd/0.01 M GdDTPA-AEP,,,N,Intermediate,A,10116.0,CHEMBL621205,,948.0,Heart,,1,1
7922,50597,In vivo,BAO_0000218,,,Biodistribution in rat heart in the presence of 0.01 M GdDTPA-BDP,,,N,Intermediate,A,10116.0,CHEMBL621206,,948.0,Heart,,1,1
7923,50597,In vivo,BAO_0000218,,,Biodistribution in rat heart in the presence of 0.01 M/0.08 M GdDTPA-AEP,,,N,Intermediate,A,10116.0,CHEMBL621207,,948.0,Heart,,1,1
7924,50597,In vivo,BAO_0000218,,,Biodistribution in rat heart in the presence of 0.05 M /0.05 M GdDTPA-AEP,,,N,Intermediate,A,10116.0,CHEMBL621208,,948.0,Heart,,1,1
7925,50597,In vivo,BAO_0000218,,,Biodistribution in rat heart in the presence of 0.05 M Gd/0.15 M lig,,,N,Intermediate,A,10116.0,CHEMBL621209,,948.0,Heart,,1,1
7926,50597,In vivo,BAO_0000218,,,Biodistribution in rat heart in the presence of 0.05 M GdDTPA-BDP,,,N,Intermediate,A,10116.0,CHEMBL876484,,948.0,Heart,,1,1
7927,50597,In vivo,BAO_0000218,,,Biodistribution in rat heart in the presence of 0.05 M/0.08 M GdDTPA-HPDP,,,N,Intermediate,A,10116.0,CHEMBL621210,,948.0,Heart,,1,1
7928,50597,In vivo,BAO_0000218,,,Biodistribution in rat heart in the presence of 0.10 M GdDTPA-BDP,,,N,Intermediate,A,10116.0,CHEMBL621211,,948.0,Heart,,1,1
7929,50597,In vivo,BAO_0000218,,,Biodistribution in rat heart in the presence of 0.10 M/0.11 M GdDTPA-AEP,,,N,Intermediate,A,10116.0,CHEMBL621212,,948.0,Heart,,1,1
7930,50597,In vivo,BAO_0000218,,,Biodistribution in rat heart in the presence of GdDTPA at 15 min,,,N,Intermediate,A,10116.0,CHEMBL621213,,948.0,Heart,,1,1
7931,50597,In vivo,BAO_0000218,,,Biodistribution in rat heart in the presence of GdDTPA at 1 hr,,,N,Intermediate,A,10116.0,CHEMBL621214,,948.0,Heart,,1,1
7932,50597,In vivo,BAO_0000218,,,Biodistribution in rat heart in the presence of GdDTPA at 30 min,,,N,Intermediate,A,10116.0,CHEMBL621215,,948.0,Heart,,1,1
7933,50597,In vivo,BAO_0000218,,,Biodistribution in rat heart in the presence of GdDTPA at 4 hr,,,N,Intermediate,A,10116.0,CHEMBL621216,,948.0,Heart,,1,1
7934,50597,In vivo,BAO_0000218,,,Biodistribution in rat heart in the presence of GdDTPA-BDP at 1 hr,,,N,Intermediate,A,10116.0,CHEMBL621217,,948.0,Heart,,1,1
7935,50597,In vivo,BAO_0000218,,,Biodistribution in rat heart in the presence of GdDTPA-BDP at 30 min,,,N,Intermediate,A,10116.0,CHEMBL621218,,948.0,Heart,,1,1
7936,50597,In vivo,BAO_0000218,,,Biodistribution in rat heart in the presence of GdDTPA-BDP at 4 hr,,,N,Intermediate,A,10116.0,CHEMBL621219,,948.0,Heart,,1,1
7937,50597,In vivo,BAO_0000218,,,Biodistribution in rat heart in the presence of GdDTPA-BDPat 15 min,,,N,Intermediate,A,10116.0,CHEMBL621220,,948.0,Heart,,1,1
7938,50597,In vivo,BAO_0000218,,,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 1 hr,,,N,Intermediate,A,10116.0,CHEMBL621221,,948.0,Heart,,1,1
7939,50597,In vivo,BAO_0000218,,,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 30 min,,,N,Intermediate,A,10116.0,CHEMBL621222,,948.0,Heart,,1,1
7940,50597,In vivo,BAO_0000218,,,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 4 hr,,,N,Intermediate,A,10116.0,CHEMBL621223,,948.0,Heart,,1,1
7941,50597,In vivo,BAO_0000218,,,Biodistribution in rat heart in the presence of GdDTPA-HPDPat 15 min,,,N,Intermediate,A,10116.0,CHEMBL876485,,948.0,Heart,,1,1
7942,50597,In vivo,BAO_0000218,,,Biodistribution in rat heart in the presence of NAC Gd/0.01 M GdDTPA-HPDP,,,N,Intermediate,A,10116.0,CHEMBL621224,,948.0,Heart,,1,1
7943,50597,In vivo,BAO_0000218,,,Biodistribution in rat heart in the presence of NCA Gd/0.01 M lip,,,N,Intermediate,A,10116.0,CHEMBL621225,,948.0,Heart,,1,1
7944,50597,In vivo,BAO_0000218,,,Biodistribution in rat heart in the presence of NCAGd/0.01 M lig,,,N,Intermediate,A,10116.0,CHEMBL621226,,948.0,Heart,,1,1
7945,50597,In vivo,BAO_0000218,,,Biodistribution in rat kidney in the presence of 0.01 M GdDTPA-BDP,,,N,Intermediate,A,10116.0,CHEMBL621227,,2113.0,Kidney,,1,1
7946,50597,In vivo,BAO_0000218,,,Biodistribution in rat kidney in the presence of 0.01 M/0.01 M GdDTPA-AEP,,,N,Intermediate,A,10116.0,CHEMBL621228,,2113.0,Kidney,,1,1
7947,50597,In vivo,BAO_0000218,,,Biodistribution in rat kidney in the presence of 0.01 M/0.08 M GdDTPA-AEP,,,N,Intermediate,A,10116.0,CHEMBL621229,,2113.0,Kidney,,1,1
7948,50597,In vivo,BAO_0000218,,,Biodistribution in rat kidney in the presence of 0.05 M Gd/0.15 M lig,,,N,Intermediate,A,10116.0,CHEMBL621230,,2113.0,Kidney,,1,1
7949,50597,In vivo,BAO_0000218,,,Biodistribution in rat kidney in the presence of 0.05 M GdDTPA-BDP; ND=No data,,,N,Intermediate,A,10116.0,CHEMBL621231,,2113.0,Kidney,,1,1
7950,50597,In vivo,BAO_0000218,,,Biodistribution in rat kidney in the presence of 0.05 M/0.05 M GdDTPA-AEP,,,N,Intermediate,A,10116.0,CHEMBL621232,,2113.0,Kidney,,1,1
7951,50597,In vivo,BAO_0000218,,,Biodistribution in rat kidney in the presence of 0.05 M/0.08 M GdDTPA-HPDP,,,N,Intermediate,A,10116.0,CHEMBL621233,,2113.0,Kidney,,1,1
7952,50597,In vivo,BAO_0000218,,,Biodistribution in rat kidney in the presence of 0.10 M GdDTPA-BDP,,,N,Intermediate,A,10116.0,CHEMBL621234,,2113.0,Kidney,,1,1
7953,50597,In vivo,BAO_0000218,,,Biodistribution in rat kidney in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data,,,N,Intermediate,A,10116.0,CHEMBL621235,,2113.0,Kidney,,1,1
7954,50597,In vivo,BAO_0000218,,,Biodistribution in rat kidney in the presence of NAC Gd/0.01 M GdDTPA-HPDP,,,N,Intermediate,A,10116.0,CHEMBL621236,,2113.0,Kidney,,1,1
7955,50597,In vivo,BAO_0000218,,,Biodistribution in rat kidney in the presence of NCA Gd/0.01 M lip,,,N,Intermediate,A,10116.0,CHEMBL621237,,2113.0,Kidney,,1,1
7956,50597,In vivo,BAO_0000218,,,Biodistribution in rat kidney in the presence of NCAGd/0.01 M lig,,,N,Intermediate,A,10116.0,CHEMBL876486,,2113.0,Kidney,,1,1
7957,50597,In vivo,BAO_0000218,,,Biodistribution in rat l. intestine in the presence of 0.01 M carrier at 1 hr,,,N,Intermediate,A,10116.0,CHEMBL622436,,160.0,Intestine,,1,1
7958,50597,In vivo,BAO_0000218,,,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 2 hr,,,N,Intermediate,A,10116.0,CHEMBL622437,,160.0,Intestine,,1,1
7959,50597,In vivo,BAO_0000218,,,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 6 hr,,,N,Intermediate,A,10116.0,CHEMBL622438,,160.0,Intestine,,1,1
7960,50597,In vivo,BAO_0000218,,,Biodistribution in rat liver by in the presence 50 Gd/kg at 15 min,,,N,Intermediate,A,10116.0,CHEMBL622439,,2107.0,Liver,,1,1
7961,50597,In vivo,BAO_0000218,,,Biodistribution in rat liver by in the presence of 0.05 M Gd/0.15 M lig,,,N,Intermediate,A,10116.0,CHEMBL622440,,2107.0,Liver,,1,1
7962,50597,In vivo,BAO_0000218,,,Biodistribution in rat liver by in the presence of NCAGd/0.01 M lig,,,N,Intermediate,A,10116.0,CHEMBL622441,,2107.0,Liver,,1,1
7963,50597,In vivo,BAO_0000218,,,Biodistribution in rat liver in the presence of 0.001 M/0.008 M GdDTPA-AEP,,,N,Intermediate,A,10116.0,CHEMBL622442,,2107.0,Liver,,1,1
7964,50597,In vivo,BAO_0000218,,,Biodistribution in rat liver in the presence of 0.01 M GdDTPA-BDP,,,N,Intermediate,A,10116.0,CHEMBL622443,,2107.0,Liver,,1,1
7965,50597,In vivo,BAO_0000218,,,Biodistribution in rat liver in the presence of 0.01 M/0.01 M GdDTPA-AEP,,,N,Intermediate,A,10116.0,CHEMBL622444,,2107.0,Liver,,1,1
7966,50597,In vivo,BAO_0000218,,,Biodistribution in rat liver in the presence of 0.05 M GdDTPA-BDP,,,N,Intermediate,A,10116.0,CHEMBL622445,,2107.0,Liver,,1,1
7967,50597,In vivo,BAO_0000218,,,Biodistribution in rat liver in the presence of 0.05 M/0.05 M GdDTPA-AEP,,,N,Intermediate,A,10116.0,CHEMBL622446,,2107.0,Liver,,1,1
7968,50597,In vivo,BAO_0000218,,,Biodistribution in rat liver in the presence of 0.05 M/0.08 M GdDTPA-HPDP,,,N,Intermediate,A,10116.0,CHEMBL622447,,2107.0,Liver,,1,1
7969,50597,In vivo,BAO_0000218,,,Biodistribution in rat liver in the presence of 0.10 M GdDTPA-BDP,,,N,Intermediate,A,10116.0,CHEMBL622448,,2107.0,Liver,,1,1
7970,50597,In vivo,BAO_0000218,,,Biodistribution in rat liver in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data,,,N,Intermediate,A,10116.0,CHEMBL622449,,2107.0,Liver,,1,1
7971,50597,In vivo,BAO_0000218,,,Biodistribution in rat liver in the presence of 50 Gd/kg at 2 hr,,,N,Intermediate,A,10116.0,CHEMBL622450,,2107.0,Liver,,1,1
7972,50597,In vivo,BAO_0000218,,,Biodistribution in rat liver in the presence of 50 Gd/kg at at 6 hr,,,N,Intermediate,A,10116.0,CHEMBL622451,,2107.0,Liver,,1,1
7973,50597,In vivo,BAO_0000218,,,Biodistribution in rat liver in the presence of GdDTPA at 15 min,,,N,Intermediate,A,10116.0,CHEMBL622452,,2107.0,Liver,,1,1
7974,50597,In vivo,BAO_0000218,,,Biodistribution in rat liver in the presence of GdDTPA at 1 hr,,,N,Intermediate,A,10116.0,CHEMBL622453,,2107.0,Liver,,1,1
7975,50597,In vivo,BAO_0000218,,,Biodistribution in rat liver in the presence of GdDTPA at 30 min,,,N,Intermediate,A,10116.0,CHEMBL622454,,2107.0,Liver,,1,1
7976,50597,In vivo,BAO_0000218,,,Biodistribution in rat liver in the presence of GdDTPA at 4 hr,,,N,Intermediate,A,10116.0,CHEMBL622455,,2107.0,Liver,,1,1
7977,50597,In vivo,BAO_0000218,,,Biodistribution in rat liver in the presence of GdDTPA-BDP at 15 min,,,N,Intermediate,A,10116.0,CHEMBL876024,,2107.0,Liver,,1,1
7978,50597,In vivo,BAO_0000218,,,T max was determined at 3 mg/kg po dose in rats,,,N,Intermediate,A,10116.0,CHEMBL622456,,,,,1,1
7979,50597,In vivo,BAO_0000218,,,"The Tmax value in female wistar rat at 100 mg/kg, p.o. dose",,,N,Intermediate,A,10116.0,CHEMBL622457,,,,,1,1
7980,50597,In vivo,BAO_0000218,,,"The Tmax value in male wistar rat at 100 mg/kg, p.o. dose",,,N,Intermediate,A,10116.0,CHEMBL622458,,,,,1,1
7981,50597,,BAO_0000218,,,The time to reach maximum concentration of compound was measured at the dose of 100 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL622459,,,,,1,1
7982,50597,,BAO_0000218,,,The time to reach maximum concentration of compound was measured at the dose of 300 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL873343,,,,,1,1
7983,50597,,BAO_0000218,,,The time to reach maximum concentration of compound was measured at the dose of 30 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL622460,,,,,1,1
7984,50597,,BAO_0000218,,,Time for maximum plasma concentration determined in rat,,,N,Intermediate,A,10116.0,CHEMBL622461,,1969.0,Plasma,,1,1
7985,50597,In vivo,BAO_0000218,,,Time for maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose,,,N,Intermediate,A,10116.0,CHEMBL622462,,1969.0,Plasma,,1,1
7986,50597,In vivo,BAO_0000218,,,Time of maximum concentration of the drug when administered orally a dose of 10 mg/kg to a fasting rat,,,N,Intermediate,A,10116.0,CHEMBL622463,,,,,1,1
7987,50597,In vivo,BAO_0000218,,,Time of maximum concentration of the drug when administered orally a dose of 1 mg/kg to a fasting rat,,,N,Intermediate,A,10116.0,CHEMBL622464,,,,,1,1
7988,50597,In vivo,BAO_0000218,,,Time of maximum concentration of the drug when administered orally a dose of 30 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL622465,,,,,1,1
7989,50597,In vivo,BAO_0000218,,,Time of maximum concentration of the drug when administered orally a dose of 3 mg/kg to a fasting rat,,,N,Intermediate,A,10116.0,CHEMBL622466,,,,,1,1
7990,50597,In vivo,BAO_0000218,,,Time of maximum concentration of the drug when administered orally at dose of 3 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL622467,,,,,1,1
7991,50597,,BAO_0000218,,,Time of maximum plasma concentration in rat,,,N,Intermediate,A,10116.0,CHEMBL622468,,1969.0,Plasma,,1,1
7992,50597,,BAO_0000218,,,"Time required by compound for reaching maximum plasma concentration was determined in rats at 10 mg/kg, p.o. dose",,,N,Intermediate,A,10116.0,CHEMBL876025,,1969.0,Plasma,,1,1
7993,50597,,BAO_0000218,,,"Time required by compound for reaching maximum plasma concentration was determined in rats at 20 mg/kg, i.p. dose",,,N,Intermediate,A,10116.0,CHEMBL622469,,1969.0,Plasma,,1,1
7994,50597,,BAO_0000218,,,"Time required by compound for reaching maximum plasma concentration was determined in rats at 2 mg/kg, i.v. dose; n/a: not applicable",,,N,Intermediate,A,10116.0,CHEMBL622470,,1969.0,Plasma,,1,1
7995,50597,In vivo,BAO_0000218,,,Time required to reach maximum concentration (Cmax) after oral administration in rat,,,N,Intermediate,A,10116.0,CHEMBL622471,,,,,1,1
7996,50597,,BAO_0000218,,,Time required to reach maximum concentration in rat plasma,,,N,Intermediate,A,10116.0,CHEMBL622472,,1969.0,Plasma,,1,1
7997,50597,In vivo,BAO_0000218,,,Time taken by the compound to achieve maximum concentration in rat plasma at 30 mg/Kg upon oral administration.,,,N,Intermediate,A,10116.0,CHEMBL622473,,1969.0,Plasma,,1,1
7998,50597,In vivo,BAO_0000218,,,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats,,,N,Intermediate,A,10116.0,CHEMBL624282,,1969.0,Plasma,,1,1
7999,50597,In vivo,BAO_0000218,,,Time taken for maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL624283,,1969.0,Plasma,,1,1
8000,50597,In vivo,BAO_0000218,,,Time taken for maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL624284,,1969.0,Plasma,,1,1
8001,50597,In vivo,BAO_0000218,,,Time taken to reach maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,,,N,Intermediate,A,10116.0,CHEMBL624285,,1969.0,Plasma,,1,1
8002,50597,In vivo,BAO_0000218,,,Time to reach Cmax after oral administration to rats,,,N,Intermediate,A,10116.0,CHEMBL624286,,,,,1,1
8003,50597,In vivo,BAO_0000218,,,Time to reach Cmax when a dose of 1 mg/kg is administered orally,,,N,Intermediate,A,10116.0,CHEMBL624287,,,,,1,1
8004,50597,,BAO_0000218,,,Time to reach maximum concentration following oral administration of 200 mg/kg in rat; value ranges from 2-4,,,N,Intermediate,A,10116.0,CHEMBL624288,,,,,1,1
8005,50597,In vivo,BAO_0000218,,,Time to reach maximum plasma concentration was evaluated at an intravenous dose of 3 mg/kg; Not applicable,,,N,Intermediate,A,10116.0,CHEMBL624289,,1969.0,Plasma,,1,1
8006,50597,In vivo,BAO_0000218,,,Time to reach maximum plasma concentration was evaluated at an oral dose of 30 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL873344,,1969.0,Plasma,,1,1
8007,50597,In vivo,BAO_0000218,,,Tmax after peroral administration (10 mg/kg) was determined in rat,,,N,Intermediate,A,10116.0,CHEMBL619623,,,,,1,1
8008,50597,In vivo,BAO_0000218,,,Tmax of compound determined in rat after iv administration at a dose of 10 mg/kg,,,N,Expert,A,10116.0,CHEMBL621399,,,,,1,1
8009,50597,In vivo,BAO_0000218,,,Tmax by oral administration at a dose of 100 uM/kg in rat was determined,,,N,Intermediate,A,10116.0,CHEMBL621400,,,,,1,1
8010,50597,In vivo,BAO_0000218,,,"Tmax in fischer rats at 5 mg/kg dose, administered intravenously",,,N,Intermediate,A,10116.0,CHEMBL621401,,,,,1,1
8011,50597,,BAO_0000218,,,Tmax was determined,,,N,Intermediate,A,10116.0,CHEMBL621402,,,,,1,1
8012,50597,,BAO_0000218,,,Tmax was determined,,,N,Intermediate,A,10116.0,CHEMBL621403,,,,,1,1
8013,50597,In vivo,BAO_0000218,,,Tmax after oral administration in rat,,,N,Intermediate,A,10116.0,CHEMBL621121,,,,,1,1
8014,50597,In vivo,BAO_0000218,,,Tmax after peroral administration in rats at 2.4 uM/kg,,,N,Intermediate,A,10116.0,CHEMBL872525,,,,,1,1
8015,50597,,BAO_0000218,,,Tmax in male rat,,,N,Intermediate,A,10116.0,CHEMBL621122,,,,,1,1
8016,50597,In vivo,BAO_0000218,,,Tmax in rat at 10 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL621123,,,,,1,1
8017,50597,In vivo,BAO_0000218,,,Tmax in rat by po administration at a dose of 40 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL621124,,,,,1,1
8018,50597,,BAO_0000218,,,Tmax in rats,,,N,Intermediate,A,10116.0,CHEMBL621125,,,,,1,1
8019,50597,In vivo,BAO_0000218,,,Tmax was measured in rats after peroral administration at 5 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL621126,,,,,1,1
8020,50597,In vivo,BAO_0000218,,,Tmax value after oral dose at a dose of 10 mg/kg in rats.,,,N,Intermediate,A,10116.0,CHEMBL621127,,,,,1,1
8021,50597,In vivo,BAO_0000218,,,Tmax value after administration of 20 mg/Kg oral dose in rat,,,N,Intermediate,A,10116.0,CHEMBL621128,,,,,1,1
8022,50597,In vivo,BAO_0000218,,,Tmax value at a dose of 10 mg/kg in male SD rats,,,N,Intermediate,A,10116.0,CHEMBL618263,,,,,1,1
8023,50597,In vivo,BAO_0000218,,,Tmax value at a dose of 100 mg/kg in male SD rats,,,N,Intermediate,A,10116.0,CHEMBL618264,,,,,1,1
8024,50597,In vivo,BAO_0000218,,,Tmax value at a dose of 50 mg/kg in male SD rats,,,N,Intermediate,A,10116.0,CHEMBL618265,,,,,1,1
8025,50597,In vivo,BAO_0000218,,,Total concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,,,N,Intermediate,A,10116.0,CHEMBL618266,,1969.0,Plasma,,1,1
8026,50597,In vivo,BAO_0000218,,,time required to reach maximum concentration (Cmax) after oral administration in rat,,,N,Intermediate,A,10116.0,CHEMBL618267,,,,,1,1
8027,50597,,BAO_0000218,,,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg ( 0-24 hr ),,,N,Intermediate,A,10116.0,CHEMBL618450,,1088.0,Urine,,1,1
8028,50597,,BAO_0000218,,,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg (0-24 hr),,,N,Intermediate,A,10116.0,CHEMBL618451,,1088.0,Urine,,1,1
8029,50597,,BAO_0000218,,,Unbound plasma was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,,,N,Intermediate,A,10116.0,CHEMBL618452,,,,,1,1
8030,50597,,BAO_0000218,,,Amount of urine output was measured in rat at a dose of 1 mg/kg/po,,,N,Intermediate,A,10116.0,CHEMBL618453,,1088.0,Urine,,1,1
8031,50597,,BAO_0000218,,,Amount of urine output was measured in rat at a dose of 10 mg/kg/po,,,N,Intermediate,A,10116.0,CHEMBL618454,,1088.0,Urine,,1,1
8032,50597,,BAO_0000218,,,Amount of urine output was measured in rat at a dose of 10 mg/kg/po; NT-Not tested,,,N,Intermediate,A,10116.0,CHEMBL618455,,1088.0,Urine,,1,1
8033,50597,In vivo,BAO_0000218,,,Volume of distribution was determined in rat after a 3 mg/kg of iv dose,,,N,Intermediate,A,10116.0,CHEMBL618456,,,,,1,1
8034,50597,In vivo,BAO_0000218,,,Compound distribution in rat tissues was determined,,,N,Intermediate,A,10116.0,CHEMBL618457,,,,,1,1
8035,50597,In vivo,BAO_0000218,,,Volume of distribution was evaluated in rat,,,N,Intermediate,A,10116.0,CHEMBL618458,,,,,1,1
8036,50597,,BAO_0000218,,,Area under the curve was determined after intravenous administration of 2.7 mg/kg in male Dawley rats,,,N,Intermediate,A,10116.0,CHEMBL618459,,,,,1,1
8037,50597,,BAO_0000218,,,Area under the curve was determined after intravenous administration of 2.8 mg/kg in male Dawley rats,,,N,Intermediate,A,10116.0,CHEMBL876733,,,,,1,1
8038,50588,,BAO_0000218,,,Area under the curve was determined after intravenous administration of 4.9 mg/kg in male Beagle dogs,,,N,Intermediate,A,9615.0,CHEMBL618460,,,,,1,1
8039,50597,,BAO_0000218,,,Area under the curve was determined after intravenous administration of 5.1 mg/kg in male Dawley rats,,,N,Intermediate,A,10116.0,CHEMBL618461,,,,,1,1
8040,22224,,BAO_0000019,,,Area under the curve was determined after oral administration (300 uM/Kg),,,U,Autocuration,A,,CHEMBL618462,,,,,0,1
8041,50597,,BAO_0000218,,,Area under the curve was determined after peroral administration of 5.0 mg/kg in male Dawley rats,,,N,Intermediate,A,10116.0,CHEMBL618463,,,,,1,1
8042,50597,,BAO_0000218,,,Area under the curve was determined after peroral administration of 5.1 mg/kg in mal Dawley rats,,,N,Intermediate,A,10116.0,CHEMBL618464,,,,,1,1
8043,50597,,BAO_0000218,,,Area under the curve was determined after peroral administration of 5.1 mg/kg in male Dawley rats,,,N,Intermediate,A,10116.0,CHEMBL618465,,,,,1,1
8044,50597,,BAO_0000218,,,Area under the curve was determined after peroral administration of 5.2 mg/kg in mal Dawley rats,,,N,Intermediate,A,10116.0,CHEMBL618466,,,,,1,1
8045,50597,,BAO_0000218,,,Area under the curve was determined after peroral administration of 5.2 mg/kg in male Dawley rats,,,N,Intermediate,A,10116.0,CHEMBL618467,,,,,1,1
8046,50597,,BAO_0000218,,,Area under the curve was determined for the compound after iv dose of 4.97 mg/kg in rats,,,N,Intermediate,A,10116.0,CHEMBL618468,,,,,1,1
8047,50588,,BAO_0000218,,,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 100 mg/kg,,,N,Intermediate,A,9615.0,CHEMBL618469,,1969.0,Plasma,,1,1
8048,50588,,BAO_0000218,,,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 20 mg/kg,,,N,Intermediate,A,9615.0,CHEMBL618470,,1969.0,Plasma,,1,1
8049,22224,,BAO_0000218,,,Plasma drug AUC in rat (PO dose),,,U,Autocuration,A,,CHEMBL618471,,,,,0,1
8050,50594,,BAO_0000218,,,Area under the tumor growth curve (AUC) in the B-6 Melanoma Model in C57/b1 mice at the dose of 1 mg/kg.,,,N,Intermediate,A,10090.0,CHEMBL618472,,,,,1,1
8051,22224,,BAO_0000218,,,Area under was determined at a dose of 30 mg/kg,,,U,Autocuration,A,,CHEMBL618473,,,,,0,1
8052,50506,,BAO_0000218,,,Average area under curve for compound at 1 mg/kg dose intravenous administration to Ferret,,,N,Intermediate,A,9669.0,CHEMBL621699,,,,,1,1
8053,50597,,BAO_0000218,,,Average area under curve for the compound at 10 mg/kg dose after intraduodenal administration to rat,,,N,Intermediate,A,10116.0,CHEMBL621700,,,,,1,1
8054,50597,,BAO_0000218,,,Average area under curve for the compound at 1 mg/kg dose after intravenous administration to rat,,,N,Intermediate,A,10116.0,CHEMBL621701,,,,,1,1
8055,50506,,BAO_0000218,,,Average area under curve at 10 mg/kg dose after intraduodenal administration to Ferret,,,N,Intermediate,A,9669.0,CHEMBL621702,,,,,1,1
8056,50588,,BAO_0000218,,,Average area under curve at 10 mg/kg intraduodenal administration to salt depleted dog,,,N,Intermediate,A,9615.0,CHEMBL621703,,,,,1,1
8057,50588,,BAO_0000218,,,Average area under curve at 1 mg/kg intravenous administration to salt depleted dog,,,N,Intermediate,A,9615.0,CHEMBL621704,,,,,1,1
8058,50597,,BAO_0000218,,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 1.0(pmol/g/h)",,,N,Intermediate,A,10116.0,CHEMBL624259,,,,,1,1
8059,50597,,BAO_0000218,,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 2.0(pmol/g/h)",,,N,Intermediate,A,10116.0,CHEMBL624260,,,,,1,1
8060,50597,,BAO_0000218,,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 4.0(pmol/g/h)",,,N,Intermediate,A,10116.0,CHEMBL624430,,,,,1,1
8061,50597,,BAO_0000218,,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 5.0(pmol/g/h)",,,N,Intermediate,A,10116.0,CHEMBL624431,,,,,1,1
8062,50597,,BAO_0000218,,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 54.0(pmol/g/h)",,,N,Intermediate,A,10116.0,CHEMBL624432,,,,,1,1
8063,50597,,BAO_0000218,,,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 10.0(pmol/g/h)",,,N,Intermediate,A,10116.0,CHEMBL624433,,,,,1,1
8064,50597,,BAO_0000218,,,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 20.0(pmol/g/h)",,,N,Intermediate,A,10116.0,CHEMBL624434,,,,,1,1
8065,50597,,BAO_0000218,,,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 40.0(pmol/g/h)",,,N,Intermediate,A,10116.0,CHEMBL624435,,,,,1,1
8066,50594,,BAO_0000218,,,Bioavailability in mouse brain after intravenous administration of 105.1 mg/kg of dose,,,N,Intermediate,A,10090.0,CHEMBL618570,,,,,1,1
8067,50594,,BAO_0000218,,,Bioavailability in mouse brain after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),,,N,Intermediate,A,10090.0,CHEMBL618571,,,,,1,1
8068,50594,,BAO_0000218,,,Bioavailability in mouse brain after oral administration of 100 mg/kg of dose,,,N,Intermediate,A,10090.0,CHEMBL618572,,,,,1,1
8069,50594,,BAO_0000218,,,Bioavailability in mouse brain after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),,,N,Intermediate,A,10090.0,CHEMBL618573,,,,,1,1
8070,50594,,BAO_0000218,,,Bioavailability in mouse serum after intravenous administration of 105.1 mg/kg of dose,,,N,Intermediate,A,10090.0,CHEMBL619267,,,,,1,1
8071,50594,,BAO_0000218,,,Bioavailability in mouse serum after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),,,N,Intermediate,A,10090.0,CHEMBL619431,,,,,1,1
8072,50594,,BAO_0000218,,,Bioavailability in mouse serum after oral administration of 100 mg/kg of dose,,,N,Intermediate,A,10090.0,CHEMBL619432,,,,,1,1
8073,50594,,BAO_0000218,,,Bioavailability in mouse serum after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),,,N,Intermediate,A,10090.0,CHEMBL619433,,,,,1,1
8074,22224,,BAO_0000218,,,AUC in mice after oral dose (50 mg/kg),,,U,Autocuration,A,,CHEMBL619434,,1969.0,Plasma,,0,1
8075,50594,,BAO_0000218,,,Blood level after oral administration in mice (50 mg/kg) was determined by bioassay procedure and represent total activity present in the serum,,,N,Intermediate,A,10090.0,CHEMBL619435,,1977.0,Serum,,1,1
8076,22224,,BAO_0000019,,,AUC (0-4 hr) ug/ml/h,,,U,Autocuration,A,,CHEMBL619436,,1969.0,Plasma,,0,1
8077,50597,,BAO_0000218,,,Compound at a dose of 10 mg/kg was orally administered to rats and Area under curve was reported,,,N,Intermediate,A,10116.0,CHEMBL619437,,,,,1,1
8078,22224,,BAO_0000218,,,Compound evaluated for AUC = Area under the nucleoside serum or brain concentration versus time curve after iv administration,,,U,Autocuration,A,,CHEMBL619438,,,,,0,1
8079,50594,,BAO_0000218,,,Compound was evaluated for Area under curve in mice,,,N,Intermediate,A,10090.0,CHEMBL619439,,,,,1,1
8080,50597,,BAO_0000218,,,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,,,N,Intermediate,A,10116.0,CHEMBL619440,,,,,1,1
8081,22224,,BAO_0000218,,,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,,,U,Autocuration,F,,CHEMBL619441,,,,,0,1
8082,50597,,BAO_0000218,,,Compound was evaluated for area under curve doses in rat at 50 mg/kg po,,,N,Intermediate,A,10116.0,CHEMBL619442,,,,,1,1
8083,22224,,BAO_0000019,,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 1,,,U,Autocuration,A,,CHEMBL875156,,,,,0,1
8084,22224,,BAO_0000019,,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 4,,,U,Autocuration,A,,CHEMBL619443,,,,,0,1
8085,22224,,BAO_0000019,,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 1,,,U,Autocuration,A,,CHEMBL619444,,,,,0,1
8086,22224,,BAO_0000019,,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 4,,,U,Autocuration,A,,CHEMBL623464,,,,,0,1
8087,50594,,BAO_0000218,,,Compound was evaluated for area under curve when administered through oral route in mouse,,,N,Intermediate,A,10090.0,CHEMBL623465,,,,,1,1
8088,50597,In vivo,BAO_0000218,,,Plasma clearance after oral administration at a dose of 2 mg/kg in rat; no data,,,N,Intermediate,A,10116.0,CHEMBL623466,,,,,1,1
8089,50597,In vivo,BAO_0000218,,,Plasma clearance after oral administration at a dose of 4 mg/kg in rat; no data,,,N,Intermediate,A,10116.0,CHEMBL623467,,,,,1,1
8090,50597,In vivo,BAO_0000218,,,Plasma clearance in rat,,,N,Intermediate,A,10116.0,CHEMBL623468,,,,,1,1
8091,50597,In vivo,BAO_0000218,,,Plasma clearance was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration,,,N,Intermediate,A,10116.0,CHEMBL622660,,,,,1,1
8092,50597,In vivo,BAO_0000218,,,Plasma clearance rate in Sprague-Dawley rats,,,N,Intermediate,A,10116.0,CHEMBL622661,,,,,1,1
8093,50597,In vivo,BAO_0000218,,,CLtot at a dose of 4 mg/kg in Rat Plasma after iv administration,,,N,Intermediate,F,10116.0,CHEMBL622662,,,,,1,1
8094,50597,In vivo,BAO_0000218,,,Pharmacokinetic property (total body clearance) in rat,,,N,Intermediate,A,10116.0,CHEMBL622663,,,,,1,1
8095,50597,In vivo,BAO_0000218,,,Pharmacokinetic property (CLtot)of the compound was measured in rat at the dose of 0.32 mg/kg i.v.,,,N,Intermediate,A,10116.0,CHEMBL622664,,,,,1,1
8096,50597,,BAO_0000218,,,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL622665,,,,,1,1
8097,50597,,BAO_0000218,,,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL622666,,,,,1,1
8098,50597,In vivo,BAO_0000218,,,Cl in rat i.v. at 2 mg/kg concentration,,,N,Intermediate,A,10116.0,CHEMBL621615,,,,,1,1
8099,50597,In vivo,BAO_0000218,,,Clearance of compound after intravenous administration in rats at 24 uM/kg,,,N,Intermediate,A,10116.0,CHEMBL621616,,,,,1,1
8100,50597,In vivo,BAO_0000218,,,Clearance was determined,,,N,Intermediate,A,10116.0,CHEMBL621617,,,,,1,1
8101,50597,In vivo,BAO_0000218,,,Clearance by intravenous administration of 3.4 mg/kg in rat,,,N,Intermediate,A,10116.0,CHEMBL621618,,,,,1,1
8102,50597,In vivo,BAO_0000218,,,Clearance was evaluated after i.v. administration in rat at a dose of 1 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL621619,,,,,1,1
8103,50597,In vivo,BAO_0000218,,,Clearance rate after i.v. administration in rats,,,N,Intermediate,A,10116.0,CHEMBL621620,,,,,1,1
8104,50597,In vivo,BAO_0000218,,,Clearance was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,,,N,Intermediate,A,10116.0,CHEMBL621786,,,,,1,1
8105,50597,In vivo,BAO_0000218,,,Clearance was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,,,N,Intermediate,A,10116.0,CHEMBL621787,,,,,1,1
8106,50597,In vivo,BAO_0000218,,,Clearance (Cl) of compound after 2 h iv infusion of 8.4 mg/kg in three rat,,,N,Intermediate,A,10116.0,CHEMBL621788,,,,,1,1
8107,50597,In vivo,BAO_0000218,,,Clearance (Cl) after oral administration in rat,,,N,Intermediate,A,10116.0,CHEMBL621789,,,,,1,1
8108,50597,In vivo,BAO_0000218,,,Compound clearance in rats was measured after intravenous administration at 3 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL621790,,,,,1,1
8109,50597,In vivo,BAO_0000218,,,Compound was tested for plasma clearance in rat,,,N,Intermediate,A,10116.0,CHEMBL621791,,1969.0,Plasma,,1,1
8110,50597,In vitro,BAO_0000218,,,In vitro microsome metabolism clearance in rat was determined,,,N,Intermediate,A,10116.0,CHEMBL621792,,,,Microsomes,1,1
8111,50597,In vitro,BAO_0000218,,,In vitro microsome metabolism clearance in rat was determined; ND denotes no data,,,N,Intermediate,A,10116.0,CHEMBL621793,,,,Microsomes,1,1
8112,50597,In vivo,BAO_0000218,,,In vivo Clearance (Cl) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,,N,Intermediate,A,10116.0,CHEMBL621794,,,,,1,1
8113,50597,In vivo,BAO_0000218,,,In vivo plasma clearance was determined,,,N,Intermediate,A,10116.0,CHEMBL621795,,1969.0,Plasma,,1,1
8114,50597,In vivo,BAO_0000218,,,Pharmacokinetic property (Clearance) for the compound (5 mg/kg iv) was determined in rats,,,N,Intermediate,A,10116.0,CHEMBL621796,,,,,1,1
8115,50597,In vivo,BAO_0000218,401.0,Hepatocyte,Pharmacokinetic property (Clearance) in rat hepatocyte i.v.,,,N,Intermediate,A,10116.0,CHEMBL621797,,2107.0,Liver,,1,1
8116,50597,In vivo,BAO_0000218,,,Pharmacokinetic property (Plasma clearance) was measured in rat,,,N,Intermediate,A,10116.0,CHEMBL621798,,,,,1,1
8117,50597,In vivo,BAO_0000218,,,Pharmacokinetic property (clearance) in rat i.v.,,,N,Intermediate,A,10116.0,CHEMBL621799,,,,,1,1
8118,50597,In vivo,BAO_0000218,,,"Plasma Clearance was evaluated in rats, iv",,,N,Intermediate,A,10116.0,CHEMBL621800,,,,,1,1
8119,50597,In vivo,BAO_0000218,,,Plasma clearance (in vivo) in rats was determined,,,N,Intermediate,A,10116.0,CHEMBL621801,,,,,1,1
8120,50597,In vivo,BAO_0000218,,,Plasma clearance for the compound was calculated at a single intravenous administration of 20 mg/kg in rat,,,N,Intermediate,A,10116.0,CHEMBL621802,,,,,1,1
8121,50597,In vivo,BAO_0000218,,,Plasma clearance was determined,,,N,Intermediate,A,10116.0,CHEMBL618596,,,,,1,1
8122,50597,In vivo,BAO_0000218,,,Plasma clearance in rat after peroral administration at 10 mg/kg concentration,,,N,Intermediate,A,10116.0,CHEMBL618597,,,,,1,1
8123,50597,In vivo,BAO_0000218,,,Plasma clearance in rat after peroral administration at 5 mg/kg concentration,,,N,Intermediate,A,10116.0,CHEMBL618598,,,,,1,1
8124,50597,In vivo,BAO_0000218,,,Plasma clearance in rats,,,N,Intermediate,A,10116.0,CHEMBL618599,,,,,1,1
8125,50597,In vivo,BAO_0000218,,,Plasma clearance rate determined in rat,,,N,Intermediate,A,10116.0,CHEMBL618600,,,,,1,1
8126,50597,In vivo,BAO_0000218,,,Plasma clearance was determined in rat,,,N,Intermediate,A,10116.0,CHEMBL618601,,,,,1,1
8127,50597,In vivo,BAO_0000218,,,Plasma clearance was determined,,,N,Intermediate,A,10116.0,CHEMBL618602,,,,,1,1
8128,50597,In vivo,BAO_0000218,,,Plasma clearance value in rat,,,N,Intermediate,A,10116.0,CHEMBL618603,,,,,1,1
8129,50597,Ex vivo,BAO_0000218,,,Clearance rate constant using isolated perfused rat liver (IPRL) assay,,,N,Intermediate,A,10116.0,CHEMBL618604,,2107.0,Liver,,1,1
8130,50597,In vivo,BAO_0000218,,,Clearance in rat,,,N,Intermediate,A,10116.0,CHEMBL618605,,,,,1,1
8131,50597,In vivo,BAO_0000218,,,Total body clearance in rat i.v. at 2 mg/kg concentration,,,N,Intermediate,A,10116.0,CHEMBL618606,,,,,1,1
8132,50597,In vivo,BAO_0000218,,,Clearance of compound in rats after intravenous administration,,,N,Intermediate,A,10116.0,CHEMBL618607,,,,,1,1
8133,50597,In vivo,BAO_0000218,,,Clearance after iv administration to rats,,,N,Intermediate,A,10116.0,CHEMBL618608,,,,,1,1
8134,50597,In vivo,BAO_0000218,,,Clearance at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg,,,N,Intermediate,A,10116.0,CHEMBL618609,,,,,1,1
8135,50597,In vivo,BAO_0000218,,,Clearance at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg,,,N,Intermediate,A,10116.0,CHEMBL618610,,,,,1,1
8136,50597,In vivo,BAO_0000218,,,Clearance at an iv dose of 15 mg/Kg and po dose of 30 mg/Kg,,,N,Intermediate,A,10116.0,CHEMBL618611,,,,,1,1
8137,50597,In vivo,BAO_0000218,,,Clearance at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg,,,N,Intermediate,A,10116.0,CHEMBL618612,,,,,1,1
8138,50597,In vivo,BAO_0000218,,,Clearance at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg,,,N,Intermediate,A,10116.0,CHEMBL618613,,,,,1,1
8139,50597,In vivo,BAO_0000218,,,Clearance at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg,,,N,Intermediate,A,10116.0,CHEMBL621076,,,,,1,1
8140,50597,In vivo,BAO_0000218,,,Clearance at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg,,,N,Intermediate,A,10116.0,CHEMBL621077,,,,,1,1
8141,50597,In vivo,BAO_0000218,,,"Clearance in fischer rats at 5 mg/kg dose, administered intravenously",,,N,Intermediate,A,10116.0,CHEMBL621078,,,,,1,1
8142,50597,In vivo,BAO_0000218,,,Clearance in rat,,,N,Intermediate,A,10116.0,CHEMBL621251,,,,,1,1
8143,50597,In vivo,BAO_0000218,,,Clearance in rat after oral administration at 10 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL621252,,,,,1,1
8144,50597,In vivo,BAO_0000218,,,Clearance in rat.,,,N,Intermediate,A,10116.0,CHEMBL621253,,,,,1,1
8145,50597,In vivo,BAO_0000218,,,Clearance rate following an oral dose of 20 mg/kg in rats,,,N,Intermediate,A,10116.0,CHEMBL621254,,,,,1,1
8146,50597,In vivo,BAO_0000218,,,Compound was evaluated for the rate of clearance in rat upon intravenous administration.,,,N,Intermediate,A,10116.0,CHEMBL621255,,,,,1,1
8147,50597,In vivo,BAO_0000218,,,Compound was tested for plasma clearance in rats after 5 mg/kg of intravenous dosing,,,N,Intermediate,A,10116.0,CHEMBL621256,,1969.0,Plasma,,1,1
8148,50597,In vivo,BAO_0000218,,,Biodistribution in rat liver in the presence of GdDTPA-BDP at 1 hr,,,N,Intermediate,A,10116.0,CHEMBL621257,,2107.0,Liver,,1,1
8149,50597,In vivo,BAO_0000218,,,Biodistribution in rat liver in the presence of GdDTPA-BDP at 30 min,,,N,Intermediate,A,10116.0,CHEMBL621258,,2107.0,Liver,,1,1
8150,50597,In vivo,BAO_0000218,,,Biodistribution in rat liver in the presence of GdDTPA-BDP at 4 hr,,,N,Intermediate,A,10116.0,CHEMBL621259,,2107.0,Liver,,1,1
8151,50597,In vivo,BAO_0000218,,,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 15 min,,,N,Intermediate,A,10116.0,CHEMBL621260,,2107.0,Liver,,1,1
8152,50597,In vivo,BAO_0000218,,,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 1 hr,,,N,Intermediate,A,10116.0,CHEMBL876494,,2107.0,Liver,,1,1
8153,50597,In vivo,BAO_0000218,,,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 30 min,,,N,Intermediate,A,10116.0,CHEMBL621261,,2107.0,Liver,,1,1
8154,50597,In vivo,BAO_0000218,,,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 4 hr,,,N,Intermediate,A,10116.0,CHEMBL621262,,2107.0,Liver,,1,1
8155,50597,In vivo,BAO_0000218,,,Biodistribution in rat liver in the presence of NAC Gd/0.01 M GdDTPA-HPDP,,,N,Intermediate,A,10116.0,CHEMBL621263,,2107.0,Liver,,1,1
8156,50597,In vivo,BAO_0000218,,,Biodistribution in rat liver in the presence of NCA Gd/0.01 M lip,,,N,Intermediate,A,10116.0,CHEMBL621264,,2107.0,Liver,,1,1
8157,50597,In vivo,BAO_0000218,,,Biodistribution in rat muscle in the presence of 0.01 M GdDTPA-BDP,,,N,Intermediate,A,10116.0,CHEMBL621265,,2385.0,Muscle tissue,,1,1
8158,50597,In vivo,BAO_0000218,,,Biodistribution in rat muscle in the presence of 0.05 M Gd/0.15 M lig,,,N,Intermediate,A,10116.0,CHEMBL621266,,2385.0,Muscle tissue,,1,1
8159,50597,In vivo,BAO_0000218,,,Biodistribution in rat muscle in the presence of 0.05 M GdDTPA-BDP,,,N,Intermediate,A,10116.0,CHEMBL621267,,2385.0,Muscle tissue,,1,1
8160,50597,In vivo,BAO_0000218,,,Biodistribution in rat muscle in the presence of 0.10 M GdDTPA-BDP,,,N,Intermediate,A,10116.0,CHEMBL621268,,2385.0,Muscle tissue,,1,1
8161,50597,In vivo,BAO_0000218,,,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 1 hr,,,N,Intermediate,A,10116.0,CHEMBL621269,,2385.0,Muscle tissue,,1,1
8162,50597,In vivo,BAO_0000218,,,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 4 hr,,,N,Intermediate,A,10116.0,CHEMBL621270,,2385.0,Muscle tissue,,1,1
8163,50597,In vivo,BAO_0000218,,,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 15 min,,,N,Intermediate,A,10116.0,CHEMBL621271,,2385.0,Muscle tissue,,1,1
8164,50597,In vivo,BAO_0000218,,,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 30 min,,,N,Intermediate,A,10116.0,CHEMBL621272,,2385.0,Muscle tissue,,1,1
8165,50597,In vivo,BAO_0000218,,,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 1 hr,,,N,Intermediate,A,10116.0,CHEMBL621273,,2385.0,Muscle tissue,,1,1
8166,50597,In vivo,BAO_0000218,,,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 4 hr,,,N,Intermediate,A,10116.0,CHEMBL621274,,2385.0,Muscle tissue,,1,1
8167,50597,In vivo,BAO_0000218,,,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 15 min,,,N,Intermediate,A,10116.0,CHEMBL876495,,2385.0,Muscle tissue,,1,1
8168,50597,In vivo,BAO_0000218,,,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 30 min,,,N,Intermediate,A,10116.0,CHEMBL621275,,2385.0,Muscle tissue,,1,1
8169,50597,In vivo,BAO_0000218,,,Biodistribution in rat muscle in the presence of NCA Gd/0.01 M lip,,,N,Intermediate,A,10116.0,CHEMBL621276,,2385.0,Muscle tissue,,1,1
8170,50597,In vivo,BAO_0000218,,,Biodistribution in rat muscle in the presence of NCAGd/0.01 M lig,,,N,Intermediate,A,10116.0,CHEMBL621277,,2385.0,Muscle tissue,,1,1
8171,50597,In vivo,BAO_0000218,,,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 2 hr,,,N,Intermediate,A,10116.0,CHEMBL621278,,160.0,Intestine,,1,1
8172,50597,In vivo,BAO_0000218,,,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 6 hr,,,N,Intermediate,A,10116.0,CHEMBL621279,,160.0,Intestine,,1,1
8173,50597,In vivo,BAO_0000218,,,Biodistribution in rat s. intestine in the presence of NCA (No carrier added),,,N,Intermediate,A,10116.0,CHEMBL621280,,160.0,Intestine,,1,1
8174,50597,In vivo,BAO_0000218,,,Biodistribution in rat spleen in the presence of 0.01 M GdDTPA-BDP,,,N,Intermediate,A,10116.0,CHEMBL621281,,2106.0,Spleen,,1,1
8175,50597,In vivo,BAO_0000218,,,Biodistribution in rat spleen in the presence of 0.05 M Gd/0.15 M lig; ND=No data,,,N,Intermediate,A,10116.0,CHEMBL621282,,2106.0,Spleen,,1,1
8176,50597,In vivo,BAO_0000218,,,Biodistribution in rat spleen in the presence of 0.05 M GdDTPA-BDP; ND=No data,,,N,Intermediate,A,10116.0,CHEMBL621283,,2106.0,Spleen,,1,1
8177,50597,In vivo,BAO_0000218,,,Biodistribution in rat spleen in the presence of 0.10 M GdDTPA-BDP,,,N,Intermediate,A,10116.0,CHEMBL621284,,2106.0,Spleen,,1,1
8178,50597,In vivo,BAO_0000218,,,Biodistribution in rat spleen in the presence of 50 Gd/kg at 15 min,,,N,Intermediate,A,10116.0,CHEMBL621285,,2106.0,Spleen,,1,1
8179,50597,In vivo,BAO_0000218,,,Biodistribution in rat spleen in the presence of 50 Gd/kg at 2 hr,,,N,Intermediate,A,10116.0,CHEMBL621286,,2106.0,Spleen,,1,1
8180,50597,In vivo,BAO_0000218,,,Biodistribution in rat spleen in the presence of 50 Gd/kg at 6 hr,,,N,Intermediate,A,10116.0,CHEMBL623220,,2106.0,Spleen,,1,1
8181,50597,In vivo,BAO_0000218,,,Biodistribution in rat spleen in the presence of NCA Gd/0.01 M lip,,,N,Intermediate,A,10116.0,CHEMBL623221,,2106.0,Spleen,,1,1
8182,50597,In vivo,BAO_0000218,,,Biodistribution in rat spleen in the presence of NCAGd/0.01 M lig,,,N,Intermediate,A,10116.0,CHEMBL876029,,2106.0,Spleen,,1,1
8183,50597,In vivo,BAO_0000218,,,Biodistribution in rat stomach in the presence of 50 Gd/kg at 15 min,,,N,Intermediate,A,10116.0,CHEMBL623222,,945.0,Stomach,,1,1
8184,50597,In vivo,BAO_0000218,,,Biodistribution in rat stomach in the presence of 50 Gd/kg at 2 hr,,,N,Intermediate,A,10116.0,CHEMBL623223,,945.0,Stomach,,1,1
8185,50597,In vivo,BAO_0000218,,,Biodistribution in rat stomach in the presence of 50 Gd/kg at 6 h; ND=No data,,,N,Intermediate,A,10116.0,CHEMBL621445,,945.0,Stomach,,1,1
8186,50597,In vivo,BAO_0000218,,,Biodistribution of [123I]-label in rat blood was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,,N,Intermediate,A,10116.0,CHEMBL621446,,178.0,Blood,,1,1
8187,50597,In vivo,BAO_0000218,,,Biodistribution of [123I]-label in rat blood was reported at 1 hr post injection. Value shown is %ID/g of tissue,,,N,Intermediate,A,10116.0,CHEMBL621447,,178.0,Blood,,1,1
8188,50597,In vivo,BAO_0000218,,,Biodistribution of [123I]-label in rat blood was reported at 2 hr post injection. Value shown is %ID/g of tissue,,,N,Intermediate,A,10116.0,CHEMBL619681,,178.0,Blood,,1,1
8189,50597,In vivo,BAO_0000218,,,Biodistribution of [123I]-label in rat blood was reported at 24 hr post injection. Value shown is %ID/g of tissue,,,N,Intermediate,A,10116.0,CHEMBL619682,,178.0,Blood,,1,1
8190,50597,In vivo,BAO_0000218,,,Biodistribution of [123I]-label in rat blood was reported at 4 hr post injection. Value shown is %ID/g of tissue,,,N,Intermediate,A,10116.0,CHEMBL619683,,178.0,Blood,,1,1
8191,50597,In vivo,BAO_0000218,,,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,,N,Intermediate,A,10116.0,CHEMBL619684,,955.0,Brain,,1,1
8192,50597,In vivo,BAO_0000218,,,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/g of tissue,,,N,Intermediate,A,10116.0,CHEMBL619685,,955.0,Brain,,1,1
8193,50597,In vivo,BAO_0000218,,,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/g of tissue,,,N,Intermediate,A,10116.0,CHEMBL619686,,955.0,Brain,,1,1
8194,50597,In vivo,BAO_0000218,,,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/g of tissue,,,N,Intermediate,A,10116.0,CHEMBL619687,,955.0,Brain,,1,1
8195,50597,In vivo,BAO_0000218,,,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/g of tissue,,,N,Intermediate,A,10116.0,CHEMBL619688,,955.0,Brain,,1,1
8196,50597,In vivo,BAO_0000218,,,Biodistribution of [123I]-label in rat heart was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,,N,Intermediate,A,10116.0,CHEMBL619689,,948.0,Heart,,1,1
8197,50597,In vivo,BAO_0000218,,,Biodistribution of [123I]-label in rat heart was reported at 1 hr post injection. Value shown is %ID/g of tissue,,,N,Intermediate,A,10116.0,CHEMBL619690,,948.0,Heart,,1,1
8198,50597,In vivo,BAO_0000218,,,Biodistribution of [123I]-label in rat heart was reported at 2 hr post injection. Value shown is %ID/g of tissue,,,N,Intermediate,A,10116.0,CHEMBL619691,,948.0,Heart,,1,1
8199,50597,In vivo,BAO_0000218,,,Terminal phase volume of distribution was measured in rat after an iv dose of 1 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL619692,,,,,1,1
8200,50597,,BAO_0000218,,,Apparent volume of the central plasma compartment (Vc) of compound determined in rat after iv administration at a dose of 10 mg/kg,,,N,Expert,A,10116.0,CHEMBL619693,,,,,1,1
8201,50597,In vivo,BAO_0000218,,,Vc value after IV dose at a dose of 5 mg/kg in rats.,,,N,Intermediate,A,10116.0,CHEMBL619694,,,,,1,1
8202,50597,In vivo,BAO_0000218,,,Apparent volume of distribution at 10 mg/kg in rat upon intravenous administration,,,N,Intermediate,A,10116.0,CHEMBL619695,,,,,1,1
8203,50597,In vivo,BAO_0000218,,,Compound was evaluated for pharmacokinetic parameter volume of distribution,,,N,Intermediate,A,10116.0,CHEMBL619696,,,,,1,1
8204,50597,In vivo,BAO_0000218,,,Compound was evaluated for volume of distribution in rat,,,N,Intermediate,A,10116.0,CHEMBL619697,,,,,1,1
8205,50597,In vivo,BAO_0000218,,,Steady state volume distribution was determined; steady state(ss),,,N,Intermediate,A,10116.0,CHEMBL619698,,,,,1,1
8206,50597,In vivo,BAO_0000218,,,Steady state volume of distribution after iv administration to rats,,,N,Intermediate,A,10116.0,CHEMBL619699,,,,,1,1
8207,50597,In vivo,BAO_0000218,,,Steady state volume of distribution dosing at 3 mg/kg iv,,,N,Intermediate,A,10116.0,CHEMBL619700,,,,,1,1
8208,50597,In vivo,BAO_0000218,,,The compound was evaluated for volume of distribution in rat,,,N,Intermediate,A,10116.0,CHEMBL619701,,,,,1,1
8209,50597,In vivo,BAO_0000218,,,The compound was tested for volume of distribution in rat,,,N,Intermediate,A,10116.0,CHEMBL619702,,,,,1,1
8210,50597,In vivo,BAO_0000218,,,The compound was tested for volume of distribution in rat at dose of 3-10 mgkg,,,N,Intermediate,A,10116.0,CHEMBL620335,,,,,1,1
8211,50597,In vivo,BAO_0000218,,,Volume distribution (VD) after oral administration in rat,,,N,Intermediate,A,10116.0,CHEMBL620336,,,,,1,1
8212,50597,In vivo,BAO_0000218,,,Volume distribution of compound in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL620337,,,,,1,1
8213,50597,In vivo,BAO_0000218,,,Volume distribution in rat,,,N,Intermediate,A,10116.0,CHEMBL620520,,,,,1,1
8214,50597,In vivo,BAO_0000218,,,Volume distribution in rat,,,N,Intermediate,A,10116.0,CHEMBL620521,,,,,1,1
8215,50597,In vivo,BAO_0000218,,,Volume distribution in rat after peroral administration at 10 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL875825,,,,,1,1
8216,50597,In vivo,BAO_0000218,,,Volume distribution in rat after peroral administration at 5 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL620522,,,,,1,1
8217,50597,In vivo,BAO_0000218,,,Volume distribution was evaluated after i.v. administration in rat at a dose of 1 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL620523,,,,,1,1
8218,50597,In vivo,BAO_0000218,,,Volume of distribution in rat.,,,N,Intermediate,A,10116.0,CHEMBL620524,,,,,1,1
8219,50597,In vivo,BAO_0000218,,,Volume of distribution in rat,,,N,Intermediate,A,10116.0,CHEMBL620525,,,,,1,1
8220,50597,In vivo,BAO_0000218,,,Volume of distribution in rat,,,N,Intermediate,A,10116.0,CHEMBL620526,,,,,1,1
8221,50597,In vivo,BAO_0000218,,,Volume of distribution in rat by iv administration,,,N,Intermediate,A,10116.0,CHEMBL620527,,,,,1,1
8222,50597,In vivo,BAO_0000218,,,Volume of distribution in rats,,,N,Intermediate,A,10116.0,CHEMBL620528,,,,,1,1
8223,50597,In vivo,BAO_0000218,,,Volume of distribution was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,,,N,Intermediate,A,10116.0,CHEMBL620529,,,,,1,1
8224,50597,,BAO_0000218,,,Volume distribution at the dose of 2 mg/kg in rat,,,N,Intermediate,A,10116.0,CHEMBL620530,,,,,1,1
8225,50597,In vivo,BAO_0000218,,,Steady state volume of distribution was determined,,,N,Intermediate,A,10116.0,CHEMBL620531,,,,,1,1
8226,22224,In vivo,BAO_0000218,,,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,,,U,Intermediate,A,9544.0,CHEMBL620532,,,,,0,1
8227,22224,In vivo,BAO_0000218,,,Compound was tested for its plasma volume distribution in Sprague Dawley rats,,,U,Intermediate,A,10116.0,CHEMBL620533,,,,,0,1
8228,22224,In vivo,BAO_0000218,,,Compound was tested for its plasma volume distribution in Sprague Dawley rats; ND is not determined,,,U,Intermediate,A,10116.0,CHEMBL620534,,,,,0,1
8229,50597,In vivo,BAO_0000218,,,Mean (%CV) PK parameters for Vdss(mL/kg).,,,N,Intermediate,A,10116.0,CHEMBL620535,,,,,1,1
8230,50597,In vivo,BAO_0000218,,,Pharmacokinetic parameter Vdss was determined at 2 mg/kg i.v. dose in rats,,,N,Intermediate,A,10116.0,CHEMBL875826,,,,,1,1
8231,50597,In vivo,BAO_0000218,,,Pharmacokinetic parameter Vdss was determined at 5 mg/kg i.v. dose in rats,,,N,Intermediate,A,10116.0,CHEMBL620536,,,,,1,1
8232,50597,In vivo,BAO_0000218,,,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,,,N,Intermediate,A,10116.0,CHEMBL620537,,,,,1,1
8233,50597,In vivo,BAO_0000218,,,Pharmacokinetic parameter volume of distribution was reported in Sprague-Dawley rat; ND=Not determined,,,N,Intermediate,A,10116.0,CHEMBL618526,,,,,1,1
8234,50597,In vivo,BAO_0000218,,,Pharmacokinetic property (Vdss) for the compound (5 mg/kg iv) was determined in rats,,,N,Intermediate,A,10116.0,CHEMBL618527,,,,,1,1
8235,50597,In vivo,BAO_0000218,,,Pharmacokinetic property (Vdss) in rat,,,N,Intermediate,A,10116.0,CHEMBL618528,,,,,1,1
8236,50597,In vivo,BAO_0000218,,,Pharmacokinetic property (vdss) was measured in rat,,,N,Intermediate,A,10116.0,CHEMBL618529,,,,,1,1
8237,50597,In vivo,BAO_0000218,,,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in rat,,,N,Intermediate,A,10116.0,CHEMBL618530,,,,,1,1
8238,50597,In vivo,BAO_0000218,,,Volume of distribution in rat,,,N,Intermediate,A,10116.0,CHEMBL618531,,,,,1,1
8239,50597,In vivo,BAO_0000218,,,The pharmacokinetic parameter volume of distribution in vivo in rats,,,N,Intermediate,A,10116.0,CHEMBL618532,,,,,1,1
8240,50597,In vivo,BAO_0000218,,,Vdss at a dose of 4 mg/kg in Rat Plasma after iv administration,,,N,Intermediate,F,10116.0,CHEMBL618533,,,,,1,1
8241,50597,In vivo,BAO_0000218,,,Vdss in rat i.v. at 2 mg/kg concentration,,,N,Intermediate,A,10116.0,CHEMBL618534,,,,,1,1
8242,50597,In vivo,BAO_0000218,,,Volume distribution after intravenous administration (1 mg/kg) in rat,,,N,Intermediate,A,10116.0,CHEMBL618535,,,,,1,1
8243,50597,In vivo,BAO_0000218,,,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,,,N,Intermediate,A,10116.0,CHEMBL618536,,,,,1,1
8244,50597,In vivo,BAO_0000218,,,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,,,N,Intermediate,A,10116.0,CHEMBL618537,,,,,1,1
8245,50597,In vivo,BAO_0000218,,,Volume distribution at a dose of 10 uM/kg in rat was determined,,,N,Intermediate,A,10116.0,CHEMBL618538,,,,,1,1
8246,50597,In vivo,BAO_0000218,,,Volume distribution in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,,,N,Intermediate,A,10116.0,CHEMBL618539,,,,,1,1
8247,50597,In vivo,BAO_0000218,,,Volume distribution was calculated in rat,,,N,Intermediate,A,10116.0,CHEMBL618540,,,,,1,1
8248,50597,In vivo,BAO_0000218,,,Volume distribution was determined,,,N,Intermediate,A,10116.0,CHEMBL618541,,,,,1,1
8249,50597,In vivo,BAO_0000218,,,Volume of distribution after intravenous administration was evaluated in rat,,,N,Intermediate,A,10116.0,CHEMBL618542,,,,,1,1
8250,50597,In vivo,BAO_0000218,,,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,,N,Intermediate,A,10116.0,CHEMBL622544,,,,,1,1
8251,50597,In vivo,BAO_0000218,,,"Volume of distribution at steady state was determined in rats at 10 mg/kg, p.o. dose; n/a: not applicable",,,N,Intermediate,A,10116.0,CHEMBL622545,,,,,1,1
8252,50597,In vivo,BAO_0000218,,,"Volume of distribution at steady state was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",,,N,Intermediate,A,10116.0,CHEMBL622546,,,,,1,1
8253,50597,In vivo,BAO_0000218,,,"Volume of distribution at steady state was determined in rats at 2 mg/kg, i.v. dose",,,N,Intermediate,A,10116.0,CHEMBL622547,,,,,1,1
8254,50597,In vivo,BAO_0000218,,,Volume of distribution in steady state was determined in rat,,,N,Intermediate,A,10116.0,CHEMBL622548,,,,,1,1
8255,50597,In vivo,BAO_0000218,,,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration,,,N,Intermediate,A,10116.0,CHEMBL622549,,,,,1,1
8256,50597,In vivo,BAO_0000218,,,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,,,N,Intermediate,A,10116.0,CHEMBL622550,,,,,1,1
8257,50594,,BAO_0000218,,,Compound was evaluated for area under curve when administered through oral route to mouse,,,N,Intermediate,A,10090.0,CHEMBL622551,,,,,1,1
8258,50597,,BAO_0000218,,,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,,,N,Intermediate,A,10116.0,CHEMBL622552,,,,,1,1
8259,50597,,BAO_0000218,,,Compound was evaluated for area under curve doses in rat at 50 mg/kg po,,,N,Intermediate,A,10116.0,CHEMBL622553,,,,,1,1
8260,22224,In vivo,BAO_0000218,,,Compound was evaluated for its bioavailability after oral administration (100 mg) to Beagle dogs,,,U,Autocuration,F,,CHEMBL622554,,,,,0,1
8261,50588,,BAO_0000218,,,Compound was evaluated for its bioavailability after oral administration (200 mg) to Beagle dogs,,,N,Intermediate,A,9615.0,CHEMBL622555,,,,,1,1
8262,50594,,BAO_0000218,,,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,,,N,Intermediate,A,10090.0,CHEMBL622556,,,,,1,1
8263,50594,,BAO_0000218,,,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,,,N,Intermediate,A,10090.0,CHEMBL622557,,,,,1,1
8264,50594,,BAO_0000218,,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg intramuscular administration to mice,,,N,Intermediate,A,10090.0,CHEMBL622558,,178.0,Blood,,1,1
8265,50594,,BAO_0000218,,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to mice,,,N,Intermediate,A,10090.0,CHEMBL622559,,178.0,Blood,,1,1
8266,50588,,BAO_0000218,,,Compound was evaluated in vivo in for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to dogs.,,,N,Intermediate,A,9615.0,CHEMBL622560,,,,,1,1
8267,50597,,BAO_0000218,,,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose,,,N,Intermediate,A,10116.0,CHEMBL622561,,,,,1,1
8268,50597,,BAO_0000218,,,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose. ,,,N,Intermediate,A,10116.0,CHEMBL622562,,,,,1,1
8269,50597,,BAO_0000218,,,Compound was tested for area under concentration -time curve from time 0 to time of last detectable concentration in three male Wistar rats at a single 5 mg/kg oral gavage dose,,,N,Intermediate,A,10116.0,CHEMBL622563,,,,,1,1
8270,22224,,BAO_0000019,,,Concentration of compound in Central nervous system,,,U,Autocuration,A,,CHEMBL622564,,,,,0,1
8271,22224,,BAO_0000019,,,Concentration of compound in Central nervous system; Not detectable,,,U,Autocuration,A,,CHEMBL622565,,,,,0,1
8272,50594,,BAO_0000218,,,"Concentration of diester in the blood, following oral administration in mice",,,N,Intermediate,A,10090.0,CHEMBL622566,,,,,1,1
8273,50594,,BAO_0000218,,,"Concentration of monoester in the blood, following oral administration in mice",,,N,Intermediate,A,10090.0,CHEMBL624515,,,,,1,1
8274,50594,,BAO_0000218,,,Concentration of the 9-[2-(Phosphonomethoxy)ethoxy]adenine in the blood following oral administration in mice,,,N,Intermediate,A,10090.0,CHEMBL624516,,,,,1,1
8275,22224,,BAO_0000019,,,Evaluated for Pharmacokinetic property: Area under the curve,,,U,Autocuration,A,,CHEMBL624517,,,,,0,1
8276,50594,,BAO_0000218,,,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after a peroral dose of 25 mg/kg in nude mice,,,N,Intermediate,A,10090.0,CHEMBL624518,,,,,1,1
8277,100710,,BAO_0000218,,,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after iv dose of 25 mg/kg in nude mice,,,N,Intermediate,A,9541.0,CHEMBL624519,,,,,1,1
8278,100710,,BAO_0000218,,,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after iv dose of 5 mg/kg expressed as Area under the curve,,,N,Intermediate,A,9541.0,CHEMBL624520,,,,,1,1
8279,100710,,BAO_0000218,,,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 10 mg/kg expressed as Area under the curve,,,N,Intermediate,A,9541.0,CHEMBL624521,,,,,1,1
8280,100710,,BAO_0000218,,,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 5 mg/kg expressed as Area under the curve,,,N,Intermediate,A,9541.0,CHEMBL624522,,,,,1,1
8281,100710,,BAO_0000218,,,In vivo antitumor efficacy in cynomolgus monkeys 0-8 hours after peroral dose of 25 mg/kg expressed as Area under the curve,,,N,Intermediate,A,9541.0,CHEMBL624523,,,,,1,1
8282,100710,,BAO_0000218,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 10 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",,,N,Intermediate,A,9541.0,CHEMBL624409,,,,,1,1
8283,100710,,BAO_0000218,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-8 hr)",,,N,Intermediate,A,9541.0,CHEMBL624410,,,,,1,1
8284,100710,,BAO_0000218,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",,,N,Intermediate,A,9541.0,CHEMBL624411,,,,,1,1
8285,100710,,BAO_0000218,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, iv and the total drug exposure was determined. (0-8 hr)",,,N,Intermediate,A,9541.0,CHEMBL623531,,,,,1,1
8286,100710,,BAO_0000218,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, perorally and the total drug exposure was determined (0-8 hr)",,,N,Intermediate,A,9541.0,CHEMBL623532,,,,,1,1
8287,100710,,BAO_0000218,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, intravenously and the total drug exposure was determined (0-8 hr)",,,N,Intermediate,A,9541.0,CHEMBL623533,,,,,1,1
8288,100710,,BAO_0000218,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",,,N,Intermediate,A,9541.0,CHEMBL623534,,,,,1,1
8289,50594,,BAO_0000218,,,In vivo antitumor efficacy in nude mice 0-24 hr after intravenous dose of 25 mg/kg expressed as Area under the curve,,,N,Intermediate,A,10090.0,CHEMBL623535,,,,,1,1
8290,50594,,BAO_0000218,,,In vivo antitumor efficacy in nude mice 0-24 hr after iperoral dose of 25 mg/kg expressed as Area under the curve,,,N,Intermediate,A,10090.0,CHEMBL623536,,,,,1,1
8291,50594,,BAO_0000218,,,In vivo antitumor efficacy in nude mice 0-24 hr after iv dose of 25 mg/kg expressed as Area under the curve,,,N,Intermediate,A,10090.0,CHEMBL623537,,,,,1,1
8292,50594,,BAO_0000218,,,In vivo antitumor efficacy in nude mice 0-24 hr after peroral dose of 25 mg/kg expressed as Area under the curve,,,N,Intermediate,A,10090.0,CHEMBL623538,,,,,1,1
8293,50594,,BAO_0000218,,,In vivo antitumor efficacy in nude mice after peroral dose of 10 mg/kg expressed as Area under the curve,,,N,Intermediate,A,10090.0,CHEMBL623539,,,,,1,1
8294,50594,,BAO_0000218,,,In vivo antitumor efficacy in nude mice after peroral dose of 25 mg/kg expressed as Area under the curve,,,N,Intermediate,A,10090.0,CHEMBL623540,,,,,1,1
8295,50594,,BAO_0000218,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined.",,,N,Intermediate,A,10090.0,CHEMBL623541,,,,,1,1
8296,50594,,BAO_0000218,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-24hr)",,,N,Intermediate,A,10090.0,CHEMBL623542,,,,,1,1
8297,50594,,BAO_0000218,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-4 hr)",,,N,Intermediate,A,10090.0,CHEMBL623543,,,,,1,1
8298,50594,,BAO_0000218,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined",,,N,Intermediate,A,10090.0,CHEMBL623544,,,,,1,1
8299,50594,,BAO_0000218,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-24hr)",,,N,Intermediate,A,10090.0,CHEMBL623545,,,,,1,1
8300,50594,,BAO_0000218,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-4 hr)",,,N,Intermediate,A,10090.0,CHEMBL623546,,,,,1,1
8301,50597,In vivo,BAO_0000218,,,Evaluated for plasma clearance after iv administration of 5 mg/kg to male Sprague-Dawley rats,,,N,Intermediate,A,10116.0,CHEMBL623547,,1969.0,Plasma,,1,1
8302,50597,In vivo,BAO_0000218,,,High i.v. clearance in Dawley rats,,,N,Intermediate,A,10116.0,CHEMBL623548,,,,,1,1
8303,50597,In vitro,BAO_0000218,,,In vitro clearance in rat liver microsomes,,,N,Intermediate,A,10116.0,CHEMBL623549,,2107.0,Liver,Microsomes,1,1
8304,50597,In vitro,BAO_0000218,,,Intrinsic clearance in rat liver microsomes was determined,,,N,Intermediate,A,10116.0,CHEMBL623550,,2107.0,Liver,Microsomes,1,1
8305,50597,In vitro,BAO_0000218,401.0,Hepatocyte,Intrinsic clearance in rat hepatocytes was determined,,,N,Intermediate,A,10116.0,CHEMBL875276,,2107.0,Liver,,1,1
8306,50597,In vivo,BAO_0000218,,,Plasma Clearance was determined,,,N,Intermediate,A,10116.0,CHEMBL621872,,,,,1,1
8307,50597,In vivo,BAO_0000218,,,Plasma clearance after intravenous administration of 0.4 mg/kg of dose in rats was determined,,,N,Intermediate,A,10116.0,CHEMBL621873,,,,,1,1
8308,50597,In vivo,BAO_0000218,,,Plasma clearance in rat.,,,N,Intermediate,A,10116.0,CHEMBL621874,,,,,1,1
8309,50597,In vivo,BAO_0000218,,,Plasma clearance in rats,,,N,Intermediate,A,10116.0,CHEMBL621875,,,,,1,1
8310,50597,In vivo,BAO_0000218,,,Plasma clearance was estimated from the AUC after 5 mg/kg intravenous dosing in rats,,,N,Intermediate,A,10116.0,CHEMBL621876,,,,,1,1
8311,50597,In vivo,BAO_0000218,,,Plasma clearance was evaluated after 10 uM/kg of intra arterial administration,,,N,Intermediate,A,10116.0,CHEMBL621877,,,,,1,1
8312,50597,In vivo,BAO_0000218,,,Plasma clearance was measured in rat,,,N,Intermediate,A,10116.0,CHEMBL621878,,,,,1,1
8313,50597,In vivo,BAO_0000218,,,Clearance after iv administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL621879,,,,,1,1
8314,50597,In vivo,BAO_0000218,,,"Tested for the plasma clearance in Dawley rat at a dose of 1 mg/kg intravenous, 2 mg/kg orally",,,N,Intermediate,A,10116.0,CHEMBL621880,,1969.0,Plasma,,1,1
8315,50597,In vivo,BAO_0000218,,,The clearance rate in mature male rat at a intravenous dose of 3 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL621881,,,,,1,1
8316,50597,In vivo,BAO_0000218,,,Total body clearance was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,,,N,Intermediate,A,10116.0,CHEMBL621882,,,,,1,1
8317,50597,In vivo,BAO_0000218,,,Total clearance at 1 mg/kg was determined in rat,,,N,Intermediate,A,10116.0,CHEMBL875283,,,,,1,1
8318,50597,In vivo,BAO_0000218,,,Total clearance at 10 mg/kg was determined in rat,,,N,Intermediate,A,10116.0,CHEMBL621883,,,,,1,1
8319,50597,In vivo,BAO_0000218,,,Clearance in rat,,,N,Intermediate,A,10116.0,CHEMBL621884,,,,,1,1
8320,50597,In vivo,BAO_0000218,,,Plasma clearance rate determined in rats,,,N,Intermediate,A,10116.0,CHEMBL621885,,,,,1,1
8321,50597,In vivo,BAO_0000218,,,Clearance of compound in rat was evaluated,,,N,Intermediate,A,10116.0,CHEMBL621886,,,,,1,1
8322,50597,In vivo,BAO_0000218,,,Plasma concentration in rats after 7 hr at 30mg/kg oral dose,,,N,Intermediate,A,10116.0,CHEMBL621887,,1969.0,Plasma,,1,1
8323,50597,In vivo,BAO_0000218,,,Pharmacokinetic property (blood clearance) in rat,,,N,Intermediate,A,10116.0,CHEMBL621888,,,,,1,1
8324,50597,In vivo,BAO_0000218,,,Plasma clearance in rat,,,N,Intermediate,A,10116.0,CHEMBL621889,,,,,1,1
8325,50597,In vivo,BAO_0000218,,,Plasma clearance in rats,,,N,Intermediate,A,10116.0,CHEMBL621890,,,,,1,1
8326,50597,In vitro,BAO_0000218,,,Intrinsic clearance of compound against NADPH-fortified rat liver microsomes,,,N,Intermediate,A,10116.0,CHEMBL621891,,2107.0,Liver,Microsomes,1,1
8327,50597,In vivo,BAO_0000218,,,Clearance in Dawley rat,,,N,Intermediate,A,10116.0,CHEMBL621892,,,,,1,1
8328,50597,In vivo,BAO_0000218,,,Clearance rat,,,N,Intermediate,A,10116.0,CHEMBL621893,,,,,1,1
8329,50597,In vivo,BAO_0000218,,,Clearance rat (dosed at 0.5 mpk IV and 2.0 mpk po.),,,N,Intermediate,A,10116.0,CHEMBL621894,,,,,1,1
8330,50597,In vivo,BAO_0000218,,,Clearance rat; Not determined,,,N,Intermediate,A,10116.0,CHEMBL621895,,,,,1,1
8331,50597,In vivo,BAO_0000218,,,Clearance rate was determined in rat at a dose of 1 mpk i.v.,,,N,Intermediate,A,10116.0,CHEMBL875284,,,,,1,1
8332,50597,In vivo,BAO_0000218,,,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND means not determined,,,N,Intermediate,A,10116.0,CHEMBL618699,,,,,1,1
8333,50597,In vivo,BAO_0000218,,,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND=not determined,,,N,Intermediate,A,10116.0,CHEMBL618700,,,,,1,1
8334,50597,In vivo,BAO_0000218,,,Clearance was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats,,,N,Intermediate,A,10116.0,CHEMBL618701,,,,,1,1
8335,50597,In vivo,BAO_0000218,,,"Clearance in plasma calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv",,,N,Intermediate,A,10116.0,CHEMBL876600,,1969.0,Plasma,,1,1
8336,50597,In vivo,BAO_0000218,,,Clearance of compound in rat after 1 mg/kg i.v. administration,,,N,Intermediate,A,10116.0,CHEMBL618702,,,,,1,1
8337,50597,In vivo,BAO_0000218,,,Compound was evaluated for Hepatic clearance in rat,,,N,Intermediate,A,10116.0,CHEMBL618703,,,,,1,1
8338,50597,In vivo,BAO_0000218,,,In vivo clearance after 5 mg/kg dose,,,N,Intermediate,A,10116.0,CHEMBL618704,,,,,1,1
8339,50597,In vivo,BAO_0000218,,,Compound was tested for plasma clearance in rats,,,N,Intermediate,A,10116.0,CHEMBL618705,,1969.0,Plasma,,1,1
8340,50597,In vivo,BAO_0000218,,,Hepatic clearance after intravenous administration was evaluated in rat,,,N,Intermediate,A,10116.0,CHEMBL618706,,,,,1,1
8341,50597,In vivo,BAO_0000218,,,Lower clearance in rat (i.v.) at 0.5 mpk,,,N,Intermediate,A,10116.0,CHEMBL618707,,,,,1,1
8342,50597,In vivo,BAO_0000218,,,Pharmacokinetic parameter expressed as plasma clearance in rat,,,N,Intermediate,A,10116.0,CHEMBL618708,,1969.0,Plasma,,1,1
8343,50597,In vivo,BAO_0000218,,,Pharmacokinetic property (Clp) in rat,,,N,Intermediate,A,10116.0,CHEMBL618709,,,,,1,1
8344,50597,In vivo,BAO_0000218,,,Plasma clearance in Sprague-Dawley rats,,,N,Intermediate,A,10116.0,CHEMBL618710,,,,,1,1
8345,50597,In vivo,BAO_0000218,,,Plasma clearance (Clp) in rat,,,N,Intermediate,A,10116.0,CHEMBL618711,,,,,1,1
8346,50597,In vivo,BAO_0000218,,,Plasma clearance for the compound was measured in rat after an iv dose of 1 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL618712,,,,,1,1
8347,50597,In vivo,BAO_0000218,,,Plasma clearance in fasted male Sprague dawely rats on administration of 0.5 mg/Kg i.v. of the compound,,,N,Intermediate,A,10116.0,CHEMBL618713,,,,,1,1
8348,50597,In vivo,BAO_0000218,,,Plasma clearance after intravenous administration of 1 mg/kg in rat,,,N,Intermediate,A,10116.0,CHEMBL618714,,,,,1,1
8349,50597,In vivo,BAO_0000218,,,Plasma clearance in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,,,N,Intermediate,A,10116.0,CHEMBL618715,,,,,1,1
8350,50597,In vivo,BAO_0000218,,,Plasma clearance in rat was determined,,,N,Intermediate,A,10116.0,CHEMBL618716,,,,,1,1
8351,50597,In vivo,BAO_0000218,,,Plasma clearance measured in rat,,,N,Intermediate,A,10116.0,CHEMBL876601,,,,,1,1
8352,50597,In vivo,BAO_0000218,,,Plasma clearance was calculated in rat,,,N,Intermediate,A,10116.0,CHEMBL618717,,,,,1,1
8353,50597,In vivo,BAO_0000218,,,Plasma clearance in rat,,,N,Intermediate,A,10116.0,CHEMBL618718,,,,,1,1
8354,50597,In vivo,BAO_0000218,,,Plasma clearance in rat,,,N,Intermediate,A,10116.0,CHEMBL618719,,,,,1,1
8355,50597,In vivo,BAO_0000218,,,Plasma clearance in rat,,,N,Intermediate,A,10116.0,CHEMBL618720,,,,,1,1
8356,50597,In vivo,BAO_0000218,,,Plasma clearance in rat,,,N,Intermediate,A,10116.0,CHEMBL618721,,,,,1,1
8357,50597,In vivo,BAO_0000218,,,Plasma clearance in rats,,,N,Intermediate,A,10116.0,CHEMBL621477,,,,,1,1
8358,50597,In vivo,BAO_0000218,,,Plasma clearance in rat,,,N,Intermediate,A,10116.0,CHEMBL621478,,,,,1,1
8359,50597,In vivo,BAO_0000218,,,Plasma clearance was evaluated in rat,,,N,Intermediate,A,10116.0,CHEMBL621479,,,,,1,1
8360,50597,In vivo,BAO_0000218,,,Plasma clearance was evaluated in rat; Not tested,,,N,Intermediate,A,10116.0,CHEMBL621480,,,,,1,1
8361,50597,In vivo,BAO_0000218,,,Plasma clearance rate was determined for the compound in rat,,,N,Intermediate,A,10116.0,CHEMBL621481,,,,,1,1
8362,50597,In vivo,BAO_0000218,,,"Plasma clearance rate was determined in rats at 10mg/kg, p.o. dose; n/a: not applicable",,,N,Intermediate,A,10116.0,CHEMBL621482,,,,,1,1
8363,50597,In vivo,BAO_0000218,,,"Plasma clearance rate was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",,,N,Intermediate,A,10116.0,CHEMBL621483,,,,,1,1
8364,50597,In vivo,BAO_0000218,,,"Plasma clearance rate was determined in rats at 2 mg/kg, i.v. dose",,,N,Intermediate,A,10116.0,CHEMBL621484,,,,,1,1
8365,50597,In vivo,BAO_0000218,,,Biodistribution of [123I]-label in rat heart was reported at 24 hr post injection. Value shown is %ID/g of tissue,,,N,Intermediate,A,10116.0,CHEMBL621485,,948.0,Heart,,1,1
8366,50597,In vivo,BAO_0000218,,,Biodistribution of [123I]-label in rat heart was reported at 4 hr post injection. Value shown is %ID/g of tissue,,,N,Intermediate,A,10116.0,CHEMBL621486,,948.0,Heart,,1,1
8367,50597,In vivo,BAO_0000218,,,Biodistribution of [123I]-label in rat intestine was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,,N,Intermediate,A,10116.0,CHEMBL621487,,160.0,Intestine,,1,1
8368,50597,In vivo,BAO_0000218,,,Biodistribution of [123I]-label in rat intestine was reported at 1 hr post injection. Value shown is %ID/g of tissue,,,N,Intermediate,A,10116.0,CHEMBL621488,,160.0,Intestine,,1,1
8369,50597,In vivo,BAO_0000218,,,Biodistribution of [123I]-label in rat intestine was reported at 2 hr post injection. Value shown is %ID/g of tissue,,,N,Intermediate,A,10116.0,CHEMBL621489,,160.0,Intestine,,1,1
8370,50597,In vivo,BAO_0000218,,,Biodistribution of [123I]-label in rat intestine was reported at 24 hr post injection. Value shown is %ID/g of tissue,,,N,Intermediate,A,10116.0,CHEMBL621490,,160.0,Intestine,,1,1
8371,50597,In vivo,BAO_0000218,,,Biodistribution of [123I]-label in rat intestine was reported at 4 hr post injection. Value shown is %ID/g of tissue,,,N,Intermediate,A,10116.0,CHEMBL621491,,160.0,Intestine,,1,1
8372,50597,In vivo,BAO_0000218,,,Biodistribution of [123I]-label in rat kidneys was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,,N,Intermediate,A,10116.0,CHEMBL621492,,2113.0,Kidney,,1,1
8373,50597,In vivo,BAO_0000218,,,Biodistribution of [123I]-label in rat kidneys was reported at 1 h post injection. Value shown is %ID/g of tissue,,,N,Intermediate,A,10116.0,CHEMBL621493,,2113.0,Kidney,,1,1
8374,50597,In vivo,BAO_0000218,,,Biodistribution of [123I]-label in rat kidneys was reported at 2 hr post injection. Value shown is %ID/g of tissue,,,N,Intermediate,A,10116.0,CHEMBL621494,,2113.0,Kidney,,1,1
8375,50597,In vivo,BAO_0000218,,,Biodistribution of [123I]-label in rat kidneys was reported at 24 hr post injection. Value shown is %ID/g of tissue,,,N,Intermediate,A,10116.0,CHEMBL621495,,2113.0,Kidney,,1,1
8376,50597,In vivo,BAO_0000218,,,Biodistribution of [123I]-label in rat kidneys was reported at 4 hr post injection. Value shown is %ID/g of tissue,,,N,Intermediate,A,10116.0,CHEMBL621496,,2113.0,Kidney,,1,1
8377,50597,In vivo,BAO_0000218,,,Biodistribution of [123I]-label in rat liver was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,,N,Intermediate,A,10116.0,CHEMBL621497,,2107.0,Liver,,1,1
8378,50597,In vivo,BAO_0000218,,,Biodistribution of [123I]-label in rat liver was reported at 1 hr post injection. Value shown is %ID/g of tissue,,,N,Intermediate,A,10116.0,CHEMBL621498,,2107.0,Liver,,1,1
8379,50597,In vivo,BAO_0000218,,,Biodistribution of [123I]-label in rat liver was reported at 2 hr post injection. Value shown is %ID/g of tissue,,,N,Intermediate,A,10116.0,CHEMBL621499,,2107.0,Liver,,1,1
8380,50597,In vivo,BAO_0000218,,,Biodistribution of [123I]-label in rat liver was reported at 24 h post injection. Value shown is %ID/g of tissue,,,N,Intermediate,A,10116.0,CHEMBL618634,,2107.0,Liver,,1,1
8381,50597,In vivo,BAO_0000218,,,Biodistribution of [123I]-label in rat liver was reported at 4 hr post injection. Value shown is %ID/g of tissue,,,N,Intermediate,A,10116.0,CHEMBL618635,,2107.0,Liver,,1,1
8382,50597,In vivo,BAO_0000218,,,Biodistribution of [123I]-label in rat lung was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,,N,Intermediate,A,10116.0,CHEMBL618636,,2048.0,Lung,,1,1
8383,50597,In vivo,BAO_0000218,,,Biodistribution of [123I]-label in rat lung was reported at 1 hr post injection. Value shown is %ID/g of tissue,,,N,Intermediate,A,10116.0,CHEMBL619737,,2048.0,Lung,,1,1
8384,50597,In vivo,BAO_0000218,,,Biodistribution of [123I]-label in rat lung was reported at 2 hr post injection. Value shown is %ID/g of tissue,,,N,Intermediate,A,10116.0,CHEMBL619738,,2048.0,Lung,,1,1
8385,50597,In vivo,BAO_0000218,,,Biodistribution of [123I]-label in rat lung was reported at 24 hr post injection. Value shown is %ID/g of tissue,,,N,Intermediate,A,10116.0,CHEMBL624329,,2048.0,Lung,,1,1
8386,50597,In vivo,BAO_0000218,,,Biodistribution of [123I]-label in rat lung was reported at 4 hr post injection. Value shown is %ID/g of tissue,,,N,Intermediate,A,10116.0,CHEMBL624330,,2048.0,Lung,,1,1
8387,50597,In vivo,BAO_0000218,,,Biodistribution of [123I]-label in rat muscle was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,,N,Intermediate,A,10116.0,CHEMBL624331,,2385.0,Muscle tissue,,1,1
8388,50597,In vivo,BAO_0000218,,,Biodistribution of [123I]-label in rat muscle was reported at 1 hr post injection. Value shown is %ID/g of tissue,,,N,Intermediate,A,10116.0,CHEMBL624332,,2385.0,Muscle tissue,,1,1
8389,50597,In vivo,BAO_0000218,,,Biodistribution of [123I]-label in rat muscle was reported at 2 hr post injection. Value shown is %ID/g of tissue,,,N,Intermediate,A,10116.0,CHEMBL624333,,2385.0,Muscle tissue,,1,1
8390,50597,In vivo,BAO_0000218,,,Biodistribution of [123I]-label in rat muscle was reported at 24 hr post injection. Value shown is %ID/g of tissue,,,N,Intermediate,A,10116.0,CHEMBL624334,,2385.0,Muscle tissue,,1,1
8391,50597,In vivo,BAO_0000218,,,Biodistribution of [123I]-label in rat muscle was reported at 4 hr post injection. Value shown is %ID/g of tissue,,,N,Intermediate,A,10116.0,CHEMBL624335,,2385.0,Muscle tissue,,1,1
8392,50597,In vivo,BAO_0000218,,,Biodistribution of [123I]-label in rat spleen was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,,N,Intermediate,A,10116.0,CHEMBL620016,,2106.0,Spleen,,1,1
8393,50597,In vivo,BAO_0000218,,,Biodistribution of [123I]-label in rat spleen was reported at 1 hr post injection. Value shown is %ID/g of tissue,,,N,Intermediate,A,10116.0,CHEMBL620169,,2106.0,Spleen,,1,1
8394,50597,In vivo,BAO_0000218,,,Biodistribution of [123I]-label in rat spleen was reported at 2 hr post injection. Value shown is %ID/g of tissue,,,N,Intermediate,A,10116.0,CHEMBL620170,,2106.0,Spleen,,1,1
8395,50597,In vivo,BAO_0000218,,,Biodistribution of [123I]-label in rat spleen was reported at 24 h post injection. Value shown is %ID/g of tissue,,,N,Intermediate,A,10116.0,CHEMBL620171,,2106.0,Spleen,,1,1
8396,50597,In vivo,BAO_0000218,,,Biodistribution of [123I]-label in rat spleen was reported at 4 hr post injection. Value shown is %ID/g of tissue,,,N,Intermediate,A,10116.0,CHEMBL620172,,2106.0,Spleen,,1,1
8397,50597,In vivo,BAO_0000218,,,Biodistribution of [123I]-label in rat stomach was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,,N,Intermediate,A,10116.0,CHEMBL620173,,945.0,Stomach,,1,1
8398,50597,In vivo,BAO_0000218,,,Biodistribution of [123I]-label in rat stomach was reported at 1 h post injection. Value shown is %ID/g of tissue,,,N,Intermediate,A,10116.0,CHEMBL620174,,945.0,Stomach,,1,1
8399,50597,In vivo,BAO_0000218,,,Biodistribution of [123I]-label in rat stomach was reported at 2 hr post injection. Value shown is %ID/g of tissue,,,N,Intermediate,A,10116.0,CHEMBL620175,,945.0,Stomach,,1,1
8400,50597,In vivo,BAO_0000218,,,Biodistribution of [123I]-label in rat stomach was reported at 24 hr post injection. Value shown is %ID/g of tissue,,,N,Intermediate,A,10116.0,CHEMBL620176,,945.0,Stomach,,1,1
8401,50597,In vivo,BAO_0000218,,,Biodistribution of [123I]-label in rat stomach was reported at 4 hr post injection. Value shown is %ID/g of tissue,,,N,Intermediate,A,10116.0,CHEMBL620177,,945.0,Stomach,,1,1
8402,50597,,BAO_0000218,,,Distribution of [123I]-label in rat brain (cerebellum) was reported at 20 min post injection. Value shown is %ID/g of tissue,,,N,Intermediate,A,10116.0,CHEMBL620178,,2037.0,Cerebellum,,1,1
8403,50597,,BAO_0000218,,,Distribution of [123I]-label in rat brain (cerebellum) was reported at 60 min post injection. Value shown is %ID/g of tissue,,,N,Intermediate,A,10116.0,CHEMBL620179,,2037.0,Cerebellum,,1,1
8404,50597,,BAO_0000218,,,Distribution of [123I]-label in rat brain (diencephalon) was reported at 20 min post injection. Value shown is %ID/g of tissue,,,N,Intermediate,A,10116.0,CHEMBL620180,,,,,1,1
8405,50597,In vivo,BAO_0000218,,,Volume of distribution of compound in rat after 1 mg/kg i.v. administration,,,N,Intermediate,A,10116.0,CHEMBL620181,,,,,1,1
8406,50597,In vivo,BAO_0000218,,,Volume of distribution of compound in rats after intravenous administration,,,N,Intermediate,A,10116.0,CHEMBL620182,,,,,1,1
8407,50597,In vivo,BAO_0000218,,,Volume of distribution in rat,,,N,Intermediate,A,10116.0,CHEMBL620183,,,,,1,1
8408,50597,In vivo,BAO_0000218,,,Volume of distribution was determined in rat at a dose of 1 mpk i.v.,,,N,Intermediate,A,10116.0,CHEMBL620184,,,,,1,1
8409,50597,In vivo,BAO_0000218,,,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND means not determined,,,N,Intermediate,A,10116.0,CHEMBL620185,,,,,1,1
8410,50597,In vivo,BAO_0000218,,,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND=not determined,,,N,Intermediate,A,10116.0,CHEMBL620186,,,,,1,1
8411,50597,In vivo,BAO_0000218,,,Volume of distribution was determined in Dawley rat,,,N,Intermediate,A,10116.0,CHEMBL620187,,,,,1,1
8412,50597,In vivo,BAO_0000218,,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,,,N,Intermediate,A,10116.0,CHEMBL620188,,,,,1,1
8413,50597,In vivo,BAO_0000218,,,Volume of distribution was reported in Sprague-Dawley rat,,,N,Intermediate,A,10116.0,CHEMBL620189,,,,,1,1
8414,50597,In vivo,BAO_0000218,,,Volumes of distribution in rat after peroral administration,,,N,Intermediate,A,10116.0,CHEMBL620190,,,,,1,1
8415,50597,In vivo,BAO_0000218,,,Volumes of distribution in rat after po administration,,,N,Intermediate,A,10116.0,CHEMBL620191,,,,,1,1
8416,50597,In vivo,BAO_0000218,,,Volumes of distribution in rat after po administration; Not determined,,,N,Intermediate,A,10116.0,CHEMBL620192,,,,,1,1
8417,50597,In vivo,BAO_0000218,,,Pharmacokinetic property (Volume) in rat i.v.,,,N,Intermediate,A,10116.0,CHEMBL620193,,,,,1,1
8418,50597,In vivo,BAO_0000218,,,Apparent volume of distribution when 3 mg/Kg dose was administered intravenously,,,N,Intermediate,A,10116.0,CHEMBL620194,,,,,1,1
8419,50597,In vivo,BAO_0000218,,,"Volume distribution in fischer rats at 5 mg/kg dose, administered intravenously",,,N,Intermediate,A,10116.0,CHEMBL876730,,,,,1,1
8420,50597,In vivo,BAO_0000218,,,Volume distribution in rat after oral administration at 10 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL620195,,,,,1,1
8421,50597,In vivo,BAO_0000218,,,Evaluated for Volume of distribution after iv administration of 5 mg/kg to male Sprague-Dawley rats,,,N,Intermediate,A,10116.0,CHEMBL620196,,,,,1,1
8422,50597,In vivo,BAO_0000218,,,Tested for volume of distribution after intravenous administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL620197,,,,,1,1
8423,50597,In vivo,BAO_0000218,,,Volume of distribution after oral administration of 6 mg/kg of dose in rats was determined,,,N,Intermediate,A,10116.0,CHEMBL620198,,,,,1,1
8424,50597,In vivo,BAO_0000218,,,Volume of distribution in rats,,,N,Intermediate,A,10116.0,CHEMBL620199,,,,,1,1
8425,50597,In vivo,BAO_0000218,,,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female wistar rats,,,N,Intermediate,A,10116.0,CHEMBL620200,,,,,1,1
8426,50597,In vivo,BAO_0000218,,,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to male wistar rats,,,N,Intermediate,A,10116.0,CHEMBL620201,,,,,1,1
8427,50597,In vivo,BAO_0000218,,,In vivo Volume distribution (Vss) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,,N,Intermediate,A,10116.0,CHEMBL620202,,,,,1,1
8428,50597,In vivo,BAO_0000218,,,In vivo Volume distribution (Vss) was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,,N,Intermediate,A,10116.0,CHEMBL620203,,,,,1,1
8429,50597,In vivo,BAO_0000218,,,In vivo Volume distribution (Vss) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat;no value,,,N,Intermediate,A,10116.0,CHEMBL620204,,,,,1,1
8430,50597,In vivo,BAO_0000218,,,In vivo Volume distribution (Vss) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,,N,Intermediate,A,10116.0,CHEMBL620205,,,,,1,1
8431,50597,In vivo,BAO_0000218,,,Pharmacokinetic parameter (Vss) in rat,,,N,Intermediate,A,10116.0,CHEMBL624664,,,,,1,1
8432,50597,In vivo,BAO_0000218,,,Pharmacokinetic property (Volume) in rat i.v.,,,N,Intermediate,A,10116.0,CHEMBL624665,,,,,1,1
8433,50597,,BAO_0000218,,,Pharmacokinetic property (Vss) in rat,,,N,Intermediate,A,10116.0,CHEMBL624666,,,,,1,1
8434,50597,In vivo,BAO_0000218,,,Steady state volume distribution (Vss) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat,,,N,Intermediate,A,10116.0,CHEMBL624667,,,,,1,1
8435,50597,In vivo,BAO_0000218,,,Steady state volume distribution (Vss) of compound after iv administration was determined in Sprague-Dawley rat,,,N,Intermediate,A,10116.0,CHEMBL624668,,,,,1,1
8436,50597,In vivo,BAO_0000218,,,Steady state volume distribution (Vss) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,,,N,Intermediate,A,10116.0,CHEMBL624669,,,,,1,1
8437,50597,In vivo,BAO_0000218,,,Steady state volume distribution (Vss) of compound(9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,,,N,Intermediate,A,10116.0,CHEMBL624670,,,,,1,1
8438,50597,In vivo,BAO_0000218,,,Steady state volume distribution (Vss) of compound(9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,,,N,Intermediate,A,10116.0,CHEMBL624671,,,,,1,1
8439,50597,In vivo,BAO_0000218,,,Steady state volume distribution in rat,,,N,Intermediate,A,10116.0,CHEMBL624672,,,,,1,1
8440,50597,In vivo,BAO_0000218,,,"Steady state volume of distribution calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv.",,,N,Intermediate,A,10116.0,CHEMBL624673,,1969.0,Plasma,,1,1
8441,50597,In vivo,BAO_0000218,,,Steady state volume of distribution determined in rat,,,N,Intermediate,A,10116.0,CHEMBL624674,,,,,1,1
8442,50597,In vivo,BAO_0000218,,,Steady-state volume of distribution was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,,,N,Intermediate,A,10116.0,CHEMBL624675,,,,,1,1
8443,50597,In vivo,BAO_0000218,,,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in rat,,,N,Intermediate,A,10116.0,CHEMBL621728,,,,,1,1
8444,50597,,BAO_0000218,,,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined,,,N,Intermediate,A,10116.0,CHEMBL621729,,,,,1,1
8445,50597,,BAO_0000218,,,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined; NC means not calculated,,,N,Intermediate,A,10116.0,CHEMBL621730,,,,,1,1
8446,50597,In vivo,BAO_0000218,,,Volume distribution in rat after administration of 2 mg/kg iv,,,N,Intermediate,A,10116.0,CHEMBL621731,,,,,1,1
8447,50597,In vivo,BAO_0000218,,,Volume distribution in rat after administration of 2 mg/kg iv,,,N,Intermediate,A,10116.0,CHEMBL621732,,,,,1,1
8448,50597,In vivo,BAO_0000218,,,Volume in steady state distribution value was determined,,,N,Intermediate,A,10116.0,CHEMBL621908,,,,,1,1
8449,50597,In vivo,BAO_0000218,,,Volume in steady state distribution value was determined; ND denotes no data,,,N,Intermediate,A,10116.0,CHEMBL875347,,,,,1,1
8450,50597,In vivo,BAO_0000218,,,Volume in steady state distribution value was determined; ND denotes not determined,,,N,Intermediate,A,10116.0,CHEMBL621909,,,,,1,1
8451,50597,In vivo,BAO_0000218,,,Volume of distribution at a steady state measured after intravenous bolus administration of 50 mg/kg of compound to rats,,,N,Intermediate,A,10116.0,CHEMBL621910,,,,,1,1
8452,50597,In vivo,BAO_0000218,,,Volume of distribution at steady state was evaluated in rats,,,N,Intermediate,A,10116.0,CHEMBL621911,,,,,1,1
8453,50597,In vivo,BAO_0000218,,,Volume of distribution at steady state was observed after intravenous administration in rat,,,N,Intermediate,A,10116.0,CHEMBL621912,,,,,1,1
8454,50597,In vivo,BAO_0000218,,,Volume of distribution in steady state was determined in rat,,,N,Intermediate,A,10116.0,CHEMBL621913,,,,,1,1
8455,50597,In vivo,BAO_0000218,,,Volume of distribution in steady state was determined in rat,,,N,Intermediate,A,10116.0,CHEMBL621914,,,,,1,1
8456,50597,In vivo,BAO_0000218,,,Volume of distribution after i.v. administration,,,N,Intermediate,A,10116.0,CHEMBL621915,,,,,1,1
8457,50597,In vivo,BAO_0000218,,,Volume of distribution was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,,,N,Intermediate,A,10116.0,CHEMBL621916,,,,,1,1
8458,50594,In vivo,BAO_0000218,,,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",,,N,Intermediate,A,10090.0,CHEMBL621917,,2107.0,Liver,,1,1
8459,50594,In vivo,BAO_0000218,,,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,,N,Intermediate,A,10090.0,CHEMBL621918,,2107.0,Liver,,1,1
8460,50594,In vivo,BAO_0000218,,,Biodistribution of compound (oxidized form) in spleen tissue,,,N,Intermediate,A,10090.0,CHEMBL621919,,2106.0,Spleen,,1,1
8461,50594,In vivo,BAO_0000218,,,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,,N,Intermediate,A,10090.0,CHEMBL621920,,2106.0,Spleen,,1,1
8462,50594,In vivo,BAO_0000218,,,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",,,N,Intermediate,A,10090.0,CHEMBL621921,,2106.0,Spleen,,1,1
8463,50594,In vivo,BAO_0000218,,,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,,N,Intermediate,A,10090.0,CHEMBL622401,,2106.0,Spleen,,1,1
8464,50594,In vivo,BAO_0000218,,,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,,N,Intermediate,A,10090.0,CHEMBL875348,,2106.0,Spleen,,1,1
8465,50594,In vivo,BAO_0000218,,,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",,,N,Intermediate,A,10090.0,CHEMBL622402,,2106.0,Spleen,,1,1
8466,50594,In vivo,BAO_0000218,,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood,,,N,Intermediate,A,10090.0,CHEMBL622403,,178.0,Blood,,1,1
8467,50594,In vivo,BAO_0000218,,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,,N,Intermediate,A,10090.0,CHEMBL622404,,178.0,Blood,,1,1
8468,50594,In vivo,BAO_0000218,,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues,,,N,Intermediate,A,10090.0,CHEMBL622405,,955.0,Brain,,1,1
8469,50594,In vivo,BAO_0000218,,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO",,,N,Intermediate,A,10090.0,CHEMBL622406,,955.0,Brain,,1,1
8470,50594,In vivo,BAO_0000218,,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,,N,Intermediate,A,10090.0,CHEMBL622407,,955.0,Brain,,1,1
8471,50594,In vivo,BAO_0000218,,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues,,,N,Intermediate,A,10090.0,CHEMBL622408,,948.0,Heart,,1,1
8472,50594,In vivo,BAO_0000218,,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO",,,N,Intermediate,A,10090.0,CHEMBL622409,,948.0,Heart,,1,1
8473,50594,In vivo,BAO_0000218,,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,,N,Intermediate,A,10090.0,CHEMBL622410,,948.0,Heart,,1,1
8474,50594,In vivo,BAO_0000218,,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney,,,N,Intermediate,A,10090.0,CHEMBL622411,,2113.0,Kidney,,1,1
8475,50594,In vivo,BAO_0000218,,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing in DMSO",,,N,Intermediate,A,10090.0,CHEMBL627864,,2113.0,Kidney,,1,1
8476,50594,In vivo,BAO_0000218,,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,,N,Intermediate,A,10090.0,CHEMBL627865,,2113.0,Kidney,,1,1
8477,50594,In vivo,BAO_0000218,,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver,,,N,Intermediate,A,10090.0,CHEMBL627866,,2107.0,Liver,,1,1
8478,50594,In vivo,BAO_0000218,,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,,N,Intermediate,A,10090.0,CHEMBL627751,,2107.0,Liver,,1,1
8479,50594,In vivo,BAO_0000218,,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen,,,N,Intermediate,A,10090.0,CHEMBL627752,,2106.0,Spleen,,1,1
8480,50594,In vivo,BAO_0000218,,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing in DMSO",,,N,Intermediate,A,10090.0,CHEMBL627753,,2106.0,Spleen,,1,1
8481,50594,In vivo,BAO_0000218,,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,,N,Intermediate,A,10090.0,CHEMBL627754,,2106.0,Spleen,,1,1
8482,50594,,BAO_0000218,,,Cellular uptake kinetics of Porphycenes saturation cell level (cs) in SSK2 murine fibrosarcoma cells,,,N,Intermediate,A,10090.0,CHEMBL627755,,,,,1,1
8483,50594,In vivo,BAO_0000218,,,Biodistribution of radioactivity in normal mice (ICR) brain after 1 hour of intravenous injection of [125I]-16(IMPY),,,N,Intermediate,A,10090.0,CHEMBL627756,,955.0,Brain,,1,1
8484,50594,In vivo,BAO_0000218,,,Biodistribution of radioactivity in normal mice (ICR) brain after 2 hours of intravenous injection of [125I]-16(IMPY),,,N,Intermediate,A,10090.0,CHEMBL627757,,955.0,Brain,,1,1
8485,50594,In vivo,BAO_0000218,,,Biodistribution of radioactivity in normal mice (ICR) brain after 2 minutes of intravenous injection of [125I]-16(IMPY),,,N,Intermediate,A,10090.0,CHEMBL627758,,955.0,Brain,,1,1
8486,50594,In vivo,BAO_0000218,,,Biodistribution of radioactivity in normal mice (ICR) brain after 24 hours of intravenous injection of [125I]-16(IMPY),,,N,Intermediate,A,10090.0,CHEMBL627759,,955.0,Brain,,1,1
8487,50594,In vivo,BAO_0000218,,,Biodistribution of radioactivity in normal mice (ICR) brain after 30 minutes of intravenous injection of [125I]-16(IMPY),,,N,Intermediate,A,10090.0,CHEMBL627760,,955.0,Brain,,1,1
8488,50594,In vivo,BAO_0000218,,,Biodistribution of radioactivity in normal mice (ICR) brain after 6 hours of intravenous injection of [125I]-16(IMPY),,,N,Intermediate,A,10090.0,CHEMBL627761,,955.0,Brain,,1,1
8489,50594,In vivo,BAO_0000218,,,Biodistribution of radioactivity in normal mice (ICR) heart after 1 hour of intravenous injection of [125I]-16(IMPY),,,N,Intermediate,A,10090.0,CHEMBL876811,,948.0,Heart,,1,1
8490,50594,In vivo,BAO_0000218,,,Biodistribution of radioactivity in normal mice (ICR) heart after 2 hours of intravenous injection of [125I]-16(IMPY),,,N,Intermediate,A,10090.0,CHEMBL627762,,948.0,Heart,,1,1
8491,50594,In vivo,BAO_0000218,,,Biodistribution of radioactivity in normal mice (ICR) heart after 2 minutes of intravenous injection of [125I]-16(IMPY),,,N,Intermediate,A,10090.0,CHEMBL627763,,948.0,Heart,,1,1
8492,50594,In vivo,BAO_0000218,,,Biodistribution of radioactivity in normal mice (ICR) heart after 24 hours of intravenous injection of [125I]-16(IMPY),,,N,Intermediate,A,10090.0,CHEMBL627764,,948.0,Heart,,1,1
8493,50594,In vivo,BAO_0000218,,,Biodistribution of radioactivity in normal mice (ICR) heart after 30 minutes of intravenous injection of [125I]-16(IMPY),,,N,Intermediate,A,10090.0,CHEMBL627765,,948.0,Heart,,1,1
8494,50594,In vivo,BAO_0000218,,,Biodistribution of radioactivity in normal mice (ICR) heart after 6 hours of intravenous injection of [125I]-16(IMPY),,,N,Intermediate,A,10090.0,CHEMBL627766,,948.0,Heart,,1,1
8495,50594,In vivo,BAO_0000218,,,Biodistribution of radioactivity in normal mice (ICR) kidney after 1 hour of intravenous injection of [125I]-16(IMPY),,,N,Intermediate,A,10090.0,CHEMBL627767,,2113.0,Kidney,,1,1
8496,50594,In vivo,BAO_0000218,,,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 hours of intravenous injection of [125I]-16(IMPY),,,N,Intermediate,A,10090.0,CHEMBL627768,,2113.0,Kidney,,1,1
8497,50594,In vivo,BAO_0000218,,,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 minutes of intravenous injection of [125I]-16(IMPY),,,N,Intermediate,A,10090.0,CHEMBL628422,,2113.0,Kidney,,1,1
8498,50594,In vivo,BAO_0000218,,,Biodistribution of radioactivity in normal mice (ICR) kidney after 24 hours of intravenous injection of [125I]-16(IMPY),,,N,Intermediate,A,10090.0,CHEMBL628423,,2113.0,Kidney,,1,1
8499,50597,In vivo,BAO_0000218,,,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing) in Dawley rat,,,N,Intermediate,A,10116.0,CHEMBL628424,,,,,1,1
8500,50597,In vivo,BAO_0000218,,,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing)) in Dawley rat,,,N,Intermediate,A,10116.0,CHEMBL628425,,,,,1,1
8501,50597,In vivo,BAO_0000218,,,Plasma clearance value was determined in rat after a 3 mg/kg of iv dose,,,N,Intermediate,A,10116.0,CHEMBL628426,,,,,1,1
8502,50597,In vivo,BAO_0000218,,,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,,N,Intermediate,A,10116.0,CHEMBL628427,,,,,1,1
8503,50597,In vivo,BAO_0000218,,,Plasma clearance was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,,,N,Intermediate,A,10116.0,CHEMBL626938,,,,,1,1
8504,50597,In vivo,BAO_0000218,,,Plasma clearance was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats,,,N,Intermediate,A,10116.0,CHEMBL626939,,,,,1,1
8505,50597,In vivo,BAO_0000218,,,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,,,N,Intermediate,A,10116.0,CHEMBL626940,,,,,1,1
8506,50597,In vivo,BAO_0000218,,,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,,,N,Intermediate,A,10116.0,CHEMBL626941,,,,,1,1
8507,50597,In vivo,BAO_0000218,,,Plasma clearance was reported in Sprague-Dawley rat,,,N,Intermediate,A,10116.0,CHEMBL626942,,,,,1,1
8508,50597,In vivo,BAO_0000218,,,Plasma clearance after intravenous administration (1 mg/kg) in rat,,,N,Intermediate,A,10116.0,CHEMBL876812,,,,,1,1
8509,50597,In vivo,BAO_0000218,,,Plasma clearance of compound in rats was evaluated,,,N,Intermediate,A,10116.0,CHEMBL626943,,,,,1,1
8510,50597,In vivo,BAO_0000218,,,Plasma clearance of compound in rats was evaluated; ND indicates not determined,,,N,Intermediate,A,10116.0,CHEMBL626944,,,,,1,1
8511,50597,In vivo,BAO_0000218,,,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration,,,N,Intermediate,A,10116.0,CHEMBL626945,,,,,1,1
8512,50597,In vivo,BAO_0000218,,,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,,,N,Intermediate,A,10116.0,CHEMBL626946,,,,,1,1
8513,50597,In vivo,BAO_0000218,,,Plasma clearance rate in Sprague-Dawley rats,,,N,Intermediate,A,10116.0,CHEMBL626856,,,,,1,1
8514,50597,In vivo,BAO_0000218,,,Plasma clearance was determined in rat after intravenous administration (0.5 mg/kg),,,N,Intermediate,A,10116.0,CHEMBL626857,,,,,1,1
8515,50597,In vivo,BAO_0000218,,,The compound was evaluated for plasma clearance in rat,,,N,Intermediate,A,10116.0,CHEMBL626858,,1969.0,Plasma,,1,1
8516,50597,In vivo,BAO_0000218,,,Total plasma clearance in rat,,,N,Intermediate,A,10116.0,CHEMBL627018,,1969.0,Plasma,,1,1
8517,50597,In vivo,BAO_0000218,,,Absorption behavior was judged by the peak blood concentration determined after oral dose of 30 mg/kg in rats.,,,N,Intermediate,A,10116.0,CHEMBL625331,,178.0,Blood,,1,1
8518,50597,In vivo,BAO_0000218,,,Blood level after a 10 mg/kg oral dose in rat expressed as Cmax was determined,,,N,Intermediate,A,10116.0,CHEMBL625332,,178.0,Blood,,1,1
8519,50597,In vivo,BAO_0000218,,,C max was determined at 10 mg/kg po dose in rats,,,N,Intermediate,A,10116.0,CHEMBL877590,,,,,1,1
8520,50597,In vivo,BAO_0000218,,,C max was determined at 3 mg/kg po dose in rats,,,N,Intermediate,A,10116.0,CHEMBL625333,,,,,1,1
8521,50597,In vivo,BAO_0000218,,,Cmax after repeated oral dose of compound at 1 mg/kg in rats,,,N,Intermediate,A,10116.0,CHEMBL625334,,,,,1,1
8522,50597,In vivo,BAO_0000218,,,Cmax after single intravenous bolus of 1 mg/kg in rats,,,N,Intermediate,A,10116.0,CHEMBL625335,,,,,1,1
8523,50597,In vivo,BAO_0000218,,,Cmax of compound at 5 mg/kg after po administration was determined in rat,,,N,Intermediate,A,10116.0,CHEMBL625336,,,,,1,1
8524,50597,In vivo,BAO_0000218,,,Cmax 24 hr after 10 mg/kg oral administration in rats,,,N,Intermediate,A,10116.0,CHEMBL625337,,,,,1,1
8525,50597,In vivo,BAO_0000218,,,Cmax 24 hr after 2 mg/kg oral administration in rats,,,N,Intermediate,A,10116.0,CHEMBL625338,,,,,1,1
8526,50597,In vivo,BAO_0000218,,,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in rat,,,N,Intermediate,A,10116.0,CHEMBL625339,,1969.0,Plasma,,1,1
8527,50597,In vivo,BAO_0000218,,,Cmax in rat after administration of 2 mg/kg iv,,,N,Intermediate,A,10116.0,CHEMBL625340,,,,,1,1
8528,50597,In vivo,BAO_0000218,,,Cmax in rat after administration of 2 mg/kg iv,,,N,Intermediate,A,10116.0,CHEMBL625341,,,,,1,1
8529,50597,In vivo,BAO_0000218,,,Cmax in rats determined 6 hours after oral dosing of 20 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL622687,,,,,1,1
8530,50597,In vivo,BAO_0000218,,,Cmax wa determined in rat plasma at 30 mg/kg after po administration,,,N,Intermediate,A,10116.0,CHEMBL622688,,1969.0,Plasma,,1,1
8531,50597,In vivo,BAO_0000218,,,Cmax was calculated as maximum concentration reached in the blood after oral administration to male F344 rats,,,N,Intermediate,A,10116.0,CHEMBL622689,,178.0,Blood,,1,1
8532,50597,In vivo,BAO_0000218,,,Cmax was calculated as maximum concentration reached in the blood in air pouch exudate after oral administration to male F344 rats,,,N,Intermediate,A,10116.0,CHEMBL620295,,178.0,Blood,,1,1
8533,50597,In vivo,BAO_0000218,,,Cmax after 10 mg/kg oral administration in rat,,,N,Intermediate,A,10116.0,CHEMBL620296,,,,,1,1
8534,50597,In vivo,BAO_0000218,,,Cmax after IV dosing at 0.5 mg/kg in rat; no data,,,N,Intermediate,A,10116.0,CHEMBL620297,,,,,1,1
8535,50597,In vivo,BAO_0000218,,,Cmax after IV dosing at 1 mg/kg in rat; no data,,,N,Intermediate,A,10116.0,CHEMBL620298,,,,,1,1
8536,50597,In vivo,BAO_0000218,,,Cmax after oral administration at 20 mpk in rats,,,N,Intermediate,A,10116.0,CHEMBL620299,,,,,1,1
8537,50597,In vivo,BAO_0000218,,,Cmax after oral administration at 20 mpk in rats; Not performed.,,,N,Intermediate,A,10116.0,CHEMBL620300,,,,,1,1
8538,50597,In vivo,BAO_0000218,,,Cmax after oral administration at 20 mpk in rats d; Not performed.,,,N,Intermediate,A,10116.0,CHEMBL620301,,,,,1,1
8539,50597,In vivo,BAO_0000218,,,Cmax after oral administration in rat,,,N,Intermediate,A,10116.0,CHEMBL620302,,,,,1,1
8540,50597,In vivo,BAO_0000218,,,Cmax after oral administration at a dose of 2 mg/kg in rat,,,N,Intermediate,A,10116.0,CHEMBL620303,,,,,1,1
8541,50597,In vivo,BAO_0000218,,,Cmax after oral administration at a dose of 4 mg/kg in rat,,,N,Intermediate,A,10116.0,CHEMBL620304,,,,,1,1
8542,50597,In vivo,BAO_0000218,,,Cmax in rats after 20 mg/kg oral dose,,,N,Intermediate,A,10116.0,CHEMBL620305,,,,,1,1
8543,50597,In vivo,BAO_0000218,,,Cmax after peroral administration in rats at 2.4 uM/kg,,,N,Intermediate,A,10116.0,CHEMBL620306,,,,,1,1
8544,50597,In vivo,BAO_0000218,,,Cmax at the dose of 2 mg/Kg administered perorally in rats,,,N,Intermediate,A,10116.0,CHEMBL620307,,,,,1,1
8545,50597,In vivo,BAO_0000218,,,Cmax at the dose of 5 mg/Kg administered perorally in rats,,,N,Intermediate,A,10116.0,CHEMBL620308,,,,,1,1
8546,50597,In vivo,BAO_0000218,,,Cmax by administering at 20 mg/kg p.o. in rats,,,N,Intermediate,A,10116.0,CHEMBL620309,,,,,1,1
8547,50597,In vivo,BAO_0000218,,,Cmax in male rat,,,N,Intermediate,A,10116.0,CHEMBL620310,,,,,1,1
8548,50597,In vivo,BAO_0000218,,,Cmax in rat,,,N,Intermediate,A,10116.0,CHEMBL620311,,,,,1,1
8549,50597,In vivo,BAO_0000218,,,Cmax in rat,,,N,Intermediate,A,10116.0,CHEMBL620312,,,,,1,1
8550,50597,In vivo,BAO_0000218,,,Cmax in rat,,,N,Intermediate,A,10116.0,CHEMBL620313,,,,,1,1
8551,50597,In vivo,BAO_0000218,,,Cmax in rat at 10 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL620314,,,,,1,1
8552,50597,In vivo,BAO_0000218,,,Cmax in rat at the dose of 1 mg/kg i.v.,,,N,Intermediate,A,10116.0,CHEMBL620315,,,,,1,1
8553,50597,In vivo,BAO_0000218,,,Cmax in rat by po administration at a dose of 40 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL620316,,,,,1,1
8554,50597,In vivo,BAO_0000218,,,Cmax in rat p.o. at 20 mg/kg concentration,,,N,Intermediate,A,10116.0,CHEMBL620317,,,,,1,1
8555,50597,In vivo,BAO_0000218,,,Cmax in rats,,,N,Intermediate,A,10116.0,CHEMBL620318,,,,,1,1
8556,50597,In vivo,BAO_0000218,,,Cmax in rats,,,N,Intermediate,A,10116.0,CHEMBL620319,,,,,1,1
8557,50597,In vivo,BAO_0000218,,,Cmax was evaluated after 20 uM/kg of peroral administration,,,N,Intermediate,A,10116.0,CHEMBL620320,,,,,1,1
8558,50597,In vivo,BAO_0000218,,,Cmax was measured in rats after peroral administration at 3 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL620321,,,,,1,1
8559,50597,In vivo,BAO_0000218,,,Cmax value after oral dose at a dose of 10 mg/kg in rats.,,,N,Intermediate,A,10116.0,CHEMBL620322,,,,,1,1
8560,50597,,BAO_0000218,,,Distribution of [123I]-label in rat brain (diencephalon) was reported at 60 min post injection. Value shown is %ID/g of tissue,,,N,Intermediate,A,10116.0,CHEMBL620323,,,,,1,1
8561,50597,,BAO_0000218,,,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue,,,N,Intermediate,A,10116.0,CHEMBL620324,,1870.0,Frontal cortex,,1,1
8562,50597,,BAO_0000218,,,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue,,,N,Intermediate,A,10116.0,CHEMBL620325,,1870.0,Frontal cortex,,1,1
8563,50597,,BAO_0000218,,,Distribution of [123I]-label in rat brain (hippocampus) was reported at 20 min post injection. Value shown is %ID/g of tissue,,,N,Intermediate,A,10116.0,CHEMBL620326,,10000000.0,Hippocampus,,1,1
8564,50597,,BAO_0000218,,,Distribution of [123I]-label in rat brain (hippocampus) was reported at 60 min post injection. Value shown is %ID/g of tissue,,,N,Intermediate,A,10116.0,CHEMBL620327,,10000000.0,Hippocampus,,1,1
8565,50597,,BAO_0000218,,,Distribution of [123I]-label in rat brain (medulla pons) was reported at 20 min post injection. Value shown is %ID/g of tissue,,,N,Intermediate,A,10116.0,CHEMBL620328,,,,,1,1
8566,50597,,BAO_0000218,,,Distribution of [123I]-label in rat brain (medulla pons) was reported at 60 min post injection. Value shown is %ID/g of tissue,,,N,Intermediate,A,10116.0,CHEMBL620329,,,,,1,1
8567,50597,,BAO_0000218,,,Distribution of [123I]-label in rat brain (midbrain) was reported at 20 min post injection. Value shown is %ID/g of tissue,,,N,Intermediate,A,10116.0,CHEMBL620330,,1891.0,Midbrain,,1,1
8568,50597,,BAO_0000218,,,Distribution of [123I]-label in rat brain (midbrain) was reported at 60 min post injection. Value shown is %ID/g of tissue,,,N,Intermediate,A,10116.0,CHEMBL875286,,1891.0,Midbrain,,1,1
8569,50597,,BAO_0000218,,,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue,,,N,Intermediate,A,10116.0,CHEMBL620331,,,,,1,1
8570,50597,,BAO_0000218,,,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue,,,N,Intermediate,A,10116.0,CHEMBL620332,,,,,1,1
8571,50597,,BAO_0000218,,,Distribution of [123I]-label in rat brain (striatum) was reported at 20 min post injection. Value shown is %ID/g of tissue,,,N,Intermediate,A,10116.0,CHEMBL620333,,2435.0,Striatum,,1,1
8572,50597,,BAO_0000218,,,Distribution of [123I]-label in rat brain (striatum) was reported at 60 min post injection. Value shown is %ID/g of tissue,,,N,Intermediate,A,10116.0,CHEMBL620334,,2435.0,Striatum,,1,1
8573,50597,,BAO_0000218,,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,,N,Intermediate,A,10116.0,CHEMBL621015,,178.0,Blood,,1,1
8574,50597,,BAO_0000218,,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,,N,Intermediate,A,10116.0,CHEMBL621016,,178.0,Blood,,1,1
8575,50597,,BAO_0000218,,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,,N,Intermediate,A,10116.0,CHEMBL621191,,178.0,Blood,,1,1
8576,50597,,BAO_0000218,,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,,N,Intermediate,A,10116.0,CHEMBL621192,,178.0,Blood,,1,1
8577,50597,,BAO_0000218,,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,,N,Intermediate,A,10116.0,CHEMBL621193,,178.0,Blood,,1,1
8578,50597,,BAO_0000218,,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,,N,Intermediate,A,10116.0,CHEMBL621194,,178.0,Blood,,1,1
8579,50597,,BAO_0000218,,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,,N,Intermediate,A,10116.0,CHEMBL624204,,178.0,Blood,,1,1
8580,50597,,BAO_0000218,,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,,N,Intermediate,A,10116.0,CHEMBL624205,,178.0,Blood,,1,1
8581,50597,,BAO_0000218,,,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,,N,Intermediate,A,10116.0,CHEMBL624206,,178.0,Blood,,1,1
8582,50597,,BAO_0000218,,,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,,N,Intermediate,A,10116.0,CHEMBL624207,,178.0,Blood,,1,1
8583,50597,,BAO_0000218,,,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,,N,Intermediate,A,10116.0,CHEMBL624208,,178.0,Blood,,1,1
8584,50597,,BAO_0000218,,,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,,N,Intermediate,A,10116.0,CHEMBL624209,,178.0,Blood,,1,1
8585,50597,,BAO_0000218,,,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,,N,Intermediate,A,10116.0,CHEMBL624210,,178.0,Blood,,1,1
8586,50597,,BAO_0000218,,,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,,N,Intermediate,A,10116.0,CHEMBL624211,,178.0,Blood,,1,1
8587,50597,,BAO_0000218,,,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,,N,Intermediate,A,10116.0,CHEMBL624212,,178.0,Blood,,1,1
8588,50597,,BAO_0000218,,,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,,N,Intermediate,A,10116.0,CHEMBL624213,,178.0,Blood,,1,1
8589,50597,,BAO_0000218,,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,,N,Intermediate,A,10116.0,CHEMBL876611,,178.0,Blood,,1,1
8590,50597,,BAO_0000218,,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,,N,Intermediate,A,10116.0,CHEMBL624214,,178.0,Blood,,1,1
8591,50597,,BAO_0000218,,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,,N,Intermediate,A,10116.0,CHEMBL624215,,178.0,Blood,,1,1
8592,50597,,BAO_0000218,,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,,N,Intermediate,A,10116.0,CHEMBL624216,,178.0,Blood,,1,1
8593,50597,,BAO_0000218,,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,,N,Intermediate,A,10116.0,CHEMBL624217,,178.0,Blood,,1,1
8594,50597,,BAO_0000218,,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,,N,Intermediate,A,10116.0,CHEMBL624218,,178.0,Blood,,1,1
8595,50597,,BAO_0000218,,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,,N,Intermediate,A,10116.0,CHEMBL624219,,178.0,Blood,,1,1
8596,50597,,BAO_0000218,,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,,N,Intermediate,A,10116.0,CHEMBL624220,,178.0,Blood,,1,1
8597,50597,,BAO_0000218,,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,,N,Intermediate,A,10116.0,CHEMBL624221,,178.0,Blood,,1,1
8598,50597,,BAO_0000218,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,,N,Intermediate,A,10116.0,CHEMBL624222,,,,,1,1
8599,50597,,BAO_0000218,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,,N,Intermediate,A,10116.0,CHEMBL624223,,,,,1,1
8600,50597,,BAO_0000218,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,,N,Intermediate,A,10116.0,CHEMBL624224,,,,,1,1
8601,50597,,BAO_0000218,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,,N,Intermediate,A,10116.0,CHEMBL624225,,,,,1,1
8602,50597,In vivo,BAO_0000218,,,Volume of solubility in solution after intravenous administration in rats at 24 uM/kg,,,N,Intermediate,A,10116.0,CHEMBL622420,,,,,1,1
8603,50597,In vivo,BAO_0000218,,,Volume of steady state distribution after i.v. administration in rats,,,N,Intermediate,A,10116.0,CHEMBL622421,,,,,1,1
8604,50597,In vivo,BAO_0000218,,,Vss after intravenous administration (5.0 mg/kg) was determined in rat,,,N,Intermediate,A,10116.0,CHEMBL622422,,,,,1,1
8605,50597,In vivo,BAO_0000218,,,Vss in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL622423,,,,,1,1
8606,50597,In vivo,BAO_0000218,,,Vss was determined,,,N,Intermediate,A,10116.0,CHEMBL622424,,,,,1,1
8607,50597,In vivo,BAO_0000218,,,Vss in rat,,,N,Intermediate,A,10116.0,CHEMBL622425,,,,,1,1
8608,50597,In vivo,BAO_0000218,,,Vss was evaluated after 10 uM/kg of intra arterial administration,,,N,Intermediate,A,10116.0,CHEMBL876612,,,,,1,1
8609,50597,In vivo,BAO_0000218,,,volume of distribution at steady state was observed after intravenous administration in rat,,,N,Intermediate,A,10116.0,CHEMBL622426,,,,,1,1
8610,50597,In vivo,BAO_0000218,,,Volume of distribution was measured in rat after an iv dose of 1 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL622427,,,,,1,1
8611,50597,In vivo,BAO_0000218,,,Pharmacokinetic (PK) parameter Vz in rat,,,N,Intermediate,A,10116.0,CHEMBL622428,,,,,1,1
8612,50597,In vivo,BAO_0000218,,,Volume distribution in rats,,,N,Intermediate,A,10116.0,CHEMBL622429,,,,,1,1
8613,50597,In vivo,BAO_0000218,,,Volume of distribution in rat; No data,,,N,Intermediate,A,10116.0,CHEMBL622430,,,,,1,1
8614,50597,In vivo,BAO_0000218,,,Volume of distribution was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,,,N,Intermediate,A,10116.0,CHEMBL622431,,,,,1,1
8615,50597,,BAO_0000218,,,% absorption predicted from in vitro rat ileum transport studies,,,N,Intermediate,A,10116.0,CHEMBL622432,,2116.0,Ileum,,1,1
8616,50597,In vivo,BAO_0000218,,,Bioavailability at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg,,,N,Intermediate,A,10116.0,CHEMBL622433,,,,,1,1
8617,50597,In vivo,BAO_0000218,,,Bioavailability at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg,,,N,Intermediate,A,10116.0,CHEMBL622434,,,,,1,1
8618,50597,In vivo,BAO_0000218,,,Bioavailability at an iv dose of 14 mg/Kg and po dose of 28 mg/Kg,,,N,Intermediate,A,10116.0,CHEMBL622435,,,,,1,1
8619,50597,In vivo,BAO_0000218,,,Bioavailability (dose 15 mg/kg i.v. and 30 mg/kg p.o.),,,N,Intermediate,A,10116.0,CHEMBL618748,,,,,1,1
8620,50597,In vivo,BAO_0000218,,,Bioavailability at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg,,,N,Intermediate,A,10116.0,CHEMBL618749,,,,,1,1
8621,50597,In vivo,BAO_0000218,,,Bioavailability at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg,,,N,Intermediate,A,10116.0,CHEMBL618750,,,,,1,1
8622,50597,In vivo,BAO_0000218,,,Bioavailability at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg,,,N,Intermediate,A,10116.0,CHEMBL618751,,,,,1,1
8623,50597,In vivo,BAO_0000218,,,Bioavailability at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg,,,N,Intermediate,A,10116.0,CHEMBL618752,,,,,1,1
8624,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL618753,,,,,1,1
8625,50597,In vivo,BAO_0000218,,,Oral bioavailability estimated by measurement of the circulating plasma levels of BMS-183920 after intravenous and oral dosing to rats for 4 determinations,,,N,Intermediate,A,10116.0,CHEMBL618754,,1969.0,Plasma,,1,1
8626,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL618755,,,,,1,1
8627,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL618756,,,,,1,1
8628,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL618757,,,,,1,1
8629,50597,In vivo,BAO_0000218,,,Bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL618758,,,,,1,1
8630,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat (dose 30 mg/kg),,,N,Intermediate,A,10116.0,CHEMBL621088,,,,,1,1
8631,50597,,BAO_0000218,,,Pharmacokinetic property (cLogP) in rat,,,N,Intermediate,A,10116.0,CHEMBL621089,,,,,1,1
8632,50597,,BAO_0000218,,,Hyperglycemic activity and change in blood glucose concentration was reported 2 hours after administration of 100 mg/Kg perorally,,,N,Intermediate,F,10116.0,CHEMBL621090,,178.0,Blood,,1,1
8633,50597,,BAO_0000218,,,Hyperglycemic activity and change in blood glucose concentration was reported 4 hours after administration of 100 mg/Kg perorally,,,N,Intermediate,F,10116.0,CHEMBL621091,,178.0,Blood,,1,1
8634,50597,In vivo,BAO_0000218,,,Clearance in rat.,,,N,Intermediate,A,10116.0,CHEMBL876731,,,,,1,1
8635,50597,In vivo,BAO_0000218,,,Compound was evaluated for its clearance when administered intravenously in rat,,,N,Intermediate,A,10116.0,CHEMBL621092,,,,,1,1
8636,50597,In vivo,BAO_0000218,,,Plasma clearance in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL621093,,,,,1,1
8637,50597,,BAO_0000218,,,Blood: Brain distribution ratio is determined in rat,,,N,Intermediate,A,10116.0,CHEMBL621094,,,,,1,1
8638,50597,,BAO_0000218,,,Blood: Brain distribution ratio is determined in rat; NQ: non quantifable,,,N,Intermediate,A,10116.0,CHEMBL621095,,,,,1,1
8639,50597,,BAO_0000218,,,Blood: Brain distribution ratio is determined in rat; NQ:non quantifable,,,N,Intermediate,A,10116.0,CHEMBL621096,,,,,1,1
8640,50597,In vivo,BAO_0000218,,,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,,N,Intermediate,A,10116.0,CHEMBL621097,,2113.0,Kidney,,1,1
8641,50597,,BAO_0000218,,,Percent dose excreted in 0-48 hours administered ip to male rat,,,N,Intermediate,F,10116.0,CHEMBL621098,,,,,1,1
8642,50597,,BAO_0000218,,,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 120 minutes after an intravenous injection is given (average of 3 rats),,,N,Intermediate,A,10116.0,CHEMBL621099,,2037.0,Cerebellum,,1,1
8643,50597,,BAO_0000218,,,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 2 minutes after an intravenous injection is given (average of 3 rats),,,N,Intermediate,A,10116.0,CHEMBL621100,,2037.0,Cerebellum,,1,1
8644,50597,,BAO_0000218,,,Uptake of radioligand [125I]-FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 2 rats),,,N,Intermediate,A,10116.0,CHEMBL621101,,2037.0,Cerebellum,,1,1
8645,50597,,BAO_0000218,,,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 3 rats),,,N,Intermediate,A,10116.0,CHEMBL621102,,2037.0,Cerebellum,,1,1
8646,50597,,BAO_0000218,,,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 60 minutes after an intravenous injection is given (average of 3 rats),,,N,Intermediate,A,10116.0,CHEMBL876732,,2037.0,Cerebellum,,1,1
8647,50597,,BAO_0000218,,,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 120 minutes after an intravenous injection is given (average of 3 rats),,,N,Intermediate,A,10116.0,CHEMBL621103,,,,,1,1
8648,50597,,BAO_0000218,,,Uptake of radioligand [125I]FIDA1 by cortex in rat after 2 minutes after an intravenous injection is given (average of 3 rats),,,N,Intermediate,A,10116.0,CHEMBL621104,,,,,1,1
8649,50597,,BAO_0000218,,,Uptake of radioligand [125I]FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 2 rats),,,N,Intermediate,A,10116.0,CHEMBL621105,,,,,1,1
8650,50597,,BAO_0000218,,,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 3 rats),,,N,Intermediate,A,10116.0,CHEMBL621106,,,,,1,1
8651,50597,,BAO_0000218,,,Uptake of radioligand [125I]FIDA1 by cortex in rat after 60 minutes after an intravenous injection is given (average of 3 rats),,,N,Intermediate,A,10116.0,CHEMBL621107,,,,,1,1
8652,50597,,BAO_0000218,,,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 120 minutes after an intravenous injection is given (average of 3 rats),,,N,Intermediate,A,10116.0,CHEMBL621108,,,,,1,1
8653,50597,,BAO_0000218,,,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 2 minutes after an intravenous injection is given (average of 3 rats),,,N,Intermediate,A,10116.0,CHEMBL621109,,,,,1,1
8654,50594,In vivo,BAO_0000218,,,Biodistribution of radioactivity in normal mice (ICR) kidney after 30 minutes of intravenous injection of [125I]-16(IMPY),,,N,Intermediate,A,10090.0,CHEMBL621110,,2113.0,Kidney,,1,1
8655,50594,In vivo,BAO_0000218,,,Biodistribution of radioactivity in normal mice (ICR) kidney after 6 hours of intravenous injection of [125I]-16(IMPY),,,N,Intermediate,A,10090.0,CHEMBL621111,,2113.0,Kidney,,1,1
8656,50594,In vivo,BAO_0000218,,,Biodistribution of radioactivity in normal mice (ICR) liver after 1 hour of intravenous injection of [125I]-16(IMPY),,,N,Intermediate,A,10090.0,CHEMBL622541,,2107.0,Liver,,1,1
8657,50594,In vivo,BAO_0000218,,,Biodistribution of radioactivity in normal mice (ICR) liver after 2 hours of intravenous injection of [125I]-16(IMPY),,,N,Intermediate,A,10090.0,CHEMBL622542,,2107.0,Liver,,1,1
8658,50594,In vivo,BAO_0000218,,,Biodistribution of radioactivity in normal mice (ICR) liver after 2 minutes of intravenous injection of [125I]-16(IMPY),,,N,Intermediate,A,10090.0,CHEMBL622543,,2107.0,Liver,,1,1
8659,50594,In vivo,BAO_0000218,,,Biodistribution of radioactivity in normal mice (ICR) liver after 24 hours of intravenous injection of [125I]-16(IMPY),,,N,Intermediate,A,10090.0,CHEMBL624412,,2107.0,Liver,,1,1
8660,50594,In vivo,BAO_0000218,,,Biodistribution of radioactivity in normal mice (ICR) liver after 30 minutes of intravenous injection of [125I]-16(IMPY),,,N,Intermediate,A,10090.0,CHEMBL624413,,2107.0,Liver,,1,1
8661,50594,In vivo,BAO_0000218,,,Biodistribution of radioactivity in normal mice (ICR) liver after 6 hours of intravenous injection of [125I]-16(IMPY),,,N,Intermediate,A,10090.0,CHEMBL624414,,2107.0,Liver,,1,1
8662,50594,In vivo,BAO_0000218,,,Biodistribution of radioactivity in normal mice (ICR) lung after 1 hour of intravenous injection of [125I]-16(IMPY),,,N,Intermediate,A,10090.0,CHEMBL624415,,2048.0,Lung,,1,1
8663,50594,In vivo,BAO_0000218,,,Biodistribution of radioactivity in normal mice (ICR) lung after 2 hours of intravenous injection of [125I]-16(IMPY),,,N,Intermediate,A,10090.0,CHEMBL624416,,2048.0,Lung,,1,1
8664,50594,In vivo,BAO_0000218,,,Biodistribution of radioactivity in normal mice (ICR) lung after 2 minutes of intravenous injection of [125I]-16(IMPY),,,N,Intermediate,A,10090.0,CHEMBL624417,,2048.0,Lung,,1,1
8665,50594,In vivo,BAO_0000218,,,Biodistribution of radioactivity in normal mice (ICR) lung after 24 hours of intravenous injection of [125I]-16(IMPY),,,N,Intermediate,A,10090.0,CHEMBL624418,,2048.0,Lung,,1,1
8666,50594,In vivo,BAO_0000218,,,Biodistribution of radioactivity in normal mice (ICR) lung after 30 minutes of intravenous injection of [125I]-16(IMPY),,,N,Intermediate,A,10090.0,CHEMBL624419,,2048.0,Lung,,1,1
8667,50594,In vivo,BAO_0000218,,,Biodistribution of radioactivity in normal mice (ICR) lung after 6 hours of intravenous injection of [125I]-16(IMPY),,,N,Intermediate,A,10090.0,CHEMBL624420,,2048.0,Lung,,1,1
8668,50594,In vivo,BAO_0000218,,,Biodistribution of radioactivity in normal mice (ICR) muscle after 1 hr of intravenous injection of [125I]-16(IMPY),,,N,Intermediate,A,10090.0,CHEMBL624421,,2385.0,Muscle tissue,,1,1
8669,50594,In vivo,BAO_0000218,,,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 hours of intravenous injection of [125I]-16(IMPY),,,N,Intermediate,A,10090.0,CHEMBL624422,,2385.0,Muscle tissue,,1,1
8670,50594,In vivo,BAO_0000218,,,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 minutes of intravenous injection of [125I]-16(IMPY),,,N,Intermediate,A,10090.0,CHEMBL624423,,2385.0,Muscle tissue,,1,1
8671,50594,In vivo,BAO_0000218,,,Biodistribution of radioactivity in normal mice (ICR) muscle after 24 hours of intravenous injection of [125I]-16(IMPY),,,N,Intermediate,A,10090.0,CHEMBL625123,,2385.0,Muscle tissue,,1,1
8672,50594,In vivo,BAO_0000218,,,Biodistribution of radioactivity in normal mice (ICR) muscle after 30 minutes of intravenous injection of [125I]-16(IMPY),,,N,Intermediate,A,10090.0,CHEMBL625124,,2385.0,Muscle tissue,,1,1
8673,50594,In vivo,BAO_0000218,,,Biodistribution of radioactivity in normal mice (ICR) muscle after 6 hours of intravenous injection of [125I]-16(IMPY),,,N,Intermediate,A,10090.0,CHEMBL625125,,2385.0,Muscle tissue,,1,1
8674,50594,In vivo,BAO_0000218,,,Biodistribution of radioactivity in normal mice (ICR) skin after 1 hour of intravenous injection of [125I]-16(IMPY),,,N,Intermediate,A,10090.0,CHEMBL625126,,14.0,Zone of skin,,1,1
8675,50594,In vivo,BAO_0000218,,,Biodistribution of radioactivity in normal mice (ICR) skin after 2 hours of intravenous injection of [125I]-16(IMPY),,,N,Intermediate,A,10090.0,CHEMBL626947,,14.0,Zone of skin,,1,1
8676,50594,In vivo,BAO_0000218,,,Biodistribution of radioactivity in normal mice (ICR) skin after 2 minutes of intravenous injection of [125I]-16(IMPY),,,N,Intermediate,A,10090.0,CHEMBL626948,,14.0,Zone of skin,,1,1
8677,50594,In vivo,BAO_0000218,,,Biodistribution of radioactivity in normal mice (ICR) skin after 24 hours of intravenous injection of [125I]-16(IMPY),,,N,Intermediate,A,10090.0,CHEMBL626949,,14.0,Zone of skin,,1,1
8678,50594,In vivo,BAO_0000218,,,Biodistribution of radioactivity in normal mice (ICR) skin after 30 minutes of intravenous injection of [125I]-16(IMPY),,,N,Intermediate,A,10090.0,CHEMBL626950,,14.0,Zone of skin,,1,1
8679,50594,In vivo,BAO_0000218,,,Biodistribution of radioactivity in normal mice (ICR) skin after 6 hours of intravenous injection of [125I]-16(IMPY),,,N,Intermediate,A,10090.0,CHEMBL626951,,14.0,Zone of skin,,1,1
8680,50594,In vivo,BAO_0000218,,,Biodistribution of radioactivity in normal mice (ICR) spleen after 1 hour of intravenous injection of [125I]-16(IMPY),,,N,Intermediate,A,10090.0,CHEMBL626952,,2106.0,Spleen,,1,1
8681,50594,In vivo,BAO_0000218,,,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 hours of intravenous injection of [125I]-16(IMPY),,,N,Intermediate,A,10090.0,CHEMBL626953,,2106.0,Spleen,,1,1
8682,50594,In vivo,BAO_0000218,,,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 minutes of intravenous injection of [125I]-16(IMPY),,,N,Intermediate,A,10090.0,CHEMBL626954,,2106.0,Spleen,,1,1
8683,50594,In vivo,BAO_0000218,,,Biodistribution of radioactivity in normal mice (ICR) spleen after 24 hours of intravenous injection of [125I]-16(IMPY),,,N,Intermediate,A,10090.0,CHEMBL626955,,2106.0,Spleen,,1,1
8684,50594,In vivo,BAO_0000218,,,Biodistribution of radioactivity in normal mice (ICR) spleen after 30 minutes of intravenous injection of [125I]-16(IMPY),,,N,Intermediate,A,10090.0,CHEMBL626956,,2106.0,Spleen,,1,1
8685,50594,In vivo,BAO_0000218,,,Biodistribution of radioactivity in normal mice (ICR) spleen after 6 hours of intravenous injection of [125I]-16(IMPY),,,N,Intermediate,A,10090.0,CHEMBL626957,,2106.0,Spleen,,1,1
8686,50594,In vivo,BAO_0000218,,,Biodistribution of radioactivity in normal mice blood after 1 hour of intravenous injection of [125I]-16(IMPY),,,N,Intermediate,A,10090.0,CHEMBL626958,,178.0,Blood,,1,1
8687,50594,In vivo,BAO_0000218,,,Biodistribution of radioactivity in normal mice blood after 2 hours of intravenous injection of [125I]-16(IMPY),,,N,Intermediate,A,10090.0,CHEMBL626959,,178.0,Blood,,1,1
8688,50594,In vivo,BAO_0000218,,,Biodistribution of radioactivity in normal mice blood after 2 minutes of intravenous injection of [125I]-16(IMPY),,,N,Intermediate,A,10090.0,CHEMBL626960,,178.0,Blood,,1,1
8689,50594,In vivo,BAO_0000218,,,Biodistribution of radioactivity in normal mice blood after 24 hours of intravenous injection of [125I]-16(IMPY),,,N,Intermediate,A,10090.0,CHEMBL626961,,178.0,Blood,,1,1
8690,50594,In vivo,BAO_0000218,,,Biodistribution of radioactivity in normal mice blood after 30 minutes of intravenous injection of [125I]-16(IMPY),,,N,Intermediate,A,10090.0,CHEMBL627589,,178.0,Blood,,1,1
8691,50594,In vivo,BAO_0000218,,,Biodistribution of radioactivity in normal mice blood after 6 hours of intravenous injection of [125I]-16(IMPY),,,N,Intermediate,A,10090.0,CHEMBL627590,,178.0,Blood,,1,1
8692,50594,,BAO_0000218,,,Time taken for EC90 was determined when tested in mouse,,,N,Intermediate,A,10090.0,CHEMBL627591,,,,,1,1
8693,50594,,BAO_0000218,,,Time taken for EC90 was determined when tested in mouse at dose 25 mg/kg,,,N,Intermediate,A,10090.0,CHEMBL627592,,,,,1,1
8694,50594,In vivo,BAO_0000218,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),,,N,Intermediate,A,10090.0,CHEMBL627593,,,,,1,1
8695,50594,,BAO_0000218,,,Half life in mice,,,N,Intermediate,A,10090.0,CHEMBL627594,,,,,1,1
8696,50594,In vivo,BAO_0000218,,,Half life period in mouse after 10 mg/Kg dose,,,N,Intermediate,A,10090.0,CHEMBL876813,,,,,1,1
8697,50594,In vivo,BAO_0000218,,,Half life period in mouse after 10 mg/kg dose,,,N,Intermediate,A,10090.0,CHEMBL627595,,,,,1,1
8698,50594,In vivo,BAO_0000218,,,Half life was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,,N,Intermediate,A,10090.0,CHEMBL627596,,,,,1,1
8699,50597,In vivo,BAO_0000218,,,Cmax value at 5 mg/kg po was determined in rat,,,N,Intermediate,A,10116.0,CHEMBL627597,,,,,1,1
8700,50597,In vivo,BAO_0000218,,,Cmax value evaluated in rat,,,N,Intermediate,A,10116.0,CHEMBL627598,,,,,1,1
8701,50597,In vivo,BAO_0000218,,,Cmax value was calculated by applying at a dose of 10 mg/Kg ip in rat brain,,,N,Intermediate,A,10116.0,CHEMBL627599,,955.0,Brain,,1,1
8702,50597,In vivo,BAO_0000218,,,Cmax value after administration of 20 mg/Kg oral dose in rat,,,N,Intermediate,A,10116.0,CHEMBL627600,,,,,1,1
8703,50597,In vivo,BAO_0000218,,,Cmax value at 1 mg/kg po in rat,,,N,Intermediate,A,10116.0,CHEMBL627601,,,,,1,1
8704,50597,In vivo,BAO_0000218,,,Cmax value at 5 mg/kg po in rat,,,N,Intermediate,A,10116.0,CHEMBL627776,,,,,1,1
8705,50597,In vivo,BAO_0000218,,,Cmax value at a dose of 10 mg/kg in male SD rats,,,N,Intermediate,A,10116.0,CHEMBL627777,,,,,1,1
8706,50597,In vivo,BAO_0000218,,,Cmax value at a dose of 100 mg/kg in male SD rats,,,N,Intermediate,A,10116.0,CHEMBL627778,,,,,1,1
8707,50597,In vivo,BAO_0000218,,,Cmax value at a dose of 50 mg/kg in male SD rats,,,N,Intermediate,A,10116.0,CHEMBL627779,,,,,1,1
8708,50597,In vivo,BAO_0000218,,,Cmax value in rats at 10 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL876814,,,,,1,1
8709,50597,In vivo,BAO_0000218,,,Cmax value was evaluated in rats at a dose of 20 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL627780,,,,,1,1
8710,50597,In vivo,BAO_0000218,,,Cmax value was determined after peroral administration of 20 mg/kg in rat,,,N,Intermediate,A,10116.0,CHEMBL627781,,,,,1,1
8711,50597,In vivo,BAO_0000218,,,Cmax value was determined between 15 and 30 minutes post administration in fisher rats; value ranges from 200-500,,,N,Intermediate,A,10116.0,CHEMBL627782,,,,,1,1
8712,50597,In vivo,BAO_0000218,,,Compound was evaluated for its pharmacokinetic parameter maximum plasma concentration (Cmax) after oral administration to rats,,,N,Intermediate,A,10116.0,CHEMBL627783,,1969.0,Plasma,,1,1
8713,50597,In vivo,BAO_0000218,,,Compound was evaluated for maximal plasma concentration in rat upon 5 mg/kg upon oral administration,,,N,Intermediate,A,10116.0,CHEMBL627784,,1969.0,Plasma,,1,1
8714,50597,In vivo,BAO_0000218,,,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female wistar rats,,,N,Intermediate,A,10116.0,CHEMBL627785,,,,,1,1
8715,50597,In vivo,BAO_0000218,,,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to male wistar rats,,,N,Intermediate,A,10116.0,CHEMBL627786,,,,,1,1
8716,50597,In vivo,BAO_0000218,,,Compound was evaluated for pharmacokinetic parameter maximum plasma concentration,,,N,Intermediate,A,10116.0,CHEMBL627787,,1969.0,Plasma,,1,1
8717,50597,In vivo,BAO_0000218,,,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 0.5 hr,,,N,Intermediate,A,10116.0,CHEMBL627788,,1969.0,Plasma,,1,1
8718,50597,In vivo,BAO_0000218,,,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 1 hr,,,N,Intermediate,A,10116.0,CHEMBL626579,,1969.0,Plasma,,1,1
8719,50597,In vivo,BAO_0000218,,,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 2 hr,,,N,Intermediate,A,10116.0,CHEMBL626580,,1969.0,Plasma,,1,1
8720,50597,In vivo,BAO_0000218,,,Compound was evaluated for the pharmacokinetic property in rats after an oral dose of 10 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL876815,,,,,1,1
8721,50597,In vivo,BAO_0000218,,,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 1 hr,,,N,Intermediate,A,10116.0,CHEMBL626581,,1969.0,Plasma,,1,1
8722,50597,In vivo,BAO_0000218,,,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 2 hr,,,N,Intermediate,A,10116.0,CHEMBL626582,,1969.0,Plasma,,1,1
8723,50597,In vivo,BAO_0000218,,,Evaluated for pharmacokinetic parameter Cmax in rat at the dose 50 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL626583,,,,,1,1
8724,50597,In vivo,BAO_0000218,,,In vivo Cmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,,N,Intermediate,A,10116.0,CHEMBL626205,,,,,1,1
8725,50597,In vivo,BAO_0000218,,,In vivo Cmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,,N,Intermediate,A,10116.0,CHEMBL626206,,,,,1,1
8726,50597,In vivo,BAO_0000218,,,In vivo Cmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,,,N,Intermediate,A,10116.0,CHEMBL626207,,,,,1,1
8727,50597,In vivo,BAO_0000218,,,In vivo Cmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,,N,Intermediate,A,10116.0,CHEMBL623882,,,,,1,1
8728,50597,In vivo,BAO_0000218,,,Maximal concentration in male Sprague-Dawley rats after 5 mg/kg intravenous dose,,,N,Intermediate,A,10116.0,CHEMBL623883,,,,,1,1
8729,50597,In vivo,BAO_0000218,,,Maximal concentration in male Sprague-Dawley rats after 10 mg/kg oral dose,,,N,Intermediate,A,10116.0,CHEMBL623884,,,,,1,1
8730,50597,In vivo,BAO_0000218,,,"In vivo maximum concentration of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)",,,N,Intermediate,A,10116.0,CHEMBL623885,,1969.0,Plasma,,1,1
8731,50597,In vivo,BAO_0000218,,,In vivo maximum concentration in rat plasma exposure after oral administration 50 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL623886,,1969.0,Plasma,,1,1
8732,50597,In vivo,BAO_0000218,,,Maximal concentration in rat was determined,,,N,Intermediate,A,10116.0,CHEMBL623887,,,,,1,1
8733,50597,In vivo,BAO_0000218,,,Maximal concentration after i.v. administration,,,N,Intermediate,A,10116.0,CHEMBL623888,,,,,1,1
8734,50597,In vivo,BAO_0000218,,,Maximal concentration (Cmax) in the rat plasma at a dose of 10 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL623889,,1969.0,Plasma,,1,1
8735,50597,In vivo,BAO_0000218,,,Maximal plasma concentration in rat after oral administration at 50 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL623890,,1969.0,Plasma,,1,1
8736,50597,In vivo,BAO_0000218,,,Cmax in rat plasma after oral dose (50 mg/Kg),,,N,Intermediate,A,10116.0,CHEMBL623891,,1969.0,Plasma,,1,1
8737,50597,In vivo,BAO_0000218,,,Maximal plasma concentration was determined.,,,N,Intermediate,A,10116.0,CHEMBL623892,,1969.0,Plasma,,1,1
8738,50597,In vivo,BAO_0000218,,,Maximal plasma drug concentration was determined,,,N,Intermediate,A,10116.0,CHEMBL623893,,1969.0,Plasma,,1,1
8739,50597,In vivo,BAO_0000218,,,Maximal concentration in rats after peroral administration,,,N,Intermediate,A,10116.0,CHEMBL877616,,,,,1,1
8740,50597,In vivo,BAO_0000218,,,Maximum concentration in rat after 2 mg/kg peroral administration,,,N,Intermediate,A,10116.0,CHEMBL623894,,,,,1,1
8741,50597,In vivo,BAO_0000218,,,Maximum concentration in rat plasma after 5 mg/kg oral gavage,,,N,Intermediate,A,10116.0,CHEMBL623895,,1969.0,Plasma,,1,1
8742,50597,In vivo,BAO_0000218,,,Maximum concentration of compound in rat was evaluated.,,,N,Intermediate,A,10116.0,CHEMBL623896,,,,,1,1
8743,50597,In vivo,BAO_0000218,,,Maximum concentration at 0.5 hr by peroral administration at a dose of 20 mg/kg in rats,,,N,Intermediate,A,10116.0,CHEMBL623897,,,,,1,1
8744,50597,In vivo,BAO_0000218,,,Maximum concentration at 2 hr by peroral administration at a dose of 20 mg/kg in rats,,,N,Intermediate,A,10116.0,CHEMBL623898,,,,,1,1
8745,50597,In vivo,BAO_0000218,,,Maximum concentration at 4 hr after administration of 5 mg/kg dose peroral in rat,,,N,Intermediate,A,10116.0,CHEMBL623899,,,,,1,1
8746,50597,In vivo,BAO_0000218,,,Maximum concentration at 4 hr by peroral administration at a dose of 20 mg/kg in rats,,,N,Intermediate,A,10116.0,CHEMBL623900,,,,,1,1
8747,50597,In vivo,BAO_0000218,,,Maximum concentration by oral administration at a dose of 100 uM/kg in rat was determined,,,N,Intermediate,A,10116.0,CHEMBL623901,,,,,1,1
8748,50597,In vivo,BAO_0000218,,,Maximum concentration was evaluated in rats,,,N,Intermediate,A,10116.0,CHEMBL623902,,,,,1,1
8749,50597,In vivo,BAO_0000218,,,Maximum concentration in CSF at 30 min following 24 mg/kg subcutaneous dose in rats,,,N,Intermediate,A,10116.0,CHEMBL623903,,1359.0,Cerebrospinal fluid,,1,1
8750,50597,In vivo,BAO_0000218,,,Maximum concentration in plasma at 30 min following 24 mg/kg subcutaneous dose in rats,,,N,Intermediate,A,10116.0,CHEMBL623904,,1969.0,Plasma,,1,1
8751,50597,In vivo,BAO_0000218,,,Maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,,,N,Intermediate,A,10116.0,CHEMBL877617,,1969.0,Plasma,,1,1
8752,50597,In vivo,BAO_0000218,,,Maximum concentration in portal vein was determined at a concentration of 10 mg/kg in rats,,,N,Intermediate,A,10116.0,CHEMBL623905,,,,,1,1
8753,50597,In vivo,BAO_0000218,,,Maximum concentration in portal vein was determined at a concentration of 20 mg/kg in rats,,,N,Intermediate,A,10116.0,CHEMBL623906,,,,,1,1
8754,50597,In vivo,BAO_0000218,,,Maximum concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,,,N,Intermediate,A,10116.0,CHEMBL623907,,1969.0,Plasma,,1,1
8755,50597,,BAO_0000218,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,,N,Intermediate,A,10116.0,CHEMBL623908,,,,,1,1
8756,50597,,BAO_0000218,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 30 min.,,,N,Intermediate,A,10116.0,CHEMBL623909,,,,,1,1
8757,50597,,BAO_0000218,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,,N,Intermediate,A,10116.0,CHEMBL623910,,,,,1,1
8758,50597,,BAO_0000218,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,,N,Intermediate,A,10116.0,CHEMBL623911,,,,,1,1
8759,50597,,BAO_0000218,,,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,,N,Intermediate,A,10116.0,CHEMBL623912,,,,,1,1
8760,50597,,BAO_0000218,,,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,,N,Intermediate,A,10116.0,CHEMBL624616,,,,,1,1
8761,50597,,BAO_0000218,,,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,,N,Intermediate,A,10116.0,CHEMBL624617,,,,,1,1
8762,50597,,BAO_0000218,,,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,,N,Intermediate,A,10116.0,CHEMBL624618,,,,,1,1
8763,50597,,BAO_0000218,,,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,,N,Intermediate,A,10116.0,CHEMBL624619,,,,,1,1
8764,50597,,BAO_0000218,,,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,,N,Intermediate,A,10116.0,CHEMBL624794,,,,,1,1
8765,50597,,BAO_0000218,,,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,,N,Intermediate,A,10116.0,CHEMBL624795,,,,,1,1
8766,50597,,BAO_0000218,,,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,,N,Intermediate,A,10116.0,CHEMBL623921,,,,,1,1
8767,50597,,BAO_0000218,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,,N,Intermediate,A,10116.0,CHEMBL623922,,,,,1,1
8768,50597,,BAO_0000218,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,,N,Intermediate,A,10116.0,CHEMBL623923,,,,,1,1
8769,50597,,BAO_0000218,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,,N,Intermediate,A,10116.0,CHEMBL623924,,,,,1,1
8770,50597,,BAO_0000218,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,,N,Intermediate,A,10116.0,CHEMBL623925,,,,,1,1
8771,50597,,BAO_0000218,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,,N,Intermediate,A,10116.0,CHEMBL623926,,,,,1,1
8772,50597,,BAO_0000218,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,,N,Intermediate,A,10116.0,CHEMBL623927,,,,,1,1
8773,50597,,BAO_0000218,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,,N,Intermediate,A,10116.0,CHEMBL623928,,,,,1,1
8774,50597,,BAO_0000218,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,,N,Intermediate,A,10116.0,CHEMBL623929,,,,,1,1
8775,50597,,BAO_0000218,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,,N,Intermediate,A,10116.0,CHEMBL623930,,,,,1,1
8776,50597,,BAO_0000218,,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,,N,Intermediate,A,10116.0,CHEMBL623931,,955.0,Brain,,1,1
8777,50597,,BAO_0000218,,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,,N,Intermediate,A,10116.0,CHEMBL622165,,955.0,Brain,,1,1
8778,50597,,BAO_0000218,,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,,N,Intermediate,A,10116.0,CHEMBL621249,,955.0,Brain,,1,1
8779,50597,,BAO_0000218,,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,,N,Intermediate,A,10116.0,CHEMBL621250,,955.0,Brain,,1,1
8780,50597,,BAO_0000218,,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,,N,Intermediate,A,10116.0,CHEMBL621448,,955.0,Brain,,1,1
8781,50597,,BAO_0000218,,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,,N,Intermediate,A,10116.0,CHEMBL621449,,955.0,Brain,,1,1
8782,50597,,BAO_0000218,,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,,N,Intermediate,A,10116.0,CHEMBL621450,,955.0,Brain,,1,1
8783,50597,,BAO_0000218,,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,,N,Intermediate,A,10116.0,CHEMBL621451,,955.0,Brain,,1,1
8784,50597,,BAO_0000218,,,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,,N,Intermediate,A,10116.0,CHEMBL621452,,955.0,Brain,,1,1
8785,50597,,BAO_0000218,,,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,,N,Intermediate,A,10116.0,CHEMBL621453,,955.0,Brain,,1,1
8786,50597,,BAO_0000218,,,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,,N,Intermediate,A,10116.0,CHEMBL621454,,955.0,Brain,,1,1
8787,50597,,BAO_0000218,,,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,,N,Intermediate,A,10116.0,CHEMBL621455,,955.0,Brain,,1,1
8788,50597,,BAO_0000218,,,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,,N,Intermediate,A,10116.0,CHEMBL621456,,955.0,Brain,,1,1
8789,50597,,BAO_0000218,,,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,,N,Intermediate,A,10116.0,CHEMBL625145,,955.0,Brain,,1,1
8790,50597,,BAO_0000218,,,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,,N,Intermediate,A,10116.0,CHEMBL875847,,955.0,Brain,,1,1
8791,50597,,BAO_0000218,,,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,,N,Intermediate,A,10116.0,CHEMBL625146,,955.0,Brain,,1,1
8792,50597,,BAO_0000218,,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,,N,Intermediate,A,10116.0,CHEMBL625147,,955.0,Brain,,1,1
8793,50597,,BAO_0000218,,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,,N,Intermediate,A,10116.0,CHEMBL625148,,955.0,Brain,,1,1
8794,50597,,BAO_0000218,,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,,N,Intermediate,A,10116.0,CHEMBL625149,,955.0,Brain,,1,1
8795,50597,,BAO_0000218,,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,,N,Intermediate,A,10116.0,CHEMBL625150,,955.0,Brain,,1,1
8796,50597,,BAO_0000218,,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,,N,Intermediate,A,10116.0,CHEMBL625151,,955.0,Brain,,1,1
8797,50597,,BAO_0000218,,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,,N,Intermediate,A,10116.0,CHEMBL625152,,955.0,Brain,,1,1
8798,50597,,BAO_0000218,,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,,N,Intermediate,A,10116.0,CHEMBL625153,,955.0,Brain,,1,1
8799,50597,,BAO_0000218,,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,,N,Intermediate,A,10116.0,CHEMBL625154,,955.0,Brain,,1,1
8800,50597,,BAO_0000218,,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,,N,Intermediate,A,10116.0,CHEMBL625155,,955.0,Brain,,1,1
8801,50597,,BAO_0000218,,,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 30 minutes after an intravenous injection is given (average of 2 rats),,,N,Intermediate,A,10116.0,CHEMBL625156,,,,,1,1
8802,50597,,BAO_0000218,,,Uptake of radioligand [125I]-FIDA1 by hippo-campus in rat after 60 minutes after an intravenous injection is given (average of 3 rats),,,N,Intermediate,A,10116.0,CHEMBL624354,,,,,1,1
8803,50597,,BAO_0000218,,,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 120 minutes after an intravenous injection is given (average of 3 rats),,,N,Intermediate,A,10116.0,CHEMBL624355,,10000000.0,Hippocampus,,1,1
8804,50597,,BAO_0000218,,,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 2 minutes after an intravenous injection is given (average of 3 rats),,,N,Intermediate,A,10116.0,CHEMBL624356,,10000000.0,Hippocampus,,1,1
8805,50597,,BAO_0000218,,,Uptake of radioligand [125I]-FIDA1 by hippocampus in rat after 30 minutes after an intravenous injection is given (average of 3 rats),,,N,Intermediate,A,10116.0,CHEMBL624357,,10000000.0,Hippocampus,,1,1
8806,50597,,BAO_0000218,,,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 60 minutes after an intravenous injection is given (average of 3 rats),,,N,Intermediate,A,10116.0,CHEMBL624358,,10000000.0,Hippocampus,,1,1
8807,50597,,BAO_0000218,,,Uptake of radioligand [125I]FIDA1 by striatum in rat after 120 minutes after an intravenous injection is given (average of 3 rats),,,N,Intermediate,A,10116.0,CHEMBL624359,,2435.0,Striatum,,1,1
8808,50597,,BAO_0000218,,,Uptake of radioligand [125I]FIDA1 by striatum in rat after 2 minutes after an intravenous injection is given (average of 3 rats),,,N,Intermediate,A,10116.0,CHEMBL624360,,2435.0,Striatum,,1,1
8809,50597,,BAO_0000218,,,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 2 rats),,,N,Intermediate,A,10116.0,CHEMBL624361,,2435.0,Striatum,,1,1
8810,50597,,BAO_0000218,,,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 3 rats),,,N,Intermediate,A,10116.0,CHEMBL624362,,2435.0,Striatum,,1,1
8811,50597,,BAO_0000218,,,Uptake of radioligand [125I]FIDA1 by striatum in rat after 60 minutes after an intravenous injection is given (average of 3 rats),,,N,Intermediate,A,10116.0,CHEMBL624363,,2435.0,Striatum,,1,1
8812,50597,In vivo,BAO_0000218,,,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,,N,Intermediate,A,10116.0,CHEMBL624364,,178.0,Blood,,1,1
8813,50597,In vivo,BAO_0000218,,,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,,N,Intermediate,A,10116.0,CHEMBL624365,,178.0,Blood,,1,1
8814,50597,In vivo,BAO_0000218,,,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,,N,Intermediate,A,10116.0,CHEMBL624366,,178.0,Blood,,1,1
8815,50597,In vivo,BAO_0000218,,,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,,N,Intermediate,A,10116.0,CHEMBL624367,,178.0,Blood,,1,1
8816,50597,In vivo,BAO_0000218,,,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,,N,Intermediate,A,10116.0,CHEMBL624368,,955.0,Brain,,1,1
8817,50597,In vivo,BAO_0000218,,,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,,N,Intermediate,A,10116.0,CHEMBL624369,,955.0,Brain,,1,1
8818,50597,In vivo,BAO_0000218,,,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 2 rats),,,N,Intermediate,A,10116.0,CHEMBL624370,,955.0,Brain,,1,1
8819,50597,In vivo,BAO_0000218,,,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,,N,Intermediate,A,10116.0,CHEMBL625069,,955.0,Brain,,1,1
8820,50597,In vivo,BAO_0000218,,,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,,N,Intermediate,A,10116.0,CHEMBL625070,,955.0,Brain,,1,1
8821,50597,In vivo,BAO_0000218,,,Biodistribution of radioligand [125I]-FIDA1 in heart of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,,N,Intermediate,A,10116.0,CHEMBL626051,,948.0,Heart,,1,1
8822,50597,In vivo,BAO_0000218,,,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,,N,Intermediate,A,10116.0,CHEMBL626052,,948.0,Heart,,1,1
8823,50597,In vivo,BAO_0000218,,,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 2 rats),,,N,Intermediate,A,10116.0,CHEMBL626053,,948.0,Heart,,1,1
8824,50597,In vivo,BAO_0000218,,,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,,N,Intermediate,A,10116.0,CHEMBL626054,,948.0,Heart,,1,1
8825,50597,In vivo,BAO_0000218,,,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,,N,Intermediate,A,10116.0,CHEMBL626055,,948.0,Heart,,1,1
8826,50597,In vivo,BAO_0000218,,,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,,N,Intermediate,A,10116.0,CHEMBL626056,,2113.0,Kidney,,1,1
8827,50597,In vivo,BAO_0000218,,,Biodistribution of radioligand [125I]-FIDA1 in kidney of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,,N,Intermediate,A,10116.0,CHEMBL626057,,2113.0,Kidney,,1,1
8828,50597,In vivo,BAO_0000218,,,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,,N,Intermediate,A,10116.0,CHEMBL625193,,2113.0,Kidney,,1,1
8829,50597,In vivo,BAO_0000218,,,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,,N,Intermediate,A,10116.0,CHEMBL625194,,2113.0,Kidney,,1,1
8830,50597,In vivo,BAO_0000218,,,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,,N,Intermediate,A,10116.0,CHEMBL625195,,2107.0,Liver,,1,1
8831,50597,In vivo,BAO_0000218,,,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,,N,Intermediate,A,10116.0,CHEMBL625196,,2107.0,Liver,,1,1
8832,50597,In vivo,BAO_0000218,,,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 2 rats),,,N,Intermediate,A,10116.0,CHEMBL625197,,2107.0,Liver,,1,1
8833,50597,In vivo,BAO_0000218,,,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,,N,Intermediate,A,10116.0,CHEMBL625198,,2107.0,Liver,,1,1
8834,50597,In vivo,BAO_0000218,,,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,,N,Intermediate,A,10116.0,CHEMBL627929,,2107.0,Liver,,1,1
8835,50597,In vivo,BAO_0000218,,,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,,N,Intermediate,A,10116.0,CHEMBL627074,,2048.0,Lung,,1,1
8836,50597,In vivo,BAO_0000218,,,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,,N,Intermediate,A,10116.0,CHEMBL627075,,2048.0,Lung,,1,1
8837,50597,In vivo,BAO_0000218,,,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 2 rats),,,N,Intermediate,A,10116.0,CHEMBL627076,,2048.0,Lung,,1,1
8838,50597,In vivo,BAO_0000218,,,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,,N,Intermediate,A,10116.0,CHEMBL627077,,2048.0,Lung,,1,1
8839,50597,In vivo,BAO_0000218,,,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,,N,Intermediate,A,10116.0,CHEMBL627078,,2048.0,Lung,,1,1
8840,50597,In vivo,BAO_0000218,,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 2 rats),,,N,Intermediate,A,10116.0,CHEMBL627079,,2385.0,Muscle tissue,,1,1
8841,50594,In vivo,BAO_0000218,,,Half life (t1/2) determined at a dose 10 mg/kg administered intraperitoneally to mice,,,N,Intermediate,A,10090.0,CHEMBL873824,,,,,1,1
8842,50594,In vivo,BAO_0000218,,,Half life in mouse plasma was determined at dose 25 mg/kg,,,N,Intermediate,A,10090.0,CHEMBL627080,,1969.0,Plasma,,1,1
8843,50594,,BAO_0000218,,,Half life was determined,,,N,Intermediate,A,10090.0,CHEMBL627081,,,,,1,1
8844,50594,In vivo,BAO_0000218,,,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration,,,N,Intermediate,A,10090.0,CHEMBL627082,,,,,1,1
8845,50594,In vivo,BAO_0000218,,,Half-life in male mice after 1 mg/kg intravenous dose,,,N,Intermediate,A,10090.0,CHEMBL627083,,,,,1,1
8847,50594,,BAO_0000218,,,Half life in mice plasma,,,N,Intermediate,A,10090.0,CHEMBL627085,,1969.0,Plasma,,1,1
8848,50594,,BAO_0000218,,,Half life in mouse,,,N,Intermediate,A,10090.0,CHEMBL627086,,,,,1,1
8849,50594,In vivo,BAO_0000218,,,Half life in mouse plasma at dose 25 mg/kg,,,N,Intermediate,A,10090.0,CHEMBL627087,,1969.0,Plasma,,1,1
8850,50594,In vivo,BAO_0000218,,,Half life when injected i.p. in mice at a dose of 50 mg/kg was determined,,,N,Intermediate,A,10090.0,CHEMBL627088,,,,,1,1
8851,50594,In vivo,BAO_0000218,,,Half life when injected intravenously in mice at a dose of 20 mg/kg was determined,,,N,Intermediate,A,10090.0,CHEMBL627089,,,,,1,1
8852,50594,In vivo,BAO_0000218,,,Half life when injected perorally in mice at a dose of 50 mg/kg was determined,,,N,Intermediate,A,10090.0,CHEMBL627090,,,,,1,1
8853,50594,In vivo,BAO_0000218,,,Half life was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),,,N,Intermediate,A,10090.0,CHEMBL627091,,,,,1,1
8854,50594,In vivo,BAO_0000218,,,"Half life was evaluated at 5 mg/kg of compound dose, administered perorally in mice",,,N,Intermediate,A,10090.0,CHEMBL627092,,,,,1,1
8855,50594,In vivo,BAO_0000218,,,"Half life was evaluated at 50 mg/kg of compound dose, administered perorally in mice",,,N,Intermediate,A,10090.0,CHEMBL876785,,,,,1,1
8856,50594,In vivo,BAO_0000218,,,Half-life by iv administration in mouse,,,N,Intermediate,A,10090.0,CHEMBL627093,,,,,1,1
8857,50594,In vivo,BAO_0000218,,,Half-life by oral administration in mouse,,,N,Intermediate,A,10090.0,CHEMBL627094,,,,,1,1
8858,50594,,BAO_0000218,,,Half-life in mice,,,N,Intermediate,A,10090.0,CHEMBL627095,,,,,1,1
8859,50594,,BAO_0000218,,,Half-life using mouse brain homogenate,,,N,Intermediate,A,10090.0,CHEMBL627096,,955.0,Brain,,1,1
8860,50594,,BAO_0000218,,,Half-life was measured in mice,,,N,Intermediate,A,10090.0,CHEMBL627097,,,,,1,1
8861,50594,In vivo,BAO_0000218,,,Half-life was measured in mouse after an iv dose of 1 mg/kg,,,N,Intermediate,A,10090.0,CHEMBL627098,,,,,1,1
8862,50594,,BAO_0000218,,,Half-life period was determined in mouse blood,,,N,Intermediate,A,10090.0,CHEMBL627099,,178.0,Blood,,1,1
8863,50594,,BAO_0000218,,,"Half-times of inhibition of PEP in in an ex vivo enzyme studies, using mice brain",,,N,Intermediate,A,10090.0,CHEMBL627100,,955.0,Brain,,1,1
8864,50594,,BAO_0000218,,,Plasma half life in mouse,,,N,Intermediate,A,10090.0,CHEMBL627101,,1969.0,Plasma,,1,1
8865,50594,,BAO_0000218,,,Stability of the peptide in the presence of mouse serum,,,N,Intermediate,A,10090.0,CHEMBL627102,,,,,1,1
8866,50594,,BAO_0000218,,,Terminal half life of compound was determined in mouse,,,N,Intermediate,A,10090.0,CHEMBL627103,,,,,1,1
8867,50594,In vivo,BAO_0000218,,,Terminal half life was evaluated in mice after intravenous administration,,,N,Intermediate,A,10090.0,CHEMBL627104,,,,,1,1
8868,50594,In vivo,BAO_0000218,,,Terminal half life was evaluated in mice after oral administration,,,N,Intermediate,A,10090.0,CHEMBL627105,,,,,1,1
8869,50594,,BAO_0000218,,,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 5.,,,N,Intermediate,A,10090.0,CHEMBL876786,,,,,1,1
8870,50594,,BAO_0000218,,,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7.,,,N,Intermediate,A,10090.0,CHEMBL873825,,,,,1,1
8871,50594,,BAO_0000218,,,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7; ND means no data,,,N,Intermediate,A,10090.0,CHEMBL627106,,,,,1,1
8872,50594,In vivo,BAO_0000218,,,half life period is evaluated by administering intravenously at 25 mg/kg in mice,,,N,Intermediate,A,10090.0,CHEMBL626336,,,,,1,1
8873,50594,In vivo,BAO_0000218,,,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice",,,N,Intermediate,A,10090.0,CHEMBL877462,,,,,1,1
8874,50594,In vivo,BAO_0000218,,,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice; NC: not calculable",,,N,Intermediate,A,10090.0,CHEMBL626337,,,,,1,1
8875,50594,,BAO_0000218,,,Half life after intraperitoneal administration of 100 mg/kg in mice,,,N,Intermediate,A,10090.0,CHEMBL626338,,,,,1,1
8876,50594,In vivo,BAO_0000218,,,Half life in BALB/C mice at the dose of 20 mg/kg by i.p. administration,,,N,Intermediate,A,10090.0,CHEMBL626339,,,,,1,1
8877,50594,In vivo,BAO_0000218,,,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration,,,N,Intermediate,A,10090.0,CHEMBL626340,,,,,1,1
8878,50594,In vivo,BAO_0000218,,,Half life in BALB/C mice at the dose of 20 mg/kg by p.o. administration,,,N,Intermediate,A,10090.0,CHEMBL625377,,,,,1,1
8879,50594,In vivo,BAO_0000218,,,Half life in BALB/C mice at the dose of 50 mg/kg by i.p. administration,,,N,Intermediate,A,10090.0,CHEMBL625378,,,,,1,1
8880,50594,In vivo,BAO_0000218,,,Half life in BALB/C mice at the dose of 50 mg/kg by p.o. administration,,,N,Intermediate,A,10090.0,CHEMBL625379,,,,,1,1
8881,22224,,BAO_0000251,,,Metabolism of compound in mini pig S9 microsomes ('+''indicates <20% largest observed peak),,,U,Autocuration,A,9823.0,CHEMBL625380,,,,Microsomes,0,1
8882,22224,,BAO_0000251,,,Metabolism of compound in mini pig S9 microsomes ('++++' indicates largest observed peak),,,U,Autocuration,A,9823.0,CHEMBL625381,,,,Microsomes,0,1
8883,22224,,BAO_0000019,,,Stability to porcine renal DHP-I,,,U,Autocuration,A,9823.0,CHEMBL625382,,,,,0,1
8884,22224,In vivo,BAO_0000218,,,Compound was tested for its half-life period at an intravenous dose of 30 ug/kg,,,U,Autocuration,A,9823.0,CHEMBL873828,,,,,0,1
8885,22224,In vivo,BAO_0000218,,,Compound was tested for its half-life period at an intravenous dose of 3 ug/kg,,,U,Autocuration,A,9823.0,CHEMBL625383,,,,,0,1
8886,22224,,BAO_0000019,,,Half-life of the parent prodrug in porcine esterase solution,,,U,Autocuration,A,9823.0,CHEMBL625384,,,,,0,1
8887,22224,,BAO_0000019,,,"First order rate constant, k was determined in in pig liver Esterase",,,U,Autocuration,A,9823.0,CHEMBL625385,,,,,0,1
8888,22224,,BAO_0000221,,,Half life of the in pig liver Esterase,,,U,Autocuration,A,9823.0,CHEMBL625386,,2107.0,Liver,,0,1
8889,22224,,BAO_0000221,,,Tested for half life period at 37 degree Celsius in PBS buffer at 11.8 pH containing porcine liver esterase,,,U,Autocuration,A,9823.0,CHEMBL623571,,2107.0,Liver,,0,1
8890,22224,,BAO_0000221,,,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH containing porcine liver esterase,,,U,Autocuration,A,9823.0,CHEMBL623572,,2107.0,Liver,,0,1
8891,22224,,BAO_0000221,,,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH in containing porcine liver esterase,,,U,Autocuration,A,9823.0,CHEMBL623573,,2107.0,Liver,,0,1
8892,22224,,BAO_0000221,,,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay,,,U,Autocuration,A,9823.0,CHEMBL623574,,2107.0,Liver,,0,1
8893,22224,,BAO_0000221,,,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay; ND is not determined,,,U,Autocuration,A,9823.0,CHEMBL623575,,2107.0,Liver,,0,1
8894,22224,,BAO_0000221,,,Half-life in the presence of pig liver esterase(PLE) was evaluated.,,,U,Autocuration,A,9823.0,CHEMBL623749,,2107.0,Liver,,0,1
8895,22224,,BAO_0000221,,,Half-life in the presence of pig liver esterase(PLE) was evaluated; Stable,,,U,Autocuration,A,9823.0,CHEMBL623750,,2107.0,Liver,,0,1
8896,22224,In vitro,BAO_0000221,,,Half-life in vitro in pig liver,,,U,Autocuration,A,9823.0,CHEMBL623751,,2107.0,Liver,,0,1
8897,22224,,BAO_0000221,,,Half-life time was determined for esterase-catalyzed hydrolysis of the phenol ester bond in porcine liver esterase,,,U,Autocuration,A,9823.0,CHEMBL623752,,2107.0,Liver,,0,1
8898,50597,In vivo,BAO_0000218,,,Maximum concentration in rat plasma after administration of 50 mg/kg dose through subcutaneous route,,,N,Intermediate,A,10116.0,CHEMBL623753,,1969.0,Plasma,,1,1
8899,50597,In vivo,BAO_0000218,,,Maximum concentration in rat plasma at 30 mg/Kg upon oral administration.,,,N,Intermediate,A,10116.0,CHEMBL623754,,1969.0,Plasma,,1,1
8900,50597,In vivo,BAO_0000218,,,Maximum concentration in rat plasma was determined,,,N,Intermediate,A,10116.0,CHEMBL623755,,1969.0,Plasma,,1,1
8901,50597,In vivo,BAO_0000218,,,Maximum concentration in rats,,,N,Intermediate,A,10116.0,CHEMBL623756,,,,,1,1
8902,50597,In vivo,BAO_0000218,,,Maximum concentration in rats at 1-2 hours,,,N,Intermediate,A,10116.0,CHEMBL623757,,,,,1,1
8903,50597,In vivo,BAO_0000218,,,Maximum concentration in rats at 1 hr was determined when dosed at 20 mg/Kg perorally,,,N,Intermediate,A,10116.0,CHEMBL623758,,,,,1,1
8904,50597,In vivo,BAO_0000218,,,Maximum concentration in whole brain at 30 min following 24 mg/kg subcutaneous dose in rats,,,N,Intermediate,A,10116.0,CHEMBL623759,,955.0,Brain,,1,1
8905,50597,In vivo,BAO_0000218,,,Maximum concentration at the dose of 2 mg/kg in rat,,,N,Intermediate,A,10116.0,CHEMBL623760,,,,,1,1
8906,50597,In vivo,BAO_0000218,,,Maximum concentration was evaluated in rats,,,N,Intermediate,A,10116.0,CHEMBL623761,,,,,1,1
8907,50597,In vivo,BAO_0000218,,,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 10 mg/kg to a fasting rat,,,N,Intermediate,A,10116.0,CHEMBL623762,,1969.0,Plasma,,1,1
8908,50597,In vivo,BAO_0000218,,,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 1 mg/kg to a fasting rat,,,N,Intermediate,A,10116.0,CHEMBL877594,,1969.0,Plasma,,1,1
8909,50597,In vivo,BAO_0000218,,,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 30 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL623763,,1969.0,Plasma,,1,1
8910,50597,In vivo,BAO_0000218,,,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL623764,,1969.0,Plasma,,1,1
8911,50597,In vivo,BAO_0000218,,,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg to a fasting rat,,,N,Intermediate,A,10116.0,CHEMBL623765,,1969.0,Plasma,,1,1
8912,50597,In vivo,BAO_0000218,,,Maximum concentration value was evaluated for high sustained blood levels in rat after 1 hr of administration,,,N,Intermediate,A,10116.0,CHEMBL623766,,178.0,Blood,,1,1
8913,50597,In vivo,BAO_0000218,,,Maximum concentration value was evaluated for high sustained blood levels in rat after 2 hr of administration,,,N,Intermediate,A,10116.0,CHEMBL623767,,178.0,Blood,,1,1
8914,50597,In vivo,BAO_0000218,,,Maximum concentration value was evaluated for high sustained blood levels in rat after 30 min of administration,,,N,Intermediate,A,10116.0,CHEMBL623768,,178.0,Blood,,1,1
8915,50597,In vivo,BAO_0000218,,,Maximum plasma concentration (Cmax) of compound (19.2 mg/kg) after po administration was determined Sprague-Dawley rat,,,N,Intermediate,A,10116.0,CHEMBL623769,,1969.0,Plasma,,1,1
8916,50597,In vivo,BAO_0000218,,,Maximum plasma concentration (Cmax) of compound (19.76 mg/kg) after po administration was determined Sprague-Dawley rat,,,N,Intermediate,A,10116.0,CHEMBL623770,,1969.0,Plasma,,1,1
8917,50597,In vivo,BAO_0000218,,,Maximum plasma concentration (Cmax) of compound (20.73 mg/kg) after po administration was determined Sprague-Dawley rat,,,N,Intermediate,A,10116.0,CHEMBL623771,,1969.0,Plasma,,1,1
8918,50597,In vivo,BAO_0000218,,,Maximum plasma concentration (Cmax) of compound (25 mg/kg) after po administration was determined Sprague-Dawley rat,,,N,Intermediate,A,10116.0,CHEMBL623772,,1969.0,Plasma,,1,1
8919,50597,In vivo,BAO_0000218,,,Maximum plasma concentration (Cmax) of compound (9.83 mg/kg) after iv administration was determined Sprague-Dawley rat,,,N,Intermediate,A,10116.0,CHEMBL623773,,1969.0,Plasma,,1,1
8920,50597,In vivo,BAO_0000218,,,Maximum plasma concentration (Cmax) of compound (9.84 mg/kg) after iv administration was determined Sprague-Dawley rat,,,N,Intermediate,A,10116.0,CHEMBL623774,,1969.0,Plasma,,1,1
8921,50597,In vivo,BAO_0000218,,,Maximum plasma concentration (Cmax) of compound (9.92 mg/kg) after iv administration was determined Sprague-Dawley rat,,,N,Intermediate,A,10116.0,CHEMBL623775,,1969.0,Plasma,,1,1
8922,50597,In vivo,BAO_0000218,,,Cmax in rat (PO dose),,,N,Intermediate,A,10116.0,CHEMBL623776,,,,,1,1
8923,50597,In vivo,BAO_0000218,,,Maximum plasma concentration determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,,N,Intermediate,A,10116.0,CHEMBL622191,,1969.0,Plasma,,1,1
8924,50597,In vivo,BAO_0000218,,,Maximum plasma concentration determined after 3 mg/kg oral administration in potassium oxonate treated rats,,,N,Intermediate,A,10116.0,CHEMBL622192,,1969.0,Plasma,,1,1
8925,50597,In vivo,BAO_0000218,,,Maximum plasma concentration determined in rat,,,N,Intermediate,A,10116.0,CHEMBL622193,,1969.0,Plasma,,1,1
8926,50597,In vivo,BAO_0000218,,,Maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL622194,,1969.0,Plasma,,1,1
8927,50597,In vivo,BAO_0000218,,,Maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL622195,,1969.0,Plasma,,1,1
8928,50597,In vivo,BAO_0000218,,,Maximum plasma concentration in rat,,,N,Intermediate,A,10116.0,CHEMBL622196,,1969.0,Plasma,,1,1
8929,50597,In vivo,BAO_0000218,,,Maximum plasma concentration measured after intravenous bolus administration of 50 mg/kg of compound to rats,,,N,Intermediate,A,10116.0,CHEMBL622197,,1969.0,Plasma,,1,1
8930,50597,In vivo,BAO_0000218,,,Maximum plasma concentration of compound present in rats at the dose of 37 mg/kg in 15 min,,,N,Intermediate,A,10116.0,CHEMBL622198,,1969.0,Plasma,,1,1
8931,50597,In vivo,BAO_0000218,,,Maximum plasma concentration of compound present in rats at the dose of 38 mg/kg in 15 min,,,N,Intermediate,A,10116.0,CHEMBL622199,,1969.0,Plasma,,1,1
8932,50597,In vivo,BAO_0000218,,,Maximum plasma concentration of compound was measured in rat,,,N,Intermediate,A,10116.0,CHEMBL622200,,1969.0,Plasma,,1,1
8933,50597,In vivo,BAO_0000218,,,Maximum plasma concentration after 20 mg/kg oral administration in rat,,,N,Intermediate,A,10116.0,CHEMBL622201,,1969.0,Plasma,,1,1
8934,50597,In vivo,BAO_0000218,,,Maximum plasma concentration after oral administration to rats,,,N,Intermediate,A,10116.0,CHEMBL623990,,1969.0,Plasma,,1,1
8935,50597,In vivo,BAO_0000218,,,Maximum plasma concentration at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,,,N,Intermediate,A,10116.0,CHEMBL623991,,1969.0,Plasma,,1,1
8936,50597,In vivo,BAO_0000218,,,"Maximum plasma concentration at a concentration of 3 mg/kg in rats, intravenously",,,N,Intermediate,A,10116.0,CHEMBL623992,,1969.0,Plasma,,1,1
8937,50597,In vivo,BAO_0000218,,,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,,,N,Intermediate,A,10116.0,CHEMBL623993,,1969.0,Plasma,,1,1
8938,50597,In vivo,BAO_0000218,,,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with control,,,N,Intermediate,A,10116.0,CHEMBL623994,,1969.0,Plasma,,1,1
8939,50597,In vivo,BAO_0000218,,,Maximum plasma concentration at a dose of 100 mg/kg in Rat Plasma after iv administration,,,N,Intermediate,F,10116.0,CHEMBL623995,,1969.0,Plasma,,1,1
8940,50597,In vivo,BAO_0000218,,,Maximum plasma concentration at a dose of 4 mg/kg in Rat Plasma after iv administration,,,N,Intermediate,F,10116.0,CHEMBL623996,,1969.0,Plasma,,1,1
8941,50597,In vivo,BAO_0000218,,,Maximum plasma concentration at a dose of 50 mg/kg in Rat Plasma after iv administration,,,N,Intermediate,F,10116.0,CHEMBL623997,,1969.0,Plasma,,1,1
8942,50597,In vivo,BAO_0000218,,,Maximum plasma concentration dosed orally in rats,,,N,Intermediate,A,10116.0,CHEMBL623998,,1969.0,Plasma,,1,1
8943,50597,In vivo,BAO_0000218,,,Maximum plasma concentration dosed orally in rats after 6 hours,,,N,Intermediate,A,10116.0,CHEMBL623999,,1969.0,Plasma,,1,1
8944,50597,In vivo,BAO_0000218,,,Maximum plasma concentration dosed orally in rats after 6 hours; ND is not detected,,,N,Intermediate,A,10116.0,CHEMBL624000,,1969.0,Plasma,,1,1
8945,50597,In vivo,BAO_0000218,,,Maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats,,,N,Intermediate,A,10116.0,CHEMBL624001,,1969.0,Plasma,,1,1
8946,50597,In vivo,BAO_0000218,,,Maximum plasma concentration in rat after po administration,,,N,Intermediate,A,10116.0,CHEMBL624002,,1969.0,Plasma,,1,1
8947,50597,In vivo,BAO_0000218,,,"Maximum plasma concentration in rats at 10 mg/kg, p.o. dose",,,N,Intermediate,A,10116.0,CHEMBL624003,,1969.0,Plasma,,1,1
8948,50597,In vivo,BAO_0000218,,,"Maximum plasma concentration in rats at 20mg/kg, i.p. dose",,,N,Intermediate,A,10116.0,CHEMBL624004,,1969.0,Plasma,,1,1
8949,50597,,BAO_0000218,,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,,N,Intermediate,A,10116.0,CHEMBL624005,,948.0,Heart,,1,1
8950,50597,,BAO_0000218,,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,,N,Intermediate,A,10116.0,CHEMBL624006,,948.0,Heart,,1,1
8951,50597,,BAO_0000218,,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,,N,Intermediate,A,10116.0,CHEMBL624007,,948.0,Heart,,1,1
8952,50597,,BAO_0000218,,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,,N,Intermediate,A,10116.0,CHEMBL624008,,948.0,Heart,,1,1
8953,50597,,BAO_0000218,,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,,N,Intermediate,A,10116.0,CHEMBL624009,,948.0,Heart,,1,1
8954,50597,,BAO_0000218,,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,,N,Intermediate,A,10116.0,CHEMBL874387,,948.0,Heart,,1,1
8955,50597,,BAO_0000218,,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,,N,Intermediate,A,10116.0,CHEMBL624010,,948.0,Heart,,1,1
8956,50597,,BAO_0000218,,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,,,N,Intermediate,A,10116.0,CHEMBL624011,,948.0,Heart,,1,1
8957,50597,,BAO_0000218,,,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,,N,Intermediate,A,10116.0,CHEMBL624012,,948.0,Heart,,1,1
8958,50597,,BAO_0000218,,,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,,N,Intermediate,A,10116.0,CHEMBL624013,,948.0,Heart,,1,1
8959,50597,,BAO_0000218,,,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,,N,Intermediate,A,10116.0,CHEMBL624736,,948.0,Heart,,1,1
8960,50597,,BAO_0000218,,,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,,N,Intermediate,A,10116.0,CHEMBL624737,,948.0,Heart,,1,1
8961,50597,,BAO_0000218,,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,,N,Intermediate,A,10116.0,CHEMBL624738,,948.0,Heart,,1,1
8962,50597,,BAO_0000218,,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,,N,Intermediate,A,10116.0,CHEMBL624739,,948.0,Heart,,1,1
8963,50597,,BAO_0000218,,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,,N,Intermediate,A,10116.0,CHEMBL624740,,948.0,Heart,,1,1
8964,50597,,BAO_0000218,,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,,N,Intermediate,A,10116.0,CHEMBL624896,,948.0,Heart,,1,1
8965,50597,,BAO_0000218,,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,,N,Intermediate,A,10116.0,CHEMBL624897,,948.0,Heart,,1,1
8966,50597,,BAO_0000218,,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,,N,Intermediate,A,10116.0,CHEMBL624108,,948.0,Heart,,1,1
8967,50597,,BAO_0000218,,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,,N,Intermediate,A,10116.0,CHEMBL624109,,948.0,Heart,,1,1
8968,50597,,BAO_0000218,,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,,N,Intermediate,A,10116.0,CHEMBL624110,,948.0,Heart,,1,1
8969,50597,,BAO_0000218,,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,,N,Intermediate,A,10116.0,CHEMBL624111,,948.0,Heart,,1,1
8970,50597,,BAO_0000218,,,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,,N,Intermediate,A,10116.0,CHEMBL624112,,948.0,Heart,,1,1
8971,50597,,BAO_0000218,,,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,,N,Intermediate,A,10116.0,CHEMBL624113,,948.0,Heart,,1,1
8972,50597,,BAO_0000218,,,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,,N,Intermediate,A,10116.0,CHEMBL619709,,948.0,Heart,,1,1
8973,50597,,BAO_0000218,,,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,,N,Intermediate,A,10116.0,CHEMBL619710,,948.0,Heart,,1,1
8974,50597,,BAO_0000218,,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,,N,Intermediate,A,10116.0,CHEMBL619711,,2113.0,Kidney,,1,1
8975,50597,,BAO_0000218,,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,,N,Intermediate,A,10116.0,CHEMBL619712,,2113.0,Kidney,,1,1
8976,50597,,BAO_0000218,,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,,N,Intermediate,A,10116.0,CHEMBL619713,,2113.0,Kidney,,1,1
8977,50597,,BAO_0000218,,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,,N,Intermediate,A,10116.0,CHEMBL619714,,2113.0,Kidney,,1,1
8978,50597,,BAO_0000218,,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,,N,Intermediate,A,10116.0,CHEMBL619715,,2113.0,Kidney,,1,1
8979,50597,,BAO_0000218,,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,,N,Intermediate,A,10116.0,CHEMBL619716,,2113.0,Kidney,,1,1
8980,50597,,BAO_0000218,,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,,N,Intermediate,A,10116.0,CHEMBL619717,,2113.0,Kidney,,1,1
8981,50597,,BAO_0000218,,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,,N,Intermediate,A,10116.0,CHEMBL619718,,2113.0,Kidney,,1,1
8982,50597,,BAO_0000218,,,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,,N,Intermediate,A,10116.0,CHEMBL619719,,2113.0,Kidney,,1,1
8983,50597,,BAO_0000218,,,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,,N,Intermediate,A,10116.0,CHEMBL875329,,2113.0,Kidney,,1,1
8984,50597,,BAO_0000218,,,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,,N,Intermediate,A,10116.0,CHEMBL619720,,2113.0,Kidney,,1,1
8985,50597,,BAO_0000218,,,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,,N,Intermediate,A,10116.0,CHEMBL619721,,2113.0,Kidney,,1,1
8986,50597,,BAO_0000218,,,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,,N,Intermediate,A,10116.0,CHEMBL619722,,2113.0,Kidney,,1,1
8987,50597,,BAO_0000218,,,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,,N,Intermediate,A,10116.0,CHEMBL619723,,2113.0,Kidney,,1,1
8988,50597,,BAO_0000218,,,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,,N,Intermediate,A,10116.0,CHEMBL619724,,2113.0,Kidney,,1,1
8989,50597,,BAO_0000218,,,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,,N,Intermediate,A,10116.0,CHEMBL619725,,2113.0,Kidney,,1,1
8990,50597,,BAO_0000218,,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,,N,Intermediate,A,10116.0,CHEMBL619726,,2113.0,Kidney,,1,1
8991,50597,,BAO_0000218,,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,,N,Intermediate,A,10116.0,CHEMBL619727,,2113.0,Kidney,,1,1
8992,50597,,BAO_0000218,,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,,N,Intermediate,A,10116.0,CHEMBL619728,,2113.0,Kidney,,1,1
8993,50597,,BAO_0000218,,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,,N,Intermediate,A,10116.0,CHEMBL619729,,2113.0,Kidney,,1,1
8994,50597,In vivo,BAO_0000218,,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,,N,Intermediate,A,10116.0,CHEMBL619730,,2385.0,Muscle tissue,,1,1
8995,50597,In vivo,BAO_0000218,,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,,N,Intermediate,A,10116.0,CHEMBL619731,,2385.0,Muscle tissue,,1,1
8996,50597,In vivo,BAO_0000218,,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 2 rats),,,N,Intermediate,A,10116.0,CHEMBL619732,,2385.0,Muscle tissue,,1,1
8997,50597,In vivo,BAO_0000218,,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,,N,Intermediate,A,10116.0,CHEMBL619733,,2385.0,Muscle tissue,,1,1
8998,50597,In vivo,BAO_0000218,,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,,N,Intermediate,A,10116.0,CHEMBL619734,,2385.0,Muscle tissue,,1,1
8999,50597,In vivo,BAO_0000218,,,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,,N,Intermediate,A,10116.0,CHEMBL619735,,14.0,Zone of skin,,1,1
9000,50597,In vivo,BAO_0000218,,,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,,N,Intermediate,A,10116.0,CHEMBL875330,,14.0,Zone of skin,,1,1
9001,50597,In vivo,BAO_0000218,,,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 2 rats),,,N,Intermediate,A,10116.0,CHEMBL628465,,14.0,Zone of skin,,1,1
9002,50597,In vivo,BAO_0000218,,,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,,N,Intermediate,A,10116.0,CHEMBL628466,,14.0,Zone of skin,,1,1
9003,50597,In vivo,BAO_0000218,,,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,,N,Intermediate,A,10116.0,CHEMBL628467,,14.0,Zone of skin,,1,1
9004,50597,In vivo,BAO_0000218,,,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,,N,Intermediate,A,10116.0,CHEMBL628468,,2106.0,Spleen,,1,1
9005,50597,In vivo,BAO_0000218,,,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,,N,Intermediate,A,10116.0,CHEMBL628469,,2106.0,Spleen,,1,1
9006,50597,In vivo,BAO_0000218,,,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 2 rats),,,N,Intermediate,A,10116.0,CHEMBL628470,,2106.0,Spleen,,1,1
9007,50597,In vivo,BAO_0000218,,,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,,N,Intermediate,A,10116.0,CHEMBL628471,,2106.0,Spleen,,1,1
9008,50597,In vivo,BAO_0000218,,,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,,N,Intermediate,A,10116.0,CHEMBL628472,,2106.0,Spleen,,1,1
9009,50597,In vivo,BAO_0000218,,,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,,N,Intermediate,A,10116.0,CHEMBL625191,,2046.0,Thyroid gland,,1,1
9010,50597,In vivo,BAO_0000218,,,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,,N,Intermediate,A,10116.0,CHEMBL625192,,2046.0,Thyroid gland,,1,1
9011,50597,In vivo,BAO_0000218,,,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 2 rats),,,N,Intermediate,A,10116.0,CHEMBL875337,,2046.0,Thyroid gland,,1,1
9012,50597,In vivo,BAO_0000218,,,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,,N,Intermediate,A,10116.0,CHEMBL626341,,2046.0,Thyroid gland,,1,1
9013,50597,In vivo,BAO_0000218,,,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,,N,Intermediate,A,10116.0,CHEMBL626342,,2046.0,Thyroid gland,,1,1
9014,50597,In vivo,BAO_0000218,,,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,,N,Intermediate,A,10116.0,CHEMBL621943,,2107.0,Liver,,1,1
9015,50597,,BAO_0000218,,,Half life in rats,,,N,Intermediate,A,10116.0,CHEMBL621944,,,,,1,1
9016,50597,,BAO_0000218,,,Mean percent inhibition of joint damage reduction in fasted rats at 35 mg/kg administered orally twice daily,,,N,Intermediate,A,10116.0,CHEMBL621945,,,,,1,1
9017,50597,,BAO_0000218,,,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver),,,N,Intermediate,A,10116.0,CHEMBL621946,,,,,1,1
9018,50597,,BAO_0000218,,,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver); ND=Not determined,,,N,Intermediate,A,10116.0,CHEMBL621947,,,,,1,1
9019,50597,,BAO_0000218,,,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver),,,N,Intermediate,A,10116.0,CHEMBL621948,,,,,1,1
9020,50597,,BAO_0000218,,,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver); ND=Not determined,,,N,Intermediate,A,10116.0,CHEMBL621949,,,,,1,1
9021,50597,,BAO_0000218,,,Rate constant (k) of clearance from isolated perfused rat liver (IPRL),,,N,Intermediate,A,10116.0,CHEMBL621950,,,,,1,1
9022,50597,,BAO_0000218,,,Tested for rate of clearance from isolated perfused rat liver (IPRL) and expressed in terms of rate constant (k); not determined,,,N,Intermediate,A,10116.0,CHEMBL621951,,,,,1,1
9023,50597,In vivo,BAO_0000218,,,Maximal blood concentration after oral administration of a 30 uM/kg dose of compound,,,N,Intermediate,A,10116.0,CHEMBL621952,,178.0,Blood,,1,1
9024,50597,,BAO_0000218,,,Stability (%) in rat liver microsomes,,,N,Intermediate,A,10116.0,CHEMBL621953,,2107.0,Liver,,1,1
9025,50597,,BAO_0000218,,,Area under curve was calculated after intravenous administration,,,N,Intermediate,A,10116.0,CHEMBL621954,,,,,1,1
9026,50597,,BAO_0000218,,,Area under the curve was calculated after iv administration in rat,,,N,Intermediate,A,10116.0,CHEMBL621955,,,,,1,1
9027,50597,,BAO_0000218,,,Area under the curve was calculated in rat after peroral administration,,,N,Intermediate,A,10116.0,CHEMBL621956,,,,,1,1
9028,50597,,BAO_0000218,,,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats,,,N,Intermediate,A,10116.0,CHEMBL621957,,,,,1,1
9029,50597,,BAO_0000218,,,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral dose of 2 mg/Kg,,,N,Intermediate,A,10116.0,CHEMBL621958,,,,,1,1
9030,50597,,BAO_0000218,,,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral of 2 mg/Kg,,,N,Intermediate,A,10116.0,CHEMBL621959,,,,,1,1
9031,50597,,BAO_0000218,,,Dose-normalized area under curve in rat (i.v.) at 0.5 mpk,,,N,Intermediate,A,10116.0,CHEMBL621960,,,,,1,1
9032,50597,,BAO_0000218,,,Dose-normalized area under curve in rat (p.o.) at 2.0 mpk,,,N,Intermediate,A,10116.0,CHEMBL621961,,,,,1,1
9033,50597,,BAO_0000218,,,p value of the compound,,,N,Intermediate,A,10116.0,CHEMBL621962,,,,,1,1
9034,50597,,BAO_0000218,,,p value of the compound,,,N,Intermediate,F,10116.0,CHEMBL876787,,,,,1,1
9035,50597,,BAO_0000218,,,p value of the compound,,,N,Intermediate,A,10116.0,CHEMBL621963,,,,,1,1
9036,50597,,BAO_0000218,,,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),,,N,Intermediate,A,10116.0,CHEMBL622637,,945.0,Stomach,,1,1
9037,50597,,BAO_0000218,,,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (20 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),,,N,Intermediate,A,10116.0,CHEMBL622638,,945.0,Stomach,,1,1
9038,50597,,BAO_0000218,,,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),,,N,Intermediate,A,10116.0,CHEMBL626561,,945.0,Stomach,,1,1
9039,22224,,BAO_0000019,,,Negative log of minimum effective dose (moles per kilogram) in rabbits (hypnotic),,,U,Autocuration,F,9986.0,CHEMBL626562,,,,,0,1
9040,22224,,BAO_0000218,,,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg ( 0-4 hr ),,,U,Autocuration,A,9986.0,CHEMBL626563,,,,,0,1
9041,22224,,BAO_0000218,,,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg (0-4 hr ),,,U,Autocuration,A,9986.0,CHEMBL626564,,,,,0,1
9042,22224,In vivo,BAO_0000218,,,Clearance was measured at the concentration of 1.11 mg/kg in rabbit blood sample,,,U,Autocuration,A,9986.0,CHEMBL626565,,,,,0,1
9043,22224,In vivo,BAO_0000218,,,Clearance was measured at the concentration of 2.0 mg/kg in rabbit blood sample,,,U,Autocuration,A,9986.0,CHEMBL626566,,,,,0,1
9044,22224,In vivo,BAO_0000218,,,Clearance rate in rabbits,,,U,Autocuration,A,9986.0,CHEMBL626567,,,,,0,1
9045,22224,In vivo,BAO_0000218,,,Plasma clearance was determined in rabbit at a dose of 5 mg/kg/h administered i.v.,,,U,Autocuration,A,9986.0,CHEMBL626568,,,,,0,1
9046,22224,In vivo,BAO_0000218,,,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,,,U,Autocuration,A,9986.0,CHEMBL626569,,,,,0,1
9047,22224,In vivo,BAO_0000218,,,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,,,U,Autocuration,A,9986.0,CHEMBL626570,,,,,0,1
9048,22224,In vivo,BAO_0000218,,,Clearance in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,,,U,Autocuration,A,9986.0,CHEMBL626571,,,,,0,1
9049,22224,In vivo,BAO_0000218,,,Evaluated for pharmacokinetic parameter Cmax in rabbit at the dose 20 mg/kg,,,U,Autocuration,A,9986.0,CHEMBL626572,,,,,0,1
9050,22224,In vivo,BAO_0000218,,,Maximum plasma concentration was determined in rabbit at a dose of 5 mg/kg/h administered i.v.,,,U,Autocuration,A,9986.0,CHEMBL626573,,1969.0,Plasma,,0,1
9051,22224,,BAO_0000251,,,Oxidation by dutch rabbit liver microsomes in presence of NADPH/O2,,,U,Autocuration,A,9986.0,CHEMBL626574,,2107.0,Liver,Microsomes,0,1
9052,22224,,BAO_0000251,,,Oxidation by dutch rabbit liver microsomes in presence of cumene hydroperoxide,,,U,Autocuration,A,9986.0,CHEMBL626575,,2107.0,Liver,Microsomes,0,1
9053,22224,,BAO_0000218,,,Dose at which bioavailability of intravenously administered compound was tested in rabbit,,,U,Autocuration,A,9986.0,CHEMBL626576,,,,,0,1
9054,22224,,BAO_0000218,,,Dose at which bioavailability of perorally administered compound was tested in rabbit,,,U,Autocuration,A,9986.0,CHEMBL626577,,,,,0,1
9055,22224,In vivo,BAO_0000218,,,The compound was tested for its bioavailability in rabbit (by oral dosage).,,,U,Autocuration,A,9986.0,CHEMBL626578,,,,,0,1
9056,22224,In vivo,BAO_0000218,,,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,,,U,Autocuration,A,9986.0,CHEMBL625263,,,,,0,1
9057,22224,In vivo,BAO_0000218,,,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,,,U,Autocuration,A,9986.0,CHEMBL625264,,,,,0,1
9058,22224,In vivo,BAO_0000218,,,Mean retention time in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,,,U,Autocuration,A,9986.0,CHEMBL625265,,,,,0,1
9059,22224,,BAO_0000251,,,Metabolism of compound in rabbit S9 microsomes ('+''indicates <20% largest observed peak),,,U,Autocuration,A,9986.0,CHEMBL625266,,,,Microsomes,0,1
9060,22224,,BAO_0000251,,,Metabolism of compound in rabbit S9 microsomes ('++++' indicates largest observed peak),,,U,Autocuration,A,9986.0,CHEMBL876796,,,,Microsomes,0,1
9061,22224,In vivo,BAO_0000218,,,Evaluated for pharmacokinetic parameter half-life in rabbit at the dose 20 mg/kg,,,U,Autocuration,A,9986.0,CHEMBL625267,,,,,0,1
9062,22224,In vivo,BAO_0000218,,,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,,,U,Autocuration,A,9986.0,CHEMBL625268,,1969.0,Plasma,,0,1
9063,22224,In vivo,BAO_0000218,,,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,,,U,Autocuration,A,9986.0,CHEMBL625269,,1969.0,Plasma,,0,1
9064,22224,In vivo,BAO_0000218,,,Plasma half-life in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,,,U,Autocuration,A,9986.0,CHEMBL624689,,1969.0,Plasma,,0,1
9065,22224,In vivo,BAO_0000218,,,Evaluated for pharmacokinetic parameter tmax in rabbit at the dose 20 mg/kg,,,U,Autocuration,A,9986.0,CHEMBL624690,,,,,0,1
9066,22224,,BAO_0000218,,,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg ( 0-24 hr ),,,U,Autocuration,A,9986.0,CHEMBL624691,,1088.0,Urine,,0,1
9067,22224,,BAO_0000218,,,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg (0-24 hr),,,U,Autocuration,A,9986.0,CHEMBL624692,,1088.0,Urine,,0,1
9068,22224,In vivo,BAO_0000218,,,The compound was evaluated for volume of distribution in rabbit at a dose of 5 mg/kg/h administered i.v.,,,U,Autocuration,A,9986.0,CHEMBL624693,,,,,0,1
9069,22224,In vivo,BAO_0000218,,,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,,,U,Autocuration,A,9986.0,CHEMBL624694,,,,,0,1
9070,22224,In vitro,BAO_0000221,,,In vitro Biological half-life in crude homogenate of rabbit renal cortex,,,U,Autocuration,A,9986.0,CHEMBL877596,,,,,0,1
9071,22224,,BAO_0000019,,,Time within which only 10% of the drug was degraded,,,U,Autocuration,A,9986.0,CHEMBL624695,,,,,0,1
9072,22224,,BAO_0000221,,,Half life period in rabbit liver homogenate,,,U,Autocuration,A,9986.0,CHEMBL624696,,2107.0,Liver,,0,1
9073,22224,,BAO_0000019,,,Half life value in rabbits,,,U,Autocuration,A,9986.0,CHEMBL624697,,,,,0,1
9074,22224,In vivo,BAO_0000218,,,Half-life was measured at the concentration of 1.11 mg/kg in rabbit blood sample,,,U,Autocuration,A,9986.0,CHEMBL624698,,178.0,Blood,,0,1
9075,22224,In vivo,BAO_0000218,,,Half-life was measured at the concentration of 2.0 mg/kg in rabbit blood sample,,,U,Autocuration,A,9986.0,CHEMBL624699,,178.0,Blood,,0,1
9076,22224,In vivo,BAO_0000218,,,Half-life period in rabbits following intravenous administration at 2 mg/kg,,,U,Autocuration,A,9986.0,CHEMBL624700,,,,,0,1
9077,50597,,BAO_0000218,,,AUC 0-8 hr value in rats at 10 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL622903,,1969.0,Plasma,,1,1
9078,50597,,BAO_0000218,,,AUC after administration at 2000 mg/kg/day in rats,,,N,Intermediate,A,10116.0,CHEMBL622904,,1969.0,Plasma,,1,1
9079,50597,,BAO_0000218,,,AUC of compound for a 2 mpk po dose of the sodium salt in rats.,,,N,Intermediate,A,10116.0,CHEMBL622905,,1969.0,Plasma,,1,1
9080,50597,,BAO_0000218,,,AUC at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,,,N,Intermediate,A,10116.0,CHEMBL622906,,1969.0,Plasma,,1,1
9081,50597,,BAO_0000218,,,AUC at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,,,N,Intermediate,A,10116.0,CHEMBL622907,,1969.0,Plasma,,1,1
9082,50597,,BAO_0000218,,,AUC in rat after oral administration at 10.5 mg/kg dose,,,N,Intermediate,A,10116.0,CHEMBL622908,,1969.0,Plasma,,1,1
9083,50597,,BAO_0000218,,,AUC in rat after oral administration at 11.2 mg/kg dose,,,N,Intermediate,A,10116.0,CHEMBL622909,,1969.0,Plasma,,1,1
9084,50597,,BAO_0000218,,,AUC in rat after oral administration at 9.7 mg/kg dose,,,N,Intermediate,A,10116.0,CHEMBL622910,,1969.0,Plasma,,1,1
9085,50597,,BAO_0000218,,,AUC in rat brain after oral administration at 10 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL622911,,955.0,Brain,,1,1
9086,50597,,BAO_0000218,,,AUC in rat p.o.,,,N,Intermediate,A,10116.0,CHEMBL622912,,1969.0,Plasma,,1,1
9087,50597,,BAO_0000218,,,AUC in rat p.o. at 20 mg/kg concentration,,,N,Intermediate,A,10116.0,CHEMBL622913,,1969.0,Plasma,,1,1
9088,50597,,BAO_0000218,,,AUC in rat plasma after oral administration at 10 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL622914,,1969.0,Plasma,,1,1
9089,50597,,BAO_0000218,,,AUC in rats,,,N,Intermediate,A,10116.0,CHEMBL622915,,1969.0,Plasma,,1,1
9090,50597,,BAO_0000218,,,AUC value after IV dose at a dose of 5 mg/kg in rats.,,,N,Intermediate,A,10116.0,CHEMBL622916,,1969.0,Plasma,,1,1
9091,50597,,BAO_0000218,,,AUC value after oral dose at a dose of 10 mg/kg in rats.,,,N,Intermediate,A,10116.0,CHEMBL622917,,1969.0,Plasma,,1,1
9092,50597,In vivo,BAO_0000218,,,"Maximum plasma concentration in rats at 2 mg/kg, i.v. dose; n/a: not applicable",,,N,Intermediate,A,10116.0,CHEMBL622918,,1969.0,Plasma,,1,1
9093,50597,In vivo,BAO_0000218,,,Maximum plasma concentration in rats when a oral dose of 200 mg/kg was given,,,N,Intermediate,A,10116.0,CHEMBL622919,,1969.0,Plasma,,1,1
9094,50597,In vivo,BAO_0000218,,,Maximum plasma concentration was evaluated in rat,,,N,Intermediate,A,10116.0,CHEMBL622920,,1969.0,Plasma,,1,1
9095,50597,In vivo,BAO_0000218,,,Maximum plasma concentration was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration,,,N,Intermediate,A,10116.0,CHEMBL622921,,1969.0,Plasma,,1,1
9096,50597,In vivo,BAO_0000218,,,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,,,N,Intermediate,A,10116.0,CHEMBL622922,,1969.0,Plasma,,1,1
9097,50597,In vivo,BAO_0000218,,,Maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose,,,N,Intermediate,A,10116.0,CHEMBL622923,,1969.0,Plasma,,1,1
9098,50597,In vivo,BAO_0000218,,,Maximum plasma concentration was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,,,N,Intermediate,A,10116.0,CHEMBL877604,,1969.0,Plasma,,1,1
9099,50597,In vivo,BAO_0000218,,,Maximum plasma concentration was evaluated in rats at an intravenous dose of 3 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL622924,,1969.0,Plasma,,1,1
9100,50597,In vivo,BAO_0000218,,,Maximum plasma concentration was evaluated in rats at an oral dose of 30 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL622925,,1969.0,Plasma,,1,1
9101,50597,In vivo,BAO_0000218,,,Maximum plasma concentration was measured when a dose of 1 mg/kg is administered orally,,,N,Intermediate,A,10116.0,CHEMBL622926,,1969.0,Plasma,,1,1
9102,50597,In vivo,BAO_0000218,,,Maximum plasma concentration (Cmax) in rat (in vivo) at a dose of 10 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL623625,,1969.0,Plasma,,1,1
9103,50597,In vivo,BAO_0000218,,,Maximum plasma drug concentration of compound determined in rat after iv administration at a dose of 10 mg/kg,,,N,Expert,A,10116.0,CHEMBL623626,,1969.0,Plasma,,1,1
9104,50597,In vivo,BAO_0000218,,,Maximum plasma drug concentration was determined,,,N,Intermediate,A,10116.0,CHEMBL623627,,1969.0,Plasma,,1,1
9105,50597,In vivo,BAO_0000218,,,Maximum concentration by intravenous administration of 3.4 mg/kg in rat,,,N,Intermediate,A,10116.0,CHEMBL623628,,,,,1,1
9106,50597,In vivo,BAO_0000218,,,Mean peak plasma concentration was observed after intravenous administration in rat,,,N,Intermediate,A,10116.0,CHEMBL623629,,1969.0,Plasma,,1,1
9107,50597,In vivo,BAO_0000218,,,Mean peak plasma concentration was observed after oral administration in rat,,,N,Intermediate,A,10116.0,CHEMBL623630,,1969.0,Plasma,,1,1
9108,50597,In vivo,BAO_0000218,,,Peak concentration (Cmax) at a dose of 10 mg/kg in rats,,,N,Intermediate,A,10116.0,CHEMBL623804,,,,,1,1
9109,50597,In vivo,BAO_0000218,,,Peak concentration (Cmax) at a dose of 20 mg/kg in rats,,,N,Intermediate,A,10116.0,CHEMBL623805,,,,,1,1
9110,50597,In vivo,BAO_0000218,,,Peak oral plasma concentration was determined in rats by oral administration,,,N,Intermediate,A,10116.0,CHEMBL623806,,1969.0,Plasma,,1,1
9111,50597,In vivo,BAO_0000218,,,Peak plasma concentration (Cmax) was determined,,,N,Intermediate,A,10116.0,CHEMBL623807,,1969.0,Plasma,,1,1
9112,50597,In vivo,BAO_0000218,,,Peak plasma concentration (Cmax) following an oral dose of 20 mg/kg in rats,,,N,Intermediate,A,10116.0,CHEMBL623808,,1969.0,Plasma,,1,1
9113,50597,In vivo,BAO_0000218,,,Peak plasma concentration (Cmax) in rats,,,N,Intermediate,A,10116.0,CHEMBL623809,,1969.0,Plasma,,1,1
9114,50597,In vivo,BAO_0000218,,,Peak plasma concentration at 1 mg/kg peroral administration,,,N,Intermediate,A,10116.0,CHEMBL623810,,1969.0,Plasma,,1,1
9115,50597,In vivo,BAO_0000218,,,Peak plasma concentration in rat,,,N,Intermediate,A,10116.0,CHEMBL623811,,1969.0,Plasma,,1,1
9116,50597,In vivo,BAO_0000218,,,"Pharmacokinetic Parameter, Cmax is observed maximum plasma concentration in Female Wistar Rats at 100 mg/kg by po administration",,,N,Intermediate,A,10116.0,CHEMBL623812,,1969.0,Plasma,,1,1
9117,50597,In vivo,BAO_0000218,,,Pharmacokinetic parameter Cmax was measured after administration into rat at 10 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL877605,,,,,1,1
9118,50597,In vivo,BAO_0000218,,,Pharmacokinetic property (Cmax) in rat,,,N,Intermediate,A,10116.0,CHEMBL623813,,,,,1,1
9119,50597,In vivo,BAO_0000218,,,Pharmacokinetic property (Cmax) was measured in rat at the dose of 0.32 mg/kg p.o.,,,N,Intermediate,A,10116.0,CHEMBL623814,,,,,1,1
9120,50597,In vivo,BAO_0000218,,,Cmax in rat after 3mg/kg oral dose,,,N,Intermediate,A,10116.0,CHEMBL623815,,,,,1,1
9121,50597,In vivo,BAO_0000218,,,Clearance in Sprague-Dawley rats after 2mg/kg oral dose,,,N,Intermediate,A,10116.0,CHEMBL623816,,,,,1,1
9122,50597,In vivo,BAO_0000218,,,Cmax in rats after 20 mg/kg oral dose,,,N,Intermediate,A,10116.0,CHEMBL623145,,,,,1,1
9123,50597,In vivo,BAO_0000218,,,Cmax in rat plasma after 30mg/kg oral dose,,,N,Intermediate,A,10116.0,CHEMBL623146,,1969.0,Plasma,,1,1
9124,50597,In vivo,BAO_0000218,,,Plasma concentration after oral administration of 100 mg/kg to rats,,,N,Intermediate,A,10116.0,CHEMBL623147,,1969.0,Plasma,,1,1
9125,50597,In vivo,BAO_0000218,,,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats,,,N,Intermediate,A,10116.0,CHEMBL623042,,955.0,Brain,,1,1
9126,50597,In vivo,BAO_0000218,,,Tested for the Cmax in rat at 10 mg/kg per orally,,,N,Intermediate,A,10116.0,CHEMBL623043,,,,,1,1
9127,50597,In vivo,BAO_0000218,,,"The Cmax value in female wistar rat at 100 mg/kg, p.o. dose",,,N,Intermediate,A,10116.0,CHEMBL623044,,,,,1,1
9128,50597,In vivo,BAO_0000218,,,"The Cmax value in male wistar rat at 100 mg/kg, p.o. dose",,,N,Intermediate,A,10116.0,CHEMBL623045,,,,,1,1
9129,50597,In vivo,BAO_0000218,,,Bioavailability as oral Cmax in rats at 30 mins,,,N,Intermediate,A,10116.0,CHEMBL623046,,,,,1,1
9130,50597,In vivo,BAO_0000218,,,Bioavailability as oral Cmax in rats at 6hr,,,N,Intermediate,A,10116.0,CHEMBL623226,,,,,1,1
9131,50597,In vivo,BAO_0000218,,,The maximum concentration of compound was measured at the dose of 100 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL623227,,,,,1,1
9132,50597,In vivo,BAO_0000218,,,The maximum concentration of compound was measured at the dose of 300 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL623228,,,,,1,1
9133,50597,In vivo,BAO_0000218,,,The maximum concentration of compound was measured at the dose of 30 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL623229,,,,,1,1
9134,50597,In vivo,BAO_0000218,,,The maximum plasma levels for the compounds were determined by LC-MS.,,,N,Intermediate,A,10116.0,CHEMBL623230,,1969.0,Plasma,,1,1
9135,50597,In vivo,BAO_0000218,,,mean peak plasma concentration was observed after intravenous administration in rat,,,N,Intermediate,A,10116.0,CHEMBL623231,,1969.0,Plasma,,1,1
9136,50597,In vivo,BAO_0000218,,,mean peak plasma concentration was observed after oral administration in rat,,,N,Intermediate,A,10116.0,CHEMBL623232,,1969.0,Plasma,,1,1
9137,50597,,BAO_0000218,,,Concentration in the plasma after intravenous administration of 1 mg/kg in rat,,,N,Intermediate,A,10116.0,CHEMBL623233,,,,,1,1
9138,50597,,BAO_0000218,,,Concentration in plasma (portal) following oral dose in rats at 0.25 hr,,,N,Intermediate,A,10116.0,CHEMBL623234,,,,,1,1
9139,50597,,BAO_0000218,,,Concentration in plasma (portal) following oral dose in rats at 1 hr,,,N,Intermediate,A,10116.0,CHEMBL623235,,,,,1,1
9140,50597,,BAO_0000218,,,Concentration in plasma (portal) following oral dose in rats at 2 hr,,,N,Intermediate,A,10116.0,CHEMBL623236,,,,,1,1
9141,50597,,BAO_0000218,,,Concentration in plasma (systemic) following oral dose in rats at 0.25 hr,,,N,Intermediate,A,10116.0,CHEMBL623237,,,,,1,1
9142,50597,,BAO_0000218,,,Concentration in plasma (systemic) following oral dose in rats at 1 hr,,,N,Intermediate,A,10116.0,CHEMBL623238,,,,,1,1
9143,50597,,BAO_0000218,,,Concentration in plasma (systemic) following oral dose in rats at 2 hr,,,N,Intermediate,A,10116.0,CHEMBL623239,,,,,1,1
9144,22224,In vivo,BAO_0000218,,,Compound was evaluated for the plasma concentration in rats versus time curves (AUC) in vivo,,,U,Intermediate,A,10116.0,CHEMBL623240,,1969.0,Plasma,,0,1
9145,50597,,BAO_0000218,,,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 2 hours",,,N,Intermediate,A,10116.0,CHEMBL623241,,1898.0,Hypothalamus,,1,1
9146,50597,,BAO_0000218,,,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 6 hours",,,N,Intermediate,A,10116.0,CHEMBL623242,,1898.0,Hypothalamus,,1,1
9147,50597,,BAO_0000218,,,"Concentration (30 mg/kg, p.o.) in rat plasma after 2 hours",,,N,Intermediate,A,10116.0,CHEMBL874394,,,,,1,1
9148,50597,,BAO_0000218,,,"Concentration (30 mg/kg, p.o.) in rat plasma after 6 hours",,,N,Intermediate,A,10116.0,CHEMBL623243,,,,,1,1
9149,50597,,BAO_0000218,,,Kidney concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL623244,,,,,1,1
9150,50597,,BAO_0000218,,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,,N,Intermediate,A,10116.0,CHEMBL623245,,2113.0,Kidney,,1,1
9151,50597,,BAO_0000218,,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,,N,Intermediate,A,10116.0,CHEMBL623246,,2113.0,Kidney,,1,1
9152,50597,,BAO_0000218,,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,,N,Intermediate,A,10116.0,CHEMBL623247,,2113.0,Kidney,,1,1
9153,50597,,BAO_0000218,,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,,N,Intermediate,A,10116.0,CHEMBL623248,,2113.0,Kidney,,1,1
9154,50597,,BAO_0000218,,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,,N,Intermediate,A,10116.0,CHEMBL623249,,2113.0,Kidney,,1,1
9155,50597,,BAO_0000218,,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,,N,Intermediate,A,10116.0,CHEMBL625072,,2107.0,Liver,,1,1
9156,50597,,BAO_0000218,,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,,N,Intermediate,A,10116.0,CHEMBL625073,,2107.0,Liver,,1,1
9157,50597,,BAO_0000218,,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,,N,Intermediate,A,10116.0,CHEMBL625074,,2107.0,Liver,,1,1
9158,50597,,BAO_0000218,,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,,N,Intermediate,A,10116.0,CHEMBL625075,,2107.0,Liver,,1,1
9159,50597,,BAO_0000218,,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min.,,,N,Intermediate,A,10116.0,CHEMBL625076,,2107.0,Liver,,1,1
9160,50597,,BAO_0000218,,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,,N,Intermediate,A,10116.0,CHEMBL625077,,2107.0,Liver,,1,1
9161,50597,,BAO_0000218,,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,,N,Intermediate,A,10116.0,CHEMBL625078,,2107.0,Liver,,1,1
9162,50597,,BAO_0000218,,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,,N,Intermediate,A,10116.0,CHEMBL874395,,2107.0,Liver,,1,1
9163,50597,,BAO_0000218,,,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,,N,Intermediate,A,10116.0,CHEMBL625079,,2107.0,Liver,,1,1
9164,50597,,BAO_0000218,,,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,,N,Intermediate,A,10116.0,CHEMBL625080,,2107.0,Liver,,1,1
9165,50597,,BAO_0000218,,,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,,N,Intermediate,A,10116.0,CHEMBL625081,,2107.0,Liver,,1,1
9166,50597,,BAO_0000218,,,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,,N,Intermediate,A,10116.0,CHEMBL625082,,2107.0,Liver,,1,1
9167,50597,,BAO_0000218,,,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,,N,Intermediate,A,10116.0,CHEMBL625083,,2107.0,Liver,,1,1
9168,50597,,BAO_0000218,,,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,,N,Intermediate,A,10116.0,CHEMBL625084,,2107.0,Liver,,1,1
9169,50597,,BAO_0000218,,,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,,N,Intermediate,A,10116.0,CHEMBL625085,,2107.0,Liver,,1,1
9170,50597,,BAO_0000218,,,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,,N,Intermediate,A,10116.0,CHEMBL625086,,2107.0,Liver,,1,1
9171,50597,,BAO_0000218,,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,,N,Intermediate,A,10116.0,CHEMBL625087,,2107.0,Liver,,1,1
9172,50597,,BAO_0000218,,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,,N,Intermediate,A,10116.0,CHEMBL625088,,2107.0,Liver,,1,1
9173,50597,,BAO_0000218,,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,,N,Intermediate,A,10116.0,CHEMBL622205,,2107.0,Liver,,1,1
9174,50597,,BAO_0000218,,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,,N,Intermediate,A,10116.0,CHEMBL622206,,2107.0,Liver,,1,1
9175,50597,,BAO_0000218,,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,,N,Intermediate,A,10116.0,CHEMBL622207,,2107.0,Liver,,1,1
9176,50597,,BAO_0000218,,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,,N,Intermediate,A,10116.0,CHEMBL622366,,2107.0,Liver,,1,1
9177,50597,,BAO_0000218,,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,,N,Intermediate,A,10116.0,CHEMBL622367,,2107.0,Liver,,1,1
9178,50597,,BAO_0000218,,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,,N,Intermediate,A,10116.0,CHEMBL875331,,2107.0,Liver,,1,1
9179,50597,,BAO_0000218,,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,,N,Intermediate,A,10116.0,CHEMBL622368,,2107.0,Liver,,1,1
9180,50597,,BAO_0000218,,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,,N,Intermediate,A,10116.0,CHEMBL622369,,2048.0,Lung,,1,1
9181,50597,,BAO_0000218,,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,,N,Intermediate,A,10116.0,CHEMBL622370,,2048.0,Lung,,1,1
9182,50597,,BAO_0000218,,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,,N,Intermediate,A,10116.0,CHEMBL622371,,2048.0,Lung,,1,1
9183,50597,,BAO_0000218,,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,,N,Intermediate,A,10116.0,CHEMBL622372,,2048.0,Lung,,1,1
9184,50597,,BAO_0000218,,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,,N,Intermediate,A,10116.0,CHEMBL622373,,2048.0,Lung,,1,1
9185,50597,,BAO_0000218,,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,,N,Intermediate,A,10116.0,CHEMBL622374,,2048.0,Lung,,1,1
9186,50597,,BAO_0000218,,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,,N,Intermediate,A,10116.0,CHEMBL622375,,2048.0,Lung,,1,1
9187,50597,,BAO_0000218,,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,,,N,Intermediate,A,10116.0,CHEMBL622376,,2048.0,Lung,,1,1
9188,50597,,BAO_0000218,,,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,,N,Intermediate,A,10116.0,CHEMBL622377,,2048.0,Lung,,1,1
9189,50597,,BAO_0000218,,,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,,N,Intermediate,A,10116.0,CHEMBL622378,,2048.0,Lung,,1,1
9190,50597,,BAO_0000218,,,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,,N,Intermediate,A,10116.0,CHEMBL622379,,2048.0,Lung,,1,1
9191,50597,,BAO_0000218,,,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,,N,Intermediate,A,10116.0,CHEMBL622380,,2048.0,Lung,,1,1
9192,50597,,BAO_0000218,,,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,,N,Intermediate,A,10116.0,CHEMBL622381,,2048.0,Lung,,1,1
9193,50597,,BAO_0000218,,,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,,N,Intermediate,A,10116.0,CHEMBL622382,,2048.0,Lung,,1,1
9194,50597,,BAO_0000218,,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min,,,N,Intermediate,A,10116.0,CHEMBL622383,,2048.0,Lung,,1,1
9195,50597,,BAO_0000218,,,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured ( 5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),,,N,Intermediate,A,10116.0,CHEMBL875332,,945.0,Stomach,,1,1
9196,50597,,BAO_0000218,,,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),,,N,Intermediate,A,10116.0,CHEMBL622384,,945.0,Stomach,,1,1
9197,50597,,BAO_0000218,,,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (2.5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),,,N,Intermediate,A,10116.0,CHEMBL622385,,945.0,Stomach,,1,1
9198,50597,,BAO_0000218,,,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),,,N,Intermediate,A,10116.0,CHEMBL622386,,945.0,Stomach,,1,1
9199,50597,,BAO_0000218,,,The compound was tested for the plasma binding in rat,,,N,Intermediate,A,10116.0,CHEMBL622387,,,,,1,1
9200,50597,,BAO_0000218,,,"Plasma concentration after intravenous aministration at 1hr, (1 mg/kg, n=3)",,,N,Intermediate,A,10116.0,CHEMBL622388,,,,,1,1
9201,50597,,BAO_0000218,,,"Plasma concentration after intravenous aministration at 30 min. (1 mg/kg, n=3)",,,N,Intermediate,A,10116.0,CHEMBL622389,,,,,1,1
9202,50597,,BAO_0000218,,,"Plasma concentration after intravenous aministration at 60 min. (1 mg/kg, n=3)",,,N,Intermediate,A,10116.0,CHEMBL622390,,,,,1,1
9203,50597,,BAO_0000218,,,Plasma concentration after oral aministration at 1 hr. (10 mg/kg),,,N,Intermediate,A,10116.0,CHEMBL622391,,,,,1,1
9204,50597,,BAO_0000218,,,Plasma concentration after oral aministration at 2 hr. (10 mg/kg),,,N,Intermediate,A,10116.0,CHEMBL622392,,,,,1,1
9205,50597,,BAO_0000218,,,Plasma concentration after oral aministration at 4 hr. (10 mg/kg),,,N,Intermediate,A,10116.0,CHEMBL622393,,,,,1,1
9206,50597,,BAO_0000218,,,Plasma level at 2 hr after administration of the compound,,,N,Intermediate,A,10116.0,CHEMBL622394,,,,,1,1
9207,50597,,BAO_0000218,,,plasma level at 2 hr after administration of the compound,,,N,Intermediate,A,10116.0,CHEMBL622395,,,,,1,1
9208,50597,,BAO_0000218,,,Stability in rat serum measured as % recovery at 1 min,,,N,Intermediate,A,10116.0,CHEMBL622396,,1977.0,Serum,,1,1
9209,50597,,BAO_0000218,,,Stability in rat serum measured as % recovery at 10 min,,,N,Intermediate,A,10116.0,CHEMBL624894,,1977.0,Serum,,1,1
9210,50597,,BAO_0000218,,,Stability in rat serum measured as % recovery at 10 mins,,,N,Intermediate,A,10116.0,CHEMBL624895,,1977.0,Serum,,1,1
9211,50597,,BAO_0000218,,,Stability in rat serum measured as % recovery at 2 hr,,,N,Intermediate,A,10116.0,CHEMBL624058,,1977.0,Serum,,1,1
9212,50597,,BAO_0000218,,,Stability in rat serum measured as % recovery at 3 min,,,N,Intermediate,A,10116.0,CHEMBL624059,,1977.0,Serum,,1,1
9213,50597,,BAO_0000218,,,Stability in rat serum measured as % recovery at 3 mins,,,N,Intermediate,A,10116.0,CHEMBL624060,,1977.0,Serum,,1,1
9214,50597,,BAO_0000218,,,Stability in rat serum measured as % recovery at 5 min,,,N,Intermediate,A,10116.0,CHEMBL624061,,1977.0,Serum,,1,1
9215,50597,,BAO_0000218,,,Stability in rat serum measured as % recovery at 5 mins,,,N,Intermediate,A,10116.0,CHEMBL624062,,1977.0,Serum,,1,1
9216,50597,In vivo,BAO_0000218,,,Alpha-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL624063,,,,,1,1
9217,50597,In vivo,BAO_0000218,,,Beta-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL624064,,,,,1,1
9218,50597,,BAO_0000218,,,Half life in plasma was determined against ovariectomized rats; t 1/2 (h) is short in plasma,,,N,Intermediate,A,10116.0,CHEMBL624065,,1969.0,Plasma,,1,1
9219,50597,,BAO_0000218,,,Half life in plasma was determined against ovariectomized rats; t1/2 is longer in plasma.,,,N,Intermediate,A,10116.0,CHEMBL624066,,1969.0,Plasma,,1,1
9220,50597,In vivo,BAO_0000218,,,Half life tested in mature male rat at a dose of 30 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL877490,,,,,1,1
9221,50597,In vivo,BAO_0000218,,,Half life after intravenous administration of 1 mg/kg in rat,,,N,Intermediate,A,10116.0,CHEMBL874442,,,,,1,1
9222,50597,In vivo,BAO_0000218,,,Half life period after administration (30 mg/kg) in rat,,,N,Intermediate,A,10116.0,CHEMBL626890,,,,,1,1
9223,50597,In vivo,BAO_0000218,,,Half life period in rat after 5 mg/Kg dose,,,N,Intermediate,A,10116.0,CHEMBL626891,,,,,1,1
9224,50597,In vivo,BAO_0000218,,,Half life period in rat after 5 mg/kg dose,,,N,Intermediate,A,10116.0,CHEMBL626892,,,,,1,1
9225,50597,,BAO_0000218,,,Half life period was determined,,,N,Intermediate,A,10116.0,CHEMBL626893,,,,,1,1
9226,50597,,BAO_0000218,,,Half life period was evaluated in rat,,,N,Intermediate,A,10116.0,CHEMBL626894,,,,,1,1
9227,50597,,BAO_0000218,,,Half life period was evaluated in rat; 0.5-1.0,,,N,Intermediate,A,10116.0,CHEMBL626895,,,,,1,1
9228,50597,,BAO_0000218,,,Half life period was evaluated in rat; 5.9-7.5,,,N,Intermediate,A,10116.0,CHEMBL626896,,,,,1,1
9229,50597,,BAO_0000218,,,Half-life in rat plasma,,,N,Intermediate,A,10116.0,CHEMBL626897,,1969.0,Plasma,,1,1
9230,50597,,BAO_0000218,,,Half-life time in rat was determined,,,N,Intermediate,A,10116.0,CHEMBL626898,,,,,1,1
9231,50597,In vivo,BAO_0000218,,,Terminal half-life after iv administration to rats,,,N,Intermediate,A,10116.0,CHEMBL626899,,,,,1,1
9232,50597,In vivo,BAO_0000218,,,Tested for iv terminal half-life dosed as a solution in male Han Wistar rats,,,N,Intermediate,A,10116.0,CHEMBL626900,,,,,1,1
9233,50597,,BAO_0000218,,,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL626901,,,,,1,1
9234,50597,In vivo,BAO_0000218,,,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg (iv),,,N,Intermediate,A,10116.0,CHEMBL626902,,,,,1,1
9235,50597,In vivo,BAO_0000218,,,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 5 umol/kg (iv),,,N,Intermediate,A,10116.0,CHEMBL626903,,,,,1,1
9236,50597,In vivo,BAO_0000218,,,Time for peak concentration (tmax) at a dose of 10 mg/kg in rats,,,N,Intermediate,A,10116.0,CHEMBL874443,,,,,1,1
9237,50597,In vivo,BAO_0000218,,,Time for peak concentration (tmax) at a dose of 20 mg/kg in rats,,,N,Intermediate,A,10116.0,CHEMBL626904,,,,,1,1
9238,50597,,BAO_0000218,,,Half life in rats,,,N,Intermediate,A,10116.0,CHEMBL626905,,,,,1,1
9239,50597,In vivo,BAO_0000218,,,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 4 mg/kg to rat,,,N,Intermediate,A,10116.0,CHEMBL873830,,1969.0,Plasma,,1,1
9240,50597,In vivo,BAO_0000218,,,Apparent half-life after single intravenous bolus of 1 mg/kg in rats,,,N,Intermediate,A,10116.0,CHEMBL626906,,,,,1,1
9241,50597,In vivo,BAO_0000218,,,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,,,N,Intermediate,A,10116.0,CHEMBL631076,,1969.0,Plasma,,1,1
9242,50597,,BAO_0000218,,,Biological half-life was measured in plasma of rats,,,N,Intermediate,A,10116.0,CHEMBL631077,,1969.0,Plasma,,1,1
9243,50597,In vivo,BAO_0000218,,,Circulatory half life measured after intravenous bolus administration of 50 mg/kg of compound to rats,,,N,Intermediate,A,10116.0,CHEMBL631078,,,,,1,1
9244,50597,In vivo,BAO_0000218,,,Compound demonstarted an oral bioavailability of 6% with the half-life time as given in rats.,,,N,Intermediate,A,10116.0,CHEMBL631079,,,,,1,1
9245,50597,In vivo,BAO_0000218,,,Compound was evaluated for half life (t1/2) upon intravenous administration of 1 mg/Kg in rats,,,N,Intermediate,A,10116.0,CHEMBL631080,,,,,1,1
9246,50597,In vivo,BAO_0000218,,,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to female wistar rats,,,N,Intermediate,A,10116.0,CHEMBL631081,,,,,1,1
9247,50597,In vivo,BAO_0000218,,,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to male wistar rats,,,N,Intermediate,A,10116.0,CHEMBL631239,,,,,1,1
9248,50597,,BAO_0000218,,,Compound was evaluated for plasma half life in rat,,,N,Intermediate,A,10116.0,CHEMBL631240,,1969.0,Plasma,,1,1
9249,50597,,BAO_0000218,,,AUC value at a dose of 5 mg/kg (p.o.) in rats,,,N,Intermediate,A,10116.0,CHEMBL631241,,1969.0,Plasma,,1,1
9250,50597,,BAO_0000218,,,AUC value after administration of 20 mg/Kg oral dose in rat,,,N,Intermediate,A,10116.0,CHEMBL631242,,1969.0,Plasma,,1,1
9251,50597,,BAO_0000218,,,AUC0-24 after repeated oral dose of compound at 1 mg/kg in rats,,,N,Intermediate,A,10116.0,CHEMBL631243,,1969.0,Plasma,,1,1
9252,50597,,BAO_0000218,,,AUC0-96 after administration at 50 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL874444,,1969.0,Plasma,,1,1
9253,50597,,BAO_0000218,,,AUC0-infinity after single intravenous bolus of 1 mg/kg in rats,,,N,Intermediate,A,10116.0,CHEMBL631244,,1969.0,Plasma,,1,1
9254,50597,,BAO_0000218,,,"Absorption behavior was judged by the area under the curve, determined after oral dose of 30 mg/kg in rats.",,,N,Intermediate,A,10116.0,CHEMBL631245,,,,,1,1
9255,50597,,BAO_0000218,,,Area under curve (0-24 hr) at a dose of 10 mg/kg in male SD rats,,,N,Intermediate,A,10116.0,CHEMBL627162,,,,,1,1
9256,50597,,BAO_0000218,,,Area under curve (0-24 hr) at a dose of 100 mg/kg in male SD rats,,,N,Intermediate,A,10116.0,CHEMBL627163,,,,,1,1
9257,50597,,BAO_0000218,,,Area under curve (0-24 hr) at a dose of 50 mg/kg in male SD rats,,,N,Intermediate,A,10116.0,CHEMBL627164,,,,,1,1
9258,50597,,BAO_0000218,,,Area under curve (AUC) at a dose 1 mg/kg was determined in rat kidney,,,N,Intermediate,A,10116.0,CHEMBL627165,,2113.0,Kidney,,1,1
9259,50597,,BAO_0000218,,,Area under curve (AUC) at a dose 1 mg/kg was determined in rat liver,,,N,Intermediate,A,10116.0,CHEMBL627166,,,,,1,1
9260,50597,,BAO_0000218,,,Area under curve (AUC) at a dose 1 mg/kg was determined in rat lung,,,N,Intermediate,A,10116.0,CHEMBL627167,,,,,1,1
9261,50597,,BAO_0000218,,,Area under curve (AUC) at a dose of 30 mg/kg in rats,,,N,Intermediate,A,10116.0,CHEMBL627822,,,,,1,1
9262,50597,,BAO_0000218,,,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats,,,N,Intermediate,A,10116.0,CHEMBL627823,,,,,1,1
9263,50597,,BAO_0000218,,,Area under curve (AUC) was calculated using trapezoidal rule. at a dose of 10 mg/kg in rats,,,N,Intermediate,A,10116.0,CHEMBL627824,,,,,1,1
9264,50597,,BAO_0000218,,,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats,,,N,Intermediate,A,10116.0,CHEMBL627825,,,,,1,1
9265,50597,,BAO_0000218,,,Area under curve (AUC0-24 h) after administration (30 mg/kg) in rat,,,N,Intermediate,A,10116.0,CHEMBL627826,,,,,1,1
9266,50597,,BAO_0000218,,,Area under curve (Pharmacokinetic property) was determined,,,N,Intermediate,A,10116.0,CHEMBL627827,,,,,1,1
9267,50597,,BAO_0000218,,,Area under curve (Pharmacokinetic property) of the compound; Not determined,,,N,Intermediate,A,10116.0,CHEMBL627828,,,,,1,1
9268,50597,,BAO_0000218,,,Area under curve after intravenous administration (1 mg/kg) in rat,,,N,Intermediate,A,10116.0,CHEMBL627829,,,,,1,1
9269,50597,,BAO_0000218,,,Area under curve by intravenous administration at a dose of 10 uM/kg in rat was determined,,,N,Intermediate,A,10116.0,CHEMBL627830,,,,,1,1
9270,50597,,BAO_0000218,,,Area under curve by oral administration at a dose of 100 uM/kg in rat was determined,,,N,Intermediate,A,10116.0,CHEMBL627831,,,,,1,1
9271,50597,,BAO_0000218,,,Area under curve in male SD rats was observed after oral administration in rat,,,N,Intermediate,A,10116.0,CHEMBL627832,,,,,1,1
9272,50597,,BAO_0000218,,,Area under curve of compound after iv administration of 20 mg/kg dose in rat,,,N,Intermediate,A,10116.0,CHEMBL627833,,,,,1,1
9273,50597,,BAO_0000218,,,Area under curve of compound determined in rat after iv administration at a dose of 10 mg/kg,,,N,Expert,A,10116.0,CHEMBL627834,,,,,1,1
9274,50597,,BAO_0000218,,,Area under curve of compound from zero time to infinity determined in rat after iv administration at a dose of 10 mg/kg,,,N,Expert,A,10116.0,CHEMBL628004,,,,,1,1
9275,50597,,BAO_0000218,,,Area under curve at 5 mg/kg po was determined in rat,,,N,Intermediate,A,10116.0,CHEMBL628005,,,,,1,1
9276,50597,,BAO_0000218,,,Area under curve in Rat at a oral dose of 5 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL628006,,,,,1,1
9277,50597,,BAO_0000218,,,Area under curve in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,,,N,Intermediate,A,10116.0,CHEMBL628007,,,,,1,1
9278,50597,,BAO_0000218,,,Area under curve was determined,,,N,Intermediate,A,10116.0,CHEMBL625676,,,,,1,1
9279,50597,,BAO_0000218,,,Area under curve after 10 mg/kg oral administration in rat at 0-24 hr,,,N,Intermediate,A,10116.0,CHEMBL631309,,,,,1,1
9280,50597,,BAO_0000218,,,Area under curve after intravenous administration at 3 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL631310,,,,,1,1
9281,50597,,BAO_0000218,,,Area under curve after peroral administration at 10 mg/kg in rat for 0-6 h,,,N,Intermediate,A,10116.0,CHEMBL631311,,,,,1,1
9282,50597,,BAO_0000218,,,Area under curve at 4 hr in rat,,,N,Intermediate,A,10116.0,CHEMBL631312,,,,,1,1
9283,50597,,BAO_0000218,,,Area under curve at a dose of 30 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL631313,,,,,1,1
9284,50597,,BAO_0000218,,,Area under curve at the dose of 2 mg/Kg administered perorally in rats,,,N,Intermediate,A,10116.0,CHEMBL631314,,,,,1,1
9285,50597,,BAO_0000218,,,Area under curve at the dose of 5 mg/Kg administered perorally in rats,,,N,Intermediate,A,10116.0,CHEMBL631315,,,,,1,1
9286,50597,,BAO_0000218,,,Area under curve for a 2-mpk po dose in SD rats,,,N,Intermediate,A,10116.0,CHEMBL631316,,,,,1,1
9287,50597,,BAO_0000218,,,Area under curve in SD rats,,,N,Intermediate,A,10116.0,CHEMBL631317,,,,,1,1
9288,50597,,BAO_0000218,,,Area under curve in rat after oral administration at 13 mg/kg dose,,,N,Intermediate,A,10116.0,CHEMBL874471,,,,,1,1
9289,50597,,BAO_0000218,,,Area under curve in rat by po administration at 0-24 hr,,,N,Intermediate,A,10116.0,CHEMBL631318,,,,,1,1
9290,50597,,BAO_0000218,,,Area under curve in rat plasma,,,N,Intermediate,A,10116.0,CHEMBL631319,,1969.0,Plasma,,1,1
9291,50597,,BAO_0000218,,,Area under curve in rat plasma for 0-4 hr after peroral administration at 10 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL631320,,,,,1,1
9292,50597,,BAO_0000218,,,Area under curve in rat plasma for 0-4 hr after peroral administration at 5 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL631321,,,,,1,1
9293,50597,,BAO_0000218,,,Area under curve was evaluated in rat at 3 mg/kg dose administered intravenously,,,N,Intermediate,A,10116.0,CHEMBL631322,,,,,1,1
9294,50597,,BAO_0000218,,,Area under curve was measured from the graph obtained from concentration Vs time after oral administration to male F344 rats,,,N,Intermediate,A,10116.0,CHEMBL631323,,,,,1,1
9295,50597,,BAO_0000218,,,Area under curve value in rat at a dose of 5 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL631324,,,,,1,1
9296,50597,,BAO_0000218,,,Area under curve was determined after oral administration in rats,,,N,Intermediate,A,10116.0,CHEMBL631325,,,,,1,1
9297,50597,,BAO_0000218,,,Area under curve was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,,,N,Intermediate,A,10116.0,CHEMBL631326,,,,,1,1
9298,50597,,BAO_0000218,,,Area under curve was determined after peroral administration in rat,,,N,Intermediate,A,10116.0,CHEMBL631327,,,,,1,1
9299,50597,,BAO_0000218,,,Area under curve was determined at a dose 30 mpk administered orally.,,,N,Intermediate,A,10116.0,CHEMBL631328,,,,,1,1
9300,50597,,BAO_0000218,,,Area under curve was determined for compound after intravenous administration in rats at 24 uM/kg,,,N,Intermediate,A,10116.0,CHEMBL631329,,,,,1,1
9301,50597,,BAO_0000218,,,Area under curve was determined for the compound by intravenous administration of 3.4 mg/kg in rat,,,N,Intermediate,A,10116.0,CHEMBL627217,,,,,1,1
9302,50597,,BAO_0000218,,,Area under curve was determined in male rat,,,N,Intermediate,A,10116.0,CHEMBL626352,,,,,1,1
9303,50597,,BAO_0000218,,,Area under curve was determined in rat after PO administration,,,N,Intermediate,A,10116.0,CHEMBL626353,,,,,1,1
9304,50597,,BAO_0000218,,,Area under curve was determined in rat after a 3 mg/kg of oral dose,,,N,Intermediate,A,10116.0,CHEMBL626354,,,,,1,1
9305,50597,,BAO_0000218,,,Area under curve was determined in rat after oral administration at a concentration 1 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL626355,,,,,1,1
9306,50597,,BAO_0000218,,,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL626356,,,,,1,1
9307,50597,,BAO_0000218,,,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg; NA= Not active,,,N,Intermediate,A,10116.0,CHEMBL626357,,,,,1,1
9308,50597,,BAO_0000218,,,Liver concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL626358,,,,,1,1
9309,50597,,BAO_0000218,,,Lung concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL626359,,,,,1,1
9310,50597,,BAO_0000218,,,Peak plasma concentration in rat at a dose of 3 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL626360,,1969.0,Plasma,,1,1
9311,50597,,BAO_0000218,,,Plasma concentration at 2 hr in rats was evaluated.,,,N,Intermediate,A,10116.0,CHEMBL626361,,,,,1,1
9312,50597,,BAO_0000218,,,Plasma concentration at 2 hr in rats was evaluated; Not available,,,N,Intermediate,A,10116.0,CHEMBL626362,,,,,1,1
9313,50597,,BAO_0000218,,,Serum concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL626363,,,,,1,1
9314,50597,,BAO_0000218,,,Tested for concentration in brain after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,,,N,Intermediate,A,10116.0,CHEMBL626970,,,,,1,1
9315,50597,,BAO_0000218,,,Tested for concentration in brain after 2 hrs of intravenous administration (5 mg/kg) to male rats,,,N,Intermediate,A,10116.0,CHEMBL626971,,,,,1,1
9316,50597,,BAO_0000218,,,Tested for plasma concentration after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,,,N,Intermediate,A,10116.0,CHEMBL626972,,1969.0,Plasma,,1,1
9317,50597,,BAO_0000218,,,Tested for plasma concentration after 2 hrs of intravenous administration (5 mg/kg) to male rats,,,N,Intermediate,A,10116.0,CHEMBL626973,,1969.0,Plasma,,1,1
9318,50597,,BAO_0000218,,,Tested for plasma concentration in the after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,,,N,Intermediate,A,10116.0,CHEMBL626974,,1969.0,Plasma,,1,1
9319,50597,,BAO_0000218,,,Tested for plasma concentration in the after 2 hrs of intravenous administration (5 mg/kg) to male rats,,,N,Intermediate,A,10116.0,CHEMBL874592,,1969.0,Plasma,,1,1
9320,50597,,BAO_0000218,,,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C,,,N,Intermediate,A,10116.0,CHEMBL626975,,,,,1,1
9321,50597,,BAO_0000218,,,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Converted to an unknown compound,,,N,Intermediate,A,10116.0,CHEMBL626976,,,,,1,1
9322,50597,,BAO_0000218,,,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not determined,,,N,Intermediate,A,10116.0,CHEMBL626977,,,,,1,1
9323,50597,,BAO_0000218,,,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not tested,,,N,Intermediate,A,10116.0,CHEMBL626978,,,,,1,1
9324,50597,,BAO_0000218,,,PK study was carried to determine the relative absorption ranking in rat.,,,N,Intermediate,A,10116.0,CHEMBL626979,,,,,1,1
9325,50597,In vivo,BAO_0000218,,,Maximum plasma concentration in Rat at a oral dose of 5 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL626980,,1969.0,Plasma,,1,1
9326,50597,,BAO_0000218,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.57-0.75 % dose/g",,,N,Intermediate,A,10116.0,CHEMBL626981,,178.0,Blood,,1,1
9327,50597,,BAO_0000218,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.63 % dose/g",,,N,Intermediate,A,10116.0,CHEMBL626982,,178.0,Blood,,1,1
9328,50597,,BAO_0000218,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.40-0.55 % dose/g",,,N,Intermediate,A,10116.0,CHEMBL626983,,178.0,Blood,,1,1
9329,50597,,BAO_0000218,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.28-0.37% dose/g",,,N,Intermediate,A,10116.0,CHEMBL622522,,178.0,Blood,,1,1
9330,50597,,BAO_0000218,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.56-0.74 % dose/g",,,N,Intermediate,A,10116.0,CHEMBL622523,,178.0,Blood,,1,1
9331,50597,,BAO_0000218,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from % dose/g",,,N,Intermediate,A,10116.0,CHEMBL622524,,178.0,Blood,,1,1
9332,50597,,BAO_0000218,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.20-2.85 % dose/g",,,N,Intermediate,A,10116.0,CHEMBL622525,,955.0,Brain,,1,1
9333,50597,,BAO_0000218,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.16-1.76 % dose/g",,,N,Intermediate,A,10116.0,CHEMBL622526,,955.0,Brain,,1,1
9334,50597,,BAO_0000218,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.96-3.72 % dose/g",,,N,Intermediate,A,10116.0,CHEMBL619849,,955.0,Brain,,1,1
9335,50597,,BAO_0000218,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.57-3.59 % dose/g",,,N,Intermediate,A,10116.0,CHEMBL619850,,955.0,Brain,,1,1
9336,50597,,BAO_0000218,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.36-1.53 % dose/g",,,N,Intermediate,A,10116.0,CHEMBL623864,,955.0,Brain,,1,1
9337,50597,,BAO_0000218,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.81-1.08 % dose/g",,,N,Intermediate,A,10116.0,CHEMBL623865,,955.0,Brain,,1,1
9338,50597,,BAO_0000218,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.84-0.98 % dose/g",,,N,Intermediate,A,10116.0,CHEMBL623866,,948.0,Heart,,1,1
9339,50597,,BAO_0000218,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.53 % dose/g",,,N,Intermediate,A,10116.0,CHEMBL623867,,948.0,Heart,,1,1
9340,50597,,BAO_0000218,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.22-1.48 % dose/g",,,N,Intermediate,A,10116.0,CHEMBL877615,,948.0,Heart,,1,1
9341,50597,,BAO_0000218,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.85-1.13 % dose/g",,,N,Intermediate,A,10116.0,CHEMBL623868,,948.0,Heart,,1,1
9342,50597,,BAO_0000218,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.55-0.63 % dose/g",,,N,Intermediate,A,10116.0,CHEMBL623869,,948.0,Heart,,1,1
9343,50597,,BAO_0000218,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.33-0.42 % dose/g",,,N,Intermediate,A,10116.0,CHEMBL623870,,948.0,Heart,,1,1
9344,50597,,BAO_0000218,,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,,,N,Intermediate,A,10116.0,CHEMBL623871,,2048.0,Lung,,1,1
9345,50597,,BAO_0000218,,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,,N,Intermediate,A,10116.0,CHEMBL623872,,2048.0,Lung,,1,1
9346,50597,,BAO_0000218,,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,,N,Intermediate,A,10116.0,CHEMBL622129,,2048.0,Lung,,1,1
9347,50597,,BAO_0000218,,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,,N,Intermediate,A,10116.0,CHEMBL622130,,2048.0,Lung,,1,1
9348,50597,,BAO_0000218,,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,,N,Intermediate,A,10116.0,CHEMBL622131,,2048.0,Lung,,1,1
9349,50597,,BAO_0000218,,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,,N,Intermediate,A,10116.0,CHEMBL622132,,2048.0,Lung,,1,1
9350,50597,,BAO_0000218,,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,,N,Intermediate,A,10116.0,CHEMBL622133,,2048.0,Lung,,1,1
9351,50597,,BAO_0000218,,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,,N,Intermediate,A,10116.0,CHEMBL622134,,2048.0,Lung,,1,1
9352,50597,,BAO_0000218,,,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,,N,Intermediate,A,10116.0,CHEMBL622135,,2048.0,Lung,,1,1
9353,50597,,BAO_0000218,,,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,,N,Intermediate,A,10116.0,CHEMBL622136,,2048.0,Lung,,1,1
9354,50597,,BAO_0000218,,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,,N,Intermediate,A,10116.0,CHEMBL622137,,2385.0,Muscle tissue,,1,1
9355,50597,,BAO_0000218,,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,,N,Intermediate,A,10116.0,CHEMBL622138,,2385.0,Muscle tissue,,1,1
9356,50597,,BAO_0000218,,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,,N,Intermediate,A,10116.0,CHEMBL623017,,2385.0,Muscle tissue,,1,1
9357,50597,,BAO_0000218,,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,,N,Intermediate,A,10116.0,CHEMBL623018,,2385.0,Muscle tissue,,1,1
9358,50597,,BAO_0000218,,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,,N,Intermediate,A,10116.0,CHEMBL623019,,2385.0,Muscle tissue,,1,1
9359,50597,,BAO_0000218,,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,,N,Intermediate,A,10116.0,CHEMBL623020,,2385.0,Muscle tissue,,1,1
9360,50597,,BAO_0000218,,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min.,,,N,Intermediate,A,10116.0,CHEMBL623021,,2385.0,Muscle tissue,,1,1
9361,50597,,BAO_0000218,,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,,,N,Intermediate,A,10116.0,CHEMBL623022,,2385.0,Muscle tissue,,1,1
9362,50597,,BAO_0000218,,,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,,N,Intermediate,A,10116.0,CHEMBL623023,,2385.0,Muscle tissue,,1,1
9363,50597,,BAO_0000218,,,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,,N,Intermediate,A,10116.0,CHEMBL623024,,2385.0,Muscle tissue,,1,1
9364,50597,,BAO_0000218,,,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,,N,Intermediate,A,10116.0,CHEMBL623025,,2385.0,Muscle tissue,,1,1
9365,50597,,BAO_0000218,,,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,,N,Intermediate,A,10116.0,CHEMBL620545,,2385.0,Muscle tissue,,1,1
9366,50597,,BAO_0000218,,,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,,N,Intermediate,A,10116.0,CHEMBL620546,,2385.0,Muscle tissue,,1,1
9367,50597,,BAO_0000218,,,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,,N,Intermediate,A,10116.0,CHEMBL620547,,2385.0,Muscle tissue,,1,1
9368,50597,,BAO_0000218,,,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,,N,Intermediate,A,10116.0,CHEMBL620548,,2385.0,Muscle tissue,,1,1
9369,50597,,BAO_0000218,,,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,,N,Intermediate,A,10116.0,CHEMBL620549,,2385.0,Muscle tissue,,1,1
9370,50597,,BAO_0000218,,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,,N,Intermediate,A,10116.0,CHEMBL620550,,2385.0,Muscle tissue,,1,1
9371,50597,,BAO_0000218,,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,,,N,Intermediate,A,10116.0,CHEMBL620551,,2385.0,Muscle tissue,,1,1
9372,50597,,BAO_0000218,,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,,N,Intermediate,A,10116.0,CHEMBL620552,,2385.0,Muscle tissue,,1,1
9373,50597,,BAO_0000218,,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,,N,Intermediate,A,10116.0,CHEMBL620553,,2385.0,Muscle tissue,,1,1
9374,50597,,BAO_0000218,,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,,N,Intermediate,A,10116.0,CHEMBL620554,,2385.0,Muscle tissue,,1,1
9375,50597,,BAO_0000218,,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,,N,Intermediate,A,10116.0,CHEMBL875845,,2385.0,Muscle tissue,,1,1
9376,50597,,BAO_0000218,,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,,N,Intermediate,A,10116.0,CHEMBL620555,,2385.0,Muscle tissue,,1,1
9377,50597,,BAO_0000218,,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,,N,Intermediate,A,10116.0,CHEMBL620556,,2385.0,Muscle tissue,,1,1
9378,50597,,BAO_0000218,,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,,N,Intermediate,A,10116.0,CHEMBL620557,,2385.0,Muscle tissue,,1,1
9379,50597,,BAO_0000218,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,,N,Intermediate,A,10116.0,CHEMBL620558,,,,,1,1
9380,50597,,BAO_0000218,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,,N,Intermediate,A,10116.0,CHEMBL620559,,,,,1,1
9381,50597,,BAO_0000218,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,,N,Intermediate,A,10116.0,CHEMBL622939,,,,,1,1
9382,50597,,BAO_0000218,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,,N,Intermediate,A,10116.0,CHEMBL622940,,,,,1,1
9383,50597,,BAO_0000218,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,,N,Intermediate,A,10116.0,CHEMBL622941,,,,,1,1
9384,50597,,BAO_0000218,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,,N,Intermediate,A,10116.0,CHEMBL622942,,,,,1,1
9385,50597,,BAO_0000218,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,,N,Intermediate,A,10116.0,CHEMBL622943,,,,,1,1
9386,50597,,BAO_0000218,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,,N,Intermediate,A,10116.0,CHEMBL622944,,,,,1,1
9387,50597,,BAO_0000218,,,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,,N,Intermediate,A,10116.0,CHEMBL622945,,,,,1,1
9388,50597,,BAO_0000218,,,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,,N,Intermediate,A,10116.0,CHEMBL622946,,,,,1,1
9389,50597,,BAO_0000218,,,Compound was evaluated for terminal half life in rat,,,N,Intermediate,A,10116.0,CHEMBL622947,,,,,1,1
9390,50597,In vivo,BAO_0000218,,,Compound was evaluated in vivo in rat for the plasma half-life at a iv dose of 3 mg/kg and oral dose of 10 mg/kg and experiment by using concentration vs time curve,,,N,Intermediate,A,10116.0,CHEMBL622948,,1969.0,Plasma,,1,1
9391,50597,In vivo,BAO_0000218,,,Compound was evaluated in vivo in rat for the plasma half-life at a oral dose of 20 mg/kg experiment by using concentration vs time curve,,,N,Intermediate,A,10116.0,CHEMBL622949,,1969.0,Plasma,,1,1
9392,50597,,BAO_0000218,,,Compound was tested for its half life in rat,,,N,Intermediate,A,10116.0,CHEMBL622950,,,,,1,1
9393,22224,In vivo,BAO_0000218,,,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,,,U,Intermediate,A,9544.0,CHEMBL622951,,1969.0,Plasma,,0,1
9394,22224,,BAO_0000366,,,Compound was tested for its plasma half life in Sprague Dawley rats,,,U,Intermediate,A,10116.0,CHEMBL622952,,1969.0,Plasma,,0,1
9395,22224,,BAO_0000366,,,Compound was tested for its plasma half life in Sprague Dawley rats; ND is not determined,,,U,Intermediate,A,10116.0,CHEMBL622953,,1969.0,Plasma,,0,1
9396,50597,,BAO_0000218,,,Compound was tested for plasma half-life period in rat,,,N,Intermediate,A,10116.0,CHEMBL873818,,1969.0,Plasma,,1,1
9397,50597,In vivo,BAO_0000218,,,Elimination half life after i.v. administration of compound in rats,,,N,Intermediate,A,10116.0,CHEMBL622954,,,,,1,1
9398,50597,In vivo,BAO_0000218,,,Elimination half-life after IV dosing at 0.5 mg/kg in rat,,,N,Intermediate,A,10116.0,CHEMBL622955,,,,,1,1
9399,50597,In vivo,BAO_0000218,,,Elimination half-life after IV dosing at 1 mg/kg in rat,,,N,Intermediate,A,10116.0,CHEMBL875229,,,,,1,1
9400,50597,In vivo,BAO_0000218,,,Elimination half-life after oral administration at a dose of 2 mg/kg in rat,,,N,Intermediate,A,10116.0,CHEMBL622956,,,,,1,1
9401,50597,In vivo,BAO_0000218,,,Elimination half-life after oral administration at a dose of 4 mg/kg in rat,,,N,Intermediate,A,10116.0,CHEMBL622957,,,,,1,1
9402,50597,In vivo,BAO_0000218,,,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined,,,N,Intermediate,A,10116.0,CHEMBL622958,,955.0,Brain,,1,1
9403,50597,In vivo,BAO_0000218,,,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma,,,N,Intermediate,A,10116.0,CHEMBL622959,,1969.0,Plasma,,1,1
9404,50597,In vivo,BAO_0000218,,,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain,,,N,Intermediate,A,10116.0,CHEMBL622960,,955.0,Brain,,1,1
9405,50597,In vivo,BAO_0000218,,,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma,,,N,Intermediate,A,10116.0,CHEMBL622961,,1969.0,Plasma,,1,1
9406,50597,In vivo,BAO_0000218,,,Evaluated for the half life in rat (in vivo),,,N,Intermediate,A,10116.0,CHEMBL622962,,,,,1,1
9407,50597,,BAO_0000218,,,Hafl life in rat,,,N,Intermediate,A,10116.0,CHEMBL622963,,,,,1,1
9408,50597,,BAO_0000218,,,Hafl life rat,,,N,Intermediate,A,10116.0,CHEMBL622964,,,,,1,1
9409,50597,,BAO_0000218,,,Hafl life rat,,,N,Intermediate,A,10116.0,CHEMBL622965,,,,,1,1
9410,50597,,BAO_0000218,,,Hafl life rat; Not determined,,,N,Intermediate,A,10116.0,CHEMBL622966,,,,,1,1
9411,50597,,BAO_0000218,,,Hafl life rat; Not determined,,,N,Intermediate,A,10116.0,CHEMBL622967,,,,,1,1
9412,50597,In vivo,BAO_0000218,,,Half life in kidney was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL622968,,2113.0,Kidney,,1,1
9413,50597,In vivo,BAO_0000218,,,Half life in liver was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL622969,,2107.0,Liver,,1,1
9414,50597,In vivo,BAO_0000218,,,Half life in lung was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL875327,,2048.0,Lung,,1,1
9415,50597,In vivo,BAO_0000218,,,Half life in rat after 1 mg/kg i.v. administration,,,N,Intermediate,A,10116.0,CHEMBL628638,,,,,1,1
9416,50597,In vivo,BAO_0000218,,,Half life in rat after 2 mg/kg peroral administration,,,N,Intermediate,A,10116.0,CHEMBL628639,,,,,1,1
9417,50597,In vivo,BAO_0000218,,,Half life in serum was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL625840,,,,,1,1
9418,50597,In vivo,BAO_0000218,,,Half life of 10 mg/kg oral dose determined in rats,,,N,Intermediate,A,10116.0,CHEMBL625841,,,,,1,1
9419,50597,In vivo,BAO_0000218,,,Half life of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,,,N,Intermediate,A,10116.0,CHEMBL625842,,,,,1,1
9420,50597,In vivo,BAO_0000218,,,Half life of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,,,N,Intermediate,A,10116.0,CHEMBL625843,,,,,1,1
9421,50597,In vivo,BAO_0000218,,,Half life of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,,,N,Intermediate,A,10116.0,CHEMBL625844,,,,,1,1
9422,50597,In vivo,BAO_0000218,,,Half life of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,,,N,Intermediate,A,10116.0,CHEMBL873822,,,,,1,1
9423,50597,In vivo,BAO_0000218,,,Half life of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,,,N,Intermediate,A,10116.0,CHEMBL625845,,,,,1,1
9424,50597,In vivo,BAO_0000218,,,Half life of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,,,N,Intermediate,A,10116.0,CHEMBL627059,,,,,1,1
9425,50597,In vivo,BAO_0000218,,,Half life of compound (9.84 mg/kg) after po administration was determined in Sprague-Dawley rat,,,N,Intermediate,A,10116.0,CHEMBL627060,,,,,1,1
9426,50597,In vivo,BAO_0000218,,,Half life of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat,,,N,Intermediate,A,10116.0,CHEMBL627061,,,,,1,1
9427,50597,In vivo,BAO_0000218,,,Half life of compound at 5 mg/kg after po administration was determined in rat,,,N,Intermediate,A,10116.0,CHEMBL627709,,,,,1,1
9428,50597,In vivo,BAO_0000218,,,Half life of compound determined after intravenous administration to rat,,,N,Intermediate,A,10116.0,CHEMBL627710,,,,,1,1
9429,50597,,BAO_0000218,,,Half life of compound was determined in rat,,,N,Intermediate,A,10116.0,CHEMBL627711,,,,,1,1
9430,50597,In vivo,BAO_0000218,,,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,,,N,Intermediate,A,10116.0,CHEMBL627712,,1969.0,Plasma,,1,1
9431,50597,In vivo,BAO_0000218,,,Half life determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,,N,Intermediate,A,10116.0,CHEMBL627713,,,,,1,1
9432,50597,In vivo,BAO_0000218,,,Half life determined after 3 mg/kg oral administration in potassium oxonate treated rats,,,N,Intermediate,A,10116.0,CHEMBL627714,,,,,1,1
9433,22224,In vivo,BAO_0000218,,,Half life determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,,,U,Intermediate,A,9541.0,CHEMBL627889,,,,,0,1
9434,22224,In vivo,BAO_0000218,,,Half life determined in rat by intravenous administration,,,U,Intermediate,A,10116.0,CHEMBL627890,,,,,0,1
9435,50597,In vivo,BAO_0000218,,,Half life determined in rats after iv administration,,,N,Intermediate,A,10116.0,CHEMBL627891,,,,,1,1
9436,50597,In vivo,BAO_0000218,,,Half life in rat plasma after administration of 2 mg/kg iv,,,N,Intermediate,A,10116.0,CHEMBL627892,,1969.0,Plasma,,1,1
9437,50597,In vivo,BAO_0000218,,,Half life in rat plasma after administration of 2 mg/kg iv,,,N,Intermediate,A,10116.0,CHEMBL627893,,1969.0,Plasma,,1,1
9438,50597,,BAO_0000218,,,Half life in rat plasma was determined,,,N,Intermediate,A,10116.0,CHEMBL627894,,1969.0,Plasma,,1,1
9439,50597,,BAO_0000218,,,Half life in rat plasma was determined; NA means not applicable,,,N,Intermediate,A,10116.0,CHEMBL627895,,1969.0,Plasma,,1,1
9440,50597,,BAO_0000218,,,Half life in rat was tested,,,N,Intermediate,A,10116.0,CHEMBL627896,,,,,1,1
9441,50597,,BAO_0000218,,,Half life measured in rat plasma,,,N,Intermediate,A,10116.0,CHEMBL627897,,1969.0,Plasma,,1,1
9442,50597,,BAO_0000218,,,Half life recorded in rats,,,N,Intermediate,A,10116.0,CHEMBL627898,,,,,1,1
9443,50597,,BAO_0000218,,,Half life was calculated,,,N,Intermediate,A,10116.0,CHEMBL627899,,,,,1,1
9444,50597,,BAO_0000218,,,Half life was calculated in rat,,,N,Intermediate,A,10116.0,CHEMBL873823,,,,,1,1
9445,50597,,BAO_0000218,,,Half life was determined,,,N,Intermediate,A,10116.0,CHEMBL627900,,,,,1,1
9446,50597,In vivo,BAO_0000218,,,Half life after 10 mg/kg oral administration in rat,,,N,Intermediate,A,10116.0,CHEMBL627901,,,,,1,1
9447,50597,In vivo,BAO_0000218,,,Half life after administering orally a dose of 10 mg/kg to a fasting rat,,,N,Intermediate,A,10116.0,CHEMBL627902,,,,,1,1
9448,50597,In vivo,BAO_0000218,,,Half life after administering orally a dose of 30 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL627903,,,,,1,1
9449,50597,,BAO_0000218,,,Area under the curve (Concentration) was determined for the compound as AUC with limits 0-8 after i.v. administration in rats,,,N,Intermediate,A,10116.0,CHEMBL627904,,,,,1,1
9450,50597,,BAO_0000218,,,Area under the curve determined under pharmacokinetic behavior of the 10 mg/kg oral dose of compound for 0-6 hours,,,N,Intermediate,A,10116.0,CHEMBL627905,,,,,1,1
9451,50597,,BAO_0000218,,,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in rat,,,N,Intermediate,A,10116.0,CHEMBL627906,,,,,1,1
9452,50597,,BAO_0000218,,,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in rat,,,N,Intermediate,A,10116.0,CHEMBL627907,,,,,1,1
9453,50597,,BAO_0000218,,,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL876783,,,,,1,1
9454,50597,,BAO_0000218,,,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg; activity was not determined,,,N,Intermediate,A,10116.0,CHEMBL627908,,,,,1,1
9455,50597,,BAO_0000218,,,Area under the curve measured after intravenous bolus administration of 50 mg/kg of compound to rats,,,N,Intermediate,A,10116.0,CHEMBL627909,,,,,1,1
9456,50597,,BAO_0000218,,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats,,,N,Intermediate,A,10116.0,CHEMBL627910,,,,,1,1
9457,50597,,BAO_0000218,,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-1),,,N,Intermediate,A,10116.0,CHEMBL627911,,,,,1,1
9458,50597,,BAO_0000218,,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-2),,,N,Intermediate,A,10116.0,CHEMBL627912,,,,,1,1
9459,50597,,BAO_0000218,,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-5),,,N,Intermediate,A,10116.0,CHEMBL627913,,,,,1,1
9460,50597,,BAO_0000218,,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(5-10),,,N,Intermediate,A,10116.0,CHEMBL627914,,,,,1,1
9461,50597,,BAO_0000218,,,Area under the curve was evaluated after 10 uM/kg of intra arterial administration,,,N,Intermediate,A,10116.0,CHEMBL627915,,,,,1,1
9462,50597,,BAO_0000218,,,Area under the curve was evaluated after 20 uM/kg of peroral administration,,,N,Intermediate,A,10116.0,CHEMBL627916,,,,,1,1
9463,50597,,BAO_0000218,,,Area under the curve was measured in rat after an iv dose of 1 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL627917,,,,,1,1
9464,50597,,BAO_0000218,,,Area under the curve was calculated for the compound at a single intravenous administration of 20 mg/kg in rat,,,N,Intermediate,A,10116.0,CHEMBL627918,,,,,1,1
9465,50597,,BAO_0000218,,,Area under the curve was determined by administering the compound at a dose of 1 mg/kg intravenously in male wistar rat,,,N,Intermediate,A,10116.0,CHEMBL627919,,,,,1,1
9466,50597,,BAO_0000218,,,Area under the curve was evaluated at an intravenous dose of 3 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL627920,,,,,1,1
9467,50597,,BAO_0000218,,,Area under the curve was evaluated at an oral dose of 30 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL627921,,,,,1,1
9468,50597,,BAO_0000218,,,Area under the effect time curves from time 0-24 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,,N,Intermediate,A,10116.0,CHEMBL627922,,,,,1,1
9469,50597,,BAO_0000218,,,Area under the effect time curves from time 0-24 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,,,N,Intermediate,A,10116.0,CHEMBL876784,,,,,1,1
9470,50597,,BAO_0000218,,,Area under the effect time curves from time 0-6 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,,N,Intermediate,A,10116.0,CHEMBL627923,,,,,1,1
9471,50597,,BAO_0000218,,,Area under the effect time curves from time 0-6 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,,,N,Intermediate,A,10116.0,CHEMBL626208,,,,,1,1
9472,50597,,BAO_0000218,,,Area under the effect time curves from time 0-infinity hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,,N,Intermediate,A,10116.0,CHEMBL626209,,,,,1,1
9473,50597,,BAO_0000218,,,Area under the effect time curves from time 0-infinity hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,,,N,Intermediate,A,10116.0,CHEMBL626210,,,,,1,1
9474,50597,,BAO_0000218,,,Area under the plasma concentration curve was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration,,,N,Intermediate,A,10116.0,CHEMBL627994,,1969.0,Plasma,,1,1
9475,50597,,BAO_0000218,,,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in rat,,,N,Intermediate,A,10116.0,CHEMBL627995,,,,,1,1
9476,50597,,BAO_0000218,,,Blood level after a 10 mg/kg oral dose in rat expressed as AUC was determined,,,N,Intermediate,A,10116.0,CHEMBL627996,,,,,1,1
9477,50597,,BAO_0000218,,,Compound at a dose 10 mg/kg was administered orally to rat and the pharmacokinetic parameter area under curve (AUC) was measured,,,N,Intermediate,A,10116.0,CHEMBL627997,,,,,1,1
9478,50597,,BAO_0000218,,,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female wistar rats,,,N,Intermediate,A,10116.0,CHEMBL627998,,,,,1,1
9479,50597,,BAO_0000218,,,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to male wistar rats,,,N,Intermediate,A,10116.0,CHEMBL628640,,,,,1,1
9480,50597,,BAO_0000218,,,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female wistar rats,,,N,Intermediate,A,10116.0,CHEMBL628641,,,,,1,1
9481,50597,,BAO_0000218,,,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to male wistar rats,,,N,Intermediate,A,10116.0,CHEMBL628642,,,,,1,1
9482,50597,,BAO_0000218,,,Compound was evaluated for area under the curve expressed as (h*ug/ml),,,N,Intermediate,A,10116.0,CHEMBL628643,,,,,1,1
9483,50597,,BAO_0000218,,,Compound was tested for area under curve in rat,,,N,Intermediate,A,10116.0,CHEMBL628644,,,,,1,1
9484,50597,,BAO_0000218,,,Concentration in rat plasma after 5 mg/kg oral gavage for 8 hours,,,N,Intermediate,A,10116.0,CHEMBL628645,,,,,1,1
9485,50597,,BAO_0000218,,,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats,,,N,Intermediate,A,10116.0,CHEMBL628646,,,,,1,1
9486,50597,,BAO_0000218,,,Dose-normalized AUC was determined in rat after peroral administration (2 mg/kg),,,N,Intermediate,A,10116.0,CHEMBL628647,,,,,1,1
9487,50597,,BAO_0000218,,,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined,,,N,Intermediate,A,10116.0,CHEMBL628648,,,,,1,1
9488,50597,,BAO_0000218,,,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma,,,N,Intermediate,A,10116.0,CHEMBL625358,,,,,1,1
9489,50597,,BAO_0000218,,,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain,,,N,Intermediate,A,10116.0,CHEMBL625359,,,,,1,1
9490,50597,,BAO_0000218,,,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma,,,N,Intermediate,A,10116.0,CHEMBL625360,,,,,1,1
9491,50597,,BAO_0000218,,,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg ( 0-8 hr ),,,N,Intermediate,A,10116.0,CHEMBL625361,,,,,1,1
9492,50597,,BAO_0000218,,,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr ),,,N,Intermediate,A,10116.0,CHEMBL625362,,,,,1,1
9493,50597,,BAO_0000218,,,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr),,,N,Intermediate,A,10116.0,CHEMBL625363,,,,,1,1
9494,50597,,BAO_0000218,,,Hepatic portal AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats,,,N,Intermediate,A,10116.0,CHEMBL625364,,,,,1,1
9495,50597,,BAO_0000218,,,In vivo Area under curve (AUC) was determined after intravenous administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,,N,Intermediate,A,10116.0,CHEMBL625365,,,,,1,1
9496,50597,,BAO_0000218,,,In vivo Area under curve (AUC) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,,N,Intermediate,A,10116.0,CHEMBL625366,,,,,1,1
9497,50597,,BAO_0000218,,,In vivo Area under curve (AUC) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,,,N,Intermediate,A,10116.0,CHEMBL625367,,,,,1,1
9498,50597,,BAO_0000218,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.98-2.56 % dose/g",,,N,Intermediate,A,10116.0,CHEMBL625368,,2113.0,Kidney,,1,1
9499,50597,,BAO_0000218,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.15-1.43 % dose/g",,,N,Intermediate,A,10116.0,CHEMBL625369,,2113.0,Kidney,,1,1
9500,50597,,BAO_0000218,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.43-4.52 % dose/g",,,N,Intermediate,A,10116.0,CHEMBL625370,,2113.0,Kidney,,1,1
9501,50597,,BAO_0000218,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.12-3.14 % dose/g",,,N,Intermediate,A,10116.0,CHEMBL625371,,2113.0,Kidney,,1,1
9502,50597,,BAO_0000218,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.40-1.60 % dose/g",,,N,Intermediate,A,10116.0,CHEMBL625372,,2113.0,Kidney,,1,1
9503,50597,,BAO_0000218,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.74-0.85 % dose/g",,,N,Intermediate,A,10116.0,CHEMBL625373,,2113.0,Kidney,,1,1
9504,50597,,BAO_0000218,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.31-1.45 % dose/g",,,N,Intermediate,A,10116.0,CHEMBL625374,,2107.0,Liver,,1,1
9505,50597,,BAO_0000218,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.90 % dose/g",,,N,Intermediate,A,10116.0,CHEMBL877593,,2107.0,Liver,,1,1
9506,50597,,BAO_0000218,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.02-2.78 % dose/g",,,N,Intermediate,A,10116.0,CHEMBL625375,,2107.0,Liver,,1,1
9507,50597,,BAO_0000218,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.64-2.38 % dose/g",,,N,Intermediate,A,10116.0,CHEMBL625376,,2107.0,Liver,,1,1
9508,50597,,BAO_0000218,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.95-1.07 % dose/g",,,N,Intermediate,A,10116.0,CHEMBL621973,,2107.0,Liver,,1,1
9509,50597,,BAO_0000218,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.61-0.81 % dose/g",,,N,Intermediate,A,10116.0,CHEMBL621974,,2107.0,Liver,,1,1
9510,50597,,BAO_0000218,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 5.01-7.13 % dose/g",,,N,Intermediate,A,10116.0,CHEMBL621975,,2048.0,Lung,,1,1
9511,50597,,BAO_0000218,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.51-3.71 % dose/g",,,N,Intermediate,A,10116.0,CHEMBL622166,,2048.0,Lung,,1,1
9512,50597,,BAO_0000218,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 10.84-13.77 % dose/g",,,N,Intermediate,A,10116.0,CHEMBL622167,,2048.0,Lung,,1,1
9513,50597,,BAO_0000218,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.92-8.51% dose/g",,,N,Intermediate,A,10116.0,CHEMBL622168,,2048.0,Lung,,1,1
9514,50597,,BAO_0000218,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.37-3.94 % dose/g",,,N,Intermediate,A,10116.0,CHEMBL622169,,2048.0,Lung,,1,1
9515,50597,,BAO_0000218,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.87-2.12 % dose/g",,,N,Intermediate,A,10116.0,CHEMBL622170,,2048.0,Lung,,1,1
9516,50597,,BAO_0000218,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 37.97-75.23 % dose/g",,,N,Intermediate,A,10116.0,CHEMBL622171,,2046.0,Thyroid gland,,1,1
9517,50597,,BAO_0000218,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.03-36.88 % dose/g",,,N,Intermediate,A,10116.0,CHEMBL622172,,2046.0,Thyroid gland,,1,1
9518,50597,,BAO_0000218,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 13.20-17.31 % dose/g",,,N,Intermediate,A,10116.0,CHEMBL622173,,2046.0,Thyroid gland,,1,1
9519,50597,,BAO_0000218,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 7.87-16.51 % dose/g",,,N,Intermediate,A,10116.0,CHEMBL622174,,2046.0,Thyroid gland,,1,1
9520,50597,,BAO_0000218,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 81.37-166.09 % dose/g",,,N,Intermediate,A,10116.0,CHEMBL622175,,2046.0,Thyroid gland,,1,1
9521,50597,,BAO_0000218,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 31.90-39.98 % dose/g",,,N,Intermediate,A,10116.0,CHEMBL622176,,2046.0,Thyroid gland,,1,1
9522,50597,,BAO_0000218,,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.41-0.83 % dose/g",,,N,Intermediate,A,10116.0,CHEMBL622177,,2046.0,Thyroid gland,,1,1
9523,50597,,BAO_0000218,,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.05-0.38 % dose/g",,,N,Intermediate,A,10116.0,CHEMBL622178,,2046.0,Thyroid gland,,1,1
9524,50597,,BAO_0000218,,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.16-0.20 % dose/g",,,N,Intermediate,A,10116.0,CHEMBL622179,,2046.0,Thyroid gland,,1,1
9525,50597,,BAO_0000218,,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.17 % dose/g",,,N,Intermediate,A,10116.0,CHEMBL622180,,2046.0,Thyroid gland,,1,1
9526,50597,,BAO_0000218,,,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,,N,Intermediate,A,10116.0,CHEMBL622181,,,,,1,1
9527,50597,,BAO_0000218,,,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,,N,Intermediate,A,10116.0,CHEMBL622182,,,,,1,1
9528,50597,,BAO_0000218,,,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,,N,Intermediate,A,10116.0,CHEMBL622183,,,,,1,1
9529,50597,,BAO_0000218,,,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,,N,Intermediate,A,10116.0,CHEMBL622184,,,,,1,1
9530,50597,,BAO_0000218,,,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,,N,Intermediate,A,10116.0,CHEMBL622185,,,,,1,1
9531,50597,,BAO_0000218,,,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,,N,Intermediate,A,10116.0,CHEMBL622186,,,,,1,1
9532,50597,,BAO_0000218,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,,N,Intermediate,A,10116.0,CHEMBL622187,,,,,1,1
9533,50597,,BAO_0000218,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,,,N,Intermediate,A,10116.0,CHEMBL625002,,,,,1,1
9534,50597,,BAO_0000218,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min,,,N,Intermediate,A,10116.0,CHEMBL622090,,,,,1,1
9535,50597,,BAO_0000218,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,,N,Intermediate,A,10116.0,CHEMBL622091,,,,,1,1
9536,50597,,BAO_0000218,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,,N,Intermediate,A,10116.0,CHEMBL622092,,,,,1,1
9537,50597,,BAO_0000218,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,,N,Intermediate,A,10116.0,CHEMBL622093,,,,,1,1
9538,50597,,BAO_0000218,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,,N,Intermediate,A,10116.0,CHEMBL622094,,,,,1,1
9539,50597,,BAO_0000218,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,,N,Intermediate,A,10116.0,CHEMBL622095,,,,,1,1
9540,50597,,BAO_0000218,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,,N,Intermediate,A,10116.0,CHEMBL622264,,,,,1,1
9541,50597,,BAO_0000218,,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,,N,Intermediate,A,10116.0,CHEMBL622265,,2106.0,Spleen,,1,1
9542,50597,,BAO_0000218,,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,,N,Intermediate,A,10116.0,CHEMBL622266,,2106.0,Spleen,,1,1
9543,50597,,BAO_0000218,,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,,N,Intermediate,A,10116.0,CHEMBL622267,,2106.0,Spleen,,1,1
9544,50597,,BAO_0000218,,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,,N,Intermediate,A,10116.0,CHEMBL622268,,2106.0,Spleen,,1,1
9545,50597,,BAO_0000218,,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,,N,Intermediate,A,10116.0,CHEMBL622269,,2106.0,Spleen,,1,1
9546,50597,,BAO_0000218,,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,,N,Intermediate,A,10116.0,CHEMBL625071,,2106.0,Spleen,,1,1
9547,50597,,BAO_0000218,,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,,N,Intermediate,A,10116.0,CHEMBL621621,,2106.0,Spleen,,1,1
9548,50597,,BAO_0000218,,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,,N,Intermediate,A,10116.0,CHEMBL621622,,2106.0,Spleen,,1,1
9549,50597,,BAO_0000218,,,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,,N,Intermediate,A,10116.0,CHEMBL621623,,2106.0,Spleen,,1,1
9550,50597,,BAO_0000218,,,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,,N,Intermediate,A,10116.0,CHEMBL621624,,2106.0,Spleen,,1,1
9551,50597,,BAO_0000218,,,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,,N,Intermediate,A,10116.0,CHEMBL621625,,2106.0,Spleen,,1,1
9552,50597,,BAO_0000218,,,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,,N,Intermediate,A,10116.0,CHEMBL621626,,2106.0,Spleen,,1,1
9553,50597,,BAO_0000218,,,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,,N,Intermediate,A,10116.0,CHEMBL621627,,2106.0,Spleen,,1,1
9554,50597,,BAO_0000218,,,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,,N,Intermediate,A,10116.0,CHEMBL621628,,2106.0,Spleen,,1,1
9555,50597,,BAO_0000218,,,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,,N,Intermediate,A,10116.0,CHEMBL875328,,2106.0,Spleen,,1,1
9556,50597,,BAO_0000218,,,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,,N,Intermediate,A,10116.0,CHEMBL621629,,2106.0,Spleen,,1,1
9557,50597,,BAO_0000218,,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,,N,Intermediate,A,10116.0,CHEMBL621630,,2106.0,Spleen,,1,1
9558,50597,,BAO_0000218,,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,,N,Intermediate,A,10116.0,CHEMBL621631,,2106.0,Spleen,,1,1
9559,50597,,BAO_0000218,,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,,N,Intermediate,A,10116.0,CHEMBL621632,,2106.0,Spleen,,1,1
9560,50597,,BAO_0000218,,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,,N,Intermediate,A,10116.0,CHEMBL621633,,2106.0,Spleen,,1,1
9561,50597,,BAO_0000218,,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,,N,Intermediate,A,10116.0,CHEMBL621634,,2106.0,Spleen,,1,1
9562,50597,,BAO_0000218,,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,,N,Intermediate,A,10116.0,CHEMBL621635,,2106.0,Spleen,,1,1
9563,50597,,BAO_0000218,,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,,N,Intermediate,A,10116.0,CHEMBL621636,,2106.0,Spleen,,1,1
9564,50597,,BAO_0000218,,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,,N,Intermediate,A,10116.0,CHEMBL621637,,2106.0,Spleen,,1,1
9565,50597,,BAO_0000218,,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,,N,Intermediate,A,10116.0,CHEMBL621638,,2106.0,Spleen,,1,1
9566,50597,,BAO_0000218,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,,N,Intermediate,A,10116.0,CHEMBL618883,,,,,1,1
9567,50597,,BAO_0000218,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,,N,Intermediate,A,10116.0,CHEMBL618884,,,,,1,1
9568,50597,,BAO_0000218,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,,N,Intermediate,A,10116.0,CHEMBL628627,,,,,1,1
9569,50597,,BAO_0000218,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,,N,Intermediate,A,10116.0,CHEMBL628628,,,,,1,1
9570,50597,,BAO_0000218,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,,N,Intermediate,A,10116.0,CHEMBL628629,,,,,1,1
9571,50597,In vivo,BAO_0000218,,,Half life after administering orally a dose of 3 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL628630,,,,,1,1
9572,50597,In vivo,BAO_0000218,,,Half life after administering orally a dose of 3 mg/kg to a fasting rat,,,N,Intermediate,A,10116.0,CHEMBL628631,,,,,1,1
9573,50597,In vivo,BAO_0000218,,,Half life after administering intravenously a dose of 1 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL628632,,,,,1,1
9574,50597,In vivo,BAO_0000218,,,Half life after oral dosing in rats,,,N,Intermediate,A,10116.0,CHEMBL628633,,,,,1,1
9575,50597,In vivo,BAO_0000218,,,Half life after the administered orally a dose of 1 mg/kg to a fasting rat,,,N,Intermediate,A,10116.0,CHEMBL628634,,,,,1,1
9576,50597,In vivo,BAO_0000218,,,Half life by intravenous administration of 3.4 mg/kg in rat,,,N,Intermediate,A,10116.0,CHEMBL627789,,,,,1,1
9577,50597,,BAO_0000218,,,Half life in rat,,,N,Intermediate,A,10116.0,CHEMBL627790,,,,,1,1
9578,50597,,BAO_0000218,,,Half life in rat,,,N,Intermediate,A,10116.0,CHEMBL627791,,,,,1,1
9579,50597,,BAO_0000218,,,Half life in rat,,,N,Intermediate,A,10116.0,CHEMBL627792,,,,,1,1
9580,50597,In vivo,BAO_0000218,,,Half life in rat after intravenous administration of the compound,,,N,Intermediate,A,10116.0,CHEMBL627793,,,,,1,1
9581,50597,In vivo,BAO_0000218,,,Half life in rat after intravenous administration of the compound; nf:unable to estimate plasma elimination half life,,,N,Intermediate,A,10116.0,CHEMBL627794,,1969.0,Plasma,,1,1
9582,50597,In vivo,BAO_0000218,,,Half life in rat after po administration of the compound,,,N,Intermediate,A,10116.0,CHEMBL627795,,,,,1,1
9583,50597,In vivo,BAO_0000218,,,Half life in rat after po administration of the compound; ND means Not determined,,,N,Intermediate,A,10116.0,CHEMBL627796,,,,,1,1
9584,50597,In vivo,BAO_0000218,,,Half life in rat after po administration of the compound; nf: unable to estimate plasma elimination half life,,,N,Intermediate,A,10116.0,CHEMBL875335,,1969.0,Plasma,,1,1
9585,50597,In vivo,BAO_0000218,,,Half life in rat after po administration of the compound; nf:unable to estimate plasma elimination half life,,,N,Intermediate,A,10116.0,CHEMBL627797,,1969.0,Plasma,,1,1
9586,50597,In vivo,BAO_0000218,,,Half life in rat i.v.,,,N,Intermediate,A,10116.0,CHEMBL627798,,,,,1,1
9587,50597,In vivo,BAO_0000218,,,Half life in rat i.v. at 2 mg/kg concentration,,,N,Intermediate,A,10116.0,CHEMBL627799,,,,,1,1
9588,50597,,BAO_0000218,,,Half life in rats,,,N,Intermediate,A,10116.0,CHEMBL627800,,,,,1,1
9589,50597,In vivo,BAO_0000218,,,Half life in rats after intravenous administration,,,N,Intermediate,A,10116.0,CHEMBL627801,,,,,1,1
9590,50597,In vivo,BAO_0000218,,,Half life in rats at the dose of 1.0 mpk by i.v. administration,,,N,Intermediate,A,10116.0,CHEMBL627802,,,,,1,1
9591,50597,,BAO_0000218,,,Half life in rat,,,N,Expert,A,10116.0,CHEMBL627803,,,,,1,1
9592,50597,In vivo,BAO_0000218,,,Half life was evaluated after intravenous administration to rats,,,N,Intermediate,A,10116.0,CHEMBL873820,,,,,1,1
9593,50597,,BAO_0000218,,,Half life was evaluated by addition of 2 mM of 2-mercaptoethanol for inactivation of semicarbazide-sensitive amine oxidase (SSAO),,,N,Intermediate,A,10116.0,CHEMBL627804,,,,,1,1
9594,50597,,BAO_0000218,,,Half life was evaluated in rat,,,N,Intermediate,A,10116.0,CHEMBL627805,,,,,1,1
9595,50597,,BAO_0000218,,,Half life was evaluated in rat,,,N,Intermediate,A,10116.0,CHEMBL627806,,,,,1,1
9596,50597,,BAO_0000218,,,Half life was evaluated in rat; Not tested,,,N,Intermediate,A,10116.0,CHEMBL627107,,,,,1,1
9597,50597,In vivo,BAO_0000218,,,Half life was evaluated when a dose of 1 mg/kg was administered intravenously to rats,,,N,Intermediate,A,10116.0,CHEMBL627108,,,,,1,1
9598,50597,In vivo,BAO_0000218,,,Half life was measured as time taken to reach the half of the initial dose in air pouch exudate after oral administration to male F344 rats,,,N,Intermediate,A,10116.0,CHEMBL627109,,,,,1,1
9599,50597,In vivo,BAO_0000218,,,Half life was measured as time taken to reach the half of the initial dose in the blood after oral administration to male F344 rats,,,N,Intermediate,A,10116.0,CHEMBL627110,,178.0,Blood,,1,1
9600,22224,In vivo,BAO_0000218,,,Half life was measured in monkey at dose of 10 mg/kg by po administration,,,U,Intermediate,A,9443.0,CHEMBL627111,,,,,0,1
9601,22224,In vivo,BAO_0000218,,,Half life was measured in monkey at dose of 10 mg/kg by po administration,,,U,Intermediate,A,9443.0,CHEMBL627112,,,,,0,1
9602,22224,In vivo,BAO_0000218,,,Half life was measured in rat at dose of 30 mg/kg by iv administration,,,U,Intermediate,A,10116.0,CHEMBL627113,,,,,0,1
9603,22224,In vivo,BAO_0000218,,,Half life was measured in rat at dose of 30 mg/kg by po administration,,,U,Intermediate,A,10116.0,CHEMBL627114,,,,,0,1
9604,50597,,BAO_0000218,,,Half life (t1/2) was determined,,,N,Intermediate,A,10116.0,CHEMBL627115,,,,,1,1
9605,50597,,BAO_0000218,,,Half life period at a dose of 10 uM/kg in rat was determined,,,N,Intermediate,A,10116.0,CHEMBL627116,,,,,1,1
9606,50597,In vivo,BAO_0000218,,,Half life period by oral administration at a dose of 100 uM/kg in rat was determined; ND is not determined,,,N,Intermediate,A,10116.0,CHEMBL627117,,,,,1,1
9607,50597,,BAO_0000218,,,Half life period was determined,,,N,Intermediate,A,10116.0,CHEMBL627118,,,,,1,1
9608,50597,In vivo,BAO_0000218,,,Half life period after intravenous administration at 20 mpk in rats,,,N,Intermediate,A,10116.0,CHEMBL627119,,,,,1,1
9609,50597,In vivo,BAO_0000218,,,Half life period after intravenous administration at 20 mpk in rats; Not performed.,,,N,Intermediate,A,10116.0,CHEMBL627120,,,,,1,1
9610,50597,In vivo,BAO_0000218,,,Half life period after intravenous administration in rat,,,N,Intermediate,A,10116.0,CHEMBL626922,,,,,1,1
9611,50597,In vivo,BAO_0000218,,,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,,,N,Intermediate,A,10116.0,CHEMBL626923,,,,,1,1
9612,50597,In vivo,BAO_0000218,,,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,,,N,Intermediate,A,10116.0,CHEMBL626924,,,,,1,1
9613,50597,,BAO_0000218,,,Half life period in 80% rat plasma at 37 degree Centigrade,,,N,Intermediate,A,10116.0,CHEMBL626925,,1969.0,Plasma,,1,1
9614,50597,,BAO_0000218,,,Half life period in SD rats,,,N,Intermediate,A,10116.0,CHEMBL626926,,,,,1,1
9615,50597,,BAO_0000218,,,Half life period in human plasma at 25 degree Celsius temperature (pH 7.4),,,N,Intermediate,A,10116.0,CHEMBL626927,,1969.0,Plasma,,1,1
9616,50597,,BAO_0000218,,,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4),,,N,Intermediate,A,10116.0,CHEMBL626928,,1969.0,Plasma,,1,1
9617,50597,,BAO_0000218,,,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,,,N,Intermediate,A,10116.0,CHEMBL626929,,1969.0,Plasma,,1,1
9618,50597,,BAO_0000218,,,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,,,N,Intermediate,A,10116.0,CHEMBL626930,,1969.0,Plasma,,1,1
9619,50597,,BAO_0000218,,,Half life period in rat,,,N,Intermediate,A,10116.0,CHEMBL626931,,,,,1,1
9620,50597,,BAO_0000218,,,Half life period in rat,,,N,Intermediate,A,10116.0,CHEMBL626932,,,,,1,1
9621,50597,,BAO_0000218,,,Half life period in rat,,,N,Intermediate,A,10116.0,CHEMBL626933,,,,,1,1
9622,50597,In vivo,BAO_0000218,,,Half life period in rat after oral administration at 10.5 mg/kg dose,,,N,Intermediate,A,10116.0,CHEMBL873826,,,,,1,1
9623,50597,In vivo,BAO_0000218,,,Half life period in rat after oral administration at 11.2 mg/kg dose,,,N,Intermediate,A,10116.0,CHEMBL626934,,,,,1,1
9624,50597,In vivo,BAO_0000218,,,Half life period in rat after oral administration at 13 mg/kg dose,,,N,Intermediate,A,10116.0,CHEMBL626935,,,,,1,1
9625,50597,In vivo,BAO_0000218,,,Half life period in rat after oral administration at 9.7 mg/kg dose,,,N,Intermediate,A,10116.0,CHEMBL626936,,,,,1,1
9626,50597,,BAO_0000218,,,In vivo Area under curve (AUC) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,,N,Intermediate,A,10116.0,CHEMBL626937,,,,,1,1
9627,50597,,BAO_0000218,,,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL625906,,,,,1,1
9628,50597,,BAO_0000218,,,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL625907,,,,,1,1
9629,50597,,BAO_0000218,,,PK study was carried to determine AUC (area under curve) value in rat,,,N,Intermediate,A,10116.0,CHEMBL625908,,,,,1,1
9630,50597,,BAO_0000218,,,Pharmacokinetic parameter AUC after intravenous administration to rats,,,N,Intermediate,A,10116.0,CHEMBL625909,,,,,1,1
9631,50597,,BAO_0000218,,,Pharmacokinetic parameter AUC after oral administration to rats,,,N,Intermediate,A,10116.0,CHEMBL625910,,,,,1,1
9632,50597,,BAO_0000218,,,Pharmacokinetic parameter AUC was evaluated intravenous administration of 3 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL625911,,,,,1,1
9633,50597,,BAO_0000218,,,Pharmacokinetic parameter AUC was evaluated when a dose of 10 mg/kg is administered orally to a fasting rat,,,N,Intermediate,A,10116.0,CHEMBL625912,,,,,1,1
9634,50597,,BAO_0000218,,,Pharmacokinetic parameter AUC was evaluated when a dose of 1 mg/kg is administered orally to a fasting rat,,,N,Intermediate,A,10116.0,CHEMBL626538,,,,,1,1
9635,50597,,BAO_0000218,,,Pharmacokinetic parameter AUC was evaluated when a dose of 30 mg/kg is administered orally,,,N,Intermediate,A,10116.0,CHEMBL876794,,,,,1,1
9636,50597,,BAO_0000218,,,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally,,,N,Intermediate,A,10116.0,CHEMBL626539,,,,,1,1
9637,50597,,BAO_0000218,,,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally to a fasting rat,,,N,Intermediate,A,10116.0,CHEMBL626540,,,,,1,1
9638,50597,,BAO_0000218,,,Pharmacokinetic parameter area under curve (AUC) was measured after administration into monkey at 3 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL626541,,,,,1,1
9639,50597,,BAO_0000218,,,Pharmacokinetic parameter area under curve (AUC) was measured after administration into rat at 10 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL626542,,,,,1,1
9640,50597,,BAO_0000218,,,Pharmacokinetic parameter area under curve was determined at 10 mg/kg po dose in rats,,,N,Intermediate,A,10116.0,CHEMBL626543,,,,,1,1
9641,50597,,BAO_0000218,,,Pharmacokinetic parameter area under curve was determined at 2 mg/kg i.v. dose in rats,,,N,Intermediate,A,10116.0,CHEMBL626544,,,,,1,1
9642,50597,,BAO_0000218,,,Pharmacokinetic parameter area under curve was determined at 3 mg/kg po dose in rats,,,N,Intermediate,A,10116.0,CHEMBL626545,,,,,1,1
9643,50597,,BAO_0000218,,,Pharmacokinetic parameter area under curve was determined at 5 mg/kg i.v. dose in rats,,,N,Intermediate,A,10116.0,CHEMBL626546,,,,,1,1
9644,50597,,BAO_0000218,,,Pharmacokinetic parameter area under curve was reported,,,N,Intermediate,A,10116.0,CHEMBL626547,,,,,1,1
9645,50597,,BAO_0000218,,,Pharmacokinetic property (AUC) in rat,,,N,Intermediate,A,10116.0,CHEMBL626548,,,,,1,1
9646,50597,,BAO_0000218,,,Pharmacokinetic property (AUC) was measured in rat at the dose of 0.32 mg/kg p.o.,,,N,Intermediate,A,10116.0,CHEMBL626549,,,,,1,1
9647,50597,,BAO_0000218,,,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.,,,N,Intermediate,A,10116.0,CHEMBL626550,,,,,1,1
9648,50597,,BAO_0000218,,,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.; Not tested,,,N,Intermediate,A,10116.0,CHEMBL626551,,,,,1,1
9649,50597,,BAO_0000218,,,Pharmacokinetic property was determined,,,N,Intermediate,A,10116.0,CHEMBL623777,,,,,1,1
9650,50597,,BAO_0000218,,,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL623778,,,,,1,1
9651,50597,,BAO_0000218,,,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg; Not tested,,,N,Intermediate,A,10116.0,CHEMBL623779,,,,,1,1
9652,50597,,BAO_0000218,,,Pharmacokinetic property( plasma concentration) was determined upon 10 mg/kg in 1% methylcellulose peroral administration in rats,,,N,Intermediate,A,10116.0,CHEMBL623780,,1969.0,Plasma,,1,1
9653,50597,,BAO_0000218,,,Pharmacokinetic property( plasma concentration) was determined upon 2 mg/kg in 1% methylcellulose peroral administration in rats,,,N,Intermediate,A,10116.0,CHEMBL622015,,1969.0,Plasma,,1,1
9654,50597,,BAO_0000218,,,Pharmacokinetic property( plasma concentration) was determined upon 3 mg/kg in 1% methylcellulose peroral administration in rats,,,N,Intermediate,A,10116.0,CHEMBL622016,,1969.0,Plasma,,1,1
9655,50597,,BAO_0000218,,,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.25 h",,,N,Intermediate,A,10116.0,CHEMBL622017,,,,,1,1
9656,50597,,BAO_0000218,,,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.5 h",,,N,Intermediate,A,10116.0,CHEMBL622018,,,,,1,1
9657,50597,,BAO_0000218,,,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 1 h",,,N,Intermediate,A,10116.0,CHEMBL622019,,,,,1,1
9658,50597,,BAO_0000218,,,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 2 h",,,N,Intermediate,A,10116.0,CHEMBL622020,,,,,1,1
9659,50597,,BAO_0000218,,,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered intravenously,,,N,Intermediate,A,10116.0,CHEMBL622021,,,,,1,1
9660,50597,,BAO_0000218,,,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered orally,,,N,Intermediate,A,10116.0,CHEMBL622022,,,,,1,1
9661,50597,,BAO_0000218,,,Plasma concentration expressed as area under curve after intravenous administration was determined in rat,,,N,Intermediate,A,10116.0,CHEMBL622023,,,,,1,1
9662,50597,,BAO_0000218,,,Plasma concentration for the compound was determined in rats at 50 mg/kg dose,,,N,Intermediate,A,10116.0,CHEMBL622024,,,,,1,1
9663,50597,,BAO_0000218,,,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of solution (formulation of compound),,,N,Intermediate,A,10116.0,CHEMBL622693,,,,,1,1
9664,50597,,BAO_0000218,,,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of suspension (formulation of compound),,,N,Intermediate,A,10116.0,CHEMBL622694,,,,,1,1
9665,50597,,BAO_0000218,,,"Plasma concentration was determined in rats at 10 mg/kg, p.o. dose",,,N,Intermediate,A,10116.0,CHEMBL622695,,,,,1,1
9666,50597,,BAO_0000218,,,"Plasma concentration was determined in rats at 20 mg/kg, i.p. dose",,,N,Intermediate,A,10116.0,CHEMBL622696,,,,,1,1
9667,50597,,BAO_0000218,,,"Plasma concentration was determined in rats at 2 mg/kg, i.v. dose",,,N,Intermediate,A,10116.0,CHEMBL622697,,,,,1,1
9668,50597,,BAO_0000218,,,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (20 mg/kg, 30 min pre-treatment)",,,N,Intermediate,A,10116.0,CHEMBL622874,,,,,1,1
9669,50597,,BAO_0000218,,,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (30 mg/kg, 30 min pre-treatment)",,,N,Intermediate,A,10116.0,CHEMBL622875,,,,,1,1
9670,50597,,BAO_0000218,,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg; Not significant,,,N,Intermediate,A,10116.0,CHEMBL622876,,,,,1,1
9671,50597,,BAO_0000218,,,Systemic AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats,,,N,Intermediate,A,10116.0,CHEMBL622877,,,,,1,1
9672,50597,,BAO_0000218,,,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats,,,N,Intermediate,A,10116.0,CHEMBL622878,,,,,1,1
9673,50597,,BAO_0000218,,,Tested for plasma concentration after intravenous administration (4.7 mg/kg) to male rats,,,N,Intermediate,A,10116.0,CHEMBL622879,,1969.0,Plasma,,1,1
9674,50597,,BAO_0000218,,,Tested for the pharmacokinetic parameter in rat and expressed as area under curve,,,N,Intermediate,A,10116.0,CHEMBL877602,,,,,1,1
9675,50597,,BAO_0000218,,,"The AUC(0-infinitive) value in female wistar rat at 100 mg/kg, p.o. dose",,,N,Intermediate,A,10116.0,CHEMBL622880,,,,,1,1
9676,50597,,BAO_0000218,,,"The AUC(0-infinitive) value in male wistar rat at 100 mg/kg, p.o. dose",,,N,Intermediate,A,10116.0,CHEMBL622881,,,,,1,1
9677,50597,,BAO_0000218,,,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose",,,N,Intermediate,A,10116.0,CHEMBL622882,,,,,1,1
9678,50597,,BAO_0000218,,,"The AUC(0-t)value in male wistar rat at 100 mg/kg, p.o. dose",,,N,Intermediate,A,10116.0,CHEMBL622883,,,,,1,1
9679,50597,,BAO_0000218,,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.16-2.39% dose/g",,,N,Intermediate,A,10116.0,CHEMBL622884,,2046.0,Thyroid gland,,1,1
9680,50597,,BAO_0000218,,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.99-1.40 % dose/g",,,N,Intermediate,A,10116.0,CHEMBL622885,,2046.0,Thyroid gland,,1,1
9681,50597,,BAO_0000218,,,Antidiuretic activity expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,,,N,Intermediate,A,10116.0,CHEMBL622886,,,,,1,1
9682,50597,,BAO_0000218,,,Antidiuretic activity expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,,,N,Intermediate,A,10116.0,CHEMBL622887,,,,,1,1
9683,50597,,BAO_0000218,,,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,,,N,Intermediate,A,10116.0,CHEMBL622888,,1088.0,Urine,,1,1
9684,50597,In vivo,BAO_0000218,,,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,,N,Intermediate,A,10116.0,CHEMBL622889,,178.0,Blood,,1,1
9685,50597,In vivo,BAO_0000218,,,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,,N,Intermediate,A,10116.0,CHEMBL622890,,178.0,Blood,,1,1
9686,50597,In vivo,BAO_0000218,,,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,,N,Intermediate,A,10116.0,CHEMBL622891,,178.0,Blood,,1,1
9687,50597,In vivo,BAO_0000218,,,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,,N,Intermediate,A,10116.0,CHEMBL877603,,178.0,Blood,,1,1
9688,50597,In vivo,BAO_0000218,,,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,,N,Intermediate,A,10116.0,CHEMBL622892,,955.0,Brain,,1,1
9689,50597,In vivo,BAO_0000218,,,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,,N,Intermediate,A,10116.0,CHEMBL622893,,955.0,Brain,,1,1
9690,50597,In vivo,BAO_0000218,,,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,,N,Intermediate,A,10116.0,CHEMBL622894,,955.0,Brain,,1,1
9691,50597,In vivo,BAO_0000218,,,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,,N,Intermediate,A,10116.0,CHEMBL622895,,955.0,Brain,,1,1
9692,50597,In vivo,BAO_0000218,,,Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration.,,,N,Intermediate,A,10116.0,CHEMBL622896,,955.0,Brain,,1,1
9693,50597,In vivo,BAO_0000218,,,"Biodistribution in Sprague-Dawley rat heart 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,,N,Intermediate,A,10116.0,CHEMBL622897,,948.0,Heart,,1,1
9694,50597,In vivo,BAO_0000218,,,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,,N,Intermediate,A,10116.0,CHEMBL622898,,948.0,Heart,,1,1
9695,50597,In vivo,BAO_0000218,,,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,,N,Intermediate,A,10116.0,CHEMBL622899,,948.0,Heart,,1,1
9696,50597,In vivo,BAO_0000218,,,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,,N,Intermediate,A,10116.0,CHEMBL622900,,2113.0,Kidney,,1,1
9697,50597,In vivo,BAO_0000218,,,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,,N,Intermediate,A,10116.0,CHEMBL624114,,2113.0,Kidney,,1,1
9698,50597,In vivo,BAO_0000218,,,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,,N,Intermediate,A,10116.0,CHEMBL624115,,2113.0,Kidney,,1,1
9699,50597,In vivo,BAO_0000218,,,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,,N,Intermediate,A,10116.0,CHEMBL624116,,2113.0,Kidney,,1,1
9700,50597,In vivo,BAO_0000218,,,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,,N,Intermediate,A,10116.0,CHEMBL624117,,2107.0,Liver,,1,1
9701,50597,In vivo,BAO_0000218,,,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,,N,Intermediate,A,10116.0,CHEMBL624118,,2107.0,Liver,,1,1
9702,50597,In vivo,BAO_0000218,,,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,,N,Intermediate,A,10116.0,CHEMBL624119,,2107.0,Liver,,1,1
9703,50597,In vivo,BAO_0000218,,,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,,N,Intermediate,A,10116.0,CHEMBL624120,,2107.0,Liver,,1,1
9704,50597,In vivo,BAO_0000218,,,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,,N,Intermediate,A,10116.0,CHEMBL624121,,2048.0,Lung,,1,1
9705,50597,In vivo,BAO_0000218,,,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,,N,Intermediate,A,10116.0,CHEMBL624122,,2048.0,Lung,,1,1
9706,50597,In vivo,BAO_0000218,,,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,,N,Intermediate,A,10116.0,CHEMBL624123,,2048.0,Lung,,1,1
9707,50597,In vivo,BAO_0000218,,,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,,N,Intermediate,A,10116.0,CHEMBL624124,,2048.0,Lung,,1,1
9708,50597,In vivo,BAO_0000218,,,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,,N,Intermediate,A,10116.0,CHEMBL624125,,2385.0,Muscle tissue,,1,1
9709,50597,In vivo,BAO_0000218,,,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,,N,Intermediate,A,10116.0,CHEMBL624126,,2385.0,Muscle tissue,,1,1
9710,50597,In vivo,BAO_0000218,,,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,,N,Intermediate,A,10116.0,CHEMBL624127,,2385.0,Muscle tissue,,1,1
9711,50597,In vivo,BAO_0000218,,,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,,N,Intermediate,A,10116.0,CHEMBL624128,,2385.0,Muscle tissue,,1,1
9712,50597,In vivo,BAO_0000218,,,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,,N,Intermediate,A,10116.0,CHEMBL624129,,14.0,Zone of skin,,1,1
9713,50597,In vivo,BAO_0000218,,,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,,N,Intermediate,A,10116.0,CHEMBL624130,,14.0,Zone of skin,,1,1
9714,50597,In vivo,BAO_0000218,,,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,,N,Intermediate,A,10116.0,CHEMBL622340,,14.0,Zone of skin,,1,1
9715,50597,In vivo,BAO_0000218,,,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,,N,Intermediate,A,10116.0,CHEMBL622341,,14.0,Zone of skin,,1,1
9716,50597,In vivo,BAO_0000218,,,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,,N,Intermediate,A,10116.0,CHEMBL622342,,160.0,Intestine,,1,1
9717,50597,In vivo,BAO_0000218,,,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,,N,Intermediate,A,10116.0,CHEMBL622343,,160.0,Intestine,,1,1
9718,50597,In vivo,BAO_0000218,,,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,,N,Intermediate,A,10116.0,CHEMBL622344,,160.0,Intestine,,1,1
9719,50597,In vivo,BAO_0000218,,,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,,N,Intermediate,A,10116.0,CHEMBL622345,,160.0,Intestine,,1,1
9720,50597,In vivo,BAO_0000218,,,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,,N,Intermediate,A,10116.0,CHEMBL622346,,2106.0,Spleen,,1,1
9721,50597,In vivo,BAO_0000218,,,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,,N,Intermediate,A,10116.0,CHEMBL622347,,2106.0,Spleen,,1,1
9722,50597,In vivo,BAO_0000218,,,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,,N,Intermediate,A,10116.0,CHEMBL622348,,2106.0,Spleen,,1,1
9723,50597,In vivo,BAO_0000218,,,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,,N,Intermediate,A,10116.0,CHEMBL622349,,2106.0,Spleen,,1,1
9724,50597,,BAO_0000218,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,,N,Intermediate,A,10116.0,CHEMBL622350,,,,,1,1
9725,50597,,BAO_0000218,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,,N,Intermediate,A,10116.0,CHEMBL622351,,,,,1,1
9726,50597,,BAO_0000218,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,,N,Intermediate,A,10116.0,CHEMBL622352,,,,,1,1
9727,50597,,BAO_0000218,,,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,,N,Intermediate,A,10116.0,CHEMBL622353,,,,,1,1
9728,50597,,BAO_0000218,,,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,,N,Intermediate,A,10116.0,CHEMBL622354,,,,,1,1
9729,50597,,BAO_0000218,,,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,,N,Intermediate,A,10116.0,CHEMBL622355,,,,,1,1
9730,50597,,BAO_0000218,,,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,,N,Intermediate,A,10116.0,CHEMBL622356,,,,,1,1
9731,50597,,BAO_0000218,,,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,,N,Intermediate,A,10116.0,CHEMBL622357,,,,,1,1
9732,50597,,BAO_0000218,,,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,,N,Intermediate,A,10116.0,CHEMBL622358,,,,,1,1
9733,50597,,BAO_0000218,,,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,,N,Intermediate,A,10116.0,CHEMBL622359,,,,,1,1
9734,50597,,BAO_0000218,,,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,,N,Intermediate,A,10116.0,CHEMBL874393,,,,,1,1
9735,50597,,BAO_0000218,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,,N,Intermediate,A,10116.0,CHEMBL622872,,,,,1,1
9736,50597,,BAO_0000218,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,,N,Intermediate,A,10116.0,CHEMBL622873,,,,,1,1
9737,50597,,BAO_0000218,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,,N,Intermediate,A,10116.0,CHEMBL623047,,,,,1,1
9738,50597,,BAO_0000218,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,,N,Intermediate,A,10116.0,CHEMBL623048,,,,,1,1
9739,50597,,BAO_0000218,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,,N,Intermediate,A,10116.0,CHEMBL623049,,,,,1,1
9740,50597,,BAO_0000218,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,,N,Intermediate,A,10116.0,CHEMBL623050,,,,,1,1
9741,50597,,BAO_0000218,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,,N,Intermediate,A,10116.0,CHEMBL623051,,,,,1,1
9742,50597,,BAO_0000218,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,,N,Intermediate,A,10116.0,CHEMBL623052,,,,,1,1
9743,50597,,BAO_0000218,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,,N,Intermediate,A,10116.0,CHEMBL626343,,,,,1,1
9744,50597,,BAO_0000218,,,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,,N,Intermediate,A,10116.0,CHEMBL626344,,,,,1,1
9745,50597,,BAO_0000218,,,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,,N,Intermediate,A,10116.0,CHEMBL626345,,,,,1,1
9746,50597,,BAO_0000218,,,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,,N,Intermediate,A,10116.0,CHEMBL626346,,,,,1,1
9747,50597,,BAO_0000218,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,,N,Intermediate,A,10116.0,CHEMBL626347,,,,,1,1
9748,50597,,BAO_0000218,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,,N,Intermediate,A,10116.0,CHEMBL626348,,,,,1,1
9749,50597,,BAO_0000218,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,,N,Intermediate,A,10116.0,CHEMBL626349,,,,,1,1
9750,50597,,BAO_0000218,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,,N,Intermediate,F,10116.0,CHEMBL626350,,,,,1,1
9751,50597,,BAO_0000218,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,,N,Intermediate,A,10116.0,CHEMBL626351,,,,,1,1
9752,50597,,BAO_0000218,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,,N,Intermediate,A,10116.0,CHEMBL627650,,,,,1,1
9753,50597,,BAO_0000218,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,,N,Intermediate,F,10116.0,CHEMBL627651,,,,,1,1
9754,50597,,BAO_0000218,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,,N,Intermediate,A,10116.0,CHEMBL627652,,,,,1,1
9755,50597,,BAO_0000218,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,,N,Intermediate,A,10116.0,CHEMBL627653,,,,,1,1
9756,50597,,BAO_0000218,,,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr blocked time interval,,,N,Intermediate,A,10116.0,CHEMBL627654,,,,,1,1
9757,50597,,BAO_0000218,,,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr low time interval,,,N,Intermediate,A,10116.0,CHEMBL627835,,,,,1,1
9758,50597,,BAO_0000218,,,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr time interval,,,N,Intermediate,A,10116.0,CHEMBL627836,,,,,1,1
9759,50597,,BAO_0000218,,,Tissue biodistribution into estrogen-primed immature female rat blood at 3 hr time interval,,,N,Intermediate,A,10116.0,CHEMBL627837,,,,,1,1
9760,50597,,BAO_0000218,,,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr blocked time interval,,,N,Intermediate,A,10116.0,CHEMBL627838,,,,,1,1
9761,50597,,BAO_0000218,,,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr low time interval,,,N,Intermediate,A,10116.0,CHEMBL875338,,,,,1,1
9762,50597,,BAO_0000218,,,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr time interval,,,N,Intermediate,A,10116.0,CHEMBL627839,,,,,1,1
9763,50597,,BAO_0000218,,,Tissue biodistribution into estrogen-primed immature female rat bone at 3 hr time interval,,,N,Intermediate,A,10116.0,CHEMBL627840,,,,,1,1
9764,50597,,BAO_0000218,,,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr blocked time interval,,,N,Intermediate,A,10116.0,CHEMBL627841,,,,,1,1
9765,50597,,BAO_0000218,,,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr low time interval,,,N,Intermediate,A,10116.0,CHEMBL627842,,,,,1,1
9766,50597,,BAO_0000218,,,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr time interval,,,N,Intermediate,A,10116.0,CHEMBL627843,,,,,1,1
9767,50597,,BAO_0000218,,,Tissue biodistribution into estrogen-primed immature female rat brain at 3 hr time interval,,,N,Intermediate,A,10116.0,CHEMBL627844,,,,,1,1
9768,50597,,BAO_0000218,,,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr blocked time interval,,,N,Intermediate,A,10116.0,CHEMBL627845,,,,,1,1
9769,50597,In vivo,BAO_0000218,,,Half life period in rat by iv administration at a dose of 3 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL627846,,,,,1,1
9770,50597,,BAO_0000218,,,Half life period in rat plasma at 25 degree Centigrade temperature (pH 7.4),,,N,Intermediate,A,10116.0,CHEMBL627847,,1969.0,Plasma,,1,1
9771,50597,,BAO_0000218,,,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4),,,N,Intermediate,A,10116.0,CHEMBL873821,,1969.0,Plasma,,1,1
9772,50597,,BAO_0000218,,,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,,,N,Intermediate,A,10116.0,CHEMBL626079,,1969.0,Plasma,,1,1
9773,50597,,BAO_0000218,,,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,,,N,Intermediate,A,10116.0,CHEMBL626080,,1969.0,Plasma,,1,1
9774,50597,,BAO_0000218,,,Half life period was evaluated in rat plasma,,,N,Intermediate,A,10116.0,CHEMBL626081,,1969.0,Plasma,,1,1
9775,50597,,BAO_0000218,,,Half life period was evaluated in rat plasma; Not tested,,,N,Intermediate,A,10116.0,CHEMBL875344,,1969.0,Plasma,,1,1
9776,50597,,BAO_0000218,,,Half life period was evaluated in rats,,,N,Intermediate,A,10116.0,CHEMBL626082,,,,,1,1
9777,50597,In vivo,BAO_0000218,,,"Half life period was evaluated in rats, iv",,,N,Intermediate,A,10116.0,CHEMBL626250,,,,,1,1
9778,50597,In vivo,BAO_0000218,,,Half life period after intravenous administration at 5 mg/kg in rat,,,N,Intermediate,A,10116.0,CHEMBL626251,,,,,1,1
9779,50597,In vivo,BAO_0000218,,,Half life period was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,,,N,Intermediate,A,10116.0,CHEMBL626252,,,,,1,1
9780,50597,In vivo,BAO_0000218,,,Half life period was determined in rat after iv administration at a dose of 5 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL626253,,,,,1,1
9781,50597,,BAO_0000218,,,Half life stability of compound was evaluated in rat plasma,,,N,Intermediate,A,10116.0,CHEMBL626254,,1969.0,Plasma,,1,1
9782,50597,In vivo,BAO_0000218,,,Half life time after intravenous administration (5.0 mg/kg) was determined in rat,,,N,Intermediate,A,10116.0,CHEMBL626255,,,,,1,1
9783,50597,In vivo,BAO_0000218,,,Half life time was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats,,,N,Intermediate,A,10116.0,CHEMBL626256,,,,,1,1
9784,50597,In vivo,BAO_0000218,,,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,,,N,Intermediate,A,10116.0,CHEMBL626257,,,,,1,1
9785,50597,In vivo,BAO_0000218,,,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat; NC means not calculated,,,N,Intermediate,A,10116.0,CHEMBL626258,,,,,1,1
9786,50597,In vivo,BAO_0000218,,,Half life was measured in fasted male administration of compound 0.5 mg/Kg i.v.,,,N,Intermediate,A,10116.0,CHEMBL626259,,,,,1,1
9787,50597,In vivo,BAO_0000218,,,Half in rat i.v.,,,N,Intermediate,A,10116.0,CHEMBL626260,,,,,1,1
9788,50597,In vivo,BAO_0000218,,,Half period in rat after intravenous administration,,,N,Intermediate,A,10116.0,CHEMBL875345,,,,,1,1
9789,50597,In vivo,BAO_0000218,,,Half-life after repeated oral dose of compound at 1 mg/kg in rats,,,N,Intermediate,A,10116.0,CHEMBL626261,,,,,1,1
9790,50597,In vitro,BAO_0000218,,,Half-life measured in in vitro Cathepsin B assay in rat liver,,,N,Intermediate,A,10116.0,CHEMBL626262,,2107.0,Liver,,1,1
9791,50597,,BAO_0000218,,,Half-life of compound was determined in rats,,,N,Intermediate,A,10116.0,CHEMBL626263,,,,,1,1
9792,50597,In vivo,BAO_0000218,,,Half-life at 10 mg/kg in rat upon intravenous administration,,,N,Intermediate,A,10116.0,CHEMBL625270,,,,,1,1
9793,50597,,BAO_0000218,,,Half-life determined in rat,,,N,Intermediate,A,10116.0,CHEMBL625271,,,,,1,1
9794,50597,,BAO_0000218,,,Half-life determined in rat,,,N,Intermediate,A,10116.0,CHEMBL625272,,,,,1,1
9795,50597,In vivo,BAO_0000218,,,Half-life in brain after intravenous administration (4.7 mg/kg) to male rats,,,N,Intermediate,A,10116.0,CHEMBL625273,,955.0,Brain,,1,1
9796,50597,,BAO_0000218,,,"Half-life in chemical and enzymatic hydrolysis, in 80% rat plasma",,,N,Intermediate,A,10116.0,CHEMBL625274,,1969.0,Plasma,,1,1
9797,50597,In vivo,BAO_0000218,,,Half-life in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL625275,,,,,1,1
9798,50597,In vivo,BAO_0000218,,,Half-life in plasma after intravenous administration (4.7 mg/kg) to male rats,,,N,Intermediate,A,10116.0,CHEMBL625276,,1969.0,Plasma,,1,1
9799,50597,,BAO_0000218,,,Half-life in rat plasma,,,N,Intermediate,A,10116.0,CHEMBL625277,,1969.0,Plasma,,1,1
9800,50597,,BAO_0000218,,,Half-life in rat plasma was determined,,,N,Intermediate,A,10116.0,CHEMBL625278,,1969.0,Plasma,,1,1
9801,50597,,BAO_0000218,,,Half-life in rat plasma; Not tested,,,N,Intermediate,A,10116.0,CHEMBL625279,,1969.0,Plasma,,1,1
9802,50597,,BAO_0000218,,,Half-life in rat serum,,,N,Intermediate,A,10116.0,CHEMBL625280,,1977.0,Serum,,1,1
9803,50597,,BAO_0000218,,,Half-life in rat serum; na is not available,,,N,Intermediate,A,10116.0,CHEMBL876797,,1977.0,Serum,,1,1
9804,50597,,BAO_0000218,,,Half-life was calculated in rat,,,N,Intermediate,A,10116.0,CHEMBL625281,,,,,1,1
9805,50597,,BAO_0000218,,,Half-life was calculated in rat plasma,,,N,Intermediate,A,10116.0,CHEMBL873827,,1969.0,Plasma,,1,1
9806,50597,,BAO_0000218,,,Half-life was determined,,,N,Intermediate,A,10116.0,CHEMBL625282,,,,,1,1
9807,50597,,BAO_0000218,,,Half-life was determined,,,N,Intermediate,A,10116.0,CHEMBL625283,,,,,1,1
9808,50597,In vivo,BAO_0000218,,,Half-life after administration of 20 mg/Kg oral dose in rat,,,N,Intermediate,A,10116.0,CHEMBL625284,,,,,1,1
9809,50597,In vivo,BAO_0000218,,,Half-life after administration of 3.2 mg/kg intravenously in male rat,,,N,Intermediate,A,10116.0,CHEMBL625285,,,,,1,1
9810,50597,In vivo,BAO_0000218,,,Half-life after intravenous administration in female rat,,,N,Intermediate,A,10116.0,CHEMBL625286,,,,,1,1
9811,50597,In vivo,BAO_0000218,,,Half-life after intravenous administration in male rat,,,N,Intermediate,A,10116.0,CHEMBL625287,,,,,1,1
9812,50597,In vivo,BAO_0000218,,,Half-life after intravenous dose in rat,,,N,Intermediate,A,10116.0,CHEMBL625288,,,,,1,1
9813,50597,,BAO_0000218,,,Half-life in a rat liver homogenate preparation,,,N,Intermediate,A,10116.0,CHEMBL625289,,2107.0,Liver,,1,1
9814,50597,,BAO_0000218,,,Half-life in plasma of rat,,,N,Intermediate,A,10116.0,CHEMBL625290,,1969.0,Plasma,,1,1
9815,50597,,BAO_0000218,,,Half-life in plasma of rat at dose of 3-10 mgkg,,,N,Intermediate,A,10116.0,CHEMBL876798,,1969.0,Plasma,,1,1
9816,50597,,BAO_0000218,,,Half-life in rat,,,N,Intermediate,A,10116.0,CHEMBL625291,,,,,1,1
9817,50597,,BAO_0000218,,,Half-life in rat,,,N,Intermediate,A,10116.0,CHEMBL625292,,,,,1,1
9818,50597,,BAO_0000218,,,Half-life in rat,,,N,Intermediate,A,10116.0,CHEMBL625293,,,,,1,1
9819,50597,,BAO_0000218,,,Half-life in rat,,,N,Intermediate,A,10116.0,CHEMBL622832,,,,,1,1
9820,50597,,BAO_0000218,,,Half-life in rat,,,N,Intermediate,A,10116.0,CHEMBL622833,,,,,1,1
9821,50597,,BAO_0000218,,,Half-life in rat,,,N,Intermediate,A,10116.0,CHEMBL622834,,,,,1,1
9822,50597,In vivo,BAO_0000218,,,Half-life in rat after oral administration at 10 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL622835,,,,,1,1
9823,50597,In vivo,BAO_0000218,,,Half-life in rat after po administration at a dose of 10 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL622836,,,,,1,1
9824,50597,In vivo,BAO_0000218,,,Half-life in rat after po administration at a dose of 10 mg/kg; nd is not determined,,,N,Intermediate,A,10116.0,CHEMBL622837,,,,,1,1
9825,50597,In vivo,BAO_0000218,,,Half-life in rat at 3 mg/kg dose administered intravenously,,,N,Intermediate,A,10116.0,CHEMBL622838,,,,,1,1
9826,50597,,BAO_0000218,,,Half-life in rat brain homogenate,,,N,Intermediate,A,10116.0,CHEMBL622839,,955.0,Brain,,1,1
9827,50597,,BAO_0000218,,,Half-life in rat plasma,,,N,Intermediate,A,10116.0,CHEMBL622840,,1969.0,Plasma,,1,1
9828,50597,,BAO_0000218,,,Half-life in rats,,,N,Intermediate,A,10116.0,CHEMBL622841,,,,,1,1
9829,50597,,BAO_0000218,,,Half-life in Dawley rats,,,N,Intermediate,A,10116.0,CHEMBL622842,,,,,1,1
9830,50597,In vitro,BAO_0000218,,,Half-life in vitro in rat plasma,,,N,Intermediate,A,10116.0,CHEMBL622843,,1969.0,Plasma,,1,1
9831,50597,In vitro,BAO_0000218,,,Half-life in vitro in rat plasma; No detectable degradation over 2 hr; no detectable degradation over 2 hours,,,N,Intermediate,A,10116.0,CHEMBL622844,,1969.0,Plasma,,1,1
9832,50597,,BAO_0000218,,,"The area under concentration-time curve(AUC) was determined at 20 mg/kg of compound dose, administered intravenously in rat",,,N,Intermediate,A,10116.0,CHEMBL622845,,,,,1,1
9833,50597,,BAO_0000218,,,The area under the curve of compound was measured at the dose of 100 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL622846,,,,,1,1
9834,50597,,BAO_0000218,,,The area under the curve of compound was measured at the dose of 300 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL622847,,,,,1,1
9835,50597,,BAO_0000218,,,The area under the curve of compound was measured at the dose of 30 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL622848,,,,,1,1
9836,50597,In vivo,BAO_0000218,,,Bioavailability as oral AUC in rats,,,N,Intermediate,A,10116.0,CHEMBL622849,,,,,1,1
9837,50597,,BAO_0000218,,,The plasma concentration versus time curve (AUC) was determined,,,N,Intermediate,A,10116.0,CHEMBL622850,,1969.0,Plasma,,1,1
9838,50597,,BAO_0000218,,,Total concentration in kidney was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL876807,,,,,1,1
9839,50597,,BAO_0000218,,,Total concentration in liver was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL622851,,,,,1,1
9840,50597,,BAO_0000218,,,Total concentration in lung was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL622852,,,,,1,1
9841,50597,,BAO_0000218,,,Total concentration in rat after 1 mg/kg i.v. administration in 24 hours,,,N,Intermediate,A,10116.0,CHEMBL622853,,,,,1,1
9842,50597,,BAO_0000218,,,Total concentration in rat after 2 mg/kg peroral administration in 24 hours,,,N,Intermediate,A,10116.0,CHEMBL622854,,,,,1,1
9843,50597,,BAO_0000218,,,Total concentration in serum was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL622855,,,,,1,1
9844,50597,,BAO_0000218,,,"Pharmacokinetic Parameter, AUC (0-infinity) is the area under the plasma concentration versus time curve extrapolated to infinity in Female Wistar Rats at 100 mg/kg by po administration",,,N,Intermediate,A,10116.0,CHEMBL622856,,1969.0,Plasma,,1,1
9845,50597,,BAO_0000218,,,"Pharmacokinetic Parameter, AUC (0-t) is the area under the plasma concentration versus time curve in Female Wistar Rats at 100 mg/kg by po administration",,,N,Intermediate,A,10116.0,CHEMBL622857,,1969.0,Plasma,,1,1
9846,50597,,BAO_0000218,,,AUC in rat after po administration at a dose of 10 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL622858,,1969.0,Plasma,,1,1
9847,50597,,BAO_0000218,,,Area under the plasma concentration-time curve in rats after oral administration at 25 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL622859,,1969.0,Plasma,,1,1
9848,50597,,BAO_0000218,,,Area under curve value 24 hr after 10 mg/kg iv administration in rats,,,N,Intermediate,A,10116.0,CHEMBL622860,,,,,1,1
9849,50597,,BAO_0000218,,,Area under curve value 24 hr after 10 mg/kg oral administration in rats,,,N,Intermediate,A,10116.0,CHEMBL622861,,,,,1,1
9850,50597,,BAO_0000218,,,Area under curve value 24 hr after 2 mg/kg iv administration in rats,,,N,Intermediate,A,10116.0,CHEMBL622862,,,,,1,1
9851,50597,,BAO_0000218,,,Area under curve value 24 hr after 2 mg/kg oral administration in rats,,,N,Intermediate,A,10116.0,CHEMBL622863,,,,,1,1
9852,50597,,BAO_0000218,,,Area under curve value 6 hr after po administration in rat,,,N,Intermediate,A,10116.0,CHEMBL623817,,,,,1,1
9853,50597,,BAO_0000218,,,Area under the curve at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,,,N,Intermediate,A,10116.0,CHEMBL623818,,,,,1,1
9854,50597,,BAO_0000218,,,"Area under the curve at a concentration of 3 mg/kg in rats, intravenously",,,N,Intermediate,A,10116.0,CHEMBL623819,,,,,1,1
9855,50597,,BAO_0000218,,,Area under the curve at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,,,N,Intermediate,A,10116.0,CHEMBL623820,,,,,1,1
9856,50597,,BAO_0000218,,,Area under the curve at a concentration of 60 mg/kg perorally in rats along with control,,,N,Intermediate,A,10116.0,CHEMBL623821,,,,,1,1
9857,50597,,BAO_0000218,,,AUC normalized for dose (AUCN) in rat,,,N,Intermediate,A,10116.0,CHEMBL623822,,1969.0,Plasma,,1,1
9858,50597,,BAO_0000218,,,Area under curve in rat after p.o. administration,,,N,Intermediate,A,10116.0,CHEMBL623823,,,,,1,1
9859,50597,,BAO_0000218,,,Area under curve in rat after p.o. administration,,,N,Intermediate,A,10116.0,CHEMBL623824,,,,,1,1
9860,50597,,BAO_0000218,,,Area under curve in rat after p.o. administration; Not determined,,,N,Intermediate,A,10116.0,CHEMBL623825,,,,,1,1
9861,50597,,BAO_0000218,,,Area under curve in rat after peroral administration,,,N,Intermediate,A,10116.0,CHEMBL622070,,,,,1,1
9862,50597,,BAO_0000218,,,Area under curve (carotid artery) value of the compound,,,N,Intermediate,A,10116.0,CHEMBL622071,,,,,1,1
9863,50597,,BAO_0000218,,,Bioavailability expressed as the area under curve of rat carotid artery,,,N,Intermediate,A,10116.0,CHEMBL622072,,,,,1,1
9864,50597,,BAO_0000218,,,Area under curve in male SD rats was observed after intravenous administration in rat,,,N,Intermediate,A,10116.0,CHEMBL622073,,,,,1,1
9865,50597,,BAO_0000218,,,Area under curve of the compound was determined,,,N,Intermediate,A,10116.0,CHEMBL622074,,,,,1,1
9866,50597,,BAO_0000218,,,Compound was evaluated for its pharmacokinetic parameter maximum area under curve AUCmax,,,N,Intermediate,A,10116.0,CHEMBL622075,,,,,1,1
9867,50597,,BAO_0000218,,,Area under the plasma concentration-time curve in rats after oral administration at 20 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL622076,,1969.0,Plasma,,1,1
9868,50597,,BAO_0000218,,,Area under the plasma concentration-time curve in rats following oral administration at 20 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL622077,,1969.0,Plasma,,1,1
9869,50597,,BAO_0000218,,,Area under curve (portal vein) value of the compound,,,N,Intermediate,A,10116.0,CHEMBL622078,,,,,1,1
9870,50597,,BAO_0000218,,,Bioavailability expressed as the area under curve of rat portal vein,,,N,Intermediate,A,10116.0,CHEMBL622079,,,,,1,1
9871,50597,,BAO_0000218,,,Area Under plasma concentration time curve in rat upon peroral administration,,,N,Intermediate,A,10116.0,CHEMBL622080,,1969.0,Plasma,,1,1
9872,50597,,BAO_0000218,,,In vivo area under curve was determined for the compound after i.v. administration at a dose of 5 mg/kg in rats,,,N,Intermediate,A,10116.0,CHEMBL877612,,,,,1,1
9873,50597,,BAO_0000218,,,In vivo area under curve was determined for the compound after oral (po) administration at a dose of 10 mg/kg in rats,,,N,Intermediate,A,10116.0,CHEMBL622081,,,,,1,1
9874,50597,,BAO_0000218,,,Compound was evaluated for oral bioavailability in rats,,,N,Intermediate,A,10116.0,CHEMBL622082,,,,,1,1
9875,50597,,BAO_0000218,,,Compound was evaluated for oral bioavailability in rats after iv administration,,,N,Intermediate,A,10116.0,CHEMBL622083,,,,,1,1
9876,50597,,BAO_0000218,,,Compound was evaluated for oral bioavailability in rats; 30-80,,,N,Intermediate,A,10116.0,CHEMBL622084,,,,,1,1
9877,50597,,BAO_0000218,,,Compound was evaluated for oral bioavailability in rats; 50-60,,,N,Intermediate,A,10116.0,CHEMBL622085,,,,,1,1
9878,50597,,BAO_0000218,,,Compound was evaluated for oral bioavailability in rats; no data,,,N,Intermediate,A,10116.0,CHEMBL622086,,,,,1,1
9879,50597,,BAO_0000218,,,Compound was evaluated for oral bioavailability in rats; peptide,,,N,Intermediate,A,10116.0,CHEMBL622087,,,,,1,1
9880,50597,,BAO_0000218,,,"Distribution of radioactivity in blood of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.03-0.03",,,N,Intermediate,A,10116.0,CHEMBL622088,,178.0,Blood,,1,1
9881,50597,,BAO_0000218,,,"Distribution of radioactivity in blood of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range-0.9-1.03",,,N,Intermediate,A,10116.0,CHEMBL622089,,178.0,Blood,,1,1
9882,50597,,BAO_0000218,,,"Distribution of radioactivity in blood of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range = 0.88-1.15",,,N,Intermediate,A,10116.0,CHEMBL623685,,178.0,Blood,,1,1
9883,50597,,BAO_0000218,,,"Distribution of radioactivity in blood of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range = 0.71-0.87",,,N,Intermediate,A,10116.0,CHEMBL623686,,178.0,Blood,,1,1
9884,50597,In vivo,BAO_0000218,,,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,,N,Intermediate,A,10116.0,CHEMBL623687,,945.0,Stomach,,1,1
9885,50597,In vivo,BAO_0000218,,,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,,N,Intermediate,A,10116.0,CHEMBL623688,,945.0,Stomach,,1,1
9886,50597,In vivo,BAO_0000218,,,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,,N,Intermediate,A,10116.0,CHEMBL623689,,945.0,Stomach,,1,1
9887,50597,In vivo,BAO_0000218,,,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,,N,Intermediate,A,10116.0,CHEMBL622485,,945.0,Stomach,,1,1
9888,50597,In vivo,BAO_0000218,,,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,,N,Intermediate,A,10116.0,CHEMBL622486,,2046.0,Thyroid gland,,1,1
9889,50597,In vivo,BAO_0000218,,,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,,N,Intermediate,A,10116.0,CHEMBL877613,,2046.0,Thyroid gland,,1,1
9890,50597,In vivo,BAO_0000218,,,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,,N,Intermediate,A,10116.0,CHEMBL622487,,2046.0,Thyroid gland,,1,1
9891,50597,In vivo,BAO_0000218,,,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,,N,Intermediate,A,10116.0,CHEMBL622488,,2046.0,Thyroid gland,,1,1
9892,50597,In vivo,BAO_0000218,,,"Biodistribution in Sprague-Dawley rats heart 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,,N,Intermediate,A,10116.0,CHEMBL622489,,948.0,Heart,,1,1
9893,50597,,BAO_0000218,,,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,,,N,Intermediate,A,10116.0,CHEMBL622490,,1088.0,Urine,,1,1
9894,50597,,BAO_0000218,,,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available,,,N,Intermediate,A,10116.0,CHEMBL622491,,1088.0,Urine,,1,1
9895,50597,,BAO_0000218,,,Compound was evaluated for percent dose tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in liver,,,N,Intermediate,A,10116.0,CHEMBL622492,,2107.0,Liver,,1,1
9896,50597,,BAO_0000218,,,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,,,N,Intermediate,A,10116.0,CHEMBL622493,,1088.0,Urine,,1,1
9897,50597,,BAO_0000218,,,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available,,,N,Intermediate,A,10116.0,CHEMBL622494,,1088.0,Urine,,1,1
9898,50597,,BAO_0000218,,,"Compound was evaluated for the biodistribution in Sprague-Dawley rats in muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,,N,Intermediate,A,10116.0,CHEMBL622495,,2385.0,Muscle tissue,,1,1
9899,50597,,BAO_0000218,,,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in rat kidney,,,N,Intermediate,A,10116.0,CHEMBL622496,,,,,1,1
9900,50597,,BAO_0000218,,,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,,,N,Intermediate,A,10116.0,CHEMBL622497,,1088.0,Urine,,1,1
9901,50597,,BAO_0000218,,,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by rats,,,N,Intermediate,A,10116.0,CHEMBL622498,,,,,1,1
9902,50597,,BAO_0000218,,,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats,,,N,Intermediate,A,10116.0,CHEMBL624918,,1088.0,Urine,,1,1
9903,50597,,BAO_0000218,,,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats; NA is <10% inhibition at 1 uM for binding data,,,N,Intermediate,A,10116.0,CHEMBL624919,,1088.0,Urine,,1,1
9904,50597,In vivo,BAO_0000218,,,Biodistribution of compound in rat blood after 5 min of administration,,,N,Intermediate,A,10116.0,CHEMBL624920,,178.0,Blood,,1,1
9905,50597,In vivo,BAO_0000218,,,Biodistribution of compound in rat blood after 5 min of administration.,,,N,Intermediate,A,10116.0,CHEMBL624921,,178.0,Blood,,1,1
9906,50597,In vivo,BAO_0000218,,,Biodistribution of compound in rat brain after 5 min of administration,,,N,Intermediate,A,10116.0,CHEMBL624922,,955.0,Brain,,1,1
9907,50597,In vivo,BAO_0000218,,,Biodistribution of compound in rat heart after 5 min of administration,,,N,Intermediate,A,10116.0,CHEMBL624923,,948.0,Heart,,1,1
9908,50597,In vivo,BAO_0000218,,,Biodistribution of compound in rat heart after 5 min of administration.,,,N,Intermediate,A,10116.0,CHEMBL624924,,948.0,Heart,,1,1
9909,50597,In vivo,BAO_0000218,,,Biodistribution of compound in rat kidney after 5 min of administration,,,N,Intermediate,A,10116.0,CHEMBL624925,,2113.0,Kidney,,1,1
9910,50597,In vivo,BAO_0000218,,,Biodistribution of compound in rat kidney after 5 min of administration.,,,N,Intermediate,A,10116.0,CHEMBL624926,,2113.0,Kidney,,1,1
9911,50597,In vivo,BAO_0000218,,,Biodistribution of compound in rat liver after 5 min of administration,,,N,Intermediate,A,10116.0,CHEMBL624927,,2107.0,Liver,,1,1
9912,50597,In vivo,BAO_0000218,,,Biodistribution of compound in rat liver after 5 min of administration.,,,N,Intermediate,A,10116.0,CHEMBL874402,,2107.0,Liver,,1,1
9913,50597,In vivo,BAO_0000218,,,Biodistribution of compound in rat lung after 5 min of administration,,,N,Intermediate,A,10116.0,CHEMBL624928,,2048.0,Lung,,1,1
9914,50597,In vivo,BAO_0000218,,,Biodistribution of compound in rat lung after 5 min of administration.,,,N,Intermediate,A,10116.0,CHEMBL624929,,2048.0,Lung,,1,1
9915,50597,In vivo,BAO_0000218,,,Biodistribution of compound in rat muscle after 5 min of administration,,,N,Intermediate,A,10116.0,CHEMBL624930,,2385.0,Muscle tissue,,1,1
9916,50597,In vivo,BAO_0000218,,,Biodistribution of compound in rat muscle after 5 min of administration.,,,N,Intermediate,A,10116.0,CHEMBL624931,,2385.0,Muscle tissue,,1,1
9917,50597,,BAO_0000218,,,In vivo heart distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,,N,Intermediate,A,10116.0,CHEMBL624932,,948.0,Heart,,1,1
9918,50597,,BAO_0000218,,,In vivo heart distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,,N,Intermediate,A,10116.0,CHEMBL624933,,948.0,Heart,,1,1
9919,50597,,BAO_0000218,,,In vivo liver distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,,N,Intermediate,A,10116.0,CHEMBL624934,,2107.0,Liver,,1,1
9920,50597,,BAO_0000218,,,In vivo liver distribution of total doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,,N,Intermediate,A,10116.0,CHEMBL624935,,2107.0,Liver,,1,1
9921,50597,,BAO_0000218,,,In vivo plasma distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,,N,Intermediate,A,10116.0,CHEMBL624936,,,,,1,1
9922,50597,,BAO_0000218,,,In vivo plasma distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,,N,Intermediate,A,10116.0,CHEMBL624937,,,,,1,1
9923,50597,,BAO_0000218,,,In vivo spleen distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,,N,Intermediate,A,10116.0,CHEMBL624938,,2106.0,Spleen,,1,1
9924,50597,,BAO_0000218,,,In vivo spleen distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,,N,Intermediate,A,10116.0,CHEMBL624939,,2106.0,Spleen,,1,1
9925,50597,,BAO_0000218,,,In vivo tumor distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,,N,Intermediate,A,10116.0,CHEMBL624940,,,,,1,1
9926,50597,,BAO_0000218,,,In vivo tumor distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,,N,Intermediate,A,10116.0,CHEMBL874403,,,,,1,1
9927,50597,,BAO_0000218,,,Compound was tested for the duration that the plasma drug concentrations remained above the IC95,,,N,Intermediate,A,10116.0,CHEMBL624941,,,,,1,1
9928,50597,,BAO_0000218,,,Dose required to lower urine osmolality to 300 mOsm/kg in rat,,,N,Intermediate,A,10116.0,CHEMBL624942,,1088.0,Urine,,1,1
9929,50597,,BAO_0000218,,,Dose required to lower urine osmolality to 300 mOsm/kg in rat; NT=Not tested,,,N,Intermediate,A,10116.0,CHEMBL624943,,1088.0,Urine,,1,1
9930,50597,In vivo,BAO_0000218,,,% Bioavailability after 1 day of the drug administration in rats,,,N,Intermediate,A,10116.0,CHEMBL624944,,,,,1,1
9931,50597,In vivo,BAO_0000218,,,% Bioavailability after 4 day of the drug administration in rats,,,N,Intermediate,A,10116.0,CHEMBL624945,,,,,1,1
9932,50597,In vivo,BAO_0000218,,,Absolute bioavailability was evaluated in rat,,,N,Intermediate,A,10116.0,CHEMBL624946,,,,,1,1
9933,50597,,BAO_0000218,,,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr low time interval,,,N,Intermediate,A,10116.0,CHEMBL624947,,,,,1,1
9934,50597,,BAO_0000218,,,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr time interval,,,N,Intermediate,A,10116.0,CHEMBL624948,,,,,1,1
9935,50597,,BAO_0000218,,,Tissue biodistribution into estrogen-primed immature female rat fat at 3 hr time interval,,,N,Intermediate,A,10116.0,CHEMBL624949,,,,,1,1
9936,50597,,BAO_0000218,,,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr blocked time interval,,,N,Intermediate,A,10116.0,CHEMBL622025,,2113.0,Kidney,,1,1
9937,50597,,BAO_0000218,,,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr low time interval,,,N,Intermediate,A,10116.0,CHEMBL622026,,2113.0,Kidney,,1,1
9938,50597,,BAO_0000218,,,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr time interval,,,N,Intermediate,A,10116.0,CHEMBL622027,,2113.0,Kidney,,1,1
9939,50597,,BAO_0000218,,,Tissue biodistribution into estrogen-primed immature female rat kidney at 3 hr time interval,,,N,Intermediate,A,10116.0,CHEMBL622028,,2113.0,Kidney,,1,1
9940,50597,,BAO_0000218,,,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr blocked time interval,,,N,Intermediate,A,10116.0,CHEMBL622029,,2107.0,Liver,,1,1
9941,50597,,BAO_0000218,,,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr low time interval,,,N,Intermediate,A,10116.0,CHEMBL622208,,2107.0,Liver,,1,1
9942,50597,,BAO_0000218,,,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr time interval,,,N,Intermediate,A,10116.0,CHEMBL622209,,2107.0,Liver,,1,1
9943,50597,,BAO_0000218,,,Tissue biodistribution into estrogen-primed immature female rat liver at 3 hr time interval,,,N,Intermediate,A,10116.0,CHEMBL622210,,2107.0,Liver,,1,1
9944,50597,,BAO_0000218,,,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr blocked time interval,,,N,Intermediate,A,10116.0,CHEMBL622211,,,,,1,1
9945,50597,,BAO_0000218,,,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr low time interval,,,N,Intermediate,A,10116.0,CHEMBL622212,,,,,1,1
9946,50597,,BAO_0000218,,,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr time interval,,,N,Intermediate,A,10116.0,CHEMBL622213,,,,,1,1
9947,50597,,BAO_0000218,,,Tissue biodistribution into estrogen-primed immature female rat lung at 3 hr time interval,,,N,Intermediate,A,10116.0,CHEMBL874404,,,,,1,1
9948,50597,,BAO_0000218,,,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr blocked time interval,,,N,Intermediate,A,10116.0,CHEMBL620452,,2385.0,Muscle tissue,,1,1
9949,50597,,BAO_0000218,,,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr low time interval,,,N,Intermediate,A,10116.0,CHEMBL620453,,2385.0,Muscle tissue,,1,1
9950,50597,,BAO_0000218,,,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr time interval,,,N,Intermediate,A,10116.0,CHEMBL620454,,2385.0,Muscle tissue,,1,1
9951,50597,,BAO_0000218,,,Tissue biodistribution into estrogen-primed immature female rat muscle at 3 hr time interval,,,N,Intermediate,A,10116.0,CHEMBL624067,,2385.0,Muscle tissue,,1,1
9952,50597,,BAO_0000218,,,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr blocked time interval,,,N,Intermediate,A,10116.0,CHEMBL624068,,,,,1,1
9953,50597,,BAO_0000218,,,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr low time interval,,,N,Intermediate,A,10116.0,CHEMBL624069,,992.0,Female gonad,,1,1
9954,50597,,BAO_0000218,,,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr time interval,,,N,Intermediate,A,10116.0,CHEMBL624070,,992.0,Female gonad,,1,1
9955,50597,,BAO_0000218,,,Tissue biodistribution into estrogen-primed immature female rat ovaries at 3 hr time interval,,,N,Intermediate,A,10116.0,CHEMBL624071,,992.0,Female gonad,,1,1
9956,50597,,BAO_0000218,,,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr blocked time interval,,,N,Intermediate,A,10116.0,CHEMBL624072,,995.0,Uterus,,1,1
9957,50597,,BAO_0000218,,,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr low time interval,,,N,Intermediate,A,10116.0,CHEMBL624073,,995.0,Uterus,,1,1
9958,50597,,BAO_0000218,,,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr time interval,,,N,Intermediate,A,10116.0,CHEMBL624788,,995.0,Uterus,,1,1
9959,50597,,BAO_0000218,,,Tissue biodistribution into estrogen-primed immature female rat uterus at 3 hr time interval,,,N,Intermediate,A,10116.0,CHEMBL624789,,995.0,Uterus,,1,1
9960,50597,,BAO_0000218,,,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr blocked time interval,,,N,Intermediate,A,10116.0,CHEMBL624790,,,,,1,1
9961,50597,,BAO_0000218,,,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr low time interval,,,N,Intermediate,A,10116.0,CHEMBL624791,,,,,1,1
9962,50597,,BAO_0000218,,,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr time interval,,,N,Intermediate,A,10116.0,CHEMBL624792,,,,,1,1
9963,50597,,BAO_0000218,,,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 3 hr time interval,,,N,Intermediate,A,10116.0,CHEMBL624793,,,,,1,1
9964,50597,,BAO_0000218,,,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr blocked time interval,,,N,Intermediate,A,10116.0,CHEMBL877491,,2385.0,Muscle tissue,,1,1
9965,50597,,BAO_0000218,,,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr low time interval,,,N,Intermediate,A,10116.0,CHEMBL624957,,2385.0,Muscle tissue,,1,1
9966,50597,,BAO_0000218,,,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr time interval,,,N,Intermediate,A,10116.0,CHEMBL624958,,2385.0,Muscle tissue,,1,1
9967,50597,,BAO_0000218,,,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 3 hr time interval,,,N,Intermediate,A,10116.0,CHEMBL624959,,2385.0,Muscle tissue,,1,1
9968,50597,,BAO_0000218,,,Dissociation constant was determined,,,N,Intermediate,A,10116.0,CHEMBL624960,,,,,1,1
9969,50597,,BAO_0000218,,,"Pharmacokinetic Parameter, Kel is elimination rate constant in Female Wistar Rats at 100 mg/kg by po administration",,,N,Intermediate,A,10116.0,CHEMBL624961,,,,,1,1
9970,50597,,BAO_0000218,,,"The Kel value in female wistar rat at 100 mg/kg, p.o. dose",,,N,Intermediate,A,10116.0,CHEMBL624962,,,,,1,1
9971,50597,,BAO_0000218,,,"The Kel value in male wistar rat at 100 mg/kg, p.o. dose",,,N,Intermediate,A,10116.0,CHEMBL624963,,,,,1,1
9972,50597,,BAO_0000218,,,Observed rate constant in 80% rat plasma at 37 degree Centigrade,,,N,Intermediate,A,10116.0,CHEMBL624964,,,,,1,1
9973,50597,,BAO_0000218,,,LogP value was evaluated in the in situ rat gut perfusion assay,,,N,Intermediate,A,10116.0,CHEMBL624965,,,,,1,1
9974,50597,In vivo,BAO_0000218,,,In vivo retention time was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,,,N,Intermediate,A,10116.0,CHEMBL624966,,,,,1,1
9975,50597,In vivo,BAO_0000218,,,Mean residence time (Pharmacokinetic property) after i.v. administration in rats,,,N,Intermediate,A,10116.0,CHEMBL624967,,,,,1,1
9976,50597,In vivo,BAO_0000218,,,Mean-residence time of compound after intravenous administration in rats at 24 uM/kg,,,N,Intermediate,A,10116.0,CHEMBL624968,,,,,1,1
9977,50597,,BAO_0000218,,,Mean residence time at a dose of 4 mg/kg in Rat Plasma after iv administration,,,N,Intermediate,A,10116.0,CHEMBL624969,,,,,1,1
9978,50597,,BAO_0000218,,,Streptococcal cell wall-washed arthritis model in rats at 10.0 mg/kg peroral dose,,,N,Expert,F,10116.0,CHEMBL624970,,,,,1,1
9979,50597,,BAO_0000218,,,Half-life was evaluated after 10 uM/kg of intra arterial administration,,,N,Intermediate,A,10116.0,CHEMBL624971,,,,,1,1
9980,50597,In vivo,BAO_0000218,,,Half-life was evaluated after 20 uM/kg of peroral administration,,,N,Intermediate,A,10116.0,CHEMBL624972,,,,,1,1
9981,50597,In vivo,BAO_0000218,,,Half-life was evaluated after i.v. administration in rat at a dose of 1 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL624973,,,,,1,1
9982,50597,,BAO_0000218,,,Half-life was evaluated in plasma of rat,,,N,Intermediate,A,10116.0,CHEMBL624974,,1969.0,Plasma,,1,1
9983,50597,In vivo,BAO_0000218,,,Half-life was evaluated in rats at an intravenous dose of 3 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL624975,,,,,1,1
9984,50597,In vivo,BAO_0000218,,,Half-life was evaluated in rats at an oral dose of 30 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL877492,,,,,1,1
9985,50597,In vivo,BAO_0000218,,,Half-life was measured in rat after an iv dose of 1 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL624976,,,,,1,1
9986,50597,In vivo,BAO_0000218,,,Half-life period of compound in rats after peroral administration,,,N,Intermediate,A,10116.0,CHEMBL624977,,,,,1,1
9987,50597,,BAO_0000218,,,Half-life period of compound was measured in rat plasma.,,,N,Intermediate,A,10116.0,CHEMBL626848,,1969.0,Plasma,,1,1
9988,50597,,BAO_0000218,,,Half-life period of compound was measured in rat plasma; ND is not determined,,,N,Intermediate,A,10116.0,CHEMBL626849,,1969.0,Plasma,,1,1
9989,50597,,BAO_0000218,,,Half-life period of compound was measured in rat plasma; not determined,,,N,Intermediate,A,10116.0,CHEMBL626850,,1969.0,Plasma,,1,1
9990,50597,In vivo,BAO_0000218,,,Half-life period in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,,,N,Intermediate,A,10116.0,CHEMBL626851,,,,,1,1
9991,50597,In vivo,BAO_0000218,,,Half-life period in rat by iv administration,,,N,Intermediate,A,10116.0,CHEMBL626852,,,,,1,1
9992,50597,In vivo,BAO_0000218,,,Half-life period in rats following intravenous administration at 2 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL626853,,,,,1,1
9993,50597,In vivo,BAO_0000218,,,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,,N,Intermediate,A,10116.0,CHEMBL626854,,,,,1,1
9994,50597,,BAO_0000218,,,Half-life period was determined for the compound in rat,,,N,Intermediate,A,10116.0,CHEMBL627486,,,,,1,1
9995,50597,In vivo,BAO_0000218,,,"Half-life period was evaluated in rat, after administering 1 mg/kg intravenously",,,N,Intermediate,A,10116.0,CHEMBL627487,,,,,1,1
9996,50597,In vivo,BAO_0000218,,,"Half-life period was evaluated in rat, after administering 10 mg/kg orally",,,N,Intermediate,A,10116.0,CHEMBL627488,,,,,1,1
9997,50597,In vivo,BAO_0000218,,,Half-life value after IV dose at a dose of 5 mg/kg in rats.,,,N,Intermediate,A,10116.0,CHEMBL627489,,,,,1,1
9998,50597,In vivo,BAO_0000218,,,Half-life was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats,,,N,Intermediate,A,10116.0,CHEMBL627490,,,,,1,1
9999,50597,In vivo,BAO_0000218,,,Half-life was determined in rat after intravenous administration (0.5 mg/kg),,,N,Intermediate,A,10116.0,CHEMBL873829,,,,,1,1
10000,50597,In vivo,BAO_0000218,,,Half-life was determined in rat at a dose of 1 mpk i.v.,,,N,Intermediate,A,10116.0,CHEMBL627655,,,,,1,1
10001,50597,In vivo,BAO_0000218,,,Half-life was determined in rat at a dose of 1 mpk i.v.; ND means not determined,,,N,Intermediate,A,10116.0,CHEMBL625994,,,,,1,1
10002,50597,In vivo,BAO_0000218,,,Half-life was determined in rat at a dose of 1 mpk i.v.; ND=not determined,,,N,Intermediate,A,10116.0,CHEMBL625995,,,,,1,1
10003,50597,,BAO_0000218,,,Half-life in rat,,,N,Intermediate,A,10116.0,CHEMBL625996,,,,,1,1
10004,50597,In vitro,BAO_0000218,,,In vitro half life in rat plasma,,,N,Intermediate,A,10116.0,CHEMBL625850,,1969.0,Plasma,,1,1
10005,50597,In vitro,BAO_0000218,,,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in rat plasma",,,N,Intermediate,A,10116.0,CHEMBL625851,,1969.0,Plasma,,1,1
10006,50597,In vitro,BAO_0000218,,,In vitro half life in rat,,,N,Intermediate,A,10116.0,CHEMBL625852,,,,,1,1
10007,50597,In vivo,BAO_0000218,,,In vivo half life period after intravenous administration in rat,,,N,Intermediate,A,10116.0,CHEMBL625853,,,,,1,1
10008,50597,In vivo,BAO_0000218,,,In vivo half-life period for compound after i.v. administration at a dose of 5 mg/kg was measured in rats,,,N,Intermediate,A,10116.0,CHEMBL625854,,,,,1,1
10009,50597,In vivo,BAO_0000218,,,In vivo half-life period for compound after oral (po) administration at a dose of 10 mg/kg was measured in rats,,,N,Intermediate,A,10116.0,CHEMBL874450,,,,,1,1
10010,50597,In vivo,BAO_0000218,,,In vivo t1/2 was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,,N,Intermediate,A,10116.0,CHEMBL625855,,,,,1,1
10011,50597,In vivo,BAO_0000218,,,In vivo t1/2 was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,,N,Intermediate,A,10116.0,CHEMBL625856,,,,,1,1
10012,50597,In vivo,BAO_0000218,,,In vivo t1/2 was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,,,N,Intermediate,A,10116.0,CHEMBL625857,,,,,1,1
10013,50597,In vivo,BAO_0000218,,,In vivo t1/2 was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,,N,Intermediate,A,10116.0,CHEMBL873831,,,,,1,1
10014,50597,In vivo,BAO_0000218,,,Longer half-life in rat (i.v.) at 0.5 mpk,,,N,Intermediate,A,10116.0,CHEMBL625858,,,,,1,1
10015,50597,In vivo,BAO_0000218,,,Longer half-life in rat (p.o.) at 2.0 mpk,,,N,Intermediate,A,10116.0,CHEMBL625859,,,,,1,1
10016,50597,,BAO_0000218,,,Pharmacokinetic property (half life) in rat,,,N,Intermediate,A,10116.0,CHEMBL625860,,,,,1,1
10017,50597,In vivo,BAO_0000218,,,Pharmacokinetic parameter half-life was determined at 10 mg/kg po dose in rats,,,N,Intermediate,A,10116.0,CHEMBL625861,,,,,1,1
10018,50597,In vivo,BAO_0000218,,,Pharmacokinetic parameter half-life was determined at 2 mg/kg i.v. dose in rats,,,N,Intermediate,A,10116.0,CHEMBL625862,,,,,1,1
10019,50597,In vivo,BAO_0000218,,,Pharmacokinetic parameter half-life was determined at 3 mg/kg po dose in rats,,,N,Intermediate,A,10116.0,CHEMBL625863,,,,,1,1
10020,50597,In vivo,BAO_0000218,,,Pharmacokinetic parameter half-life was determined at 5 mg/kg i.v. dose in rats,,,N,Intermediate,A,10116.0,CHEMBL625864,,,,,1,1
10021,50597,In vivo,BAO_0000218,,,Pharmacokinetic property (t1/2) for the compound (5 mg/kg iv) was determined in rats,,,N,Intermediate,A,10116.0,CHEMBL625865,,,,,1,1
10022,50597,In vivo,BAO_0000218,,,Pharmacokinetic half time was determined intravenously in rats.,,,N,Intermediate,A,10116.0,CHEMBL625866,,,,,1,1
10023,50597,In vivo,BAO_0000218,,,Plasma half life in rat after 5 mg/kg oral gavage; 6-8 hours,,,N,Intermediate,A,10116.0,CHEMBL625867,,1969.0,Plasma,,1,1
10024,50597,,BAO_0000218,,,Plasma half life of hydrolysis of the compound,,,N,Intermediate,A,10116.0,CHEMBL625868,,1969.0,Plasma,,1,1
10025,50597,In vivo,BAO_0000218,,,Plasma half life was reported after a intravenous dose of 1 mg/kg in Dawley rat,,,N,Intermediate,A,10116.0,CHEMBL625869,,1969.0,Plasma,,1,1
10026,50597,,BAO_0000218,,,Plasma half life period was calculated in rat,,,N,Intermediate,A,10116.0,CHEMBL874451,,1969.0,Plasma,,1,1
10027,50597,,BAO_0000218,,,Plasma half-life in Sprague-Dawley rats,,,N,Intermediate,A,10116.0,CHEMBL625870,,1969.0,Plasma,,1,1
10028,50597,,BAO_0000218,,,Plasma half-life in Sprague-Dawley rats; Not determined,,,N,Intermediate,A,10116.0,CHEMBL625871,,1969.0,Plasma,,1,1
10029,50597,,BAO_0000218,,,Plasma half-life in rats,,,N,Intermediate,A,10116.0,CHEMBL625872,,1969.0,Plasma,,1,1
10030,50597,,BAO_0000218,,,Plasma half-life in rats; <MQL,,,N,Intermediate,A,10116.0,CHEMBL625873,,1969.0,Plasma,,1,1
10031,50597,,BAO_0000218,,,Plasma half-life period (0-8 h) was determined,,,N,Intermediate,A,10116.0,CHEMBL625874,,1969.0,Plasma,,1,1
10032,50597,,BAO_0000218,,,Plasma half-life period (0-8 h) was determined in Sprague-Dawley rat,,,N,Intermediate,A,10116.0,CHEMBL625875,,1969.0,Plasma,,1,1
10033,50597,In vivo,BAO_0000218,,,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,,,N,Intermediate,A,10116.0,CHEMBL625876,,1969.0,Plasma,,1,1
10034,50597,In vivo,BAO_0000218,,,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,,,N,Intermediate,A,10116.0,CHEMBL631258,,1969.0,Plasma,,1,1
10035,50597,,BAO_0000218,,,Plasma half-life was determined in Sprague-Dawley rats after 0-8 h administration of the compound,,,N,Intermediate,A,10116.0,CHEMBL631259,,1969.0,Plasma,,1,1
10036,50597,,BAO_0000218,,,Plasma half-life was determined in Sprague-Dawley rats after 0-8 hr administration of the compound; Not determined,,,N,Intermediate,A,10116.0,CHEMBL631260,,1969.0,Plasma,,1,1
10037,50597,,BAO_0000218,,,"Distribution of radioactivity in blood of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range = 0.68-1.03",,,N,Intermediate,A,10116.0,CHEMBL631261,,178.0,Blood,,1,1
10038,50597,,BAO_0000218,,,"Distribution of radioactivity in blood of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.45-0.48",,,N,Intermediate,A,10116.0,CHEMBL631262,,178.0,Blood,,1,1
10039,50597,,BAO_0000218,,,"Distribution of radioactivity in blood of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range-0.81-1",,,N,Intermediate,A,10116.0,CHEMBL631263,,178.0,Blood,,1,1
10040,50597,,BAO_0000218,,,"Distribution of radioactivity in brain tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.007-0.008",,,N,Intermediate,A,10116.0,CHEMBL631264,,,,,1,1
10041,50597,,BAO_0000218,,,"Distribution of radioactivity in brain tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.18-0.22",,,N,Intermediate,A,10116.0,CHEMBL631265,,,,,1,1
10042,50597,,BAO_0000218,,,"Distribution of radioactivity in brain tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.77-0.97",,,N,Intermediate,A,10116.0,CHEMBL631266,,,,,1,1
10043,50597,,BAO_0000218,,,"Distribution of radioactivity in brain tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.08-0.13",,,N,Intermediate,A,10116.0,CHEMBL631267,,,,,1,1
10044,50597,,BAO_0000218,,,"Distribution of radioactivity in brain tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.25-0.37",,,N,Intermediate,A,10116.0,CHEMBL631268,,,,,1,1
10045,50597,,BAO_0000218,,,"Distribution of radioactivity in brain tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.03-0.04",,,N,Intermediate,A,10116.0,CHEMBL631269,,,,,1,1
10046,50597,,BAO_0000218,,,"Distribution of radioactivity in brain tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.74-0.94",,,N,Intermediate,A,10116.0,CHEMBL631270,,,,,1,1
10047,50597,,BAO_0000218,,,"Distribution of radioactivity in heart tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.02",,,N,Intermediate,A,10116.0,CHEMBL631271,,948.0,Heart,,1,1
10048,50597,,BAO_0000218,,,"Distribution of radioactivity in heart tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.5-0.63",,,N,Intermediate,A,10116.0,CHEMBL631272,,948.0,Heart,,1,1
10049,50597,,BAO_0000218,,,"Distribution of radioactivity in heart tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.35-1.55",,,N,Intermediate,A,10116.0,CHEMBL631273,,948.0,Heart,,1,1
10050,50597,,BAO_0000218,,,"Distribution of radioactivity in heart tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.24-0.38",,,N,Intermediate,A,10116.0,CHEMBL631274,,948.0,Heart,,1,1
10051,50597,,BAO_0000218,,,"Distribution of radioactivity in heart tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.55-0.82",,,N,Intermediate,A,10116.0,CHEMBL631275,,948.0,Heart,,1,1
10052,50597,,BAO_0000218,,,"Distribution of radioactivity in heart tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.16-0.2",,,N,Intermediate,A,10116.0,CHEMBL626984,,948.0,Heart,,1,1
10053,50597,,BAO_0000218,,,"Distribution of radioactivity in heart tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.13-1.29",,,N,Intermediate,A,10116.0,CHEMBL626985,,948.0,Heart,,1,1
10054,50597,,BAO_0000218,,,"Distribution of radioactivity in liver tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.02",,,N,Intermediate,A,10116.0,CHEMBL626986,,2107.0,Liver,,1,1
10055,50597,,BAO_0000218,,,"Distribution of radioactivity in liver tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.71-0.93",,,N,Intermediate,A,10116.0,CHEMBL626987,,2107.0,Liver,,1,1
10056,50597,,BAO_0000218,,,"Distribution of radioactivity in liver tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 2.91-3.53",,,N,Intermediate,A,10116.0,CHEMBL626988,,2107.0,Liver,,1,1
10057,50597,,BAO_0000218,,,"Distribution of radioactivity in liver tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.42-0.62",,,N,Intermediate,A,10116.0,CHEMBL626989,,2107.0,Liver,,1,1
10058,50597,,BAO_0000218,,,"Distribution of radioactivity in liver tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.97-1.41",,,N,Intermediate,A,10116.0,CHEMBL626990,,2107.0,Liver,,1,1
10059,50597,,BAO_0000218,,,"Distribution of radioactivity in liver tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.19-0.23",,,N,Intermediate,A,10116.0,CHEMBL626991,,2107.0,Liver,,1,1
10060,50597,,BAO_0000218,,,"Distribution of radioactivity in liver tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 2.49-2.82",,,N,Intermediate,A,10116.0,CHEMBL626992,,2107.0,Liver,,1,1
10061,50597,,BAO_0000218,,,"Distribution of radioactivity in lung tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.03",,,N,Intermediate,A,10116.0,CHEMBL626993,,2048.0,Lung,,1,1
10062,50597,,BAO_0000218,,,"Distribution of radioactivity in lung tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.66-0.77",,,N,Intermediate,A,10116.0,CHEMBL874593,,2048.0,Lung,,1,1
10063,50597,,BAO_0000218,,,"Distribution of radioactivity in lung tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.17-1.42",,,N,Intermediate,A,10116.0,CHEMBL626994,,2048.0,Lung,,1,1
10064,50597,,BAO_0000218,,,"Distribution of radioactivity in lung tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.47-0.58",,,N,Intermediate,A,10116.0,CHEMBL626995,,2048.0,Lung,,1,1
10065,50597,,BAO_0000218,,,"Distribution of radioactivity in lung tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.65-0.87",,,N,Intermediate,A,10116.0,CHEMBL626190,,2048.0,Lung,,1,1
10066,50597,,BAO_0000218,,,"Distribution of radioactivity in lung tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.28-0.31",,,N,Intermediate,A,10116.0,CHEMBL626191,,2048.0,Lung,,1,1
10067,50597,,BAO_0000218,,,"Distribution of radioactivity in lung tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.98-1.22",,,N,Intermediate,A,10116.0,CHEMBL626364,,2048.0,Lung,,1,1
10068,50597,,BAO_0000218,,,"Distribution of radioactivity in thyroid tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 406-499",,,N,Intermediate,A,10116.0,CHEMBL626365,,2046.0,Thyroid gland,,1,1
10069,50597,,BAO_0000218,,,"Distribution of radioactivity in thyroid tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 53.0-96",,,N,Intermediate,A,10116.0,CHEMBL626366,,2046.0,Thyroid gland,,1,1
10070,50597,,BAO_0000218,,,"Distribution of radioactivity in thyroid tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 6.65-8.0.8",,,N,Intermediate,A,10116.0,CHEMBL626367,,2046.0,Thyroid gland,,1,1
10071,50597,,BAO_0000218,,,"Distribution of radioactivity in thyroid tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 92-159",,,N,Intermediate,A,10116.0,CHEMBL626368,,2046.0,Thyroid gland,,1,1
10072,50597,,BAO_0000218,,,"Distribution of radioactivity in thyroid tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 18.74-30.84",,,N,Intermediate,A,10116.0,CHEMBL626369,,2046.0,Thyroid gland,,1,1
10073,50597,,BAO_0000218,,,"Distribution of radioactivity in thyroid tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 156-207",,,N,Intermediate,A,10116.0,CHEMBL626370,,2046.0,Thyroid gland,,1,1
10074,50597,In vivo,BAO_0000218,,,"Bioavailability (F) was evaluated in rat, after administering 1 mg/kg intravenously",,,N,Intermediate,A,10116.0,CHEMBL626371,,,,,1,1
10075,50597,In vivo,BAO_0000218,,,"Bioavailability (F) was evaluated in rat, after administering 10 mg/kg orally",,,N,Intermediate,A,10116.0,CHEMBL626372,,,,,1,1
10076,50597,In vivo,BAO_0000218,,,Bioavailability after a dose of 10 mg/kg p.o.,,,N,Intermediate,A,10116.0,CHEMBL626373,,,,,1,1
10077,50597,In vivo,BAO_0000218,,,Bioavailability after peroral administration (10 mg/kg) was determined in rat,,,N,Intermediate,A,10116.0,CHEMBL626374,,,,,1,1
10078,50597,In vivo,BAO_0000218,,,Bioavailability in fasted male administration of 2 mg/Kg of compound p.o.,,,N,Intermediate,A,10116.0,CHEMBL626375,,,,,1,1
10079,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat (Sprague-Dawley) (fasted male) (dose 2 mg/kg),,,N,Intermediate,A,10116.0,CHEMBL626376,,,,,1,1
10080,50597,In vivo,BAO_0000218,,,Bioavailability in rat po was determined,,,N,Intermediate,A,10116.0,CHEMBL626377,,,,,1,1
10081,50597,In vivo,BAO_0000218,,,Bioavailability of compound at 10 mg/kg in rat after oral administration,,,N,Intermediate,A,10116.0,CHEMBL626378,,,,,1,1
10082,50597,In vivo,BAO_0000218,,,Bioavailability of compound at 3 mg/kg in rat after i.v. administration,,,N,Intermediate,A,10116.0,CHEMBL626379,,,,,1,1
10083,50597,In vivo,BAO_0000218,,,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),,,N,Intermediate,A,10116.0,CHEMBL626380,,,,,1,1
10084,50597,In vivo,BAO_0000218,,,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),,,N,Intermediate,A,10116.0,CHEMBL626381,,,,,1,1
10085,50597,In vivo,BAO_0000218,,,Bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL626382,,,,,1,1
10086,50597,In vivo,BAO_0000218,,,Bioavailability in rat (Sprague-Dawley) (female),,,N,Intermediate,A,10116.0,CHEMBL626383,,,,,1,1
10087,50597,In vivo,BAO_0000218,,,Bioavailability in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL874652,,,,,1,1
10088,50597,In vivo,BAO_0000218,,,Bioavailability in rat (Sprague-Dawley) (male) (dose 10-20 mg/kg),,,N,Intermediate,A,10116.0,CHEMBL626384,,,,,1,1
10089,50597,In vivo,BAO_0000218,,,Bioavailability in rat (Sprague-Dawley) (male) (dose 1 mg/kg i.v. and 3 mg/kg p.o.) measured from 0.3 to 6 hr,,,N,Intermediate,A,10116.0,CHEMBL626385,,,,,1,1
10090,50597,In vivo,BAO_0000218,,,Bioavailability in rat at an oral dose of 2 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL626386,,,,,1,1
10091,50597,In vivo,BAO_0000218,,,Bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL626387,,,,,1,1
10092,50597,In vivo,BAO_0000218,,,Bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL626388,,,,,1,1
10093,50597,In vivo,BAO_0000218,,,Bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL626389,,,,,1,1
10094,50597,In vivo,BAO_0000218,,,Bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL626390,,,,,1,1
10095,50597,In vivo,BAO_0000218,,,Bioavailability in rat was reported at the dose of 6 mg/kg in 25% PEG-300,,,N,Intermediate,A,10116.0,CHEMBL626391,,,,,1,1
10096,50597,In vivo,BAO_0000218,,,Bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL626392,,,,,1,1
10097,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL626393,,,,,1,1
10098,50597,In vivo,BAO_0000218,,,Bioavailability was determined in rat,,,N,Intermediate,A,10116.0,CHEMBL623026,,,,,1,1
10099,50597,In vivo,BAO_0000218,,,Bioavailability,,,N,Intermediate,A,10116.0,CHEMBL623027,,,,,1,1
10100,50597,In vivo,BAO_0000218,,,Bioavailability,,,N,Intermediate,A,10116.0,CHEMBL623028,,,,,1,1
10101,50597,In vivo,BAO_0000218,,,Bioavailability in rat after 1 day dosing,,,N,Intermediate,A,10116.0,CHEMBL623029,,,,,1,1
10102,50597,In vivo,BAO_0000218,,,Bioavailability in rat after 4 day dosing,,,N,Intermediate,A,10116.0,CHEMBL623030,,,,,1,1
10103,50597,In vivo,BAO_0000218,,,Bioavailability after IV dosing at 0.5 mg/kg in rat; no data,,,N,Intermediate,A,10116.0,CHEMBL623031,,,,,1,1
10104,50597,In vivo,BAO_0000218,,,Bioavailability after IV dosing at 1 mg/kg in rat; no data,,,N,Intermediate,A,10116.0,CHEMBL623032,,,,,1,1
10105,50597,In vivo,BAO_0000218,,,Bioavailability after oral administration at a dose of 2 mg/kg in rat,,,N,Intermediate,A,10116.0,CHEMBL623033,,,,,1,1
10106,50597,In vivo,BAO_0000218,,,Bioavailability after oral administration at a dose of 4 mg/kg in rat,,,N,Intermediate,A,10116.0,CHEMBL623034,,,,,1,1
10107,50597,In vivo,BAO_0000218,,,Bioavailability at 4 hr after administration of 5 mg/kg dose peroral in rat,,,N,Intermediate,A,10116.0,CHEMBL623035,,,,,1,1
10108,50597,In vivo,BAO_0000218,,,Bioavailability at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,,,N,Intermediate,A,10116.0,CHEMBL623036,,,,,1,1
10109,50597,In vivo,BAO_0000218,,,Bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v. and 2 mg/kg p.o.),,,N,Intermediate,A,10116.0,CHEMBL623037,,,,,1,1
10110,50597,In vivo,BAO_0000218,,,Bioavailability by intravenous administration of 3.4 mg/kg in rat,,,N,Intermediate,A,10116.0,CHEMBL623038,,,,,1,1
10111,50597,In vivo,BAO_0000218,,,Bioavailability from rat plasma at a single oral dose of 25 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL874385,,1969.0,Plasma,,1,1
10112,50597,In vivo,BAO_0000218,,,Bioavailability in rat (Fisher) (fasted),,,N,Intermediate,A,10116.0,CHEMBL623039,,,,,1,1
10113,22224,In vivo,BAO_0000218,,,Bioavailability in monkey after po administration of 10 mg/kg dose,,,U,Intermediate,A,9443.0,CHEMBL623040,,,,,0,1
10114,22224,In vivo,BAO_0000218,,,Oral bioavailability in monkey (dose 10 mg/kg),,,U,Intermediate,A,9443.0,CHEMBL623041,,,,,0,1
10115,50597,In vivo,BAO_0000218,,,Bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL623741,,,,,1,1
10116,50597,In vivo,BAO_0000218,,,Bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL623742,,,,,1,1
10117,50597,In vivo,BAO_0000218,,,Bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL623743,,,,,1,1
10118,50597,In vivo,BAO_0000218,,,Bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL623744,,,,,1,1
10119,50597,In vivo,BAO_0000218,,,Bioavailability in rat (dose 2.0 mg/kg p.o.),,,N,Intermediate,A,10116.0,CHEMBL623745,,,,,1,1
10120,50597,In vivo,BAO_0000218,,,Bioavailability in rat (dose 5 mg/kg p.o. and 1 mg/kg i.v.),,,N,Intermediate,A,10116.0,CHEMBL623746,,,,,1,1
10121,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat (dose 5 mg/kg p.o.),,,N,Intermediate,A,10116.0,CHEMBL623747,,,,,1,1
10122,22224,In vivo,BAO_0000218,,,Bioavailability in rat after po administration of 30 mg/kg dose,,,U,Intermediate,A,10116.0,CHEMBL623748,,,,,0,1
10123,22224,In vivo,BAO_0000218,,,Bioavailability in rat after po administration of 30 mg/kg dose,,,U,Intermediate,A,10116.0,CHEMBL623916,,,,,0,1
10124,50597,In vivo,BAO_0000218,,,Bioavailability in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,,,N,Intermediate,A,10116.0,CHEMBL623917,,,,,1,1
10125,50597,In vivo,BAO_0000218,,,Bioavailability in rat (dose 2 mg/kg i.v.),,,N,Intermediate,A,10116.0,CHEMBL623918,,,,,1,1
10126,50597,In vivo,BAO_0000218,,,Bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL874386,,,,,1,1
10127,50597,In vivo,BAO_0000218,,,Bioavailability in rat; Only traces detected in rat plasma,,,N,Intermediate,A,10116.0,CHEMBL623919,,1969.0,Plasma,,1,1
10128,50597,In vivo,BAO_0000218,,,Bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL623920,,,,,1,1
10129,50597,In vivo,BAO_0000218,,,Bioavailability upon oral administration of compound,,,N,Intermediate,A,10116.0,CHEMBL623148,,,,,1,1
10130,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat (Sprague-Dawley) (dose 15 mg/kg),,,N,Intermediate,A,10116.0,CHEMBL623149,,,,,1,1
10131,50597,In vivo,BAO_0000218,,,Bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL623150,,,,,1,1
10132,50597,In vivo,BAO_0000218,,,"Bioavailability was evaluated in rats at a dose of 20 mg/kg, under fasting state",,,N,Intermediate,A,10116.0,CHEMBL623151,,,,,1,1
10133,50597,In vivo,BAO_0000218,,,"Bioavailability was evaluated in rats at a dose of 20 mg/kg, under fed state",,,N,Intermediate,A,10116.0,CHEMBL623152,,,,,1,1
10134,50597,,BAO_0000218,,,Streptococcal cell wall-washed arthritis model in rats at 3.0 mg/kg peroral dose,,,N,Expert,F,10116.0,CHEMBL623153,,,,,1,1
10135,50597,,BAO_0000218,,,Streptococcal cell wall-washed arthritis model in rats at 30.0 mg/kg peroral dose,,,N,Expert,F,10116.0,CHEMBL623154,,,,,1,1
10136,50597,,BAO_0000218,,,In vitro and metabolic stability was determined,,,N,Intermediate,A,10116.0,CHEMBL623155,,,,,1,1
10137,50597,,BAO_0000218,,,In vitro metabolic stability in rat hepatocytes,,,N,Intermediate,A,10116.0,CHEMBL623156,,,,,1,1
10138,50597,,BAO_0000218,,,In vitro metabolic stability in rat was measured as pmol/min/mg/protein,,,N,Intermediate,A,10116.0,CHEMBL623157,,,,,1,1
10139,50597,In vitro,BAO_0000218,401.0,Hepatocyte,Metabolic rate for compound was observed in rat hepatocytes,,,N,Intermediate,A,10116.0,CHEMBL623158,,2107.0,Liver,,1,1
10140,50597,,BAO_0000218,,,In vitro metabolic stability determined after 30 min of incubation in rat hepatic microsomes,,,N,Intermediate,A,10116.0,CHEMBL623159,,,,,1,1
10141,50597,,BAO_0000218,,,Metabolism of compound in rat S9 microsomes ('+''indicates <20% largest observed peak),,,N,Intermediate,A,10116.0,CHEMBL874390,,,,,1,1
10142,50597,,BAO_0000218,,,Metabolism of compound in rat S9 microsomes ('++++' indicates largest observed peak),,,N,Intermediate,A,10116.0,CHEMBL623160,,,,,1,1
10143,50597,,BAO_0000218,,,Metabolism of compound in rat S9 microsomes; Trace,,,N,Intermediate,A,10116.0,CHEMBL623161,,,,,1,1
10144,50597,,BAO_0000218,,,Metabolism was measured as percent loss at 4 hr in rat hepatocytes,,,N,Intermediate,A,10116.0,CHEMBL623162,,,,,1,1
10145,50597,,BAO_0000218,,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex 5-HIAA,,,N,Intermediate,A,10116.0,CHEMBL623163,,,,,1,1
10146,50597,,BAO_0000218,,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex 5-HT,,,N,Intermediate,A,10116.0,CHEMBL623164,,,,,1,1
10147,50597,,BAO_0000218,,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex DA,,,N,Intermediate,A,10116.0,CHEMBL623165,,,,,1,1
10148,50597,,BAO_0000218,,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex DOPAC,,,N,Intermediate,A,10116.0,CHEMBL623166,,,,,1,1
10149,50597,,BAO_0000218,,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex HVA,,,N,Intermediate,A,10116.0,CHEMBL624983,,,,,1,1
10150,50597,,BAO_0000218,,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex NE,,,N,Intermediate,A,10116.0,CHEMBL624984,,,,,1,1
10151,50597,,BAO_0000218,,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Hippocampus 5-HIAA,,,N,Intermediate,A,10116.0,CHEMBL624985,,,,,1,1
10152,50597,,BAO_0000218,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus 5-HT,,,N,Intermediate,A,10116.0,CHEMBL622970,,,,,1,1
10153,50597,,BAO_0000218,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DA; below level of detection,,,N,Intermediate,A,10116.0,CHEMBL622971,,,,,1,1
10154,50597,,BAO_0000218,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DA; below the levels of detection,,,N,Intermediate,A,10116.0,CHEMBL622972,,,,,1,1
10155,50597,,BAO_0000218,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DOPAC; below level of detection,,,N,Intermediate,A,10116.0,CHEMBL622973,,,,,1,1
10156,50597,,BAO_0000218,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DOPAC; below the levels of detection,,,N,Intermediate,A,10116.0,CHEMBL622974,,,,,1,1
10157,50597,,BAO_0000218,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus HVA; below level of detection,,,N,Intermediate,A,10116.0,CHEMBL622975,,,,,1,1
10158,50597,,BAO_0000218,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus HVA; below the levels of detection,,,N,Intermediate,A,10116.0,CHEMBL622976,,,,,1,1
10159,50597,,BAO_0000218,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus NE,,,N,Intermediate,A,10116.0,CHEMBL622977,,,,,1,1
10160,50597,,BAO_0000218,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex 5-HIAA,,,N,Intermediate,A,10116.0,CHEMBL624351,,,,,1,1
10161,50597,,BAO_0000218,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex 5-HT,,,N,Intermediate,A,10116.0,CHEMBL624352,,,,,1,1
10162,50597,,BAO_0000218,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DA,,,N,Intermediate,A,10116.0,CHEMBL624353,,,,,1,1
10163,50597,,BAO_0000218,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DOPAC,,,N,Intermediate,A,10116.0,CHEMBL622397,,,,,1,1
10164,50597,,BAO_0000218,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex HVA,,,N,Intermediate,A,10116.0,CHEMBL622398,,,,,1,1
10165,50597,,BAO_0000218,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex NE,,,N,Intermediate,A,10116.0,CHEMBL622399,,,,,1,1
10166,50597,,BAO_0000218,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DA,,,N,Intermediate,A,10116.0,CHEMBL622400,,,,,1,1
10167,50597,,BAO_0000218,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus 5-HIAA,,,N,Intermediate,A,10116.0,CHEMBL628428,,,,,1,1
10168,50597,,BAO_0000218,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus 5-HT,,,N,Intermediate,A,10116.0,CHEMBL628590,,,,,1,1
10169,50597,,BAO_0000218,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DA; below level of detection,,,N,Intermediate,A,10116.0,CHEMBL628591,,,,,1,1
10170,50597,,BAO_0000218,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DA; below the levels of detection,,,N,Intermediate,A,10116.0,CHEMBL628592,,,,,1,1
10171,50597,,BAO_0000218,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DOPAC; below level of detection,,,N,Intermediate,A,10116.0,CHEMBL628593,,,,,1,1
10172,50597,,BAO_0000218,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DOPAC; below the levels of detection,,,N,Intermediate,A,10116.0,CHEMBL875333,,,,,1,1
10173,50597,,BAO_0000218,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus HVA; below level of detection,,,N,Intermediate,A,10116.0,CHEMBL628594,,,,,1,1
10174,50597,,BAO_0000218,,,Plasma half-life was determined in Sprague-Dawley rats after 0-8 hr of administration,,,N,Intermediate,A,10116.0,CHEMBL628595,,1969.0,Plasma,,1,1
10175,50597,,BAO_0000218,,,Stability in rat plasma was determined,,,N,Intermediate,A,10116.0,CHEMBL628596,,1969.0,Plasma,,1,1
10176,50597,,BAO_0000218,,,Stability in rat plasma was determined; ND= no data,,,N,Intermediate,A,10116.0,CHEMBL628597,,1969.0,Plasma,,1,1
10177,50597,,BAO_0000218,,,Tested for plasma half life period in rat (0-8 hr),,,N,Intermediate,A,10116.0,CHEMBL628598,,1969.0,Plasma,,1,1
10178,50597,,BAO_0000218,,,Tested for plasma half life period in rat (0-8 hr); Not determined,,,N,Intermediate,A,10116.0,CHEMBL628599,,1969.0,Plasma,,1,1
10179,50597,In vivo,BAO_0000218,,,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in rat,,,N,Intermediate,A,10116.0,CHEMBL628600,,,,,1,1
10180,50597,In vivo,BAO_0000218,,,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in rat,,,N,Intermediate,A,10116.0,CHEMBL628601,,,,,1,1
10181,50597,,BAO_0000218,,,Tested for the half life in rat,,,N,Intermediate,A,10116.0,CHEMBL628602,,,,,1,1
10182,50597,In vitro,BAO_0000218,,,Tested in vitro for the time for half reactivation against rat small intestinal glucoamylase,,,N,Intermediate,A,10116.0,CHEMBL628603,,,,,1,1
10183,50597,In vitro,BAO_0000218,,,Tested in vitro for the time for half reactivation against rat small intestinal glucoamylase; ND=Not determined,,,N,Intermediate,A,10116.0,CHEMBL628604,,,,,1,1
10184,50597,In vitro,BAO_0000218,,,Tested in vitro for the time for half reactivation against rat small intestinal isomaltase,,,N,Intermediate,A,10116.0,CHEMBL628605,,,,,1,1
10185,50597,In vitro,BAO_0000218,,,Tested in vitro for the time for half reactivation against rat small intestinal isomaltase; ND=Not determined,,,N,Intermediate,A,10116.0,CHEMBL628606,,,,,1,1
10186,50597,In vitro,BAO_0000218,,,Tested in vitro for the time for half reactivation against rat small intestinal sucrase,,,N,Intermediate,A,10116.0,CHEMBL628607,,,,,1,1
10187,50597,,BAO_0000218,,,The biological half life the compound was measured at the dose of 100 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL628608,,,,,1,1
10188,50597,,BAO_0000218,,,The biological half life the compound was measured at the dose of 30 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL628609,,,,,1,1
10189,50597,,BAO_0000218,,,The compound was evaluated for plasma half life period in rat,,,N,Intermediate,A,10116.0,CHEMBL628610,,1969.0,Plasma,,1,1
10190,50597,In vivo,BAO_0000218,,,"The half life value in female wistar rat at 100 mg/kg, p.o. dose",,,N,Intermediate,A,10116.0,CHEMBL873819,,,,,1,1
10191,50597,In vivo,BAO_0000218,,,"The half life value in male wistar rat at 100 mg/kg, p.o. dose",,,N,Intermediate,A,10116.0,CHEMBL628611,,,,,1,1
10192,50597,In vivo,BAO_0000218,,,The pharmacokinetic parameter half-life period in vivo in rats,,,N,Intermediate,A,10116.0,CHEMBL628612,,,,,1,1
10193,50597,In vivo,BAO_0000218,,,"The pharmacokinetic property, Half-life was determined",,,N,Intermediate,A,10116.0,CHEMBL628613,,,,,1,1
10194,50597,In vivo,BAO_0000218,,,"The pharmacokinetic property, Half-life in rat in vivo",,,N,Intermediate,A,10116.0,CHEMBL628614,,,,,1,1
10195,50597,In vivo,BAO_0000218,,,"The pharmacokinetic property, Half-life was determined; ND denotes no data",,,N,Intermediate,A,10116.0,CHEMBL628615,,,,,1,1
10196,50597,In vivo,BAO_0000218,,,"The pharmacokinetic property, Half-life was determined; ND denotes not determined",,,N,Intermediate,A,10116.0,CHEMBL628616,,,,,1,1
10197,50597,,BAO_0000218,,,The plasma half life period in rats,,,N,Intermediate,A,10116.0,CHEMBL627924,,1969.0,Plasma,,1,1
10198,50597,,BAO_0000218,,,The release rate of the free drug from the substrate in rat liver lysosomal preparation by rat liver lysosomal assay,,,N,Intermediate,A,10116.0,CHEMBL627925,,2107.0,Liver,,1,1
10199,50597,In vivo,BAO_0000218,,,half life in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,,,N,Intermediate,A,10116.0,CHEMBL627926,,,,,1,1
10200,50597,,BAO_0000218,,,t1/2 (apparent elimination)of the compound was determined,,,N,Intermediate,A,10116.0,CHEMBL627927,,,,,1,1
10201,50597,,BAO_0000218,,,t1/2 value in rat,,,N,Intermediate,A,10116.0,CHEMBL627928,,,,,1,1
10202,50597,,BAO_0000218,,,Half life in rat,,,N,Intermediate,A,10116.0,CHEMBL627539,,,,,1,1
10203,50597,In vivo,BAO_0000218,,,"Half life period calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv",,,N,Intermediate,A,10116.0,CHEMBL876790,,1969.0,Plasma,,1,1
10204,50597,In vivo,BAO_0000218,,,Pharmacokinetic property (t1/2beta) was measured in rat at the dose of 0.32 mg/kg i.v.,,,N,Intermediate,A,10116.0,CHEMBL858186,,,,,1,1
10205,50597,,BAO_0000218,,,Half-life period in fasted rats,,,N,Intermediate,A,10116.0,CHEMBL627540,,,,,1,1
10206,50597,In vivo,BAO_0000218,,,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female wistar rats,,,N,Intermediate,A,10116.0,CHEMBL627541,,,,,1,1
10207,50597,In vivo,BAO_0000218,,,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to male wistar rats,,,N,Intermediate,A,10116.0,CHEMBL627715,,,,,1,1
10208,50597,In vivo,BAO_0000218,,,Evaluated for pharmacokinetic parameter tmax in rat at the dose 50 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL627716,,,,,1,1
10209,50597,,BAO_0000218,,,Maximum time required to achieve Cmax was determined in rat,,,N,Intermediate,A,10116.0,CHEMBL627717,,,,,1,1
10210,50597,In vivo,BAO_0000218,,,Time calculated to reach Cmax at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,,,N,Intermediate,A,10116.0,CHEMBL627718,,,,,1,1
10211,50597,In vivo,BAO_0000218,,,Time calculated to reach Cmax at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,,,N,Intermediate,A,10116.0,CHEMBL627719,,,,,1,1
10212,50597,In vivo,BAO_0000218,,,Time calculated to reach Cmax at a concentration of 60 mg/kg perorally in rats along with control,,,N,Intermediate,A,10116.0,CHEMBL627720,,,,,1,1
10213,50597,In vivo,BAO_0000218,,,Time to reach maximum concentration in rat after 2 mg/kg peroral administration,,,N,Intermediate,A,10116.0,CHEMBL627721,,,,,1,1
10214,50597,In vivo,BAO_0000218,,,Time to reach maximum concentration in rat after 2 mg/kg peroral administration; 4-6,,,N,Intermediate,A,10116.0,CHEMBL627722,,,,,1,1
10215,50597,In vivo,BAO_0000218,,,Tmax of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,,,N,Intermediate,A,10116.0,CHEMBL627723,,,,,1,1
10216,50597,In vivo,BAO_0000218,,,Tmax of compound (19.76 mg/kg) after po administration was determined in Sprague-Dawley rat,,,N,Intermediate,A,10116.0,CHEMBL626058,,,,,1,1
10217,50597,In vivo,BAO_0000218,,,Tmax of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,,,N,Intermediate,A,10116.0,CHEMBL626059,,,,,1,1
10218,50597,In vivo,BAO_0000218,,,Tmax of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,,,N,Intermediate,A,10116.0,CHEMBL626060,,,,,1,1
10219,50597,In vivo,BAO_0000218,,,Tmax at a dose of 4 mg/kg in Rat Plasma after iv administration,,,N,Intermediate,A,10116.0,CHEMBL626061,,1969.0,Plasma,,1,1
10220,50597,In vivo,BAO_0000218,,,Tmax determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,,N,Intermediate,A,10116.0,CHEMBL876791,,,,,1,1
10221,50597,In vivo,BAO_0000218,,,Tmax determined after 3 mg/kg oral administration in potassium oxonate treated rats,,,N,Intermediate,A,10116.0,CHEMBL626062,,,,,1,1
10222,50597,In vivo,BAO_0000218,,,Tmax at the dose of 2 mg/Kg administered perorally in rats,,,N,Intermediate,A,10116.0,CHEMBL626063,,,,,1,1
10223,50597,In vivo,BAO_0000218,,,Tmax at the dose of 5 mg/Kg administered perorally in rats,,,N,Intermediate,A,10116.0,CHEMBL626064,,,,,1,1
10224,50597,In vivo,BAO_0000218,,,tmax at a dose of 100 mg/kg in Rat Plasma after iv administration,,,N,Intermediate,A,10116.0,CHEMBL626065,,1969.0,Plasma,,1,1
10225,50597,In vivo,BAO_0000218,,,tmax at a dose of 50 mg/kg in Rat Plasma after iv administration,,,N,Intermediate,A,10116.0,CHEMBL626066,,1969.0,Plasma,,1,1
10226,50597,In vivo,BAO_0000218,,,tmax upon peroral administration of 10.0 mg/Kg dose in rat,,,N,Intermediate,A,10116.0,CHEMBL626067,,,,,1,1
10227,50597,,BAO_0000218,,,Percent total excretion of 3-(thiomethyl)acetaminophen glucuronide,,,N,Intermediate,F,10116.0,CHEMBL626068,,,,,1,1
10228,50597,,BAO_0000218,,,Percent total excretion of 3-(thiomethyl)acetaminophen sulfate,,,N,Intermediate,F,10116.0,CHEMBL626069,,,,,1,1
10229,50597,,BAO_0000218,,,Percent total excretion of 3-methoxyacetaminophen glucuronide,,,N,Intermediate,F,10116.0,CHEMBL626070,,,,,1,1
10230,50597,,BAO_0000218,,,Percent total excretion of N-methoxyacetaminophen glucuronide,,,N,Intermediate,F,10116.0,CHEMBL626071,,,,,1,1
10231,50597,,BAO_0000218,,,Percent total excretion of N-methoxyacetaminophen sulfate,,,N,Intermediate,F,10116.0,CHEMBL626072,,,,,1,1
10232,50597,,BAO_0000218,,,Percent total excretion of acetaminophen,,,N,Intermediate,F,10116.0,CHEMBL626073,,,,,1,1
10233,50597,,BAO_0000218,,,"Distribution of radioactivity in thyroid tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 6.19-7.22",,,N,Intermediate,A,10116.0,CHEMBL626741,,2046.0,Thyroid gland,,1,1
10234,50597,,BAO_0000218,,,"Percent instability was measured by Rat S9 liver slice metabolism assay, in vitro",,,N,Intermediate,A,10116.0,CHEMBL626742,,,,,1,1
10235,50597,,BAO_0000218,,,Plasma clearance following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats,,,N,Intermediate,A,10116.0,CHEMBL626743,,,,,1,1
10236,50597,,BAO_0000218,,,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,,,N,Intermediate,A,10116.0,CHEMBL876792,,,,,1,1
10237,50597,,BAO_0000218,,,Volume of distribution following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,,,N,Intermediate,A,10116.0,CHEMBL626744,,,,,1,1
10238,50597,,BAO_0000218,,,Compound was tested for antidiuretic activity in rats,,,N,Intermediate,A,10116.0,CHEMBL626745,,,,,1,1
10239,50597,In vivo,BAO_0000218,,,AUC in rat after 3mg/kg oral dose,,,N,Intermediate,A,10116.0,CHEMBL626746,,1969.0,Plasma,,1,1
10240,50597,,BAO_0000218,,,Ratio in brain to that of rat plasma for 2 hr after peroral administration at 10 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL626747,,,,,1,1
10241,50597,,BAO_0000218,,,Ratio in brain to that of rat plasma for 2 hr after peroral administration at 5 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL626748,,,,,1,1
10242,50597,,BAO_0000218,,,Bioavailability administered orally at a dose of 10 mg/kg to rats,,,N,Intermediate,A,10116.0,CHEMBL626749,,,,,1,1
10243,50597,,BAO_0000218,,,Oral Bioavailability was determined,,,N,Intermediate,A,10116.0,CHEMBL626750,,,,,1,1
10244,50597,,BAO_0000218,,,Oral bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL626751,,,,,1,1
10245,50597,,BAO_0000218,,,Oral bioavailability in rat; Not performed.,,,N,Intermediate,A,10116.0,CHEMBL626913,,,,,1,1
10246,50597,,BAO_0000218,,,Bioavailability,,,N,Intermediate,A,10116.0,CHEMBL626914,,,,,1,1
10247,50597,,BAO_0000218,,,Bioavailability was determined; ND denotes no data,,,N,Intermediate,A,10116.0,CHEMBL626915,,,,,1,1
10248,50597,,BAO_0000218,,,Biliary excretion when administered intravenously at a dose of 2.5 mg/kg in rats,,,N,Intermediate,A,10116.0,CHEMBL626916,,,,,1,1
10249,50597,,BAO_0000218,,,Biliary excretion when administered intravenously at a dose of 5 mg/kg in rats,,,N,Intermediate,A,10116.0,CHEMBL626917,,,,,1,1
10250,50597,,BAO_0000218,,,Binding towards rat plasma protein at 10 uM,,,N,Intermediate,A,10116.0,CHEMBL626918,,,,,1,1
10251,50597,,BAO_0000218,,,Binding towards rat plasma protein at 100 uM,,,N,Intermediate,A,10116.0,CHEMBL626919,,,,,1,1
10252,50597,In vivo,BAO_0000218,,,Bioavailability in rat (dose 20 mg/kg p.o.),,,N,Intermediate,A,10116.0,CHEMBL626920,,,,,1,1
10253,50597,In vivo,BAO_0000218,,,Bioavailability was determined after oral administration of compound 18 at a dose of 4 mg/kg to rat,,,N,Intermediate,A,10116.0,CHEMBL621976,,,,,1,1
10254,50597,In vivo,BAO_0000218,,,Bioavailability in rat after 5 mg/kg oral gavage,,,N,Intermediate,A,10116.0,CHEMBL877599,,,,,1,1
10255,50597,In vivo,BAO_0000218,,,Bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL621977,,,,,1,1
10256,50597,In vivo,BAO_0000218,,,Bioavailability in rat (dose 1 mg/kg i.v.),,,N,Intermediate,A,10116.0,CHEMBL621978,,,,,1,1
10257,50597,In vivo,BAO_0000218,,,Bioavailability in rat (dose 3 mg/kg p.o.),,,N,Intermediate,A,10116.0,CHEMBL621979,,,,,1,1
10258,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL621980,,,,,1,1
10259,50597,In vivo,BAO_0000218,,,Bioavailability of the compound in rats after administration of 30 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL621981,,,,,1,1
10260,50597,In vivo,BAO_0000218,,,Bioavailability after administration of 10 mg/kg in rats,,,N,Intermediate,A,10116.0,CHEMBL621982,,,,,1,1
10261,50597,In vivo,BAO_0000218,,,Bioavailability after administration of 2 mg/kg in rats,,,N,Intermediate,A,10116.0,CHEMBL882953,,,,,1,1
10262,50597,In vivo,BAO_0000218,,,Bioavailability by oral administration at a dose of 100 uM/kg in rat was determined,,,N,Intermediate,A,10116.0,CHEMBL621983,,,,,1,1
10263,50597,In vivo,BAO_0000218,,,Bioavailability in dogs was determined; high,,,N,Intermediate,A,10116.0,CHEMBL621984,,,,,1,1
10264,50597,In vivo,BAO_0000218,,,Bioavailability in monkey after intravenous administration at 1 mpk,,,N,Intermediate,A,10116.0,CHEMBL621985,,,,,1,1
10265,50597,In vivo,BAO_0000218,,,Bioavailability in monkey after peroral administration at 10 mpk,,,N,Intermediate,A,10116.0,CHEMBL621986,,,,,1,1
10266,50597,In vivo,BAO_0000218,,,Bioavailability in rat after intravenous administration at 1 mpk,,,N,Intermediate,A,10116.0,CHEMBL621987,,,,,1,1
10267,50597,In vivo,BAO_0000218,,,Bioavailability in rat after intravenous administration at 2 mpk,,,N,Intermediate,F,10116.0,CHEMBL877600,,,,,1,1
10268,50597,In vivo,BAO_0000218,,,Bioavailability in rat after peroral administration at 30 mpk,,,N,Intermediate,A,10116.0,CHEMBL621988,,,,,1,1
10269,50597,In vivo,BAO_0000218,,,Bioavailability in rat after peroral administration at at 100 mpk,,,N,Intermediate,F,10116.0,CHEMBL621989,,,,,1,1
10270,50597,In vivo,BAO_0000218,,,Bioavailability in rats was evaluated,,,N,Intermediate,A,10116.0,CHEMBL621990,,,,,1,1
10271,50597,In vivo,BAO_0000218,,,Bioavailability was calculated after an intravenous dose of 0.3 mg/Kg in rats after 6 hr,,,N,Intermediate,A,10116.0,CHEMBL621991,,,,,1,1
10272,50597,In vivo,BAO_0000218,,,Bioavailability was calculated after an intravenous dose of 1 mg/Kg in rats after 6 hr,,,N,Intermediate,A,10116.0,CHEMBL621992,,,,,1,1
10273,50597,In vivo,BAO_0000218,,,Bioavailability was calculated after peroral dose of 3.0 mg/Kg in rats after 4 hr,,,N,Intermediate,A,10116.0,CHEMBL621993,,,,,1,1
10274,50597,In vivo,BAO_0000218,,,Bioavailability was calculated after peroral dose of 3.0 mg/Kg in rats after 6 hr,,,N,Intermediate,A,10116.0,CHEMBL621994,,,,,1,1
10275,50597,In vivo,BAO_0000218,,,Bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL621995,,,,,1,1
10276,50597,In vivo,BAO_0000218,,,Bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL621996,,,,,1,1
10277,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat (dose 10 mg/kg),,,N,Intermediate,A,10116.0,CHEMBL621997,,,,,1,1
10278,50597,In vivo,BAO_0000218,,,Bioavailability in rat after po administration at a dose of 10 mg/kg; nd is not determined,,,N,Intermediate,A,10116.0,CHEMBL621998,,,,,1,1
10279,50597,In vivo,BAO_0000218,,,Bioavailability upon peroral administration of 10.0 mg/Kg dose in rat,,,N,Intermediate,A,10116.0,CHEMBL621999,,,,,1,1
10280,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL622000,,,,,1,1
10281,50597,In vivo,BAO_0000218,,,Bioavailability was measured in rat after oral administration; 2-4,,,N,Intermediate,A,10116.0,CHEMBL622001,,,,,1,1
10282,50597,In vivo,BAO_0000218,,,Bioavailability was measured in rat after oral administration; 3-7,,,N,Intermediate,A,10116.0,CHEMBL622002,,,,,1,1
10283,50597,In vivo,BAO_0000218,,,Bioavailability in rat (intraduodenal administration),,,N,Intermediate,A,10116.0,CHEMBL622003,,,,,1,1
10284,50597,In vivo,BAO_0000218,,,Bioavailability in rat (intraduodenal administration),,,N,Intermediate,A,10116.0,CHEMBL877601,,,,,1,1
10285,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL624871,,,,,1,1
10286,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL622004,,,,,1,1
10287,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg p.o.),,,N,Intermediate,A,10116.0,CHEMBL882954,,,,,1,1
10288,50597,In vivo,BAO_0000218,,,Bioavailability was evaluated when a dose of 3 mg/kg was administered orally,,,N,Intermediate,A,10116.0,CHEMBL622005,,,,,1,1
10289,50597,In vivo,BAO_0000218,,,Bioavailability was evaluated when a dose of 3 mg/kg was administered orally to a fasting rat,,,N,Intermediate,A,10116.0,CHEMBL622006,,,,,1,1
10290,50597,In vivo,BAO_0000218,,,Bioavailability was measured in rat,,,N,Intermediate,A,10116.0,CHEMBL622007,,,,,1,1
10291,50597,In vivo,BAO_0000218,,,Bioavailability was reported,,,N,Intermediate,A,10116.0,CHEMBL622008,,,,,1,1
10292,50597,In vivo,BAO_0000218,,,Bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),,,N,Intermediate,A,10116.0,CHEMBL622009,,,,,1,1
10293,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),,,N,Intermediate,A,10116.0,CHEMBL622010,,,,,1,1
10294,50597,In vivo,BAO_0000218,,,Bioavailability was determined upon 10 mg/kg in 1% methylcellulose peroral administration in rats,,,N,Intermediate,A,10116.0,CHEMBL622011,,,,,1,1
10295,50597,In vivo,BAO_0000218,,,Bioavailability in rat (dose 2 mg/kg in 1% methylcellulose p.o.),,,N,Intermediate,A,10116.0,CHEMBL622012,,,,,1,1
10296,50597,In vivo,BAO_0000218,,,Bioavailability in rat (dose 3 mg/kg in 1% methylcellulose ),,,N,Intermediate,A,10116.0,CHEMBL622013,,,,,1,1
10297,50597,In vivo,BAO_0000218,,,Bioavailability was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,,,N,Intermediate,A,10116.0,CHEMBL622014,,,,,1,1
10298,50597,In vivo,BAO_0000218,,,Bioavailability was determined at 3 mg/kg po dose in rats,,,N,Intermediate,A,10116.0,CHEMBL624749,,,,,1,1
10299,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat (dose 2 mg/kg),,,N,Intermediate,A,10116.0,CHEMBL624750,,,,,1,1
10300,50597,In vivo,BAO_0000218,,,"Bioavailability was determined in rats at 10 mg/kg, p.o. dose",,,N,Intermediate,A,10116.0,CHEMBL624751,,,,,1,1
10301,50597,In vivo,BAO_0000218,,,"Bioavailability was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",,,N,Intermediate,A,10116.0,CHEMBL624752,,,,,1,1
10302,50597,In vivo,BAO_0000218,,,"Bioavailability was determined in rats at 2 mg/kg, i.v. dose; n/a: not applicable",,,N,Intermediate,A,10116.0,CHEMBL624753,,,,,1,1
10303,50597,In vivo,BAO_0000218,,,Bioavailability was evaluated in rat after peroral administration at a dose of 1 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL624754,,,,,1,1
10304,50597,In vivo,BAO_0000218,,,Bioavailability was evaluated in rats at an intravenous dose of 3 mg/kg; Not applicable,,,N,Intermediate,A,10116.0,CHEMBL624755,,,,,1,1
10305,50597,In vivo,BAO_0000218,,,Bioavailability was evaluated in rats at an oral dose of 30 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL624756,,,,,1,1
10306,50597,In vivo,BAO_0000218,,,Bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL624757,,,,,1,1
10307,50597,In vivo,BAO_0000218,,,Bioavailability was evaluated in rats at an intravenous dose of 3 mg/kg; Not applicable,,,N,Intermediate,A,10116.0,CHEMBL624758,,,,,1,1
10308,50597,In vivo,BAO_0000218,,,Bioavailability was evaluated in rats at an oral dose of 30 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL622270,,,,,1,1
10309,50597,In vivo,BAO_0000218,,,Bioavailability in rat (Sprague-Dawley),,,N,Intermediate,A,10116.0,CHEMBL622271,,,,,1,1
10310,50597,In vivo,BAO_0000218,,,Bioavailability in rat at the dose of 2 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL622272,,,,,1,1
10311,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL622273,,,,,1,1
10312,50597,In vivo,BAO_0000218,,,Bioavailability in rat (cannulated) (dose 2 mg/kg),,,N,Intermediate,A,10116.0,CHEMBL622274,,,,,1,1
10313,50597,In vivo,BAO_0000218,,,Bioavailability value of compound in rats was determined after peroral administration,,,N,Intermediate,A,10116.0,CHEMBL622275,,,,,1,1
10314,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat (dose 20 mg/kg),,,N,Intermediate,A,10116.0,CHEMBL622276,,,,,1,1
10315,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL622277,,,,,1,1
10316,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat (dose 5 mg/kg),,,N,Intermediate,A,10116.0,CHEMBL622278,,,,,1,1
10317,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL622279,,,,,1,1
10318,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL622280,,,,,1,1
10319,50597,In vivo,BAO_0000218,,,Compound was evaluated for oral bioavailability in rats; 15-27 %,,,N,Intermediate,A,10116.0,CHEMBL624083,,,,,1,1
10320,50597,In vivo,BAO_0000218,,,Compound was evaluated for pharmacokinetic parameter percent bioavailability at 18 h,,,N,Intermediate,A,10116.0,CHEMBL624084,,,,,1,1
10321,50597,In vivo,BAO_0000218,,,Compound was evaluated for pharmacokinetic property in rats after an oral dose of 10 mg/kg and the value was reported as oral bioavailability (F),,,N,Intermediate,A,10116.0,CHEMBL624085,,,,,1,1
10322,50597,In vivo,BAO_0000218,,,Compound was tested for bioavailability in rats,,,N,Intermediate,A,10116.0,CHEMBL624086,,,,,1,1
10323,50597,In vivo,BAO_0000218,,,Bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL624087,,,,,1,1
10324,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL624088,,,,,1,1
10325,22224,In vivo,BAO_0000218,,,Compound was tested for oral bioavailability in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po.,,,U,Intermediate,A,9544.0,CHEMBL624089,,,,,0,1
10326,22224,In vivo,BAO_0000218,,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v. and 2 mg/kg p.o.),,,U,Intermediate,A,10116.0,CHEMBL624090,,,,,0,1
10327,50597,In vivo,BAO_0000218,,,Evaluated for the bioavailability in rat (in vivo),,,N,Intermediate,A,10116.0,CHEMBL624091,,,,,1,1
10328,50597,In vivo,BAO_0000218,,,F value of compound in rats was determined after peroral administration,,,N,Intermediate,A,10116.0,CHEMBL624092,,,,,1,1
10329,50597,In vivo,BAO_0000218,,,In vivo Oral bioavailability (F)was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,,N,Intermediate,A,10116.0,CHEMBL624093,,,,,1,1
10330,50597,In vivo,BAO_0000218,,,In vivo Oral bioavailability (F)was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,,N,Intermediate,A,10116.0,CHEMBL624094,,,,,1,1
10331,50597,In vivo,BAO_0000218,,,In vivo Oral bioavailability (F)was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,,,N,Intermediate,A,10116.0,CHEMBL624095,,,,,1,1
10332,50597,In vivo,BAO_0000218,,,In vivo Oral bioavailability (F)was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,,N,Intermediate,A,10116.0,CHEMBL624096,,,,,1,1
10333,50597,In vivo,BAO_0000218,,,"In vivo percent of absolute bioavailability obtained from blood plasma levels analyzed by means of GC/MS (dose 5 uM/kg i.v. and 40 uM/kg, p.o.)",,,N,Intermediate,A,10116.0,CHEMBL624097,,,,,1,1
10334,50597,In vivo,BAO_0000218,,,Maximum fall in carotid flow in rat,,,N,Intermediate,A,10116.0,CHEMBL624098,,,,,1,1
10335,50597,In vivo,BAO_0000218,,,Oral Bioavailability after intravenous administration (1 mg/kg) in rat,,,N,Intermediate,A,10116.0,CHEMBL874392,,,,,1,1
10336,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat (dose 5 mg/kg),,,N,Intermediate,A,10116.0,CHEMBL624099,,,,,1,1
10337,50597,In vivo,BAO_0000218,,,Oral bioavailability (F%) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,,,N,Intermediate,A,10116.0,CHEMBL624100,,,,,1,1
10338,50597,In vivo,BAO_0000218,,,Oral bioavailability (F%) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,,,N,Intermediate,A,10116.0,CHEMBL624101,,,,,1,1
10339,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat (male Wistar),,,N,Intermediate,A,10116.0,CHEMBL624102,,,,,1,1
10340,50597,In vivo,BAO_0000218,,,Oral bioavailability after administration (30 mg/kg) in rat; good,,,N,Intermediate,A,10116.0,CHEMBL624103,,,,,1,1
10341,50597,In vivo,BAO_0000218,,,Oral bioavailability at the dose of 2 mg/kg in rat,,,N,Intermediate,A,10116.0,CHEMBL624104,,,,,1,1
10342,50597,In vivo,BAO_0000218,,,Oral bioavailability determined in rats,,,N,Intermediate,A,10116.0,CHEMBL624105,,,,,1,1
10343,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat (Sprague-Dawley) (male) (dose 50 mg/kg p.o.),,,N,Intermediate,A,10116.0,CHEMBL624106,,,,,1,1
10344,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat (dose single 10 mg/kg),,,N,Intermediate,A,10116.0,CHEMBL624107,,,,,1,1
10345,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat (dose single 10 mg/kg),,,N,Intermediate,A,10116.0,CHEMBL623943,,,,,1,1
10346,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat (dose 5 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL623944,,,,,1,1
10347,50597,,BAO_0000218,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus HVA; below the levels of detection,,,N,Intermediate,A,10116.0,CHEMBL623945,,,,,1,1
10348,50597,,BAO_0000218,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus NE,,,N,Intermediate,A,10116.0,CHEMBL623946,,,,,1,1
10349,50597,,BAO_0000218,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex 5-HIAA,,,N,Intermediate,A,10116.0,CHEMBL623947,,,,,1,1
10350,50597,,BAO_0000218,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex 5-HT,,,N,Intermediate,A,10116.0,CHEMBL623948,,,,,1,1
10351,50597,,BAO_0000218,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex DA,,,N,Intermediate,A,10116.0,CHEMBL623949,,,,,1,1
10352,50597,,BAO_0000218,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex DOPAC,,,N,Intermediate,A,10116.0,CHEMBL623950,,,,,1,1
10353,50597,,BAO_0000218,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex HVA,,,N,Intermediate,A,10116.0,CHEMBL874398,,,,,1,1
10354,50597,,BAO_0000218,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex NE,,,N,Intermediate,A,10116.0,CHEMBL623951,,,,,1,1
10355,50597,,BAO_0000218,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus 5-HIAA,,,N,Intermediate,A,10116.0,CHEMBL623952,,,,,1,1
10356,50597,,BAO_0000218,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus 5-HT,,,N,Intermediate,A,10116.0,CHEMBL623953,,,,,1,1
10357,50597,,BAO_0000218,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DA; below level of detection,,,N,Intermediate,A,10116.0,CHEMBL623954,,,,,1,1
10358,50597,,BAO_0000218,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DA; below the levels of detection,,,N,Intermediate,A,10116.0,CHEMBL623955,,,,,1,1
10359,50597,,BAO_0000218,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DOPAC; below level of detection,,,N,Intermediate,A,10116.0,CHEMBL623956,,,,,1,1
10360,50597,,BAO_0000218,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DOPAC; below the levels of detection,,,N,Intermediate,A,10116.0,CHEMBL627807,,,,,1,1
10361,50597,,BAO_0000218,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus HVA; below level of detection,,,N,Intermediate,A,10116.0,CHEMBL627808,,,,,1,1
10362,50597,,BAO_0000218,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus HVA; below the levels of detection,,,N,Intermediate,A,10116.0,CHEMBL627809,,,,,1,1
10363,50597,,BAO_0000218,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus NE,,,N,Intermediate,A,10116.0,CHEMBL627810,,,,,1,1
10364,50597,,BAO_0000218,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex 5-HIAA",,,N,Intermediate,A,10116.0,CHEMBL627811,,,,,1,1
10365,50597,,BAO_0000218,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex 5-HT",,,N,Intermediate,A,10116.0,CHEMBL627812,,,,,1,1
10366,50597,,BAO_0000218,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex DA",,,N,Intermediate,A,10116.0,CHEMBL627813,,,,,1,1
10367,50597,,BAO_0000218,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex DOPAC",,,N,Intermediate,A,10116.0,CHEMBL627814,,,,,1,1
10368,50597,,BAO_0000218,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex HVA",,,N,Intermediate,A,10116.0,CHEMBL875336,,,,,1,1
10369,50597,,BAO_0000218,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex NE",,,N,Intermediate,A,10116.0,CHEMBL627815,,,,,1,1
10370,50597,,BAO_0000218,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus 5-HIAA",,,N,Intermediate,A,10116.0,CHEMBL627816,,,,,1,1
10371,50597,,BAO_0000218,,,"Momoamine and metabolic levels observed at 3 h postdrug against, at a dose of 20 mg/kg Hippocampus 5-HT",,,N,Intermediate,A,10116.0,CHEMBL627817,,,,,1,1
10372,50597,,BAO_0000218,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus DA; below the levels of detection",,,N,Intermediate,A,10116.0,CHEMBL627818,,,,,1,1
10373,50597,,BAO_0000218,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus DOPAC; below the levels of detection",,,N,Intermediate,A,10116.0,CHEMBL627819,,,,,1,1
10374,50597,,BAO_0000218,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus HVA; below the levels of detection",,,N,Intermediate,A,10116.0,CHEMBL627820,,,,,1,1
10375,50597,,BAO_0000218,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus NE",,,N,Intermediate,A,10116.0,CHEMBL627821,,,,,1,1
10376,50597,,BAO_0000218,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex 5-HIAA,,,N,Intermediate,A,10116.0,CHEMBL628464,,,,,1,1
10377,50597,,BAO_0000218,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex 5-HT,,,N,Intermediate,A,10116.0,CHEMBL626239,,,,,1,1
10378,50597,,BAO_0000218,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex DA,,,N,Intermediate,A,10116.0,CHEMBL626240,,,,,1,1
10379,50597,,BAO_0000218,,,Momoamine and metabolic levels observed at 3 h postdrug against at a dose of 20 mg/kg Frontal cortex DOPAC,,,N,Intermediate,A,10116.0,CHEMBL626241,,,,,1,1
10380,50597,,BAO_0000218,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex HVA,,,N,Intermediate,A,10116.0,CHEMBL626242,,,,,1,1
10381,50597,,BAO_0000218,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex NE,,,N,Intermediate,A,10116.0,CHEMBL626243,,,,,1,1
10382,50597,,BAO_0000218,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus 5-HIAA,,,N,Intermediate,A,10116.0,CHEMBL626244,,,,,1,1
10383,50597,,BAO_0000218,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus 5-HT; below level of detection,,,N,Intermediate,A,10116.0,CHEMBL626907,,,,,1,1
10384,50597,,BAO_0000218,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus DA; below level of detection,,,N,Intermediate,A,10116.0,CHEMBL626908,,,,,1,1
10385,50597,,BAO_0000218,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus DOPAC; below level of detection,,,N,Intermediate,A,10116.0,CHEMBL626909,,,,,1,1
10386,50597,,BAO_0000218,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus HVA; below level of detection,,,N,Intermediate,A,10116.0,CHEMBL626910,,,,,1,1
10387,50597,,BAO_0000218,,,Percent total excretion of acetaminophen cysteine conjugate,,,N,Intermediate,F,10116.0,CHEMBL875342,,,,,1,1
10388,50597,,BAO_0000218,,,Percent total excretion of acetaminophen glucuronide,,,N,Intermediate,F,10116.0,CHEMBL626911,,,,,1,1
10389,50597,,BAO_0000218,,,Percent total excretion of acetaminophen sulfate,,,N,Intermediate,F,10116.0,CHEMBL626912,,,,,1,1
10390,50597,,BAO_0000218,,,Percent total excretion of acetaminophen-mercapturic acid,,,N,Intermediate,F,10116.0,CHEMBL627065,,,,,1,1
10391,50597,,BAO_0000218,,,Amount of urine output was measured in rat at a dose of 10 mg/kg administered orally,,,N,Intermediate,A,10116.0,CHEMBL627066,,1088.0,Urine,,1,1
10392,50597,In vivo,BAO_0000218,,,Volume of distribution in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL627067,,,,,1,1
10393,22224,In vivo,BAO_0000218,,,Biodistribution of compound in rat muscle after 5 min of administration,,,U,Autocuration,A,8656.0,CHEMBL627068,,2385.0,Muscle tissue,,0,1
10394,22224,In vivo,BAO_0000218,,,Biodistribution of compound in rat muscle after 5 min of administration.,,,U,Autocuration,A,8656.0,CHEMBL627069,,2385.0,Muscle tissue,,0,1
10395,22224,In vivo,BAO_0000218,,,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),,,U,Autocuration,A,9940.0,CHEMBL627070,,,,,0,1
10396,22224,In vivo,BAO_0000218,,,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),,,U,Autocuration,A,9940.0,CHEMBL627071,,,,,0,1
10397,22224,In vivo,BAO_0000218,,,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),,,U,Autocuration,A,9940.0,CHEMBL627072,,,,,0,1
10398,22224,In vivo,BAO_0000218,,,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),,,U,Autocuration,A,9940.0,CHEMBL627073,,,,,0,1
10399,22224,In vivo,BAO_0000218,,,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),,,U,Autocuration,A,9940.0,CHEMBL625387,,,,,0,1
10400,22224,In vivo,BAO_0000218,,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),,,U,Autocuration,A,9940.0,CHEMBL625388,,,,,0,1
10401,22224,In vivo,BAO_0000218,,,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),,,U,Autocuration,A,9940.0,CHEMBL625389,,1969.0,Plasma,,0,1
10402,22224,In vivo,BAO_0000218,,,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),,,U,Autocuration,A,9940.0,CHEMBL875343,,1969.0,Plasma,,0,1
10403,50497,,BAO_0000218,,,Biological half life period of compound was measured against snake venom phosphodiesterase (SVPDE),,,N,Intermediate,A,8570.0,CHEMBL876795,,,,,1,1
10404,50497,,BAO_0000218,,,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards snake venom (SV-PDE) at a concentration of 4 microg,,,N,Intermediate,A,8570.0,CHEMBL626552,,,,,1,1
10405,50497,,BAO_0000218,,,Enzymatic stability was assessed with snake venom phosphodiesterase (SV PDE) exonuclase,,,N,Intermediate,A,8570.0,CHEMBL626553,,,,,1,1
10406,22224,,BAO_0000366,,,The human biological plasma half life of the compound,,,U,Autocuration,A,9606.0,CHEMBL626554,,1969.0,Plasma,,0,1
10407,50597,,BAO_0000218,,,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,,,N,Intermediate,A,10116.0,CHEMBL626555,,1088.0,Urine,,1,1
10408,50597,,BAO_0000218,,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 120 min after iv administration compound,,,N,Intermediate,A,10116.0,CHEMBL626556,,,,,1,1
10409,50597,,BAO_0000218,,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 15 after iv administration of compound,,,N,Intermediate,A,10116.0,CHEMBL626557,,,,,1,1
10410,50597,,BAO_0000218,,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 240 min after iv administration compound,,,N,Intermediate,A,10116.0,CHEMBL626558,,,,,1,1
10411,50597,,BAO_0000218,,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 30 min after iv administration of compound,,,N,Intermediate,A,10116.0,CHEMBL626559,,,,,1,1
10412,50597,,BAO_0000218,,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 5 min after iv administration of compound,,,N,Intermediate,A,10116.0,CHEMBL626560,,,,,1,1
10413,50597,,BAO_0000218,,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 60 min after iv administration of compound,,,N,Intermediate,A,10116.0,CHEMBL876803,,,,,1,1
10414,50597,,BAO_0000218,,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 120 min after iv administration compound,,,N,Intermediate,A,10116.0,CHEMBL627964,,,,,1,1
10415,50597,,BAO_0000218,,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 15 min after iv administration of compound,,,N,Intermediate,A,10116.0,CHEMBL627965,,,,,1,1
10416,50597,,BAO_0000218,,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 240 min after iv administration compound,,,N,Intermediate,A,10116.0,CHEMBL627966,,,,,1,1
10417,50597,,BAO_0000218,,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 30 min after iv administration of compound,,,N,Intermediate,A,10116.0,CHEMBL627967,,,,,1,1
10418,50597,,BAO_0000218,,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 5 min after iv administration of compound,,,N,Intermediate,A,10116.0,CHEMBL627968,,,,,1,1
10419,50597,,BAO_0000218,,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 60 min after iv administration of compound,,,N,Intermediate,A,10116.0,CHEMBL627969,,,,,1,1
10420,50597,,BAO_0000218,,,Distribution of Se-75 activity in Liver of female Sprague-Dawley Rat 5 min after iv administration of compound,,,N,Intermediate,A,10116.0,CHEMBL627970,,,,,1,1
10421,50597,,BAO_0000218,,,Distribution of Se-75 activity in blood of female Sprague-Dawley Rat 120 min after iv administration of compound,,,N,Intermediate,A,10116.0,CHEMBL627971,,178.0,Blood,,1,1
10422,50597,,BAO_0000218,,,Distribution of Se-75 activity in blood of female Sprague-Dawley Rat 240 min after iv administration of compound,,,N,Intermediate,A,10116.0,CHEMBL627972,,178.0,Blood,,1,1
10423,180,,BAO_0000357,,,Dissociation constant against binding to human cyclophilin A,,,D,Expert,B,9606.0,CHEMBL856029,,,,,9,1
10424,11591,,BAO_0000019,,,Michaelis-Menten constant for inhibitory activity against bovine liver glyoxalase II,,,H,Expert,B,9913.0,CHEMBL627973,,,,,8,1
10425,22224,,BAO_0000019,,,-Log C was determined by performing the electroshock minimum test,,,U,Autocuration,A,,CHEMBL627974,,,,,0,1
10426,22224,,BAO_0000019,,,-Log C was determined by performing the foot shock test,,,U,Autocuration,A,,CHEMBL627975,,,,,0,1
10427,22224,,BAO_0000019,,,-Log C was determined by performing the incl screen test,,,U,Autocuration,A,,CHEMBL627976,,,,,0,1
10428,22224,,BAO_0000019,,,-Log C was determined by performing the maximum electroshock test,,,U,Autocuration,A,,CHEMBL627977,,,,,0,1
10429,22224,,BAO_0000019,,,-Log C was determined by performing the pentylenetetrazole test,,,U,Autocuration,A,,CHEMBL627978,,,,,0,1
10430,22224,,BAO_0000019,,,Tested for experimental arotinoid inhibitory dose,,,U,Autocuration,A,,CHEMBL627979,,,,,0,1
10431,22224,,BAO_0000019,,,Negative log transformed activity,,,U,Autocuration,A,,CHEMBL876804,,,,,0,1
10432,22224,,BAO_0000019,,,"Negative log of Langmuir's alpha constant (-log alpha), which is inversely proportional to the effective binding constant (protein binding)",,,U,Autocuration,A,,CHEMBL627980,,,,,0,1
10433,50512,,BAO_0000218,,,Dissociation constant was evaluated on guinea pig bladder at M3 muscarinic receptor,,,N,Intermediate,A,10141.0,CHEMBL627981,,,,,1,1
10434,50512,,BAO_0000218,,,Dissociation constant was evaluated on guinea pig heart (force) at M2 muscarinic receptor,,,N,Intermediate,A,10141.0,CHEMBL627982,,,,,1,1
10435,50512,,BAO_0000218,,,Dissociation constant was evaluated on guinea pig heart (rate) at M2 muscarinic receptor,,,N,Intermediate,A,10141.0,CHEMBL627983,,,,,1,1
10436,50512,,BAO_0000218,,,Dissociation constant was evaluated on guinea pig ileum at M3 muscarinic receptor,,,N,Intermediate,A,10141.0,CHEMBL627984,,2116.0,Ileum,,1,1
10437,22229,,BAO_0000100,,,Solubility in water was determined; values expressed as -log,,,U,Autocuration,P,,CHEMBL627985,,,,,0,1
10438,22224,,BAO_0000019,,,Ratio of Kcat to that of Km was determined,,,U,Autocuration,A,,CHEMBL627986,,,,,0,1
10439,22224,,BAO_0000019,,,Observed first order rate constant,,,U,Autocuration,A,,CHEMBL627987,,,,,0,1
10440,22224,,BAO_0000019,,,Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours,,,U,Autocuration,A,,CHEMBL627988,,,,,0,1
10441,50597,In vivo,BAO_0000218,,,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female wistar rats,,,N,Intermediate,A,10116.0,CHEMBL627989,,,,,1,1
10442,50597,In vivo,BAO_0000218,,,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to male wistar rats,,,N,Intermediate,A,10116.0,CHEMBL627990,,,,,1,1
10443,50597,In vivo,BAO_0000218,,,Oral Bioavailability after administration of 10 mg/kg in male rat,,,N,Intermediate,A,10116.0,CHEMBL876805,,,,,1,1
10444,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat (dose 10 mg/kg i.v. and 50 mg/kg p.o.),,,N,Intermediate,A,10116.0,CHEMBL627991,,,,,1,1
10445,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL627992,,,,,1,1
10446,50597,In vivo,BAO_0000218,,,Oral bioavailability after oral (po) administration at a dose of 10 mg/kg was measured in rats,,,N,Intermediate,A,10116.0,CHEMBL627993,,,,,1,1
10447,50597,In vivo,BAO_0000218,,,Oral bioavailability at 1 mg/kg was determined in rat,,,N,Intermediate,A,10116.0,CHEMBL622817,,,,,1,1
10448,50597,In vivo,BAO_0000218,,,Oral bioavailability at 10 mg/kg was determined in rat,,,N,Intermediate,A,10116.0,CHEMBL622818,,,,,1,1
10449,50597,In vivo,BAO_0000218,,,"Oral bioavailability in fischer rats at 30 mg/kg dose, administered perorally",,,N,Intermediate,A,10116.0,CHEMBL622819,,,,,1,1
10450,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL872267,,,,,1,1
10451,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL622820,,,,,1,1
10452,50597,In vivo,BAO_0000218,,,Oral bioavailability after intravenous administration in rats at 24 uM/kg,,,N,Intermediate,A,10116.0,CHEMBL622821,,,,,1,1
10453,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL622822,,,,,1,1
10454,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL622823,,,,,1,1
10455,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL622824,,,,,1,1
10456,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat at a dose of 3 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL622825,,,,,1,1
10457,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat after oral administration at 10 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL622901,,,,,1,1
10458,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL622902,,,,,1,1
10459,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL621844,,,,,1,1
10460,50597,In vivo,BAO_0000218,,,Oral bioavailability in Dawley rats,,,N,Intermediate,A,10116.0,CHEMBL621845,,,,,1,1
10461,50597,In vivo,BAO_0000218,,,Oral bioavailability,,,N,Intermediate,A,10116.0,CHEMBL621846,,,,,1,1
10462,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat (dose 30 mg/kg),,,N,Intermediate,A,10116.0,CHEMBL621847,,,,,1,1
10463,50597,In vivo,BAO_0000218,,,Bioavailability in rat at a concentration of 15 mg/kg perorally in rat along with 100 mg/kg 11,,,N,Intermediate,A,10116.0,CHEMBL877609,,,,,1,1
10464,50597,In vivo,BAO_0000218,,,Bioavailability in rat (dose 3 mg/kg i.v.),,,N,Intermediate,A,10116.0,CHEMBL621848,,,,,1,1
10465,50597,In vivo,BAO_0000218,,,Bioavailability in rat at a concentration of 60 mg/kg perorally in rat along with 100 mg/kg 11,,,N,Intermediate,A,10116.0,CHEMBL621849,,,,,1,1
10466,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat (dose 60 mg/kg p.o.),,,N,Intermediate,A,10116.0,CHEMBL622030,,,,,1,1
10467,50597,In vivo,BAO_0000218,,,Percent oral bioavailability determined in rats,,,N,Intermediate,A,10116.0,CHEMBL622031,,,,,1,1
10468,50597,In vivo,BAO_0000218,,,Tested for percent bioavailability after oral administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL622032,,,,,1,1
10469,50597,In vivo,BAO_0000218,,,The compound was evaluated for bioavailability in rats; 32-51,,,N,Intermediate,A,10116.0,CHEMBL622033,,,,,1,1
10470,50597,In vivo,BAO_0000218,,,Bioavailability in rat (dose 20 mg/kg p.o.),,,N,Intermediate,A,10116.0,CHEMBL622034,,,,,1,1
10471,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL622035,,,,,1,1
10472,50597,In vivo,BAO_0000218,,,Bioavailability percent in rat at the dose of 2 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL882966,,,,,1,1
10473,50597,In vivo,BAO_0000218,,,Bioavailability was evaluated after 20 uM/kg of peroral administration,,,N,Intermediate,A,10116.0,CHEMBL622036,,,,,1,1
10474,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL622037,,,,,1,1
10475,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL622038,,,,,1,1
10476,50597,In vivo,BAO_0000218,,,Bioavailability in rats,,,N,Intermediate,A,10116.0,CHEMBL622039,,,,,1,1
10477,50597,In vivo,BAO_0000218,,,Biodistribution of radiolabeled compound in rat blood after 24 hr postinjection activity expressed as %ID/Organ,,,N,Intermediate,A,10116.0,CHEMBL622040,,178.0,Blood,,1,1
10478,50597,In vivo,BAO_0000218,,,Biodistribution of radiolabeled compound in rat blood after 24 hr activity expressed as %ID/Organ,,,N,Intermediate,A,10116.0,CHEMBL622041,,178.0,Blood,,1,1
10479,50597,In vivo,BAO_0000218,,,Biodistribution of radiolabeled compound in rat blood after 2 hr activity expressed as %ID/Organ,,,N,Intermediate,A,10116.0,CHEMBL622042,,178.0,Blood,,1,1
10480,50597,In vivo,BAO_0000218,,,Biodistribution of radiolabeled compound in rat blood after 30 min activity expressed as %ID/Organ,,,N,Intermediate,A,10116.0,CHEMBL622043,,178.0,Blood,,1,1
10481,50597,In vivo,BAO_0000218,,,Biodistribution of radiolabeled compound in rat blood after 5 min activity expressed as %ID/Organ,,,N,Intermediate,A,10116.0,CHEMBL622044,,178.0,Blood,,1,1
10482,50597,In vivo,BAO_0000218,,,Biodistribution of radiolabeled compound in rat bone after 24 hr activity expressed as %ID/Organ,,,N,Intermediate,A,10116.0,CHEMBL622045,,10000001.0,Bone,,1,1
10483,50597,In vivo,BAO_0000218,,,Biodistribution of radiolabeled compound in rat bone after 2 hr activity expressed as %ID/Organ,,,N,Intermediate,A,10116.0,CHEMBL622046,,10000001.0,Bone,,1,1
10484,50597,In vivo,BAO_0000218,,,Biodistribution of radiolabeled compound in rat bone after 30 min activity expressed as %ID/Organ,,,N,Intermediate,A,10116.0,CHEMBL622047,,10000001.0,Bone,,1,1
10485,50597,In vivo,BAO_0000218,,,Biodistribution of radiolabeled compound in rat bone after 5 min activity expressed as %ID/Organ,,,N,Intermediate,A,10116.0,CHEMBL877610,,10000001.0,Bone,,1,1
10486,50597,In vivo,BAO_0000218,,,Biodistribution of radiolabeled compound in rat brain after 24 hr activity expressed as %ID/Organ,,,N,Intermediate,A,10116.0,CHEMBL622048,,955.0,Brain,,1,1
10487,50597,In vivo,BAO_0000218,,,Biodistribution of radiolabeled compound in rat brain after 2 hr activity expressed as %ID/Organ,,,N,Intermediate,A,10116.0,CHEMBL622049,,955.0,Brain,,1,1
10488,50597,In vivo,BAO_0000218,,,Biodistribution of radiolabeled compound in rat brain after 30 min activity expressed as %ID/Organ,,,N,Intermediate,A,10116.0,CHEMBL622050,,955.0,Brain,,1,1
10489,50597,In vivo,BAO_0000218,,,Biodistribution of radiolabeled compound in rat brain after 5 min activity expressed as %ID/Organ,,,N,Intermediate,A,10116.0,CHEMBL622051,,955.0,Brain,,1,1
10490,50597,In vivo,BAO_0000218,,,Biodistribution of radiolabeled compound in rat fat after 24 hr activity expressed as %ID/Organ,,,N,Intermediate,A,10116.0,CHEMBL622052,,,,,1,1
10491,50597,In vivo,BAO_0000218,,,Biodistribution of radiolabeled compound in rat fat after 2 hr activity expressed as %ID/Organ,,,N,Intermediate,A,10116.0,CHEMBL622053,,,,,1,1
10492,50597,In vivo,BAO_0000218,,,Biodistribution of radiolabeled compound in rat fat after 30 min activity expressed as %ID/Organ,,,N,Intermediate,A,10116.0,CHEMBL622054,,,,,1,1
10493,50597,In vivo,BAO_0000218,,,Biodistribution of radiolabeled compound in rat fat after 5 min activity expressed as %ID/Organ,,,N,Intermediate,A,10116.0,CHEMBL622055,,,,,1,1
10494,50597,In vivo,BAO_0000218,,,Oral bioavailability in rats was determined; High,,,N,Intermediate,A,10116.0,CHEMBL622056,,,,,1,1
10495,50597,In vivo,BAO_0000218,,,Oral bioavailability in the rat was determined,,,N,Intermediate,A,10116.0,CHEMBL622057,,,,,1,1
10496,50597,In vivo,BAO_0000218,,,Oral bioavailability measured by the ratio of intravenous to oral area under concentration.,,,N,Intermediate,A,10116.0,CHEMBL628008,,,,,1,1
10497,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat (dose 10 mg/kg p.o. and 3 mg/kg i.v.),,,N,Intermediate,A,10116.0,CHEMBL622058,,,,,1,1
10498,50597,In vivo,BAO_0000218,,,Oral bioavailability of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,,,N,Intermediate,A,10116.0,CHEMBL622059,,,,,1,1
10499,50597,In vivo,BAO_0000218,,,Oral bioavailability of compound (19.76 mg/kg) after po administration was determined in Sprague-Dawley rat,,,N,Intermediate,A,10116.0,CHEMBL622060,,,,,1,1
10500,50597,In vivo,BAO_0000218,,,Oral bioavailability of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,,,N,Intermediate,A,10116.0,CHEMBL622061,,,,,1,1
10501,50597,In vivo,BAO_0000218,,,Oral bioavailability of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,,,N,Intermediate,A,10116.0,CHEMBL622062,,,,,1,1
10502,50597,In vivo,BAO_0000218,,,Oral bioavailability of compound at a dose of 20 mg/kg was determined after oral administration in rat,,,N,Intermediate,A,10116.0,CHEMBL622063,,,,,1,1
10503,50597,In vivo,BAO_0000218,,,Oral bioavailability of compound determined in rat after iv administration at a dose of 10 mg/kg,,,N,Expert,A,10116.0,CHEMBL877611,,,,,1,1
10504,50597,In vivo,BAO_0000218,,,Oral bioavailability of compound in Sprague Dawley rats,,,N,Intermediate,A,10116.0,CHEMBL622064,,,,,1,1
10505,50597,In vivo,BAO_0000218,,,Oral bioavailability of compound in rat,,,N,Intermediate,A,10116.0,CHEMBL622065,,,,,1,1
10506,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat (dose 2 mg/kg),,,N,Intermediate,A,10116.0,CHEMBL622066,,,,,1,1
10507,50597,In vivo,BAO_0000218,,,Oral bioavailability of compound in rat was determined,,,N,Intermediate,A,10116.0,CHEMBL622067,,,,,1,1
10508,50597,In vivo,BAO_0000218,,,Oral bioavailability of compound in rats,,,N,Intermediate,A,10116.0,CHEMBL622068,,,,,1,1
10509,50597,In vivo,BAO_0000218,,,Oral bioavailability of compound was determined in rats,,,N,Intermediate,A,10116.0,CHEMBL622069,,,,,1,1
10510,50597,In vivo,BAO_0000218,,,Oral bioavailability at a dose of 30 mg/kg in rats,,,N,Intermediate,A,10116.0,CHEMBL624796,,,,,1,1
10511,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat (dose 10 mg/kg),,,N,Intermediate,A,10116.0,CHEMBL624797,,,,,1,1
10512,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat (dose 10 mg/kg),,,N,Intermediate,A,10116.0,CHEMBL623053,,,,,1,1
10513,50597,In vivo,BAO_0000218,,,Oral bioavailability evaluated in rat,,,N,Intermediate,A,10116.0,CHEMBL623054,,,,,1,1
10514,50597,In vivo,BAO_0000218,,,Oral bioavailability in fasted rat,,,N,Intermediate,A,10116.0,CHEMBL623055,,,,,1,1
10515,50597,In vivo,BAO_0000218,,,Oral bioavailability in fed rat,,,N,Intermediate,A,10116.0,CHEMBL623056,,,,,1,1
10516,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat (mature male) (dose 30 mg/kg),,,N,Intermediate,A,10116.0,CHEMBL623057,,,,,1,1
10517,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL623058,,,,,1,1
10518,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat (dose 10 mg/kg p.o.),,,N,Intermediate,A,10116.0,CHEMBL623059,,,,,1,1
10519,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat after administration of 10 mg/kg po,,,N,Intermediate,A,10116.0,CHEMBL623060,,,,,1,1
10520,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL623061,,,,,1,1
10521,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL623062,,,,,1,1
10522,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL623063,,,,,1,1
10523,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL623064,,,,,1,1
10524,50597,In vivo,BAO_0000218,,,Oral bioavailability in ratrs,,,N,Intermediate,A,10116.0,CHEMBL623065,,,,,1,1
10525,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL623066,,,,,1,1
10526,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL623067,,,,,1,1
10527,50597,In vivo,BAO_0000218,,,Oral bioavailability in rats was determined; High,,,N,Intermediate,A,10116.0,CHEMBL623068,,,,,1,1
10528,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL623069,,,,,1,1
10529,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL623070,,,,,1,1
10530,50597,In vivo,BAO_0000218,,,Oral bioavailability was calculated in rat,,,N,Intermediate,A,10116.0,CHEMBL623071,,,,,1,1
10531,50597,In vivo,BAO_0000218,,,Oral bioavailability,,,N,Intermediate,A,10116.0,CHEMBL623072,,,,,1,1
10532,50597,In vivo,BAO_0000218,,,Oral bioavailability,,,N,Intermediate,A,10116.0,CHEMBL623073,,,,,1,1
10533,50597,In vivo,BAO_0000218,,,Oral bioavailability,,,N,Intermediate,A,10116.0,CHEMBL623074,,,,,1,1
10534,50597,In vivo,BAO_0000218,,,Oral bioavailability,,,N,Intermediate,A,10116.0,CHEMBL623075,,,,,1,1
10535,50597,In vivo,BAO_0000218,,,Oral bioavailability after i.v. administration,,,N,Intermediate,A,10116.0,CHEMBL623076,,,,,1,1
10536,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),,,N,Intermediate,A,10116.0,CHEMBL623077,,,,,1,1
10537,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat (Sprague-Dawley),,,N,Intermediate,A,10116.0,CHEMBL623078,,,,,1,1
10538,50597,In vivo,BAO_0000218,,,Oral bioavailability in Sprague-Dawley rats,,,N,Intermediate,A,10116.0,CHEMBL623079,,,,,1,1
10539,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),,,N,Intermediate,A,10116.0,CHEMBL623080,,,,,1,1
10540,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),,,N,Intermediate,A,10116.0,CHEMBL623081,,,,,1,1
10541,50597,In vivo,BAO_0000218,,,Oral bioavailability in Sprague-Dawley rats at a dose of 2 mg/kg by po administration,,,N,Intermediate,A,10116.0,CHEMBL623082,,,,,1,1
10542,50597,In vivo,BAO_0000218,,,Oral bioavailability in fasted rat,,,N,Intermediate,A,10116.0,CHEMBL874400,,,,,1,1
10543,50597,In vivo,BAO_0000218,,,Oral bioavailability in fed rat,,,N,Intermediate,A,10116.0,CHEMBL623083,,,,,1,1
10544,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL623084,,,,,1,1
10545,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL623085,,,,,1,1
10546,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL623086,,,,,1,1
10547,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL623087,,,,,1,1
10548,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL623088,,,,,1,1
10549,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL623089,,,,,1,1
10550,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL623090,,,,,1,1
10551,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL623091,,,,,1,1
10552,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL623092,,,,,1,1
10553,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL623093,,,,,1,1
10554,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL874401,,,,,1,1
10555,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL623094,,,,,1,1
10556,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL623095,,,,,1,1
10557,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat after peroral administration at 10 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL623096,,,,,1,1
10558,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat after peroral administration at 5 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL624913,,,,,1,1
10559,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat (dose 2.8 mg/kg p.o.),,,N,Intermediate,A,10116.0,CHEMBL624914,,,,,1,1
10560,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat by po administration at a dose of 40 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL624915,,,,,1,1
10561,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat; Not measured,,,N,Intermediate,A,10116.0,CHEMBL624916,,,,,1,1
10562,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL624917,,,,,1,1
10563,50597,,BAO_0000218,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus NE,,,N,Intermediate,A,10116.0,CHEMBL625157,,,,,1,1
10564,50597,,BAO_0000218,,,In vitro metabolic potential in rat liver microsomes,,,N,Intermediate,A,10116.0,CHEMBL625158,,2107.0,Liver,,1,1
10565,50597,In vivo,BAO_0000218,,,"Oral availability was tested for plasma levels at a dose of 40 mg/kg, after 6 hr of in fed fisher rats.",,,N,Intermediate,A,10116.0,CHEMBL625159,,,,,1,1
10566,50597,In vivo,BAO_0000218,,,"In vivo percentage mean absolute bioavailability of compound in rat after an oral dose of 10 mg/kg (in water, N=4)",,,N,Intermediate,A,10116.0,CHEMBL625160,,,,,1,1
10567,50597,In vivo,BAO_0000218,,,Oral bioavailability of intravenously administered compound (3 mg/kg) was tested in rats,,,N,Intermediate,A,10116.0,CHEMBL625161,,,,,1,1
10568,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL625162,,,,,1,1
10569,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL625163,,,,,1,1
10570,50597,In vivo,BAO_0000218,,,Oral bioavailability in rats at 10 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL625164,,,,,1,1
10571,50597,In vivo,BAO_0000218,,,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,,N,Intermediate,A,10116.0,CHEMBL625165,,,,,1,1
10572,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL625166,,,,,1,1
10573,50597,,BAO_0000218,,,Tested for effective permeability across the rat intestinal membrane using mass balance analysis,,,N,Intermediate,A,10116.0,CHEMBL625167,,,,,1,1
10574,50597,,BAO_0000218,,,Tested for effective permeability across the rat intestinal membrane using mass balance analysis at 0.01 mM concentration,,,N,Intermediate,A,10116.0,CHEMBL625168,,,,,1,1
10575,50597,In vivo,BAO_0000218,,,Plasma clearance of the compound,,,N,Intermediate,A,10116.0,CHEMBL625169,,,,,1,1
10576,50597,In vivo,BAO_0000218,,,Plasma clearance at 10 mg/kg in rat upon intravenous administration,,,N,Intermediate,A,10116.0,CHEMBL626264,,,,,1,1
10577,50597,In vivo,BAO_0000218,,,Plasma clearance upon intravenous administration of 1 mg/Kg in rats,,,N,Intermediate,A,10116.0,CHEMBL626265,,,,,1,1
10578,50597,In vivo,BAO_0000218,,,The compound was tested for plasma clearance in rat,,,N,Intermediate,A,10116.0,CHEMBL626266,,1969.0,Plasma,,1,1
10579,50597,In vivo,BAO_0000218,,,The compound was tested for plasma clearance in rat at dose of 3-10 mgkg,,,N,Intermediate,A,10116.0,CHEMBL626267,,1969.0,Plasma,,1,1
10580,50597,,BAO_0000218,,,Plasma concentration upon oral administration of 1 mg/Kg in rats,,,N,Intermediate,A,10116.0,CHEMBL626268,,,,,1,1
10581,50597,,BAO_0000218,,,Peak plasma level between 0.5 and 1.0 hour in Dawley rats; value ranges from 1021-2551,,,N,Intermediate,A,10116.0,CHEMBL626269,,,,,1,1
10582,50597,,BAO_0000218,,,Plasma level after intravenous administration in rat model of FeCl3-induced carotid thrombosis,,,N,Intermediate,A,10116.0,CHEMBL626270,,,,,1,1
10583,50597,,BAO_0000218,,,Plasma protein binding was determined after intravenous administration of 1 mg/kg in rat,,,N,Intermediate,A,10116.0,CHEMBL626271,,,,,1,1
10584,50597,,BAO_0000218,,,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1",,,N,Intermediate,A,10116.0,CHEMBL626272,,,,,1,1
10585,50597,,BAO_0000218,,,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not determined",,,N,Intermediate,A,10116.0,CHEMBL626273,,,,,1,1
10586,50597,,BAO_0000218,,,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not determined",,,N,Intermediate,A,10116.0,CHEMBL875346,,,,,1,1
10587,50597,,BAO_0000218,,,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not stable",,,N,Intermediate,A,10116.0,CHEMBL626274,,,,,1,1
10588,50597,,BAO_0000218,,,Compound was tested for protein binding in rat plasma,,,N,Intermediate,A,10116.0,CHEMBL626275,,,,,1,1
10589,50597,,BAO_0000218,,,Compound was evaluated for absorption of radioligand following oral administration to bile duct cannulated rat. ,,,N,Intermediate,A,10116.0,CHEMBL624646,,,,,1,1
10590,50597,,BAO_0000218,,,Compound was evaluated for absorption of radioligand upon oral administration to bile duct cannulated rats,,,N,Intermediate,A,10116.0,CHEMBL624647,,,,,1,1
10591,50597,,BAO_0000218,,,In vitro metabolism in rat liver microsomes was evaluated to determine diminishing of glucuronidation rate,,,N,Intermediate,A,10116.0,CHEMBL624648,,2107.0,Liver,,1,1
10592,50597,,BAO_0000218,,,Area under curve ratio was determined (po/iv) in rat,,,N,Intermediate,A,10116.0,CHEMBL624649,,,,,1,1
10593,50597,,BAO_0000218,,,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 15 mins after i.v. administration,,,N,Intermediate,A,10116.0,CHEMBL624650,,,,,1,1
10594,50597,,BAO_0000218,,,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 2 mins after i.v. administration,,,N,Intermediate,A,10116.0,CHEMBL624651,,,,,1,1
10595,50597,,BAO_0000218,,,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 65 mins after i.v. administration,,,N,Intermediate,A,10116.0,CHEMBL624652,,,,,1,1
10596,50597,,BAO_0000218,,,Compound was tested for brain/plasma ratio after oral administration at 10 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL624653,,,,,1,1
10597,50597,,BAO_0000218,,,Ratio of AUCbrain to AUCplasma,,,N,Intermediate,A,10116.0,CHEMBL624654,,,,,1,1
10598,50597,,BAO_0000218,,,Ratio of brain to plasma,,,N,Intermediate,A,10116.0,CHEMBL624655,,,,,1,1
10599,50597,,BAO_0000218,,,Ratio of the AUC values of brain and plasma after intravenous administration (4.7 mg/kg) to male rats was evaluated,,,N,Intermediate,A,10116.0,CHEMBL624656,,,,,1,1
10600,50597,,BAO_0000218,,,Ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats was evaluated,,,N,Intermediate,A,10116.0,CHEMBL624657,,,,,1,1
10601,50597,,BAO_0000218,,,Ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats was evaluated,,,N,Intermediate,A,10116.0,CHEMBL624658,,,,,1,1
10602,50597,,BAO_0000218,,,Selectivity ratio for biodistribution in brain and blood of rats after 15 minutes; Expressed as percent dose/gram ratio,,,N,Intermediate,A,10116.0,CHEMBL624659,,,,,1,1
10603,50597,,BAO_0000218,,,Selectivity ratio for biodistribution in brain and blood of rats after 2 minutes; Expressed as percent dose/gram ratio,,,N,Intermediate,A,10116.0,CHEMBL624660,,,,,1,1
10604,50597,,BAO_0000218,,,Selectivity ratio for biodistribution in brain and blood of rats after 60 minutes; Expressed as percent dose/gram ratio,,,N,Intermediate,A,10116.0,CHEMBL624661,,,,,1,1
10605,50597,,BAO_0000218,,,Steady state brain :blood ratio was determined,,,N,Intermediate,A,10116.0,CHEMBL624662,,,,,1,1
10606,50597,,BAO_0000218,,,Tested for ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,,,N,Intermediate,A,10116.0,CHEMBL625199,,,,,1,1
10607,50597,,BAO_0000218,,,Tested for ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats; ND = not determined,,,N,Intermediate,A,10116.0,CHEMBL625200,,,,,1,1
10608,50597,,BAO_0000218,,,Tested for ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats,,,N,Intermediate,A,10116.0,CHEMBL625201,,,,,1,1
10609,50597,,BAO_0000218,,,Tested for ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats; ND = not determined,,,N,Intermediate,A,10116.0,CHEMBL625202,,,,,1,1
10610,50597,,BAO_0000218,,,Percentage recovery after 3h incubation with rat hapatocytes was determined,,,N,Intermediate,A,10116.0,CHEMBL625203,,,,,1,1
10611,50597,,BAO_0000218,,,Percentage recovery in rat hepatic microsomal fractions under oxidative conditions after 1 hour,,,N,Intermediate,A,10116.0,CHEMBL625204,,,,,1,1
10612,50597,,BAO_0000218,,,Percentage recovery in rhesus monkey hepatic microsomal fractions under oxidative conditions after 1 hour,,,N,Intermediate,A,10116.0,CHEMBL625205,,,,,1,1
10613,50597,,BAO_0000218,,,Recovery rate from urine and bile was determined after iv administration at 20 mg/kg in rats,,,N,Intermediate,A,10116.0,CHEMBL625206,,,,,1,1
10614,22224,,BAO_0000019,,,"Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours; not measured, No site available for protein conjugation.",,,U,Autocuration,A,,CHEMBL625207,,,,,0,1
10615,22224,,BAO_0000019,,,Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours; not measured.,,,U,Autocuration,A,,CHEMBL625208,,,,,0,1
10616,50587,,BAO_0000218,495.0,Caco-2,In vivo absorption in Caco-2 cell line monolayers was determined,,,N,Intermediate,A,9606.0,CHEMBL625209,,,,,1,1
10617,22229,,BAO_0000100,,,Calculated partition coefficient (clogP),,,U,Autocuration,P,,CHEMBL625210,,,,,0,1
10618,50597,,BAO_0000218,,,Area under curve was determine after peroral administration at 10 mpk in Rat,,,N,Intermediate,A,10116.0,CHEMBL625211,,,,,1,1
10619,50797,,BAO_0000218,,,Area under curve was determine after peroral administration at 10 mpk in Rhesus,,,N,Intermediate,A,9544.0,CHEMBL625212,,,,,1,1
10620,50597,,BAO_0000218,,,Area under curve was determine after peroral administration at 160 mpk in Rat,,,N,Intermediate,A,10116.0,CHEMBL625213,,,,,1,1
10621,50597,,BAO_0000218,,,Area under curve was determine after peroral administration at 20 mpk in Rat,,,N,Intermediate,A,10116.0,CHEMBL625214,,,,,1,1
10622,50597,,BAO_0000218,,,Area under curve was determine after peroral administration at 50 mpk in Rat,,,N,Intermediate,A,10116.0,CHEMBL874542,,,,,1,1
10623,22229,,BAO_0000100,,,Calculated partition coefficient (clogP) (AlogP),,,U,Autocuration,P,,CHEMBL625215,,,,,0,1
10624,22224,,BAO_0000019,,,Activated partial thromboplastin time measured,,,U,Autocuration,A,,CHEMBL625216,,,,,0,1
10625,22224,,BAO_0000100,,,Compound was evaluated for the aqueous solubility (AS) in mg/mL (Measured in 0.2 M phosphate buffer of pH 7.4),,,U,Autocuration,P,,CHEMBL625217,,,,,0,1
10626,22224,,BAO_0000100,,,Compound was evaluated for the aqueous solubility (AS) in mg/mL (Measured in 0.2 M phosphate buffer of pH 7.4); ND=Not determined (AS mg/mL),,,U,Autocuration,P,,CHEMBL625218,,,,,0,1
10627,50588,,BAO_0000218,,,AUC (Area under curve) was determined after intravenous administration at a dose 1 mg/kg in dog,,,N,Intermediate,A,9615.0,CHEMBL622864,,1969.0,Plasma,,1,1
10628,50597,,BAO_0000218,,,AUC (Area under curve) was determined after intravenous administration at a dose 2 mg/kg in rat.,,,N,Intermediate,A,10116.0,CHEMBL622865,,1969.0,Plasma,,1,1
10629,50597,,BAO_0000218,,,AUC (Area under curve) was determined after peroral administration at a dose 10 mg/kg in rat.,,,N,Intermediate,A,10116.0,CHEMBL622866,,1969.0,Plasma,,1,1
10630,50588,,BAO_0000218,,,AUC (Area under curve) was determined after peroral administration at a dose 5 mg/kg in dog,,,N,Intermediate,A,9615.0,CHEMBL622867,,1969.0,Plasma,,1,1
10631,50512,,BAO_0000218,,,AUC (ng h/mL) value after oral administration of 10 mg/kg in guinea pig.,,,N,Intermediate,A,10141.0,CHEMBL876808,,1969.0,Plasma,,1,1
10632,22224,,BAO_0000019,,,AUC in brain,,,U,Autocuration,A,,CHEMBL627725,,955.0,Brain,,0,1
10633,22224,,BAO_0000019,,,AUC in serum,,,U,Autocuration,A,,CHEMBL627726,,1977.0,Serum,,0,1
10634,22224,,BAO_0000019,,,AUC was determined,,,U,Autocuration,A,,CHEMBL627727,,1969.0,Plasma,,0,1
10635,22224,,BAO_0000019,,,AUC of the compound.,,,U,Autocuration,A,,CHEMBL627728,,1969.0,Plasma,,0,1
10636,22224,,BAO_0000019,,,AUC value (0-4 hr),,,U,Autocuration,A,,CHEMBL627729,,1969.0,Plasma,,0,1
10637,22224,,BAO_0000019,,,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 150 uMol/kg,",,,U,Autocuration,A,,CHEMBL627730,,1969.0,Plasma,,0,1
10638,22224,,BAO_0000019,,,AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 300 uMol/kg,,,U,Autocuration,A,,CHEMBL627731,,1969.0,Plasma,,0,1
10639,22224,,BAO_0000019,,,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 300 uMol/kg,",,,U,Autocuration,A,,CHEMBL627732,,1969.0,Plasma,,0,1
10640,22224,,BAO_0000019,,,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 700 uMol/kg,",,,U,Autocuration,A,,CHEMBL627733,,1969.0,Plasma,,0,1
10641,50597,,BAO_0000218,,,AUC(area under curve) was determined after intravenous administration in rats,,,N,Intermediate,A,10116.0,CHEMBL627734,,1969.0,Plasma,,1,1
10642,50597,,BAO_0000218,,,AUC(area under curve) was determined after oral administration in rats,,,N,Intermediate,A,10116.0,CHEMBL627735,,1969.0,Plasma,,1,1
10643,50512,,BAO_0000218,,,AUC(ng h/mL)values after oral administration of 10 mg/kg in guinea pig.,,,N,Intermediate,A,10141.0,CHEMBL627736,,1969.0,Plasma,,1,1
10644,50597,,BAO_0000218,,,AUC(ng h/mL)values after oral administration of 10 mg/kg in rat.,,,N,Intermediate,A,10116.0,CHEMBL876809,,1969.0,Plasma,,1,1
10645,22224,,BAO_0000019,,,Area Under Curve after oral dosing of 100 uM/Kg,,,U,Autocuration,A,,CHEMBL627737,,,,,0,1
10646,22224,,BAO_0000019,,,Area Under Curve after oral dosing of 30 uM/Kg,,,U,Autocuration,A,,CHEMBL627738,,,,,0,1
10647,22224,,BAO_0000019,,,Area Under Curve was measured by ploting the graph between concentration verses time,,,U,Autocuration,A,,CHEMBL627739,,,,,0,1
10648,50588,,BAO_0000218,,,Area under concentration-time curve of compound was determined in dog at 25 mg/kg orally,,,N,Intermediate,A,9615.0,CHEMBL626143,,,,,1,1
10649,22224,,BAO_0000218,,,Area under concentration-time curve of compound was determined in monkey at 25 mg/kg orally,,,U,Autocuration,A,314293.0,CHEMBL626144,,,,,0,1
10650,50592,,BAO_0000218,,,Area under concentration-time curve of compound was determined in rabbit at 25 mg/kg orally,,,N,Intermediate,A,9986.0,CHEMBL626145,,,,,1,1
10651,50597,,BAO_0000218,,,Area under concentration-time curve of compound was determined in rat at 25 mg/kg orally,,,N,Intermediate,A,10116.0,CHEMBL626146,,,,,1,1
10652,50597,,BAO_0000218,,,Area under curve (AUC) is the drug concentrations in blood samples of rats with arterial catheters at 5 min and 12 hr plotted against time,,,N,Intermediate,A,10116.0,CHEMBL626147,,178.0,Blood,,1,1
10653,22224,,BAO_0000019,,,Area under curve (AUC) was determined,,,U,Autocuration,A,,CHEMBL626148,,,,,0,1
10654,22224,,BAO_0000218,,,Area under curve (AUC) following ip administration at 1 mg/kg,,,U,Autocuration,A,,CHEMBL626149,,,,,0,1
10655,22224,,BAO_0000019,,,Area under curve (AUC) was determined; ND is Not determined,,,U,Autocuration,A,,CHEMBL626150,,,,,0,1
10656,50588,,BAO_0000218,,,Area under curve (AUC) was determined in dogs fed after intravenous administration of 25 mg/kg of the compound,,,N,Intermediate,A,9615.0,CHEMBL626151,,,,,1,1
10657,50588,,BAO_0000218,,,Area under curve (AUC) was determined in dogs fed after oral administration of 25 mg/kg of the compound,,,N,Intermediate,A,9615.0,CHEMBL626152,,,,,1,1
10658,50588,,BAO_0000218,,,Area under curve (AUC) was determined in fasted dogs after oral administration of 25 mg/kg of the compound,,,N,Intermediate,A,9615.0,CHEMBL626153,,,,,1,1
10659,22224,,BAO_0000019,,,Area under curve (AUR) was determined,,,U,Autocuration,A,,CHEMBL626154,,,,,0,1
10660,22224,,BAO_0000019,,,Area under curve at 1 uM/dg administered intravenously,,,U,Autocuration,A,,CHEMBL626155,,,,,0,1
10661,22224,,BAO_0000019,,,Area under curve at 10 uM/dg administered perorally,,,U,Autocuration,A,,CHEMBL626156,,,,,0,1
10662,22224,,BAO_0000019,,,Area under curve at 2 uM/dg administered intravenously,,,U,Autocuration,A,,CHEMBL626157,,,,,0,1
10663,22224,,BAO_0000019,,,Area under curve at 20 uM/dg administered perorally,,,U,Autocuration,A,,CHEMBL626158,,,,,0,1
10664,50588,,BAO_0000218,,,Area under curve at a peroral dose of 3 mg/kg in dog,,,N,Intermediate,A,9615.0,CHEMBL626159,,,,,1,1
10665,50597,,BAO_0000218,,,Area under curve at a peroral dose of 3 mg/kg in rat,,,N,Intermediate,A,10116.0,CHEMBL626160,,,,,1,1
10666,50588,,BAO_0000218,,,Area under curve at an iv dose of 1 mg/kg in dog,,,N,Intermediate,A,9615.0,CHEMBL626161,,,,,1,1
10667,50597,,BAO_0000218,,,Area under curve at an iv dose of 1 mg/kg in rat,,,N,Intermediate,A,10116.0,CHEMBL626162,,,,,1,1
10668,22224,,BAO_0000019,,,Area under curve gives the effective duration for the angiotensin II antagonist effect of the compound.,,,U,Autocuration,A,,CHEMBL626163,,,,,0,1
10669,22224,,BAO_0000019,,,Area under curve gives the effective duration for the angiotensin II antagonist effect.,,,U,Autocuration,A,,CHEMBL626164,,,,,0,1
10670,50594,,BAO_0000218,,,Area under curve measured as conc vs time after intravenous administration to mice.,,,N,Intermediate,A,10090.0,CHEMBL626165,,,,,1,1
10671,50594,,BAO_0000218,,,Area under curve measured as conc vs time after peroral administration to mice.,,,N,Intermediate,A,10090.0,CHEMBL626166,,,,,1,1
10672,50588,,BAO_0000218,,,Area under curve of acid 2a was determined by HPLC at a dosage of 2.27 mg/kg administered intravenously by bolus method in dog,,,N,Intermediate,A,9615.0,CHEMBL626167,,,,,1,1
10673,50588,,BAO_0000218,,,Area under curve of acid 2a was determined by HPLC at a dosage of 5.45 mg/kg administered intragastrically by capsule method in dog,,,N,Intermediate,A,9615.0,CHEMBL626168,,,,,1,1
10674,50588,,BAO_0000218,,,Area under curve of acid 2a was determined by HPLC at a dosage of 5.45 mg/kg administered intragastrically by gavage method in dog,,,N,Intermediate,A,9615.0,CHEMBL877463,,,,,1,1
10675,50588,,BAO_0000218,,,Area under curve of acid 2a was determined by HPLC at a dosage of 54.5 mg/kg administered intragastrically by capsule method in dog,,,N,Intermediate,A,9615.0,CHEMBL626169,,,,,1,1
10676,50597,In vivo,BAO_0000218,,,Biodistribution of radiolabeled compound in rat heart after 24 hr activity expressed as %ID/Organ,,,N,Intermediate,A,10116.0,CHEMBL626170,,948.0,Heart,,1,1
10677,50597,In vivo,BAO_0000218,,,Biodistribution of radiolabeled compound in rat heart after 2 hr activity expressed as %ID/Organ,,,N,Intermediate,A,10116.0,CHEMBL626171,,948.0,Heart,,1,1
10678,50597,In vivo,BAO_0000218,,,Biodistribution of radiolabeled compound in rat heart after 30 min activity expressed as %ID/Organ,,,N,Intermediate,A,10116.0,CHEMBL626172,,948.0,Heart,,1,1
10679,50597,In vivo,BAO_0000218,,,Biodistribution of radiolabeled compound in rat heart after 5 min activity expressed as %ID/Organ,,,N,Intermediate,A,10116.0,CHEMBL626173,,948.0,Heart,,1,1
10680,50597,In vivo,BAO_0000218,,,Biodistribution of radiolabeled compound in rat kidney after 24 hr postinjection activity expressed as %ID/Organ,,,N,Intermediate,A,10116.0,CHEMBL626174,,2113.0,Kidney,,1,1
10681,50597,In vivo,BAO_0000218,,,Biodistribution of radiolabeled compound in rat kidney after 24 hr activity expressed as %ID/Organ,,,N,Intermediate,A,10116.0,CHEMBL626175,,2113.0,Kidney,,1,1
10682,50597,In vivo,BAO_0000218,,,Biodistribution of radiolabeled compound in rat kidney after 2 hr activity expressed as %ID/Organ,,,N,Intermediate,A,10116.0,CHEMBL626176,,2113.0,Kidney,,1,1
10683,50597,In vivo,BAO_0000218,,,Biodistribution of radiolabeled compound in rat kidney after 30 min activity expressed as %ID/Organ,,,N,Intermediate,A,10116.0,CHEMBL626177,,2113.0,Kidney,,1,1
10684,50597,In vivo,BAO_0000218,,,Biodistribution of radiolabeled compound in rat kidney after 5 min activity expressed as %ID/Organ,,,N,Intermediate,A,10116.0,CHEMBL622499,,2113.0,Kidney,,1,1
10685,50597,In vivo,BAO_0000218,,,Biodistribution of radiolabeled compound in rat liver after 24 hr postinjection activity expressed as %ID/Organ,,,N,Intermediate,A,10116.0,CHEMBL622500,,2107.0,Liver,,1,1
10686,50597,In vivo,BAO_0000218,,,Biodistribution of radiolabeled compound in rat liver after 24 hr activity expressed as %ID/Organ,,,N,Intermediate,A,10116.0,CHEMBL622501,,2107.0,Liver,,1,1
10687,50597,In vivo,BAO_0000218,,,Biodistribution of radiolabeled compound in rat liver after 2 hr activity expressed as %ID/Organ,,,N,Intermediate,A,10116.0,CHEMBL622502,,2107.0,Liver,,1,1
10688,50597,In vivo,BAO_0000218,,,Biodistribution of radiolabeled compound in rat liver after 30 min activity expressed as %ID/Organ,,,N,Intermediate,A,10116.0,CHEMBL622503,,2107.0,Liver,,1,1
10689,50597,In vivo,BAO_0000218,,,Biodistribution of radiolabeled compound in rat liver after 5 min activity expressed as %ID/Organ,,,N,Intermediate,A,10116.0,CHEMBL877614,,2107.0,Liver,,1,1
10690,50597,In vivo,BAO_0000218,,,Biodistribution of radiolabeled compound in rat lung after 24 hr activity expressed as %ID/Organ,,,N,Intermediate,A,10116.0,CHEMBL624839,,2048.0,Lung,,1,1
10691,50597,In vivo,BAO_0000218,,,Biodistribution of radiolabeled compound in rat lung after 2 hr activity expressed as %ID/Organ,,,N,Intermediate,A,10116.0,CHEMBL624840,,2048.0,Lung,,1,1
10692,50597,In vivo,BAO_0000218,,,Biodistribution of radiolabeled compound in rat lung after 30 min activity expressed as %ID/Organ,,,N,Intermediate,A,10116.0,CHEMBL624841,,2048.0,Lung,,1,1
10693,50597,In vivo,BAO_0000218,,,Biodistribution of radiolabeled compound in rat lung after 5 min activity expressed as %ID/Organ,,,N,Intermediate,A,10116.0,CHEMBL624842,,2048.0,Lung,,1,1
10694,50597,In vivo,BAO_0000218,,,Biodistribution of radiolabeled compound in rat muscle after 24 hr activity expressed as %ID/Organ,,,N,Intermediate,A,10116.0,CHEMBL624843,,2385.0,Muscle tissue,,1,1
10695,50597,In vivo,BAO_0000218,,,Biodistribution of radiolabeled compound in rat muscle after 2 hr activity expressed as %ID/Organ,,,N,Intermediate,A,10116.0,CHEMBL624844,,2385.0,Muscle tissue,,1,1
10696,50597,In vivo,BAO_0000218,,,Biodistribution of radiolabeled compound in rat muscle after 30 min activity expressed as %ID/Organ,,,N,Intermediate,A,10116.0,CHEMBL624845,,2385.0,Muscle tissue,,1,1
10697,50597,In vivo,BAO_0000218,,,Biodistribution of radiolabeled compound in rat muscle after 5 min activity expressed as %ID/Organ,,,N,Intermediate,A,10116.0,CHEMBL621904,,2385.0,Muscle tissue,,1,1
10698,50597,In vivo,BAO_0000218,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 15 mins after i.v. administration,,,N,Intermediate,A,10116.0,CHEMBL621905,,178.0,Blood,,1,1
10699,50597,In vivo,BAO_0000218,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 2 mins after i.v. administration,,,N,Intermediate,A,10116.0,CHEMBL874382,,178.0,Blood,,1,1
10700,50597,In vivo,BAO_0000218,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 65 mins after i.v. administration,,,N,Intermediate,A,10116.0,CHEMBL621906,,178.0,Blood,,1,1
10701,50597,In vivo,BAO_0000218,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 15 mins after i.v. administration,,,N,Intermediate,A,10116.0,CHEMBL621907,,955.0,Brain,,1,1
10702,50597,In vivo,BAO_0000218,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 2 mins after i.v. administration,,,N,Intermediate,A,10116.0,CHEMBL622096,,955.0,Brain,,1,1
10703,50597,In vivo,BAO_0000218,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 65 mins after i.v. administration,,,N,Intermediate,A,10116.0,CHEMBL622097,,955.0,Brain,,1,1
10704,50597,In vivo,BAO_0000218,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 15 mins after i.v. administration,,,N,Intermediate,A,10116.0,CHEMBL622098,,948.0,Heart,,1,1
10705,50597,In vivo,BAO_0000218,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 2 mins after i.v. administration,,,N,Intermediate,A,10116.0,CHEMBL622099,,948.0,Heart,,1,1
10706,50597,In vivo,BAO_0000218,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 65 mins after i.v. administration,,,N,Intermediate,A,10116.0,CHEMBL622100,,948.0,Heart,,1,1
10707,50597,In vivo,BAO_0000218,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 15 mins after i.v. administration,,,N,Intermediate,A,10116.0,CHEMBL622101,,2113.0,Kidney,,1,1
10708,50597,In vivo,BAO_0000218,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 2 mins after i.v. administration,,,N,Intermediate,A,10116.0,CHEMBL622102,,2113.0,Kidney,,1,1
10709,50597,In vivo,BAO_0000218,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 65 mins after i.v. administration,,,N,Intermediate,A,10116.0,CHEMBL622103,,2113.0,Kidney,,1,1
10710,50597,In vivo,BAO_0000218,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 15 mins after i.v. administration,,,N,Intermediate,A,10116.0,CHEMBL622104,,2107.0,Liver,,1,1
10711,50597,In vivo,BAO_0000218,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 2 mins after i.v. administration,,,N,Intermediate,A,10116.0,CHEMBL622105,,2107.0,Liver,,1,1
10712,50597,In vivo,BAO_0000218,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 65 mins after i.v. administration,,,N,Intermediate,A,10116.0,CHEMBL622106,,2107.0,Liver,,1,1
10713,50597,In vivo,BAO_0000218,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 15 mins after i.v. administration,,,N,Intermediate,A,10116.0,CHEMBL622107,,2048.0,Lung,,1,1
10714,50597,In vivo,BAO_0000218,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 2 mins after i.v. administration,,,N,Intermediate,A,10116.0,CHEMBL622108,,2048.0,Lung,,1,1
10715,50597,In vivo,BAO_0000218,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 65 mins after i.v. administration,,,N,Intermediate,A,10116.0,CHEMBL622109,,2048.0,Lung,,1,1
10716,50597,In vivo,BAO_0000218,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 15 mins after i.v. administration,,,N,Intermediate,A,10116.0,CHEMBL622110,,2385.0,Muscle tissue,,1,1
10717,50597,In vivo,BAO_0000218,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 2 mins after i.v. administration,,,N,Intermediate,A,10116.0,CHEMBL622111,,2385.0,Muscle tissue,,1,1
10718,50597,In vivo,BAO_0000218,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 65 mins after i.v. administration,,,N,Intermediate,A,10116.0,CHEMBL874383,,2385.0,Muscle tissue,,1,1
10719,50597,In vivo,BAO_0000218,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 15 mins after i.v. administration,,,N,Intermediate,A,10116.0,CHEMBL622112,,14.0,Zone of skin,,1,1
10720,50597,In vivo,BAO_0000218,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 2 mins after i.v. administration,,,N,Intermediate,A,10116.0,CHEMBL622113,,14.0,Zone of skin,,1,1
10721,50597,In vivo,BAO_0000218,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 65 mins after i.v. administration,,,N,Intermediate,A,10116.0,CHEMBL622114,,14.0,Zone of skin,,1,1
10722,50597,In vivo,BAO_0000218,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 15 mins after i.v. administration,,,N,Intermediate,A,10116.0,CHEMBL622115,,2106.0,Spleen,,1,1
10723,50597,In vivo,BAO_0000218,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 2 mins after i.v. administration,,,N,Intermediate,A,10116.0,CHEMBL622116,,2106.0,Spleen,,1,1
10724,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL622117,,,,,1,1
10725,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL622118,,,,,1,1
10726,50597,In vivo,BAO_0000218,,,Oral bioavailability in rats at 6 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL622119,,,,,1,1
10727,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat (dose 6 mg/kg),,,N,Intermediate,A,10116.0,CHEMBL622120,,,,,1,1
10728,50597,In vivo,BAO_0000218,,,Oral bioavailability in rats at 6 mg/kg dose; Not tested,,,N,Intermediate,A,10116.0,CHEMBL622121,,,,,1,1
10729,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL622122,,,,,1,1
10730,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL622123,,,,,1,1
10731,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL622124,,,,,1,1
10732,50597,In vivo,BAO_0000218,,,Bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL622125,,,,,1,1
10733,50597,In vivo,BAO_0000218,,,Oral bioavailability,,,N,Intermediate,A,10116.0,CHEMBL622126,,,,,1,1
10734,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),,,N,Intermediate,A,10116.0,CHEMBL620455,,,,,1,1
10735,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL620456,,,,,1,1
10736,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL620457,,,,,1,1
10737,50597,In vivo,BAO_0000218,,,Oral bioavailability was evaluated; Not tested,,,N,Intermediate,A,10116.0,CHEMBL620458,,,,,1,1
10738,50597,In vivo,BAO_0000218,,,Oral bioavailability,,,N,Intermediate,A,10116.0,CHEMBL620459,,,,,1,1
10739,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat by oral dosing,,,N,Intermediate,A,10116.0,CHEMBL620460,,,,,1,1
10740,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat (dose 10 mg/kg p.o.),,,N,Intermediate,A,10116.0,CHEMBL620461,,,,,1,1
10741,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat (Sprague-Dawley),,,N,Intermediate,A,10116.0,CHEMBL620462,,,,,1,1
10742,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),,,N,Intermediate,A,10116.0,CHEMBL620463,,,,,1,1
10743,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),,,N,Intermediate,A,10116.0,CHEMBL620464,,,,,1,1
10744,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),,,N,Intermediate,A,10116.0,CHEMBL620465,,,,,1,1
10745,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg p.o.),,,N,Intermediate,A,10116.0,CHEMBL620466,,,,,1,1
10746,50597,In vivo,BAO_0000218,,,Oral bioavailability was calculated in Spragun Dawley rat at oral dosage of 1 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL620467,,,,,1,1
10747,50597,In vivo,BAO_0000218,,,Oral bioavailability was calculated in Spragun Dawley rat at oral dosage of 2 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL620468,,,,,1,1
10748,50597,In vivo,BAO_0000218,,,Oral bioavailability was calculated in rats using an average of the intravenous AUC at peroral dose of 5 mgkg in solution form,,,N,Intermediate,A,10116.0,CHEMBL620469,,,,,1,1
10749,50597,In vivo,BAO_0000218,,,Oral bioavailability was calculated in rats using an average of the intravenous AUC at peroral dose of 5 mgkg in suspension form,,,N,Intermediate,A,10116.0,CHEMBL620470,,,,,1,1
10750,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL620471,,,,,1,1
10751,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL620472,,,,,1,1
10752,50597,In vivo,BAO_0000218,,,Oral bioavailability of compound at 5 mg/kg after po administration was determined in rat,,,N,Intermediate,A,10116.0,CHEMBL620473,,,,,1,1
10753,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL620474,,,,,1,1
10754,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat (Sprague-Dawley) (fasted male) (dose 10 mg/kg),,,N,Intermediate,A,10116.0,CHEMBL620475,,,,,1,1
10755,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL620476,,,,,1,1
10756,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL620477,,,,,1,1
10757,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat after oral administration at 10.5 mg/kg dose,,,N,Intermediate,A,10116.0,CHEMBL620478,,,,,1,1
10758,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat after oral administration at 11.2 mg/kg dose,,,N,Intermediate,A,10116.0,CHEMBL618768,,,,,1,1
10759,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat after oral administration at 13 mg/kg dose,,,N,Intermediate,A,10116.0,CHEMBL618769,,,,,1,1
10760,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat after oral administration at 9.7 mg/kg dose,,,N,Intermediate,A,10116.0,CHEMBL618770,,,,,1,1
10761,50597,In vivo,BAO_0000218,,,Oral bioavailability (dose 20 mg/kg p.o.),,,N,Intermediate,A,10116.0,CHEMBL618771,,,,,1,1
10762,50597,In vivo,BAO_0000218,,,Oral bioavailability was determined in rat after oral administration at a concentration 1 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL618772,,,,,1,1
10763,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat at 10 mg/kg of the compound,,,N,Intermediate,A,10116.0,CHEMBL618773,,,,,1,1
10764,50597,In vivo,BAO_0000218,,,Bioavailability in rat at a concentration of 15 mg/kg perorally in rat along with 100 mg/kg 11,,,N,Intermediate,A,10116.0,CHEMBL875842,,,,,1,1
10765,50597,In vivo,BAO_0000218,,,Bioavailability in rat (dose 3 mg/kg i.v.),,,N,Intermediate,A,10116.0,CHEMBL618774,,,,,1,1
10766,50597,In vivo,BAO_0000218,,,Bioavailability in rat at a concentration of 60 mg/kg perorally in rat along with 100 mg/kg 11,,,N,Intermediate,A,10116.0,CHEMBL618775,,,,,1,1
10767,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat (dose 60 mg/kg p.o.),,,N,Intermediate,A,10116.0,CHEMBL618776,,,,,1,1
10768,50597,In vivo,BAO_0000218,,,Percent bioavailability (F) in rats after iv administration,,,N,Intermediate,A,10116.0,CHEMBL618777,,,,,1,1
10769,50597,In vivo,BAO_0000218,,,Percent bioavailability (F) in rats after oral dose of 10 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL618778,,,,,1,1
10770,50597,In vivo,BAO_0000218,,,Bioavailability in rat (dose 5 uM/kg p.o.),,,N,Intermediate,A,10116.0,CHEMBL618779,,,,,1,1
10771,50597,In vivo,BAO_0000218,,,Oral bioavailability,,,N,Intermediate,A,10116.0,CHEMBL618780,,,,,1,1
10772,50597,In vivo,BAO_0000218,,,Bioavailability in rat (dose 2 mg/kg p.o.),,,N,Intermediate,A,10116.0,CHEMBL618781,,,,,1,1
10773,50597,In vivo,BAO_0000218,,,Percent bioavailability at the dose of 5 mg/Kg administered perorally in rats,,,N,Intermediate,A,10116.0,CHEMBL618782,,,,,1,1
10774,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat (dose 20 mg/kg),,,N,Intermediate,A,10116.0,CHEMBL618783,,,,,1,1
10775,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL618784,,,,,1,1
10776,50597,In vivo,BAO_0000218,,,Percent oral bioavailability evaluated in rat,,,N,Intermediate,A,10116.0,CHEMBL618785,,,,,1,1
10777,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL618786,,,,,1,1
10778,50597,In vivo,BAO_0000218,,,Percent oral bioavailability in rat; Not determined,,,N,Intermediate,A,10116.0,CHEMBL618787,,,,,1,1
10779,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL618788,,,,,1,1
10780,50597,In vivo,BAO_0000218,,,Bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL618789,,,,,1,1
10781,50597,In vivo,BAO_0000218,,,Pharmacokinetic property (oral bioavailability) in rat (dose given as a solution),,,N,Intermediate,A,10116.0,CHEMBL618790,,,,,1,1
10782,50597,In vivo,BAO_0000218,,,Pharmacokinetic property (oral bioavailability) in rat (dose given as a suspension),,,N,Intermediate,A,10116.0,CHEMBL618791,,,,,1,1
10783,50597,In vivo,BAO_0000218,,,Pharmacokinetic property (F) was measured in rat at the dose of 0.32 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL875843,,,,,1,1
10784,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat (dose 20 mg/kg p.o.),,,N,Intermediate,A,10116.0,CHEMBL618792,,,,,1,1
10785,50597,In vivo,BAO_0000218,,,Cmax at a dose of 30 mg/kg in rat,,,N,Intermediate,A,10116.0,CHEMBL623395,,,,,1,1
10786,22224,In vivo,BAO_0000218,,,Cmax in monkeys at a dose of 1 mg/kg,,,U,Autocuration,A,314293.0,CHEMBL623396,,,,,0,1
10787,50597,In vivo,BAO_0000218,,,Cmax in rat,,,N,Intermediate,A,10116.0,CHEMBL623397,,,,,1,1
10788,50597,In vivo,BAO_0000218,,,Cmax in rats at a dose of 1 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL623398,,,,,1,1
10789,50594,In vivo,BAO_0000218,,,Cmax was measured in mice after an oral dose of 50 mg/kg.,,,N,Intermediate,A,10090.0,CHEMBL623399,,,,,1,1
10790,22224,In vivo,BAO_0000218,,,"Cmax value at a dose of 12.7 uM/kg, po",,,U,Autocuration,A,,CHEMBL623400,,,,,0,1
10791,22224,In vivo,BAO_0000218,,,"Cmax value at a dose of 6.3 uM/kg, iv",,,U,Autocuration,A,,CHEMBL623401,,,,,0,1
10792,22224,In vivo,BAO_0000218,,,"Cmax value at a dose of 7.1 uM/kg, iv",,,U,Autocuration,A,,CHEMBL623402,,,,,0,1
10793,22224,In vivo,BAO_0000218,,,Cmax value of compound was determined after 1 hr,,,U,Autocuration,A,,CHEMBL623403,,,,,0,1
10794,22224,In vivo,BAO_0000218,,,Cmax value of the compound,,,U,Autocuration,A,,CHEMBL623404,,,,,0,1
10795,50597,In vivo,BAO_0000218,,,Cmax value administered intraintestinal in rats.,,,N,Intermediate,A,10116.0,CHEMBL625997,,,,,1,1
10796,50597,In vivo,BAO_0000218,,,Cmax value administered perorally was determined in rat; Not determined,,,N,Intermediate,A,10116.0,CHEMBL625998,,,,,1,1
10797,22224,In vivo,BAO_0000218,,,Cmax value at the dose of 2.3 mg/kg,,,U,Autocuration,A,,CHEMBL625999,,,,,0,1
10798,22224,In vivo,BAO_0000218,,,Cmax value at the dose of 5 mg/kg,,,U,Autocuration,A,,CHEMBL626000,,,,,0,1
10799,22224,In vivo,BAO_0000218,,,Cmax value in the period of 8 hr after dosing. ,,,U,Autocuration,A,,CHEMBL626001,,,,,0,1
10800,22224,In vivo,BAO_0000218,,,Cmax value at a oral dose of 20 mg/kg; Not tested,,,U,Autocuration,A,,CHEMBL626002,,,,,0,1
10801,22224,In vivo,BAO_0000218,,,Cmax value at a oral dose of 20 mg/kg,,,U,Autocuration,A,,CHEMBL626003,,,,,0,1
10802,50597,In vivo,BAO_0000218,,,Cmax value was determined between 15 and 30 minutes post administration in fisher rats; value ranges from 200-500,,,N,Intermediate,A,10116.0,CHEMBL626004,,,,,1,1
10803,50512,In vivo,BAO_0000218,,,Cmax(ng /mL)values after oral administration of 10 mg/kg in guinea pig.,,,N,Intermediate,A,10141.0,CHEMBL626005,,,,,1,1
10804,50597,In vivo,BAO_0000218,,,Cmax(ng /mL)values after oral administration of 10 mg/kg in rat.,,,N,Intermediate,A,10116.0,CHEMBL626006,,,,,1,1
10805,50597,In vivo,BAO_0000218,,,Compound at a dose of 10 mg/kg was orally administered to rats and maximum plasma concentration was reported,,,N,Intermediate,A,10116.0,CHEMBL626007,,1969.0,Plasma,,1,1
10806,50594,In vivo,BAO_0000218,,,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,,,N,Intermediate,A,10090.0,CHEMBL626008,,1969.0,Plasma,,1,1
10807,50588,In vivo,BAO_0000218,,,Compound was evaluated for maximum plasma concentration levels in dogs for the orally delivered compound in 0.05 M citric acid,,,N,Intermediate,A,9615.0,CHEMBL626009,,2107.0,Liver,,1,1
10808,50588,In vivo,BAO_0000218,,,Compound was evaluated in vivo for its concentration after a peroral administration 40 mg/kg in dogs.,,,N,Intermediate,A,9615.0,CHEMBL626010,,,,,1,1
10809,50594,In vivo,BAO_0000218,,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a intramuscular administration 40 mg/kg in mice,,,N,Intermediate,A,10090.0,CHEMBL626011,,178.0,Blood,,1,1
10810,50594,In vivo,BAO_0000218,,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration 40 mg/kg in mice,,,N,Intermediate,A,10090.0,CHEMBL626012,,178.0,Blood,,1,1
10811,50594,In vivo,BAO_0000218,,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration of 40 mg/kg in mice,,,N,Intermediate,A,10090.0,CHEMBL626013,,178.0,Blood,,1,1
10812,50594,In vivo,BAO_0000218,,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after an intramuscular administration of 40 mg/kg in mice,,,N,Intermediate,A,10090.0,CHEMBL626014,,178.0,Blood,,1,1
10813,50594,In vivo,BAO_0000218,,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after an intramuscular administration of 40 mg/kg in mice.,,,N,Intermediate,A,10090.0,CHEMBL877496,,178.0,Blood,,1,1
10814,50588,In vivo,BAO_0000218,,,Compound was tested Growth Hormone(GH) release after 0.5 mg/kg administration (Po) in Beagle dogs,,,N,Intermediate,F,9615.0,CHEMBL626015,,,,,1,1
10815,50588,In vivo,BAO_0000218,,,Compound was tested Growth Hormone(GH) release after 10 mg/kg administration (Po) in Beagle dogs,,,N,Intermediate,F,9615.0,CHEMBL626016,,,,,1,1
10816,50588,In vivo,BAO_0000218,,,Compound was tested Growth Hormone(GH) release after 2.5 mg/kg administration (Po) in Beagle dogs,,,N,Intermediate,F,9615.0,CHEMBL626017,,,,,1,1
10817,50588,In vivo,BAO_0000218,,,Bioavailability as maximal plasma concentration in dogs,,,N,Intermediate,A,9615.0,CHEMBL626018,,1969.0,Plasma,,1,1
10818,50588,In vivo,BAO_0000218,,,Bioavailability as maximal plasma concentration in dogs,,,N,Intermediate,A,9615.0,CHEMBL626692,,1969.0,Plasma,,1,1
10819,50597,In vivo,BAO_0000218,,,Bioavailability as maximal plasma concentration in rats,,,N,Intermediate,A,10116.0,CHEMBL626693,,1969.0,Plasma,,1,1
10820,22224,In vivo,BAO_0000218,,,Bioavailability as maximal plasma concentration in rats,,,U,Autocuration,A,10116.0,CHEMBL626694,,1969.0,Plasma,,0,1
10821,50588,In vivo,BAO_0000218,,,Compound was tested for maximum blood concentration after 0.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,,,N,Intermediate,A,9615.0,CHEMBL626695,,178.0,Blood,,1,1
10822,50588,In vivo,BAO_0000218,,,Compound was tested for maximum blood concentration after 10 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,,,N,Intermediate,A,9615.0,CHEMBL626696,,178.0,Blood,,1,1
10823,50588,In vivo,BAO_0000218,,,Compound was tested for maximum blood concentration after 2.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,,,N,Intermediate,A,9615.0,CHEMBL626697,,178.0,Blood,,1,1
10824,50588,In vivo,BAO_0000218,,,Compound was tested for maximum concentration in blood after 0.5 mg/kg administration (Po) in Beagle dogs; nd = Not Detectable,,,N,Intermediate,A,9615.0,CHEMBL626859,,178.0,Blood,,1,1
10825,50588,In vivo,BAO_0000218,,,Compound was tested for maximum concentration in blood after 10 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,,,N,Intermediate,A,9615.0,CHEMBL626860,,178.0,Blood,,1,1
10826,50588,In vivo,BAO_0000218,,,Compound was tested for maximum concentration in blood after 2.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,,,N,Intermediate,A,9615.0,CHEMBL626861,,178.0,Blood,,1,1
10827,50597,In vivo,BAO_0000218,,,Compound was tested for maximum observed concentration in three male Wistar rats at a single 5 mg/kg oral gavage dose,,,N,Intermediate,A,10116.0,CHEMBL626296,,,,,1,1
10828,22224,In vivo,BAO_0000218,,,Compound was tested for the max. conc. when administered perorally(po) 30 mg/kg,,,U,Autocuration,A,,CHEMBL626297,,,,,0,1
10829,22224,In vivo,BAO_0000218,,,Compound was tested for the max. plasma conc. when administered intraperitoneally (ip) 30 mg/kg.,,,U,Autocuration,A,,CHEMBL626298,,1969.0,Plasma,,0,1
10830,50597,In vivo,BAO_0000218,,,"Drug plasma level in rat was determined on the last day of dosing at 1,2,4.8 and 24 hr and ED50 was evaluated",,,N,Intermediate,A,10116.0,CHEMBL626299,,1969.0,Plasma,,1,1
10831,50597,In vivo,BAO_0000218,,,Effect of ip administration of compound on plasma concentration of allo-pregnanolone (AP) in rats after 30 min.,,,N,Intermediate,A,10116.0,CHEMBL626300,,1969.0,Plasma,,1,1
10832,50597,In vivo,BAO_0000218,,,Effect of ip administration of compound on plasma concentration of allotetrahydrodeoxy corticosterone(THDOC) in rats after 30 min.,,,N,Intermediate,A,10116.0,CHEMBL626301,,1969.0,Plasma,,1,1
10833,50597,In vivo,BAO_0000218,,,Effect of ip administration of compound on plasma concentration of corticosterone (CTS) in rats after 30 min.,,,N,Intermediate,A,10116.0,CHEMBL626962,,1969.0,Plasma,,1,1
10834,50597,In vivo,BAO_0000218,,,Effect of ip administration of compound on plasma concentration of pregnenolone (PRE) in rats after 30 min.,,,N,Intermediate,A,10116.0,CHEMBL626963,,1969.0,Plasma,,1,1
10835,50597,In vivo,BAO_0000218,,,Effect of ip administration of compound on plasma concentration of progesterone (PRO) in rats after 30 min.,,,N,Intermediate,A,10116.0,CHEMBL626964,,1969.0,Plasma,,1,1
10836,100710,In vivo,BAO_0000218,,,In vivo antitumor efficacy expressed as maximum plasma concentration 0.4 hr after a peroral dose of 25 mg/kg in cynomolgus monkeys,,,N,Intermediate,A,9541.0,CHEMBL626965,,1969.0,Plasma,,1,1
10837,50594,In vivo,BAO_0000218,,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,,,N,Intermediate,A,10090.0,CHEMBL626966,,1969.0,Plasma,,1,1
10838,50594,In vivo,BAO_0000218,,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,,,N,Intermediate,A,10090.0,CHEMBL626967,,1969.0,Plasma,,1,1
10839,100710,In vivo,BAO_0000218,,,In vivo antitumor efficacy expressed as maximum plasma concentration after a peroral dose of 10 mg/kg in cynomolgus monkeys,,,N,Intermediate,A,9541.0,CHEMBL626968,,1969.0,Plasma,,1,1
10840,50597,,BAO_0000218,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.89-1.24,,,N,Intermediate,A,10116.0,CHEMBL626969,,948.0,Heart,,1,1
10841,50597,,BAO_0000218,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.24-2.58,,,N,Intermediate,A,10116.0,CHEMBL627126,,948.0,Heart,,1,1
10842,50597,,BAO_0000218,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.24-0.28,,,N,Intermediate,A,10116.0,CHEMBL631276,,948.0,Heart,,1,1
10843,50597,,BAO_0000218,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.52-0.62,,,N,Intermediate,A,10116.0,CHEMBL631277,,948.0,Heart,,1,1
10844,50597,,BAO_0000218,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.68-0.84,,,N,Intermediate,A,10116.0,CHEMBL631278,,948.0,Heart,,1,1
10845,50597,,BAO_0000218,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.75-1.03,,,N,Intermediate,A,10116.0,CHEMBL874457,,948.0,Heart,,1,1
10846,50597,,BAO_0000218,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.96-2.46,,,N,Intermediate,A,10116.0,CHEMBL631279,,948.0,Heart,,1,1
10847,50597,,BAO_0000218,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.36-0.42,,,N,Intermediate,A,10116.0,CHEMBL631280,,948.0,Heart,,1,1
10848,50597,,BAO_0000218,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.58-0.82,,,N,Intermediate,A,10116.0,CHEMBL631281,,948.0,Heart,,1,1
10849,50597,,BAO_0000218,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.24-1.46,,,N,Intermediate,A,10116.0,CHEMBL631968,,948.0,Heart,,1,1
10850,50597,,BAO_0000218,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 2.36-3.96,,,N,Intermediate,A,10116.0,CHEMBL631969,,948.0,Heart,,1,1
10851,50597,,BAO_0000218,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.24-0.29,,,N,Intermediate,A,10116.0,CHEMBL631970,,948.0,Heart,,1,1
10852,50597,,BAO_0000218,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.39-0.74,,,N,Intermediate,A,10116.0,CHEMBL631971,,948.0,Heart,,1,1
10853,50597,,BAO_0000218,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.79-0.85,,,N,Intermediate,A,10116.0,CHEMBL631972,,948.0,Heart,,1,1
10854,50597,,BAO_0000218,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.64-0.86,,,N,Intermediate,A,10116.0,CHEMBL630435,,948.0,Heart,,1,1
10855,50597,,BAO_0000218,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.68-2.23,,,N,Intermediate,A,10116.0,CHEMBL630436,,948.0,Heart,,1,1
10856,50597,,BAO_0000218,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.19-0.23,,,N,Intermediate,A,10116.0,CHEMBL630437,,948.0,Heart,,1,1
10857,50597,,BAO_0000218,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.22-0.29,,,N,Intermediate,A,10116.0,CHEMBL630438,,948.0,Heart,,1,1
10858,50597,,BAO_0000218,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.58-0.75,,,N,Intermediate,A,10116.0,CHEMBL630439,,948.0,Heart,,1,1
10859,50597,,BAO_0000218,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.42-1.82,,,N,Intermediate,A,10116.0,CHEMBL630440,,2113.0,Kidney,,1,1
10860,50597,,BAO_0000218,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.24-3.12,,,N,Intermediate,A,10116.0,CHEMBL630441,,2113.0,Kidney,,1,1
10861,50597,,BAO_0000218,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.62-0.92,,,N,Intermediate,A,10116.0,CHEMBL630442,,2113.0,Kidney,,1,1
10862,50597,,BAO_0000218,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.12-2.04,,,N,Intermediate,A,10116.0,CHEMBL625234,,2113.0,Kidney,,1,1
10863,50597,,BAO_0000218,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.59-2.03,,,N,Intermediate,A,10116.0,CHEMBL625235,,2113.0,Kidney,,1,1
10864,50597,,BAO_0000218,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.14-1.4,,,N,Intermediate,A,10116.0,CHEMBL625236,,2113.0,Kidney,,1,1
10865,50597,,BAO_0000218,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.56-1.83,,,N,Intermediate,A,10116.0,CHEMBL625237,,2113.0,Kidney,,1,1
10866,50597,,BAO_0000218,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.58-0.73,,,N,Intermediate,A,10116.0,CHEMBL626125,,2113.0,Kidney,,1,1
10867,50597,,BAO_0000218,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 1.67-2.11,,,N,Intermediate,A,10116.0,CHEMBL626126,,2113.0,Kidney,,1,1
10868,50597,,BAO_0000218,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.64-3.43,,,N,Intermediate,A,10116.0,CHEMBL626127,,2113.0,Kidney,,1,1
10869,50597,,BAO_0000218,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 3.18-4.74,,,N,Intermediate,A,10116.0,CHEMBL626128,,2113.0,Kidney,,1,1
10870,50597,,BAO_0000218,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.62-1.13,,,N,Intermediate,A,10116.0,CHEMBL626129,,2113.0,Kidney,,1,1
10871,50597,,BAO_0000218,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.73-2.64,,,N,Intermediate,A,10116.0,CHEMBL626130,,2113.0,Kidney,,1,1
10872,50597,,BAO_0000218,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 13.02-19.07,,,N,Intermediate,A,10116.0,CHEMBL626131,,2113.0,Kidney,,1,1
10873,50597,,BAO_0000218,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.89-1.19,,,N,Intermediate,A,10116.0,CHEMBL626132,,2113.0,Kidney,,1,1
10874,50597,,BAO_0000218,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.17-1.48,,,N,Intermediate,A,10116.0,CHEMBL626752,,2113.0,Kidney,,1,1
10875,50597,,BAO_0000218,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.48-0.72,,,N,Intermediate,A,10116.0,CHEMBL626753,,2113.0,Kidney,,1,1
10876,50597,,BAO_0000218,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.49-0.57,,,N,Intermediate,A,10116.0,CHEMBL626754,,2113.0,Kidney,,1,1
10877,50597,,BAO_0000218,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.99-1.24,,,N,Intermediate,A,10116.0,CHEMBL626755,,2113.0,Kidney,,1,1
10878,50597,,BAO_0000218,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.23-1.78,,,N,Intermediate,A,10116.0,CHEMBL626756,,2107.0,Liver,,1,1
10879,50597,,BAO_0000218,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.43-2.92,,,N,Intermediate,A,10116.0,CHEMBL626757,,2107.0,Liver,,1,1
10880,50597,,BAO_0000218,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.81-1.18,,,N,Intermediate,A,10116.0,CHEMBL626758,,2107.0,Liver,,1,1
10881,50597,,BAO_0000218,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.37-1.74,,,N,Intermediate,A,10116.0,CHEMBL626759,,2107.0,Liver,,1,1
10882,50597,,BAO_0000218,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 4.01-4.81,,,N,Intermediate,A,10116.0,CHEMBL626760,,2107.0,Liver,,1,1
10883,50588,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),,,N,Intermediate,A,9615.0,CHEMBL626394,,,,,1,1
10884,50588,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration,,,N,Intermediate,A,9615.0,CHEMBL626395,,,,,1,1
10885,50588,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration (0-6 hr),,,N,Intermediate,A,9615.0,CHEMBL626396,,,,,1,1
10886,50588,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),,,N,Intermediate,A,9615.0,CHEMBL626397,,,,,1,1
10887,50588,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),,,N,Intermediate,A,9615.0,CHEMBL626398,,,,,1,1
10888,50588,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),,,N,Intermediate,A,9615.0,CHEMBL626399,,,,,1,1
10889,50597,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration,,,N,Intermediate,A,10116.0,CHEMBL874653,,,,,1,1
10890,50597,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,,N,Intermediate,A,10116.0,CHEMBL626400,,,,,1,1
10891,50597,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr),,,N,Intermediate,A,10116.0,CHEMBL626401,,,,,1,1
10892,50597,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),,,N,Intermediate,A,10116.0,CHEMBL626402,,,,,1,1
10893,50597,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),,,N,Intermediate,A,10116.0,CHEMBL626403,,,,,1,1
10894,50597,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,,N,Intermediate,A,10116.0,CHEMBL626404,,,,,1,1
10895,50597,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration,,,N,Intermediate,A,10116.0,CHEMBL626405,,,,,1,1
10896,50597,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,,N,Intermediate,A,10116.0,CHEMBL625529,,,,,1,1
10897,50597,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration (0-5 hr),,,N,Intermediate,A,10116.0,CHEMBL625530,,,,,1,1
10898,50597,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),,,N,Intermediate,A,10116.0,CHEMBL625531,,,,,1,1
10899,50597,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),,,N,Intermediate,A,10116.0,CHEMBL625532,,,,,1,1
10900,50597,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,,N,Intermediate,A,10116.0,CHEMBL625533,,,,,1,1
10901,50597,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration,,,N,Intermediate,A,10116.0,CHEMBL875474,,,,,1,1
10902,50597,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,,N,Intermediate,A,10116.0,CHEMBL625534,,,,,1,1
10903,50597,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr),,,N,Intermediate,A,10116.0,CHEMBL625535,,,,,1,1
10904,50597,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0 - 5 hr),,,N,Intermediate,A,10116.0,CHEMBL625536,,,,,1,1
10905,50597,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),,,N,Intermediate,A,10116.0,CHEMBL625537,,,,,1,1
10906,50597,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,,N,Intermediate,A,10116.0,CHEMBL625538,,,,,1,1
10907,50597,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration,,,N,Intermediate,A,10116.0,CHEMBL625539,,,,,1,1
10908,50597,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,,N,Intermediate,A,10116.0,CHEMBL625540,,,,,1,1
10909,50597,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),,,N,Intermediate,A,10116.0,CHEMBL625541,,,,,1,1
10910,50597,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),,,N,Intermediate,A,10116.0,CHEMBL625542,,,,,1,1
10911,50597,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),,,N,Intermediate,A,10116.0,CHEMBL625543,,,,,1,1
10912,50597,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,,N,Intermediate,A,10116.0,CHEMBL625544,,,,,1,1
10913,50588,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.312 mg/kg after ip administration,,,N,Intermediate,A,9615.0,CHEMBL625545,,,,,1,1
10914,50588,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),,,N,Intermediate,A,9615.0,CHEMBL625546,,,,,1,1
10915,50588,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.625 mg/kg after ip administration,,,N,Intermediate,A,9615.0,CHEMBL625547,,,,,1,1
10916,50588,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),,,N,Intermediate,A,9615.0,CHEMBL625548,,,,,1,1
10917,50588,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),,,N,Intermediate,A,9615.0,CHEMBL625549,,,,,1,1
10918,50588,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 10 mg/kg after ip administration (0-6 hr),,,N,Intermediate,A,9615.0,CHEMBL625550,,,,,1,1
10919,50588,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),,,N,Intermediate,A,9615.0,CHEMBL625551,,,,,1,1
10920,50588,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),,,N,Intermediate,A,9615.0,CHEMBL875475,,,,,1,1
10921,50588,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),,,N,Intermediate,A,9615.0,CHEMBL625552,,,,,1,1
10922,50588,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration (0-6 hr),,,N,Intermediate,A,9615.0,CHEMBL625553,,,,,1,1
10923,50588,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),,,N,Intermediate,A,9615.0,CHEMBL625554,,,,,1,1
10924,50588,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),,,N,Intermediate,A,9615.0,CHEMBL625555,,,,,1,1
10925,50588,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),,,N,Intermediate,A,9615.0,CHEMBL625556,,,,,1,1
10926,50588,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration,,,N,Intermediate,A,9615.0,CHEMBL624986,,,,,1,1
10927,50588,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration (0-6 hr),,,N,Intermediate,A,9615.0,CHEMBL624987,,,,,1,1
10928,50588,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),,,N,Intermediate,A,9615.0,CHEMBL624988,,,,,1,1
10929,50588,In vivo,BAO_0000218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; -2/-14,,,N,Intermediate,A,9615.0,CHEMBL624989,,1637.0,Artery,,1,1
10930,50588,In vivo,BAO_0000218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; -4/-4,,,N,Intermediate,A,9615.0,CHEMBL624990,,1637.0,Artery,,1,1
10931,50588,In vivo,BAO_0000218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; 4/7,,,N,Intermediate,A,9615.0,CHEMBL874391,,1637.0,Artery,,1,1
10932,50588,In vivo,BAO_0000218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3/10 range; -3/0/4,,,N,Intermediate,A,9615.0,CHEMBL624991,,1637.0,Artery,,1,1
10933,50588,In vivo,BAO_0000218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; -6/0,,,N,Intermediate,A,9615.0,CHEMBL624992,,1637.0,Artery,,1,1
10934,50588,In vivo,BAO_0000218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 10/31,,,N,Intermediate,A,9615.0,CHEMBL624993,,1637.0,Artery,,1,1
10935,50588,In vivo,BAO_0000218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 11/-19,,,N,Intermediate,A,9615.0,CHEMBL624994,,1637.0,Artery,,1,1
10936,50588,In vivo,BAO_0000218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 14/6,,,N,Intermediate,A,9615.0,CHEMBL624995,,1637.0,Artery,,1,1
10937,50588,In vivo,BAO_0000218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 19/25,,,N,Intermediate,A,9615.0,CHEMBL624996,,1637.0,Artery,,1,1
10938,50588,In vivo,BAO_0000218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 19/3,,,N,Intermediate,A,9615.0,CHEMBL624997,,1637.0,Artery,,1,1
10939,50588,In vivo,BAO_0000218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 2/16,,,N,Intermediate,A,9615.0,CHEMBL624998,,1637.0,Artery,,1,1
10940,50588,In vivo,BAO_0000218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 6/2,,,N,Intermediate,A,9615.0,CHEMBL624999,,1637.0,Artery,,1,1
10941,50588,In vivo,BAO_0000218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 7/26,,,N,Intermediate,A,9615.0,CHEMBL882955,,1637.0,Artery,,1,1
10942,50588,In vivo,BAO_0000218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 8/49,,,N,Intermediate,A,9615.0,CHEMBL625000,,1637.0,Artery,,1,1
10943,50588,In vivo,BAO_0000218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 8/8,,,N,Intermediate,A,9615.0,CHEMBL625001,,1637.0,Artery,,1,1
10944,50588,In vivo,BAO_0000218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 9/-18,,,N,Intermediate,A,9615.0,CHEMBL625089,,1637.0,Artery,,1,1
10945,50588,In vivo,BAO_0000218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/60 range; 13/23,,,N,Intermediate,A,9615.0,CHEMBL625090,,1637.0,Artery,,1,1
10946,50588,In vivo,BAO_0000218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 3 range,,,N,Intermediate,A,9615.0,CHEMBL625091,,1637.0,Artery,,1,1
10947,50588,In vivo,BAO_0000218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 3/10 range; -7/-11,,,N,Intermediate,A,9615.0,CHEMBL625092,,1637.0,Artery,,1,1
10948,50588,In vivo,BAO_0000218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 1/3 dose range; 6/-7,,,N,Intermediate,A,9615.0,CHEMBL625093,,1637.0,Artery,,1,1
10949,50588,In vivo,BAO_0000218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 10/30 dose range; -13/19,,,N,Intermediate,A,9615.0,CHEMBL625094,,1637.0,Artery,,1,1
10950,50588,In vivo,BAO_0000218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 3/10 dose range; 30/47,,,N,Intermediate,A,9615.0,CHEMBL625095,,1637.0,Artery,,1,1
10951,50588,In vivo,BAO_0000218,,,Compound was evaluated for its bioavailability in the dogs,,,N,Intermediate,A,9615.0,CHEMBL625096,,,,,1,1
10952,50597,In vivo,BAO_0000218,,,Compound was evaluated for its bioavailability in the rats,,,N,Intermediate,A,10116.0,CHEMBL625097,,,,,1,1
10953,22224,In vivo,BAO_0000218,,,Compound was evaluated for oral bioavailability,,,U,Autocuration,A,,CHEMBL882956,,,,,0,1
10954,50597,In vivo,BAO_0000218,,,Compound was evaluated for percentage of Oral bioavailability in rats,,,N,Intermediate,A,10116.0,CHEMBL625098,,,,,1,1
10955,22224,In vivo,BAO_0000218,,,Bioavailability in guinea pig,,,U,Autocuration,A,10141.0,CHEMBL625099,,,,,0,1
10956,50597,In vivo,BAO_0000218,,,Compound was evaluated for the oral bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL625100,,,,,1,1
10957,50588,In vivo,BAO_0000218,,,Compound was evaluated for the oral bioavailability in dog,,,N,Intermediate,A,9615.0,CHEMBL625101,,,,,1,1
10958,50597,In vivo,BAO_0000218,,,Compound was evaluated for the oral bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL874396,,,,,1,1
10959,22224,In vivo,BAO_0000218,,,Bioavailability in dog (dosed i.v.),,,U,Autocuration,F,9615.0,CHEMBL625102,,,,,0,1
10960,50588,In vivo,BAO_0000218,,,Compound was tested for in vivo bioavailability in dog,,,N,Intermediate,A,9615.0,CHEMBL625103,,,,,1,1
10961,100712,In vivo,BAO_0000218,,,Compound was tested for in vivo bioavailability in hamsters,,,N,Intermediate,A,10026.0,CHEMBL625104,,,,,1,1
10962,22224,In vivo,BAO_0000218,,,Compound was tested for in vivo bioavailability in monkey,,,U,Autocuration,A,314293.0,CHEMBL625105,,,,,0,1
10963,50597,In vivo,BAO_0000218,,,Compound was tested for in vivo bioavailability in rat,,,N,Intermediate,A,10116.0,CHEMBL625106,,,,,1,1
10964,22224,In vivo,BAO_0000218,,,Oral bioavailability in mouse,,,U,Autocuration,A,10090.0,CHEMBL625107,,,,,0,1
10965,50594,In vivo,BAO_0000218,,,Compound was tested for percent of oral bioavailability in mice; 56-74,,,N,Intermediate,A,10090.0,CHEMBL625108,,,,,1,1
10966,22224,In vivo,BAO_0000218,,,Oral bioavailability in mouse (nude) (dose of 25 mg/kg),,,U,Autocuration,A,10090.0,CHEMBL625109,,,,,0,1
10967,22224,In vivo,BAO_0000218,,,Bioavailability in cynomolgus monkey (dose 25 mg/kg i.v.),,,U,Autocuration,A,9541.0,CHEMBL625110,,,,,0,1
10968,22224,In vivo,BAO_0000218,,,Bioavailability in cynomolgus monkey (dose 5 mg/kg i.v.),,,U,Autocuration,A,9541.0,CHEMBL625111,,,,,0,1
10969,50594,In vivo,BAO_0000218,,,Oral bioavailability in mouse (nude) (dose 25 mg/kg i.v.),,,N,Intermediate,A,10090.0,CHEMBL625112,,,,,1,1
10970,50594,In vivo,BAO_0000218,,,Oral bioavailability in nude mice,,,N,Intermediate,A,10090.0,CHEMBL875334,,,,,1,1
10971,22224,In vivo,BAO_0000218,,,Bioavailability in monkey (i.d. dosing),,,U,Autocuration,A,9443.0,CHEMBL628617,,,,,0,1
10972,22224,In vivo,BAO_0000218,,,Bioavailability in rat,,,U,Autocuration,A,10116.0,CHEMBL628618,,,,,0,1
10973,22224,In vivo,BAO_0000218,,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 10%,,,U,Autocuration,A,,CHEMBL628619,,,,,0,1
10974,22224,In vivo,BAO_0000218,,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 20%,,,U,Autocuration,A,,CHEMBL628620,,,,,0,1
10975,100710,In vivo,BAO_0000218,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 10 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",,,N,Intermediate,A,9541.0,CHEMBL628621,,,,,1,1
10976,100710,In vivo,BAO_0000218,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",,,N,Intermediate,A,9541.0,CHEMBL628622,,,,,1,1
10977,100710,In vivo,BAO_0000218,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",,,N,Intermediate,A,9541.0,CHEMBL628623,,,,,1,1
10978,100710,In vivo,BAO_0000218,,,Maximal plasma concentration in cynomolgus monkeys after 10 mg/kg oral dose,,,N,Intermediate,A,9541.0,CHEMBL628624,,1969.0,Plasma,,1,1
10979,50594,In vivo,BAO_0000218,,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,,,N,Intermediate,A,10090.0,CHEMBL628625,,1969.0,Plasma,,1,1
10980,100710,In vivo,BAO_0000218,,,Maximal plasma concentration in cynomolgus monkeys after 5 mg/kg oral dose,,,N,Intermediate,A,9541.0,CHEMBL628626,,1969.0,Plasma,,1,1
10981,50594,In vivo,BAO_0000218,,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,,,N,Intermediate,A,10090.0,CHEMBL627041,,1969.0,Plasma,,1,1
10982,50594,In vivo,BAO_0000218,,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,,,N,Intermediate,A,10090.0,CHEMBL627042,,1969.0,Plasma,,1,1
10983,50594,In vivo,BAO_0000218,,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,,,N,Intermediate,A,10090.0,CHEMBL627043,,1969.0,Plasma,,1,1
10984,22224,In vivo,BAO_0000218,,,In vivo evaluation of maximum plasma concentration at a dose of 10 mg/kg,,,U,Autocuration,A,,CHEMBL627044,,1969.0,Plasma,,0,1
10985,50594,In vivo,BAO_0000218,,,Cmax in mouse plasma,,,N,Intermediate,A,10090.0,CHEMBL627045,,1969.0,Plasma,,1,1
10986,22224,In vivo,BAO_0000218,,,Max plasma concentration was measured by 40 mg/kg dose of peroral administration.,,,U,Autocuration,A,,CHEMBL627046,,1969.0,Plasma,,0,1
10987,50597,In vivo,BAO_0000218,,,Maximal plasma concentration in rat,,,N,Intermediate,A,10116.0,CHEMBL627047,,1969.0,Plasma,,1,1
10988,50597,In vivo,BAO_0000218,,,Maximal plasma level when administered 1 mg/kg perorally (po) in rat,,,N,Intermediate,A,10116.0,CHEMBL627048,,1969.0,Plasma,,1,1
10989,50597,In vivo,BAO_0000218,,,Maximum concentration at an intraduodenal dose of 5.2 mg/kg in rat,,,N,Intermediate,A,10116.0,CHEMBL627049,,,,,1,1
10990,50597,In vivo,BAO_0000218,,,Maximum concentration at an intraduodenal dose of 6.6 mg/kg in rat,,,N,Intermediate,A,10116.0,CHEMBL627050,,,,,1,1
10991,50597,In vivo,BAO_0000218,,,Maximum concentration at an intravenous dose of 5.5 mg/kg in rat,,,N,Intermediate,A,10116.0,CHEMBL627051,,,,,1,1
10992,50597,In vivo,BAO_0000218,,,Maximum concentration at an intravenous dose of 6.5 mg/kg in rat,,,N,Intermediate,A,10116.0,CHEMBL627052,,,,,1,1
10993,50597,In vivo,BAO_0000218,,,Maximum concentration at an peroral dose of 6.2 mg/kg in rat,,,N,Intermediate,A,10116.0,CHEMBL627053,,,,,1,1
10994,50597,In vivo,BAO_0000218,,,Maximum concentration at an peroral dose of 6.3 mg/kg in rat,,,N,Intermediate,A,10116.0,CHEMBL627054,,,,,1,1
10995,50594,In vivo,BAO_0000218,,,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered intravenously to nude mice at a dose of 25 mg/kg,,,N,Intermediate,A,10090.0,CHEMBL627055,,,,,1,1
10996,50594,In vivo,BAO_0000218,,,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg,,,N,Intermediate,A,10090.0,CHEMBL627056,,,,,1,1
10997,50594,In vivo,BAO_0000218,,,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg (micronized sample),,,N,Intermediate,A,10090.0,CHEMBL627057,,,,,1,1
10998,50594,In vivo,BAO_0000218,,,Maximum concentration (Cmax) using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. compound was administered intravenously to nude mice at a dose of 25 mg/kg,,,N,Intermediate,A,10090.0,CHEMBL627058,,,,,1,1
10999,50594,In vivo,BAO_0000218,,,Maximum concentration (Cmax) using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg,,,N,Intermediate,A,10090.0,CHEMBL626211,,,,,1,1
11000,22224,In vivo,BAO_0000218,,,Maximum Concentration of the compound.,,,U,Autocuration,A,,CHEMBL626212,,,,,0,1
11001,50588,In vivo,BAO_0000218,,,Maximum Concentration was measured after iv administration into Beagle dog,,,N,Intermediate,A,9615.0,CHEMBL626213,,,,,1,1
11002,50588,In vivo,BAO_0000218,,,Maximum Concentration was measured after iv administration into Beagle dog.,,,N,Intermediate,A,9615.0,CHEMBL626214,,,,,1,1
11003,50588,In vivo,BAO_0000218,,,Maximum Concentration was measured after po administration into Beagle dog,,,N,Intermediate,A,9615.0,CHEMBL626215,,,,,1,1
11004,50588,In vivo,BAO_0000218,,,Maximum Concentration was measured after po administration into Beagle dog.,,,N,Intermediate,A,9615.0,CHEMBL626216,,,,,1,1
11005,22224,In vivo,BAO_0000218,,,Maximum blood level reached after an dose of 10.6 uM/kg intravenously,,,U,Autocuration,A,,CHEMBL626217,,178.0,Blood,,0,1
11006,22224,In vivo,BAO_0000218,,,Maximum blood level reached after an iv dose of 12.2 uM/kg,,,U,Autocuration,A,,CHEMBL626218,,178.0,Blood,,0,1
11007,22224,In vivo,BAO_0000218,,,Maximum blood level reached after an oral dose 14.7 uM/kg oral route,,,U,Autocuration,A,,CHEMBL626219,,178.0,Blood,,0,1
11008,22224,In vivo,BAO_0000218,,,Maximum blood level reached after an oral dose of 14.7 uM/kg intravenous route,,,U,Autocuration,A,,CHEMBL626220,,178.0,Blood,,0,1
11009,22224,In vivo,BAO_0000218,,,Maximum blood level reached after an oral dose of 5.0 mg/kg,,,U,Autocuration,A,,CHEMBL626221,,178.0,Blood,,0,1
11010,22224,In vivo,BAO_0000218,,,Maximum blood level reached at dose of 10.6 uM/kg orally,,,U,Autocuration,A,,CHEMBL626222,,178.0,Blood,,0,1
11011,50512,In vivo,BAO_0000218,,,Maximum concentration (Cmax) in guinea pigs at 2 mg/kg after oral administration,,,N,Intermediate,A,10141.0,CHEMBL626223,,,,,1,1
11012,50512,In vivo,BAO_0000218,,,Maximum concentration (Cmax) in guinea pigs at 3 mg/kg after oral administration,,,N,Intermediate,A,10141.0,CHEMBL626224,,,,,1,1
11013,50597,In vivo,BAO_0000218,,,Maximum concentration achieved in rat brain when administered intraperitoneally at a dose of 10 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL626225,,955.0,Brain,,1,1
11014,50597,In vivo,BAO_0000218,,,Maximum concentration achieved in rat brain when administered intravenously at a dose of 10 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL626226,,955.0,Brain,,1,1
11015,50597,In vivo,BAO_0000218,,,Maximum concentration achieved in rat brain when administered perorally at a dose of 100 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL626227,,955.0,Brain,,1,1
11016,50597,In vivo,BAO_0000218,,,Maximum concentration achieved in rat brain when administered perorally at a dose of 10 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL626228,,955.0,Brain,,1,1
11017,50597,In vivo,BAO_0000218,,,Maximum concentration achieved in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL626229,,,,,1,1
11018,50597,In vivo,BAO_0000218,,,Maximum concentration achieved in rat plasma when administered intravenously at a dose of 10 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL626921,,,,,1,1
11019,50597,In vivo,BAO_0000218,,,Maximum concentration achieved in rat plasma when administered perorally at a dose of 100 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL876793,,,,,1,1
11020,50597,In vivo,BAO_0000218,,,Maximum concentration achieved in rat plasma when administered perorally at a dose of 10 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL625309,,,,,1,1
11021,50278,In vivo,BAO_0000218,,,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),,,N,Intermediate,A,1423.0,CHEMBL625310,,,,,1,1
11022,22224,In vivo,BAO_0000218,,,Maximum concentration determined in monkeys dosed intravenously with 30 mg/kg,,,U,Autocuration,A,314293.0,CHEMBL625311,,,,,0,1
11023,50597,In vivo,BAO_0000218,,,Maximum concentration determined in rats dosed intravenously with 20 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL625312,,,,,1,1
11024,22224,In vivo,BAO_0000218,,,Maximum concentration for the bioavailability at a dose of 20 mg/kg administered orally,,,U,Autocuration,A,,CHEMBL625313,,,,,0,1
11025,50594,In vivo,BAO_0000218,,,Maximum concentration in male CD-1 mice after sc administration of 20 mg/kg,,,N,Intermediate,A,10090.0,CHEMBL625314,,,,,1,1
11026,50597,In vivo,BAO_0000218,,,Maximum concentration in male rats after iv administration of 20 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL625315,,,,,1,1
11027,50597,,BAO_0000218,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.06-1.29,,,N,Intermediate,A,10116.0,CHEMBL625316,,2107.0,Liver,,1,1
11028,50597,,BAO_0000218,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.77-2.08,,,N,Intermediate,A,10116.0,CHEMBL625317,,2107.0,Liver,,1,1
11029,50597,,BAO_0000218,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.54-0.89,,,N,Intermediate,A,10116.0,CHEMBL625318,,2107.0,Liver,,1,1
11030,50597,,BAO_0000218,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 1.57-1.66,,,N,Intermediate,A,10116.0,CHEMBL625319,,2107.0,Liver,,1,1
11031,50597,,BAO_0000218,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.06-2.71,,,N,Intermediate,A,10116.0,CHEMBL625320,,2107.0,Liver,,1,1
11032,50597,,BAO_0000218,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 2.98-3.22,,,N,Intermediate,A,10116.0,CHEMBL625321,,2107.0,Liver,,1,1
11033,50597,,BAO_0000218,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.73-1.45,,,N,Intermediate,A,10116.0,CHEMBL625322,,2107.0,Liver,,1,1
11034,50597,,BAO_0000218,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.03-1.31,,,N,Intermediate,A,10116.0,CHEMBL876801,,2107.0,Liver,,1,1
11035,50597,,BAO_0000218,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 6.76-10.44,,,N,Intermediate,A,10116.0,CHEMBL625323,,2107.0,Liver,,1,1
11036,50597,,BAO_0000218,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.47-1.17,,,N,Intermediate,A,10116.0,CHEMBL625324,,2107.0,Liver,,1,1
11037,50597,,BAO_0000218,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.12-1.44,,,N,Intermediate,A,10116.0,CHEMBL625325,,2107.0,Liver,,1,1
11038,50597,,BAO_0000218,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.38-0.57,,,N,Intermediate,A,10116.0,CHEMBL625326,,2107.0,Liver,,1,1
11039,50597,,BAO_0000218,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.75-1.14,,,N,Intermediate,A,10116.0,CHEMBL625327,,2107.0,Liver,,1,1
11040,50597,,BAO_0000218,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 1.36-1.74,,,N,Intermediate,A,10116.0,CHEMBL625328,,2107.0,Liver,,1,1
11041,50597,,BAO_0000218,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.05-1.5,,,N,Intermediate,A,10116.0,CHEMBL625329,,2048.0,Lung,,1,1
11042,50597,,BAO_0000218,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 3.10-3.77,,,N,Intermediate,A,10116.0,CHEMBL625330,,2048.0,Lung,,1,1
11043,50597,,BAO_0000218,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.4-0.54,,,N,Intermediate,A,10116.0,CHEMBL627774,,2048.0,Lung,,1,1
11044,50597,,BAO_0000218,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.58-0.86,,,N,Intermediate,A,10116.0,CHEMBL627775,,2048.0,Lung,,1,1
11045,50597,,BAO_0000218,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.77-0.86,,,N,Intermediate,A,10116.0,CHEMBL627949,,2048.0,Lung,,1,1
11046,50597,,BAO_0000218,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.86-1.13,,,N,Intermediate,A,10116.0,CHEMBL627950,,2048.0,Lung,,1,1
11047,50597,,BAO_0000218,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 2.26-2.89,,,N,Intermediate,A,10116.0,CHEMBL627951,,2048.0,Lung,,1,1
11048,50597,,BAO_0000218,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.54-0.7,,,N,Intermediate,A,10116.0,CHEMBL627952,,2048.0,Lung,,1,1
11049,50597,,BAO_0000218,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.6-0.66,,,N,Intermediate,A,10116.0,CHEMBL627953,,2048.0,Lung,,1,1
11050,50597,,BAO_0000218,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.35-1.74,,,N,Intermediate,A,10116.0,CHEMBL627954,,2048.0,Lung,,1,1
11051,50597,,BAO_0000218,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 3.62-7.08,,,N,Intermediate,A,10116.0,CHEMBL627955,,2048.0,Lung,,1,1
11052,50597,,BAO_0000218,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.47-0.56,,,N,Intermediate,A,10116.0,CHEMBL627956,,2048.0,Lung,,1,1
11053,50597,,BAO_0000218,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.54-1.07,,,N,Intermediate,A,10116.0,CHEMBL876802,,2048.0,Lung,,1,1
11054,50597,,BAO_0000218,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.76-0.91,,,N,Intermediate,A,10116.0,CHEMBL627957,,2048.0,Lung,,1,1
11055,50597,,BAO_0000218,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.61-0.86,,,N,Intermediate,A,10116.0,CHEMBL627958,,2048.0,Lung,,1,1
11056,50597,,BAO_0000218,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 2.11-3.79,,,N,Intermediate,A,10116.0,CHEMBL627959,,2048.0,Lung,,1,1
11057,50597,,BAO_0000218,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.3-0.36,,,N,Intermediate,A,10116.0,CHEMBL627960,,2048.0,Lung,,1,1
11058,50597,,BAO_0000218,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.36-0.44,,,N,Intermediate,A,10116.0,CHEMBL627961,,2048.0,Lung,,1,1
11059,50597,,BAO_0000218,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.5-0.65,,,N,Intermediate,A,10116.0,CHEMBL627962,,2048.0,Lung,,1,1
11060,50597,,BAO_0000218,,,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,,,N,Intermediate,A,10116.0,CHEMBL627963,,,,,1,1
11061,50597,,BAO_0000218,,,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,,,N,Intermediate,A,10116.0,CHEMBL624759,,,,,1,1
11062,50597,,BAO_0000218,,,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,,,N,Intermediate,A,10116.0,CHEMBL624760,,,,,1,1
11063,50597,,BAO_0000218,,,Distribution of radiolabeled compound in intestinal contents of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,,,N,Intermediate,A,10116.0,CHEMBL624761,,,,,1,1
11064,50597,,BAO_0000218,,,Distribution of radiolabeled compound in intestinal contents of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,,,N,Intermediate,A,10116.0,CHEMBL877607,,,,,1,1
11065,50597,,BAO_0000218,,,Distribution of radiolabeled compound in liver of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,,,N,Intermediate,A,10116.0,CHEMBL624762,,2107.0,Liver,,1,1
11066,50597,,BAO_0000218,,,Distribution of radiolabeled compound in liver of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,,,N,Intermediate,A,10116.0,CHEMBL624763,,2107.0,Liver,,1,1
11067,50597,,BAO_0000218,,,Distribution of radiolabeled compound in liver of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,,,N,Intermediate,A,10116.0,CHEMBL624764,,2107.0,Liver,,1,1
11068,50597,,BAO_0000218,,,Distribution of radiolabeled compound in liver of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,,,N,Intermediate,A,10116.0,CHEMBL624765,,2107.0,Liver,,1,1
11069,50597,,BAO_0000218,,,Distribution of radiolabeled compound in liver of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,,,N,Intermediate,A,10116.0,CHEMBL624766,,2107.0,Liver,,1,1
11070,50588,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),,,N,Intermediate,A,9615.0,CHEMBL624767,,,,,1,1
11071,50588,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration,,,N,Intermediate,A,9615.0,CHEMBL624768,,,,,1,1
11072,50588,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration (0-6 hr),,,N,Intermediate,A,9615.0,CHEMBL624769,,,,,1,1
11073,50588,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),,,N,Intermediate,A,9615.0,CHEMBL624770,,,,,1,1
11074,50588,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),,,N,Intermediate,A,9615.0,CHEMBL624771,,,,,1,1
11075,50588,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),,,N,Intermediate,A,9615.0,CHEMBL624772,,,,,1,1
11076,50597,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration,,,N,Intermediate,A,10116.0,CHEMBL624773,,,,,1,1
11077,50597,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,,N,Intermediate,A,10116.0,CHEMBL624774,,,,,1,1
11078,50597,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr),,,N,Intermediate,A,10116.0,CHEMBL624775,,,,,1,1
11079,50597,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),,,N,Intermediate,A,10116.0,CHEMBL624776,,,,,1,1
11080,50597,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),,,N,Intermediate,A,10116.0,CHEMBL624777,,,,,1,1
11081,50597,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,,N,Intermediate,A,10116.0,CHEMBL624778,,,,,1,1
11082,50597,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration,,,N,Intermediate,A,10116.0,CHEMBL624779,,,,,1,1
11083,50597,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),,,N,Intermediate,A,10116.0,CHEMBL624780,,,,,1,1
11084,50597,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),,,N,Intermediate,A,10116.0,CHEMBL624781,,,,,1,1
11085,50597,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,,N,Intermediate,A,10116.0,CHEMBL877608,,,,,1,1
11086,50597,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration (0-5 hr),,,N,Intermediate,A,10116.0,CHEMBL624782,,,,,1,1
11087,50597,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,,N,Intermediate,A,10116.0,CHEMBL624783,,,,,1,1
11088,50597,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration,,,N,Intermediate,A,10116.0,CHEMBL624784,,,,,1,1
11089,50597,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,,N,Intermediate,A,10116.0,CHEMBL624785,,,,,1,1
11090,50597,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr),,,N,Intermediate,A,10116.0,CHEMBL624786,,,,,1,1
11091,50597,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),,,N,Intermediate,A,10116.0,CHEMBL624787,,,,,1,1
11092,50597,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,,N,Intermediate,A,10116.0,CHEMBL628676,,,,,1,1
11093,50597,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration,,,N,Intermediate,A,10116.0,CHEMBL621842,,,,,1,1
11094,50597,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,,N,Intermediate,A,10116.0,CHEMBL621843,,,,,1,1
11095,50597,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),,,N,Intermediate,A,10116.0,CHEMBL623873,,,,,1,1
11096,50597,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),,,N,Intermediate,A,10116.0,CHEMBL623874,,,,,1,1
11097,50597,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),,,N,Intermediate,A,10116.0,CHEMBL623875,,,,,1,1
11098,50597,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,,N,Intermediate,A,10116.0,CHEMBL623876,,,,,1,1
11099,50588,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.312 mg/kg after ip administration,,,N,Intermediate,A,9615.0,CHEMBL623877,,,,,1,1
11100,50588,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),,,N,Intermediate,A,9615.0,CHEMBL623878,,,,,1,1
11101,50588,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.625 mg/kg after ip administration,,,N,Intermediate,A,9615.0,CHEMBL623879,,,,,1,1
11102,50588,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),,,N,Intermediate,A,9615.0,CHEMBL623880,,,,,1,1
11103,50588,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),,,N,Intermediate,A,9615.0,CHEMBL623881,,,,,1,1
11104,50588,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 10 mg/kg after ip administration (0-6 hr),,,N,Intermediate,A,9615.0,CHEMBL623957,,,,,1,1
11105,50588,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),,,N,Intermediate,A,9615.0,CHEMBL623958,,,,,1,1
11106,50588,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),,,N,Intermediate,A,9615.0,CHEMBL623959,,,,,1,1
11107,50588,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),,,N,Intermediate,A,9615.0,CHEMBL623960,,,,,1,1
11108,50588,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration (0-6 hr),,,N,Intermediate,A,9615.0,CHEMBL623961,,,,,1,1
11109,50588,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),,,N,Intermediate,A,9615.0,CHEMBL623962,,,,,1,1
11110,50588,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),,,N,Intermediate,A,9615.0,CHEMBL624676,,,,,1,1
11111,50588,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),,,N,Intermediate,A,9615.0,CHEMBL624677,,,,,1,1
11112,50588,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration,,,N,Intermediate,A,9615.0,CHEMBL624678,,,,,1,1
11113,50588,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration (0-6 hr),,,N,Intermediate,A,9615.0,CHEMBL624679,,,,,1,1
11114,50588,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),,,N,Intermediate,A,9615.0,CHEMBL624680,,,,,1,1
11115,22224,In vivo,BAO_0000218,,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 27%,,,U,Autocuration,A,,CHEMBL624849,,,,,0,1
11116,22224,In vivo,BAO_0000218,,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 4%,,,U,Autocuration,A,,CHEMBL624850,,,,,0,1
11117,22224,In vivo,BAO_0000218,,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 54%,,,U,Autocuration,A,,CHEMBL874399,,,,,0,1
11118,22224,In vivo,BAO_0000218,,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 72%,,,U,Autocuration,A,,CHEMBL624851,,,,,0,1
11119,22224,In vivo,BAO_0000218,,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 76%,,,U,Autocuration,A,,CHEMBL624852,,,,,0,1
11120,22224,In vivo,BAO_0000218,,,Oral bioavailability in rat (dose 10 mg/kg),,,U,Autocuration,A,10116.0,CHEMBL624853,,,,,0,1
11121,22224,In vivo,BAO_0000218,,,Oral bioavailability in rat (Sprague-Dawley),,,U,Autocuration,A,10116.0,CHEMBL624854,,,,,0,1
11122,22224,In vivo,BAO_0000218,,,Oral bioavailability in rat,,,U,Autocuration,A,10116.0,CHEMBL624855,,,,,0,1
11123,22224,In vivo,BAO_0000218,,,Oral bioavailability in rats was determined in vivo,,,U,Autocuration,A,10116.0,CHEMBL624856,,,,,0,1
11124,22224,In vivo,BAO_0000218,,,Oral bioavailability in dog,,,U,Autocuration,A,9615.0,CHEMBL882957,,,,,0,1
11125,22224,In vivo,BAO_0000218,,,Oral bioavailability of compound in monkey,,,U,Autocuration,A,314293.0,CHEMBL624857,,,,,0,1
11126,50597,In vivo,BAO_0000218,,,Oral bioavailability of compound in rat,,,N,Intermediate,A,10116.0,CHEMBL622202,,,,,1,1
11127,22224,In vivo,BAO_0000218,,,Bioavailability in rat of PMEA prodrug,,,U,Autocuration,A,10116.0,CHEMBL622203,,,,,0,1
11128,50597,In vivo,BAO_0000218,,,Oral bioavailability of compound was evaluated relative to that of PMEA in rat; Not determined due to lack of solubility,,,N,Intermediate,A,10116.0,CHEMBL625522,,,,,1,1
11129,22224,In vivo,BAO_0000218,,,Serum conc at 3 hours following 25 mg/kg dose,,,U,Autocuration,A,9544.0,CHEMBL622868,,,,,0,1
11130,22224,In vivo,BAO_0000218,,,Urine conc 0-5 hours following 25 mg/kg dose,,,U,Autocuration,A,9544.0,CHEMBL622869,,1088.0,Urine,,0,1
11131,22224,In vivo,BAO_0000218,,,Urine conc 0-24 hours following 25 mg/kg dose,,,U,Autocuration,A,9544.0,CHEMBL622870,,1088.0,Urine,,0,1
11132,22224,In vivo,BAO_0000218,,,Oral bioavailability in African green monkeys; 20-25,,,U,Autocuration,A,9534.0,CHEMBL622871,,,,,0,1
11133,100710,In vivo,BAO_0000218,,,Oral bioavailability in cynomolgus monkey.,,,N,Intermediate,A,9541.0,CHEMBL620560,,,,,1,1
11134,22224,In vivo,BAO_0000218,,,Oral bioavailability in dog,,,U,Autocuration,A,9615.0,CHEMBL620561,,,,,0,1
11135,50588,In vivo,BAO_0000218,,,Oral bioavailability in dog at 10 mg/kg oral dose,,,N,Intermediate,A,9615.0,CHEMBL620562,,,,,1,1
11136,100712,In vivo,BAO_0000218,,,Oral bioavailability in hamster at 10 mg/kg oral dose,,,N,Intermediate,A,10026.0,CHEMBL620563,,,,,1,1
11137,50597,In vivo,BAO_0000218,,,Oral bioavailability in rat at 10 mg/kg oral dose,,,N,Intermediate,A,10116.0,CHEMBL620564,,,,,1,1
11138,22224,In vivo,BAO_0000218,,,Oral bioavailability in rat,,,U,Autocuration,A,10116.0,CHEMBL872265,,,,,0,1
11139,22224,In vivo,BAO_0000218,,,Oral bioavailability in rat,,,U,Autocuration,A,10116.0,CHEMBL620565,,,,,0,1
11140,22224,In vivo,BAO_0000218,,,Oral bioavailability,,,U,Autocuration,A,9347.0,CHEMBL620566,,,,,0,1
11141,22224,In vivo,BAO_0000218,,,Oral bioavailability was determined; range 49-102%,,,U,Autocuration,A,,CHEMBL620567,,,,,0,1
11142,50588,In vivo,BAO_0000218,,,Oral bioavailability was determined in dogs,,,N,Intermediate,A,9615.0,CHEMBL620568,,,,,1,1
11143,22224,In vivo,BAO_0000218,,,Oral bioavailability in rat,,,U,Autocuration,A,10116.0,CHEMBL620569,,,,,0,1
11144,22224,In vivo,BAO_0000218,,,Oral bioavailability,,,U,Autocuration,A,9347.0,CHEMBL620570,,,,,0,1
11145,22224,In vivo,BAO_0000218,,,Oral bioavailability was determined; Not orally available,,,U,Autocuration,A,,CHEMBL620571,,,,,0,1
11146,50594,In vivo,BAO_0000218,,,Percent bioavailability was administered by using 0.4% Methyl cellulose (MC) as vehicle to nude mice at a dose of 25 mg/kg (micronized sample),,,N,Intermediate,A,10090.0,CHEMBL620572,,,,,1,1
11147,22224,In vivo,BAO_0000218,,,Bioavailability in mouse (nude) (dose 0.4% Methylcellulose (MC) as vehicle 25 mg/kg),,,U,Autocuration,A,10090.0,CHEMBL620573,,,,,0,1
11148,22224,In vivo,BAO_0000218,,,Bioavailability in mouse (nude) using 20% aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle 25 mg/kg,,,U,Autocuration,A,10090.0,CHEMBL620574,,,,,0,1
11149,22224,In vivo,BAO_0000218,,,Oral bioavailability in Rhesus monkey,,,U,Autocuration,A,9544.0,CHEMBL620575,,,,,0,1
11150,22224,In vivo,BAO_0000218,,,Oral bioavailability in dog (female mongrel),,,U,Autocuration,A,9615.0,CHEMBL620576,,,,,0,1
11151,22224,In vivo,BAO_0000218,,,Percent oral bioavailability of perorally administered compound (30 mg/kg) was tested,,,U,Autocuration,A,,CHEMBL875846,,,,,0,1
11152,22224,In vivo,BAO_0000218,,,Oral bioavailability in dog,,,U,Autocuration,A,9615.0,CHEMBL620577,,,,,0,1
11153,22224,In vivo,BAO_0000218,,,Percentage Bioavailability was evaluated.,,,U,Autocuration,A,,CHEMBL620578,,,,,0,1
11154,22224,In vivo,BAO_0000218,,,Bioavailability in rat administered i.d.,,,U,Autocuration,A,10116.0,CHEMBL620579,,,,,0,1
11155,22224,In vivo,BAO_0000218,,,Bioavailability,,,U,Autocuration,A,9347.0,CHEMBL621248,,,,,0,1
11156,22224,In vivo,BAO_0000218,,,Bioavailability in dog (male Beagle) i.v. administration,,,U,Autocuration,A,9615.0,CHEMBL625390,,,,,0,1
11157,22224,In vivo,BAO_0000218,,,"Bioavailability in rat (dose 20 mg/kg p.o. in 1% methocel, and 5 mg/kg i.v. in PEG400)",,,U,Autocuration,A,10116.0,CHEMBL625391,,,,,0,1
11158,22224,In vivo,BAO_0000218,,,Bioavailability in monkey (dose 10 mg/kg i.d. or 0.3 mg/kg i.v.),,,U,Autocuration,A,9443.0,CHEMBL872266,,,,,0,1
11159,22224,In vivo,BAO_0000218,,,Oral bioavailability in rat (Sprague-Dawley) (male),,,U,Autocuration,A,10116.0,CHEMBL625392,,,,,0,1
11160,50597,In vivo,BAO_0000218,,,The oral bioavailability was measured on rats after oral administration,,,N,Intermediate,A,10116.0,CHEMBL625393,,,,,1,1
11161,50597,In vivo,BAO_0000218,,,Bioavailability was evaluated in rat at an intravenous dose of 3 mg/kg and peroral dose of 5 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL625394,,,,,1,1
11162,50797,In vivo,BAO_0000218,,,Bioavailability was evaluated in rhesus monkey at an intravenous dose of 1 mg/kg and peroral dose of 1 mg/kg,,,N,Intermediate,A,9544.0,CHEMBL625395,,,,,1,1
11163,22224,In vivo,BAO_0000218,,,Bioavailability in rat (dose 10 mg/kg i.d.),,,U,Autocuration,A,10116.0,CHEMBL625396,,,,,0,1
11164,22224,In vivo,BAO_0000218,,,Bioavailability in dog (male Beagle) i.v. administration,,,U,Autocuration,A,9615.0,CHEMBL625397,,,,,0,1
11165,50594,In vivo,BAO_0000218,,,Biodistribution in CD-1 mice was determined after 1 minute in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),,,N,Intermediate,A,10090.0,CHEMBL625398,,,,,1,1
11166,50594,In vivo,BAO_0000218,,,Biodistribution in CD-1 mice was determined after 1 minute in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),,,N,Intermediate,A,10090.0,CHEMBL625399,,178.0,Blood,,1,1
11167,50594,In vivo,BAO_0000218,,,Biodistribution in CD-1 mice was determined after 1 minute in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),,,N,Intermediate,A,10090.0,CHEMBL626074,,2037.0,Cerebellum,,1,1
11168,50594,In vivo,BAO_0000218,,,Biodistribution in CD-1 mice was determined after 1 minute in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),,,N,Intermediate,A,10090.0,CHEMBL626075,,,,,1,1
11169,50597,In vivo,BAO_0000218,,,Maximum concentration in plasma (Cmax) was evaluated in rat at an intravenous dose of 3 mg/kg and peroral dose of 5 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL626076,,1969.0,Plasma,,1,1
11170,50797,In vivo,BAO_0000218,,,Maximum concentration in plasma (Cmax) was evaluated in rhesus monkey at an intravenous dose of 1 mg/kg and peroral dose of 1 mg/kg,,,N,Intermediate,A,9544.0,CHEMBL626077,,1969.0,Plasma,,1,1
11171,50597,In vivo,BAO_0000218,,,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 1 mg/kg in rat (normalized to a 1 mg/kg dose),,,N,Intermediate,A,10116.0,CHEMBL626078,,178.0,Blood,,1,1
11172,22224,In vivo,BAO_0000218,,,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 2.5 mg/kg in rat (normalized to a 1 mg/kg dose),,,U,Autocuration,A,,CHEMBL625846,,178.0,Blood,,0,1
11173,22224,In vivo,BAO_0000218,,,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 5.0 mg/kg GP (normalized to a 1 mg/kg dose),,,U,Autocuration,A,,CHEMBL625847,,178.0,Blood,,0,1
11174,50597,In vivo,BAO_0000218,,,Maximum concentration observed in rats at an oral dose of 50 mg/kg,,,N,Expert,A,10116.0,CHEMBL625848,,,,,1,1
11175,50597,In vivo,BAO_0000218,,,Maximum concentration of compound in plasma administered orally to rats,,,N,Intermediate,A,10116.0,CHEMBL625849,,1969.0,Plasma,,1,1
11176,50588,In vivo,BAO_0000218,,,"Maximum concentration (10 mg/kg, orally) in plasma of dogs",,,N,Intermediate,A,9615.0,CHEMBL626023,,1969.0,Plasma,,1,1
11177,50588,In vivo,BAO_0000218,,,"Maximum concentration (10 mg/kg, perorally) in plasma of dogs",,,N,Intermediate,A,9615.0,CHEMBL626024,,1969.0,Plasma,,1,1
11178,50588,In vivo,BAO_0000218,,,"Maximum concentration (5 mg/kg, intravenously) in plasma of dogs",,,N,Intermediate,A,9615.0,CHEMBL626025,,1969.0,Plasma,,1,1
11179,22224,In vivo,BAO_0000218,,,Maximum concentration after 10 mg/kg by oral administration,,,U,Autocuration,A,,CHEMBL626026,,,,,0,1
11180,22224,In vivo,BAO_0000218,,,Maximum concentration at a dose of 1.5 mg/kg,,,U,Autocuration,A,,CHEMBL626027,,,,,0,1
11181,22224,In vivo,BAO_0000218,,,Maximum concentration at a dose of 2.0 mg/kg,,,U,Autocuration,A,,CHEMBL626028,,,,,0,1
11182,50588,In vivo,BAO_0000218,,,Maximum concentration in dog plasma,,,N,Intermediate,A,9615.0,CHEMBL626029,,1969.0,Plasma,,1,1
11183,22224,In vivo,BAO_0000218,,,Maximum concentration in plasma after administration of 10 umol/kg dose perorally,,,U,Autocuration,A,,CHEMBL626030,,1969.0,Plasma,,0,1
11184,22224,In vivo,BAO_0000218,,,Maximum concentration in plasma after administration of 2 umol/kg dose intravenously,,,U,Autocuration,A,,CHEMBL626031,,1969.0,Plasma,,0,1
11185,22224,In vivo,BAO_0000218,,,Maximum concentration in plasma after administration of 4 umol/kg dose intravenously,,,U,Autocuration,A,,CHEMBL626032,,1969.0,Plasma,,0,1
11186,22224,In vivo,BAO_0000218,,,Maximum concentration in plasma after administration of 40 umol/kg dose perorally,,,U,Autocuration,A,,CHEMBL626033,,1969.0,Plasma,,0,1
11187,22224,In vivo,BAO_0000218,,,Maximum concentration in plasma after administration of 5 umol/kg dose intravenously,,,U,Autocuration,A,,CHEMBL626034,,1969.0,Plasma,,0,1
11188,50588,In vivo,BAO_0000218,,,Maximum concentration in plasma after oral administration in dog (25 mg/kg),,,N,Intermediate,A,9615.0,CHEMBL626035,,1969.0,Plasma,,1,1
11189,22224,In vivo,BAO_0000218,,,Maximum concentration in plasma at Tmax,,,U,Autocuration,A,,CHEMBL626036,,1969.0,Plasma,,0,1
11190,50588,In vivo,BAO_0000218,,,Maximum concentration in plasma recorded 0-6 hr post dose in dog at 10 mg/kg oral dose,,,N,Expert,A,9615.0,CHEMBL626037,,1969.0,Plasma,,1,1
11191,100712,In vivo,BAO_0000218,,,Maximum concentration in plasma recorded in the period 0-6 hr post dose in hamster at 10 mg/kg oral dose,,,N,Intermediate,A,10026.0,CHEMBL626038,,1969.0,Plasma,,1,1
11192,50597,In vivo,BAO_0000218,,,Maximum concentration in plasma recorded in the period 0-6 hr post dose in rat at 10 mg/kg oral dose,,,N,Intermediate,A,10116.0,CHEMBL626039,,1969.0,Plasma,,1,1
11193,50597,In vivo,BAO_0000218,,,Maximum concentration in plasma was determined by oral administration to rats at 20 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL626040,,1969.0,Plasma,,1,1
11194,50592,In vivo,BAO_0000218,,,Maximum concentration present in the rabbit plasma following peroral administration of 10 mg/kg,,,N,Intermediate,A,9986.0,CHEMBL626041,,1969.0,Plasma,,1,1
11195,22224,In vivo,BAO_0000218,,,Maximum concentration was calculated,,,U,Autocuration,A,,CHEMBL626042,,,,,0,1
11196,22224,In vivo,BAO_0000218,,,Maximum concentration was calculated.,,,U,Autocuration,A,,CHEMBL626043,,,,,0,1
11197,22224,In vivo,BAO_0000218,,,Maximum concentration at a peroral dose of 10 mg/kg,,,U,Autocuration,A,,CHEMBL626044,,,,,0,1
11198,22224,In vivo,BAO_0000218,,,Maximum concentration of the drug at 10 uM/dg administered perorally,,,U,Autocuration,A,,CHEMBL626045,,,,,0,1
11199,22224,In vivo,BAO_0000218,,,Maximum concentration of the drug at 2 uM/dg administered intravenously,,,U,Autocuration,A,,CHEMBL626046,,,,,0,1
11200,50588,In vivo,BAO_0000218,,,"Maximum concentration of the unchanged compound in dog plasma, recorded in the period 0-6 hr post dose.",,,N,Intermediate,A,9615.0,CHEMBL626047,,1969.0,Plasma,,1,1
11201,100712,In vivo,BAO_0000218,,,"Maximum concentration of the unchanged compound in hamster plasma, recorded in the period 0-6 hr post dose.",,,N,Intermediate,A,10026.0,CHEMBL626048,,1969.0,Plasma,,1,1
11202,50597,In vivo,BAO_0000218,,,"Maximum concentration of the unchanged compound in rat plasma, recorded in the period 0-6 hr post dose.",,,N,Intermediate,A,10116.0,CHEMBL626049,,1969.0,Plasma,,1,1
11203,50597,In vivo,BAO_0000218,,,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in anesthetized rat at 60 mg/kg oral dose,,,N,Intermediate,A,10116.0,CHEMBL626050,,1969.0,Plasma,,1,1
11204,50588,In vivo,BAO_0000218,,,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in dog at 5 mg/kg oral dose,,,N,Intermediate,A,9615.0,CHEMBL874541,,1969.0,Plasma,,1,1
11205,100712,In vivo,BAO_0000218,,,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in hamster at 40 mg/kg oral dose,,,N,Intermediate,A,10026.0,CHEMBL622826,,1969.0,Plasma,,1,1
11206,100712,In vivo,BAO_0000218,,,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose to hamster at 40 mg/kg oral dose,,,N,Intermediate,A,10026.0,CHEMBL622827,,1969.0,Plasma,,1,1
11207,50597,In vivo,BAO_0000218,,,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in anesthetized rat at 25 mg/kg oral dose,,,N,Intermediate,A,10116.0,CHEMBL622828,,1969.0,Plasma,,1,1
11208,50597,In vivo,BAO_0000218,,,Maximum concentration of unchanged drug in rat plasma in the period 0-24 hr after dosing,,,N,Intermediate,A,10116.0,CHEMBL622829,,1969.0,Plasma,,1,1
11209,50597,In vivo,BAO_0000218,,,Maximum concentration reached following intravenous administration in male rat,,,N,Intermediate,A,10116.0,CHEMBL876806,,,,,1,1
11210,50588,In vivo,BAO_0000218,,,Maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 10 mg/kg dosage administered perorally in dog,,,N,Intermediate,A,9615.0,CHEMBL622830,,,,,1,1
11211,50597,In vivo,BAO_0000218,,,Maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 5 mg/kg dosage administered perorally in rats,,,N,Intermediate,A,10116.0,CHEMBL622831,,,,,1,1
11212,50588,In vivo,BAO_0000218,,,Maximum concentration was measured after peroral administration of 10 mg/kg of drug in male Beagle dogs,,,N,Intermediate,A,9615.0,CHEMBL626794,,,,,1,1
11213,50597,In vivo,BAO_0000218,,,Maximum concentration was measured after peroral administration of 5.0 mg/kg of drug in male Dawley rats,,,N,Intermediate,A,10116.0,CHEMBL626795,,,,,1,1
11214,50597,In vivo,BAO_0000218,,,Maximum concentration was measured after peroral administration of 5.1 mg/kg of drug in male Dawley rats,,,N,Intermediate,A,10116.0,CHEMBL626796,,,,,1,1
11215,50597,In vivo,BAO_0000218,,,Maximum concentration was measured after peroral administration of 5.2 mg/kg of drug in male Dawley rats,,,N,Intermediate,A,10116.0,CHEMBL626797,,,,,1,1
11216,50597,In vivo,BAO_0000218,,,Maximum drug concentration is determined after oral dosing in rats.,,,N,Intermediate,A,10116.0,CHEMBL626798,,,,,1,1
11217,50588,In vivo,BAO_0000218,,,Maximum observed concentration in oral (5 mg/kg) fasted dogs,,,N,Intermediate,A,9615.0,CHEMBL626799,,,,,1,1
11218,50588,In vivo,BAO_0000218,,,Maximum observed concentration in oral (5 mg/kg) fed dogs,,,N,Intermediate,A,9615.0,CHEMBL626800,,,,,1,1
11219,22224,In vivo,BAO_0000218,,,Maximum plasma concentration,,,U,Autocuration,A,,CHEMBL626801,,1969.0,Plasma,,0,1
11220,50597,In vivo,BAO_0000218,,,Maximum plasma concentration (Cmax) was determined in rats after intraduodenal administration of the drug,,,N,Intermediate,A,10116.0,CHEMBL876816,,1969.0,Plasma,,1,1
11221,50597,In vivo,BAO_0000218,,,Maximum plasma concentration following oral administration of 26.3 mg/kg in rats,,,N,Intermediate,A,10116.0,CHEMBL626802,,1969.0,Plasma,,1,1
11222,50588,In vivo,BAO_0000218,,,Maximum plasma concentration following oral administration of 3.8 mg/kg in Beagle dog,,,N,Intermediate,A,9615.0,CHEMBL626803,,1969.0,Plasma,,1,1
11223,22224,In vivo,BAO_0000218,,,Maximum plasma concentration following oral administration of 30 umol/kg,,,U,Autocuration,A,,CHEMBL626804,,1969.0,Plasma,,0,1
11224,50597,,BAO_0000218,,,Distribution of radiolabeled compound in plasma of rat 1 hr after ip administration of dose,,,N,Intermediate,A,10116.0,CHEMBL626805,,1969.0,Plasma,,1,1
11225,50597,,BAO_0000218,,,Distribution of radiolabeled compound in plasma of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,,,N,Intermediate,A,10116.0,CHEMBL626309,,1969.0,Plasma,,1,1
11226,50597,,BAO_0000218,,,Distribution of radiolabeled compound in plasma of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,,,N,Intermediate,A,10116.0,CHEMBL626310,,1969.0,Plasma,,1,1
11227,50597,,BAO_0000218,,,Distribution of radiolabeled compound in plasma of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,,,N,Intermediate,A,10116.0,CHEMBL626311,,1969.0,Plasma,,1,1
11228,50597,,BAO_0000218,,,Distribution of radiolabeled compound in plasma of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,,,N,Intermediate,A,10116.0,CHEMBL626312,,1969.0,Plasma,,1,1
11229,50597,,BAO_0000218,,,Distribution of radiolabeled compound in uterus of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,,,N,Intermediate,A,10116.0,CHEMBL626313,,995.0,Uterus,,1,1
11230,50597,,BAO_0000218,,,Distribution of radiolabeled compound in uterus of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,,,N,Intermediate,A,10116.0,CHEMBL626314,,995.0,Uterus,,1,1
11231,50597,,BAO_0000218,,,Distribution of radiolabeled compound in uterus of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,,,N,Intermediate,A,10116.0,CHEMBL626315,,995.0,Uterus,,1,1
11232,50597,,BAO_0000218,,,Distribution of radiolabeled compound in uterus of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,,,N,Intermediate,A,10116.0,CHEMBL626316,,995.0,Uterus,,1,1
11233,50597,,BAO_0000218,,,Distribution of radiolabeled compound in uterus of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,,,N,Intermediate,A,10116.0,CHEMBL626317,,995.0,Uterus,,1,1
11234,50597,,BAO_0000218,,,Distribution of rat erythrocytes for tube 2 on rate of aging in 2 mL of cell suspension; Minus (-),,,N,Intermediate,A,10116.0,CHEMBL626318,,,,,1,1
11235,50597,,BAO_0000218,,,Distribution of rat erythrocytes for tube 2 on rate of aging in 2 mL of cell suspension; Plus (+),,,N,Intermediate,A,10116.0,CHEMBL626319,,,,,1,1
11236,50597,,BAO_0000218,,,Distribution of rat erythrocytes for tube 3 on rate of aging in 2 mL of cell suspension; Minus (-),,,N,Intermediate,A,10116.0,CHEMBL626320,,,,,1,1
11237,50597,,BAO_0000218,,,Distribution of rat erythrocytes for tube 3 on rate of aging in 2 mL of cell suspension; Plus (+),,,N,Intermediate,A,10116.0,CHEMBL875053,,,,,1,1
11238,50597,,BAO_0000218,,,Distribution of rat erythrocytes for tube 4 on rate of aging in 2 mL of cell suspension; Minus (-),,,N,Intermediate,A,10116.0,CHEMBL626321,,,,,1,1
11239,50597,,BAO_0000218,,,Distribution of rat erythrocytes for tube 4 on rate of aging in 2 mL of cell suspension; Plus (+),,,N,Intermediate,A,10116.0,CHEMBL626322,,,,,1,1
11240,50597,,BAO_0000218,,,Distribution of rat erythrocytes for tube 5 on rate of aging in 2 mL of cell suspension; Minus (-),,,N,Intermediate,A,10116.0,CHEMBL626323,,,,,1,1
11241,50597,,BAO_0000218,,,Distribution of rat erythrocytes for tube 5 on rate of aging in 2 mL of cell suspension; Plus (+),,,N,Intermediate,A,10116.0,CHEMBL626324,,,,,1,1
11242,50597,,BAO_0000218,,,Distribution of rat erythrocytes for tube 6 on rate of aging in 2 mL of cell suspension; Minus (-),,,N,Intermediate,A,10116.0,CHEMBL626325,,,,,1,1
11243,50597,,BAO_0000218,,,Distribution of rat erythrocytes for tube 6 on rate of aging in 2 mL of cell suspension; Plus (+),,,N,Intermediate,A,10116.0,CHEMBL626326,,,,,1,1
11244,50597,,BAO_0000218,,,Distribution of rat erythrocytes for tube 7 on rate of aging in 2 mL of cell suspension; Plus (+),,,N,Intermediate,A,10116.0,CHEMBL626327,,,,,1,1
11245,50597,,BAO_0000218,,,Distribution of rat erythrocytes for tube 1 on rate of aging in 2 mL of cell suspension; Minus (-),,,N,Intermediate,A,10116.0,CHEMBL626328,,,,,1,1
11246,50597,,BAO_0000218,,,"Distribution in blood of rat 5 min after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL626329,,178.0,Blood,,1,1
11247,50597,,BAO_0000218,,,"Distribution in blood of rat, 15 min after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL626330,,178.0,Blood,,1,1
11248,50597,,BAO_0000218,,,"Distribution in blood of rat, 1 hr after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL626331,,178.0,Blood,,1,1
11249,50597,,BAO_0000218,,,"Distribution in blood of rat, 2 hr after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL626332,,178.0,Blood,,1,1
11250,50597,,BAO_0000218,,,"Distribution in blood of rat, 30 min after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL626333,,178.0,Blood,,1,1
11251,50597,,BAO_0000218,,,"Distribution in blood of rat, 4 hr after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL626334,,178.0,Blood,,1,1
11252,50597,,BAO_0000218,,,"Distribution in blood of rat, 6 hr after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL626335,,178.0,Blood,,1,1
11253,50597,,BAO_0000218,,,"Distribution in blood of rat, 8 hr after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL624798,,178.0,Blood,,1,1
11254,50597,,BAO_0000218,,,"Distribution in brain of rat, 15 min after intravenous administered, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL624799,,955.0,Brain,,1,1
11255,50597,,BAO_0000218,,,"Distribution in brain of rat, 1 hr after intravenous administered, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL624800,,955.0,Brain,,1,1
11256,50597,,BAO_0000218,,,"Distribution in brain of rat, 2 hr after intravenous administered, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL624801,,955.0,Brain,,1,1
11257,50597,,BAO_0000218,,,"Distribution in brain of rat, 30 min after intravenous administered, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL624802,,955.0,Brain,,1,1
11258,50597,,BAO_0000218,,,"Distribution in brain of rat, 4 hr after intravenous administered, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL624803,,955.0,Brain,,1,1
11259,50597,,BAO_0000218,,,"Distribution in brain of rat, 5 min after intravenous administered, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL624804,,955.0,Brain,,1,1
11260,50597,,BAO_0000218,,,"Distribution in brain of rat, 6 hr after intravenous administered, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL624805,,955.0,Brain,,1,1
11261,50597,,BAO_0000218,,,"Distribution in brain of rat, 8 hr after intravenous administered, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL624806,,955.0,Brain,,1,1
11262,50597,,BAO_0000218,,,"Distribution in rat fat 15 min after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL624807,,,,,1,1
11263,50597,,BAO_0000218,,,"Distribution in rat fat 1 hr after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL624808,,,,,1,1
11264,50597,,BAO_0000218,,,"Distribution in rat fat 2 hr after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL624809,,,,,1,1
11265,50597,,BAO_0000218,,,"Distribution in rat fat 30 min after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL624810,,,,,1,1
11266,50597,,BAO_0000218,,,"Distribution in rat fat 4 hr after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL877618,,,,,1,1
11267,50597,,BAO_0000218,,,"Distribution in rat fat 5 min after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL624811,,,,,1,1
11268,50597,,BAO_0000218,,,"Distribution in rat fat 6 hr after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL624812,,,,,1,1
11269,50597,,BAO_0000218,,,"Distribution in rat fat 8 hr after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL624813,,,,,1,1
11270,50597,,BAO_0000218,,,"Distribution in rat heart 15 min after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL624814,,,,,1,1
11271,50597,,BAO_0000218,,,"Distribution in rat heart 1 hr after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL624815,,,,,1,1
11272,50597,,BAO_0000218,,,"Distribution in rat heart 2 hr after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL624816,,,,,1,1
11273,50597,,BAO_0000218,,,"Distribution in rat heart 30 min after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL624817,,,,,1,1
11274,50588,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),,,N,Intermediate,A,9615.0,CHEMBL624818,,,,,1,1
11275,50588,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration,,,N,Intermediate,A,9615.0,CHEMBL624819,,,,,1,1
11276,50588,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration (0-6 hr),,,N,Intermediate,A,9615.0,CHEMBL624820,,,,,1,1
11277,50588,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),,,N,Intermediate,A,9615.0,CHEMBL624821,,,,,1,1
11278,50588,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),,,N,Intermediate,A,9615.0,CHEMBL624822,,,,,1,1
11279,50588,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),,,N,Intermediate,A,9615.0,CHEMBL624823,,,,,1,1
11280,50212,,BAO_0000218,,,Observed diffusion coefficient in organic solvent for Escherichia coli,,,N,Intermediate,A,562.0,CHEMBL624824,,,,,1,1
11281,50597,,BAO_0000218,,,"Concentration of compound in blood of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",,,N,Intermediate,A,10116.0,CHEMBL624825,,178.0,Blood,,1,1
11282,50597,,BAO_0000218,,,"Concentration of compound in blood of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",,,N,Intermediate,A,10116.0,CHEMBL624826,,178.0,Blood,,1,1
11283,50597,,BAO_0000218,,,"Concentration of compound in left atrium of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",,,N,Intermediate,A,10116.0,CHEMBL876817,,2081.0,Cardiac atrium,,1,1
11284,50597,,BAO_0000218,,,"Concentration of compound in left atrium of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",,,N,Intermediate,A,10116.0,CHEMBL624827,,2081.0,Cardiac atrium,,1,1
11285,50597,,BAO_0000218,,,"Concentration of compound in left ventricle of of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",,,N,Intermediate,A,10116.0,CHEMBL624828,,,,,1,1
11286,50597,,BAO_0000218,,,"Concentration of compound in left ventricle of of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",,,N,Intermediate,A,10116.0,CHEMBL624829,,,,,1,1
11287,50597,,BAO_0000218,,,"Concentration of compound in liver of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",,,N,Intermediate,A,10116.0,CHEMBL624830,,2107.0,Liver,,1,1
11288,50597,,BAO_0000218,,,"Concentration of compound in liver of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",,,N,Intermediate,A,10116.0,CHEMBL624831,,2107.0,Liver,,1,1
11289,50597,,BAO_0000218,,,"Concentration of compound in right atrium of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",,,N,Intermediate,A,10116.0,CHEMBL624832,,2081.0,Cardiac atrium,,1,1
11290,50597,,BAO_0000218,,,"Concentration of compound in right atrium of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",,,N,Intermediate,A,10116.0,CHEMBL624833,,2081.0,Cardiac atrium,,1,1
11291,50597,,BAO_0000218,,,"Concentration of compound in right ventricle of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",,,N,Intermediate,A,10116.0,CHEMBL624834,,,,,1,1
11292,50597,,BAO_0000218,,,"Concentration of compound in right ventricle of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",,,N,Intermediate,A,10116.0,CHEMBL624835,,,,,1,1
11293,50597,,BAO_0000218,,,"Concentration of compound in spleen of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",,,N,Intermediate,A,10116.0,CHEMBL624836,,2106.0,Spleen,,1,1
11294,50597,,BAO_0000218,,,"Concentration of compound in spleen of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",,,N,Intermediate,A,10116.0,CHEMBL624837,,2106.0,Spleen,,1,1
11295,50597,,BAO_0000218,,,Distribution of radioactivity of radiolabeled compound in blood of female rats 30 minutes after intravenous administration,,,N,Intermediate,A,10116.0,CHEMBL624838,,178.0,Blood,,1,1
11296,50597,,BAO_0000218,,,Distribution of radioactivity of radiolabeled compound in blood of female rats 5 minutes after intravenous administration,,,N,Intermediate,A,10116.0,CHEMBL622188,,178.0,Blood,,1,1
11297,50597,,BAO_0000218,,,Distribution of radioactivity of radiolabeled compound in heart of female rats 30 minutes after intravenous administration,,,N,Intermediate,A,10116.0,CHEMBL622189,,948.0,Heart,,1,1
11298,50597,,BAO_0000218,,,Distribution of radioactivity of radiolabeled compound in heart of female rats 30 minutes after intravenous administration at,,,N,Intermediate,A,10116.0,CHEMBL622190,,948.0,Heart,,1,1
11299,50597,,BAO_0000218,,,Distribution of radioactivity of radiolabeled compound in heart of female rats 5 minutes after intravenous administration,,,N,Intermediate,A,10116.0,CHEMBL625170,,948.0,Heart,,1,1
11300,50597,,BAO_0000218,,,Distribution of radioactivity of radiolabeled compound in kidney of female rats 30 minutes after intravenous administration,,,N,Intermediate,A,10116.0,CHEMBL625171,,2113.0,Kidney,,1,1
11301,50597,,BAO_0000218,,,Distribution of radioactivity of radiolabeled compound in kidney of female rats 30 minutes after intravenous administration,,,N,Intermediate,A,10116.0,CHEMBL625172,,2113.0,Kidney,,1,1
11302,50597,,BAO_0000218,,,Distribution of radioactivity of radiolabeled compound in kidney of female rats 5 minutes after intravenous administration,,,N,Intermediate,A,10116.0,CHEMBL625173,,2113.0,Kidney,,1,1
11303,50597,,BAO_0000218,,,Distribution of radioactivity of radiolabeled compound in liver of female rats 30 minutes after intravenous administration,,,N,Intermediate,A,10116.0,CHEMBL625174,,2107.0,Liver,,1,1
11304,50597,,BAO_0000218,,,Distribution of radioactivity of radiolabeled compound in liver of female rats 5 minutes after intravenous administration,,,N,Intermediate,A,10116.0,CHEMBL625175,,2107.0,Liver,,1,1
11305,50597,,BAO_0000218,,,Distribution of radioactivity of radiolabeled compound in liver of female rats 5 minutes after intravenous administration at,,,N,Intermediate,A,10116.0,CHEMBL625176,,2107.0,Liver,,1,1
11306,50597,,BAO_0000218,,,Distribution of radioactivity of radiolabeled compound in lung of female rats 30 minutes after intravenous administration,,,N,Intermediate,A,10116.0,CHEMBL625177,,2048.0,Lung,,1,1
11307,50597,,BAO_0000218,,,Distribution of radioactivity of radiolabeled compound in lung of female rats 5 minutes after intravenous administration,,,N,Intermediate,A,10116.0,CHEMBL625178,,2048.0,Lung,,1,1
11308,50597,,BAO_0000218,,,Distribution of radioactivity of radiolabeled compound in lung of female rats 5 minutes after intravenous administration at,,,N,Intermediate,A,10116.0,CHEMBL625179,,2048.0,Lung,,1,1
11309,50597,,BAO_0000218,,,Distribution of radioactivity of radiolabeled compound in lung of female rats 30 minutes after intravenous administration,,,N,Intermediate,A,10116.0,CHEMBL625180,,2048.0,Lung,,1,1
11310,22224,,BAO_0000218,,,"Original dose appeared in the bile as unchanged compound, which was eliminated at a fairly constant rate over the first 4 hr following the iv administration",,,U,Autocuration,A,,CHEMBL625181,,,,,0,1
11311,50594,,BAO_0000218,,,Percentage of dose recovered after 0-6 hr in the urine of mice was measured.,,,N,Intermediate,A,10090.0,CHEMBL625182,,1088.0,Urine,,1,1
11312,50597,,BAO_0000218,,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat blood as Percent of injected dose per gram in the organ,,,N,Intermediate,A,10116.0,CHEMBL625183,,,,,1,1
11313,50597,,BAO_0000218,,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose in the total organ,,,N,Intermediate,A,10116.0,CHEMBL875848,,,,,1,1
11314,50597,,BAO_0000218,,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose per gram in the organ,,,N,Intermediate,A,10116.0,CHEMBL622260,,,,,1,1
11315,50597,,BAO_0000218,,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose in the total organ,,,N,Intermediate,A,10116.0,CHEMBL622261,,,,,1,1
11316,50597,,BAO_0000218,,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose per gram in the organ,,,N,Intermediate,A,10116.0,CHEMBL622262,,,,,1,1
11317,50597,,BAO_0000218,,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose in the total organ,,,N,Intermediate,A,10116.0,CHEMBL622263,,2113.0,Kidney,,1,1
11318,50597,,BAO_0000218,,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,,,N,Intermediate,A,10116.0,CHEMBL622418,,2113.0,Kidney,,1,1
11319,50597,,BAO_0000218,,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose in the total organ,,,N,Intermediate,A,10116.0,CHEMBL622419,,2107.0,Liver,,1,1
11320,50594,In vivo,BAO_0000218,,,Biodistribution in CD-1 mice was determined after 1 minute in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),,,N,Intermediate,A,10090.0,CHEMBL623388,,,,,1,1
11321,50594,In vivo,BAO_0000218,,,Biodistribution in CD-1 mice was determined after 1 minute in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),,,N,Intermediate,A,10090.0,CHEMBL623389,,2107.0,Liver,,1,1
11322,50594,In vivo,BAO_0000218,,,Biodistribution in CD-1 mice was determined after 1 minute in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),,,N,Intermediate,A,10090.0,CHEMBL623390,,,,,1,1
11323,50594,In vivo,BAO_0000218,,,Biodistribution in CD-1 mice was determined after 120 minutes in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),,,N,Intermediate,A,10090.0,CHEMBL623391,,,,,1,1
11324,50594,In vivo,BAO_0000218,,,Biodistribution in CD-1 mice was determined after 120 minutes in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),,,N,Intermediate,A,10090.0,CHEMBL623392,,178.0,Blood,,1,1
11325,50594,In vivo,BAO_0000218,,,Biodistribution in CD-1 mice was determined after 120 minutes in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),,,N,Intermediate,A,10090.0,CHEMBL623393,,2037.0,Cerebellum,,1,1
11326,50594,In vivo,BAO_0000218,,,Biodistribution in CD-1 mice was determined after 120 minutes in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),,,N,Intermediate,A,10090.0,CHEMBL623394,,,,,1,1
11327,50594,In vivo,BAO_0000218,,,Biodistribution in CD-1 mice was determined after 120 minutes in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),,,N,Intermediate,A,10090.0,CHEMBL618885,,,,,1,1
11328,50594,In vivo,BAO_0000218,,,Biodistribution in CD-1 mice was determined after 120 minutes in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),,,N,Intermediate,A,10090.0,CHEMBL618886,,2107.0,Liver,,1,1
11329,50594,In vivo,BAO_0000218,,,Biodistribution in CD-1 mice was determined after 120 minutes in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),,,N,Intermediate,A,10090.0,CHEMBL618887,,,,,1,1
11330,50594,In vivo,BAO_0000218,,,Biodistribution in CD-1 mice was determined after 30 minutes in Striatum (expressed as percent injected dose per gram normalized to a 25 g mouse),,,N,Intermediate,A,10090.0,CHEMBL619535,,,,,1,1
11331,50594,In vivo,BAO_0000218,,,Biodistribution in CD-1 mice was determined after 30 minutes in blood (expressed as percent injected dose per gram normalized to a 25 g mouse),,,N,Intermediate,A,10090.0,CHEMBL619536,,178.0,Blood,,1,1
11332,50594,In vivo,BAO_0000218,,,Biodistribution in CD-1 mice was determined after 30 minutes in cerebellum (expressed as percent injected dose per gram normalized to a 25 g mouse),,,N,Intermediate,A,10090.0,CHEMBL619537,,2037.0,Cerebellum,,1,1
11333,50594,In vivo,BAO_0000218,,,Biodistribution in CD-1 mice was determined after 30 minutes in cortex (expressed as percent injected dose per gram normalized to a 25 g mouse),,,N,Intermediate,A,10090.0,CHEMBL619705,,,,,1,1
11334,50594,In vivo,BAO_0000218,,,Biodistribution in CD-1 mice was determined after 30 minutes in femur (expressed as percent injected dose per gram normalized to a 25 g mouse),,,N,Intermediate,A,10090.0,CHEMBL619706,,,,,1,1
11335,50594,In vivo,BAO_0000218,,,Biodistribution in CD-1 mice was determined after 30 minutes in liver (expressed as percent injected dose per gram normalized to a 25 g mouse),,,N,Intermediate,A,10090.0,CHEMBL619707,,2107.0,Liver,,1,1
11336,50594,In vivo,BAO_0000218,,,Biodistribution in CD-1 mice was determined after 30 minutes in lung (expressed as percent injected dose per gram normalized to a 25 g mouse),,,N,Intermediate,A,10090.0,CHEMBL619708,,,,,1,1
11337,50594,In vivo,BAO_0000218,,,Biodistribution in CD-1 mice was determined after 5 minute in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),,,N,Intermediate,A,10090.0,CHEMBL625219,,,,,1,1
11338,50594,In vivo,BAO_0000218,,,Biodistribution in CD-1 mice was determined after 5 minute in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),,,N,Intermediate,A,10090.0,CHEMBL625220,,178.0,Blood,,1,1
11339,50594,In vivo,BAO_0000218,,,Biodistribution in CD-1 mice was determined after 5 minute in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),,,N,Intermediate,A,10090.0,CHEMBL625221,,2037.0,Cerebellum,,1,1
11340,50594,In vivo,BAO_0000218,,,Biodistribution in CD-1 mice was determined after 5 minute in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),,,N,Intermediate,A,10090.0,CHEMBL625222,,,,,1,1
11341,50594,In vivo,BAO_0000218,,,Biodistribution in CD-1 mice was determined after 5 minute in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),,,N,Intermediate,A,10090.0,CHEMBL625223,,,,,1,1
11342,50594,In vivo,BAO_0000218,,,Biodistribution in CD-1 mice was determined after 5 minute in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),,,N,Intermediate,A,10090.0,CHEMBL625224,,2107.0,Liver,,1,1
11343,50594,In vivo,BAO_0000218,,,Biodistribution in CD-1 mice was determined after 5 minute in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),,,N,Intermediate,A,10090.0,CHEMBL625225,,,,,1,1
11344,50597,In vivo,BAO_0000218,,,Biodistribution in Rat blood after 24 hours of iv administration,,,N,Intermediate,A,10116.0,CHEMBL625226,,178.0,Blood,,1,1
11345,50597,In vivo,BAO_0000218,,,Biodistribution in Rat blood after 24 hours of iv administration; per g of tissue,,,N,Intermediate,A,10116.0,CHEMBL625227,,178.0,Blood,,1,1
11346,50597,In vivo,BAO_0000218,,,Biodistribution in Rat blood after 30 minutes of iv administration,,,N,Intermediate,A,10116.0,CHEMBL625228,,178.0,Blood,,1,1
11347,50597,In vivo,BAO_0000218,,,Biodistribution in Rat blood after 30 minutes of iv administration; per g of tissue,,,N,Intermediate,A,10116.0,CHEMBL875354,,178.0,Blood,,1,1
11348,50597,In vivo,BAO_0000218,,,Biodistribution in Rat blood after 5 minutes of iv administration,,,N,Intermediate,A,10116.0,CHEMBL625229,,178.0,Blood,,1,1
11349,50597,In vivo,BAO_0000218,,,Biodistribution in Rat blood after 5 minutes of iv administration; per g of tissue,,,N,Intermediate,A,10116.0,CHEMBL625230,,178.0,Blood,,1,1
11350,50597,In vivo,BAO_0000218,,,Biodistribution in Rat heart after 24 hours of iv administration,,,N,Intermediate,A,10116.0,CHEMBL625231,,948.0,Heart,,1,1
11351,50597,In vivo,BAO_0000218,,,Biodistribution in Rat heart after 24 hours of iv administration; per g of tissue,,,N,Intermediate,A,10116.0,CHEMBL625900,,948.0,Heart,,1,1
11352,50597,In vivo,BAO_0000218,,,Biodistribution in Rat heart after 30 minutes of iv administration,,,N,Intermediate,A,10116.0,CHEMBL625901,,948.0,Heart,,1,1
11353,50597,In vivo,BAO_0000218,,,Biodistribution in Rat heart after 30 minutes of iv administration; per g of tissue,,,N,Intermediate,A,10116.0,CHEMBL625902,,948.0,Heart,,1,1
11354,50597,In vivo,BAO_0000218,,,Biodistribution in Rat heart after 5 minutes of iv administration,,,N,Intermediate,A,10116.0,CHEMBL625903,,948.0,Heart,,1,1
11355,50597,In vivo,BAO_0000218,,,Biodistribution in Rat heart after 5 minutes of iv administration; per g of tissue,,,N,Intermediate,A,10116.0,CHEMBL625904,,948.0,Heart,,1,1
11356,50597,In vivo,BAO_0000218,,,Biodistribution in Rat liver after 24 hours of iv administration,,,N,Intermediate,A,10116.0,CHEMBL625905,,2107.0,Liver,,1,1
11357,50597,In vivo,BAO_0000218,,,Biodistribution in Rat liver after 24 hours of iv administration; per g of tissue,,,N,Intermediate,A,10116.0,CHEMBL627861,,2107.0,Liver,,1,1
11358,50597,In vivo,BAO_0000218,,,Biodistribution in Rat liver after 30 minutes of iv administration,,,N,Intermediate,A,10116.0,CHEMBL627862,,2107.0,Liver,,1,1
11359,50597,In vivo,BAO_0000218,,,Biodistribution in Rat liver after 30 minutes of iv administration; per g of tissue,,,N,Intermediate,A,10116.0,CHEMBL627863,,2107.0,Liver,,1,1
11360,50597,In vivo,BAO_0000218,,,Biodistribution in Rat liver after 30 minutes of iv administration,,,N,Intermediate,A,10116.0,CHEMBL627769,,2107.0,Liver,,1,1
11361,50588,In vivo,BAO_0000218,,,Maximum plasma concentration in Beagle dogs at oral dose of 20 mg/kg and an intravenous dose of 5 mg/kg was administered,,,N,Intermediate,A,9615.0,CHEMBL627770,,1969.0,Plasma,,1,1
11362,100710,In vivo,BAO_0000218,,,Cmax in cynomolgus monkey (PO dose),,,N,Intermediate,A,9541.0,CHEMBL627771,,,,,1,1
11363,50597,In vivo,BAO_0000218,,,Cmax in rat (PO dose),,,N,Intermediate,A,10116.0,CHEMBL627772,,,,,1,1
11364,50597,In vivo,BAO_0000218,,,Cmax in rat (PO dose),,,N,Intermediate,A,10116.0,CHEMBL627773,,,,,1,1
11365,50597,In vivo,BAO_0000218,,,Maximum plasma concentration in rats after an oral dose of 5 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL621922,,1969.0,Plasma,,1,1
11366,50597,In vivo,BAO_0000218,,,Cmax in rat plasma after oral dose (10 mg/kg),,,N,Intermediate,A,10116.0,CHEMBL621923,,1969.0,Plasma,,1,1
11367,22224,In vivo,BAO_0000218,,,Cmax in plasma after oral dose (10 mg/kg),,,U,Autocuration,A,,CHEMBL621924,,1969.0,Plasma,,0,1
11368,50588,In vivo,BAO_0000218,,,Maximum plasma concentration of compound was determined in dog at 25 mg/kg orally,,,N,Intermediate,A,9615.0,CHEMBL621925,,1969.0,Plasma,,1,1
11369,22224,In vivo,BAO_0000218,,,Maximum plasma concentration of compound was determined in monkey at 25 mg/kg orally,,,U,Autocuration,A,314293.0,CHEMBL621926,,1969.0,Plasma,,0,1
11370,50592,In vivo,BAO_0000218,,,Maximum plasma concentration of compound was determined in rabbit at 25 mg/kg orally,,,N,Intermediate,A,9986.0,CHEMBL621927,,1969.0,Plasma,,1,1
11371,50597,In vivo,BAO_0000218,,,Maximum plasma concentration of compound was determined in rat at 25 mg/kg orally,,,N,Intermediate,A,10116.0,CHEMBL621928,,1969.0,Plasma,,1,1
11372,50597,In vivo,BAO_0000218,,,Maximum plasma concentration after p.o. (10 mpk) administration in rats.,,,N,Intermediate,A,10116.0,CHEMBL621929,,1969.0,Plasma,,1,1
11373,50594,In vivo,BAO_0000218,,,Maximum plasma concentration (Cmax) after p.o. administration of 200 mg/kg in mice,,,N,Intermediate,A,10090.0,CHEMBL621930,,1969.0,Plasma,,1,1
11374,50597,In vivo,BAO_0000218,,,Maximum plasma concentration after oral dosing in rat,,,N,Intermediate,A,10116.0,CHEMBL621931,,1969.0,Plasma,,1,1
11375,22224,In vivo,BAO_0000218,,,Maximum plasma concentration evaluated in 100% PEG solution at a dose of 20 mg/kg orally,,,U,Autocuration,A,,CHEMBL621932,,1969.0,Plasma,,0,1
11376,22224,In vivo,BAO_0000218,,,Maximum plasma concentration evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,,,U,Autocuration,A,,CHEMBL621933,,1969.0,Plasma,,0,1
11377,50588,In vivo,BAO_0000218,,,Maximum plasma concentration in dogs at 0.5 mg/kg dose upon oral administration,,,N,Intermediate,A,9615.0,CHEMBL621934,,1969.0,Plasma,,1,1
11378,50588,In vivo,BAO_0000218,,,Maximum plasma concentration in dogs at 1 mg/kg dose upon oral administration,,,N,Intermediate,A,9615.0,CHEMBL621935,,1969.0,Plasma,,1,1
11379,50597,In vivo,BAO_0000218,,,Maximum plasma concentration in rat upon oral administration of 40 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL621936,,1969.0,Plasma,,1,1
11380,22224,In vivo,BAO_0000218,,,Maximum plasma concentration was determined,,,U,Autocuration,A,,CHEMBL621937,,1969.0,Plasma,,0,1
11381,22224,In vivo,BAO_0000218,,,Maximum plasma concentration was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,,,U,Autocuration,A,,CHEMBL621938,,1969.0,Plasma,,0,1
11382,22224,In vivo,BAO_0000218,,,Maximum plasma concentration was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,,,U,Autocuration,A,,CHEMBL621939,,1969.0,Plasma,,0,1
11383,22224,In vivo,BAO_0000218,,,Maximum plasma concentration was evaluated in 10% of PEG suspension at a dose of 20 mg/kg orally,,,U,Autocuration,A,,CHEMBL621940,,1969.0,Plasma,,0,1
11384,22224,In vivo,BAO_0000218,,,Maximum plasma concentration was evaluated in 100% of PEG solution at a dose of 20 mg/kg orally,,,U,Autocuration,A,,CHEMBL621941,,1969.0,Plasma,,0,1
11385,22224,In vivo,BAO_0000218,,,Maximum plasma concentration was evaluated in DMA:H2O solution at a dose of 20 mg/kg orally,,,U,Autocuration,A,,CHEMBL621942,,1969.0,Plasma,,0,1
11386,22224,In vivo,BAO_0000218,,,Maximum plasma concentration was evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,,,U,Autocuration,A,,CHEMBL626178,,1969.0,Plasma,,0,1
11387,22224,In vivo,BAO_0000218,,,Maximum plasma concentration was evaluated in Hp-beta-CD solution at a dose of 20 mg/kg orally,,,U,Autocuration,A,,CHEMBL626179,,1969.0,Plasma,,0,1
11388,22224,In vivo,BAO_0000218,,,Maximum plasma concentration was evaluated in saline solution at a dose of 20 mg/kg orally,,,U,Autocuration,A,,CHEMBL626180,,1969.0,Plasma,,0,1
11389,50597,In vivo,BAO_0000218,,,Plasma Cmax in rat (PO dose),,,N,Intermediate,A,10116.0,CHEMBL626181,,1969.0,Plasma,,1,1
11390,50597,In vivo,BAO_0000218,,,Maximum serum concentration after po dose of 5.22 mg/kg in rats,,,N,Intermediate,A,10116.0,CHEMBL626182,,,,,1,1
11391,50597,In vivo,BAO_0000218,,,Maximum serum concentration after po dose of 5.46 mg/kg in rats,,,N,Intermediate,A,10116.0,CHEMBL626183,,,,,1,1
11392,50597,In vivo,BAO_0000218,,,Maximum serum concentration was determined for the compound after po dose of 5.01 mg/kg in rats,,,N,Intermediate,A,10116.0,CHEMBL626184,,,,,1,1
11393,50597,In vivo,BAO_0000218,,,Maximum serum concentration was determined for the compound after po dose of 5.03 mg/kg in rats,,,N,Intermediate,A,10116.0,CHEMBL626185,,,,,1,1
11394,50588,In vivo,BAO_0000218,,,Maximum plasma concentration (Cmax) was determined in dogs fed after oral administration of 25 mg/kg of the compound.,,,N,Intermediate,A,9615.0,CHEMBL626186,,1969.0,Plasma,,1,1
11395,50588,In vivo,BAO_0000218,,,Maximum plasma concentration (Cmax) was determined in fasted dogs after oral administration of 25 mg/kg of the compound.,,,N,Intermediate,A,9615.0,CHEMBL877589,,1969.0,Plasma,,1,1
11396,22224,In vivo,BAO_0000218,,,Maximum concentration of the drug at 1 uM/dg administered intravenously,,,U,Autocuration,A,,CHEMBL626187,,,,,0,1
11397,22224,In vivo,BAO_0000218,,,Maximum concentration of the drug at 20 uM/dg administered perorally,,,U,Autocuration,A,,CHEMBL626188,,,,,0,1
11398,22224,In vivo,BAO_0000218,,,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg,,,U,Autocuration,A,,CHEMBL626189,,,,,0,1
11399,22224,In vivo,BAO_0000218,,,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg; b = No compound detectable in blood above the detection limit of 0.1 uM,,,U,Autocuration,A,,CHEMBL626855,,178.0,Blood,,0,1
11400,22224,In vivo,BAO_0000218,,,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg; b denotes No compound detectable in blood above the detection limit of 0.1 uM,,,U,Autocuration,A,,CHEMBL623781,,178.0,Blood,,0,1
11401,22224,In vivo,BAO_0000218,,,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg;b = No compound detectable in blood above the detection limit of 0.1 uM,,,U,Autocuration,A,,CHEMBL623782,,178.0,Blood,,0,1
11402,50597,In vivo,BAO_0000218,,,Oral absorption expressed as peak plasma conc (Cmax) after oral dosing of 50 mg/kg in rat,,,N,Intermediate,A,10116.0,CHEMBL623783,,1969.0,Plasma,,1,1
11403,50588,In vivo,BAO_0000218,,,Cmax in dog plasma after 1mg/kg oral dose,,,N,Intermediate,A,9615.0,CHEMBL623784,,1969.0,Plasma,,1,1
11404,50588,In vivo,BAO_0000218,,,Bioavailability as maximal plasma concentration in dogs after 2.5 mg/kg oral dose,,,N,Intermediate,A,9615.0,CHEMBL623785,,1969.0,Plasma,,1,1
11405,50597,In vivo,BAO_0000218,,,Bioavailability as maximal plasma concentration in rats after 10 mg/kg oral dose,,,N,Intermediate,A,10116.0,CHEMBL623786,,1969.0,Plasma,,1,1
11406,50597,In vivo,BAO_0000218,,,Oral maximum concentration in rat,,,N,Intermediate,A,10116.0,CHEMBL623787,,,,,1,1
11407,50597,In vivo,BAO_0000218,,,Oral maximum concentration in rat,,,N,Intermediate,A,10116.0,CHEMBL623788,,,,,1,1
11408,50594,In vivo,BAO_0000218,,,Oral plasma concentration in mice at 100 mg/kg dosage within 4-hr time frame.,,,N,Intermediate,A,10090.0,CHEMBL623789,,1969.0,Plasma,,1,1
11409,50594,In vivo,BAO_0000218,,,Peak concentration in blood after intravenous administration to mice,,,N,Intermediate,A,10090.0,CHEMBL623790,,178.0,Blood,,1,1
11410,50594,In vivo,BAO_0000218,,,Peak concentration in blood after peroral administration to mice,,,N,Intermediate,A,10090.0,CHEMBL623791,,178.0,Blood,,1,1
11411,50597,In vivo,BAO_0000218,,,Peak concentration in rat plasma was determined,,,N,Intermediate,A,10116.0,CHEMBL623792,,1969.0,Plasma,,1,1
11412,22224,In vivo,BAO_0000218,,,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of monkey after oral administration of 0.05 mmol/kg,,,U,Autocuration,A,314293.0,CHEMBL623793,,1969.0,Plasma,,0,1
11413,50594,In vivo,BAO_0000218,,,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of mouse after oral administration of 0.05 mmol/kg,,,N,Intermediate,A,10090.0,CHEMBL623794,,1969.0,Plasma,,1,1
11414,50597,In vivo,BAO_0000218,,,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of rat after oral administration of 0.05 mmol/kg,,,N,Intermediate,A,10116.0,CHEMBL623795,,1969.0,Plasma,,1,1
11415,50597,,BAO_0000218,,,"Distribution in rat heart 4 hr after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL623796,,,,,1,1
11416,50597,,BAO_0000218,,,"Distribution in rat heart 5 min after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL623797,,,,,1,1
11417,50597,,BAO_0000218,,,"Distribution in rat heart 6 hr after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL623798,,,,,1,1
11418,50597,,BAO_0000218,,,"Distribution in rat heart 8 hr after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL623799,,,,,1,1
11419,50597,,BAO_0000218,,,"Distribution in rat intestine 15 min after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL624490,,160.0,Intestine,,1,1
11420,50597,,BAO_0000218,,,"Distribution in rat intestine 1 hr after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL624491,,160.0,Intestine,,1,1
11421,50597,,BAO_0000218,,,"Distribution in rat intestine 2 hr after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL624492,,160.0,Intestine,,1,1
11422,50597,,BAO_0000218,,,"Distribution in rat intestine 30 min after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL624493,,160.0,Intestine,,1,1
11423,50597,,BAO_0000218,,,"Distribution in rat intestine 4 hr after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL877595,,160.0,Intestine,,1,1
11424,50597,,BAO_0000218,,,"Distribution in rat intestine 5 min after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL624494,,160.0,Intestine,,1,1
11425,50597,,BAO_0000218,,,"Distribution in rat intestine 6 hr after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL624495,,160.0,Intestine,,1,1
11426,50597,,BAO_0000218,,,"Distribution in rat intestine 8 hr after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL624681,,160.0,Intestine,,1,1
11427,50597,,BAO_0000218,,,"Distribution in rat kidney, 15 min after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL624682,,,,,1,1
11428,50597,,BAO_0000218,,,"Distribution in rat kidney, 1 hr after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL624683,,,,,1,1
11429,50597,,BAO_0000218,,,"Distribution in rat kidney, 2 hr after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL624684,,,,,1,1
11430,50597,,BAO_0000218,,,"Distribution in rat kidney, 30 min after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL624685,,,,,1,1
11431,50597,,BAO_0000218,,,"Distribution in rat kidney, 4 hr after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL624686,,,,,1,1
11432,50597,,BAO_0000218,,,"Distribution in rat kidney, 5 min after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL624687,,,,,1,1
11433,50597,,BAO_0000218,,,"Distribution in rat kidney, 6 hr after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL624688,,,,,1,1
11434,50597,,BAO_0000218,,,"Distribution in rat kidney, 8 hr after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL627161,,,,,1,1
11435,50597,,BAO_0000218,,,"Distribution in rat liver 15 min after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL622127,,,,,1,1
11436,50597,,BAO_0000218,,,"Distribution in rat liver 1 hr after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL622128,,,,,1,1
11437,50597,,BAO_0000218,,,"Distribution in rat liver 2 hr after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL874384,,,,,1,1
11438,50597,,BAO_0000218,,,"Distribution in rat liver 30 min after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL624898,,,,,1,1
11439,50597,,BAO_0000218,,,"Distribution in rat liver 4 hr after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL624899,,,,,1,1
11440,50597,,BAO_0000218,,,"Distribution in rat liver 5 min after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL624900,,,,,1,1
11441,50597,,BAO_0000218,,,"Distribution in rat liver 6 hr after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL624901,,,,,1,1
11442,50597,,BAO_0000218,,,"Distribution in rat liver 8 hr after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL624902,,,,,1,1
11443,50597,,BAO_0000218,,,"Distribution in rat lungs 15 min after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL624903,,,,,1,1
11444,50597,,BAO_0000218,,,"Distribution in rat lungs 1 hr after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL624904,,,,,1,1
11445,50597,,BAO_0000218,,,"Distribution in rat lungs 2 hr after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL624905,,,,,1,1
11446,50597,,BAO_0000218,,,"Distribution in rat lungs 30 min after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL624906,,,,,1,1
11447,50597,,BAO_0000218,,,"Distribution in rat lungs 4 hr after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL624907,,,,,1,1
11448,50597,,BAO_0000218,,,"Distribution in rat lungs 5 min after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL624908,,,,,1,1
11449,50597,,BAO_0000218,,,"Distribution in rat lungs 6 hr after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL624909,,,,,1,1
11450,50597,,BAO_0000218,,,"Distribution in rat lungs 8 hr after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL624910,,,,,1,1
11451,50597,,BAO_0000218,,,"Distribution in rat muscle 15 min after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL624911,,2385.0,Muscle tissue,,1,1
11452,50597,,BAO_0000218,,,"Distribution in rat muscle 1 hr after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL874388,,2385.0,Muscle tissue,,1,1
11453,50597,,BAO_0000218,,,"Distribution in rat muscle 2 hr after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL624912,,2385.0,Muscle tissue,,1,1
11454,50597,,BAO_0000218,,,"Distribution in rat muscle 30 min after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL622930,,2385.0,Muscle tissue,,1,1
11455,50597,,BAO_0000218,,,"Distribution in rat muscle 4 hr after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL623121,,2385.0,Muscle tissue,,1,1
11456,50597,,BAO_0000218,,,"Distribution in rat muscle 5 min after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL623122,,2385.0,Muscle tissue,,1,1
11457,50597,,BAO_0000218,,,"Distribution in rat muscle 6 hr after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL623123,,2385.0,Muscle tissue,,1,1
11458,50597,,BAO_0000218,,,"Distribution in rat muscle 8 hr after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL623124,,2385.0,Muscle tissue,,1,1
11459,50597,,BAO_0000218,,,"Distribution in rat pancreas 15 min after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL623125,,,,,1,1
11460,50597,,BAO_0000218,,,"Distribution in rat pancreas 1 hr after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL623126,,,,,1,1
11461,50597,,BAO_0000218,,,"Distribution in rat pancreas 2 hr after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL623127,,,,,1,1
11462,50597,,BAO_0000218,,,"Distribution in rat pancreas 30 min after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL623128,,,,,1,1
11463,50597,,BAO_0000218,,,"Distribution in rat pancreas 4 hr after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL623129,,,,,1,1
11464,50597,,BAO_0000218,,,"Distribution in rat pancreas 5 min after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL623130,,,,,1,1
11465,50597,,BAO_0000218,,,"Distribution in rat pancreas 6 hr after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL623131,,,,,1,1
11466,50597,,BAO_0000218,,,"Distribution in rat pancreas 8 hr after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL623132,,,,,1,1
11467,50597,,BAO_0000218,,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose per gram in the organ,,,N,Intermediate,A,10116.0,CHEMBL623133,,2107.0,Liver,,1,1
11468,50597,,BAO_0000218,,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat lung as Percent of injected dose per gram in the organ,,,N,Intermediate,A,10116.0,CHEMBL623134,,,,,1,1
11469,50597,,BAO_0000218,,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat blood as Percent of injected dose per gram in the organ,,,N,Intermediate,A,10116.0,CHEMBL874389,,,,,1,1
11470,50597,,BAO_0000218,,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose in the total organ,,,N,Intermediate,A,10116.0,CHEMBL623135,,,,,1,1
11471,50597,,BAO_0000218,,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose per gram in the organ,,,N,Intermediate,A,10116.0,CHEMBL623136,,,,,1,1
11472,50597,,BAO_0000218,,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose in the total organ,,,N,Intermediate,A,10116.0,CHEMBL623137,,,,,1,1
11473,50597,,BAO_0000218,,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose per gram in the organ,,,N,Intermediate,A,10116.0,CHEMBL623138,,,,,1,1
11474,50597,,BAO_0000218,,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose in the total organ,,,N,Intermediate,A,10116.0,CHEMBL623139,,2113.0,Kidney,,1,1
11475,50597,,BAO_0000218,,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,,,N,Intermediate,A,10116.0,CHEMBL623140,,2113.0,Kidney,,1,1
11476,50597,,BAO_0000218,,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose in the total organ,,,N,Intermediate,A,10116.0,CHEMBL623141,,2107.0,Liver,,1,1
11477,50597,,BAO_0000218,,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose per gram in the organ,,,N,Intermediate,A,10116.0,CHEMBL623142,,2107.0,Liver,,1,1
11478,50597,,BAO_0000218,,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat lung as Percent of injected dose per gram in the organ,,,N,Intermediate,A,10116.0,CHEMBL623143,,,,,1,1
11479,50594,,BAO_0000218,,,The total amount of penciclovir recovered in the urine over a 48-h period was determined by HPLC using a C18 reversed-phase column in mouse.,,,N,Intermediate,A,10090.0,CHEMBL623144,,1088.0,Urine,,1,1
11480,50597,,BAO_0000218,,,The total amount of penciclovir recovered in the urine over a 48-h period was determined by HPLC using a C18 reversed-phase column in rat.,,,N,Intermediate,A,10116.0,CHEMBL623405,,1088.0,Urine,,1,1
11481,50597,,BAO_0000218,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat blood as Percent of injected dose per gram in the organ,,,N,Intermediate,A,10116.0,CHEMBL624074,,,,,1,1
11482,50597,,BAO_0000218,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose in the total organ,,,N,Intermediate,A,10116.0,CHEMBL624075,,,,,1,1
11483,50597,,BAO_0000218,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose per gram in the organ,,,N,Intermediate,A,10116.0,CHEMBL624076,,,,,1,1
11484,50597,,BAO_0000218,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose in the total organ,,,N,Intermediate,A,10116.0,CHEMBL624077,,,,,1,1
11485,50597,,BAO_0000218,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose per gram in the organ,,,N,Intermediate,A,10116.0,CHEMBL624078,,,,,1,1
11486,50597,,BAO_0000218,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose in the total organ,,,N,Intermediate,A,10116.0,CHEMBL624079,,2113.0,Kidney,,1,1
11487,50597,,BAO_0000218,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,,,N,Intermediate,A,10116.0,CHEMBL624261,,2113.0,Kidney,,1,1
11488,50597,,BAO_0000218,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose in the total organ,,,N,Intermediate,A,10116.0,CHEMBL624262,,,,,1,1
11489,50597,,BAO_0000218,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose per gram in the organ,,,N,Intermediate,A,10116.0,CHEMBL624263,,,,,1,1
11490,50597,,BAO_0000218,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat lung as Percent of injected dose per gram in the organ,,,N,Intermediate,A,10116.0,CHEMBL624264,,,,,1,1
11491,50597,,BAO_0000218,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat blood as Percent of injected dose per gram in the organ,,,N,Intermediate,A,10116.0,CHEMBL624265,,,,,1,1
11492,50597,,BAO_0000218,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose in the total organ,,,N,Intermediate,A,10116.0,CHEMBL624266,,,,,1,1
11493,50597,,BAO_0000218,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose per gram in the organ,,,N,Intermediate,A,10116.0,CHEMBL624267,,,,,1,1
11494,50597,,BAO_0000218,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose in the total organ,,,N,Intermediate,A,10116.0,CHEMBL624268,,,,,1,1
11495,50597,,BAO_0000218,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose per gram in the organ,,,N,Intermediate,A,10116.0,CHEMBL875227,,,,,1,1
11496,50597,,BAO_0000218,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose in the total organ,,,N,Intermediate,A,10116.0,CHEMBL624269,,2113.0,Kidney,,1,1
11497,50597,,BAO_0000218,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,,,N,Intermediate,A,10116.0,CHEMBL624270,,2113.0,Kidney,,1,1
11498,50597,,BAO_0000218,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose in the total organ,,,N,Intermediate,A,10116.0,CHEMBL624271,,,,,1,1
11499,50597,,BAO_0000218,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose per gram in the organ,,,N,Intermediate,A,10116.0,CHEMBL624272,,,,,1,1
11500,50597,,BAO_0000218,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat lung as Percent of injected dose per gram in the organ,,,N,Intermediate,A,10116.0,CHEMBL624273,,,,,1,1
11501,50597,,BAO_0000218,,,Urinary excretion in rat after 0-4 hours of oral administration at 50 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL624274,,1088.0,Urine,,1,1
11502,50597,,BAO_0000218,,,Urinary excretion in rat after 4-8 hours of oral administration at 50 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL624275,,1088.0,Urine,,1,1
11503,50597,,BAO_0000218,,,Urinary excretion in rat after 8-24 hours of oral administration at 50 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL624276,,1088.0,Urine,,1,1
11504,50597,,BAO_0000218,,,Urinary recovery expressed as percentage dose in male rats after iv administration of 20 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL624277,,1088.0,Urine,,1,1
11505,22224,,BAO_0000019,,,% dose converted to 2-amino-5-chlorophenyl sulfate,,,U,Autocuration,A,,CHEMBL624278,,,,,0,1
11506,22224,,BAO_0000019,,,% dose converted to 4-(S-amino-N-{[(4-chlorophenyl)amino]carbonyl}sulfonimidoyl)benzoic acid (compound 41),,,U,Autocuration,A,,CHEMBL624279,,,,,0,1
11507,50597,,BAO_0000218,,,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 0-24 hr",,,N,Intermediate,A,10116.0,CHEMBL624280,,1988.0,Feces,,1,1
11508,50597,,BAO_0000218,,,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 24-48 hr",,,N,Intermediate,A,10116.0,CHEMBL624281,,1988.0,Feces,,1,1
11509,50597,,BAO_0000218,,,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 0-24 hr",,,N,Intermediate,A,10116.0,CHEMBL622933,,1988.0,Feces,,1,1
11510,50597,,BAO_0000218,,,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 24-48 hr",,,N,Intermediate,A,10116.0,CHEMBL622934,,1988.0,Feces,,1,1
11511,50597,In vivo,BAO_0000218,,,Biodistribution in Rat liver after 30 minutes of iv administration; per g of tissue,,,N,Intermediate,A,10116.0,CHEMBL622935,,2107.0,Liver,,1,1
11512,50597,In vivo,BAO_0000218,,,Biodistribution in Rat liver after 5 minutes of iv administration,,,N,Intermediate,A,10116.0,CHEMBL622936,,2107.0,Liver,,1,1
11513,50597,In vivo,BAO_0000218,,,Biodistribution in Rat liver after 5 minutes of iv administration; per g of tissue,,,N,Intermediate,A,10116.0,CHEMBL875228,,2107.0,Liver,,1,1
11514,50597,In vivo,BAO_0000218,,,Biodistribution in Rat lung after 24 hours of iv administration,,,N,Intermediate,A,10116.0,CHEMBL622937,,2048.0,Lung,,1,1
11515,50597,In vivo,BAO_0000218,,,Biodistribution in Rat lung after 24 hours of iv administration; per g of tissue,,,N,Intermediate,A,10116.0,CHEMBL622938,,2048.0,Lung,,1,1
11516,50597,In vivo,BAO_0000218,,,Biodistribution in Rat lung after 30 minutes of iv administration,,,N,Intermediate,A,10116.0,CHEMBL619736,,2048.0,Lung,,1,1
11517,50597,In vivo,BAO_0000218,,,Biodistribution in Rat lung after 30 minutes of iv administration; per g of tissue,,,N,Intermediate,A,10116.0,CHEMBL625117,,2048.0,Lung,,1,1
11518,50597,In vivo,BAO_0000218,,,Biodistribution in Rat lung after 5 minutes of iv administration,,,N,Intermediate,A,10116.0,CHEMBL625118,,2048.0,Lung,,1,1
11519,50597,In vivo,BAO_0000218,,,Biodistribution in Rat lung after 5 minutes of iv administration; per g of tissue,,,N,Intermediate,A,10116.0,CHEMBL625119,,2048.0,Lung,,1,1
11520,50597,In vivo,BAO_0000218,,,"Biodistribution in rat cerebellum, expressed as percent I.D./g tissue",,,N,Intermediate,A,10116.0,CHEMBL625120,,2037.0,Cerebellum,,1,1
11521,50597,In vivo,BAO_0000218,,,"Biodistribution in rat superior coliculus, expressed as percent I.D./g tissue",,,N,Intermediate,A,10116.0,CHEMBL625121,,,,,1,1
11522,50597,In vivo,BAO_0000218,,,"Biodistribution in rat thalamus, expressed as percent I.D./g tissue",,,N,Intermediate,A,10116.0,CHEMBL625122,,10000006.0,Thalamus,,1,1
11523,50597,In vivo,BAO_0000218,,,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 2 min,,,N,Intermediate,A,10116.0,CHEMBL622204,,178.0,Blood,,1,1
11524,50597,In vivo,BAO_0000218,,,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 30 min,,,N,Intermediate,A,10116.0,CHEMBL877503,,178.0,Blood,,1,1
11525,50597,In vivo,BAO_0000218,,,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 60 min,,,N,Intermediate,A,10116.0,CHEMBL627127,,178.0,Blood,,1,1
11526,22224,In vivo,BAO_0000218,,,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 2 min,,,U,Autocuration,A,,CHEMBL627128,,10000000.0,Hippocampus,,0,1
11527,22224,In vivo,BAO_0000218,,,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 30 min,,,U,Autocuration,A,,CHEMBL627129,,10000000.0,Hippocampus,,0,1
11528,22224,In vivo,BAO_0000218,,,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 60 min,,,U,Autocuration,A,,CHEMBL627130,,10000000.0,Hippocampus,,0,1
11529,50597,In vivo,BAO_0000218,,,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 2 min,,,N,Intermediate,A,10116.0,CHEMBL627131,,955.0,Brain,,1,1
11530,50597,In vivo,BAO_0000218,,,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 30 min,,,N,Intermediate,A,10116.0,CHEMBL627132,,955.0,Brain,,1,1
11531,50597,In vivo,BAO_0000218,,,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 60 min,,,N,Intermediate,A,10116.0,CHEMBL627133,,955.0,Brain,,1,1
11532,50597,In vivo,BAO_0000218,,,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 2 min,,,N,Intermediate,A,10116.0,CHEMBL627134,,2037.0,Cerebellum,,1,1
11533,50597,In vivo,BAO_0000218,,,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 30 min,,,N,Intermediate,A,10116.0,CHEMBL627135,,2037.0,Cerebellum,,1,1
11534,50597,In vivo,BAO_0000218,,,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 60 min,,,N,Intermediate,A,10116.0,CHEMBL627136,,2037.0,Cerebellum,,1,1
11535,50597,In vivo,BAO_0000218,,,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 2 min,,,N,Intermediate,A,10116.0,CHEMBL628435,,,,,1,1
11536,50597,In vivo,BAO_0000218,,,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 30 min,,,N,Intermediate,A,10116.0,CHEMBL628436,,,,,1,1
11537,50597,In vivo,BAO_0000218,,,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 60 min,,,N,Intermediate,A,10116.0,CHEMBL628437,,,,,1,1
11538,50597,In vivo,BAO_0000218,,,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 2 min,,,N,Intermediate,A,10116.0,CHEMBL628438,,948.0,Heart,,1,1
11539,50597,In vivo,BAO_0000218,,,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 30 min,,,N,Intermediate,A,10116.0,CHEMBL628439,,948.0,Heart,,1,1
11540,50597,In vivo,BAO_0000218,,,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 60 min,,,N,Intermediate,A,10116.0,CHEMBL628440,,948.0,Heart,,1,1
11541,50597,In vivo,BAO_0000218,,,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 2 min,,,N,Intermediate,A,10116.0,CHEMBL628441,,10000000.0,Hippocampus,,1,1
11542,50597,In vivo,BAO_0000218,,,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 30 min,,,N,Intermediate,A,10116.0,CHEMBL628442,,10000000.0,Hippocampus,,1,1
11543,50597,In vivo,BAO_0000218,,,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 60 min,,,N,Intermediate,A,10116.0,CHEMBL628443,,10000000.0,Hippocampus,,1,1
11544,50597,In vivo,BAO_0000218,,,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 2 min,,,N,Intermediate,A,10116.0,CHEMBL628444,,2113.0,Kidney,,1,1
11545,50597,In vivo,BAO_0000218,,,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 30 min,,,N,Intermediate,A,10116.0,CHEMBL628445,,2113.0,Kidney,,1,1
11546,50597,In vivo,BAO_0000218,,,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 60 min,,,N,Intermediate,A,10116.0,CHEMBL877504,,2113.0,Kidney,,1,1
11547,50597,In vivo,BAO_0000218,,,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 2 min,,,N,Intermediate,A,10116.0,CHEMBL628446,,2107.0,Liver,,1,1
11548,50597,In vivo,BAO_0000218,,,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 30 min,,,N,Intermediate,A,10116.0,CHEMBL626874,,2107.0,Liver,,1,1
11549,50597,In vivo,BAO_0000218,,,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 60 min,,,N,Intermediate,A,10116.0,CHEMBL626875,,2107.0,Liver,,1,1
11550,50597,In vivo,BAO_0000218,,,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 2 min,,,N,Intermediate,A,10116.0,CHEMBL626876,,2048.0,Lung,,1,1
11551,50597,In vivo,BAO_0000218,,,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 30 min,,,N,Intermediate,A,10116.0,CHEMBL626877,,2048.0,Lung,,1,1
11552,50597,In vivo,BAO_0000218,,,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 60 min,,,N,Intermediate,A,10116.0,CHEMBL626878,,2048.0,Lung,,1,1
11553,50597,In vivo,BAO_0000218,,,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 2 min,,,N,Intermediate,A,10116.0,CHEMBL626879,,2385.0,Muscle tissue,,1,1
11554,22224,In vivo,BAO_0000218,,,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of monkey after oral administration of 0.05 mmol/kg,,,U,Autocuration,A,314293.0,CHEMBL626880,,1969.0,Plasma,,0,1
11555,50594,In vivo,BAO_0000218,,,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of mouse after oral administration of 0.05 mmol/kg,,,N,Intermediate,A,10090.0,CHEMBL626881,,1969.0,Plasma,,1,1
11556,50597,In vivo,BAO_0000218,,,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of rat after oral administration of 0.05 mmol/kg,,,N,Intermediate,A,10116.0,CHEMBL626882,,1969.0,Plasma,,1,1
11557,50588,In vivo,BAO_0000218,,,Peak plasma concentration was measured in dogs,,,N,Intermediate,A,9615.0,CHEMBL626883,,1969.0,Plasma,,1,1
11558,50597,In vivo,BAO_0000218,,,Pharmacokinetic Parameter (Cmax) was evaluated at 10 mg/kg (p.o.) in Wistar rats,,,N,Intermediate,A,10116.0,CHEMBL626884,,,,,1,1
11559,50597,In vivo,BAO_0000218,,,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given intravenously at dose 15 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL626885,,,,,1,1
11560,50597,In vivo,BAO_0000218,,,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given peroral at dose 30 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL626886,,,,,1,1
11561,50597,In vivo,BAO_0000218,,,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given peroral at dose 80 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL626887,,,,,1,1
11562,50597,In vivo,BAO_0000218,,,Pharmacokinetic parameter (Cmax) was evaluated at 10 mg/kg (p.o.) in Wistar rats,,,N,Intermediate,A,10116.0,CHEMBL626888,,,,,1,1
11563,50588,In vivo,BAO_0000218,,,Pharmacokinetic parameter Cmax determined after intravenous administration of 15 mg/kg to dog,,,N,Intermediate,A,9615.0,CHEMBL626889,,,,,1,1
11564,22224,In vivo,BAO_0000218,,,Pharmacokinetic parameter Cmax determined after intravenous administration of 25 mg/kg to monkey,,,U,Autocuration,A,314293.0,CHEMBL626761,,,,,0,1
11565,50588,In vivo,BAO_0000218,,,Pharmacokinetic parameter Cmax determined after intravenous administration of 30 mg/kg abd antacid (CaCO3 dosed orally 10 min prior to and 60 min postdosing) to dog,,,N,Intermediate,A,9615.0,CHEMBL626762,,,,,1,1
11566,50588,In vivo,BAO_0000218,,,Pharmacokinetic parameter Cmax determined after intravenous administration of 30 mg/kg to dog,,,N,Intermediate,A,9615.0,CHEMBL626763,,,,,1,1
11567,50597,In vivo,BAO_0000218,,,Pharmacokinetic parameter Cmax determined after intravenous administration of 50 mg/kg to rat,,,N,Intermediate,A,10116.0,CHEMBL626764,,,,,1,1
11568,50597,In vivo,BAO_0000218,,,Pharmacokinetic parameter Cmax determined after intravenous administration of 60 mg/kg to rat,,,N,Intermediate,A,10116.0,CHEMBL626765,,,,,1,1
11569,50588,In vivo,BAO_0000218,,,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to dog,,,N,Intermediate,A,9615.0,CHEMBL626766,,,,,1,1
11570,50597,In vivo,BAO_0000218,,,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to rat,,,N,Intermediate,A,10116.0,CHEMBL626767,,,,,1,1
11571,50597,In vivo,BAO_0000218,,,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to rat; No levels,,,N,Intermediate,A,10116.0,CHEMBL626768,,,,,1,1
11572,50588,In vivo,BAO_0000218,,,Pharmacokinetic parameter Cmax determined after peroral administration of 15 mg/kg to dog,,,N,Intermediate,A,9615.0,CHEMBL626769,,,,,1,1
11573,50588,In vivo,BAO_0000218,,,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to dog,,,N,Intermediate,A,9615.0,CHEMBL874463,,,,,1,1
11574,22224,In vivo,BAO_0000218,,,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to monkey,,,U,Autocuration,A,314293.0,CHEMBL626770,,,,,0,1
11575,22224,In vivo,BAO_0000218,,,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to monkey; No levels,,,U,Autocuration,A,314293.0,CHEMBL626771,,,,,0,1
11576,50597,In vivo,BAO_0000218,,,Pharmacokinetic parameter Cmax determined after peroral administration of 50 mg/kg to rat,,,N,Intermediate,A,10116.0,CHEMBL626772,,,,,1,1
11577,100710,In vivo,BAO_0000218,,,Pharmacokinetic parameter Cmax for the compound was evaluated in nude cynomolgus monkeys after oral administration. ,,,N,Intermediate,A,9541.0,CHEMBL626773,,,,,1,1
11578,50594,In vivo,BAO_0000218,,,Pharmacokinetic parameter Cmax for the compound was evaluated in nude mice after oral administration. ,,,N,Intermediate,A,10090.0,CHEMBL626774,,,,,1,1
11579,50588,In vivo,BAO_0000218,,,Pharmacokinetic parameter Cmax has been determined in fed Beagle dogs at a dose of 375 mg/kg,,,N,Intermediate,A,9615.0,CHEMBL626775,,,,,1,1
11580,50588,In vivo,BAO_0000218,,,Pharmacokinetic parameter Cmax has been determined in fed Beagle dogs at a dose of 500 mg/kg,,,N,Intermediate,A,9615.0,CHEMBL626776,,,,,1,1
11581,50597,In vivo,BAO_0000218,,,Maximum concentration (Cmax) in rat when administered orally,,,N,Intermediate,A,10116.0,CHEMBL626777,,,,,1,1
11582,22224,In vivo,BAO_0000218,,,Maximal concentration in monkey plasma after 25 mg/kg oral dose,,,U,Autocuration,A,314293.0,CHEMBL626778,,1969.0,Plasma,,0,1
11583,22224,In vivo,BAO_0000218,,,"Mean Cmax in rats after 5 mg/kg oral dose, range (0.17-0.20)",,,U,Autocuration,A,10116.0,CHEMBL626779,,,,,0,1
11584,22224,In vivo,BAO_0000218,,,"Mean Cmax in rats after 5 mg/kg oral dose, range (0.4-0.8)",,,U,Autocuration,A,10116.0,CHEMBL626780,,,,,0,1
11585,22224,In vivo,BAO_0000218,,,Cmax in rat plasma after single 5 mg/kg oral cassette gavage dose,,,U,Autocuration,A,,CHEMBL626781,,1969.0,Plasma,,0,1
11586,50597,In vivo,BAO_0000218,,,Pharmacokinetic profile Cmax was evaluated in rats,,,N,Intermediate,A,10116.0,CHEMBL632164,,,,,1,1
11587,50588,In vivo,BAO_0000218,,,Pharmacokinetic property(Cmax- maximum concentration) after oral administration in dog (25 mg/kg),,,N,Intermediate,A,9615.0,CHEMBL632165,,,,,1,1
11588,50594,In vivo,BAO_0000218,,,Pharmacokinetic property(Cmax- maximum concentration) after oral administration in mice (50 mg/kg),,,N,Intermediate,A,10090.0,CHEMBL632166,,,,,1,1
11589,50588,In vivo,BAO_0000218,,,Pharmacokinetic property(Cmax- maximum concentration) after oral administration to dog (25 mg/kg),,,N,Intermediate,A,9615.0,CHEMBL632167,,,,,1,1
11590,50594,In vivo,BAO_0000218,,,Pharmacokinetic property(Cmax- maximum concentration) after oral administration to mice (50 mg/kg),,,N,Intermediate,A,10090.0,CHEMBL632168,,,,,1,1
11591,22224,In vivo,BAO_0000218,,,Cmax in rat plasma,,,U,Autocuration,A,10116.0,CHEMBL632169,,1969.0,Plasma,,0,1
11592,50588,In vivo,BAO_0000218,,,Cmax in dog plasma after 30mg/kg oral dose,,,N,Intermediate,A,9615.0,CHEMBL632170,,1969.0,Plasma,,1,1
11593,50597,In vivo,BAO_0000218,,,Cmax in rat plasma after 30mg/kg oral dose,,,N,Intermediate,A,10116.0,CHEMBL632171,,1969.0,Plasma,,1,1
11594,50597,In vivo,BAO_0000218,,,Plasma level in rats at 30 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL632172,,1969.0,Plasma,,1,1
11595,50594,In vivo,BAO_0000218,,,Tested for maximum plasma concentration in mice,,,N,Intermediate,A,10090.0,CHEMBL632173,,1969.0,Plasma,,1,1
11596,50597,In vivo,BAO_0000218,,,"The Cmax value in female wistar rat at 100 mg/kg, p.o. dose",,,N,Intermediate,A,10116.0,CHEMBL632174,,,,,1,1
11597,50597,In vivo,BAO_0000218,,,The Cmax values in female wistar rats.,,,N,Intermediate,A,10116.0,CHEMBL632175,,,,,1,1
11598,50588,In vivo,BAO_0000218,,,The Peak plasma concentration was measured in dogs after oral administration of 1 mg/kg dose,,,N,Intermediate,A,9615.0,CHEMBL632176,,1969.0,Plasma,,1,1
11599,50597,In vivo,BAO_0000218,,,The Peak plasma concentration was measured in rats after oral administration of 1 mg/kg dose,,,N,Intermediate,A,10116.0,CHEMBL632177,,1969.0,Plasma,,1,1
11600,50597,In vivo,BAO_0000218,,,The compound tested for maximum observed plasma concentration in rats and is expressed in microgram/mL.,,,N,Intermediate,A,10116.0,CHEMBL632178,,1969.0,Plasma,,1,1
11601,50597,In vivo,BAO_0000218,,,The compound was tested for Cmax value pharmacokinetic parameter in the male Sprague-Dawley rat.,,,N,Intermediate,A,10116.0,CHEMBL632179,,,,,1,1
11602,50597,In vivo,BAO_0000218,,,The compound was tested for maximum blood level reached in rats at 15.9 uM/kg after peroral administration.,,,N,Intermediate,A,10116.0,CHEMBL632180,,178.0,Blood,,1,1
11603,50597,In vivo,BAO_0000218,,,The compound was tested for maximum blood level reached in rats at 15.9 uM/Kg after intravenous administration.,,,N,Intermediate,A,10116.0,CHEMBL632181,,178.0,Blood,,1,1
11604,50597,In vivo,BAO_0000218,,,The compound was tested for maximum blood level reached in rats at 15.9 uM/Kg after peroral administration.,,,N,Intermediate,A,10116.0,CHEMBL632182,,178.0,Blood,,1,1
11605,22224,In vivo,BAO_0000218,,,The maximum concentration observed (Cmax) in the blood sample at indicated time point (tmax) at a dose 50 mg/Kg administered orally in mice.,,,U,Autocuration,A,10090.0,CHEMBL632183,,178.0,Blood,,0,1
11606,50588,In vivo,BAO_0000218,,,The maximum concentration of the compound was measured in dog at dose 5 mg/kg after peroral administration.,,,N,Intermediate,A,9615.0,CHEMBL632184,,,,,1,1
11607,50597,In vivo,BAO_0000218,,,The maximum concentration of the compound was measured in rat at dose 1 mg/kg after peroral administration.,,,N,Intermediate,A,10116.0,CHEMBL874470,,,,,1,1
11608,50597,,BAO_0000218,,,"Distribution in rat skin 15 min after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL631302,,,,,1,1
11609,50597,,BAO_0000218,,,"Distribution in rat skin 1 hr after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL631303,,,,,1,1
11610,50597,,BAO_0000218,,,"Distribution in rat skin 2 hr after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL631304,,,,,1,1
11611,50597,,BAO_0000218,,,"Distribution in rat skin 30 min after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL631305,,,,,1,1
11612,50597,,BAO_0000218,,,"Distribution in rat skin 4 hr after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL631306,,,,,1,1
11613,50597,,BAO_0000218,,,"Distribution in rat skin 5 min after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL631307,,,,,1,1
11614,50597,,BAO_0000218,,,"Distribution in rat skin 6 hr after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL631308,,,,,1,1
11615,50597,,BAO_0000218,,,"Distribution in rat skin 8 hr after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL625557,,,,,1,1
11616,50597,,BAO_0000218,,,"Distribution in rat spleen 15 min after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL625558,,2106.0,Spleen,,1,1
11617,50597,,BAO_0000218,,,"Distribution in rat spleen 1 hr after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL625559,,2106.0,Spleen,,1,1
11618,50597,,BAO_0000218,,,"Distribution in rat spleen 2 hr after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL625560,,2106.0,Spleen,,1,1
11619,50597,,BAO_0000218,,,"Distribution in rat spleen 30 min after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL625561,,2106.0,Spleen,,1,1
11620,50597,,BAO_0000218,,,"Distribution in rat spleen 4 hr after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL625562,,2106.0,Spleen,,1,1
11621,50597,,BAO_0000218,,,"Distribution in rat spleen 5 min after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL875320,,2106.0,Spleen,,1,1
11622,50597,,BAO_0000218,,,"Distribution in rat spleen 6 hr after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL625563,,2106.0,Spleen,,1,1
11623,50597,,BAO_0000218,,,"Distribution in rat spleen 8 hr after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL625564,,2106.0,Spleen,,1,1
11624,50597,,BAO_0000218,,,"Distribution in rat uterus 15 min after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL625565,,995.0,Uterus,,1,1
11625,50597,,BAO_0000218,,,"Distribution in rat uterus 1 hr after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL625566,,995.0,Uterus,,1,1
11626,50597,,BAO_0000218,,,"Distribution in rat uterus 2 hr after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL625567,,995.0,Uterus,,1,1
11627,50597,,BAO_0000218,,,"Distribution in rat uterus 30 min after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL625568,,995.0,Uterus,,1,1
11628,50597,,BAO_0000218,,,"Distribution in rat uterus 4 hr after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL628217,,995.0,Uterus,,1,1
11629,50597,,BAO_0000218,,,"Distribution in rat uterus 5 min after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL628218,,995.0,Uterus,,1,1
11630,50597,,BAO_0000218,,,"Distribution in rat uterus 6 hr after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL628219,,995.0,Uterus,,1,1
11631,50597,,BAO_0000218,,,"Distribution in rat uterus 8 hr after intravenous administration, injected dose/gm",,,N,Intermediate,A,10116.0,CHEMBL628220,,995.0,Uterus,,1,1
11632,22224,,BAO_0000019,,,Distribution in the blood after 120 min of intravenous administration,,,U,Autocuration,A,,CHEMBL628221,,,,,0,1
11633,22224,,BAO_0000019,,,Distribution in the blood after 15 min of intravenous administration,,,U,Autocuration,A,,CHEMBL628222,,,,,0,1
11634,22224,,BAO_0000019,,,Distribution in the blood after 30 min of intravenous administration,,,U,Autocuration,A,,CHEMBL628223,,,,,0,1
11635,22224,,BAO_0000019,,,Distribution in the blood after 5 min of intravenous administration,,,U,Autocuration,A,,CHEMBL628224,,,,,0,1
11636,22224,,BAO_0000019,,,Distribution in the blood after 60 min of intravenous administration,,,U,Autocuration,A,,CHEMBL628225,,,,,0,1
11637,22224,,BAO_0000019,,,Distribution in the blood after 90 min of intravenous administration,,,U,Autocuration,A,,CHEMBL628226,,,,,0,1
11638,22224,,BAO_0000019,,,Distribution in the bone after 120 min of intravenous administration,,,U,Autocuration,A,,CHEMBL628227,,,,,0,1
11639,22224,,BAO_0000019,,,Distribution in the bone after 15 min of intravenous administration,,,U,Autocuration,A,,CHEMBL875481,,,,,0,1
11640,22224,,BAO_0000019,,,Distribution in the bone after 30 min of intravenous administration,,,U,Autocuration,A,,CHEMBL628228,,,,,0,1
11641,22224,,BAO_0000019,,,Distribution in the bone after 5 min of intravenous administration,,,U,Autocuration,A,,CHEMBL628229,,,,,0,1
11642,22224,,BAO_0000019,,,Distribution in the bone after 60 min of intravenous administration,,,U,Autocuration,A,,CHEMBL628230,,,,,0,1
11643,22224,,BAO_0000019,,,Distribution in the bone after 90 min of intravenous administration,,,U,Autocuration,A,,CHEMBL628231,,,,,0,1
11644,22224,,BAO_0000019,,,Distribution in the heart after 120 min of intravenous administration,,,U,Autocuration,A,,CHEMBL628232,,,,,0,1
11645,22224,,BAO_0000019,,,Distribution in the heart after 15 min of intravenous administration,,,U,Autocuration,A,,CHEMBL628233,,,,,0,1
11646,22224,,BAO_0000019,,,Distribution in the heart after 30 min of intravenous administration,,,U,Autocuration,A,,CHEMBL628234,,,,,0,1
11647,22224,,BAO_0000019,,,Distribution in the heart after 5 min of intravenous administration,,,U,Autocuration,A,,CHEMBL628235,,,,,0,1
11648,22224,,BAO_0000019,,,Distribution in the heart after 60 min of intravenous administration,,,U,Autocuration,A,,CHEMBL628236,,,,,0,1
11649,22224,,BAO_0000019,,,Distribution in the heart after 90 min of intravenous administration,,,U,Autocuration,A,,CHEMBL628237,,,,,0,1
11650,22224,,BAO_0000019,,,Distribution in the kidneys after 120 min of intravenous administration,,,U,Autocuration,A,,CHEMBL628238,,,,,0,1
11651,22224,,BAO_0000019,,,Distribution in the kidneys after 15 min of intravenous administration,,,U,Autocuration,A,,CHEMBL628239,,,,,0,1
11652,22224,,BAO_0000019,,,Distribution in the kidneys after 30 min of intravenous administration,,,U,Autocuration,A,,CHEMBL628240,,,,,0,1
11653,22224,,BAO_0000019,,,Distribution in the kidneys after 5 min of intravenous administration,,,U,Autocuration,A,,CHEMBL628241,,,,,0,1
11654,22224,,BAO_0000019,,,Distribution in the kidneys after 60 min of intravenous administration,,,U,Autocuration,A,,CHEMBL628242,,,,,0,1
11655,22224,,BAO_0000019,,,Distribution in the kidneys after 90 min of intravenous administration,,,U,Autocuration,A,,CHEMBL875482,,,,,0,1
11656,22224,,BAO_0000019,,,Distribution in the liver after 120 min of intravenous administration,,,U,Autocuration,A,,CHEMBL628243,,,,,0,1
11657,22224,,BAO_0000019,,,Distribution in the liver after 15 min of intravenous administration,,,U,Autocuration,A,,CHEMBL628244,,,,,0,1
11658,22224,,BAO_0000019,,,Distribution in the liver after 30 min of intravenous administration,,,U,Autocuration,A,,CHEMBL628245,,,,,0,1
11659,22224,,BAO_0000019,,,Distribution in the liver after 5 min of intravenous administration,,,U,Autocuration,A,,CHEMBL628246,,,,,0,1
11660,22224,,BAO_0000019,,,Distribution in the liver after 60 min of intravenous administration,,,U,Autocuration,A,,CHEMBL628247,,,,,0,1
11661,22224,,BAO_0000019,,,Distribution in the liver after 90 min of intravenous administration,,,U,Autocuration,A,,CHEMBL628248,,,,,0,1
11662,22224,,BAO_0000019,,,Distribution in the lung after 120 min of intravenous administration,,,U,Autocuration,A,,CHEMBL628249,,,,,0,1
11663,50594,,BAO_0000218,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in solution, iv and the total drug exposure was determined. (0-24hr)",,,N,Intermediate,A,10090.0,CHEMBL625452,,,,,1,1
11664,50594,,BAO_0000218,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in solution, perorally and the total drug exposure was determined (0-24hr)",,,N,Intermediate,A,10090.0,CHEMBL625453,,,,,1,1
11665,50594,,BAO_0000218,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, micronized free base in 20% HPbetaCD, iv and the total drug exposure was determined. (0-24hr)",,,N,Intermediate,A,10090.0,CHEMBL625454,,,,,1,1
11666,50594,,BAO_0000218,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, micronized free base in 20% HPbetaCD, perorally and the total drug exposure was determined (0-24hr)",,,N,Intermediate,A,10090.0,CHEMBL623844,,,,,1,1
11667,50597,,BAO_0000218,,,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 1 mg/kg (normalized to a 1 mg/kg dose) in rat,,,N,Intermediate,A,10116.0,CHEMBL623845,,,,,1,1
11668,50597,,BAO_0000218,,,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 2.5 mg/kg (normalized to a 1 mg/kg dose) in rat,,,N,Intermediate,A,10116.0,CHEMBL623846,,,,,1,1
11669,22224,,BAO_0000218,,,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 5.0 mg/kg (normalized to a 1 mg/kg dose) GP,,,U,Autocuration,A,,CHEMBL623847,,,,,0,1
11670,100710,,BAO_0000218,,,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using HPLC assay,,,N,Intermediate,A,9541.0,CHEMBL623848,,,,,1,1
11671,100710,,BAO_0000218,,,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,,,N,Intermediate,A,9541.0,CHEMBL623849,,,,,1,1
11672,100710,,BAO_0000218,,,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using HPLC assay,,,N,Intermediate,A,9541.0,CHEMBL623850,,,,,1,1
11673,100710,,BAO_0000218,,,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,,,N,Intermediate,A,9541.0,CHEMBL623851,,,,,1,1
11674,22224,,BAO_0000218,,,Integrated area under the plasma drug level-time curve was determined in portal circulation after intraduodenal dose of 10 mg/kg in monkey,,,U,Autocuration,A,314293.0,CHEMBL623852,,,,,0,1
11675,50506,,BAO_0000218,,,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret,,,N,Intermediate,A,9669.0,CHEMBL624551,,,,,1,1
11676,50506,,BAO_0000218,,,"Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret, determined by renin inhibition assay",,,N,Intermediate,A,9669.0,CHEMBL624552,,,,,1,1
11677,22224,,BAO_0000218,,,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey,,,U,Autocuration,A,314293.0,CHEMBL624553,,,,,0,1
11678,22224,,BAO_0000218,,,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey determined by renin inhibition assay,,,U,Autocuration,A,314293.0,CHEMBL624554,,,,,0,1
11679,50597,,BAO_0000218,,,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat,,,N,Intermediate,A,10116.0,CHEMBL624555,,,,,1,1
11680,50597,,BAO_0000218,,,"Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",,,N,Intermediate,A,10116.0,CHEMBL624741,,,,,1,1
11681,50588,,BAO_0000218,,,"Intravenous integrated area under the concentration vs time curve, for compound in dog plasma",,,N,Intermediate,A,9615.0,CHEMBL624742,,,,,1,1
11682,100712,,BAO_0000218,,,"Intravenous integrated area under the concentration vs time curve, for compound in hamster plasma",,,N,Intermediate,A,10026.0,CHEMBL624743,,,,,1,1
11683,50597,,BAO_0000218,,,"Intravenous integrated area under the concentration vs time curve, for compound in rat plasma",,,N,Intermediate,A,10116.0,CHEMBL877606,,,,,1,1
11684,22224,,BAO_0000218,,,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg,,,U,Autocuration,A,,CHEMBL624744,,,,,0,1
11685,22224,,BAO_0000218,,,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg; b = No compound detectable in blood above the detection limit of 0.1 uM,,,U,Autocuration,A,,CHEMBL624745,,178.0,Blood,,0,1
11686,22224,,BAO_0000218,,,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg; b denotes No compound detectable in blood above the detection limit of 0.1 uM,,,U,Autocuration,A,,CHEMBL624746,,178.0,Blood,,0,1
11687,22224,,BAO_0000218,,,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg;b = No compound detectable in blood above the detection limit of 0.1 uM,,,U,Autocuration,A,,CHEMBL624747,,178.0,Blood,,0,1
11688,22224,,BAO_0000019,,,Oral absorption expressed as Area under curve was determined,,,U,Autocuration,A,,CHEMBL624748,,,,,0,1
11689,50588,,BAO_0000218,,,Oral absorption kinetics (AUC) was determined after administration of compound orally at 1 mg/kg in dogs,,,N,Intermediate,A,9615.0,CHEMBL622504,,,,,1,1
11690,50588,,BAO_0000218,,,"Oral integrated area under the concentration vs time curve, for compound in dog plasma",,,N,Intermediate,A,9615.0,CHEMBL622505,,,,,1,1
11691,100712,,BAO_0000218,,,"Oral integrated area under the concentration vs time curve, for compound in hamster plasma",,,N,Intermediate,A,10026.0,CHEMBL622506,,,,,1,1
11692,100712,,BAO_0000218,,,"Oral integrated area under the concentration vs time curve, for compound in hamster plasma",,,N,Intermediate,A,10026.0,CHEMBL622507,,,,,1,1
11693,50597,,BAO_0000218,,,"Oral integrated area under the concentration vs time curve, for compound in rat plasma",,,N,Intermediate,A,10116.0,CHEMBL622508,,,,,1,1
11694,22224,,BAO_0000019,,,Pharmacokinetic parameter AUC in mice following a single dose intravenous administration of the compound,,,U,Autocuration,A,,CHEMBL622509,,,,,0,1
11695,50597,,BAO_0000218,,,Pharmacokinetic Parameter [Area under curve (AUC)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,,,N,Intermediate,A,10116.0,CHEMBL622510,,,,,1,1
11696,50597,,BAO_0000218,,,Pharmacokinetic parameter (AUC) was determined after administering 1 mg/kg of compound intravenously in rat no.3 belonging to phenotype EM (extensive metabolizer),,,N,Intermediate,A,10116.0,CHEMBL622511,,,,,1,1
11697,100710,,BAO_0000218,,,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered intravenously at 0.5 mg/kg concentration,,,N,Intermediate,A,9541.0,CHEMBL622512,,,,,1,1
11698,100710,,BAO_0000218,,,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered intravenously at 1 mg/kg concentration,,,N,Intermediate,A,9541.0,CHEMBL622513,,,,,1,1
11699,100710,,BAO_0000218,,,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered po at 5 mg/kg concentration,,,N,Intermediate,A,9541.0,CHEMBL622514,,,,,1,1
11700,50588,,BAO_0000218,,,Pharmacokinetic parameter AUC calculated in dog when the compound was administered intravenously at 2 mg/kg concentration,,,N,Intermediate,A,9615.0,CHEMBL622515,,,,,1,1
11701,50588,,BAO_0000218,,,Pharmacokinetic parameter AUC calculated in dog when the compound was administered po at 5 mg/kg concentration,,,N,Intermediate,A,9615.0,CHEMBL622516,,,,,1,1
11702,50597,,BAO_0000218,,,Pharmacokinetic parameter AUC calculated in rat when the compound was administered intravenously at 5 mg/kg concentration,,,N,Intermediate,A,10116.0,CHEMBL622517,,,,,1,1
11703,50597,,BAO_0000218,,,Pharmacokinetic parameter AUC calculated in rat when the compound was administered po at 12 mg/kg concentration,,,N,Intermediate,A,10116.0,CHEMBL622518,,,,,1,1
11704,50597,,BAO_0000218,,,Pharmacokinetic parameter AUC calculated in rat when the compound was administered po at 20 mg/kg concentration,,,N,Intermediate,A,10116.0,CHEMBL622519,,,,,1,1
11705,50597,In vivo,BAO_0000218,,,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 30 min,,,N,Intermediate,A,10116.0,CHEMBL622520,,2385.0,Muscle tissue,,1,1
11706,50597,In vivo,BAO_0000218,,,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 60 min,,,N,Intermediate,A,10116.0,CHEMBL622521,,2385.0,Muscle tissue,,1,1
11707,50594,In vivo,BAO_0000218,,,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 2 min,,,N,Intermediate,A,10090.0,CHEMBL625113,,14.0,Zone of skin,,1,1
11708,50597,In vivo,BAO_0000218,,,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 30 min,,,N,Intermediate,A,10116.0,CHEMBL625114,,14.0,Zone of skin,,1,1
11709,50597,In vivo,BAO_0000218,,,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 60 min,,,N,Intermediate,A,10116.0,CHEMBL874397,,14.0,Zone of skin,,1,1
11710,50597,In vivo,BAO_0000218,,,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 2 min,,,N,Intermediate,A,10116.0,CHEMBL625115,,2106.0,Spleen,,1,1
11711,50597,In vivo,BAO_0000218,,,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 30 min,,,N,Intermediate,A,10116.0,CHEMBL625116,,2106.0,Spleen,,1,1
11712,50597,In vivo,BAO_0000218,,,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 60 min,,,N,Intermediate,A,10116.0,CHEMBL623932,,2106.0,Spleen,,1,1
11713,50597,In vivo,BAO_0000218,,,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 2 min,,,N,Intermediate,A,10116.0,CHEMBL623933,,2435.0,Striatum,,1,1
11714,50597,In vivo,BAO_0000218,,,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 30 min,,,N,Intermediate,A,10116.0,CHEMBL623934,,2435.0,Striatum,,1,1
11715,50597,In vivo,BAO_0000218,,,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 60 min,,,N,Intermediate,A,10116.0,CHEMBL623935,,2435.0,Striatum,,1,1
11716,50597,In vivo,BAO_0000218,,,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 2 min,,,N,Intermediate,A,10116.0,CHEMBL623936,,2046.0,Thyroid gland,,1,1
11717,50597,In vivo,BAO_0000218,,,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 30 min,,,N,Intermediate,A,10116.0,CHEMBL623937,,2046.0,Thyroid gland,,1,1
11718,50597,In vivo,BAO_0000218,,,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 60 min,,,N,Intermediate,A,10116.0,CHEMBL623938,,2046.0,Thyroid gland,,1,1
11719,50594,,BAO_0000218,,,In vivo biodistribution in mice blood bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,,N,Intermediate,A,10090.0,CHEMBL623939,,,,,1,1
11720,50594,,BAO_0000218,,,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 10 ug/g,,,N,Intermediate,A,10090.0,CHEMBL623940,,,,,1,1
11721,50594,,BAO_0000218,,,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 20 ug/g,,,N,Intermediate,A,10090.0,CHEMBL623941,,,,,1,1
11722,50594,,BAO_0000218,,,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,,N,Intermediate,A,10090.0,CHEMBL627216,,,,,1,1
11723,50594,,BAO_0000218,,,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,,N,Intermediate,A,10090.0,CHEMBL623942,,,,,1,1
11724,50594,,BAO_0000218,,,In vivo biodistribution in mice brain bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,,N,Intermediate,A,10090.0,CHEMBL618793,,955.0,Brain,,1,1
11725,50594,,BAO_0000218,,,In vivo biodistribution in mice brain bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,,N,Intermediate,A,10090.0,CHEMBL618794,,955.0,Brain,,1,1
11726,50594,,BAO_0000218,,,In vivo biodistribution in mice brain bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,,N,Intermediate,A,10090.0,CHEMBL618795,,955.0,Brain,,1,1
11727,50594,,BAO_0000218,,,In vivo biodistribution in mice eyes bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,,N,Intermediate,A,10090.0,CHEMBL618796,,,,,1,1
11728,50594,,BAO_0000218,,,In vivo biodistribution in mice eyes bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,,N,Intermediate,A,10090.0,CHEMBL618797,,,,,1,1
11729,50594,,BAO_0000218,,,In vivo biodistribution in mice kidney bearing intracerebral GL261 gliomas at the dose of 10 microg of boron/g/day,,,N,Intermediate,A,10090.0,CHEMBL618798,,2113.0,Kidney,,1,1
11730,50594,,BAO_0000218,,,In vivo biodistribution in mice kidney bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,,N,Intermediate,A,10090.0,CHEMBL618799,,2113.0,Kidney,,1,1
11731,50594,,BAO_0000218,,,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 10 ug/g,,,N,Intermediate,A,10090.0,CHEMBL618800,,2113.0,Kidney,,1,1
11732,50594,,BAO_0000218,,,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 20 ug/g,,,N,Intermediate,A,10090.0,CHEMBL618801,,2113.0,Kidney,,1,1
11733,50594,,BAO_0000218,,,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,,N,Intermediate,A,10090.0,CHEMBL618802,,2113.0,Kidney,,1,1
11734,50594,,BAO_0000218,,,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,,N,Intermediate,A,10090.0,CHEMBL618803,,2113.0,Kidney,,1,1
11735,50594,,BAO_0000218,,,In vivo biodistribution in mice liver bearing intracerebral GL261 gliomas at the dose of 10 microg of boron/g/day,,,N,Intermediate,A,10090.0,CHEMBL618804,,2107.0,Liver,,1,1
11736,50594,,BAO_0000218,,,In vivo biodistribution in mice liver bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,,N,Intermediate,A,10090.0,CHEMBL618805,,2107.0,Liver,,1,1
11737,50594,,BAO_0000218,,,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 10 ug/g,,,N,Intermediate,A,10090.0,CHEMBL618806,,2107.0,Liver,,1,1
11738,50594,,BAO_0000218,,,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 20 ug/g,,,N,Intermediate,A,10090.0,CHEMBL618807,,2107.0,Liver,,1,1
11739,50594,,BAO_0000218,,,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,,N,Intermediate,A,10090.0,CHEMBL618808,,2107.0,Liver,,1,1
11740,50594,,BAO_0000218,,,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,,N,Intermediate,A,10090.0,CHEMBL618809,,2107.0,Liver,,1,1
11741,50594,,BAO_0000218,,,In vivo biodistribution in mice muscle bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,,N,Intermediate,A,10090.0,CHEMBL618810,,2385.0,Muscle tissue,,1,1
11742,50594,,BAO_0000218,,,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 10 ug/g,,,N,Intermediate,A,10090.0,CHEMBL618811,,2385.0,Muscle tissue,,1,1
11743,50594,,BAO_0000218,,,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 20 ug/g,,,N,Intermediate,A,10090.0,CHEMBL875844,,2385.0,Muscle tissue,,1,1
11744,50594,,BAO_0000218,,,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,,N,Intermediate,A,10090.0,CHEMBL618812,,2385.0,Muscle tissue,,1,1
11745,50594,,BAO_0000218,,,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,,N,Intermediate,A,10090.0,CHEMBL618813,,2385.0,Muscle tissue,,1,1
11746,50594,,BAO_0000218,,,In vivo biodistribution in mice skin bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,,N,Intermediate,A,10090.0,CHEMBL618814,,,,,1,1
11747,50594,,BAO_0000218,,,In vivo biodistribution in mice skin bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,,N,Intermediate,A,10090.0,CHEMBL618815,,,,,1,1
11748,50594,,BAO_0000218,,,In vivo biodistribution in mice skin bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,,N,Intermediate,A,10090.0,CHEMBL618816,,,,,1,1
11749,50594,,BAO_0000218,,,In vivo biodistribution in mice skin by pump bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,,N,Intermediate,A,10090.0,CHEMBL618817,,,,,1,1
11750,50594,,BAO_0000218,,,In vivo biodistribution in mice skin by pump bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,,N,Intermediate,A,10090.0,CHEMBL620544,,,,,1,1
11751,50597,In vivo,BAO_0000218,,,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after intraperitoneal administration.,,,N,Intermediate,A,10116.0,CHEMBL626230,,,,,1,1
11752,50597,In vivo,BAO_0000218,,,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after intravenous administration.,,,N,Intermediate,A,10116.0,CHEMBL626231,,,,,1,1
11753,50597,In vivo,BAO_0000218,,,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after peroral administration.,,,N,Intermediate,A,10116.0,CHEMBL626232,,,,,1,1
11754,50588,In vivo,BAO_0000218,,,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on dog.,,,N,Intermediate,A,9615.0,CHEMBL626233,,1969.0,Plasma,,1,1
11755,50597,In vivo,BAO_0000218,,,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on rat,,,N,Intermediate,A,10116.0,CHEMBL626234,,1969.0,Plasma,,1,1
11756,50597,In vivo,BAO_0000218,,,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on rat.,,,N,Intermediate,A,10116.0,CHEMBL875341,,1969.0,Plasma,,1,1
11757,50587,In vivo,BAO_0000218,,,The maximum plasma concentration (100 mg/kg) administered orally in human,,,N,Intermediate,A,9606.0,CHEMBL626235,,1969.0,Plasma,,1,1
11758,22224,In vivo,BAO_0000218,,,The maximum plasma concentration (12.5 mg/kg) administered intravenously in marmoset,,,U,Autocuration,A,9481.0,CHEMBL626236,,1969.0,Plasma,,0,1
11759,22224,In vivo,BAO_0000218,,,The maximum plasma concentration (12.5 mg/kg) administered intravenously in monkey,,,U,Autocuration,A,314293.0,CHEMBL626237,,1969.0,Plasma,,0,1
11760,50588,In vivo,BAO_0000218,,,The maximum plasma concentration (15 mg/kg) administered intravenously in dog,,,N,Intermediate,A,9615.0,CHEMBL626238,,1969.0,Plasma,,1,1
11761,50587,In vivo,BAO_0000218,,,The maximum plasma concentration (200 mg/kg) administered orally in human,,,N,Intermediate,A,9606.0,CHEMBL622412,,1969.0,Plasma,,1,1
11762,50597,In vivo,BAO_0000218,,,The maximum plasma concentration (25 mg/kg) administered intravenously in rat,,,N,Intermediate,A,10116.0,CHEMBL623114,,1969.0,Plasma,,1,1
11763,22224,In vivo,BAO_0000218,,,The maximum plasma concentration (25 mg/kg) administered orally in marmoset,,,U,Autocuration,A,9481.0,CHEMBL623115,,1969.0,Plasma,,0,1
11764,22224,In vivo,BAO_0000218,,,The maximum plasma concentration (25 mg/kg) administered orally in monkey,,,U,Autocuration,A,314293.0,CHEMBL623116,,1969.0,Plasma,,0,1
11765,22224,In vivo,BAO_0000218,,,The maximum plasma concentration (30 mg/kg) administered orally in dog,,,U,Autocuration,A,9615.0,CHEMBL623117,,1969.0,Plasma,,0,1
11766,50587,In vivo,BAO_0000218,,,The maximum plasma concentration (400 mg/kg) administered orally in human,,,N,Intermediate,A,9606.0,CHEMBL623118,,1969.0,Plasma,,1,1
11767,50597,In vivo,BAO_0000218,,,The maximum plasma concentration (50 mg/kg) administered orally in fasted rat,,,N,Intermediate,A,10116.0,CHEMBL623119,,1969.0,Plasma,,1,1
11768,50597,In vivo,BAO_0000218,,,The maximum plasma concentration (50 mg/kg) administered orally in rat,,,N,Intermediate,A,10116.0,CHEMBL623120,,1969.0,Plasma,,1,1
11769,50587,In vivo,BAO_0000218,,,The maximum plasma concentration (800 mg/kg) administered orally in human,,,N,Intermediate,A,9606.0,CHEMBL623286,,1969.0,Plasma,,1,1
11770,50597,In vivo,BAO_0000218,,,The maximum plasma concentration was measured on rats,,,N,Intermediate,A,10116.0,CHEMBL623287,,1969.0,Plasma,,1,1
11771,50597,In vivo,BAO_0000218,,,The maximum plasma concentration was measured on rats after oral administration,,,N,Intermediate,A,10116.0,CHEMBL623288,,1969.0,Plasma,,1,1
11772,50597,In vivo,BAO_0000218,,,Plasma drug Cmax in rat (PO dose),,,N,Intermediate,A,10116.0,CHEMBL623289,,1969.0,Plasma,,1,1
11773,22224,In vivo,BAO_0000218,,,Time taken to reach maximum concentration after administration of 2 umol/kg dose intravenously,,,U,Autocuration,A,,CHEMBL623290,,,,,0,1
11774,50588,In vivo,BAO_0000218,,,maximum Plasma concentration in Dog was determined after Peroral administration,,,N,Intermediate,A,9615.0,CHEMBL623291,,1969.0,Plasma,,1,1
11775,50597,In vivo,BAO_0000218,,,maximum Plasma concentration in Rats was determined after Peroral administration,,,N,Intermediate,A,10116.0,CHEMBL623292,,1969.0,Plasma,,1,1
11776,50588,In vivo,BAO_0000218,,,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in dog,,,N,Intermediate,A,9615.0,CHEMBL623293,,1969.0,Plasma,,1,1
11777,22224,In vivo,BAO_0000218,,,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in monkey,,,U,Autocuration,A,314293.0,CHEMBL623294,,1969.0,Plasma,,0,1
11778,50597,In vivo,BAO_0000218,,,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in rat,,,N,Intermediate,A,10116.0,CHEMBL623295,,1969.0,Plasma,,1,1
11779,50594,In vivo,BAO_0000218,,,maximum concentration was measured when administered through oral route in mice,,,N,Intermediate,A,10090.0,CHEMBL623296,,,,,1,1
11780,50594,,BAO_0000218,,,Compound was evaluated for Cmax/Tmax when administered through oral route in mouse; Value is 0.93/1,,,N,Intermediate,A,10090.0,CHEMBL875349,,,,,1,1
11781,22224,,BAO_0000019,,,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 0.34/1,,,U,Autocuration,A,314293.0,CHEMBL623297,,,,,0,1
11782,22224,,BAO_0000019,,,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 0.81/1.6,,,U,Autocuration,A,314293.0,CHEMBL623298,,,,,0,1
11783,22224,,BAO_0000019,,,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 1.1/1.3,,,U,Autocuration,A,314293.0,CHEMBL623299,,,,,0,1
11784,50597,,BAO_0000218,,,Pharmacokinetic parameter was evaluated in rats,,,N,Intermediate,A,10116.0,CHEMBL623300,,,,,1,1
11785,50594,,BAO_0000218,,,Plasma concentration at time-0 was measured in mice at 100 mg/kg after intraperitoneal administration with 90% DMSO as vehicle,,,N,Intermediate,A,10090.0,CHEMBL623301,,,,,1,1
11786,50594,,BAO_0000218,,,Plasma concentration at time-0 was measured in mice at 100 mg/kg after intraperitoneal administration with saline(pH=11.4) as vehicle,,,N,Intermediate,A,10090.0,CHEMBL623302,,,,,1,1
11787,50594,,BAO_0000218,,,Plasma concentration at time-0 was measured in mice at 120 mg/kg after intraperitoneal administration with 90% DMSO as vehicle,,,N,Intermediate,A,10090.0,CHEMBL623303,,,,,1,1
11788,50594,,BAO_0000218,,,Plasma concentration at time-0 was measured in mice at 40 mg/kg after intravenous administration with saline(pH=11.4) as vehicle,,,N,Intermediate,A,10090.0,CHEMBL623304,,,,,1,1
11789,50594,,BAO_0000218,,,Plasma concentration at time-0 was measured in mice at 40 mg/kg after intravenous administration with 90% DMSO as vehicle,,,N,Intermediate,A,10090.0,CHEMBL623305,,,,,1,1
11790,50597,,BAO_0000218,,,Effect of ip administration of compound on plasma concentration of allo-pregnanolone (AP) in rats(Cerebral Cortex) after 30 min.,,,N,Intermediate,A,10116.0,CHEMBL623306,,1969.0,Plasma,,1,1
11791,50597,,BAO_0000218,,,Effect of ip administration of compound on plasma concentration of allotetrahydrodeoxy corticosterone(THDOC) in rats(Cerebral Cortex) after 30 min.,,,N,Intermediate,A,10116.0,CHEMBL623307,,1969.0,Plasma,,1,1
11792,50597,,BAO_0000218,,,Effect of ip administration of compound on plasma concentration of pregnenolone (PRE) in rats(Cerebral Cortex) after 30 min.,,,N,Intermediate,A,10116.0,CHEMBL623308,,1969.0,Plasma,,1,1
11793,50594,,BAO_0000218,,,Effect of ip administration of compound on plasma concentration of progesterone (PRO) in rats(Cerebral Cortex) after 30 min.,,,N,Intermediate,A,10090.0,CHEMBL623309,,1969.0,Plasma,,1,1
11794,50594,,BAO_0000218,,,Plasma Concentration after 120 min of oral administration to mice,,,N,Intermediate,A,10090.0,CHEMBL623310,,,,,1,1
11795,50594,,BAO_0000218,,,Plasma Concentration after 30 min of oral administration to mice,,,N,Intermediate,A,10090.0,CHEMBL623311,,,,,1,1
11796,100710,,BAO_0000218,,,Plasma Concentration after 60 min of oral administration to mice,,,N,Intermediate,A,9541.0,CHEMBL623312,,,,,1,1
11797,50594,,BAO_0000218,,,Plasma Concentration after 60 min of oral administration to mice; Not determined,,,N,Intermediate,A,10090.0,CHEMBL875350,,,,,1,1
11798,50594,,BAO_0000218,,,Plasma Concentration after 90 min of oral administration to mice,,,N,Intermediate,A,10090.0,CHEMBL628635,,,,,1,1
11799,50597,,BAO_0000218,,,Plasma concentration level in rat after 1 hour of oral administration at 50 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL628636,,,,,1,1
11800,50597,,BAO_0000218,,,Plasma concentration level in rat after 15 hours of oral administration at 50 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL628637,,,,,1,1
11801,50597,,BAO_0000218,,,Plasma concentration level in rat after 4 hours of oral administration at 50 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL628058,,,,,1,1
11802,50597,,BAO_0000218,,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 0-1 hr time,,,N,Intermediate,A,10116.0,CHEMBL628059,,,,,1,1
11803,50597,,BAO_0000218,,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 1-2 hr time,,,N,Intermediate,A,10116.0,CHEMBL628060,,,,,1,1
11804,22224,,BAO_0000019,,,Distribution in the lung after 15 min of intravenous administration,,,U,Autocuration,A,,CHEMBL628061,,,,,0,1
11805,22224,,BAO_0000019,,,Distribution in the lung after 30 min of intravenous administration,,,U,Autocuration,A,,CHEMBL628062,,,,,0,1
11806,22224,,BAO_0000019,,,Distribution in the lung after 5 min of intravenous administration,,,U,Autocuration,A,,CHEMBL628063,,,,,0,1
11807,22224,,BAO_0000019,,,Distribution in the lung after 60 min of intravenous administration,,,U,Autocuration,A,,CHEMBL628064,,,,,0,1
11808,22224,,BAO_0000019,,,Distribution in the lung after 90 min of intravenous administration,,,U,Autocuration,A,,CHEMBL628065,,,,,0,1
11809,22224,,BAO_0000019,,,Distribution in the muscle after 120 min of intravenous administration,,,U,Autocuration,A,,CHEMBL628066,,2385.0,Muscle tissue,,0,1
11810,22224,,BAO_0000019,,,Distribution in the muscle after 15 min of intravenous administration,,,U,Autocuration,A,,CHEMBL628067,,2385.0,Muscle tissue,,0,1
11811,50594,,BAO_0000218,,,Distribution in the muscle after 30 min of intravenous administration,,,N,Intermediate,A,10090.0,CHEMBL874646,,2385.0,Muscle tissue,,1,1
11812,22224,,BAO_0000019,,,Distribution in the muscle after 5 min of intravenous administration,,,U,Autocuration,A,,CHEMBL628068,,2385.0,Muscle tissue,,0,1
11813,22224,,BAO_0000019,,,Distribution in the muscle after 60 min of intravenous administration,,,U,Autocuration,A,,CHEMBL628069,,2385.0,Muscle tissue,,0,1
11814,22224,,BAO_0000019,,,Distribution in the muscle after 90 min of intravenous administration,,,U,Autocuration,A,,CHEMBL628070,,2385.0,Muscle tissue,,0,1
11815,22224,,BAO_0000019,,,Distribution in the spleen after 120 min of intravenous administration,,,U,Autocuration,A,,CHEMBL628071,,2106.0,Spleen,,0,1
11816,22224,,BAO_0000019,,,Distribution in the spleen after 15 min of intravenous administration,,,U,Autocuration,A,,CHEMBL628072,,2106.0,Spleen,,0,1
11817,22224,,BAO_0000019,,,Distribution in the spleen after 30 min of intravenous administration,,,U,Autocuration,A,,CHEMBL628073,,2106.0,Spleen,,0,1
11818,22224,,BAO_0000019,,,Distribution in the spleen after 5 min of intravenous administration,,,U,Autocuration,A,,CHEMBL628074,,2106.0,Spleen,,0,1
11819,22224,,BAO_0000019,,,Distribution in the spleen after 60 min of intravenous administration,,,U,Autocuration,A,,CHEMBL628075,,2106.0,Spleen,,0,1
11820,22224,,BAO_0000019,,,Distribution in the spleen after 90 min of intravenous administration,,,U,Autocuration,A,,CHEMBL628076,,2106.0,Spleen,,0,1
11821,50597,,BAO_0000218,,,Evaluated for distribution at 0.5 hr after intravenous administration in adrenal cortex of female Sprague Dawley rats,,,N,Intermediate,A,10116.0,CHEMBL628077,,1235.0,Adrenal cortex,,1,1
11822,50597,,BAO_0000218,,,Evaluated for distribution at 0.5 hr after intravenous administration in blood of female Sprague Dawley rats,,,N,Intermediate,A,10116.0,CHEMBL628078,,178.0,Blood,,1,1
11823,50597,,BAO_0000218,,,Evaluated for distribution at 0.5 hr after intravenous administration in liver of female Sprague Dawley rats,,,N,Intermediate,A,10116.0,CHEMBL628079,,2107.0,Liver,,1,1
11824,50597,,BAO_0000218,,,Evaluated for distribution at 0.5 hr after intravenous administration in ovary of female Sprague Dawley rats,,,N,Intermediate,A,10116.0,CHEMBL628080,,992.0,Female gonad,,1,1
11825,50597,,BAO_0000218,,,Evaluated for distribution at 0.5 hr after intravenous administration in thyroid of female Sprague Dawley rats,,,N,Intermediate,A,10116.0,CHEMBL628081,,2046.0,Thyroid gland,,1,1
11826,50597,,BAO_0000218,,,Evaluated for distribution at 24 hours after intravenous administration in adrenal cortex of female Sprague Dawley rats,,,N,Intermediate,A,10116.0,CHEMBL628082,,1235.0,Adrenal cortex,,1,1
11827,50597,,BAO_0000218,,,Evaluated for distribution at 24 hours after intravenous administration in blood of female Sprague Dawley rats,,,N,Intermediate,A,10116.0,CHEMBL874647,,178.0,Blood,,1,1
11828,50597,,BAO_0000218,,,Evaluated for distribution at 24 hours after intravenous administration in liver of female Sprague Dawley rats,,,N,Intermediate,A,10116.0,CHEMBL626406,,2107.0,Liver,,1,1
11829,50597,,BAO_0000218,,,Evaluated for distribution at 24 hours after intravenous administration in ovary of female Sprague Dawley rats,,,N,Intermediate,A,10116.0,CHEMBL626407,,992.0,Female gonad,,1,1
11830,50597,,BAO_0000218,,,Evaluated for distribution at 24 hours after intravenous administration in thyroid of female Sprague Dawley rats,,,N,Intermediate,A,10116.0,CHEMBL626408,,2046.0,Thyroid gland,,1,1
11831,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.07-0.09",,,N,Intermediate,A,10116.0,CHEMBL626409,,178.0,Blood,,1,1
11832,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.10-0.13",,,N,Intermediate,A,10116.0,CHEMBL626410,,178.0,Blood,,1,1
11833,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.18-0.24",,,N,Intermediate,A,10116.0,CHEMBL626411,,178.0,Blood,,1,1
11834,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.19-0.24",,,N,Intermediate,A,10116.0,CHEMBL626412,,178.0,Blood,,1,1
11835,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.22-0.32",,,N,Intermediate,A,10116.0,CHEMBL626413,,178.0,Blood,,1,1
11836,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.25-0.32",,,N,Intermediate,A,10116.0,CHEMBL626414,,178.0,Blood,,1,1
11837,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.10-0.14",,,N,Intermediate,A,10116.0,CHEMBL626415,,178.0,Blood,,1,1
11838,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.25-0.34",,,N,Intermediate,A,10116.0,CHEMBL626416,,178.0,Blood,,1,1
11839,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.27-0.33",,,N,Intermediate,A,10116.0,CHEMBL627062,,178.0,Blood,,1,1
11840,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.32-0.46",,,N,Intermediate,A,10116.0,CHEMBL627063,,178.0,Blood,,1,1
11841,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.40-0.45",,,N,Intermediate,A,10116.0,CHEMBL627064,,178.0,Blood,,1,1
11842,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.44-0.52",,,N,Intermediate,A,10116.0,CHEMBL627227,,178.0,Blood,,1,1
11843,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.08-0.09",,,N,Intermediate,A,10116.0,CHEMBL627228,,178.0,Blood,,1,1
11844,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.12-0.14",,,N,Intermediate,A,10116.0,CHEMBL627229,,178.0,Blood,,1,1
11845,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.13-0.15",,,N,Intermediate,A,10116.0,CHEMBL625792,,178.0,Blood,,1,1
11846,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.15-0.20",,,N,Intermediate,A,10116.0,CHEMBL625793,,178.0,Blood,,1,1
11847,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.15-0.23",,,N,Intermediate,A,10116.0,CHEMBL625794,,178.0,Blood,,1,1
11848,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.16-0.21",,,N,Intermediate,A,10116.0,CHEMBL625795,,178.0,Blood,,1,1
11849,50594,,BAO_0000218,,,Pharmacokinetic parameter AUC for the compound after intravenous administration into BALB/c Mice in plasma samples.,,,N,Intermediate,A,10090.0,CHEMBL625796,,,,,1,1
11850,50588,,BAO_0000218,,,Pharmacokinetic parameter AUC has been determined in fed Beagle dogs at a dose of 375 mg/kg,,,N,Intermediate,A,9615.0,CHEMBL625797,,,,,1,1
11851,50588,,BAO_0000218,,,Pharmacokinetic parameter AUC has been determined in fed Beagle dogs at a dose of 500 mg/kg,,,N,Intermediate,A,9615.0,CHEMBL625798,,,,,1,1
11852,22224,,BAO_0000218,,,Pharmacokinetic parameter AUC evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,,,U,Autocuration,A,,CHEMBL875613,,,,,0,1
11853,22224,,BAO_0000218,,,Pharmacokinetic parameter AUC was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,,,U,Autocuration,A,,CHEMBL625799,,,,,0,1
11854,22224,,BAO_0000218,,,Pharmacokinetic parameter AUC was evaluated in 10% PEG suspension at a dose of 20 mg/kg orally,,,U,Autocuration,A,,CHEMBL625800,,,,,0,1
11855,22224,,BAO_0000218,,,Pharmacokinetic parameter AUC was evaluated in 100% PEG solution at a dose of 20 mg/kg orally,,,U,Autocuration,A,,CHEMBL625801,,,,,0,1
11856,22224,,BAO_0000218,,,Pharmacokinetic parameter AUC was evaluated in DMA:H2O solution at a dose of 20 mg/kg orally,,,U,Autocuration,A,,CHEMBL625802,,,,,0,1
11857,22224,,BAO_0000218,,,Pharmacokinetic parameter AUC was evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,,,U,Autocuration,A,,CHEMBL625803,,,,,0,1
11858,22224,,BAO_0000019,,,Pharmacokinetic parameter AUC was evaluated in Hp-beta-CD solution,,,U,Autocuration,A,,CHEMBL625804,,,,,0,1
11859,22224,,BAO_0000218,,,Pharmacokinetic parameter AUC was evaluated in saline solution at a dose of 20 mg/kg orally,,,U,Autocuration,A,,CHEMBL622530,,,,,0,1
11860,50594,,BAO_0000218,,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice brain; AUC (mM.h); not detected,,,N,Intermediate,A,10090.0,CHEMBL622531,,,,,1,1
11861,50594,,BAO_0000218,,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),,,N,Intermediate,A,10090.0,CHEMBL622532,,,,,1,1
11862,50594,,BAO_0000218,,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),,,N,Intermediate,A,10090.0,CHEMBL623176,,,,,1,1
11863,50594,,BAO_0000218,,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice brain; AUC (mM.h),,,N,Intermediate,A,10090.0,CHEMBL623177,,,,,1,1
11864,50594,,BAO_0000218,,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),,,N,Intermediate,A,10090.0,CHEMBL623178,,,,,1,1
11865,50594,,BAO_0000218,,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration using FMAddA as substrate in mice brain; AUC 0-r (mM.h); not detected,,,N,Intermediate,A,10090.0,CHEMBL623179,,,,,1,1
11866,50594,,BAO_0000218,,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice brain; AUC (mM.h),,,N,Intermediate,A,10090.0,CHEMBL623180,,,,,1,1
11867,50594,,BAO_0000218,,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),,,N,Intermediate,A,10090.0,CHEMBL623181,,,,,1,1
11868,50594,,BAO_0000218,,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),,,N,Intermediate,A,10090.0,CHEMBL624131,,,,,1,1
11869,50594,,BAO_0000218,,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration using 2`-F-ara-ddI as substrate in mice serum; AUC (mM.h),,,N,Intermediate,A,10090.0,CHEMBL624132,,,,,1,1
11870,50594,,BAO_0000218,,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by oral administration in mice serum; AUC 0-r (mM.h),,,N,Intermediate,A,10090.0,CHEMBL624133,,,,,1,1
11871,50594,,BAO_0000218,,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h).,,,N,Intermediate,A,10090.0,CHEMBL624846,,,,,1,1
11872,50594,,BAO_0000218,,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by oral administration in mice serum.; AUC 0-r (mM.h),,,N,Intermediate,A,10090.0,CHEMBL624847,,,,,1,1
11873,50594,,BAO_0000218,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),,,N,Intermediate,A,10090.0,CHEMBL624848,,,,,1,1
11874,50594,,BAO_0000218,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),,,N,Intermediate,A,10090.0,CHEMBL625012,,,,,1,1
11875,50594,,BAO_0000218,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),,,N,Intermediate,A,10090.0,CHEMBL625013,,,,,1,1
11876,50594,,BAO_0000218,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice brain; AUC 0-r (mM.h); not detected,,,N,Intermediate,A,10090.0,CHEMBL625014,,,,,1,1
11877,50594,,BAO_0000218,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum; AUC (mM.h),,,N,Intermediate,A,10090.0,CHEMBL625015,,,,,1,1
11878,50594,,BAO_0000218,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum; AUC 0-r (mM.h),,,N,Intermediate,A,10090.0,CHEMBL625016,,,,,1,1
11879,50594,,BAO_0000218,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral in mice brain; AUC (mM.h); not detected,,,N,Intermediate,A,10090.0,CHEMBL625017,,,,,1,1
11880,50594,,BAO_0000218,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),,,N,Intermediate,A,10090.0,CHEMBL625018,,,,,1,1
11881,50594,,BAO_0000218,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration mice serum.; AUC 0-r (mM.h),,,N,Intermediate,A,10090.0,CHEMBL625019,,,,,1,1
11882,50594,,BAO_0000218,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice brain.; AUC 0-r (mM.h),,,N,Intermediate,A,10090.0,CHEMBL625020,,,,,1,1
11883,50594,,BAO_0000218,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum.,,,N,Intermediate,A,10090.0,CHEMBL625021,,,,,1,1
11884,50597,,BAO_0000218,,,Pharmacokinetic parameter [area under curve (AUC)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,,,N,Intermediate,A,10116.0,CHEMBL625022,,,,,1,1
11885,50594,,BAO_0000218,,,Pharmacokinetic parameter area under the curve (0-24 hr) for the compound was evaluated in nude mice after oral administration. ,,,N,Intermediate,A,10090.0,CHEMBL625023,,,,,1,1
11886,100710,,BAO_0000218,,,Pharmacokinetic parameter area under the curve (0-48 h) for the compound was evaluated in nude cynomolgus monkeys after oral administration,,,N,Intermediate,A,9541.0,CHEMBL625024,,,,,1,1
11887,100710,,BAO_0000218,,,Pharmacokinetic parameter area under the curve (0-48 h) for the compound was evaluated in nude cynomolgus monkeys after oral administration. ,,,N,Intermediate,A,9541.0,CHEMBL627626,,,,,1,1
11888,22224,,BAO_0000218,,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in brain,,,U,Autocuration,A,,CHEMBL627627,,955.0,Brain,,0,1
11889,22224,,BAO_0000218,,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in serum,,,U,Autocuration,A,,CHEMBL627628,,1977.0,Serum,,0,1
11890,22224,,BAO_0000218,,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in brain,,,U,Autocuration,A,,CHEMBL627629,,955.0,Brain,,0,1
11891,22224,,BAO_0000218,,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in serum,,,U,Autocuration,A,,CHEMBL627630,,1977.0,Serum,,0,1
11892,22224,,BAO_0000019,,,Pharmacokinetic parameter was evaluated which is represented as AUC when administered 5 mg/Kg orally; range (0.19-0.35),,,U,Autocuration,A,,CHEMBL627631,,,,,0,1
11893,22224,,BAO_0000218,,,Pharmacokinetic parameter was evaluated which is represented as AUC when administered 5 mg/kg intravenously; range (2.1-2.3),,,U,Autocuration,A,,CHEMBL629515,,,,,0,1
11894,50594,,BAO_0000218,,,In vivo biodistribution in mice spleen bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,,N,Intermediate,A,10090.0,CHEMBL629516,,2106.0,Spleen,,1,1
11895,50594,,BAO_0000218,,,In vivo biodistribution in mice spleen bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,,N,Intermediate,A,10090.0,CHEMBL629517,,2106.0,Spleen,,1,1
11896,50594,,BAO_0000218,,,In vivo biodistribution in mice spleen bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,,N,Intermediate,A,10090.0,CHEMBL629518,,2106.0,Spleen,,1,1
11897,50594,,BAO_0000218,,,In vivo biodistribution in mice tumor bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,,N,Intermediate,A,10090.0,CHEMBL877499,,,,,1,1
11898,50594,,BAO_0000218,,,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 20 ug/g,,,N,Intermediate,A,10090.0,CHEMBL629519,,,,,1,1
11899,50594,,BAO_0000218,,,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,,N,Intermediate,A,10090.0,CHEMBL629520,,,,,1,1
11900,50594,,BAO_0000218,,,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,,N,Intermediate,A,10090.0,CHEMBL629521,,,,,1,1
11901,50594,,BAO_0000218,,,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Heart (H) and Blood (B),,,N,Intermediate,A,10090.0,CHEMBL629522,,,,,1,1
11902,50594,,BAO_0000218,,,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Heart (H) and Lung (L),,,N,Intermediate,A,10090.0,CHEMBL629523,,,,,1,1
11903,50594,,BAO_0000218,,,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Tumor (T) and Muscle (M),,,N,Intermediate,A,10090.0,CHEMBL629524,,,,,1,1
11904,50594,,BAO_0000218,,,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Tumor (T) and blood (B),,,N,Intermediate,A,10090.0,CHEMBL629525,,,,,1,1
11905,50594,,BAO_0000218,,,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Heart (H) and Blood (B),,,N,Intermediate,A,10090.0,CHEMBL629526,,,,,1,1
11906,50594,,BAO_0000218,,,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Heart (H) and Lung (L),,,N,Intermediate,A,10090.0,CHEMBL629527,,,,,1,1
11907,50594,,BAO_0000218,,,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Tumor (T) and Muscle (M),,,N,Intermediate,A,10090.0,CHEMBL629528,,,,,1,1
11908,50594,,BAO_0000218,,,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Tumor (T) and blood (B),,,N,Intermediate,A,10090.0,CHEMBL629529,,,,,1,1
11909,50594,,BAO_0000218,,,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Heart (H) and Blood (B),,,N,Intermediate,A,10090.0,CHEMBL629530,,,,,1,1
11910,50594,,BAO_0000218,,,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Heart (H) and Lung (L),,,N,Intermediate,A,10090.0,CHEMBL629531,,,,,1,1
11911,50594,,BAO_0000218,,,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Tumor (T) and Muscle (M),,,N,Intermediate,A,10090.0,CHEMBL628656,,,,,1,1
11912,50594,,BAO_0000218,,,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Tumor (T) and blood (B),,,N,Intermediate,A,10090.0,CHEMBL628657,,,,,1,1
11913,50597,In vivo,BAO_0000218,,,"Biodistribution in abdominal Dawley rat after 30min, expressed as percent injected dose/g",,,N,Intermediate,A,10116.0,CHEMBL628658,,,,,1,1
11914,50597,In vivo,BAO_0000218,,,"Biodistribution in abdominal of mature female Dawley rat after 10min, expressed as percent injected dose/g",,,N,Intermediate,A,10116.0,CHEMBL628659,,,,,1,1
11915,50597,In vivo,BAO_0000218,,,"Biodistribution in abdominal of mature female Dawley rat after 15min, expressed as percent injected dose/g",,,N,Intermediate,A,10116.0,CHEMBL877500,,,,,1,1
11916,50597,In vivo,BAO_0000218,,,"Biodistribution in abdominal of mature female Dawley rat after 1h, expressed as percent injected dose/g",,,N,Intermediate,A,10116.0,CHEMBL628660,,,,,1,1
11917,50597,In vivo,BAO_0000218,,,"Biodistribution in abdominal of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,,N,Intermediate,A,10116.0,CHEMBL628661,,,,,1,1
11918,50597,In vivo,BAO_0000218,,,"Biodistribution in abdominal of mature female Dawley rat after 30min, expressed as percent injected dose/g",,,N,Intermediate,A,10116.0,CHEMBL628662,,,,,1,1
11919,50597,In vivo,BAO_0000218,,,"Biodistribution in abdominal of mature female Dawley rat after 45min, expressed as percent injected dose/g",,,N,Intermediate,A,10116.0,CHEMBL628663,,,,,1,1
11920,50597,In vivo,BAO_0000218,,,"Biodistribution in abdominal of mature female Dawley rat after 5min, expressed as percent injected dose/g",,,N,Intermediate,A,10116.0,CHEMBL628664,,,,,1,1
11921,50597,In vivo,BAO_0000218,,,"Biodistribution in blood of mature female Dawley rat after 10min, expressed as percent injected dose/g",,,N,Intermediate,A,10116.0,CHEMBL628665,,178.0,Blood,,1,1
11922,50597,In vivo,BAO_0000218,,,"Biodistribution in blood of mature female Dawley rat after 15min, expressed as percent injected dose/g",,,N,Intermediate,A,10116.0,CHEMBL628666,,178.0,Blood,,1,1
11923,50597,In vivo,BAO_0000218,,,"Biodistribution in blood of mature female Dawley rat after 1h, expressed as percent injected dose/g",,,N,Intermediate,A,10116.0,CHEMBL628667,,178.0,Blood,,1,1
11924,50597,In vivo,BAO_0000218,,,"Biodistribution in blood of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,,N,Intermediate,A,10116.0,CHEMBL628668,,178.0,Blood,,1,1
11925,50597,In vivo,BAO_0000218,,,"Biodistribution in blood of mature female Dawley rat after 30min, expressed as percent injected dose/g",,,N,Intermediate,A,10116.0,CHEMBL628669,,178.0,Blood,,1,1
11926,50597,In vivo,BAO_0000218,,,"Biodistribution in blood of mature female Dawley rat after 45min, expressed as percent injected dose/g",,,N,Intermediate,A,10116.0,CHEMBL628670,,178.0,Blood,,1,1
11927,50597,In vivo,BAO_0000218,,,"Biodistribution in blood of mature female Dawley rat after 5min, expressed as percent injected dose/g",,,N,Intermediate,A,10116.0,CHEMBL628671,,178.0,Blood,,1,1
11928,50597,In vivo,BAO_0000218,,,"Biodistribution in bone of mature female Dawley rat after 10min, expressed as percent injected dose/g",,,N,Intermediate,A,10116.0,CHEMBL628672,,10000001.0,Bone,,1,1
11929,50597,In vivo,BAO_0000218,,,"Biodistribution in bone of mature female Dawley rat after 1h, expressed as percent injected dose/g",,,N,Intermediate,A,10116.0,CHEMBL630300,,10000001.0,Bone,,1,1
11930,50597,In vivo,BAO_0000218,,,"Biodistribution in bone of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,,N,Intermediate,A,10116.0,CHEMBL629787,,10000001.0,Bone,,1,1
11931,50597,In vivo,BAO_0000218,,,"Biodistribution in bone of mature female Dawley rat after 30min, expressed as percent injected dose/g",,,N,Intermediate,A,10116.0,CHEMBL629788,,10000001.0,Bone,,1,1
11932,50597,In vivo,BAO_0000218,,,"Biodistribution in brain of mature female Dawley rat after 10min, expressed as percent injected dose/g",,,N,Intermediate,A,10116.0,CHEMBL629789,,955.0,Brain,,1,1
11933,50597,In vivo,BAO_0000218,,,"Biodistribution in brain of mature female Dawley rat after 15min, expressed as percent injected dose/g",,,N,Intermediate,A,10116.0,CHEMBL629790,,955.0,Brain,,1,1
11934,50597,In vivo,BAO_0000218,,,"Biodistribution in brain of mature female Dawley rat after 1h, expressed as percent injected dose/g",,,N,Intermediate,A,10116.0,CHEMBL629791,,955.0,Brain,,1,1
11935,50597,In vivo,BAO_0000218,,,"Biodistribution in brain of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,,N,Intermediate,A,10116.0,CHEMBL629792,,955.0,Brain,,1,1
11936,50597,In vivo,BAO_0000218,,,"Biodistribution in brain of mature female Dawley rat after 30min, expressed as percent injected dose/g",,,N,Intermediate,A,10116.0,CHEMBL629793,,955.0,Brain,,1,1
11937,50597,In vivo,BAO_0000218,,,"Biodistribution in brain of mature female Dawley rat after 45min, expressed as percent injected dose/g",,,N,Intermediate,A,10116.0,CHEMBL629794,,955.0,Brain,,1,1
11938,50597,,BAO_0000218,,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 2-3 hr time,,,N,Intermediate,A,10116.0,CHEMBL874459,,,,,1,1
11939,50597,,BAO_0000218,,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 3-4 hr time,,,N,Intermediate,A,10116.0,CHEMBL629795,,,,,1,1
11940,50597,,BAO_0000218,,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 4-5 hr time,,,N,Intermediate,A,10116.0,CHEMBL629796,,,,,1,1
11941,50597,,BAO_0000218,,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 5-6 hr time,,,N,Intermediate,A,10116.0,CHEMBL629797,,,,,1,1
11942,50597,,BAO_0000218,,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 6-24 h time,,,N,Intermediate,A,10116.0,CHEMBL629798,,,,,1,1
11943,50597,In vivo,BAO_0000218,,,Biodistribution studied in the adrenals of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,,N,Intermediate,A,10116.0,CHEMBL629799,,2369.0,Adrenal gland,,1,1
11944,50597,In vivo,BAO_0000218,,,Biodistribution studied in the adrenals of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,,N,Intermediate,A,10116.0,CHEMBL629800,,2369.0,Adrenal gland,,1,1
11945,50597,In vivo,BAO_0000218,,,Biodistribution studied in the adrenals of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,,N,Intermediate,A,10116.0,CHEMBL629801,,2369.0,Adrenal gland,,1,1
11946,50597,In vivo,BAO_0000218,,,Biodistribution studied in the adrenals of immature Fischer female rats at 5 hour,,,N,Intermediate,A,10116.0,CHEMBL629802,,2369.0,Adrenal gland,,1,1
11947,50597,In vivo,BAO_0000218,,,Biodistribution studied in the adrenals of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,,N,Intermediate,A,10116.0,CHEMBL629803,,2369.0,Adrenal gland,,1,1
11948,50597,In vivo,BAO_0000218,,,Biodistribution studied in the blood of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,,N,Intermediate,A,10116.0,CHEMBL629804,,178.0,Blood,,1,1
11949,50597,In vivo,BAO_0000218,,,Biodistribution studied in the blood of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,,N,Intermediate,A,10116.0,CHEMBL629805,,178.0,Blood,,1,1
11950,50597,In vivo,BAO_0000218,,,Biodistribution studied in the blood of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,,,N,Intermediate,A,10116.0,CHEMBL629806,,178.0,Blood,,1,1
11951,50597,In vivo,BAO_0000218,,,Biodistribution studied in the blood of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,,N,Intermediate,A,10116.0,CHEMBL629807,,178.0,Blood,,1,1
11952,50597,In vivo,BAO_0000218,,,Biodistribution studied in the blood of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,,N,Intermediate,A,10116.0,CHEMBL629808,,178.0,Blood,,1,1
11953,50597,In vivo,BAO_0000218,,,Biodistribution studied in the brain of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,,N,Intermediate,A,10116.0,CHEMBL629809,,955.0,Brain,,1,1
11954,50597,In vivo,BAO_0000218,,,Biodistribution studied in the brain of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,,N,Intermediate,A,10116.0,CHEMBL629810,,955.0,Brain,,1,1
11955,50597,In vivo,BAO_0000218,,,Biodistribution studied in the brain of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,,,N,Intermediate,A,10116.0,CHEMBL629811,,955.0,Brain,,1,1
11956,50597,In vivo,BAO_0000218,,,Biodistribution studied in the brain of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,,N,Intermediate,A,10116.0,CHEMBL629812,,955.0,Brain,,1,1
11957,50597,In vivo,BAO_0000218,,,Biodistribution studied in the brain of immature Fischer female rats at 5 hou; activity is expressed as inductive dose / gram,,,N,Intermediate,A,10116.0,CHEMBL629813,,955.0,Brain,,1,1
11958,50597,In vivo,BAO_0000218,,,Biodistribution studied in the brain of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,,N,Intermediate,A,10116.0,CHEMBL874460,,955.0,Brain,,1,1
11959,50597,In vivo,BAO_0000218,,,Biodistribution studied in the fat of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,,N,Intermediate,A,10116.0,CHEMBL629814,,,,,1,1
11960,50597,In vivo,BAO_0000218,,,Biodistribution studied in the fat of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,,N,Intermediate,A,10116.0,CHEMBL629815,,,,,1,1
11961,50597,In vivo,BAO_0000218,,,Biodistribution studied in the fat of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,,N,Intermediate,A,10116.0,CHEMBL629816,,,,,1,1
11962,50597,In vivo,BAO_0000218,,,Biodistribution studied in the fat of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,,N,Intermediate,A,10116.0,CHEMBL629817,,,,,1,1
11963,50597,In vivo,BAO_0000218,,,Biodistribution studied in the kidneys of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,,N,Intermediate,A,10116.0,CHEMBL626643,,2113.0,Kidney,,1,1
11964,50597,In vivo,BAO_0000218,,,Biodistribution studied in the kidneys of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,,N,Intermediate,A,10116.0,CHEMBL626644,,2113.0,Kidney,,1,1
11965,50597,In vivo,BAO_0000218,,,Biodistribution studied in the kidneys of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,,N,Intermediate,A,10116.0,CHEMBL626806,,2113.0,Kidney,,1,1
11966,50597,In vivo,BAO_0000218,,,Biodistribution studied in the kidneys of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,,N,Intermediate,A,10116.0,CHEMBL626807,,2113.0,Kidney,,1,1
11967,50597,In vivo,BAO_0000218,,,Biodistribution studied in the liver of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,,N,Intermediate,A,10116.0,CHEMBL627261,,2107.0,Liver,,1,1
11968,50597,In vivo,BAO_0000218,,,Biodistribution studied in the liver of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,,N,Intermediate,A,10116.0,CHEMBL627262,,2107.0,Liver,,1,1
11969,50597,In vivo,BAO_0000218,,,Biodistribution studied in the liver of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,,N,Intermediate,A,10116.0,CHEMBL627263,,2107.0,Liver,,1,1
11970,50597,In vivo,BAO_0000218,,,Biodistribution studied in the liver of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,,N,Intermediate,A,10116.0,CHEMBL627264,,2107.0,Liver,,1,1
11971,50597,In vivo,BAO_0000218,,,Biodistribution studied in the lungs of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,,N,Intermediate,A,10116.0,CHEMBL627265,,2048.0,Lung,,1,1
11972,50597,In vivo,BAO_0000218,,,Biodistribution studied in the lungs of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,,N,Intermediate,A,10116.0,CHEMBL627266,,2048.0,Lung,,1,1
11973,50597,In vivo,BAO_0000218,,,Biodistribution studied in the lungs of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,,N,Intermediate,A,10116.0,CHEMBL627267,,2048.0,Lung,,1,1
11974,50597,In vivo,BAO_0000218,,,Biodistribution studied in the lungs of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,,N,Intermediate,A,10116.0,CHEMBL627268,,2048.0,Lung,,1,1
11975,50597,In vivo,BAO_0000218,,,Biodistribution studied in the muscle of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,,N,Intermediate,A,10116.0,CHEMBL627269,,2385.0,Muscle tissue,,1,1
11976,50597,In vivo,BAO_0000218,,,Biodistribution studied in the muscle of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,,N,Intermediate,A,10116.0,CHEMBL627270,,2385.0,Muscle tissue,,1,1
11977,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 0.95-1.44",,,N,Intermediate,A,10116.0,CHEMBL627271,,,,,1,1
11978,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 1.39-2.43",,,N,Intermediate,A,10116.0,CHEMBL627946,,,,,1,1
11979,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.47-2.96",,,N,Intermediate,A,10116.0,CHEMBL875472,,,,,1,1
11980,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.67-3.69",,,N,Intermediate,A,10116.0,CHEMBL627947,,,,,1,1
11981,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.67-4.31",,,N,Intermediate,A,10116.0,CHEMBL627948,,,,,1,1
11982,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 3.17-4.70",,,N,Intermediate,A,10116.0,CHEMBL628113,,,,,1,1
11983,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration.; dose/g, range 2.20-2.97",,,N,Intermediate,A,10116.0,CHEMBL628114,,,,,1,1
11984,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 0.90-1.46",,,N,Intermediate,A,10116.0,CHEMBL628115,,,,,1,1
11985,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.72-3.52",,,N,Intermediate,A,10116.0,CHEMBL628116,,,,,1,1
11986,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.78-3.62",,,N,Intermediate,A,10116.0,CHEMBL628117,,,,,1,1
11987,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.82-3.86",,,N,Intermediate,A,10116.0,CHEMBL628118,,,,,1,1
11988,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 3.80-5.74",,,N,Intermediate,A,10116.0,CHEMBL628119,,,,,1,1
11989,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 1.05-1.57",,,N,Intermediate,A,10116.0,CHEMBL628120,,,,,1,1
11990,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 1.93-3.58",,,N,Intermediate,A,10116.0,CHEMBL628121,,,,,1,1
11991,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 2.88-4.32",,,N,Intermediate,A,10116.0,CHEMBL628122,,,,,1,1
11992,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3-3.70",,,N,Intermediate,A,10116.0,CHEMBL627297,,,,,1,1
11993,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3.21-3.92",,,N,Intermediate,A,10116.0,CHEMBL627298,,,,,1,1
11994,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3.51-5.44",,,N,Intermediate,A,10116.0,CHEMBL627299,,,,,1,1
11995,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 0.24-0.31",,,N,Intermediate,A,10116.0,CHEMBL627300,,,,,1,1
11996,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 10.5-14.4",,,N,Intermediate,A,10116.0,CHEMBL627301,,,,,1,1
11997,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 6.28-7.41",,,N,Intermediate,A,10116.0,CHEMBL627302,,,,,1,1
11998,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 6.47-10.2",,,N,Intermediate,A,10116.0,CHEMBL627303,,,,,1,1
11999,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 7.21-7.95",,,N,Intermediate,A,10116.0,CHEMBL627304,,,,,1,1
12000,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 8.28-10.72",,,N,Intermediate,A,10116.0,CHEMBL627305,,,,,1,1
12001,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 1.04-2.56",,,N,Intermediate,A,10116.0,CHEMBL627306,,,,,1,1
12002,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 10.7-16.9",,,N,Intermediate,A,10116.0,CHEMBL623982,,,,,1,1
12003,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 11.7-14.6",,,N,Intermediate,A,10116.0,CHEMBL623983,,,,,1,1
12004,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 14.4-20.1",,,N,Intermediate,A,10116.0,CHEMBL623984,,,,,1,1
12005,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 4.78-9.72",,,N,Intermediate,A,10116.0,CHEMBL623985,,,,,1,1
12006,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 9.87-11.9",,,N,Intermediate,A,10116.0,CHEMBL623986,,,,,1,1
12007,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 0.17-0.25",,,N,Intermediate,A,10116.0,CHEMBL623987,,,,,1,1
12008,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 3.33-4.68",,,N,Intermediate,A,10116.0,CHEMBL623988,,,,,1,1
12009,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 4.59-8.81",,,N,Intermediate,A,10116.0,CHEMBL623989,,,,,1,1
12010,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 4.62-5.60",,,N,Intermediate,A,10116.0,CHEMBL622215,,,,,1,1
12011,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 5.02-6.57",,,N,Intermediate,A,10116.0,CHEMBL622216,,,,,1,1
12012,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 5.67-8.41",,,N,Intermediate,A,10116.0,CHEMBL877481,,,,,1,1
12013,22224,,BAO_0000218,,,Pharmacokinetic parameter was evaluated which is represented as AUC when administered orally a dose of 5 mg/kg; range (4.2-8.8),,,U,Autocuration,A,,CHEMBL622217,,,,,0,1
12014,50594,,BAO_0000218,,,Pharmacokinetic parameters was measured at 55 mg/kg dose by oral administration in mice serum.; AUC 0-r (mM.h),,,N,Intermediate,A,10090.0,CHEMBL622218,,,,,1,1
12015,50597,,BAO_0000218,,,Pharmacokinetic profile AUC was evaluated in rats,,,N,Intermediate,A,10116.0,CHEMBL622219,,,,,1,1
12016,22224,,BAO_0000019,,,Pharmacokinetic property (Area under curve),,,U,Autocuration,A,,CHEMBL622220,,,,,0,1
12017,50588,,BAO_0000218,,,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration in dog (25 mg/kg).",,,N,Intermediate,A,9615.0,CHEMBL622221,,,,,1,1
12018,50594,,BAO_0000218,,,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration in mice (50 mg/kg).",,,N,Intermediate,A,10090.0,CHEMBL622222,,,,,1,1
12019,50588,,BAO_0000218,,,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration to dog (25 mg/kg).",,,N,Intermediate,A,9615.0,CHEMBL622223,,,,,1,1
12020,50594,,BAO_0000218,,,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration to mice (50 mg/kg).",,,N,Intermediate,A,10090.0,CHEMBL622224,,,,,1,1
12021,22224,,BAO_0000019,,,Plasma concentration (AUC) was determined,,,U,Autocuration,A,,CHEMBL622225,,,,,0,1
12022,22224,,BAO_0000019,,,Plasma concentration (AUC) was determined; Not detectable,,,U,Autocuration,A,,CHEMBL622226,,,,,0,1
12023,50512,,BAO_0000218,,,Prolongation of time to collapse in guinea pig treated with aerosolized histamine was measured in vivo as area under curve (AUC),,,N,Intermediate,A,10141.0,CHEMBL624154,,,,,1,1
12024,50597,,BAO_0000218,,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL624155,,,,,1,1
12025,50597,,BAO_0000218,,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg; Not significant,,,N,Intermediate,A,10116.0,CHEMBL624156,,,,,1,1
12026,50597,,BAO_0000218,,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 60 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL624157,,,,,1,1
12027,50597,,BAO_0000218,,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 7.5 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL624158,,,,,1,1
12028,50597,,BAO_0000218,,,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 1,,,N,Intermediate,A,10116.0,CHEMBL624159,,,,,1,1
12029,50597,,BAO_0000218,,,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 2,,,N,Intermediate,A,10116.0,CHEMBL624160,,,,,1,1
12030,50597,,BAO_0000218,,,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 3,,,N,Intermediate,A,10116.0,CHEMBL624161,,,,,1,1
12031,50597,,BAO_0000218,,,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 4,,,N,Intermediate,A,10116.0,CHEMBL624162,,,,,1,1
12032,50588,,BAO_0000218,,,Tested for pharmacokinetic parameter in fasted Beagle dogs (Area Under Curve value) iv administration.,,,N,Intermediate,A,9615.0,CHEMBL624163,,,,,1,1
12033,50597,,BAO_0000218,,,"The AUC(0-infinitive) value in female wistar rat at 100 mg/kg, p.o. dose",,,N,Intermediate,A,10116.0,CHEMBL624164,,,,,1,1
12034,50597,,BAO_0000218,,,The AUC(0-infinity) values in female wistar rats.,,,N,Intermediate,A,10116.0,CHEMBL624165,,,,,1,1
12035,50597,,BAO_0000218,,,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose",,,N,Intermediate,A,10116.0,CHEMBL624166,,,,,1,1
12036,50597,,BAO_0000218,,,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose in mice",,,N,Intermediate,A,10116.0,CHEMBL624167,,,,,1,1
12037,50597,,BAO_0000218,,,The AUC(0-t)values in female wistar rats.,,,N,Intermediate,A,10116.0,CHEMBL624168,,,,,1,1
12038,50597,,BAO_0000218,,,The Area under the concentration time curve of compound was measured on rats,,,N,Intermediate,A,10116.0,CHEMBL624169,,,,,1,1
12039,50587,,BAO_0000218,,,The area under curve (100 mg/kg) administered orally in humans,,,N,Intermediate,A,9606.0,CHEMBL624170,,,,,1,1
12040,22224,,BAO_0000218,,,The area under curve (12.5 mg/kg) administered intravenously in marmoset,,,U,Autocuration,A,9481.0,CHEMBL624171,,,,,0,1
12041,22224,,BAO_0000218,,,The area under curve (12.5 mg/kg) administered intravenously in monkey,,,U,Autocuration,A,314293.0,CHEMBL624172,,,,,0,1
12042,50588,,BAO_0000218,,,The area under curve (15 mg/kg) administered intravenously in dog,,,N,Intermediate,A,9615.0,CHEMBL624173,,,,,1,1
12043,50587,,BAO_0000218,,,The area under curve (200 mg/kg) administered orally in humans,,,N,Intermediate,A,9606.0,CHEMBL877488,,,,,1,1
12044,50597,,BAO_0000218,,,The area under curve (25 mg/kg) administered intravenously in rat,,,N,Intermediate,A,10116.0,CHEMBL624174,,,,,1,1
12045,22224,,BAO_0000218,,,The area under curve (25 mg/kg) administered orally in marmoset,,,U,Autocuration,A,9481.0,CHEMBL624175,,,,,0,1
12046,22224,,BAO_0000218,,,The area under curve (25 mg/kg) administered orally in monkey,,,U,Autocuration,A,314293.0,CHEMBL624176,,,,,0,1
12047,50588,,BAO_0000218,,,The area under curve (30 mg/kg) administered orally in dog,,,N,Intermediate,A,9615.0,CHEMBL624177,,,,,1,1
12048,50587,,BAO_0000218,,,The area under curve (400 mg/kg) administered orally in humans,,,N,Intermediate,A,9606.0,CHEMBL624178,,,,,1,1
12049,50597,,BAO_0000218,,,The area under curve (50 mg/kg) administered orally in fasted rat,,,N,Intermediate,A,10116.0,CHEMBL624179,,,,,1,1
12050,50597,,BAO_0000218,,,The area under curve (50 mg/kg) administered orally in rat,,,N,Intermediate,A,10116.0,CHEMBL627689,,,,,1,1
12051,50587,,BAO_0000218,,,The area under curve (800 mg/kg) administered orally in humans,,,N,Intermediate,A,9606.0,CHEMBL627690,,,,,1,1
12052,22224,,BAO_0000019,,,The compound was evaluated for area under the curve,,,U,Autocuration,A,,CHEMBL627691,,,,,0,1
12053,22224,,BAO_0000019,,,The compound was evaluated for area under the curve in marmosets,,,U,Autocuration,A,9481.0,CHEMBL627692,,,,,0,1
12054,22224,,BAO_0000019,,,The compound was evaluated for area under the curve in marmosets,,,U,Autocuration,A,9481.0,CHEMBL627693,,,,,0,1
12055,50597,,BAO_0000218,,,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,,,N,Intermediate,A,10116.0,CHEMBL627694,,,,,1,1
12056,50597,,BAO_0000218,,,The compound was tested for the area of the change in MABP versus time curve at dose 10 mg/kg (po) in conscious spontaneously hypertensive rat,,,N,Intermediate,A,10116.0,CHEMBL627695,,,,,1,1
12057,22224,,BAO_0000218,,,The compound was tested for the area of the change in MABP versus time curve at dose 10 mg/kg (po),,,U,Autocuration,A,,CHEMBL627696,,,,,0,1
12058,50597,,BAO_0000218,,,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,,,N,Intermediate,A,10116.0,CHEMBL627697,,,,,1,1
12059,50597,,BAO_0000218,,,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,,,N,Intermediate,A,10116.0,CHEMBL627698,,,,,1,1
12060,50597,,BAO_0000218,,,The compound was tested for the area of the change in MABP versus time curve at dose 5 mg/kg (po) in conscious spontaneously hypertensive rat,,,N,Intermediate,A,10116.0,CHEMBL627699,,,,,1,1
12061,50597,,BAO_0000218,,,Total absorption was estimated by area under curve (AUC) after intravenous administration in rat,,,N,Intermediate,A,10116.0,CHEMBL627700,,,,,1,1
12062,50597,,BAO_0000218,,,Total drug exposure is determined after oral dosing in rats.,,,N,Intermediate,A,10116.0,CHEMBL627701,,,,,1,1
12063,22224,,BAO_0000218,,,Total drug exposure (5 mg/kg) when administered intravenously,,,U,Autocuration,A,,CHEMBL627702,,,,,0,1
12064,22224,,BAO_0000218,,,Total drug exposure (5 mg/kg) when administered orally,,,U,Autocuration,A,,CHEMBL627703,,,,,0,1
12065,22224,,BAO_0000218,,,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.01 mg/kg) in monkey,,,U,Autocuration,A,314293.0,CHEMBL626873,,,,,0,1
12066,50597,,BAO_0000218,,,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.05 mg/kg) in rat,,,N,Intermediate,A,10116.0,CHEMBL629583,,,,,1,1
12067,50588,,BAO_0000218,,,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.1 mg/kg) in dog,,,N,Intermediate,A,9615.0,CHEMBL629584,,,,,1,1
12068,50588,,BAO_0000218,,,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in dog,,,N,Intermediate,A,9615.0,CHEMBL629585,,,,,1,1
12069,50597,In vivo,BAO_0000218,,,"Biodistribution in brain of mature female Dawley rat after 5min, expressed as percent injected dose/g",,,N,Intermediate,A,10116.0,CHEMBL629586,,955.0,Brain,,1,1
12070,50597,In vivo,BAO_0000218,,,"Biodistribution in brain of mature female Dawley rat after 30min, expressed as percent injected dose/g",,,N,Intermediate,A,10116.0,CHEMBL629587,,955.0,Brain,,1,1
12071,50597,In vivo,BAO_0000218,,,"Biodistribution in fat of mature female Dawley rat after 10min, expressed as percent injected dose/g",,,N,Intermediate,A,10116.0,CHEMBL629588,,,,,1,1
12072,50597,In vivo,BAO_0000218,,,"Biodistribution in fat of mature female Dawley rat after 15min, expressed as percent injected dose/g",,,N,Intermediate,A,10116.0,CHEMBL629589,,,,,1,1
12073,50597,In vivo,BAO_0000218,,,"Biodistribution in fat of mature female Dawley rat after 1h, expressed as percent injected dose/g",,,N,Intermediate,A,10116.0,CHEMBL629590,,,,,1,1
12074,50597,In vivo,BAO_0000218,,,"Biodistribution in fat of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,,N,Intermediate,A,10116.0,CHEMBL629591,,,,,1,1
12075,50597,In vivo,BAO_0000218,,,"Biodistribution in fat of mature female Dawley rat after 30min, expressed as percent injected dose/g",,,N,Intermediate,A,10116.0,CHEMBL629592,,,,,1,1
12076,50597,In vivo,BAO_0000218,,,"Biodistribution in fat of mature female Dawley rat after 45min, expressed as percent injected dose/g",,,N,Intermediate,A,10116.0,CHEMBL629593,,,,,1,1
12077,50597,In vivo,BAO_0000218,,,"Biodistribution in fat of mature female Dawley rat after 5min, expressed as percent injected dose/g",,,N,Intermediate,A,10116.0,CHEMBL629594,,,,,1,1
12078,50597,In vivo,BAO_0000218,,,"Biodistribution in heart of mature female Dawley rat after 10min, expressed as percent injected dose/g",,,N,Intermediate,A,10116.0,CHEMBL629595,,948.0,Heart,,1,1
12079,50597,In vivo,BAO_0000218,,,"Biodistribution in heart of mature female Dawley rat after 15min, expressed as percent injected dose/g",,,N,Intermediate,A,10116.0,CHEMBL630290,,948.0,Heart,,1,1
12080,50597,In vivo,BAO_0000218,,,"Biodistribution in heart of mature female Dawley rat after 1h, expressed as percent injected dose/g",,,N,Intermediate,A,10116.0,CHEMBL627137,,948.0,Heart,,1,1
12081,50597,In vivo,BAO_0000218,,,"Biodistribution in heart of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,,N,Intermediate,A,10116.0,CHEMBL627138,,948.0,Heart,,1,1
12082,50597,In vivo,BAO_0000218,,,"Biodistribution in heart of mature female Dawley rat after 30min, expressed as percent injected dose/g",,,N,Intermediate,A,10116.0,CHEMBL627139,,948.0,Heart,,1,1
12083,50597,In vivo,BAO_0000218,,,"Biodistribution in heart of mature female Dawley rat after 45min, expressed as percent injected dose/g",,,N,Intermediate,A,10116.0,CHEMBL627140,,948.0,Heart,,1,1
12084,50597,In vivo,BAO_0000218,,,"Biodistribution in heart of mature female Dawley rat after 5min, expressed as percent injected dose/g",,,N,Intermediate,A,10116.0,CHEMBL627141,,948.0,Heart,,1,1
12085,50597,In vivo,BAO_0000218,,,"Biodistribution in kidney of mature female Dawley rat after 10min, expressed as percent injected dose/g",,,N,Intermediate,A,10116.0,CHEMBL627142,,2113.0,Kidney,,1,1
12086,50597,In vivo,BAO_0000218,,,"Biodistribution in kidney of mature female Dawley rat after 15min, expressed as percent injected dose/g",,,N,Intermediate,A,10116.0,CHEMBL627143,,2113.0,Kidney,,1,1
12087,50597,In vivo,BAO_0000218,,,"Biodistribution in kidney of mature female Dawley rat after 1h, expressed as percent injected dose/g",,,N,Intermediate,A,10116.0,CHEMBL874449,,2113.0,Kidney,,1,1
12088,50597,In vivo,BAO_0000218,,,"Biodistribution in kidney of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,,N,Intermediate,A,10116.0,CHEMBL627144,,2113.0,Kidney,,1,1
12089,50597,In vivo,BAO_0000218,,,"Biodistribution in kidney of mature female Dawley rat after 30min, expressed as percent injected dose/g",,,N,Intermediate,A,10116.0,CHEMBL627145,,2113.0,Kidney,,1,1
12090,50597,In vivo,BAO_0000218,,,"Biodistribution in kidney of mature female Dawley rat after 45min, expressed as percent injected dose/g",,,N,Intermediate,A,10116.0,CHEMBL627146,,2113.0,Kidney,,1,1
12091,50597,In vivo,BAO_0000218,,,"Biodistribution in kidney of mature female Dawley rat after 5min, expressed as percent injected dose/g",,,N,Intermediate,A,10116.0,CHEMBL627147,,2113.0,Kidney,,1,1
12092,50597,In vivo,BAO_0000218,,,"Biodistribution in liver of mature female Dawley rat after 10min, expressed as percent injected dose/g",,,N,Intermediate,A,10116.0,CHEMBL627148,,2107.0,Liver,,1,1
12093,50597,In vivo,BAO_0000218,,,"Biodistribution in lung of mature female Dawley rat after 10min, expressed as percent injected dose/g",,,N,Intermediate,A,10116.0,CHEMBL627149,,2048.0,Lung,,1,1
12094,50597,In vivo,BAO_0000218,,,"Biodistribution in lung of mature female Dawley rat after 15min, expressed as percent injected dose/g",,,N,Intermediate,A,10116.0,CHEMBL632160,,2048.0,Lung,,1,1
12095,50597,In vivo,BAO_0000218,,,"Biodistribution in lung of mature female Dawley rat after 1h, expressed as percent injected dose/g",,,N,Intermediate,A,10116.0,CHEMBL632161,,2048.0,Lung,,1,1
12096,50597,In vivo,BAO_0000218,,,"Biodistribution in lung of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,,N,Intermediate,A,10116.0,CHEMBL632162,,2048.0,Lung,,1,1
12097,50597,In vivo,BAO_0000218,,,"Biodistribution in lung of mature female Dawley rat after 30min, expressed as percent injected dose/g",,,N,Intermediate,A,10116.0,CHEMBL632163,,2048.0,Lung,,1,1
12098,50597,In vivo,BAO_0000218,,,"Biodistribution in lung of mature female Dawley rat after 45min, expressed as percent injected dose/g",,,N,Intermediate,A,10116.0,CHEMBL874469,,2048.0,Lung,,1,1
12099,50597,In vivo,BAO_0000218,,,"Biodistribution in lung of mature female Dawley rat after 5min, expressed as percent injected dose/g",,,N,Intermediate,A,10116.0,CHEMBL627182,,2048.0,Lung,,1,1
12100,50597,In vivo,BAO_0000218,,,"Biodistribution in muscle of mature female Dawley rat after 10min, expressed as percent injected dose/g",,,N,Intermediate,A,10116.0,CHEMBL627183,,2385.0,Muscle tissue,,1,1
12101,50597,In vivo,BAO_0000218,,,"Biodistribution in muscle of mature female Dawley rat after 15min, expressed as percent injected dose/g",,,N,Intermediate,A,10116.0,CHEMBL627184,,2385.0,Muscle tissue,,1,1
12102,50597,In vivo,BAO_0000218,,,"Biodistribution in muscle of mature female Dawley rat after 1h, expressed as percent injected dose/g",,,N,Intermediate,A,10116.0,CHEMBL627185,,2385.0,Muscle tissue,,1,1
12103,50597,In vivo,BAO_0000218,,,"Biodistribution in muscle of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,,N,Intermediate,A,10116.0,CHEMBL627186,,2385.0,Muscle tissue,,1,1
12104,50597,In vivo,BAO_0000218,,,"Biodistribution in muscle of mature female Dawley rat after 30min, expressed as percent injected dose/g",,,N,Intermediate,A,10116.0,CHEMBL627187,,2385.0,Muscle tissue,,1,1
12105,50597,In vivo,BAO_0000218,,,"Biodistribution in muscle of mature female Dawley rat after 45min, expressed as percent injected dose/g",,,N,Intermediate,A,10116.0,CHEMBL627188,,2385.0,Muscle tissue,,1,1
12106,50597,In vivo,BAO_0000218,,,"Biodistribution in muscle of mature female Dawley rat after 5min, expressed as percent injected dose/g",,,N,Intermediate,A,10116.0,CHEMBL627189,,2385.0,Muscle tissue,,1,1
12107,50597,In vivo,BAO_0000218,,,"Biodistribution inl ilver of mature female Dawley rat after 30min, expressed as percent injected dose/g",,,N,Intermediate,A,10116.0,CHEMBL627190,,,,,1,1
12108,50597,In vivo,BAO_0000218,,,"Biodistribution inl iver of mature female Dawley rat after 15min, expressed as percent injected dose/g",,,N,Intermediate,A,10116.0,CHEMBL627191,,2107.0,Liver,,1,1
12109,50597,In vivo,BAO_0000218,,,"Biodistribution inl iver of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,,N,Intermediate,A,10116.0,CHEMBL627192,,2107.0,Liver,,1,1
12110,50597,In vivo,BAO_0000218,,,"Biodistribution inl iver of mature female Dawley rat after 5min, expressed as percent injected dose/g",,,N,Intermediate,A,10116.0,CHEMBL627193,,2107.0,Liver,,1,1
12111,50597,In vivo,BAO_0000218,,,Biodistribution studied in the muscle of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,,,N,Intermediate,A,10116.0,CHEMBL874590,,2385.0,Muscle tissue,,1,1
12112,50597,In vivo,BAO_0000218,,,Biodistribution studied in the muscle of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,,N,Intermediate,A,10116.0,CHEMBL627194,,2385.0,Muscle tissue,,1,1
12113,50597,In vivo,BAO_0000218,,,Biodistribution studied in the muscle of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,,N,Intermediate,A,10116.0,CHEMBL627195,,2385.0,Muscle tissue,,1,1
12114,50597,In vivo,BAO_0000218,,,Biodistribution studied in the ovaries of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,,N,Intermediate,A,10116.0,CHEMBL627196,,992.0,Female gonad,,1,1
12115,50597,In vivo,BAO_0000218,,,Biodistribution studied in the ovaries of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,,N,Intermediate,A,10116.0,CHEMBL627197,,992.0,Female gonad,,1,1
12116,50597,In vivo,BAO_0000218,,,Biodistribution studied in the ovaries of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,,N,Intermediate,A,10116.0,CHEMBL627198,,992.0,Female gonad,,1,1
12117,50597,In vivo,BAO_0000218,,,Biodistribution studied in the ovaries of immature Fischer female rats at 5 hour,,,N,Intermediate,A,10116.0,CHEMBL627199,,992.0,Female gonad,,1,1
12118,50597,In vivo,BAO_0000218,,,Biodistribution studied in the ovaries of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,,N,Intermediate,A,10116.0,CHEMBL627200,,992.0,Female gonad,,1,1
12119,50597,In vivo,BAO_0000218,,,Biodistribution studied in the plasma of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,,N,Intermediate,A,10116.0,CHEMBL627201,,1969.0,Plasma,,1,1
12120,50597,In vivo,BAO_0000218,,,Biodistribution studied in the plasma of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,,N,Intermediate,A,10116.0,CHEMBL627202,,1969.0,Plasma,,1,1
12121,50597,In vivo,BAO_0000218,,,Biodistribution studied in the plasma of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,,N,Intermediate,A,10116.0,CHEMBL627203,,1969.0,Plasma,,1,1
12122,50597,In vivo,BAO_0000218,,,Biodistribution studied in the plasma of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,,N,Intermediate,A,10116.0,CHEMBL627204,,1969.0,Plasma,,1,1
12123,50597,In vivo,BAO_0000218,,,Biodistribution studied in the spleen of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,,N,Intermediate,A,10116.0,CHEMBL627205,,2106.0,Spleen,,1,1
12124,50597,In vivo,BAO_0000218,,,Biodistribution studied in the spleen of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,,N,Intermediate,A,10116.0,CHEMBL627206,,2106.0,Spleen,,1,1
12125,50597,In vivo,BAO_0000218,,,Biodistribution studied in the spleen of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,,N,Intermediate,A,10116.0,CHEMBL627207,,2106.0,Spleen,,1,1
12126,50597,In vivo,BAO_0000218,,,Biodistribution studied in the spleen of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,,N,Intermediate,A,10116.0,CHEMBL627208,,2106.0,Spleen,,1,1
12127,50597,In vivo,BAO_0000218,,,Biodistribution studied in the thyroid of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,,N,Intermediate,A,10116.0,CHEMBL627209,,2046.0,Thyroid gland,,1,1
12128,50597,In vivo,BAO_0000218,,,Biodistribution studied in the thyroid of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,,N,Intermediate,A,10116.0,CHEMBL627210,,2046.0,Thyroid gland,,1,1
12129,50597,In vivo,BAO_0000218,,,Biodistribution studied in the thyroid of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,,N,Intermediate,A,10116.0,CHEMBL627211,,2046.0,Thyroid gland,,1,1
12130,50597,In vivo,BAO_0000218,,,Biodistribution studied in the thyroid of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,,N,Intermediate,A,10116.0,CHEMBL627212,,2046.0,Thyroid gland,,1,1
12131,50597,In vivo,BAO_0000218,,,Biodistribution studied in the uterus of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,,N,Intermediate,A,10116.0,CHEMBL627213,,995.0,Uterus,,1,1
12132,50597,In vivo,BAO_0000218,,,Biodistribution studied in the uterus of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,,N,Intermediate,A,10116.0,CHEMBL626599,,995.0,Uterus,,1,1
12133,50597,In vivo,BAO_0000218,,,Biodistribution studied in the uterus of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,,N,Intermediate,A,10116.0,CHEMBL626600,,995.0,Uterus,,1,1
12134,50597,In vivo,BAO_0000218,,,Biodistribution studied in the uterus of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,,N,Intermediate,A,10116.0,CHEMBL626601,,995.0,Uterus,,1,1
12135,22224,,BAO_0000019,,,C(f=2) is the concentration at which the half life (t1/2) in the time course of inhibition of BChE by DFP increased by twofold in the presence of compound,,,U,Autocuration,A,,CHEMBL627484,,,,,0,1
12136,100710,,BAO_0000218,,,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg),,,N,Intermediate,A,9541.0,CHEMBL627485,,1969.0,Plasma,,1,1
12137,100710,,BAO_0000218,,,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg); Not applicable,,,N,Intermediate,A,9541.0,CHEMBL628147,,1969.0,Plasma,,1,1
12138,100710,,BAO_0000218,,,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg); Not determined,,,N,Intermediate,A,9541.0,CHEMBL628148,,1969.0,Plasma,,1,1
12139,50588,,BAO_0000218,,,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg),,,N,Intermediate,A,9615.0,CHEMBL628149,,1969.0,Plasma,,1,1
12140,50588,,BAO_0000218,,,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg) in experiment 1,,,N,Intermediate,A,9615.0,CHEMBL628150,,1969.0,Plasma,,1,1
12141,50588,,BAO_0000218,,,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg) in experiment 2,,,N,Intermediate,A,9615.0,CHEMBL628318,,1969.0,Plasma,,1,1
12142,50588,,BAO_0000218,,,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg); Not applicable,,,N,Intermediate,A,9615.0,CHEMBL628319,,1969.0,Plasma,,1,1
12143,50588,,BAO_0000218,,,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 )",,,N,Intermediate,A,9615.0,CHEMBL875609,,,,,1,1
12144,22224,,BAO_0000019,,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 10,,,U,Autocuration,A,,CHEMBL628320,,,,,0,1
12145,22224,,BAO_0000019,,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 10.5,,,U,Autocuration,A,,CHEMBL628321,,,,,0,1
12146,22224,,BAO_0000019,,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 6.8,,,U,Autocuration,A,,CHEMBL628322,,,,,0,1
12147,22224,,BAO_0000019,,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 7.2,,,U,Autocuration,A,,CHEMBL628323,,,,,0,1
12148,22224,,BAO_0000019,,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 7.6,,,U,Autocuration,A,,CHEMBL628324,,,,,0,1
12149,22224,,BAO_0000019,,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 8.2,,,U,Autocuration,A,,CHEMBL628325,,,,,0,1
12150,22224,,BAO_0000019,,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 9.6,,,U,Autocuration,A,,CHEMBL628326,,,,,0,1
12151,50588,,BAO_0000218,,,"Concentration of compound in adrenal medulla of dog 2, after administering intravenously",,,N,Intermediate,A,9615.0,CHEMBL628327,,1236.0,Adrenal medulla,,1,1
12152,50588,,BAO_0000218,,,"Concentration of compound in adrenal medulla of dog1, after administering intravenously",,,N,Intermediate,A,9615.0,CHEMBL628328,,1236.0,Adrenal medulla,,1,1
12153,50588,,BAO_0000218,,,"Concentration of compound in blood of dog 1, after administering intravenously",,,N,Intermediate,A,9615.0,CHEMBL628329,,178.0,Blood,,1,1
12154,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration.; dose/g, range 0.23-0.29",,,N,Intermediate,A,10116.0,CHEMBL628330,,2107.0,Liver,,1,1
12155,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.22-0.30",,,N,Intermediate,A,10116.0,CHEMBL628331,,2107.0,Liver,,1,1
12156,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.55-0.71",,,N,Intermediate,A,10116.0,CHEMBL628332,,2107.0,Liver,,1,1
12157,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.57-0.72",,,N,Intermediate,A,10116.0,CHEMBL628333,,2107.0,Liver,,1,1
12158,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 1.51-2.23",,,N,Intermediate,A,10116.0,CHEMBL628334,,2107.0,Liver,,1,1
12159,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 2.30-3.12",,,N,Intermediate,A,10116.0,CHEMBL628335,,2107.0,Liver,,1,1
12160,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 0.93-1.20",,,N,Intermediate,A,10116.0,CHEMBL628336,,2107.0,Liver,,1,1
12161,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.04-2.56",,,N,Intermediate,A,10116.0,CHEMBL628337,,2107.0,Liver,,1,1
12162,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.06-1.70",,,N,Intermediate,A,10116.0,CHEMBL628338,,2107.0,Liver,,1,1
12163,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.26-2.45",,,N,Intermediate,A,10116.0,CHEMBL875610,,2107.0,Liver,,1,1
12164,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 3.12-4.56",,,N,Intermediate,A,10116.0,CHEMBL628339,,2107.0,Liver,,1,1
12165,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 4.12-6.30",,,N,Intermediate,A,10116.0,CHEMBL628340,,2107.0,Liver,,1,1
12166,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.14-0.19",,,N,Intermediate,A,10116.0,CHEMBL628341,,2107.0,Liver,,1,1
12167,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.15-0.19",,,N,Intermediate,A,10116.0,CHEMBL622214,,2107.0,Liver,,1,1
12168,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.24-0.30",,,N,Intermediate,A,10116.0,CHEMBL623167,,2107.0,Liver,,1,1
12169,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.44-0.54",,,N,Intermediate,A,10116.0,CHEMBL623168,,2107.0,Liver,,1,1
12170,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.73-1.19",,,N,Intermediate,A,10116.0,CHEMBL623169,,2107.0,Liver,,1,1
12171,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 1.08-2.31",,,N,Intermediate,A,10116.0,CHEMBL623170,,2107.0,Liver,,1,1
12172,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration.; dose/g, range 0.34-0.47",,,N,Intermediate,A,10116.0,CHEMBL627224,,2048.0,Lung,,1,1
12173,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.83-1.21",,,N,Intermediate,A,10116.0,CHEMBL875634,,2048.0,Lung,,1,1
12174,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.91-1.74",,,N,Intermediate,A,10116.0,CHEMBL627225,,2048.0,Lung,,1,1
12175,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.99-1.23",,,N,Intermediate,A,10116.0,CHEMBL627226,,2048.0,Lung,,1,1
12176,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 1.07-1.30",,,N,Intermediate,A,10116.0,CHEMBL626083,,2048.0,Lung,,1,1
12177,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 1.12-1.39",,,N,Intermediate,A,10116.0,CHEMBL626084,,2048.0,Lung,,1,1
12178,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.51-0.66",,,N,Intermediate,A,10116.0,CHEMBL626085,,2048.0,Lung,,1,1
12179,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.95-1.49",,,N,Intermediate,A,10116.0,CHEMBL626086,,2048.0,Lung,,1,1
12180,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.96-1.35",,,N,Intermediate,A,10116.0,CHEMBL626087,,2048.0,Lung,,1,1
12181,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.18-1.44",,,N,Intermediate,A,10116.0,CHEMBL626088,,2048.0,Lung,,1,1
12182,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.20-1.52",,,N,Intermediate,A,10116.0,CHEMBL626089,,2048.0,Lung,,1,1
12183,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.41-2.17",,,N,Intermediate,A,10116.0,CHEMBL626090,,2048.0,Lung,,1,1
12184,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.28-0.33",,,N,Intermediate,A,10116.0,CHEMBL626091,,2048.0,Lung,,1,1
12185,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.81-1.13",,,N,Intermediate,A,10116.0,CHEMBL626092,,2048.0,Lung,,1,1
12186,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.83-2.11",,,N,Intermediate,A,10116.0,CHEMBL626093,,2048.0,Lung,,1,1
12187,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.94-1.36",,,N,Intermediate,A,10116.0,CHEMBL626094,,2048.0,Lung,,1,1
12188,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.97-1.54",,,N,Intermediate,A,10116.0,CHEMBL626095,,2048.0,Lung,,1,1
12189,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 1.07-1.26",,,N,Intermediate,A,10116.0,CHEMBL626096,,2048.0,Lung,,1,1
12190,22224,,BAO_0000218,,,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in monkey,,,U,Autocuration,A,314293.0,CHEMBL626097,,,,,0,1
12191,50597,,BAO_0000218,,,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in rat,,,N,Intermediate,A,10116.0,CHEMBL626098,,,,,1,1
12192,22224,,BAO_0000218,,,compound was evaluated for area under the plasma concentration vs. time curve at different dose 27.5 mg/kg DMP323 equiv,,,U,Autocuration,A,,CHEMBL626099,,1969.0,Plasma,,0,1
12193,22224,,BAO_0000218,,,compound was evaluated for area under the plasma concentration vs. time curve at different dose 7.7 mg/kg DMP323 equiv,,,U,Autocuration,A,,CHEMBL626100,,1969.0,Plasma,,0,1
12194,50588,,BAO_0000218,,,AUC 0-inf in dog,,,N,Intermediate,A,9615.0,CHEMBL626101,,1969.0,Plasma,,1,1
12195,50512,,BAO_0000218,,,AUC 0-inf in guinea pig,,,N,Intermediate,A,10141.0,CHEMBL626102,,1969.0,Plasma,,1,1
12196,50588,,BAO_0000218,,,AUC 0-t in dog,,,N,Intermediate,A,9615.0,CHEMBL626103,,1969.0,Plasma,,1,1
12197,50512,,BAO_0000218,,,AUC 0-t in guinea pig,,,N,Intermediate,A,10141.0,CHEMBL628391,,1969.0,Plasma,,1,1
12198,50597,,BAO_0000218,,,The compound was tested for brain to plasma partition in rat,,,N,Intermediate,A,10116.0,CHEMBL628392,,,,,1,1
12199,50597,,BAO_0000218,,,The compound was tested for brain to plasma partition in rat.,,,N,Intermediate,A,10116.0,CHEMBL628393,,,,,1,1
12200,22224,,BAO_0000019,,,Area under curve was determined for 0-6 hr duration using dihydralazine as reference drug for the peak blood pressure,,,U,Autocuration,A,,CHEMBL628394,,178.0,Blood,,0,1
12201,50588,,BAO_0000218,,,Area under concentration-time curve of compound was determined in dog at 5 mg/kg intravenously admn.,,,N,Intermediate,A,9615.0,CHEMBL628395,,,,,1,1
12202,22224,,BAO_0000218,,,Area under concentration-time curve of compound was determined in monkey at 5 mg/kg intravenously admn.,,,U,Autocuration,A,314293.0,CHEMBL628396,,,,,0,1
12203,50592,,BAO_0000218,,,Area under concentration-time curve of compound was determined in rabbit at 5 mg/kg intravenously admn.,,,N,Intermediate,A,9986.0,CHEMBL628397,,,,,1,1
12204,50597,,BAO_0000218,,,Area under concentration-time curve of compound was determined in rat at 5 mg/kg intravenously admn.,,,N,Intermediate,A,10116.0,CHEMBL628398,,,,,1,1
12205,50797,,BAO_0000218,,,Area under curve obtained at a dose of 10 mg/kg when administered orally to rhesus monkey,,,N,Intermediate,A,9544.0,CHEMBL628399,,,,,1,1
12206,50588,,BAO_0000218,,,The Plasma area under the compound concentration -time curve was measured in dogs after oral administration of 1 mg/kg dose,,,N,Intermediate,A,9615.0,CHEMBL628400,,,,,1,1
12207,50597,,BAO_0000218,,,The Plasma area under the compound concentration -time curve was measured in rats after oral administration of 1 mg/kg dose,,,N,Intermediate,A,10116.0,CHEMBL874907,,,,,1,1
12208,22224,,BAO_0000019,,,Area under curve of the compound was determined,,,U,Autocuration,A,,CHEMBL628401,,,,,0,1
12209,22224,,BAO_0000218,,,AUC in monkeys at a dose of 1 mg/kg,,,U,Autocuration,A,314293.0,CHEMBL628402,,1969.0,Plasma,,0,1
12210,50597,,BAO_0000218,,,AUC in rats at a dose of 1 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL628403,,1969.0,Plasma,,1,1
12211,22224,,BAO_0000019,,,Compound was evaluated for the overall absorbance loss at pH of 2,,,U,Autocuration,A,,CHEMBL628404,,,,,0,1
12212,22224,,BAO_0000019,,,Compound was evaluated for the overall absorbance loss at pH of 4,,,U,Autocuration,A,,CHEMBL628405,,,,,0,1
12213,22224,,BAO_0000019,,,Compound was evaluated for the overall absorbance loss at pH of 7,,,U,Autocuration,A,,CHEMBL628406,,,,,0,1
12214,50597,,BAO_0000218,,,Compound was evaluated for its absorption in the rats,,,N,Intermediate,A,10116.0,CHEMBL628407,,,,,1,1
12215,50597,,BAO_0000218,,,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight per mole of pro drug,,,N,Intermediate,A,10116.0,CHEMBL628408,,1088.0,Urine,,1,1
12216,50597,,BAO_0000218,,,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight.,,,N,Intermediate,A,10116.0,CHEMBL629171,,1088.0,Urine,,1,1
12217,50597,,BAO_0000218,,,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight per mole of pro drug,,,N,Intermediate,A,10116.0,CHEMBL629172,,1088.0,Urine,,1,1
12218,50597,,BAO_0000218,,,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of per moiety tranexamic acid,,,N,Intermediate,A,10116.0,CHEMBL629173,,1088.0,Urine,,1,1
12219,50597,,BAO_0000218,,,In vitro percent permeability into rat ileum,,,N,Intermediate,A,10116.0,CHEMBL629174,,,,,1,1
12220,50597,,BAO_0000218,,,In vitro percent permeability into rat ileum; Range is 10-17,,,N,Intermediate,A,10116.0,CHEMBL629175,,,,,1,1
12221,50597,,BAO_0000218,,,In vitro percent permeability into rat ileum; Range is 10-18,,,N,Intermediate,A,10116.0,CHEMBL629176,,,,,1,1
12222,50597,,BAO_0000218,,,In vitro percent permeability into rat ileum; Range is 10-19,,,N,Intermediate,A,10116.0,CHEMBL629177,,,,,1,1
12223,50597,,BAO_0000218,,,In vitro percent permeability into rat ileum; Range is 12-15,,,N,Intermediate,A,10116.0,CHEMBL629178,,,,,1,1
12224,50597,,BAO_0000218,,,In vitro percent permeability into rat ileum; Range is 13-19,,,N,Intermediate,A,10116.0,CHEMBL631869,,,,,1,1
12225,50597,,BAO_0000218,,,In vitro percent permeability into rat ileum; Range is 14-17,,,N,Intermediate,A,10116.0,CHEMBL631870,,,,,1,1
12226,50597,,BAO_0000218,,,In vitro percent permeability into rat ileum; Range is 15-18,,,N,Intermediate,A,10116.0,CHEMBL631871,,,,,1,1
12227,50597,,BAO_0000218,,,In vitro percent permeability into rat ileum; Range is 2-5,,,N,Intermediate,A,10116.0,CHEMBL631872,,,,,1,1
12228,22224,,BAO_0000221,,,In vitro percent permeability into rat ileum; Range is 23-42,,,U,Autocuration,A,,CHEMBL875775,,2116.0,Ileum,,0,1
12229,50597,,BAO_0000218,,,In vitro percent permeability into rat ileum; Range is 28-36,,,N,Intermediate,A,10116.0,CHEMBL631873,,,,,1,1
12230,50597,,BAO_0000218,,,In vitro percent permeability into rat ileum; Range is 29-35,,,N,Intermediate,A,10116.0,CHEMBL631874,,,,,1,1
12231,50597,,BAO_0000218,,,In vitro percent permeability into rat ileum; Range is 46-66,,,N,Intermediate,A,10116.0,CHEMBL631875,,,,,1,1
12232,50597,,BAO_0000218,,,In vitro percent permeability into rat ileum; Range is 50-68,,,N,Intermediate,A,10116.0,CHEMBL631876,,,,,1,1
12233,50597,,BAO_0000218,,,In vitro percent permeability into rat ileum; Range is 78-81,,,N,Intermediate,A,10116.0,CHEMBL631877,,,,,1,1
12234,50597,,BAO_0000218,,,In vitro percent permeability into rat ileum; insol indicates not soluble in aqueous buffer,,,N,Intermediate,A,10116.0,CHEMBL631878,,,,,1,1
12235,50597,,BAO_0000218,,,In vitro percent permeability into rat ileum; nd indicates not detected,,,N,Intermediate,A,10116.0,CHEMBL631879,,,,,1,1
12236,50597,,BAO_0000218,,,In vitro percent permeability into rat ileum; nt indicates not detected,,,N,Intermediate,A,10116.0,CHEMBL631880,,,,,1,1
12237,50597,,BAO_0000218,,,In vitro percent permeability into rat ileum; nt indicates not tested,,,N,Intermediate,A,10116.0,CHEMBL631881,,,,,1,1
12238,50597,,BAO_0000218,,,Compound was tested for oral absorption in bile-duct cannulated rats,,,N,Intermediate,A,10116.0,CHEMBL631882,,,,,1,1
12239,50597,,BAO_0000218,,,Compound was tested for oral absorption in bile-duct cannulated rats.,,,N,Intermediate,A,10116.0,CHEMBL630749,,,,,1,1
12240,50587,,BAO_0000218,,,Oral absorption using Caco-2 cell monolayers.,,,N,Intermediate,A,9606.0,CHEMBL630750,,,,,1,1
12241,50587,,BAO_0000218,,,Percent of the drug absorbed after administration to humans was determined,,,N,Intermediate,A,9606.0,CHEMBL630253,,,,,1,1
12242,50597,,BAO_0000218,,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 120 minutes.,,,N,Intermediate,A,10116.0,CHEMBL630254,,1969.0,Plasma,,1,1
12243,50597,,BAO_0000218,,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 15 minutes.,,,N,Intermediate,A,10116.0,CHEMBL630255,,1969.0,Plasma,,1,1
12244,50597,,BAO_0000218,,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 180 minutes.,,,N,Intermediate,A,10116.0,CHEMBL630256,,1969.0,Plasma,,1,1
12245,50597,In vivo,BAO_0000218,,,"Biodistribution inl liver of mature female Dawley rat after 1h, expressed as percent injected dose/g",,,N,Intermediate,A,10116.0,CHEMBL875781,,2107.0,Liver,,1,1
12246,50597,In vivo,BAO_0000218,,,"Biodistribution inl liver of mature female Dawley rat after 30min, expressed as percent injected dose/g",,,N,Intermediate,A,10116.0,CHEMBL630257,,2107.0,Liver,,1,1
12247,50597,In vivo,BAO_0000218,,,"Biodistribution inl liver of mature female Dawley rat after 45min, expressed as percent injected dose/g",,,N,Intermediate,A,10116.0,CHEMBL630258,,2107.0,Liver,,1,1
12248,50597,,BAO_0000218,,,"Distribution of radioactivity in rat blood after 2 minutes of iv administration at the dose of 10.05-0.07 gram of tissue, expressed as percent injected dose per gram of tissue",,,N,Intermediate,A,10116.0,CHEMBL630259,,,,,1,1
12249,50597,,BAO_0000218,,,"Distribution of radioactivity in rat striatum after 5 minutes of iv administration at the dose of 1.89-3.73 g of tissue, expressed as percent injected dose per gram of tissue",,,N,Intermediate,A,10116.0,CHEMBL630260,,2435.0,Striatum,,1,1
12250,50597,,BAO_0000218,,,"Distribution of radioactivity in rat striatum after 5 minutes of iv administration at the dose of 3.44-4.80 g of tissue, expressed as percent injected dose per gram of tissue",,,N,Intermediate,A,10116.0,CHEMBL630261,,2435.0,Striatum,,1,1
12251,50597,,BAO_0000218,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat and 5-alpha-DHT was reported,,,N,Intermediate,A,10116.0,CHEMBL630262,,,,,1,1
12252,50597,,BAO_0000218,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat blood at 1 hour time,,,N,Intermediate,A,10116.0,CHEMBL630263,,,,,1,1
12253,50597,,BAO_0000218,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat blood at 2 hours time,,,N,Intermediate,A,10116.0,CHEMBL630264,,,,,1,1
12254,50597,,BAO_0000218,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat fat at 0.5 hours time,,,N,Intermediate,A,10116.0,CHEMBL630265,,,,,1,1
12255,50597,,BAO_0000218,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat fat at 4 hours time,,,N,Intermediate,A,10116.0,CHEMBL630266,,,,,1,1
12256,50597,,BAO_0000218,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat kidney at 0.5 hours time,,,N,Intermediate,A,10116.0,CHEMBL630267,,2113.0,Kidney,,1,1
12257,50597,,BAO_0000218,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat kidney at 4 hours time,,,N,Intermediate,A,10116.0,CHEMBL630268,,2113.0,Kidney,,1,1
12258,50597,,BAO_0000218,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat liver at 1 hour time,,,N,Intermediate,A,10116.0,CHEMBL630269,,,,,1,1
12259,50597,,BAO_0000218,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat liver at 2 hours time,,,N,Intermediate,A,10116.0,CHEMBL630270,,,,,1,1
12260,50597,,BAO_0000218,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat lung at 1 hour time,,,N,Intermediate,A,10116.0,CHEMBL630141,,2048.0,Lung,,1,1
12261,50597,,BAO_0000218,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat lung at 2 hours time,,,N,Intermediate,A,10116.0,CHEMBL630142,,2048.0,Lung,,1,1
12262,50597,,BAO_0000218,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat muscle at 0.5 hours time,,,N,Intermediate,A,10116.0,CHEMBL630143,,2385.0,Muscle tissue,,1,1
12263,50597,,BAO_0000218,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat muscle at 4 hours time,,,N,Intermediate,A,10116.0,CHEMBL630144,,2385.0,Muscle tissue,,1,1
12264,50597,,BAO_0000218,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate at 0.5 hours time,,,N,Intermediate,A,10116.0,CHEMBL630145,,2367.0,Prostate gland,,1,1
12265,50597,,BAO_0000218,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate at 4 hours time,,,N,Intermediate,A,10116.0,CHEMBL630146,,2367.0,Prostate gland,,1,1
12266,50597,,BAO_0000218,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood,,,N,Intermediate,A,10116.0,CHEMBL630147,,,,,1,1
12267,50597,,BAO_0000218,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood at 1 hours time,,,N,Intermediate,A,10116.0,CHEMBL630148,,,,,1,1
12268,50597,,BAO_0000218,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood at 2 hours time,,,N,Intermediate,A,10116.0,CHEMBL630149,,,,,1,1
12269,50597,,BAO_0000218,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat spleen at 1 hour time,,,N,Intermediate,A,10116.0,CHEMBL630150,,2106.0,Spleen,,1,1
12270,50597,,BAO_0000218,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat spleen at 2 hours time,,,N,Intermediate,A,10116.0,CHEMBL630151,,2106.0,Spleen,,1,1
12271,50597,,BAO_0000218,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat thyroid at 0.5 hours time,,,N,Intermediate,A,10116.0,CHEMBL632031,,2046.0,Thyroid gland,,1,1
12272,50597,,BAO_0000218,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat thyroid at 4 hours time,,,N,Intermediate,A,10116.0,CHEMBL632032,,2046.0,Thyroid gland,,1,1
12273,50597,,BAO_0000218,,,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat fat at 1 hour time,,,N,Intermediate,A,10116.0,CHEMBL632033,,,,,1,1
12274,50597,,BAO_0000218,,,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat kidney at 1 hour time,,,N,Intermediate,A,10116.0,CHEMBL632034,,,,,1,1
12275,50597,,BAO_0000218,,,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat muscle at 1 hour time,,,N,Intermediate,A,10116.0,CHEMBL632035,,2385.0,Muscle tissue,,1,1
12276,50597,,BAO_0000218,,,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat prostrateat 1 hour time,,,N,Intermediate,A,10116.0,CHEMBL632036,,,,,1,1
12277,50597,,BAO_0000218,,,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat thyroid at 1 hour time,,,N,Intermediate,A,10116.0,CHEMBL632037,,2046.0,Thyroid gland,,1,1
12278,50597,,BAO_0000218,,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 10 minutes,,,N,Intermediate,A,10116.0,CHEMBL632038,,178.0,Blood,,1,1
12279,50597,,BAO_0000218,,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 15 minutes,,,N,Intermediate,A,10116.0,CHEMBL632039,,178.0,Blood,,1,1
12280,50597,,BAO_0000218,,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 20 minutes,,,N,Intermediate,A,10116.0,CHEMBL632040,,178.0,Blood,,1,1
12281,50597,,BAO_0000218,,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 30 minutes,,,N,Intermediate,A,10116.0,CHEMBL632041,,178.0,Blood,,1,1
12282,50588,,BAO_0000218,,,"Concentration of compound in blood of dog 2, after administering intravenously",,,N,Intermediate,A,9615.0,CHEMBL632042,,178.0,Blood,,1,1
12283,50588,,BAO_0000218,,,"Concentration of compound in left ventricle of dog 1, after administering intravenously",,,N,Intermediate,A,9615.0,CHEMBL632043,,,,,1,1
12284,50588,,BAO_0000218,,,"Concentration of compound in left ventricle of dog 2, after administering intravenously",,,N,Intermediate,A,9615.0,CHEMBL632044,,,,,1,1
12285,50588,,BAO_0000218,,,"Concentration of compound in liver of dog 1, after administering intravenously",,,N,Intermediate,A,9615.0,CHEMBL632045,,2107.0,Liver,,1,1
12286,50588,,BAO_0000218,,,"Concentration of compound in liver of dog 2, after administering intravenously",,,N,Intermediate,A,9615.0,CHEMBL632046,,2107.0,Liver,,1,1
12287,50588,,BAO_0000218,,,"Concentration of compound in lung of dog 1, after administering intravenously",,,N,Intermediate,A,9615.0,CHEMBL632047,,2048.0,Lung,,1,1
12288,50588,,BAO_0000218,,,"Concentration of compound in lung of dog 2, after administering intravenously",,,N,Intermediate,A,9615.0,CHEMBL632048,,2048.0,Lung,,1,1
12289,50588,,BAO_0000218,,,"Concentration of compound in muscle of dog 1, after administering intravenously",,,N,Intermediate,A,9615.0,CHEMBL632049,,2385.0,Muscle tissue,,1,1
12290,50588,,BAO_0000218,,,"Concentration of compound in muscle of dog 2, after administering intravenously",,,N,Intermediate,A,9615.0,CHEMBL876418,,2385.0,Muscle tissue,,1,1
12291,50588,,BAO_0000218,,,"Concentration of compound in spleen of dog 1,after administering intravenously",,,N,Intermediate,A,9615.0,CHEMBL632050,,2106.0,Spleen,,1,1
12292,50588,,BAO_0000218,,,"Concentration of compound in spleen of dog 2, after administering intravenously",,,N,Intermediate,A,9615.0,CHEMBL632051,,2106.0,Spleen,,1,1
12293,22224,,BAO_0000218,,,Concentration of liberated compound in serum after 120 min at the dose of 50 mg/kg (po).,,,U,Autocuration,F,,CHEMBL632052,,,,,0,1
12294,22224,,BAO_0000218,,,Concentration of liberated compound in serum after 240 min at the dose of 50 mg/kg (po).,,,U,Autocuration,F,,CHEMBL632053,,,,,0,1
12295,22224,,BAO_0000218,,,Concentration of liberated compound in serum after 30 min at the dose of 50 mg/kg (po).,,,U,Autocuration,A,,CHEMBL632054,,,,,0,1
12296,22224,,BAO_0000218,,,Concentration of liberated compound in serum after 30 min at the dose of 50 mg/kg (po).,,,U,Autocuration,F,,CHEMBL632055,,,,,0,1
12297,22224,,BAO_0000218,,,Concentration of liberated compound in serum after 60 min at the dose of 50 mg/kg (po).,,,U,Autocuration,F,,CHEMBL631181,,,,,0,1
12298,22224,,BAO_0000218,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous after 1.5 hr,,,U,Autocuration,A,,CHEMBL631182,,,,,0,1
12299,22224,,BAO_0000218,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,,,U,Autocuration,A,,CHEMBL631183,,,,,0,1
12300,22224,,BAO_0000218,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,,,U,Autocuration,A,,CHEMBL631184,,,,,0,1
12301,22224,,BAO_0000218,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,,,U,Autocuration,A,,CHEMBL629774,,,,,0,1
12302,22224,,BAO_0000218,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,,,U,Autocuration,A,,CHEMBL629775,,,,,0,1
12303,22224,,BAO_0000218,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,,,U,Autocuration,A,,CHEMBL876549,,,,,0,1
12304,22224,,BAO_0000218,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,,,U,Autocuration,A,,CHEMBL628172,,,,,0,1
12305,22224,,BAO_0000218,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,,,U,Autocuration,A,,CHEMBL628173,,,,,0,1
12306,22224,,BAO_0000218,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous after 1.5 hr,,,U,Autocuration,A,,CHEMBL628174,,,,,0,1
12307,22224,,BAO_0000218,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage a after 4.0 hr,,,U,Autocuration,A,,CHEMBL628175,,,,,0,1
12308,22224,,BAO_0000218,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,,,U,Autocuration,A,,CHEMBL628176,,,,,0,1
12309,22224,,BAO_0000218,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,,,U,Autocuration,A,,CHEMBL628177,,,,,0,1
12310,22224,,BAO_0000218,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,,,U,Autocuration,A,,CHEMBL628178,,,,,0,1
12311,22224,,BAO_0000218,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,,,U,Autocuration,A,,CHEMBL628179,,,,,0,1
12312,22224,,BAO_0000218,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg i intravenous dosage after 1.0 hr; insufficient gastric juice produced,,,U,Autocuration,A,,CHEMBL628180,,,,,0,1
12313,22224,,BAO_0000218,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage a after 2.5 hr,,,U,Autocuration,A,,CHEMBL628181,,,,,0,1
12314,22224,,BAO_0000218,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,,,U,Autocuration,A,,CHEMBL628182,,,,,0,1
12315,22224,,BAO_0000218,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,,,U,Autocuration,A,,CHEMBL628183,,,,,0,1
12316,22224,,BAO_0000218,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr; ND means not determined,,,U,Autocuration,A,,CHEMBL628184,,,,,0,1
12317,22224,,BAO_0000218,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,,,U,Autocuration,A,,CHEMBL628185,,,,,0,1
12318,22224,,BAO_0000218,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,,,U,Autocuration,A,,CHEMBL875617,,,,,0,1
12319,22224,,BAO_0000218,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr; ND means not determined,,,U,Autocuration,A,,CHEMBL628186,,,,,0,1
12320,22224,,BAO_0000218,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,,,U,Autocuration,A,,CHEMBL628187,,,,,0,1
12321,22224,,BAO_0000218,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,,,U,Autocuration,A,,CHEMBL628188,,,,,0,1
12322,22224,,BAO_0000218,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr,,,U,Autocuration,A,,CHEMBL628189,,,,,0,1
12323,22224,,BAO_0000218,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr; ND means not determined,,,U,Autocuration,A,,CHEMBL628190,,,,,0,1
12324,22224,,BAO_0000218,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,,,U,Autocuration,A,,CHEMBL628191,,,,,0,1
12325,22224,,BAO_0000218,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr; ND means not determined,,,U,Autocuration,A,,CHEMBL626513,,,,,0,1
12326,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 19-24",,,N,Intermediate,A,10116.0,CHEMBL626514,,2046.0,Thyroid gland,,1,1
12327,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 26-40",,,N,Intermediate,A,10116.0,CHEMBL626515,,2046.0,Thyroid gland,,1,1
12328,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 29-44",,,N,Intermediate,A,10116.0,CHEMBL626516,,2046.0,Thyroid gland,,1,1
12329,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 32-42",,,N,Intermediate,A,10116.0,CHEMBL626517,,2046.0,Thyroid gland,,1,1
12330,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 33-60",,,N,Intermediate,A,10116.0,CHEMBL626518,,2046.0,Thyroid gland,,1,1
12331,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 4-7",,,N,Intermediate,A,10116.0,CHEMBL626519,,2046.0,Thyroid gland,,1,1
12332,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 13-18",,,N,Intermediate,A,10116.0,CHEMBL626520,,2046.0,Thyroid gland,,1,1
12333,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 16-32",,,N,Intermediate,A,10116.0,CHEMBL626521,,2046.0,Thyroid gland,,1,1
12334,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 22-25",,,N,Intermediate,A,10116.0,CHEMBL626522,,2046.0,Thyroid gland,,1,1
12335,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 26-49",,,N,Intermediate,A,10116.0,CHEMBL626523,,2046.0,Thyroid gland,,1,1
12336,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 29-36",,,N,Intermediate,A,10116.0,CHEMBL626524,,2046.0,Thyroid gland,,1,1
12337,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 5-8",,,N,Intermediate,A,10116.0,CHEMBL626688,,2046.0,Thyroid gland,,1,1
12338,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 26-42",,,N,Intermediate,A,10116.0,CHEMBL626689,,2046.0,Thyroid gland,,1,1
12339,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 30-53",,,N,Intermediate,A,10116.0,CHEMBL626690,,2046.0,Thyroid gland,,1,1
12340,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 32-43",,,N,Intermediate,A,10116.0,CHEMBL626691,,2046.0,Thyroid gland,,1,1
12341,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 35-53",,,N,Intermediate,A,10116.0,CHEMBL627319,,2046.0,Thyroid gland,,1,1
12342,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 5-12",,,N,Intermediate,A,10116.0,CHEMBL624052,,2046.0,Thyroid gland,,1,1
12343,50597,,BAO_0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 55-102",,,N,Intermediate,A,10116.0,CHEMBL624053,,2046.0,Thyroid gland,,1,1
12344,50597,,BAO_0000218,,,In vivo distribution of the drug in plasma was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,,,N,Intermediate,A,10116.0,CHEMBL624054,,,,,1,1
12345,50597,,BAO_0000218,,,In vivo distribution of the drug in plasma was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,,,N,Intermediate,A,10116.0,CHEMBL624055,,,,,1,1
12346,50597,,BAO_0000218,,,In vivo distribution of the drug in plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,,,N,Intermediate,A,10116.0,CHEMBL624056,,,,,1,1
12347,50597,,BAO_0000218,,,In vivo distribution of the drug in uterus was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,,,N,Intermediate,A,10116.0,CHEMBL624057,,995.0,Uterus,,1,1
12348,50597,,BAO_0000218,,,In vivo distribution of the drug in uterus was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,,,N,Intermediate,A,10116.0,CHEMBL622281,,995.0,Uterus,,1,1
12349,50597,,BAO_0000218,,,In vivo distribution of the drug in uterus was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,,,N,Intermediate,A,10116.0,CHEMBL622282,,995.0,Uterus,,1,1
12350,50597,,BAO_0000218,,,In vivo distribution of the drug in uterus/plasma was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,,,N,Intermediate,A,10116.0,CHEMBL622283,,995.0,Uterus,,1,1
12351,50597,,BAO_0000218,,,In vivo distribution of the drug in uterus/plasma was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,,,N,Intermediate,A,10116.0,CHEMBL622284,,995.0,Uterus,,1,1
12352,50597,,BAO_0000218,,,In vivo distribution of the drug in uterus/plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,,,N,Intermediate,A,10116.0,CHEMBL622285,,995.0,Uterus,,1,1
12353,50597,,BAO_0000218,,,In vivo distribution of the drug in uterus/plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,,,N,Intermediate,A,10116.0,CHEMBL622286,,995.0,Uterus,,1,1
12354,22224,,BAO_0000100,,,Distribution coefficient (D %) between octanol and buffer of pH 7.4,,,U,Autocuration,P,,CHEMBL622287,,,,,0,1
12355,50594,,BAO_0000218,,,Partition coefficient (logD7.4),,,N,Intermediate,A,10090.0,CHEMBL622288,,,,,1,1
12356,50594,,BAO_0000218,,,"Percentage of radioactivity in P1 subregion in mouse brain that contains nuclei and cell debris, after Jugular Vein Injection",,,N,Intermediate,A,10090.0,CHEMBL622289,,,,,1,1
12357,50594,,BAO_0000218,,,"Percentage of radioactivity in P2 subregion in mouse brain that contains myelin fragments, synaptosomes (pinched-nerve endings), and mitochondria after Jugular Vein Injection",,,N,Intermediate,A,10090.0,CHEMBL622290,,955.0,Brain,,1,1
12358,50594,,BAO_0000218,,,Percentage of radioactivity in P3 subregion in mouse brain that contains microsomal fraction after Jugular Vein Injection,,,N,Intermediate,A,10090.0,CHEMBL622291,,,,,1,1
12359,50594,,BAO_0000218,,,Percentage of radioactivity in S3 which is the soluble fraction in mouse brain after Jugular Vein Injection,,,N,Intermediate,A,10090.0,CHEMBL622292,,955.0,Brain,,1,1
12360,50594,,BAO_0000218,,,"Percentage of total protein recovered in P1 subregion in mouse brain that contains nuclei and cell debris, after Jugular Vein Injection",,,N,Intermediate,A,10090.0,CHEMBL622293,,,,,1,1
12361,50594,,BAO_0000218,,,"Percentage of total protein recovered in P2 subregion in mouse brain that contains myelin fragments, synaptosomes (pinched-nerve endings), and mitochondria after Jugular Vein Injection",,,N,Intermediate,A,10090.0,CHEMBL622294,,955.0,Brain,,1,1
12362,50594,,BAO_0000218,,,Percentage of total protein recovered in P3 subregion in mouse brain that contains microsomal fraction after Jugular Vein Injection,,,N,Intermediate,A,10090.0,CHEMBL622295,,,,,1,1
12363,50597,,BAO_0000218,,,Percentage of total protein recovered in S3 which is the soluble fraction in mouse brain after Jugular Vein Injection,,,N,Intermediate,A,10116.0,CHEMBL622296,,955.0,Brain,,1,1
12364,50597,,BAO_0000218,,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 2 minutes.,,,N,Intermediate,A,10116.0,CHEMBL874409,,1969.0,Plasma,,1,1
12365,50597,,BAO_0000218,,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 240 minutes.,,,N,Intermediate,A,10116.0,CHEMBL622297,,1969.0,Plasma,,1,1
12366,50597,,BAO_0000218,,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 30 minutes.,,,N,Intermediate,A,10116.0,CHEMBL622298,,1969.0,Plasma,,1,1
12367,50597,,BAO_0000218,,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 45 minutes.,,,N,Intermediate,A,10116.0,CHEMBL622299,,1969.0,Plasma,,1,1
12368,50597,,BAO_0000218,,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 5 minutes.,,,N,Intermediate,A,10116.0,CHEMBL622300,,1969.0,Plasma,,1,1
12369,50597,,BAO_0000218,,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 60 minutes.,,,N,Intermediate,A,10116.0,CHEMBL622301,,1969.0,Plasma,,1,1
12370,50597,,BAO_0000218,,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 90 minutes.,,,N,Intermediate,A,10116.0,CHEMBL622302,,1969.0,Plasma,,1,1
12371,50597,,BAO_0000218,,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 120 minutes.,,,N,Intermediate,A,10116.0,CHEMBL622303,,1969.0,Plasma,,1,1
12372,50597,,BAO_0000218,,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 15 minutes.,,,N,Intermediate,A,10116.0,CHEMBL622304,,1969.0,Plasma,,1,1
12373,50597,,BAO_0000218,,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 15 minutes;nd=not determined,,,N,Intermediate,A,10116.0,CHEMBL622305,,1969.0,Plasma,,1,1
12374,50597,,BAO_0000218,,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 180 minutes.,,,N,Intermediate,A,10116.0,CHEMBL622306,,1969.0,Plasma,,1,1
12375,50597,,BAO_0000218,,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 2 minutes;nd=not determined,,,N,Intermediate,A,10116.0,CHEMBL626864,,1969.0,Plasma,,1,1
12376,50597,,BAO_0000218,,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 240 minutes.,,,N,Intermediate,A,10116.0,CHEMBL626865,,1969.0,Plasma,,1,1
12377,50597,,BAO_0000218,,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 240 minutes;nd=not determined,,,N,Intermediate,A,10116.0,CHEMBL626866,,1969.0,Plasma,,1,1
12378,50597,,BAO_0000218,,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 30 minutes.,,,N,Intermediate,A,10116.0,CHEMBL626867,,1969.0,Plasma,,1,1
12379,50597,,BAO_0000218,,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 45 minutes.,,,N,Intermediate,A,10116.0,CHEMBL626868,,1969.0,Plasma,,1,1
12380,50597,,BAO_0000218,,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 45 minutes;nd=not determined,,,N,Intermediate,A,10116.0,CHEMBL626869,,1969.0,Plasma,,1,1
12381,50597,,BAO_0000218,,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 5 minutes.,,,N,Intermediate,A,10116.0,CHEMBL626870,,1969.0,Plasma,,1,1
12382,50597,,BAO_0000218,,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 5 minutes;nd=not determined,,,N,Intermediate,A,10116.0,CHEMBL626871,,1969.0,Plasma,,1,1
12383,50597,,BAO_0000218,,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 60 minutes.,,,N,Intermediate,A,10116.0,CHEMBL626872,,1969.0,Plasma,,1,1
12384,50597,,BAO_0000218,,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 90 minutes.,,,N,Intermediate,A,10116.0,CHEMBL632185,,1969.0,Plasma,,1,1
12385,50597,,BAO_0000218,,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 90 minutes;nd=not determined,,,N,Intermediate,A,10116.0,CHEMBL632186,,1969.0,Plasma,,1,1
12386,22224,,BAO_0000019,,,Amount of acetic acid produced by the compound,,,U,Autocuration,A,,CHEMBL629310,,,,,0,1
12387,22224,,BAO_0000019,,,Apparent first-order rate of solvolysis for the bipinnatin-A(A4) was determined,,,U,Autocuration,A,,CHEMBL629311,,,,,0,1
12388,50597,,BAO_0000218,,,Log of (Cbrain/Cblood) in rats,,,N,Intermediate,A,10116.0,CHEMBL629312,,,,,1,1
12389,22224,,BAO_0000221,,,Compound in absence of MPM cell homogenate at pH 3 to isolate compound 4 (ng),,,U,Autocuration,A,,CHEMBL629313,,,,,0,1
12390,22224,,BAO_0000221,,,Compound in absence of MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),,,U,Autocuration,A,,CHEMBL629314,,,,,0,1
12391,22224,,BAO_0000221,,,Compound in absence of MPM cell homogenate at pH 7 to isolate compound 4 (ng),,,U,Autocuration,A,,CHEMBL629315,,,,,0,1
12392,22224,,BAO_0000219,,,Compound in presence of MPM cells and in absence of inactivator at pH 8 to isolate compound 4 (ng),,,U,Autocuration,B,,CHEMBL629316,,,,,0,1
12393,22224,,BAO_0000221,,,Compound treated in absence of MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),,,U,Autocuration,A,,CHEMBL629317,,,,,0,1
12394,22224,,BAO_0000019,,,Compound treated with MPM cell homogenate at pH 3 to isolate compound 4 (ng),,,U,Autocuration,A,,CHEMBL629318,,,,,0,1
12395,22224,,BAO_0000019,,,Compound treated with MPM cell homogenate at pH 3.5 to isolate compound 4 (ng),,,U,Autocuration,A,,CHEMBL877497,,,,,0,1
12396,22224,,BAO_0000019,,,Compound treated with MPM cell homogenate at pH 4 to isolate compound 4 (ng),,,U,Autocuration,A,,CHEMBL629319,,,,,0,1
12397,22224,,BAO_0000019,,,Compound treated with MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),,,U,Autocuration,A,,CHEMBL629320,,,,,0,1
12398,22224,,BAO_0000019,,,Compound treated with MPM cell homogenate at pH 5 to isolate compound 4 (ng),,,U,Autocuration,A,,CHEMBL629496,,,,,0,1
12399,22224,,BAO_0000019,,,Compound treated with MPM cell homogenate at pH 5.5 to isolate compound 4 (ng),,,U,Autocuration,A,,CHEMBL629497,,,,,0,1
12400,22224,,BAO_0000019,,,Compound treated with MPM cell homogenate at pH 6 to isolate compound 4 (ng),,,U,Autocuration,A,,CHEMBL629498,,,,,0,1
12401,22224,,BAO_0000019,,,Compound treated with MPM cell homogenate at pH 6.5 to isolate compound 4 (ng),,,U,Autocuration,A,,CHEMBL629499,,,,,0,1
12402,22224,,BAO_0000019,,,Compound treated with MPM cell homogenate at pH 7 to isolate compound 4 (ng),,,U,Autocuration,A,,CHEMBL629500,,,,,0,1
12403,22224,,BAO_0000019,,,Compound treated with MPM cell homogenate at pH 7.5 to isolate compound 4 (ng),,,U,Autocuration,A,,CHEMBL629501,,,,,0,1
12404,22224,,BAO_0000019,,,Compound treated with MPM cell homogenate at pH 8 to isolate compound 4 (ng),,,U,Autocuration,A,,CHEMBL629502,,,,,0,1
12405,22224,In vivo,BAO_0000218,,,Compound was evaluated for its urinary recovery after oral administration (100 mg) to Beagle dogs,,,U,Autocuration,F,,CHEMBL629503,,,,,0,1
12406,50588,,BAO_0000218,,,Compound was evaluated for its urinary recovery after oral administration (200 mg) to Beagle dogs,,,N,Intermediate,A,9615.0,CHEMBL629504,,,,,1,1
12407,22224,,BAO_0000019,,,Compound was evaluated for the rate of degradation by Carboxypeptidase A.,,,U,Autocuration,A,,CHEMBL629505,,,,,0,1
12408,22224,,BAO_0000019,,,Compound was evaluated for total body clearance,,,U,Autocuration,A,,CHEMBL629506,,,,,0,1
12409,22224,,BAO_0000019,,,Compound was evaluated for volume of distribution at steady state,,,U,Autocuration,A,,CHEMBL629507,,,,,0,1
12410,22224,,BAO_0000019,,,Compound was tested for hydrolysis by acetylcholinesterase and the kinetic constant KOH- was reported.,,,U,Autocuration,A,,CHEMBL877498,,,,,0,1
12411,22224,,BAO_0000019,,,Percentage of the diamine which is monoprotonated at pH 7.4,,,U,Autocuration,A,,CHEMBL629508,,,,,0,1
12412,22224,,BAO_0000019,,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells,,,U,Autocuration,A,,CHEMBL629509,,,,,0,1
12413,50597,,BAO_0000218,,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 5 minutes,,,N,Intermediate,A,10116.0,CHEMBL629510,,178.0,Blood,,1,1
12414,50597,,BAO_0000218,,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,,,N,Intermediate,A,10116.0,CHEMBL629511,,178.0,Blood,,1,1
12415,50597,,BAO_0000218,,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,,,N,Intermediate,A,10116.0,CHEMBL629512,,178.0,Blood,,1,1
12416,50597,,BAO_0000218,,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,,,N,Intermediate,A,10116.0,CHEMBL629513,,178.0,Blood,,1,1
12417,50597,,BAO_0000218,,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 30 minutes,,,N,Intermediate,A,10116.0,CHEMBL629514,,178.0,Blood,,1,1
12418,50597,,BAO_0000218,,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,,,N,Intermediate,A,10116.0,CHEMBL628447,,178.0,Blood,,1,1
12419,50597,,BAO_0000218,,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 10 minutes,,,N,Intermediate,A,10116.0,CHEMBL628448,,178.0,Blood,,1,1
12420,50597,,BAO_0000218,,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 15 minutes,,,N,Intermediate,A,10116.0,CHEMBL628449,,178.0,Blood,,1,1
12421,50597,,BAO_0000218,,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 20 minutes,,,N,Intermediate,A,10116.0,CHEMBL631119,,178.0,Blood,,1,1
12422,50597,,BAO_0000218,,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 30 minutes,,,N,Intermediate,A,10116.0,CHEMBL631120,,178.0,Blood,,1,1
12423,50597,,BAO_0000218,,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 5 minutes,,,N,Intermediate,A,10116.0,CHEMBL631121,,178.0,Blood,,1,1
12424,50597,,BAO_0000218,,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 min,,,N,Intermediate,A,10116.0,CHEMBL874458,,178.0,Blood,,1,1
12425,50597,,BAO_0000218,,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,,,N,Intermediate,A,10116.0,CHEMBL631122,,178.0,Blood,,1,1
12426,50597,,BAO_0000218,,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,,,N,Intermediate,A,10116.0,CHEMBL631123,,178.0,Blood,,1,1
12427,50597,,BAO_0000218,,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,,,N,Intermediate,A,10116.0,CHEMBL631124,,178.0,Blood,,1,1
12428,50597,,BAO_0000218,,,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,,,N,Intermediate,A,10116.0,CHEMBL631125,,178.0,Blood,,1,1
12429,50597,,BAO_0000218,,,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,,,N,Intermediate,A,10116.0,CHEMBL631290,,178.0,Blood,,1,1
12430,50597,,BAO_0000218,,,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,,,N,Intermediate,A,10116.0,CHEMBL631291,,178.0,Blood,,1,1
12431,50597,,BAO_0000218,,,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,,,N,Intermediate,A,10116.0,CHEMBL631292,,178.0,Blood,,1,1
12432,50597,,BAO_0000218,,,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,,,N,Intermediate,A,10116.0,CHEMBL631293,,178.0,Blood,,1,1
12433,50597,,BAO_0000218,,,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,,,N,Intermediate,A,10116.0,CHEMBL631294,,178.0,Blood,,1,1
12434,50597,,BAO_0000218,,,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,,,N,Intermediate,A,10116.0,CHEMBL631295,,178.0,Blood,,1,1
12435,50597,,BAO_0000218,,,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 30 minutes,,,N,Intermediate,A,10116.0,CHEMBL631296,,178.0,Blood,,1,1
12436,50597,,BAO_0000218,,,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,,,N,Intermediate,A,10116.0,CHEMBL631297,,178.0,Blood,,1,1
12437,22224,,BAO_0000218,,,Maximum biodistribution (Bmax) was determined.,,,U,Autocuration,A,,CHEMBL631298,,,,,0,1
12438,50594,,BAO_0000218,,,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 1.5625 (mg/kg) intravenous dose in 6 mice,,,N,Intermediate,A,10090.0,CHEMBL631299,,,,,1,1
12439,50594,,BAO_0000218,,,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 10 (mg/kg) intravenous dose in 6 mice,,,N,Intermediate,A,10090.0,CHEMBL631300,,,,,1,1
12440,50594,,BAO_0000218,,,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 3.125 (mg/kg) intravenous dose in 6 mice,,,N,Intermediate,A,10090.0,CHEMBL631301,,,,,1,1
12441,50594,,BAO_0000218,,,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 6.25 (mg/kg) intravenous dose in 6 mice,,,N,Intermediate,A,10090.0,CHEMBL630291,,,,,1,1
12442,22224,,BAO_0000218,,,Brain concentration after 0.25 hr at a dose of 10 mg/kg when administered intraperitoneally,,,U,Autocuration,A,,CHEMBL630292,,,,,0,1
12443,22224,,BAO_0000218,,,Brain concentration after 0.25 h at a dose of 10 mg/kg when administered intravenously,,,U,Autocuration,A,,CHEMBL630293,,,,,0,1
12444,22224,,BAO_0000218,,,Brain concentration after 0.5 h at a dose of 100 mg/kg when administered perorally,,,U,Autocuration,A,,CHEMBL630294,,,,,0,1
12445,22224,,BAO_0000218,,,Brain concentration after 0.5 h at a dose of 10 mg/kg when administered intraperitoneally,,,U,Autocuration,A,,CHEMBL630295,,,,,0,1
12446,22224,,BAO_0000218,,,Brain concentration after 0.5 hr at a dose of 10 mg/kg when administered intravenously,,,U,Autocuration,A,,CHEMBL630296,,,,,0,1
12447,22224,,BAO_0000218,,,Brain concentration after 0.5 hr at a dose of 10 mg/kg when administered perorally,,,U,Autocuration,A,,CHEMBL626782,,,,,0,1
12448,22224,,BAO_0000218,,,Brain concentration after 1 hr at a dose of 100 mg/kg when administered perorally,,,U,Autocuration,A,,CHEMBL626783,,,,,0,1
12449,22224,,BAO_0000218,,,Brain concentration after 1 hr at a dose of 10 mg/kg when administered intraperitoneally,,,U,Autocuration,A,,CHEMBL626784,,,,,0,1
12450,22224,,BAO_0000218,,,Brain concentration after 1 hr at a dose of 10 mg/kg when administered intravenously,,,U,Autocuration,A,,CHEMBL626785,,,,,0,1
12451,22224,,BAO_0000218,,,Brain concentration after 1 hr at a dose of 10 mg/kg when administered perorally,,,U,Autocuration,A,,CHEMBL626786,,,,,0,1
12452,22224,,BAO_0000218,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,,,U,Autocuration,A,,CHEMBL626787,,,,,0,1
12453,22224,,BAO_0000218,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr; ND means not determined,,,U,Autocuration,A,,CHEMBL626788,,,,,0,1
12454,22224,,BAO_0000218,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,,,U,Autocuration,A,,CHEMBL625927,,,,,0,1
12455,50597,,BAO_0000218,,,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,,N,Intermediate,A,10116.0,CHEMBL625928,,178.0,Blood,,1,1
12456,50597,,BAO_0000218,,,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected,,,N,Intermediate,A,10116.0,CHEMBL625929,,178.0,Blood,,1,1
12457,50597,,BAO_0000218,,,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected.,,,N,Intermediate,A,10116.0,CHEMBL625930,,178.0,Blood,,1,1
12458,50597,,BAO_0000218,,,"Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound, Compound was found to be in trace amount.",,,N,Intermediate,A,10116.0,CHEMBL625931,,178.0,Blood,,1,1
12459,50597,,BAO_0000218,,,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound; ND is Not Detected.,,,N,Intermediate,A,10116.0,CHEMBL627230,,178.0,Blood,,1,1
12460,50597,,BAO_0000218,,,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,,N,Intermediate,A,10116.0,CHEMBL627231,,178.0,Blood,,1,1
12461,50597,,BAO_0000218,,,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,,,N,Intermediate,A,10116.0,CHEMBL627232,,178.0,Blood,,1,1
12462,50597,,BAO_0000218,,,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected.,,,N,Intermediate,A,10116.0,CHEMBL627233,,178.0,Blood,,1,1
12463,50597,,BAO_0000218,,,Concentration 5a detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,,N,Intermediate,A,10116.0,CHEMBL875470,,178.0,Blood,,1,1
12464,50597,,BAO_0000218,,,Concentration 5a detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,,N,Intermediate,A,10116.0,CHEMBL627234,,178.0,Blood,,1,1
12465,50597,,BAO_0000218,,,Concentration 5b detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,,N,Intermediate,A,10116.0,CHEMBL627235,,178.0,Blood,,1,1
12466,50597,,BAO_0000218,,,Concentration 5b detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,,N,Intermediate,A,10116.0,CHEMBL627236,,178.0,Blood,,1,1
12467,50597,,BAO_0000218,,,Concentration 5c detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,,N,Intermediate,A,10116.0,CHEMBL627237,,178.0,Blood,,1,1
12468,50597,,BAO_0000218,,,Concentration 5c detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,,N,Intermediate,A,10116.0,CHEMBL627238,,178.0,Blood,,1,1
12469,50597,,BAO_0000218,,,Concentration 5d detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,,N,Intermediate,A,10116.0,CHEMBL627239,,178.0,Blood,,1,1
12470,50597,,BAO_0000218,,,Concentration 5d detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,,N,Intermediate,A,10116.0,CHEMBL627240,,178.0,Blood,,1,1
12471,50597,,BAO_0000218,,,Concentration 5e detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,,N,Intermediate,A,10116.0,CHEMBL627241,,178.0,Blood,,1,1
12472,50597,,BAO_0000218,,,Concentration 5e detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,,N,Intermediate,A,10116.0,CHEMBL627242,,178.0,Blood,,1,1
12473,50597,,BAO_0000218,,,Concentration 5f detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound; ND is Not Detected,,,N,Intermediate,A,10116.0,CHEMBL627243,,178.0,Blood,,1,1
12474,50597,,BAO_0000218,,,Concentration 5f detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,,,N,Intermediate,A,10116.0,CHEMBL627244,,178.0,Blood,,1,1
12475,50597,,BAO_0000218,,,Concentration 6a detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,,N,Intermediate,A,10116.0,CHEMBL627245,,178.0,Blood,,1,1
12476,50597,,BAO_0000218,,,Concentration 6a detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,,N,Intermediate,A,10116.0,CHEMBL627246,,178.0,Blood,,1,1
12477,50597,,BAO_0000218,,,Concentration 6c detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,,N,Intermediate,A,10116.0,CHEMBL627247,,178.0,Blood,,1,1
12478,50597,,BAO_0000218,,,Concentration 6c detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,,N,Intermediate,A,10116.0,CHEMBL627248,,178.0,Blood,,1,1
12479,50597,,BAO_0000218,,,Concentration 6d detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,,N,Intermediate,A,10116.0,CHEMBL627249,,178.0,Blood,,1,1
12480,50597,,BAO_0000218,,,Concentration 6d detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,,N,Intermediate,A,10116.0,CHEMBL625569,,178.0,Blood,,1,1
12481,50597,,BAO_0000218,,,Concentration 6e detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,,N,Intermediate,A,10116.0,CHEMBL625570,,178.0,Blood,,1,1
12482,50597,,BAO_0000218,,,Concentration 6e detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,,N,Intermediate,A,10116.0,CHEMBL625571,,178.0,Blood,,1,1
12483,50597,,BAO_0000218,,,Concentration 6f detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected,,,N,Intermediate,A,10116.0,CHEMBL625572,,178.0,Blood,,1,1
12484,50597,,BAO_0000218,,,Concentration 6f detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,,,N,Intermediate,A,10116.0,CHEMBL625573,,178.0,Blood,,1,1
12485,50597,,BAO_0000218,,,Concentration detected in blood of rat 1 hr after an oral dose of 200 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL625574,,178.0,Blood,,1,1
12486,50597,,BAO_0000218,,,Concentration detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,,,N,Intermediate,A,10116.0,CHEMBL626245,,178.0,Blood,,1,1
12487,50597,,BAO_0000218,,,Concentration detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,,N,Intermediate,A,10116.0,CHEMBL626246,,178.0,Blood,,1,1
12488,22224,,BAO_0000218,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,,,U,Autocuration,A,,CHEMBL626247,,,,,0,1
12489,22224,,BAO_0000218,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,,,U,Autocuration,A,,CHEMBL626248,,,,,0,1
12490,22224,,BAO_0000218,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.5 hr,,,U,Autocuration,A,,CHEMBL626249,,,,,0,1
12491,22224,,BAO_0000218,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,,,U,Autocuration,A,,CHEMBL626420,,,,,0,1
12492,22224,,BAO_0000218,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,,,U,Autocuration,A,,CHEMBL626421,,,,,0,1
12493,22224,,BAO_0000218,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,,,U,Autocuration,A,,CHEMBL626422,,,,,0,1
12494,22224,,BAO_0000218,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,,,U,Autocuration,A,,CHEMBL626423,,,,,0,1
12495,22224,,BAO_0000218,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,,,U,Autocuration,A,,CHEMBL626424,,,,,0,1
12496,50588,,BAO_0000218,,,Volume of distribution in Beagles dog at a dose of 1 mg/kg given intravenously,,,N,Intermediate,A,9615.0,CHEMBL626425,,,,,1,1
12497,50597,,BAO_0000218,,,Volume of distribution in CD rat at a dose of 5 mg/kg given intravenously,,,N,Intermediate,A,10116.0,CHEMBL875476,,,,,1,1
12498,100710,,BAO_0000218,,,Volume of distribution in Cynomolgus monkey at a dose of 5 mg/kg given intravenously,,,N,Intermediate,A,9541.0,CHEMBL626426,,,,,1,1
12499,22224,,BAO_0000100,,,Distribution coefficient and iron(III) complex was measured at an aqueous phase buffered at pH 7.4 and octanol,,,U,Autocuration,P,,CHEMBL626427,,,,,0,1
12500,22224,,BAO_0000100,,,Distribution coefficient was measured at an aqueous phase buffered at pH 7.4 and octanol,,,U,Autocuration,P,,CHEMBL626428,,,,,0,1
12501,22224,,BAO_0000019,,,Iron clearance was stimulated by the compound was expressed as % distribution of excreted Fe in bile by subcutaneous dose of 150 umol/kg,,,U,Autocuration,A,,CHEMBL626429,,,,,0,1
12502,22224,,BAO_0000019,,,Iron clearance was stimulated by the compound was expressed as % distribution of excreted Fe in urine by subcutaneous dose of 150 umol/kg,,,U,Autocuration,A,,CHEMBL625025,,1088.0,Urine,,0,1
12503,50597,,BAO_0000218,,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,,,N,Intermediate,A,10116.0,CHEMBL625026,,178.0,Blood,,1,1
12504,50597,,BAO_0000218,,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,,,N,Intermediate,A,10116.0,CHEMBL625027,,178.0,Blood,,1,1
12505,50597,,BAO_0000218,,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,,,N,Intermediate,A,10116.0,CHEMBL874410,,178.0,Blood,,1,1
12506,50597,,BAO_0000218,,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,,,N,Intermediate,A,10116.0,CHEMBL625028,,178.0,Blood,,1,1
12507,50597,,BAO_0000218,,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,,,N,Intermediate,A,10116.0,CHEMBL625029,,178.0,Blood,,1,1
12508,50597,,BAO_0000218,,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,,,N,Intermediate,A,10116.0,CHEMBL625030,,178.0,Blood,,1,1
12509,50597,,BAO_0000218,,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,,N,Intermediate,A,10116.0,CHEMBL625031,,178.0,Blood,,1,1
12510,50597,,BAO_0000218,,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,,,N,Intermediate,A,10116.0,CHEMBL625032,,178.0,Blood,,1,1
12511,50597,,BAO_0000218,,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,,,N,Intermediate,A,10116.0,CHEMBL625033,,178.0,Blood,,1,1
12512,50597,,BAO_0000218,,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,,,N,Intermediate,A,10116.0,CHEMBL625034,,178.0,Blood,,1,1
12513,50597,,BAO_0000218,,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,,,N,Intermediate,A,10116.0,CHEMBL624872,,948.0,Heart,,1,1
12514,50597,,BAO_0000218,,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,,,N,Intermediate,A,10116.0,CHEMBL624873,,948.0,Heart,,1,1
12515,50597,,BAO_0000218,,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,,,N,Intermediate,A,10116.0,CHEMBL624874,,948.0,Heart,,1,1
12516,50597,,BAO_0000218,,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,,,N,Intermediate,A,10116.0,CHEMBL624875,,948.0,Heart,,1,1
12517,50597,,BAO_0000218,,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,,,N,Intermediate,A,10116.0,CHEMBL624876,,948.0,Heart,,1,1
12518,50597,,BAO_0000218,,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,,,N,Intermediate,A,10116.0,CHEMBL624877,,948.0,Heart,,1,1
12519,50597,,BAO_0000218,,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,,,N,Intermediate,A,10116.0,CHEMBL624878,,948.0,Heart,,1,1
12520,50597,,BAO_0000218,,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,,,N,Intermediate,A,10116.0,CHEMBL624879,,948.0,Heart,,1,1
12521,50597,,BAO_0000218,,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,,N,Intermediate,A,10116.0,CHEMBL624880,,948.0,Heart,,1,1
12522,50597,,BAO_0000218,,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 10 min (radiolabeled with [125I]-,,,N,Intermediate,A,10116.0,CHEMBL624881,,948.0,Heart,,1,1
12523,50597,,BAO_0000218,,,"Concentration was measured in heart tissue of unfasted Fischer 344 rats, administered intravenous, after 5 minute (radiolabeled with [125I]-",,,N,Intermediate,A,10116.0,CHEMBL624882,,948.0,Heart,,1,1
12524,50597,,BAO_0000218,,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,,,N,Intermediate,A,10116.0,CHEMBL624883,,2113.0,Kidney,,1,1
12525,50597,,BAO_0000218,,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,,,N,Intermediate,A,10116.0,CHEMBL624884,,2113.0,Kidney,,1,1
12526,50597,,BAO_0000218,,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,,,N,Intermediate,A,10116.0,CHEMBL624885,,2113.0,Kidney,,1,1
12527,50597,,BAO_0000218,,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,,,N,Intermediate,A,10116.0,CHEMBL624886,,2113.0,Kidney,,1,1
12528,50597,,BAO_0000218,,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,,,N,Intermediate,A,10116.0,CHEMBL624887,,2113.0,Kidney,,1,1
12529,50597,,BAO_0000218,,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,,,N,Intermediate,A,10116.0,CHEMBL624888,,2113.0,Kidney,,1,1
12530,50597,,BAO_0000218,,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,,,N,Intermediate,A,10116.0,CHEMBL624889,,2113.0,Kidney,,1,1
12531,50597,,BAO_0000218,,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,,,N,Intermediate,A,10116.0,CHEMBL624890,,2113.0,Kidney,,1,1
12532,50597,,BAO_0000218,,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,,N,Intermediate,A,10116.0,CHEMBL621964,,2113.0,Kidney,,1,1
12533,50597,,BAO_0000218,,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,,,N,Intermediate,A,10116.0,CHEMBL621965,,2113.0,Kidney,,1,1
12534,50597,,BAO_0000218,,,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,,,N,Intermediate,A,10116.0,CHEMBL621966,,2107.0,Liver,,1,1
12535,50597,,BAO_0000218,,,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,,,N,Intermediate,A,10116.0,CHEMBL621967,,2107.0,Liver,,1,1
12536,50597,,BAO_0000218,,,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,,,N,Intermediate,A,10116.0,CHEMBL622164,,2107.0,Liver,,1,1
12537,22224,,BAO_0000019,,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid insoluble (nucleic acids),,,U,Autocuration,A,,CHEMBL623097,,,,,0,1
12538,22224,,BAO_0000019,,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid insoluble (protein),,,U,Autocuration,A,,CHEMBL623098,,,,,0,1
12539,22224,,BAO_0000019,,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid soluble,,,U,Autocuration,A,,CHEMBL623099,,,,,0,1
12540,22224,,BAO_0000019,,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; total uptake,,,U,Autocuration,A,,CHEMBL623100,,,,,0,1
12541,50597,,BAO_0000218,,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated Number of new tumors observed",,,N,Intermediate,A,10116.0,CHEMBL628673,,,,,1,1
12542,50597,,BAO_0000218,,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated complete percent remission indicates tumor not palpable.",,,N,Intermediate,A,10116.0,CHEMBL628674,,,,,1,1
12543,50597,,BAO_0000218,,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated number of tumors at the beginning of the test.",,,N,Intermediate,A,10116.0,CHEMBL628675,,,,,1,1
12544,50597,,BAO_0000218,,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated of percent static tumors indicates size of tumor 51-150% of the initial size",,,N,Intermediate,A,10116.0,CHEMBL627644,,,,,1,1
12545,50597,,BAO_0000218,,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated partial percent remission indicates reduction of initial tumor size <=50%.",,,N,Intermediate,A,10116.0,CHEMBL627645,,,,,1,1
12546,50597,,BAO_0000218,,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent progress in tumor size indicates >150% of the initial size",,,N,Intermediate,A,10116.0,CHEMBL627646,,,,,1,1
12547,50597,,BAO_0000218,,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent static tumors indicates size of tumor 51-150% of the initial size",,,N,Intermediate,A,10116.0,CHEMBL627647,,,,,1,1
12548,50597,,BAO_0000218,,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent tumor area measured as the average on the 28th day of therapy.",,,N,Intermediate,A,10116.0,CHEMBL627648,,,,,1,1
12549,50597,,BAO_0000218,,,Free level in rat plasma,,,N,Intermediate,A,10116.0,CHEMBL627649,,,,,1,1
12550,22224,,BAO_0000019,,,Level reaching in blood plasma of rat or human was determined,,,U,Autocuration,A,,CHEMBL628313,,,,,0,1
12551,50597,,BAO_0000218,,,Log (Cbrain/Cblood) in rats,,,N,Intermediate,A,10116.0,CHEMBL628314,,,,,1,1
12552,22224,,BAO_0000019,,,Mean percentage of compound transport through P-glycoprotein; expressed as p-glycoprotein affinity,,,U,Autocuration,A,,CHEMBL628315,,,,,0,1
12553,22224,,BAO_0000019,,,Mean percentage of compound transport through membrane; expressed as membrane transport,,,U,Autocuration,A,,CHEMBL628316,,,,,0,1
12554,22224,,BAO_0000218,,,Metabolic breakdown to the o-sulfate of p-chloroaniline (2-amino-5-chlorophenyl sulfate) by giving 100 mg/kg oral doses of the compound,,,U,Autocuration,A,,CHEMBL628317,,,,,0,1
12555,22224,,BAO_0000019,,,Michaelis-Menten constant was measured in the inactivation of HPK; Km x 10 e5,,,U,Autocuration,A,,CHEMBL628473,,,,,0,1
12556,22224,,BAO_0000019,,,"Michaelis-Menten constant was measured in the inactivation of HPK; Km x 10 e5, ND=Not determined",,,U,Autocuration,A,,CHEMBL628474,,,,,0,1
12557,22224,,BAO_0000019,,,Michaelis-Menten constant was measured in the inactivation of trypsin; Km x 10 e5,,,U,Autocuration,A,,CHEMBL628475,,,,,0,1
12558,22224,,BAO_0000019,,,Net water uptake by a carrier mediated transport (%cm) mechanism,,,U,Autocuration,A,,CHEMBL628476,,,,,0,1
12559,22224,,BAO_0000218,,,Peak concentration was determined in portal circulation after intraduodenal dose of 10 mg/kg in monkey,,,U,Autocuration,A,314293.0,CHEMBL628477,,,,,0,1
12560,50506,,BAO_0000218,,,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret,,,N,Intermediate,A,9669.0,CHEMBL628478,,,,,1,1
12561,50506,,BAO_0000218,,,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret, determined by renin inhibition assay",,,N,Intermediate,A,9669.0,CHEMBL628479,,,,,1,1
12562,22224,,BAO_0000218,,,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey,,,U,Autocuration,A,314293.0,CHEMBL628480,,,,,0,1
12563,22224,,BAO_0000218,,,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey, determined by renin inhibition assay",,,U,Autocuration,A,314293.0,CHEMBL628481,,,,,0,1
12564,50597,,BAO_0000218,,,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat,,,N,Intermediate,A,10116.0,CHEMBL628482,,,,,1,1
12565,50597,,BAO_0000218,,,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",,,N,Intermediate,A,10116.0,CHEMBL628483,,,,,1,1
12566,50597,,BAO_0000218,,,"Peak plasma concentration at a dose of 10 mg/kg, ip route in rat suspended in carboxymethyl cellulose (CMC);ND is defined as no-data.",,,N,Intermediate,A,10116.0,CHEMBL628484,,1969.0,Plasma,,1,1
12567,50597,,BAO_0000218,,,"Peak plasma concentration at a dose of 100 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",,,N,Intermediate,A,10116.0,CHEMBL628485,,1969.0,Plasma,,1,1
12568,100710,,BAO_0000218,,,"Peak plasma concentration at a dose of 20 mg/kg, oral route in monkey (Macaca fascicularis) suspended in carboxymethyl cellulose (CMC);Range is between (5.5-6)",,,N,Intermediate,A,9541.0,CHEMBL628486,,1969.0,Plasma,,1,1
12569,50587,,BAO_0000218,,,"Peak plasma concentration at a dose of 200 mg/kg, oral route in human",,,N,Intermediate,A,9606.0,CHEMBL628487,,1969.0,Plasma,,1,1
12570,50597,,BAO_0000218,,,"Peak plasma concentration at a dose of 25 mg/kg, ip route in rat suspended in carboxymethyl cellulose (CMC);ND is defined as no-data.",,,N,Intermediate,A,10116.0,CHEMBL628488,,1969.0,Plasma,,1,1
12571,50597,,BAO_0000218,,,"Peak plasma concentration at a dose of 25 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",,,N,Intermediate,A,10116.0,CHEMBL628489,,1969.0,Plasma,,1,1
12572,50597,,BAO_0000218,,,"Peak plasma concentration at a dose of 50 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",,,N,Intermediate,A,10116.0,CHEMBL628490,,1969.0,Plasma,,1,1
12573,100710,,BAO_0000218,,,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using HPLC assay,,,N,Intermediate,A,9541.0,CHEMBL628491,,,,,1,1
12574,100710,,BAO_0000218,,,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using HPLC assay,,,N,Intermediate,A,9541.0,CHEMBL877507,,,,,1,1
12575,22224,,BAO_0000218,,,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,,,U,Autocuration,A,,CHEMBL628492,,,,,0,1
12576,22224,,BAO_0000019,,,% metabolized in monkey S-9 after 2 hours (10 ug/mL),,,U,Autocuration,A,314293.0,CHEMBL628493,,,,,0,1
12577,22224,,BAO_0000019,,,% metabolized in monkey S-9 after 2 hours (1 ug/ml),,,U,Autocuration,A,314293.0,CHEMBL628494,,,,,0,1
12578,22224,,BAO_0000019,,,% metabolized in monkey S-9 after 2 hours (10 ug/ml),,,U,Autocuration,A,314293.0,CHEMBL628495,,,,,0,1
12579,50587,,BAO_0000218,,,Permeability in Caco-2 assay at 10E-6,,,N,Intermediate,A,9606.0,CHEMBL628496,,,,,1,1
12580,22224,,BAO_0000218,,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in brain,,,U,Autocuration,A,,CHEMBL628497,,955.0,Brain,,0,1
12581,22224,,BAO_0000218,,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in brain,,,U,Autocuration,A,,CHEMBL628498,,955.0,Brain,,0,1
12582,22224,,BAO_0000019,,,Plasma protein binding was determined,,,U,Autocuration,A,,CHEMBL628499,,,,,0,1
12583,22224,,BAO_0000218,,,Brain concentration after 2 hr at a dose of 100 mg/kg when administered perorally,,,U,Autocuration,A,,CHEMBL627656,,,,,0,1
12584,22224,,BAO_0000218,,,Brain concentration after 2 hr at a dose of 10 mg/kg when administered intraperitoneally,,,U,Autocuration,A,,CHEMBL627657,,,,,0,1
12585,22224,,BAO_0000218,,,Brain concentration after 2 hr at a dose of 10 mg/kg when administered intravenously,,,U,Autocuration,A,,CHEMBL626808,,,,,0,1
12586,22224,,BAO_0000218,,,Brain concentration after 2 hr at a dose of 10 mg/kg when administered perorally,,,U,Autocuration,A,,CHEMBL626809,,,,,0,1
12587,22224,,BAO_0000218,,,Brain concentration after 4 hr at a dose of 100 mg/kg when administered perorally,,,U,Autocuration,A,,CHEMBL626810,,,,,0,1
12588,22224,,BAO_0000218,,,Brain concentration after 4 hr at a dose of 10 mg/kg when administered intraperitoneally,,,U,Autocuration,A,,CHEMBL626811,,,,,0,1
12589,22224,,BAO_0000218,,,Brain concentration after 4 hr at a dose of 10 mg/kg when administered intravenously,,,U,Autocuration,A,,CHEMBL874465,,,,,0,1
12590,22224,,BAO_0000218,,,Brain concentration after 4 hr at a dose of 10 mg/kg when administered perorally,,,U,Autocuration,A,,CHEMBL626812,,,,,0,1
12591,22224,,BAO_0000218,,,Brain concentration after 6 hr at a dose of 100 mg/kg when administered perorally,,,U,Autocuration,A,,CHEMBL626813,,,,,0,1
12592,22224,,BAO_0000218,,,Brain concentration after 6 hr at a dose of 10 mg/kg when administered perorally,,,U,Autocuration,A,,CHEMBL626814,,,,,0,1
12593,22224,,BAO_0000019,,,Bullaticin index relates the IC50 values by normalizing to the value of bullatacin for easy comparison.,,,U,Autocuration,A,,CHEMBL626815,,,,,0,1
12594,22224,,BAO_0000019,,,Partition coefficient (logP),,,U,Autocuration,A,,CHEMBL628566,,,,,0,1
12595,22229,,BAO_0000100,,,Calculated partition coefficient (clogP) (CLOGP3 V3.4),,,U,Autocuration,P,,CHEMBL628567,,,,,0,1
12596,22229,,BAO_0000100,,,Calculated partition coefficient (clogP),,,U,Autocuration,P,,CHEMBL628568,,,,,0,1
12597,50588,In vivo,BAO_0000218,,,C max in dog,,,N,Intermediate,A,9615.0,CHEMBL628569,,,,,1,1
12598,50512,In vivo,BAO_0000218,,,C max in guinea pig,,,N,Intermediate,A,10141.0,CHEMBL628570,,,,,1,1
12599,22224,In vivo,BAO_0000218,,,C max value was evaluated,,,U,Autocuration,A,,CHEMBL628571,,,,,0,1
12600,22224,In vivo,BAO_0000218,,,Cmax value after oral dose of 0.1 mg//kg,,,U,Autocuration,A,,CHEMBL628572,,,,,0,1
12601,22224,In vivo,BAO_0000218,,,Cmax value after oral dose of 0.3 mg/kg,,,U,Autocuration,A,,CHEMBL628573,,,,,0,1
12602,22224,In vivo,BAO_0000218,,,Cmax value after oral dose of 1 mg/kg,,,U,Autocuration,A,,CHEMBL628574,,,,,0,1
12603,22224,In vivo,BAO_0000218,,,Cmax value after oral dose of 10 mg/kg,,,U,Autocuration,A,,CHEMBL628575,,,,,0,1
12604,22224,In vivo,BAO_0000218,,,Cmax value after oral dose of 23.4 mg/kg,,,U,Autocuration,A,,CHEMBL628576,,,,,0,1
12605,22224,In vivo,BAO_0000218,,,Cmax value after oral dose of 3 mg/kg,,,U,Autocuration,A,,CHEMBL628577,,,,,0,1
12606,22224,In vivo,BAO_0000218,,,Cmax value after oral dose of 3.87 mg/kg,,,U,Autocuration,A,,CHEMBL628578,,,,,0,1
12607,50588,In vivo,BAO_0000218,,,Cmax value in female Beagle dogs,,,N,Intermediate,A,9615.0,CHEMBL874466,,,,,1,1
12608,50597,In vivo,BAO_0000218,,,Cmax value in male rats,,,N,Intermediate,A,10116.0,CHEMBL628579,,,,,1,1
12609,50597,In vivo,BAO_0000218,,,Cmax value in rat plasma when administered 20 mg/kg perorally,,,N,Intermediate,A,10116.0,CHEMBL628580,,1969.0,Plasma,,1,1
12610,50588,In vivo,BAO_0000218,,,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,,,N,Intermediate,A,9615.0,CHEMBL628581,,1969.0,Plasma,,1,1
12611,50588,In vivo,BAO_0000218,,,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,,,N,Intermediate,A,9615.0,CHEMBL628582,,1969.0,Plasma,,1,1
12612,50588,,BAO_0000218,,,Peak concentration of compound at Time = 0 was determined in dog at 5 mg/kg intravenously admn.,,,N,Intermediate,A,9615.0,CHEMBL628583,,,,,1,1
12613,22224,,BAO_0000218,,,Peak concentration of compound at Time = 0 was determined in monkey at 5 mg/kg intravenously admn.,,,U,Autocuration,A,314293.0,CHEMBL625782,,,,,0,1
12614,50592,,BAO_0000218,,,Peak concentration of compound at Time = 0 was determined in rabbit at 5 mg/kg intravenously admn.,,,N,Intermediate,A,9986.0,CHEMBL625783,,,,,1,1
12615,50597,,BAO_0000218,,,Peak concentration of compound at Time = 0 was determined in rat at 5 mg/kg intravenously admn.,,,N,Intermediate,A,10116.0,CHEMBL625784,,,,,1,1
12616,50797,,BAO_0000218,,,Total plasma concentration at 24 hr at a dose of 10 mg/kg when administered orally to rhesus monkey,,,N,Intermediate,A,9544.0,CHEMBL625785,,1969.0,Plasma,,1,1
12617,50597,,BAO_0000218,,,C5min (nM) value was determined in rats after intravenous dose of 5 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL625786,,,,,1,1
12618,22224,,BAO_0000019,,,C6h was measured as concentration obtained after 6 hr of oral administration in air pouch exudate,,,U,Autocuration,A,,CHEMBL874467,,,,,0,1
12619,50588,,BAO_0000218,,,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 )",,,N,Intermediate,A,9615.0,CHEMBL625787,,,,,1,1
12620,50677,,BAO_0000218,,,cytotoxicity against HIV protease enzyme.,,,N,Intermediate,A,12721.0,CHEMBL625964,,,,,1,1
12621,50594,,BAO_0000218,,,Apparent clearance in mice after intravenous administration of 105.1 mg/kg of dose,,,N,Intermediate,A,10090.0,CHEMBL625965,,,,,1,1
12622,50594,,BAO_0000218,,,Apparent clearance in mice after oral administration of 100 mg/kg of dose,,,N,Intermediate,A,10090.0,CHEMBL625966,,,,,1,1
12623,50588,In vivo,BAO_0000218,,,The plasma clearance in dog.,,,N,Intermediate,A,9615.0,CHEMBL625967,,1969.0,Plasma,,1,1
12624,50597,In vivo,BAO_0000218,,,The plasma clearance in rat.,,,N,Intermediate,A,10116.0,CHEMBL625968,,1969.0,Plasma,,1,1
12625,50597,In vivo,BAO_0000218,,,Clearance from plasma in male Sprague-Dawley rats,,,N,Intermediate,A,10116.0,CHEMBL625969,,1969.0,Plasma,,1,1
12626,100710,In vivo,BAO_0000218,,,Clearance from plasma in male cynomolgus monkeys,,,N,Intermediate,A,9541.0,CHEMBL625970,,1969.0,Plasma,,1,1
12627,50588,In vivo,BAO_0000218,,,"Clearance of compound (5 mg/kg, intravenously), in dog plasma",,,N,Intermediate,A,9615.0,CHEMBL625971,,1969.0,Plasma,,1,1
12628,50588,In vivo,BAO_0000218,,,Clearance of compound in dog plasma,,,N,Intermediate,A,9615.0,CHEMBL625972,,1969.0,Plasma,,1,1
12629,50587,In vivo,BAO_0000218,,,Clearance of compound in human plasma,,,N,Intermediate,A,9606.0,CHEMBL625973,,1969.0,Plasma,,1,1
12630,50588,In vivo,BAO_0000218,,,Clearance of compound when administered intravenously as a mixture (five-in-one dose) to a single dog.,,,N,Intermediate,A,9615.0,CHEMBL625974,,,,,1,1
12631,50588,In vivo,BAO_0000218,,,Clearance of compound when administered intravenously as an individual dose to a single dog.,,,N,Intermediate,A,9615.0,CHEMBL625975,,,,,1,1
12632,50588,In vivo,BAO_0000218,,,"Clearance (10 mg/kg, intravenously) in dog plasma",,,N,Intermediate,A,9615.0,CHEMBL625976,,1969.0,Plasma,,1,1
12633,50588,In vivo,BAO_0000218,,,Clearance value in dog,,,N,Intermediate,A,9615.0,CHEMBL625977,,,,,1,1
12634,50512,In vivo,BAO_0000218,,,Clearance value in guinea pig,,,N,Intermediate,A,10141.0,CHEMBL625978,,,,,1,1
12635,50597,In vivo,BAO_0000218,,,Clearance values in rats after iv administration.,,,N,Intermediate,A,10116.0,CHEMBL874468,,,,,1,1
12636,22224,In vivo,BAO_0000218,,,Compound was tested for plasma clearance on administered orally as aqueous solutions at 1 mpk and by iv at 0.2 mpk,,,U,Autocuration,A,,CHEMBL625421,,1969.0,Plasma,,0,1
12637,50592,In vivo,BAO_0000218,,,In vivo clearance (5 mg/kg) was determined in rabbits,,,N,Intermediate,A,9986.0,CHEMBL625422,,,,,1,1
12638,50597,In vivo,BAO_0000218,,,Plasma Clearance rate was determined for the compound in rats,,,N,Intermediate,A,10116.0,CHEMBL625423,,,,,1,1
12639,22224,In vivo,BAO_0000218,,,Plasma Clearance rate was determined for the compound in squirrel monkeys,,,U,Autocuration,A,9520.0,CHEMBL625424,,,,,0,1
12640,50597,In vivo,BAO_0000218,,,Plasma clearance in rat,,,N,Intermediate,A,10116.0,CHEMBL625425,,,,,1,1
12641,22224,In vivo,BAO_0000218,,,Plasma clearance of the compound,,,U,Autocuration,A,,CHEMBL625426,,,,,0,1
12642,50512,In vivo,BAO_0000218,,,Plasma clearance in guinea pigs at 2 mg/kg after iv administration,,,N,Intermediate,A,10141.0,CHEMBL625427,,,,,1,1
12643,50512,In vivo,BAO_0000218,,,Plasma clearance in guinea pigs at 3 mg/kg after iv administration,,,N,Intermediate,A,10141.0,CHEMBL625428,,,,,1,1
12644,22224,In vivo,BAO_0000218,,,Plasma clearance was determined,,,U,Autocuration,A,,CHEMBL625429,,,,,0,1
12645,50588,In vivo,BAO_0000218,,,Plasma clearance rate (CL) was determined in dogs after intravenous administration of 25 mg/kg of the compound.,,,N,Intermediate,A,9615.0,CHEMBL625430,,,,,1,1
12646,50597,In vivo,BAO_0000218,,,Plasma clearance rate was determined for the compound in rats,,,N,Intermediate,A,10116.0,CHEMBL625431,,,,,1,1
12647,22224,In vivo,BAO_0000218,,,Plasma clearance rate was determined for the compound in squirrel monkeys,,,U,Autocuration,A,9520.0,CHEMBL627307,,,,,0,1
12648,22224,In vivo,BAO_0000218,,,Slow clearance (CL) was determined,,,U,Autocuration,A,,CHEMBL627308,,,,,0,1
12649,22224,,BAO_0000218,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,,,U,Autocuration,A,,CHEMBL627309,,,,,0,1
12650,22224,,BAO_0000218,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr; insufficient gastric juice produced,,,U,Autocuration,A,,CHEMBL627310,,,,,0,1
12651,22224,,BAO_0000218,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr,,,U,Autocuration,A,,CHEMBL627311,,,,,0,1
12652,22224,,BAO_0000218,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,,,U,Autocuration,A,,CHEMBL627312,,,,,0,1
12653,22224,,BAO_0000218,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr,,,U,Autocuration,A,,CHEMBL627313,,,,,0,1
12654,22224,,BAO_0000218,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,,,U,Autocuration,A,,CHEMBL627314,,,,,0,1
12655,22224,,BAO_0000218,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,,,U,Autocuration,A,,CHEMBL627315,,,,,0,1
12656,22224,,BAO_0000218,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,,,U,Autocuration,A,,CHEMBL627316,,,,,0,1
12657,22224,,BAO_0000218,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,,,U,Autocuration,A,,CHEMBL627317,,,,,0,1
12658,22224,,BAO_0000218,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,,,U,Autocuration,A,,CHEMBL627318,,,,,0,1
12659,22224,,BAO_0000218,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.5 hr,,,U,Autocuration,A,,CHEMBL627999,,,,,0,1
12660,22224,,BAO_0000218,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,,,U,Autocuration,A,,CHEMBL628000,,,,,0,1
12661,22224,,BAO_0000218,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,,,U,Autocuration,A,,CHEMBL628001,,,,,0,1
12662,22224,,BAO_0000218,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,,,U,Autocuration,A,,CHEMBL628002,,,,,0,1
12663,22224,,BAO_0000218,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,,,U,Autocuration,A,,CHEMBL625610,,,,,0,1
12664,22224,,BAO_0000218,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,,,U,Autocuration,A,,CHEMBL625611,,,,,0,1
12665,22224,,BAO_0000218,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr,,,U,Autocuration,A,,CHEMBL625612,,,,,0,1
12666,22224,,BAO_0000218,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr,,,U,Autocuration,A,,CHEMBL625613,,,,,0,1
12667,22224,,BAO_0000218,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,,,U,Autocuration,A,,CHEMBL875479,,,,,0,1
12668,22224,,BAO_0000218,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,,,U,Autocuration,A,,CHEMBL625614,,,,,0,1
12669,22224,,BAO_0000218,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,,,U,Autocuration,A,,CHEMBL625615,,,,,0,1
12670,22224,,BAO_0000218,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr,,,U,Autocuration,A,,CHEMBL626302,,,,,0,1
12671,50597,,BAO_0000218,,,Cumulative concentration 6b and compound 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,,N,Intermediate,A,10116.0,CHEMBL626303,,178.0,Blood,,1,1
12672,50597,,BAO_0000218,,,Cumulative concentration 6b and compound 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,,N,Intermediate,A,10116.0,CHEMBL627420,,178.0,Blood,,1,1
12673,50597,,BAO_0000218,,,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 1 hour relative to initial concentration of 1 uM,,,N,Intermediate,A,10116.0,CHEMBL627421,,,,,1,1
12674,50597,,BAO_0000218,,,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 24 hour relative to initial concentration of 1 uM,,,N,Intermediate,A,10116.0,CHEMBL625695,,,,,1,1
12675,50597,,BAO_0000218,,,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 4 hour relative to initial concentration of 1 uM,,,N,Intermediate,A,10116.0,CHEMBL625696,,,,,1,1
12676,50594,,BAO_0000218,,,Distribution of compound in mice brain was measured after 1 hr,,,N,Intermediate,A,10090.0,CHEMBL875606,,955.0,Brain,,1,1
12677,50594,,BAO_0000218,,,Distribution of compound in mice brain was measured after 24 hr r,,,N,Intermediate,A,10090.0,CHEMBL625697,,955.0,Brain,,1,1
12678,50594,,BAO_0000218,,,Distribution of compound in mice brain was measured after 2 hr,,,N,Intermediate,A,10090.0,CHEMBL625698,,955.0,Brain,,1,1
12679,50594,,BAO_0000218,,,Distribution of compound in mice brain was measured after 3 hr,,,N,Intermediate,A,10090.0,CHEMBL625699,,955.0,Brain,,1,1
12680,50594,,BAO_0000218,,,Distribution of compound in mice brain was measured after 6 hr,,,N,Intermediate,A,10090.0,CHEMBL625700,,955.0,Brain,,1,1
12681,50594,,BAO_0000218,,,Distribution of compound in mice liver was measured after 1 hr,,,N,Intermediate,A,10090.0,CHEMBL625701,,,,,1,1
12682,50594,,BAO_0000218,,,Distribution of compound in mice liver was measured after 24 hr; b=Undetected,,,N,Intermediate,A,10090.0,CHEMBL625702,,,,,1,1
12683,50594,,BAO_0000218,,,Distribution of compound in mice liver was measured after 2 hr,,,N,Intermediate,A,10090.0,CHEMBL625703,,,,,1,1
12684,50594,,BAO_0000218,,,Distribution of compound in mice liver was measured after 3 hr,,,N,Intermediate,A,10090.0,CHEMBL625704,,,,,1,1
12685,50594,,BAO_0000218,,,Distribution of compound in mice liver was measured after 6 hr,,,N,Intermediate,A,10090.0,CHEMBL625705,,,,,1,1
12686,50588,,BAO_0000218,,,Distribution in dog adrenal medulla 30 min after administration.,,,N,Intermediate,A,9615.0,CHEMBL625706,,1236.0,Adrenal medulla,,1,1
12687,50588,,BAO_0000218,,,Distribution in dog adrenal medulla 72 hours after administration.,,,N,Intermediate,A,9615.0,CHEMBL625707,,1236.0,Adrenal medulla,,1,1
12688,50588,,BAO_0000218,,,Distribution in female dog Ovary 24 hours after administration.,,,N,Intermediate,A,9615.0,CHEMBL625708,,,,,1,1
12689,50588,,BAO_0000218,,,Distribution in female dog Ovary 72 hours after administration.,,,N,Intermediate,A,9615.0,CHEMBL625709,,,,,1,1
12690,50588,,BAO_0000218,,,Distribution in female dog adipose 24 hours after administration.,,,N,Intermediate,A,9615.0,CHEMBL624180,,,,,1,1
12691,50588,,BAO_0000218,,,Distribution in female dog adipose 72 hours after administration.,,,N,Intermediate,A,9615.0,CHEMBL624181,,,,,1,1
12692,50588,,BAO_0000218,,,Distribution in female dog adrenal cortex 72 hours after administration.,,,N,Intermediate,A,9615.0,CHEMBL624182,,1235.0,Adrenal cortex,,1,1
12693,50588,,BAO_0000218,,,Distribution in female dog adrenal cortex 72 hours after administration.,,,N,Intermediate,A,9615.0,CHEMBL624183,,1235.0,Adrenal cortex,,1,1
12694,50597,,BAO_0000218,,,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,,,N,Intermediate,A,10116.0,CHEMBL624184,,2107.0,Liver,,1,1
12695,50597,,BAO_0000218,,,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,,,N,Intermediate,A,10116.0,CHEMBL877489,,2107.0,Liver,,1,1
12696,50597,,BAO_0000218,,,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,,N,Intermediate,A,10116.0,CHEMBL624185,,2107.0,Liver,,1,1
12697,50597,,BAO_0000218,,,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,,,N,Intermediate,A,10116.0,CHEMBL624186,,2107.0,Liver,,1,1
12698,50597,,BAO_0000218,,,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,,,N,Intermediate,A,10116.0,CHEMBL624187,,2107.0,Liver,,1,1
12699,50597,,BAO_0000218,,,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,,,N,Intermediate,A,10116.0,CHEMBL624188,,2107.0,Liver,,1,1
12700,50597,,BAO_0000218,,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,,,N,Intermediate,A,10116.0,CHEMBL624189,,2048.0,Lung,,1,1
12701,50597,,BAO_0000218,,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,,,N,Intermediate,A,10116.0,CHEMBL624190,,2048.0,Lung,,1,1
12702,50597,,BAO_0000218,,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,,,N,Intermediate,A,10116.0,CHEMBL624191,,2048.0,Lung,,1,1
12703,50597,,BAO_0000218,,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,,,N,Intermediate,A,10116.0,CHEMBL624192,,2048.0,Lung,,1,1
12704,50597,,BAO_0000218,,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,,,N,Intermediate,A,10116.0,CHEMBL624193,,2048.0,Lung,,1,1
12705,50597,,BAO_0000218,,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,,,N,Intermediate,A,10116.0,CHEMBL624194,,2048.0,Lung,,1,1
12706,50597,,BAO_0000218,,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,,,N,Intermediate,A,10116.0,CHEMBL624891,,2048.0,Lung,,1,1
12707,50597,,BAO_0000218,,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,,,N,Intermediate,A,10116.0,CHEMBL624892,,2048.0,Lung,,1,1
12708,50597,,BAO_0000218,,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,,,N,Intermediate,A,10116.0,CHEMBL624893,,2048.0,Lung,,1,1
12709,50597,,BAO_0000218,,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,,N,Intermediate,A,10116.0,CHEMBL627632,,2048.0,Lung,,1,1
12710,50597,,BAO_0000218,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,,,N,Intermediate,A,10116.0,CHEMBL627633,,,,,1,1
12711,50597,,BAO_0000218,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,,,N,Intermediate,A,10116.0,CHEMBL627634,,,,,1,1
12712,50597,,BAO_0000218,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,,,N,Intermediate,A,10116.0,CHEMBL627635,,,,,1,1
12713,50597,,BAO_0000218,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,,,N,Intermediate,A,10116.0,CHEMBL627636,,,,,1,1
12714,50597,,BAO_0000218,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,,,N,Intermediate,A,10116.0,CHEMBL626816,,,,,1,1
12715,50597,,BAO_0000218,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,,,N,Intermediate,A,10116.0,CHEMBL626817,,,,,1,1
12716,50597,,BAO_0000218,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,,,N,Intermediate,A,10116.0,CHEMBL626818,,,,,1,1
12717,50597,,BAO_0000218,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,,,N,Intermediate,A,10116.0,CHEMBL626819,,,,,1,1
12718,50597,,BAO_0000218,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,,,N,Intermediate,A,10116.0,CHEMBL626820,,,,,1,1
12719,50597,,BAO_0000218,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,,N,Intermediate,A,10116.0,CHEMBL626821,,,,,1,1
12720,50597,,BAO_0000218,,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,,,N,Intermediate,A,10116.0,CHEMBL626822,,2046.0,Thyroid gland,,1,1
12721,50597,,BAO_0000218,,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,,,N,Intermediate,A,10116.0,CHEMBL626823,,2046.0,Thyroid gland,,1,1
12722,50597,,BAO_0000218,,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,,,N,Intermediate,A,10116.0,CHEMBL626824,,2046.0,Thyroid gland,,1,1
12723,50597,,BAO_0000218,,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,,,N,Intermediate,A,10116.0,CHEMBL626825,,2046.0,Thyroid gland,,1,1
12724,50597,,BAO_0000218,,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,,,N,Intermediate,A,10116.0,CHEMBL626826,,2046.0,Thyroid gland,,1,1
12725,50597,,BAO_0000218,,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,,,N,Intermediate,A,10116.0,CHEMBL626827,,2046.0,Thyroid gland,,1,1
12726,50597,,BAO_0000218,,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,,,N,Intermediate,A,10116.0,CHEMBL626828,,2046.0,Thyroid gland,,1,1
12727,50597,,BAO_0000218,,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,,,N,Intermediate,A,10116.0,CHEMBL626829,,2046.0,Thyroid gland,,1,1
12728,50597,,BAO_0000218,,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,,N,Intermediate,A,10116.0,CHEMBL626830,,2046.0,Thyroid gland,,1,1
12729,50597,,BAO_0000218,,,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,,,N,Intermediate,A,10116.0,CHEMBL627150,,,,,1,1
12730,50597,,BAO_0000218,,,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,,N,Intermediate,A,10116.0,CHEMBL627151,,,,,1,1
12731,50597,,BAO_0000218,,,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,,,N,Intermediate,A,10116.0,CHEMBL627152,,,,,1,1
12732,50597,,BAO_0000218,,,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,,N,Intermediate,A,10116.0,CHEMBL627153,,,,,1,1
12733,22224,,BAO_0000019,,,Rate of acetate production by the compound was determined,,,U,Autocuration,A,,CHEMBL627154,,,,,0,1
12734,22224,,BAO_0000019,,,Rate of acetate production by the compound was determined; Not determined,,,U,Autocuration,A,,CHEMBL627155,,,,,0,1
12735,22224,,BAO_0000019,,,Rate of hydrolysis of nitrocefin by compound was evaluated in water,,,U,Autocuration,A,,CHEMBL627156,,,,,0,1
12736,22224,,BAO_0000019,,,Reductive elimination of leaving group was determined at pH 7.4; expressed as loss of parent,,,U,Autocuration,A,,CHEMBL627157,,,,,0,1
12737,50592,,BAO_0000218,,,Relative concentration of compound (70 mg/Kg) in brain compared to concentration in plasma (160 ug/mL) at the time of tissue collection from rabbit; relative concentration,,,N,Intermediate,A,9986.0,CHEMBL627158,,,,,1,1
12738,50592,,BAO_0000218,,,Relative concentration of compound (70 mg/Kg) in lung compared to concentration in plasma (160 ug/mL) at the time of tissue collection from rabbit; relative concentration,,,N,Intermediate,A,9986.0,CHEMBL627159,,1969.0,Plasma,,1,1
12739,50594,,BAO_0000218,,,Relative concentration of compound in brain compared to concentration in plasma (0.4 ug/mL) at the time of tissue collection from mice; relative concentration,,,N,Intermediate,A,10090.0,CHEMBL627160,,,,,1,1
12740,50597,,BAO_0000218,,,Relative concentration of compound in brain compared to concentration in plasma (3.5 ug/mL) at the time of tissue collection from mice; relative concentration,,,N,Intermediate,A,10116.0,CHEMBL628540,,,,,1,1
12741,50597,,BAO_0000218,,,Relative concentration of compound in lung compared to concentration in plasma (0.4 ug/mL) at the time of tissue collection from mice; relative concentration,,,N,Intermediate,A,10116.0,CHEMBL628541,,1969.0,Plasma,,1,1
12742,50597,,BAO_0000218,,,Relative concentration of compound in lung compared to concentration in plasma (3.5 ug/mL) at the time of tissue collection from mice; relative concentration,,,N,Intermediate,A,10116.0,CHEMBL628542,,1969.0,Plasma,,1,1
12743,22229,,BAO_0000100,,,Solubility after at a pH 1.2,,,U,Autocuration,P,,CHEMBL628543,,,,,0,1
12744,22229,,BAO_0000100,,,Solubility after at pH 1.2,,,U,Autocuration,P,,CHEMBL628544,,,,,0,1
12745,22229,,BAO_0000100,,,Solubility after injection of water,,,U,Autocuration,P,,CHEMBL628545,,,,,0,1
12746,22224,,BAO_0000019,,,Statistical significance of IC 50 values; Expressed as R value,,,U,Autocuration,A,,CHEMBL628546,,,,,0,1
12747,22224,,BAO_0000019,,,Systemic availability with respect to methyldopa was determined,,,U,Autocuration,A,,CHEMBL874455,,,,,0,1
12748,50597,,BAO_0000218,,,Tissue distribution of the in rat brain relative to plasma concentration of 1 ug/kg; relative concentration,,,N,Intermediate,A,10116.0,CHEMBL628547,,,,,1,1
12749,50597,,BAO_0000218,,,Tissue distribution of the in rat lung relative to plasma concentration of 1 ug/kg; relative concentration,,,N,Intermediate,A,10116.0,CHEMBL628548,,1969.0,Plasma,,1,1
12750,50592,,BAO_0000218,,,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit 1 lung, and radioactivity content in feces was estimated",,,N,Intermediate,A,9986.0,CHEMBL628549,,1988.0,Feces,,1,1
12751,50592,,BAO_0000218,,,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit 1 liver, and radioactivity content in feces was estimated",,,N,Intermediate,A,9986.0,CHEMBL628550,,1988.0,Feces,,1,1
12752,50592,,BAO_0000218,,,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit3, and radioactivity content in feces was estimated at total hours",,,N,Intermediate,A,9986.0,CHEMBL628551,,1988.0,Feces,,1,1
12753,50592,,BAO_0000218,,,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit1, and radioactivity content in urine was estimated at 0-2 hr",,,N,Intermediate,A,9986.0,CHEMBL628552,,1088.0,Urine,,1,1
12754,50592,,BAO_0000218,,,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 0-24 hr",,,N,Intermediate,A,9986.0,CHEMBL628553,,1088.0,Urine,,1,1
12755,50592,,BAO_0000218,,,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 0-48 hr",,,N,Intermediate,A,9986.0,CHEMBL628554,,1088.0,Urine,,1,1
12756,50592,,BAO_0000218,,,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 24-48 h",,,N,Intermediate,A,9986.0,CHEMBL628555,,1088.0,Urine,,1,1
12757,50592,,BAO_0000218,,,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 48-72 h",,,N,Intermediate,A,9986.0,CHEMBL628556,,1088.0,Urine,,1,1
12758,50592,,BAO_0000218,,,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit kidney, and radioactivity content in feces was estimated",,,N,Intermediate,A,9986.0,CHEMBL628557,,2113.0,Kidney,,1,1
12759,50592,,BAO_0000218,,,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated",,,N,Intermediate,A,9986.0,CHEMBL628558,,1988.0,Feces,,1,1
12760,50592,,BAO_0000218,,,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 1 lung, and radioactivity content in feces was estimated at",,,N,Intermediate,A,9986.0,CHEMBL628559,,1988.0,Feces,,1,1
12761,50592,,BAO_0000218,,,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit1plasma, and radioactivity content in feces was estimated",,,N,Intermediate,A,9986.0,CHEMBL628560,,1988.0,Feces,,1,1
12762,50592,,BAO_0000218,,,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at total hours",,,N,Intermediate,A,9986.0,CHEMBL874456,,1088.0,Urine,,1,1
12763,50592,,BAO_0000218,,,"200 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit4, and radioactivity content in feces was estimated at 0-48 hr",,,N,Intermediate,A,9986.0,CHEMBL628561,,1988.0,Feces,,1,1
12764,50592,,BAO_0000218,,,"200 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit4, and radioactivity content in feces was estimated at total hours",,,N,Intermediate,A,9986.0,CHEMBL628562,,1988.0,Feces,,1,1
12765,50592,,BAO_0000218,,,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit2, and radioactivity content in urine was estimated at 0-4 hr",,,N,Intermediate,A,9986.0,CHEMBL628563,,1088.0,Urine,,1,1
12766,50592,,BAO_0000218,,,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at",,,N,Intermediate,A,9986.0,CHEMBL628564,,1088.0,Urine,,1,1
12767,50592,,BAO_0000218,,,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at 24-48 h",,,N,Intermediate,A,9986.0,CHEMBL628565,,1088.0,Urine,,1,1
12768,50592,,BAO_0000218,,,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at 48-72 h",,,N,Intermediate,A,9986.0,CHEMBL631248,,1088.0,Urine,,1,1
12769,50592,,BAO_0000218,,,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at total hours",,,N,Intermediate,A,9986.0,CHEMBL631249,,1088.0,Urine,,1,1
12770,50592,,BAO_0000218,,,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 kidney, and radioactivity content in feces was estimated",,,N,Intermediate,A,9986.0,CHEMBL627214,,2113.0,Kidney,,1,1
12771,50592,,BAO_0000218,,,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 liver, and radioactivity content in feces was estimated",,,N,Intermediate,A,9986.0,CHEMBL874591,,1988.0,Feces,,1,1
12772,50592,,BAO_0000218,,,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 lung, and radioactivity content in feces was estimated",,,N,Intermediate,A,9986.0,CHEMBL627215,,1988.0,Feces,,1,1
12773,50592,,BAO_0000218,,,200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 plasma and radioactivity content in feces was estimated,,,N,Intermediate,A,9986.0,CHEMBL625471,,1988.0,Feces,,1,1
12774,50592,,BAO_0000218,,,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 1,,,N,Intermediate,A,9986.0,CHEMBL625472,,,,,1,1
12775,50592,,BAO_0000218,,,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 3 by Gas-liquid chromatographic analysis,,,N,Intermediate,A,9986.0,CHEMBL625473,,,,,1,1
12776,50588,In vivo,BAO_0000218,,,Tested for pharmacokinetic parameter in fasted Beagle dogs (Clearance value of the compound) iv administration.,,,N,Intermediate,A,9615.0,CHEMBL625474,,,,,1,1
12777,50588,In vivo,BAO_0000218,,,The clearance was measured in dog at dose 5 mg/kg after intravenous administration.,,,N,Intermediate,A,9615.0,CHEMBL625475,,,,,1,1
12778,50597,In vivo,BAO_0000218,,,The clearance was measured in rat at dose 12 mg/kg after intravenous administration.,,,N,Intermediate,A,10116.0,CHEMBL625476,,,,,1,1
12779,50597,In vivo,BAO_0000218,,,The clearance was measured in rat at dose 1 mg/kg after intravenous administration.,,,N,Intermediate,A,10116.0,CHEMBL625477,,,,,1,1
12780,50597,In vivo,BAO_0000218,,,The clearance was measured in rat at dose 30 mg/kg after intravenous administration.,,,N,Intermediate,A,10116.0,CHEMBL625478,,,,,1,1
12781,50597,In vitro,BAO_0000218,,,The compound was evaluated for clearance value in rat isolated esophageal tunica muscularis mucose,,,N,Intermediate,A,10116.0,CHEMBL625479,,,esophageal tunica muscularis mucosae,,1,1
12782,50597,In vitro,BAO_0000218,,,The compound was evaluated for the value in rat isolated esophageal tunica muscularis mucose,,,N,Intermediate,A,10116.0,CHEMBL625480,,,esophageal tunica muscularis mucosae,,1,1
12783,50597,In vivo,BAO_0000218,,,The compound was tested for systemic plasma clearance(CL) in rats and is expressed in mL/min/kg.,,,N,Intermediate,A,10116.0,CHEMBL625481,,1969.0,Plasma,,1,1
12784,50597,In vivo,BAO_0000218,,,Total body clearance at an intravenous dose of 5.2 mg/kg in rat,,,N,Intermediate,A,10116.0,CHEMBL625482,,,,,1,1
12785,50597,In vivo,BAO_0000218,,,Total body clearance at an intravenous dose of 5.5 mg/kg in rat,,,N,Intermediate,A,10116.0,CHEMBL625483,,,,,1,1
12786,50597,In vivo,BAO_0000218,,,Total body clearance at an intravenous dose of 6.3 mg/kg in rat,,,N,Intermediate,A,10116.0,CHEMBL625484,,,,,1,1
12787,50597,In vivo,BAO_0000218,,,Total body clearance at an intravenous dose of 6.5 mg/kg in rat,,,N,Intermediate,A,10116.0,CHEMBL625485,,,,,1,1
12788,50588,In vivo,BAO_0000218,,,Total plasma clearance value was obtained after intravenous administration of 1.8 mg/kg of drug in male Beagle dogs,,,N,Intermediate,A,9615.0,CHEMBL625486,,1969.0,Plasma,,1,1
12789,50597,In vivo,BAO_0000218,,,Total plasma clearance value was obtained after intravenous administration of 2.5 mg/kg of drug in male Dawley rats,,,N,Intermediate,A,10116.0,CHEMBL625487,,1969.0,Plasma,,1,1
12790,50597,In vivo,BAO_0000218,,,Total plasma clearance value was obtained after intravenous administration of 2.6 mg/kg of drug in male Dawley rats,,,N,Intermediate,A,10116.0,CHEMBL625488,,1969.0,Plasma,,1,1
12791,50597,In vivo,BAO_0000218,,,Total plasma clearance value was obtained after intravenous administration of 2.7 mg/kg of drug in male Dawley rats,,,N,Intermediate,A,10116.0,CHEMBL625489,,1969.0,Plasma,,1,1
12792,50597,In vivo,BAO_0000218,,,Total plasma clearance value was obtained after intravenous administration of 2.8 mg/kg of drug in male Dawley rats,,,N,Intermediate,A,10116.0,CHEMBL625490,,1969.0,Plasma,,1,1
12793,50588,In vivo,BAO_0000218,,,Total plasma clearance value was obtained after intravenous administration of 4.9 mg/kg of drug in male Beagle dogs,,,N,Intermediate,A,9615.0,CHEMBL625491,,1969.0,Plasma,,1,1
12794,50597,In vivo,BAO_0000218,,,Total plasma clearance value was obtained after intravenous administration of 5.1 mg/kg of drug in male Dawley rats,,,N,Intermediate,A,10116.0,CHEMBL625492,,1969.0,Plasma,,1,1
12795,50587,In vivo,BAO_0000218,,,plasma clearance in human,,,N,Intermediate,A,9606.0,CHEMBL625493,,1969.0,Plasma,,1,1
12796,50597,In vivo,BAO_0000218,,,Pharmacokinetic parameter (CL/F ) was evaluated in Spargue-Dawley rat when given intravenously at dose 15 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL625494,,,,,1,1
12797,50597,In vivo,BAO_0000218,,,Pharmacokinetic parameter (CL/F ) was evaluated in Spargue-Dawley rat when given peroral at dose 30 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL625495,,,,,1,1
12798,50597,In vivo,BAO_0000218,,,Pharmacokinetic parameter (CL/F) was evaluated in Spargue-Dawley rat when given peroral at dose 80 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL625496,,,,,1,1
12799,22229,,BAO_0000100,,,1-Octanol/water partition coefficient measured at 7.4,,,U,Autocuration,P,,CHEMBL625497,,,,,0,1
12800,22229,,BAO_0000100,,,Calculated partition coefficient (clogP),,,U,Autocuration,P,,CHEMBL625498,,,,,0,1
12801,22224,,BAO_0000019,,,Partition coefficient (logP),,,U,Autocuration,A,,CHEMBL625499,,,,,0,1
12802,22229,,BAO_0000100,,,Calculated partition coefficient (clogP),,,U,Autocuration,P,,CHEMBL625500,,,,,0,1
12803,22229,,BAO_0000100,,,Calculated partition coefficient (clogP),,,U,Autocuration,P,,CHEMBL625501,,,,,0,1
12804,22229,,BAO_0000100,,,Calculated partition coefficient (clogP),,,U,Autocuration,P,,CHEMBL625502,,,,,0,1
12805,22229,,BAO_0000100,,,Calculated partition coefficient (clogP) (relative to BAY K 8644),,,U,Autocuration,P,,CHEMBL625503,,,,,0,1
12806,22229,,BAO_0000100,,,Calculated partition coefficient (clogP),,,U,Autocuration,P,,CHEMBL625504,,,,,0,1
12807,22229,,BAO_0000100,,,Calculated partition coefficient (clogP),,,U,Autocuration,P,,CHEMBL625505,,,,,0,1
12808,22229,,BAO_0000100,,,Calculated partition coefficient of the compound,,,U,Autocuration,P,,CHEMBL625506,,,,,0,1
12809,22224,,BAO_0000019,,,Partition coefficient (logP),,,U,Autocuration,A,,CHEMBL625507,,,,,0,1
12810,22229,,BAO_0000100,,,Calculated partition coefficient (clogP),,,U,Autocuration,P,,CHEMBL625508,,,,,0,1
12811,22229,,BAO_0000100,,,Calculated partition coefficient (clogP),,,U,Autocuration,P,,CHEMBL625509,,,,,0,1
12812,22229,,BAO_0000100,,,Calculated partition coefficient (clogP),,,U,Autocuration,P,,CHEMBL625510,,,,,0,1
12813,22229,,BAO_0000100,,,Calculated partition coefficient (clogP),,,U,Autocuration,P,,CHEMBL883125,,,,,0,1
12814,22229,,BAO_0000100,,,Calculated partition coefficient (clogP),,,U,Autocuration,P,,CHEMBL625511,,,,,0,1
12815,22224,,BAO_0000019,,,Partition coefficient of the compound,,,U,Autocuration,A,,CHEMBL874650,,,,,0,1
12816,22224,,BAO_0000019,,,Partition coefficient of the compound,,,U,Autocuration,A,,CHEMBL625512,,,,,0,1
12817,22224,,BAO_0000019,,,Partition coefficient of compound was determined,,,U,Autocuration,A,,CHEMBL625513,,,,,0,1
12818,22224,,BAO_0000019,,,Partition coefficient was determined,,,U,Autocuration,A,,CHEMBL625514,,,,,0,1
12819,22229,,BAO_0000100,,,Calculated partition coefficient (clogP),,,U,Autocuration,P,,CHEMBL625515,,,,,0,1
12820,22229,,BAO_0000100,,,partition coefficient of compound was determined,,,U,Autocuration,P,,CHEMBL625516,,,,,0,1
12821,50588,In vivo,BAO_0000218,,,The total body administered intravenously in dog,,,N,Intermediate,A,9615.0,CHEMBL625517,,,,,1,1
12822,50597,In vivo,BAO_0000218,,,The total body administered intravenously in rats,,,N,Intermediate,A,10116.0,CHEMBL625518,,,,,1,1
12823,50594,,BAO_0000218,,,Time taken for the administration to female NIH mice weighing 25-30 g.,,,N,Intermediate,A,10090.0,CHEMBL625519,,,,,1,1
12824,22224,,BAO_0000019,,,Time taken for the administration,,,U,Autocuration,A,,CHEMBL625520,,,,,0,1
12825,50588,In vivo,BAO_0000218,,,Total clearance of compound was determined in dog at 5 mg/kg intravenously admn.,,,N,Intermediate,A,9615.0,CHEMBL874651,,,,,1,1
12826,22224,In vivo,BAO_0000218,,,Total clearance of compound was determined in monkey at 5 mg/kg intravenously admn.,,,U,Autocuration,A,314293.0,CHEMBL625521,,,,,0,1
12827,50592,In vivo,BAO_0000218,,,Total clearance of compound was determined in rabbit at 5 mg/kg intravenously admn.,,,N,Intermediate,A,9986.0,CHEMBL623171,,,,,1,1
12828,50597,In vivo,BAO_0000218,,,Total clearance of compound was determined in rat at 5 mg/kg intravenously admn.,,,N,Intermediate,A,10116.0,CHEMBL623853,,,,,1,1
12829,22224,,BAO_0000019,,,Plasma clearance for the compound was determined.,,,U,Autocuration,A,,CHEMBL623854,,,,,0,1
12830,22224,,BAO_0000100,,,CLog P value of the compound,,,U,Autocuration,P,,CHEMBL874405,,,,,0,1
12831,22229,,BAO_0000100,,,Calculated partition coefficient (clogP),,,U,Autocuration,P,,CHEMBL623855,,,,,0,1
12832,22229,,BAO_0000100,,,Calculated partition coefficient (clogP),,,U,Autocuration,P,,CHEMBL623856,,,,,0,1
12833,22224,,BAO_0000100,,,ClogP value of the compound; nd ='no data',,,U,Autocuration,P,,CHEMBL623857,,,,,0,1
12834,22224,,BAO_0000100,,,ClogP value of the compound; nd ='not determined',,,U,Autocuration,P,,CHEMBL623858,,,,,0,1
12835,22224,,BAO_0000100,,,CLog P was determined,,,U,Autocuration,P,,CHEMBL623859,,,,,0,1
12836,22229,,BAO_0000100,,,Calculated partition coefficient (clogP),,,U,Autocuration,P,,CHEMBL839829,,,,,0,1
12837,22224,,BAO_0000019,,,CLogP was calculated,,,U,Autocuration,A,,CHEMBL623860,,,,,0,1
12838,22224,,BAO_0000019,,,CLogP value was determined,,,U,Autocuration,A,,CHEMBL623861,,,,,0,1
12839,22224,,BAO_0000019,,,CLogP value was evaluated using http://esc.syrres.com/interkow/kowdemo.htm.,,,U,Autocuration,A,,CHEMBL623862,,,,,0,1
12840,22229,,BAO_0000100,,,Calculated partition coefficient (clogP),,,U,Autocuration,P,,CHEMBL874406,,,,,0,1
12841,22229,,BAO_0000100,,,Calculated partition coefficient (clogP),,,U,Autocuration,P,,CHEMBL623863,,,,,0,1
12842,22229,,BAO_0000100,,,Calculated partition coefficient (clogP),,,U,Autocuration,P,,CHEMBL624021,,,,,0,1
12843,50588,,BAO_0000218,,,Distribution in female dog adrenal medulla 24 hours after administration.,,,N,Intermediate,A,9615.0,CHEMBL624022,,1236.0,Adrenal medulla,,1,1
12844,50588,,BAO_0000218,,,Distribution in female dog adrenal medulla 72 hours after administration.,,,N,Intermediate,A,9615.0,CHEMBL624023,,1236.0,Adrenal medulla,,1,1
12845,50588,,BAO_0000218,,,Distribution in female dog bile 24 hours after administration.,,,N,Intermediate,A,9615.0,CHEMBL624024,,,,,1,1
12846,50588,,BAO_0000218,,,Distribution in female dog bile 72 hr after administration.,,,N,Intermediate,A,9615.0,CHEMBL624025,,,,,1,1
12847,50588,,BAO_0000218,,,Distribution in female dog blood 24 hours after administration.,,,N,Intermediate,A,9615.0,CHEMBL624026,,,,,1,1
12848,50588,,BAO_0000218,,,Distribution in female dog blood 72 hours after administration.,,,N,Intermediate,A,9615.0,CHEMBL624027,,,,,1,1
12849,50588,,BAO_0000218,,,Distribution in female dog heart 24 hours after administration.,,,N,Intermediate,A,9615.0,CHEMBL624028,,,,,1,1
12850,50588,,BAO_0000218,,,Distribution in female dog heart 72 hours after administration.,,,N,Intermediate,A,9615.0,CHEMBL624029,,,,,1,1
12851,50588,,BAO_0000218,,,Distribution in female dog kidney 24 hours after administration.,,,N,Intermediate,A,9615.0,CHEMBL624030,,,,,1,1
12852,50588,,BAO_0000218,,,Distribution in female dog kidney 72 hours after administration.,,,N,Intermediate,A,9615.0,CHEMBL624031,,,,,1,1
12853,50588,,BAO_0000218,,,Distribution in female dog large intestine 24 hours after administration.,,,N,Intermediate,A,9615.0,CHEMBL624032,,160.0,Intestine,,1,1
12854,50588,,BAO_0000218,,,Distribution in female dog large intestine 72 hours after administration.,,,N,Intermediate,A,9615.0,CHEMBL874407,,160.0,Intestine,,1,1
12855,50588,,BAO_0000218,,,Distribution in female dog liver 24 hours after administration.,,,N,Intermediate,A,9615.0,CHEMBL624033,,,,,1,1
12856,50588,,BAO_0000218,,,Distribution in female dog liver 72 hours after administration.,,,N,Intermediate,A,9615.0,CHEMBL624034,,,,,1,1
12857,50588,,BAO_0000218,,,Distribution in female dog lung 24 hours after administration.,,,N,Intermediate,A,9615.0,CHEMBL624035,,,,,1,1
12858,50588,,BAO_0000218,,,Distribution in female dog lung 72 hours after administration.,,,N,Intermediate,A,9615.0,CHEMBL624036,,,,,1,1
12859,50588,,BAO_0000218,,,Distribution in female dog muscle 24 hours after administration.,,,N,Intermediate,A,9615.0,CHEMBL624037,,2385.0,Muscle tissue,,1,1
12860,50588,,BAO_0000218,,,Distribution in female dog muscle 72 hours after administration.,,,N,Intermediate,A,9615.0,CHEMBL624038,,2385.0,Muscle tissue,,1,1
12861,50588,,BAO_0000218,,,Distribution in female dog pancreas 24 hours after administration.,,,N,Intermediate,A,9615.0,CHEMBL624039,,,,,1,1
12862,50588,,BAO_0000218,,,Distribution in female dog pancreas 72 hours after administration.,,,N,Intermediate,A,9615.0,CHEMBL624040,,,,,1,1
12863,50588,,BAO_0000218,,,Distribution in female dog small intestine 24 hours after administration.,,,N,Intermediate,A,9615.0,CHEMBL624041,,160.0,Intestine,,1,1
12864,50588,,BAO_0000218,,,Distribution in female dog small intestine 72 hours after administration.,,,N,Intermediate,A,9615.0,CHEMBL624042,,160.0,Intestine,,1,1
12865,50588,,BAO_0000218,,,Distribution in female dog spleen 24 hours after administration.,,,N,Intermediate,A,9615.0,CHEMBL624043,,2106.0,Spleen,,1,1
12866,50588,,BAO_0000218,,,Distribution in female dog spleen 72 hours after administration.,,,N,Intermediate,A,9615.0,CHEMBL624044,,2106.0,Spleen,,1,1
12867,50588,,BAO_0000218,,,Distribution in female dog stomach 24 hours after administration.,,,N,Intermediate,A,9615.0,CHEMBL624045,,945.0,Stomach,,1,1
12868,50588,,BAO_0000218,,,Distribution in female dog stomach 72 hours after administration.,,,N,Intermediate,A,9615.0,CHEMBL624046,,945.0,Stomach,,1,1
12869,50588,,BAO_0000218,,,Distribution in female dog thyroid 24 hours after administration.,,,N,Intermediate,A,9615.0,CHEMBL624047,,2046.0,Thyroid gland,,1,1
12870,50588,,BAO_0000218,,,Distribution in female dog thyroid 72 hours after administration.,,,N,Intermediate,A,9615.0,CHEMBL624048,,2046.0,Thyroid gland,,1,1
12871,50588,,BAO_0000218,,,Distribution in female dog urine 24 hours after administration.,,,N,Intermediate,A,9615.0,CHEMBL874408,,1088.0,Urine,,1,1
12872,50588,,BAO_0000218,,,Distribution in female dog urine 72 hr after administration.,,,N,Intermediate,A,9615.0,CHEMBL624049,,1088.0,Urine,,1,1
12873,22224,,BAO_0000218,,,Mean plasma concentration measured 1 h following an oral dose of 30 mg/kg,,,U,Autocuration,A,,CHEMBL624050,,1969.0,Plasma,,0,1
12874,22224,,BAO_0000019,,,Plasma concentration at 7 hr after intravenous dosing,,,U,Autocuration,A,,CHEMBL624051,,,,,0,1
12875,50597,,BAO_0000218,,,Plasma concentration of 3 mg/kg iv after 0.25 hr in rats,,,N,Intermediate,A,10116.0,CHEMBL623278,,,,,1,1
12876,50597,,BAO_0000218,,,Plasma concentration of 3 mg/kg iv after 0.5 hr in rats,,,N,Intermediate,A,10116.0,CHEMBL623279,,,,,1,1
12877,50597,,BAO_0000218,,,Plasma concentration of 3 mg/kg iv after 1 hr in rats,,,N,Intermediate,A,10116.0,CHEMBL623280,,,,,1,1
12878,50597,,BAO_0000218,,,Plasma concentration of 3 mg/kg iv after 2 hr in rats,,,N,Intermediate,A,10116.0,CHEMBL623963,,,,,1,1
12879,50597,,BAO_0000218,,,Plasma concentration of 3 mg/kg iv after 4 hr in rats,,,N,Intermediate,A,10116.0,CHEMBL623964,,,,,1,1
12880,50597,,BAO_0000218,,,Plasma concentration of 3 mg/kg iv after 6 hr in rats,,,N,Intermediate,A,10116.0,CHEMBL623965,,,,,1,1
12881,50597,,BAO_0000218,,,Plasma concentration of 3 mg/kg po after 0.083 hr in rats,,,N,Intermediate,A,10116.0,CHEMBL623966,,,,,1,1
12882,50597,,BAO_0000218,,,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.083 h,,,N,Intermediate,A,10116.0,CHEMBL874415,,,,,1,1
12883,50597,,BAO_0000218,,,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.25 hr,,,N,Intermediate,A,10116.0,CHEMBL623967,,,,,1,1
12884,50597,,BAO_0000218,,,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.5 hr,,,N,Intermediate,A,10116.0,CHEMBL623968,,,,,1,1
12885,50597,,BAO_0000218,,,Plasma concentration after 3 mg/kg peroral dosing in rat at 1 hr,,,N,Intermediate,A,10116.0,CHEMBL623969,,,,,1,1
12886,50597,,BAO_0000218,,,Plasma concentration after 3 mg/kg peroral dosing in rat at 2 hr,,,N,Intermediate,A,10116.0,CHEMBL628409,,,,,1,1
12887,50597,,BAO_0000218,,,Plasma concentration after 3 mg/kg peroral dosing in rat at 4 hr,,,N,Intermediate,A,10116.0,CHEMBL628410,,,,,1,1
12888,50597,,BAO_0000218,,,Plasma concentration after 3 mg/kg peroral dosing in rat at 6 hr,,,N,Intermediate,A,10116.0,CHEMBL628411,,,,,1,1
12889,50597,,BAO_0000218,,,Plasma concentration after 3 mg/kg peroral dosing in rat at 8 hr,,,N,Intermediate,A,10116.0,CHEMBL628412,,,,,1,1
12890,22224,,BAO_0000019,,,Tested for the highest concentration at which toxicity was not observed or the concentration which provided the highest number of net grain counts,,,U,Autocuration,A,,CHEMBL628413,,,,,0,1
12891,22224,,BAO_0000019,,,The concentration in plasmat; Not determined,,,U,Autocuration,A,,CHEMBL628414,,1969.0,Plasma,,0,1
12892,50597,,BAO_0000218,,,Tissue level at 10 mg/kg/po in wistar rats in blood,,,N,Intermediate,A,10116.0,CHEMBL628415,,,,,1,1
12893,50597,,BAO_0000218,,,Tissue level at 10 mg/kg/po in wistar rats in brown fat,,,N,Intermediate,A,10116.0,CHEMBL628416,,,,,1,1
12894,50597,,BAO_0000218,,,Tissue level at 10 mg/kg/po in wistar rats in heart,,,N,Intermediate,A,10116.0,CHEMBL628417,,,,,1,1
12895,50597,,BAO_0000218,,,Tissue level at 10 mg/kg/po in wistar rats in liver,,,N,Intermediate,A,10116.0,CHEMBL874908,,2107.0,Liver,,1,1
12896,50597,,BAO_0000218,,,Tissue level at 10 mg/kg/po in wistar rats in plasma,,,N,Intermediate,A,10116.0,CHEMBL628418,,,,,1,1
12897,50597,,BAO_0000218,,,Tissue level at 10 mg/kg/po in wistar rats in skeletal muscle,,,N,Intermediate,A,10116.0,CHEMBL628419,,2385.0,Muscle tissue,,1,1
12898,50597,,BAO_0000218,,,Tissue level at 10 mg/kg/po in wistar rats in subcutaneous fat,,,N,Intermediate,A,10116.0,CHEMBL628420,,,,,1,1
12899,22224,,BAO_0000019,,,Water solubility at 37 degree C.,,,U,Autocuration,A,,CHEMBL628421,,,,,0,1
12900,22229,,BAO_0000100,,,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 13.5 hr,,,U,Autocuration,P,,CHEMBL626726,,,,,0,1
12901,22229,,BAO_0000100,,,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,,,U,Autocuration,P,,CHEMBL626727,,,,,0,1
12902,50597,,BAO_0000218,,,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,,,N,Intermediate,A,10116.0,CHEMBL626728,,178.0,Blood,,1,1
12903,50597,,BAO_0000218,,,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,,,N,Intermediate,A,10116.0,CHEMBL626729,,178.0,Blood,,1,1
12904,50597,,BAO_0000218,,,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,,,N,Intermediate,A,10116.0,CHEMBL626730,,178.0,Blood,,1,1
12905,50597,,BAO_0000218,,,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,,,N,Intermediate,A,10116.0,CHEMBL626731,,178.0,Blood,,1,1
12906,50597,,BAO_0000218,,,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,,,N,Intermediate,A,10116.0,CHEMBL626732,,178.0,Blood,,1,1
12907,50597,,BAO_0000218,,,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,,,N,Intermediate,A,10116.0,CHEMBL626733,,948.0,Heart,,1,1
12908,50597,,BAO_0000218,,,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,,,N,Intermediate,A,10116.0,CHEMBL626734,,948.0,Heart,,1,1
12909,50597,,BAO_0000218,,,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,,,N,Intermediate,A,10116.0,CHEMBL626735,,948.0,Heart,,1,1
12910,50597,,BAO_0000218,,,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,,,N,Intermediate,A,10116.0,CHEMBL874909,,948.0,Heart,,1,1
12911,50597,,BAO_0000218,,,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,,,N,Intermediate,A,10116.0,CHEMBL626736,,948.0,Heart,,1,1
12912,50597,,BAO_0000218,,,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,,,N,Intermediate,A,10116.0,CHEMBL626737,,2113.0,Kidney,,1,1
12913,50597,,BAO_0000218,,,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,,,N,Intermediate,A,10116.0,CHEMBL630999,,2113.0,Kidney,,1,1
12914,50597,,BAO_0000218,,,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,,,N,Intermediate,A,10116.0,CHEMBL631000,,2113.0,Kidney,,1,1
12915,50597,,BAO_0000218,,,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,,,N,Intermediate,A,10116.0,CHEMBL631001,,2113.0,Kidney,,1,1
12916,50597,,BAO_0000218,,,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,,,N,Intermediate,A,10116.0,CHEMBL631002,,2113.0,Kidney,,1,1
12917,50597,,BAO_0000218,,,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,,,N,Intermediate,A,10116.0,CHEMBL631003,,2107.0,Liver,,1,1
12918,50597,,BAO_0000218,,,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,,,N,Intermediate,A,10116.0,CHEMBL631004,,2107.0,Liver,,1,1
12919,50597,,BAO_0000218,,,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,,,N,Intermediate,A,10116.0,CHEMBL631005,,2107.0,Liver,,1,1
12920,50597,,BAO_0000218,,,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,,,N,Intermediate,A,10116.0,CHEMBL631006,,2107.0,Liver,,1,1
12921,50597,,BAO_0000218,,,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,,,N,Intermediate,A,10116.0,CHEMBL631007,,2107.0,Liver,,1,1
12922,50597,,BAO_0000218,,,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,,,N,Intermediate,A,10116.0,CHEMBL631008,,2048.0,Lung,,1,1
12923,50597,,BAO_0000218,,,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,,,N,Intermediate,A,10116.0,CHEMBL631009,,2048.0,Lung,,1,1
12924,50597,,BAO_0000218,,,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,,,N,Intermediate,A,10116.0,CHEMBL631010,,2048.0,Lung,,1,1
12925,50597,,BAO_0000218,,,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,,,N,Intermediate,A,10116.0,CHEMBL631011,,2048.0,Lung,,1,1
12926,50597,,BAO_0000218,,,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,,,N,Intermediate,A,10116.0,CHEMBL631012,,2048.0,Lung,,1,1
12927,50597,,BAO_0000218,,,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,,,N,Intermediate,A,10116.0,CHEMBL630271,,2046.0,Thyroid gland,,1,1
12928,50597,,BAO_0000218,,,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,,,N,Intermediate,A,10116.0,CHEMBL630272,,2046.0,Thyroid gland,,1,1
12929,50597,,BAO_0000218,,,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,,,N,Intermediate,A,10116.0,CHEMBL630273,,2046.0,Thyroid gland,,1,1
12930,50597,,BAO_0000218,,,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,,,N,Intermediate,A,10116.0,CHEMBL630274,,2046.0,Thyroid gland,,1,1
12931,50597,,BAO_0000218,,,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,,,N,Intermediate,A,10116.0,CHEMBL630275,,2046.0,Thyroid gland,,1,1
12932,50597,,BAO_0000218,,,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 15 minutes (radiolabeled with [125I]-,,,N,Intermediate,A,10116.0,CHEMBL875782,,,,,1,1
12933,50597,,BAO_0000218,,,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 2 minutes (radiolabeled with [125I]-,,,N,Intermediate,A,10116.0,CHEMBL630276,,,,,1,1
12934,50597,,BAO_0000218,,,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 30 minutes (radiolabeled with [125I]-,,,N,Intermediate,A,10116.0,CHEMBL630277,,,,,1,1
12935,50597,,BAO_0000218,,,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 5 minutes (radiolabeled with [125I]-,,,N,Intermediate,A,10116.0,CHEMBL630278,,,,,1,1
12936,50597,,BAO_0000218,,,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 60 minutes (radiolabeled with [125I]-,,,N,Intermediate,A,10116.0,CHEMBL630279,,,,,1,1
12937,22224,,BAO_0000019,,,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 10 mg/Kg,,,U,Autocuration,A,,CHEMBL630280,,,,,0,1
12938,22224,,BAO_0000019,,,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,,,U,Autocuration,A,,CHEMBL630281,,,,,0,1
12939,50592,,BAO_0000218,,,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 4 by Gas-liquid chromatographic analysis,,,N,Intermediate,A,9986.0,CHEMBL630282,,,,,1,1
12940,50592,,BAO_0000218,,,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 2,,,N,Intermediate,A,9986.0,CHEMBL630283,,,,,1,1
12941,22224,,BAO_0000019,,,Alkylating activity (0.1 mM) was determined at pH 7.4; expressed as OD (540n m)/mM of drug),,,U,Autocuration,A,,CHEMBL630284,,,,,0,1
12942,22224,,BAO_0000019,,,Alkylating activity was determined,,,U,Autocuration,A,,CHEMBL630285,,,,,0,1
12943,22224,,BAO_0000251,,,Amount of metabolites in the microsomal medium after 90 min incubation of BTCP (500 uM),,,U,Autocuration,A,,CHEMBL630286,,,,Microsomes,0,1
12944,50592,,BAO_0000218,,,"Formation of metabolite by rabbit liver microsomal preparation in absence of NADPH, at 2 hours",,,N,Intermediate,A,9986.0,CHEMBL630069,,,,,1,1
12945,50592,,BAO_0000218,,,"Formation of metabolite by rabbit liver microsomal preparation in presence of Co-O2 (90:10),at 2 hour",,,N,Intermediate,A,9986.0,CHEMBL630070,,,,,1,1
12946,50592,,BAO_0000218,,,"Formation of metabolite by rabbit liver microsomal preparation in presence of N2,at 2 hour",,,N,Intermediate,A,9986.0,CHEMBL630071,,,,,1,1
12947,50592,,BAO_0000218,,,"Formation of metabolite by rabbit liver microsomal preparation in presence of NADPH, at 2 hours",,,N,Intermediate,A,9986.0,CHEMBL630072,,,,,1,1
12948,50592,,BAO_0000218,,,"Formation of metabolite by rabbit liver microsomal preparation in presence of SKF525A,at 2 hour",,,N,Intermediate,A,9986.0,CHEMBL875110,,,,,1,1
12949,50597,,BAO_0000218,,,Compound was tested for antidiuretic activity in rats,,,N,Intermediate,A,10116.0,CHEMBL630073,,,,,1,1
12950,22224,,BAO_0000019,,,Compound was tested for inactivation kinetic values,,,U,Autocuration,A,,CHEMBL630074,,,,,0,1
12951,22224,In vivo,BAO_0000218,,,Compound was evaluated for the average apparent volume of distribution when administered through intravenous route,,,U,Autocuration,A,,CHEMBL630075,,,,,0,1
12952,22224,,BAO_0000019,,,Dissociation rate calculated from the first-order equation using the t1/2 value,,,U,Autocuration,A,,CHEMBL630076,,,,,0,1
12953,22229,,BAO_0000100,,,Compound was evaluated for pKa by titration of the compounds in 1:2 methyl alcohol and water,,,U,Autocuration,P,,CHEMBL630077,,,,,0,1
12954,22229,,BAO_0000100,,,Aqueous solubility was measured,,,U,Autocuration,P,,CHEMBL630078,,,,,0,1
12955,22229,,BAO_0000100,,,Aqueous solubility was measured at a pH 4,,,U,Autocuration,P,,CHEMBL630079,,,,,0,1
12956,22229,,BAO_0000100,,,Aqueous solubility (pH 7),,,U,Autocuration,P,,CHEMBL630080,,,,,0,1
12957,22229,,BAO_0000100,,,Aqueous solubility was measured at a pH 9,,,U,Autocuration,P,,CHEMBL630081,,,,,0,1
12958,22224,,BAO_0000019,,,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents",,,U,Autocuration,A,,CHEMBL630082,,,,,0,1
12959,22224,,BAO_0000019,,,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents.",,,U,Autocuration,A,,CHEMBL630083,,,,,0,1
12960,22224,,BAO_0000019,,,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents.",,,U,Autocuration,A,,CHEMBL630084,,,,,0,1
12961,22229,,BAO_0000100,,,Aqueous solubility of the compound,,,U,Autocuration,P,,CHEMBL629198,,,,,0,1
12962,22229,,BAO_0000100,,,Aqueous solubility at 37 degree Celsius at pH 7.38,,,U,Autocuration,P,,CHEMBL629199,,,,,0,1
12963,22229,,BAO_0000100,,,Aqueous solubility in pH 7.4 phosphate buffer,,,U,Autocuration,P,,CHEMBL629200,,,,,0,1
12964,50588,,BAO_0000218,,,Mean arterial pressure response following 10 mg/kg intraduodenal administration to salt depleted dog,,,N,Intermediate,A,9615.0,CHEMBL629201,,,,,1,1
12965,50588,,BAO_0000218,,,Mean arterial pressure response following 1 mg/kg intravenous administration to salt depleted dog,,,N,Intermediate,A,9615.0,CHEMBL629202,,,,,1,1
12966,50587,,BAO_0000218,,,Percentage of aspirin formed during hydrolysis in 10% human plasma at pH 7.4 at 37 degrees celsius,,,N,Intermediate,A,9606.0,CHEMBL875111,,,,,1,1
12967,50587,,BAO_0000218,,,Percentage of aspirin formed during hydrolysis in undiluted human plasma at pH 7.4 at 37 degrees celsius,,,N,Intermediate,A,9606.0,CHEMBL629203,,,,,1,1
12968,50587,,BAO_0000218,,,The percentage of aspirin formed during hydrolysis in 100% human plasma at pH 7.4 at 37 degrees celsius,,,N,Intermediate,A,9606.0,CHEMBL629204,,,,,1,1
12969,50587,,BAO_0000218,,,The percentage of aspirin formed during hydrolysis in 20% human plasma at pH 7.4 at 37 degrees celsius,,,N,Intermediate,A,9606.0,CHEMBL629205,,,,,1,1
12970,50587,,BAO_0000218,,,The percentage of aspirin formed during hydrolysis in 60% human plasma at pH 7.4 at 37 degrees celsius,,,N,Intermediate,A,9606.0,CHEMBL629206,,,,,1,1
12971,22224,,BAO_0000019,,,The percentage of aspirin formed during hydrolysis in 80% human plasma at pH 7.4 at 37 degrees celsius,,,U,Autocuration,A,,CHEMBL631185,,,,,0,1
12972,50597,,BAO_0000218,,,Compound was evaluated for the average bile flow rat in rats,,,N,Intermediate,A,10116.0,CHEMBL631186,,,,,1,1
12973,50592,,BAO_0000218,,,"Effect of compound on cartilage in surgically induced osteoarthritis (OA) model in rabbit at 15 mg/kg, value are relative to activity of RS-130830 (7.9+/-1.5) at 25 mg/kg",,,N,Intermediate,A,9986.0,CHEMBL631187,,,,,1,1
12974,50592,,BAO_0000218,,,"Effect of compound on cartilage in surgically induced osteoarthritis (OA) model in rabbit at 25 mg/kg, value are relative to activity of RS-130830 (7.9+/-1.5) at 25 mg/kg",,,N,Intermediate,A,9986.0,CHEMBL631188,,,,,1,1
12975,22224,,BAO_0000019,,,Average half life period was determined,,,U,Autocuration,A,,CHEMBL876419,,,,,0,1
12976,22224,,BAO_0000019,,,Average half life period was determined,,,U,Autocuration,A,,CHEMBL631189,,,,,0,1
12977,50602,,BAO_0000218,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 0.8 mg/kg per day.,,,N,Intermediate,A,10298.0,CHEMBL631190,,,,,1,1
12978,50602,,BAO_0000218,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 0.8 mg/kg per day.,,,N,Intermediate,A,10298.0,CHEMBL631191,,,,,1,1
12979,50602,,BAO_0000218,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day.,,,N,Intermediate,A,10298.0,CHEMBL631192,,,,,1,1
12980,50602,,BAO_0000218,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 3.1 mg/kg per day.,,,N,Intermediate,A,10298.0,CHEMBL632400,,,,,1,1
12981,50602,,BAO_0000218,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day.,,,N,Intermediate,A,10298.0,CHEMBL630564,,,,,1,1
12982,50602,,BAO_0000218,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day.,,,N,Intermediate,A,10298.0,CHEMBL630565,,,,,1,1
12983,50602,,BAO_0000218,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.02 mg/kg per day.,,,N,Intermediate,A,10298.0,CHEMBL630566,,,,,1,1
12984,50602,,BAO_0000218,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.06 mg/kg per day.,,,N,Intermediate,A,10298.0,CHEMBL631229,,,,,1,1
12985,50602,,BAO_0000218,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.25 mg/kg per day.,,,N,Intermediate,A,10298.0,CHEMBL631230,,,,,1,1
12986,22229,,BAO_0000100,,,Calculated partition coefficient (clogP),,,U,Autocuration,P,,CHEMBL876428,,,,,0,1
12987,22229,,BAO_0000100,,,Calculated partition coefficient (clogP),,,U,Autocuration,P,,CHEMBL631231,,,,,0,1
12988,22229,,BAO_0000100,,,Calculated partition coefficient (clogP) (MacLogP),,,U,Autocuration,P,,CHEMBL631232,,,,,0,1
12989,22224,,BAO_0000019,,,Hydrophilicity was determined,,,U,Autocuration,A,,CHEMBL631233,,,,,0,1
12990,22229,,BAO_0000100,,,Calculated partition coefficient (clogP),,,U,Autocuration,P,,CHEMBL631234,,,,,0,1
12991,22224,,BAO_0000019,,,Increased absorption was determined,,,U,Autocuration,A,,CHEMBL883126,,,,,0,1
12992,22224,,BAO_0000100,,,Lipophilicity value was evaluated,,,U,Autocuration,P,,CHEMBL631235,,,,,0,1
12993,22224,,BAO_0000100,,,Log P value of the compound.,,,U,Autocuration,P,,CHEMBL631236,,,,,0,1
12994,22224,,BAO_0000019,,,Partition coefficient of compound was determined,,,U,Autocuration,A,,CHEMBL631237,,,,,0,1
12995,22229,,BAO_0000100,,,Calculated partition coefficient (clogP),,,U,Autocuration,P,,CHEMBL631238,,,,,0,1
12996,22229,,BAO_0000100,,,Calculated partition coefficient (clogP),,,U,Autocuration,P,,CHEMBL876429,,,,,0,1
12997,22224,,BAO_0000019,,,Partition coefficient was measured by medchem software; Not calculated,,,U,Autocuration,A,,CHEMBL631414,,,,,0,1
12998,22224,,BAO_0000100,,,Partition coefficient was measured by octanol-water using standard shake-flask method,,,U,Autocuration,P,,CHEMBL631415,,,,,0,1
12999,22229,,BAO_0000100,,,Calculated partition coefficient (clogP),,,U,Autocuration,P,,CHEMBL631416,,,,,0,1
13000,22224,,BAO_0000019,,,Partition coefficient (logP),,,U,Autocuration,A,,CHEMBL631417,,,,,0,1
13001,22229,,BAO_0000100,,,Calculated partition coefficient (clogP),,,U,Autocuration,P,,CHEMBL631418,,,,,0,1
13002,22229,,BAO_0000100,,,The Octanol/Water partition coefficient CLogP,,,U,Autocuration,P,,CHEMBL631419,,,,,0,1
13003,22224,,BAO_0000019,,,The pharmacokinetic parameter C Log p was reported,,,U,Autocuration,A,,CHEMBL631420,,,,,0,1
13004,22229,,BAO_0000100,,,Calculated partition coefficient (clogP),,,U,Autocuration,P,,CHEMBL631421,,,,,0,1
13005,22229,,BAO_0000100,,,Calculated partition coefficient (clogP),,,U,Autocuration,P,,CHEMBL631422,,,,,0,1
13006,22229,,BAO_0000100,,,Calculated partition coefficient (clogP),,,U,Autocuration,P,,CHEMBL631423,,,,,0,1
13007,50597,In vivo,BAO_0000218,,,Clearance rate in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL876430,,1969.0,Plasma,,1,1
13008,50597,In vivo,BAO_0000218,,,Clearance rate in rat plasma when administered intravenously at a dose of 10 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL631424,,1969.0,Plasma,,1,1
13009,50588,In vivo,BAO_0000218,,,Compound was administered intravenously in dog to evaluate plasma clearance values,,,N,Intermediate,A,9615.0,CHEMBL631425,,1969.0,Plasma,,1,1
13010,22224,In vivo,BAO_0000218,,,Compound was administered intravenously in monkey to evaluate plasma clearance values,,,U,Autocuration,A,314293.0,CHEMBL631426,,1969.0,Plasma,,0,1
13011,50594,In vivo,BAO_0000218,,,Compound was administered intravenously in mouse to evaluate plasma clearance values,,,N,Intermediate,A,10090.0,CHEMBL631427,,1969.0,Plasma,,1,1
13012,50588,In vivo,BAO_0000218,,,Compound was evaluated in vivo for plasma clearance in dog after intravenous dose at 2 mg/Kg,,,N,Intermediate,A,9615.0,CHEMBL631428,,1969.0,Plasma,,1,1
13013,50797,In vitro,BAO_0000218,,,Intrinsic clearance in Rhesus liver microsome,,,N,Intermediate,A,9544.0,CHEMBL631429,,2107.0,Liver,Microsomes,1,1
13014,50588,In vitro,BAO_0000218,,,Intrinsic clearance in dog liver microsome,,,N,Intermediate,A,9615.0,CHEMBL631430,,2107.0,Liver,Microsomes,1,1
13015,50597,In vitro,BAO_0000218,,,Intrinsic clearance in rat liver microsome,,,N,Intermediate,A,10116.0,CHEMBL631431,,2107.0,Liver,Microsomes,1,1
13016,50797,In vivo,BAO_0000218,,,Low plasma clearance was calculated in rhesus monkey,,,N,Intermediate,A,9544.0,CHEMBL631432,,1969.0,Plasma,,1,1
13017,50588,In vivo,BAO_0000218,,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,,,N,Intermediate,A,9615.0,CHEMBL631433,,,,,1,1
13018,22224,In vivo,BAO_0000218,,,Plasma clearance after intravenous dose of 0.3 mg/kg,,,U,Autocuration,A,,CHEMBL631434,,,,,0,1
13019,22224,In vivo,BAO_0000218,,,Plasma clearance after intravenous dose of 1 mg/kg,,,U,Autocuration,A,,CHEMBL631435,,,,,0,1
13020,22224,In vivo,BAO_0000218,,,Plasma clearance after intravenous dose of 3 mg/kg,,,U,Autocuration,A,,CHEMBL631436,,,,,0,1
13021,22224,In vivo,BAO_0000218,,,Plasma clearance after intravenous dose of 3.87 mg/kg,,,U,Autocuration,A,,CHEMBL631437,,,,,0,1
13022,50597,In vivo,BAO_0000218,,,Plasma clearance after peroral administration at 10 mpk in Rat,,,N,Intermediate,A,10116.0,CHEMBL631438,,,,,1,1
13023,50797,In vivo,BAO_0000218,,,Plasma clearance after peroral administration at 10 mpk in Rhesus,,,N,Intermediate,A,9544.0,CHEMBL876431,,,,,1,1
13024,50588,In vivo,BAO_0000218,,,Plasma clearance after peroral administration at 10 mpk in dog,,,N,Intermediate,A,9615.0,CHEMBL631439,,,,,1,1
13025,50597,In vivo,BAO_0000218,,,Totla clearance of compound reported after 5 mg/kg i.v. dose in rat,,,N,Intermediate,A,10116.0,CHEMBL631440,,,,,1,1
13026,22224,,BAO_0000019,,,Compound was evaluated for physico-chemical property of Critical micellar concentration (CMC),,,U,Autocuration,A,,CHEMBL631441,,,,,0,1
13027,22224,,BAO_0000019,,,Critical Micellar concentration was determined,,,U,Autocuration,A,,CHEMBL631442,,,,,0,1
13028,22224,,BAO_0000019,,,Critical Micellar concentration of the compound. was determined,,,U,Autocuration,A,,CHEMBL626525,,,,,0,1
13029,22224,,BAO_0000019,,,Critical micelle concentration determined from the plots of the fluorescence intensity as a function of compound concentration,,,U,Autocuration,A,,CHEMBL627168,,,,,0,1
13030,22224,,BAO_0000019,,,Critical micellar concentration was measured in water by the dye solubilization method,,,U,Autocuration,A,,CHEMBL875618,,,,,0,1
13031,22224,,BAO_0000019,,,Hydrolysis turn over determined from the plots of the fluorescence assay quantified by HPLC,,,U,Autocuration,B,,CHEMBL626612,,,,,0,1
13032,22224,,BAO_0000019,,,CMR value (relative to BAY K 8644),,,U,Autocuration,A,,CHEMBL626613,,,,,0,1
13033,22224,,BAO_0000019,,,Carbamoylating activity was determined,,,U,Autocuration,A,,CHEMBL626614,,,,,0,1
13034,22224,,BAO_0000218,,,Hypotension peak is percentage change from predose baseline pressure observed after intraduodenal dose of 10 mg/kg in monkey,,,U,Autocuration,A,314293.0,CHEMBL626615,,,,,0,1
13035,22224,,BAO_0000019,,,Compound was evaluated for induced thermal stabilization for compound: DNA ratio of 1:10 at 0.1 to 0.2 degrees Centigrade.,,,U,Autocuration,A,,CHEMBL626616,,,,,0,1
13036,22224,,BAO_0000019,,,Compound was evaluated for induced thermal stabilization for compound: DNA ratio of 1:5 at 0.1 to 0.2 degrees Centigrade.,,,U,Autocuration,A,,CHEMBL626617,,,,,0,1
13037,50588,In vivo,BAO_0000218,,,Clearance from dog plasma after intravenous injection of 1 mg/kg of compound,,,N,Intermediate,A,9615.0,CHEMBL626618,,1969.0,Plasma,,1,1
13038,50597,In vivo,BAO_0000218,,,Clearance from rat plasma after intravenous injection of 1 mg/kg of compound,,,N,Intermediate,A,10116.0,CHEMBL626619,,1969.0,Plasma,,1,1
13039,50588,In vivo,BAO_0000218,,,"Clearance rate at 0.46 mg/kg, iv, in dogs",,,N,Intermediate,A,9615.0,CHEMBL626620,,,,,1,1
13040,50597,In vivo,BAO_0000218,,,"Clearance rate at 5.5 mg/kg, iv, in rat",,,N,Intermediate,A,10116.0,CHEMBL626621,,,,,1,1
13041,100710,In vivo,BAO_0000218,,,Pharmacokinetic parameter Cl calculated in cynomolgus monkey when the compound was administered intravenously at 1 mg/kg concentration,,,N,Intermediate,A,9541.0,CHEMBL626622,,,,,1,1
13042,100710,In vivo,BAO_0000218,,,Pharmacokinetic parameter Cl calculated in cynomolgus monkey when the compound was administered intravenously at 0.5 mg/kg concentration,,,N,Intermediate,A,9541.0,CHEMBL626623,,,,,1,1
13043,50588,In vivo,BAO_0000218,,,Pharmacokinetic parameter Cl calculated in dog when the compound was administered intravenously at 2 mg/kg concentration,,,N,Intermediate,A,9615.0,CHEMBL626624,,,,,1,1
13044,50597,In vivo,BAO_0000218,,,Pharmacokinetic parameter Cl calculated in rat when the compound was administered intravenously at 5 mg/kg concentration,,,N,Intermediate,A,10116.0,CHEMBL626625,,,,,1,1
13045,50597,Ex vivo,BAO_0000218,,,Clearance rate constant using isolated perfused rat liver (IPRL) assay,,,N,Intermediate,A,10116.0,CHEMBL626626,,2107.0,Liver,,1,1
13046,22224,In vivo,BAO_0000218,,,Tested for the total clearance of the compound,,,U,Autocuration,A,,CHEMBL626627,,,,,0,1
13047,50588,In vivo,BAO_0000218,,,The clearance was measured in dogs after intravenous administration of 1 mg/kg dose,,,N,Intermediate,A,9615.0,CHEMBL626628,,,,,1,1
13048,22224,In vivo,BAO_0000218,,,Total body clearance was determined,,,U,Autocuration,A,,CHEMBL626629,,,,,0,1
13049,50597,,BAO_0000218,,,Mean Chlorine excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL626630,,,,,1,1
13050,50597,,BAO_0000218,,,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL626631,,,,,1,1
13051,22229,,BAO_0000100,,,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Centigrade after 8.0 hr,,,U,Autocuration,P,,CHEMBL626632,,,,,0,1
13052,22229,,BAO_0000100,,,Solubility of 150 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,,,U,Autocuration,P,,CHEMBL626633,,,,,0,1
13053,22229,,BAO_0000100,,,Solubility of 150 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 8.0 hr,,,U,Autocuration,P,,CHEMBL626634,,,,,0,1
13054,22229,,BAO_0000100,,,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 13.5 hr,,,U,Autocuration,P,,CHEMBL626635,,,,,0,1
13055,22229,,BAO_0000100,,,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,,,U,Autocuration,P,,CHEMBL626636,,,,,0,1
13056,22229,,BAO_0000100,,,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Centigrade after 8.0 hr,,,U,Autocuration,P,,CHEMBL626637,,,,,0,1
13057,50339,,BAO_0000218,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 10.9 uM/Kg/day),,,N,Intermediate,A,4754.0,CHEMBL626638,,,,,1,1
13058,50339,,BAO_0000218,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 2.3 uM/Kg/day,,,N,Intermediate,A,4754.0,CHEMBL626639,,,,,1,1
13059,50339,,BAO_0000218,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 23.3 uM/Kg/day,,,N,Intermediate,A,4754.0,CHEMBL626640,,,,,1,1
13060,50339,,BAO_0000218,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 4.8 uM/Kg/day,,,N,Intermediate,A,4754.0,CHEMBL626641,,,,,1,1
13061,50339,,BAO_0000218,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 9.2 uM/Kg/day,,,N,Intermediate,A,4754.0,CHEMBL627272,,,,,1,1
13062,50339,,BAO_0000218,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted uM/Kg/day,,,N,Intermediate,A,4754.0,CHEMBL627273,,,,,1,1
13063,50339,,BAO_0000218,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 0.027 (uM/kg/day),,,N,Intermediate,A,4754.0,CHEMBL627441,,,,,1,1
13064,50339,,BAO_0000218,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 0.27 (uM/kg/day),,,N,Intermediate,A,4754.0,CHEMBL628355,,,,,1,1
13065,50339,,BAO_0000218,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 13.3 (uM/kg/day),,,N,Intermediate,A,4754.0,CHEMBL628356,,,,,1,1
13066,50339,,BAO_0000218,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 2.7 (uM/kg/day),,,N,Intermediate,A,4754.0,CHEMBL628357,,,,,1,1
13067,50339,,BAO_0000218,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 22.1 (uM/kg/day),,,N,Intermediate,A,4754.0,CHEMBL628358,,,,,1,1
13068,50339,,BAO_0000218,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 66.3 (uM/kg/day),,,N,Intermediate,A,4754.0,CHEMBL622307,,,,,1,1
13069,22224,,BAO_0000019,,,Conversion rate by hydrolysis of compound in plasma after 2 hr at a pH of 1.0,,,U,Autocuration,A,,CHEMBL622527,,,,,0,1
13070,22224,,BAO_0000019,,,Conversion rate by hydrolysis of compound in plasma after 2 hr at a pH of 1.0; Not detectable,,,U,Autocuration,A,,CHEMBL622528,,,,,0,1
13071,22224,,BAO_0000019,,,Conversion rate by hydrolysis of compound in plasma after 4 hr at a pH of 7.4,,,U,Autocuration,A,,CHEMBL622529,,,,,0,1
13072,22224,,BAO_0000019,,,Conversion rate by hydrolysis of compound in plasma after 4 hr at a pH of 7.4; Not detectable,,,U,Autocuration,A,,CHEMBL622992,,,,,0,1
13073,22224,,BAO_0000019,,,Conversion rate by hydrolysis of compound in plasma after 6 hr. ,,,U,Autocuration,A,,CHEMBL622993,,,,,0,1
13074,22224,,BAO_0000019,,,Conversion rate by hydrolysis of compound in plasma after 6 h; Not detectable,,,U,Autocuration,A,,CHEMBL622994,,,,,0,1
13075,50597,,BAO_0000218,,,"In vitro rate constant, correlation coefficient for the conversion to progesterone in rat liver homogenate",,,N,Intermediate,A,10116.0,CHEMBL622995,,,,,1,1
13076,50597,,BAO_0000218,,,"In vitro rate constant, correlation coefficient for the conversion to progesterone in whole rat blood.",,,N,Intermediate,A,10116.0,CHEMBL622996,,,,,1,1
13077,50597,,BAO_0000218,,,"In vitro rate constant, correlation coefficient for the disappearance in rat liver homogenate",,,N,Intermediate,A,10116.0,CHEMBL622997,,,,,1,1
13078,50597,,BAO_0000218,,,"In vitro rate constant, correlation coefficient for the disappearance in rat brain homogenate",,,N,Intermediate,A,10116.0,CHEMBL622998,,,,,1,1
13079,22224,,BAO_0000218,,,Cp max following ip administration at 1 mg/kg,,,U,Autocuration,A,,CHEMBL622999,,,,,0,1
13080,22224,In vivo,BAO_0000218,,,Maximum concentration in plasma was reported at 0.5 hour,,,U,Autocuration,A,,CHEMBL623000,,1969.0,Plasma,,0,1
13081,22224,In vivo,BAO_0000218,,,Maximum concentration in plasma was reported at 2 hour,,,U,Autocuration,A,,CHEMBL623001,,1969.0,Plasma,,0,1
13082,50594,,BAO_0000218,,,Cellular uptake kinetics of Porphycenes saturation cell level (cs) in SSK3 murine fibrosarcoma cells,,,N,Intermediate,A,10090.0,CHEMBL623002,,,,,1,1
13083,22229,,BAO_0000100,,,Aqueous solubility in 25 mM N-glycyl-glycine and 10 mM MgSO4 (pH 7.8),,,U,Autocuration,P,,CHEMBL623003,,,,,0,1
13084,22224,,BAO_0000019,,,Steady state concentration was evaluated,,,U,Autocuration,A,,CHEMBL623004,,,,,0,1
13085,22224,,BAO_0000019,,,Partition coefficient (logP),,,U,Autocuration,A,,CHEMBL623005,,,,,0,1
13086,22224,,BAO_0000019,,,Partition coefficient (logD7.4),,,U,Autocuration,A,,CHEMBL623006,,,,,0,1
13087,50597,In vivo,BAO_0000218,,,Biodistribution of {18]Fluoro-CGP 12388 (60 minutes post injection) in liver of male wistar rats,,,N,Intermediate,A,10116.0,CHEMBL623007,,2107.0,Liver,,1,1
13088,50597,In vivo,BAO_0000218,,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in bone of male wistar rats,,,N,Intermediate,A,10116.0,CHEMBL623008,,10000001.0,Bone,,1,1
13089,50597,In vivo,BAO_0000218,,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in cerebellum of male wistar rats,,,N,Intermediate,A,10116.0,CHEMBL876654,,2037.0,Cerebellum,,1,1
13090,50597,In vivo,BAO_0000218,,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in cortex of male wistar rats,,,N,Intermediate,A,10116.0,CHEMBL623009,,,,,1,1
13091,50597,In vivo,BAO_0000218,,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in fat of male wistar rats,,,N,Intermediate,A,10116.0,CHEMBL623010,,,,,1,1
13092,50597,In vivo,BAO_0000218,,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in heart of male wistar rats,,,N,Intermediate,A,10116.0,CHEMBL623011,,948.0,Heart,,1,1
13093,50597,In vivo,BAO_0000218,,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in intestine of male wistar rats,,,N,Intermediate,A,10116.0,CHEMBL623012,,160.0,Intestine,,1,1
13094,22224,,BAO_0000019,,,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg,,,U,Autocuration,A,,CHEMBL623013,,,,,0,1
13095,22224,,BAO_0000019,,,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli euivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,,,U,Autocuration,A,,CHEMBL623014,,,,,0,1
13096,22224,,BAO_0000019,,,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 10 mg/Kg,,,U,Autocuration,A,,CHEMBL623015,,1088.0,Urine,,0,1
13097,22224,,BAO_0000019,,,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,,,U,Autocuration,A,,CHEMBL623016,,1088.0,Urine,,0,1
13098,22224,,BAO_0000019,,,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 25 mg/Kg,,,U,Autocuration,A,,CHEMBL624858,,1088.0,Urine,,0,1
13099,50597,,BAO_0000218,,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 10 mg/Kg.,,,N,Intermediate,A,10116.0,CHEMBL624859,,,,,1,1
13100,50597,,BAO_0000218,,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,,,N,Intermediate,A,10116.0,CHEMBL624860,,,,,1,1
13101,50597,,BAO_0000218,,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,,,N,Intermediate,A,10116.0,CHEMBL624861,,,,,1,1
13102,50597,,BAO_0000218,,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg,,,N,Intermediate,A,10116.0,CHEMBL624862,,,,,1,1
13103,50597,,BAO_0000218,,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg.,,,N,Intermediate,A,10116.0,CHEMBL624863,,,,,1,1
13104,50597,,BAO_0000218,,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli euivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,,,N,Intermediate,A,10116.0,CHEMBL876655,,,,,1,1
13105,50588,,BAO_0000218,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog,,,N,Intermediate,A,9615.0,CHEMBL624864,,,,,1,1
13106,50588,,BAO_0000218,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 0-99,,,N,Intermediate,A,9615.0,CHEMBL624865,,,,,1,1
13107,50588,,BAO_0000218,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,,,N,Intermediate,A,9615.0,CHEMBL624866,,,,,1,1
13108,50588,,BAO_0000218,,,Salidiuretic activity in dog following i.v. dosing at 5 mg/kg,,,N,Expert,F,9615.0,CHEMBL624867,,,,,1,1
13109,50588,,BAO_0000218,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 400-599,,,N,Intermediate,A,9615.0,CHEMBL624868,,,,,1,1
13110,50588,,BAO_0000218,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600- 799,,,N,Intermediate,A,9615.0,CHEMBL628450,,,,,1,1
13111,50588,,BAO_0000218,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600-799,,,N,Intermediate,A,9615.0,CHEMBL628451,,,,,1,1
13112,50588,,BAO_0000218,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 800-899,,,N,Intermediate,A,9615.0,CHEMBL628452,,,,,1,1
13113,50588,,BAO_0000218,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,,,N,Intermediate,A,9615.0,CHEMBL628453,,,,,1,1
13114,50588,,BAO_0000218,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; act above 5 mg/kg,,,N,Intermediate,A,9615.0,CHEMBL628454,,,,,1,1
13115,50588,,BAO_0000218,,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog,,,N,Intermediate,A,9615.0,CHEMBL628455,,,,,1,1
13116,50588,,BAO_0000218,,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 0-99,,,N,Intermediate,A,9615.0,CHEMBL628456,,,,,1,1
13117,50588,,BAO_0000218,,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,,,N,Intermediate,A,9615.0,CHEMBL628457,,,,,1,1
13118,50588,,BAO_0000218,,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-299,,,N,Intermediate,A,9615.0,CHEMBL877505,,,,,1,1
13119,50588,,BAO_0000218,,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 250-399,,,N,Intermediate,A,9615.0,CHEMBL628458,,,,,1,1
13120,50588,,BAO_0000218,,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 400-599,,,N,Intermediate,A,9615.0,CHEMBL628459,,,,,1,1
13121,50588,,BAO_0000218,,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600-799,,,N,Intermediate,A,9615.0,CHEMBL628460,,,,,1,1
13122,50588,,BAO_0000218,,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 800-899,,,N,Intermediate,A,9615.0,CHEMBL628461,,,,,1,1
13123,22224,,BAO_0000218,,,"Evaluated for salidiuretic activity measured as sodium ion excretion in Rat, administered orally at a dose of 16.5 mg/kg",,,U,Autocuration,B,,CHEMBL628462,,,,,0,1
13124,50588,,BAO_0000218,,,Compound administered orally at a dose of 1 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,,,N,Intermediate,A,9615.0,CHEMBL628463,,,,,1,1
13125,50597,,BAO_0000218,,,"Evaluated for salidiuretic activity measured as sodium ion excretion in Rat, administered orally at a dose of 50 mg/kg",,,N,Expert,F,10116.0,CHEMBL625666,,,,,1,1
13126,22224,,BAO_0000218,,,Compound administered orally at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,,,U,Autocuration,B,,CHEMBL625667,,,,,0,1
13127,50597,,BAO_0000218,,,Compound administered orally at a dose of 81 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,,,N,Expert,A,10116.0,CHEMBL625668,,,,,1,1
13128,50597,,BAO_0000218,,,Compound administered orally was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,,,N,Intermediate,A,10116.0,CHEMBL625669,,,,,1,1
13129,22224,,BAO_0000019,,,Compound was tested for diuretic activity in potassium content of the 3-h sample was measured by flame photometry,,,U,Autocuration,A,,CHEMBL625670,,,,,0,1
13130,50597,,BAO_0000218,,,Compound was tested for diuretic activity in potassium content of the 3-h sample was measured by flame photometry in rat,,,N,Intermediate,A,10116.0,CHEMBL625671,,,,,1,1
13131,50602,,BAO_0000218,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 1 mg/kg per day.,,,N,Intermediate,A,10298.0,CHEMBL625672,,,,,1,1
13132,50602,,BAO_0000218,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 0.8 mg/kg administered subcutaneously,,,N,Intermediate,A,10298.0,CHEMBL625673,,,,,1,1
13133,50602,,BAO_0000218,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 0.8 mg/kg administered subcutaneously.,,,N,Intermediate,A,10298.0,CHEMBL625674,,,,,1,1
13134,50602,,BAO_0000218,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously,,,N,Intermediate,A,10298.0,CHEMBL625675,,,,,1,1
13135,50602,,BAO_0000218,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously.,,,N,Intermediate,A,10298.0,CHEMBL627637,,,,,1,1
13136,50602,,BAO_0000218,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered orally.,,,N,Intermediate,A,10298.0,CHEMBL627638,,,,,1,1
13137,50602,,BAO_0000218,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered subcutaneously,,,N,Intermediate,A,10298.0,CHEMBL627639,,,,,1,1
13138,50602,,BAO_0000218,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered subcutaneously.,,,N,Intermediate,A,10298.0,CHEMBL627640,,,,,1,1
13139,50602,,BAO_0000218,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered orally.,,,N,Intermediate,A,10298.0,CHEMBL627641,,,,,1,1
13140,50602,,BAO_0000218,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 50 mg/kg administered orally.,,,N,Intermediate,A,10298.0,CHEMBL627642,,,,,1,1
13141,50602,,BAO_0000218,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 50 mg/kg administered orally.,,,N,Intermediate,A,10298.0,CHEMBL877506,,,,,1,1
13142,50594,,BAO_0000218,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously.,,,N,Intermediate,A,10090.0,CHEMBL627275,,,,,1,1
13143,50506,,BAO_0000218,,,"Average area under curve value dosed at 0.3 mg/kg, iv in ferrets.",,,N,Intermediate,A,9669.0,CHEMBL627643,,,,,1,1
13144,50506,,BAO_0000218,,,"Average area under curve value dosed at 10 mg/kg, id in ferrets.",,,N,Intermediate,A,9669.0,CHEMBL631246,,,,,1,1
13145,50506,,BAO_0000218,,,"Average area under curve value dosed at 10 mg/kg, id in ferrets.",,,N,Intermediate,A,9669.0,CHEMBL631247,,,,,1,1
13146,50506,,BAO_0000218,,,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from portal blood).,,,N,Intermediate,A,9669.0,CHEMBL629532,,,,,1,1
13147,50506,,BAO_0000218,,,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from arterial blood).,,,N,Intermediate,A,9669.0,CHEMBL629533,,,,,1,1
13148,50506,,BAO_0000218,,,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from portal blood).,,,N,Intermediate,A,9669.0,CHEMBL629534,,,,,1,1
13149,50506,,BAO_0000218,,,Average peak plasma drug concentration after iv dose of 0.3 mg/kg in ferrets.,,,N,Intermediate,A,9669.0,CHEMBL629535,,,,,1,1
13150,22224,,BAO_0000019,,,Pharmacokinetic parameter :drug bound to plasma was reported,,,U,Autocuration,A,,CHEMBL625932,,,,,0,1
13151,22224,,BAO_0000019,,,compound was evaluated for drug bound in plasma,,,U,Autocuration,A,,CHEMBL625933,,,,,0,1
13152,50597,,BAO_0000218,,,The Brain concentration compared to plasma concentration in rats after oral administration of 1 mg/kg dose,,,N,Intermediate,A,10116.0,CHEMBL625934,,,,,1,1
13153,22224,,BAO_0000218,,,Bioavailability,,,U,Autocuration,A,9347.0,CHEMBL625935,,,,,0,1
13154,50597,,BAO_0000218,,,Compound at a dose of 10 mg/kg was orally administered to rats and Bioavailability was reported,,,N,Intermediate,A,10116.0,CHEMBL625936,,,,,1,1
13155,50597,,BAO_0000218,,,Compound at a dose of 10 mg/kg was orally administered to rats and Bioavailability was reported; Not tested,,,N,Intermediate,A,10116.0,CHEMBL625937,,,,,1,1
13156,50588,,BAO_0000218,,,Oral bioavailability in Beagle dogs at oral dose of 20 mg/kg and an intravenous dose of 5 mg/kg was administered,,,N,Intermediate,A,9615.0,CHEMBL625938,,,,,1,1
13157,50597,,BAO_0000218,,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-1 hr after the treatment.,,,N,Intermediate,A,10116.0,CHEMBL625939,,1970.0,Bile,,1,1
13158,50597,,BAO_0000218,,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-2 hr after the treatment.,,,N,Intermediate,A,10116.0,CHEMBL625940,,1970.0,Bile,,1,1
13159,50597,,BAO_0000218,,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-3 hr after the treatment.,,,N,Intermediate,A,10116.0,CHEMBL874464,,1970.0,Bile,,1,1
13160,50597,,BAO_0000218,,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-4 hr after the treatment.,,,N,Intermediate,A,10116.0,CHEMBL625941,,1970.0,Bile,,1,1
13161,50597,,BAO_0000218,,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-5 hr after the treatment.,,,N,Intermediate,A,10116.0,CHEMBL625942,,1970.0,Bile,,1,1
13162,50597,,BAO_0000218,,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-6 hr after the treatment.,,,N,Intermediate,A,10116.0,CHEMBL625943,,1970.0,Bile,,1,1
13163,50587,,BAO_0000218,,,In vitro protein binding in human serum at 5 ug/ml,,,N,Intermediate,A,9606.0,CHEMBL625944,,1977.0,Serum,,1,1
13164,22224,,BAO_0000019,,,Serum protein binding ability was measured,,,U,Autocuration,A,,CHEMBL625945,,,,,0,1
13165,22224,,BAO_0000019,,,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),,,U,Autocuration,A,,CHEMBL625946,,,,,0,1
13166,22224,In vivo,BAO_0000218,,,Oral bioavailability in dog,,,U,Autocuration,A,9615.0,CHEMBL625947,,,,,0,1
13167,50597,In vivo,BAO_0000218,,,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,,,N,Intermediate,A,10116.0,CHEMBL625948,,,,,1,1
13168,22224,In vivo,BAO_0000218,,,Absolute oral bioavailability at an iv dose of 14 mg/kg,,,U,Autocuration,A,,CHEMBL625949,,,,,0,1
13169,22224,In vivo,BAO_0000218,,,Absolute oral bioavailability at an iv dose of 15.2 mg/kg,,,U,Autocuration,A,,CHEMBL625950,,,,,0,1
13170,22224,In vivo,BAO_0000218,,,Oral bioavailability (dose 15 mg/kg i.v.),,,U,Autocuration,A,9347.0,CHEMBL625951,,,,,0,1
13171,22224,In vivo,BAO_0000218,,,Absolute oral bioavailability at an peroral dose of 15 mg/kg orally.,,,U,Autocuration,A,,CHEMBL625952,,,,,0,1
13172,22224,In vivo,BAO_0000218,,,Absolute oral bioavailability at an peroral dose of 30 mg/kg orally,,,U,Autocuration,A,,CHEMBL625953,,,,,0,1
13173,22224,In vivo,BAO_0000218,,,Absolute oral bioavailability at an peroral dose of 30.2 mg/kg orally.,,,U,Autocuration,A,,CHEMBL625954,,,,,0,1
13174,22224,In vivo,BAO_0000218,,,Absolute oral bioavailability at an peroral dose of 30.3 mg/kg orally.,,,U,Autocuration,A,,CHEMBL882959,,,,,0,1
13175,50588,In vivo,BAO_0000218,,,Apparent bioavailability in dogs at 15 mg/kg in an iv vs po dosing regimen,,,N,Intermediate,A,9615.0,CHEMBL625955,,,,,1,1
13176,22224,In vivo,BAO_0000218,,,Bioavailability in ferret,,,U,Autocuration,A,9669.0,CHEMBL625956,,,,,0,1
13177,100710,In vivo,BAO_0000218,,,Bioavailability after intraduodenal administration at a dose 10 mg/kg in cynomolgus monkeys using renin inhibition assay,,,N,Intermediate,A,9541.0,CHEMBL625957,,,,,1,1
13178,50597,,BAO_0000218,,,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL625958,,,,,1,1
13179,50597,,BAO_0000218,,,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL625959,,,,,1,1
13180,50597,,BAO_0000218,,,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL626642,,,,,1,1
13181,50597,,BAO_0000218,,,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL631330,,,,,1,1
13182,50597,,BAO_0000218,,,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL631331,,,,,1,1
13183,50597,,BAO_0000218,,,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,,,N,Intermediate,A,10116.0,CHEMBL631332,,,,,1,1
13184,50597,,BAO_0000218,,,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL631333,,,,,1,1
13185,50597,,BAO_0000218,,,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL632018,,,,,1,1
13186,50597,,BAO_0000218,,,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL632019,,,,,1,1
13187,50597,,BAO_0000218,,,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL632020,,,,,1,1
13188,50597,,BAO_0000218,,,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL632021,,,,,1,1
13189,50597,,BAO_0000218,,,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL632022,,,,,1,1
13190,50597,,BAO_0000218,,,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL632023,,,,,1,1
13191,50597,,BAO_0000218,,,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL632024,,,,,1,1
13192,50597,,BAO_0000218,,,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL874472,,,,,1,1
13193,50597,,BAO_0000218,,,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL632025,,,,,1,1
13194,50597,,BAO_0000218,,,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL632026,,,,,1,1
13195,50597,,BAO_0000218,,,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL632027,,,,,1,1
13196,50597,,BAO_0000218,,,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL632028,,,,,1,1
13197,50597,,BAO_0000218,,,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL626430,,,,,1,1
13198,50597,,BAO_0000218,,,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL626431,,,,,1,1
13199,50597,,BAO_0000218,,,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL626432,,,,,1,1
13200,50597,,BAO_0000218,,,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL626433,,,,,1,1
13201,50597,,BAO_0000218,,,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL626434,,,,,1,1
13202,50597,,BAO_0000218,,,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL627280,,,,,1,1
13203,50597,,BAO_0000218,,,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL627281,,,,,1,1
13204,50597,,BAO_0000218,,,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL627282,,,,,1,1
13205,22224,,BAO_0000019,,,Total body clearance was measured at given dose,,,U,Autocuration,A,,CHEMBL627283,,,,,0,1
13206,22224,,BAO_0000218,,,Total body clearance was measured at given dose.,,,U,Autocuration,A,,CHEMBL627284,,,,,0,1
13207,50597,,BAO_0000218,,,Metabolic clearance from the body in rat,,,N,Intermediate,A,10116.0,CHEMBL627285,,,,,1,1
13208,22224,In vivo,BAO_0000218,,,Renal clearance from the body,,,U,Autocuration,A,,CHEMBL627286,,,,,0,1
13209,50597,In vivo,BAO_0000218,,,Renal clearance from the body in rat,,,N,Intermediate,A,10116.0,CHEMBL875477,,,,,1,1
13210,50597,In vivo,BAO_0000218,,,Tested for pharmacokinetic parameter to calculate the total body clearance at a dosage of 12 mg/kg in rat,,,N,Intermediate,A,10116.0,CHEMBL627287,,,,,1,1
13211,50588,In vivo,BAO_0000218,,,Tested for pharmacokinetic parameter to calculate the total body clearance at a dosage of 2.5 mg/kg in dog,,,N,Intermediate,A,9615.0,CHEMBL627288,,,,,1,1
13212,50597,,BAO_0000218,,,Total clearance from the body in rat,,,N,Intermediate,A,10116.0,CHEMBL627289,,,,,1,1
13213,50597,In vivo,BAO_0000218,,,Clearance into cortex from rat plasma or PBS,,,N,Intermediate,A,10116.0,CHEMBL627290,,1969.0,Plasma,,1,1
13214,22224,In vivo,BAO_0000218,,,Clearance at an iv dose of 15 mg/Kg and po dose of 120 mg/Kg,,,U,Autocuration,A,,CHEMBL627291,,,,,0,1
13215,22224,In vivo,BAO_0000218,,,Clearance at an iv dose of 15 mg/Kg and po dose of 240 mg/Kg,,,U,Autocuration,A,,CHEMBL627292,,,,,0,1
13216,22224,In vivo,BAO_0000218,,,Clearance at an iv dose of 15 mg/Kg and po dose of 29.1 mg/Kg,,,U,Autocuration,A,,CHEMBL627293,,,,,0,1
13217,22224,In vivo,BAO_0000218,,,Clearance at an iv dose of 15 mg/Kg and po dose of 30 mg/Kg,,,U,Autocuration,A,,CHEMBL627294,,,,,0,1
13218,22224,In vivo,BAO_0000218,,,Clearance at an iv dose of 15 mg/Kg and po dose of 60 mg/Kg,,,U,Autocuration,A,,CHEMBL875478,,,,,0,1
13219,22224,In vivo,BAO_0000218,,,Clearance was determined,,,U,Autocuration,A,,CHEMBL627295,,,,,0,1
13220,50594,In vivo,BAO_0000218,,,Clearance was measured in mouse after administration of compound 20 mg/kg intravenously,,,N,Intermediate,A,10090.0,CHEMBL627296,,,,,1,1
13221,50592,In vivo,BAO_0000218,,,Clearance was measured in rabbit after administration of compound 20 mg/kg intravenously,,,N,Intermediate,A,9986.0,CHEMBL626119,,,,,1,1
13222,50597,In vivo,BAO_0000218,,,Clearance was measured in rat after administration of compound 20 mg/kg intravenously,,,N,Intermediate,A,10116.0,CHEMBL626120,,,,,1,1
13223,50597,In vivo,BAO_0000218,,,Clearance in rat after iv dose (100 ug/kg),,,N,Intermediate,A,10116.0,CHEMBL626121,,,,,1,1
13224,22224,In vivo,BAO_0000218,,,Clearance in guinea pig,,,U,Autocuration,A,10141.0,CHEMBL626122,,,,,0,1
13225,50597,In vivo,BAO_0000218,,,Compound was evaluated for clearance in rat,,,N,Intermediate,A,10116.0,CHEMBL626123,,,,,1,1
13226,50588,In vivo,BAO_0000218,,,Compound was evaluated for the clearance in dog,,,N,Intermediate,A,9615.0,CHEMBL623456,,,,,1,1
13227,50597,In vivo,BAO_0000218,,,Compound was evaluated for the clearance in rat,,,N,Intermediate,A,10116.0,CHEMBL623457,,,,,1,1
13228,50597,In vivo,BAO_0000218,,,Compound was tested in vivo for clearance after iv administration in the rat,,,N,Intermediate,A,10116.0,CHEMBL623458,,,,,1,1
13229,22224,In vivo,BAO_0000218,,,IV clearance determined at an iv dose of 14 mg/kg,,,U,Autocuration,A,,CHEMBL623459,,,,,0,1
13230,22224,In vivo,BAO_0000218,,,IV clearance determined at an iv dose of 15.2 mg/kg,,,U,Autocuration,A,,CHEMBL875484,,,,,0,1
13231,22224,In vivo,BAO_0000218,,,IV clearance determined at an iv dose of 15 mg/kg,,,U,Autocuration,A,,CHEMBL623460,,,,,0,1
13232,22224,In vivo,BAO_0000218,,,IV clearance determined at an peroral dose of 30 mg/kg.,,,U,Autocuration,A,,CHEMBL623461,,,,,0,1
13233,22224,In vivo,BAO_0000218,,,IV clearance determined at an peroral dose of 30.2 mg/kg.,,,U,Autocuration,A,,CHEMBL623462,,,,,0,1
13234,22224,In vivo,BAO_0000218,,,IV clearance determined at an peroral dose of 30.3 mg/kg.,,,U,Autocuration,A,,CHEMBL627386,,,,,0,1
13235,50597,In vivo,BAO_0000218,,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in kidney of male wistar rats,,,N,Intermediate,A,10116.0,CHEMBL627387,,2113.0,Kidney,,1,1
13236,50597,In vivo,BAO_0000218,,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in liver of male wistar rats,,,N,Intermediate,A,10116.0,CHEMBL627388,,2107.0,Liver,,1,1
13237,50597,In vivo,BAO_0000218,,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in lung of male wistar rats,,,N,Intermediate,A,10116.0,CHEMBL627389,,2048.0,Lung,,1,1
13238,50597,In vivo,BAO_0000218,,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in muscle of male wistar rats,,,N,Intermediate,A,10116.0,CHEMBL627390,,2385.0,Muscle tissue,,1,1
13239,50597,In vivo,BAO_0000218,,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in plasma of male wistar rats,,,N,Intermediate,A,10116.0,CHEMBL627391,,1969.0,Plasma,,1,1
13240,50597,In vivo,BAO_0000218,,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in red blood cells of male wistar rats,,,N,Intermediate,A,10116.0,CHEMBL627392,,,,,1,1
13241,50597,In vivo,BAO_0000218,,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in spleen of male wistar rats,,,N,Intermediate,A,10116.0,CHEMBL627393,,2106.0,Spleen,,1,1
13242,50597,In vivo,BAO_0000218,,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in trachea of male wistar rats,,,N,Intermediate,A,10116.0,CHEMBL627394,,3126.0,Trachea,,1,1
13243,50597,In vivo,BAO_0000218,,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in bone of male wistar rats,,,N,Intermediate,A,10116.0,CHEMBL627395,,10000001.0,Bone,,1,1
13244,50597,In vivo,BAO_0000218,,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in cerebellum of male wistar rats,,,N,Intermediate,A,10116.0,CHEMBL875485,,2037.0,Cerebellum,,1,1
13245,50597,In vivo,BAO_0000218,,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in cortex of male wistar rats,,,N,Intermediate,A,10116.0,CHEMBL627396,,,,,1,1
13246,50597,In vivo,BAO_0000218,,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in fat of male wistar rats,,,N,Intermediate,A,10116.0,CHEMBL627397,,,,,1,1
13247,50597,In vivo,BAO_0000218,,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in heart of male wistar rats,,,N,Intermediate,A,10116.0,CHEMBL627398,,948.0,Heart,,1,1
13248,50597,In vivo,BAO_0000218,,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in intestine bone of male wistar rats,,,N,Intermediate,A,10116.0,CHEMBL627399,,10000001.0,Bone,,1,1
13249,50597,In vivo,BAO_0000218,,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in kidney of male wistar rats,,,N,Intermediate,A,10116.0,CHEMBL627400,,2113.0,Kidney,,1,1
13250,50597,In vivo,BAO_0000218,,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in liver of male wistar rats,,,N,Intermediate,A,10116.0,CHEMBL627401,,2107.0,Liver,,1,1
13251,50597,In vivo,BAO_0000218,,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in lung of male wistar rats,,,N,Intermediate,A,10116.0,CHEMBL627402,,2048.0,Lung,,1,1
13252,50597,In vivo,BAO_0000218,,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in muscle of male wistar rats,,,N,Intermediate,A,10116.0,CHEMBL627403,,2385.0,Muscle tissue,,1,1
13253,50597,In vivo,BAO_0000218,,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in plasma of male wistar rats,,,N,Intermediate,A,10116.0,CHEMBL627404,,1969.0,Plasma,,1,1
13254,50597,In vivo,BAO_0000218,,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in red blood cells of male wistar rats,,,N,Intermediate,A,10116.0,CHEMBL623101,,,,,1,1
13255,50597,In vivo,BAO_0000218,,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in spleen of male wistar rats,,,N,Intermediate,A,10116.0,CHEMBL877480,,2106.0,Spleen,,1,1
13256,50597,In vivo,BAO_0000218,,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in trachea of male wistar rats,,,N,Intermediate,A,10116.0,CHEMBL623102,,3126.0,Trachea,,1,1
13257,50597,In vivo,BAO_0000218,,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in bone of male wistar rats,,,N,Intermediate,A,10116.0,CHEMBL623103,,10000001.0,Bone,,1,1
13258,50597,In vivo,BAO_0000218,,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in cerebellum of male wistar rats,,,N,Intermediate,A,10116.0,CHEMBL623104,,2037.0,Cerebellum,,1,1
13259,50597,In vivo,BAO_0000218,,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in cortex of male wistar rats,,,N,Intermediate,A,10116.0,CHEMBL623105,,,,,1,1
13260,50597,In vivo,BAO_0000218,,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in fat of male wistar rats,,,N,Intermediate,A,10116.0,CHEMBL623106,,,,,1,1
13261,50597,In vivo,BAO_0000218,,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in heart of male wistar rats,,,N,Intermediate,A,10116.0,CHEMBL623107,,948.0,Heart,,1,1
13262,50597,In vivo,BAO_0000218,,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in intestine of male wistar rats,,,N,Intermediate,A,10116.0,CHEMBL623108,,160.0,Intestine,,1,1
13263,50597,In vivo,BAO_0000218,,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in kidney of male wistar rats,,,N,Intermediate,A,10116.0,CHEMBL623109,,2113.0,Kidney,,1,1
13264,50597,In vivo,BAO_0000218,,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in liver of male wistar rats,,,N,Intermediate,A,10116.0,CHEMBL623110,,2107.0,Liver,,1,1
13265,50597,In vivo,BAO_0000218,,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in lung of male wistar rats,,,N,Intermediate,A,10116.0,CHEMBL623111,,2048.0,Lung,,1,1
13266,50597,In vivo,BAO_0000218,,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in muscle of male wistar rats,,,N,Intermediate,A,10116.0,CHEMBL625060,,2385.0,Muscle tissue,,1,1
13267,50597,In vivo,BAO_0000218,,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in plasma of male wistar rats,,,N,Intermediate,A,10116.0,CHEMBL625061,,1969.0,Plasma,,1,1
13268,50597,In vivo,BAO_0000218,,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in red blood cells of male wistar rats,,,N,Intermediate,A,10116.0,CHEMBL625062,,,,,1,1
13269,50597,In vivo,BAO_0000218,,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in spleen of male wistar rats,,,N,Intermediate,A,10116.0,CHEMBL625063,,2106.0,Spleen,,1,1
13270,50597,In vivo,BAO_0000218,,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in trachea of male wistar rats,,,N,Intermediate,A,10116.0,CHEMBL625064,,3126.0,Trachea,,1,1
13271,50597,In vivo,BAO_0000218,,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in bone of male wistar rats,,,N,Intermediate,A,10116.0,CHEMBL625065,,10000001.0,Bone,,1,1
13272,50597,In vivo,BAO_0000218,,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in cerebellum of male wistar rats,,,N,Intermediate,A,10116.0,CHEMBL625066,,2037.0,Cerebellum,,1,1
13273,50597,In vivo,BAO_0000218,,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in cortex of male wistar rats,,,N,Intermediate,A,10116.0,CHEMBL625067,,,,,1,1
13274,50597,In vivo,BAO_0000218,,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in fat of male wistar rats,,,N,Intermediate,A,10116.0,CHEMBL625068,,,,,1,1
13275,50597,In vivo,BAO_0000218,,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in heart of male wistar rats,,,N,Intermediate,A,10116.0,CHEMBL622159,,948.0,Heart,,1,1
13276,50597,In vivo,BAO_0000218,,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in intestine of male wistar rats,,,N,Intermediate,A,10116.0,CHEMBL622160,,160.0,Intestine,,1,1
13277,50597,In vivo,BAO_0000218,,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in kidney of male wistar rats,,,N,Intermediate,A,10116.0,CHEMBL622161,,2113.0,Kidney,,1,1
13278,50597,In vivo,BAO_0000218,,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in lung of male wistar rats,,,N,Intermediate,A,10116.0,CHEMBL622162,,2048.0,Lung,,1,1
13279,50597,In vivo,BAO_0000218,,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in muscle of male wistar rats,,,N,Intermediate,A,10116.0,CHEMBL622163,,2385.0,Muscle tissue,,1,1
13280,50597,In vivo,BAO_0000218,,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in plasma of male wistar rats,,,N,Intermediate,A,10116.0,CHEMBL622313,,1969.0,Plasma,,1,1
13281,50597,In vivo,BAO_0000218,,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in red blood cells of male wistar rats,,,N,Intermediate,A,10116.0,CHEMBL622314,,,,,1,1
13282,50597,In vivo,BAO_0000218,,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in spleen of male wistar rats,,,N,Intermediate,A,10116.0,CHEMBL622315,,2106.0,Spleen,,1,1
13283,50597,In vivo,BAO_0000218,,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in trachea of male wistar rats,,,N,Intermediate,A,10116.0,CHEMBL622316,,3126.0,Trachea,,1,1
13284,50212,,BAO_0000218,,,Normal diffusion coefficient in water for Escherichia coli,,,N,Intermediate,A,562.0,CHEMBL877486,,,,,1,1
13285,22224,,BAO_0000019,,,Average max percent decrease in RVR (renal vascular resistance) was determined,,,U,Autocuration,A,,CHEMBL622317,,,,,0,1
13286,22224,,BAO_0000019,,,Average max percent decrease in RVR (renal vascular resistance) was determined.,,,U,Autocuration,A,,CHEMBL622318,,,,,0,1
13287,22224,,BAO_0000019,,,In vitro stability to pepsin promoting hydrolysis after 1 hr incubation time,,,U,Autocuration,A,,CHEMBL622319,,,,,0,1
13288,22224,,BAO_0000019,,,In vitro stability to pepsin promoting hydrolysis after 2 hr incubation time,,,U,Autocuration,A,,CHEMBL622320,,,,,0,1
13289,22224,,BAO_0000019,,,In vitro stability to pepsin promoting hydrolysis after 64h incubation time,,,U,Autocuration,A,,CHEMBL622321,,,,,0,1
13290,22224,,BAO_0000019,,,In vitro stability to pepsin promoting hydrolysis after 84 hr incubation time,,,U,Autocuration,A,,CHEMBL622322,,,,,0,1
13291,22224,,BAO_0000019,,,Compound was tested for diuretic activity in sodium content of the 3-h sample was measured by flame photometry,,,U,Autocuration,A,,CHEMBL622323,,,,,0,1
13292,50597,,BAO_0000218,,,Compound was tested for diuretic activity in sodium content of the 3-h sample was measured by flame photometry in rat,,,N,Intermediate,A,10116.0,CHEMBL622324,,,,,1,1
13293,50588,,BAO_0000218,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 0.03mg/kg, po",,,N,Intermediate,A,9615.0,CHEMBL622325,,1088.0,Urine,,1,1
13294,50588,,BAO_0000218,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",,,N,Intermediate,A,9615.0,CHEMBL622326,,1088.0,Urine,,1,1
13295,50588,,BAO_0000218,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 10.0 mg/kg, po",,,N,Intermediate,A,9615.0,CHEMBL877487,,1088.0,Urine,,1,1
13296,50588,,BAO_0000218,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 1 mg/kg, po",,,N,Intermediate,A,9615.0,CHEMBL622327,,1088.0,Urine,,1,1
13297,50588,,BAO_0000218,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 3.0 mg/kg, po",,,N,Intermediate,A,9615.0,CHEMBL622328,,1088.0,Urine,,1,1
13298,50588,,BAO_0000218,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 30 mg/kg, po",,,N,Intermediate,A,9615.0,CHEMBL622329,,1088.0,Urine,,1,1
13299,50588,,BAO_0000218,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",,,N,Intermediate,A,9615.0,CHEMBL622330,,1088.0,Urine,,1,1
13300,50588,,BAO_0000218,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 0.3mg/kg, po",,,N,Intermediate,A,9615.0,CHEMBL622331,,1088.0,Urine,,1,1
13301,50588,,BAO_0000218,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",,,N,Intermediate,A,9615.0,CHEMBL622332,,1088.0,Urine,,1,1
13302,50588,,BAO_0000218,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 3 mg/kg, po",,,N,Intermediate,A,9615.0,CHEMBL622333,,1088.0,Urine,,1,1
13303,22224,,BAO_0000218,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",,,U,Autocuration,A,314293.0,CHEMBL627658,,1088.0,Urine,,0,1
13304,22224,,BAO_0000218,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 10mg/kg, po",,,U,Autocuration,A,314293.0,CHEMBL630428,,1088.0,Urine,,0,1
13305,22224,,BAO_0000218,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",,,U,Autocuration,A,314293.0,CHEMBL630429,,1088.0,Urine,,0,1
13306,22224,,BAO_0000218,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 30 mg/kg, po",,,U,Autocuration,A,314293.0,CHEMBL630430,,1088.0,Urine,,0,1
13307,22224,,BAO_0000218,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 3 mg/kg, po",,,U,Autocuration,A,314293.0,CHEMBL630431,,1088.0,Urine,,0,1
13308,50597,,BAO_0000218,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",,,N,Intermediate,A,10116.0,CHEMBL630432,,1088.0,Urine,,1,1
13309,50597,,BAO_0000218,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 0.3mg/kg, po",,,N,Intermediate,A,10116.0,CHEMBL630433,,1088.0,Urine,,1,1
13310,50597,,BAO_0000218,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 1.0mg/kg, po",,,N,Intermediate,A,10116.0,CHEMBL630434,,1088.0,Urine,,1,1
13311,50597,,BAO_0000218,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 10.0mg/kg, po",,,N,Intermediate,A,10116.0,CHEMBL629372,,1088.0,Urine,,1,1
13312,50597,,BAO_0000218,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 100.0mg/kg, po",,,N,Intermediate,A,10116.0,CHEMBL629553,,1088.0,Urine,,1,1
13313,50597,,BAO_0000218,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 2.1 mg/kg, po",,,N,Intermediate,A,10116.0,CHEMBL629554,,1088.0,Urine,,1,1
13314,50597,,BAO_0000218,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 20.8mg/kg, po",,,N,Intermediate,A,10116.0,CHEMBL874447,,1088.0,Urine,,1,1
13315,50597,,BAO_0000218,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 207.6mg/kg, po",,,N,Intermediate,A,10116.0,CHEMBL629555,,1088.0,Urine,,1,1
13316,50597,,BAO_0000218,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 3.0mg/kg, po",,,N,Intermediate,A,10116.0,CHEMBL629556,,1088.0,Urine,,1,1
13317,50597,,BAO_0000218,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded rats at 30.0 mg/kg, po",,,N,Intermediate,A,10116.0,CHEMBL629557,,1088.0,Urine,,1,1
13318,50597,,BAO_0000218,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 6.9mg/kg, po",,,N,Intermediate,A,10116.0,CHEMBL629558,,1088.0,Urine,,1,1
13319,50597,,BAO_0000218,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 69.2mg/kg, po",,,N,Intermediate,A,10116.0,CHEMBL629559,,1088.0,Urine,,1,1
13320,50597,,BAO_0000218,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 691.9mg/kg, po",,,N,Intermediate,A,10116.0,CHEMBL629560,,1088.0,Urine,,1,1
13321,50588,,BAO_0000218,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.03mg/kg, po",,,N,Intermediate,A,9615.0,CHEMBL629561,,1088.0,Urine,,1,1
13322,50588,,BAO_0000218,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",,,N,Intermediate,A,9615.0,CHEMBL629562,,1088.0,Urine,,1,1
13323,50588,,BAO_0000218,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.3mg/kg, po",,,N,Intermediate,A,9615.0,CHEMBL629563,,1088.0,Urine,,1,1
13324,50588,,BAO_0000218,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",,,N,Intermediate,A,9615.0,CHEMBL629564,,1088.0,Urine,,1,1
13325,50588,,BAO_0000218,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 10.0mg/kg, po",,,N,Intermediate,A,9615.0,CHEMBL629565,,1088.0,Urine,,1,1
13326,50588,,BAO_0000218,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",,,N,Intermediate,A,9615.0,CHEMBL629566,,1088.0,Urine,,1,1
13327,50588,,BAO_0000218,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded dogs at 1 mg/kg, po",,,N,Intermediate,A,9615.0,CHEMBL629567,,1088.0,Urine,,1,1
13328,50588,,BAO_0000218,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 3.0mg/kg, po",,,N,Intermediate,A,9615.0,CHEMBL629568,,1088.0,Urine,,1,1
13329,50588,,BAO_0000218,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 30mg/kg, po",,,N,Intermediate,A,9615.0,CHEMBL629569,,1088.0,Urine,,1,1
13330,50588,,BAO_0000218,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 3mg/kg, po",,,N,Intermediate,A,9615.0,CHEMBL629570,,1088.0,Urine,,1,1
13331,22224,,BAO_0000218,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",,,U,Autocuration,A,314293.0,CHEMBL629571,,1088.0,Urine,,0,1
13332,22224,In vivo,BAO_0000218,,,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,,,U,Autocuration,A,10116.0,CHEMBL629572,,,,,0,1
13333,22224,In vivo,BAO_0000218,,,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,,,U,Autocuration,A,10116.0,CHEMBL629573,,,,,0,1
13334,22224,In vivo,BAO_0000218,,,Bioavailability (dose 20 mg/kg),,,U,Autocuration,A,9347.0,CHEMBL629574,,,,,0,1
13335,22224,In vivo,BAO_0000218,,,Bioavailability in dog,,,U,Autocuration,A,9615.0,CHEMBL629575,,,,,0,1
13336,22224,In vivo,BAO_0000218,,,Bioavailability in rat (Sprague-Dawley) (male),,,U,Autocuration,A,10116.0,CHEMBL874448,,,,,0,1
13337,22224,In vivo,BAO_0000218,,,Bioavailability in monkey (dose 10 mg/kg i.d.),,,U,Autocuration,A,9443.0,CHEMBL629576,,,,,0,1
13338,22224,In vivo,BAO_0000218,,,Bioavailability in rat,,,U,Autocuration,A,10116.0,CHEMBL629577,,,,,0,1
13339,22224,In vivo,BAO_0000218,,,Bioavailability in rat,,,U,Autocuration,A,10116.0,CHEMBL629578,,,,,0,1
13340,22224,In vivo,BAO_0000218,,,Bioavailability in dog (dose 3.0 mg/kg p.o.),,,U,Autocuration,A,9615.0,CHEMBL629579,,,,,0,1
13341,22224,In vivo,BAO_0000218,,,Bioavailability in dog (dose of 1.0 mg/kg i.v.) 0.5 hr,,,U,Autocuration,A,9615.0,CHEMBL882958,,,,,0,1
13342,50505,In vivo,BAO_0000218,,,Bioavailability was calculated after peroral dose of 10 mg/Kg in chimp,,,N,Intermediate,A,9598.0,CHEMBL629580,,,,,1,1
13343,22224,In vivo,BAO_0000218,,,Bioavailability,,,U,Autocuration,A,9347.0,CHEMBL629581,,,,,0,1
13344,22224,In vivo,BAO_0000218,,,Bioavailability in squirrel monkey,,,U,Autocuration,A,9520.0,CHEMBL629582,,,,,0,1
13345,50588,In vivo,BAO_0000218,,,Bioavailability was evaluated in dog,,,N,Intermediate,A,9615.0,CHEMBL628522,,,,,1,1
13346,100712,In vivo,BAO_0000218,,,Bioavailability was evaluated in hamster,,,N,Intermediate,A,10026.0,CHEMBL625432,,,,,1,1
13347,22224,In vivo,BAO_0000218,,,Bioavailability in rat,,,U,Autocuration,A,10116.0,CHEMBL625433,,,,,0,1
13348,50597,In vivo,BAO_0000218,,,Bioavailability was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL625434,,1969.0,Plasma,,1,1
13349,50597,In vivo,BAO_0000218,,,Bioavailability was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg; <Tr>,,,N,Intermediate,A,10116.0,CHEMBL625435,,1969.0,Plasma,,1,1
13350,22224,In vivo,BAO_0000218,,,Bioavailability in rat (dose 10 mg/kg p.o.),,,U,Autocuration,A,10116.0,CHEMBL625436,,,,,0,1
13351,100710,In vivo,BAO_0000218,,,Bioavailability was measured in cynomolgus monkeys.,,,N,Intermediate,A,9541.0,CHEMBL874588,,,,,1,1
13352,50594,In vivo,BAO_0000218,,,Bioavailability was measured in nude mice.,,,N,Intermediate,A,10090.0,CHEMBL625437,,,,,1,1
13353,22224,In vivo,BAO_0000218,,,Bioavailability in ferret (dose 10 mg/kg i.d.),,,U,Autocuration,A,9669.0,CHEMBL625438,,,,,0,1
13354,22224,In vivo,BAO_0000218,,,Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 0.3 mg/kg intravenous dose),,,U,Autocuration,A,314293.0,CHEMBL625439,,,,,0,1
13355,22224,In vivo,BAO_0000218,,,"Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 0.3 mg/kg intravenous dose), determined by renin inhibition assay",,,U,Autocuration,A,314293.0,CHEMBL625440,,,,,0,1
13356,22224,In vivo,BAO_0000218,,,Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 1 mg/kg intravenous dose),,,U,Autocuration,A,314293.0,CHEMBL625441,,,,,0,1
13357,22224,In vivo,BAO_0000218,,,Bioavailability in rat (dose 10 mg/kg i.d.),,,U,Autocuration,A,10116.0,CHEMBL625442,,,,,0,1
13358,50597,In vivo,BAO_0000218,,,"Bioavailability was determined after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",,,N,Intermediate,A,10116.0,CHEMBL625443,,,,,1,1
13359,22224,In vivo,BAO_0000218,,,Bioavailability was determined; extremely poor,,,U,Autocuration,A,,CHEMBL625444,,,,,0,1
13360,50594,In vivo,BAO_0000218,,,% bioavailability in mice after oral administration of prodrug,,,N,Intermediate,A,10090.0,CHEMBL625445,,,,,1,1
13361,50588,In vivo,BAO_0000218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose 10/30 range (low/high); -21/-5,,,N,Intermediate,A,9615.0,CHEMBL625446,,,,,1,1
13362,50588,In vivo,BAO_0000218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -2/6,,,N,Intermediate,A,9615.0,CHEMBL882960,,,,,1,1
13363,50588,In vivo,BAO_0000218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -4/-14,,,N,Intermediate,A,9615.0,CHEMBL625447,,,,,1,1
13364,50588,In vivo,BAO_0000218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -5/-12,,,N,Intermediate,A,9615.0,CHEMBL625448,,,,,1,1
13365,50588,In vivo,BAO_0000218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3/10 range (low/high); -1/-7/-11,,,N,Intermediate,A,9615.0,CHEMBL625449,,,,,1,1
13366,50588,In vivo,BAO_0000218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high),,,N,Intermediate,A,9615.0,CHEMBL874589,,,,,1,1
13367,50588,In vivo,BAO_0000218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -1/-9,,,N,Intermediate,A,9615.0,CHEMBL625450,,,,,1,1
13368,50588,In vivo,BAO_0000218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -11/-28,,,N,Intermediate,A,9615.0,CHEMBL625451,,,,,1,1
13369,50588,In vivo,BAO_0000218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -13/-29,,,N,Intermediate,A,9615.0,CHEMBL626584,,,,,1,1
13370,50588,In vivo,BAO_0000218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -13/30,,,N,Intermediate,A,9615.0,CHEMBL626585,,,,,1,1
13371,50588,In vivo,BAO_0000218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -16/-18,,,N,Intermediate,A,9615.0,CHEMBL626586,,,,,1,1
13372,50588,In vivo,BAO_0000218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -16/-35,,,N,Intermediate,A,9615.0,CHEMBL626587,,,,,1,1
13373,50588,In vivo,BAO_0000218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -19/-50,,,N,Intermediate,A,9615.0,CHEMBL626588,,,,,1,1
13374,50588,In vivo,BAO_0000218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -21/-29,,,N,Intermediate,A,9615.0,CHEMBL626589,,,,,1,1
13375,50588,In vivo,BAO_0000218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -24/-56,,,N,Intermediate,A,9615.0,CHEMBL626590,,,,,1,1
13376,50588,In vivo,BAO_0000218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -25/-33,,,N,Intermediate,A,9615.0,CHEMBL626591,,,,,1,1
13377,50588,In vivo,BAO_0000218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -3/-13,,,N,Intermediate,A,9615.0,CHEMBL627181,,,,,1,1
13378,50588,In vivo,BAO_0000218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -5/-47,,,N,Intermediate,A,9615.0,CHEMBL628083,,,,,1,1
13379,22224,In vivo,BAO_0000218,,,IV clearance determined at an peroral dose of 15 mg/kg.,,,U,Autocuration,A,,CHEMBL628084,,,,,0,1
13380,50064,In vivo,BAO_0000218,,,Mouse oral clearance was measured against Hymenolepiasis nana.,,,N,Expert,F,102285.0,CHEMBL628085,,,,,1,1
13381,50545,In vivo,BAO_0000218,,,Mouse oral clearance was measured against Nematospiroides dubius,,,N,Expert,F,6339.0,CHEMBL628086,,,,,1,1
13382,22224,In vivo,BAO_0000218,,,Mouse oral clearance was measured against N. dubius; NT is Not Tested,,,U,Autocuration,F,,CHEMBL628087,,,,,0,1
13383,50594,In vivo,BAO_0000218,,,Mouse oral clearance was measured against N. nana; NT is Not Tested,,,N,Intermediate,A,10090.0,CHEMBL628088,,,,,1,1
13384,22224,In vivo,BAO_0000218,,,Mouse oral clearance was measured against N. nana; NT is Not Tested,,,U,Autocuration,B,,CHEMBL628089,,,,,0,1
13385,22224,In vivo,BAO_0000218,,,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 10 J/cm e2 ultraviolet-A radiation,,,U,Autocuration,A,,CHEMBL628090,,,,,0,1
13386,22224,In vivo,BAO_0000218,,,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 6 J/cm e2 ultraviolet-A radiation,,,U,Autocuration,A,,CHEMBL628091,,,,,0,1
13387,22224,In vivo,BAO_0000218,,,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 8 J/cm e2 ultraviolet-A radiation,,,U,Autocuration,A,,CHEMBL628092,,,,,0,1
13388,22224,In vivo,BAO_0000218,,,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 9 J/cm e2 ultraviolet-A radiation,,,U,Autocuration,A,,CHEMBL628093,,,,,0,1
13389,22224,In vivo,BAO_0000218,,,Percentage of clearance of psoriatic lesions by the compound at dose of 10 J/cm e2 ultraviolet-A radiation,,,U,Autocuration,A,,CHEMBL875607,,,,,0,1
13390,22224,In vivo,BAO_0000218,,,Percentage of clearance of psoriatic lesions by the compound at dose of 4 J/cm e2 ultraviolet-A radiation,,,U,Autocuration,A,,CHEMBL625710,,,,,0,1
13391,22224,In vivo,BAO_0000218,,,Percentage of clearance of psoriatic lesions by the compound at dose of 6 J/cm e2 ultraviolet-A radiation,,,U,Autocuration,A,,CHEMBL625711,,,,,0,1
13392,22224,In vivo,BAO_0000218,,,Percentage of clearance of psoriatic lesions by the compound at dose of 8 J/cm e2 ultraviolet-A radiation,,,U,Autocuration,A,,CHEMBL625712,,,,,0,1
13393,22224,In vivo,BAO_0000218,,,Percentage of clearance of psoriatic lesions by the compound at dose of 9 J/cm e2 ultraviolet-A radiation,,,U,Autocuration,A,,CHEMBL625713,,,,,0,1
13394,50588,In vivo,BAO_0000218,,,Pharmacokinetic parameter clearance was determined in fed Beagle dogs after iv administration of 1.5 mg/kg,,,N,Intermediate,A,9615.0,CHEMBL625714,,,,,1,1
13395,50797,In vivo,BAO_0000218,,,Plasma clearance after intravenous administration dosing (30 mg/kg) in Rhesus monkey,,,N,Intermediate,A,9544.0,CHEMBL625715,,,,,1,1
13396,50597,In vivo,BAO_0000218,,,Plasma clearance after intravenous administration dosing (30 mg/kg) in rat,,,N,Intermediate,A,10116.0,CHEMBL625716,,,,,1,1
13397,50597,In vivo,BAO_0000218,,,Plasma clearance after intravenous administration iv dosing of 3 mg/kg in rat,,,N,Intermediate,A,10116.0,CHEMBL625717,,,,,1,1
13398,50597,In vivo,BAO_0000218,,,Plasma clearance was determined for the compound in rats,,,N,Intermediate,A,10116.0,CHEMBL625718,,,,,1,1
13399,50597,In vivo,BAO_0000218,,,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 1,,,N,Intermediate,A,10116.0,CHEMBL625719,,,,,1,1
13400,50597,In vivo,BAO_0000218,,,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 2,,,N,Intermediate,A,10116.0,CHEMBL625720,,,,,1,1
13401,50597,In vivo,BAO_0000218,,,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 3,,,N,Intermediate,A,10116.0,CHEMBL625721,,,,,1,1
13402,50597,In vivo,BAO_0000218,,,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 4,,,N,Intermediate,A,10116.0,CHEMBL625722,,,,,1,1
13403,50597,In vivo,BAO_0000218,,,The compound was tested for systemic clearance pharmacokinetic parameter in the male Sprague-Dawley rat.,,,N,Intermediate,A,10116.0,CHEMBL625723,,,,,1,1
13404,50545,In vivo,BAO_0000218,,,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.0125 concentration of diet.,,,N,Intermediate,A,6339.0,CHEMBL625724,,,,,1,1
13405,50545,In vivo,BAO_0000218,,,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.025 concentration of diet.,,,N,Intermediate,A,6339.0,CHEMBL625725,,,,,1,1
13406,50545,In vivo,BAO_0000218,,,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.05 concentration of diet.,,,N,Intermediate,A,6339.0,CHEMBL625726,,,,,1,1
13407,50545,In vivo,BAO_0000218,,,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.1 concentration of diet.,,,N,Intermediate,A,6339.0,CHEMBL875608,,,,,1,1
13408,50545,In vivo,BAO_0000218,,,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.2 concentration of diet.,,,N,Intermediate,A,6339.0,CHEMBL625727,,,,,1,1
13409,22224,In vivo,BAO_0000218,,,Urinary clearance was determined in rat at 100 mg/kg os dosage;ND is defined as no-data.,,,U,Autocuration,A,10116.0,CHEMBL625728,,1088.0,Urine,,0,1
13410,22224,In vivo,BAO_0000218,,,Total clearance was determined in rat at 10 mg/kg intraperitoneal dosage,,,U,Autocuration,A,10116.0,CHEMBL625729,,,,,0,1
13411,22224,In vivo,BAO_0000218,,,Total clearance was determined in rat at 25 mg/kg os dosage;ND is defined as no-data.,,,U,Autocuration,A,10116.0,CHEMBL625730,,,,,0,1
13412,22224,In vivo,BAO_0000218,,,Urinary clearance was determined in rat at 10 mg/kg intraperitoneal dosage,,,U,Autocuration,A,10116.0,CHEMBL625731,,1088.0,Urine,,0,1
13413,22224,In vivo,BAO_0000218,,,Urinary clearance was determined in rat at 25 mg/kg os dosage,,,U,Autocuration,A,10116.0,CHEMBL626417,,1088.0,Urine,,0,1
13414,50587,In vivo,BAO_0000218,,,Urinary clearance was determined at 100 mg/kg oral dosage in human,,,N,Intermediate,A,9606.0,CHEMBL626418,,1088.0,Urine,,1,1
13415,50588,In vivo,BAO_0000218,,,Urinary clearance was determined at 20 mg/kg oral dosage in dog(beagle);ND is defined as no-data.,,,N,Intermediate,A,9615.0,CHEMBL626419,,1088.0,Urine,,1,1
13416,50588,In vivo,BAO_0000218,,,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,,,N,Intermediate,A,9615.0,CHEMBL626592,,1969.0,Plasma,,1,1
13417,50597,In vivo,BAO_0000218,,,Plasma concentration in rats after 7 hr at 30mg/kg oral dose,,,N,Intermediate,A,10116.0,CHEMBL626593,,1969.0,Plasma,,1,1
13418,50597,In vivo,BAO_0000218,,,Clearance was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,,,N,Intermediate,A,10116.0,CHEMBL626594,,,,,1,1
13419,50588,In vivo,BAO_0000218,,,Clearance rate in dogs,,,N,Intermediate,A,9615.0,CHEMBL625035,,,,,1,1
13420,22224,In vitro,BAO_0000019,,,Compound was measured for intrinsic clearance,,,U,Autocuration,A,,CHEMBL625036,,,,,0,1
13421,22229,,BAO_0000100,,,Calculated partition coefficient (clogP),,,U,Autocuration,P,,CHEMBL625037,,,,,0,1
13422,22229,,BAO_0000100,,,Calculated partition coefficient (clogP),,,U,Autocuration,P,,CHEMBL625038,,,,,0,1
13423,22229,,BAO_0000100,,,Calculated partition coefficient (clogP),,,U,Autocuration,P,,CHEMBL625039,,,,,0,1
13424,22229,,BAO_0000100,,,Calculated partition coefficient (clogP),,,U,Autocuration,P,,CHEMBL625040,,,,,0,1
13425,22229,,BAO_0000100,,,Calculated partition coefficient (clogP),,,U,Autocuration,P,,CHEMBL625041,,,,,0,1
13426,22229,,BAO_0000100,,,Calculated partition coefficient (clogP),,,U,Autocuration,P,,CHEMBL625042,,,,,0,1
13427,22224,,BAO_0000019,,,Partition coefficient of the compound,,,U,Autocuration,A,,CHEMBL874411,,,,,0,1
13428,22224,,BAO_0000019,,,Permeability,,,U,Autocuration,A,,CHEMBL625043,,,,,0,1
13429,22229,,BAO_0000100,,,Calculated partition coefficient (clogP),,,U,Autocuration,P,,CHEMBL625044,,,,,0,1
13430,22224,,BAO_0000019,,,Partition coefficient (logD),,,U,Autocuration,A,,CHEMBL625045,,,,,0,1
13431,22229,,BAO_0000100,,,Calculated partition coefficient (clogP) (CLOGP3 V3.4),,,U,Autocuration,P,,CHEMBL625046,,,,,0,1
13432,22229,,BAO_0000100,,,Calculated partition coefficient (clogP) (CLOGP3 V3.4),,,U,Autocuration,P,,CHEMBL625047,,,,,0,1
13433,22229,,BAO_0000100,,,Calculated partition coefficient (clogP),,,U,Autocuration,P,,CHEMBL625048,,,,,0,1
13434,22229,,BAO_0000100,,,Calculated partition coefficient (clogP),,,U,Autocuration,P,,CHEMBL625049,,,,,0,1
13435,22229,,BAO_0000100,,,Calculated logarithm of partition coefficient (P) was determined,,,U,Autocuration,P,,CHEMBL625050,,,,,0,1
13436,22229,,BAO_0000100,,,Calculated partition coefficient (clogP),,,U,Autocuration,P,,CHEMBL625051,,,,,0,1
13437,22229,,BAO_0000100,,,Calculated partition coefficient (clogP),,,U,Autocuration,P,,CHEMBL874412,,,,,0,1
13438,22229,,BAO_0000100,,,Calculated partition coefficient (clogP),,,U,Autocuration,P,,CHEMBL625052,,,,,0,1
13439,22229,,BAO_0000100,,,Calculated partition coefficient (clogP),,,U,Autocuration,P,,CHEMBL625053,,,,,0,1
13440,22224,,BAO_0000019,,,In vitro stability to pepsin promoting hydrolysis after 8 hr incubation time,,,U,Autocuration,A,,CHEMBL623250,,,,,0,1
13441,22224,,BAO_0000019,,,In vitro stability to trypsin promoting hydrolysis after 1 hr incubation time,,,U,Autocuration,A,,CHEMBL623251,,,,,0,1
13442,22224,,BAO_0000019,,,In vitro stability to trypsin promoting hydrolysis after 2 hr incubation time,,,U,Autocuration,A,,CHEMBL623252,,,,,0,1
13443,22224,,BAO_0000019,,,In vitro stability to trypsin promoting hydrolysis after 64h incubation time,,,U,Autocuration,A,,CHEMBL623253,,,,,0,1
13444,22224,,BAO_0000019,,,In vitro stability to trypsin promoting hydrolysis after 84 hr incubation time,,,U,Autocuration,A,,CHEMBL623254,,,,,0,1
13445,22224,,BAO_0000019,,,In vitro stability to trypsin promoting hydrolysis after 8 hr incubation time,,,U,Autocuration,A,,CHEMBL623255,,,,,0,1
13446,22224,,BAO_0000019,,,Percent degradation of compound at a pH of 1 over a 18 hr period,,,U,Autocuration,A,,CHEMBL626831,,,,,0,1
13447,22224,,BAO_0000019,,,Percent degradation of compound at pH of 1 over an 18 hr period,,,U,Autocuration,A,,CHEMBL877494,,,,,0,1
13448,22224,,BAO_0000019,,,Delta Logarithm of Partition Coefficient value was determined.,,,U,Autocuration,A,,CHEMBL626832,,,,,0,1
13449,22224,,BAO_0000019,,,Delta logPoct-cyc,,,U,Autocuration,A,,CHEMBL626833,,,,,0,1
13450,22224,,BAO_0000100,,,Lipophilicity estimated on reversed phase TLC,,,U,Autocuration,P,,CHEMBL626834,,,,,0,1
13451,22224,,BAO_0000019,,,Delta Tm value ( Tmdrug-DNA )-TmDNA ) was obtained for the covalently cross-linked compound in the absence of formaldehyde using calf thymus DNA.,,,U,Autocuration,A,,CHEMBL626835,,,,,0,1
13452,22224,,BAO_0000019,,,Delta logPoct-cyc,,,U,Autocuration,A,,CHEMBL626836,,,,,0,1
13453,22229,,BAO_0000100,,,Change in logarithm of partition coefficient of the compound,,,U,Autocuration,P,,CHEMBL626837,,,,,0,1
13454,22224,,BAO_0000019,,,Delta logD (pH 6.5),,,U,Autocuration,A,,CHEMBL626838,,,,,0,1
13455,22224,,BAO_0000100,,,"Partition coefficient by standard shake-flask techniquesat 37 C, using octanol and cyclohexane",,,U,Autocuration,P,,CHEMBL626839,,,,,0,1
13456,22224,,BAO_0000019,,,Oxygen pressure at which hemoglobin is 50% oxygenated; negative sign indicates that P50 of modified Hb is lower than that of unmodified Hb,,,U,Autocuration,A,,CHEMBL626840,,,,,0,1
13457,22224,,BAO_0000019,,,Deoxyribose-damaging property as a measure of hydroxyl-radical formation (uM of malondialdehyde/mmol of deoxyribose released by 75 uM test compound),,,U,Autocuration,A,,CHEMBL626841,,,,,0,1
13458,22224,,BAO_0000219,,,Peak depolarizations produced by injections of 100 micro M Ins p3 isomers in nine cells,,,U,Autocuration,A,,CHEMBL626842,,,,,0,1
13459,22224,,BAO_0000219,,,Peak depolarizations produced by injections of 100 micro M Ins p3 isomers in six cells,,,U,Autocuration,A,,CHEMBL626843,,,,,0,1
13460,50597,,BAO_0000218,,,Amount of deuterium retained was reported after normal workup in beta-naphthoflavone-treated male rats with the substrate rac 7-D,,,N,Intermediate,A,10116.0,CHEMBL626844,,,,,1,1
13461,50597,,BAO_0000218,,,Amount of deuterium retained was reported after normal workup in rats,,,N,Intermediate,A,10116.0,CHEMBL877495,,,,,1,1
13462,50597,,BAO_0000218,,,Amount of deuterium retained was reported after reincubation followed by normal workup in phenobarbital treated male rats,,,N,Intermediate,A,10116.0,CHEMBL626845,,,,,1,1
13463,50597,,BAO_0000218,,,Amount of deuterium retained was reported after reincubation followed by normal workup in phenobarbital treated male rats with rac 8-D,,,N,Intermediate,A,10116.0,CHEMBL626846,,,,,1,1
13464,50597,,BAO_0000218,,,Compound incubated with microsomal preparations from beta-naphthoflavone-treated male rats with the substrate rac 7-D and the amount of deuterium retained was reported after reincubation followed by normal workup,,,N,Intermediate,A,10116.0,CHEMBL626847,,,,,1,1
13465,50597,,BAO_0000218,,,Compound incubated with microsomal preparations from beta-naphthoflavone-treated male rats with the substrate rac 7-D and the amount of deuterium retained was reported after reincubation followed by normal workup,,,N,Intermediate,A,10116.0,CHEMBL628677,,,,,1,1
13466,50597,,BAO_0000218,,,Compound incubated with microsomal preparations from phenobarbital treated male rats with the substrate rac 8-D and the amount of deuterium retained was reported after normal workup,,,N,Intermediate,A,10116.0,CHEMBL628678,,,,,1,1
13467,22224,,BAO_0000019,,,Compound was subjected to electrochemical oxidation,,,U,Autocuration,A,,CHEMBL628679,,,,,0,1
13468,22224,,BAO_0000019,,,Compound was subjected to photochemical oxidation,,,U,Autocuration,A,,CHEMBL628680,,,,,0,1
13469,22224,,BAO_0000019,,,Oxidation of compound by Chloroperoxidase in presence of ethylperoxide,,,U,Autocuration,A,,CHEMBL628681,,,,,0,1
13470,22224,,BAO_0000019,,,Oxidation of compound by horseradish peroxidase in presence of hydroperoxide,,,U,Autocuration,A,,CHEMBL628682,,,,,0,1
13471,22224,,BAO_0000019,,,Oxidation of compound by methemoglobin in presence of hydroperoxide,,,U,Autocuration,A,,CHEMBL628683,,,,,0,1
13472,50597,,BAO_0000218,,,Percent diffusion through fuzzy rat skin after 48 h of incubation,,,N,Intermediate,A,10116.0,CHEMBL628684,,,,,1,1
13473,22229,,BAO_0000100,,,Dissociation constant (pKa),,,U,Autocuration,P,,CHEMBL877501,,,,,0,1
13474,22224,,BAO_0000100,,,Dissociation constant value of the compound; ND means not determined.,,,U,Autocuration,P,,CHEMBL628685,,,,,0,1
13475,50597,,BAO_0000218,,,% distribution of the radioiron in blood of rat followed by intravenous injection of chelating agent,,,N,Intermediate,A,10116.0,CHEMBL628686,,178.0,Blood,,1,1
13476,50597,,BAO_0000218,,,% distribution of the radioiron in blood of rats followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,,,N,Intermediate,A,10116.0,CHEMBL628687,,178.0,Blood,,1,1
13477,50597,,BAO_0000218,,,% distribution of the radioiron in rat kidney followed by intravenous injection of chelating agent,,,N,Intermediate,A,10116.0,CHEMBL628688,,,,,1,1
13478,50597,,BAO_0000218,,,% distribution of the radioiron in rat kidney followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,,,N,Intermediate,A,10116.0,CHEMBL628689,,,,,1,1
13479,50597,,BAO_0000218,,,% distribution of the radioiron in rat liver followed by intravenous injection of chelating agent,,,N,Intermediate,A,10116.0,CHEMBL628690,,2107.0,Liver,,1,1
13480,50597,,BAO_0000218,,,% distribution of the radioiron in rat liver followed by intravenous injection of transferrin preincubated with 10 mg of chelating agent,,,N,Intermediate,A,10116.0,CHEMBL629363,,2107.0,Liver,,1,1
13481,50597,,BAO_0000218,,,% distribution of the radioiron in rat spleen followed by intravenous injection of chelating agent,,,N,Intermediate,A,10116.0,CHEMBL629364,,2106.0,Spleen,,1,1
13482,50597,,BAO_0000218,,,% distribution of the radioiron in rat spleen followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,,,N,Intermediate,A,10116.0,CHEMBL629365,,2106.0,Spleen,,1,1
13483,50597,,BAO_0000218,,,% excretion of ferritin determined in faces of rat followed by intravenous injection of chelating agent,,,N,Intermediate,A,10116.0,CHEMBL629366,,,,,1,1
13484,50597,,BAO_0000218,,,% excretion of ferritin determined in urine of rat followed by intravenous injection of chelating agent,,,N,Intermediate,A,10116.0,CHEMBL629367,,1088.0,Urine,,1,1
13485,50597,,BAO_0000218,,,% excretion of radioiron determined in feces of rat followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,,,N,Intermediate,A,10116.0,CHEMBL629368,,1988.0,Feces,,1,1
13486,50597,,BAO_0000218,,,% excretion of radioiron determined in urine of rat followed by intravenous injection of transferrin preincubated with 10 mg of chelating agent,,,N,Intermediate,A,10116.0,CHEMBL877502,,1088.0,Urine,,1,1
13487,50594,,BAO_0000218,,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into cerebellum,,,N,Intermediate,A,10090.0,CHEMBL629369,,2037.0,Cerebellum,,1,1
13488,50594,,BAO_0000218,,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into cortex,,,N,Intermediate,A,10090.0,CHEMBL629370,,955.0,Brain,,1,1
13489,22224,,BAO_0000218,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded monkey at 10 mg/kg, po",,,U,Autocuration,A,314293.0,CHEMBL629371,,1088.0,Urine,,0,1
13490,22224,,BAO_0000218,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",,,U,Autocuration,A,314293.0,CHEMBL626276,,1088.0,Urine,,0,1
13491,22224,,BAO_0000218,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 30mg/kg, po",,,U,Autocuration,A,314293.0,CHEMBL626277,,1088.0,Urine,,0,1
13492,22224,,BAO_0000218,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 3mg/kg, po",,,U,Autocuration,A,314293.0,CHEMBL631250,,1088.0,Urine,,0,1
13493,50597,,BAO_0000218,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",,,N,Intermediate,A,10116.0,CHEMBL631251,,1088.0,Urine,,1,1
13494,50597,,BAO_0000218,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 0.3mg/kg, po",,,N,Intermediate,A,10116.0,CHEMBL631252,,1088.0,Urine,,1,1
13495,50597,,BAO_0000218,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 1.0 mg/kg, po",,,N,Intermediate,A,10116.0,CHEMBL631253,,1088.0,Urine,,1,1
13496,50597,,BAO_0000218,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 10.0mg/kg, po",,,N,Intermediate,A,10116.0,CHEMBL631254,,1088.0,Urine,,1,1
13497,50597,,BAO_0000218,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 100.0 mg/kg, po",,,N,Intermediate,A,10116.0,CHEMBL631255,,1088.0,Urine,,1,1
13498,50597,,BAO_0000218,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 2.1 mg/kg, po",,,N,Intermediate,A,10116.0,CHEMBL631256,,1088.0,Urine,,1,1
13499,50597,,BAO_0000218,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 20.8mg/kg, po",,,N,Intermediate,A,10116.0,CHEMBL631257,,1088.0,Urine,,1,1
13500,50597,,BAO_0000218,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 207.6 mg/kg, po",,,N,Intermediate,A,10116.0,CHEMBL628009,,1088.0,Urine,,1,1
13501,50597,,BAO_0000218,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 3.0mg/kg, po",,,N,Intermediate,A,10116.0,CHEMBL628010,,1088.0,Urine,,1,1
13502,50597,,BAO_0000218,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 30.0mg/kg, po",,,N,Intermediate,A,10116.0,CHEMBL628011,,1088.0,Urine,,1,1
13503,50597,,BAO_0000218,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 6.9 mg/kg, po",,,N,Intermediate,A,10116.0,CHEMBL628012,,1088.0,Urine,,1,1
13504,50597,,BAO_0000218,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 69.2mg/kg, po",,,N,Intermediate,A,10116.0,CHEMBL628013,,1088.0,Urine,,1,1
13505,50597,,BAO_0000218,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 691.9mg/kg, po",,,N,Intermediate,A,10116.0,CHEMBL628014,,1088.0,Urine,,1,1
13506,50588,,BAO_0000218,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 0.03 mg/kg, po",,,N,Intermediate,A,9615.0,CHEMBL628015,,1088.0,Urine,,1,1
13507,50588,,BAO_0000218,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",,,N,Intermediate,A,9615.0,CHEMBL628016,,1088.0,Urine,,1,1
13508,50588,,BAO_0000218,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 0.3 mg/kg, po",,,N,Intermediate,A,9615.0,CHEMBL874461,,1088.0,Urine,,1,1
13509,50588,,BAO_0000218,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",,,N,Intermediate,A,9615.0,CHEMBL628017,,1088.0,Urine,,1,1
13510,50588,,BAO_0000218,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 10.0mg/kg, po",,,N,Intermediate,A,9615.0,CHEMBL628018,,1088.0,Urine,,1,1
13511,50588,,BAO_0000218,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",,,N,Intermediate,A,9615.0,CHEMBL628019,,1088.0,Urine,,1,1
13512,50588,,BAO_0000218,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 1 mg/kg, po",,,N,Intermediate,A,9615.0,CHEMBL628020,,1088.0,Urine,,1,1
13513,50588,,BAO_0000218,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 30 mg/kg, po",,,N,Intermediate,A,9615.0,CHEMBL628021,,1088.0,Urine,,1,1
13514,50588,,BAO_0000218,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 3mg/kg, po",,,N,Intermediate,A,9615.0,CHEMBL628022,,1088.0,Urine,,1,1
13515,50588,,BAO_0000218,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 3.0mg/kg, po",,,N,Intermediate,A,9615.0,CHEMBL628023,,1088.0,Urine,,1,1
13516,22224,,BAO_0000218,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",,,U,Autocuration,A,314293.0,CHEMBL628024,,1088.0,Urine,,0,1
13517,22224,,BAO_0000218,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 10mg/kg, po",,,U,Autocuration,A,314293.0,CHEMBL628025,,1088.0,Urine,,0,1
13518,22224,,BAO_0000218,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",,,U,Autocuration,A,314293.0,CHEMBL628026,,1088.0,Urine,,0,1
13519,22224,,BAO_0000218,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 30mg/kg, po",,,U,Autocuration,A,314293.0,CHEMBL628027,,1088.0,Urine,,0,1
13520,22224,,BAO_0000218,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 3mg/kg, po",,,U,Autocuration,A,314293.0,CHEMBL628028,,1088.0,Urine,,0,1
13521,50597,,BAO_0000218,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",,,N,Intermediate,A,10116.0,CHEMBL628029,,1088.0,Urine,,1,1
13522,50597,,BAO_0000218,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 0.3 mg/kg, po",,,N,Intermediate,A,10116.0,CHEMBL628030,,1088.0,Urine,,1,1
13523,50597,,BAO_0000218,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 1.0mg/kg, po",,,N,Intermediate,A,10116.0,CHEMBL628031,,1088.0,Urine,,1,1
13524,50597,,BAO_0000218,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 10.0 mg/kg, po",,,N,Intermediate,A,10116.0,CHEMBL628032,,1088.0,Urine,,1,1
13525,50597,,BAO_0000218,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 100.0 mg/kg, po",,,N,Intermediate,A,10116.0,CHEMBL628033,,1088.0,Urine,,1,1
13526,50597,,BAO_0000218,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 2.08 mg/kg, po",,,N,Intermediate,A,10116.0,CHEMBL628034,,1088.0,Urine,,1,1
13527,50597,,BAO_0000218,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 207.6mg/kg, po",,,N,Intermediate,A,10116.0,CHEMBL628035,,1088.0,Urine,,1,1
13528,50597,,BAO_0000218,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 3.0 mg/kg, po",,,N,Intermediate,A,10116.0,CHEMBL628036,,1088.0,Urine,,1,1
13529,50597,,BAO_0000218,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 30.0mg/kg, po",,,N,Intermediate,A,10116.0,CHEMBL874462,,1088.0,Urine,,1,1
13530,50588,In vivo,BAO_0000218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -8/-38,,,N,Intermediate,A,9615.0,CHEMBL628037,,,,,1,1
13531,50588,In vivo,BAO_0000218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); 13/-25,,,N,Intermediate,A,9615.0,CHEMBL628123,,,,,1,1
13532,50588,In vivo,BAO_0000218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); 27/-15,,,N,Intermediate,A,9615.0,CHEMBL628124,,,,,1,1
13533,50588,In vivo,BAO_0000218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -2/-19,,,N,Intermediate,A,9615.0,CHEMBL628125,,,,,1,1
13534,50588,In vivo,BAO_0000218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/60 range (low/high); -3/-4,,,N,Intermediate,A,9615.0,CHEMBL628126,,,,,1,1
13535,50588,In vivo,BAO_0000218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3 range (low/high),,,N,Intermediate,A,9615.0,CHEMBL628127,,,,,1,1
13536,50588,In vivo,BAO_0000218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3/10 range (low/high); -9/24,,,N,Intermediate,A,9615.0,CHEMBL628128,,,,,1,1
13537,50588,In vivo,BAO_0000218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3/10 range (low/high); 3/-1,,,N,Intermediate,A,9615.0,CHEMBL628129,,,,,1,1
13538,50588,In vivo,BAO_0000218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/030 range (low/high); 12/23,,,N,Intermediate,A,9615.0,CHEMBL628130,,,,,1,1
13539,50588,In vivo,BAO_0000218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 1/3,,,N,Intermediate,A,9615.0,CHEMBL628131,,,,,1,1
13540,50588,In vivo,BAO_0000218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 6/16,,,N,Intermediate,A,9615.0,CHEMBL628132,,,,,1,1
13541,50588,In vivo,BAO_0000218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 7/14,,,N,Intermediate,A,9615.0,CHEMBL628133,,,,,1,1
13542,50588,In vivo,BAO_0000218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3/10 range (low/high); 4/4/23,,,N,Intermediate,A,9615.0,CHEMBL628134,,,,,1,1
13543,50588,In vivo,BAO_0000218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 10/14,,,N,Intermediate,A,9615.0,CHEMBL628135,,,,,1,1
13544,50588,In vivo,BAO_0000218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 11/15,,,N,Intermediate,A,9615.0,CHEMBL628136,,,,,1,1
13545,50588,In vivo,BAO_0000218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 11/44,,,N,Intermediate,A,9615.0,CHEMBL628137,,,,,1,1
13546,50588,In vivo,BAO_0000218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 14/28,,,N,Intermediate,A,9615.0,CHEMBL628138,,,,,1,1
13547,50588,In vivo,BAO_0000218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 15-28,,,N,Intermediate,A,9615.0,CHEMBL628139,,,,,1,1
13548,50588,In vivo,BAO_0000218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 2/3,,,N,Intermediate,A,9615.0,CHEMBL628140,,,,,1,1
13549,50588,In vivo,BAO_0000218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 26/32,,,N,Intermediate,A,9615.0,CHEMBL628141,,,,,1,1
13550,50588,In vivo,BAO_0000218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 5/1,,,N,Intermediate,A,9615.0,CHEMBL628142,,,,,1,1
13551,50588,In vivo,BAO_0000218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 5/12,,,N,Intermediate,A,9615.0,CHEMBL628143,,,,,1,1
13552,50588,In vivo,BAO_0000218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 6/7,,,N,Intermediate,A,9615.0,CHEMBL628144,,,,,1,1
13553,50588,In vivo,BAO_0000218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 7/6,,,N,Intermediate,A,9615.0,CHEMBL628145,,,,,1,1
13554,50588,In vivo,BAO_0000218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 8/12,,,N,Intermediate,A,9615.0,CHEMBL628146,,,,,1,1
13555,50588,In vivo,BAO_0000218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 8/27,,,N,Intermediate,A,9615.0,CHEMBL625355,,,,,1,1
13556,50588,In vivo,BAO_0000218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 9/14,,,N,Intermediate,A,9615.0,CHEMBL625356,,,,,1,1
13557,50588,In vivo,BAO_0000218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 9/16,,,N,Intermediate,A,9615.0,CHEMBL625357,,,,,1,1
13558,50588,In vivo,BAO_0000218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/60 range (low/high); 12/23,,,N,Intermediate,A,9615.0,CHEMBL625527,,,,,1,1
13559,50588,In vivo,BAO_0000218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3 range (low/high),,,N,Intermediate,A,9615.0,CHEMBL875473,,,,,1,1
13560,50588,In vivo,BAO_0000218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3/10 range (low/high); 10/22,,,N,Intermediate,A,9615.0,CHEMBL625528,,,,,1,1
13561,50597,In vivo,BAO_0000218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3/10 range (low/high); 4/12,,,N,Intermediate,A,10116.0,CHEMBL626304,,,,,1,1
13562,50588,In vivo,BAO_0000218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a 10/30 dose range; 11/-11,,,N,Intermediate,A,9615.0,CHEMBL624138,,1637.0,Artery,,1,1
13563,22229,,BAO_0000100,,,Calculated partition coefficient (clogP),,,U,Autocuration,P,,CHEMBL624139,,,,,0,1
13564,22229,,BAO_0000100,,,Calculated partition coefficient (clogP),,,U,Autocuration,P,,CHEMBL624140,,,,,0,1
13565,22229,,BAO_0000100,,,Calculated partition coefficient (clogP),,,U,Autocuration,P,,CHEMBL624141,,,,,0,1
13566,22229,,BAO_0000100,,,Calculated partition coefficient (clogP),,,U,Autocuration,P,,CHEMBL624142,,,,,0,1
13567,22229,,BAO_0000100,,,Calculated partition coefficient (clogP),,,U,Autocuration,P,,CHEMBL624143,,,,,0,1
13568,22229,,BAO_0000100,,,Calculated partition coefficient (clogP),,,U,Autocuration,P,,CHEMBL624144,,,,,0,1
13569,22229,,BAO_0000100,,,Calculated partition coefficient (clogP),,,U,Autocuration,P,,CHEMBL624145,,,,,0,1
13570,22229,,BAO_0000100,,,Calculated partition coefficient (clogP),,,U,Autocuration,P,,CHEMBL624146,,,,,0,1
13571,22229,,BAO_0000100,,,Calculated partition coefficient (clogP),,,U,Autocuration,P,,CHEMBL624147,,,,,0,1
13572,22229,,BAO_0000100,,,Calculated partition coefficient (clogP) (MacLogP),,,U,Autocuration,P,,CHEMBL883123,,,,,0,1
13573,22224,,BAO_0000019,,,Partition coefficient (logP),,,U,Autocuration,A,,CHEMBL624148,,,,,0,1
13574,22224,,BAO_0000019,,,Kinetic parameter was determined,,,U,Autocuration,A,,CHEMBL874416,,,,,0,1
13575,22229,,BAO_0000100,,,Calculated partition coefficient (clogP),,,U,Autocuration,P,,CHEMBL624149,,,,,0,1
13576,22229,,BAO_0000100,,,Calculated partition coefficient (clogP),,,U,Autocuration,P,,CHEMBL624150,,,,,0,1
13577,22224,,BAO_0000100,,,Lipophilicity was determined,,,U,Autocuration,P,,CHEMBL624151,,,,,0,1
13578,22224,,BAO_0000100,,,Lipophilicity was determined,,,U,Autocuration,P,,CHEMBL624152,,,,,0,1
13579,22224,,BAO_0000100,,,Lipophilicity was determined,,,U,Autocuration,P,,CHEMBL622139,,,,,0,1
13580,22229,,BAO_0000100,,,Calculated partition coefficient (clogP),,,U,Autocuration,P,,CHEMBL622140,,,,,0,1
13581,22224,,BAO_0000100,,,Lipophilicity was determined,,,U,Autocuration,P,,CHEMBL622141,,,,,0,1
13582,22224,,BAO_0000100,,,Lipophilicity in octanol-water,,,U,Autocuration,P,,CHEMBL622142,,,,,0,1
13583,22229,,BAO_0000100,,,Calculated partition coefficient (clogP),,,U,Autocuration,P,,CHEMBL622143,,,,,0,1
13584,22229,,BAO_0000100,,,Octanol-water partition coefficient was determined,,,U,Autocuration,P,,CHEMBL622144,,,,,0,1
13585,22224,,BAO_0000019,,,Partition coefficient (logP),,,U,Autocuration,A,,CHEMBL877473,,,,,0,1
13586,22229,,BAO_0000100,,,Calculated partition coefficient (clogP),,,U,Autocuration,P,,CHEMBL622145,,,,,0,1
13587,22224,,BAO_0000019,,,Partition coefficient was determined; ND means not determined,,,U,Autocuration,A,,CHEMBL622146,,,,,0,1
13588,22229,,BAO_0000100,,,Calculated partition coefficient (clogP),,,U,Autocuration,P,,CHEMBL622147,,,,,0,1
13589,22224,,BAO_0000019,,,Partition coefficient of the compound,,,U,Autocuration,A,,CHEMBL622148,,,,,0,1
13590,22224,,BAO_0000019,,,Permeability was determined,,,U,Autocuration,A,,CHEMBL883124,,,,,0,1
13591,22229,,BAO_0000100,,,The compound was evaluated for the partition coefficient,,,U,Autocuration,P,,CHEMBL622149,,,,,0,1
13592,22224,,BAO_0000019,,,Partition coefficient (logP),,,U,Autocuration,A,,CHEMBL622150,,,,,0,1
13593,22224,,BAO_0000100,,,The lipophilicity was reported,,,U,Autocuration,P,,CHEMBL622151,,,,,0,1
13594,22229,,BAO_0000100,,,logarithm of the octanol-water partition coefficient for the compound,,,U,Autocuration,P,,CHEMBL622152,,,,,0,1
13595,22224,,BAO_0000019,,,Clogp value was determined,,,U,Autocuration,A,,CHEMBL622153,,,,,0,1
13596,22224,In vivo,BAO_0000218,,,Clp at a dose of 1.5 mg/kg,,,U,Autocuration,A,,CHEMBL877474,,,,,0,1
13597,22224,In vivo,BAO_0000218,,,Clp at a dose of 2.0 mg/kg,,,U,Autocuration,A,,CHEMBL622154,,,,,0,1
13598,22224,In vivo,BAO_0000218,,,"Clp, plasma clearance at a dose of 10 mg/kg",,,U,Autocuration,A,,CHEMBL622155,,1969.0,Plasma,,0,1
13599,22224,In vivo,BAO_0000218,,,"Clp, plasma clearance at a dose of 50 mg/kg",,,U,Autocuration,A,,CHEMBL622156,,1969.0,Plasma,,0,1
13600,50597,In vivo,BAO_0000218,,,Compound was tested for plasma clearance in rat,,,N,Intermediate,A,10116.0,CHEMBL622157,,1969.0,Plasma,,1,1
13601,50597,In vivo,BAO_0000218,,,Compound was tested for plasma clearance in rat; Not determined,,,N,Intermediate,A,10116.0,CHEMBL622158,,1969.0,Plasma,,1,1
13602,50597,In vivo,BAO_0000218,,,Plasma clearance (pharmacokinetic parameter) in rat (in vivo) at a dose of 10 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL622807,,,,,1,1
13603,50797,In vivo,BAO_0000218,,,Plasma clearance (pharmacokinetic parameter) in rhesus (in vivo) at a dose of 5 mg/kg,,,N,Intermediate,A,9544.0,CHEMBL622808,,,,,1,1
13604,22224,In vivo,BAO_0000218,,,Plasma clearance by iv administration at a dose 0.003 ug/mL,,,U,Autocuration,A,,CHEMBL622809,,,,,0,1
13605,22224,In vivo,BAO_0000218,,,Plasma clearance determined,,,U,Autocuration,A,,CHEMBL622810,,,,,0,1
13606,100712,In vivo,BAO_0000218,,,Plasma clearance after iv administration at 3 mg/kg in hamster,,,N,Intermediate,A,10026.0,CHEMBL876653,,,,,1,1
13607,100712,In vivo,BAO_0000218,,,Plasma clearance after iv administration at 4 mg/kg in hamster,,,N,Intermediate,A,10026.0,CHEMBL622811,,,,,1,1
13608,50597,In vivo,BAO_0000218,,,Rate of clearance in rat was determined,,,N,Intermediate,A,10116.0,CHEMBL622986,,,,,1,1
13609,50597,In vivo,BAO_0000218,,,Total plasma clearance Clp was determined for the compound after iv dose of 5.06 mg/kg in rats,,,N,Intermediate,A,10116.0,CHEMBL622987,,1969.0,Plasma,,1,1
13610,50597,In vivo,BAO_0000218,,,Total plasma clearance after iv dose of 5.10 mg/kg in rats,,,N,Intermediate,A,10116.0,CHEMBL622988,,1969.0,Plasma,,1,1
13611,50597,In vivo,BAO_0000218,,,Total plasma clearance was determined for the compound after iv dose of 4.74 mg/kg in rats,,,N,Intermediate,A,10116.0,CHEMBL622989,,1969.0,Plasma,,1,1
13612,50597,In vivo,BAO_0000218,,,Total plasma clearance was determined for the compound after iv dose of 4.97 mg/kg in rats,,,N,Intermediate,A,10116.0,CHEMBL622990,,1969.0,Plasma,,1,1
13613,22224,In vivo,BAO_0000218,,,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.01 mg/kg) in monkey,,,U,Autocuration,A,314293.0,CHEMBL622991,,1969.0,Plasma,,0,1
13614,50597,In vivo,BAO_0000218,,,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.05 mg/kg) in rat,,,N,Intermediate,A,10116.0,CHEMBL622227,,1969.0,Plasma,,1,1
13615,50588,In vivo,BAO_0000218,,,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.1 mg/kg) in dog,,,N,Intermediate,A,9615.0,CHEMBL622228,,1969.0,Plasma,,1,1
13616,50597,In vivo,BAO_0000218,,,Clpl value in rat,,,N,Intermediate,A,10116.0,CHEMBL622229,,,,,1,1
13617,50512,In vivo,BAO_0000218,,,Cmax (ng /mL) value after oral administration of 10 mg/kg in guinea pig.,,,N,Intermediate,A,10141.0,CHEMBL622230,,,,,1,1
13618,50597,In vivo,BAO_0000218,,,Cmax after an oral dose of 10 uM/Kg in male Sprague-Dawley rats,,,N,Intermediate,A,10116.0,CHEMBL622231,,,,,1,1
13619,100710,In vivo,BAO_0000218,,,Cmax after an oral dose of 10 uM/Kg in male cynomolgus monkeys,,,N,Intermediate,A,9541.0,CHEMBL622232,,,,,1,1
13620,22224,In vivo,BAO_0000218,,,Cmax in minutes at a iv dose of 1.0(pmol/g/h).,,,U,Autocuration,A,,CHEMBL622233,,,,,0,1
13621,22224,In vivo,BAO_0000218,,,Cmax in minutes at a iv dose of 2.0(pmol/g/h).,,,U,Autocuration,A,,CHEMBL622234,,,,,0,1
13622,22224,In vivo,BAO_0000218,,,Cmax in minutes at a iv dose of 4.0(pmol/g/h).,,,U,Autocuration,A,,CHEMBL622235,,,,,0,1
13623,22224,In vivo,BAO_0000218,,,Cmax in minutes at a iv dose of 5.0(pmol/g/h).,,,U,Autocuration,A,,CHEMBL622236,,,,,0,1
13624,22224,In vivo,BAO_0000218,,,Cmax in minutes at a iv dose of 54.0(pmol/g/h).,,,U,Autocuration,A,,CHEMBL622237,,,,,0,1
13625,22224,In vivo,BAO_0000218,,,Cmax in minutes at a po dose of 10.0(pmol/g/h).,,,U,Autocuration,A,,CHEMBL877482,,,,,0,1
13626,22224,In vivo,BAO_0000218,,,Cmax in minutes at a po dose of 20.0(pmol/g/h).,,,U,Autocuration,A,,CHEMBL622238,,,,,0,1
13627,22224,In vivo,BAO_0000218,,,Cmax in minutes at a po dose of 40.0(pmol/g/h).,,,U,Autocuration,A,,CHEMBL622239,,,,,0,1
13628,22224,In vivo,BAO_0000218,,,Cmax was calculated as maximum concentration reached in the blood,,,U,Autocuration,A,,CHEMBL622240,,178.0,Blood,,0,1
13629,22224,In vivo,BAO_0000218,,,Cmax was calculated as maximum concentration reached in the blood in air pouch exudate,,,U,Autocuration,A,,CHEMBL622241,,178.0,Blood,,0,1
13630,50597,In vivo,BAO_0000218,,,Cmax was determine after peroral administration at 10 mpk in Rat,,,N,Intermediate,A,10116.0,CHEMBL631013,,,,,1,1
13631,50797,In vivo,BAO_0000218,,,Cmax was determine after peroral administration at 10 mpk in Rhesus,,,N,Intermediate,A,9544.0,CHEMBL631014,,,,,1,1
13632,50588,In vivo,BAO_0000218,,,Cmax was determine after peroral administration at 10 mpk in dog,,,N,Intermediate,A,9615.0,CHEMBL631015,,,,,1,1
13633,50597,In vivo,BAO_0000218,,,Cmax was determine after peroral administration at 160 mpk in Rat,,,N,Intermediate,A,10116.0,CHEMBL631016,,,,,1,1
13634,50597,In vivo,BAO_0000218,,,Cmax was determine after peroral administration at 20 mpk in Rat,,,N,Intermediate,A,10116.0,CHEMBL631017,,,,,1,1
13635,50597,In vivo,BAO_0000218,,,Cmax was determine after peroral administration at 50 mpk in Rat,,,N,Intermediate,A,10116.0,CHEMBL631018,,,,,1,1
13636,22224,In vivo,BAO_0000218,,,Cmax was determined,,,U,Autocuration,A,,CHEMBL631019,,,,,0,1
13637,50594,,BAO_0000218,,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into hippocampus,,,N,Intermediate,A,10090.0,CHEMBL875761,,955.0,Brain,,1,1
13638,50594,,BAO_0000218,,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into hypothalamus,,,N,Intermediate,A,10090.0,CHEMBL631020,,955.0,Brain,,1,1
13639,50594,,BAO_0000218,,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into pons and medulla,,,N,Intermediate,A,10090.0,CHEMBL631669,,955.0,Brain,,1,1
13640,50594,,BAO_0000218,,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into rest of the brain,,,N,Intermediate,A,10090.0,CHEMBL631670,,955.0,Brain,,1,1
13641,50594,,BAO_0000218,,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into striatum,,,N,Intermediate,A,10090.0,CHEMBL631671,,2435.0,Striatum,,1,1
13642,50597,,BAO_0000218,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.31-0.4,,,N,Intermediate,A,10116.0,CHEMBL631672,,178.0,Blood,,1,1
13643,50597,,BAO_0000218,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.97-1.12,,,N,Intermediate,A,10116.0,CHEMBL631673,,178.0,Blood,,1,1
13644,50597,,BAO_0000218,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.35-0.37,,,N,Intermediate,A,10116.0,CHEMBL631856,,178.0,Blood,,1,1
13645,50597,,BAO_0000218,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.72-1.03,,,N,Intermediate,A,10116.0,CHEMBL631857,,178.0,Blood,,1,1
13646,50597,,BAO_0000218,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.95-1.06,,,N,Intermediate,A,10116.0,CHEMBL631858,,178.0,Blood,,1,1
13647,50597,,BAO_0000218,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.35-0.4,,,N,Intermediate,A,10116.0,CHEMBL631859,,178.0,Blood,,1,1
13648,50597,,BAO_0000218,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.73-0.85,,,N,Intermediate,A,10116.0,CHEMBL631860,,178.0,Blood,,1,1
13649,50597,,BAO_0000218,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.65-0.83,,,N,Intermediate,A,10116.0,CHEMBL631861,,178.0,Blood,,1,1
13650,50597,,BAO_0000218,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.69-0.84,,,N,Intermediate,A,10116.0,CHEMBL631862,,178.0,Blood,,1,1
13651,50597,,BAO_0000218,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.28-0.46,,,N,Intermediate,A,10116.0,CHEMBL631863,,178.0,Blood,,1,1
13652,50597,,BAO_0000218,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.38-1.5,,,N,Intermediate,A,10116.0,CHEMBL631864,,178.0,Blood,,1,1
13653,50597,,BAO_0000218,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.34-0.48,,,N,Intermediate,A,10116.0,CHEMBL631865,,178.0,Blood,,1,1
13654,50597,,BAO_0000218,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.58-1.17,,,N,Intermediate,A,10116.0,CHEMBL631866,,178.0,Blood,,1,1
13655,50597,,BAO_0000218,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.0-1.24,,,N,Intermediate,A,10116.0,CHEMBL629360,,178.0,Blood,,1,1
13656,50597,,BAO_0000218,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.28-0.37,,,N,Intermediate,A,10116.0,CHEMBL629361,,178.0,Blood,,1,1
13657,50597,,BAO_0000218,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.54-0.63,,,N,Intermediate,A,10116.0,CHEMBL629362,,178.0,Blood,,1,1
13658,50597,,BAO_0000218,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.25-0.32,,,N,Intermediate,A,10116.0,CHEMBL630740,,178.0,Blood,,1,1
13659,50597,,BAO_0000218,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.49-0.58,,,N,Intermediate,A,10116.0,CHEMBL630741,,178.0,Blood,,1,1
13660,50597,,BAO_0000218,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.58-0.77,,,N,Intermediate,A,10116.0,CHEMBL630742,,178.0,Blood,,1,1
13661,50597,,BAO_0000218,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.20-0.25,,,N,Intermediate,A,10116.0,CHEMBL630743,,,,,1,1
13662,50597,,BAO_0000218,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.05-1.25,,,N,Intermediate,A,10116.0,CHEMBL630744,,,,,1,1
13663,50597,,BAO_0000218,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.03-0.03,,,N,Intermediate,A,10116.0,CHEMBL630745,,,,,1,1
13664,50597,,BAO_0000218,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.03-0.06,,,N,Intermediate,A,10116.0,CHEMBL630746,,,,,1,1
13665,50597,,BAO_0000218,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.34-0.5,,,N,Intermediate,A,10116.0,CHEMBL630747,,,,,1,1
13666,50597,,BAO_0000218,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.17-0.20,,,N,Intermediate,A,10116.0,CHEMBL630748,,,,,1,1
13667,50597,,BAO_0000218,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.81-1.26,,,N,Intermediate,A,10116.0,CHEMBL632056,,,,,1,1
13668,50597,,BAO_0000218,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.03-0.06,,,N,Intermediate,A,10116.0,CHEMBL632057,,,,,1,1
13669,50597,,BAO_0000218,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.18-0.36,,,N,Intermediate,A,10116.0,CHEMBL632058,,,,,1,1
13670,50597,,BAO_0000218,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.28-0.37,,,N,Intermediate,A,10116.0,CHEMBL632059,,,,,1,1
13671,50597,,BAO_0000218,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.97-2.17,,,N,Intermediate,A,10116.0,CHEMBL632060,,,,,1,1
13672,50597,,BAO_0000218,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.02-0.03,,,N,Intermediate,A,10116.0,CHEMBL632061,,,,,1,1
13673,50597,,BAO_0000218,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.05-0.07,,,N,Intermediate,A,10116.0,CHEMBL629207,,,,,1,1
13674,50597,,BAO_0000218,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.35-0.72,,,N,Intermediate,A,10116.0,CHEMBL629208,,,,,1,1
13675,50597,,BAO_0000218,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.15-0.19,,,N,Intermediate,A,10116.0,CHEMBL629209,,,,,1,1
13676,50597,,BAO_0000218,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.76-1.42,,,N,Intermediate,A,10116.0,CHEMBL629210,,,,,1,1
13677,50597,,BAO_0000218,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.02-0.03,,,N,Intermediate,A,10116.0,CHEMBL629211,,,,,1,1
13678,50597,,BAO_0000218,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.03-0.06,,,N,Intermediate,A,10116.0,CHEMBL629212,,,,,1,1
13679,50597,,BAO_0000218,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.05-0.06,,,N,Intermediate,A,10116.0,CHEMBL629213,,,,,1,1
13680,50597,,BAO_0000218,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 6.9mg/kg, po",,,N,Intermediate,A,10116.0,CHEMBL629214,,1088.0,Urine,,1,1
13681,50597,,BAO_0000218,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 69.2 mg/kg, po",,,N,Intermediate,A,10116.0,CHEMBL629215,,1088.0,Urine,,1,1
13682,50597,,BAO_0000218,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 691.9 mg/kg, po",,,N,Intermediate,A,10116.0,CHEMBL635154,,1088.0,Urine,,1,1
13683,50597,,BAO_0000218,,,Oral diuretic activity measured by Na+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),,,N,Intermediate,A,10116.0,CHEMBL629216,,,,,1,1
13684,50597,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration,,,N,Intermediate,A,10116.0,CHEMBL629217,,,,,1,1
13685,50597,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,,N,Intermediate,A,10116.0,CHEMBL629218,,,,,1,1
13686,50597,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration (0-5 hr),,,N,Intermediate,A,10116.0,CHEMBL629219,,,,,1,1
13687,50597,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),,,N,Intermediate,A,10116.0,CHEMBL629220,,,,,1,1
13688,50597,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),,,N,Intermediate,A,10116.0,CHEMBL629221,,,,,1,1
13689,50597,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,,N,Intermediate,A,10116.0,CHEMBL631127,,,,,1,1
13690,50597,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration,,,N,Intermediate,A,10116.0,CHEMBL631128,,,,,1,1
13691,50597,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,,N,Intermediate,A,10116.0,CHEMBL631129,,,,,1,1
13692,50597,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration (0-5 hr),,,N,Intermediate,A,10116.0,CHEMBL631130,,,,,1,1
13693,50597,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),,,N,Intermediate,A,10116.0,CHEMBL631131,,,,,1,1
13694,50597,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),,,N,Intermediate,A,10116.0,CHEMBL631132,,,,,1,1
13695,50597,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,,N,Intermediate,A,10116.0,CHEMBL631133,,,,,1,1
13696,50597,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration,,,N,Intermediate,A,10116.0,CHEMBL631134,,,,,1,1
13697,50597,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,,N,Intermediate,A,10116.0,CHEMBL875120,,,,,1,1
13698,50597,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration (0-5 hr),,,N,Intermediate,A,10116.0,CHEMBL631135,,,,,1,1
13699,50597,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0 - 5 hr),,,N,Intermediate,A,10116.0,CHEMBL631136,,,,,1,1
13700,50597,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),,,N,Intermediate,A,10116.0,CHEMBL631137,,,,,1,1
13701,50597,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,,N,Intermediate,A,10116.0,CHEMBL631138,,,,,1,1
13702,50597,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration,,,N,Intermediate,A,10116.0,CHEMBL631139,,,,,1,1
13703,50597,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,,N,Intermediate,A,10116.0,CHEMBL631140,,,,,1,1
13704,50597,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration (0-5 hr),,,N,Intermediate,A,10116.0,CHEMBL631141,,,,,1,1
13705,50597,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),,,N,Intermediate,A,10116.0,CHEMBL631142,,,,,1,1
13706,50597,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),,,N,Intermediate,A,10116.0,CHEMBL631143,,,,,1,1
13707,50597,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,,N,Intermediate,A,10116.0,CHEMBL631144,,,,,1,1
13708,50588,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.312 mg/kg after ip administration,,,N,Intermediate,A,9615.0,CHEMBL631145,,,,,1,1
13709,50588,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),,,N,Intermediate,A,9615.0,CHEMBL631146,,,,,1,1
13710,50588,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.625 mg/kg after ip administration,,,N,Intermediate,A,9615.0,CHEMBL631147,,,,,1,1
13711,50588,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),,,N,Intermediate,A,9615.0,CHEMBL631148,,,,,1,1
13712,50588,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),,,N,Intermediate,A,9615.0,CHEMBL631149,,,,,1,1
13713,50588,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 10 mg/kg after ip administration (0-6 hr),,,N,Intermediate,A,9615.0,CHEMBL631150,,,,,1,1
13714,50588,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),,,N,Intermediate,A,9615.0,CHEMBL631151,,,,,1,1
13715,50588,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),,,N,Intermediate,A,9615.0,CHEMBL631152,,,,,1,1
13716,50588,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),,,N,Intermediate,A,9615.0,CHEMBL631443,,,,,1,1
13717,50588,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration (0-6 hr),,,N,Intermediate,A,9615.0,CHEMBL631444,,,,,1,1
13718,50588,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),,,N,Intermediate,A,9615.0,CHEMBL631445,,,,,1,1
13719,50588,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),,,N,Intermediate,A,9615.0,CHEMBL631446,,,,,1,1
13720,50588,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg g after ip administration (0-6 hr),,,N,Intermediate,A,9615.0,CHEMBL631447,,,,,1,1
13721,50588,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),,,N,Intermediate,A,9615.0,CHEMBL631448,,,,,1,1
13722,50588,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration,,,N,Intermediate,A,9615.0,CHEMBL631449,,,,,1,1
13723,50588,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration (0-6 hr),,,N,Intermediate,A,9615.0,CHEMBL631450,,,,,1,1
13724,50588,,BAO_0000218,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),,,N,Intermediate,A,9615.0,CHEMBL629724,,,,,1,1
13725,50594,In vivo,BAO_0000218,,,"Biodistribution in mice skin, after 24 hr of intravenous aadministration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,,N,Intermediate,A,10090.0,CHEMBL629725,,14.0,Zone of skin,,1,1
13726,50594,In vivo,BAO_0000218,,,"Biodistribution in mice skin, after 48 hr of intravenous administration of 1-2 ug ofcompound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,,N,Intermediate,A,10090.0,CHEMBL629726,,14.0,Zone of skin,,1,1
13727,50594,In vivo,BAO_0000218,,,"Biodistribution in mice spleen, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,,N,Intermediate,A,10090.0,CHEMBL629727,,2106.0,Spleen,,1,1
13728,50594,In vivo,BAO_0000218,,,"Biodistribution in mice spleen, after 1 hr of intravenous aadministration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,,N,Intermediate,A,10090.0,CHEMBL630404,,2106.0,Spleen,,1,1
13729,50594,In vivo,BAO_0000218,,,"Biodistribution in mice spleen, after 24 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,,N,Intermediate,A,10090.0,CHEMBL630405,,2106.0,Spleen,,1,1
13730,50594,In vivo,BAO_0000218,,,"Biodistribution in mice spleen, after 48 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,,N,Intermediate,A,10090.0,CHEMBL630406,,2106.0,Spleen,,1,1
13731,50594,In vivo,BAO_0000218,,,"Biodistribution in mice stomach, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,,N,Intermediate,A,10090.0,CHEMBL630407,,945.0,Stomach,,1,1
13732,50594,In vivo,BAO_0000218,,,"Biodistribution in mice stomach, after 1 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,,N,Intermediate,A,10090.0,CHEMBL630573,,945.0,Stomach,,1,1
13733,50594,In vivo,BAO_0000218,,,"Biodistribution in mice stomach, after 24 hr of intravenous administration of 1-2 ug of ofcompound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,,N,Intermediate,A,10090.0,CHEMBL630574,,945.0,Stomach,,1,1
13734,50594,In vivo,BAO_0000218,,,"Biodistribution in mice stomach, after 48 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,,N,Intermediate,A,10090.0,CHEMBL630575,,945.0,Stomach,,1,1
13735,50594,In vivo,BAO_0000218,,,"Biodistribution in mice tail, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,,N,Intermediate,A,10090.0,CHEMBL630576,,,,,1,1
13736,50594,In vivo,BAO_0000218,,,"Biodistribution in mice tail, after 1 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,,N,Intermediate,A,10090.0,CHEMBL630577,,,,,1,1
13737,50594,In vivo,BAO_0000218,,,"Biodistribution in mice tail, after 24 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,,N,Intermediate,A,10090.0,CHEMBL630578,,,,,1,1
13738,50594,In vivo,BAO_0000218,,,"Biodistribution in mice tail, after 48 hr of intravenous administration of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,,N,Intermediate,A,10090.0,CHEMBL630579,,,,,1,1
13739,50594,,BAO_0000218,,,Percent of injected 238-Plutonium(IV) in mice kidney at 24 hr (orally administered),,,N,Intermediate,A,10090.0,CHEMBL630580,,2113.0,Kidney,,1,1
13740,50594,,BAO_0000218,,,Percent of injected 238-Plutonium(IV) in mice kidneys at 24 h,,,N,Intermediate,A,10090.0,CHEMBL630581,,2113.0,Kidney,,1,1
13741,50594,,BAO_0000218,,,Percent of injected 238-Plutonium(IV) in mice kidneys at 24 hr (orally administered),,,N,Intermediate,A,10090.0,CHEMBL630582,,2113.0,Kidney,,1,1
13742,50594,,BAO_0000218,,,Percent of injected 238-Plutonium(IV) in mice liver at 24 h,,,N,Intermediate,A,10090.0,CHEMBL630583,,,,,1,1
13743,50594,,BAO_0000218,,,Percent of injected 238-Plutonium(IV) in mice liver at 24 hr (orally administered),,,N,Intermediate,A,10090.0,CHEMBL630584,,,,,1,1
13744,50594,,BAO_0000218,,,Percent of injected 238-Plutonium(IV) in mice skeleton at 24 h,,,N,Intermediate,A,10090.0,CHEMBL630585,,,,,1,1
13745,50594,,BAO_0000218,,,Percent of injected 238-Plutonium(IV) in mice skeleton at 24 hr (orally administered),,,N,Intermediate,A,10090.0,CHEMBL630586,,,,,1,1
13746,50594,,BAO_0000218,,,Percent of injected 238-Plutonium(IV) in mice soft tissue at 24 h,,,N,Intermediate,A,10090.0,CHEMBL630587,,,,,1,1
13747,50594,,BAO_0000218,,,Percent of injected 238-Plutonium(IV) in mice soft tissue at 24 hr (orally administered),,,N,Intermediate,A,10090.0,CHEMBL630588,,,,,1,1
13748,50594,,BAO_0000218,,,Percent of injected 238-Plutonium(IV) in mice whole body at 24 h,,,N,Intermediate,A,10090.0,CHEMBL630589,,,,,1,1
13749,50594,,BAO_0000218,,,Percent of injected 238-Plutonium(IV) in mice whole body at 24 hr (orally administered),,,N,Intermediate,A,10090.0,CHEMBL630590,,,,,1,1
13750,22224,,BAO_0000019,,,Removal of 238-Plutonium(IV) in feces at 24 h,,,U,Autocuration,A,,CHEMBL630591,,1988.0,Feces,,0,1
13751,22224,,BAO_0000019,,,Removal of 238-Plutonium(IV) in feces at 24 hr (orally administered),,,U,Autocuration,A,,CHEMBL630592,,1988.0,Feces,,0,1
13752,22224,,BAO_0000019,,,Removal of 238-Plutonium(IV) in gastrointestinal (GI) contents at 24 h,,,U,Autocuration,A,,CHEMBL630593,,,,,0,1
13753,22224,,BAO_0000019,,,Removal of 238-Plutonium(IV) in gastrointestinal (GI) contents at 24 hr (orally administered),,,U,Autocuration,A,,CHEMBL630594,,,,,0,1
13754,22224,,BAO_0000019,,,Removal of 238-Plutonium(IV) in urine 0-4 h (orally administered),,,U,Autocuration,A,,CHEMBL630595,,1088.0,Urine,,0,1
13755,22224,,BAO_0000019,,,Removal of 238-Plutonium(IV) in urine 4-24 hr (orally administered),,,U,Autocuration,A,,CHEMBL630596,,1088.0,Urine,,0,1
13756,22224,,BAO_0000019,,,Removal of 238-Plutonium(IV) in urine after 0-24 h,,,U,Autocuration,A,,CHEMBL630597,,1088.0,Urine,,0,1
13757,22224,,BAO_0000019,,,Removal of 238-Plutonium(IV) in urine after 0-24 hr (orally administered),,,U,Autocuration,A,,CHEMBL630598,,1088.0,Urine,,0,1
13758,22224,,BAO_0000019,,,Removal of 238-Plutonium(IV) in urine after 0-4 h,,,U,Autocuration,A,,CHEMBL630599,,1088.0,Urine,,0,1
13759,22224,,BAO_0000019,,,Removal of 238-Plutonium(IV) in urine after 0-4 hr (orally administered),,,U,Autocuration,A,,CHEMBL630600,,1088.0,Urine,,0,1
13760,22224,,BAO_0000019,,,Removal of 238-Plutonium(IV) in urine after 4-24 h,,,U,Autocuration,A,,CHEMBL630601,,1088.0,Urine,,0,1
13761,22224,,BAO_0000019,,,Removal of 238-Plutonium(IV) in urine after 4-24 hr (orally administered),,,U,Autocuration,A,,CHEMBL630602,,1088.0,Urine,,0,1
13762,22224,,BAO_0000019,,,Removal of 238-Plutonium(IV) in urine at 0-4 hr (orally administered),,,U,Autocuration,A,,CHEMBL630603,,1088.0,Urine,,0,1
13763,22224,,BAO_0000019,,,Removal of 238-Plutonium(IV) in urine at 4-24 hr (orally administered),,,U,Autocuration,A,,CHEMBL630604,,1088.0,Urine,,0,1
13764,50597,In vivo,BAO_0000218,,,Biodistribution in blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL624869,,178.0,Blood,,1,1
13765,50597,In vivo,BAO_0000218,,,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL624870,,178.0,Blood,,1,1
13766,50597,In vivo,BAO_0000218,,,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,,N,Intermediate,A,10116.0,CHEMBL623189,,178.0,Blood,,1,1
13767,50597,In vivo,BAO_0000218,,,Biodistribution in blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL623190,,178.0,Blood,,1,1
13768,50597,In vivo,BAO_0000218,,,Biodistribution in blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL623191,,178.0,Blood,,1,1
13769,50597,In vivo,BAO_0000218,,,Biodistribution in fat of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL623192,,,,,1,1
13770,50597,In vivo,BAO_0000218,,,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL623193,,,,,1,1
13771,50597,In vivo,BAO_0000218,,,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,,N,Intermediate,A,10116.0,CHEMBL623194,,,,,1,1
13772,50597,In vivo,BAO_0000218,,,Biodistribution in fat of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL623195,,,,,1,1
13773,50597,In vivo,BAO_0000218,,,Biodistribution in fat of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL623196,,,,,1,1
13774,50597,,BAO_0000218,,,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 15 microCi of the drug and 15 micro g of estradiol,,,N,Intermediate,A,10116.0,CHEMBL623197,,,,,1,1
13775,50597,,BAO_0000218,,,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,,,N,Intermediate,A,10116.0,CHEMBL623198,,,,,1,1
13776,50597,,BAO_0000218,,,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 50 microCi of the drug and 15 ug of estradiol,,,N,Intermediate,A,10116.0,CHEMBL623199,,,,,1,1
13777,50597,,BAO_0000218,,,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 100 microCi of drug in 10%ethanol saline,,,N,Intermediate,A,10116.0,CHEMBL623200,,2385.0,Muscle tissue,,1,1
13778,50597,,BAO_0000218,,,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 120 microCi of drug in 10%ethanol saline,,,N,Intermediate,A,10116.0,CHEMBL623201,,2385.0,Muscle tissue,,1,1
13779,50597,,BAO_0000218,,,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 15 microCi of drug in 10%ethanol saline,,,N,Intermediate,A,10116.0,CHEMBL623202,,2385.0,Muscle tissue,,1,1
13780,50597,,BAO_0000218,,,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 50 microCi of drug in 10%ethanol saline,,,N,Intermediate,A,10116.0,CHEMBL623203,,2385.0,Muscle tissue,,1,1
13781,50597,,BAO_0000218,,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 100 microCi of drug in 10%ethanol saline,,,N,Intermediate,A,10116.0,CHEMBL623204,,2385.0,Muscle tissue,,1,1
13782,50597,,BAO_0000218,,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 100 microCi of the drug and 15 ug of estradiol,,,N,Intermediate,A,10116.0,CHEMBL623205,,2385.0,Muscle tissue,,1,1
13783,50597,,BAO_0000218,,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 120 microCi of drug in 10%ethanol saline,,,N,Intermediate,A,10116.0,CHEMBL623206,,2385.0,Muscle tissue,,1,1
13784,50597,,BAO_0000218,,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 120 microCi of the drug and 15 micro g of estradiol,,,N,Intermediate,A,10116.0,CHEMBL623207,,2385.0,Muscle tissue,,1,1
13785,50597,,BAO_0000218,,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 15 microCi of the drug and 15 ug of estradiol,,,N,Intermediate,A,10116.0,CHEMBL623208,,2385.0,Muscle tissue,,1,1
13786,50597,,BAO_0000218,,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,,,N,Intermediate,A,10116.0,CHEMBL623209,,2385.0,Muscle tissue,,1,1
13787,50597,,BAO_0000218,,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 50 microCi of the drug and 15 ug of estradiol,,,N,Intermediate,A,10116.0,CHEMBL623210,,2385.0,Muscle tissue,,1,1
13788,50597,,BAO_0000218,,,Tested in vivo for the biodistribution in rat fat at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,,,N,Intermediate,A,10116.0,CHEMBL623211,,,,,1,1
13789,50597,,BAO_0000218,,,Tested in vivo for the biodistribution in rat uterus at 1 hour after intravenous dose of 120 microCi of drug in 10%ethanol saline,,,N,Intermediate,A,10116.0,CHEMBL623212,,995.0,Uterus,,1,1
13790,22224,,BAO_0000019,,,Tested in vitro for intrinsic activity relative to quinpirole,,,U,Autocuration,A,,CHEMBL623213,,,,,0,1
13791,22224,,BAO_0000019,,,"Relative ion enhancement, determined in pulsed ultrafiltration",,,U,Autocuration,A,,CHEMBL623214,,,,,0,1
13792,22224,,BAO_0000019,,,% ionization at the pH 7.4 at 37 degree Centigrade,,,U,Autocuration,A,,CHEMBL623215,,,,,0,1
13793,22224,,BAO_0000019,,,Percentage ionization was measured,,,U,Autocuration,A,,CHEMBL623216,,,,,0,1
13794,50591,,BAO_0000218,,,Association constant of binding of compound with calf thymus DNA was determined by using equilibrium dialysis.,,,N,Intermediate,A,9913.0,CHEMBL623217,,,,,1,1
13795,22224,,BAO_0000019,,,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 Pseudo-first-order rate constant,,,U,Autocuration,A,,CHEMBL623218,,,,,0,1
13796,22224,,BAO_0000019,,,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 phosphate buffer Pseudo-first-order rate constant,,,U,Autocuration,A,,CHEMBL623913,,,,,0,1
13797,22224,,BAO_0000019,,,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 phosphate buffer pseudo-first-order rate constant 0.1 mM EDTA,,,U,Autocuration,A,,CHEMBL623914,,,,,0,1
13798,22229,,BAO_0000100,,,Compound was evaluated for the partition coefficient in octanol/water,,,U,Autocuration,P,,CHEMBL623915,,,,,0,1
13799,22229,,BAO_0000100,,,Compound was evaluated for the partition coefficient in octanol/water (1-octanol / 10 mM phosphate buffer at pH 7.4),,,U,Autocuration,P,,CHEMBL624080,,,,,0,1
13800,22224,,BAO_0000019,,,Equilibrium constant measured by the pulse radiolysis at pH 7,,,U,Autocuration,A,,CHEMBL624081,,,,,0,1
13801,50587,,BAO_0000218,,,In vitro hydrolytic rate constant determined in human blood,,,N,Intermediate,A,9606.0,CHEMBL624082,,,,,1,1
13802,50587,,BAO_0000218,,,In vitro oxidation of compound to its pyridinium salt (3) in presence of human plasma,,,N,Intermediate,A,9606.0,CHEMBL625054,,,,,1,1
13803,22224,,BAO_0000019,,,In vitro oxidation of compound to its pyridinium salt (3) in presence of hydrogen peroxide,,,U,Autocuration,A,,CHEMBL877485,,,,,0,1
13804,50594,,BAO_0000218,,,In vitro oxidation of compound to its pyridinium salt (3) in presence of mouse brain homogenate,,,N,Intermediate,A,10090.0,CHEMBL625055,,,,,1,1
13805,50594,,BAO_0000218,,,In vitro oxidation of compound to its pyridinium salt (3) in presence of mouse liver homogenate,,,N,Intermediate,A,10090.0,CHEMBL625056,,,,,1,1
13806,50587,,BAO_0000218,,,In vitro oxidation of compound in presence of human plasma,,,N,Intermediate,A,9606.0,CHEMBL625057,,,,,1,1
13807,22224,,BAO_0000019,,,In vitro oxidation of compound in presence of hydrogen peroxide,,,U,Autocuration,A,,CHEMBL625058,,,,,0,1
13808,50594,,BAO_0000218,,,In vitro oxidation of compound in presence of mouse brain homogenate,,,N,Intermediate,A,10090.0,CHEMBL625059,,,,,1,1
13809,50594,,BAO_0000218,,,In vitro oxidation of compound in presence of mouse liver homogenate,,,N,Intermediate,A,10090.0,CHEMBL629536,,,,,1,1
13810,50597,,BAO_0000218,,,Mean potassium excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL629537,,,,,1,1
13811,50597,,BAO_0000218,,,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL629538,,,,,1,1
13812,50597,,BAO_0000218,,,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL629539,,,,,1,1
13813,50597,,BAO_0000218,,,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL874445,,,,,1,1
13814,50597,,BAO_0000218,,,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL629540,,,,,1,1
13815,50597,,BAO_0000218,,,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL629541,,,,,1,1
13816,50597,,BAO_0000218,,,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL629542,,,,,1,1
13817,50597,,BAO_0000218,,,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,,,N,Intermediate,A,10116.0,CHEMBL630243,,,,,1,1
13818,50597,,BAO_0000218,,,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL630244,,,,,1,1
13819,50597,,BAO_0000218,,,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL630245,,,,,1,1
13820,50597,,BAO_0000218,,,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL630246,,,,,1,1
13821,50597,,BAO_0000218,,,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL630247,,,,,1,1
13822,50597,,BAO_0000218,,,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL630248,,,,,1,1
13823,50597,In vivo,BAO_0000218,,,Biodistribution in rat blood at 240 minutes after dose administration.,,,N,Intermediate,A,10116.0,CHEMBL630249,,178.0,Blood,,1,1
13824,50597,In vivo,BAO_0000218,,,Biodistribution in rat blood at 30 minutes after dose administration.,,,N,Intermediate,A,10116.0,CHEMBL630250,,178.0,Blood,,1,1
13825,50597,In vivo,BAO_0000218,,,Biodistribution in rat blood at 360 minutes after dose administration.,,,N,Intermediate,A,10116.0,CHEMBL630251,,178.0,Blood,,1,1
13826,50597,In vivo,BAO_0000218,,,Biodistribution in rat blood at 3 hr after dose administration.,,,N,Intermediate,A,10116.0,CHEMBL630252,,178.0,Blood,,1,1
13827,50597,In vivo,BAO_0000218,,,Biodistribution in rat blood at 60 minutes after dose administration.,,,N,Intermediate,A,10116.0,CHEMBL630408,,178.0,Blood,,1,1
13828,50597,In vivo,BAO_0000218,,,Biodistribution in rat cerebellum at 120 minutes after dose administration.,,,N,Intermediate,A,10116.0,CHEMBL630409,,2037.0,Cerebellum,,1,1
13829,50597,In vivo,BAO_0000218,,,Biodistribution in rat cerebellum at 1440 minutes after dose administration.,,,N,Intermediate,A,10116.0,CHEMBL874446,,2037.0,Cerebellum,,1,1
13830,50597,In vivo,BAO_0000218,,,Biodistribution in rat cerebellum at 15 minutes after dose administration.,,,N,Intermediate,A,10116.0,CHEMBL630410,,2037.0,Cerebellum,,1,1
13831,50597,In vivo,BAO_0000218,,,Biodistribution in rat cerebellum at 240 minutes after dose administration.,,,N,Intermediate,A,10116.0,CHEMBL630411,,2037.0,Cerebellum,,1,1
13832,50597,In vivo,BAO_0000218,,,Biodistribution in rat cerebellum at 30 minutes after dose administration.,,,N,Intermediate,A,10116.0,CHEMBL630412,,2037.0,Cerebellum,,1,1
13833,50597,In vivo,BAO_0000218,,,Biodistribution in rat cerebellum at 360 minutes after dose administration.,,,N,Intermediate,A,10116.0,CHEMBL630413,,2037.0,Cerebellum,,1,1
13834,50597,In vivo,BAO_0000218,,,Biodistribution in rat cerebellum at 3 hr after dose administration.,,,N,Intermediate,A,10116.0,CHEMBL630414,,2037.0,Cerebellum,,1,1
13835,50597,In vivo,BAO_0000218,,,Biodistribution in rat cerebellum at 60 minutes after dose administration.,,,N,Intermediate,A,10116.0,CHEMBL630415,,2037.0,Cerebellum,,1,1
13836,50597,In vivo,BAO_0000218,,,Biodistribution in rat cortex at 120 minutes after dose administration.,,,N,Intermediate,A,10116.0,CHEMBL630416,,,,,1,1
13837,50597,In vivo,BAO_0000218,,,Biodistribution in rat cortex at 1440 minutes after dose administration.,,,N,Intermediate,A,10116.0,CHEMBL630417,,,,,1,1
13838,50597,In vivo,BAO_0000218,,,Biodistribution in rat cortex at 15 minutes after dose administration.,,,N,Intermediate,A,10116.0,CHEMBL630418,,,,,1,1
13839,50597,In vivo,BAO_0000218,,,Biodistribution in rat cortex at 240 minutes after dose administration.,,,N,Intermediate,A,10116.0,CHEMBL630419,,,,,1,1
13840,50597,In vivo,BAO_0000218,,,Biodistribution in rat cortex at 30 minutes after dose administration.,,,N,Intermediate,A,10116.0,CHEMBL630420,,,,,1,1
13841,50597,In vivo,BAO_0000218,,,Biodistribution in rat cortex at 360 minutes after dose administration.,,,N,Intermediate,A,10116.0,CHEMBL630421,,,,,1,1
13842,50597,In vivo,BAO_0000218,,,Biodistribution in rat cortex at 3 hr after dose administration.,,,N,Intermediate,A,10116.0,CHEMBL630422,,,,,1,1
13843,50597,In vivo,BAO_0000218,,,Biodistribution in rat cortex at 60 minutes after dose administration.,,,N,Intermediate,A,10116.0,CHEMBL630423,,,,,1,1
13844,50597,In vivo,BAO_0000218,,,Biodistribution in rat heart at 120 minutes after dose administration.,,,N,Intermediate,A,10116.0,CHEMBL630424,,948.0,Heart,,1,1
13845,50597,In vivo,BAO_0000218,,,Biodistribution in rat heart at 15 minutes after dose administration.,,,N,Intermediate,A,10116.0,CHEMBL630425,,948.0,Heart,,1,1
13846,50597,In vivo,BAO_0000218,,,Biodistribution in rat heart at 240 minutes after dose administration.,,,N,Intermediate,A,10116.0,CHEMBL629462,,948.0,Heart,,1,1
13847,50597,In vivo,BAO_0000218,,,Biodistribution in rat heart at 30 minutes after dose administration.,,,N,Intermediate,A,10116.0,CHEMBL630426,,948.0,Heart,,1,1
13848,50597,In vivo,BAO_0000218,,,Biodistribution in rat heart at 360 minutes after dose administration.,,,N,Intermediate,A,10116.0,CHEMBL630427,,948.0,Heart,,1,1
13849,50597,In vivo,BAO_0000218,,,Biodistribution in rat heart at 3 hr after dose administration.,,,N,Intermediate,A,10116.0,CHEMBL625877,,948.0,Heart,,1,1
13850,50597,In vivo,BAO_0000218,,,Biodistribution in rat heart at 60 minutes after dose administration.,,,N,Intermediate,A,10116.0,CHEMBL625878,,948.0,Heart,,1,1
13851,50597,In vivo,BAO_0000218,,,Biodistribution in rat hippocampus at 1440 minutes after dose administration.,,,N,Intermediate,A,10116.0,CHEMBL625879,,10000000.0,Hippocampus,,1,1
13852,50597,In vivo,BAO_0000218,,,Biodistribution in rat hippocampus at 240 minutes after dose administration.,,,N,Intermediate,A,10116.0,CHEMBL625880,,10000000.0,Hippocampus,,1,1
13853,50597,In vivo,BAO_0000218,,,Biodistribution in rat hippocampus at 30 minutes after dose administration.,,,N,Intermediate,A,10116.0,CHEMBL625881,,10000000.0,Hippocampus,,1,1
13854,50597,In vivo,BAO_0000218,,,Biodistribution in rat hippocampus at 360 minutes after dose administration.,,,N,Intermediate,A,10116.0,CHEMBL625882,,10000000.0,Hippocampus,,1,1
13855,50597,In vivo,BAO_0000218,,,Biodistribution in rat hippocampus at 15 minutes after dose administration.,,,N,Intermediate,A,10116.0,CHEMBL625883,,10000000.0,Hippocampus,,1,1
13856,50597,In vivo,BAO_0000218,,,Biodistribution in rat kidney at 120 minutes after dose administration.,,,N,Intermediate,A,10116.0,CHEMBL625884,,2113.0,Kidney,,1,1
13857,50597,In vivo,BAO_0000218,,,Biodistribution in rat kidney at 1440 minutes after dose administration.,,,N,Intermediate,A,10116.0,CHEMBL625885,,2113.0,Kidney,,1,1
13858,50597,In vivo,BAO_0000218,,,Biodistribution in rat kidney at 15 minutes after dose administration.,,,N,Intermediate,A,10116.0,CHEMBL628649,,2113.0,Kidney,,1,1
13859,50597,In vivo,BAO_0000218,,,Biodistribution in rat kidney at 240 minutes after dose administration.,,,N,Intermediate,A,10116.0,CHEMBL628650,,2113.0,Kidney,,1,1
13860,50597,In vivo,BAO_0000218,,,Biodistribution in rat kidney at 30 minutes after dose administration.,,,N,Intermediate,A,10116.0,CHEMBL628651,,2113.0,Kidney,,1,1
13861,50597,In vivo,BAO_0000218,,,Biodistribution in rat kidney at 360 minutes after dose administration.,,,N,Intermediate,A,10116.0,CHEMBL628652,,2113.0,Kidney,,1,1
13862,50597,In vivo,BAO_0000218,,,Biodistribution in rat kidney at 60 minutes after dose administration.,,,N,Intermediate,A,10116.0,CHEMBL628653,,2113.0,Kidney,,1,1
13863,50597,In vivo,BAO_0000218,,,Biodistribution in rat liver at 120 minutes after dose administration.,,,N,Intermediate,A,10116.0,CHEMBL628654,,2107.0,Liver,,1,1
13864,50597,In vivo,BAO_0000218,,,Biodistribution in rat liver at 1440 minutes after dose administration.,,,N,Intermediate,A,10116.0,CHEMBL628655,,2107.0,Liver,,1,1
13865,50597,In vivo,BAO_0000218,,,Biodistribution in rat liver at 15 minutes after dose administration.,,,N,Intermediate,A,10116.0,CHEMBL625238,,2107.0,Liver,,1,1
13866,50597,In vivo,BAO_0000218,,,Biodistribution in rat liver at 240 minutes after dose administration.,,,N,Intermediate,A,10116.0,CHEMBL625239,,2107.0,Liver,,1,1
13867,50597,In vivo,BAO_0000218,,,Biodistribution in rat liver at 30 minutes after dose administration.,,,N,Intermediate,A,10116.0,CHEMBL625240,,2107.0,Liver,,1,1
13868,50597,In vivo,BAO_0000218,,,Biodistribution in rat liver at 360 minutes after dose administration.,,,N,Intermediate,A,10116.0,CHEMBL625241,,2107.0,Liver,,1,1
13869,50597,In vivo,BAO_0000218,,,Biodistribution in rat liver at 60 minutes after dose administration.,,,N,Intermediate,A,10116.0,CHEMBL625242,,2107.0,Liver,,1,1
13870,50597,In vivo,BAO_0000218,,,Biodistribution in rat lung at 120 minutes after dose administration.,,,N,Intermediate,A,10116.0,CHEMBL874587,,2048.0,Lung,,1,1
13871,50597,In vivo,BAO_0000218,,,Biodistribution in rat lung at 1440 minutes after dose administration.,,,N,Intermediate,A,10116.0,CHEMBL625405,,2048.0,Lung,,1,1
13872,50597,In vivo,BAO_0000218,,,Biodistribution in rat lung at 15 minutes after dose administration.,,,N,Intermediate,A,10116.0,CHEMBL625406,,2048.0,Lung,,1,1
13873,50597,In vivo,BAO_0000218,,,Biodistribution in rat lung at 240 minutes after dose administration.,,,N,Intermediate,A,10116.0,CHEMBL625407,,2048.0,Lung,,1,1
13874,50597,In vivo,BAO_0000218,,,Biodistribution in rat lung at 30 minutes after dose administration.,,,N,Intermediate,A,10116.0,CHEMBL625408,,2048.0,Lung,,1,1
13875,50597,In vivo,BAO_0000218,,,Biodistribution in rat lung at 360 minutes after dose administration.,,,N,Intermediate,A,10116.0,CHEMBL625409,,2048.0,Lung,,1,1
13876,50597,,BAO_0000218,,,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of calcium deficient buffer,,,N,Intermediate,A,10116.0,CHEMBL625410,,1515.0,Thoracic aorta,,1,1
13877,50597,,BAO_0000218,,,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of nifedipine,,,N,Intermediate,A,10116.0,CHEMBL625411,,1515.0,Thoracic aorta,,1,1
13878,50597,,BAO_0000218,,,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of verapamil,,,N,Intermediate,A,10116.0,CHEMBL625412,,1515.0,Thoracic aorta,,1,1
13879,50597,,BAO_0000218,,,Percent of maximal contractile response to compound in rat thoracic aorta strips presence of PBZ and CIR,,,N,Intermediate,A,10116.0,CHEMBL625413,,1515.0,Thoracic aorta,,1,1
13880,50597,,BAO_0000218,,,Percent of maximal contractile response to compound in rat thoracic aorta strips v,,,N,Intermediate,A,10116.0,CHEMBL625414,,1515.0,Thoracic aorta,,1,1
13881,50597,,BAO_0000218,,,Percent of maximal contractile response to compound with phenoxybenzamine pretreatment on rat thoracic aorta strips,,,N,Intermediate,A,10116.0,CHEMBL625415,,1515.0,Thoracic aorta,,1,1
13882,50597,,BAO_0000218,,,Percent of maximal contractile response to compound without phenoxybenzamine pretreatment on rat thoracic aorta strips,,,N,Intermediate,A,10116.0,CHEMBL625416,,1515.0,Thoracic aorta,,1,1
13883,50597,,BAO_0000218,,,% of the total radioactive dose of compound present in the 0-24 hour urine after a single 5 mg/kg dose administered intravenously in rats,,,N,Intermediate,A,10116.0,CHEMBL625417,,1088.0,Urine,,1,1
13884,50597,,BAO_0000218,,,Compound at the dose 10 mg/kg administered intraperitoneally was evaluated for the excretion rate in rats in 7 days through feces,,,N,Intermediate,A,10116.0,CHEMBL625418,,1988.0,Feces,,1,1
13885,50597,,BAO_0000218,,,Compound at the dose 10 mg/kg administered intraperitoneally was evaluated for the excretion rate in rats in 7 days through urine,,,N,Intermediate,A,10116.0,CHEMBL625419,,1088.0,Urine,,1,1
13886,50597,,BAO_0000218,,,Compound was evaluated for the biliary excretion in the anesthetized rats in 6 hours after intravenous doses 1 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL625420,,,,,1,1
13887,50597,,BAO_0000218,,,Compound was evaluated for the biliary excretion in the anesthetized rats in 6 hours after intravenous doses 10 mg/kg,,,N,Intermediate,A,10116.0,CHEMBL626996,,,,,1,1
13888,50597,,BAO_0000218,,,"Compound was evaluated for the cumulative excretion rate in rats at the dose 10 mg/kg, intraperitoneally for 18 days through feces",,,N,Intermediate,A,10116.0,CHEMBL626997,,1988.0,Feces,,1,1
13889,50597,,BAO_0000218,,,"Compound was evaluated for the cumulative excretion rate in rats at the dose 10 mg/kg, intraperitoneally for 18 days through urine",,,N,Intermediate,A,10116.0,CHEMBL626998,,1088.0,Urine,,1,1
13890,50597,,BAO_0000218,,,"Compound was evaluated for the in rats after the dose of 5 mg/kg intravenously, at the dose 4 hour biliary excretion",,,N,Intermediate,A,10116.0,CHEMBL626999,,,,,1,1
13891,50594,,BAO_0000218,,,faecal levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-30h,,,N,Intermediate,A,10090.0,CHEMBL627000,,,,,1,1
13892,50594,,BAO_0000218,,,fecal levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-30h,,,N,Intermediate,A,10090.0,CHEMBL627001,,,,,1,1
13893,50594,,BAO_0000218,,,fecal levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-30h,,,N,Intermediate,A,10090.0,CHEMBL627002,,,,,1,1
13894,50594,,BAO_0000218,,,fecal levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-30h,,,N,Intermediate,A,10090.0,CHEMBL627003,,,,,1,1
13895,50594,,BAO_0000218,,,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-24 hr,,,N,Intermediate,A,10090.0,CHEMBL627004,,1088.0,Urine,,1,1
13896,50594,,BAO_0000218,,,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-6 hr,,,N,Intermediate,A,10090.0,CHEMBL627005,,1088.0,Urine,,1,1
13897,50594,,BAO_0000218,,,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 24-30 hr,,,N,Intermediate,A,10090.0,CHEMBL874594,,1088.0,Urine,,1,1
13898,50594,,BAO_0000218,,,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-24 hr,,,N,Intermediate,A,10090.0,CHEMBL627006,,1088.0,Urine,,1,1
13899,50594,,BAO_0000218,,,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-6 hr,,,N,Intermediate,A,10090.0,CHEMBL627007,,1088.0,Urine,,1,1
13900,50594,,BAO_0000218,,,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 24-30 hr,,,N,Intermediate,A,10090.0,CHEMBL627884,,1088.0,Urine,,1,1
13901,50594,,BAO_0000218,,,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-24 hr,,,N,Intermediate,A,10090.0,CHEMBL627885,,1088.0,Urine,,1,1
13902,50594,,BAO_0000218,,,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-6 hr,,,N,Intermediate,A,10090.0,CHEMBL627886,,1088.0,Urine,,1,1
13903,50594,,BAO_0000218,,,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 24-30 hr,,,N,Intermediate,A,10090.0,CHEMBL627887,,1088.0,Urine,,1,1
13904,50594,,BAO_0000218,,,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-24 hr,,,N,Intermediate,A,10090.0,CHEMBL627888,,1088.0,Urine,,1,1
13905,50594,,BAO_0000218,,,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-6 hr,,,N,Intermediate,A,10090.0,CHEMBL628057,,1088.0,Urine,,1,1
13906,50594,,BAO_0000218,,,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 24-30 hr,,,N,Intermediate,A,10090.0,CHEMBL627405,,1088.0,Urine,,1,1
13907,50588,,BAO_0000218,,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,,,N,Intermediate,A,9615.0,CHEMBL627406,,1088.0,Urine,,1,1
13908,50588,,BAO_0000218,,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,,,N,Intermediate,A,9615.0,CHEMBL627407,,1088.0,Urine,,1,1
13909,50588,,BAO_0000218,,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,,,N,Intermediate,A,9615.0,CHEMBL627408,,1088.0,Urine,,1,1
13910,50588,,BAO_0000218,,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,,,N,Intermediate,A,9615.0,CHEMBL627409,,1088.0,Urine,,1,1
13911,50588,,BAO_0000218,,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,,,N,Intermediate,A,9615.0,CHEMBL875486,,1088.0,Urine,,1,1
13912,50588,,BAO_0000218,,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,,,N,Intermediate,A,9615.0,CHEMBL627410,,1088.0,Urine,,1,1
13913,50588,,BAO_0000218,,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,,,N,Intermediate,A,9615.0,CHEMBL627411,,1088.0,Urine,,1,1
13914,50588,,BAO_0000218,,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,,,N,Intermediate,A,9615.0,CHEMBL627412,,1088.0,Urine,,1,1
13915,50588,,BAO_0000218,,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,,,N,Intermediate,A,9615.0,CHEMBL627413,,1088.0,Urine,,1,1
13916,50588,,BAO_0000218,,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,,,N,Intermediate,A,9615.0,CHEMBL627414,,1088.0,Urine,,1,1
13917,50588,,BAO_0000218,,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 10.1 uM/Kg of drug,,,N,Intermediate,A,9615.0,CHEMBL627415,,1088.0,Urine,,1,1
13918,50588,,BAO_0000218,,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 102 uM/Kg of drug,,,N,Intermediate,A,9615.0,CHEMBL627416,,1088.0,Urine,,1,1
13919,50588,,BAO_0000218,,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 3.40 uM/Kg of drug,,,N,Intermediate,A,9615.0,CHEMBL627417,,1088.0,Urine,,1,1
13920,50588,,BAO_0000218,,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 3.76 uM/Kg of drug,,,N,Intermediate,A,9615.0,CHEMBL627418,,1088.0,Urine,,1,1
13921,50588,,BAO_0000218,,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 34.1 uM/Kg of drug,,,N,Intermediate,A,9615.0,CHEMBL627419,,1088.0,Urine,,1,1
13922,50588,,BAO_0000218,,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 50.8 uM/Kg of drug,,,N,Intermediate,A,9615.0,CHEMBL627320,,1088.0,Urine,,1,1
13923,50588,,BAO_0000218,,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 68.1 uM/Kg of drug,,,N,Intermediate,A,9615.0,CHEMBL627321,,1088.0,Urine,,1,1
13924,50597,In vivo,BAO_0000218,,,Biodistribution in kidney of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL627322,,2113.0,Kidney,,1,1
13925,50597,In vivo,BAO_0000218,,,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL627323,,2113.0,Kidney,,1,1
13926,50597,In vivo,BAO_0000218,,,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,,N,Intermediate,A,10116.0,CHEMBL627491,,2113.0,Kidney,,1,1
13927,50597,In vivo,BAO_0000218,,,Biodistribution in kidney of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL627492,,2113.0,Kidney,,1,1
13928,50597,In vivo,BAO_0000218,,,Biodistribution in kidney of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL627493,,2113.0,Kidney,,1,1
13929,50597,In vivo,BAO_0000218,,,Biodistribution in liver of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL627494,,2107.0,Liver,,1,1
13930,50597,In vivo,BAO_0000218,,,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL627495,,2107.0,Liver,,1,1
13931,50597,In vivo,BAO_0000218,,,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,,N,Intermediate,A,10116.0,CHEMBL627496,,2107.0,Liver,,1,1
13932,50597,In vivo,BAO_0000218,,,Biodistribution in liver of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL627497,,2107.0,Liver,,1,1
13933,50597,In vivo,BAO_0000218,,,Biodistribution in liver of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL627498,,2107.0,Liver,,1,1
13934,50597,In vivo,BAO_0000218,,,Biodistribution in lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL627499,,2048.0,Lung,,1,1
13935,50597,In vivo,BAO_0000218,,,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL627500,,2048.0,Lung,,1,1
13936,50597,In vivo,BAO_0000218,,,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,,N,Intermediate,A,10116.0,CHEMBL627501,,2048.0,Lung,,1,1
13937,50597,In vivo,BAO_0000218,,,Biodistribution in lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL625616,,2048.0,Lung,,1,1
13938,50597,In vivo,BAO_0000218,,,Biodistribution in lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL625617,,2048.0,Lung,,1,1
13939,50597,In vivo,BAO_0000218,,,Biodistribution in muscle of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL625618,,2385.0,Muscle tissue,,1,1
13940,50597,In vivo,BAO_0000218,,,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL625619,,2385.0,Muscle tissue,,1,1
13941,50597,In vivo,BAO_0000218,,,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,,N,Intermediate,A,10116.0,CHEMBL625620,,2385.0,Muscle tissue,,1,1
13942,50597,In vivo,BAO_0000218,,,Biodistribution in muscle of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL625621,,2385.0,Muscle tissue,,1,1
13943,50597,In vivo,BAO_0000218,,,Biodistribution in muscle of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL625622,,2385.0,Muscle tissue,,1,1
13944,50597,In vivo,BAO_0000218,,,Biodistribution in spleen of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL625788,,2106.0,Spleen,,1,1
13945,50597,In vivo,BAO_0000218,,,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL625789,,2106.0,Spleen,,1,1
13946,50597,In vivo,BAO_0000218,,,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,,N,Intermediate,A,10116.0,CHEMBL625790,,2106.0,Spleen,,1,1
13947,50597,In vivo,BAO_0000218,,,Biodistribution in spleen of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL625791,,2106.0,Spleen,,1,1
13948,50597,In vivo,BAO_0000218,,,Biodistribution in spleen of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL622334,,2106.0,Spleen,,1,1
13949,50597,In vivo,BAO_0000218,,,Biodistribution in thyroid of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL622335,,2046.0,Thyroid gland,,1,1
13950,50597,In vivo,BAO_0000218,,,Biodistribution in thyroid of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL622336,,2046.0,Thyroid gland,,1,1
13951,50597,In vivo,BAO_0000218,,,Biodistribution in thyroid of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,,N,Intermediate,A,10116.0,CHEMBL622337,,2046.0,Thyroid gland,,1,1
13952,50597,In vivo,BAO_0000218,,,Biodistribution in thyroid of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL622338,,2046.0,Thyroid gland,,1,1
13953,50597,In vivo,BAO_0000218,,,Biodistribution in thyroid of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL622339,,2046.0,Thyroid gland,,1,1
13954,50597,In vivo,BAO_0000218,,,Biodistribution in uterus / blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL624153,,,,,1,1
13955,50597,In vivo,BAO_0000218,,,Biodistribution in uterus / blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL628430,,,,,1,1
13956,50597,In vivo,BAO_0000218,,,Biodistribution in uterus / blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,,N,Intermediate,A,10116.0,CHEMBL628431,,,,,1,1
13957,50597,In vivo,BAO_0000218,,,Biodistribution in uterus / blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL628432,,,,,1,1
13958,50597,In vivo,BAO_0000218,,,Biodistribution in uterus / blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL628433,,,,,1,1
13959,50597,In vivo,BAO_0000218,,,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",,,N,Intermediate,A,10116.0,CHEMBL628434,,2106.0,Spleen,,1,1
13960,50597,In vivo,BAO_0000218,,,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",,,N,Intermediate,A,10116.0,CHEMBL626789,,2106.0,Spleen,,1,1
13961,50597,In vivo,BAO_0000218,,,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2)",,,N,Intermediate,A,10116.0,CHEMBL626790,,2106.0,Spleen,,1,1
13962,50597,In vivo,BAO_0000218,,,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",,,N,Intermediate,A,10116.0,CHEMBL626791,,2106.0,Spleen,,1,1
13963,50597,In vivo,BAO_0000218,,,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",,,N,Intermediate,A,10116.0,CHEMBL626792,,2106.0,Spleen,,1,1
13964,50597,In vivo,BAO_0000218,,,"Biodistribution in uterus / spleen, muscle, lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",,,N,Intermediate,A,10116.0,CHEMBL626793,,2106.0,Spleen,,1,1
13965,50597,,BAO_0000218,,,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL627436,,,,,1,1
13966,50597,,BAO_0000218,,,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL627437,,,,,1,1
13967,50597,,BAO_0000218,,,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL627438,,,,,1,1
13968,50597,,BAO_0000218,,,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL627439,,,,,1,1
13969,50597,,BAO_0000218,,,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL627440,,,,,1,1
13970,50597,,BAO_0000218,,,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL627602,,,,,1,1
13971,50597,,BAO_0000218,,,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL627603,,,,,1,1
13972,50597,,BAO_0000218,,,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL627604,,,,,1,1
13973,50597,,BAO_0000218,,,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL627605,,,,,1,1
13974,50597,,BAO_0000218,,,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL627606,,,,,1,1
13975,50597,,BAO_0000218,,,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL627607,,,,,1,1
13976,50597,,BAO_0000218,,,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL627608,,,,,1,1
13977,50597,,BAO_0000218,,,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL627609,,,,,1,1
13978,50597,,BAO_0000218,,,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL627610,,,,,1,1
13979,50597,,BAO_0000218,,,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL627611,,,,,1,1
13980,50597,,BAO_0000218,,,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL627612,,,,,1,1
13981,22229,,BAO_0000100,,,Octanol:water partition coefficient is evaluated,,,U,Autocuration,P,,CHEMBL627613,,,,,0,1
13982,22224,,BAO_0000100,,,Partition coefficient in 1-octanol/water system,,,U,Autocuration,P,,CHEMBL627614,,,,,0,1
13983,22224,,BAO_0000100,,,Partition coefficient in 1-octanol/water system measured using radio active compounds,,,U,Autocuration,P,,CHEMBL627615,,,,,0,1
13984,22224,,BAO_0000100,,,Partition coefficient in octanol/water system was determined,,,U,Autocuration,P,,CHEMBL627616,,,,,0,1
13985,22224,,BAO_0000100,,,Partition coefficient in octanol/water system was determined using [14C]-labeled compounds.,,,U,Autocuration,P,,CHEMBL627617,,,,,0,1
13986,22224,,BAO_0000019,,,Pseudo-first-order rate constant at pH 10 and 35 degrees Centigrade,,,U,Autocuration,A,,CHEMBL627618,,,,,0,1
13987,22224,,BAO_0000019,,,"Pseudo-first-order rate constant at pH 10, micro=0.5, 35 degrees Centigrade",,,U,Autocuration,A,,CHEMBL627619,,,,,0,1
13988,22224,,BAO_0000019,,,Pseudo-first-order rate constant of the compound,,,U,Autocuration,A,,CHEMBL627620,,,,,0,1
13989,22224,,BAO_0000019,,,Pseudo-first-order rate constant with 1-min time point,,,U,Autocuration,A,,CHEMBL627621,,,,,0,1
13990,22224,,BAO_0000019,,,Pseudo-first-order rate constant without 1-min time point,,,U,Autocuration,A,,CHEMBL627622,,,,,0,1
13991,22224,,BAO_0000019,,,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 0.5 mM EDTA,,,U,Autocuration,A,,CHEMBL627623,,,,,0,1
13992,22224,,BAO_0000019,,,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 50 mM EDTA,,,U,Autocuration,A,,CHEMBL627624,,,,,0,1
13993,22224,,BAO_0000019,,,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 70 mM EDTA,,,U,Autocuration,A,,CHEMBL627625,,,,,0,1
13994,22224,,BAO_0000019,,,Rate constants determined using 31P NMR Kinetics experiments at 37 degrees Centigrade,,,U,Autocuration,A,,CHEMBL628523,,,,,0,1
13995,22224,,BAO_0000019,,,The alkaline hydrolysis second order rate constant(K OH) of the compound,,,U,Autocuration,A,,CHEMBL628524,,,,,0,1
13996,22224,,BAO_0000019,,,The efflux rate constant of the compound,,,U,Autocuration,A,,CHEMBL628525,,,,,0,1
13997,22224,,BAO_0000019,,,The reaction rate constant (K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,,,U,Autocuration,A,,CHEMBL625732,,,,,0,1
13998,22224,,BAO_0000019,,,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,,,U,Autocuration,A,,CHEMBL625733,,,,,0,1
13999,22224,,BAO_0000019,,,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,,,U,Autocuration,F,,CHEMBL625734,,,,,0,1
14000,22224,,BAO_0000019,,,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine; ND= not determined,,,U,Autocuration,A,,CHEMBL625913,,,,,0,1
14001,22224,,BAO_0000019,,,Association constant was evaluated towards synthetic peptidoglycan analogue Ac2-Lys-D-Ala-D-Ala,,,U,Autocuration,A,,CHEMBL625914,,,,,0,1
14002,22224,,BAO_0000019,,,Equilibrium association (binding) constant interacting with Unilamellar Vesicles of electroneutral DMPC in PBSbuffer at pH 7.4 and 37 C,,,U,Autocuration,A,,CHEMBL625915,,,,,0,1
14003,22224,,BAO_0000019,,,Equilibrium association (binding) constant interacting with Unilamellar Vesicles of negatively charged DMPG in PBS buffer at pH 7.4 and 37 C,,,U,Autocuration,A,,CHEMBL625916,,,,,0,1
14004,22224,,BAO_0000019,,,Evaluated for the mustard reactivity by determining rate constant for hydrolysis of mustard in aqueous acetone (K H),,,U,Autocuration,A,,CHEMBL625917,,,,,0,1
14005,22224,,BAO_0000019,,,"Effective biomolecular rate constant at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,U,Autocuration,A,,CHEMBL625918,,,,,0,1
14006,22224,,BAO_0000019,,,"Effective biomolecular rate constant at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,U,Autocuration,A,,CHEMBL625919,,,,,0,1
14007,22224,,BAO_0000019,,,"Effective biomolecular rate constant at the concentration 0.790 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,U,Autocuration,A,,CHEMBL625920,,,,,0,1
14008,22224,,BAO_0000019,,,"Effective biomolecular rate constant at the concentration 1.00 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,U,Autocuration,A,,CHEMBL874453,,,,,0,1
14009,22224,,BAO_0000019,,,"Effective biomolecular rate constant in the conditions of 25degreeC,pH 7.6",,,U,Autocuration,A,,CHEMBL625921,,,,,0,1
14010,22224,,BAO_0000019,,,Evaluated for the mustard reactivity by determining rate constant for alkylation of 4-(4-nitrobenzyl)pyridine using NBP alkylation assay,,,U,Autocuration,A,,CHEMBL625922,,,,,0,1
14011,22224,,BAO_0000019,,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,U,Autocuration,A,,CHEMBL625923,,,,,0,1
14012,22224,,BAO_0000019,,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,U,Autocuration,A,,CHEMBL625924,,,,,0,1
14013,22224,,BAO_0000019,,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.790 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,U,Autocuration,A,,CHEMBL625925,,,,,0,1
14014,22224,,BAO_0000019,,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 1.00 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,U,Autocuration,A,,CHEMBL625926,,,,,0,1
14015,50597,In vivo,BAO_0000218,,,Biodistribution in rat lung at 60 minutes after dose administration.,,,N,Intermediate,A,10116.0,CHEMBL627704,,2048.0,Lung,,1,1
14016,50597,In vivo,BAO_0000218,,,Biodistribution in rat pons/medulla at 120 minutes after dose administration.,,,N,Intermediate,A,10116.0,CHEMBL627705,,,,,1,1
14017,50597,In vivo,BAO_0000218,,,Biodistribution in rat pons/medulla at 15 minutes after dose administration.,,,N,Intermediate,A,10116.0,CHEMBL627706,,,,,1,1
14018,50597,In vivo,BAO_0000218,,,Biodistribution in rat pons/medulla at 240 minutes after dose administration.,,,N,Intermediate,A,10116.0,CHEMBL627707,,,,,1,1
14019,50597,In vivo,BAO_0000218,,,Biodistribution in rat pons/medulla at 30 minutes after dose administration.,,,N,Intermediate,A,10116.0,CHEMBL627708,,,,,1,1
14020,50597,In vivo,BAO_0000218,,,Biodistribution in rat pons/medulla at 360 minutes after dose administration.,,,N,Intermediate,A,10116.0,CHEMBL628361,,,,,1,1
14021,50597,In vivo,BAO_0000218,,,Biodistribution in rat pons/medulla at 60 minutes after dose administration.,,,N,Intermediate,A,10116.0,CHEMBL628362,,,,,1,1
14022,50597,In vivo,BAO_0000218,,,Biodistribution in rat striatum at 120 minutes after dose administration.,,,N,Intermediate,A,10116.0,CHEMBL628363,,2435.0,Striatum,,1,1
14023,50597,In vivo,BAO_0000218,,,Biodistribution in rat striatum at 1440 minutes after dose administration.,,,N,Intermediate,A,10116.0,CHEMBL628364,,2435.0,Striatum,,1,1
14024,50597,In vivo,BAO_0000218,,,Biodistribution in rat striatum at 15 minutes after dose administration.,,,N,Intermediate,A,10116.0,CHEMBL628365,,2435.0,Striatum,,1,1
14025,50597,In vivo,BAO_0000218,,,Biodistribution in rat striatum at 240 minutes after dose administration.,,,N,Intermediate,A,10116.0,CHEMBL874454,,2435.0,Striatum,,1,1
14026,50597,In vivo,BAO_0000218,,,Biodistribution in rat striatum at 30 minutes after dose administration.,,,N,Intermediate,A,10116.0,CHEMBL628531,,2435.0,Striatum,,1,1
14027,50597,In vivo,BAO_0000218,,,Biodistribution in rat striatum at 360 minutes after dose administration.,,,N,Intermediate,A,10116.0,CHEMBL628532,,2435.0,Striatum,,1,1
14028,50597,In vivo,BAO_0000218,,,Biodistribution in rat striatum at 3 hr after dose administration.,,,N,Intermediate,A,10116.0,CHEMBL628533,,2435.0,Striatum,,1,1
14029,50597,In vivo,BAO_0000218,,,Biodistribution in rat striatum at 60 minutes after dose administration.,,,N,Intermediate,A,10116.0,CHEMBL628534,,2435.0,Striatum,,1,1
14030,50597,In vivo,BAO_0000218,,,Biodistribution in rat thyroid at 120 minutes after dose administration.,,,N,Intermediate,A,10116.0,CHEMBL628535,,2046.0,Thyroid gland,,1,1
14031,50597,In vivo,BAO_0000218,,,Biodistribution in rat thyroid at 1440 minutes after dose administration.,,,N,Intermediate,A,10116.0,CHEMBL628536,,2046.0,Thyroid gland,,1,1
14032,50597,In vivo,BAO_0000218,,,Biodistribution in rat thyroid at 15 minutes after dose administration.,,,N,Intermediate,A,10116.0,CHEMBL628537,,2046.0,Thyroid gland,,1,1
14033,50597,In vivo,BAO_0000218,,,Biodistribution in rat thyroid at 240 minutes after dose administration.,,,N,Intermediate,A,10116.0,CHEMBL628538,,2046.0,Thyroid gland,,1,1
14034,50597,In vivo,BAO_0000218,,,Biodistribution in rat thyroid at 30 minutes after dose administration.,,,N,Intermediate,A,10116.0,CHEMBL628539,,2046.0,Thyroid gland,,1,1
14035,50597,In vivo,BAO_0000218,,,Biodistribution in rat thyroid at 360 minutes after dose administration.,,,N,Intermediate,A,10116.0,CHEMBL630297,,2046.0,Thyroid gland,,1,1
14036,50597,In vivo,BAO_0000218,,,Biodistribution in rat thyroid at 60 minutes after dose administration.,,,N,Intermediate,A,10116.0,CHEMBL630298,,2046.0,Thyroid gland,,1,1
14037,50597,In vivo,BAO_0000218,,,Biodistribution in rest of brain of rat 120 minutes after dose administration.,,,N,Intermediate,A,10116.0,CHEMBL630299,,955.0,Brain,,1,1
14038,50597,In vivo,BAO_0000218,,,Biodistribution in rest of brain of rat at 1440 minutes after dose administration.,,,N,Intermediate,A,10116.0,CHEMBL628094,,955.0,Brain,,1,1
14039,50597,In vivo,BAO_0000218,,,Biodistribution in rest of brain of rat at 15 minutes after dose administration.,,,N,Intermediate,A,10116.0,CHEMBL628095,,955.0,Brain,,1,1
14040,50597,In vivo,BAO_0000218,,,Biodistribution in rest of brain of rat at 240 minutes after dose administration.,,,N,Intermediate,A,10116.0,CHEMBL874648,,955.0,Brain,,1,1
14041,50597,In vivo,BAO_0000218,,,Biodistribution in rest of brain of rat at 30 minutes after dose administration.,,,N,Intermediate,A,10116.0,CHEMBL628096,,955.0,Brain,,1,1
14042,50597,In vivo,BAO_0000218,,,Biodistribution in rest of brain of rat at 360 minutes after dose administration.,,,N,Intermediate,A,10116.0,CHEMBL628097,,955.0,Brain,,1,1
14043,50597,In vivo,BAO_0000218,,,Biodistribution in rest of brain of rat at 60 minutes after dose administration.,,,N,Intermediate,A,10116.0,CHEMBL628098,,955.0,Brain,,1,1
14044,22224,,BAO_0000019,,,"Mean rate constant for the hydrolysis of compound in buffers at pH 6.5, at 37 degrees Celsius in incubation mixture - d(A)-d(T) (10:1)",,,U,Autocuration,A,,CHEMBL628099,,,,,0,1
14045,22224,,BAO_0000019,,,"Mean rate constant for the hydrolysis of compound in buffers at pH 6.5, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (10:1)",,,U,Autocuration,A,,CHEMBL628100,,,,,0,1
14046,22224,,BAO_0000019,,,Mean rate constant for the hydrolysis of compound in buffers at pH 7.4 at 37 degrees Centigrade in incubation mixture - d(A)-d(T) (10:!),,,U,Autocuration,A,,CHEMBL628101,,,,,0,1
14047,22224,,BAO_0000019,,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - 5'-GMP/5'-CMP (1:1)",,,U,Autocuration,A,,CHEMBL628102,,,,,0,1
14048,22224,,BAO_0000019,,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(A)-d(T) (1:1)",,,U,Autocuration,A,,CHEMBL628103,,,,,0,1
14049,22224,,BAO_0000019,,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (10:1)",,,U,Autocuration,A,,CHEMBL628104,,,,,0,1
14050,22224,,BAO_0000019,,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (1:1)",,,U,Autocuration,A,,CHEMBL628105,,,,,0,1
14051,22224,,BAO_0000019,,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(T) (10:1)",,,U,Autocuration,A,,CHEMBL628106,,,,,0,1
14052,50597,,BAO_0000218,,,Mean urine volume excretion in conscious rats at a dose of 0.3 mg/kg given orally,,,N,Intermediate,A,10116.0,CHEMBL628107,,1088.0,Urine,,1,1
14053,22224,,BAO_0000218,,,Mean urine volume excretion in conscious rats at a dose of 0.3 mg/kg given orally,,,U,Autocuration,F,,CHEMBL628108,,1088.0,Urine,,0,1
14054,50597,,BAO_0000218,,,Mean urine volume excretion in conscious rats at a dose of 1.0 mg/kg given orally,,,N,Intermediate,A,10116.0,CHEMBL628109,,1088.0,Urine,,1,1
14055,22224,,BAO_0000218,,,Mean urine volume excretion in conscious rats at a dose of 1.0 mg/kg given orally,,,U,Autocuration,F,,CHEMBL625299,,1088.0,Urine,,0,1
14056,50597,,BAO_0000218,,,Mean urine volume excretion in conscious rats at a dose of 10 mg/kg given orally,,,N,Intermediate,A,10116.0,CHEMBL625300,,1088.0,Urine,,1,1
14057,50597,,BAO_0000218,,,Mean urine volume excretion in conscious rats at a dose of 100 mg/kg given orally,,,N,Intermediate,A,10116.0,CHEMBL625301,,1088.0,Urine,,1,1
14058,50597,,BAO_0000218,,,Mean urine volume excretion in conscious rats at a dose of 3.0 mg/kg given orally,,,N,Intermediate,A,10116.0,CHEMBL625302,,1088.0,Urine,,1,1
14059,50597,,BAO_0000218,,,Mean urine volume excretion in conscious rats at a dose of 30 mg/kg given orally,,,N,Intermediate,A,10116.0,CHEMBL874649,,1088.0,Urine,,1,1
14060,50597,,BAO_0000218,,,In vitro metabolic stability of the test compound was evaluated after incubation in the presence of freshly isolated rat hepatocytes,,,N,Intermediate,A,10116.0,CHEMBL625303,,,,,1,1
14061,50597,,BAO_0000218,,,In vitro metabolic stability of the test compound was evaluated after incubation in the presence of freshly isolated rat hepatocytes; NA= Not tested,,,N,Intermediate,A,10116.0,CHEMBL625463,,,,,1,1
14062,50587,,BAO_0000218,,,In vitro metabolism in human liver microsomes,,,N,Intermediate,A,9606.0,CHEMBL625464,,2107.0,Liver,,1,1
14063,50587,,BAO_0000218,,,Metabolism (NADH oxidation) by recombinant human NAD(P)H: quinone oxidoreductase (NQO1) is evaluated.,,,N,Intermediate,A,9606.0,CHEMBL625465,,,,,1,1
14064,50588,,BAO_0000218,,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 9.06 uM/Kg of drug,,,N,Intermediate,A,9615.0,CHEMBL625466,,1088.0,Urine,,1,1
14065,50588,,BAO_0000218,,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 9.6 uM/Kg of drug,,,N,Intermediate,A,9615.0,CHEMBL625467,,1088.0,Urine,,1,1
14066,50597,,BAO_0000218,,,Total electrolytic excretion of chlorine in urine of rats after intravenous administration of 7.94 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL625468,,1088.0,Urine,,1,1
14067,50597,,BAO_0000218,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 0 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL625469,,1088.0,Urine,,1,1
14068,50597,,BAO_0000218,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 1.01 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL625470,,1088.0,Urine,,1,1
14069,50597,,BAO_0000218,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 1.13 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL632418,,1088.0,Urine,,1,1
14070,50597,,BAO_0000218,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 10.1 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL627250,,1088.0,Urine,,1,1
14071,50597,,BAO_0000218,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 102 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL627251,,1088.0,Urine,,1,1
14072,50597,,BAO_0000218,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 105 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL627252,,1088.0,Urine,,1,1
14073,50597,,BAO_0000218,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 11.3 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL627253,,1088.0,Urine,,1,1
14074,50597,,BAO_0000218,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 113 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL627254,,1088.0,Urine,,1,1
14075,50597,,BAO_0000218,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 19.5 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL875471,,1088.0,Urine,,1,1
14076,50597,,BAO_0000218,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 195 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL627255,,1088.0,Urine,,1,1
14077,50597,,BAO_0000218,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 21.7 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL627256,,1088.0,Urine,,1,1
14078,50597,,BAO_0000218,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 217 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL627257,,1088.0,Urine,,1,1
14079,50597,,BAO_0000218,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 23.9 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL627258,,1088.0,Urine,,1,1
14080,50597,,BAO_0000218,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 239 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL627259,,1088.0,Urine,,1,1
14081,50597,,BAO_0000218,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 24.9 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL627260,,1088.0,Urine,,1,1
14082,50597,,BAO_0000218,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 249 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL623256,,1088.0,Urine,,1,1
14083,50597,,BAO_0000218,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 25.9 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL874413,,1088.0,Urine,,1,1
14084,50597,,BAO_0000218,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 259 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL623257,,1088.0,Urine,,1,1
14085,50597,,BAO_0000218,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 26.5 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL623258,,1088.0,Urine,,1,1
14086,50597,,BAO_0000218,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 265 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL623259,,1088.0,Urine,,1,1
14087,50597,,BAO_0000218,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 27 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL623260,,1088.0,Urine,,1,1
14088,50597,,BAO_0000218,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 27.9 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL623261,,1088.0,Urine,,1,1
14089,50597,,BAO_0000218,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 270 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL623262,,1088.0,Urine,,1,1
14090,50597,,BAO_0000218,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 279 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL623263,,1088.0,Urine,,1,1
14091,50597,,BAO_0000218,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.2 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL623264,,1088.0,Urine,,1,1
14092,50597,,BAO_0000218,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.22 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL623265,,1088.0,Urine,,1,1
14093,50597,,BAO_0000218,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.9 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL623266,,1088.0,Urine,,1,1
14094,50597,,BAO_0000218,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 282 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL623267,,1088.0,Urine,,1,1
14095,50597,,BAO_0000218,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 289 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL623268,,1088.0,Urine,,1,1
14096,50597,,BAO_0000218,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 3.40 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL623269,,1088.0,Urine,,1,1
14097,50597,,BAO_0000218,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 3.76 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL623270,,1088.0,Urine,,1,1
14098,50597,,BAO_0000218,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 30.2 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL623271,,1088.0,Urine,,1,1
14099,50597,,BAO_0000218,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 302 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL623272,,1088.0,Urine,,1,1
14100,50597,,BAO_0000218,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 31.6 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL623273,,1088.0,Urine,,1,1
14101,50597,,BAO_0000218,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 316 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL623274,,1088.0,Urine,,1,1
14102,50597,,BAO_0000218,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 32.4 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL874414,,1088.0,Urine,,1,1
14103,50597,,BAO_0000218,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 324 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL623275,,1088.0,Urine,,1,1
14104,50597,,BAO_0000218,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.0 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL629150,,1088.0,Urine,,1,1
14105,50597,,BAO_0000218,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.1 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL623276,,1088.0,Urine,,1,1
14106,50597,,BAO_0000218,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.8 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL623277,,1088.0,Urine,,1,1
14107,50597,,BAO_0000218,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 341 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL623112,,1088.0,Urine,,1,1
14108,50597,,BAO_0000218,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 348 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL623113,,1088.0,Urine,,1,1
14109,50597,,BAO_0000218,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 37.6 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL623800,,1088.0,Urine,,1,1
14110,50597,,BAO_0000218,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 58.4 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL623801,,1088.0,Urine,,1,1
14111,50597,In vivo,BAO_0000218,,,"Biodistribution in uterus / spleen, muscle, lungs of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",,,N,Intermediate,A,10116.0,CHEMBL623802,,2106.0,Spleen,,1,1
14112,50597,In vivo,BAO_0000218,,,Biodistribution in uterus of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL623803,,995.0,Uterus,,1,1
14113,50597,In vivo,BAO_0000218,,,Biodistribution in uterus of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL623970,,995.0,Uterus,,1,1
14114,50597,In vivo,BAO_0000218,,,Biodistribution in uterus of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL623971,,995.0,Uterus,,1,1
14115,50597,In vivo,BAO_0000218,,,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 10 min post injection (Average of three to five animals),,,N,Intermediate,A,10116.0,CHEMBL623972,,178.0,Blood,,1,1
14116,50597,In vivo,BAO_0000218,,,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 30 min post injection (Average of three to five animals),,,N,Intermediate,A,10116.0,CHEMBL623973,,178.0,Blood,,1,1
14117,50597,In vivo,BAO_0000218,,,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 5 min post injection (Average of three to five animals),,,N,Intermediate,A,10116.0,CHEMBL623974,,178.0,Blood,,1,1
14118,50597,In vivo,BAO_0000218,,,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 60 min post injection (Average of three to five animals),,,N,Intermediate,A,10116.0,CHEMBL623975,,178.0,Blood,,1,1
14119,50597,In vivo,BAO_0000218,,,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 10 min post injection (Average of three to five animals),,,N,Intermediate,A,10116.0,CHEMBL623976,,955.0,Brain,,1,1
14120,50597,In vivo,BAO_0000218,,,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 30 min post injection (Average of three to five animals),,,N,Intermediate,A,10116.0,CHEMBL623977,,955.0,Brain,,1,1
14121,50597,In vivo,BAO_0000218,,,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 5 min post injection (Average of three to five animals),,,N,Intermediate,A,10116.0,CHEMBL623978,,955.0,Brain,,1,1
14122,50597,In vivo,BAO_0000218,,,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 60 min post injection (Average of three to five animals),,,N,Intermediate,A,10116.0,CHEMBL623979,,955.0,Brain,,1,1
14123,50597,In vivo,BAO_0000218,,,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 10 min post injection (Average of three to five animals),,,N,Intermediate,A,10116.0,CHEMBL623980,,,,,1,1
14124,50597,In vivo,BAO_0000218,,,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 30 min post injection (Average of three to five animals),,,N,Intermediate,A,10116.0,CHEMBL623981,,,,,1,1
14125,50597,In vivo,BAO_0000218,,,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 5 min post injection (Average of three to five animals),,,N,Intermediate,A,10116.0,CHEMBL626278,,,,,1,1
14126,50597,In vivo,BAO_0000218,,,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 60 min post injection (Average of three to five animals),,,N,Intermediate,A,10116.0,CHEMBL626279,,,,,1,1
14127,50594,In vivo,BAO_0000218,,,Biodistribution in mice bladder plus excreted urine was determined,,,N,Intermediate,A,10090.0,CHEMBL626280,,,,,1,1
14128,50594,,BAO_0000218,,,"Percentage biodistribution in mouse blood, 10 minutes post injection",,,N,Intermediate,A,10090.0,CHEMBL626281,,,,,1,1
14129,50594,,BAO_0000218,,,"Percentage biodistribution in mouse blood, 30 minutes post injection",,,N,Intermediate,A,10090.0,CHEMBL626282,,,,,1,1
14130,50594,,BAO_0000218,,,"Percentage biodistribution in mouse blood, 5 minutes post injection",,,N,Intermediate,A,10090.0,CHEMBL626283,,,,,1,1
14131,50594,,BAO_0000218,,,"Percentage biodistribution in mouse blood, 60 minutes post injection",,,N,Intermediate,A,10090.0,CHEMBL626284,,,,,1,1
14132,50594,,BAO_0000218,,,"Percentage biodistribution in mouse brain, 10 minutes post injection",,,N,Intermediate,A,10090.0,CHEMBL626285,,955.0,Brain,,1,1
14133,50594,,BAO_0000218,,,"Percentage biodistribution in mouse brain, 30 minutes post injection",,,N,Intermediate,A,10090.0,CHEMBL626286,,955.0,Brain,,1,1
14134,50594,,BAO_0000218,,,"Percentage biodistribution in mouse brain, 5 minutes post injection",,,N,Intermediate,A,10090.0,CHEMBL626287,,955.0,Brain,,1,1
14135,50594,,BAO_0000218,,,"Percentage biodistribution in mouse brain, 60 minutes post injection",,,N,Intermediate,A,10090.0,CHEMBL626288,,955.0,Brain,,1,1
14136,50594,,BAO_0000218,,,"Percentage biodistribution in mouse heart, 10 minutes post injection",,,N,Intermediate,A,10090.0,CHEMBL626289,,,,,1,1
14137,50594,,BAO_0000218,,,"Percentage biodistribution in mouse heart, 30 minutes post injection",,,N,Intermediate,A,10090.0,CHEMBL626290,,,,,1,1
14138,50594,,BAO_0000218,,,"Percentage biodistribution in mouse heart, 5 minutes post injection",,,N,Intermediate,A,10090.0,CHEMBL626291,,,,,1,1
14139,50594,,BAO_0000218,,,"Percentage biodistribution in mouse heart, 60 minutes post injection",,,N,Intermediate,A,10090.0,CHEMBL839888,,,,,1,1
14140,50594,,BAO_0000218,,,"Percentage biodistribution in mouse intestine, 10 minutes post injection",,,N,Intermediate,A,10090.0,CHEMBL626292,,160.0,Intestine,,1,1
14141,50594,,BAO_0000218,,,"Percentage biodistribution in mouse intestine, 30 minutes post injection",,,N,Intermediate,A,10090.0,CHEMBL626293,,160.0,Intestine,,1,1
14142,50594,,BAO_0000218,,,"Percentage biodistribution in mouse intestine, 5 minutes post injection",,,N,Intermediate,A,10090.0,CHEMBL626294,,160.0,Intestine,,1,1
14143,50594,,BAO_0000218,,,"Percentage biodistribution in mouse intestine, 60 minutes post injection",,,N,Intermediate,A,10090.0,CHEMBL626295,,160.0,Intestine,,1,1
14144,50594,,BAO_0000218,,,"Percentage biodistribution in mouse liver, 10 minutes post injection",,,N,Intermediate,A,10090.0,CHEMBL627659,,2107.0,Liver,,1,1
14145,50594,,BAO_0000218,,,"Percentage biodistribution in mouse liver, 30 minutes of post injection",,,N,Intermediate,A,10090.0,CHEMBL627660,,2107.0,Liver,,1,1
14146,50594,,BAO_0000218,,,"Percentage biodistribution in mouse liver, 5 minutes post injection",,,N,Intermediate,A,10090.0,CHEMBL627661,,2107.0,Liver,,1,1
14147,50594,In vivo,BAO_0000218,,,Biodistribution in mice liver at 60 minutes of post injection,,,N,Intermediate,A,10090.0,CHEMBL627662,,2107.0,Liver,,1,1
14148,50594,In vivo,BAO_0000218,,,Biodistribution in mice lungs at 10 min of post injection,,,N,Intermediate,A,10090.0,CHEMBL627663,,2048.0,Lung,,1,1
14149,50594,,BAO_0000218,,,"Percentage biodistribution in mouse lung, 30 minutes post injection",,,N,Intermediate,A,10090.0,CHEMBL627664,,,,,1,1
14150,50594,,BAO_0000218,,,"Percentage biodistribution in mousee lung, 5 minutes post injection",,,N,Intermediate,A,10090.0,CHEMBL627665,,,,,1,1
14151,50594,In vivo,BAO_0000218,,,Biodistribution in mice lungs at 60 min of post injection,,,N,Intermediate,A,10090.0,CHEMBL627666,,2048.0,Lung,,1,1
14152,50594,,BAO_0000218,,,Percentage biodistribution in mouse spleen,,,N,Intermediate,A,10090.0,CHEMBL627667,,2106.0,Spleen,,1,1
14153,50594,,BAO_0000218,,,Percentage biodistribution in mouse stomach,,,N,Intermediate,A,10090.0,CHEMBL627668,,945.0,Stomach,,1,1
14154,50594,,BAO_0000218,,,Mean biodistribution and elimination data in urine was reported 24 h after administering compound intravenously in tumor-bearing female BALB-C mice.,,,N,Intermediate,A,10090.0,CHEMBL627669,,1088.0,Urine,,1,1
14155,22224,In vivo,BAO_0000218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in bladder,,,U,Autocuration,A,,CHEMBL627670,,1255.0,Urinary bladder,,0,1
14156,22224,In vivo,BAO_0000218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in blood,,,U,Autocuration,A,,CHEMBL627671,,178.0,Blood,,0,1
14157,22224,In vivo,BAO_0000218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in bone,,,U,Autocuration,A,,CHEMBL627672,,1474.0,Bone element,,0,1
14158,22224,In vivo,BAO_0000218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in fat,,,U,Autocuration,A,,CHEMBL627673,,,,,0,1
14159,22224,In vivo,BAO_0000218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in kidney,,,U,Autocuration,A,,CHEMBL627674,,2113.0,Kidney,,0,1
14160,22224,In vivo,BAO_0000218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in liver,,,U,Autocuration,A,,CHEMBL627675,,2107.0,Liver,,0,1
14161,22224,In vivo,BAO_0000218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in lung,,,U,Autocuration,A,,CHEMBL627676,,2048.0,Lung,,0,1
14162,22224,In vivo,BAO_0000218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in muscle,,,U,Autocuration,A,,CHEMBL627677,,2385.0,Muscle tissue,,0,1
14163,22224,,BAO_0000019,,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator in the conditions of 25degreeC,pH 7.6",,,U,Autocuration,A,,CHEMBL627678,,,,,0,1
14164,50597,,BAO_0000218,,,Affinity for protein binding expressed as association constant in fresh rat serum,,,N,Intermediate,A,10116.0,CHEMBL627679,,1977.0,Serum,,1,1
14165,22224,,BAO_0000019,,,Kinetic constant (Kcat) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation,,,U,Autocuration,A,,CHEMBL627680,,,,,0,1
14166,22224,,BAO_0000019,,,Kinetic constant (Kcat) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation; Inactive,,,U,Autocuration,A,,CHEMBL627681,,,,,0,1
14167,22224,,BAO_0000019,,,Inactivation constant (Kinact) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation,,,U,Autocuration,A,,CHEMBL627682,,,,,0,1
14168,22224,,BAO_0000019,,,Inactivation constant (Kinact) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation; Inactive,,,U,Autocuration,A,,CHEMBL627683,,,,,0,1
14169,22224,,BAO_0000019,,,The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 2.4,,,U,Autocuration,A,,CHEMBL627684,,,,,0,1
14170,22224,,BAO_0000019,,,"The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 2.4; Significant cyclization occurred during nitro reduction, precluding isolation of the pure amine and determination of rate constants",,,U,Autocuration,A,,CHEMBL874441,,,,,0,1
14171,22224,,BAO_0000019,,,The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 6.8; No cyclization detected over 4 h,,,U,Autocuration,A,,CHEMBL627685,,,,,0,1
14172,22224,,BAO_0000019,,,"The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 6.8; Significant cyclization occurred during nitro reduction, precluding isolation of the pure amine and determination of rate constants",,,U,Autocuration,A,,CHEMBL627686,,,,,0,1
14173,22224,,BAO_0000019,,,Apparent rate constant Koff for inactivation of dTMP synthase.,,,U,Autocuration,A,,CHEMBL627687,,,,,0,1
14174,22224,,BAO_0000019,,,The irreversible inhibitor activity by second order rate equation.,,,U,Autocuration,A,,CHEMBL627688,,,,,0,1
14175,50597,,BAO_0000218,,,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at 1 mg/kg concentration,,,N,Intermediate,A,10116.0,CHEMBL628038,,,,,1,1
14176,50597,,BAO_0000218,,,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at 5 mg/kg concentration,,,N,Intermediate,A,10116.0,CHEMBL628039,,,,,1,1
14177,50597,,BAO_0000218,,,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at vehicle concentration,,,N,Intermediate,A,10116.0,CHEMBL628040,,,,,1,1
14178,22224,,BAO_0000019,,,Dissociation rate calculated from the first-order equation using t1/2 value,,,U,Autocuration,A,,CHEMBL628041,,,,,0,1
14179,22224,,BAO_0000019,,,The compound was tested for Binding constant against DNA,,,U,Autocuration,A,,CHEMBL630226,,,,,0,1
14180,22224,,BAO_0000019,,,First order rate constant for cyclization of the compound,,,U,Autocuration,A,,CHEMBL628042,,,,,0,1
14181,22224,,BAO_0000019,,,First order rate constant of compound was determined in 50 mM phosphate buffer (pH 7.4) at 24 degree celsius,,,U,Autocuration,A,,CHEMBL625232,,,,,0,1
14182,22224,,BAO_0000019,,,First order rate constant of compound was determined in 50 mM phosphate buffer (pH 7.4) at 37 degree celsius,,,U,Autocuration,A,,CHEMBL625233,,,,,0,1
14183,22224,,BAO_0000019,,,Hydrolysis rate constant was determined,,,U,Autocuration,A,,CHEMBL625979,,,,,0,1
14184,22224,,BAO_0000019,,,Observed first order rate constant,,,U,Autocuration,A,,CHEMBL625980,,,,,0,1
14185,22224,,BAO_0000019,,,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,,,U,Autocuration,A,,CHEMBL625981,,,,,0,1
14186,22224,,BAO_0000019,,,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,,,U,Autocuration,A,,CHEMBL625982,,,,,0,1
14187,22224,,BAO_0000019,,,Second-order rate constant for attack on PNPA at 25 degree Centigrade,,,U,Autocuration,A,,CHEMBL625983,,,,,0,1
14188,22224,,BAO_0000019,,,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,,U,Autocuration,A,,CHEMBL625984,,,,,0,1
14189,22224,,BAO_0000019,,,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,,U,Autocuration,A,,CHEMBL625985,,,,,0,1
14190,22224,,BAO_0000019,,,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,,U,Autocuration,A,,CHEMBL625986,,,,,0,1
14191,22224,,BAO_0000019,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,U,Autocuration,A,,CHEMBL625987,,,,,0,1
14192,22224,,BAO_0000019,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,U,Autocuration,A,,CHEMBL625988,,,,,0,1
14193,22224,,BAO_0000019,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,U,Autocuration,A,,CHEMBL625989,,,,,0,1
14194,22224,,BAO_0000019,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,U,Autocuration,A,,CHEMBL625990,,,,,0,1
14195,22224,,BAO_0000019,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,U,Autocuration,A,,CHEMBL625991,,,,,0,1
14196,22224,,BAO_0000019,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,U,Autocuration,A,,CHEMBL625992,,,,,0,1
14197,22224,,BAO_0000019,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,U,Autocuration,A,,CHEMBL625993,,,,,0,1
14198,22224,,BAO_0000019,,,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,,U,Autocuration,A,,CHEMBL631973,,,,,0,1
14199,22224,,BAO_0000019,,,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,,U,Autocuration,A,,CHEMBL632143,,,,,0,1
14200,22224,,BAO_0000019,,,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,,U,Autocuration,A,,CHEMBL632144,,,,,0,1
14201,22224,,BAO_0000019,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,U,Autocuration,A,,CHEMBL632145,,,,,0,1
14202,22224,,BAO_0000019,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,U,Autocuration,A,,CHEMBL632146,,,,,0,1
14203,22224,,BAO_0000019,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,U,Autocuration,A,,CHEMBL632147,,,,,0,1
14204,22224,,BAO_0000019,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,U,Autocuration,A,,CHEMBL632148,,,,,0,1
14205,22224,,BAO_0000019,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,U,Autocuration,A,,CHEMBL632149,,,,,0,1
14206,22224,,BAO_0000019,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,U,Autocuration,A,,CHEMBL632150,,,,,0,1
14207,22224,,BAO_0000019,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,U,Autocuration,A,,CHEMBL632151,,,,,0,1
14208,50587,,BAO_0000218,,,Metabolism (NADH oxidation) by recombinant human NAD(P)H: quinone oxidoreductase (NQO1) is evaluated; not detected,,,N,Intermediate,A,9606.0,CHEMBL632152,,,,,1,1
14209,50587,,BAO_0000218,,,Metabolism after 30 min of incubation with human liver microsomes in the absence of cofactor NADH (2.0 mM) at a concentration of 25 uM,,,N,Intermediate,A,9606.0,CHEMBL632153,,,,,1,1
14210,50587,,BAO_0000218,,,Metabolism after 30 min of incubation with human liver microsomes in the presence of cofactor NADH (2.0 mM) at a concentration of 25 uM,,,N,Intermediate,A,9606.0,CHEMBL632154,,,,,1,1
14211,50602,,BAO_0000218,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day; Tested mice 10,,,N,Intermediate,A,10298.0,CHEMBL632155,,,,,1,1
14212,50602,,BAO_0000218,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day; Total mice tested 10,,,N,Intermediate,A,10298.0,CHEMBL632156,,,,,1,1
14213,50602,,BAO_0000218,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 3.1 mg/kg per day; Tested mice 10,,,N,Intermediate,A,10298.0,CHEMBL632157,,,,,1,1
14214,50602,,BAO_0000218,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day; Tested mice 10,,,N,Intermediate,A,10298.0,CHEMBL632158,,,,,1,1
14215,50602,,BAO_0000218,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day; Total mice tested 10,,,N,Intermediate,A,10298.0,CHEMBL632159,,,,,1,1
14216,50602,,BAO_0000218,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at dose 0.8 mg/kg per day; Tested mice 10,,,N,Intermediate,A,10298.0,CHEMBL626305,,,,,1,1
14217,50602,,BAO_0000218,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at dose 3.1 mg/kg per day; Total mice tested 10,,,N,Intermediate,A,10298.0,CHEMBL626306,,,,,1,1
14218,50602,,BAO_0000218,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.02 mg/kg per day; Tested mice 10,,,N,Intermediate,A,10298.0,CHEMBL626307,,,,,1,1
14219,50602,,BAO_0000218,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.06 mg/kg per day; Tested mice 10,,,N,Intermediate,A,10298.0,CHEMBL626308,,,,,1,1
14220,50602,,BAO_0000218,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.25 mg/kg per day; Tested mice 10,,,N,Intermediate,A,10298.0,CHEMBL626479,,,,,1,1
14221,50602,,BAO_0000218,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 1 mg/kg per day; Tested mice 10,,,N,Intermediate,A,10298.0,CHEMBL626480,,,,,1,1
14222,22229,,BAO_0000100,,,Calculated partition coefficient (clogP) (MlogP),,,U,Autocuration,P,,CHEMBL626481,,,,,0,1
14223,22224,,BAO_0000019,,,Equipotent potent ratio relative to carbachol (nicotinic activity),,,U,Autocuration,A,,CHEMBL626482,,,,,0,1
14224,50588,,BAO_0000218,,,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 ); NA denotes not available",,,N,Intermediate,A,9615.0,CHEMBL626483,,,,,1,1
14225,50588,,BAO_0000218,,,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 );NA denotes not available",,,N,Intermediate,A,9615.0,CHEMBL626484,,,,,1,1
14226,22229,,BAO_0000100,,,Solubility at pH 7.4 in micro g/mL;NA denotes available,,,U,Autocuration,P,,CHEMBL626485,,,,,0,1
14227,22229,,BAO_0000100,,,Solubility at pH 7.4 in micro g/mL;NA denotes not available,,,U,Autocuration,P,,CHEMBL626486,,,,,0,1
14228,22229,,BAO_0000100,,,Solubility at pH 7.4 in ug/mL;NA denotes not available,,,U,Autocuration,P,,CHEMBL626487,,,,,0,1
14229,50588,In vivo,BAO_0000218,,,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,,,N,Intermediate,A,9615.0,CHEMBL626488,,1969.0,Plasma,,1,1
14230,50597,,BAO_0000218,,,Affinity for protein binding expressed as association constant in fresh rat serum; ND is Not Determined.,,,N,Intermediate,A,10116.0,CHEMBL626489,,1977.0,Serum,,1,1
14231,22224,,BAO_0000019,,,Area under the MAP curve measured over 5 min; ND means Not determined,,,U,Autocuration,A,,CHEMBL626490,,,,,0,1
14232,22224,,BAO_0000100,,,Lipophilicity expressed as the negative logarithm of the equilibrium constant; ND denotes no data.,,,U,Autocuration,P,,CHEMBL626491,,,,,0,1
14233,22229,,BAO_0000100,,,The apparent partition coefficient(D) in cyclohexane-0.05 M phosphate buffer (pH 7.4) at 21 degree celsius; not determined,,,U,Autocuration,P,,CHEMBL626492,,,,,0,1
14234,22224,,BAO_0000019,,,Half-life was measured in the presence of NADPH at 20 uM; No inhibition,,,U,Autocuration,A,,CHEMBL626493,,,,,0,1
14235,50597,In vivo,BAO_0000218,,,Half life after oral administration to Sprague-Dawley rats; NT is Not tested,,,N,Intermediate,A,10116.0,CHEMBL626494,,,,,1,1
14236,22224,In vivo,BAO_0000218,,,Half life after oral tested,,,U,Autocuration,A,,CHEMBL626495,,,,,0,1
14237,50597,,BAO_0000218,,,Half life was determined in plasma of rat; NT indicates not tested,,,N,Intermediate,A,10116.0,CHEMBL626496,,1969.0,Plasma,,1,1
14238,50597,In vivo,BAO_0000218,,,Oral bioavailability after oral administration to Sprague-Dawley rats; NT is Not tested,,,N,Intermediate,A,10116.0,CHEMBL626497,,,,,1,1
14239,22224,In vivo,BAO_0000218,,,Oral bioavailability after oral tested,,,U,Autocuration,A,,CHEMBL626498,,,,,0,1
14240,50597,,BAO_0000218,,,The bioavailability in rats at 15.9 uM/Kg after intravenous administration; NT=Not tested (F),,,N,Intermediate,A,10116.0,CHEMBL626499,,,,,1,1
14241,50597,,BAO_0000218,,,The compound was tested for volume of distribution in rat at 15.9 uM/Kg after peroral administration; NT=Not tested (Vd L/Kg),,,N,Intermediate,A,10116.0,CHEMBL626500,,,,,1,1
14242,50597,,BAO_0000218,,,half life was determined in plasma of rat; NT indicates not tested,,,N,Intermediate,A,10116.0,CHEMBL626501,,1969.0,Plasma,,1,1
14243,50597,,BAO_0000218,,,half life was determined in plasma of rat; NT means not tested,,,N,Intermediate,A,10116.0,CHEMBL626502,,1969.0,Plasma,,1,1
14244,50597,,BAO_0000218,,,Mean sodium excretion in rats (Control/Drug treatment value); Value 0.41/2.32,,,N,Intermediate,A,10116.0,CHEMBL626503,,,,,1,1
14245,50597,,BAO_0000218,,,Mean sodium excretion in rats (Control/Drug treatment value); inactive,,,N,Intermediate,A,10116.0,CHEMBL626504,,,,,1,1
14246,50597,,BAO_0000218,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.17/0.43,,,N,Intermediate,A,10116.0,CHEMBL626505,,,,,1,1
14247,50597,,BAO_0000218,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.2/0.38,,,N,Intermediate,A,10116.0,CHEMBL626506,,,,,1,1
14248,50597,,BAO_0000218,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.26/0.23,,,N,Intermediate,A,10116.0,CHEMBL626507,,,,,1,1
14249,50597,,BAO_0000218,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.28/0.26,,,N,Intermediate,A,10116.0,CHEMBL626508,,,,,1,1
14250,50597,,BAO_0000218,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.31/0.35,,,N,Intermediate,A,10116.0,CHEMBL626509,,,,,1,1
14251,50597,,BAO_0000218,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.35/2.88,,,N,Intermediate,A,10116.0,CHEMBL875480,,,,,1,1
14252,50597,,BAO_0000218,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.29,,,N,Intermediate,A,10116.0,CHEMBL626510,,,,,1,1
14253,50597,,BAO_0000218,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.47,,,N,Intermediate,A,10116.0,CHEMBL626511,,,,,1,1
14254,50597,,BAO_0000218,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.49,,,N,Intermediate,A,10116.0,CHEMBL626512,,,,,1,1
14255,50597,,BAO_0000218,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.38/0.23,,,N,Intermediate,A,10116.0,CHEMBL628208,,,,,1,1
14256,50597,,BAO_0000218,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.39/0.22,,,N,Intermediate,A,10116.0,CHEMBL628209,,,,,1,1
14257,50597,,BAO_0000218,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/0.48,,,N,Intermediate,A,10116.0,CHEMBL628210,,,,,1,1
14258,50597,,BAO_0000218,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/1.49,,,N,Intermediate,A,10116.0,CHEMBL628211,,,,,1,1
14259,50597,,BAO_0000218,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/2.06,,,N,Intermediate,A,10116.0,CHEMBL628212,,,,,1,1
14260,50597,,BAO_0000218,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.42/0.65,,,N,Intermediate,A,10116.0,CHEMBL628213,,,,,1,1
14261,50597,,BAO_0000218,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 65.2 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL628214,,1088.0,Urine,,1,1
14262,50597,,BAO_0000218,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 71.6 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL628215,,1088.0,Urine,,1,1
14263,50597,,BAO_0000218,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 71.8 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL628216,,1088.0,Urine,,1,1
14264,50597,,BAO_0000218,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 74.8 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL626595,,1088.0,Urine,,1,1
14265,50597,,BAO_0000218,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 77.5 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL626596,,1088.0,Urine,,1,1
14266,50597,,BAO_0000218,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 79.4 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL626597,,1088.0,Urine,,1,1
14267,50597,,BAO_0000218,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 80.9 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL626598,,1088.0,Urine,,1,1
14268,50597,,BAO_0000218,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 83.8 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL622242,,1088.0,Urine,,1,1
14269,50597,,BAO_0000218,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 84.5 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL622243,,1088.0,Urine,,1,1
14270,50597,,BAO_0000218,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 84.7 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL622244,,1088.0,Urine,,1,1
14271,50597,,BAO_0000218,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 86.7 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL622245,,1088.0,Urine,,1,1
14272,50597,,BAO_0000218,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 86.9 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL622246,,1088.0,Urine,,1,1
14273,50597,,BAO_0000218,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 9.06 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL622247,,1088.0,Urine,,1,1
14274,50597,,BAO_0000218,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 90.6 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL622248,,1088.0,Urine,,1,1
14275,50597,,BAO_0000218,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 94.9 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL877483,,1088.0,Urine,,1,1
14276,50597,,BAO_0000218,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 97.1 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL622249,,1088.0,Urine,,1,1
14277,50588,,BAO_0000218,,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,,,N,Intermediate,A,9615.0,CHEMBL622250,,1088.0,Urine,,1,1
14278,50588,,BAO_0000218,,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,,,N,Intermediate,A,9615.0,CHEMBL622251,,1088.0,Urine,,1,1
14279,50588,,BAO_0000218,,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,,,N,Intermediate,A,9615.0,CHEMBL622252,,1088.0,Urine,,1,1
14280,50588,,BAO_0000218,,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,,,N,Intermediate,A,9615.0,CHEMBL622253,,1088.0,Urine,,1,1
14281,50588,,BAO_0000218,,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,,,N,Intermediate,A,9615.0,CHEMBL622254,,1088.0,Urine,,1,1
14282,50588,,BAO_0000218,,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,,,N,Intermediate,A,9615.0,CHEMBL622255,,1088.0,Urine,,1,1
14283,50588,,BAO_0000218,,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,,,N,Intermediate,A,9615.0,CHEMBL622256,,1088.0,Urine,,1,1
14284,50588,,BAO_0000218,,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,,,N,Intermediate,A,9615.0,CHEMBL622257,,1088.0,Urine,,1,1
14285,50588,,BAO_0000218,,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,,,N,Intermediate,A,9615.0,CHEMBL622258,,1088.0,Urine,,1,1
14286,50588,,BAO_0000218,,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,,,N,Intermediate,A,9615.0,CHEMBL622259,,1088.0,Urine,,1,1
14287,50588,,BAO_0000218,,,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 10.1 uM/Kg of drug,,,N,Intermediate,A,9615.0,CHEMBL622927,,1088.0,Urine,,1,1
14288,50588,,BAO_0000218,,,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 3.40 uM/Kg of drug,,,N,Intermediate,A,9615.0,CHEMBL622928,,1088.0,Urine,,1,1
14289,50588,,BAO_0000218,,,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 3.76 uM/Kg of drug,,,N,Intermediate,A,9615.0,CHEMBL622929,,1088.0,Urine,,1,1
14290,50588,,BAO_0000218,,,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 9.06 uM/Kg of drug,,,N,Intermediate,A,9615.0,CHEMBL623182,,1088.0,Urine,,1,1
14291,50588,,BAO_0000218,,,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 9.6 uM/Kg of drug,,,N,Intermediate,A,9615.0,CHEMBL623183,,1088.0,Urine,,1,1
14292,50597,,BAO_0000218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 0 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL623184,,1088.0,Urine,,1,1
14293,50597,,BAO_0000218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 1.01 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL623185,,1088.0,Urine,,1,1
14294,50597,,BAO_0000218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 1.13 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL877484,,1088.0,Urine,,1,1
14295,50597,,BAO_0000218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 10.1 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL627274,,1088.0,Urine,,1,1
14296,50597,,BAO_0000218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 102 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL623186,,1088.0,Urine,,1,1
14297,50597,,BAO_0000218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 105 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL623187,,1088.0,Urine,,1,1
14298,50597,,BAO_0000218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 11.3 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL623188,,1088.0,Urine,,1,1
14299,50597,,BAO_0000218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 113 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL628055,,1088.0,Urine,,1,1
14300,50597,,BAO_0000218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 19.5 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL628056,,1088.0,Urine,,1,1
14301,50597,,BAO_0000218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 195 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL628200,,1088.0,Urine,,1,1
14302,50597,,BAO_0000218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 21.7 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL628201,,1088.0,Urine,,1,1
14303,50597,,BAO_0000218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 217 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL628202,,1088.0,Urine,,1,1
14304,50597,,BAO_0000218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 23.9 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL628203,,1088.0,Urine,,1,1
14305,50597,,BAO_0000218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 239 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL628204,,1088.0,Urine,,1,1
14306,50597,,BAO_0000218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 24.9 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL628205,,1088.0,Urine,,1,1
14307,50597,,BAO_0000218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 249 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL628206,,1088.0,Urine,,1,1
14308,22224,In vivo,BAO_0000218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d),,,U,Autocuration,A,,CHEMBL628207,,2367.0,Prostate gland,,0,1
14309,22224,In vivo,BAO_0000218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d)/biood,,,U,Autocuration,A,,CHEMBL627220,,2367.0,Prostate gland,,0,1
14310,22224,In vivo,BAO_0000218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d)/muscle,,,U,Autocuration,A,,CHEMBL627221,,2385.0,Muscle tissue,,0,1
14311,22224,In vivo,BAO_0000218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v),,,U,Autocuration,A,,CHEMBL627222,,2367.0,Prostate gland,,0,1
14312,22224,In vivo,BAO_0000218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v)/blood,,,U,Autocuration,A,,CHEMBL627223,,,,,0,1
14313,22224,In vivo,BAO_0000218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v)/muscle,,,U,Autocuration,A,,CHEMBL632062,,2385.0,Muscle tissue,,0,1
14314,22224,In vivo,BAO_0000218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in spleen,,,U,Autocuration,A,,CHEMBL632063,,2106.0,Spleen,,0,1
14315,22224,In vivo,BAO_0000218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in bladder,,,U,Autocuration,A,,CHEMBL632064,,1255.0,Urinary bladder,,0,1
14316,22224,In vivo,BAO_0000218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in blood,,,U,Autocuration,A,,CHEMBL632065,,178.0,Blood,,0,1
14317,22224,In vivo,BAO_0000218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in bone,,,U,Autocuration,A,,CHEMBL632066,,1474.0,Bone element,,0,1
14318,22224,In vivo,BAO_0000218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in fat,,,U,Autocuration,A,,CHEMBL632067,,,,,0,1
14319,22224,In vivo,BAO_0000218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in kidney,,,U,Autocuration,A,,CHEMBL629188,,2113.0,Kidney,,0,1
14320,22224,In vivo,BAO_0000218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in liver,,,U,Autocuration,A,,CHEMBL629189,,2107.0,Liver,,0,1
14321,22224,In vivo,BAO_0000218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in lung,,,U,Autocuration,A,,CHEMBL629190,,2048.0,Lung,,0,1
14322,22224,In vivo,BAO_0000218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in muscle,,,U,Autocuration,A,,CHEMBL629191,,2385.0,Muscle tissue,,0,1
14323,22224,In vivo,BAO_0000218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (d),,,U,Autocuration,A,,CHEMBL629192,,2367.0,Prostate gland,,0,1
14324,22224,In vivo,BAO_0000218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (d)/muscle,,,U,Autocuration,A,,CHEMBL629193,,2385.0,Muscle tissue,,0,1
14325,22224,In vivo,BAO_0000218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v),,,U,Autocuration,A,,CHEMBL629194,,2367.0,Prostate gland,,0,1
14326,22224,In vivo,BAO_0000218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v)/blood,,,U,Autocuration,A,,CHEMBL629195,,,,,0,1
14327,22224,In vivo,BAO_0000218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v)/muscle,,,U,Autocuration,A,,CHEMBL629373,,2385.0,Muscle tissue,,0,1
14328,22224,In vivo,BAO_0000218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in spleen,,,U,Autocuration,A,,CHEMBL629374,,2106.0,Spleen,,0,1
14329,22224,In vivo,BAO_0000218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked)i n prostate (d)/biood,,,U,Autocuration,A,,CHEMBL629375,,2367.0,Prostate gland,,0,1
14330,22224,In vivo,BAO_0000218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in bladder,,,U,Autocuration,A,,CHEMBL629376,,1255.0,Urinary bladder,,0,1
14331,22224,In vivo,BAO_0000218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in blood,,,U,Autocuration,A,,CHEMBL629377,,178.0,Blood,,0,1
14332,22224,In vivo,BAO_0000218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in bone,,,U,Autocuration,A,,CHEMBL629378,,1474.0,Bone element,,0,1
14333,22224,In vivo,BAO_0000218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in fat,,,U,Autocuration,A,,CHEMBL629379,,,,,0,1
14334,22224,In vivo,BAO_0000218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in kidney,,,U,Autocuration,A,,CHEMBL629151,,2113.0,Kidney,,0,1
14335,22224,In vivo,BAO_0000218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in liver,,,U,Autocuration,A,,CHEMBL629152,,2107.0,Liver,,0,1
14336,22224,In vivo,BAO_0000218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in lung,,,U,Autocuration,A,,CHEMBL629153,,2048.0,Lung,,0,1
14337,22224,In vivo,BAO_0000218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in muscle,,,U,Autocuration,A,,CHEMBL629154,,2385.0,Muscle tissue,,0,1
14338,22224,In vivo,BAO_0000218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d),,,U,Autocuration,A,,CHEMBL629155,,2367.0,Prostate gland,,0,1
14339,22224,In vivo,BAO_0000218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d)/biood,,,U,Autocuration,A,,CHEMBL629156,,2367.0,Prostate gland,,0,1
14340,22224,In vivo,BAO_0000218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d)/muscle,,,U,Autocuration,A,,CHEMBL629157,,2385.0,Muscle tissue,,0,1
14341,22224,In vivo,BAO_0000218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v),,,U,Autocuration,A,,CHEMBL629158,,2367.0,Prostate gland,,0,1
14342,22224,In vivo,BAO_0000218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v)/blood,,,U,Autocuration,A,,CHEMBL629159,,,,,0,1
14343,22224,In vivo,BAO_0000218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v)/muscle,,,U,Autocuration,A,,CHEMBL629160,,2385.0,Muscle tissue,,0,1
14344,22224,In vivo,BAO_0000218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in spleen,,,U,Autocuration,A,,CHEMBL629161,,2106.0,Spleen,,0,1
14345,22224,In vivo,BAO_0000218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in bladder,,,U,Autocuration,A,,CHEMBL629162,,1255.0,Urinary bladder,,0,1
14346,22224,In vivo,BAO_0000218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in blood,,,U,Autocuration,A,,CHEMBL629163,,178.0,Blood,,0,1
14347,22224,In vivo,BAO_0000218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in bone,,,U,Autocuration,A,,CHEMBL629164,,1474.0,Bone element,,0,1
14348,22224,In vivo,BAO_0000218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in fat,,,U,Autocuration,A,,CHEMBL629165,,,,,0,1
14349,22224,In vivo,BAO_0000218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in liver,,,U,Autocuration,A,,CHEMBL629166,,2107.0,Liver,,0,1
14350,22224,In vivo,BAO_0000218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in lung,,,U,Autocuration,A,,CHEMBL629167,,2048.0,Lung,,0,1
14351,22224,In vivo,BAO_0000218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in muscle,,,U,Autocuration,A,,CHEMBL629168,,2385.0,Muscle tissue,,0,1
14352,22224,,BAO_0000019,,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 100 uM,,,U,Autocuration,A,,CHEMBL629169,,,,,0,1
14353,22224,,BAO_0000019,,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 100 uM; no inhibition is observed at this concentration,,,U,Autocuration,A,,CHEMBL629170,,,,,0,1
14354,22224,,BAO_0000019,,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 10 uM,,,U,Autocuration,A,,CHEMBL631153,,,,,0,1
14355,22224,,BAO_0000019,,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 10 uM; too active and complete inhibition is observed,,,U,Autocuration,A,,CHEMBL875121,,,,,0,1
14356,22224,,BAO_0000019,,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 1 uM,,,U,Autocuration,A,,CHEMBL631154,,,,,0,1
14357,22224,,BAO_0000019,,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 1 uM; too active and complete inhibition is observed,,,U,Autocuration,A,,CHEMBL631155,,,,,0,1
14358,22224,,BAO_0000019,,,Hydrolysis rate constant was determined,,,U,Autocuration,A,,CHEMBL631156,,,,,0,1
14359,22224,,BAO_0000019,,,"K2, The intrinsic biomolecular reactivation rate constant on VX at 25 degree Centigrade",,,U,Autocuration,A,,CHEMBL631157,,,,,0,1
14360,22224,,BAO_0000019,,,"K2, The intrinsic biomolecular reactivation rate constant on paraxon at 25 degree Centigrade",,,U,Autocuration,A,,CHEMBL631158,,,,,0,1
14361,22224,,BAO_0000019,,,"K2, The intrinsic biomolecular reactivation rate constant on sarin at 25 degree Centigrade",,,U,Autocuration,A,,CHEMBL631159,,,,,0,1
14362,22224,,BAO_0000019,,,Observed second order rate constant,,,U,Autocuration,A,,CHEMBL631160,,,,,0,1
14363,22224,,BAO_0000019,,,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,,,U,Autocuration,A,,CHEMBL631161,,,,,0,1
14364,22224,,BAO_0000019,,,Rate constant for decay of compound was determined in 50 mM phosphate buffer (pH 7.4) at 24 degree celsius,,,U,Autocuration,A,,CHEMBL631162,,,,,0,1
14365,22224,,BAO_0000019,,,Rate constant for decay of compound was determined in 50 mM phosphate buffer (pH 7.4) at 37 degree celsius,,,U,Autocuration,A,,CHEMBL630313,,,,,0,1
14366,22224,,BAO_0000019,,,"k2, The intrinsic biomolecular reactivation rate constant on paraxon at 25 degree Centigrade",,,U,Autocuration,A,,CHEMBL630314,,,,,0,1
14367,22224,,BAO_0000019,,,"k2, The intrinsic biomolecular reactivation rate constant on sarin at 25 degree Centigrade",,,U,Autocuration,A,,CHEMBL630315,,,,,0,1
14368,22224,,BAO_0000019,,,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,,U,Autocuration,A,,CHEMBL630316,,,,,0,1
14369,22224,,BAO_0000019,,,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,,U,Autocuration,A,,CHEMBL630986,,,,,0,1
14370,22224,,BAO_0000019,,,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,,U,Autocuration,A,,CHEMBL630987,,,,,0,1
14371,22224,,BAO_0000019,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0(or )in RMPI 1640 cell culture medium containing 10%FCS,,,U,Autocuration,A,,CHEMBL630988,,,,,0,1
14372,22224,,BAO_0000019,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,U,Autocuration,A,,CHEMBL630989,,,,,0,1
14373,22224,,BAO_0000019,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,U,Autocuration,A,,CHEMBL630990,,,,,0,1
14374,22224,,BAO_0000019,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,U,Autocuration,A,,CHEMBL630991,,,,,0,1
14375,22224,,BAO_0000019,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,U,Autocuration,A,,CHEMBL630992,,,,,0,1
14376,22224,,BAO_0000019,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,U,Autocuration,A,,CHEMBL630993,,,,,0,1
14377,22224,,BAO_0000019,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,U,Autocuration,A,,CHEMBL630994,,,,,0,1
14378,50597,,BAO_0000218,,,Rate constants of compound was determined at muscarinic receptor in the rat cerebral cortex,,,N,Intermediate,A,10116.0,CHEMBL630995,,,,,1,1
14379,22224,,BAO_0000019,,,Association constant for compound at 31 degree C was determined,,,U,Autocuration,A,,CHEMBL629252,,,,,0,1
14380,22224,,BAO_0000019,,,Calculated antagonist equilibrium dissociation constant of the compound,,,U,Autocuration,A,,CHEMBL629253,,,,,0,1
14381,22224,,BAO_0000019,,,Calculated antagonist equilibrium dissociation constant of the compound; No statistically significant antagonism observed,,,U,Autocuration,A,,CHEMBL629944,,,,,0,1
14382,50512,,BAO_0000218,,,Dissociation constants vs LTE4 on guinea pig trachea,,,N,Intermediate,A,10141.0,CHEMBL629945,,3126.0,Trachea,,1,1
14383,22224,,BAO_0000019,,,"Tested for hydrolysis in presence of boric acid by UV spectrophotometry, dissociation constant was evaluated at the pH < 8",,,U,Autocuration,A,,CHEMBL629946,,,,,0,1
14384,22224,,BAO_0000019,,,"Tested for hydrolysis in presence of boric acid, rate constant was evaluated at the pH 8.5",,,U,Autocuration,A,,CHEMBL629947,,,,,0,1
14385,22224,,BAO_0000019,,,"Tested for hydrolysis in presence of boric acid, rate constant was evaluated at the pH 9.5",,,U,Autocuration,A,,CHEMBL629948,,,,,0,1
14386,22224,,BAO_0000019,,,"Tested for hydrolysis in presence of phenylboronic acid, rate constant was evaluated at the pH 9.5",,,U,Autocuration,A,,CHEMBL856024,,,,,0,1
14387,22224,,BAO_0000019,,,Affinity constant KD value was derived from TMP,,,U,Autocuration,A,,CHEMBL629949,,,,,0,1
14388,22224,,BAO_0000019,,,Apparent dissociation (binding) rate constant was evaluated,,,U,Autocuration,A,,CHEMBL629950,,,,,0,1
14389,22224,,BAO_0000100,,,Dissociation constant (KD) of the compound,,,U,Autocuration,P,,CHEMBL630127,,,,,0,1
14390,22224,,BAO_0000100,,,Dissociation constant determined by heteronuclear 1H/15N correlation NMR spectroscopy,,,U,Autocuration,P,,CHEMBL630128,,,,,0,1
14391,22224,,BAO_0000100,,,Dissociation constant from ESR titration experiments,,,U,Autocuration,P,,CHEMBL630129,,,,,0,1
14392,22224,,BAO_0000019,,,Dissociation constant was evaluated which is similar to Ki (inhibitory constant),,,U,Autocuration,,,CHEMBL630130,,,,,0,1
14393,22224,,BAO_0000100,,,Dissociation constant was evaluated.,,,U,Autocuration,P,,CHEMBL875234,,,,,0,1
14394,22224,,BAO_0000100,,,Dissociation constant was reported,,,U,Autocuration,P,,CHEMBL630131,,,,,0,1
14395,50597,,BAO_0000218,,,Dissociation constant was determined in rat pituitary cells.,,,N,Intermediate,A,10116.0,CHEMBL630132,,,,,1,1
14396,22224,,BAO_0000019,,,Equilibrium dissociation constant of CA complex for enantiomer 1 of compound,,,U,Autocuration,A,,CHEMBL630133,,,,,0,1
14397,22224,,BAO_0000019,,,Equilibrium dissociation constant of CA complex for enantiomer 2 of compound,,,U,Autocuration,A,,CHEMBL630134,,,,,0,1
14398,22224,,BAO_0000019,,,Equilibrium dissociation constant of the compound,,,U,Autocuration,A,,CHEMBL630135,,,,,0,1
14399,22224,,BAO_0000019,,,Equilibrium dissociation constant was determined,,,U,Autocuration,A,,CHEMBL630136,,,,,0,1
14400,22224,,BAO_0000019,,,Kinetic constant KD was evaluated,,,U,Autocuration,A,,CHEMBL630137,,,,,0,1
14401,22224,,BAO_0000019,,,Tested for dissociation constant of the compound; Value ranges from 0.1-0.3,,,U,Autocuration,A,,CHEMBL630138,,,,,0,1
14402,22224,,BAO_0000019,,,Equilibrium association constant interacting with unilamellar vesicles of electroneutral in PBS buffer at pH 7.4,,,U,Autocuration,A,,CHEMBL630139,,,,,0,1
14403,22224,,BAO_0000019,,,Rate constant for hydrolysis in aqueous acetone.,,,U,Autocuration,A,,CHEMBL630140,,,,,0,1
14404,22224,,BAO_0000019,,,Disassociation constant (KI) was obtained from Cheng and Prusoff equation for quercetin trypsin complex,,,U,Autocuration,A,,CHEMBL875235,,,,,0,1
14405,50597,,BAO_0000218,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.43/2.86,,,N,Intermediate,A,10116.0,CHEMBL876439,,,,,1,1
14406,50597,,BAO_0000218,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.44/2.68,,,N,Intermediate,A,10116.0,CHEMBL630605,,,,,1,1
14407,50597,,BAO_0000218,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.45/1.55,,,N,Intermediate,A,10116.0,CHEMBL630606,,,,,1,1
14408,50597,,BAO_0000218,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.48/0.95,,,N,Intermediate,A,10116.0,CHEMBL630607,,,,,1,1
14409,50597,,BAO_0000218,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.5/1.79,,,N,Intermediate,A,10116.0,CHEMBL630608,,,,,1,1
14410,50597,,BAO_0000218,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.51/0.66,,,N,Intermediate,A,10116.0,CHEMBL630609,,,,,1,1
14411,50597,,BAO_0000218,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.52/2.02,,,N,Intermediate,A,10116.0,CHEMBL630610,,,,,1,1
14412,50597,,BAO_0000218,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.61//0.37,,,N,Intermediate,A,10116.0,CHEMBL630611,,,,,1,1
14413,50597,,BAO_0000218,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.71/0.36,,,N,Intermediate,A,10116.0,CHEMBL629552,,,,,1,1
14414,50597,,BAO_0000218,,,Mean sodium excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL629733,,,,,1,1
14415,50597,,BAO_0000218,,,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL629734,,,,,1,1
14416,50597,,BAO_0000218,,,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL629735,,,,,1,1
14417,50597,,BAO_0000218,,,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL629736,,,,,1,1
14418,50597,,BAO_0000218,,,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL629737,,,,,1,1
14419,50597,,BAO_0000218,,,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL629738,,,,,1,1
14420,50597,,BAO_0000218,,,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL629739,,,,,1,1
14421,50597,,BAO_0000218,,,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,,,N,Intermediate,A,10116.0,CHEMBL629740,,,,,1,1
14422,50597,,BAO_0000218,,,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL629741,,,,,1,1
14423,50597,,BAO_0000218,,,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL629742,,,,,1,1
14424,50597,,BAO_0000218,,,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL629743,,,,,1,1
14425,50597,,BAO_0000218,,,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL629744,,,,,1,1
14426,50597,,BAO_0000218,,,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL629745,,,,,1,1
14427,50597,,BAO_0000218,,,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL629746,,,,,1,1
14428,50597,,BAO_0000218,,,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL629747,,,,,1,1
14429,50597,,BAO_0000218,,,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL629748,,,,,1,1
14430,50597,,BAO_0000218,,,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL629749,,,,,1,1
14431,50597,,BAO_0000218,,,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL629750,,,,,1,1
14432,50597,,BAO_0000218,,,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL629751,,,,,1,1
14433,50597,,BAO_0000218,,,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL629752,,,,,1,1
14434,50597,,BAO_0000218,,,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL629753,,,,,1,1
14435,50597,,BAO_0000218,,,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL629754,,,,,1,1
14436,50597,,BAO_0000218,,,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL629755,,,,,1,1
14437,50597,,BAO_0000218,,,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL629756,,,,,1,1
14438,50597,,BAO_0000218,,,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL629757,,,,,1,1
14439,50597,,BAO_0000218,,,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL629758,,,,,1,1
14440,50597,,BAO_0000218,,,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL629759,,,,,1,1
14441,50597,,BAO_0000218,,,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL629760,,,,,1,1
14442,50597,,BAO_0000218,,,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,,,N,Intermediate,A,10116.0,CHEMBL876443,,,,,1,1
14443,50588,,BAO_0000218,,,Na+ excretion mequiv /kg in 6 conscious female dogs administered perorally during 0-6 hr,,,N,Intermediate,A,9615.0,CHEMBL629761,,,,,1,1
14444,50588,,BAO_0000218,,,Na+ excretion mequiv /kg in conscious female dogs administered perorally during 0-6 hr,,,N,Intermediate,A,9615.0,CHEMBL629762,,,,,1,1
14445,50594,,BAO_0000218,,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 10 ml/kg perorally,,,N,Intermediate,A,10090.0,CHEMBL629763,,,,,1,1
14446,50594,,BAO_0000218,,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 2 ml/kg perorally,,,N,Intermediate,A,10090.0,CHEMBL629764,,,,,1,1
14447,50594,,BAO_0000218,,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 2 ml/kg perorally,,,N,Intermediate,A,10090.0,CHEMBL629765,,,,,1,1
14448,50594,,BAO_0000218,,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 50 ml/kg perorally,,,N,Intermediate,A,10090.0,CHEMBL629766,,,,,1,1
14449,50594,,BAO_0000218,,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 10 ml/kg perorally,,,N,Intermediate,A,10090.0,CHEMBL629767,,,,,1,1
14450,50588,,BAO_0000218,,,Na+ excretion mequiv/kg in 4 conscious female dogs administered perorally during 0-6 hr,,,N,Intermediate,A,9615.0,CHEMBL629768,,,,,1,1
14451,50594,,BAO_0000218,,,Na+ excretion mequiv/kg in 4 saline-loaded mice administered at a dose 50 ml/kg perorally,,,N,Intermediate,A,10090.0,CHEMBL629769,,,,,1,1
14452,50588,,BAO_0000218,,,Na+ excretion mequiv/kg in 6 conscious female dogs administered perorally during 0-6 hr,,,N,Intermediate,A,9615.0,CHEMBL629770,,,,,1,1
14453,50588,,BAO_0000218,,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 0.3 ml/kg perorally,,,N,Intermediate,A,9615.0,CHEMBL629771,,,,,1,1
14454,50594,,BAO_0000218,,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 10 ml/kg perorally,,,N,Intermediate,A,10090.0,CHEMBL629772,,,,,1,1
14455,50594,,BAO_0000218,,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 10 ml/kg perorally,,,N,Intermediate,A,10090.0,CHEMBL629773,,,,,1,1
14456,50594,,BAO_0000218,,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 2 ml/kg perorally,,,N,Intermediate,A,10090.0,CHEMBL625455,,,,,1,1
14457,50594,,BAO_0000218,,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 250 ml/kg perorally,,,N,Intermediate,A,10090.0,CHEMBL625456,,,,,1,1
14458,50594,,BAO_0000218,,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 3 ml/kg perorally,,,N,Intermediate,A,10090.0,CHEMBL625457,,,,,1,1
14459,50597,,BAO_0000218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 25.9 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL625458,,1088.0,Urine,,1,1
14460,50597,,BAO_0000218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 259 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL625459,,1088.0,Urine,,1,1
14461,50597,,BAO_0000218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 26.5 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL875483,,1088.0,Urine,,1,1
14462,50597,,BAO_0000218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 265 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL634779,,1088.0,Urine,,1,1
14463,50597,,BAO_0000218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 27 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL625460,,1088.0,Urine,,1,1
14464,50597,,BAO_0000218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 27.9 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL626117,,1088.0,Urine,,1,1
14465,50597,,BAO_0000218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 270 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL626118,,1088.0,Urine,,1,1
14466,50597,,BAO_0000218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 279 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL628342,,1088.0,Urine,,1,1
14467,50597,,BAO_0000218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.2 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL628343,,1088.0,Urine,,1,1
14468,50597,,BAO_0000218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.22 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL628344,,1088.0,Urine,,1,1
14469,50597,,BAO_0000218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.9 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL628345,,1088.0,Urine,,1,1
14470,50597,,BAO_0000218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 282 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL628346,,1088.0,Urine,,1,1
14471,50597,,BAO_0000218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 289 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL628347,,1088.0,Urine,,1,1
14472,50597,,BAO_0000218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 3.40 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL628348,,1088.0,Urine,,1,1
14473,50597,,BAO_0000218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 3.76 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL628349,,1088.0,Urine,,1,1
14474,50597,,BAO_0000218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 30.2 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL875611,,1088.0,Urine,,1,1
14475,50597,,BAO_0000218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 302 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL628350,,1088.0,Urine,,1,1
14476,50597,,BAO_0000218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 31.6 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL628351,,1088.0,Urine,,1,1
14477,50597,,BAO_0000218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 316 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL628352,,1088.0,Urine,,1,1
14478,50597,,BAO_0000218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 32.4 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL628353,,1088.0,Urine,,1,1
14479,50597,,BAO_0000218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 324 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL628354,,1088.0,Urine,,1,1
14480,50597,,BAO_0000218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.0 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL626667,,1088.0,Urine,,1,1
14481,50597,,BAO_0000218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.1 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL626668,,1088.0,Urine,,1,1
14482,50597,,BAO_0000218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.8 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL626669,,1088.0,Urine,,1,1
14483,50597,,BAO_0000218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 341 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL626670,,1088.0,Urine,,1,1
14484,50597,,BAO_0000218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 348 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL626671,,1088.0,Urine,,1,1
14485,50597,,BAO_0000218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 37.6 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL626672,,1088.0,Urine,,1,1
14486,50597,,BAO_0000218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 50.8 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL626673,,1088.0,Urine,,1,1
14487,50597,,BAO_0000218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 58.4 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL626674,,1088.0,Urine,,1,1
14488,50597,,BAO_0000218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 65.2 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL626675,,1088.0,Urine,,1,1
14489,50597,,BAO_0000218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 68.1 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL626676,,1088.0,Urine,,1,1
14490,50597,,BAO_0000218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 7.94 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL626677,,1088.0,Urine,,1,1
14491,50597,,BAO_0000218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 71.6 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL626678,,1088.0,Urine,,1,1
14492,50597,,BAO_0000218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 71.8 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL626679,,1088.0,Urine,,1,1
14493,50597,,BAO_0000218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 74.8 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL875612,,1088.0,Urine,,1,1
14494,50597,,BAO_0000218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 77.5 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL626680,,1088.0,Urine,,1,1
14495,50597,,BAO_0000218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 79.4 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL626681,,1088.0,Urine,,1,1
14496,50597,,BAO_0000218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 80.9 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL626682,,1088.0,Urine,,1,1
14497,50597,,BAO_0000218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 83.8 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL626683,,1088.0,Urine,,1,1
14498,50597,,BAO_0000218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 84.5 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL626684,,1088.0,Urine,,1,1
14499,50597,,BAO_0000218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 84.7 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL626685,,1088.0,Urine,,1,1
14500,50597,,BAO_0000218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 86.7 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL626686,,1088.0,Urine,,1,1
14501,50597,,BAO_0000218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 86.9 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL626687,,1088.0,Urine,,1,1
14502,50597,,BAO_0000218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 9.06 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL624978,,1088.0,Urine,,1,1
14503,50597,,BAO_0000218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 90.6 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL624979,,1088.0,Urine,,1,1
14504,50597,,BAO_0000218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 94.9 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL624980,,1088.0,Urine,,1,1
14505,50597,,BAO_0000218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 97.1 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL624981,,1088.0,Urine,,1,1
14506,50588,,BAO_0000218,,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,,,N,Intermediate,A,9615.0,CHEMBL624982,,1088.0,Urine,,1,1
14507,22224,In vivo,BAO_0000218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d),,,U,Autocuration,A,,CHEMBL627564,,2367.0,Prostate gland,,0,1
14508,22224,In vivo,BAO_0000218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v),,,U,Autocuration,A,,CHEMBL627565,,2367.0,Prostate gland,,0,1
14509,22224,In vivo,BAO_0000218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v)/blood,,,U,Autocuration,A,,CHEMBL627566,,,,,0,1
14510,22224,In vivo,BAO_0000218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v)/muscle,,,U,Autocuration,A,,CHEMBL627567,,2385.0,Muscle tissue,,0,1
14511,22224,In vivo,BAO_0000218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in spleen,,,U,Autocuration,A,,CHEMBL627568,,2106.0,Spleen,,0,1
14512,22224,In vivo,BAO_0000218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hr in kidney,,,U,Autocuration,A,,CHEMBL627569,,2113.0,Kidney,,0,1
14513,22224,In vivo,BAO_0000218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in bladder,,,U,Autocuration,A,,CHEMBL627570,,1255.0,Urinary bladder,,0,1
14514,22224,In vivo,BAO_0000218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in blood,,,U,Autocuration,A,,CHEMBL627571,,178.0,Blood,,0,1
14515,22224,In vivo,BAO_0000218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in bone,,,U,Autocuration,A,,CHEMBL627572,,1474.0,Bone element,,0,1
14516,22224,In vivo,BAO_0000218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in fat,,,U,Autocuration,A,,CHEMBL627573,,,,,0,1
14517,22224,In vivo,BAO_0000218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in kidney,,,U,Autocuration,A,,CHEMBL627574,,2113.0,Kidney,,0,1
14518,22224,In vivo,BAO_0000218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in liver,,,U,Autocuration,A,,CHEMBL627575,,2107.0,Liver,,0,1
14519,22224,In vivo,BAO_0000218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in lung,,,U,Autocuration,A,,CHEMBL627576,,2048.0,Lung,,0,1
14520,22224,In vivo,BAO_0000218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in muscle,,,U,Autocuration,A,,CHEMBL627577,,2385.0,Muscle tissue,,0,1
14521,22224,In vivo,BAO_0000218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d),,,U,Autocuration,A,,CHEMBL627578,,2367.0,Prostate gland,,0,1
14522,22224,In vivo,BAO_0000218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d)/biood,,,U,Autocuration,A,,CHEMBL627579,,2367.0,Prostate gland,,0,1
14523,22224,In vivo,BAO_0000218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d)/muscle,,,U,Autocuration,A,,CHEMBL627580,,2385.0,Muscle tissue,,0,1
14524,22224,In vivo,BAO_0000218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v),,,U,Autocuration,A,,CHEMBL627581,,2367.0,Prostate gland,,0,1
14525,22224,In vivo,BAO_0000218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v)/blood,,,U,Autocuration,A,,CHEMBL627582,,,,,0,1
14526,22224,In vivo,BAO_0000218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v)/muscle,,,U,Autocuration,A,,CHEMBL627583,,2385.0,Muscle tissue,,0,1
14527,22224,In vivo,BAO_0000218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in spleen,,,U,Autocuration,A,,CHEMBL627584,,2106.0,Spleen,,0,1
14528,22224,In vivo,BAO_0000218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d)/biood,,,U,Autocuration,A,,CHEMBL627585,,2367.0,Prostate gland,,0,1
14529,22224,In vivo,BAO_0000218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d)/muscle,,,U,Autocuration,A,,CHEMBL627586,,2385.0,Muscle tissue,,0,1
14530,50597,In vivo,BAO_0000218,,,Biodistribution of the Radiolabeled FBWAY compound in rat Cerebellum at 30 min co-injected with 200 nmol of WAY 100635,,,N,Intermediate,A,10116.0,CHEMBL627587,,,,,1,1
14531,50597,In vivo,BAO_0000218,,,Biodistribution of the Radiolabeled FBWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,,,N,Intermediate,A,10116.0,CHEMBL627588,,,,,1,1
14532,50597,In vivo,BAO_0000218,,,Biodistribution of the Radiolabeled FBWAY compound in rat cortex at 30 min co-injected with 200 nmol of WAY 100635,,,N,Intermediate,A,10116.0,CHEMBL628250,,,,,1,1
14533,50597,In vivo,BAO_0000218,,,Biodistribution of the Radiolabeled FBWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,,,N,Intermediate,A,10116.0,CHEMBL628251,,,,,1,1
14534,50597,In vivo,BAO_0000218,,,Biodistribution of the Radiolabeled FBWAY compound in rat hippocampus at 30 min co-injected with 200 nmol of WAY 100635,,,N,Intermediate,A,10116.0,CHEMBL628252,,10000000.0,Hippocampus,,1,1
14535,50597,In vivo,BAO_0000218,,,Biodistribution of the Radiolabeled FBWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,,,N,Intermediate,A,10116.0,CHEMBL628253,,10000000.0,Hippocampus,,1,1
14536,50597,In vivo,BAO_0000218,,,Biodistribution of the Radiolabeled FBWAY compound in rat hypothalamus at 30 min co-injected with 200 nmol of WAY 100635,,,N,Intermediate,A,10116.0,CHEMBL628254,,1898.0,Hypothalamus,,1,1
14537,50597,In vivo,BAO_0000218,,,Biodistribution of the Radiolabeled FBWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635,,,N,Intermediate,A,10116.0,CHEMBL877493,,1898.0,Hypothalamus,,1,1
14538,50597,In vivo,BAO_0000218,,,Biodistribution of the Radiolabeled FCWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,,,N,Intermediate,A,10116.0,CHEMBL628255,,,,,1,1
14539,50597,In vivo,BAO_0000218,,,Biodistribution of the Radiolabeled FCWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,,,N,Intermediate,A,10116.0,CHEMBL628256,,,,,1,1
14540,50597,In vivo,BAO_0000218,,,Biodistribution of the Radiolabeled FCWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,,,N,Intermediate,A,10116.0,CHEMBL628257,,10000000.0,Hippocampus,,1,1
14541,50597,In vivo,BAO_0000218,,,Biodistribution of the Radiolabeled FCWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635,,,N,Intermediate,A,10116.0,CHEMBL628258,,1898.0,Hypothalamus,,1,1
14542,50597,In vivo,BAO_0000218,,,Biodistribution of the Radiolabeled MeFBWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,,,N,Intermediate,A,10116.0,CHEMBL628259,,,,,1,1
14543,50597,In vivo,BAO_0000218,,,Biodistribution of the Radiolabeled MeFBWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,,,N,Intermediate,A,10116.0,CHEMBL628429,,,,,1,1
14544,50597,In vivo,BAO_0000218,,,Biodistribution of the Radiolabeled MeFBWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,,,N,Intermediate,A,10116.0,CHEMBL626862,,10000000.0,Hippocampus,,1,1
14545,50597,In vivo,BAO_0000218,,,Biodistribution of the Radiolabeled MeFBWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635; Not determined,,,N,Intermediate,A,10116.0,CHEMBL626863,,1898.0,Hypothalamus,,1,1
14546,50597,In vivo,BAO_0000218,,,Biodistribution of the [11C]-radiolabeled compound in rat cerebellum,,,N,Intermediate,A,10116.0,CHEMBL625886,,2037.0,Cerebellum,,1,1
14547,50597,In vivo,BAO_0000218,,,Biodistribution of the [11C]-radiolabeled compound in rat cerebellum co-injected with 50 nM of WAY 100635.,,,N,Intermediate,A,10116.0,CHEMBL625887,,2037.0,Cerebellum,,1,1
14548,50597,In vivo,BAO_0000218,,,Biodistribution of the [11C]-radiolabeled compound in rat cortex,,,N,Intermediate,A,10116.0,CHEMBL625888,,,,,1,1
14549,50597,In vivo,BAO_0000218,,,Biodistribution of the [11C]-radiolabeled compound in rat cortex co-injected with 50 nM of WAY 100635.,,,N,Intermediate,A,10116.0,CHEMBL625889,,,,,1,1
14550,50597,In vivo,BAO_0000218,,,Biodistribution of the [11C]-radiolabeled compound in rat hippocampus,,,N,Intermediate,A,10116.0,CHEMBL625890,,10000000.0,Hippocampus,,1,1
14551,50597,In vivo,BAO_0000218,,,Biodistribution of the [11C]-radiolabeled compound in rat hippocampus co-injected with 50 nM of WAY 100635.,,,N,Intermediate,A,10116.0,CHEMBL625891,,10000000.0,Hippocampus,,1,1
14552,50597,In vivo,BAO_0000218,,,Biodistribution of the [11C]-radiolabeled compound in rat hypothalamus,,,N,Intermediate,A,10116.0,CHEMBL625892,,1898.0,Hypothalamus,,1,1
14553,50597,In vivo,BAO_0000218,,,Biodistribution of the [11C]-radiolabeled compound in rat hypothalamus co-injected with 50 nM of WAY 100635.,,,N,Intermediate,A,10116.0,CHEMBL625893,,1898.0,Hypothalamus,,1,1
14554,50597,In vivo,BAO_0000218,,,Biodistribution of the [18F]-radiolabeled compound in rat cerebellum,,,N,Intermediate,A,10116.0,CHEMBL625894,,2037.0,Cerebellum,,1,1
14555,50597,In vivo,BAO_0000218,,,Biodistribution of the [18F]-radiolabeled compound in rat cortex,,,N,Intermediate,A,10116.0,CHEMBL625895,,,,,1,1
14556,22224,,BAO_0000019,,,Reaction rate parameter value for phosphate with transfer with respect to ATP,,,U,Autocuration,A,,CHEMBL625896,,,,,0,1
14557,22224,,BAO_0000019,,,"Tested for hydrolysis in presence of boric acid, dissociation constant was evaluated at the pH 8.5(Apparent inhibition constant)",,,U,Autocuration,A,,CHEMBL625897,,,,,0,1
14558,22224,,BAO_0000019,,,"Tested for hydrolysis in presence of boric acid, dissociation constant was evaluated at the pH 9.5(Apparent inhibition constant)",,,U,Autocuration,A,,CHEMBL625898,,,,,0,1
14559,22224,,BAO_0000019,,,"Tested for hydrolysis in presence of phenylboronic acid, dissociation constant was evaluated at the pH 9.5(Apparent inhibition constant)",,,U,Autocuration,A,,CHEMBL625899,,,,,0,1
14560,22224,,BAO_0000019,,,Reaction rate parameter value for phosphate with transfer with respect to ATP,,,U,Autocuration,A,,CHEMBL626124,,,,,0,1
14561,50212,,BAO_0000218,,,Ability to inhibit Escherichia coli adenylate kinase II activity expressed as half maximal velocity,,,N,Intermediate,A,562.0,CHEMBL628500,,,,,1,1
14562,50597,,BAO_0000218,,,"Ability to inhibit rat adenylate kinase II, activity expressed as half-maximal velocity",,,N,Intermediate,A,10116.0,CHEMBL857856,,,,,1,1
14563,50597,,BAO_0000218,,,"Ability to inhibit rat adenylate kinase III, activity expressed as half-maximal velocity",,,N,Intermediate,A,10116.0,CHEMBL628501,,,,,1,1
14564,22224,,BAO_0000019,,,"Compound was evaluated for the Michaelis-Menten constant, Km in a generic protein phosphatase stopped assay system",,,U,Autocuration,A,,CHEMBL628502,,,,,0,1
14565,22224,,BAO_0000019,,,Kinetic parameter KM (nM) for the MAO-B catalyzed oxidation of the compound.,,,U,Autocuration,A,,CHEMBL628503,,,,,0,1
14566,22224,,BAO_0000019,,,Kinetic parameter KM at pH 7.4 and 37 degree Centigrade,,,U,Autocuration,A,,CHEMBL628504,,,,,0,1
14567,22224,,BAO_0000019,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as KM; Not determined",,,U,Autocuration,A,,CHEMBL628505,,,,,0,1
14568,22224,,BAO_0000019,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as KM",,,U,Autocuration,A,,CHEMBL874452,,,,,0,1
14569,22224,,BAO_0000019,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as KM; Not determined",,,U,Autocuration,A,,CHEMBL628506,,,,,0,1
14570,22224,,BAO_0000019,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as KM; Not determined",,,U,Autocuration,A,,CHEMBL628507,,,,,0,1
14571,22224,,BAO_0000019,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as KM",,,U,Autocuration,A,,CHEMBL628508,,,,,0,1
14572,22224,,BAO_0000019,,,Michaelis constant (KM) was evaluated,,,U,Autocuration,A,,CHEMBL628509,,,,,0,1
14573,22224,,BAO_0000019,,,Reaction rate parameter value for phosphate with transfer with respect to ATP,,,U,Autocuration,A,,CHEMBL628510,,,,,0,1
14574,22224,,BAO_0000019,,,Substrate concentration for half maximal velocity was reported for rat hexokinase I,,,U,Autocuration,B,,CHEMBL628511,,,,,0,1
14575,22224,,BAO_0000019,,,Substrate concentration for half maximal velocity was reported for rat hexokinase II,,,U,Autocuration,B,,CHEMBL628512,,,,,0,1
14576,22224,,BAO_0000019,,,Substrate concentration for half maximal velocity was reported for rat hexokinase III,,,U,Autocuration,B,,CHEMBL628513,,,,,0,1
14577,22224,,BAO_0000019,,,Substrate concentration for half maximal velocity was reported for yeast hexokinase,,,U,Autocuration,B,,CHEMBL628514,,,,,0,1
14578,22224,,BAO_0000019,,,Pseudo-first-order rate constant for alkylation of NBP in 50% aqueous acetone at 66 degrees celsius with 50 uM and 25 uM of NBP.,,,U,Autocuration,A,,CHEMBL628515,,,,,0,1
14579,22224,,BAO_0000019,,,Rate constant for alkylation of 4-(4-nitrobenzyl)pyridine,,,U,Autocuration,A,,CHEMBL628516,,,,,0,1
14580,22224,,BAO_0000019,,,Bimolecular rate constant (KOH) at 25 degree C (m = 0.5),,,U,Autocuration,A,,CHEMBL628517,,,,,0,1
14581,22224,,BAO_0000019,,,its bimolecular rate constant (KOH) at 25 degree C (m = 0.5),,,U,Autocuration,A,,CHEMBL628518,,,,,0,1
14582,22224,,BAO_0000019,,,Acid dissociation constant evaluated towards Hematin mu-oxo dimer,,,U,Autocuration,A,,CHEMBL628519,,,,,0,1
14583,22224,,BAO_0000019,,,Acid dissociation constant evaluated towards Hematin mu-oxo dimer; Not available,,,U,Autocuration,A,,CHEMBL628520,,,,,0,1
14584,22224,,BAO_0000019,,,Binding constant was determined,,,U,Autocuration,A,,CHEMBL628521,,,,,0,1
14585,22224,,BAO_0000019,,,Alkylation of 4-(4-nitrobenzyl)pyridine (NBP) by the compound at a temperature of 66 degree Centigrade,,,U,Autocuration,A,,CHEMBL630443,,,,,0,1
14586,22224,,BAO_0000019,,,Alkylation of 4-(4-nitrobenzyl)pyridine (NBP) by the compound at a temperature of 66 degree centigrade; Not determined,,,U,Autocuration,A,,CHEMBL630444,,,,,0,1
14587,22224,,BAO_0000019,,,Rate constant with triethylamine at 30 degree C in 0.1 M potassium chloride was expressed as Kamine,,,U,Autocuration,A,,CHEMBL857732,,,,,0,1
14588,22224,,BAO_0000100,,,Octanol-water apparent distribution coefficient measured in TRIS buffer at a pH 7.4.,,,U,Autocuration,P,,CHEMBL630445,,,,,0,1
14589,22224,,BAO_0000019,,,Catalytic rate constant of the compound,,,U,Autocuration,A,,CHEMBL630446,,,,,0,1
14590,22224,,BAO_0000019,,,inactivation rate constant calculated from experimental IC50 value for dipeptidyl peptidase IV inhibition,,,U,Autocuration,B,,CHEMBL630447,,,,,0,1
14591,22224,,BAO_0000019,,,Catalytic constant expressed as Kinetic behavior of enzyme (PicK/6-His),,,U,Autocuration,A,,CHEMBL630448,,,,,0,1
14592,22224,,BAO_0000019,,,Catalytic rate constant against phospholipase A2 was determined,,,U,Autocuration,A,,CHEMBL630449,,,,,0,1
14593,22224,,BAO_0000019,,,"Compound was evaluated for catalytic constant, Kcat",,,U,Autocuration,A,,CHEMBL630450,,,,,0,1
14594,22224,,BAO_0000019,,,Compound was tested for hydrolysis by acetylcholinesterase and the kinetic constant (kcat) which is a first-order rate constant was determined,,,U,Autocuration,A,,CHEMBL630451,,,,,0,1
14595,22224,,BAO_0000019,,,Kcat calculated from 0.693/T1/2,,,U,Autocuration,A,,CHEMBL630452,,,,,0,1
14596,22224,,BAO_0000019,,,Kcat was determined,,,U,Autocuration,A,,CHEMBL630453,,,,,0,1
14597,22224,,BAO_0000019,,,Kcat against class A PCI beta-lactamase catalyzed lactone hydrolysis,,,U,Autocuration,A,,CHEMBL630454,,,,,0,1
14598,22224,,BAO_0000019,,,Kcat against class A TEM beta-lactamase catalyzed lactone hydrolysis,,,U,Autocuration,A,,CHEMBL630455,,,,,0,1
14599,22224,,BAO_0000019,,,Kcat against class C P99 beta-lactamase catalyzed lactone hydrolysis,,,U,Autocuration,A,,CHEMBL631487,,,,,0,1
14600,22224,,BAO_0000019,,,Kcat value was determined,,,U,Autocuration,A,,CHEMBL631488,,,,,0,1
14601,22224,,BAO_0000019,,,Kinetic constant for the hydrolysis by the catalyst CPA was evaluated,,,U,Autocuration,A,,CHEMBL876440,,,,,0,1
14602,22224,,BAO_0000019,,,Kinetic constant for the hydrolysis by the catalyst McAbIIF9D8 was evaluated,,,U,Autocuration,A,,CHEMBL631489,,,,,0,1
14603,22224,,BAO_0000019,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as Kcat; Not determined",,,U,Autocuration,A,,CHEMBL857742,,,,,0,1
14604,22224,,BAO_0000019,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat",,,U,Autocuration,A,,CHEMBL631490,,,,,0,1
14605,22224,,BAO_0000019,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as Kcat; Not determined",,,U,Autocuration,A,,CHEMBL631491,,,,,0,1
14606,22224,,BAO_0000019,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as Kcat; Not determined",,,U,Autocuration,A,,CHEMBL631492,,,,,0,1
14607,22224,,BAO_0000019,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat",,,U,Autocuration,A,,CHEMBL631493,,,,,0,1
14608,22224,,BAO_0000019,,,Kinetic parameter for rate of conversion to PABA was determined,,,U,Autocuration,A,,CHEMBL631494,,,,,0,1
14609,22224,,BAO_0000019,,,Rate acceleration expressed as ratio of Kcat to Kuncat was evaluated,,,U,Autocuration,A,,CHEMBL631495,,,,,0,1
14610,50597,,BAO_0000218,,,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 48-72 hr",,,N,Intermediate,A,10116.0,CHEMBL631496,,1988.0,Feces,,1,1
14611,50597,,BAO_0000218,,,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 0-24 hr",,,N,Intermediate,A,10116.0,CHEMBL631497,,1088.0,Urine,,1,1
14612,50597,,BAO_0000218,,,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 24-48 hr",,,N,Intermediate,A,10116.0,CHEMBL631498,,1088.0,Urine,,1,1
14613,50597,,BAO_0000218,,,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 0-24 hr",,,N,Intermediate,A,10116.0,CHEMBL629776,,1088.0,Urine,,1,1
14614,50597,,BAO_0000218,,,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 24-48 hr",,,N,Intermediate,A,10116.0,CHEMBL629777,,1088.0,Urine,,1,1
14615,50597,,BAO_0000218,,,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 48-72 hr",,,N,Intermediate,A,10116.0,CHEMBL629778,,1088.0,Urine,,1,1
14616,50597,,BAO_0000218,,,Cumulative dose excreted after intraduodenal administration at 0-0.5 hours in rats,,,N,Intermediate,A,10116.0,CHEMBL630456,,,,,1,1
14617,50597,,BAO_0000218,,,Cumulative dose excreted after intraduodenal administration at 0.5-1.0 hours in rats,,,N,Intermediate,A,10116.0,CHEMBL630457,,,,,1,1
14618,50597,,BAO_0000218,,,Cumulative dose excreted after intraduodenal administration at 1.0-1.5 hours in rats,,,N,Intermediate,A,10116.0,CHEMBL630458,,,,,1,1
14619,50597,,BAO_0000218,,,Cumulative dose excreted after intraduodenal administration at 1.5-2.0 hours in rats,,,N,Intermediate,A,10116.0,CHEMBL630459,,,,,1,1
14620,50597,,BAO_0000218,,,Cumulative dose excreted after intraduodenal administration at 2-3 hours in rats,,,N,Intermediate,A,10116.0,CHEMBL630460,,,,,1,1
14621,50597,,BAO_0000218,,,Cumulative dose excreted after intraduodenal administration at 3-4 hours in rats,,,N,Intermediate,A,10116.0,CHEMBL876550,,,,,1,1
14622,50597,,BAO_0000218,,,Cumulative dose excreted after intraduodenal administration at 4-6 hours in rats,,,N,Intermediate,A,10116.0,CHEMBL630461,,,,,1,1
14623,50597,,BAO_0000218,,,Cumulative dose excreted after intraduodenal administration at 6-8 hours in rats,,,N,Intermediate,A,10116.0,CHEMBL630462,,,,,1,1
14624,50597,,BAO_0000218,,,Cumulative dose excreted after intraduodenal administration at 8-24 hours in rats,,,N,Intermediate,A,10116.0,CHEMBL630463,,,,,1,1
14625,50597,,BAO_0000218,,,Cumulative dose excreted after intravenous administration at 0-0.5 hours in rats,,,N,Intermediate,A,10116.0,CHEMBL630464,,,,,1,1
14626,50597,,BAO_0000218,,,Cumulative dose excreted after intravenous administration at 0.5-1 hours in rats,,,N,Intermediate,A,10116.0,CHEMBL630465,,,,,1,1
14627,50597,,BAO_0000218,,,Cumulative dose excreted after intravenous administration at 1.0-1.5 hours in rats,,,N,Intermediate,A,10116.0,CHEMBL630466,,,,,1,1
14628,50597,,BAO_0000218,,,Cumulative dose excreted after intravenous administration at 1.5-2 hours in rats,,,N,Intermediate,A,10116.0,CHEMBL630467,,,,,1,1
14629,50597,,BAO_0000218,,,Cumulative dose excreted after intravenous administration at 2-3 hours in rats,,,N,Intermediate,A,10116.0,CHEMBL630633,,,,,1,1
14630,50597,,BAO_0000218,,,Cumulative dose excreted after intravenous administration at 3-4 hours in rats,,,N,Intermediate,A,10116.0,CHEMBL630634,,,,,1,1
14631,50597,,BAO_0000218,,,Cumulative dose excreted after intravenous administration at 4-6 hours in rats,,,N,Intermediate,A,10116.0,CHEMBL630635,,,,,1,1
14632,50597,,BAO_0000218,,,Cumulative dose excreted after intravenous administration at 6-8 hours in rats,,,N,Intermediate,A,10116.0,CHEMBL630636,,,,,1,1
14633,50597,,BAO_0000218,,,Cumulative dose excreted after intravenous administration at 8-24 hours in rats,,,N,Intermediate,A,10116.0,CHEMBL630637,,,,,1,1
14634,50592,,BAO_0000218,,,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated (total)",,,N,Intermediate,A,9986.0,CHEMBL630638,,1988.0,Feces,,1,1
14635,50592,,BAO_0000218,,,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 0-24 h",,,N,Intermediate,A,9986.0,CHEMBL630639,,1988.0,Feces,,1,1
14636,50592,,BAO_0000218,,,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 24-48 h",,,N,Intermediate,A,9986.0,CHEMBL630640,,1988.0,Feces,,1,1
14637,50592,,BAO_0000218,,,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 48-72 h",,,N,Intermediate,A,9986.0,CHEMBL876551,,1988.0,Feces,,1,1
14638,50592,,BAO_0000218,,,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated (total)",,,N,Intermediate,A,9986.0,CHEMBL630641,,1088.0,Urine,,1,1
14639,50592,,BAO_0000218,,,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 0-6 h",,,N,Intermediate,A,9986.0,CHEMBL630642,,1088.0,Urine,,1,1
14640,50592,,BAO_0000218,,,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 24-48 h",,,N,Intermediate,A,9986.0,CHEMBL630643,,1088.0,Urine,,1,1
14641,50592,,BAO_0000218,,,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 48-72 h",,,N,Intermediate,A,9986.0,CHEMBL630644,,1088.0,Urine,,1,1
14642,50592,,BAO_0000218,,,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 6-24 h",,,N,Intermediate,A,9986.0,CHEMBL630645,,1088.0,Urine,,1,1
14643,50592,,BAO_0000218,,,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated (total)",,,N,Intermediate,A,9986.0,CHEMBL625599,,1988.0,Feces,,1,1
14644,50592,,BAO_0000218,,,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 0-24 h",,,N,Intermediate,A,9986.0,CHEMBL625600,,1988.0,Feces,,1,1
14645,50592,,BAO_0000218,,,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 24-48 h",,,N,Intermediate,A,9986.0,CHEMBL625601,,1988.0,Feces,,1,1
14646,50592,,BAO_0000218,,,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 48-72 h",,,N,Intermediate,A,9986.0,CHEMBL625602,,1988.0,Feces,,1,1
14647,50592,,BAO_0000218,,,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated (total)",,,N,Intermediate,A,9986.0,CHEMBL627470,,1088.0,Urine,,1,1
14648,50592,,BAO_0000218,,,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 0-6 h",,,N,Intermediate,A,9986.0,CHEMBL627471,,1088.0,Urine,,1,1
14649,50592,,BAO_0000218,,,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 24-48 h",,,N,Intermediate,A,9986.0,CHEMBL627472,,1088.0,Urine,,1,1
14650,50592,,BAO_0000218,,,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 48-72 h",,,N,Intermediate,A,9986.0,CHEMBL627473,,1088.0,Urine,,1,1
14651,50592,,BAO_0000218,,,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 6-24 h",,,N,Intermediate,A,9986.0,CHEMBL627474,,1088.0,Urine,,1,1
14652,50597,In vivo,BAO_0000218,,,Biodistribution in rat blood post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,,N,Intermediate,A,10116.0,CHEMBL627475,,178.0,Blood,,1,1
14653,50597,In vivo,BAO_0000218,,,Biodistribution in rat blood post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,,N,Intermediate,A,10116.0,CHEMBL627476,,178.0,Blood,,1,1
14654,50588,,BAO_0000218,,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,,,N,Intermediate,A,9615.0,CHEMBL627477,,1088.0,Urine,,1,1
14655,50588,,BAO_0000218,,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,,,N,Intermediate,A,9615.0,CHEMBL627478,,1088.0,Urine,,1,1
14656,50588,,BAO_0000218,,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,,,N,Intermediate,A,9615.0,CHEMBL627479,,1088.0,Urine,,1,1
14657,50588,,BAO_0000218,,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,,,N,Intermediate,A,9615.0,CHEMBL627480,,1088.0,Urine,,1,1
14658,50588,,BAO_0000218,,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,,,N,Intermediate,A,9615.0,CHEMBL627481,,1088.0,Urine,,1,1
14659,50588,,BAO_0000218,,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,,,N,Intermediate,A,9615.0,CHEMBL627482,,1088.0,Urine,,1,1
14660,50588,,BAO_0000218,,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,,,N,Intermediate,A,9615.0,CHEMBL627483,,1088.0,Urine,,1,1
14661,50588,,BAO_0000218,,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,,,N,Intermediate,A,9615.0,CHEMBL875636,,1088.0,Urine,,1,1
14662,50588,,BAO_0000218,,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,,,N,Intermediate,A,9615.0,CHEMBL625764,,1088.0,Urine,,1,1
14663,50588,,BAO_0000218,,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 10.1 uM/Kg of drug,,,N,Intermediate,A,9615.0,CHEMBL625765,,1088.0,Urine,,1,1
14664,50588,,BAO_0000218,,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 102 uM/Kg of drug,,,N,Intermediate,A,9615.0,CHEMBL625766,,1088.0,Urine,,1,1
14665,50588,,BAO_0000218,,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 3.40 uM/Kg of drug,,,N,Intermediate,A,9615.0,CHEMBL625767,,1088.0,Urine,,1,1
14666,50588,,BAO_0000218,,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 3.76 uM/Kg of drug,,,N,Intermediate,A,9615.0,CHEMBL625768,,1088.0,Urine,,1,1
14667,50588,,BAO_0000218,,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 34.1 uM/Kg of drug,,,N,Intermediate,A,9615.0,CHEMBL625769,,1088.0,Urine,,1,1
14668,50588,,BAO_0000218,,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 50.8 uM/Kg of drug,,,N,Intermediate,A,9615.0,CHEMBL625770,,1088.0,Urine,,1,1
14669,50588,,BAO_0000218,,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 68.1 uM/Kg of drug,,,N,Intermediate,A,9615.0,CHEMBL625771,,1088.0,Urine,,1,1
14670,50588,,BAO_0000218,,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 9.060 uM/Kg of drug,,,N,Intermediate,A,9615.0,CHEMBL625772,,1088.0,Urine,,1,1
14671,50588,,BAO_0000218,,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 9.6 uM/Kg of drug,,,N,Intermediate,A,9615.0,CHEMBL625773,,1088.0,Urine,,1,1
14672,50597,,BAO_0000218,,,Total electrolytic excretion of sodium in urine of rats after intravenous administration of 7.94 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL625774,,1088.0,Urine,,1,1
14673,50597,,BAO_0000218,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 0 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL625775,,1088.0,Urine,,1,1
14674,50597,,BAO_0000218,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 1.01 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL625776,,1088.0,Urine,,1,1
14675,50597,,BAO_0000218,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 1.13 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL625777,,1088.0,Urine,,1,1
14676,50597,,BAO_0000218,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 10.1 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL625778,,1088.0,Urine,,1,1
14677,50597,,BAO_0000218,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 102 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL625779,,1088.0,Urine,,1,1
14678,50597,,BAO_0000218,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 105 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL625780,,1088.0,Urine,,1,1
14679,50597,,BAO_0000218,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 11.3 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL625781,,1088.0,Urine,,1,1
14680,50597,,BAO_0000218,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 113 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL875637,,1088.0,Urine,,1,1
14681,50597,,BAO_0000218,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 19.5 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL626473,,1088.0,Urine,,1,1
14682,50597,,BAO_0000218,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 195 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL626474,,1088.0,Urine,,1,1
14683,50597,,BAO_0000218,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 21.7 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL626475,,1088.0,Urine,,1,1
14684,50597,,BAO_0000218,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 217 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL626476,,1088.0,Urine,,1,1
14685,50597,,BAO_0000218,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 23.9 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL634397,,1088.0,Urine,,1,1
14686,50597,,BAO_0000218,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 239 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL626477,,1088.0,Urine,,1,1
14687,50597,,BAO_0000218,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 24.9 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL631069,,1088.0,Urine,,1,1
14688,50597,,BAO_0000218,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 249 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL631070,,1088.0,Urine,,1,1
14689,50597,,BAO_0000218,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 25.9 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL631071,,1088.0,Urine,,1,1
14690,50597,,BAO_0000218,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 259 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL631072,,1088.0,Urine,,1,1
14691,50597,,BAO_0000218,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 26.5 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL631073,,1088.0,Urine,,1,1
14692,50597,,BAO_0000218,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 265 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL631074,,1088.0,Urine,,1,1
14693,50597,,BAO_0000218,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 27 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL631075,,1088.0,Urine,,1,1
14694,50597,,BAO_0000218,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 27.9 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL631725,,1088.0,Urine,,1,1
14695,50597,,BAO_0000218,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 270 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL631726,,1088.0,Urine,,1,1
14696,50597,,BAO_0000218,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 279 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL631727,,1088.0,Urine,,1,1
14697,50597,,BAO_0000218,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 28.2 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL631728,,1088.0,Urine,,1,1
14698,50597,,BAO_0000218,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 28.9 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL631729,,1088.0,Urine,,1,1
14699,50597,,BAO_0000218,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 282 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL631730,,1088.0,Urine,,1,1
14700,50597,,BAO_0000218,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 289 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL631731,,1088.0,Urine,,1,1
14701,50597,,BAO_0000218,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 3.40 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL631910,,1088.0,Urine,,1,1
14702,50597,In vivo,BAO_0000218,,,Biodistribution of the [18F]-radiolabeled compound in rat hippocampus,,,N,Intermediate,A,10116.0,CHEMBL631911,,10000000.0,Hippocampus,,1,1
14703,50597,In vivo,BAO_0000218,,,Biodistribution of the [18F]-radiolabeled compound in rat hypothalamus,,,N,Intermediate,A,10116.0,CHEMBL631912,,1898.0,Hypothalamus,,1,1
14704,50597,In vivo,BAO_0000218,,,Biodistribution of the [18F]-radiolabeled compound in rat hypothalamus; Not determined,,,N,Intermediate,A,10116.0,CHEMBL631913,,1898.0,Hypothalamus,,1,1
14705,50597,In vivo,BAO_0000218,,,Biodistribution in blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL631914,,178.0,Blood,,1,1
14706,50597,In vivo,BAO_0000218,,,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL631915,,178.0,Blood,,1,1
14707,50597,In vivo,BAO_0000218,,,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,,N,Intermediate,A,10116.0,CHEMBL875778,,178.0,Blood,,1,1
14708,50597,In vivo,BAO_0000218,,,Biodistribution in blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL631916,,178.0,Blood,,1,1
14709,50597,In vivo,BAO_0000218,,,Biodistribution in blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL631917,,178.0,Blood,,1,1
14710,50597,In vivo,BAO_0000218,,,Biodistribution in blood of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL631918,,178.0,Blood,,1,1
14711,50597,In vivo,BAO_0000218,,,Biodistribution in blood of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL631919,,178.0,Blood,,1,1
14712,50597,In vivo,BAO_0000218,,,Biodistribution in blood of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,,N,Intermediate,A,10116.0,CHEMBL631920,,178.0,Blood,,1,1
14713,50597,In vivo,BAO_0000218,,,Biodistribution in blood of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL631921,,178.0,Blood,,1,1
14714,50597,In vivo,BAO_0000218,,,Biodistribution in blood of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL631922,,178.0,Blood,,1,1
14715,50597,In vivo,BAO_0000218,,,Biodistribution in blood of immature femalee rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,,N,Intermediate,A,10116.0,CHEMBL631923,,178.0,Blood,,1,1
14716,50597,In vivo,BAO_0000218,,,Biodistribution in fat of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL631924,,,,,1,1
14717,50597,In vivo,BAO_0000218,,,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL630234,,,,,1,1
14718,50597,In vivo,BAO_0000218,,,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,,N,Intermediate,A,10116.0,CHEMBL630235,,,,,1,1
14719,50597,In vivo,BAO_0000218,,,Biodistribution in fat of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL630236,,,,,1,1
14720,50597,In vivo,BAO_0000218,,,Biodistribution in fat of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL630237,,,,,1,1
14721,50597,In vivo,BAO_0000218,,,Biodistribution in fat of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL630238,,,,,1,1
14722,50597,In vivo,BAO_0000218,,,Biodistribution in fat of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL630239,,,,,1,1
14723,50597,In vivo,BAO_0000218,,,Biodistribution in fat of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,,N,Intermediate,A,10116.0,CHEMBL630303,,,,,1,1
14724,50597,In vivo,BAO_0000218,,,Biodistribution in fat of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL630304,,,,,1,1
14725,50597,In vivo,BAO_0000218,,,Biodistribution in fat of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL630305,,,,,1,1
14726,50597,In vivo,BAO_0000218,,,Biodistribution in kidney of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL630306,,2113.0,Kidney,,1,1
14727,50597,In vivo,BAO_0000218,,,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL630307,,2113.0,Kidney,,1,1
14728,50597,In vivo,BAO_0000218,,,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,,N,Intermediate,A,10116.0,CHEMBL630308,,2113.0,Kidney,,1,1
14729,50597,In vivo,BAO_0000218,,,Biodistribution in kidney of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL630309,,2113.0,Kidney,,1,1
14730,50597,In vivo,BAO_0000218,,,Biodistribution in kidney of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL629309,,2113.0,Kidney,,1,1
14731,50597,In vivo,BAO_0000218,,,Biodistribution in kidney of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL629993,,2113.0,Kidney,,1,1
14732,50597,In vivo,BAO_0000218,,,Biodistribution in kidney of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL629994,,2113.0,Kidney,,1,1
14733,50597,In vivo,BAO_0000218,,,Biodistribution in kidney of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,,N,Intermediate,A,10116.0,CHEMBL629995,,2113.0,Kidney,,1,1
14734,50597,In vivo,BAO_0000218,,,Biodistribution in kidney of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL631993,,2113.0,Kidney,,1,1
14735,50597,In vivo,BAO_0000218,,,Biodistribution in kidney of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL631994,,2113.0,Kidney,,1,1
14736,50597,In vivo,BAO_0000218,,,Biodistribution in kidney of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL631995,,2113.0,Kidney,,1,1
14737,50597,In vivo,BAO_0000218,,,Biodistribution in liver of Iimmature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,,N,Intermediate,A,10116.0,CHEMBL631996,,2107.0,Liver,,1,1
14738,50597,In vivo,BAO_0000218,,,Biodistribution in liver of Iimmature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL631997,,2107.0,Liver,,1,1
14739,50597,In vivo,BAO_0000218,,,Biodistribution in liver of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL631998,,2107.0,Liver,,1,1
14740,50597,In vivo,BAO_0000218,,,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL631999,,2107.0,Liver,,1,1
14741,50597,In vivo,BAO_0000218,,,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,,N,Intermediate,A,10116.0,CHEMBL632000,,2107.0,Liver,,1,1
14742,50597,In vivo,BAO_0000218,,,Biodistribution in liver of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL632001,,2107.0,Liver,,1,1
14743,50597,In vivo,BAO_0000218,,,Biodistribution in liver of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL874424,,2107.0,Liver,,1,1
14744,50597,In vivo,BAO_0000218,,,Biodistribution in liver of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL632002,,2107.0,Liver,,1,1
14745,50597,In vivo,BAO_0000218,,,Biodistribution in liver of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL632003,,2107.0,Liver,,1,1
14746,22224,,BAO_0000019,,,Rate acceleration expressed as ratio of Kcat to Kuncat was evaluated,,,U,Autocuration,A,,CHEMBL632004,,,,,0,1
14747,22224,,BAO_0000019,,,Compound was tested for amidase rate in the presence of N62C fully characterised enzyme,,,U,Autocuration,A,,CHEMBL632005,,,,,0,1
14748,22224,,BAO_0000019,,,Compound was tested for amidase rate in the presence of N62C screen enzyme,,,U,Autocuration,A,,CHEMBL632006,,,,,0,1
14749,22224,,BAO_0000019,,,Compound was tested for amidase rate in the presence of S166C fully characterised enzyme,,,U,Autocuration,A,,CHEMBL632007,,,,,0,1
14750,22224,,BAO_0000019,,,Compound was tested for amidase rate in the presence of S166C screen enzyme,,,U,Autocuration,A,,CHEMBL632008,,,,,0,1
14751,22224,,BAO_0000019,,,Compound was tested for esterase rate in the presence of N62C fully characterised enzyme,,,U,Autocuration,A,,CHEMBL632009,,,,,0,1
14752,22224,,BAO_0000019,,,Compound was tested for esterase rate in the presence of N62C screen enzyme,,,U,Autocuration,A,,CHEMBL632010,,,,,0,1
14753,22224,,BAO_0000019,,,Compound was tested for esterase rate in the presence of S166C fully characterised enzyme,,,U,Autocuration,A,,CHEMBL857750,,,,,0,1
14754,22224,,BAO_0000019,,,Compound was tested for esterase rate in the presence of S166C screen enzyme,,,U,Autocuration,A,,CHEMBL632011,,,,,0,1
14755,22224,,BAO_0000019,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",,,U,Autocuration,A,,CHEMBL632012,,,,,0,1
14756,22224,,BAO_0000019,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",,,U,Autocuration,A,,CHEMBL632013,,,,,0,1
14757,22224,,BAO_0000019,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as Kcat/KM",,,U,Autocuration,A,,CHEMBL632014,,,,,0,1
14758,22224,,BAO_0000019,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",,,U,Autocuration,A,,CHEMBL629622,,,,,0,1
14759,22224,,BAO_0000019,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",,,U,Autocuration,A,,CHEMBL629623,,,,,0,1
14760,22224,,BAO_0000019,,,"Rate constant at 30 degree C in phosphate buffer pH 7.1, 0.5 % acetonitrile was expressed as Kcat/KM",,,U,Autocuration,A,,CHEMBL629624,,,,,0,1
14761,22224,,BAO_0000019,,,Ratio of Kcat to that of Km was determined,,,U,Autocuration,A,,CHEMBL629625,,,,,0,1
14762,22224,,BAO_0000019,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat/Kuncat",,,U,Autocuration,A,,CHEMBL629626,,,,,0,1
14763,22224,,BAO_0000019,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat/Kuncat",,,U,Autocuration,A,,CHEMBL629627,,,,,0,1
14764,22224,,BAO_0000019,,,"Compound was evaluated for constant, Kd",,,U,Autocuration,A,,CHEMBL629628,,,,,0,1
14765,22224,,BAO_0000019,,,Deacylation rate constant(Kd fast) was determined by proflavin displacement assay,,,U,Autocuration,A,,CHEMBL629629,,,,,0,1
14766,22224,,BAO_0000019,,,Deacylation rate constant(Kd slow) was determined by proflavin displacement assay,,,U,Autocuration,A,,CHEMBL629630,,,,,0,1
14767,22224,,BAO_0000019,,,Dissociation Constant of compound determined,,,U,Autocuration,A,,CHEMBL856030,,,,,0,1
14768,22224,,BAO_0000019,,,Dissociation constant for the binding of compound to PDZ3 from PSD-95 was determined,,,U,Autocuration,B,,CHEMBL629631,,,,,0,1
14769,22224,,BAO_0000019,,,Dissociation constant for the binding of compound to PDZ3 from PSD-95 was determined; No data,,,U,Autocuration,B,,CHEMBL629632,,,,,0,1
14770,22224,,BAO_0000100,,,Dissociation constant of compound with Fructose was determined,,,U,Autocuration,P,,CHEMBL629633,,,,,0,1
14771,22224,,BAO_0000100,,,Dissociation constant of compound with Fructose was determined; Not determined,,,U,Autocuration,P,,CHEMBL629634,,,,,0,1
14772,22224,,BAO_0000100,,,Dissociation constant of compound with Lactulose was determined,,,U,Autocuration,P,,CHEMBL629635,,,,,0,1
14773,22224,,BAO_0000100,,,Dissociation constant of compound with Lactulose was determined; Not determined,,,U,Autocuration,P,,CHEMBL629636,,,,,0,1
14774,22224,,BAO_0000100,,,Dissociation constant of the Compound,,,U,Autocuration,P,,CHEMBL629637,,,,,0,1
14775,22224,,BAO_0000100,,,Dissociation constant by non-linear regression analysis,,,U,Autocuration,P,,CHEMBL629638,,,,,0,1
14776,22224,,BAO_0000100,,,Dissociation constant was determined,,,U,Autocuration,P,,CHEMBL629639,,,,,0,1
14777,22224,,BAO_0000100,,,Dissociation constant of the compound; value ranges from 0.81-1.2 nM,,,U,Autocuration,P,,CHEMBL629640,,,,,0,1
14778,22224,,BAO_0000100,,,Dissociation constant was determined,,,U,Autocuration,P,,CHEMBL629641,,,,,0,1
14779,22224,,BAO_0000100,,,Dissociation constant was determined,,,U,Autocuration,P,,CHEMBL631344,,,,,0,1
14780,50597,,BAO_0000218,,,Equilibrium dissociation constant based on membrane concentration in rat smooth muscle,,,N,Intermediate,A,10116.0,CHEMBL631345,,2385.0,Muscle tissue,,1,1
14781,22224,,BAO_0000019,,,The dissociation constant determined by fluorescence displacement assay,,,U,Autocuration,A,,CHEMBL631346,,,,,0,1
14782,22224,,BAO_0000019,,,kd value surface plasmon resonance (SPR) method,,,U,Autocuration,A,,CHEMBL631524,,,,,0,1
14783,50597,,BAO_0000218,,,Equilibrium dissociation constant based on aqueous concentration in rat smooth muscle,,,N,Intermediate,A,10116.0,CHEMBL631525,,2385.0,Muscle tissue,,1,1
14784,22224,,BAO_0000019,,,First dissociation constant of the binding of compound to V30M TTR,,,U,Autocuration,F,,CHEMBL631526,,,,,0,1
14785,22224,,BAO_0000019,,,Second dissociation constant of the binding of compound to V30M TTR,,,U,Autocuration,F,,CHEMBL631527,,,,,0,1
14786,22224,,BAO_0000019,,,"Compound was evaluated for equilibrium constant, Ke",,,U,Autocuration,A,,CHEMBL631528,,,,,0,1
14787,22224,,BAO_0000019,,,Equilibrium constant from the dorsal raphe and the ventromedial hypothalamus,,,U,Autocuration,A,,CHEMBL631529,,1898.0,Hypothalamus,,0,1
14788,22224,,BAO_0000019,,,Equilibrium constant from the dorsal raphe and the ventromedial hypothalamus; inactive,,,U,Autocuration,A,,CHEMBL631530,,1898.0,Hypothalamus,,0,1
14789,22224,,BAO_0000019,,,Keff is the effective biomolecular rate constant on VX for reactivation at pH 7.8 at 25 degree Centigrade,,,U,Autocuration,A,,CHEMBL631531,,,,,0,1
14790,22224,,BAO_0000019,,,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,,,U,Autocuration,A,,CHEMBL631532,,,,,0,1
14791,22224,,BAO_0000019,,,Keff is the effective biomolecular rate constant on sarin for reactivation at pH 7.8 at 25 degree Centigrade,,,U,Autocuration,A,,CHEMBL631533,,,,,0,1
14792,50594,,BAO_0000218,,,In vitro biotransformation of compound along with coformycin in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,,,N,Intermediate,A,10090.0,CHEMBL876552,,,,,1,1
14793,50594,,BAO_0000218,,,In vitro biotransformation of compound along with coformycin in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-A) analyte,,,N,Intermediate,A,10090.0,CHEMBL631534,,,,,1,1
14794,50594,,BAO_0000218,,,In vitro biotransformation of compound in mice brain homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,,,N,Intermediate,A,10090.0,CHEMBL631535,,,,,1,1
14795,50594,,BAO_0000218,,,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,,,N,Intermediate,A,10090.0,CHEMBL631536,,,,,1,1
14796,50594,,BAO_0000218,,,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-hypoxanthine(ara-H) analyte,,,N,Intermediate,A,10090.0,CHEMBL631537,,,,,1,1
14797,50594,,BAO_0000218,,,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-A) analyte,,,N,Intermediate,A,10090.0,CHEMBL631538,,,,,1,1
14798,50594,,BAO_0000218,,,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-H) analyte,,,N,Intermediate,A,10090.0,CHEMBL631539,,,,,1,1
14799,50594,,BAO_0000218,,,In vitro biotransformation of compound in mice serum 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,,,N,Intermediate,A,10090.0,CHEMBL631540,,,,,1,1
14800,50597,,BAO_0000218,,,Pharmacokinetic Parameter [Kel(1/h)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,,,N,Intermediate,A,10116.0,CHEMBL625637,,,,,1,1
14801,50597,,BAO_0000218,,,Pharmacokinetic parameter [Kel(1/h)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,,,N,Intermediate,A,10116.0,CHEMBL625638,,,,,1,1
14802,50597,,BAO_0000218,,,"The Kel value in female wistar rat at 100 mg/kg, p.o. dose",,,N,Intermediate,A,10116.0,CHEMBL625639,,,,,1,1
14803,50597,In vivo,BAO_0000218,,,Biodistribution in rat brain post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,,N,Intermediate,A,10116.0,CHEMBL625640,,955.0,Brain,,1,1
14804,50597,In vivo,BAO_0000218,,,Biodistribution in rat brain post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,,N,Intermediate,A,10116.0,CHEMBL625641,,955.0,Brain,,1,1
14805,50597,In vivo,BAO_0000218,,,Biodistribution in rat heart post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,,N,Intermediate,A,10116.0,CHEMBL625642,,948.0,Heart,,1,1
14806,50597,In vivo,BAO_0000218,,,Biodistribution in rat heart post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,,N,Intermediate,A,10116.0,CHEMBL625643,,948.0,Heart,,1,1
14807,50597,In vivo,BAO_0000218,,,Biodistribution in rat kidney post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,,N,Intermediate,A,10116.0,CHEMBL625644,,2113.0,Kidney,,1,1
14808,50597,In vivo,BAO_0000218,,,Biodistribution in rat kidney post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,,N,Intermediate,A,10116.0,CHEMBL625645,,2113.0,Kidney,,1,1
14809,50597,In vivo,BAO_0000218,,,Biodistribution in rat liver post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,,N,Intermediate,A,10116.0,CHEMBL625646,,2107.0,Liver,,1,1
14810,50597,In vivo,BAO_0000218,,,Biodistribution in rat liver post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,,N,Intermediate,A,10116.0,CHEMBL625647,,2107.0,Liver,,1,1
14811,50597,In vivo,BAO_0000218,,,Biodistribution in rat lung post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,,N,Intermediate,A,10116.0,CHEMBL625648,,2048.0,Lung,,1,1
14812,50597,In vivo,BAO_0000218,,,Biodistribution in rat lung post intravenous injection for 60 min of [99mTc]-TRODAT ligand expressed as percent dose per organ,,,N,Intermediate,A,10116.0,CHEMBL625649,,2048.0,Lung,,1,1
14813,50597,In vivo,BAO_0000218,,,Biodistribution in rat muscle post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,,N,Intermediate,A,10116.0,CHEMBL625650,,2385.0,Muscle tissue,,1,1
14814,50597,In vivo,BAO_0000218,,,Biodistribution in rat muscle post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,,N,Intermediate,A,10116.0,CHEMBL625651,,2385.0,Muscle tissue,,1,1
14815,50597,In vivo,BAO_0000218,,,Biodistribution in rat skin post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,,N,Intermediate,A,10116.0,CHEMBL625652,,14.0,Zone of skin,,1,1
14816,50597,In vivo,BAO_0000218,,,Biodistribution in rat skin post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,,N,Intermediate,A,10116.0,CHEMBL625653,,14.0,Zone of skin,,1,1
14817,50597,In vivo,BAO_0000218,,,Biodistribution in rat spleen post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,,N,Intermediate,A,10116.0,CHEMBL625654,,2106.0,Spleen,,1,1
14818,50597,In vivo,BAO_0000218,,,Biodistribution in rat spleen post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,,N,Intermediate,A,10116.0,CHEMBL625655,,2106.0,Spleen,,1,1
14819,50597,In vivo,BAO_0000218,,,Biodistribution of Compound in rat blood after 15 minutes of administration,,,N,Intermediate,A,10116.0,CHEMBL625656,,178.0,Blood,,1,1
14820,50597,In vivo,BAO_0000218,,,Biodistribution of Compound in rat blood after 2 minutes of administration,,,N,Intermediate,A,10116.0,CHEMBL625657,,178.0,Blood,,1,1
14821,50597,In vivo,BAO_0000218,,,Biodistribution of Compound in rat brain after 15 minutes of administration,,,N,Intermediate,A,10116.0,CHEMBL625658,,955.0,Brain,,1,1
14822,50597,In vivo,BAO_0000218,,,Biodistribution of Compound in rat brain after 2 minutes of administration,,,N,Intermediate,A,10116.0,CHEMBL625659,,955.0,Brain,,1,1
14823,50597,In vivo,BAO_0000218,,,Biodistribution of Compound in rat heart after 15 minutes of administration,,,N,Intermediate,A,10116.0,CHEMBL625660,,948.0,Heart,,1,1
14824,50597,In vivo,BAO_0000218,,,Biodistribution of Compound in rat heart after 2 minutes of administration,,,N,Intermediate,A,10116.0,CHEMBL625661,,948.0,Heart,,1,1
14825,50597,In vivo,BAO_0000218,,,Biodistribution of Compound in rat liver after 15 minutes of administration,,,N,Intermediate,A,10116.0,CHEMBL625662,,2107.0,Liver,,1,1
14826,50597,In vivo,BAO_0000218,,,Biodistribution of Compound in rat liver after 2 minutes of administration,,,N,Intermediate,A,10116.0,CHEMBL625663,,2107.0,Liver,,1,1
14827,50597,In vivo,BAO_0000218,,,Biodistribution of Compound in rat lung after 15 minutes of administration,,,N,Intermediate,A,10116.0,CHEMBL875621,,2048.0,Lung,,1,1
14828,50597,In vivo,BAO_0000218,,,Biodistribution of Compound in rat lung after 2 minutes of administration,,,N,Intermediate,A,10116.0,CHEMBL628382,,2048.0,Lung,,1,1
14829,50597,In vivo,BAO_0000218,,,Biodistribution of Compound in rat muscle after 15 minutes of administration,,,N,Intermediate,A,10116.0,CHEMBL628383,,2385.0,Muscle tissue,,1,1
14830,50597,In vivo,BAO_0000218,,,Biodistribution of Compound in rat muscle after 2 minutes of administration,,,N,Intermediate,A,10116.0,CHEMBL628384,,2385.0,Muscle tissue,,1,1
14831,50597,,BAO_0000218,,,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 2 mins,,,N,Intermediate,A,10116.0,CHEMBL628385,,,,,1,1
14832,50597,,BAO_0000218,,,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 30 mins,,,N,Intermediate,A,10116.0,CHEMBL875753,,,,,1,1
14833,50597,,BAO_0000218,,,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 60 mins,,,N,Intermediate,A,10116.0,CHEMBL628386,,,,,1,1
14834,50597,,BAO_0000218,,,Organ distribution in rat blood 2 minutes after intravenous injection,,,N,Intermediate,A,10116.0,CHEMBL628387,,,,,1,1
14835,50597,,BAO_0000218,,,Organ distribution in rat blood 2 hr after intravenous injection,,,N,Intermediate,A,10116.0,CHEMBL628388,,,,,1,1
14836,50597,,BAO_0000218,,,Organ distribution in rat blood 30 minutes after intravenous injection,,,N,Intermediate,A,10116.0,CHEMBL628389,,,,,1,1
14837,50597,,BAO_0000218,,,Organ distribution in rat blood 30 min after intravenous injection,,,N,Intermediate,A,10116.0,CHEMBL632756,,,,,1,1
14838,50597,,BAO_0000218,,,Organ distribution in rat brain 2 minutes after intravenous injection,,,N,Intermediate,A,10116.0,CHEMBL628390,,,,,1,1
14839,50597,,BAO_0000218,,,Organ distribution in rat brain 2 hr after intravenous injection,,,N,Intermediate,A,10116.0,CHEMBL631811,,,,,1,1
14840,50597,,BAO_0000218,,,Organ distribution in rat brain 30 minutes after intravenous injection,,,N,Intermediate,A,10116.0,CHEMBL631812,,,,,1,1
14841,50597,,BAO_0000218,,,Organ distribution in rat heart 2 minutes after intravenous injection,,,N,Intermediate,A,10116.0,CHEMBL631813,,,,,1,1
14842,50597,,BAO_0000218,,,Organ distribution in rat heart 2 hr after intravenous injection,,,N,Intermediate,A,10116.0,CHEMBL631814,,,,,1,1
14843,50597,,BAO_0000218,,,Organ distribution in rat heart 30 minutes after intravenous injection,,,N,Intermediate,A,10116.0,CHEMBL631815,,,,,1,1
14844,50597,,BAO_0000218,,,Organ distribution in rat kidney 2 minutes after intravenous injection,,,N,Intermediate,A,10116.0,CHEMBL631816,,,,,1,1
14845,50597,,BAO_0000218,,,Organ distribution in rat kidney 2 hr after intravenous injection,,,N,Intermediate,A,10116.0,CHEMBL875758,,,,,1,1
14846,50597,,BAO_0000218,,,Organ distribution in rat kidney 30 minutes after intravenous injection,,,N,Intermediate,A,10116.0,CHEMBL631817,,,,,1,1
14847,50597,,BAO_0000218,,,Organ distribution in rat liver 2 minutes after intravenous injection,,,N,Intermediate,A,10116.0,CHEMBL631818,,2107.0,Liver,,1,1
14848,50597,,BAO_0000218,,,Organ distribution in rat liver 2 hr after intravenous injection,,,N,Intermediate,A,10116.0,CHEMBL631819,,2107.0,Liver,,1,1
14849,50597,,BAO_0000218,,,Organ distribution in rat liver 30 minutes after intravenous injection,,,N,Intermediate,A,10116.0,CHEMBL631820,,2107.0,Liver,,1,1
14850,50597,,BAO_0000218,,,Organ distribution in rat lung 2 minutes after intravenous injection,,,N,Intermediate,A,10116.0,CHEMBL631821,,,,,1,1
14851,50597,,BAO_0000218,,,Organ distribution in rat lung 2 hr after intravenous injection,,,N,Intermediate,A,10116.0,CHEMBL631822,,,,,1,1
14852,50597,,BAO_0000218,,,Organ distribution in rat lung 30 minutes after intravenous injection,,,N,Intermediate,A,10116.0,CHEMBL631823,,,,,1,1
14853,50597,,BAO_0000218,,,Organ distribution in rat muscle 2 minutes after intravenous injection,,,N,Intermediate,A,10116.0,CHEMBL631824,,2385.0,Muscle tissue,,1,1
14854,50597,,BAO_0000218,,,Organ distribution in rat muscle 2 hr after intravenous injection,,,N,Intermediate,A,10116.0,CHEMBL631825,,2385.0,Muscle tissue,,1,1
14855,50597,,BAO_0000218,,,Organ distribution in rat muscle 30 minutes after intravenous injection,,,N,Intermediate,A,10116.0,CHEMBL631826,,2385.0,Muscle tissue,,1,1
14856,50594,In vivo,BAO_0000218,,,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Blood (B),,,N,Intermediate,A,10090.0,CHEMBL631827,,,,,1,1
14857,50594,In vivo,BAO_0000218,,,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Heart (H),,,N,Intermediate,A,10090.0,CHEMBL631828,,,,,1,1
14858,50594,In vivo,BAO_0000218,,,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Lung (L),,,N,Intermediate,A,10090.0,CHEMBL631829,,,,,1,1
14859,50597,,BAO_0000218,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 3.76 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL875759,,1088.0,Urine,,1,1
14860,50597,,BAO_0000218,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 30.20 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL631830,,1088.0,Urine,,1,1
14861,50597,,BAO_0000218,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 302 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL631831,,1088.0,Urine,,1,1
14862,50597,,BAO_0000218,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 31.6 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL631832,,1088.0,Urine,,1,1
14863,50597,,BAO_0000218,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 316 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL631833,,1088.0,Urine,,1,1
14864,50597,,BAO_0000218,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 32.4 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL631834,,1088.0,Urine,,1,1
14865,50597,,BAO_0000218,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 324 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL631835,,1088.0,Urine,,1,1
14866,50597,,BAO_0000218,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.0 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL631836,,1088.0,Urine,,1,1
14867,50597,,BAO_0000218,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.1 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL631837,,1088.0,Urine,,1,1
14868,50597,,BAO_0000218,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.8 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL631838,,1088.0,Urine,,1,1
14869,50597,,BAO_0000218,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 341 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL631839,,1088.0,Urine,,1,1
14870,50597,,BAO_0000218,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 348 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL631840,,1088.0,Urine,,1,1
14871,50597,,BAO_0000218,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 37.6 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL631841,,1088.0,Urine,,1,1
14872,50597,,BAO_0000218,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 58.4 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL631842,,1088.0,Urine,,1,1
14873,50597,,BAO_0000218,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 65.2 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL631843,,1088.0,Urine,,1,1
14874,50597,,BAO_0000218,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 71.6 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL631844,,1088.0,Urine,,1,1
14875,50597,,BAO_0000218,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 71.8 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL631845,,1088.0,Urine,,1,1
14876,50597,,BAO_0000218,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 74.8 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL631846,,1088.0,Urine,,1,1
14877,50597,,BAO_0000218,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 77.5 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL875760,,1088.0,Urine,,1,1
14878,50597,,BAO_0000218,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 79.4 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL632199,,1088.0,Urine,,1,1
14879,50597,,BAO_0000218,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 80.9 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL631847,,1088.0,Urine,,1,1
14880,50597,,BAO_0000218,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 83.8 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL631848,,1088.0,Urine,,1,1
14881,50597,,BAO_0000218,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 84.5 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL628707,,1088.0,Urine,,1,1
14882,50597,,BAO_0000218,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 84.7 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL628708,,1088.0,Urine,,1,1
14883,50597,,BAO_0000218,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 86.7 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL628709,,1088.0,Urine,,1,1
14884,50597,,BAO_0000218,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 86.9 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL628710,,1088.0,Urine,,1,1
14885,50597,,BAO_0000218,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 9.06 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL628711,,1088.0,Urine,,1,1
14886,50597,,BAO_0000218,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 90.6 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL628712,,1088.0,Urine,,1,1
14887,50597,,BAO_0000218,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 94.9 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL628713,,1088.0,Urine,,1,1
14888,50597,,BAO_0000218,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 97.1 uM/Kg of drug,,,N,Intermediate,A,10116.0,CHEMBL628714,,1088.0,Urine,,1,1
14889,50597,,BAO_0000218,,,"excretion rate in rats after the dose of 5 mg/kg intravenously, at the dose 4 hour Rate of biliary excretion; 0.06-0.15%/h",,,N,Intermediate,A,10116.0,CHEMBL628715,,,,,1,1
14890,22224,,BAO_0000019,,,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 3.75-120 uM,,,U,Autocuration,A,,CHEMBL629179,,,,,0,1
14891,22224,,BAO_0000019,,,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 30 uM,,,U,Autocuration,A,,CHEMBL629180,,,,,0,1
14892,22224,,BAO_0000019,,,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 7.5-120 uM,,,U,Autocuration,A,,CHEMBL875108,,,,,0,1
14893,22224,,BAO_0000019,,,Percent lipid extracted at 0.5 hr from adrenal cortex liver using CHCl3/CH3OH.,,,U,Autocuration,A,,CHEMBL629181,,1235.0,Adrenal cortex,,0,1
14894,22224,,BAO_0000019,,,Percent lipid extracted at 0.5 hr from adrenal cortex liver using CHCl3/CH3OH.,,,U,Autocuration,A,,CHEMBL629182,,1235.0,Adrenal cortex,,0,1
14895,22224,,BAO_0000019,,,Percent lipid extracted at 0.5 hr from liver plasma using CHCl3/CH3OH.,,,U,Autocuration,A,,CHEMBL629183,,,,,0,1
14896,22224,,BAO_0000019,,,Percent lipid extracted at 0.5 hr from liver using CHCl3/CH3OH.,,,U,Autocuration,A,,CHEMBL629184,,,,,0,1
14897,22224,,BAO_0000019,,,Percent lipid extracted at 24 hours from adrenal cortex using CHCl3/CH3OH.,,,U,Autocuration,A,,CHEMBL629185,,1235.0,Adrenal cortex,,0,1
14898,22224,,BAO_0000019,,,Percent lipid extracted at 24 hours from adrenal cortex liver using CHCl3/CH3OH.,,,U,Autocuration,A,,CHEMBL629186,,1235.0,Adrenal cortex,,0,1
14899,22224,,BAO_0000019,,,Percent lipid extracted at 24 hours from liverliver using CHCl3/CH3OH.,,,U,Autocuration,A,,CHEMBL629187,,,,,0,1
14900,22224,,BAO_0000019,,,Percent lipid extracted at 24 hours from plasma using CHCl3/CH3OH.,,,U,Autocuration,A,,CHEMBL629887,,,,,0,1
14901,22224,,BAO_0000019,,,Percent lipid extracted at 24 hours from plasmaliver using CHCl3/CH3OH.,,,U,Autocuration,A,,CHEMBL629888,,,,,0,1
14902,22224,,BAO_0000019,,,Percent lipid extracted at 24 hr from liver using CHCl3/CH3OH.,,,U,Autocuration,A,,CHEMBL629889,,,,,0,1
14903,22224,,BAO_0000019,,,Percent parent compound extracted at 0.5 hr from adrenal cortex using CHCl3/CH3OH.,,,U,Autocuration,A,,CHEMBL629890,,1235.0,Adrenal cortex,,0,1
14904,22224,,BAO_0000019,,,Percent parent compound extracted at 0.5 hr from liver using CHCl3/CH3OH.,,,U,Autocuration,A,,CHEMBL629891,,,,,0,1
14905,22224,,BAO_0000019,,,Percent parent compound extracted at 0.5 hr from plasma using CHCl3/CH3OH.,,,U,Autocuration,A,,CHEMBL629892,,,,,0,1
14906,22224,,BAO_0000019,,,Percent parent compound extracted at 24 hours from adrenal cortex using CHCl3/CH3OH.,,,U,Autocuration,A,,CHEMBL629893,,1235.0,Adrenal cortex,,0,1
14907,22224,,BAO_0000019,,,Percent parent compound extracted at 24 hours from liver using CHCl3/CH3OH.,,,U,Autocuration,A,,CHEMBL629894,,,,,0,1
14908,22224,,BAO_0000019,,,Percent parent compound extracted at 24 hours from plasma using CHCl3/CH3OH.,,,U,Autocuration,A,,CHEMBL629895,,,,,0,1
14909,22224,In vivo,BAO_0000218,,,"+Ratio of intravenous to oral integrated area under the concentration vs time curve, for compound in dog plasma",,,U,Autocuration,A,9615.0,CHEMBL875109,,,,,0,1
14910,22224,In vivo,BAO_0000218,,,Absolute bioavailability in male cynomolgus monkeys,,,U,Autocuration,A,9541.0,CHEMBL629896,,,,,0,1
14911,22224,In vivo,BAO_0000218,,,Absolute bioavailability in maleSprague-Dawley rats,,,U,Autocuration,A,10116.0,CHEMBL629897,,,,,0,1
14912,50597,In vivo,BAO_0000218,,,Biodistribution in liver of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,,N,Intermediate,A,10116.0,CHEMBL629898,,2107.0,Liver,,1,1
14913,50597,In vivo,BAO_0000218,,,Biodistribution in liver of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL630057,,2107.0,Liver,,1,1
14914,50597,In vivo,BAO_0000218,,,Biodistribution in liver of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL630058,,2107.0,Liver,,1,1
14915,50597,In vivo,BAO_0000218,,,Biodistribution in lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL630059,,2048.0,Lung,,1,1
14916,50597,In vivo,BAO_0000218,,,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL630060,,2048.0,Lung,,1,1
14917,50597,In vivo,BAO_0000218,,,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,,N,Intermediate,A,10116.0,CHEMBL630061,,2048.0,Lung,,1,1
14918,50597,In vivo,BAO_0000218,,,Biodistribution in lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL630062,,2048.0,Lung,,1,1
14919,50597,In vivo,BAO_0000218,,,Biodistribution in lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL630063,,2048.0,Lung,,1,1
14920,50597,In vivo,BAO_0000218,,,Biodistribution in lungs of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL630064,,2048.0,Lung,,1,1
14921,50597,In vivo,BAO_0000218,,,Biodistribution in lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL630065,,2048.0,Lung,,1,1
14922,50597,In vivo,BAO_0000218,,,Biodistribution in lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,,N,Intermediate,A,10116.0,CHEMBL630066,,2048.0,Lung,,1,1
14923,50597,In vivo,BAO_0000218,,,Biodistribution in lungs of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL630067,,2048.0,Lung,,1,1
14924,50597,In vivo,BAO_0000218,,,Biodistribution in lungs of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL630068,,2048.0,Lung,,1,1
14925,50597,In vivo,BAO_0000218,,,Biodistribution in muscle of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL631113,,2385.0,Muscle tissue,,1,1
14926,50597,In vivo,BAO_0000218,,,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL631114,,2385.0,Muscle tissue,,1,1
14927,50597,In vivo,BAO_0000218,,,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,,N,Intermediate,A,10116.0,CHEMBL631115,,2385.0,Muscle tissue,,1,1
14928,50597,In vivo,BAO_0000218,,,Biodistribution in muscle of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL631116,,2385.0,Muscle tissue,,1,1
14929,50597,In vivo,BAO_0000218,,,Biodistribution in muscle of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL630528,,2385.0,Muscle tissue,,1,1
14930,50597,In vivo,BAO_0000218,,,Biodistribution in muscle of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL630529,,2385.0,Muscle tissue,,1,1
14931,50597,In vivo,BAO_0000218,,,Biodistribution in muscle of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL630530,,2385.0,Muscle tissue,,1,1
14932,50597,In vivo,BAO_0000218,,,Biodistribution in muscle of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,,N,Intermediate,A,10116.0,CHEMBL630531,,2385.0,Muscle tissue,,1,1
14933,50597,In vivo,BAO_0000218,,,Biodistribution in muscle of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL630532,,2385.0,Muscle tissue,,1,1
14934,50597,In vivo,BAO_0000218,,,Biodistribution in muscle of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL630533,,2385.0,Muscle tissue,,1,1
14935,50594,In vivo,BAO_0000218,,,Biodistribution in normal mice blood after 120 hr,,,N,Intermediate,A,10090.0,CHEMBL630534,,178.0,Blood,,1,1
14936,50594,In vivo,BAO_0000218,,,Biodistribution in normal mice blood after 24 hr,,,N,Intermediate,A,10090.0,CHEMBL630535,,178.0,Blood,,1,1
14937,50594,In vivo,BAO_0000218,,,Biodistribution in normal mice blood after 4 hr,,,N,Intermediate,A,10090.0,CHEMBL630536,,178.0,Blood,,1,1
14938,50594,In vivo,BAO_0000218,,,Biodistribution in normal mice bone after 120 hr,,,N,Intermediate,A,10090.0,CHEMBL630537,,10000001.0,Bone,,1,1
14939,50594,In vivo,BAO_0000218,,,Biodistribution in normal mice bone after 24 hr,,,N,Intermediate,A,10090.0,CHEMBL630538,,10000001.0,Bone,,1,1
14940,50594,In vivo,BAO_0000218,,,Biodistribution in normal mice bone after 4 hr,,,N,Intermediate,A,10090.0,CHEMBL630539,,10000001.0,Bone,,1,1
14941,50594,In vivo,BAO_0000218,,,Biodistribution in normal mice heart after 120 hr,,,N,Intermediate,A,10090.0,CHEMBL630540,,948.0,Heart,,1,1
14942,50594,In vivo,BAO_0000218,,,Biodistribution in normal mice heart after 24 hr,,,N,Intermediate,A,10090.0,CHEMBL630541,,948.0,Heart,,1,1
14943,50594,In vivo,BAO_0000218,,,Biodistribution in normal mice heart after 4 hr,,,N,Intermediate,A,10090.0,CHEMBL630542,,948.0,Heart,,1,1
14944,50594,In vivo,BAO_0000218,,,Biodistribution in normal mice kidney after 120 hr,,,N,Intermediate,A,10090.0,CHEMBL630543,,2113.0,Kidney,,1,1
14945,50594,In vivo,BAO_0000218,,,Biodistribution in normal mice kidney after 24 hr,,,N,Intermediate,A,10090.0,CHEMBL630544,,2113.0,Kidney,,1,1
14946,50594,In vivo,BAO_0000218,,,Biodistribution in normal mice kidney after 4 hr,,,N,Intermediate,A,10090.0,CHEMBL630545,,2113.0,Kidney,,1,1
14947,50594,In vivo,BAO_0000218,,,Biodistribution in normal mice liver after 120 hr,,,N,Intermediate,A,10090.0,CHEMBL630546,,2107.0,Liver,,1,1
14948,50594,In vivo,BAO_0000218,,,Biodistribution in normal mice liver after 24 hr,,,N,Intermediate,A,10090.0,CHEMBL630547,,2107.0,Liver,,1,1
14949,50594,In vivo,BAO_0000218,,,Biodistribution in normal mice liver after 4 hr,,,N,Intermediate,A,10090.0,CHEMBL630548,,2107.0,Liver,,1,1
14950,50594,In vivo,BAO_0000218,,,Biodistribution in normal mice spleen after 120 hr,,,N,Intermediate,A,10090.0,CHEMBL630549,,2106.0,Spleen,,1,1
14951,50594,In vivo,BAO_0000218,,,Biodistribution in normal mice spleen after 24 hr,,,N,Intermediate,A,10090.0,CHEMBL630550,,2106.0,Spleen,,1,1
14952,50594,In vivo,BAO_0000218,,,Biodistribution in normal mice spleen after 4 hr,,,N,Intermediate,A,10090.0,CHEMBL876426,,2106.0,Spleen,,1,1
14953,50597,In vivo,BAO_0000218,,,Biodistribution in spleen of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL630551,,2106.0,Spleen,,1,1
14954,50597,In vivo,BAO_0000218,,,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL630552,,2106.0,Spleen,,1,1
14955,50597,In vivo,BAO_0000218,,,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,,N,Intermediate,A,10116.0,CHEMBL630553,,2106.0,Spleen,,1,1
14956,50597,In vivo,BAO_0000218,,,Biodistribution in spleen of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL630554,,2106.0,Spleen,,1,1
14957,50597,In vivo,BAO_0000218,,,Biodistribution in spleen of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL630555,,2106.0,Spleen,,1,1
14958,50597,In vivo,BAO_0000218,,,Biodistribution in spleen of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL630556,,2106.0,Spleen,,1,1
14959,50597,In vivo,BAO_0000218,,,Biodistribution in spleen of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL630557,,2106.0,Spleen,,1,1
14960,50597,In vivo,BAO_0000218,,,Biodistribution in spleen of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,,N,Intermediate,A,10116.0,CHEMBL630558,,2106.0,Spleen,,1,1
14961,50597,In vivo,BAO_0000218,,,Biodistribution in spleen of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL630559,,2106.0,Spleen,,1,1
14962,50597,In vivo,BAO_0000218,,,Biodistribution in spleen of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL630560,,2106.0,Spleen,,1,1
14963,50597,In vivo,BAO_0000218,,,Biodistribution in thyroid of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,,N,Intermediate,A,10116.0,CHEMBL876427,,2046.0,Thyroid gland,,1,1
14964,50597,,BAO_0000218,,,The Kel values in female wistar rats.,,,N,Intermediate,A,10116.0,CHEMBL630561,,,,,1,1
14965,22224,,BAO_0000019,,,The equilibrium constant pair at a pH of 7.0 and temperature of 25 degree Centigrade,,,U,Autocuration,A,,CHEMBL630562,,,,,0,1
14966,22224,,BAO_0000019,,,Hydrolysis rate constant of the compound,,,U,Autocuration,A,,CHEMBL630563,,,,,0,1
14967,22229,,BAO_0000100,,,Headecane/water partition coefficient expressed as the equilibrium ratio of the molar concentration in n-hexadecane to that in the buffer,,,U,Autocuration,P,,CHEMBL629673,,,,,0,1
14968,22224,,BAO_0000019,,,"Hydrolysis in acetone/water (50:50) at a pH of 8.0, T=66 degree Centigrade",,,U,Autocuration,A,,CHEMBL629674,,,,,0,1
14969,22224,,BAO_0000019,,,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree Centigrade",,,U,Autocuration,A,,CHEMBL629675,,,,,0,1
14970,22224,,BAO_0000019,,,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree centigrade; No data",,,U,Autocuration,A,,CHEMBL629676,,,,,0,1
14971,22224,,BAO_0000019,,,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree centigrade; Not determined",,,U,Autocuration,A,,CHEMBL629677,,,,,0,1
14972,22224,,BAO_0000019,,,Apparent inactivation rate constant was evaluated,,,U,Autocuration,A,,CHEMBL629678,,,,,0,1
14973,22224,,BAO_0000019,,,Compound was evaluated for equilibrium constant K obtained from the ratio of reverse rate constants at 25 degree Centigrade.,,,U,Autocuration,A,,CHEMBL629679,,,,,0,1
14974,22224,,BAO_0000019,,,Compound was evaluated for equilibrium constant K obtained from the ratio of reverse rate constants at 37 degree Centigrade,,,U,Autocuration,A,,CHEMBL629680,,,,,0,1
14975,22224,,BAO_0000019,,,Compound was evaluated for the Ki value for peptide alcohol for competitive inhibition in the presence of Mn2+ ions at pH 7.5,,,U,Autocuration,A,,CHEMBL629681,,,,,0,1
14976,22224,,BAO_0000019,,,Compound was tested for the inhibition of antibody-catalyzed hydrolysis.,,,U,Autocuration,A,,CHEMBL629682,,,,,0,1
14977,22224,,BAO_0000019,,,DBH (dopamine beta-hydroxylase) activity expressed as Ki value determined by degree to which compound inhibited conversion of tyramine to octopamine,,,U,Autocuration,A,,CHEMBL629683,,,,,0,1
14978,22224,,BAO_0000019,,,Dissociation constant against constrictor response to the compound blocked competitively by phentolamine for alpha-mediated events,,,U,Autocuration,F,,CHEMBL629684,,,,,0,1
14979,22224,,BAO_0000100,,,Dissociation constant was determined,,,U,Autocuration,P,,CHEMBL629685,,,,,0,1
14980,22224,,BAO_0000100,,,Dissociation constant was determined,,,U,Autocuration,P,,CHEMBL629686,,,,,0,1
14981,22224,,BAO_0000100,,,Dissociation constant at pH 7.4,,,U,Autocuration,P,,CHEMBL872932,,,,,0,1
14982,22224,,BAO_0000100,,,Dissociation constant in presence of 1 mM dithiothreitol,,,U,Autocuration,P,,CHEMBL629687,,,,,0,1
14983,22224,,BAO_0000019,,,Kinetic Parameter Ki for Inhibition of Type 1 5-alpha-reductase,,,U,Autocuration,A,,CHEMBL872931,,,,,0,1
14984,22224,,BAO_0000019,,,Kinetic Parameter Ki for Inhibition of Type 1 5-alpha-reductase,,,U,Autocuration,A,,CHEMBL628151,,,,,0,1
14985,22224,,BAO_0000019,,,Kinetic Parameter Ki for Inhibition of Type-2 5-alpha-reductase,,,U,Autocuration,A,,CHEMBL628152,,,,,0,1
14986,22224,,BAO_0000019,,,Kinetic Parameter Ki for Inhibition of Type-2 5-alpha-reductase,,,U,Autocuration,A,,CHEMBL628153,,,,,0,1
14987,22224,,BAO_0000019,,,Kinetic constant for aromatization of androstenedione,,,U,Autocuration,A,,CHEMBL628154,,,,,0,1
14988,22224,,BAO_0000019,,,Kinetic constant for aromatization of testosterone,,,U,Autocuration,A,,CHEMBL628155,,,,,0,1
14989,22224,,BAO_0000019,,,Kinetic parameter for hydrolysis of 1 by Antibody 2D10 after addition of compound 12,,,U,Autocuration,A,,CHEMBL628156,,,,,0,1
14990,22224,,BAO_0000019,,,Local inhibition constant was determined,,,U,Autocuration,A,,CHEMBL628157,,,,,0,1
14991,50347,,BAO_0000218,,,Rate of inactivation of sterol methyl transferase from Saccharomyces cerevisiae using mechanism based inhibitor,,,N,Intermediate,A,4932.0,CHEMBL857533,,,,,1,1
14992,22224,,BAO_0000100,,,Dissociation constant value of the compound,,,U,Autocuration,P,,CHEMBL628158,,,,,0,1
14993,22224,,BAO_0000019,,,In vitro permeability through cornea without epithelium,,,U,Autocuration,A,,CHEMBL628159,,964.0,Cornea,,0,1
14994,22224,,BAO_0000019,,,In vitro permeability through intact cornea,,,U,Autocuration,A,,CHEMBL875616,,964.0,Cornea,,0,1
14995,50592,,BAO_0000218,,,Evaluated for first order rate constant (Kin) for transcorneal penetration in anesthetized rabbits,,,N,Intermediate,A,9986.0,CHEMBL628160,,964.0,Cornea,,1,1
14996,22224,,BAO_0000019,,,Rate of enzyme inactivation for the compound was determined,,,U,Autocuration,A,,CHEMBL628161,,,,,0,1
14997,22224,,BAO_0000019,,,In vitro permeability through cornea without epithelium,,,U,Autocuration,A,,CHEMBL628162,,964.0,Cornea,,0,1
14998,22224,,BAO_0000019,,,In vitro permeability through intact cornea,,,U,Autocuration,A,,CHEMBL628163,,964.0,Cornea,,0,1
14999,22224,,BAO_0000019,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0300 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,U,Autocuration,A,,CHEMBL628164,,,,,0,1
15000,22224,,BAO_0000019,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0384 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,U,Autocuration,A,,CHEMBL628165,,,,,0,1
15001,22224,,BAO_0000019,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0395 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,U,Autocuration,A,,CHEMBL628166,,,,,0,1
15002,22224,,BAO_0000019,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0500 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,U,Autocuration,A,,CHEMBL628167,,,,,0,1
15003,22224,,BAO_0000019,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.050 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,U,Autocuration,A,,CHEMBL628168,,,,,0,1
15004,22224,,BAO_0000019,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0767 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,U,Autocuration,A,,CHEMBL628169,,,,,0,1
15005,22224,,BAO_0000019,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0790 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,U,Autocuration,A,,CHEMBL628170,,,,,0,1
15006,22224,,BAO_0000019,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0800 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,U,Autocuration,A,,CHEMBL628171,,,,,0,1
15007,22224,,BAO_0000019,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.100 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,U,Autocuration,A,,CHEMBL627434,,,,,0,1
15008,22224,,BAO_0000019,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.200 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,U,Autocuration,A,,CHEMBL627435,,,,,0,1
15009,22224,,BAO_0000019,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.300 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,U,Autocuration,A,,CHEMBL628110,,,,,0,1
15010,22224,,BAO_0000019,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.384 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,U,Autocuration,A,,CHEMBL628111,,,,,0,1
15011,22224,,BAO_0000019,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.395 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,U,Autocuration,A,,CHEMBL628112,,,,,0,1
15012,22224,,BAO_0000019,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,U,Autocuration,A,,CHEMBL628260,,,,,0,1
15013,22224,,BAO_0000019,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,U,Autocuration,A,,CHEMBL628261,,,,,0,1
15014,50594,In vivo,BAO_0000218,,,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Muscle (M),,,N,Intermediate,A,10090.0,CHEMBL628262,,,,,1,1
15015,50587,In vivo,BAO_0000218,,,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Tumor (T) cells,,,N,Intermediate,A,9606.0,CHEMBL628263,,,,,1,1
15016,50594,In vivo,BAO_0000218,,,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Blood (B),,,N,Intermediate,A,10090.0,CHEMBL628264,,,,,1,1
15017,50594,In vivo,BAO_0000218,,,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Heart (H),,,N,Intermediate,A,10090.0,CHEMBL628265,,,,,1,1
15018,50594,In vivo,BAO_0000218,,,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Lung (L),,,N,Intermediate,A,10090.0,CHEMBL628266,,,,,1,1
15019,50594,In vivo,BAO_0000218,,,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Muscle (M),,,N,Intermediate,A,10090.0,CHEMBL628267,,,,,1,1
15020,50594,In vivo,BAO_0000218,,,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Tumor (T) cells,,,N,Intermediate,A,10090.0,CHEMBL628268,,,,,1,1
15021,50594,In vivo,BAO_0000218,,,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Blood (B),,,N,Intermediate,A,10090.0,CHEMBL628269,,,,,1,1
15022,50594,In vivo,BAO_0000218,,,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Heart (H),,,N,Intermediate,A,10090.0,CHEMBL628270,,,,,1,1
15023,50594,In vivo,BAO_0000218,,,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Lung (L),,,N,Intermediate,A,10090.0,CHEMBL628271,,,,,1,1
15024,50594,In vivo,BAO_0000218,,,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Muscle (M),,,N,Intermediate,A,10090.0,CHEMBL628272,,,,,1,1
